FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Peterson, MJ
Kahn, JA
Kerrigan, MV
Gutmann, JM
Harrow, JJ
AF Peterson, Matthew J.
Kahn, Julie A.
Kerrigan, Michael V.
Gutmann, Joseph M.
Harrow, Jeffrey J.
TI Pressure ulcer risk of patient handling sling use
SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT
LA English
DT Article
DE decubitus ulcer; interface pressure; patient handling; patient handling
sling; patient lifting; patient moving and lifting; patient
repositioning; pressure sore; pressure ulcer; pressure ulcer risk;
spinal cord injury
ID INJURIES
AB Patient handling slings and lifts reduce the risk of musculoskeletal injuries for healthcare providers. However, no published evidence exists of their safety with respect to pressure ulceration for vulnerable populations, specifically persons with spinal cord injury, nor do any studies compare slings for pressure distribution. High-resolution interface pressure mapping was used to describe and quantify risks associated with pressure ulceration due to normal forces and identify at-risk anatomical locations. We evaluated 23 patient handling slings with 4 non-disabled adults. Sling-participant interface pressures were recorded while participants lay supine on a hospital bed and while they were suspended during typical patient transfers. Sling-participant interface pressures were greatest while participants were suspended for all seated and supine slings and exceeded 200 mm Hg for all seated slings. Interface pressures were greatest along the sling seams (edges), regardless of position or sling type. The anatomical areas most at risk while participants were suspended in seated slings were the posterior upper and lower thighs. For supine slings, the perisacral area, ischial tuberosities, and greater trochanters were most at risk. The duration of time spent in slings, especially while suspended, should be limited.
C1 [Peterson, Matthew J.; Gutmann, Joseph M.] James A Haley Vet Hosp, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Innovat Disabil & Rehabil, Tampa, FL USA.
[Kahn, Julie A.] Univ S Florida, Dept Chem & Biomed Engn, Tampa, FL USA.
[Kerrigan, Michael V.] US Patent & Trademark Off, Alexandria, VA USA.
[Harrow, Jeffrey J.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
RP Peterson, MJ (reprint author), James A Haley Vet Hosp 151R, HSR&D Ctr Innovat Disabil & Rehabil Res CINDRR, 8900 Grand Oak Cir, Tampa, FL 33637 USA.
EM Matthew.Peterson1@va.gov
FU VA Central Office Occupational Health Strategic Healthcare Group
[SPTOF00A1]
FX This work was supported by the VA Central Office Occupational Health
Strategic Healthcare Group (no. SPTOF00A1).
NR 16
TC 0
Z9 0
U1 2
U2 3
PU JOURNAL REHAB RES & DEV
PI BALTIMORE
PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET,
BALTIMORE, MD 21202-4051 USA
SN 0748-7711
EI 1938-1352
J9 J REHABIL RES DEV
JI J. Rehabil. Res. Dev.
PY 2015
VL 52
IS 3
BP 291
EP 300
DI 10.1682/JRRD.2014.06.0140
PG 10
WC Rehabilitation
SC Rehabilitation
GA CN0NR
UT WOS:000358111100004
PM 26237005
ER
PT J
AU Danilack, VA
Okunbor, O
Richardson, CR
Teylan, M
Moy, ML
AF Danilack, Valery A.
Okunbor, Osarenoma
Richardson, Caroline R.
Teylan, Merilee
Moy, Marilyn L.
TI Performance of a pedometer to measure physical activity in a US cohort
with chronic obstructive pulmonary disease
SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT
LA English
DT Article
DE continuous walking; COPD; exercise; functional capacity; intermittent
steps; Omron; pedometer; physical activity; pulmonary disease; StepWatch
Activity Monitor
ID DAILY STEP COUNT; RESPIRATORY SOCIETY STATEMENT; ACTIVITY MONITORS;
WALKING PROGRAM; DAILY-LIFE; COPD; VALIDITY; REHABILITATION; MORTALITY;
PATTERNS
AB Objective assessment of physical activity (PA) in chronic obstructive pulmonary disease (COPD) is important. We examined the performance of the Omron HJ-720ITC pedometer. A sample of 176 persons with stable COPD wore the Omron and the StepWatch Activity Monitor (SAM) in the clinic and the community. A 4 s step filter in the Omron screens out erroneous intermittent steps; it captures continuous walking that lasts >4 s. The SAM captures all intermittent and continuous steps walked. Omron-steps were compared with manually counted steps in the clinic and with SAM-steps in the community. We calculated the intraclass correlation coefficient for the first 2 d, the first 3 d, etc., up to 14 d. The Omron registered >/= 90% of the manually counted steps from the in-clinic walk in 155 of 176 subjects (88%). In the community, 47 +/-16% of SAM-steps were continuous ones that were captured by the Omron. For the Omron and the SAM, at least 7 d of monitoring should be used to capture decreases in PA on weekend days and obtain optimum reliability for all Global Initiative for Chronic Obstructive Lung Disease stages. The Omron accurately and reliably measures continuous walking in COPD. The Omron may be ideal for use in PA interventions that promote continuous walking as exercise.
C1 [Danilack, Valery A.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA.
[Danilack, Valery A.; Okunbor, Osarenoma; Teylan, Merilee; Moy, Marilyn L.] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Dept Vet Affairs, Boston, MA USA.
[Richardson, Caroline R.] VA Ctr Clin Management Res, Ann Arbor, MI USA.
[Richardson, Caroline R.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA.
[Moy, Marilyn L.] VA Rehabil Res & Dev Serv, Washington, DC USA.
[Moy, Marilyn L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Moy, ML (reprint author), VA Boston Healthcare Syst, Pulm & Crit Care Sect, 1400 VFW Pkwy,Mail Code 111PI, West Roxbury, MA 02132 USA.
EM marilyn.moy@va.gov
FU VA, Veterans Health Administration; Rehabilitation Research and
Development Service through VA Career Development [F6847W]
FX This material was based on work supported by the VA, Veterans Health
Administration, Rehabilitation Research and Development Service through
a VA Career Development Award (F6847W) to Dr. Moy.
NR 44
TC 3
Z9 3
U1 1
U2 4
PU JOURNAL REHAB RES & DEV
PI BALTIMORE
PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET,
BALTIMORE, MD 21202-4051 USA
SN 0748-7711
EI 1938-1352
J9 J REHABIL RES DEV
JI J. Rehabil. Res. Dev.
PY 2015
VL 52
IS 3
BP 333
EP 342
DI 10.1682/JRRD.2014.11.0282
PG 10
WC Rehabilitation
SC Rehabilitation
GA CN0NR
UT WOS:000358111100008
PM 26230737
ER
PT J
AU Ghodbane, M
Stucky, EC
Maguire, TJ
Schloss, RS
Shreiber, DI
Zahn, JD
Yarmush, ML
AF Ghodbane, Mehdi
Stucky, Elizabeth C.
Maguire, Tim J.
Schloss, Rene S.
Shreiber, David I.
Zahn, Jeffrey D.
Yarmush, Martin L.
TI Development and validation of a microfluidic immunoassay capable of
multiplexing parallel samples in microliter volumes
SO LAB ON A CHIP
LA English
DT Article
ID RAT HIPPOCAMPAL SLICES; TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY;
INFLAMMATORY CYTOKINES; PROTEIN BIOMARKERS; CHIP; DIAGNOSTICS; SYSTEM;
CELLS; LIPOPOLYSACCHARIDE
AB Immunoassays are widely utilized due to their ability to quantify a vast assortment of biomolecules relevant to biological research and clinical diagnostics. Recently, immunoassay capabilities have been improved by the development of multiplex assays that simultaneously measure multiple analytes in a single sample. However, these assays are hindered by high costs of reagents and relatively large sample requirements. For example, in vitro screening systems currently dedicate individual wells to each time point of interest and this limitation is amplified in screening studies when the investigation of many experimental conditions is necessary; resulting in large volumes for analysis, a correspondingly high cost and a limited temporal experimental design. Microfluidics based immunoassays have been developed in order to overcome these drawbacks. Together, previous studies have demonstrated on-chip assays with either a large dynamic range, high performance sensitivity, and/or the ability to process samples in parallel on a single chip. In this report, we develop a multiplex immunoassay possessing all of these parallel characteristics using commercially available reagents, which allows the analytes of interest to be easily changed. The device presented can measure 6 proteins in 32 samples simultaneously using only 4.2 mu L of sample volume. High quality standard curves are generated for all 6 analytes included in the analysis, and spiked samples are quantified throughout the working range of the assay. In addition, we demonstrate a strong correlation (R-2 = 0.8999) between in vitro supernatant measurements using our device and those obtained from a bench-top multiplex immunoassay. Finally, we describe cytokine secretion in an in vitro inflammatory hippocampus culture system, establishing proof-of-concept of the ability to use this platform as an in vitro screening tool. The low-volume, multiplexing abilities of the microdevice described in this report could be broadly applied to numerous situations where sample volumes and costs are limiting.
C1 [Ghodbane, Mehdi; Maguire, Tim J.; Schloss, Rene S.; Shreiber, David I.; Zahn, Jeffrey D.; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA.
[Stucky, Elizabeth C.] Rutgers State Univ, Dept Chem & Biochem Engn, Piscataway, NJ 08854 USA.
[Yarmush, Martin L.] Massachusetts Gen Hosp, Ctr Engn Med Surg Serv, Boston, MA 02114 USA.
RP Yarmush, ML (reprint author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.
EM yarmush@rci.rutgers.edu
OI Stucky Hunter, Elizabeth/0000-0003-0797-9453
FU National Institute of Health [P41EB002503, UH2TR000503]; National
Institute of Health Rutgers Biotechnology Training Program
[T32GM008339]; National Science Foundation Integrated Science and
Engineering of Stem Cells Program [DGE0801620]; New Jersey Commission on
Brain Injury Research [CBIR12IRG019]
FX This work was partially funded by the National Institute of Health
grants P41EB002503 and UH2TR000503, the National Institute of Health
Rutgers Biotechnology Training Program (T32GM008339), the National
Science Foundation Integrated Science and Engineering of Stem Cells
Program (DGE0801620), The New Jersey Commission on Brain Injury Research
grant CBIR12IRG019, and Corning Inc. The authors would like to thank Dr.
Bhaskar Mitra and Henry Yu for support in developing the fabrication
protocols, and Prof. Lawrence Williams for productive discussion in
designing the experiments.
NR 57
TC 4
Z9 4
U1 2
U2 18
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PY 2015
VL 15
IS 15
BP 3211
EP 3221
DI 10.1039/c5lc00398a
PG 11
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience
& Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
Other Topics
GA CM9IU
UT WOS:000358022900014
PM 26130452
ER
PT S
AU Galarreta-Valverde, MA
Zoghbi, JM
Pereira, F
Beregi, JP
Mekkaoui, C
Jackowski, MP
AF Galarreta-Valverde, Miguel A.
Zoghbi, Jihan M.
Pereira, Fabricio
Beregi, Jean-Paul
Mekkaoui, Choukri
Jackowski, Marcel P.
BE Hadjiiski, LM
Tourassi, GD
TI Characterization of Vascular Tree Architecture using the Tokunaga
Taxonomy
SO MEDICAL IMAGING 2015: COMPUTER-AIDED DIAGNOSIS
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Computer-Aided Diagnosis (CAD) Conference at the SPIE Medical Imaging
Symposium
CY FEB 22-25, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Dev Inc, Bruker
DE Magnetic resonance imaging; computed tomography angiography; vascular
architecture; 3D blood vessel; Tokunaga taxonomy
AB The diagnosis of cardiovascular disease is usually assisted by resonance angiography (MRA) or computed tomography angiography (CTA) imaging. The identification of abnormal vascular architecture from angiographic three-dimensional images is therefore crucial to the diagnosis of cardiovascular disease. Automated detection and quantification of vascular structure and architecture thus holds significant clinical value. In this work, we employ a Lindenmayer system to represent vascular trees from angiographic images and describe a quantitative measure based on the Tokunaga taxonomy to differentiate vascular architectures. Synthetic vessel architectures with varying bifurcation patterns were compared and results showed that this architectural measure is proportional to the level of branching. In real MRA images, this measure was able to differentiate between normal and abnormal intracerebral vasculature containing an aneurysm. Hence, this methodology not only allows for compact representation of vascular architectures but also provides a quantitative metric of bifurcation complexity, which has the potential to characterize different types of vascular abnormalities.
C1 [Galarreta-Valverde, Miguel A.; Zoghbi, Jihan M.; Jackowski, Marcel P.] Univ Sao Paulo, Inst Math & Stat, Dept Comp Sci, Sao Paulo, Brazil.
[Pereira, Fabricio; Beregi, Jean-Paul; Mekkaoui, Choukri] Univ Hosp Ctr Nimes, Dept Radiol, Nimes, France.
[Pereira, Fabricio; Beregi, Jean-Paul; Mekkaoui, Choukri] Res Team EA 2415, Nimes, France.
[Beregi, Jean-Paul; Mekkaoui, Choukri] Univ Montpellier, Fac Med, F-34059 Montpellier, France.
[Mekkaoui, Choukri] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,Athinoula A Martinos Ctr B, Boston, MA 02115 USA.
RP Galarreta-Valverde, MA (reprint author), Univ Sao Paulo, Inst Math & Stat, Dept Comp Sci, Sao Paulo, Brazil.
EM mjack@ime.usp.br
RI Jackowski, Marcel/G-7602-2012
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-504-9
J9 PROC SPIE
PY 2015
VL 9414
AR 941438
DI 10.1117/12.2080854
PG 6
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BD0US
UT WOS:000357728600109
ER
PT S
AU Nappi, JJ
Regge, D
Yoshida, H
AF Naeppi, Janne J.
Regge, Daniele
Yoshida, Hiroyuki
BE Hadjiiski, LM
Tourassi, GD
TI Context-specific method for detection of soft-tissue lesions in
non-cathartic low-dose dual-energy CT colonography
SO MEDICAL IMAGING 2015: COMPUTER-AIDED DIAGNOSIS
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Computer-Aided Diagnosis (CAD) Conference at the SPIE Medical Imaging
Symposium
CY FEB 22-25, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Dev Inc, Bruker
DE Computer-aided detection; polyp detection; false-positive reduction;
dual-energy CT; noncathartic preparation; virtual colonoscopy
ID ADENOMATOUS POLYPS; PSEUDO-ENHANCEMENT; REDUCTION
AB In computed tomographic colonography (CTC), orally administered fecal-tagging agents can be used to indicate residual feces and fluid that could otherwise hide or imitate lesions on CTC images of the colon. Although the use of fecal tagging improves the detection accuracy of CTC, it can introduce image artifacts that may cause lesions that are covered by fecal tagging to have a different visual appearance than those not covered by fecal tagging. This can distort the values of image-based computational features, thereby reducing the accuracy of computer-aided detection (CADe). We developed a context-specific method that performs the detection of lesions separately on lumen regions covered by air and on those covered by fecal tagging, thereby facilitating the optimization of detection parameters separately for these regions and their detected lesion candidates to improve the detection accuracy of CADe. For pilot evaluation, the method was integrated into a dual-energy CADe (DE-CADe) scheme and evaluated by use of leave-one-patient-out evaluation on 66 clinical non-cathartic low-dose dual-energy CTC (DE-CTC) cases that were acquired at a low effective radiation dose and reconstructed by use of iterative image reconstruction. There were 22 colonoscopy-confirmed lesions >= 6 mm in size in 21 patients. The DE-CADe scheme detected 96% of the lesions at a median of 6 FP detections per patient. These preliminary results indicate that the use of context-specific detection can yield high detection accuracy of CADe in non-cathartic low-dose DE-CTC examinations.
C1 [Naeppi, Janne J.; Yoshida, Hiroyuki] Massachusetts Gen Hosp, Dept Radiol, Imaging Res 3D, Boston, MA 02114 USA.
[Naeppi, Janne J.; Yoshida, Hiroyuki] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Regge, Daniele] Inst Canc Res & Treatment, IT-10060 Turin, Italy.
RP Nappi, JJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Imaging Res 3D, 25 New Chardon St,Suite 400C, Boston, MA 02114 USA.
EM janne.nappi@mgh.harvard.edu; yoshida.hiro@mgh.harvard.edu
OI Nappi, Janne/0000-0002-0108-0992
FU NCI NIH HHS [R01 CA166816, R03 CA156664, R03 CA182107, R01 CA095279]
NR 22
TC 0
Z9 0
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-504-9
J9 PROC SPIE
PY 2015
VL 9414
AR 94142Y
DI 10.1117/12.2081284
PG 7
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BD0US
UT WOS:000357728600102
PM 25964710
ER
PT S
AU Tachibana, R
Nappi, JJ
Kim, SH
Yoshida, H
AF Tachibana, Rie
Naeppi, Janne J.
Kim, Se Hyung
Yoshida, Hiroyuki
BE Hadjiiski, LM
Tourassi, GD
TI Electronic cleansing for dual-energy CT colonography based on material
decomposition and virtual monochromatic imaging
SO MEDICAL IMAGING 2015: COMPUTER-AIDED DIAGNOSIS
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Computer-Aided Diagnosis (CAD) Conference at the SPIE Medical Imaging
Symposium
CY FEB 22-25, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Dev Inc, Bruker
DE Colon; virtual cleansing; dual-energy CT; random forest; virtual
colonoscopy
ID TOMOGRAPHY
AB CT colonography (CTC) uses orally administered fecal-tagging agents to enhance retained fluid and feces that would otherwise obscure or imitate polyps on CTC images. To visualize the complete region of colon without residual materials, electronic cleansing (EC) can be used to perform virtual subtraction of the tagged materials from CTC images. However, current EC methods produce subtraction artifacts and they can fail to subtract unclearly tagged feces. We developed a novel multi-material EC (MUMA-EC) method that uses dual-energy CTC (DE-CTC) and machine-learning methods to improve the performance of EC. In our method, material decomposition is performed to calculate water-iodine decomposition images and virtual monochromatic (VIM) images. Using the images, a random forest classifier is used to label the regions of lumen air, soft tissue, fecal tagging, and their partial-volume boundaries. The electronically cleansed images are synthesized from the multi-material and VIM image volumes. For pilot evaluation, we acquired the clinical DE-CTC data of 7 patients. Preliminary results suggest that the proposed MUMA-EC method is effective and that it minimizes the three types of image artifacts that were present in previous EC methods.
C1 [Tachibana, Rie; Naeppi, Janne J.; Yoshida, Hiroyuki] Massachusetts Gen Hosp, Dept Radiol, Imaging Res 3D, Boston, MA 02114 USA.
[Tachibana, Rie; Naeppi, Janne J.; Yoshida, Hiroyuki] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Kim, Se Hyung] Seoul Natl Univ Hosp, Seoul 110744, South Korea.
RP Yoshida, H (reprint author), Massachusetts Gen Hosp, Dept Radiol, Imaging Res 3D, 25 New Chardon St,Suite 400C, Boston, MA 02114 USA.
EM rtachibana@mgh.harvard.edu; janne.nappi@mgh.harvard.edu;
yoshida.hiro@mgh.harvard.edu
FU NCI NIH HHS [R01 CA095279, R03 CA156664, R01 CA166816]
NR 12
TC 1
Z9 1
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-504-9
J9 PROC SPIE
PY 2015
VL 9414
AR 94140Q
DI 10.1117/12.2082375
PG 7
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BD0US
UT WOS:000357728600025
PM 25844029
ER
PT S
AU Wu, J
Ou, YM
Weinstein, SP
Conant, EF
Yu, N
Hoshmand, V
Keller, B
Ashraf, AB
Rosen, M
DeMichele, A
Davatzikos, C
Kontos, D
AF Wu, Jia
Ou, Yangming
Weinstein, Susan P.
Conant, Emily F.
Yu, Ning
Hoshmand, Vahid
Keller, Brad
Ashraf, Ahmed B.
Rosen, Mark
DeMichele, Angela
Davatzikos, Christos
Kontos, Despina
BE Hadjiiski, LM
Tourassi, GD
TI Quantification of Tumor Changes during Neoadjuvant Chemotherapy with
Longitudinal Breast DCE-MRI Registration
SO MEDICAL IMAGING 2015: COMPUTER-AIDED DIAGNOSIS
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Computer-Aided Diagnosis (CAD) Conference at the SPIE Medical Imaging
Symposium
CY FEB 22-25, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Dev Inc, Bruker
DE Deformable Registration; Breast Tumor; DCE-MRI; Tumor Response;
Neoadjuvant Chemotherapy
ID CANCER-TREATMENT RESPONSE; PARAMETRIC RESPONSE; PATHOLOGICAL RESPONSE;
IMAGE REGISTRATION; SURVIVAL; PREDICTION; RECIST; ADENOCARCINOMA;
CRITERIA; MAPS
AB Imaging plays a central role in the evaluation of breast tumor response to neoadjuvant chemotherapy. Image-based assessment of tumor change via deformable registration is a powerful, quantitative method potentially to explore novel information of tumor heterogeneity, structure, function, and treatment response. In this study, we continued a previous pilot study to further validate the feasibility of an open source deformable registration algorithm DRAMMS developed within our group as a means to analyze spatio-temporal tumor changes for a set of 14 patients with DCE-MR imaging. Two experienced breast imaging radiologists marked landmarks according to their anatomical meaning on image sets acquired before and during chemotherapy. Yet, chemotherapy remarkably changed the anatomical structure of both tumor and normal breast tissue, leading to significant discrepancies between both raters for landmarks in certain areas. Therefore, we proposed a novel method to grade the manually denoted landmarks into different challenge levels based on the inter-rater agreement, where a high level indicates significant discrepancies and considerable amounts of anatomical structure changes, which would indeed impose giant problem for the following registration algorithm. It is interesting to observe that DRAMMS performed in a similar manner as the human raters: landmark errors increased as inter-rater differences rose. Among all selected six deformable registration algorithms, DRAMMS achieves the highest overall accuracy, which is around 5.5 mm, while the average difference between human raters is 3 mm. Moreover, DRAMMS performed consistently well within both tumor and normal tissue regions. Lastly, we comprehensively tuned the fundamental parameters of DRAMMS to better understand DRAMMS to guide similar works in the future. Overall, we further validated that DRAMMS is a powerful registration tool to accurately quantify tumor changes and potentially predict early tumor response to chemotherapy. Therefore, future studies that aim at examining if DRAMMS can generate valuable biomarkers for tumor response prediction during chemotherapy become feasible.
C1 [Wu, Jia; Weinstein, Susan P.; Conant, Emily F.; Keller, Brad; Ashraf, Ahmed B.; Rosen, Mark; DeMichele, Angela; Davatzikos, Christos; Kontos, Despina] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Ou, Yangming] Harvard Univ, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Yu, Ning; Hoshmand, Vahid] Univ Penn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA.
RP Kontos, D (reprint author), Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
EM Despina.Kontos@uphs.upenn.edu
OI Ou, Yangming/0000-0002-7726-6208; Weinstein, Susan/0000-0001-6159-1500
NR 25
TC 0
Z9 0
U1 1
U2 16
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-504-9
J9 PROC SPIE
PY 2015
VL 9414
AR 94141Z
DI 10.1117/12.2081938
PG 7
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BD0US
UT WOS:000357728600069
ER
PT S
AU Naeser, MA
Martin, PI
Ho, MD
Krengel, MH
Bogdanova, Y
Knight, JA
Yee, MK
Zafonte, R
Frazier, J
Hamblin, MR
Koo, BB
AF Naeser, Margaret A.
Martin, Paula I.
Ho, Michael D.
Krengel, Maxine H.
Bogdanova, Yelena
Knight, Jeffrey A.
Yee, Megan K.
Zafonte, Ross
Frazier, Judith
Hamblin, Michael R.
Koo, Bang-Bon
BE George, T
Dutta, AK
Islam, MS
TI Red/near-infrared light-emitting diode therapy for traumatic brain
injury
SO MICRO- AND NANOTECHNOLOGY SENSORS, SYSTEMS, AND APPLICATIONS VII
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Micro- and Nanotechnology Sensors, Systems, and
Applications VII
CY APR 20-24, 2015
CL Baltimore, MD
SP SPIE
DE Traumatic brain injury; TBI; photobiomodulation therapy; TBI treatment;
cognitive dysfunction; light emitting diodes LED; post-concussion
syndrome; sports head injury; PTSD; LLLT
ID POSTTRAUMATIC-STRESS-DISORDER; DEFAULT MODE NETWORK; LEVEL LASER
THERAPY; COLLEGIATE FOOTBALL PLAYERS; INTRINSIC CONNECTIVITY NETWORKS;
CONTROLLED CORTICAL IMPACT; ALTERED WORKING-MEMORY; DIFFUSE AXONAL
INJURY; FUNCTIONAL CONNECTIVITY; HEAD-INJURY
AB This invited paper reviews our research with scalp application of red/near-infrared (NIR) light-emitting diodes (LED) to improve cognition in chronic, traumatic brain injury(1). Application of red/NIR light improves mitochondrial function (especially hypoxic/compromised cells) promoting increased ATP, important for cellular metabolism. Nitric oxide is released locally, increasing regional cerebral blood flow. Eleven chronic, mTBI participants with closed-head injury and cognitive dysfunction received 18 outpatient treatments (MWF, 6 Wks) starting at 10 Mo. to 8 Yr. post-mTBI (MVA, sports-related, IED blast injury). LED therapy is non-invasive, painless, non-thermal (FDA-cleared, non-significant risk device). Each LED cluster head (2.1 '' diameter, 500mW, 22.2mW/cm(2)) was applied 10 min (13J/cm(2)) to 11 scalp placements: midline, from front-to-back hairline; and bilaterally on dorsolateral prefrontal cortex, temporal, and parietal areas. Testing performed pre- and post-LED (+ 1 Wk, 1 and 2 Mo post-18th treatment) showed significant linear trend for LED effect over time, on improved executive function and verbal memory. Fewer PTSD symptoms were reported. New studies at VA Boston include TBI patients treated with transcranial LED (26J/cm(2)); or treated with only intranasal red, 633nm and NIR, 810nm diodes placed into the nostrils (25 min, 6.5mW, 11.4J/cm(2)). Intranasal LEDs are hypothesized to deliver photons to hippocampus. Results are similar to Naeser et al. (2014). Actigraphy sleep data show increased sleep time (average, + 1 Hr/night) post-18th transcranial or intranasal LED treatment. LED treatments may be self-administered at home (Naeser et al., 2011). A sham-controlled study with Gulf War Illness Veterans is underway.
C1 [Naeser, Margaret A.; Martin, Paula I.; Ho, Michael D.; Krengel, Maxine H.; Bogdanova, Yelena; Knight, Jeffrey A.; Yee, Megan K.] VA Boston Healthcare Syst 12A, Boston, MA 02130 USA.
[Naeser, Margaret A.; Martin, Paula I.; Ho, Michael D.; Krengel, Maxine H.; Yee, Megan K.] Boston Univ, Dept Neurol, Sch Med, Boston, MA 02118 USA.
[Bogdanova, Yelena; Knight, Jeffrey A.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02118 USA.
[Knight, Jeffrey A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA USA.
[Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Cambridge, MA 02138 USA.
[Zafonte, Ross] Spaulding Rehabil Hosp, Charlestown, MA 02129 USA.
[Zafonte, Ross] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Zafonte, Ross] Brigham & Womens Hosp, Boston, MA 02114 USA.
[Frazier, Judith] Spaulding Rehabil Hosp, TBI Res Program, Charlestown, MA 02129 USA.
[Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Koo, Bang-Bon] Boston Univ, Ctr Biomed Imaging, Boston, MA 02118 USA.
RP Naeser, MA (reprint author), VA Boston Healthcare Syst 12A, 150 So Huntington Ave, Boston, MA 02130 USA.
EM mnaeser@bu.edu
OI Koo, Bang-bon/0000-0001-7423-5572
NR 129
TC 0
Z9 0
U1 1
U2 11
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-583-4
J9 PROC SPIE
PY 2015
VL 9467
AR 94670M
DI 10.1117/12.2176345
PG 21
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
Optics; Physics, Applied
SC Engineering; Science & Technology - Other Topics; Optics; Physics
GA BD0IX
UT WOS:000357259000015
ER
PT S
AU Zhang, YS
Wang, YC
Murray, CK
Hamblin, MR
Gu, Y
Dai, TH
AF Zhang, Yunsong
Wang, Yucheng
Murray, Clinton K.
Hamblin, Michael R.
Gu, Ying
Dai, Tianhong
BE George, T
Dutta, AK
Islam, MS
TI Antimicrobial blue light therapy for Candida albicans burn infection in
mice
SO MICRO- AND NANOTECHNOLOGY SENSORS, SYSTEMS, AND APPLICATIONS VII
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Micro- and Nanotechnology Sensors, Systems, and
Applications VII
CY APR 20-24, 2015
CL Baltimore, MD
SP SPIE
DE Photodynamic inactivation; endogenous porphyrins; fungus; animal model;
bioluminescence imagining
ID MRSA IN-VITRO; PHOTODYNAMIC THERAPY; PSEUDOMONAS-AERUGINOSA;
STREPTOCOCCUS-MUTANS; BACTERIA; INACTIVATION; RESISTANCE; BIOFILM;
EPIDEMIOLOGY; MECHANISMS
AB In this preclinical study, we investigated the utility of antimicrobial blue light therapy for Candida albicans infection in acutely burned mice. A bioluminescent strain of C. albicans was used. The susceptibilities to blue light inactivation were compared between C. albicans and human keratinocyte. In vitro serial passaging of C. albicans on blue light exposure was performed to evaluate the potential development of resistance to blue light inactivation. A mouse model of acute thermal burn injury infected with the bioluminescent strain of C. albicans was developed. Blue light (415 nm) was delivered to mouse burns for decolonization of C. albicans. Bioluminescence imaging was used to monitor in real time the extent of fungal infection in mouse burns. Experimental results showed that C. albicans was approximately 42-fold more susceptible to blue light inactivation in vitro than human keratinocyte (P=0.0022). Serial passaging of C. albicans on blue light exposure implied a tendency for the fungal susceptibility to blue light inactivation to decrease with the numbers of passages. Blue light reduced fungal burden by over 4-log10 (99.99%) in acute mouse burns infected with C. albicans in comparison to infected mouse burns without blue light therapy (P=0.015).
C1 [Zhang, Yunsong] Jinan Univ, Guangzhou Red Cross Hosp, Dept Burn & Plast Surg, Guangzhou 510760, Guangdong, Peoples R China.
[Zhang, Yunsong; Wang, Yucheng; Hamblin, Michael R.; Dai, Tianhong] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Zhang, Yunsong; Wang, Yucheng; Hamblin, Michael R.; Dai, Tianhong] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Wang, Yucheng; Gu, Ying] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing 100853, Peoples R China.
[Wang, Yucheng] Nankai Univ, Coll Med, Tianjin 300071, Peoples R China.
[Murray, Clinton K.] Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA.
RP Zhang, YS (reprint author), Jinan Univ, Guangzhou Red Cross Hosp, Dept Burn & Plast Surg, Guangzhou 510760, Guangdong, Peoples R China.
NR 43
TC 0
Z9 0
U1 0
U2 5
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-583-4
J9 PROC SPIE
PY 2015
VL 9467
AR 94670K
DI 10.1117/12.2178232
PG 13
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
Optics; Physics, Applied
SC Engineering; Science & Technology - Other Topics; Optics; Physics
GA BD0IX
UT WOS:000357259000014
ER
PT J
AU Koumarianou, A
Kaltsas, G
Kulke, MH
Oberg, K
Strosberg, JR
Spada, F
Galdy, S
Barberis, M
Fumagalli, C
Berruti, A
Fazio, N
AF Koumarianou, Anna
Kaltsas, Gregory
Kulke, Matthew H.
Oberg, Kjell
Strosberg, Jonathan R.
Spada, Francesca
Galdy, Salvatore
Barberis, Massimo
Fumagalli, Caterina
Berruti, Alfredo
Fazio, Nicola
TI Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and
Clinical Aspects
SO NEUROENDOCRINOLOGY
LA English
DT Article
DE Neuroendocrine neoplasms; Pancreatic neuroendocrine neoplasms;
Neuroendocrine carcinomas; Ki-67 labelling index; Progression-free
survival
ID ISLET-CELL-CARCINOMA; PHASE-II TRIAL; O-6-ALKYLGUANINE-DNA
ALKYLTRANSFERASE ACTIVITY; METHYLGUANINE-DNA METHYLTRANSFERASE;
PANCREATIC ENDOCRINE CARCINOMAS; O-6-METHYLGUANINE-DNA
METHYLTRANSFERASE; GLIOBLASTOMA-MULTIFORME; ALKYLATING-AGENTS; MALIGNANT
PARAGANGLIOMA; APLASTIC-ANEMIA
AB Alkylating agents, such as streptozocin and dacarbazine, have been reported as active in neuroendocrine neoplasms (NENs). Temozolomide (TMZ) is an oral, potentially less toxic derivative of dacarbazine, which has shown activity both as a single agent and in combination with other drugs. Nevertheless, its role in NENs has not been well defined. Several retrospective and prospective phase I-II studies have been published describing its use in a variety of NENs. In a retrospective series, the combination of capecitabine and TMZ was reported to be associated with a particularly high tumour response in pancreatic NENs as a first-line treatment. Although in NENs, determination of the CP-nnethylguanineDNA methyltransferase (MGMT) status has been suggested as a predictive biomarker of response, its role still remains investigational, awaiting validation along with the establishment of the optimal detection method. Metronomic schedules have been reported to potentially overcome MGMT-related drug resistance. Toxicity is manageable if well monitored. We reviewed the literature regarding pharmacological and clinical aspects of TMZ, focusing on specific settings of NENs, different schedules, toxicity and safety profiles, and potential predictive biomarkers of response. (C) 2015 S. Karger AG, Basel
C1 [Koumarianou, Anna] Attikon Univ Hosp, Hematol Oncol Unit, Dept Internal Med 4, GR-12462 Athens, Greece.
[Kaltsas, Gregory] Natl Tech Univ Athens, Dept Pathophysiol, Endocrine Unit, Athens, Greece.
[Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Strosberg, Jonathan R.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Oberg, Kjell] Univ Uppsala Hosp, Dept Endocrine Oncol, Uppsala, Sweden.
[Spada, Francesca; Galdy, Salvatore; Fazio, Nicola] European Inst Oncol, Gastrointestinal Med Oncol & Neuroendocrine Tumor, IT-20141 Milan, Italy.
[Barberis, Massimo; Fumagalli, Caterina] European Inst Oncol, Div Pathol, IT-20141 Milan, Italy.
[Berruti, Alfredo] Univ Brescia, Dipartimento Specialita Med Chirurg Sci Radiol &, Azienda Osped Spedali Civili, Brescia, Italy.
RP Koumarianou, A (reprint author), Attikon Univ Hosp, Hematol Oncol Unit, Dept Internal Med 4, Rimini 1, GR-12462 Athens, Greece.
EM akoumari@yahoo.com; nicola.fazio@ieo.it
OI Koumarianou, Anna/0000-0002-4159-2511; fazio, nicola/0000-0001-6869-0704
NR 86
TC 8
Z9 8
U1 1
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0028-3835
EI 1423-0194
J9 NEUROENDOCRINOLOGY
JI Neuroendocrinology
PY 2015
VL 101
IS 4
BP 274
EP 288
DI 10.1159/000430816
PG 15
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA CN0KV
UT WOS:000358103400002
PM 25924937
ER
PT J
AU Mirzakhani, H
van Noorden, MS
Swen, J
Nozari, A
Guchelaar, HJ
AF Mirzakhani, Hooman
van Noorden, Martijn S.
Swen, Jesse
Nozari, Ala
Guchelaar, Henk-Jan
TI Pharmacogenetics in electroconvulsive therapy and adjunctive medications
SO PHARMACOGENOMICS
LA English
DT Review
DE depression; ECT; efficacy; pharmacogenetics; safety
ID MAJOR DEPRESSIVE DISORDER; NEUROLEPTIC MALIGNANT SYNDROME;
TREATMENT-RESISTANT DEPRESSION; APOLIPOPROTEIN-E POLYMORPHISM;
POSITRON-EMISSION-TOMOGRAPHY; WHITE-MATTER ABNORMALITIES; 5-HT1A
RECEPTOR-BINDING; ADD-ON TRIAL; NEUROTROPHIC FACTOR; TREATMENT RESPONSE
AB Electroconvulsive therapy (ECT) has shown apparent efficacy in treatment of patients with depression and other mental illnesses who do not respond to psychotropic medications or need urgent control of their symptoms. Pharmacogenetics contributes to an individual's sensitivity and response to a variety of drugs. Clinical insights into pharmacogenetics of ECT and adjunctive medications not only improves its safety and efficacy in the indicated patients, but can also lead to the identification of novel treatments in psychiatric disorders through understanding of potential molecular and biological mechanisms involved. In this review, we explore the indications of pharmacogenetics role in safety and efficacy of ECT and present the evidence for its role in patients with psychiatric disorders undergoing ECT.
C1 [Mirzakhani, Hooman] Brigham & Womens Hosp, Channing Div Network Med, Dept Med, Boston, MA 02115 USA.
[Mirzakhani, Hooman] Harvard Univ, Sch Med, Div Biomed Informat, Boston, MA USA.
[Mirzakhani, Hooman; Swen, Jesse; Guchelaar, Henk-Jan] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands.
[van Noorden, Martijn S.] Leiden Univ, Med Ctr, Dept Psychiat, Leiden, Netherlands.
[Nozari, Ala] Massachusetts Gen Hosp, Dept Anesthesia, Orthoped Anesthesia Div, Boston, MA 02114 USA.
[Nozari, Ala] Harvard Univ, Sch Med, Boston, MA USA.
RP Guchelaar, HJ (reprint author), Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands.
EM h.j.guchelaar@lumc.nl
OI Mirzakhani, Hooman/0000-0002-2290-4436
NR 113
TC 1
Z9 1
U1 2
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PY 2015
VL 16
IS 9
BP 1015
EP 1031
DI 10.2217/pgs.15.57
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CM7IJ
UT WOS:000357864700010
PM 26115083
ER
PT J
AU Diamond, SJ
Sonnenberg, A
AF Diamond, Sarah J.
Sonnenberg, Amnon
TI A game theoretic approach to repeated foreign body ingestion
SO ENDOSCOPY
LA English
DT Editorial Material
ID ENDOSCOPY; BODIES
C1 Portland VA Med Ctr, Portland, OR USA.
[Diamond, Sarah J.; Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 5
TC 1
Z9 1
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0013-726X
EI 1438-8812
J9 ENDOSCOPY
JI Endoscopy
PY 2015
VL 47
SU 1
BP E79
EP E80
DI 10.1055/s-0034-1390920
PG 2
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA CL2RC
UT WOS:000356791200021
PM 25926224
ER
PT J
AU Hashash, JG
Habib-Bein, N
Khalid, A
Francis, FF
AF Hashash, Jana G.
Habib-Bein, Nadia
Khalid, Asif
Francis, Fadi F.
TI Recurrent bladder cancer presenting as rectal linitis plastica
SO ENDOSCOPY
LA English
DT Editorial Material
C1 [Hashash, Jana G.; Khalid, Asif; Francis, Fadi F.] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA.
[Habib-Bein, Nadia] Univ Pittsburgh, Dept Microbiol, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA.
RP Hashash, JG (reprint author), Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, 200 Lothrop St,M2,C Wing, Pittsburgh, PA 15213 USA.
EM alhashashj@upmc.edu
NR 2
TC 0
Z9 0
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0013-726X
EI 1438-8812
J9 ENDOSCOPY
JI Endoscopy
PY 2015
VL 47
SU 1
BP E102
EP E103
DI 10.1055/s-0034-1391300
PG 2
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA CL2RC
UT WOS:000356791200032
PM 25734804
ER
PT J
AU Logan, DE
Koo, KH
Kilmer, JR
Blayney, JA
Lewis, MA
AF Logan, Diane E.
Koo, Kelly H.
Kilmer, Jason R.
Blayney, Jessica A.
Lewis, Melissa A.
TI Use of Drinking Protective Behavioral Strategies and Sexual Perceptions
and Behaviors in US College Students
SO JOURNAL OF SEX RESEARCH
LA English
DT Article
ID ALCOHOL-RELATED CONSEQUENCES; NEGATIVE CONSEQUENCES; CONDOM USE;
HEAVY-DRINKING; 1ST YEAR; EXPECTANCIES; CONSUMPTION; ADOLESCENTS; RISK;
GENDER
AB Alcohol use among college students is linked to an increased likelihood of engaging in risky sexual behaviors, including casual sex and unprotected sex. These behaviors increase college students' risks for negative social and health-related consequences. This study examined the relationship between drinking behaviors and protective behavioral strategies (PBS), expectancies and perceptions of sexual risk, and actual alcohol-related sexual behaviors and consequences. Sexually active college students completed Web-based self-report measures of drinking behaviors and use of PBS, alcohol expectancies and perceptions of risk, and sexual behaviors and related consequences (n = 524; 57.1% women). Findings indicated that PBS were related to lower expectancies of sexual risk and sexual disinhibition, and among lighter drinkers, lower expectancies of sexual enhancement from alcohol. PBS were also related to decreased perceptions of sexual-related risks, some alcohol-related sexual behaviors, including number of drinks before/during sex, and number of sexual consequences, but were not related to abstaining during sex, frequency of alcohol-related sexual behaviors, or general condom use. These findings demonstrate a disconnect between perceived and actual risks among college students, such that decreased perceptions of risk may not be associated with protective behaviors. Prevention and intervention implications are discussed.
C1 [Logan, Diane E.] Brown Univ, Dept Behav & Social Sci, Providence, RI 02912 USA.
[Koo, Kelly H.] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA.
[Koo, Kelly H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Kilmer, Jason R.; Lewis, Melissa A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Kilmer, Jason R.] Univ Washington, Div Student Life, Hlth & Wellness, Seattle, WA 98195 USA.
[Blayney, Jessica A.] SUNY Buffalo, Dept Psychol, Buffalo, NY 14260 USA.
RP Logan, DE (reprint author), Brown Univ, Sch Publ Hlth, Dept Behav & Social Sci, Ctr Alcohol & Addict Studies, Box G-S121-4, Providence, RI 02912 USA.
EM diane_logan@brown.edu
FU National Institute on Alcohol Abuse and Alcoholism [K01AA016966,
1F31AA018238-01A1, 2T32AA007459]
FX Data collection and manuscript preparation was supported by National
Institute on Alcohol Abuse and Alcoholism Grant K01AA016966 awarded to
M. A. Lewis. Manuscript preparation was supported by National Institute
on Alcohol Abuse and Alcoholism Grant 1F31AA018238-01A1 awarded to D. E.
Logan and National Institute on Alcohol Abuse and Alcoholism Grant
2T32AA007459 awarded to P. Monti.
NR 66
TC 1
Z9 1
U1 6
U2 13
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0022-4499
EI 1559-8519
J9 J SEX RES
JI J. Sex Res.
PY 2015
VL 52
IS 5
BP 558
EP 569
DI 10.1080/00224499.2014.964167
PG 12
WC Psychology, Clinical; Social Sciences, Interdisciplinary
SC Psychology; Social Sciences - Other Topics
GA CM1FA
UT WOS:000357425100007
PM 25350078
ER
PT J
AU Sawatsky, AP
Zickmund, SL
Berlacher, K
Lesky, D
Granieri, R
AF Sawatsky, Adam P.
Zickmund, Susan L.
Berlacher, Kathryn
Lesky, Dan
Granieri, Rosanne
TI Understanding the challenges to facilitating active learning in the
resident conferences: a qualitative study of internal medicine faculty
and resident perspectives
SO MEDICAL EDUCATION ONLINE
LA English
DT Article
DE medical education; graduate medical education; conference; lecture;
active learning; lifelong learning
ID TRAINING EXAMINATION SCORES; CONFERENCE ATTENDANCE; NOON CONFERENCE;
EDUCATION.; PROGRAMS
AB Background: In the Next Accreditation System, the Accreditation Council for Graduate Medical Education outlines milestones for medical knowledge and requires regular didactic sessions in residency training. There are many challenges to facilitating active learning in resident conferences, and we need to better understand resident learning preferences and faculty perspectives on facilitating active learning. The goal of this study was to identify challenges to facilitating active learning in resident conferences, both through identifying specific implementation barriers and identifying differences in perspective between faculty and residents on effective teaching and learning strategies.
Methods: The investigators invited core residency faculty to participate in focus groups. The investigators used a semistructured guide to facilitate discussion about learning preferences and teaching perspectives in the conference setting and used an 'editing approach' within a grounded theory framework to qualitative analysis to code the transcripts and analyze the results. Data were compared to previously collected data from seven resident focus groups.
Results: Three focus groups with 20 core faculty were conducted. We identified three domains pertaining to facilitating active learning in resident conferences: barriers to facilitating active learning formats, similarities and differences in faculty and resident learning preferences, and divergence between faculty and resident opinions about effective teaching strategies. Faculty identified several setting, faculty, and resident barriers to facilitating active learning in resident conferences. When compared to residents, faculty expressed similar learning preferences; the main differences were in motivations for conference attendance and type of content. Resident preferences and faculty perspectives differed on the amount of information appropriate for lecture and the role of active participation in resident conferences.
Conclusion: This study highlights several challenges to facilitating active learning in resident conferences and provides insights for residency faculty who seek to transform the conference learning environment within their residency program.
C1 [Sawatsky, Adam P.] Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA.
[Zickmund, Susan L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Berlacher, Kathryn] Univ Pittsburgh, Sch Med, Div Cardiol, Pittsburgh, PA USA.
[Lesky, Dan] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Granieri, Rosanne] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA.
RP Sawatsky, AP (reprint author), Mayo Clin, Div Gen Internal Med, 200 1st St SW, Rochester, MN 55905 USA.
EM sawatsky.adam@mayo.edu
FU Division of General Internal Medicine; Faculty Award at the University
of Pittsburgh
FX The authors thank the Division of General Internal Medicine Fellow and
Faculty Award at the University of Pittsburgh for funding this project.
NR 28
TC 0
Z9 0
U1 1
U2 6
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1087-2981
J9 MED EDUC ONLINE
JI Med. Educ. Online
PY 2015
VL 20
AR 27289
DI 10.3402/meo.v20.27289
PG 7
WC Education & Educational Research
SC Education & Educational Research
GA CM3MN
UT WOS:000357586500001
PM 26160805
ER
PT J
AU Madigan, MC
McEnaney, RM
Shukla, AJ
Hong, GY
Kelley, EE
Tarpey, MM
Gladwin, M
Zuckerbraun, BS
Tzeng, E
AF Madigan, Michael C.
McEnaney, Ryan M.
Shukla, Ankur J.
Hong, Guiying
Kelley, Eric E.
Tarpey, Margaret M.
Gladwin, Mark
Zuckerbraun, Brian S.
Tzeng, Edith
TI Xanthine Oxidoreductase Function Contributes to Normal Wound Healing
SO MOLECULAR MEDICINE
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; EGF-RECEPTOR PHOSPHORYLATION;
ISCHEMIA-REPERFUSION INJURY; ENDOTHELIAL GROWTH-FACTOR; IMPAIRED SKIN
REPAIR; MIGRATION IN-VITRO; OXIDATIVE STRESS; HYDROGEN-PEROXIDE;
DEFICIENT MICE; REDOX CONTROL
AB Chronic, nonhealing wounds result in patient morbidity and disability. Reactive oxygen species (ROS) and nitric oxide (NO) are both required for normal wound repair, and derangements of these result in impaired healing. Xanthine oxidoreductase (XOR) has the unique capacity to produce both ROS and NO. We hypothesize that XOR contributes to normal wound healing. Cutaneous wounds were created in C57Bl6 mice. XOR was inhibited with dietary tungsten or allopurinol. Topical hydrogen peroxide (H2O2, 0.15%) or allopurinol (30 mu g) was applied to wounds every other day. Wounds were monitored until closure or collected at d 5 to assess XOR expression and activity, cell proliferation and histology. The effects of XOR, nitrite, H2O2 and allopurinol on keratinocyte cell (KC) and endothelial cell (EC) behavior were assessed. We identified XOR expression and activity in the skin and wound edges as well as granulation tissue. Cultured human KCs also expressed XOR. Tungsten significantly inhibited XOR activity and impaired healing with reduced ROS production with reduced angiogenesis and KC proliferation. The expression and activity of other tungsten-sensitive enzymes were minimal in the wound tissues. Oral allopurinol did not reduce XOR activity or alter wound healing but topical allopurinol significantly reduced XOR activity and delayed healing. Topical H2O2 restored wound healing in tungsten-fed mice. In vitro, nitrite and H2O2 both stimulated KC and EC proliferation and EC migration. These studies demonstrate for the first time that XOR is abundant in wounds and participates in normal wound healing through effects on ROS production.
C1 [Madigan, Michael C.; McEnaney, Ryan M.; Shukla, Ankur J.; Hong, Guiying; Tarpey, Margaret M.; Zuckerbraun, Brian S.; Tzeng, Edith] Dept Vet Affairs Med Ctr, Surg Serv, Pittsburgh, PA USA.
[Madigan, Michael C.; McEnaney, Ryan M.; Shukla, Ankur J.; Hong, Guiying; Zuckerbraun, Brian S.; Tzeng, Edith] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Kelley, Eric E.; Tarpey, Margaret M.] Univ Pittsburgh, Dept Anesthesia, Pittsburgh, PA USA.
[Gladwin, Mark] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
RP Tzeng, E (reprint author), VA Pittsburgh Healthcare Syst, Vasc Surg, A1010 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM tzenge@upmc.edu
FU Department of Veterans Affairs, Veterans Health Administration; Office
of Biomedical Laboratory Research and Development - National Institutes
of Health (NIH) [NIH T32 HL098036, NIH R01 HL058115]; NIH [R01HL098032,
R01HL096973, PO1HL103455]; Institute for Transfusion Medicine;
Hemophilia Center of Western Pennsylvania
FX We gratefully acknowledge the excellent technical assistance provided by
NJ Hundley, SI Zharikov and N Cantu-Medellin. This material is based on
work supported in part by the Department of Veterans Affairs, Veterans
Health Administration and Office of Biomedical Laboratory Research and
Development (ET), through funding from the National Institutes of Health
(NIH) (NIH T32 HL098036 to MC Madigan, RM McEnaney and AJ Shukla and NIH
R01 HL058115 to MM Tarpey). M Gladwin received research support from NIH
grants R01HL098032, R01HL096973 and PO1HL103455 as well as from the
Institute for Transfusion Medicine and the Hemophilia Center of Western
Pennsylvania.
NR 51
TC 4
Z9 4
U1 2
U2 8
PU FEINSTEIN INST MED RES
PI MANHASSET
PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PY 2015
VL 21
BP 313
EP 322
DI 10.2119/molmed.2014.00191
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA CM4JW
UT WOS:000357651800008
PM 25879627
ER
PT S
AU Schwartz, E
Jakab, A
Kasprian, G
Zollei, L
Langs, G
AF Schwartz, Ernst
Jakab, Andras
Kasprian, Gregor
Zoellei, Lilla
Langs, Georg
BE Durrleman, S
Fletcher, T
Gerig, G
Niethammer, M
Pennec, X
TI A Locally Linear Method for Enforcing Temporal Smoothness in Serial
Image Registration
SO SPATIO-TEMPORAL IMAGE ANALYSIS FOR LONGITUDINAL AND TIME-SERIES IMAGE
DATA
SE Lecture Notes in Computer Science
LA English
DT Proceedings Paper
CT 3rd International Workshop on Spatiotemporal Image Analysis for
Longitudinal and Time-Series Image Data (STIA)
CY SEP 18, 2014
CL Boston, MA
SP Sci Comp & Imaging Inst, Natl Alliance Med Image Comp, Ctr Rech, Inst Cerveau Moelle Epiniere
ID IN-UTERO; BRAIN; ATLAS; DIFFEOMORPHISMS; DEFORMATION; TEMPLATE
AB Deformation fields obtained from image registration are commonly used for deriving measurements of morphological changes between reference and follow-up images. As the underlying image matching problem is ill-posed, the exact shape of these deformation fields is often dependent on the regularization method. In longitudinal and cross-sectional studies this effect is amplified if time between acquisitions varies and smoothness between serial deformations is neglected. Existing solutions suffer from high computational costs, strong modeling assumptions and the bias towards a single reference image. In this paper, we propose a computationally efficient solution to this problem via a temporal smoothing formulation in the one-parameter subgroup of diffeomorphisms parametrized by stationary velocity fields. When applied to modeling fetal brain development, the proposed regularization results in smooth deformation fields over time and high data fidelity.
C1 [Schwartz, Ernst; Jakab, Andras; Langs, Georg] Med Univ Vienna, CIR Lab, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria.
[Schwartz, Ernst; Jakab, Andras; Kasprian, Gregor; Langs, Georg] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria.
[Zoellei, Lilla] Massachusetts Gen Hosp, Lab Computat Neuroimaging, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
RP Schwartz, E (reprint author), Med Univ Vienna, CIR Lab, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria.
EM ernst.schwartz@meduniwien.ac.at
OI Kasprian, Gregor/0000-0003-3858-3347
NR 29
TC 2
Z9 2
U1 2
U2 2
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 978-3-319-14905-9; 978-3-319-14904-2
J9 LECT NOTES COMPUT SC
PY 2015
VL 8682
BP 13
EP 24
DI 10.1007/978-3-319-14905-9_2
PG 12
WC Computer Science, Artificial Intelligence; Computer Science, Theory &
Methods
SC Computer Science
GA BD0SU
UT WOS:000357678700002
ER
PT J
AU Yang, AM
Xiao, X
Zhao, MF
LaRue, AC
Schulte, BA
Wang, GY
AF Yang, Aimin
Xiao, Xia
Zhao, Mingfeng
LaRue, Amanda C.
Schulte, Bradley A.
Wang, Gavin Y.
TI Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR
Inhibition
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; MAMMALIAN TARGET; ANTITUMOR-ACTIVITY; RAPAMYCIN;
PTEN; PATHWAY; AZD8055; CANCER; LEUKEMOGENESIS; SENESCENCE
AB Abnormal activation of the mammalian target of rapamycin (mTOR) signaling pathway has been observed in a variety of human cancers. Therefore, targeting of the mTOR pathway is an attractive strategy for cancer treatment and several mTOR inhibitors, including AZD8055 (AZD), a novel dual mTORC1/2 inhibitor, are currently in clinical trials. Although bone marrow (BM) suppression is one of the primary side effects of anticancer drugs, it is not known if pharmacological inhibition of dual mTORC1/2 affects BM hematopoietic stem and progenitor cells (HSPCs) function and plasticity. Here we report that dual inhibition of mTORC1/2 by AZD or its analogue (KU-63794) depletes mouse BM Lin(-)Sca-1(+)c-Kit(+) cells in cultures via the induction of apoptotic cell death. Subsequent colony-forming unit (CFU) assays revealed that inhibition of mTORC1/2 suppresses the clonogenic function of hematopoietic progenitor cells (HPCs) in a dose-dependent manner. Surprisingly, we found that dual inhibition of mTORC1/2 markedly inhibits the growth of day-14 cobblestone area-forming cells (CAFCs) but enhances the generation of day-35 CAFCs. Given the fact that day-14 and day-35 CAFCs are functional surrogates of HPCs and hematopoietic stem cells (HSCs), respectively, these results suggest that dual inhibition of mTORC1/2 may have distinct effects on HPCs versus HSCs.
C1 [Yang, Aimin; Xiao, Xia; LaRue, Amanda C.; Schulte, Bradley A.; Wang, Gavin Y.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Xiao, Xia; Zhao, Mingfeng] Tianjin First Ctr Hosp, Dept Hematol, Tianjin 300192, Peoples R China.
[LaRue, Amanda C.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA.
[LaRue, Amanda C.; Wang, Gavin Y.] Med Univ S Carolina, Hollings Canc Ctr, Canc Genes & Mol Regulat Program, Charleston, SC 29425 USA.
RP Wang, GY (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
EM wangy@musc.edu
FU National Heart, Lung and Blood Institute (NHLBI) [HL106451]; Hollings
Cancer Center [P30 CA138313]; South Carolina Clinical & Translational
Research (SCTR) Institute; Medical University of South Carolina CTSA,
NIH/NCATS Grant [UL1TR000062]
FX This study was supported, in part, by a Grant from the National Heart,
Lung and Blood Institute (NHLBI) no. HL106451 (Gavin Y. Wang) and a
pilot grant from the Hollings Cancer Center (Gavin Y. Wang) via P30
CA138313. This work was also supported in part by the South Carolina
Clinical & Translational Research (SCTR) Institute, with an academic
home at the Medical University of South Carolina CTSA, NIH/NCATS Grant
no. UL1TR000062.
NR 31
TC 1
Z9 1
U1 0
U2 2
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1687-966X
EI 1687-9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2015
AR 561404
DI 10.1155/2015/561404
PG 9
WC Cell & Tissue Engineering
SC Cell Biology
GA CM6QG
UT WOS:000357813000001
ER
PT J
AU Nadol, JB
Marshall, JD
Bronson, RT
AF Nadol, Joseph B., Jr.
Marshall, Jan D.
Bronson, Roderick T.
TI Histopathology of the Human Inner Ear in Alstrom's Syndrome
SO AUDIOLOGY AND NEURO-OTOLOGY
LA English
DT Article
DE Alstrom's syndrome; ALMS1; Human; Histopathology; Inner ear
ID ALMS1; DEAFNESS
AB Alstrom's syndrome is an autosomal recessive syndromic genetic disorder caused by mutations in the ALMS1 gene. Sensorineural hearing loss occurs in greater than 85% of patients. Histopathology of the inner ear abnormalities in the human has not previously been fully described. Histopathology of the inner ear in Alstrom's syndrome is presented in 2 genetically confirmed cases. The predominant histopathologic correlates of the sensorineural loss were degeneration of the organ of Corti, both inner and outer hair cells, degeneration of spiral ganglion cells, and atrophy of the stria vascularis and spiral ligament. (C) 2015 S. Karger AG, Basel
C1 [Nadol, Joseph B., Jr.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Otopathol Lab, Boston, MA 02115 USA.
[Nadol, Joseph B., Jr.; Bronson, Roderick T.] Harvard Univ, Sch Med, Boston, MA USA.
[Marshall, Jan D.; Bronson, Roderick T.] Jackson Lab, Bar Harbor, ME 04609 USA.
RP Nadol, JB (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02115 USA.
EM joseph_nadol@meei.harvard.edu
FU NIH grant [HD036878, U24DC011943]
FX Supported by: NIH grant HD036878 (J.D.M.) and NIH grant U24DC011943
(J.B.N.).
NR 15
TC 1
Z9 1
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1420-3030
EI 1421-9700
J9 AUDIOL NEURO-OTOL
JI Audiol. Neuro-Otol.
PY 2015
VL 20
IS 4
BP 267
EP 272
DI 10.1159/000381935
PG 6
WC Audiology & Speech-Language Pathology; Neurosciences;
Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Neurosciences & Neurology;
Otorhinolaryngology
GA CM3PV
UT WOS:000357596100008
PM 26111748
ER
PT B
AU Silva, GV
Palacios, IF
AF Silva, Guilherme V.
Palacios, Igor F.
BE Sievert, H
Qureshi, SA
Wilson, N
Hijazi, ZM
TI Transseptal left heart catheterization
SO INTERVENTIONS IN STRUCTURAL, VALVULAR, AND CONGENITAL HEART DISEASE
LA English
DT Article; Book Chapter
ID TRANS-SEPTAL CATHETERIZATION; CARDIAC-CATHETERIZATION; LEFT ATRIAL;
COMPLICATIONS; EXPERIENCE; DISEASE; SAFETY
C1 [Silva, Guilherme V.] Texas Heart Inst, Houston, TX 77025 USA.
[Palacios, Igor F.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Silva, GV (reprint author), Texas Heart Inst, Houston, TX 77025 USA.
NR 34
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4822-1564-9; 978-1-4822-1563-2
PY 2015
BP 145
EP 152
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA BC7ZN
UT WOS:000355441100016
ER
PT B
AU Palacios, IF
Silva, GV
AF Palacios, Igor F.
Silva, Guilherme V.
BE Sievert, H
Qureshi, SA
Wilson, N
Hijazi, ZM
TI Mitral and tricuspid valve stenosis: Percutaneous mitral valvuloplasty
SO INTERVENTIONS IN STRUCTURAL, VALVULAR, AND CONGENITAL HEART DISEASE
LA English
DT Article; Book Chapter
ID LEFT-HEART CATHETERIZATION; PREVIOUS SURGICAL COMMISSUROTOMY;
TRANS-SEPTAL CATHETERIZATION; BALLOON VALVOTOMY; FOLLOW-UP; TRANSSEPTAL
CATHETERIZATION; CARDIAC-CATHETERIZATION; LEFT ATRIAL; RANDOMIZED-TRIAL;
ADULT PATIENTS
C1 [Palacios, Igor F.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Silva, Guilherme V.] Texas Heart Inst, Houston, TX 77025 USA.
RP Palacios, IF (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
NR 70
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4822-1564-9; 978-1-4822-1563-2
PY 2015
BP 349
EP 360
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA BC7ZN
UT WOS:000355441100039
ER
PT J
AU Gustafson, DR
Morris, MC
Scarmeas, N
Shah, RC
Sijben, J
Yaffe, K
Zhu, XW
AF Gustafson, Deborah R.
Morris, Martha Clare
Scarmeas, Nikolaos
Shah, Raj C.
Sijben, John
Yaffe, Kristine
Zhu, Xiongwei
TI New Perspectives on Alzheimer's Disease and Nutrition
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; cognition disorders; diet therapy; neuronal
membrane; nutrition
ID MILD COGNITIVE IMPAIRMENT; BODY-MASS INDEX; POLYUNSATURATED FATTY-ACID;
DOCOSAHEXAENOIC ACID; MEDITERRANEAN DIET; OXIDATIVE STRESS; VITAMIN-E;
CONTROLLED-TRIAL; OLDER-ADULTS; CARDIOVASCULAR-DISEASE
AB Accumulating evidence shows nutritional factors influence the risk of developing Alzheimer's disease (AD) and its rate of clinical progression. Dietary and lifestyle guidelines to help adults reduce their risk have been developed. However, the clinical dementia picture remains complex, and further evidence is required to demonstrate that modifying nutritional status can protect the brain and prevent, delay, or reduce pathophysiological consequences of AD. Moreover, there is a pressing need for further research because of the global epidemic of overweight and obesity combined with longer life expectancy of the general population and generally observed decreases in body weight with aging and AD. A new research approach is needed, incorporating more sophisticated models to account for complex scenarios influencing the relationship between nutritional status and AD. Systematic research should identify and address evidence gaps. Integrating longitudinal epidemiological data with biomarkers of disease, including brain imaging technology, and randomized controlled interventions may provide greater insights into progressive and subtle neurological changes associated with dietary factors in individuals at risk for or living with AD. In addition, greater understanding of mechanisms involved in nutritional influences on AD risk and progression, such as oxidative stress and loss of neuronal membrane integrity, will better inform possible interventional strategies. There is consensus among the authors that nutritional deficits, and even states of excess, are associated with AD, but more work is needed to determine cause and effect. Appropriately designed diets or nutritional interventions may play a role, but additional research is needed on their clinical-cognitive effectiveness.
C1 [Gustafson, Deborah R.] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA.
[Gustafson, Deborah R.] Univ Gothenburg, Sect Psychiat & Neurochem, NeuroPsychiat Epidemiol Unit, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden.
[Morris, Martha Clare] Rush Univ, Med Ctr, Dept Internal Med, Sect Nutr & Nutr Epidemiol, Chicago, IL 60612 USA.
[Scarmeas, Nikolaos] Columbia Univ, Gertrude H Sergievsky Ctr, Dept Neurol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10027 USA.
[Scarmeas, Nikolaos] Univ Athens, Dept Social Med Psychiat & Neurol, Athens 11528, Greece.
[Shah, Raj C.] Rush Univ, Med Ctr, Dept Family Med, Chicago, IL 60612 USA.
[Shah, Raj C.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA.
[Sijben, John] Nutricia Res, Nutricia Adv Med Nutr, Utrecht, Netherlands.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Zhu, Xiongwei] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
RP Yaffe, K (reprint author), Univ Calif San Francisco, Psychiat, 4150 Clement St, San Francisco, CA 94121 USA.
EM kristine.yaffe@ucsf.edu
FU Swedish Research Council for Health, Working Life and Welfare [AGECAP
2013-2300]; EU [211696]; ESPA-EU program Excellence Grant (ARISTEIA)
[189 10276/8/9/2011]; European Social Fund; Greek National resources;
Ministry for Health and Social Solidarity (Greece)
[DeltaY2beta/oiotakappa.51657/14.4.2009]; Illinois Department of Public
Health; National Institute on Aging; National Institute on Environmental
Health Sciences
FX The authors received the following support: Deborah R. Gustafson:
Swedish Research Council for Health, Working Life and Welfare (AGECAP
2013-2300) and EU 7th framework LipiDiDiet project (FP7/2007-2015) under
grant agreement no. 211696; Nikolaos Scarmeas: 189 10276/8/9/2011 from
the ESPA-EU program Excellence Grant (ARISTEIA) which is co-funded by
the European Social Fund and Greek National resources; and Delta Y2
beta/o iota kappa.51657/14.4.2009 from the Ministry for Health and
Social Solidarity (Greece); Raj C Shah: The Illinois Department of
Public Health; Morris MC: National Institute on Aging and National
Institute on Environmental Health Sciences.
NR 143
TC 7
Z9 7
U1 4
U2 16
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 46
IS 4
BP 1111
EP 1127
DI 10.3233/JAD-150084
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA CM1GM
UT WOS:000357429300026
PM 26402637
ER
PT S
AU Davis, CP
West, JA
AF Davis, Christopher P.
West, Jason A.
BE Nakagawa, S
Hirose, T
TI Purification of Specific Chromatin Regions Using Oligonucleotides:
Capture Hybridization Analysis of RNA Targets (CHART)
SO NUCLEAR BODIES AND NONCODING RNAS: METHODS AND PROTOCOLS
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE CHART; RNA; lncRNA; lincRNA; ncRNA; Chromatin
ID NONCODING RNA; MAPS
AB cation of genomic binding sites and proteins associated with noncoding RNAs will lead to more complete mechanistic characterization of the regulatory activities of noncoding RNAs. Capture hybridization analysis of RNA targets (CHART) is a powerful technique wherein specific RNA molecules are isolated from cross-linked nuclear extracts using complementary, biotinylated capture oligonucleotides, allowing subsequent identification of genomic DNA and proteins cross-linked to the RNA of interest. Here, we describe the procedure for CHART and list strategies to optimize nuclear extract preparation, capture oligonucleotide design, and isolation of nucleic acids and proteins enriched through CHART.
C1 [Davis, Christopher P.; West, Jason A.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Davis, Christopher P.; West, Jason A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[West, Jason A.] Amgen Inc, Therapeut Innovat Unit, Cambridge, MA USA.
RP Davis, CP (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
RI West, Jason/I-4445-2014
OI West, Jason/0000-0002-7252-8651
NR 5
TC 3
Z9 3
U1 1
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-4939-2253-6; 978-1-4939-2252-9
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2015
VL 1262
BP 167
EP 182
DI 10.1007/978-1-4939-2253-6_10
D2 10.1007/978-1-4939-2253-6
PG 16
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Genetics
& Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA BD0TO
UT WOS:000357692500011
PM 25555581
ER
PT J
AU McDonald, LT
Mehrotra, M
LaRue, AC
AF McDonald, Lindsay T.
Mehrotra, Meenal
LaRue, Amanda C.
TI Hematopoietic Origin of Murine Lung Fibroblasts
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID INDUCED PULMONARY-FIBROSIS; MESENCHYMAL STEM-CELLS; BONE-MARROW;
CIRCULATING FIBROCYTES; IN-VITRO; MYOFIBROBLASTS; IDENTIFICATION;
RECONSTITUTION; PROLIFERATION; PRECURSORS
AB Multiple origins, including the bone marrow, have been suggested to contribute to fibroblast populations in the lung. Using bone marrow reconstitution strategies, the present study tested the hypothesis that the bone marrow hematopoietic stem cell (HSC) gives rise to lung tissue fibroblasts in vivo. Data demonstrate that the nonadherent bone marrow fraction is enriched for CD45(+) HSC-derived cells and was able to reconstitute hematopoiesis in lethally irradiated animals. Analysis of peripheral blood and lung tissues from engrafted mice demonstrated the ability of this population to give rise to CD45(+)/Discoidin-Domain Receptor-2(+) (DDR2) circulating fibroblast precursors (CFPs) in blood and fibroblast populations in lung. An HSC origin for lung fibroblasts was confirmed using a novel clonal cell transplantation method in which the bone marrow is reconstituted by a clonal population derived from a single HSC. Together, these findings provide evidence for an HSC contribution to lung fibroblasts and demonstrate a circulating intermediate through the CD45(+)/DDR2(+) HSC-derived CFP.
C1 [McDonald, Lindsay T.; LaRue, Amanda C.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
[McDonald, Lindsay T.; Mehrotra, Meenal; LaRue, Amanda C.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[LaRue, Amanda C.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
RP LaRue, AC (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
EM laruerc@musc.edu
FU VA [BX-12-011]
FX This work was supported by a VA merit awarded to Amanda C. LaRue
(BX-12-011). The authors thank the staff of the Radiation Oncology
Department of the Medical University of South Carolina in irradiation of
mice, and the animal care staff of the Ralph H. Johnson VAMC. They also
acknowledge the Hollings Cancer Center Flow Cytometry Core P30 CA138313.
NR 41
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1687-966X
EI 1687-9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2015
AR 159713
DI 10.1155/2015/159713
PG 11
WC Cell & Tissue Engineering
SC Cell Biology
GA CM2EY
UT WOS:000357493800001
ER
PT J
AU Yin, R
Hamblin, MR
AF Yin, Rui
Hamblin, Michael R.
TI Antimicrobial Photosensitizers: Drug Discovery Under the Spotlight
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Antimicrobial photodynamic therapy; bacteria; bacteriochlorin; chlorin;
fullerene; fungi; infection; natural product; phenothiazinium salt;
phthalocyanine; porphyrin; titania photocatalysis; xanthene dye
ID MEDIATED PHOTODYNAMIC THERAPY; STAPHYLOCOCCUS-EPIDERMIDIS BIOFILMS;
TOLUIDINE-BLUE-O; RESISTANT PSEUDOMONAS-AERUGINOSA; HELICOBACTER-PYLORI
INFECTION; SINGLET OXYGEN GENERATION; GRAM-NEGATIVE BACTERIA;
N-METHYL-PYRIDYL; IN-VITRO; CANDIDA-ALBICANS
AB Although photodynamic therapy (PDT) was discovered over a hundred years ago by its ability to destroy microorganisms, it has been developed mainly as a cancer therapy. In recent years, due to the inexorable rise in multi-antibiotic resistant strains of pathogens, PDT is being considered as a versatile antimicrobial approach to which microbial cells will not be able to develop resistance. The goal of this review is to survey the different classes of chemical compounds that have been tested as antimicrobial . Some of these compounds have been known for many years, while others have been rationally designed based on recently discovered structural principles. Tetrapyrrole-based compounds (some of which are approved as cancer therapies) that efficiently generate singlet oxygen are more efficient and broad-spectrum when they bear cationic charges, As the macrocycle structure moves from porphyrins to chlorins to phthalocyanines to bacteriochlorins the long wavelength absorption moves to the near-infrared where tissue penetration is better. Four main types of natural products have been tested: curcumin, riboflavin, hypericin and psoralens. Phenothiazinium dyes, such as methylene blue and toluidine blue, have been tested, and some are clinically approved. A variety of non-phenothiazinium dyes with xanthene, triarylmethane and indocyanine structures have also been tested. New ring structures based on BODIPY, squaraine and fullerene cages can also mediate antimicrobial PDT. Finally the process of photocatalysis using titanium dioxide can also have medical uses. Designing new antimicrobial photosensitizers is likely to keep chemists engaged for a long time to come.
C1 [Yin, Rui] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing 40038, Peoples R China.
[Yin, Rui; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Yin, Rui; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.
EM Hamblin@helix.mgh.harvard.edu
FU NIH [R01AI050875]
FX Michael R Hamblin is supported by NIH grant R01AI050875.
NR 235
TC 11
Z9 11
U1 15
U2 71
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2015
VL 22
IS 18
BP 2159
EP 2185
PG 27
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA CL5ZL
UT WOS:000357044400005
PM 25787964
ER
PT S
AU Jordan, JT
Wen, PY
AF Jordan, Justin T.
Wen, Patrick Y.
BE Raizer, J
Parsa, A
TI Novel Chemotherapeutic Approaches in Adult High-Grade Gliomas
SO CURRENT UNDERSTANDING AND TREATMENT OF GLIOMAS
SE Cancer Treatment and Research
LA English
DT Article; Book Chapter
DE Glioma; Glioblastoma; Targeted therapy; Chemotherapy
ID RECURRENT MALIGNANT GLIOMA; PHASE-II TRIAL; NEWLY-DIAGNOSED
GLIOBLASTOMA; BRAIN-TUMOR CONSORTIUM; GROWTH-FACTOR RECEPTOR; EGFR
KINASE INHIBITORS; ADVANCED SOLID TUMORS; RADIATION-THERAPY; IMATINIB
MESYLATE; I/II TRIAL
AB Despite decades of advancing science and clinical trials, average survival remains dismal for individuals with high-grade gliomas. Our understanding of the genetic and molecular aberrations that contribute to the aggressive nature of these tumors is continually growing, as is our ability to target such specific traits. Herein, we review the major classes of such targeted therapies, as well as the relevant clinical trial outcomes regarding their efficacy.
C1 [Jordan, Justin T.; Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02215 USA.
[Wen, Patrick Y.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Neurooncol,Dept Neurol, Boston, MA 02115 USA.
RP Wen, PY (reprint author), Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM pwen@partners.org
NR 121
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0927-3042
BN 978-3-319-12048-5; 978-3-319-12047-8
J9 CANCER TREAT RES
JI Canc. Treat. Res.
PY 2015
VL 163
BP 117
EP 142
D2 10.1007/978-3-319-12048-5
PG 26
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA BD0KN
UT WOS:000357285600008
PM 25468229
ER
PT J
AU Hoggatt, KJ
Jamison, AL
Lehavot, K
Cucciare, MA
Timko, C
Simpson, TL
AF Hoggatt, Katherine J.
Jamison, Andrea L.
Lehavot, Keren
Cucciare, Michael A.
Timko, Christine
Simpson, Tracy L.
TI Alcohol and Drug Misuse, Abuse, and Dependence in Women Veterans
SO EPIDEMIOLOGIC REVIEWS
LA English
DT Article
DE alcohol; drugs; gender; military; substance-related disorders; veterans;
women
ID SUBSTANCE USE DISORDERS; POSTTRAUMATIC-STRESS-DISORDER; VA HEALTH-CARE;
NURSING-HOME RESIDENTS; FEMALE VETERANS; MENTAL-HEALTH; AFGHANISTAN
VETERANS; GENDER-DIFFERENCES; UNITED-STATES; MILITARY SERVICE
AB We conducted a systematic literature review on substance misuse, abuse, and dependence in women veterans, including National Guard/reserve members. We identified 837 articles published between 1980 and 2013. Of 56 included studies, 32 reported rates of alcohol misuse, binge drinking, or other unhealthy alcohol use not meeting diagnostic criteria for abuse or dependence, and 33 reported rates of drug misuse or diagnosed alcohol or drug use disorders. Rates ranged from 4% to 37% for alcohol misuse and from 7% to 25% for binge drinking; among Veterans Health Administration (VA) health-care system outpatients, rates ranged from 3% to 16% for substance use disorder. Studies comparing women veterans and civilians reported no clear differences in binge or heavy drinking. Substance misuse rates were generally lower among women veterans than men veterans. Substance misuse was associated with higher rates of trauma, psychiatric and medical conditions, and increased mortality and suicide rates. Most studies included only VA patients, and many used only VA medical record data; therefore, the reported substance misuse rates likely do not reflect true prevalence. Rates also varied by assessment method, source of data, and the subgroups studied. Further efforts to develop epidemiologically valid prevalence estimates are needed to capture the true health burden of substance misuse in women veterans, particularly those not using VA care.
C1 [Hoggatt, Katherine J.] VA Greater Los Angeles, Hlth Serv Res & Dev Ctr, Study Healthcare Innovat Implementat & Policy, Sepulveda, CA 91343 USA.
RP Hoggatt, KJ (reprint author), VA Greater Los Angeles, Hlth Serv Res & Dev Ctr, Study Healthcare Innovat Implementat & Policy, 16111 Plummer St Mailstop 152, Sepulveda, CA 91343 USA.
EM khoggatt@ucla.edu
FU VA HSRD [SDR 10-012, CX 000867, CDA 08-004-3, RCS 00-001]; VA HSRD/QUERI
[CDA 11-261]
FX This work was supported by VA HSR&D (SDR 10-012), with excerpts
presented at the VA Substance Use Disorder Workgroup of the Women's
Health Research Consortium. Funding was also provided through a VA
HSR&D/QUERI Career Development Award (CDA 11-261) to K. J. H., a VA
CSR&D Career Development Award (CX 000867) to K. L., a VA HSR&D Career
Development Award (CDA 08-004-3) to M. A. C., and a VA HSR&D Senior
Research Career Scientist Award (RCS 00-001) to C. T.
NR 119
TC 8
Z9 8
U1 3
U2 16
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0193-936X
EI 1478-6729
J9 EPIDEMIOL REV
JI Epidemiol. Rev.
PY 2015
VL 37
IS 1
BP 23
EP 37
DI 10.1093/epirev/mxu010
PG 15
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CL3ZX
UT WOS:000356892800003
PM 25608962
ER
PT J
AU Theodoroff, SM
Lewis, MS
Folmer, RL
Henry, JA
Carlson, KF
AF Theodoroff, Sarah M.
Lewis, M. Samantha
Folmer, Robert L.
Henry, James A.
Carlson, Kathleen F.
TI Hearing Impairment and Tinnitus: Prevalence, Risk Factors, and Outcomes
in US Service Members and Veterans Deployed to the Iraq and Afghanistan
Wars
SO EPIDEMIOLOGIC REVIEWS
LA English
DT Article
DE hearing loss; prevalence; risk factors; tinnitus; veterans' health
ID TRAUMATIC BRAIN-INJURY; OPERATION ENDURING FREEDOM; COMBAT WOUNDS; BLAST
INJURY; GLOBAL WAR; MECHANISM; TERROR; AIDS
AB Hearing loss and tinnitus are the 2 most prevalent service-connected disabilities among veterans in the United States. Veterans of Operations Enduring Freedom, Iraqi Freedom, and New Dawn have been exposed to multiple hazards associated with these conditions, such as blasts/explosions, ototoxic chemicals, and most notably high levels of noise. We conducted a systematic literature review of evidence on 1) prevalence of, 2) risk and protective factors for, and 3) functional and quality-of-life outcomes of hearing impairment and tinnitus in US Operations Enduring Freedom, Iraqi Freedom, and New Dawn veterans and military personnel. We identified studies published from 2001 through 2013 using PubMed, PsycINFO, REHABDATA, Cochrane Library, pearling, and expert recommendation. Peer-reviewed English language articles describing studies of 30 or more adults were included if they informed one or more key questions. A total of 839 titles/abstracts were reviewed for relevance by investigators trained in critical analysis of literature; 14 studies met inclusion criteria. Of these, 13 studies presented data on prevalence and 4 on risk/protective factors, respectively. There were no included studies reporting on outcomes. Findings from this systematic review will help inform clinicians, researchers, and policy makers on future resource and research needs pertaining to hearing impairment and tinnitus in this newest generation of veterans.
C1 [Theodoroff, Sarah M.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA.
RP Theodoroff, SM (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA.
EM sarah.theodoroff@va.gov
FU Department of Defense Congressionally Directed Medical Research Programs
[PR121146]; Veterans Health Administration Health Services Research and
Development Service [CDA 08-025]; National Center for Rehabilitative
Auditory Research - VA RR&D at the Portland VA Medical Center [C9230C]
FX This work was supported, in part, by the Department of Defense
Congressionally Directed Medical Research Programs (PR121146 to J. A.
H.) and a career development grant from the Veterans Health
Administration Health Services Research and Development Service (CDA
08-025 to K. F. C.). Additional support was provided by the National
Center for Rehabilitative Auditory Research (funded by VA RR&D grant
C9230C) at the Portland VA Medical Center.
NR 46
TC 4
Z9 4
U1 2
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0193-936X
EI 1478-6729
J9 EPIDEMIOL REV
JI Epidemiol. Rev.
PY 2015
VL 37
IS 1
BP 71
EP 85
DI 10.1093/epirev/mxu005
PG 15
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CL3ZX
UT WOS:000356892800006
PM 25600417
ER
PT J
AU Beste, LA
Ioannou, GN
AF Beste, Lauren A.
Ioannou, George N.
TI Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the
US Department of Veterans Affairs
SO EPIDEMIOLOGIC REVIEWS
LA English
DT Article
DE epidemiology; hepatitis C virus; United States; veterans
ID SUSTAINED VIROLOGICAL RESPONSE; UNITED-STATES VETERANS; GENOTYPE 1
INFECTION; TREATMENT ELIGIBILITY; ANTIVIRAL THERAPY; VIRAL-HEPATITIS;
PLUS RIBAVIRIN; RISK-FACTORS; COHORT; CARE
AB Chronic hepatitis C virus (HCV) is the most common blood-borne pathogen in the United States. HCV disproportionately affects Veterans Affairs (VA) health-care users: 174,302 HCV-infected veterans were in VA care in 2013, making the VA the world's largest HCV care provider. This systematic review identified 546 articles related to HCV in the VA. After assessment by 2 independent reviewers, 28 articles describing prevalence and treatment of HCV in VA users ultimately met inclusion criteria. Most VA patients currently living with HCV infection were born between 1945 and 1965 and were infected with HCV between 1970 and 1990. To prevent HCV-related complications such as cirrhosis, hepatocellular carcinoma, and death, medical personnel must identify and treat HCV. However, antiviral therapy has historically been limited by medication side effects, contraindications, and patient acceptance. Although treatment initiation rates are higher in the VA than in the general United States, only 23% of VA HCV patients have received treatment and, of those, only a minority were cured. Recent development of more effective and tolerable antiviral agents represents a major pharmacological breakthrough. Eradication of HCV is theoretically possible for the majority of HCV patients for the first time, although new barriers, such as high drug costs, may limit future uptake.
C1 [Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Beste, LA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way,S-111 GI, Seattle, WA 98108 USA.
EM lauren.beste@va.gov
NR 60
TC 15
Z9 15
U1 2
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0193-936X
EI 1478-6729
J9 EPIDEMIOL REV
JI Epidemiol. Rev.
PY 2015
VL 37
IS 1
BP 131
EP 143
DI 10.1093/epirev/mxu002
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CL3ZX
UT WOS:000356892800010
PM 25600415
ER
PT J
AU Sun, GB
Haining, R
Lin, H
Oreskovic, NM
He, J
AF Sun, Guibo
Haining, Robert
Lin, Hui
Oreskovic, Nicolas M.
He, Jie
TI Comparing the perception with the reality of walking in a hilly
environment: an accessibility method applied to a University campus in
Hong Kong
SO GEOSPATIAL HEALTH
LA English
DT Article
DE walking; hilly environment; accessibility; perception; geographic
information system
ID PHYSICAL-ACTIVITY; DISTANCE; SPACE; TIME
AB The influence of hilliness on walking behavior could be a consequence of the real effect of the local topography, but individual perception of the difficulties associated with walking in a hilly environment may also be important. Previous studies have found that people's perceptions do not necessarily match well with the realities of walking in hilly environments. There are a few methods that can be used to visualize the geography of that difference for use by urban planners and public health practitioners. A walking accessibility measure that allows comparison of perception and reality is proposed and implemented in this study. We note that difficulties in calculating accessibility measures in the present context arise primarily from problems with data quality, three-dimensional pedestrian network modelling and the adequacy of accessibility methods for describing and predicting walking behavior. We present practical strategies for addressing these issues using geographic information systems. Our method is illustrated by calculating accessibility for a hilly university campus in Hong Kong. Walking behaviors on, and people's perceptions of, this hilly environment were obtained through walking diaries and a survey. The article concludes with suggested directions for the future development of walking accessibility measures along with some ideas about their applicability to the practice of planning and designing a walkable environment.
C1 [Sun, Guibo; Lin, Hui] Chinese Univ Hong Kong, Inst Space & Earth Informat Sci, Shatin, Hong Kong, Peoples R China.
[Haining, Robert] Univ Cambridge, Dept Geog, Cambridge CB2 1TN, England.
[Lin, Hui] Chinese Univ Hong Kong, Dept Geog & Resource Management, Shatin, Hong Kong, Peoples R China.
[Oreskovic, Nicolas M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Oreskovic, Nicolas M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[He, Jie] Harvard Univ, Sch Med, Boston, MA USA.
[He, Jie] Tianjin Univ, Sch Architecture, Tianjin, Peoples R China.
RP Lin, H (reprint author), Chinese Univ Hong Kong, Inst Space & Earth Informat Sci, Fok Ying Tung Remote Sensing Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM huilin@cuhk.edu.hk
FU program Introducing Talents of Discipline to Universities [B13011];
National Natural Science Foundation of China [51478300]; National Heart,
Lung, and Blood Institute [K23HL103841]
FX Funding: this study is partially supported by program Introducing
Talents of Discipline to Universities (B13011). Guibo Sun and Jie He are
supported by a National Natural Science Foundation of China (51478300).
Nicolas Oreskovic is supported by a grant from the National Heart, Lung,
and Blood Institute (K23HL103841).
NR 24
TC 0
Z9 0
U1 1
U2 9
PU UNIV NAPLES FEDERICO II
PI NAPLES
PA FAC VET MED, DEP PATHOLOGY & ANIMAL HEALTH, VET PARASITOLOGY, VIA DELLA
VETERINARIA 1, NAPLES, 80137, ITALY
SN 1827-1987
EI 1970-7096
J9 GEOSPATIAL HEALTH
JI Geospatial Health
PY 2015
VL 10
IS 1
BP 32
EP 39
DI 10.4081/gh.2015.340
PG 8
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA CL0FJ
UT WOS:000356615300006
ER
PT J
AU Amalakuhan, B
Adams, SG
AF Amalakuhan, Bravein
Adams, Sandra G.
TI Improving outcomes in chronic obstructive pulmonary disease: the role of
the interprofessional approach
SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LA English
DT Review
DE optimal care; shared decision-making; co-morbidities
ID RANDOMIZED CONTROLLED-TRIAL; SMOKING-CESSATION; LUNG TRANSPLANTATION;
INTERNATIONAL SOCIETY; MANAGEMENT PROGRAM; PHYSICAL-ACTIVITY;
SLEEP-APNEA; ADULT LUNG; COPD; REHABILITATION
AB Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, places substantial time and cost burden on the health care system, and is now the third leading cause of death in the US. Many interventions are available to appropriately manage patients with COPD; however, fully implementing these strategies to help improve outcomes may be difficult. Collaboration between an interprofessional team of health care professionals (which includes physicians, nurses, respiratory therapists, physical therapists, dietitians, pharmacists, and many others) and COPD patients and caregivers is necessary to optimally manage these patients and to truly impact outcomes in this devastating disease. Prescribing evidence-based non-pharmacological and pharmacological therapies is an important start, but a true team-based approach is critical to successfully implement comprehensive care in patients with COPD. The goal of this review is to employ a case-based approach to provide practical information regarding the roles of the interprofessional team in implementing strategies to optimally manage COPD patients.
C1 [Amalakuhan, Bravein; Adams, Sandra G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA.
[Amalakuhan, Bravein; Adams, Sandra G.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
RP Adams, SG (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care Syst, Pulm Dis Sect 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM adamssg@uthscsa.edu
FU National Institute of Health; Veterans Affairs Cooperative Studies
Program; CHEST Foundation; University of Texas System Patient Safety
Grant; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim
Pharmaceuticals, Inc; GlaxoSmithKline; Novartis Pharmaceuticals AG
FX Sandra Adams has funded research by National Institute of Health,
Veterans Affairs Cooperative Studies Program, CHEST Foundation,
University of Texas System Patient Safety Grant, AstraZeneca
Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc,
GlaxoSmithKline, and Novartis Pharmaceuticals AG, and is the President
of a not-for-profit organization entitled WipeDiseases Foundation.
Bravein Amalakuhan reports no conflict of interest in this work.
NR 66
TC 4
Z9 4
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2005
J9 INT J CHRONIC OBSTR
JI Int. J. Chronic Obstr. Pulm. Dis.
PY 2015
VL 10
BP 1225
EP 1232
DI 10.2147/COPD.S71450
PG 8
WC Respiratory System
SC Respiratory System
GA CL5VV
UT WOS:000357031300003
PM 26170651
ER
PT J
AU O'Day, DH
Eshak, K
Myre, MA
AF O'Day, Danton H.
Eshak, Kristeen
Myre, Michael A.
TI Calmodulin Binding Proteins and Alzheimer's Disease
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Review
DE Alzheimer's disease; calcium; calcium channels; calmodulin; calmodulin
binding proteins; cholesterol metabolism; endocytosis; genome wide
association studies; neuroinflammation
ID AMYLOID-PRECURSOR-PROTEIN; TANDEM MASS-SPECTROMETRY; NEURONAL
CELL-DEATH; KINASE-II; TAU-PROTEIN; NMDA RECEPTORS; CALCIUM HYPOTHESIS;
MUTANT PRESENILIN; COMMON VARIANTS; CYCLE REENTRY
AB The small, calcium-sensor protein, calmodulin, is ubiquitously expressed and central to cell function in all cell types. Here the literature linking calmodulin to Alzheimer's disease is reviewed. Several experimentally-verified calmodulin-binding proteins are involved in the formation of amyloid-beta plaques including amyloid-beta protein precursor, beta-secretase, presenilin-1, and ADAM10. Many others possess potential calmodulin-binding domains that remain to be verified. Three calmodulin binding proteins are associated with the formation of neurofibrillary tangles: two kinases (CaMKII, CDK5) and one protein phosphatase (PP2B or calcineurin). Many of the genes recently identified by genome wide association studies and other studies encode proteins that contain putative calmodulin-binding domains but only a couple (e.g., APOE, BIN1) have been experimentally confirmed as calmodulin binding proteins. At least two receptors involved in calcium metabolism and linked to Alzheimer's disease (mAchR; NMDAR) have also been identified as calmodulin-binding proteins. In addition to this, many proteins that are involved in other cellular events intimately associated with Alzheimer's disease including calcium channel function, cholesterol metabolism, neuroinflammation, endocytosis, cell cycle events, and apoptosis have been tentatively or experimentally verified as calmodulin binding proteins. The use of calmodulin as a potential biomarker and as a therapeutic target is discussed.
C1 [O'Day, Danton H.] Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada.
[O'Day, Danton H.] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada.
[Eshak, Kristeen] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada.
[Myre, Michael A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res,Richard B Simches Res Ctr, Boston, MA USA.
RP O'Day, DH (reprint author), Univ Toronto, Dept Biol, 3359 Mississauga Rd North, Mississauga, ON L5L 1C6, Canada.
EM danton.oday@utoronto.ca
FU Natural Sciences and Engineering Research Council of Canada [A6807]
FX Robert J. Huber is thanked for his constructive comments on a draft of
this manuscript. This work was supported by the Natural Sciences and
Engineering Research Council of Canada (DHO'D; A6807).
NR 138
TC 2
Z9 2
U1 2
U2 10
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 46
IS 3
BP 553
EP 569
DI 10.3233/JAD-142772
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA CL4ZJ
UT WOS:000356967200001
PM 25812852
ER
PT J
AU Munro, CE
Donovan, NJ
Guercio, BJ
Wigman, SE
Schultz, AP
Amariglio, RE
Rentz, DM
Johnson, KA
Sperling, RA
Marshall, GA
AF Munro, Catherine E.
Donovan, Nancy J.
Guercio, Brendan J.
Wigman, Sarah E.
Schultz, Aaron P.
Amariglio, Rebecca E.
Rentz, Dorene M.
Johnson, Keith A.
Sperling, Reisa A.
Marshall, Gad A.
TI Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive
Impairment
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; apathy; functional magnetic resonance imaging; mild
cognitive impairment; neuropsychiatric symptoms
ID DEFAULT MODE NETWORK; LATE-LIFE DEPRESSION; ALZHEIMERS-DISEASE;
EXECUTIVE FUNCTION; APATHY; DEMENTIA; SPECTRUM; FMRI; PROGRESSION;
TOMOGRAPHY
AB Background: Neuropsychiatric symptoms (NPS), such as apathy and depression, commonly accompany cognitive and functional decline in early Alzheimer's disease (AD). Prior studies have shown associations between affective NPS and neurodegeneration of medial frontal and inferior temporal regions in mild cognitive impairment (MCI) and AD dementia.
Objective: To investigate the association between functional connectivity in four brain networks and NPS in elderly with MCI.
Methods: NPS were assessed using the Neuropsychiatric Inventory in 42 subjects with MCI. Resting-state functional connectivity in four networks (default mode network, fronto-parietal control network (FPCN), dorsal attention network, and ventral attention network) was assessed using seed-based magnetic resonance imaging. Factor analysis was used to identify two factors of NPS: Affective and Hyperactivity. Linear regression models were utilized with the neuropsychiatric factors as the dependent variable and the four networks as the predictors of interest. Covariates included age, gender, premorbid intelligence, processing speed, memory, head movement, and signal-to-noise ratio. These analyses were repeated with the individual items of the affective factor, using the same predictors.
Results: There was a significant association between greater Affective factor symptoms and reduced FPCN connectivity (p = 0.03). There was no association between the Hyperactivity factor and any of the networks. Secondary analyses revealed an association between greater apathy and reduced FPCN connectivity (p = 0.005), but none in other networks.
Conclusions: Decreased connectivity in the FPCN may be associated with greater affective symptoms, particularly apathy, early in AD. These findings extend prior studies, using different functional imaging modalities in individuals with greater disease severity.
C1 [Munro, Catherine E.; Wigman, Sarah E.; Schultz, Aaron P.; Amariglio, Rebecca E.; Rentz, Dorene M.; Sperling, Reisa A.; Marshall, Gad A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Johnson, Keith A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Johnson, Keith A.] Harvard Univ, Sch Med, Boston, MA USA.
[Donovan, Nancy J.; Amariglio, Rebecca E.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Boston, MA USA.
[Donovan, Nancy J.; Wigman, Sarah E.; Amariglio, Rebecca E.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Donovan, Nancy J.; Amariglio, Rebecca E.; Rentz, Dorene M.] Harvard Univ, Sch Med, Dept Psychiat, Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Marshall, GA (reprint author), Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, 221 Longwood Ave,BL-104 H, Boston, MA 02115 USA.
EM gamarshall@partners.org
FU Rosalinde and Arthur Gilbert Foundation/AFAR New Investigator Awards in
Alzheimer's Disease [R01 AG027435, K23 AG033634, K24AG035007,
R03AG045080]; Massachusetts Alzheimer's Disease Research Center [P50
AG005134]; Harvard Aging Brain Study [P01 AGO36694, R01 AG037497];
Harvard Medical School Department of Psychiatry; Harvard Medical School
Scholars in Medicine Office; Janssen Alzheimer Immunotherapy;
Wyeth/Pfizer Pharmaceuticals; Eisai Inc.; Eli Lilly and Company; Avid
Radiopharmaceuticals; Bristol-Myers-Squibb
FX This study was supported by R01 AG027435, K23 AG033634, K24AG035007,
R03AG045080, the Rosalinde and Arthur Gilbert Foundation/AFAR New
Investigator Awards in Alzheimer's Disease, the Massachusetts
Alzheimer's Disease Research Center (P50 AG005134), and the Harvard
Aging Brain Study (P01 AGO36694, R01 AG037497). The authors have also
received research salary support from the Harvard Medical School
Department of Psychiatry Dupont-Warren Fellowship and Livingston Award
and the Harvard Medical School Scholars in Medicine Office.; The authors
have received research salary support from Janssen Alzheimer
Immunotherapy (GAM, REA), Wyeth/Pfizer Pharmaceuticals (GAM, REA), Eisai
Inc. (GAM), Eli Lilly and Company (GAM), Avid Radiopharmaceuticals
(KAJ), and Bristol-Myers-Squibb (GAM, RAS).
NR 59
TC 3
Z9 3
U1 1
U2 6
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 46
IS 3
BP 727
EP 735
DI 10.3233/JAD-150017
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA CL4ZJ
UT WOS:000356967200016
PM 25854929
ER
PT J
AU Dhimolea, E
Groen, R
Aedin, C
Nicholas, M
Kornelia, P
Constantine, M
AF Dhimolea, Eugen
Groen, Richard
Aedin, Culhane
Nicholas, Mitsiades
Kornelia, Polyak
Constantine, Mitsiades
TI Non-malignant cells from metastatic niches induce estrogen
receptor-positive breast cancer cell resistance to therapy
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Dhimolea, Eugen; Groen, Richard; Aedin, Culhane; Kornelia, Polyak; Constantine, Mitsiades] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Nicholas, Mitsiades] Baylor Coll Med, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA B54
DI 10.1158/1538-7445.CHTME14-B54
PG 2
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300103
ER
PT J
AU Eisinger-Mathason, TSK
Zhang, MS
Qiong, Q
Skuli, N
Nakazawa, MS
Karakasheva, T
Mucaj, V
Shay, JES
Stangenberg, L
Pure, E
Yoon, SS
Kirsch, DG
Simon, MC
AF Eisinger-Mathason, T. S. Karin
Zhang, Minsi
Qiong, Qiu
Skuli, Nicolas
Nakazawa, Michael S.
Karakasheva, Tatiana
Mucaj, Vera
Shay, Jessica E. S.
Stangenberg, Lars
Pure, Ellen
Yoon, Sam S.
Kirsch, David G.
Simon, M. Celeste
TI Hypoxia-dependent modification of collagen networks promotes sarcoma
metastasis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Eisinger-Mathason, T. S. Karin; Skuli, Nicolas; Nakazawa, Michael S.; Karakasheva, Tatiana; Mucaj, Vera; Shay, Jessica E. S.; Pure, Ellen; Simon, M. Celeste] Univ Penn, Philadelphia, PA 19104 USA.
[Zhang, Minsi; Qiong, Qiu; Kirsch, David G.] Duke Univ, Durham, NC USA.
[Stangenberg, Lars] Massachusets Gen Hosp, Boston, MA USA.
[Yoon, Sam S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA A41
DI 10.1158/1538-7445.CHTME14-A41
PG 1
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300029
ER
PT J
AU Guerriero, JL
Letai, A
AF Guerriero, Jennifer L.
Letai, Anthony
TI Modulation of tumor-associated macrophages towards an antitumor
phenotype
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Guerriero, Jennifer L.; Letai, Anthony] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA A17
DI 10.1158/1538-7445.CHTME14-A17
PG 1
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300014
ER
PT J
AU Kozono, D
Li, J
Nitta, M
Sampetrean, O
Ng, K
Gonda, D
Kushwaha, D
Hiroko, M
Harismendy, O
Becher, O
Kwon, CH
Ligon, KL
Saya, H
Carter, BS
Pizzo, D
Vandenberg, S
Chen, CC
AF Kozono, David
Li, Jie
Nitta, Masayuki
Sampetrean, Oltea
Ng, Kimberly
Gonda, David
Kushwaha, Deepa
Hiroko, Matsui
Harismendy, Olivier
Becher, Oren
Kwon, Chang-Hyuk
Ligon, Keith L.
Saya, Hideyuki
Carter, Bob S.
Pizzo, Donald
Vandenberg, Scott
Chen, Clark C.
TI Epigenetic regulation of MYC drives dynamic transition between tumor
initiating states in glioblastoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Kozono, David; Nitta, Masayuki; Ng, Kimberly; Kushwaha, Deepa; Ligon, Keith L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Li, Jie; Gonda, David; Hiroko, Matsui; Harismendy, Olivier; Carter, Bob S.; Pizzo, Donald; Vandenberg, Scott; Chen, Clark C.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Sampetrean, Oltea] Div Gene Regulat, Tokyo, Japan.
[Becher, Oren] Duke Univ, Med Ctr, Durham, NC USA.
[Kwon, Chang-Hyuk] Ohio State Univ, Columbus, OH 43210 USA.
[Saya, Hideyuki] Keio Univ, Tokyo, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA PR13
DI 10.1158/1538-7445.CHTME14-PR13
PG 2
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300149
ER
PT J
AU Laws, DA
Kraft, AS
Leddy, LR
LaRue, AC
AF Laws, Dayvia A.
Kraft, Andrew S.
Leddy, Lee R.
LaRue, Amanda C.
TI The role of circulating fibroblast precursors in promoting metastatic
sarcoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Laws, Dayvia A.; Kraft, Andrew S.; Leddy, Lee R.] Med Univ S Carolina, Charleston, SC 29425 USA.
[LaRue, Amanda C.] Ralph H Johnson VAMC, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA A46
DI 10.1158/1538-7445.CHTME14-A46
PG 1
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300031
ER
PT J
AU Mumenthaler, S
Foo, J
Choi, N
Pao, W
Agus, D
Michor, F
Mallick, P
AF Mumenthaler, Shannon
Foo, Jasmine
Choi, Nathan
Pao, William
Agus, David
Michor, Franziska
Mallick, Parag
TI Spatio-temporal heterogeneity in the tumor microenvironment influences
the evolutionary dynamics of drug resistance
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Mumenthaler, Shannon; Choi, Nathan; Agus, David] Univ So Calif, Los Angeles, CA USA.
[Foo, Jasmine] Univ Minnesota, Minneapolis, MN USA.
[Pao, William] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Michor, Franziska] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mallick, Parag] Stanford Univ, Palo Alto, CA 94304 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA PR16
DI 10.1158/1538-7445.CHTME14-PR16
PG 1
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300152
ER
PT J
AU Pittet, M
AF Pittet, Mikael
TI Cancer-promoting immunity
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Pittet, Mikael] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA IA04
DI 10.1158/1538-7445.CHTME14-IA04
PG 1
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300127
ER
PT J
AU Roccaro, AM
Sacco, A
Moschetta, M
Maiso, P
Mishima, Y
Aljawai, Y
Facchetti, F
Kruschinski, A
Rossi, G
Ghobrial, IM
AF Roccaro, Aldo M.
Sacco, Antonio
Moschetta, Michele
Maiso, Patricia
Mishima, Yuji
Aljawai, Yosra
Facchetti, Fabio
Kruschinski, Anna
Rossi, Giuseppe
Ghobrial, Irene M.
TI In vivo targeting of stromal-derived factor-1 as a strategy to prevent
myeloma cell dissemination to distant bone marrow niches
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Roccaro, Aldo M.; Sacco, Antonio; Moschetta, Michele; Maiso, Patricia; Mishima, Yuji; Aljawai, Yosra; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Facchetti, Fabio; Rossi, Giuseppe] Spedali Civil Brescia, I-25125 Brescia, Italy.
[Kruschinski, Anna] NOXXON Pharma, Berlin, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA PR14
DI 10.1158/1538-7445.CHTME14-PR14
PG 2
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300150
ER
PT J
AU Roccaro, AM
Sacco, A
Maiso, P
Moschetta, M
Manier, S
Mishima, Y
Reagan, M
Aljawai, Y
Ghobrial, IM
AF Roccaro, Aldo M.
Sacco, Antonio
Maiso, Patricia
Moschetta, Michele
Manier, Salomon
Mishima, Yuji
Reagan, Michaela
Aljawai, Yosra
Ghobrial, Irene M.
TI Stroma-derived exosomes mediate progression in multiple meyloma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Roccaro, Aldo M.; Sacco, Antonio; Maiso, Patricia; Moschetta, Michele; Manier, Salomon; Mishima, Yuji; Reagan, Michaela; Aljawai, Yosra; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Reagan, Michaela/E-3549-2017
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA B62
DI 10.1158/1538-7445.CHTME14-B62
PG 2
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300108
ER
PT J
AU Sevenich, L
Bowman, R
Mason, S
Quail, D
Rapaport, F
Elie, B
Brogi, E
Brastianos, P
Hahn, W
Holsinger, L
Massague, J
Leslie, C
Joyce, JA
AF Sevenich, Lisa
Bowman, Robert
Mason, Steve
Quail, Daniela
Rapaport, Franck
Elie, Benelita
Brogi, Edi
Brastianos, Priscilla
Hahn, William
Holsinger, Leslie
Massague, Joan
Leslie, Christina
Joyce, Johanna A.
TI A brain metastasis-promoting role for cathepsin S identified from
analysis of tumor- and stroma-supplied proteolytic networks
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Sevenich, Lisa; Bowman, Robert; Mason, Steve; Quail, Daniela; Rapaport, Franck; Elie, Benelita; Brogi, Edi; Massague, Joan; Leslie, Christina; Joyce, Johanna A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Brastianos, Priscilla; Hahn, William] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Holsinger, Leslie] Virobay Inc, Menlo Pk, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA IA18
DI 10.1158/1538-7445.CHTME14-IA18
PG 1
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300136
ER
PT J
AU Sigmans, J
Noort, W
Lindsley, C
Pan, L
Aalders, L
Bariteau, M
Ebert, B
Aster, J
Steidl, U
Schuringa, J
Yuan, HP
de Bruijn, J
Raymakers, R
Lokhorst, H
Mutis, T
Martens, A
Mitsiades, C
Groen, R
AF Sigmans, Jessica
Noort, Willy
Lindsley, Coleman
Pan, Li
Aalders, Linda
Bariteau, Megan
Ebert, Benjamin
Aster, Jon
Steidl, Uli
Schuringa, Jan
Yuan, Huipin
de Bruijn, Joost
Raymakers, Reinier
Lokhorst, Henk
Mutis, Tuna
Martens, Anton
Mitsiades, Constantine
Groen, Richard
TI Biological insights into tumor-bone marrow microenvironment interactions
derived from a humanized murine model
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Sigmans, Jessica; Noort, Willy; Aalders, Linda; Raymakers, Reinier; Lokhorst, Henk; Mutis, Tuna; Martens, Anton; Groen, Richard] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[Lindsley, Coleman; Bariteau, Megan; Ebert, Benjamin; Mitsiades, Constantine] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Pan, Li; Aster, Jon] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Steidl, Uli] Albert Einstein Coll Med, New York, NY USA.
[Schuringa, Jan] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[Yuan, Huipin; de Bruijn, Joost] Xpand Biotechnol BV, Bilthoven, Netherlands.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA PR12
DI 10.1158/1538-7445.CHTME14-PR12
PG 1
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300148
ER
PT J
AU Xiong, Y
Laws, DA
LaRue, AC
AF Xiong, Ying
Laws, Dayvia A.
LaRue, Amanda C.
TI Hematopoietic stem cell-derived adipocytes promote tumor progression
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Cellular Heterogeneity in the Tumor
Microenvironment
CY FEB 26-MAR 01, 2014
CL San Diego, CA
SP AACR
C1 [Xiong, Ying; Laws, Dayvia A.] Med Univ S Carolina, Charleston, SC 29425 USA.
[LaRue, Amanda C.] Ralph H Johnson VAMC, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2015
VL 75
IS 1
SU S
MA A77
DI 10.1158/1538-7445.CHTME14-A77
PG 1
WC Oncology
SC Oncology
GA CL0JZ
UT WOS:000356630300057
ER
PT J
AU Hatef, E
Sena, DF
Fallano, KA
Crews, J
Do, DV
AF Hatef, Elham
Sena, Dayse F.
Fallano, Katherine A.
Crews, Jonathan
Do, Diana V.
TI Pneumatic retinopexy versus scleral buckle for repairing simple
rhegmatogenous retinal detachments
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID CLINICAL-TRIAL; MANAGEMENT; SURGERY
AB Background
Rhegmatogenous retinal detachment (RRD) is a full-thickness break in the sensory retina, caused by vitreous traction on the retina. While pneumatic retinopexy, scleral buckle, and vitrectomy are the accepted surgical interventions for eyes with RRD, their relative effectiveness has remained controversial.
Objectives
The objectives of this review were to assess the effectiveness and safety of pneumatic retinopexy versus scleral buckle or pneumatic retinopexy versus a combination treatment of scleral buckle and vitrectomy for people with RRD. The secondary objectives were to summarize any data on economic measures and quality of life.
Search methods
We searchedCENTRAL (which contains theCochrane Eyes andVisionGroupTrialsRegister) (2014, Issue 12), OvidMEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to January 2015), EMBASE (January 1980 to January 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to January 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and theWorld Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 13 January 2015.
Selection criteria
We included all randomized or quasi-randomized controlled trials comparing the effectiveness of pneumatic retinopexy versus scleral buckle (with or without vitrectomy) for eyes with RRD.
Data collection and analysis
After screening for eligibility, two review authors independently extracted study characteristics, methods, and outcomes. We followed systematic review standards as set forth by The Cochrane Collaboration.
Main results
We included two randomized controlled trials (218 eyes of 216 participants) comparing the effectiveness of pneumatic retinopexy versus scleral buckle for eyes with RRD. We identified no studies investigating the comparison of pneumatic retinopexy versus a combination treatment of scleral buckle and vitrectomy. Of the two included studies, one was a small study with 20 participants enrolled in Ireland and followed for an average of 16 months. The second study was larger with 196 participants (198 eyes) enrolled in the United States and followed for at least 6 months. Cautious interpretation of the results is warranted, since we graded the evidence as low to moderate quality due to insufficient reporting of study methods and imprecision and inconsistency among study results.
Both studies showed fewer eyes achieving retinal reattachment in the pneumatic retinopexy group compared with the scleral buckle group by six-months follow-up (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.77 to 1.02, 218 eyes); however, we are uncertain as to whether the intervention has an important effect on reattachment because the results are imprecise. Eyes in the pneumatic retinopexy group also were more likely to have had a recurrence of retinal detachment by six-months follow-up (RR 1.80, 95% CI 1.00 to 3.24, 218 eyes); however, we are uncertain as to whether the intervention has an important effect on recurrence because the lower CI equals no difference. Neither study reported mean change in visual acuity, quality of life data, or economic measures. Differences between the pneumatic retinopexy group and scleral buckle group were uncertain due to small numbers of events with respect to operative ocular adverse events (RR 0.67, 95% CI 0.32 to 1.42, 218 eyes), development of cataract (RR 0.92, 95% CI 0.06 to 14.54, 198 eyes), glaucoma (RR 0.31, 95% CI 0.03 to 2.91, 198 eyes), macular pucker (RR 0.74, 95% CI 0.20 to 2.67, 198 eyes), and proliferative vitreoretinopathy (RR 0.94, 95% CI 0.30 to 2.96, 218 eyes). Fewer eyes in the pneumatic retinopexy group compared with the scleral buckle group experienced choroidal detachment (RR 0.17, 95% CI 0.05 to 0.57, 198 eyes) or myopic shift equal to or greater than 1 diopter spherical equivalent (RR 0.04, 95% CI 0.01 to 0.13, 198 eyes).
Authors' conclusions
The evidence suggests that pneumatic retinopexy may result in lower rates of reattachment and higher rates of recurrence than scleral buckle for eyes with RRD, but does not rule out no difference between procedures. The relative safety of the procedures is uncertain and the relative effects of these procedures in terms of other patient-important outcomes, such as visual acuity and quality of life, is unknown. Due to the limited information available between pneumatic retinopexy and scleral buckle procedures, future research addressing these evidence gaps are warranted.
C1 [Hatef, Elham] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
[Sena, Dayse F.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Fallano, Katherine A.] Univ Rochester, Sch Med, Flaum Eye Inst, Rochester, NY USA.
[Crews, Jonathan; Do, Diana V.] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA.
RP Hatef, E (reprint author), Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 North Wolfe St,Wilmer B-43, Baltimore, MD 21287 USA.
EM ehatef@jhsph.edu
FU National Eye Institute, National Institutes of Health, USA; National
Institute for Health Research (NIHR), UK; Department of Health through
National Institute for Health Research; NIHR; [1 U01 EY020522]
FX National Eye Institute, National Institutes of Health, USA.;
Methodological support provided by the Cochrane Eyes and Vision Group,
US Project funded by grant 1 U01 EY020522; National Institute for Health
Research (NIHR), UK.; Richard Wormald, Co-ordinating Editor for the
Cochrane Eyes and Vision Group (CEVG) acknowledges financial support for
his CEVG research sessions from the Department of Health through the
award made by the National Institute for Health Research to Moorfields
Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for
a Specialist Biomedical Research Centre for Ophthalmology.; The NIHR
also funds the CEVG Editorial Base in London.
NR 32
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2015
IS 5
AR CD008350
DI 10.1002/14651858.CD008350.pub2
PG 33
WC Medicine, General & Internal
SC General & Internal Medicine
GA CK1UR
UT WOS:000355993600029
PM 25950286
ER
PT J
AU Kang, A
Nigwekar, SU
Perkovic, V
Kulshrestha, S
Zoungas, S
Navaneethan, SD
Cass, A
Gallagher, MP
Ninomiya, T
Strippoli, GFM
Jardine, MJ
AF Kang, Amy
Nigwekar, Sagar U.
Perkovic, Vlado
Kulshrestha, Satyarth
Zoungas, Sophia
Navaneethan, Sankar D.
Cass, Alan
Gallagher, Martin P.
Ninomiya, Toshiharu
Strippoli, Giovanni F. M.
Jardine, Meg J.
TI Interventions for lowering plasma homocysteine levels in kidney
transplant recipients
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID VASCULAR OUTCOME REDUCTION; FOLIC-ACID SUPPLEMENTATION; INTIMA-MEDIA
THICKNESS; STAGE RENAL-DISEASE; RANDOMIZED CONTROLLED-TRIAL;
PLACEBO-CONTROLLED TRIAL; CARDIOVASCULAR-DISEASE; B-VITAMINS; FAVORIT
TRIAL; MYOCARDIAL-INFARCTION
AB Background
Elevated homocysteine levels have been shown to be an independent risk factor for cardiovascular disease. However studies of homocysteine lowering in general and end-stage kidney disease (ESKD) populations have not demonstrated a reduction in cardiovascular event rates. Kidney transplant recipients have high homocysteine levels, high cardiovascular event rates and, unlike the ESKD population, may achieve normalisation of homocysteine levels with homocysteine lowering therapies. Thus may benefit from homocysteine lowering therapy.
Objectives
To evaluate the effects of established homocysteine lowering therapy on cardiovascular mortality in patients with functioning kidney transplants.
Search methods
We searched the Cochrane Renal Group's Specialised Register to 16 March 2015 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.
Selection criteria
Randomised controlled trials of any therapy that has been shown to significantly lower homocysteine levels conducted in people with functioning kidney transplants. Studies were to be included if they compared homocysteine lowering therapy with placebo or usual care, or compare higher versus lower doses of homocysteine lowering therapy.
Data collection and analysis
Two authors independently assessed study quality and extracted data. Results were to be expressed as the risk ratio (RR) for dichotomous outcomes or mean difference (MD) for continuous outcomes with 95% confidence intervals (CI). Data was to be pooled using the random effects model.
Main results
The literature search yielded 359 reports of which only one study was identified that met our inclusion criteria and reported relevant clinical endpoints. This study randomised 4110 adult participants with a functioning kidney transplant and elevated homocysteine levels to folic acid plus high dose B multivitamins or low dose multivitamins who were followed for amean 4.0 years. Despite effectively lowering homocysteine levels) in homocysteine levels at follow-up (MD -4.40 mu mol/L, 95% CI -5.98 to -2.82) there was no evidence the intervention impacted on any of the outcomes reported including cardiovascular mortality (RR 0.91, 95% CI 0.69 to 1.20), allcause mortality (RR 1.04, 95% CI 0.88 to 1.22), myocardial infarction (RR 1.02, 95% CI 0.77 to 1.35), stroke (RR 1.08, 95% CI 0.69 to 1.71), commencement of renal replacement therapy (RR 1.12, 95% CI 0.91 to 1.37) or all reported adverse events (RR 1.02, 95% CI 0.87 to 1.20). There was no evidence the intervention impacted on the primary endpoint of the study, a cardiovascular event composite (RR 0.99, 95% CI 0.85 to 1.15). The study was of high quality.
Authors' conclusions
There is no current evidence to support the use of homocysteine lowering therapy for cardiovascular disease prevention in kidney transplant recipients.
C1 [Kang, Amy] Univ Sydney, Sydney Med Sch, Camperdown, NSW, Australia.
[Nigwekar, Sagar U.] Harvard Univ, Brigham & Womens Hosp, Massachusetts Gen Hosp, Scholars Clin Sci Program,Med Sch, Boston, MA 02115 USA.
[Perkovic, Vlado] George Inst Global Hlth, Camperdown, NSW, Australia.
[Kulshrestha, Satyarth] Univ Iowa, Carver Coll Med, Nephrol, Iowa City, IA USA.
[Zoungas, Sophia] Monash Univ, Sch Publ Hlth & Prevent Med, Monash Ctr Hlth Res & Implementat, Diabet & Vasc Res Program, Clayton, Vic, Australia.
[Navaneethan, Sankar D.] Cleveland Clin, Glickman Urol & Kidney Inst, Dept Nephrol & Hypertens, Cleveland, OH 44106 USA.
[Cass, Alan] Menzies Sch Hlth Res, Casuarina, Australia.
[Gallagher, Martin P.; Ninomiya, Toshiharu] George Inst Global Hlth, Renal & Metab Div, Camperdown, NSW, Australia.
[Strippoli, Giovanni F. M.] Childrens Hosp Westmead, Ctr Kidney Res, Cochrane Renal Grp, Westmead, NSW, Australia.
[Strippoli, Giovanni F. M.] Univ Bari, Dept Emergency & Organ Transplantat, Bari, Italy.
[Strippoli, Giovanni F. M.] Diaverum Med Sci Off, Lund, Sweden.
[Strippoli, Giovanni F. M.] Diaverum Acad, Bari, Italy.
[Jardine, Meg J.] Univ Sydney, George Inst Global Hlth, Camperdown, NSW 2050, Australia.
[Jardine, Meg J.] Concord Repatriat Gen Hosp, Dept Renal Med, Concord, Australia.
RP Jardine, MJ (reprint author), Univ Sydney, George Inst Global Hlth, POB M201,Missenden Rd, Camperdown, NSW 2050, Australia.
EM mjardine@georgeinstitute.org.au
FU George Institute for Global Health, Australia
FX Internal sources; The George Institute for Global Health, Australia.
NR 82
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2015
IS 5
AR UNSP CD007910
DI 10.1002/14651858.CD007910.pub2
PG 29
WC Medicine, General & Internal
SC General & Internal Medicine
GA CK1UR
UT WOS:000355993600026
PM 25938479
ER
PT J
AU Maxwell, LJ
Zochling, J
Boonen, A
Singh, JA
Veras, MMS
Ghogomu, ET
Jandu, MB
Tugwell, P
Wells, GA
AF Maxwell, Lara J.
Zochling, Jane
Boonen, Annelies
Singh, Jasvinder A.
Veras, Mirella M. S.
Ghogomu, Elizabeth Tanjong
Jandu, Maria Benkhalti
Tugwell, Peter
Wells, George A.
TI TNF-alpha inhibitors for ankylosing spondylitis
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID PLACEBO-CONTROLLED TRIAL; NECROSIS-FACTOR-ALPHA; LOW-DOSE INFLIXIMAB;
SOCIETY CLASSIFICATION CRITERIA; REDUCES SPINAL INFLAMMATION;
PATIENT-REPORTED OUTCOMES; SHORT-TERM IMPROVEMENT; ETANERCEPT 50 MG;
PHASE-III TRIAL; DOUBLE-BLIND
AB Background
TNF (tumor necrosis factor)-alpha inhibitors block a key protein in the inflammatory chain reaction responsible for joint inflammation, pain, and damage in ankylosing spondylitis.
Objectives
To assess the benefit and harms of adalimumab, etanercept, golimumab, and infliximab (TNF-alpha inhibitors) in peoplewith ankylosing spondylitis.
Search methods We searched the following databases to January 26, 2009: MEDLINE (from 1966); EMBASE (from 1980); the Cochrane Central Register of Controlled Trials (CENTRAL; 2008, Issue 4); ACP Journal Club; CINAHL (from1982); and ISIWeb of Knowledge (from 1900). We ran updated searches in May 2012, October 2013, and in June 2014 for McMaster PLUS. We searched major regulatory agencies for safety warnings and clinicaltrials. gov for registered trials.
Selection criteria
Randomized controlled trials (RCTs) comparing adalimumab, etanercept, golimumab and infliximab to placebo, other drugs or usual care in patients with ankylosing spondylitis, reported in abstract or full-text.
Data collection and analysis
Two authors independently assessed search results, risk of bias, and extracted data. We conducted Bayesian mixed treatment comparison (MTC) meta-analyses using WinBUGS software. To investigate a class-effect of harms across biologics, we pooled harms data using Review Manager 5.
Main results
We included twenty-one, short-term(24 weeks or less) RCTs with a total of 3308 participants; 18 contributed data to the MTC analysis: adalimumab (4 studies), etanercept (8 studies), golimumab (2 studies), infliximab (3 studies), and one head-to-head study (etanercept versus infliximab) which was unblinded and considered at a higher risk of bias. The risk of selection and detection bias was low or unclear for most of the studies. The risk of selective outcome reporting was low for most studies as they reported on outcomes recommended by the Assessment of SpondyloArthritis international Society. We found little heterogeneity and no significant inconsistency in the MTC analyses. The majority of the studies were funded by pharmaceutical companies. Most studies permitted concomitant therapy of stable doses of disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, or corticosteroids, but allowances varied across studies.
Compared with placebo, there was high quality evidence that patients on an anti-TNF agent were three to four times more likely to achieve an ASAS40 response (assessing spinal pain, function, and inflammation, as measured by the mean of intensity and duration of morning stiffness, and patient global assessment) by six months (adalimumab: risk ratio (RR) 3.53, 95% credible interval (Crl) 2.49 to 4.91; etanercept: RR 3.31, 95% Crl 2.38 to 4.53; golimumab: RR 2.90, 95% Crl 1.90 to 4.23; infliximab: RR 4.07, 95% Crl 2.80 to 5.74, with a 25% to 40% absolute difference between treatment and placebo groups. The number needed to treat (NNT) to achieve an ASAS 40 response ranged from 3 to 5.
There was high quality evidence of improvement in physical function on a 0 to 10 scale (adalimumab: mean difference (MD) -1.6, 95% Crl -2.2 to -0.9; etanercept: MD -1.1, 95% CrI -1.6 to -0.6; golimumab: MD -1.5, 95% Crl -2.3 to -0.7; infliximab: MD 2.1, 95% Crl -2.7 to -1.4, with an 11% to 21% absolute difference between treatment and placebo groups. The NNT to achieve the minimally clinically important difference of 0.7 points ranged from 2 to 4.
Compared with placebo, there was moderate quality evidence (downgraded for imprecision) that patients on an anti-TNF agent were more likely to achieve an ASAS partial remission by six months (adalimumab: RR 6.28, 95% Crl 3.13 to 12.78; etanercept: RR 4.24, 95% Crl 2.31 to 8.09; golimumab: RR 5.18, 95% Crl 1.90 to 14.79; infliximab: RR 15.41, 95% Crl 5.09 to 47.98 with a 10% to 44% absolute difference between treatment and placebo groups. The NNT to achieve an ASAS partial remission response ranged from 3 to 11.
There was low to moderate level evidence of a greater reduction in spinal inflammation as measured by magnetic resonance imaging though the absolute differences were small and the clinical relevance of the difference was unclear: adalimumab (1 trial; -6% (95% confidence interval (CI) -12% to 0.05%); 1 trial: 53.6% mean decrease from baseline versus 9.4% mean increase in the placebo group), golimumab (1 trial; -2.5%, (95% CI -5.6% to -0.7%)), and infliximab (1 trial; -3% (95% CI -4% to -2.4%)).
Radiographic progression was measured in one trial (N = 60) of etanercept versus placebo and it found that radiologic changes were similar in both groups (detailed data not provided).
There were few events of withdrawals due to adverse events leading to imprecision around the estimates. When all the anti-TNF agents were combined against placebo, there was moderate quality evidence from 16 studies of an increased risk of withdrawals due to adverse events in the anti-TNF group (Peto odds ratio (OR) 2.44, 95% CI 1.26 to 4.72; total events: 38/1637 in biologic group; 7/986 in placebo) though the absolute increase in harm was small (1%; 95% CI 0% to 2%).
Due to low event rates, evidence of the effect of individual TNF-inhibitors against placebo or for all four biologics pooled together versus placebo on serious adverse events is inconclusive (moderate quality; downgraded for imprecision). For all anti-TNF pooled versus placebo based on 16 studies: Peto OR 1.45, 95% CI 0.85 to 2.48; 51/1530 in biologic group; 18/878 in placebo; absolute difference: 1% (95% CI 0% to 2%).
Using indirect comparison methodology, and one head-to-head study of etanercept versus infliximab, wide confidence intervals meant that results were inconclusive for evidence of differences in themajor outcomes between different anti-TNF agents. Regulatory agencies have published warnings about rare adverse events of serious infections, including tuberculosis, malignancies and lymphoma.
Authors' conclusions
There is moderate to high quality evidence that anti-TNF agents improve clinical symptoms in the treatment of ankylosing spondylitis. More participants withdrew due to adverse events when on an anti-TNF agent but we did not find evidence of an increase in serious adverse events, though event rates were low and trials had a short duration. The short-term toxicity profile appears acceptable. Based on indirect comparison methodology, we are uncertain whether there are differences between anti-TNF agents in terms of the key benefit or harm outcomes.
C1 [Maxwell, Lara J.] Ottawa Hosp Res Inst, Ctr Practice Changing Res, Ottawa, ON K1H 8L6, Canada.
[Zochling, Jane] Menzies Res Inst, Hobart, Tas, Australia.
[Boonen, Annelies] Caphri Res Inst, Dept Rheumatol, NL-6202 AZ Maastricht, Netherlands.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA.
[Veras, Mirella M. S.] Univ Montreal, Ecole Readaptac, Montreal, PQ, Canada.
[Ghogomu, Elizabeth Tanjong] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada.
[Jandu, Maria Benkhalti] Univ Ottawa, Inst Populat Hlth, Ctr Global Hlth, Ottawa, ON, Canada.
[Tugwell, Peter] Univ Ottawa, Dept Med, Fac Med, Ottawa, ON, Canada.
[Wells, George A.] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
RP Maxwell, LJ (reprint author), Ottawa Hosp Res Inst, Ctr Practice Changing Res, Ottawa Hosp Gen Campus,501 Smyth Rd,Box 711, Ottawa, ON K1H 8L6, Canada.
EM lmaxwell@uottawa.ca
OI Tugwell, Peter/0000-0001-5062-0556
FU Institute of Population Health, University of Ottawa, Canada;
Rheumazentrum Ruhrgebiet, Germany; NIHR Cochrane Incentive Award, UK
FX Internal sources; Institute of Population Health, University of Ottawa,
Canada.; Rheumazentrum Ruhrgebiet, Germany.; External sources; NIHR
Cochrane Incentive Award 2013, UK.; Award to assist with completion of
the review.
NR 109
TC 11
Z9 12
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2015
IS 4
AR CD005468
DI 10.1002/14651858.CD005468.pub2
PG 144
WC Medicine, General & Internal
SC General & Internal Medicine
GA CK1UQ
UT WOS:000355993500018
PM 25887212
ER
PT J
AU Guex, AA
Vachicouras, N
Hight, AE
Brown, MC
Lee, DJ
Lacour, SP
AF Guex, Amelie A.
Vachicouras, Nicolas
Hight, Ariel Edward
Brown, M. Christian
Lee, Daniel J.
Lacour, Stephanie P.
TI Conducting polymer electrodes for auditory brainstem implants
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID POLY(3,4-ETHYLENEDIOXYTHIOPHENE) PEDOT; ELECTRICAL-STIMULATION;
MICROELECTRODE ARRAYS; NEURAL STIMULATION; RECORDINGS; CHARGE; RAT
AB The auditory brainstem implant (ABI) restores hearing in patients with damaged auditory nerves. One of the main ideas to improve the efficacy of ABIs is to increase spatial specificity of stimulation, in order to minimize extra-auditory side-effects and to maximize the tonotopy of stimulation. This study reports on the development of a microfabricated conformable electrode array with small (100 mm diameter) electrode sites. The latter are coated with a conducting polymer, PEDOT: PSS, to offer high charge injection properties and to safely stimulate the auditory system with small stimulation sites. We report on the design and fabrication of the polymer implant, and characterize the coatings in physiological conditions in vitro and under mechanical deformation. We characterize the coating electrochemically and during bending tests. We present a proof of principle experiment where the auditory system is efficiently activated by the flexible polymeric interface in a rat model in vivo. These results demonstrate the potential of using conducting polymer coatings on small electrode sites for electrochemically safe and efficient stimulation of the central auditory system.
C1 [Guex, Amelie A.; Vachicouras, Nicolas; Lacour, Stephanie P.] Ecole Polytech Fed Lausanne, Ctr Neuroprosthet, Lausanne, Switzerland.
[Hight, Ariel Edward; Brown, M. Christian; Lee, Daniel J.] Harvard Univ, Sch Med, Eaton Peabody Labs, Boston, MA 02115 USA.
[Hight, Ariel Edward; Brown, M. Christian; Lee, Daniel J.] Harvard Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Massachusetts Eye & Ear Infirm,Dept Otol & Laryng, Boston, MA 02115 USA.
RP Lacour, SP (reprint author), Ecole Polytech Fed Lausanne, Ctr Neuroprosthet, Lausanne, Switzerland.
EM stephanie.lacour@epfl.ch
RI Lacour, Stephanie/E-6375-2010
FU Fondation Bertarelli; National Institute of Health [DC01089]
FX This work was supported by the Fondation Bertarelli and the National
Institute of Health (grant DC01089).
NR 23
TC 1
Z9 1
U1 5
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 2050-750X
EI 2050-7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2015
VL 3
IS 25
BP 5021
EP 5027
DI 10.1039/c5tb00099h
PG 7
WC Materials Science, Biomaterials
SC Materials Science
GA CK6YS
UT WOS:000356375800012
PM 26207184
ER
PT J
AU Williams, DA
Kogan, JR
Hauer, KE
Yamashita, T
Aagaard, EM
AF Williams, David A.
Kogan, Jennifer R.
Hauer, Karen E.
Yamashita, Traci
Aagaard, Eva M.
TI The impact of exposure to shift-based schedules on medical students
SO MEDICAL EDUCATION ONLINE
LA English
DT Article
DE duty-hour reform; shift-based schedules; medical students; internal
medicine clerkship; team fragmentation
ID SURGICAL RESIDENTS; ROLE-MODELS; DUTY HOURS; CONTINUITY; EXPERIENCE;
CLERKSHIP; TEACHERS; DESCRIBE; REFORM; CARE
AB Background: With new resident duty-hour regulations, resident work schedules have progressively transitioned towards shift-based systems, sometimes resulting in increased team fragmentation. We hypothesized that exposure to shift-based schedules and subsequent team fragmentation would negatively affect medical student experiences during their third-year internal medicine clerkship.
Design: As part of a larger national study on duty-hour reform, 67 of 150 eligible third-year medical students completed surveys about career choice, teaching and supervision, assessment, patient care, well-being, and attractiveness of a career in internal medicine after completing their internal medicine clerkship. Students who rotated to hospitals with shift-based systems were compared to those who did not. Non-demographic variables used a five-point Likert scale. Chi-squared and Fisher's exact tests were used to assess the relationships between exposure to shift-based schedules and student responses. Questions with univariate p50.1 were included in multivariable logistic regression models.
Results: Thirty-six students (54%) were exposed to shift-based schedules. Students exposed to shift-based schedules were less likely to perceive that their attendings were committed to teaching (odds ratio [OR] 0.35, 95% confidence interval [CI]: 0.13-0.90, p = 0.01) or perceive that residents had sufficient exposure to assess their performance (OR 0.29, 95% CI: 0.09-0.91, p = 0.03). However, those students were more likely to feel their interns were able to observe them at the bedside (OR 1.89, 95% CI: 1.08-3.13, p = 0.02) and had sufficient exposure to assess their performance (OR 3.00, 95% CI: 1.01-8.86, p = 0.05).
Conclusions: These findings suggest that shift-based schedules designed in response to duty-hour reform may have important broader implications for the teaching environment.
C1 [Williams, David A.] Univ Colorado, Sch Med, Dept Internal Med, Denver Vet Affairs Med Ctr, Aurora, CO USA.
[Kogan, Jennifer R.] Univ Penn, Dept Med, Perleman Sch Med, Philadelphia, PA 19104 USA.
[Hauer, Karen E.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA.
[Yamashita, Traci; Aagaard, Eva M.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA.
RP Williams, DA (reprint author), Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO 80220 USA.
EM david.williams18@va.gov
NR 27
TC 0
Z9 0
U1 0
U2 2
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1087-2981
J9 MED EDUC ONLINE
JI Med. Educ. Online
PY 2015
VL 20
AR 27434
DI 10.3402/meo.v20.27434
PG 6
WC Education & Educational Research
SC Education & Educational Research
GA CK9ZG
UT WOS:000356597500001
PM 26095587
ER
PT B
AU Fenves, AZ
Shchelochkov, OA
AF Fenves, Andrew Z.
Shchelochkov, Oleg A.
BE Rothkopf, MM
Nusbaum, MJ
Haverstick, LP
TI Hyperammonemic Encephalopathy after Roux-en-Y Gastric Bypass Surgery
SO METABOLIC MEDICINE AND SURGERY
LA English
DT Article; Book Chapter
ID BARIATRIC-SURGERY
C1 [Fenves, Andrew Z.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Shchelochkov, Oleg A.] Univ Iowa Hosp & Clin, Dept Pediat, Div Genet, Iowa City, IA 52242 USA.
RP Fenves, AZ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
NR 12
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4665-6712-2; 978-1-4665-6711-5
PY 2015
BP 373
EP 381
PG 9
WC Endocrinology & Metabolism; Nutrition & Dietetics; Surgery
SC Endocrinology & Metabolism; Nutrition & Dietetics; Surgery
GA BC6XI
UT WOS:000354561800023
ER
PT B
AU Kudsk, KA
Pierre, JF
AF Kudsk, Kenneth A.
Pierre, Joseph F.
BE Rothkopf, MM
Nusbaum, MJ
Haverstick, LP
TI Nutrition and Immunity of the Gut
SO METABOLIC MEDICINE AND SURGERY
LA English
DT Article; Book Chapter
ID RESPIRATORY-TRACT IMMUNITY; MAJOR ABDOMINAL-TRAUMA; LYMPHOID-TISSUE;
PARENTERAL-NUTRITION; MUCOSAL IMMUNITY; ENTERAL NUTRITION; BACTERIAL
PNEUMONIA; SEPTIC MORBIDITY; INNATE IMMUNITY; SMALL-INTESTINE
C1 [Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
[Pierre, Joseph F.] Univ Chicago, Dept Med, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA.
RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.
NR 55
TC 0
Z9 0
U1 0
U2 1
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4665-6712-2; 978-1-4665-6711-5
PY 2015
BP 457
EP 468
PG 12
WC Endocrinology & Metabolism; Nutrition & Dietetics; Surgery
SC Endocrinology & Metabolism; Nutrition & Dietetics; Surgery
GA BC6XI
UT WOS:000354561800027
ER
PT J
AU Xu, AJ
Niciu, MJ
Lundin, NB
Luckenbaugh, DA
Ionescu, DF
Richards, EM
Voort, JLV
Ballard, ED
Brutsche, NE
Machado-Vieira, R
Zarate, CA
AF Xu, Annie J.
Niciu, Mark J.
Lundin, Nancy B.
Luckenbaugh, David A.
Ionescu, Dawn F.
Richards, Erica M.
Voort, Jennifer L. Vande
Ballard, Elizabeth D.
Brutsche, Nancy E.
Machado-Vieira, Rodrigo
Zarate, Carlos A., Jr.
TI Lithium and Valproate Levels Do Not Correlate with Ketamine's
Antidepressant Efficacy in Treatment-Resistant Bipolar Depression
SO NEURAL PLASTICITY
LA English
DT Article
ID GLYCOGEN-SYNTHASE KINASE-3; ADD-ON TRIAL; MAJOR DEPRESSION; NEUROTROPHIC
FACTOR; MOOD STABILIZERS; DISORDER; INHIBITION; ALPHA; CARBAMAZEPINE;
ANTAGONISTS
AB Ketamine and lithium both inhibit glycogen synthase kinase 3. In addition, lithium and ketamine have synergistic antidepressant-like effects at individually subeffective doses in rodents. We hypothesized that ketamine's antidepressant effects would be improved by therapeutic doses of lithium versus valproate and that serum lithium levels would positively correlate with ketamine's antidepressant efficacy. Thirty-six patients with treatment-resistant bipolar depression maintained on therapeutic-dose lithium (n = 23, 0.79 +/- 0.15 mEq/L) or valproate (n = 13, 79.6 +/- 12.4 mg/mL) received 0.5 mg/kg ketamine infusion in a randomized, double-blind, placebo-controlled, crossover trial. The primary depression outcome measure-the Montgomery-Asberg Depression Rating Scale (MADRS)-was assessed before infusion and at numerous postinfusion time points. Both lithium (F-1,F-118 = 152.08, p < 0.001, and d = 2.27) and valproate (F-1,F-128 = 20.12, p < 0.001, and d = 0.79) significantly improved depressive symptoms, but no statistically significant difference was observed between mood stabilizer groups (F-1,F-28 = 2.51, p = 0.12, and d = 0.60). Serum lithium and valproate levels did not correlate with ketamine's antidepressant efficacy. Although the study was potentially underpowered, our results suggest that lithiummay not potentiate ketamine's antidepressant efficacy in treatment-resistant bipolar depression.
C1 [Xu, Annie J.] New York Med Coll, Valhalla, NY 10595 USA.
[Niciu, Mark J.; Lundin, Nancy B.; Luckenbaugh, David A.; Richards, Erica M.; Ballard, Elizabeth D.; Brutsche, Nancy E.; Machado-Vieira, Rodrigo; Zarate, Carlos A., Jr.] NIMH, NIH, Expt Therapeut & Pathophysiol Branch, Bethesda, MD 20892 USA.
[Ionescu, Dawn F.] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
[Voort, Jennifer L. Vande] Mayo Clin, Dept Psychiat, Rochester, MN 55905 USA.
[Voort, Jennifer L. Vande] Mayo Clin, Psychol Serv, Rochester, MN 55905 USA.
RP Zarate, CA (reprint author), NIMH, NIH, Expt Therapeut & Pathophysiol Branch, 10 Ctr Dr,Bldg 10-CRC, Bethesda, MD 20892 USA.
EM zaratec@mail.nih.gov
RI Ionescu, Dawn/K-5675-2015;
OI MACHADO-VIEIRA, RODRIGO/0000-0002-4830-1190
FU Intramural Research Program of the National Institute of Mental Health,
National Institutes of Health (IRP-NIMH-NIH; Bethesda, MD, USA); 7SE
Inpatient Mood and Anxiety Disorders Research Unit of the IRP-NIMH-NIH
FX The authors gratefully acknowledge the support of the Intramural
Research Program of the National Institute of Mental Health, National
Institutes of Health (IRP-NIMH-NIH; Bethesda, MD, USA), and thank the
7SE Inpatient Mood and Anxiety Disorders Research Unit of the
IRP-NIMH-NIH for their support. Ioline Henter (NIMH) provided excellent
editorial assistance.
NR 40
TC 2
Z9 2
U1 1
U2 2
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2090-5904
EI 1687-5443
J9 NEURAL PLAST
JI Neural. Plast.
PY 2015
AR 858251
DI 10.1155/2015/858251
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA CL1PD
UT WOS:000356715100001
ER
PT J
AU George, S
AF George, Suzanne
TI Fifteen Years of Kinase Inhibition in Gastrointestinal Stromal Tumor:
Clinical Implications of Tumor Genotyping
SO ONCOLOGIST
LA English
DT Meeting Abstract
C1 [George, Suzanne] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PY 2015
VL 20
SU 1
MA 8
BP S4
EP S4
PG 1
WC Oncology
SC Oncology
GA CL1BR
UT WOS:000356677900009
ER
PT J
AU Johnson, BE
AF Johnson, Bruce E.
TI Implications of Genomic Diversity in Lung Cancers
SO ONCOLOGIST
LA English
DT Meeting Abstract
C1 [Johnson, Bruce E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PY 2015
VL 20
SU 1
MA 9
BP S5
EP S5
PG 1
WC Oncology
SC Oncology
GA CL1BR
UT WOS:000356677900010
ER
PT J
AU Stahlman, S
Javanbakht, M
Cochran, S
Shoptaw, S
Hamilton, AB
Gorbach, PM
AF Stahlman, Shauna
Javanbakht, Marjan
Cochran, Susan
Shoptaw, Steven
Hamilton, Alison B.
Gorbach, Pamina M.
TI A comparison of self-reported sexual risk behaviours between US civilian
and active duty military women
SO SEXUAL HEALTH
LA English
DT Article
ID TRANSMITTED INFECTIONS; UNITED-STATES; SUBSTANCE USE; RECRUITS; TRENDS
AB Women in the US military report a high prevalence of sexual risk behaviours, such as binge drinking and new or multiple sexual partnerships. However, demographical differences pose challenges to making comparisons with civilians. Two public-use datasets were used to compare prevalence of sexual risk behaviours between sexually active military and civilian women, after adjusting for demographic factors. It was found that women in the military reported a higher prevalence of binge drinking and new/multiple sexual partners as compared with civilians, which suggests that military women are a high-risk group and the military environment may at least partially facilitate these risk behaviours.
C1 [Stahlman, Shauna; Javanbakht, Marjan; Cochran, Susan; Gorbach, Pamina M.] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.
[Hamilton, Alison B.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Shoptaw, Steven] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90095 USA.
RP Stahlman, S (reprint author), Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.
EM sstahlman@ucla.edu
OI Shoptaw, Steven/0000-0002-3583-0026
FU NIMH NIH HHS [P30 MH058107]
NR 16
TC 1
Z9 1
U1 0
U2 3
PU CSIRO PUBLISHING
PI CLAYTON
PA UNIPARK, BLDG 1, LEVEL 1, 195 WELLINGTON RD, LOCKED BAG 10, CLAYTON, VIC
3168, AUSTRALIA
SN 1448-5028
EI 1449-8987
J9 SEX HEALTH
JI Sex Health
PY 2015
VL 12
IS 3
BP 272
EP 275
DI 10.1071/SH14211
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CK7EV
UT WOS:000356395300015
PM 25844558
ER
PT J
AU Matteucci, E
Giampietro, O
Covolan, V
Giustarini, D
Fanti, P
Rossi, R
AF Matteucci, Elena
Giampietro, Ottavio
Covolan, Vera
Giustarini, Daniela
Fanti, Paolo
Rossi, Ranieri
TI Insulin administration: present strategies and future directions for a
noninvasive (possibly more physiological) delivery
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE type 1 diabetes mellitus; drug formulations; drug administration routes;
insulin; portal system; nanoparticles; biodegradable polymers
ID TRANSDERMAL DRUG-DELIVERY; TIME-ACTION PROFILE; SUBCUTANEOUSLY INJECTED
INSULIN; INHALED TECHNOSPHERE INSULIN; RANDOMIZED CONTROLLED-TRIAL;
SOLID LIPID NANOPARTICLES; REGULAR HUMAN INSULIN; ORAL INSULIN;
DIABETES-MELLITUS; IN-VIVO
AB Insulin is a life-saving medication for people with type 1 diabetes, but traditional insulin replacement therapy is based on multiple daily subcutaneous injections or continuous subcutaneous pump-regulated infusion. Nonphysiologic delivery of subcutaneous insulin implies a rapid and sustained increase in systemic insulin levels due to the loss of concentration gradient between portal and systemic circulations. In fact, the liver degrades about half of the endogenous insulin secreted by the pancreas into the venous portal system. The reverse insulin distribution has short- and long-term effects on glucose metabolism. Thus, researchers have explored less-invasive administration routes based on innovative pharmaceutical formulations, which preserve hormone stability and ensure the therapeutic effectiveness. This review examines some of the recent proposals from clinical and material chemistry point of view, giving particular attention to patients' (and diabetologists') ideal requirements that organic chemistry could meet.
C1 [Matteucci, Elena; Giampietro, Ottavio] Univ Pisa, Dept Clin & Expt Med, I-56100 Pisa, Italy.
[Covolan, Vera] Univ Pisa, Dept Chem & Ind Chem, I-56100 Pisa, Italy.
[Giustarini, Daniela; Rossi, Ranieri] Univ Siena, Lab Pharmacol & Toxicol, Dept Life Sci, I-53100 Siena, Italy.
[Fanti, Paolo] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Matteucci, E (reprint author), Dipartimento Med Clin & Sperimentale, Via Roma 67, I-56126 Pisa, Italy.
EM elena.matteucci@med.unipi.it
NR 75
TC 4
Z9 4
U1 3
U2 24
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2015
VL 9
BP 3109
EP 3118
DI 10.2147/DDDT.S79322
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CK6RA
UT WOS:000356354100001
PM 26124635
ER
PT J
AU Mottalib, A
Sakr, M
Shehabeldin, M
Hamdy, O
AF Mottalib, Adham
Sakr, Mahmoud
Shehabeldin, Mohamed
Hamdy, Osama
TI Diabetes Remission after Nonsurgical Intensive Lifestyle Intervention in
Obese Patients with Type 2 Diabetes
SO JOURNAL OF DIABETES RESEARCH
LA English
DT Article
ID BETA-CELL FUNCTION; CARDIOVASCULAR RISK-FACTORS; BARIATRIC SURGERY;
INSULIN SENSITIVITY; GLUCOSE-TOLERANCE; WEIGHT MANAGEMENT; MELLITUS;
RESISTANCE; THERAPY; METAANALYSIS
AB Partial or complete remission from type 2 diabetes was recently observed after bariatric surgeries. Limited data is available about the possibility of inducing diabetes remission through intensive weight reduction. We retrospectively evaluated diabetes remissions after one year of the Weight Achievement and Intensive Treatment (Why WAIT) program, a 12-week intensive program for diabetes weight management in real-world clinical practice. Among 120 obese patients with type 2 diabetes who completed the program, 88 patients returned for follow-up at one year. Nineteen patients (21.6%) had major improvement in their glycemic control, defined as achieving an A1C < 6.5% after one year. Four patients (4.5%) achieved either partial or complete diabetes remission defined as A1C < 6.5% and < 5.7%, respectively, on no antihyperglycemic medications for one year; 2 achieved partial remission (2.3%) and 2 achieved complete remission (2.3%). At the time of intervention, patients who achieved diabetes remission had shorter diabetes duration (< 5 years) and lower A1C (< 8%) and were treated with fewer than 2 oral medications. They achieved a weight reduction of > 7% after 12 weeks. These results indicate that a subset of obese patients with type 2 diabetes is appropriate for intensive lifestyle intervention with the aim of inducing diabetes remission.
C1 [Mottalib, Adham; Sakr, Mahmoud; Shehabeldin, Mohamed; Hamdy, Osama] Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Hamdy, O (reprint author), Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.
EM osama.hamdy@joslin.harvard.edu
OI Mottalib, Adham/0000-0002-8573-6329
FU Metagenics, Inc.; Neurometrix, Inc.
FX Osama Hamdy is a Consultant for Abbott Nutrition, Merck & Co., Inc.
Research Support was received from Metagenics, Inc., and Neurometrix,
Inc.
NR 27
TC 1
Z9 1
U1 1
U2 3
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6745
EI 2314-6753
J9 J DIABETES RES
JI J. Diabetes Res.
PY 2015
AR 468704
DI 10.1155/2015/468704
PG 4
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA CK5JB
UT WOS:000356258800001
ER
PT J
AU Asselin, P
Knezevic, S
Kornfeld, S
Cirnigliaro, C
Agranova-Breyter, I
Bauman, WA
Spungen, AM
AF Asselin, Pierre
Knezevic, Steven
Kornfeld, Stephen
Cirnigliaro, Christopher
Agranova-Breyter, Irina
Bauman, William A.
Spungen, Ann M.
TI Heart rate and oxygen demand of powered exoskeleton-assisted walking in
persons with paraplegia
SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT
LA English
DT Article
DE 6MWT; ambulatory device; energy expenditure; metabolic; overground
walking; oxygen uptake; paraplegia; powered exoskeleton; reciprocating
gait orthosis; RGO; spinal cord injury
ID SPINAL-CORD-INJURY; RECIPROCATING-GAIT ORTHOSIS; QUALITY-OF-LIFE;
ELECTRICAL-STIMULATION; ENERGY-EXPENDITURE; HYBRID ORTHOSIS; EXERCISE;
INDIVIDUALS; PERFORMANCE; COST
AB Historically, persons with paralysis have limited options for overground ambulation. Recently, powered exoskeletons, which are systems that translate the user's body movements to activate motors that move the lower limbs through a predetermined gait pattern, have become available. As part of an ongoing clinical study (NCT01454570), eight nonambulatory persons with paraplegia were trained to ambulate with a powered exoskeleton. Measurements of oxygen uptake (VO2) and heart rate (HR) were recorded for 6 mm each during each maneuver while sitting, standing, and walking. The average value of VO2 during walking (11.2 +/- 1.7 mL/kg/min) was significantly higher than for sitting and standing (3.5 +/- 0.4 and 4.3 +/- 0.9 mL/kg/min, respectively; p < 0.001). The HR response during walking was significantly greater than that of either sitting or standing (118 +/- 21 vs 70 +/- 10 and 81 +/- 12 beats per minute, respectively; p < 0.001). Persons with paraplegia were able to ambulate efficiently using the powered exoskeleton for overground ambulation, providing the potential for functional gain and improved fitness.
C1 [Asselin, Pierre; Knezevic, Steven; Kornfeld, Stephen; Cirnigliaro, Christopher; Bauman, William A.; Spungen, Ann M.] Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs VA Rehabil Res & Dev, Bronx, NY USA.
[Kornfeld, Stephen] Spinal Cord Injury Patient Care Ctr, Bronx, NY USA.
[Agranova-Breyter, Irina] James J Peters VA Med Ctr, Rehabil Med, Bronx, NY USA.
[Bauman, William A.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
[Bauman, William A.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA.
RP Spungen, AM (reprint author), 130 W Kingsbridge Rd,Rm 7A-13, Bronx, NY 10468 USA.
EM Ann.spungen@va.gov
FU VA Rehabilitation Research & Development National Center of Excellence
for the Medical Consequences of Spinal Cord Injury [VA RRD B9212C]
FX Funding/Support: This material was based on work supported by the VA
Rehabilitation Research & Development National Center of Excellence for
the Medical Consequences of Spinal Cord Injury (VA RR&D B9212C). Two of
the four ReWalk devices were obtained on a loaner basis at no cost from
Argo Medical Technologies (Marlborough, Massachusetts). Orthopedic shoes
used in this trial were donated by Aetrex Worldwide Inc. (Teaneck, New
Jersey).
NR 55
TC 5
Z9 5
U1 0
U2 10
PU JOURNAL REHAB RES & DEV
PI BALTIMORE
PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET,
BALTIMORE, MD 21202-4051 USA
SN 0748-7711
EI 1938-1352
J9 J REHABIL RES DEV
JI J. Rehabil. Res. Dev.
PY 2015
VL 52
IS 2
BP 147
EP 158
DI 10.1682/JRRD.2014.02.0060
PG 12
WC Rehabilitation
SC Rehabilitation
GA CK6DB
UT WOS:000356317600003
PM 26230182
ER
PT J
AU Littman, AJ
Thompson, ML
Arterburn, DE
Bouldin, E
Haselkorn, JK
Sangeorzan, BJ
Boyko, EJ
AF Littman, Alyson J.
Thompson, Mary Lou
Arterburn, David E.
Bouldin, Erin
Haselkorn, Jodie K.
Sangeorzan, Bruce J.
Boyko, Edward J.
TI Lower-limb amputation and body weight changes in men
SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT
LA English
DT Article
DE adult; lower-limb amputation; men; obesity; partial foot amputation; toe
amputation; transfemoral amputation; transtibial amputation; Veterans;
weight change
ID CARDIOVASCULAR-DISEASE; UNITED-STATES; PSYCHOSOCIAL ADJUSTMENT;
RISK-ADJUSTMENT; PREVALENCE; MORTALITY; VETERANS; AMPUTEES; OBESITY;
HEALTH
AB Little is known about the relationship between lower-limb amputation (LLA) and subsequent changes in body weight. We conducted a retrospective cohort study using clinical and administrative databases to identify and follow weight changes in 759 males with amputation (partial foot amputation [PFA], n = 396; transtibial amputation [TTA], n = 267; and transfemoral amputation [TFA], n = 96) and 3,790 men without amputation frequency-matched (5:1) on age, body mass index, diabetes, and calendar year from eight Department of Veterans Affairs medical care facilities in the Pacific Northwest. We estimated and compared longitudinal percent weight change from baseline up to 39 mo of follow-up in men with and without amputation. Weight gain in the 2 yr after amputation was significantly more in men with an amputation than without, and in men with a TTA or TFA (8%-9% increase) than in men with a PFA (3%-6% increase). Generally, percent weight gain peaked at 2 yr and was followed by some weight loss in the third year. These findings indicate that LLA is often followed by clinically important weight gain. Future studies are needed to better understand the reasons for weight gain and to identify intervention strategies to prevent excess weight gain and the deleterious consequences that may ensue.
C1 [Littman, Alyson J.; Thompson, Mary Lou; Bouldin, Erin; Boyko, Edward J.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Littman, Alyson J.; Bouldin, Erin; Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Thompson, Mary Lou] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA.
[Haselkorn, Jodie K.] Univ Washington, VA Puget Sound Hlth Care Syst, Multiple Sclerosis Ctr Excellence West, Seattle, WA 98195 USA.
[Haselkorn, Jodie K.] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA.
[Haselkorn, Jodie K.; Sangeorzan, Bruce J.] Univ Washington, Harborview Med Ctr, VA Puget Sound Hlth Care Syst, VA Ctr Excellence Limb Loss Prevent & Prosthet En, Seattle, WA 98104 USA.
[Haselkorn, Jodie K.; Sangeorzan, Bruce J.] Univ Washington, Harborview Med Ctr, Dept Orthopaed & Sports Med, Seattle, WA 98104 USA.
RP Littman, AJ (reprint author), VA Puget Sound Med Ctr, Seattle Epidemiol Res & Informat Ctr, 1100 Olive Way,Metropolitan Pk West,Suite 1400, Seattle, WA 98101 USA.
EM alyson.littman@va.gov
OI Bouldin, Erin/0000-0001-7550-309X
FU VA Office of Research and Development Cooperative Studies Program;
Seattle Epidemiologic Research and Information Center of the VA; VA
Rehabilitation Research and Development Career Development Award [6982]
FX Funding/Support: This material was based on work supported in part by
the VA Office of Research and Development Cooperative Studies Program.
The Seattle Epidemiologic Research and Information Center of the VA
provided support for this research. Dr. Littman's time was also
supported by a VA Rehabilitation Research and Development Career
Development Award (grant 6982).
NR 20
TC 2
Z9 2
U1 1
U2 6
PU JOURNAL REHAB RES & DEV
PI BALTIMORE
PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET,
BALTIMORE, MD 21202-4051 USA
SN 0748-7711
EI 1938-1352
J9 J REHABIL RES DEV
JI J. Rehabil. Res. Dev.
PY 2015
VL 52
IS 2
BP 159
EP 169
DI 10.1682/JRRD.2014.07.0166
PG 11
WC Rehabilitation
SC Rehabilitation
GA CK6DB
UT WOS:000356317600004
PM 26244755
ER
PT J
AU Barks, L
Luther, SL
Brown, LM
Schulz, B
Bowen, ME
Powell-Cope, G
AF Barks, Lelia
Luther, Stephen L.
Brown, Lisa M.
Schulz, Brian
Bowen, Mary Elizabeth
Powell-Cope, Gail
TI Development and initial validation of the Seated Posture Scale
SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT
LA English
DT Article
DE elder; geriatric; long-term care; posture; reliability; seat; SPS;
validity; Veteran; wheelchair
ID WHEELCHAIR; RELIABILITY; RESIDENTS; PERFUSION; PRESSURE; CHILDREN
AB Literature shows that some health outcomes (e.g., eating, breathing, and speaking) are directly related to posture. Evidence of outcomes mediated by wheelchair seated posture is limited to interface pressure, physical function, and wheelchair skills and safety. This study's purpose was to develop and validate a rapid, low-burden, paper-pencil assessment of wheelchair seated posture for research use and to test feasibility of its use with a sample of older adults. We used a prospective design and a convenience sample of older adults who were receiving rehabilitation services in a community living center. Forty-nine older wheelchair users participated. Main measures were the Seated Posture Scale (SPS), Modified Ashworth Scale, Barthel Index, Visual Descriptor Scale, scale-content validity index (S-CVI), Cronbach alpha, and test-retest reliability. Rating by six experts yielded the overall content validity score (S-CVI) of 0.744. Total SPS score correlated positively with physical function (Barthel Index, r = 0.46, p < 0.001) and negatively with muscle tone (Modified Ashworth Scale, r = -0.44, p = 0.001), supporting SPS construct validity. Internal consistency was 0.66 (Cronbach alpha). Test-retest reliability yielded Pearson product-moment correlations of 0.89 to 0.99. We conclude that the SPS has sufficient preliminary validity and reliability to support its use as an evaluation of wheelchair seated posture in outcomes research.
C1 [Barks, Lelia; Luther, Stephen L.; Brown, Lisa M.; Bowen, Mary Elizabeth; Powell-Cope, Gail] James A Haley Vet Hosp, Ctr Innovat Disabil & Rehabil Res, Tampa, FL 33612 USA.
[Barks, Lelia; Luther, Stephen L.; Brown, Lisa M.; Bowen, Mary Elizabeth; Powell-Cope, Gail] Dept Vet Affairs VA, Rehabil Res & Dev Serv, Washington, DC USA.
[Brown, Lisa M.; Schulz, Brian] Univ S Florida, Sch Aging Studies, Tampa, FL USA.
[Bowen, Mary Elizabeth] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Bowen, Mary Elizabeth] Ctr West Chester Univ, W Chester, PA USA.
RP Barks, L (reprint author), Hlth Serv Res & Dev Rehabil Res & Dev Ctr Innovat, 8900 Grand Oak Cir, Tampa, FL 33637 USA.
EM Lelia.Barks@va.gov
OI Powell-Cope, Gail/0000-0002-4608-0128
FU VA Office of Academic Affiliations; VA Office of Research and
Development, Rehabilitation Research and Development Service (Career
Development Award) [07646-W, 2]
FX Funding/Support: This material was based on work supported initially by
the VA Office of Academic Affiliations (postdoctoral fellowship) and
later by the VA Office of Research and Development, Rehabilitation
Research and Development Service (Career Development Award 2 No.
07646-W).
NR 27
TC 0
Z9 0
U1 0
U2 0
PU JOURNAL REHAB RES & DEV
PI BALTIMORE
PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET,
BALTIMORE, MD 21202-4051 USA
SN 0748-7711
EI 1938-1352
J9 J REHABIL RES DEV
JI J. Rehabil. Res. Dev.
PY 2015
VL 52
IS 2
BP 201
EP 210
DI 10.1682/JRRD.2014.04.0100
PG 10
WC Rehabilitation
SC Rehabilitation
GA CK6DB
UT WOS:000356317600008
PM 26230339
ER
PT S
AU Jin, YN
Yin, ZY
Yao, YY
Wang, H
Wu, MY
Kalra, M
De Man, B
AF Jin, Yannan
Yin, Zhye
Yao, Yangyang
Wang, Hui
Wu, Mingye
Kalra, Mannudeep
De Man, Bruno
BE Hoeschen, C
Kontos, D
TI Patient Specific Tube Current Modulation for CT Dose Reduction
SO MEDICAL IMAGING 2015: PHYSICS OF MEDICAL IMAGING
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Medical Imaging - Physics of Medical Imaging
CY FEB 22-25, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Devices Inc, Bruker, Carestream Health Inc, GE Healthcare, American Assoc Physicists Med, American Physiolog Soc, Comp Assisted Radiol & Surg, Med Image Percept Soc, Radiolog Soc N America, Soc Imaging Informat Med, World Mol Imaging Soc, DICOM Stand Comm
DE Computed Tomography; dose reduction; mA modulation; patient-specific
dose optimization
ID IMAGE QUALITY; STRATEGIES; PHANTOM
AB Radiation exposure during CT imaging has drawn growing concern from academia, industry as well as the general public. Sinusoidal tube current modulation has been available in most commercial products and used routinely in clinical practice. To further exploit the potential of tube current modulation, Sperl et al. proposed a Computer-Assisted Scan Protocol and Reconstruction (CASPAR) scheme [6] that modulates the tube current based on the clinical applications and patient specific information. The purpose of this study is to accelerate the CASPAR scheme to make it more practical for clinical use and investigate its dose benefit for different clinical applications. The Monte Carlo simulation in the original CASPAR scheme was substituted by the dose reconstruction to accelerate the optimization process. To demonstrate the dose benefit, we used the CATSIM package generate the projection data and perform standard FDK reconstruction. The NCAT phantom at thorax position was used in the simulation. We chose three clinical cases (routine chest scan, coronary CT angiography with and without breast avoidance) and compared the dose level with different mA modulation schemes (patient specific, sinusoidal and constant mA) with matched image quality. The simulation study of three clinical cases demonstrated that the patient specific mA modulation could significantly reduce the radiation dose compared to sinusoidal modulation. The dose benefits depend on the clinical application and object shape. With matched image quality, for chest scan the patient specific mA profile reduced the dose by about 15% compared to the sinusoid mA modulation; for the organ avoidance scan the dose reduction to the breast was over 50% compared to the constant mA baseline.
C1 [Jin, Yannan; Yin, Zhye; De Man, Bruno] GE Global Res Ctr, CT Syst & Applicat Lab, Niskayuna, NY 12309 USA.
[Yao, Yangyang; Wang, Hui; Wu, Mingye] GE Global Res Ctr, CT & Xray Lab, Shanghai, Peoples R China.
[Kalra, Mannudeep] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Jin, YN (reprint author), GE Global Res Ctr, CT Syst & Applicat Lab, Niskayuna, NY 12309 USA.
NR 13
TC 1
Z9 1
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-502-5
J9 PROC SPIE
PY 2015
VL 9412
AR 94122Z
DI 10.1117/12.2081486
PG 6
WC Optics; Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging
GA BC8EX
UT WOS:000355581700096
ER
PT S
AU Nasirudin, RA
Tachibana, R
Nappi, JJ
Mei, K
Kopp, FK
Rummeny, EJ
Yoshida, H
Noel, PB
AF Nasirudin, Radin A.
Tachibana, Rie
Naeppi, Janne J.
Mei, Kai
Kopp, Felix K.
Rummeny, Ernst J.
Yoshida, Hiroyuki
Noel, Peter B.
BE Hoeschen, C
Kontos, D
TI A comparison of material decomposition techniques for dual-energy CT
colonography
SO MEDICAL IMAGING 2015: PHYSICS OF MEDICAL IMAGING
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Medical Imaging - Physics of Medical Imaging
CY FEB 22-25, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Devices Inc, Bruker, Carestream Health Inc, GE Healthcare, American Assoc Physicists Med, American Physiolog Soc, Comp Assisted Radiol & Surg, Med Image Percept Soc, Radiolog Soc N America, Soc Imaging Informat Med, World Mol Imaging Soc, DICOM Stand Comm
DE Dual-Energy CT; CT Colonography; Computer-Aided Design; Material
Decomposition
ID POLYPS; PERFORMANCE; EXPERIENCE; CAD
AB In recent years, dual-energy computed tomography (DECT) has been widely used in the clinical routine due to improved diagnostics capability from additional spectral information. One promising application for DECT is CT colonography (CTC) in combination with computer-aided diagnosis (CAD) for detection of lesions and polyps. While CAD has demonstrated in the past that it is able to detect small polyps, its performance is highly dependent on the quality of the input data. The presence of artifacts such as beam-hardening and noise in ultra-low-dose CTC may severely degrade detection performances of small polyps. In this work, we investigate and compare virtual monochromatic images, generated by image-based decomposition and projection-based decomposition, with respect to CAD performance. In the image-based method, reconstructed images are firstly decomposed into water and iodine before the virtual monochromatic images are calculated. On the contrary, in the projection-based method, the projection data are first decomposed before calculation of virtual monochromatic projection and reconstruction. Both material decomposition methods are evaluated with regards to the accuracy of iodine detection. Further, the performance of the virtual monochromatic images is qualitatively and quantitatively assessed. Preliminary results show that the projection-based method does not only have a more accurate detection of iodine, but also delivers virtual monochromatic images with reduced beam hardening artifacts in comparison with the image-based method. With regards to the CAD performance, the projection-based method yields an improved detection performance of polyps in comparison with that of the image-based method.
C1 [Nasirudin, Radin A.; Mei, Kai; Kopp, Felix K.; Rummeny, Ernst J.; Noel, Peter B.] Tech Univ Munich, Dept Diagnost & Intervent Radiol, D-80290 Munich, Germany.
[Tachibana, Rie; Naeppi, Janne J.; Yoshida, Hiroyuki] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Imaging Res D3, Boston, MA USA.
RP Nasirudin, RA (reprint author), Tech Univ Munich, Dept Diagnost & Intervent Radiol, D-80290 Munich, Germany.
OI Noel, Peter/0000-0002-9671-6171
NR 10
TC 0
Z9 0
U1 0
U2 1
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-502-5
J9 PROC SPIE
PY 2015
VL 9412
AR 94124F
DI 10.1117/12.2081982
PG 6
WC Optics; Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging
GA BC8EX
UT WOS:000355581700145
ER
PT S
AU Viana, RS
Galarreta-Valverde, MA
Mekkaoui, C
Yoriyaz, H
Jackowski, MP
AF Viana, Rodrigo S.
Galarreta-Valverde, Miguel A.
Mekkaoui, Choukri
Yoriyaz, Helio
Jackowski, Marcel P.
BE Hoeschen, C
Kontos, D
TI NSECT sinogram sampling optimization by normalized mutual information
SO MEDICAL IMAGING 2015: PHYSICS OF MEDICAL IMAGING
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Medical Imaging - Physics of Medical Imaging
CY FEB 22-25, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Devices Inc, Bruker, Carestream Health Inc, GE Healthcare, American Assoc Physicists Med, American Physiolog Soc, Comp Assisted Radiol & Surg, Med Image Percept Soc, Radiolog Soc N America, Soc Imaging Informat Med, World Mol Imaging Soc, DICOM Stand Comm
DE Neutron stimulated emission computed tomography; mutual information;
MCNP5; radon transform; image reconstruction
ID CANCER
AB Neutron Stimulated Emission Computed Tomography (NSECT) is an emerging noninvasive imaging technique that measures the distribution of isotopes from biological tissue using fast-neutron inelastic scattering reaction. As a high-energy neutron beam illuminates the sample, the excited nuclei emit gamma rays whose energies are unique to the emitting nuclei. Tomographic images of each element in the spectrum can then be reconstructed to represent the spatial distribution of elements within the sample using a first generation tomographic scan. NSECT's high radiation dose deposition, however, requires a sampling strategy that can yield maximum image quality under a reasonable radiation dose. In this work, we introduce an NSECT sinogram sampling technique based on the Normalized Mutual Information (NMI) of the reconstructed images. By applying the Radon Transform on the ground-truth image obtained from a carbon-based synthetic phantom, different NSECT sinogram configurations were simulated and compared by using the NMI as a similarity measure. The proposed methodology was also applied on NSECT images acquired using MCNP5 Monte Carlo simulations of the same phantom to validate our strategy. Results show that NMI can be used to robustly predict the quality of the reconstructed NSECT images, leading to an optimal NSECT acquisition and a minimal absorbed dose by the patient.
C1 [Viana, Rodrigo S.; Yoriyaz, Helio] IPEN CEN, Inst Nucl Energy Res, Nucl Engn Ctr, Sao Paulo, SP, Brazil.
[Galarreta-Valverde, Miguel A.; Jackowski, Marcel P.] Univ Sao Paulo, Dept Comp Sci, Inst Math & Stat, Sao Paulo, SP, Brazil.
[Mekkaoui, Choukri] Univ Hosp Ctr Nimes, Dept Radiol, Nimes, France.
[Mekkaoui, Choukri] Res Team EA 2415, Nimes, France.
[Mekkaoui, Choukri] Univ Montpellier, Fac Med, F-34059 Montpellier, France.
[Mekkaoui, Choukri] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,Athinoula A Martinos Ctr B, Boston, MA 02115 USA.
RP Viana, RS (reprint author), IPEN CEN, Inst Nucl Energy Res, Nucl Engn Ctr, Sao Paulo, SP, Brazil.
EM mjack@ime.usp.br
RI Jackowski, Marcel/G-7602-2012; Yoriyaz, Helio/K-1874-2012
OI Yoriyaz, Helio/0000-0003-4023-236X
NR 11
TC 0
Z9 0
U1 0
U2 1
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-502-5
J9 PROC SPIE
PY 2015
VL 9412
AR 94122B
DI 10.1117/12.2082496
PG 6
WC Optics; Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging
GA BC8EX
UT WOS:000355581700076
ER
PT J
AU Li, J
Ji, L
Chen, JP
Zhang, WG
Ye, ZJ
AF Li, Jing
Ji, Ling
Chen, Jieping
Zhang, Wengeng
Ye, Zhijia
TI Wnt/beta-Catenin Signaling Pathway in Skin Carcinogenesis and Therapy
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID NEURAL CREST STEM; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HAIR FOLLICLE
MORPHOGENESIS; BETA-CATENIN; CUTANEOUS MELANOMA; MALIGNANT-MELANOMA;
CELL CARCINOMA; ADULT SKIN; VITAMIN-D; WNT
AB Cooperating with other signaling pathways, Wnt signaling controls cell proliferation, morphology, motility, and embryonic development destination and maintains the homeostasis of tissues including skin, blood, intestine, and brain by regulating somatic stem cells and their niches throughout adult life. Abnormal regulation of Wnt pathways leads to neoplastic proliferation in these tissues. Recent research shows that Wnt signaling is also associated with the regulation of cancer stem cells (CSCs) through a similar mechanism to that observed in normal adult stem cells. Thus, the Wnt/beta-catenin signaling pathway has been intensively studied and characterized. For this review, we will focus on the regulation of the Wnt/beta-catenin signaling pathway in skin cancer. With the important role in stemness and skin CSC proliferation, the Wnt/beta-catenin signaling pathway and its elements have the potential to be targets for skin cancer therapy.
C1 [Li, Jing; Ji, Ling; Ye, Zhijia] Third Mil Med Univ, Inst Trop Med, Chongqing 400038, Peoples R China.
[Ji, Ling] Third Mil Med Univ, Southwest Hosp, Dept Hematol, Chongqing 400038, Peoples R China.
[Zhang, Wengeng] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Dept Surg, Boston, MA 02114 USA.
RP Zhang, WG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Dept Surg, 51 Blossom St, Boston, MA 02114 USA.
EM wengeng.zhang@mgh.harvard.edu; zjye@tmmu.edu.cn
FU National Natural Science Foundation of China [81170471, 31371393];
Natural Science Foundation of Chongqing Science & Technology Commission
[cstc2013jjB10027]
FX This research was supported by the National Natural Science Foundation
of China (81170471, 31371393) and the Natural Science Foundation of
Chongqing Science & Technology Commission (cstc2013jjB10027).
NR 73
TC 0
Z9 0
U1 1
U2 3
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 964842
DI 10.1155/2015/964842
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CJ5JG
UT WOS:000355523000001
ER
PT J
AU Huang, YY
Luo, DZ
Hamblin, MR
AF Huang, Ying-Ying
Luo, Dianzhong
Hamblin, Michael R.
TI Stable Synthetic Bacteriochlorins: Potent Light-Activated Anti-Cancer
Drugs
SO CURRENT ORGANIC CHEMISTRY
LA English
DT Article
DE Anti-cancer drugs; near-infrared light; photodynamic therapy; reactive
oxygen species; stable synthetic bacteriochlorins; structure-function
relationship
ID PHOTODYNAMIC THERAPY ROLE; IN-VITRO; CREMOPHOR EL; 2ND-GENERATION
PHOTOSENSITIZER; CENTRAL METAL; CANCER-CELLS; FLUORESCENCE; DELIVERY;
DERIVATIVES; MECHANISMS
AB Photodynamic therapy (PDT) uses non-toxic dyes called photosensitizers (PS) to absorb light of visible or near-infrared wavelengths at non-thermal power densities that (in the presence of oxygen) combine together to produce reactive oxygen species (ROS). The main ROS formed are singlet oxygen and hydroxyl radicals that can both have cytotoxic effects. PDT has two separate mechanisms of specificity due to specific accumulation in the tumor coupled with spatially confined illumination. The first-generation PS were porphyrins, but due to the need for long-wavelength activation to improve tissue penetration, second-generation chlorins (far red) and bacteriochlorins (BC) (near infrared [NIR]) have been investigated. This review covers quantitative structure-function relationship with charge and lipophilicity, the effect the central metal atom has on determining the photochemical mechanism, the effect that electron withdrawing di-cyano groups have on preventing photobleaching, the improvement in activity found when micellar nanocarriers are employed, and the relative superiority of mono-substitution over symmetrical di-substitution. Finally, the necessity for long-wavelength (730 nm) activation is underlined by looking at PDT of pigmented melanoma in vitro and in a mouse model of melanoma.
C1 [Huang, Ying-Ying; Luo, Dianzhong] Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, Nanning 530021, Guangxi Zhuang, Peoples R China.
[Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), BAR414,40 Blossom St, Boston, MA 02114 USA.
EM Hamblin@helix.mgh.harvard.edu
FU US NIH [R01AI050875]; National Science Foundation of China [81060200]
FX YYH and MRH were supported by US NIH grant R01AI050875. DL was supported
by National Science Foundation of China (81060200).
NR 43
TC 5
Z9 5
U1 2
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1385-2728
EI 1875-5348
J9 CURR ORG CHEM
JI Curr. Org. Chem.
PY 2015
VL 19
IS 10
BP 948
EP 957
PG 10
WC Chemistry, Organic
SC Chemistry
GA CJ3IT
UT WOS:000355377300007
ER
PT J
AU Devkota, S
Chang, EB
AF Devkota, Suzanne
Chang, Eugene B.
TI Interactions between Diet, Bile Acid Metabolism, Gut Microbiota, and
Inflammatory Bowel Diseases
SO DIGESTIVE DISEASES
LA English
DT Article
DE Bile acids; Diet; Inflammatory bowel disease; Microbiome; Pathobiont
ID SULFATE-REDUCING BACTERIA; BILOPHILA-WADSWORTHIA; ULCERATIVE-COLITIS;
HYDROGEN-SULFIDE; EPIDEMIOLOGY; PATHOGENESIS; PREVALENCE; HEALTHY; FAT
AB The composite human gut microbiomes of Western populations have changed over the past century, brought on by new environmental triggers that often have a negative impact on human health. Diets high in saturated fats and refined sugars and low in fiber are leading candidates for these events and for triggering the increased prevalence of immune-mediated diseases like inflammatory bowel disease (IBD). Our studies have shown that consumption of a 'Western' diet high in saturated (milk-derived) fat (MF) or n-6 polyunsaturated (safflower oil) fat have similar effects on the structure of the colonic microbiome of wild-type and IL-1 10(-/-) mice, characterized by increased Bacteroidetes and decreased Firmicutes. However, the MF diet uniquely promotes the expansion of an immunogenic sulfite-reducing pathobiont, Bilophila wadsworthia, a member of the Deltaproteo-bacteria and minor component of the gut microbiome. This bacterial bloom results from a ME diet-induced shift in hepatic conjugation of bile acids, from glycocholic to taurocholic (TC) acid, which is important for solubilizing the more hydrophobic ME diet. However, it is also responsible for delivery of taurine-derived sulfur to the distal bowel, promoting the assemblage of bile-tolerant microbes such as B. wadsworthia. The bloom of this species promotes a Th1-mediated immune response and the development of colitis in IL-10(-/-) mice. A similar bloom of B. wadsworthia is seen when IL-10(-/-) mice are fed a low-fat diet supplemented with TC. B. wadsworthia colonization of monoassociated germ-free IL-10(-/-) mice was dependent on the host consuming either a high-saturated ME diet or the gavage with TC. Together, these data provide a plausible explanation for the link between diseases such as IBD and dietary-mediated selection of gut microbial pathobionts in genetically susceptible hosts. With this knowledge, it may be possible to mitigate the bloom of these types of pathobionts by modifying the conjugation states of bile acids. (C) 2015 S. Karger AG, Basel
C1 [Devkota, Suzanne] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Devkota, Suzanne] Harvard Univ, Sch Med, Boston, MA USA.
[Chang, Eugene B.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
RP Chang, EB (reprint author), Knapp Ctr Biomed Discovery, 900 E 57th St, Chicago, IL 60637 USA.
EM echang@medicine.bsd.uchicago.edu
FU National Institutes of Health [P30 DK42086, R37 DK47722, R01 DK097268,
T32 DK07074, F32 DK09025]; Leona M. and Harry B. Helmsley Charitable
Trust; Gastro-Intestinal Research Foundation of Chicago
FX The authors received funding from the National Institutes of Health
grants P30 DK42086, R37 DK47722, R01 DK097268, T32 DK07074 to E.B.C and
F32 DK09025 (to S.D.), the Leona M. and Harry B. Helmsley Charitable
Trust, and the Gastro-Intestinal Research Foundation of Chicago.
NR 20
TC 9
Z9 9
U1 8
U2 32
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0257-2753
EI 1421-9875
J9 DIGEST DIS
JI Dig. Dis.
PY 2015
VL 33
IS 3
BP 351
EP 356
DI 10.1159/000371687
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CJ6XN
UT WOS:000355638600010
PM 26045269
ER
PT J
AU Chen, KJ
Lee, MS
Xu, H
Zhang, QH
AF Chen, Ke-Ji
Lee, Myeong Soo
Xu, Hao
Zhang, Qunhao
TI Complementary/Alternative Medicine in Cardiovascular Diseases 2014
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Editorial Material
C1 [Chen, Ke-Ji; Xu, Hao] China Acad Chinese Med Sci, Xiyuan Hosp, Ctr Cardiovasc, Beijing 100091, Peoples R China.
[Lee, Myeong Soo] Korea Inst Oriental Med, Div Clin Res, Taejon 305811, South Korea.
[Zhang, Qunhao] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA.
RP Chen, KJ (reprint author), China Acad Chinese Med Sci, Xiyuan Hosp, Ctr Cardiovasc, Beijing 100091, Peoples R China.
EM kjchenvip@163.com
RI Lee, Myeong Soo/C-8147-2013
OI Lee, Myeong Soo/0000-0001-6651-7641
NR 0
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2015
AR 349375
DI 10.1155/2015/349375
PG 2
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA CJ9DZ
UT WOS:000355804000001
ER
PT J
AU Wilson, R
Anzueto, A
Miravitlles, M
Arvis, P
Haverstock, D
Trajanovic, M
Sethi, S
AF Wilson, Robert
Anzueto, Antonio
Miravitlles, Marc
Arvis, Pierre
Haverstock, Daniel
Trajanovic, Mila
Sethi, Sanjay
TI Prognostic factors for clinical failure of exacerbations in elderly
outpatients with moderate-to-severe COPD
SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LA English
DT Article
DE AECOPD; clinical failure; prognostic factor; long-term outcome; poor
outcome
ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM
OUTCOMES; CHRONIC-BRONCHITIS; ANTIBIOTIC-TREATMENT; ORAL PREDNISONE;
MORTALITY; RISK; CARE; CORTICOSTEROIDS
AB Background: Acute exacerbations represent a significant burden for patients with moderate-to-severe chronic obstructive pulmonary disease. Each exacerbation episode is frequently associated with a lengthy recovery and impaired quality of life. Prognostic factors for outpatients that may predict poor outcome after treatment with antibiotics recommended in the guidelines, are not fully understood. We aimed to identify pretherapy factors predictive of clinical failure in elderly (>= 60 years old) outpatients with acute Anthonisen type 1 exacerbations.
Trial registration: NCT00656747.
Methods: Based on the moxifloxacin in AECOPDs (acute exacerbations of chronic obstructive pulmonary disease) trial (MAESTRAL) database, this study evaluated pretherapy demographic, clinical, sputum bacteriological factors using multivariate logistic regression analysis, with internal validation by bootstrap replicates, to investigate their possible association with clinical failure at end of therapy (EOT) and 8 weeks posttherapy.
Results: The analyses found that the independent factors predicting clinical failure at EOT were more frequent exacerbations, increased respiratory rate and lower body temperature at exacerbation, treatment with long-acting anticholinergic drugs, and in vitro bacterial resistance to study drug. The independent factors predicting poor outcome at 8 weeks posttherapy included wheezing at preexacerbation, mild or moderate (vs extreme) sleep disturbances, lower body temperature at exacerbation, forced expiratory volume in 1 second <30%, lower body mass index, concomitant systemic corticosteroids for the current exacerbation, maintenance long-acting beta(2)-agonist and long-acting anticholinergic treatments, and positive sputum culture at EOT.
Conclusion: Several bacteriological, historical, treatment-related factors were identified as predictors of early (EOT) and later (8 weeks posttherapy) clinical failure in this older outpatient population with moderate-to-severe chronic obstructive pulmonary disease. These patients should be closely monitored and sputum cultures considered before and after treatment.
C1 [Wilson, Robert] Royal Brompton Hosp, Host Def Unit, London SW3 6NP, England.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Miravitlles, Marc] Hosp Univ Vall dHebron, CIBER Enfermedades Resp CIBERES, Pneumol Dept, Barcelona, Spain.
[Arvis, Pierre] Bayer HealthCare Pharmaceut, Loos, France.
[Haverstock, Daniel] Bayer HealthCare Pharmaceut, Whippany, NJ USA.
[Trajanovic, Mila] Bayer HealthCare Pharmaceut, Toronto, ON, Canada.
[Sethi, Sanjay] SUNY Buffalo, Buffalo, NY 14260 USA.
RP Wilson, R (reprint author), Royal Brompton Hosp, Host Def Unit, Sydney St, London SW3 6NP, England.
EM r.wilson@rbht.nhs.uk
OI Miravitlles, Marc/0000-0002-9850-9520
FU Bayer HealthCare, Germany; Bayer HealthCare
FX This study was supported by Bayer HealthCare, Germany. Editorial
assistance was provided by Highfield Communication, Oxford, UK,
sponsored by Bayer HealthCare. The authors thank Mr Feng Zhan, inVentive
Health, US, for his invaluable support in the bootstrapping and logistic
regression analyses.
NR 38
TC 0
Z9 0
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2005
J9 INT J CHRONIC OBSTR
JI Int. J. Chronic Obstr. Pulm. Dis.
PY 2015
VL 10
DI 10.2147/COPD.S80926
PG 9
WC Respiratory System
SC Respiratory System
GA CJ9VG
UT WOS:000355850700001
ER
PT J
AU Steinhauer, SR
Condray, R
Pless, ML
AF Steinhauer, Stuart R.
Condray, Ruth
Pless, Misha L.
TI Pharmacological Isolation of Cognitive Components Influencing the
Pupillary Light Reflex
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NORADRENERGIC LOCUS-COERULEUS; FUNCTIONAL NEUROANATOMY;
SCHIZOPHRENIC-PATIENTS; DAPIPRAZOLE; MODULATION; AROUSAL; ROLES
AB Cognitive operations can be detected by reduction of the pupillary light response. Neurophysiological pathways mediating this reduction have not been distinguished. We utilized selective blockade of pupillary sphincter or dilator muscles to isolate parasympathetic or sympathetic activity during cognition, without modifying central processes. Pupil diameter was measured during the light reaction in 29 normal adults under three processing levels: No Task, during an easy task (Add 1), or a difficult task (Subtract 7). At three separate sessions, the pupil was treated with placebo, tropicamide (blocking the muscarinic sphincter receptor), or dapiprazole (blocking the adrenergic dilator receptor). With placebo, pupil diameter increased with increasing task difficulty. The light reaction was reduced only in the Subtract 7 condition. Dapiprazole (which decreased overall diameter) showed similar task-related changes in diameter and light reflex as for placebo. Following tropicamide (which increased overall diameter), there was a further increase in diameter only in the difficult task. Findings suggest two separate inhibitory components at the parasympathetic oculomotor center. Changes in baseline diameter are likely related to reticular activation. Inhibition of the light reaction in the difficult task is likely associated with cortical afferents. Sustained sympathetic activity also was present during the difficult task.
C1 [Steinhauer, Stuart R.; Condray, Ruth] VA Pittsburgh Healthcare Syst, Biometr Res Program, Pittsburgh, PA 15240 USA.
[Steinhauer, Stuart R.] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15260 USA.
[Pless, Misha L.] Luzerner Kantonsspital, Zentrum Neurol & Neurorehabil, Leitender Arzt Neuroophthalmol & Neurol Augenklin, CH-6000 Luzern 16, Switzerland.
RP Steinhauer, SR (reprint author), VA Pittsburgh Healthcare Syst, Biometr Res Program, 151R,Univ Dr C, Pittsburgh, PA 15240 USA.
EM sthauer@pitt.edu
FU USPHS Grant [MH55762]; Medical Research Service of the United States
Department of Veterans Affairs
FX This work was supported by USPHS Grant MH55762 and by the Medical
Research Service of the United States Department of Veterans Affairs.
The authors thank Dr. Richard Rosen for additional ophthalmological
screening, and the nursing and pharmacy services of the VA Pittsburgh
Healthcare System for valuable assistance.
NR 24
TC 0
Z9 0
U1 2
U2 3
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
AR 179542
DI 10.1155/2015/179542
PG 7
WC Medicine, Research & Experimental; Ophthalmology
SC Research & Experimental Medicine; Ophthalmology
GA CJ9EZ
UT WOS:000355806600001
ER
PT J
AU Hamza, B
Irimia, D
AF Hamza, Bashar
Irimia, Daniel
TI Whole blood human neutrophil trafficking in a microfluidic model of
infection and inflammation
SO LAB ON A CHIP
LA English
DT Article
ID LEUKOCYTE MIGRATION; LIPID MEDIATORS; IN-VIVO; RESOLUTION; MECHANISMS;
ZEBRAFISH; DISEASES; SITES; DROP
AB Appropriate inflammatory responses to wounds and infections require adequate numbers of neutrophils arriving at injury sites. Both insufficient and excessive neutrophil recruitment can be detrimental, favouring systemic spread of microbes or triggering severe tissue damage. Despite its importance in health and disease, the trafficking of neutrophils through tissues remains difficult to control and the mechanisms regulating it are insufficiently understood. These mechanisms are also complex and difficult to isolate using traditional in vivo models. Here we designed a microfluidic model of tissue infection/inflammation, in which human neutrophils emerge from a droplet-size samples of whole blood and display bi-directional traffic between this and micro-chambers containing chemoattractant and microbe-like particles. Two geometrical barriers restrict the entrance of red blood cells from the blood to the micro-chambers and simulate the mechanical function of the endothelial barrier separating the cells in blood from cells in tissues. We found that in the presence of chemoattractant, the number of neutrophils departing the chambers by retrotaxis is in dynamic equilibrium with the neutrophils recruited by chemotaxis. We also found that in the presence of microbe-like particles, the number of neutrophils trapped in the chambers is proportional to the number of particles. Together, the dynamic equilibrium between migration, reversed-migration and trapping processes determine the optimal number of neutrophils at a site. These neutrophils are continuously refreshed and responsive to the number of microbes. Further studies using this infection-inflammationon- a-chip-model could help study the processes of inflammation resolution. The new in vitro experimental tools may also eventually help testing new therapeutic strategies to limit neutrophil accumulation in tissues during chronic inflammation, without increasing the risk for infections.
C1 [Hamza, Bashar] Massachusetts Gen Hosp, BioMEMS Resource Ctr, Dept Surg, Boston, MA 02129 USA.
[Irimia, Daniel] Harvard Univ, Sch Med, Boston, MA 02129 USA.
[Irimia, Daniel] MGH, CNY, Charlestown, MA 02129 USA.
RP Irimia, D (reprint author), Harvard Univ, Sch Med, Boston, MA 02129 USA.
EM dirimia@hms.harvard.edu
FU National Institutes of Health [GM092804, EB0025003]
FX We thank Drs. Anna Robertson and Steven Renshaw at the University of
Sheffield for the helpful discussions and Dr. Joseph Martel and Mr.
Robert Kimmerling for their assistance with COMSOL-based simulations.
Moreover, we thank Mr. Octavio Hurtado for assistance with device
fabrication at the BioMEMS Resource Center Clean room. This work was
supported by the National Institutes of Health (GM092804, EB0025003).
NR 36
TC 8
Z9 8
U1 3
U2 16
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PY 2015
VL 15
IS 12
BP 2625
EP 2633
DI 10.1039/c5lc00245a
PG 9
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience
& Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
Other Topics
GA CJ6WF
UT WOS:000355635200011
PM 25987163
ER
PT S
AU Sun, PZ
Zhou, IY
Igarashi, T
Guo, YK
Xiao, G
Wu, RH
AF Sun, Phillip Zhe
Zhou, Iris Yuewen
Igarashi, Takahiro
Guo, Yingkun
Xiao, Gang
Wu, Renhua
BE Gimi, B
Molthen, RC
TI Simplified correction of B-1 inhomogeneity for chemical exchange
saturation transfer (CEST) MRI measurement with surface transceiver coil
SO MEDICAL IMAGING 2015: BIOMEDICAL APPLICATIONS IN MOLECULAR, STRUCTURAL,
AND FUNCTIONAL IMAGING
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Medical Imaging - Biomedical Applications in Molecular,
Structural, and Functional Imaging
CY FEB 24-26, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Devices Inc, Bruker
ID PH; ACIDOSIS; STROKE
AB Chemical exchange saturation transfer (CEST) MRI is sensitive to dilute exchangeable protons and local properties such as pH and temperate, yet its susceptibility to field inhomogeneity limits its in vivo applications. Particularly, CEST measurement varies with RF irradiation power, the dependence of which is complex due to concomitant direct RF saturation (RF spillover) effect. Because the volume transmitters provide relatively homogeneous RF field, they have been conventionally used for CEST imaging despite of their elevated specific absorption rate (SAR) and relatively low sensitivity than surface coils. To address this limitation, we developed an efficient B-1 inhomogeneity correction algorithm that enables CEST MRI using surface transceiver coils. This is built on recent work that showed the inverse CEST asymmetry analysis (CESTRind) is not susceptible to confounding RF spillover effect. We here postulated that the linear relationship between RF power level and CESTRind can be extended for correcting B-1 inhomogeneity induced CEST MRI artifacts. Briefly, we prepared a tissue-like Creatine gel pH phantom and collected multi-parametric MRI including relaxation, field map and CEST MRI under multiple RF power levels, using a conventional surface transceiver coil. The raw CEST images showed substantial heterogeneity due to B-1 inhomogeneity, with pH contrast to noise ratio (CNR) being 8.8. In comparison, pH MRI CNR of the field-inhomogeneity corrected CEST MRI was found to be 17.2, substantially higher than that without correction. To summarize, our study validated an efficient field inhomogeneity correction that enables sensitive CEST MRI with surface transceiver, promising for in vivo translation.
C1 [Sun, Phillip Zhe; Zhou, Iris Yuewen; Igarashi, Takahiro; Xiao, Gang] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
[Sun, Phillip Zhe; Zhou, Iris Yuewen; Igarashi, Takahiro; Xiao, Gang] Harvard Univ, Sch Med, Charlestown, MA USA.
[Guo, Yingkun] Sichuan Univ, West China Univ Hosp 2, Dept Radiol, Chengdu 610064, Peoples R China.
[Wu, Renhua] Shantou Univ, Affiliated Hosp 2, Coll Med, Dept Radiol, Shantou, Guangdong, Peoples R China.
RP Sun, PZ (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
RI Zhou, Iris Yuwen/A-2089-2017
OI Zhou, Iris Yuwen/0000-0002-4351-7398
NR 8
TC 0
Z9 0
U1 3
U2 4
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-507-0
J9 PROC SPIE
PY 2015
VL 9417
AR 94171H
DI 10.1117/12.2082653
PG 6
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC8GL
UT WOS:000355665600049
ER
PT S
AU Zhou, IY
Igarashi, T
Guo, Y
Sun, PZ
AF Zhou, Iris Yuewen
Igarashi, Takahiro
Guo, Yingkun
Sun, Phillip Zhe
BE Gimi, B
Molthen, RC
TI Quantification of in vivo pH-weighted amide proton transfer (APT) MRI in
acute ischemic stroke
SO MEDICAL IMAGING 2015: BIOMEDICAL APPLICATIONS IN MOLECULAR, STRUCTURAL,
AND FUNCTIONAL IMAGING
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Medical Imaging - Biomedical Applications in Molecular,
Structural, and Functional Imaging
CY FEB 24-26, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Devices Inc, Bruker
DE CEST; Amide proton transfer (APT) imaging; MRI; Acute ischemic stroke;
pH
ID SATURATION-TRANSFER CEST; TRANSFER RATIO MEASUREMENTS; ACUTE
CEREBRAL-ISCHEMIA; MAGNETIZATION-TRANSFER; CHEMICAL-EXCHANGE;
INTRACELLULAR PH; CONTRAST AGENTS; PENUMBRA; LACTATE; ERRORS
AB Amide proton transfer (APT) imaging is a specific form of chemical exchange saturation transfer (CEST) MRI that probes the pH-dependent amide proton exchange. The endogenous APT MRI is sensitive to tissue acidosis, which may complement the commonly used perfusion and diffusion scans for characterizing heterogeneous ischemic tissue damage. Whereas the saturation transfer asymmetry analysis (MTRasym) may reasonably compensate for direct RF saturation, in vivo MTRasym is however, susceptible to an intrinsically asymmetric shift (MTR'(asym)). Specifically, the reference scan for the endogenous APT MRI is 7 ppm upfield from that of the label scan, and subjects to concomitant RF irradiation effects, including nuclear overhauser effect (NOE)-mediated saturation transfer and semisolid macromolecular magnetization transfer. As such, the commonly used asymmetry analysis could not fully compensate for such slightly asymmetric concomitant RF irradiation effects, and MTRasym has to be delineated in order to properly characterize the pH-weighted APT MRI contrast. Given that there is very little change in relaxation time immediately after ischemia and the concomitant RF irradiation effects only minimally depends on pH, the APT contrast can be obtained as the difference of MTRasym between the normal and ischemic regions. Thereby, the endogenous amide proton concentration and exchange rate can be solved using a dual 2-pool model, and the in vivo MTR'(asym) can be calculated by subtracting the solved APT contrast from asymmetry analysis (i.e., MTR'(asym) = MTRasym-APTR). In addition, MTR'(asym) can be quantified using the classical 2-pool exchange model. In sum, our study delineated the conventional in vivo pH-sensitive MTRasym contrast so that pH-specific contrast can be obtained for imaging ischemic tissue acidosis.
SUMMARY
Amide proton transfer (APT) imaging is pH sensitive, and has been shown promising to complement perfusion and diffusion MRI for stratifying heterogeneous ischemic tissue injury. Whereas conventional asymmetry analysis (MTRasym) reasonably compensates for the direct RF saturation effect, it is susceptible to an intrinsically asymmetric shift (MTR'(asym)). To improve tissue acidosis mapping, we delineated pH-sensitive APT effect from confounding factors using an animal model of stroke. We quantified concentration and exchange rate for both APT and nuclear overhauser effects (NOE). Our study elucidated conventional pH-weighted MTRasym contrast so that more specific pH-sensitive images can be obtained for characterizing ischemic acidosis.
C1 [Zhou, Iris Yuewen] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
RP Zhou, IY (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
RI Zhou, Iris Yuwen/A-2089-2017
OI Zhou, Iris Yuwen/0000-0002-4351-7398
NR 22
TC 0
Z9 0
U1 1
U2 3
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-507-0
J9 PROC SPIE
PY 2015
VL 9417
AR 94170E
DI 10.1117/12.2082683
PG 6
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC8GL
UT WOS:000355665600012
ER
PT S
AU Zhou, IY
Igarashi, T
Guo, Y
Sun, PZ
AF Zhou, Iris Yuewen
Igarashi, Takahiro
Guo, Yingkun
Sun, Phillip Zhe
BE Gimi, B
Molthen, RC
TI Susceptibility weighted imaging of stroke brain in response to
normobaric oxygen (NBO) therapy
SO MEDICAL IMAGING 2015: BIOMEDICAL APPLICATIONS IN MOLECULAR, STRUCTURAL,
AND FUNCTIONAL IMAGING
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Medical Imaging - Biomedical Applications in Molecular,
Structural, and Functional Imaging
CY FEB 24-26, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Devices Inc, Bruker
DE Normobaric oxygen (NBO) therapy; Acute ischemic stroke; Susceptibility
weighted imaging; MRI
ID FOCAL CEREBRAL-ISCHEMIA; RAT MODEL; HYPEROXIA
AB The neuroprotective effect of oxygen leads to recent interest in normobaric oxygen (NBO) therapy after acute ischemic stroke. However, the mechanism remains unclear and inconsistent outcomes were reported in human studies. Because NBO aims to improve brain tissue oxygenation by enhancing oxygen delivery to ischemic tissue, monitoring the oxygenation level changes in response to NBO becomes necessary to elucidate the mechanism and to assess the efficacy. Susceptibility weighted imaging (SWI) which provides a new MRI contrast by combining the magnitude and phase images is fit for purpose. SWI is sensitive to deoxyhemoglobin level changes and thus can be used to evaluate the cerebral metabolic rate of oxygen. In this study, SWI was used for in vivo monitoring of oxygenation changes in a rat model of permanent middle cerebral artery occlusion (MCAO) before, during and after 30 min of NBO treatment. Regions of interest in ischemic core, penumbra and contralateral normal area were generated based on diffusion-weighted imaging and perfusion imaging. Significant differences in SWI indicating different oxygenation levels were generally found: contralateral normal > penumbra > ischemic core. Ischemic core showed insignificant increase in oxygenation during NBO and returned to pre-treatment level after termination of NBO. Meanwhile, the oxygenation levels slightly increased in contralateral normal and penumbra regions during NBO and significantly decreased to a level lower than pre-treatment after termination of NBO, indicating secondary metabolic disruption upon the termination of transient metabolic support from oxygen. Further investigation of NBO effect combined with reperfusion is necessary while SWI can be used to detect hemorrhagic transformation after reperfusion.
SUMMARY
Normobaric oxygen (NBO) is under investigation as a neuroprotective therapy for acute ischemic stroke. However, the mechanism remains unclear and inconsistent outcomes were reported. We used susceptibility weighted imaging (SWI) to monitor the oxygenation response to NBO in rat stroke model. The oxygenation levels slightly increased in contralateral normal and penumbra regions during NBO and significantly decreased to a level lower than pre-treatment after NBO stopped, indicating secondary metabolic disruption upon the termination of transient metabolic support from oxygen. Further investigation of NBO effect combined with reperfusion is necessary while SWI can be used to detect hemorrhagic transformation after reperfusion.
C1 [Zhou, Iris Yuewen] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
RP Zhou, IY (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
RI Zhou, Iris Yuwen/A-2089-2017
OI Zhou, Iris Yuwen/0000-0002-4351-7398
NR 11
TC 0
Z9 0
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-507-0
J9 PROC SPIE
PY 2015
VL 9417
AR 94170D
DI 10.1117/12.2082655
PG 6
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC8GL
UT WOS:000355665600011
ER
PT S
AU Xing, FX
Ye, CY
Woo, J
Stone, M
Prince, JL
AF Xing, Fangxu
Ye, Chuyang
Woo, Jonghye
Stone, Maureen
Prince, Jerry L.
BE Ourselin, S
Styner, MA
TI Relating Speech Production to Tongue Muscle Compressions Using Tagged
and High-resolution Magnetic Resonance Imaging
SO MEDICAL IMAGING 2015: IMAGE PROCESSING
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Medical Imaging - Image Processing
CY FEB 24-26, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Devices Inc, Bruker, American Assoc Physicists Med, American Physiolog Soc, Comp Assisted Radiol & Surg, Med Image Percept Soc, Radiolog Soc N America, Soc Imaging Informat Med, World Mol Imaging Soc, DICOM Stand Comm
DE Speech; tongue; muscle; MRI; tagged; motion; strain; fiber; compression
ID CANCER; MOTION; MRI
AB The human tongue is composed of multiple internal muscles that work collaboratively during the production of speech. Assessment of muscle mechanics can help understand the creation of tongue motion, interpret clinical observations, and predict surgical outcomes. Although various methods have been proposed for computing the tongue's motion, associating motion with muscle activity in an interdigitated fiber framework has not been studied. In this work, we aim to develop a method that reveals different tongue muscles' activities in different time phases during speech. We use four-dimensional tagged magnetic resonance (MR) images and static high-resolution MR images to obtain tongue motion and muscle anatomy, respectively. Then we compute strain tensors and local tissue compression along the muscle fiber directions in order to reveal their shortening pattern. This process relies on the support from multiple image analysis methods, including super-resolution volume reconstruction from MR image slices, segmentation of internal muscles, tracking the incompressible motion of tissue points using tagged images, propagation of muscle fiber directions over time, and calculation of strain in the line of action, etc. We evaluated the method on a control subject and two post-glossectomy patients in a controlled speech task. The normal subject's tongue muscle activity shows high correspondence with the production of speech in different time instants, while both patients' muscle activities show different patterns from the control due to their resected tongues. This method shows potential for relating overall tongue motion to particular muscle activity, which may provide novel information for future clinical and scientific studies.
C1 [Xing, Fangxu; Ye, Chuyang; Prince, Jerry L.] Johns Hopkins Univ, Dept Elect & Comp Engn, Baltimore, MD 21218 USA.
[Woo, Jonghye] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA.
[Stone, Maureen] Univ Maryland, Sch Dent, Dept Neural & Pain Sci, Baltimore, MD 21201 USA.
RP Xing, FX (reprint author), Johns Hopkins Univ, Dept Elect & Comp Engn, Image Anal & Commun Lab, Baltimore, MD 21218 USA.
EM fxing1@jhu.edu
NR 13
TC 0
Z9 0
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-503-2
J9 PROC SPIE
PY 2015
VL 9413
AR 94131L
DI 10.1117/12.2081652
PG 6
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC8GE
UT WOS:000355653800055
ER
PT J
AU Marzec, LN
Carey, EP
Lambert-Kerzner, AC
Del Giacco, EJ
Melnyk, SD
Bryson, CL
Fahdi, IE
Bosworth, HB
Fiocchi, F
Ho, PM
AF Marzec, Lucas N.
Carey, Evan P.
Lambert-Kerzner, Anne C.
Del Giacco, Eric J.
Melnyk, Stephanie D.
Bryson, Chris L.
Fahdi, Ibrahim E.
Bosworth, Hayden B.
Fiocchi, Fran
Ho, P. Michael
TI Cognitive dysfunction and poor health literacy are common in veterans
presenting with acute coronary syndrome: insights from the MEDICATION
study
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE medication adherence
ID UNIVERSITY MENTAL STATUS; MYOCARDIAL-INFARCTION; HOSPITAL DISCHARGE;
HEART-FAILURE; ADHERENCE; INTERVENTION; DEMENTIA; DISCONTINUATION;
PREVALENCE; MORTALITY
AB Background: Patient nonadherence to cardiac medications following acute coronary syndrome (ACS) is associated with increased risk of recurrent events. However, the prevalence of cognitive dysfunction and poor health literacy among ACS patients and their association with medication nonadherence are poorly understood.
Methods: We assessed rates of cognitive dysfunction and poor health literacy among participants of a clinical trial that tested the effectiveness of an intervention to improve medication adherence in patients hospitalized with ACS. Of 254 patients, 249 completed the Rapid Estimate of Adult Literacy in Medicine, Revised (REALM-R) survey, an assessment of risk for poor literacy, and the St Louis University Mental Status (SLUMS) exam, a tool assessing for neurocognitive deficits, during ACS hospitalization. We assessed if SLUMS or REALM-R scores were associated with medication adherence.
Results: Based on SLUMS score, 14% of patients were categorized as having dementia, and 52% with mild neurocognitive disorder (MNCD). Based on REALM-R score of. 6, 34% of patients were categorized as at risk for poor health literacy. There was no association between poor health literacy and medication nonadherence. Of those with MNCD, 35.5% were nonadherent, compared to 17.5% with normal cognitive function and 6.7% with dementia. In multivariable analysis, cognitive dysfunction was associated with medication nonadherence (P=0.007), mainly due to an association between MNCD and nonadherence (odds ratio = 12.2, 95% confidence interval = 1.9 to 243; P= 0.007). Cognitive status was not associated with adherence in patients randomized to the intervention.
Conclusion: Cognitive dysfunction and risk for poor health literacy are common in patients hospitalized with ACS. We found an association between MNCD and medication nonadherence in the usual care group but not in the intervention group. These findings suggest efforts to screen for MNCD are needed during ACS hospitalization to identify patients at risk for nonadherence and who may benefit from an adherence intervention.
C1 [Marzec, Lucas N.; Carey, Evan P.; Lambert-Kerzner, Anne C.; Ho, P. Michael] Denver VA Med Ctr, Div Cardiol, Denver, CO USA.
[Del Giacco, Eric J.; Fahdi, Ibrahim E.] Little Rock VA Med Ctr, Dept Med, Little Rock, AR USA.
[Melnyk, Stephanie D.; Bosworth, Hayden B.] Durham VA Med Ctr, Dept Med, Durham, NC USA.
[Bryson, Chris L.] Puget Sound VA Med Ctr, Dept Med, Seattle, WA USA.
[Fiocchi, Fran] Amer Coll Cardiol, Washington, DC USA.
RP Marzec, LN (reprint author), Acad Off 1, Room 7104,12631 E 17th Ave,Campus Box B-130, Aurora, CO 80045 USA.
EM lucas.marzec@ucdenver.edu
NR 22
TC 0
Z9 0
U1 2
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2015
VL 9
BP 745
EP 751
DI 10.2147/PPA.S75110
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA CJ9WW
UT WOS:000355855000001
PM 26089651
ER
PT J
AU Kim, KS
Hong, SW
Kim, H
Cho, M
Kim, S
Hur, W
Yun, SH
Yoon, SK
Hahn, SK
AF Kim, Ki Su
Hong, Sung Woo
Kim, Hyemin
Cho, Minsoo
Kim, Seonghoon
Hur, Wonhee
Yun, Seok Hyun
Yoon, Seung Kew
Hahn, Sei Kwang
TI Hyaluronate-Flt1 peptide conjugate/epirubicin micelles for theranostic
application to liver cancers
SO RSC ADVANCES
LA English
DT Article
ID HYALURONIC-ACID DERIVATIVES; DRUG-DELIVERY SYSTEMS; POLYMERIC MICELLES;
ANTI-FLT1 PEPTIDE; CONJUGATE; DOXORUBICIN; NEOVASCULARIZATION;
NANOPARTICLES; EPIRUBICIN; RECEPTOR
AB Cancer theranostic systems using polymeric micelles are emerging for simultaneous diagnosis and therapy. In this work, we have developed hyaluronate (HA)-Flt1 peptide conjugate micelles encapsulating epirubicin for theranostic treatment of hepatocellular carcinoma. Intravital bioimaging without labelling and in vivo anti-tumor therapeutic effect clearly confirmed the feasibility of HA-Flt1 peptide conjugate/epirubicin micelles for target-specific theranostic treatment of liver cancers.
C1 [Kim, Ki Su; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA.
[Kim, Ki Su; Yun, Seok Hyun] Harvard Univ, Sch Med, Cambridge, MA 02139 USA.
[Hong, Sung Woo; Hur, Wonhee; Yoon, Seung Kew] Catholic Univ Korea, Liver Res Ctr, Seoul 137701, South Korea.
[Hong, Sung Woo; Hur, Wonhee; Yoon, Seung Kew] Catholic Univ Korea, WHO Collaborating Ctr Viral Hepatitis, Seoul 137701, South Korea.
[Kim, Hyemin; Cho, Minsoo; Hahn, Sei Kwang] Pohang Univ Sci & Technol POSTECH, Dept Mat Sci & Engn, Pohang 790784, Gyeongbuk, South Korea.
[Kim, Seonghoon] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol, Taejon 305338, South Korea.
RP Hahn, SK (reprint author), Pohang Univ Sci & Technol POSTECH, Dept Mat Sci & Engn, 77 Cheongam Ro, Pohang 790784, Gyeongbuk, South Korea.
EM skhanb@postech.ac.kr
FU Korean Health Technology R&D Project, Ministry of Health and Welfare,
Korea [HI14C1658]; Bio & Medical Technology Development Program of the
National Research Foundation (NRF) - Korean government (MEST)
[2012M3A9C6049791]
FX This research was supported by a grant of the Korean Health Technology
R&D Project, Ministry of Health and Welfare, Korea (HI14C1658) and the
Bio & Medical Technology Development Program (no. 2012M3A9C6049791) of
the National Research Foundation (NRF) funded by the Korean government
(MEST).
NR 23
TC 3
Z9 3
U1 0
U2 14
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 60
BP 48615
EP 48618
DI 10.1039/c5ra07464a
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA CJ8GN
UT WOS:000355738300056
ER
PT J
AU Eswara, JR
Heney, NM
Wu, CL
McDougal, WS
AF Eswara, Jairam R.
Heney, Niall M.
Wu, Chin-Lee
McDougal, W. Scott
TI Long-Term Outcomes of Organ Preservation in Patients with Small Cell
Carcinoma of the Bladder
SO UROLOGIA INTERNATIONALIS
LA English
DT Article
DE Small cell carcinoma; Bladder; Cystectomy; Chemotherapy; Radiation
ID URINARY-BLADDER; CLINICOPATHOLOGICAL ANALYSIS; UROTHELIAL CANCER;
CHEMOTHERAPY; EXPERIENCE; SURVIVAL; TRACT
AB Background: Small cell carcinoma of the bladder is an uncommon but clinically aggressive disease. There is no standard surgical or medical management for the disease. Methods: Between 1995 and 2009, 28 patients underwent transurethral resection (TUR) and/or cystectomy, chemotherapy, and/or radiation for small cell carcinoma of the bladder at our institution. Results: The median follow-up for survivors was 34 months. Patients presented most often with muscle-invasive disease (T2-4 - 89%), and 21% had lymph node/ distant metastases. Tobacco use and chemical exposure were noted in 64 and 4% of patients, respectively. Patients with T1-2N0M0 had a median survival of 22 months compared to 8 months for those with more advanced disease (p = 0.03). Patients with T3-4 or nodal/metastatic disease who were given chemotherapy had an improved survival compared to those with T3-4 or nodal/metastatic disease who did not undergo chemotherapy (13 vs. 4 months, p =0.005). The median time to recurrence of the entire cohort was 8 months, overall and cancer-specific survival was 14 months, and 5-year survival was 11%. Conclusions: Small cell carcinoma of the bladder is an aggressive disease with poor outcomes. Patients with T1-2N0M0 disease survived longer than those with advanced disease. Patients with T3-4 or nodal/metastatic disease had improved survival with chemotherapy. (C) 2015 S. Karger AG, Basel
C1 [Eswara, Jairam R.; Heney, Niall M.; McDougal, W. Scott] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Eswara, JR (reprint author), Massachusetts Gen Hosp, Dept Urol, 55 Fruit St, Boston, MA 02114 USA.
EM jeswara@partners.org
NR 15
TC 3
Z9 3
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-1138
EI 1423-0399
J9 UROL INT
JI Urol.Int.
PY 2015
VL 94
IS 4
BP 401
EP 405
DI 10.1159/000366522
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA CK0GZ
UT WOS:000355885000005
PM 25660255
ER
PT J
AU Geiger-Gritsch, S
Oberaigner, W
Muhlberger, N
Siebert, U
Ladurner, M
Klocker, H
Horninger, W
AF Geiger-Gritsch, Sabine
Oberaigner, Wilhelm
Muehlberger, Nikolai
Siebert, Uwe
Ladurner, Michael
Klocker, Helmut
Horninger, Wolfgang
TI Patient-Reported Urinary Incontinence and Erectile Dysfunction Following
Radical Prostatectomy: Results from the European Prostate Centre
Innsbruck
SO UROLOGIA INTERNATIONALIS
LA English
DT Article
DE Erectile dysfunction; Prostatectomy; Prostatic neoplasms; Urinary
incontinence
ID QUALITY-OF-LIFE; SURGICAL APPROACH; CANCER MORTALITY; CONTINENCE;
METAANALYSIS; POTENCY; OUTCOMES; IMPACT; TRIAL; INDEX
AB Introduction: Urinary and erectile functions were assessed by using self-administered validated questionnaires in patients undergoing radical prostatectomy. Materials and Methods: In a prospective observational study, a total of 253 consecutive patients diagnosed with clinically localised prostate cancer between 2008 and 2009 at the European Prostate Centre Innsbruck were included. Patient-reported outcomes were assessed before radical prostatectomy and 12 months postoperatively using the validated International Consultation on Incontinence Questionnaire (ICIQ) and the International Index of Erectile Function (IIEF). The Wilcoxon signed-rank test and Chi square statistics were used for analysis. Results: The study showed that before radical prostatectomy, urinary incontinence of various severity grades was reported in 18.8, postoperatively in 63.0% (p < 0.001) and erectile dysfunction of various degrees was reported in 39.6 at baseline compared to 80.1% 12 months postoperatively (p < 0.001). Conclusions: This study suggests that radical prostatectomy is associated with a significantly increased risk of urinary incontinence and erectile dysfunction 12 months postoperatively. (C) 2015 S. Karger AG, Basel
C1 [Geiger-Gritsch, Sabine; Oberaigner, Wilhelm] Canc Registry Tyrol, Tyrolean State Hosp Ltd, Dept Clin Epidemiol, A-6020 Innsbruck, Austria.
[Geiger-Gritsch, Sabine; Oberaigner, Wilhelm; Muehlberger, Nikolai; Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth & Hlth Technol Assessment, Hall In Tirol, Austria.
[Muehlberger, Nikolai; Siebert, Uwe] Med Univ Innsbruck, Oncotyrol Ctr Personalised Canc Med, Area Hlth Technol Assessment & Bioinformat 4, A-6020 Innsbruck, Austria.
[Ladurner, Michael; Klocker, Helmut; Horninger, Wolfgang] Med Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria.
[Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02115 USA.
[Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA.
[Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
RP Geiger-Gritsch, S (reprint author), Canc Registry Tyrol, Tyrolean State Hosp Ltd, Dept Clin Epidemiol, Anichstr 35, A-6020 Innsbruck, Austria.
EM Sabine.Geiger-Gritsch@tilak.at
FU COMET Center ONCOTYROL - Austrian Federal Ministries BMVIT/BMWFJ (via
FFG); Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT)
FX This work was supported by the COMET Center ONCOTYROL, which is funded
by the Austrian Federal Ministries BMVIT/BMWFJ (via FFG) and the Tiroler
Zukunftsstiftung/Standortagentur Tirol (SAT).
NR 37
TC 5
Z9 5
U1 1
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-1138
EI 1423-0399
J9 UROL INT
JI Urol.Int.
PY 2015
VL 94
IS 4
BP 419
EP 427
DI 10.1159/000369475
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA CK0GZ
UT WOS:000355885000008
PM 25662301
ER
PT J
AU Patel, V
Zhang, XL
Tautiva, NA
Nyabera, AN
Owa, OO
Baidya, M
Sung, HC
Taunk, PS
Abdollahi, S
Charles, S
Gonnella, RA
Gadi, N
Duong, KT
Fawver, JN
Ran, CZ
Jalonen, TO
Murray, IVJ
AF Patel, Viharkumar
Zhang, Xueli
Tautiva, Nicolas A.
Nyabera, Akwe N.
Owa, Opeyemi O.
Baidya, Melvin
Sung, Hee Chang
Taunk, Pardeep S.
Abdollahi, Shahrzad
Charles, Stacey
Gonnella, Rachel A.
Gadi, Nikhita
Duong, Karen T.
Fawver, Janelle N.
Ran, Chongzhao
Jalonen, Tuula O.
Murray, Ian V. J.
TI Small Molecules and Alzheimer's Disease: Misfolding, Metabolism and
Imaging
SO CURRENT ALZHEIMER RESEARCH
LA English
DT Article
DE Alzheimer's disease; amyloid binding; animal models; ATP; brain imaging;
near infrared fluorescence; small compounds
ID IN-VIVO DETECTION; A-BETA OLIGOMERS; MILD COGNITIVE IMPAIRMENT; UNFOLDED
PROTEIN RESPONSE; TRANSGENIC MOUSE MODEL; POSITRON-EMISSION-TOMOGRAPHY;
AMYLOID PRECURSOR PROTEIN; OXIDATIVE STRESS; METHYLENE-BLUE;
ENDOPLASMIC-RETICULUM
AB Small molecule interactions with amyloid proteins have had a huge impact in Alzheimer's disease (AD), especially in three specific areas: amyloid folding, metabolism and brain imaging. Amyloid plaque amelioration or prevention have, until recently, driven drug development, and only a few drugs have been advanced for use in AD. Amyloid proteins undergo misfolding and oligomerization via intermediates, eventually forming protease resistant amyloid fibrils. These fibrils accumulate to form the hallmark amyloid plaques and tangles of AD. Amyloid binding compounds can be grouped into three categories, those that: i) prevent or reverse misfolding, ii) halt misfolding or trap intermediates, and iii) accelerate the formation of stable and inert amyloid fibrils. Such compounds include hydralazine, glycosaminoglycans, curcumin, beta sheet breakers, catecholamines, and ATP. The versatility of amyloid binding compounds suggests that the amyloid structure may serve as a scaffold for the future development of sensors to detect such compounds. Metabolic dysfunction is one of the earliest pathological features of AD. In fact, AD is often referred to as type 3 diabetes due to the presence of insulin resistance in the brain. A recent study indicates that altering metabolism improves cognitive function. While metabolic reprogramming is one therapeutic avenue for AD, it is more widely used in some cancer therapies. FDA approved drugs such as metformin, dichloroacetic acid (DCA), and methylene blue can alter metabolism. These drugs can therefore be potentially applied in alleviating metabolic dysfunction in AD. Brain imaging has made enormous strides over the past decade, offering a new window to the mind. Recently, there has been remarkable development of compounds that have the ability to image both types of pathological amyloids: tau and amyloid beta. We have focused on the low cost, simple to use, near infrared fluorescence (NIRF) imaging probes for amyloid beta (A beta), with specific attention on recent developments to further improve contrast, specificity, and sensitivity. With advances in imaging technologies, such fluorescent imaging probes will open new diagnostic avenues.
C1 [Patel, Viharkumar; Tautiva, Nicolas A.; Nyabera, Akwe N.; Owa, Opeyemi O.; Baidya, Melvin; Sung, Hee Chang; Taunk, Pardeep S.; Abdollahi, Shahrzad; Charles, Stacey; Gonnella, Rachel A.; Gadi, Nikhita; Jalonen, Tuula O.; Murray, Ian V. J.] St Georges Univ, Sch Med, Dept Physiol & Neurosci, St Georges, Grenada.
[Zhang, Xueli] Southeast Univ, ZhongDa Hosp, Dept Pharm, Nanjing 210009, Jiangsu, Peoples R China.
[Ran, Chongzhao] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiol,Mol Imaging Lab, MGH MIT HMS Athinoula Martinos Ctr Biomed Imaging, Charlestown, MA USA.
RP Murray, IVJ (reprint author), St Georges Univ, Dept Physiol & Neurosci, POB 7, St Georges, Grenada.
EM imurray@sgu.edu
NR 230
TC 9
Z9 9
U1 4
U2 41
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1567-2050
EI 1875-5828
J9 CURR ALZHEIMER RES
JI Curr. Alzheimer Res.
PY 2015
VL 12
IS 5
BP 445
EP 461
PG 17
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CJ0ST
UT WOS:000355189000007
PM 25938871
ER
PT J
AU Marshall, GA
Zoller, AS
Lorius, N
Amariglio, RE
Locascio, JJ
Johnson, KA
Sperling, RA
Rentz, DM
AF Marshall, Gad A.
Zoller, Amy S.
Lorius, Natacha
Amariglio, Rebecca E.
Locascio, Joseph J.
Johnson, Keith A.
Sperling, Reisa A.
Rentz, Dorene M.
CA Alzheimer's Dis Neuroimaging Initi
TI Functional Activities Questionnaire Items that Best Discriminate and
Predict Progression from Clinically Normal to Mild Cognitive Impairment
SO CURRENT ALZHEIMER RESEARCH
LA English
DT Article
DE Activities of daily living; Alzheimer's disease; clinical assessment;
clinically normal elderly; daily functioning; mild cognitive impairment
ID ALZHEIMERS-DISEASE SPECTRUM; DATA SET UDS; INSTRUMENTAL ACTIVITIES;
EVERYDAY FUNCTION; DEMENTIA; COMMUNITY; ASSOCIATION; CENTERS; DECLINE;
SELF
AB Background: Impairment in instrumental activities of daily living (IADL) emerges in the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia. Some IADL scales are sensitive to early deficits in MCI, but none have been validated for detecting subtle functional changes in clinically normal (CN) elderly at risk for AD. Methods: Data from 624 subjects participating in the Alzheimer's Disease Neuroimaging Initiative and 524 subjects participating in the Massachusetts Alzheimer's Disease Research Center, which are two large cohorts including CN elderly and MCI subjects, were used to determine which Functional Activities Questionnaire items best discriminate between and predict progression from CN to MCI. Results: We found that "Remembering appointments" and "assembling tax records" best discriminated between CN and MCI subjects, while worse performance on "paying attention and understanding a TV program", "paying bills/balancing checkbook", and "heating water and turning off the stove" predicted greater hazard of progressing from a diagnosis of CN to MCI. Conclusions: These results demonstrate that certain questions are especially sensitive in detecting the earliest functional changes in CN elderly at risk for AD. As the field moves toward earlier intervention in preclinical AD, it is important to determine which IADL changes can be detected at that stage and track decline over time.
C1 [Marshall, Gad A.; Lorius, Natacha; Amariglio, Rebecca E.; Johnson, Keith A.; Sperling, Reisa A.; Rentz, Dorene M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA.
[Marshall, Gad A.; Lorius, Natacha; Amariglio, Rebecca E.; Johnson, Keith A.; Sperling, Reisa A.; Rentz, Dorene M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Marshall, Gad A.; Zoller, Amy S.; Lorius, Natacha; Amariglio, Rebecca E.; Locascio, Joseph J.; Johnson, Keith A.; Sperling, Reisa A.; Rentz, Dorene M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA.
[Marshall, Gad A.; Lorius, Natacha; Amariglio, Rebecca E.; Locascio, Joseph J.; Sperling, Reisa A.; Rentz, Dorene M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA.
[Zoller, Amy S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
[Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
RP Marshall, GA (reprint author), Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, 221 Longwood Ave,BL-104H, Boston, MA 02115 USA.
EM gamarshall@partners.org
FU ADNI [U01 AG024904]; DOD ADNI [W81XWH-12-2-0012]; MADRC [P50 AG005134,
R01 AG027435, K23 AG033634, K24 AG035007]; Harvard Aging Brain Study
[P01 AGO36694]; National Institute on Aging; National Institute of
Biomedical Imaging and Bioengineering; Canadian Institutes of Health
Research
FX This study was supported by ADNI (U01 AG024904), DOD ADNI
(W81XWH-12-2-0012), the MADRC (P50 AG005134), R01 AG027435, K23
AG033634, K24 AG035007, and the Harvard Aging Brain Study (P01
AGO36694). ADNI is funded by the National Institute on Aging, the
National Institute of Biomedical Imaging and Bioengineering, and through
generous contributions from the following: Alzheimer's Association;
Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec
Inc.; Bristol- Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals,
Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated
company Genentech, Inc.; GE Healthcare; Innogenetics, N. V.; IXICO Ltd.;
Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson &
Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck
& Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis
Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier;
Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes
of Health Research is providing funds to support ADNI clinical sites in
Canada. Private sector contributions are facilitated by the Foundation
for the National Institutes of Health (www.fnih.org). The grantee
organization is the Northern California Institute for Research and
Education, and the study is coordinated by the Alzheimer's Disease
Cooperative Study at the University of California, San Diego. ADNI data
are disseminated by the Laboratory for Neuro Imaging at the University
of Southern California.
NR 41
TC 0
Z9 0
U1 1
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1567-2050
EI 1875-5828
J9 CURR ALZHEIMER RES
JI Curr. Alzheimer Res.
PY 2015
VL 12
IS 5
BP 493
EP 502
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CJ0ST
UT WOS:000355189000010
PM 26017560
ER
PT J
AU Dording, CM
Schettler, PJ
Dalton, ED
Parkin, SR
Walker, RSW
Fehling, KB
Fava, M
Mischoulon, D
AF Dording, Christina M.
Schettler, Pamela J.
Dalton, Elizabeth D.
Parkin, Susannah R.
Walker, Rosemary S. W.
Fehling, Kara B.
Fava, Maurizio
Mischoulon, David
TI A Double-Blind Placebo-Controlled Trial of Maca Root as Treatment for
Antidepressant-Induced Sexual Dysfunction in Women
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID LEPIDIUM-MEYENII MACA; ADULT HEALTHY-MEN; DESIRE DISORDER; EXTRACT;
RATS; QUESTIONNAIRE; BUPROPION; SYMPTOMS; VALIDITY; BEHAVIOR
AB Objective. We sought to demonstrate that maca root may be an effective treatment for antidepressant-induced sexual dysfunction (AISD) in women. Method. We conducted a 12-week, double-blind, placebo-controlled trial of maca root (3.0 g/day) in 45 female outpatients (mean age of 41.5 +/- 12.5 years) with SSRI/SNRI-induced sexual dysfunction whose depression remitted. Endpoints were improvement in sexual functioning as per the Arizona Sexual Experience Scale (ASEX) and the Massachusetts General Hospital Sexual Function Questionnaire (MGH-SFQ). Results. 45 of 57 consented females were randomized, and 42 (30 premenopausal and 12 postmenopausal women) were eligible for a modified intent-to-treat analysis based on having had at least one postmedication visit. Remission rates by the end of treatment were higher for the maca than the placebo group, based on attainment of an ASEX total score <= 10 (9.5% for maca versus 4.8% for placebo), attaining an MGH-SFQ score <= 12 (30.0% for maca versus 20.0% for placebo) and reaching an MGH-SFQ score <= 8 (9.5% for maca versus 5.0% for placebo). Higher remission rates for the maca versus placebo group were associated with postmenopausal status. Maca was well tolerated. Conclusion. Maca root may alleviate SSRI-induced sexual dysfunction in postmenopausal women. This trial is registered with NCT00568126.
C1 [Dording, Christina M.; Dalton, Elizabeth D.; Parkin, Susannah R.; Walker, Rosemary S. W.; Fehling, Kara B.; Fava, Maurizio; Mischoulon, David] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA.
[Schettler, Pamela J.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
RP Dording, CM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA.
EM cdording@partners.org
FU National Center of Complementary and Alternative Medicine (NCCAM)
FX Dr. Christina M. Dording was supported by an R21 grant from the National
Center of Complementary and Alternative Medicine (NCCAM).
NR 35
TC 1
Z9 1
U1 3
U2 18
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2015
AR 949036
DI 10.1155/2015/949036
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA CJ4TQ
UT WOS:000355480200001
ER
PT J
AU Fleming, JT
Clark, S
Camargo, CA
Rudders, SA
AF Fleming, Jude T.
Clark, Sunday
Camargo, Carlos A., Jr.
Rudders, Susan A.
TI Early Treatment of Food-Induced Anaphylaxis with Epinephrine Is
Associated with a Lower Risk of Hospitalization
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Food allergy; Epinephrine; Early treatment; Pediatrics; Emergency
department; Anaphylaxis; Hospitalization
ID EMERGENCY-DEPARTMENT; INJECTABLE EPINEPHRINE; UNITED-STATES; ALLERGY;
MANAGEMENT; CHILDREN; UPDATE; GUIDELINES; EPIPEN
AB BACKGROUND: Food-induced anaphylaxis (FIA) is potentially life threatening. Prompt administration of epinephrine is universally recommended by current treatment guidelines.
OBJECTIVE: To identify factors associated with early epinephrine treatment for FIA and to specifically examine the association between early epinephrine treatment and hospitalization.
METHODS: A chart review study conducted at Hasbro Children's Hospital/Rhode Island Hospital. By using the International Classification of Diseases, Ninth Revision codes, we identified all patients who presented to the emergency department with FIA between January 1, 2004, and December 31, 2009. Early epinephrine treatment was defined as receipt of epinephrine before arrival to the emergency department. The independent association between early epinephrine treatment and hospitalization was assessed using logistic regression.
RESULTS: Among the 384 emergency department visits for FIA identified during the study period, 234 patients received epinephrine (61%). Among this subset, most (164 [70%]) received early epinephrine treatment, whereas a smaller number of patients (70 [30%]) first received epinephrine in the emergency department (late treatment). Patients who received early epinephrine treatment were older (7.4 vs 4.3 years; P = .008), were more likely to have a known food allergy (66% vs 34%; P < .001), and were more likely to own an epinephrine autoinjector (80% vs 23%; P < .001). Patients treated early were less likely to be hospitalized (17% vs 43%; P < .001). After adjusting for age, sex, and race, the patients who received early epinephrine treatment remained at significantly decreased risk of hospitalization compared with those who received late epinephrine treatment (odds ratio 0.25 [95% CI, 0.12-0.49]).
CONCLUSIONS: In this population, early treatment of FIA with epinephrine was associated with significantly lower risk of hospitalization. Accordingly, this study supports the benefit of prompt administration of epinephrine for the treatment of FIA. (C) 2014 American Academy of Allergy, Asthma & Immunology
C1 [Fleming, Jude T.; Rudders, Susan A.] Brown Univ, Hasbro Childrens Hosp, Rhode Isl Hosp, Div Asthma & Allergy,Dept Pediat,Alpert Med Sch, Providence, RI 02912 USA.
[Clark, Sunday] Weill Cornell Med Coll, Dept Emergency Med, New York, NY USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Allergy Immunol,Dept Med, Boston, MA USA.
RP Rudders, SA (reprint author), Rhode Isl Hosp, Hasbro Childrens Hosp, 593 Eddy St, Providence, RI 02906 USA.
EM srudders@lifespan.org
FU Department of Pediatrics at Hasbro Children's Hospital/Rhode Island
Hospital
FX The study was supported, in part, by institutional funding from the
Department of Pediatrics at Hasbro Children's Hospital/Rhode Island
Hospital.
NR 26
TC 17
Z9 17
U1 5
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JAN-FEB
PY 2015
VL 3
IS 1
BP 57
EP 62
DI 10.1016/j.jaip.2014.07.004
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA CH7IS
UT WOS:000354210100008
PM 25577619
ER
PT J
AU Guyer, AC
Saff, RR
Conroy, M
Blumenthal, KG
Camargo, CA
Long, AA
Banerji, A
AF Guyer, Autumn C.
Saff, Rebecca R.
Conroy, Michelle
Blumenthal, Kimberly G.
Camargo, Carlos A., Jr.
Long, Aidan A.
Banerji, Aleena
TI Comprehensive Allergy Evaluation Is Useful in the Subsequent Care of
Patients with Drug Hypersensitivity Reactions During Anesthesia
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Allergic reactions during anesthesia; Drug allergy; Drug
hypersensitivity reaction; General anesthetics; Hypersensitivity
reactions during anesthesia; Intraoperative anaphylaxis; Perioperative
anaphylaxis; Tryptase
ID ANAPHYLACTOID REACTIONS; RISK STRATIFICATION; CLINICAL-FEATURES;
MASTOCYTOSIS; FRANCE; ANTIBIOTICS; GRANISETRON; ONDANSETRON; GUIDELINES;
MANAGEMENT
AB BACKGROUND: For patients with a history of drug hypersensitivity reaction (HSR) during anesthesia, strategies to minimize risk with subsequent anesthesia are unclear. Identification of the cause of HSR during anesthesia remains challenging.
OBJECTIVE: To determine the success of a comprehensive allergy evaluation and management plan for patients with HSR during anesthesia, including identification of the causative agent and review of outcomes during subsequent anesthesia exposure.
METHODS: We performed chart reviews of patients referred for the evaluation of HSR during anesthesia between 2003 and 2012. Data collection included patient characteristics, signs/symptoms of HSR during anesthesia, and subsequent outcomes. Patients underwent comprehensive allergy evaluation including skin testing for identifying potential culprit agents, and the results were used to provide recommendations for any subsequent anesthesia.
RESULTS: Over the 10-year study period, 73 patients with HSR during anesthesia were referred for further evaluation. Thirteen patients (18%) had positive skin test results to a drug received during anesthesia. One patient with a positive skin test result was diagnosed with mastocytosis. The causative agents identified in these 13 patients included latex, beta-lactam antibiotics, neuromuscular blockers, tetracaine, odansetron, and fentanyl. On follow-up, 47 of the 73 patients (64%) subsequently underwent procedures requiring anesthesia. Using our recommendations from evaluation and testing, 45 of these 47 patients (96%) successfully tolerated subsequent anesthesia. The 2 patients who developed recurrent HSR during anesthesia were later diagnosed with mast cell disorders.
CONCLUSIONS: Our comprehensive evaluation and management plan minimizes risk with subsequent anesthesia even when the cause of HSR could not be identified. Baseline tryptase levels may be helpful in this patient population to diagnose mast cell disorders. (C) 2014 American Academy of Allergy, Asthma & Immunology
C1 [Guyer, Autumn C.] Beth Israel Deaconess Med Ctr, Div Allergy & Inflammat, Dept Med, Brookline, MA 02445 USA.
[Saff, Rebecca R.; Conroy, Michelle; Blumenthal, Kimberly G.; Camargo, Carlos A., Jr.; Long, Aidan A.; Banerji, Aleena] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA.
RP Guyer, AC (reprint author), Beth Israel Deaconess Med Ctr, Div Allergy & Inflammat, Dept Med, One Brookline Pl,Ste 623, Brookline, MA 02445 USA.
EM aguyer@bidmc.harvard.edu
FU First Consult
FX A. Guyer has received payment for manuscript development from First
Consult and receives royalties from UpToDate. The rest of the authors
declare that they have no relevant conflicts of interest.
NR 35
TC 10
Z9 10
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JAN-FEB
PY 2015
VL 3
IS 1
BP 94
EP 100
DI 10.1016/j.jaip.2014.11.011
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA CH7IS
UT WOS:000354210100014
PM 25577625
ER
PT J
AU Donovan, NJ
Hsu, DC
Dagley, AS
Schultz, AP
Amariglio, RE
Mormino, EC
Okereke, OI
Rentz, DM
Johnson, KA
Sperling, RA
Marshall, GA
AF Donovan, Nancy J.
Hsu, David C.
Dagley, Alexander S.
Schultz, Aaron P.
Amariglio, Rebecca E.
Mormino, Elizabeth C.
Okereke, Olivia I.
Rentz, Dorene M.
Johnson, Keith A.
Sperling, Reisa A.
Marshall, Gad A.
TI Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively
Normal Older Adults
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; biomarkers; neurodegeneration; normal cognition;
preclinical; subthreshold depressive symptoms
ID LATE-LIFE DEPRESSION; PRIMARY-CARE PATIENTS; RECURRENT MAJOR DEPRESSION;
PITTSBURGH COMPOUND-B; GERIATRIC DEPRESSION; SUBSYNDROMAL DEPRESSION;
HIPPOCAMPAL VOLUME; AMYLOID BURDEN; NEUROPSYCHIATRIC PREDICTORS;
LATE-ONSET
AB Even low levels of depressive symptoms are associated with an increased risk of cognitive decline in older adults without overt cognitive impairment (CN). Our objective was to examine whether very low, "subthreshold symptoms of depression" are associated with Alzheimer's disease (AD) biomarkers of neurodegeneration in CN adults and whether these associations are specific to particular depressive symptoms. We analyzed data from 248 community-dwelling CN older adults, including measurements of cortical amyloid burden, neurodegeneration markers of hippocampal volume (HV) and cerebral F-18-fluorodeoxyglucose (FDG) metabolism in a composite of AD-related regions and the 30-item Geriatric Depression Scale (GDS). Participants with GDS > 10 were excluded. General linear regression models evaluated the cross-sectional relations of GDS to HV or FDG in separate backward elimination models. Predictors included GDS total score, age, gender, premorbid intelligence, a binary amyloid variable and its interaction with GDS. Principal component analyses of GDS item scores revealed three factors (the Dysphoria, Apathy-Anhedonia, and Anxiety-Concentration Factors). In secondary analyses, GDS total score was replaced with the three factor scores in repeated models. Higher GDS score (p = 0.03) was significantly associated with lower HV and was marginally related (p = 0.06) to FDG hypometabolism. In secondary models, higher Dysphoria (p = 0.02) and Apathy-Anhedonia (p = 0.05) were related to lower HV while higher Apathy-Anhedonia (p = 0.003) was the sole factor related to FDG hypometabolism. Amyloid was not a significant predictor in any model. In conclusion, very low-level dysphoria, apathy and anhedonia may point to neurodegeneration in AD-related regions but this association appears to be independent of amyloid burden.
C1 [Donovan, Nancy J.; Amariglio, Rebecca E.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA.
[Donovan, Nancy J.; Amariglio, Rebecca E.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Donovan, Nancy J.; Hsu, David C.; Dagley, Alexander S.; Amariglio, Rebecca E.; Okereke, Olivia I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Dagley, Alexander S.; Schultz, Aaron P.; Amariglio, Rebecca E.; Mormino, Elizabeth C.; Marshall, Gad A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Hsu, David C.; Dagley, Alexander S.; Schultz, Aaron P.; Okereke, Olivia I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA.
[Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
RP Donovan, NJ (reprint author), Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, 221 Longwood Ave,BL-104H, Boston, MA 02115 USA.
EM njdonovan@partners.org
RI Okereke, Olivia/R-9934-2016
FU Harvard Medical School Department of Psychiatry Dupont-Warren Fellowship
[R03 AG045080, R01 AG027435, K23 AG033634, K24 AG035007]; Massachusetts
Alzheimer's Disease Research Center [P50 AG005134]; Harvard Aging Brain
Study [P01 AGO36694, R01 AG037497]
FX This study was supported by R03 AG045080, R01 AG027435, K23 AG033634,
K24 AG035007, the Harvard Medical School Department of Psychiatry
Dupont-Warren Fellowship and Livingston Award, the Massachusetts
Alzheimer's Disease Research Center (P50 AG005134) and the Harvard Aging
Brain Study (P01 AGO36694, R01 AG037497).
NR 64
TC 9
Z9 9
U1 0
U2 5
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 46
IS 1
BP 63
EP 73
DI 10.3233/JAD-142940
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA CI5HO
UT WOS:000354786000007
PM 25697700
ER
PT J
AU Martinez, J
Harris, C
Jalali, C
Tung, J
Meyer, R
AF Martinez, Johanna
Harris, Christina
Jalali, Cathy
Tung, Judy
Meyer, Robert
TI Using peer-assisted learning to teach and evaluate residents'
musculoskeletal skills
SO MEDICAL EDUCATION ONLINE
LA English
DT Article
DE medical education; clinical skills; OSCE; peer learning; physical exam
ID MEDICAL-STUDENTS; EDUCATION; IMPLEMENTATION; RHEUMATOLOGY; KNOWLEDGE;
FACULTY; EXAM
AB Although direct observation and corrective feedback are established methods of increasing select aspects of residents' musculoskeletal (MSK) clinical skills, the evaluation and management of patients with MSK complaints remains an underemphasized part of internal medicine training. This paper reports on the development of an innovative peer-assisted learning (PAL) model to teach five MSK areas (back, knee, shoulder, neck, or hip pain). Based on data from 42 participating interns and 44 senior residents from an urban US academic medical center, results from an objective structured clinical exam (OSCE) demonstrate gains in both knowledge and self-reported confidence in MSK skills. Moreover, subsequent focus group results reveal a strong preference for the PAL model. In conclusion, an educational module that utilizes the OSCE format holds much promise for teaching MSK skills to both intern and senior residents.
C1 [Martinez, Johanna; Jalali, Cathy; Tung, Judy; Meyer, Robert] New York Presbyterian Weill Cornell Med Ctr, New York, NY 10021 USA.
[Harris, Christina] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
RP Martinez, J (reprint author), New York Presbyterian Weill Cornell Med Ctr, 505 East 70th St,HT 4, New York, NY 10021 USA.
EM jom9050@med.cornell.edu
NR 21
TC 1
Z9 1
U1 2
U2 5
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1087-2981
J9 MED EDUC ONLINE
JI Med. Educ. Online
PY 2015
VL 20
AR 27255
DI 10.3402/meo.v20.27255
PG 4
WC Education & Educational Research
SC Education & Educational Research
GA CJ3SP
UT WOS:000355404500001
PM 26028495
ER
PT J
AU Han, JF
Alvarez-Breckenridge, CA
Wang, QE
Yu, JH
AF Han, Jianfeng
Alvarez-Breckenridge, Christopher A.
Wang, Qi-En
Yu, Jianhua
TI TGF-beta signaling and its targeting for glioma treatment
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Review
DE TGF-beta; TGF-beta signaling; glioma; gliomagenesis; glioma treatment
ID GROWTH-FACTOR-BETA; I KINASE INHIBITOR; CENTRAL-NERVOUS-SYSTEM;
NATURAL-KILLER-CELLS; HUMAN GLIOBLASTOMA; STEM-CELLS; MALIGNANT GLIOMAS;
NK CELLS; IMMUNE SURVEILLANCE; INITIATING CELLS
AB Transforming growth factor-beta (TGF-beta) is a pleiotropic cytokine, secreted by a variety of cells including immune cells, tumor cells, and stromal cells. TGF-beta signaling is dysregulated in cancer patients, and this aberrant signaling at least in part contributes to initiation and progression of many cancers including glioma. The dysregulated signaling components provide molecular targets for the treatment of glioma. In this article, we review TGF-beta signaling and its targeting in glioma.
C1 [Han, Jianfeng; Yu, Jianhua] Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA.
[Han, Jianfeng; Wang, Qi-En; Yu, Jianhua] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Alvarez-Breckenridge, Christopher A.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RP Yu, JH (reprint author), Ohio State Univ, Dept Internal Med, Div Hematol, Biomed Res Tower 816,460 West 12th Ave, Columbus, OH 43210 USA.
EM jianhua.yu@osumc.edu
FU National Institutes of Health [CA155521]
FX This review was supported by the grant CA155521 from the National
Institutes of Health. The authors sincerely thank David M. Lucas for his
careful and critical reading of this manuscript.
NR 78
TC 21
Z9 22
U1 1
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2015
VL 5
IS 3
BP 945
EP 955
PG 11
WC Oncology
SC Oncology
GA CI5DJ
UT WOS:000354772800006
PM 26045979
ER
PT J
AU Zhang, RC
Zhang, YH
An, T
Guo, X
Yin, SJ
Wang, YH
Januzzi, JL
Cappola, TP
Zhang, J
AF Zhang, Rongcheng
Zhang, Yuhui
An, Tao
Guo, Xiao
Yin, Shijie
Wang, Yunhong
Januzzi, James L.
Cappola, Thomas P.
Zhang, Jian
TI Prognostic value of sST2 and galectin-3 for death relative to renal
function in patients hospitalized for heart failure
SO BIOMARKERS IN MEDICINE
LA English
DT Article
DE biomarker; cardiac remodeling; death; eGFR; galectin-3; heart failure;
NT-proBNP; prognosis; renal function; sST2
ID SOLUBLE ST2; FIBROSIS; STRATIFICATION; EXPRESSION; PLASMA
AB Aim: To evaluate the associations of soluble ST2 (sST2) and galectin-3 with death relative to renal function in patients with heart failure (HF). Methods: Eleven-hundred-and-sixty-one patients hospitalized for HF with 1-year follow up were enrolled for biomarkers analysis. Results: Patients were divided into two groups based on eGFR of either > or 60 ml/min/1.73 m(2). sST2 was independently associated with death in both categories of renal function, while galectin-3 lost this significance after addition of NT-proBNP to the model of patients with eGFR 60 ml/min/1.73 m(2). Conclusion: In patients with HF, sST2 improved prediction for death beyond risk factors without being influenced by renal function, however, the prognostic value of galectin-3 is less clear below an eGFR of 60 ml/min/1.73 m(2).
C1 [Zhang, Rongcheng; Zhang, Yuhui; An, Tao; Guo, Xiao; Yin, Shijie; Wang, Yunhong; Zhang, Jian] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Heart Failure Ctr,Fuwai Hosp, Beijing 100037, Peoples R China.
[Zhang, Rongcheng; Zhang, Yuhui; An, Tao; Guo, Xiao; Yin, Shijie; Wang, Yunhong; Zhang, Jian] Peking Union Med Coll, Beijing 100037, Peoples R China.
[Januzzi, James L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Cappola, Thomas P.] Univ Penn, Sch Med, Penn Cardiovasc Inst, Philadelphia, PA 19104 USA.
RP Zhang, J (reprint author), Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Heart Failure Ctr,Fuwai Hosp, Beijing 100037, Peoples R China.
EM fwzhangjian62@126.com
FU Critical Diagnostics; Key Projects in the National Science & Technology
Pillar Program of the 12th Five-year Plan Period, Beijing, China
[2011BAI11B02]
FX JL Januzzi has received grant support and consulting income from
Critical Diagnostics. This study was supported by grants from the Key
Projects in the National Science & Technology Pillar Program of the 12th
Five-year Plan Period (no. 2011BAI11B02, project for heart failure),
Beijing, China. ST2 assays were provided by Critical Diagnostics, and
NT-proBNP assays were provided by Alere, Inc. Neither of these companies
had role in study design, data collection and analysis, decision to
publish or preparation of the manuscript. The authors have no other
relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript apart from those
disclosed.
NR 25
TC 1
Z9 3
U1 1
U2 6
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1752-0363
EI 1752-0371
J9 BIOMARK MED
JI Biomark. Med.
PY 2015
VL 9
IS 5
BP 433
EP 441
DI 10.2217/bmm.15.12
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CI3KX
UT WOS:000354647700005
PM 25985174
ER
PT J
AU Drain, PK
Gounder, L
Grobler, A
Sahid, F
Bassett, IV
Moosa, MYS
AF Drain, Paul K.
Gounder, Lilishia
Grobler, Anneke
Sahid, Faieza
Bassett, Ingrid V.
Moosa, Mahomed-Yunus S.
TI Urine lipoarabinomannan to monitor antituberculosis therapy response and
predict mortality in an HIV-endemic region: a prospective cohort study
SO BMJ OPEN
LA English
DT Article
ID PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; SPUTUM; DIAGNOSIS
AB Objective: To determine if urinary lipoarabinomannan (LAM) may serve as a biomarker to monitor antituberculosis (TB) therapy response, and whether LAM results before and after treatment are predictive of patient outcomes.
Design: Prospective cohort.
Setting: Outpatient referral clinic and tertiary hospital in South Africa.
Participants: Adults (>= 18 years) with >= 2 TB-related symptoms (cough, fever, weight loss, night sweats) for >= 2 weeks being initiated on anti-TB therapy.
Interventions: On enrolment, we obtained urine and nebulised sputum specimens, offered HIV testing and started participants on anti-TB therapy for >= 6 months. We collected urine samples after the 2-month intensive treatment phase and at the completion of anti-TB therapy. Positive LAM results were graded from 1 (low) to 5 (high). Participants were followed for >3 years.
Outcome measures: The primary outcome was change in urine LAM results during anti-TB therapy. The secondary outcome was all-cause mortality.
Results: Among 90 participants, 57 (63%) had culture-confirmed pulmonary TB. Among the 88 participants tested, 82 (93%) were HIV-infected with median CD4 168/mm(3) (IQR 89-256/mm(3)). During anti-TB therapy, the percentage of LAM-positive participants decreased from baseline to 2 months (32% to 16%), and from baseline to 6-months (32% to 10%) (p values <0.005). In multivariate longitudinal analyses, urine LAM positivity and grade decreased among those with culture-confirmed pulmonary TB (p<0.0001), and had no change in sputum culture-negative participants. At the 2-month visit, participants with positive laboratory-based LAM or rapid LAM with >= 2+ grade had a significantly greater risk of mortality. In analyses adjusted for age, sex, baseline Karnofsky score and HIV status, participants with a rapid LAM >= 2+ grade after 2 months of anti-TB therapy had a 5.6-fold (95% CI 1.2 to 25.2) greater risk of mortality.
Conclusions: Rapid urine LAM testing may be a valuable tool to monitor anti-TB therapy response and to assess prognosis of patients being treated for pulmonary TB in HIV-endemic regions.
C1 [Drain, Paul K.; Bassett, Ingrid V.] Med Practice Evaluat Ctr, Boston, MA 02117 USA.
[Drain, Paul K.; Bassett, Ingrid V.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Gounder, Lilishia] Inkosi Albert Luthuli Cent Hosp, Natl Hlth Lab Serv, Dept Virol, Durban, South Africa.
[Grobler, Anneke] Ctr AIDS Programme Res South Africa, Durban, South Africa.
[Sahid, Faieza] Univ Witwatersrand, Johannesburg, South Africa.
[Moosa, Mahomed-Yunus S.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Infect Dis, Durban, South Africa.
RP Drain, PK (reprint author), Med Practice Evaluat Ctr, Boston, MA 02117 USA.
EM pdrain@partners.org
FU Medical Research Council of South Africa; Howard Hughes Medical
Institute; KwaZulu-Natal Research Institute for TB and HIV (K-RITH);
UK's Department for International Development; Harvard Global Health
Institute; Fogarty International Clinical Research Scholars and Fellows
Program at Vanderbilt University [R24 TW007988]; Infectious Disease
Society of America Education & Research Foundation (IDSA ERF); National
Foundation for Infectious Diseases (NFID); Program in AIDS Clinical
Research Training Grant [T32 AI007433]; National Institute of Allergy
and Infectious Disease [K23 AI108293]; Harvard University Center for
AIDS Research [P30 AI060354]; Massachusetts General Hospital Executive
Committee on Research; National Institute of Mental Health [R01
MH090326]; Claflin Distinguished Scholar Award
FX This study was funded by the Medical Research Council of South Africa,
the Howard Hughes Medical Institute, the KwaZulu-Natal Research
Institute for TB and HIV (K-RITH), and the UK's Department for
International Development. Dr Drain was supported by the Harvard Global
Health Institute, the Fogarty International Clinical Research Scholars
and Fellows Program at Vanderbilt University (R24 TW007988), the
Infectious Disease Society of America Education & Research Foundation
(IDSA ERF) and National Foundation for Infectious Diseases (NFID), The
Program in AIDS Clinical Research Training Grant (T32 AI007433), the
National Institute of Allergy and Infectious Disease (K23 AI108293), the
Harvard University Center for AIDS Research (P30 AI060354) and the
Massachusetts General Hospital Executive Committee on Research. Dr
Bassett was supported by the National Institute of Mental Health R01
MH090326 (IVB) and the Claflin Distinguished Scholar Award (IVB).
NR 29
TC 7
Z9 7
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2015
VL 5
IS 4
AR e006833
DI 10.1136/bmjopen-2014-006833
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI4GB
UT WOS:000354705000036
PM 25877271
ER
PT J
AU Scott, J
Rouhani, S
Greiner, A
Albutt, K
Kuwert, P
Hacker, MR
VanRooyen, M
Bartels, S
AF Scott, Jennifer
Rouhani, Shada
Greiner, Ashley
Albutt, Katherine
Kuwert, Philipp
Hacker, Michele R.
VanRooyen, Michael
Bartels, Susan
TI Respondent-driven sampling to assess mental health outcomes, stigma and
acceptance among women raising children born from sexual
violence-related pregnancies in eastern Democratic Republic of Congo
SO BMJ OPEN
LA English
DT Article
ID HIDDEN POPULATIONS; CONTROLLED-TRIAL; PRIMARY-CARE; SURVIVORS;
STIGMATIZATION; REJECTION; ATTITUDES; THERAPY; VICTIMS; ASSAULT
AB Objectives: Assess mental health outcomes among women raising children from sexual violence-related pregnancies (SVRPs) in eastern Democratic Republic of Congo and stigma toward and acceptance of women and their children.
Design: Participants were recruited using respondent-driven sampling.
Setting: Bukavu, Democratic Republic of Congo in 2012.
Participants: 757 adult women raising children from SVRPs were interviewed. A woman aged 18 and older was eligible for the study if she self-identified as a sexual violence survivor since the start of the conflict (similar to 1996), conceived an SVRP, delivered a liveborn child and was currently raising the child. A woman was ineligible for the study if the SVRP ended with a spontaneous abortion or fetal demise or the child was not currently living or in the care of the biological mother.
Intervention: Trained female Congolese interviewers verbally administered a quantitative survey after obtaining verbal informed consent.
Outcome measures: Symptom criteria for major depressive disorder, post-traumatic stress disorder, anxiety and suicidality were assessed, as well as stigma toward the woman and her child. Acceptance of the woman and child from the spouse, family and community were analysed.
Results: 48.6% met symptom criteria for major depressive disorder, 57.9% for post-traumatic stress disorder, 43.3% for anxiety and 34.2% reported suicidality. Women who reported stigma from the community (38.4%) or who reported stigma toward the child from the spouse (42.9%), family (31.8%) or community (38.1%) were significantly more likely to meet symptom criteria for most mental health disorders. Although not statistically significant, participants who reported acceptance and acceptance of their children from the spouse, family and community were less likely to meet symptom criteria.
Conclusions: Women raising children from SVRPs experience symptoms of mental health disorders. Programming addressing stigma and acceptance following sexual violence may improve mental health outcomes in this population.
C1 [Scott, Jennifer; Hacker, Michele R.] Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA.
[Scott, Jennifer] Brigham & Womens Hosp, Div Womens Hlth, Boston, MA 02115 USA.
[Scott, Jennifer; Rouhani, Shada; Greiner, Ashley; Albutt, Katherine; VanRooyen, Michael; Bartels, Susan] Harvard Humanitarian Initiat, Cambridge, MA 02138 USA.
[Scott, Jennifer; Rouhani, Shada; Greiner, Ashley; Albutt, Katherine; Hacker, Michele R.; VanRooyen, Michael; Bartels, Susan] Harvard Univ, Sch Med, Boston, MA USA.
[Rouhani, Shada; VanRooyen, Michael] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA.
[Greiner, Ashley; Bartels, Susan] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.
[Albutt, Katherine] Massachusetts Gen Hosp, Dept Gen Surg, Boston, MA 02114 USA.
[Kuwert, Philipp] HELIOS Hansehosp Stralsund, Univ Med Greifswald, Dept Psychiat & Psychotherapy, Stralsund, Germany.
[Hacker, Michele R.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[VanRooyen, Michael; Bartels, Susan] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Bartels, S (reprint author), Harvard Humanitarian Initiat, Cambridge, MA 02138 USA.
EM susanabartels@gmail.com
FU Harvard Medical School; Harvard Humanitarian Initiative; Harvard
Catalyst\The Harvard Clinical and Translational Science Center (National
Institutes of Health) [8UL1TR000170-05]; Harvard University
FX The study was funded by the Eleanor and Miles Shore Fellowship from
Harvard Medical School and funding from Harvard Humanitarian Initiative.
Data analysis was supported by Harvard Catalyst vertical bar The Harvard
Clinical and Translational Science Center (National Institutes of Health
Award 8UL1TR000170-05 and financial contributions from Harvard
University and affiliated academic health centers).
NR 43
TC 2
Z9 2
U1 2
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2015
VL 5
IS 4
AR e007057
DI 10.1136/bmjopen-2014-007057
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI4GB
UT WOS:000354705000053
PM 25854968
ER
PT J
AU Watase, H
Hagiwara, Y
Chiba, T
Camargo, CA
Hasegawa, K
AF Watase, Hiroko
Hagiwara, Yusuke
Chiba, Takuyo
Camargo, Carlos A., Jr.
Hasegawa, Kohei
CA Japanese Emergency Med Network
TI Multicentre observational study of adults with asthma exacerbations: who
are the frequent users of the emergency department in Japan?
SO BMJ OPEN
LA English
DT Article
ID FOLLOW-UP; CARE; PREDICTORS; SMOKING; RISK
AB Objectives: Emergency department (ED) visits for asthma exacerbation reflect a failure of longitudinal asthma management. However, little is known about the characteristics of patients with frequent ED visits (>= 2 visits in a 1-year period). We aimed to characterise the adult patients who frequently presented to the ED for asthma exacerbation in Japan.
Design: A multicentre chart review study of 23 EDs across Japan.
Participants: Adults aged 18-54 years who presented to the ED with asthma exacerbation from 2009 to 2011.
Outcome measures: Frequency of ED visits for asthma exacerbation in a 1-year period, including the index ED visit.
Results: Of the 1002 eligible patients, 218 (22%) had frequent ED visits, accounting for 48% of total ED visits for asthma exacerbation in the 1-year period. Specifically, 12% had 2 ED visits and 10% had >= 3 visits. In these patients, guideline-recommended chronic management was suboptimal. For example, among patients with >= 3 ED visits, only 63% were treated with inhaled corticosteroids and 49% were current smokers. In a multinomial logistic regression model, markers of chronic asthma severity (history of hospitalisation for asthma and use of inhaled corticosteroids) were significantly associated with a higher frequency of ED visits (both p<0.05).
Conclusions: This multicentre study in Japan demonstrated that many patients are frequent ED users for asthma exacerbation. We also found that their asthma control management is suboptimal, most likely contributing to worse chronic severity and more frequent ED visits. Further dissemination and adoption of evidence-based guidelines are required to reduce asthma morbidity in this high-risk population.
C1 [Watase, Hiroko; Hagiwara, Yusuke; Chiba, Takuyo; Hasegawa, Kohei] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Hagiwara, Yusuke] Tokyo Metropolitan Childrens Med Ctr, Dept Emergency Med, Tokyo, Japan.
[Chiba, Takuyo] Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA USA.
[Camargo, Carlos A., Jr.; Hasegawa, Kohei] Harvard Univ, Massachusetts Gen Hosp, Dept Emergency Med, Sch Med, Boston, MA USA.
RP Watase, H (reprint author), Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
EM hiroko7@uw.edu
FU St. Luke's Life Science Institute (Tokyo, Japan)
FX This study was supported by a grant from St. Luke's Life Science
Institute (Tokyo, Japan).
NR 24
TC 2
Z9 2
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2015
VL 5
IS 4
AR e007435
DI 10.1136/bmjopen-2014-007435
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI4GB
UT WOS:000354705000098
PM 25922104
ER
PT J
AU Zulman, DM
Chee, CP
Wagner, TH
Yoon, J
Cohen, DM
Holmes, TH
Ritchie, C
Asch, SM
AF Zulman, Donna M.
Chee, Christine Pal
Wagner, Todd H.
Yoon, Jean
Cohen, Danielle M.
Holmes, Tyson H.
Ritchie, Christine
Asch, Steven M.
TI Multimorbidity and healthcare utilisation among high-cost patients in
the US Veterans Affairs Health Care System
SO BMJ OPEN
LA English
DT Article
ID COMORBID MENTAL-DISORDERS; AVERAGE COST; VA; BENEFICIARIES; PREVALENCE;
DEPRESSION; PRINCIPLES; MANAGEMENT; STAYS
AB Objectives: To investigate the relationship between multimorbidity and healthcare utilisation patterns among the highest cost patients in a large, integrated healthcare system.
Design: In this retrospective cross-sectional study of all patients in the U.S. Veterans Affairs (VA) Health Care System, we aggregated costs of individuals' outpatient and inpatient care, pharmacy services and VA-sponsored contract care received in 2010. We assessed chronic condition prevalence, multimorbidity as measured by comorbidity count, and multisystem multimorbidity (number of body systems affected by chronic conditions) among the 5% highest cost patients. Using multivariate regression, we examined the association between multimorbidity and healthcare utilisation and costs, adjusting for age, sex, race/ethnicity, marital status, homelessness and health insurance status.
Setting: USAVA Health Care System.
Participants: 5.2 million VA patients.
Measures: Annual total costs; absolute and share of costs generated through outpatient, inpatient, pharmacy and VA-sponsored contract care; number of visits to primary, specialty and mental healthcare; number of emergency department visits and hospitalisations.
Results: The 5% highest cost patients (n=261 699) accounted for 47% of total VA costs. Approximately two-thirds of these patients had chronic conditions affecting >= 3 body systems. Patients with cancer and schizophrenia were less likely to have documented comorbid conditions than other high-cost patients. Multimorbidity was generally associated with greater outpatient and inpatient utilisation. However, increased multisystem multimorbidity was associated with a higher outpatient share of total costs (1.6 percentage points per affected body system, p<0.01) but a lower inpatient share of total costs (-0.6 percentage points per affected body system, p<0.01).
Conclusions: Multisystem multimorbidity is common among high-cost VA patients. While some patients might benefit from disease-specific programmes, for most patients with multimorbidity there is a need for interventions that coordinate and maximise efficiency of outpatient services across multiple conditions.
C1 [Zulman, Donna M.; Chee, Christine Pal; Wagner, Todd H.; Yoon, Jean; Asch, Steven M.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA.
[Zulman, Donna M.; Cohen, Danielle M.; Asch, Steven M.] Stanford Univ, Div Gen Med Disciplines, Stanford, CA 94305 USA.
[Chee, Christine Pal; Wagner, Todd H.; Yoon, Jean] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA.
[Wagner, Todd H.] Stanford Univ, Hlth Res & Policy, Stanford, CA 94305 USA.
[Holmes, Tyson H.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Ritchie, Christine] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Ritchie, Christine] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Zulman, DM (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA.
EM dzulman@stanford.edu
FU U.S. Department of Veterans Affairs (VA) HSR&D Career Development Award
[CDA 12-173]; VA Office of Specialty Care Services (Specialty/Surgical
Care Neighborhood Team Based Model Pilot Program); Advanced Illness and
Multimorbidity Geriatric Academic Leadership Award [1K07AG31779];
[SDR-ECN-99017-1]
FX DMZ is supported by a U.S. Department of Veterans Affairs (VA) HSR&D
Career Development Award (CDA 12-173). CPC, THW, and JY received core
funding SDR-ECN-99017-1 to the VA Health Economics Resource Center. THH
and DMC are supported in part by the VA Office of Specialty Care
Services (Specialty/Surgical Care Neighborhood Team Based Model Pilot
Program). CR is supported by the Advanced Illness and Multimorbidity
Geriatric Academic Leadership Award (1K07AG31779).
NR 34
TC 12
Z9 12
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2015
VL 5
IS 4
AR e007771
DI 10.1136/bmjopen-2015-007771
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI4GB
UT WOS:000354705000122
PM 25882486
ER
PT J
AU Liu, CZ
Litscher, G
Liang, FR
Kong, J
Wang, LP
Wang, L
AF Liu, Cun-Zhi
Litscher, Gerhard
Liang, Fan-Rong
Kong, Jian
Wang, Lin-Peng
Wang, Lu
TI Deqi Sensation in Different Kinds of Acupuncture 2014
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Editorial Material
C1 [Liu, Cun-Zhi] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Acupuncture & Moxibust Dept, Beijing 100010, Peoples R China.
[Litscher, Gerhard; Wang, Lu] Med Univ Graz, Res Unit Complementary & Integrat Laser Med, Res Unit Biomed Engn Anesthesia & Intens Care Med, TCM Res Ctr Graz, A-8036 Graz, Austria.
[Liang, Fan-Rong] Chengdu Univ Tradit Chinese Med, Coll Acupuncture & Massage, Chengdu 610075, Sichuan, Peoples R China.
[Kong, Jian] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02129 USA.
[Wang, Lin-Peng] Capital Med Univ, Sch Tradit Chinese Med, Beijing 100069, Peoples R China.
RP Liu, CZ (reprint author), Capital Med Univ, Beijing Hosp Tradit Chinese Med, Acupuncture & Moxibust Dept, 23 Meishuguanhou St, Beijing 100010, Peoples R China.
EM lcz623780@126.com
OI Litscher, Gerhard/0000-0001-6287-0130
NR 0
TC 0
Z9 0
U1 1
U2 4
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2015
AR 306138
DI 10.1155/2015/306138
PG 1
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA CJ0RJ
UT WOS:000355185000001
ER
PT J
AU Toi, M
Winer, EP
Benson, JR
Inamoto, T
Forbes, JF
von Minckwitz, G
Robertson, JFR
Grobmyer, SR
Jatoi, I
Sasano, H
Kunkler, I
Ho, AY
Yamauchi, C
Chow, LWC
Huang, CS
Han, W
Noguchi, S
Pegram, MD
Yamauchi, H
Lee, ES
Larionov, AA
Bevilacqua, JLB
Yoshimura, M
Sugie, T
Yamauchi, A
Krop, IE
Noh, DY
Klimberg, VS
AF Toi, Masakazu
Winer, Eric P.
Benson, John R.
Inamoto, Takashi
Forbes, John F.
von Minckwitz, Gunter
Robertson, John F. R.
Grobmyer, Stephen R.
Jatoi, Ismail
Sasano, Hironobu
Kunkler, Ian
Ho, Alice Y.
Yamauchi, Chikako
Chow, Louis W. C.
Huang, Chiun-Sheng
Han, Wonshik
Noguchi, Shinzaburo
Pegram, Mark D.
Yamauchi, Hideko
Lee, Eun-Sook
Larionov, Alexey A.
Bevilacqua, Jose L. B.
Yoshimura, Michio
Sugie, Tomoharu
Yamauchi, Akira
Krop, Ian E.
Noh, Dong Young
Klimberg, V. Suzanne
CA 2014 Kyoto Breast Canc Consensus C
TI Personalization of loco-regional care for primary breast cancer patients
(part 1)
SO FUTURE ONCOLOGY
LA English
DT Article
DE axillary conserving therapy; breast cancer; loco-regional care;
preoperative systemic therapy; sentinel lymph node biopsy
ID LYMPH-NODE BIOPSY; SURGICAL ADJUVANT BREAST; AXILLARY DISSECTION;
SENTINEL-NODE; NEOADJUVANT CHEMOTHERAPY; CLINICAL-TRIAL; SURGERY;
FLUORESCENCE; MULTICENTER
AB Kyoto Breast Cancer Consensus Conference, Kyoto, Japan, 18-20 February 2014 The loco-regional management of breast cancer is increasingly complex with application of primary systemic therapies, oncoplastic techniques and genetic testing for breast cancer susceptibility. Personalization of loco-regional treatment is integral to optimization of breast cancer care. Clinical and pathological tumor stage, biological features and host factors influence loco-regional treatment strategies and extent of surgical procedures. Key issues including axillary staging, axillary treatment, radiation therapy, primary systemic therapy (PST), preoperative hormonal therapy and genetic predisposition were identified and discussed at the Kyoto Breast Cancer Consensus Conference (KBCCC2014). In the first of a two part conference scene, consensus recommendations for axillary management are presented and focus on the following topics: indications for completion axillary lymph node dissection in primary surgical patients with 2 macrometastases or any sentinel nodal deposits after PST; the timing of sentinel lymph node biopsy in the context of PST; use of axillary irradiation as a component of primary treatment plans and the role of intraoperative node assessment in the post-Z0011 era.
C1 [Toi, Masakazu] Kyoto Univ, Grad Sch Med, Breast Surg, Sakyo Ku, Kyoto 6068507, Japan.
[Winer, Eric P.; Krop, Ian E.] Harvard Univ, Sch Med, Breast Oncol Ctr, Dana Farber Canc Inst,Brigham & Womens Canc Ctr, Boston, MA 02215 USA.
[Benson, John R.] Addenbrookes Hosp, Cambridge Breast Unit, Cambridge, England.
[Benson, John R.] Univ Cambridge, Cambridge, England.
[Inamoto, Takashi] Tenri Hlth Care Univ, Fac Hlth Care, Nara, Japan.
[Forbes, John F.] Univ Newcastle, Surg Oncol, Newcastle, NSW 2300, Australia.
[von Minckwitz, Gunter] German Breast Grp, Frankfurt, Germany.
[Robertson, John F. R.] Univ Nottingham, Breast Surg, Royal Derby Hosp, Nottingham NG7 2RD, England.
[Grobmyer, Stephen R.] Case Western Reserve Univ, Cleveland Clin, Cleveland, OH 44195 USA.
[Grobmyer, Stephen R.] Case Western Reserve Univ, Lerner Coll Med, Cleveland, OH 44195 USA.
[Jatoi, Ismail] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Sasano, Hironobu] Tohoku Univ, Sch Med, Pathol, Sendai, Miyagi 980, Japan.
[Kunkler, Ian] Univ Edinburgh, Edinburgh Canc Res UK Ctr, Edinburgh EH8 9YL, Midlothian, Scotland.
[Ho, Alice Y.] Mem Sloan Kettering Canc Ctr, Radiat Oncol, New York, NY 10065 USA.
[Yamauchi, Chikako] Shiga Med Ctr Adults, Radiat Oncol, Moriyama, Japan.
[Chow, Louis W. C.] Univ Hong Kong, UNIMED Med Inst, Hong Kong, Hong Kong, Peoples R China.
[Huang, Chiun-Sheng] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Surg, Taipei 10764, Taiwan.
[Han, Wonshik; Lee, Eun-Sook; Noh, Dong Young] Seoul Natl Univ Hosp, Surg, Seoul 110744, South Korea.
[Noguchi, Shinzaburo] Osaka Univ, Breast & Endocrine Surg, Grad Sch Med, Osaka, Japan.
[Pegram, Mark D.] Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA.
[Yamauchi, Hideko] St Lukes Hosp, Dept Surg, Tokyo, Japan.
[Larionov, Alexey A.] Univ Cambridge, Stat & Computat Biol Lab, Canc Res UK Cambridge Inst, Cambridge CB2 1TN, England.
[Bevilacqua, Jose L. B.] AC Camargo Canc Ctr, Dept Breast Surg, Sao Paulo, Brazil.
[Yoshimura, Michio] Kyoto Univ, Grad Sch Med, Radiat Oncol, Kyoto, Japan.
[Sugie, Tomoharu] Kansai Med Univ, Beast Surg, Osaka, Japan.
[Yamauchi, Akira] Kitano Hosp, Breast Ctr, Tazuke Kofukai Med Res Inst, Osaka, Japan.
[Klimberg, V. Suzanne] Univ Arkansas Med Sci, Surg, Rockefeller Canc Inst, Little Rock, AR 72205 USA.
RP Toi, M (reprint author), Kyoto Univ, Grad Sch Med, Breast Surg, Sakyo Ku, 54 Shogoin Kawara Cho, Kyoto 6068507, Japan.
EM toi@kuhp.kyoto-u.ac.jp
RI Bevilacqua, Jose Luiz/J-7739-2012; Larionov, Alexey/A-5088-2010; Han,
Wonshik/B-3699-2008;
OI Larionov, Alexey/0000-0001-6374-9391; Huang,
Chiun-Sheng/0000-0002-6557-211X
NR 17
TC 3
Z9 3
U1 0
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PY 2015
VL 11
IS 9
BP 1297
EP 1300
DI 10.2217/fon.15.65
PG 4
WC Oncology
SC Oncology
GA CH9XR
UT WOS:000354390500002
PM 25952777
ER
PT J
AU Toi, M
Winer, EP
Benson, JR
Inamoto, T
Forbes, JF
von Minckwitz, G
Robertson, JFR
Grobmyer, SR
Jatoi, I
Sasano, H
Kunkler, I
Ho, AY
Yamauchi, C
Chow, LWC
Huang, CS
Han, W
Noguchi, S
Pegram, MD
Yamauchi, H
Lee, ES
Larionov, AA
Bevilacqua, JLB
Yoshimura, M
Sugie, T
Yamauchi, A
Krop, IE
Noh, DY
Klimberg, VS
AF Toi, Masakazu
Winer, Eric P.
Benson, John R.
Inamoto, Takashi
Forbes, John F.
von Minckwitz, Gunter
Robertson, John F. R.
Grobmyer, Stephen R.
Jatoi, Ismail
Sasano, Hironobu
Kunkler, Ian
Ho, Alice Y.
Yamauchi, Chikako
Chow, Louis W. C.
Huang, Chiun-Sheng
Han, Wonshik
Noguchi, Shinzaburo
Pegram, Mark D.
Yamauchi, Hideko
Lee, Eun-Sook
Larionov, Alexey A.
Bevilacqua, Jose L. B.
Yoshimura, Michio
Sugie, Tomoharu
Yamauchi, Akira
Krop, Ian E.
Noh, Dong Young
Klimberg, V. Suzanne
CA 2014 Kyoto Breast Canc Consensus C
TI Personalization of loco-regional care for primary breast cancer patients
(part 2)
SO FUTURE ONCOLOGY
LA English
DT Article
DE breast cancer; BRCA1/2; luminal type; postmastectomy radiation therapy
ID NEOADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIALS; SENTINEL-NODE;
RADIOTHERAPY; METAANALYSIS; RECURRENCE; SURGERY; DISSECTION; MASTECTOMY;
THERAPY
AB Kyoto Breast Cancer Consensus Conference, Kyoto, Japan, 18-20 February 2014 The loco-regional management of breast cancer is increasingly complex with application of primary systemic therapies, oncoplastic techniques and genetic testing for breast cancer susceptibility. Personalization of loco-regional treatment is integral to optimization of breast cancer care. Clinical and pathological tumor stage, biological features and host factors influence loco-regional treatment strategies and extent of surgical procedures. Key issues including axillary staging, axillary treatment, radiation therapy, primary systemic therapy (PST), preoperative hormonal therapy and genetic predisposition were identified and discussed at the Kyoto Breast Cancer Consensus Conference (KBCCC2014). In the second of a two part conference scene, consensus recommendations for radiation treatment, primary systemic therapies and management of genetic predisposition are reported and focus on the following topics: influence of both clinical response to PST and stage at presentation on recommendations for postmastectomy radiotherapy; use of regional nodal irradiation in selected node-positive patients and those with adverse pathological factors; extent of surgical resection following downstaging of tumors with PST; use of preoperative hormonal therapy in premenopausal women with larger, node-negative luminal A-like tumors and managing increasing demands for contralateral prophylactic mastectomy in patients with a unilateral sporadic breast cancer.
C1 [Toi, Masakazu] Kyoto Univ, Grad Sch Med, Breast Surg, Sakyo Ku, Kyoto 6068507, Japan.
[Winer, Eric P.; Krop, Ian E.] Harvard Univ, Sch Med, Breast Oncol Ctr, Dana Farber Canc Inst,Brigham & Womens Canc Ctr, Boston, MA 02215 USA.
[Benson, John R.] Addenbrookes Hosp, Cambridge Breast Unit, Cambridge, England.
[Benson, John R.] Univ Cambridge, Cambridge, England.
[Inamoto, Takashi] Tenri Hlth Care Univ, Fac Hlth Care, Nara, Japan.
[Forbes, John F.] Univ Newcastle, Surg Oncol, Newcastle, NSW 2300, Australia.
[von Minckwitz, Gunter] German Breast Grp, Frankfurt, Germany.
[Robertson, John F. R.] Univ Nottingham, Breast Surg, Royal Derby Hosp, Nottingham NG7 2RD, England.
[Grobmyer, Stephen R.] Case Western Reserve Univ, Cleveland Clin, Cleveland, OH 44195 USA.
[Grobmyer, Stephen R.] Case Western Reserve Univ, Lerner Coll Med, Cleveland, OH 44195 USA.
[Jatoi, Ismail] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Sasano, Hironobu] Tohoku Univ, Sch Med, Pathol, Sendai, Miyagi 980, Japan.
[Kunkler, Ian] Univ Edinburgh, Edinburgh Canc Res UK Ctr, Edinburgh EH8 9YL, Midlothian, Scotland.
[Ho, Alice Y.] Mem Sloan Kettering Canc Ctr, Radiat Oncol, New York, NY 10065 USA.
[Yamauchi, Chikako] Shiga Med Ctr Adults, Radiat Oncol, Moriyama, Japan.
[Chow, Louis W. C.] Univ Hong Kong, UNIMED Med Inst, Hong Kong, Hong Kong, Peoples R China.
[Huang, Chiun-Sheng] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Surg, Taipei 10764, Taiwan.
[Han, Wonshik; Lee, Eun-Sook; Noh, Dong Young] Seoul Natl Univ Hosp, Surg, Seoul 110744, South Korea.
[Noguchi, Shinzaburo] Osaka Univ, Breast & Endocrine Surg, Grad Sch Med, Osaka, Japan.
[Pegram, Mark D.] Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA.
[Yamauchi, Hideko] St Lukes Hosp, Dept Surg, Tokyo, Japan.
[Larionov, Alexey A.] Univ Cambridge, Stat & Computat Biol Lab, Canc Res UK Cambridge Inst, Cambridge CB2 1TN, England.
[Bevilacqua, Jose L. B.] AC Camargo Canc Ctr, Dept Breast Surg, Sao Paulo, Brazil.
[Yoshimura, Michio] Kyoto Univ, Grad Sch Med, Radiat Oncol, Kyoto, Japan.
[Sugie, Tomoharu] Kansai Med Univ, Beast Surg, Osaka, Japan.
[Yamauchi, Akira] Kitano Hosp, Breast Ctr, Tazuke Kofukai Med Res Inst, Osaka, Japan.
Univ Arkansas Med Sci, Surg, Rockefeller Canc Inst, Little Rock, AR 72205 USA.
RP Toi, M (reprint author), Kyoto Univ, Grad Sch Med, Breast Surg, Sakyo Ku, 54 Shogoin Kawara Cho, Kyoto 6068507, Japan.
EM toi@kuhp.kyoto-u.ac.jp
RI Bevilacqua, Jose Luiz/J-7739-2012; Larionov, Alexey/A-5088-2010; Han,
Wonshik/B-3699-2008;
OI Larionov, Alexey/0000-0001-6374-9391; Huang,
Chiun-Sheng/0000-0002-6557-211X
NR 20
TC 0
Z9 0
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PY 2015
VL 11
IS 9
BP 1301
EP 1305
DI 10.2217/fon.15.66
PG 5
WC Oncology
SC Oncology
GA CH9XR
UT WOS:000354390500003
PM 25952778
ER
PT J
AU Wahlstrom, LC
Scott, JP
Tuliao, AP
DiLillo, D
McChargue, DE
AF Wahlstrom, Laura C.
Scott, Jillian Panuzio
Tuliao, Antover P.
DiLillo, David
McChargue, Dennis E.
TI Posttraumatic Stress Disorder Symptoms, Emotion Dysregulation, and
Aggressive Behavior Among Incarcerated Methamphetamine Users
SO JOURNAL OF DUAL DIAGNOSIS
LA English
DT Article
DE PTSD; methamphetamine; aggression; emotion regulation; incarceration
ID INTIMATE PARTNER VIOLENCE; MILITARY VETERANS; COMBAT VETERANS; ANGER;
TRAUMA; PTSD; MEN; PERPETRATION; ABUSE; DIFFICULTIES
AB Objective: Methamphetamine use remains a prevalent problem in the United States and is linked to numerous deleterious outcomes, including aggressive behavior, criminal activity, and incarceration. Given these associations, a greater understanding of factors that contribute to aggression among users of methamphetamine is needed, particularly within criminal justice settings, where users of this drug are overrepresented. Methods: The present study examined the relationships between posttraumatic stress disorder (PTSD) symptoms and emotion dysregulation and in-prison physical aggression among incarcerated males who identified as methamphetamine users (N = 60). Results: Participants' average age was 34.4years (SD = 7.9), and they were predominantly European American (n = 48, 80%), had spent an average of 6.53years incarcerated (SD = 4.64), and perpetrated about 1.54 acts of aggression (SD = 6.74) during the past three months. Bivariate correlations found that greater PTSD symptoms (p <.001), greater impulse control difficulties (p <.001), and limited access to emotion regulation strategies (p <.05) were associated with aggression perpetrated in prison. However, results from multiple regression analyses indicated that only PTSD symptoms (p <.001) and nonacceptance of emotional responses (p <.03) were predictive of aggression. Regression analyses also suggested that impulse control difficulties (p <.001), limited access to emotion regulation strategies (p <.04), and nonacceptance of emotional responses (p <.001) interacted with PTSD symptoms to predict increased aggressive behavior. The first interaction ran counter to study hypotheses: At greater levels of PTSD symptoms, those with greater acceptance of emotional responses reported greater aggression perpetration than those with lesser acceptance of emotional responses. The other two interactions were in line with hypotheses, showing that at greater levels of PTSD symptoms, those with greater impulse control difficulties (or lesser access to emotion regulation strategies) reported more aggressive behaviors. Conclusions: Consistent with theories of aggression, study findings suggest that PTSD symptoms bolster the risk of aggression via various forms emotion dysregulation. Results shed light on potential mechanisms that promote in-prison aggression and violent recidivism among this population.
C1 [Wahlstrom, Laura C.] Cent Texas VA Hlth Care Syst, Temple, TX USA.
[Scott, Jillian Panuzio] VA Boston Healthcare Syst, Boston, MA USA.
[Scott, Jillian Panuzio] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Tuliao, Antover P.; DiLillo, David; McChargue, Dennis E.] Univ Nebraska, Dept Psychol, Lincoln, NE 68588 USA.
RP McChargue, DE (reprint author), Univ Nebraska, Dept Psychol, 238 Burnett Hall, Lincoln, NE 68588 USA.
EM dmcchargue2@unl.edu
FU Nebraska State Penitentiary; Nebraska Crime Commission
FX The authors thank the Nebraska State Penitentiary and the Nebraska Crime
Commission for their support in accomplishing this project.
NR 61
TC 2
Z9 2
U1 4
U2 17
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1550-4263
EI 1550-4271
J9 J DUAL DIAGN
JI J. Dual Diagn.
PY 2015
VL 11
IS 2
BP 118
EP 127
DI 10.1080/15504263.2015.1025026
PG 10
WC Psychology, Clinical; Substance Abuse; Psychiatry
SC Psychology; Substance Abuse; Psychiatry
GA CI5GP
UT WOS:000354782900004
PM 25781457
ER
PT J
AU Morgan, P
Embry, A
Perry, L
Holthaus, K
Gregory, CM
AF Morgan, Patrick
Embry, Aaron
Perry, Lindsay
Holthaus, Katy
Gregory, Chris M.
TI Feasibility of lower-limb muscle power training to enhance locomotor
function poststroke
SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT
LA English
DT Article
DE exercise; locomotion; locomotor function; muscle; optimization of
walking; poststroke; rehabilitation; strengthening; stroke; walking
ID LEG POWER; CHRONIC STROKE; GAIT SPEED; PHYSICAL PERFORMANCE; KNEE
EXTENSION; OLDER WOMEN; REHABILITATION; STRENGTH; MOBILITY; INDIVIDUALS
AB Poststroke motor control is characterized by greatly reduced muscle power generation. To date, the extent to which muscle power limits walking performance or whether its remediation should be a primary component of locomotor rehabilitation has yet to be established. The purpose of this study was to examine the feasibility and the effects of Poststroke Optimization of Walking using Explosive Resistance training, an intervention aimed at improving poststroke muscular and locomotor function. Twelve subjects (6-60 mo poststroke) participated in 24 training sessions (3 sessions/wk for 8 wk). Exercises included leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking. We measured self-selected and fastest comfortable walking speeds as well as knee extensor and plantar flexor strength and power at pretraining, posttraining, and 8 wk follow-up time points. In addition, we also performed a number of clinical assessments commonly used in poststroke rehabilitation trials. Following training, significant improvements in lower-limb muscle strength and power were realized and accompanied by improvements in self-selected as well as fastest comfortable walking speeds. No changes in clinical assessments resulted from training.
C1 [Morgan, Patrick; Embry, Aaron; Perry, Lindsay; Holthaus, Katy; Gregory, Chris M.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Embry, Aaron; Perry, Lindsay; Gregory, Chris M.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA.
[Gregory, Chris M.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA.
RP Gregory, CM (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA.
EM gregoryc@musc.edu
FU Department of Veterans Affairs (VA), Office of Research and Development,
Rehabilitation Research and Development Service [AHA-11BGIA7450016];
Ralph H. Johnson VA Medical Center, Charleston, South Carolina
FX Funding/Support: This material was based on work supported by the
Department of Veterans Affairs (VA), Office of Research and Development,
Rehabilitation Research and Development Service (grant
AHA-11BGIA7450016) and the Ralph H. Johnson VA Medical Center,
Charleston, South Carolina.
NR 31
TC 2
Z9 2
U1 1
U2 7
PU JOURNAL REHAB RES & DEV
PI BALTIMORE
PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET,
BALTIMORE, MD 21202-4051 USA
SN 0748-7711
EI 1938-1352
J9 J REHABIL RES DEV
JI J. Rehabil. Res. Dev.
PY 2015
VL 52
IS 1
BP 77
EP 84
DI 10.1682/JRRD.2014.04.0109
PG 8
WC Rehabilitation
SC Rehabilitation
GA CI8YI
UT WOS:000355057200008
PM 26186176
ER
PT J
AU Udemba, A
Smith, G
Nguyen, QD
Kaliszczak, M
Carroll, L
Fortt, R
Fuchter, MJ
Aboagye, EO
AF Udemba, A.
Smith, G.
Nguyen, Q. -D.
Kaliszczak, M.
Carroll, L.
Fortt, R.
Fuchter, M. J.
Aboagye, E. O.
TI Design, synthesis and initial characterisation of a radiolabelled
[F-18]pyrimidoindolone probe for detecting activated caspase-3/7
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; PET TRACER; APOPTOSIS; CANCER; TUMORS
AB Evasion of apoptosis is one of the six initially proposed hallmarks of cancer, and as such, a method to detect apoptosis in a tumour would be of considerable interest in both clinical trials of new cancer therapeutics, as well as for routine patient management. Activation of caspase-3/7 is a key biomarker of cellular apoptosis. Herein we describe the design, synthesis and initial characterisation of the first pyrimidoindolone compound for detection of caspase-3/7 activation using positron emission tomography.
C1 [Udemba, A.; Kaliszczak, M.; Carroll, L.; Aboagye, E. O.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Comprehens Canc Imaging Ctr, London W12 0NN, England.
[Smith, G.] Inst Canc Res, London SW7 3RP, England.
[Nguyen, Q. -D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lurie Family Imaging Ctr,Ctr Biomed Imaging Oncol, Boston, MA 02215 USA.
[Fortt, R.] St Thomas Hosp, Kings Coll London, Div Imaging Sci & Biomed Engn, London SE1 7EH, England.
[Fuchter, M. J.] Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AY, England.
RP Aboagye, EO (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Comprehens Canc Imaging Ctr, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.
EM e.aboagye@imperial.ac.uk
OI Smith, Graham/0000-0002-0762-3812
FU CRUK/EPSRC.MRC/DoH (England) [C2536/A10337]
FX We thank CRUK/EPSRC.MRC/DoH (England) for funding (grant C2536/A10337).
NR 22
TC 0
Z9 0
U1 3
U2 15
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1477-0520
EI 1477-0539
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2015
VL 13
IS 19
BP 5418
EP 5423
DI 10.1039/c5ob00058k
PG 6
WC Chemistry, Organic
SC Chemistry
GA CH7HC
UT WOS:000354205600016
PM 25865735
ER
PT S
AU Olson, ES
Nakajima, HH
AF Olson, Elizabeth S.
Nakajima, Hideko H.
BE Choi, B
Kollias, N
Zeng, H
Kang, HW
Wong, BJF
Ilgner, JF
Nuttal, A
Richter, CP
Skala, MC
Dewhirst, MW
Tearney, GJ
Gregory, KW
Marcu, L
Mandelis, A
TI A family of fiber-optic based pressure sensors for intracochlear
measurements
SO PHOTONIC THERAPEUTICS AND DIAGNOSTICS XI
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Photonic Therapeutics and Diagnostics XI
CY FEB 07-08, 2015
CL San Francisco, CA
SP SPIE, Assoc Res Otolaryngol
DE pressure sensor; fiber optic; cochlea; middle ear
ID ROUND-WINDOW STIMULATION; HUMAN TEMPORAL BONES; MIDDLE-EAR; SOUND
PRESSURES; COCHLEAR PARTITION; TYMPANIC MEMBRANE; CANAL DEHISCENCE;
GERBIL; TRANSMISSION; CHINCHILLA
AB Fiber-optic pressure sensors have been developed for measurements of intracochlear pressure. The present family of transducers includes an 81 mu m diameter sensor employing a SLED light source and single-mode optic fiber, and LED/multi-mode sensors with 126 and 202 mu m diameter. The 126 mu m diameter pressure sensor also has been constructed with an electrode adhered to its side, for coincident pressure and voltage measurements. These sensors have been used for quantifying cochlear mechanical impedances, informing our understanding of conductive hearing loss and its remediation, and probing the operation of the cochlear amplifier.
C1 [Olson, Elizabeth S.] Columbia Univ, Dept Otolaryngol Head & Neck Surg & Biomed Engn, New York, NY 10027 USA.
[Nakajima, Hideko H.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA USA.
RP Olson, ES (reprint author), Columbia Univ, Dept Otolaryngol Head & Neck Surg & Biomed Engn, New York, NY 10027 USA.
NR 30
TC 1
Z9 1
U1 0
U2 7
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-393-9
J9 PROC SPIE
PY 2015
VL 9303
AR 93031O
DI 10.1117/12.2178056
PG 7
WC Engineering, Biomedical; Optics
SC Engineering; Optics
GA BC6PW
UT WOS:000354366400029
ER
PT J
AU Turetsky, A
Lee, K
Song, J
Giedt, RJ
Kim, E
Kovach, AE
Hochberg, EP
Castro, CM
Lee, H
Weissleder, R
AF Turetsky, Anna
Lee, Kyungheon
Song, Jun
Giedt, Randy J.
Kim, Eunha
Kovach, Alexandra E.
Hochberg, Ephraim P.
Castro, Cesar M.
Lee, Hakho
Weissleder, Ralph
TI On Chip Analysis of CNS Lymphoma in Cerebrospinal Fluid
SO THERANOSTICS
LA English
DT Article
DE lymphoma; microfluidics; point-of-care; cerebrospinal fluid; drug
testing
ID B-CELL LYMPHOMA; CENTRAL-NERVOUS-SYSTEM; NON-HODGKINS-LYMPHOMA; OCCULT
LEPTOMENINGEAL DISEASE; BRUTONS TYROSINE KINASE; FLOW-CYTOMETRY; CD20
EXPRESSION; GENE-EXPRESSION; RISK-FACTORS; INVOLVEMENT
AB Molecular profiling of central nervous system lymphomas in cerebrospinal fluid (CSF) samples can be challenging due to the paucicellular and limited nature of the samples. Presented herein is a microfluidic platform for complete CSF lymphoid cell analysis, including single cell capture in sub-nanoliter traps, and molecular and chemotherapeutic response profiling via on-chip imaging, all in less than one hour. The system can detect scant lymphoma cells and quantitate their kappa/lambda immunoglobulin light chain restriction patterns. The approach can be further customized for measurement of additional biomarkers, such as those for differential diagnosis of lymphoma subtypes or for prognosis, as well as for imaging exposure to experimental drugs.
C1 [Turetsky, Anna; Lee, Kyungheon; Song, Jun; Giedt, Randy J.; Kim, Eunha; Castro, Cesar M.; Lee, Hakho; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Song, Jun] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Kovach, Alexandra E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Hochberg, Ephraim P.; Castro, Cesar M.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA.
EM rweissleder@mgh.harvard.edu
FU Harvard Biophysics Graduate Program under NIH training grant
[T32008313]; NSF Graduate Research Fellowship [DGE0946799, DGE1144152]
FX Authors 1, 2, and 3 contributed equally to this work. We thank A. Letai,
T. Gilmore, and R. Ryan for cell lines, and the Harvard Center for
Nanoscale Systems for use of their Nanofabrication cleanroom facility.
A.T. was supported by the Harvard Biophysics Graduate Program under NIH
training grant T32008313 and by an NSF Graduate Research Fellowship
under grant numbers DGE0946799 and DGE1144152.
NR 40
TC 2
Z9 2
U1 0
U2 7
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2015
VL 5
IS 8
BP 796
EP 804
DI 10.7150/thno.11220
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CI7QT
UT WOS:000354959900002
PM 26000053
ER
PT J
AU Kim, YR
Kim, S
Choi, JW
Choi, SY
Lee, SH
Kim, H
Hahn, SK
Koh, GY
Yun, SH
AF Kim, Yi Rang
Kim, Seonghoon
Choi, Jin Woo
Choi, Sung Yong
Lee, Sang-Hee
Kim, Homin
Hahn, Sei Kwang
Koh, Gou Young
Yun, Seok Hyun
TI Bioluminescence-Activated Deep-Tissue Photodynamic Therapy of Cancer
SO THERANOSTICS
LA English
DT Article
DE Photodynamic Therapy; Bioluminescence; Photosensitizers; Resonance
Energy Transfer; Cancer; Photobiology; Photomedicine
ID ENERGY-TRANSFER BRET; IN-VIVO; BREAST-CANCER; MULTIDRUG-RESISTANCE;
IONIZING-RADIATION; CELLULAR UPTAKE; CHLORIN E6; EX-VIVO; LIGHT;
PHOTOIMMUNOTHERAPY
AB Optical energy can trigger a variety of photochemical processes useful for therapies. Owing to the shallow penetration of light in tissues, however, the clinical applications of light-activated therapies have been limited. Bioluminescence resonant energy transfer (BRET) may provide a new way of inducing photochemical activation. Here, we show that efficient bioluminescence energy-induced photodynamic therapy (PDT) of macroscopic tumors and metastases in deep tissue. For monolayer cell culture in vitro incubated with Chlorin e6, BRET energy of about 1 nJ per cell generated as strong cytotoxicity as red laser light irradiation at 2.2 mW/cm(2) for 180 s. Regional delivery of bioluminescence agents via draining lymphatic vessels killed tumor cells spread to the sentinel and secondary lymph nodes, reduced distant metastases in the lung and improved animal survival. Our results show the promising potential of novel bioluminescence-activated PDT.
C1 [Kim, Yi Rang; Kim, Seonghoon; Koh, Gou Young; Yun, Seok Hyun] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol WCU, Taejon 305701, South Korea.
[Kim, Yi Rang; Choi, Sung Yong; Lee, Sang-Hee; Kim, Homin; Koh, Gou Young] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Taejon 305701, South Korea.
[Kim, Yi Rang] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
[Choi, Jin Woo] Wonkwang Univ, Sch Dent, Wonkwang Inst Dent Res, Dept Pharmacol, Iksan 570749, Chonbuk, South Korea.
[Choi, Jin Woo; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA.
[Hahn, Sei Kwang] Pohang Univ Sci & Technol POSTECH, Dept Mat Sci & Engn, Pohang 790784, Gyeongbuk, South Korea.
[Yun, Seok Hyun] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
RP Yun, SH (reprint author), Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol WCU, 291 Daehak Ro, Taejon 305701, South Korea.
EM syun@hms.harvard.edu
RI Koh, Gou Young /C-1615-2011
FU Korea National Research Foundation of Korea [R31-2008-000-10071-0]; Bio
& Medical Technology Development Program [2012M3A9C6049791]; Mid-career
Researcher Program of the National Research Foundation (NRF) - Korean
government (MEST) [2012R1A2A2A06045773]; MGH ECOR Fund for Medical
Discovery; US National Institutes of Health [U54CA143837, P41EB015903]
FX We thank S. Kim for technical help on TEM, and Dr. Tayyaba Hasan at
Wellman Center and Drs. Myung-Gyu Choi and Jae-Myung Park at Seoul St.
Mary's Hospital for discussions. This work was funded by the Korea
National Research Foundation of Korea (R31-2008-000-10071-0), the Bio &
Medical Technology Development Program (2012M3A9C6049791), and
Mid-career Researcher Program (2012R1A2A2A06045773) of the National
Research Foundation (NRF) funded by the Korean government (MEST), and
also by MGH ECOR Fund for Medical Discovery and the US National
Institutes of Health (U54CA143837, P41EB015903).
NR 73
TC 7
Z9 7
U1 10
U2 57
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2015
VL 5
IS 8
BP 805
EP 817
DI 10.7150/thno.11520
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CI7QT
UT WOS:000354959900003
PM 26000054
ER
PT S
AU Dhou, S
Hurwitz, M
Mishra, P
Berbeco, R
Lewis, J
AF Dhou, Salam
Hurwitz, Martina
Mishra, Pankaj
Berbeco, Ross
Lewis, John
BE Yaniv, ZR
Webster, RJ
TI 4DCBCT-based motion modeling and 3D fluoroscopic image generation for
lung cancer radiotherapy
SO MEDICAL IMAGING 2015: IMAGE-GUIDED PROCEDURES, ROBOTIC INTERVENTIONS,
AND MODELING
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Medical Imaging - Image-Guided Procedures, Robotic
Interventions, and Modeling
CY FEB 22-24, 2015
CL Orlando, FL
SP SPIE, ALIO Ind, Alpin Med Syst, Modus Med Devices Inc, Bruker, Siemens, Natl Diagnost Imaging
ID RESPIRATORY MOTION; XCAT PHANTOM; ARTIFACTS
AB A method is developed to build patient-specific motion models based on 4DCBCT images taken at treatment time and use them to generate 3D time-varying images (referred to as 3D fluoroscopic images). Motion models are built by applying Principal Component Analysis (PCA) on the displacement vector fields (DVFs) estimated by performing deformable image registration on each phase of 4DCBCT relative to a reference phase. The resulting PCA coefficients are optimized iteratively by comparing 2D projections captured at treatment time with projections estimated using the motion model. The optimized coefficients are used to generate 3D fluoroscopic images. The method is evaluated using anthropomorphic physical and digital phantoms reproducing real patient trajectories. For physical phantom datasets, the average tumor localization error (TLE) and (95th percentile) in two datasets were 0.95 (2.2) mm. For digital phantoms assuming superior image quality of 4DCT and no anatomic or positioning disparities between 4DCT and treatment time, the average TLE and the image intensity error (TIE) in six datasets were smaller using 4DCT-based motion models. When simulating positioning disparities and tumor baseline shifts at treatment time compared to planning 4DCT, the average TLE (95th percentile) and TIE were 4.2 (5.4) mm and 0.15 using 4DCT-based models, while they were 1.2 (2.2) mm and 0.10 using 4DCBCT-based ones, respectively. 4DCBCT-based models were shown to perform better when there are positioning and tumor baseline shift uncertainties at treatment time. Thus, generating 3D fluoroscopic images based on 4DCBCT-based motion models can capture both inter- and intra- fraction anatomical changes during treatment.
C1 [Dhou, Salam; Hurwitz, Martina; Berbeco, Ross; Lewis, John] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dhou, Salam; Hurwitz, Martina; Berbeco, Ross; Lewis, John] Harvard Univ, Sch Med, Boston, MA USA.
[Mishra, Pankaj] Varian Med Syst, Palo Alto, CA USA.
RP Dhou, S (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
NR 19
TC 0
Z9 0
U1 1
U2 1
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-505-6
J9 PROC SPIE
PY 2015
VL 9415
AR 941510
DI 10.1117/12.2082291
PG 8
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC6PU
UT WOS:000354365300034
ER
PT S
AU Hamblin, MR
AF Hamblin, Michael R.
BE Chen, WR
TI Strategies to potentiate immune response after photodynamic therapy
SO BIOPHOTONICS AND IMMUNE RESPONSES X
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Biophotonics and Immune Responses X
CY FEB 09-10, 2015
CL San Francisco, CA
SP SPIE
DE Photodynamic therapy; anti-tumor immunity; dendritic cells; cytotoxic T
cells; tumor antigens; T-regulatory cells; immunostimulants
ID COLONY-STIMULATING FACTOR; LOW-DOSE CYCLOPHOSPHAMIDE; MHC-CLASS-I;
VULVAL INTRAEPITHELIAL NEOPLASIA; TRANSITIONAL CELL-CARCINOMA;
REGULATORY T-CELLS; ANTITUMOR IMMUNITY; DENDRITIC CELLS; TUMOR-IMMUNITY;
STREPTOCOCCAL PREPARATION
AB Photodynamic therapy (PDT) has been used as a cancer therapy for forty years but has not yet advanced to a mainstream cancer treatment. Although PDT has been shown to be an efficient photochemical way to destroy local tumors by a combination of non-toxic dyes and harmless visible light, it is its additional effects in mediating the stimulation of the host immune system that gives PDT a great potential to become more widely used. Although the stimulation of tumor-specific cytotoxic T-cells that can destroy distant tumor deposits after PDT has been reported in some animal models, it remains the exception rather than the rule. This realization has prompted several investigators to test various combination approaches that could potentiate the immune recognition of tumor antigens that have been released after PDT. Some of these combination approaches use immunostimulants including various microbial preparations that activate Toll-like receptors and other receptors for pathogen associated molecular patterns. Other approaches use cytokines and growth factors whether directly administered or genetically encoded. Other promising approaches involve depleting regulatory T-cells and epigenetic reversal agents. We believe that by understanding the methods employed by tumors to evade immune response and neutralizing them, more precise ways of potentiating PDT-induced immunity can be devised.
C1 [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
NR 94
TC 0
Z9 0
U1 0
U2 5
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-414-1
J9 PROC SPIE
PY 2015
VL 9324
AR 932405
DI 10.1117/12.2081029
PG 15
WC Immunology; Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Immunology; Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC5XU
UT WOS:000353632200001
ER
PT S
AU Wang, J
Li, B
Wu, MX
AF Wang, Ji
Li, Bo
Wu, Mei X.
BE Chen, WR
TI Non-ablative fractional laser in conjunction with microneedle arrays for
improved cutaneous vaccination
SO BIOPHOTONICS AND IMMUNE RESPONSES X
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Biophotonics and Immune Responses X
CY FEB 09-10, 2015
CL San Francisco, CA
SP SPIE
DE Biodegradable micro-needle; non-ablative fractional laser;
double-stranded DNA
ID CYCLIC GMP-AMP; DENDRITIC CELLS; CYTOSOLIC DNA; INTRADERMAL DELIVERY;
SKIN VACCINATION; ANTIMICROBIAL PEPTIDE; ANTIGEN PRESENTATION;
IMMUNE-RESPONSES; INFLUENZA-VIRUS; INNATE IMMUNITY
AB Skin is more potent than the muscle for vaccination, but it is not a common site for immunization to date, in part, owing to a relatively high rate of pains and skin irritation and difficulty of administration. Here, we show effective and lesion-free cutaneous vaccination by a combination of a biodegradable microneedle array (MNs) and a FDA-approved non-ablative fractional laser (NAFL). Delivering a vaccine into many micropores, instead of a single "big" pore, in the skin effectively segregated vaccine-induced inflammation into many microzones and resulted in quick resolution of the inflammation, provided that distances between any two micropores were far enough. When the inoculation site was treated by NAFL, prior to insertion of the MNs comprised of PR8 model influenza vaccine, the mice displayed vigorous antigen-uptake, giving rise to strong, Th1-biased immunity. The mice were protected from a challenge of homologous influenza virus at a high dose as well as heterologous H1N1 and H3N2 viruses. The adjuvant effect of NAFL was ascribed primarily to activation of the dsDNA sensing pathway by dsDNA released from laser-damaged skin cells. Thus, mice deficient in the dsDNA sensing pathway, but not Toll like receptor (TLR) or inflammasome pathways, showed poor response to NAFL. Importantly, both mice and swine exhibited strong, protective immunity, but no overt skin reactions with this approach, in sharp contrast to intradermal injections that caused severe, overt skin reactions. The effective lesion-free transcutaneous vaccination merits further clinical studies.
C1 [Wu, Mei X.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
RP Wu, MX (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 50 Blossom St,Edwards 222, Boston, MA 02114 USA.
EM mwu5@mgh.harvard.org
NR 53
TC 0
Z9 0
U1 0
U2 2
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-414-1
J9 PROC SPIE
PY 2015
VL 9324
AR 932409
DI 10.1117/12.2079304
PG 17
WC Immunology; Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Immunology; Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC5XU
UT WOS:000353632200003
ER
PT J
AU Luoto, TM
Iverson, GL
Losoi, H
Waljas, M
Tenovuo, O
Kataja, A
Brander, A
Ohman, J
AF Luoto, Teemu M.
Iverson, Grant L.
Losoi, Heidi
Waljas, Minna
Tenovuo, Olli
Kataja, Anneli
Brander, Antti
Ohman, Juha
TI Clinical correlates of retrograde amnesia in mild traumatic brain injury
SO BRAIN INJURY
LA English
DT Article
DE Concussion; head injury; post-concussion syndrome; retrograde amnesia;
return to work; traumatic brain injury
ID CLOSED-HEAD-INJURY; POST-CONCUSSION SYMPTOMS; POSTTRAUMATIC AMNESIA;
TEMPORAL-LOBE; SCANDINAVIAN GUIDELINES; INITIAL MANAGEMENT; PRACTICAL
SCALE; MEMORY; IMPAIRMENT; PREDICTORS
AB Primary objective: The purpose of this study was to examine the clinical significance of retrograde amnesia (RA) in patients with acute mild traumatic brain injuries (MTBI).
Methods and procedures: An emergency department sample of patients (n = 75), aged 18-60 years, with no pre-morbid medical or psychiatric conditions, who met the WHO criteria for MTBI were enrolled in this prospective, descriptive, follow-up study. This study examined the presence and duration of RA in relation to socio-demographics, MTBI severity markers including neuroimaging (CT, MRI) and clinical outcomes (Rivermead post-concussion symptoms questionnaire, post-concussion syndrome (PCS) diagnosis and return to work (RTW) status) at 2 weeks, 1 month and 6 months post-injury.
Main outcomes and results: GCS scores and duration of post-traumatic amnesia (PTA) were related to RA. Those with GCS scores of 14 vs. 15 were more likely to have RA (chi(2) (1) = 13.70, p<0.0001) and a longer duration (Mann-Whitney U = 56.0, p<0.0001, d = 1.15) of RA. The duration of RA and PTA correlated positively (Spearman rho(75) = 0.42, p<0.0001) and those with RA had longer durations of PTA (Mann-Whitney U = 228.5, p = 0.001, d = 1.21). During the follow-up, the presence and duration of RA were not significantly associated with PCS diagnosis or time to RTW.
Conclusions: In this study, the presence and duration of RA was not associated with outcome.
C1 [Luoto, Teemu M.; Losoi, Heidi; Waljas, Minna; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, FI-33521 Tampere, Finland.
[Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Iverson, Grant L.] Red Sox Fdn, Boston, MA USA.
[Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA.
[Tenovuo, Olli] Univ Turku, Dept Rehabil & Brain Trauma, Turku, Finland.
[Tenovuo, Olli] Univ Turku, Cent Hosp, FIN-20520 Turku, Finland.
[Kataja, Anneli; Brander, Antti] Tampere Univ Hosp, Dept Radiol, Med Imaging Ctr, FI-33521 Tampere, Finland.
RP Luoto, TM (reprint author), Tampere Univ Hosp, P Box 2000, FI-33521 Tampere, Finland.
EM teemu.luoto@pshp.fi
OI Ohman, Juha/0000-0002-6592-1367; Luoto, Teemu/0000-0002-7329-3284
FU Medical Research Fund of Tampere University Hospital
FX The authors thank research assistants Anne Simi and Marika
Suopanki-Ervasti for their contribution in data collection. This study
was done as part of the first author's PhD thesis research program. A
portion of this study was presented at the 9th World Congress on Brain
Injury in Edinburgh, Scotland, in March 2012. This study has been
supported by the Medical Research Fund of Tampere University Hospital.
NR 56
TC 2
Z9 2
U1 2
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PY 2015
VL 29
IS 5
BP 565
EP 572
DI 10.3109/02699052.2014.1002421
PG 8
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA CH3GL
UT WOS:000353917000004
PM 25789824
ER
PT J
AU Negraes, PD
Trujillo, CA
Pillat, MM
Teng, YD
Ulrich, H
AF Negraes, Priscilla D.
Trujillo, Cleber A.
Pillat, Micheli M.
Teng, Yang D.
Ulrich, Henning
TI Roles of Kinins in the Nervous System
SO CELL TRANSPLANTATION
LA English
DT Review
DE Bradykinin; B1BKR and B2BKR; Neural differentiation; Neuroprotection;
Inflammation
ID SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; BRADYKININ B-1 RECEPTOR;
NEURAL STEM-CELLS; TISSUE KALLIKREIN; B2 RECEPTOR; ALZHEIMERS-DISEASE;
ISCHEMIC-STROKE; INHIBITING APOPTOSIS; KINASE ACTIVATION
AB The kallikrein kinin system (KKS) is an endogenous pathway involved in many biological processes. Although primarily related to blood pressure control and inflammation, its activation goes beyond these effects. Neurogenesis and neuroprotection might be stimulated by bradykinin being of great interest for clinical applications following brain injury. This peptide is also an important player in spinal cord injury pathophysiology and recovery, in which bradykinin receptor blockers represent substantial therapeutic potential. Here, we highlight the participation of kinin receptors and especially bradykinin in mediating ischemia pathophysiology in the central and peripheral nervous systems. Moreover, we explore the recent advances on mechanistic and therapeutic targets for biological, pathological, and neural repair processes involving kinins.
C1 [Negraes, Priscilla D.; Pillat, Micheli M.; Ulrich, Henning] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.
[Trujillo, Cleber A.] Univ Calif San Diego, Sch Med, Dept Pediat, Rady Childrens Hosp San Diego,Stem Cell Program, La Jolla, CA 92093 USA.
[Teng, Yang D.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA.
[Teng, Yang D.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Teng, Yang D.] VABHS, Div SCI Res, Boston, MA USA.
RP Ulrich, H (reprint author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Ave Prof Linen Prestes 748, BR-05508900 Sao Paulo, Brazil.
EM henning@iq.usp.br
RI Ulrich, Henning/C-5245-2013
OI Ulrich, Henning/0000-0002-2114-3815
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho
Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil
FX This work was supported by research grants from Fundacao de Amparo a
Pesquisa do Estado de Sao Paulo (FAPESP) and Conselho Nacional de
Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil. The authors
declare no conflict of interest.
NR 101
TC 5
Z9 6
U1 0
U2 5
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0963-6897
EI 1555-3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2015
VL 24
IS 4
SI SI
BP 613
EP 623
DI 10.3727/096368915X687778
PG 11
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
Transplantation
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA CH3KD
UT WOS:000353928700004
PM 25839228
ER
PT J
AU Koh, SH
Liang, AC
Takahashi, Y
Maki, T
Shindo, A
Osumi, N
Zhao, J
Lin, H
Holder, JC
Chuang, TT
McNeish, JD
Arai, K
Lo, EH
AF Koh, S. H.
Liang, A. C.
Takahashi, Y.
Maki, T.
Shindo, A.
Osumi, N.
Zhao, J.
Lin, H.
Holder, J. C.
Chuang, T. T.
McNeish, J. D.
Arai, K.
Lo, E. H.
TI Differential Effects of Isoxazole-9 on Neural Stein/Progenitor Cells,
Oligodendrocyte Precursor Cells, and Endothelial Progenitor Cells in
Primary Culture
SO CELL TRANSPLANTATION
LA English
DT Meeting Abstract
CT 22nd Annual Meeting of the
American-Society-for-Neural-Therapy-and-Repair (ASNTR)
CY APR 30-MAY 02, 2015
CL Clearwater, FL
SP Amer Soc Neural Therapy & Repair
C1 [Koh, S. H.; Liang, A. C.; Takahashi, Y.; Maki, T.; Shindo, A.; Arai, K.; Lo, E. H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neuroprotect Res Lab, Cambridge, MA 02138 USA.
[Koh, S. H.; Liang, A. C.; Takahashi, Y.; Maki, T.; Shindo, A.; Arai, K.; Lo, E. H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Neuroprotect Res Lab, Cambridge, MA 02138 USA.
[Koh, S. H.] Hanyang Univ, Coll Med, Dept Neurol, Seoul 133791, South Korea.
[Takahashi, Y.; Osumi, N.] Tohoku Univ, Grad Sch Med, United Ctr Adv Res & Translat Med, Div Dev Neurosci, Sendai, Miyagi 980, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0963-6897
EI 1555-3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2015
VL 24
IS 4
SI SI
BP 763
EP 763
PG 1
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
Transplantation
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA CH3KD
UT WOS:000353928700052
ER
PT J
AU Liang, AC
Maki, T
Shindo, A
Mandeville, ET
Som, AT
Chuang, TT
McNeish, JD
Holder, JC
Lo, EH
Arai, K
AF Liang, A. C.
Maki, T.
Shindo, A.
Mandeville, E. T.
Som, A. T.
Chuang, T. T.
McNeish, J. D.
Holder, J. C.
Lo, E. H.
Arai, K.
TI Aging Disturbs Regenerative Responses in Neural Stein/Progenitor Cells
and Oligodendrocyte Precursor Cells in Spontaneous Hypertensive Rats
SO CELL TRANSPLANTATION
LA English
DT Meeting Abstract
CT 22nd Annual Meeting of the
American-Society-for-Neural-Therapy-and-Repair (ASNTR)
CY APR 30-MAY 02, 2015
CL Clearwater, FL
SP Amer Soc Neural Therapy & Repair
C1 [Liang, A. C.; Maki, T.; Shindo, A.; Mandeville, E. T.; Som, A. T.; Lo, E. H.; Arai, K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Radiol, Cambridge, MA 02138 USA.
[Liang, A. C.; Maki, T.; Shindo, A.; Mandeville, E. T.; Som, A. T.; Lo, E. H.; Arai, K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Neurol, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0963-6897
EI 1555-3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2015
VL 24
IS 4
SI SI
BP 764
EP 764
PG 1
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
Transplantation
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA CH3KD
UT WOS:000353928700054
ER
PT J
AU Miyamoto, N
Maki, T
Liang, AC
Shindo, A
Itoh, K
Lo, EK
Lok, J
Arai, K
AF Miyamoto, N.
Maki, T.
Liang, A. C.
Shindo, A.
Itoh, K.
Lo, E. K.
Lok, J.
Arai, K.
TI Endogenous Brain-Derived Neurotrophic Factor Promotes Oligodendrogenesis
by Mediating Signals From Astrocytes to Oligodendrocyte Precursor Cells
SO CELL TRANSPLANTATION
LA English
DT Meeting Abstract
CT 22nd Annual Meeting of the
American-Society-for-Neural-Therapy-and-Repair (ASNTR)
CY APR 30-MAY 02, 2015
CL Clearwater, FL
SP Amer Soc Neural Therapy & Repair
C1 [Miyamoto, N.; Maki, T.; Liang, A. C.; Shindo, A.; Itoh, K.; Lo, E. K.; Lok, J.; Arai, K.] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Cambridge, MA USA.
[Miyamoto, N.; Maki, T.; Liang, A. C.; Shindo, A.; Itoh, K.; Lo, E. K.; Lok, J.; Arai, K.] Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, Cambridge, MA USA.
[Miyamoto, N.; Maki, T.; Liang, A. C.; Shindo, A.; Itoh, K.; Lo, E. K.; Lok, J.; Arai, K.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Lok, J.] Massachusetts Gen Hosp, Dept Pediat, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0963-6897
EI 1555-3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2015
VL 24
IS 4
SI SI
BP 766
EP 766
PG 1
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
Transplantation
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA CH3KD
UT WOS:000353928700060
ER
PT J
AU Huffman, JC
DuBois, CM
Millstein, RA
Celano, CM
Wexler, D
AF Huffman, Jeff C.
DuBois, Christina M.
Millstein, Rachel A.
Celano, Christopher M.
Wexler, Deborah
TI Positive Psychological Interventions for Patients with Type 2 Diabetes:
Rationale, Theoretical Model, and Intervention Development
SO JOURNAL OF DIABETES RESEARCH
LA English
DT Review
ID RANDOMIZED-CONTROLLED-TRIAL; PROMOTE PHYSICAL-ACTIVITY; MOTIVATIONAL
ENHANCEMENT THERAPY; COGNITIVE-BEHAVIORAL THERAPY; SELF-DETERMINATION
THEORY; CORONARY-HEART-DISEASE; GLYCEMIC CONTROL; WEIGHT-LOSS;
LIFE-STYLE; DISPOSITIONAL OPTIMISM
AB Most patients with type 2 diabetes (T2D) have suboptimal adherence to recommended diet, physical activity, and/or medication. Current approaches to improve health behaviors in T2D have been variably effective, and successful interventions are often complex and intensive. It is therefore vital to develop interventions that are simple, well-accepted, and applicable to a wide range of patients who suffer from T2D. One approach may be to boost positive psychological states, such as positive affect or optimism, as these constructs have been prospectively and independently linked to improvements in health behaviors. Positive psychology (PP) interventions, which utilize systematic exercises to increase optimism, well-being, and positive affect, consistently increase positive states and are easily delivered to patients with chronic illnesses. However, to our knowledge, PP interventions have not been formally tested in T2D. In this paper, we review a theoretical model for the use of PP interventions to target health behaviors in T2D, describe the structure and content of a PP intervention for T2D patients, and describe baseline data from a single-arm proof-of-concept (N = 15) intervention study in T2D patients with or without depression. We also discuss how PP interventions could be combined with motivational interviewing (MI) interventions to provide a blended psychological-behavioral approach.
C1 [Huffman, Jeff C.; DuBois, Christina M.; Millstein, Rachel A.; Celano, Christopher M.; Wexler, Deborah] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Huffman, Jeff C.; Millstein, Rachel A.; Celano, Christopher M.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Wexler, Deborah] Massachusetts Gen Hosp, Dept Med, MGH Diabet Ctr, Boston, MA 02114 USA.
RP Huffman, JC (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
EM jhuffman@partners.org
FU NIH Grant [R01HL113272]
FX This work was supported in part by NIH Grant R01HL113272 to Dr. Jeff
Huffman.
NR 151
TC 0
Z9 0
U1 9
U2 25
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6745
EI 2314-6753
J9 J DIABETES RES
JI J. Diabetes Res.
PY 2015
AR 428349
DI 10.1155/2015/428349
PG 18
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA CH8ZO
UT WOS:000354325900001
ER
PT J
AU Hou, HW
Bhattacharyya, RP
Hung, DT
Han, J
AF Hou, Han Wei
Bhattacharyya, Roby P.
Hung, Deborah T.
Han, Jongyoon
TI Direct detection and drug-resistance profiling of bacteremias using
inertial microfluidics
SO LAB ON A CHIP
LA English
DT Article
ID STAPHYLOCOCCUS-AUREUS; CLINICAL MICROBIOLOGY; RAPID IDENTIFICATION;
INFECTIOUS-DISEASES; SEQUENCE-ANALYSIS; SEPTIC SHOCK; WHOLE-BLOOD;
SEPARATION; BACTERIAL; PCR
AB Detection of bacteria in bloodstream infections and their antibiotic susceptibility patterns is critical to guide therapeutic decision-making for optimal patient care. Current culture-based assays are too slow (> 48 h), leading to excessive up-front use of broad-spectrum antibiotics and/or incorrect antibiotic choices due to resistant bacteria, each with deleterious consequences for patient care and public health. To approach this problem, we describe a method to rapidly isolate bacteria from whole blood using inertial microfluidics and directly determine pathogen identity and antibiotic susceptibility with hybridization-based RNA detection. Using the principle of Dean flow fractionation, bacteria are separated from host blood cells in a label-free separation method with efficient recovery of even low abundance bacteria. Ribosomal RNA detection can then be applied for direct identification of low abundance pathogens (similar to 100 per mL) from blood without culturing or enzymatic amplification. Messenger RNA detection of antibiotic-responsive transcripts after brief drug exposure permits rapid susceptibility determination from bacteria with minimal culturing (similar to 10(5) per mL). This unique coupling of microfluidic cell separation with RNA-based molecular detection techniques represents significant progress towards faster diagnostics (similar to 8 hours) to guide antibiotic therapy.
C1 [Hou, Han Wei; Han, Jongyoon] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
[Bhattacharyya, Roby P.; Hung, Deborah T.] Broad Inst, Cambridge, MA 02142 USA.
[Bhattacharyya, Roby P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02115 USA.
[Han, Jongyoon] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
RP Hung, DT (reprint author), Broad Inst, Cambridge, MA 02142 USA.
EM hung@molbio.mgh.harvard.edu; jyhan@mit.edu
FU MIT's Microsystems Technology Laboratories; DARPA DLT (Dialysis-Like
Therapeutics) program under SSC Pacific [N66001-11-1-4182]; KL2/Catalyst
Medical Research Investigator Training award from Harvard Catalyst \ The
Harvard Clinical Translational Science Center (National Center for
Research Resources); KL2/Catalyst Medical Research Investigator Training
award from Harvard Catalyst \ The Harvard Clinical Translational Science
Center (National Center for Advancing Translational Sciences, National
Institutes of Health) [1KL2TR001100-01]; Lee Kong Chian School of
Medicine (LKCMedicine, Singapore) Postdoctoral Fellowship
FX This work is supported by the use of MIT's Microsystems Technology
Laboratories, as well as the financial support by DARPA DLT
(Dialysis-Like Therapeutics) program, under SSC Pacific grant
N66001-11-1-4182. This work was also conducted with the support of a
KL2/Catalyst Medical Research Investigator Training award (an appointed
KL2 award, to R.P.B.) from Harvard Catalyst vertical bar The Harvard
Clinical Translational Science Center (National Center for Research
Resources and the National Center for Advancing Translational Sciences,
National Institutes of Health Award 1KL2TR001100-01). The content is
solely the responsibility of the authors and does not represent the
official views of Harvard Catalyst, Harvard University and its
affiliated academic health care centers, the National Institutes of
Health, or DARPA. H.W.H. is supported by Lee Kong Chian School of
Medicine (LKCMedicine, Singapore) Postdoctoral Fellowship.
NR 57
TC 16
Z9 16
U1 8
U2 55
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PY 2015
VL 15
IS 10
BP 2297
EP 2307
DI 10.1039/c5lc00311c
PG 11
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience
& Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
Other Topics
GA CH7DU
UT WOS:000354196600016
PM 25882432
ER
PT S
AU Dong, TT
Zhang, Q
Hamblin, MR
Wu, MX
AF Dong, Tingting
Zhang, Qi
Hamblin, Michael R.
Wu, Mei X.
BE Hamblin, MR
Carroll, JD
Arany, P
TI Low level light in combination with metabolic modulators for effective
therapy
SO MECHANISMS FOR LOW-LIGHT THERAPY X
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Mechanisms for Low-Light Therapy X
CY FEB 07-08, 2015
CL San Francisco, CA
SP SPIE, THOR Photomedicine Ltd
DE TBI; hypoxia; Low Level Light; Lactate/Pyruvate; mitochondrial function
ID TRAUMATIC BRAIN-INJURY; RAT-LIVER MITOCHONDRIA; TREATMENT STRATEGIES;
TRANSCRANIAL LASER; ENERGY-METABOLISM; UNITED-STATES; SPINAL-CORD;
IN-VITRO; HYPOXIA; LACTATE
AB Vascular damage occurs frequently at the injured brain causing hypoxia and is associated with poor outcomes in the clinics. We found high levels of glycolysis, reduced ATP generation, and increased formation of reactive oxygen species (ROS) and apoptosis in neurons under hypoxia. Strikingly, these adverse events were reversed significantly by noninvasive exposure of injured brain to low-level light (LLL). LLL illumination sustained the mitochondrial membrane potential, constrained cytochrome C leakage in hypoxic cells, and protected them from apoptosis, underscoring a unique property of LLL. The effect of LLL was further bolstered by combination with metabolic substrates such as pyruvate or lactate both in vivo and in vitro. The combinational treatment retained memory and learning activities of injured mice to a normal level, whereas those treated with LLL or pyruvate alone, or sham light displayed partial or severe deficiency in these cognitive functions. In accordance with well-protected learning and memory function, the hippocampal region primarily responsible for learning and memory was completely protected by a combination of LLL and pyruvate, in marked contrast to the severe loss of hippocampal tissue due to secondary damage in control mice. These data clearly suggest that energy metabolic modulators can additively or synergistically enhance the therapeutic effect of LLL in energy-producing insufficient tissues like injured brain.
C1 [Dong, Tingting; Zhang, Qi; Hamblin, Michael R.; Wu, Mei X.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA.
RP Wu, MX (reprint author), 50 Blossom St, Boston, MA 02114 USA.
EM mwu5@mgh.harvard.edu
NR 49
TC 0
Z9 0
U1 0
U2 1
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-399-1
J9 PROC SPIE
PY 2015
VL 9309
AR 93090A
DI 10.1117/12.2079363
PG 22
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC6EU
UT WOS:000353877400009
ER
PT S
AU Hamblin, MR
de Sousa, MVP
Arany, PR
Carroll, JD
Patthoff, D
AF Hamblin, Michael R.
Pires de Sousa, Marcelo Victor
Arany, Praveen R.
Carroll, James D.
Patthoff, Donald
BE Hamblin, MR
Carroll, JD
Arany, P
TI Low Level Laser (Light) Therapy and Photobiomodulation: The Path Forward
SO MECHANISMS FOR LOW-LIGHT THERAPY X
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Mechanisms for Low-Light Therapy X
CY FEB 07-08, 2015
CL San Francisco, CA
SP SPIE, THOR Photomedicine Ltd
DE low level laser (light) therapy; LLLT; photobiomodulation; mechanism of
action; mitochondria; TRP ion channels; new indications; new light
sources
ID NEAR-INFRARED LIGHT; POTENTIAL TRP CHANNELS; BIPHASIC DOSE-RESPONSE;
MPTP-TREATED MICE; BONE-MARROW; MOUSE MODEL; STEM-CELLS;
NEUROPROTECTION; DEGENERATION; INFLAMMATION
AB Low level laser (light) therapy (LLLT) also known as photobiomodulation (PBM) therapy has been practiced for almost fifty years, and hundreds of positive clinical trials and thousands of laboratory studies have been published. Despite these impressive accomplishments LLLT has still not reached the stage of acceptance by mainstream medicine. The reasons for this were discussed at a recent Optical Society of America (OSA) Incubator meeting in Washington DC in 2014. Uncertainty about mechanisms was highlighted, and this paper will describe the current thinking. To drive LLLT towards mainstream medicine, we need better guidelines with standardized protocols and consistent parameters. Studies should be published in higher impact scientific and medical journals. Companies should avoid false promises and deceptive marketing, and physicians should receive a clearly defined return on investment with insurance reimbursement.
C1 [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA USA.
[Pires de Sousa, Marcelo Victor] Univ Sao Paulo, Inst Phys, Lab Radiat Dosimetry & Med Phys, Sao Paulo, Brazil.
[Arany, Praveen R.] NIDCR, NIH, Bethesda, MD USA.
[Carroll, James D.] THOR Photomed Ltd, Chesham, England.
[Patthoff, Donald] Gen Dent, Martinsburg, WV USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
NR 58
TC 2
Z9 2
U1 3
U2 10
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-399-1
J9 PROC SPIE
PY 2015
VL 9309
AR 930902
DI 10.1117/12.2084049
PG 11
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC6EU
UT WOS:000353877400002
ER
PT S
AU Xuan, WJ
Huang, LY
Vatansever, F
Agrawal, T
Hamblin, MR
AF Xuan, Weijun
Huang, Liyi
Vatansever, Fatma
Agrawal, Tanupriya
Hamblin, Michael R.
BE Hamblin, MR
Carroll, JD
Arany, P
TI Transcranial low-level laser therapy increases memory, learning,
neuroprogenitor cells, BDNF and synaptogenesis in mice with traumatic
brain injury.
SO MECHANISMS FOR LOW-LIGHT THERAPY X
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Mechanisms for Low-Light Therapy X
CY FEB 07-08, 2015
CL San Francisco, CA
SP SPIE, THOR Photomedicine Ltd
DE traumatic brain injury; LLLT; neurogenesis; synaptogenesis; BDNF;
dentate gyrus
ID ADULT NEUROGENESIS; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; DENTATE
GYRUS; LIGHT THERAPY; ISCHEMIA; EXERCISE; STROKE; RAT; NEUROPROTECTION
AB Increasing concern is evident over the epidemic of traumatic brain injury in both civilian and military medicine, and the lack of approved treatments. Transcranial low level laser therapy tLLLT) is a new approach in which near infrared laser is delivered to the head, penetrates the scalp and skull to reach the brain. We asked whether tLLLT at 810-nm could improve memory and learning in mice with controlled cortical impact traumatic brain injury. We investigated the mechanism of action by immunofluorescence studies in sections from brains of mice sacrificed at different times. Mice with TBI treated with 1 or 3 daily laser applications performed better on Morris Water Maze test at 28 days. Laser treated mice had increased BrdU incorporation into NeuN positive cells in the dentate gyrus and subventricular zone indicating formation of neuroprogenitor cells at 7 days and less at 28 days. Markers of neuron migration (DCX and Tuj1) were also increased, as was the neurotrophin, brain derived neurotrophic factor (BDNF) at 7 days. Markers of synaptogenesis (formation of new connections between existing neurons) were increased in the perilesional cortex at 28 days. tLLLT is proposed to be able to induce the brain to repair itself after injury. However its ability to induce neurogenesis and synaptogenesis suggests that tLLLT may have much wider applications to neurodegenerative and psychiatric disorders.
C1 [Xuan, Weijun; Huang, Liyi; Vatansever, Fatma; Agrawal, Tanupriya; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Xuan, Weijun; Huang, Liyi; Vatansever, Fatma; Agrawal, Tanupriya; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Xuan, Weijun] Tradit Chinese Med Univ Guangxi, Dept Otolaryngol, Nanning, Peoples R China.
[Huang, Liyi] Guangxi Med Univ, Dept Infect Dis, Affiliated Coll & Hosp 1, Nanning, Peoples R China.
[Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA USA.
RP Xuan, WJ (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
NR 46
TC 0
Z9 0
U1 2
U2 7
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-399-1
J9 PROC SPIE
PY 2015
VL 9309
AR 93090C
DI 10.1117/12.2081022
PG 10
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC6EU
UT WOS:000353877400010
ER
PT J
AU Yang, YF
Hou, LF
El Ouaamari, A
Xin, LJ
AF Yang, Yifu
Hou, Lifei
El Ouaamari, Abdelfattah
Xin, Lijun
TI Anti-Inflammatory Natural Products
SO MEDIATORS OF INFLAMMATION
LA English
DT Editorial Material
C1 [Yang, Yifu] Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai 201203, Peoples R China.
[Hou, Lifei] Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Hou, Lifei] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[El Ouaamari, Abdelfattah] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Xin, Lijun] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA.
RP Yang, YF (reprint author), Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai 201203, Peoples R China.
EM yangyifu@mail.shcnc.ac.cn
NR 2
TC 0
Z9 0
U1 0
U2 2
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2015
AR 608613
DI 10.1155/2015/608613
PG 1
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA CH9BW
UT WOS:000354332000001
ER
PT J
AU Apetoh, L
Smyth, MJ
Drake, CG
Abastado, JP
Apte, RN
Ayyoub, M
Blay, JY
Bonneville, M
Butterfield, LH
Caignard, A
Castelli, C
Cavallo, F
Celis, E
Chen, LP
Colombo, MP
Comin-Anduix, B
Coukos, G
Dhodapkar, MV
Dranoff, G
Frazer, IH
Fridman, WH
Gabrilovich, DI
Gilboa, E
Gnjatic, S
Jager, D
Kalinski, P
Kaufman, HL
Kiessling, R
Kirkwood, J
Knuth, A
Liblau, R
Lotze, MT
Lugli, E
Marincola, F
Melero, I
Melief, CJ
Mempel, TR
Mittendorf, EA
Odun, K
Overwijk, WW
Palucka, AK
Parmiani, G
Ribas, A
Romero, P
Schreiber, RD
Schuler, G
Srivastava, PK
Tartour, E
Valmori, D
van der Burg, SH
van der Bruggen, P
van den Eynde, BJ
Wang, E
Zou, WP
Whiteside, TL
Speiser, DE
Pardoll, DM
Restifo, NP
Anderson, AC
AF Apetoh, Lionel
Smyth, Mark J.
Drake, Charles G.
Abastado, Jean-Pierre
Apte, Ron N.
Ayyoub, Maha
Blay, Jean-Yves
Bonneville, Marc
Butterfield, Lisa H.
Caignard, Anne
Castelli, Chiara
Cavallo, Federica
Celis, Esteban
Chen, Lieping
Colombo, Mario P.
Comin-Anduix, Begona
Coukos, Georges
Dhodapkar, Madhav V.
Dranoff, Glenn
Frazer, Ian H.
Fridman, Wolf-Herve
Gabrilovich, Dmitry I.
Gilboa, Eli
Gnjatic, Sacha
Jaeger, Dirk
Kalinski, Pawel
Kaufman, Howard L.
Kiessling, Rolf
Kirkwood, John
Knuth, Alexander
Liblau, Roland
Lotze, Michael T.
Lugli, Enrico
Marincola, Francesco
Melero, Ignacio
Melief, Cornelis J.
Mempel, Thorsten R.
Mittendorf, Elizabeth A.
Odun, Kunle
Overwijk, Willem W.
Palucka, Anna Karolina
Parmiani, Giorgio
Ribas, Antoni
Romero, Pedro
Schreiber, Robert D.
Schuler, Gerold
Srivastava, Pramod K.
Tartour, Eric
Valmori, Danila
van der Burg, Sjoerd H.
van der Bruggen, Pierre
van den Eynde, Benoit J.
Wang, Ena
Zou, Weiping
Whiteside, Theresa L.
Speiser, Daniel E.
Pardoll, Drew M.
Restifo, Nicholas P.
Anderson, Ana C.
TI Consensus nomenclature for CD8(+) T cell phenotypes in cancer
SO ONCOIMMUNOLOGY
LA English
DT Article
DE anergy; anticancer immunity; CD8(+) T cells; cytotoxicity; exhaustion;
effector; IFN gamma; senescence; stemness
ID CHRONIC VIRAL-INFECTION; ANTIGEN-LOSS VARIANTS; TUMOR-SPECIFIC CTL;
ANTITUMOR IMMUNITY; REPLICATIVE SENESCENCE; MELANOMA PATIENTS;
INTERFERON-GAMMA; DENDRITIC CELLS; IN-VITRO; INHIBITORY RECEPTORS
C1 [Apetoh, Lionel] INSERM, UMR 866, Dijon, France.
[Apetoh, Lionel] Ctr Georges Francois Leclerc, Dijon, France.
[Apetoh, Lionel] Univ Bourgogne, Dijon, France.
[Smyth, Mark J.] QIMR Berghofer Med Res Inst, Herston, Qld, Australia.
[Drake, Charles G.; Pardoll, Drew M.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Abastado, Jean-Pierre] Inst Rech Int Servier, Suresnes, France.
[Apte, Ron N.] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol, Immunol & Genet, Beer Sheva, Israel.
[Ayyoub, Maha; Valmori, Danila] INSERM, U1102, Equipe Labellisee Ligue Canc, Inst Cancerol Ouest, Nantes St Hreblain, France.
[Blay, Jean-Yves] Canc Res Ctr Lyon, INSERM UMR 1052, CNRS UMR 5286, Ctr Leon Berard, Lyon, France.
[Blay, Jean-Yves] Dept Med Oncol, Lyon, France.
[Bonneville, Marc] CRCNA, INSERM U892, CNRS UMR 6299, Nantes, France.
[Bonneville, Marc] Inst Merienx, Lyon, France.
[Butterfield, Lisa H.] Univ Pittsburgh, Inst Canc, Dept Med, Pittsburgh, PA USA.
[Butterfield, Lisa H.] Univ Pittsburgh, Inst Canc, Dept Surg, Pittsburgh, PA USA.
[Butterfield, Lisa H.] Univ Pittsburgh, Inst Canc, Dept Immunol, Pittsburgh, PA USA.
[Caignard, Anne] INSERM UMR 1116, Paris, France.
[Castelli, Chiara] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Unit Immunotherapy Human Tumor, Milan, Italy.
[Cavallo, Federica] Univ Turin, Ctr Mol Biotechnol, Dept Mol Biotechnol & Hlth Sci, I-10124 Turin, Italy.
[Celis, Esteban] Georgia Regents Univ, Ctr Canc, Canc Immunol, Inflammat & Tolerance Program, Augusta, GA USA.
[Chen, Lieping] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
[Chen, Lieping] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA.
[Colombo, Mario P.] Fdn IRCCS Ist Nazl Tumori, Mol Immunol Unit, Dept Expt Oncol & Mol Med, Milan, Italy.
[Comin-Anduix, Begona; Ribas, Antoni] Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr Los Angels, Los Angeles, CA 90024 USA.
[Coukos, Georges; Romero, Pedro; Speiser, Daniel E.] Univ Lausanne, Dept Oncol, Ludwig Ctr Canc Res, CH-1015 Lausanne, Switzerland.
[Dranoff, Glenn] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Dranoff, Glenn] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Dranoff, Glenn] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Dranoff, Glenn; Anderson, Ana C.] Harvard Univ, Sch Med, Boston, MA USA.
[Frazer, Ian H.] Univ Queensland, Brisbane, Qld 4072, Australia.
[Fridman, Wolf-Herve] Univ Paris 05, Cordeliers Res Ctr, Paris, France.
[Gabrilovich, Dmitry I.] Wistar Inst Anat & Biol, Translat Tumor Immunol, Philadelphia, PA 19104 USA.
[Gilboa, Eli] Univ Miami, Miller Sch Med, Dodson Interdisciplinary Immunotherapy Inst, Dept Microbiol & Immunol,Sylvester Comprehens Can, Miami, FL USA.
[Gnjatic, Sacha] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
[Jaeger, Dirk] Univ Heidelberg Hosp, Internal Med 4, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany.
[Kalinski, Pawel] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Kaufman, Howard L.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
[Kiessling, Rolf] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
[Kirkwood, John] Univ Pittsburgh, Dept Med, Sch Med, Div Hematol Oncol, Pittsburgh, PA USA.
[Kirkwood, John] Univ Pittsburgh, Inst Canc, Melanoma & Skin Canc Program, Pittsburgh, PA USA.
[Knuth, Alexander] Natl Ctr Canc Care & Res, Doha, Qatar.
[Liblau, Roland] INSERM UMR 1043, Toulouse, France.
[Liblau, Roland] CNRS, U5282, Toulouse, France.
[Liblau, Roland] Univ Toulouse, UPS, Ctr Physiopathol Toulouse Purpan, Toulouse, France.
[Liblau, Roland] CHU Toulouse Purpan, Toulouse, France.
[Lotze, Michael T.] Univ Pittsburgh, Sch Hlth Sci, Hillman Canc Ctr, Pittsburgh, PA USA.
[Lugli, Enrico] Humanitas Clin & Res Ctr, Unit Clin & Expt Immunol, Rozzano, Italy.
[Marincola, Francesco; Wang, Ena] Sidra Med & Res Ctr, Res Branch, Doha, Qatar.
[Melero, Ignacio] Univ Navarra, Div Oncol, Ctr Appl Med Res & Clin, E-31080 Pamplona, Spain.
[Melief, Cornelis J.] Leiden Univ, ISA Pharmaceut, NL-2300 RA Leiden, Netherlands.
[Mempel, Thorsten R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA USA.
[Mittendorf, Elizabeth A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
[Odun, Kunle] Roswell Pk Canc Inst, Dept Gynecol Oncol, Buffalo, NY 14263 USA.
[Odun, Kunle] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA.
[Overwijk, Willem W.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA.
[Palucka, Anna Karolina] Jackson Lab Genom Med, Farmington, CT USA.
[Parmiani, Giorgio] Univ Hosp, Div Med Oncol & Immunotherapy, Siena, Italy.
[Schreiber, Robert D.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Schuler, Gerold] Univ Klinikum Erlangen, Dept Dermatol, Erlangen, Germany.
[Srivastava, Pramod K.] Univ Connecticut, Ctr Hlth, Carole & Ray Neag Comprehens Canc Ctr, Ctr Immunotherapy Canc & Infect Dis, Farmington, CT USA.
[Tartour, Eric] Univ Paris 05, Sorbonne Paris Cite, INSERM U970, Dept Clin Oncol, Paris, France.
[Tartour, Eric] Serv Immunol Biol, Hop Europeen Georges Pompidou, Paris, France.
[Valmori, Danila] Univ Nantes, Fac Med, F-44035 Nantes, France.
[van der Burg, Sjoerd H.] Leiden Univ, Med Ctr, Leiden, Netherlands.
[van der Bruggen, Pierre; van den Eynde, Benoit J.] Catholic Univ Louvain, Brussels Branch, Ludwig Inst Canc Res, Duve Inst, B-1200 Brussels, Belgium.
[Zou, Weiping] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI USA.
[Whiteside, Theresa L.] Univ Pittsburgh, Dept Pathol, Inst Canc, Immunol & Otolaryngol, Pittsburgh, PA USA.
[Restifo, Nicholas P.] Natl Canc Inst, NIH, Bethesda, MD USA.
[Anderson, Ana C.] Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA.
RP Apetoh, L (reprint author), INSERM, UMR 866, Dijon, France.
EM lionel.apetoh@inserm.fr; acanderson@partners.org
RI Caignard, Anne/F-8159-2013; Valmori, Danila/K-2439-2015; Smyth,
Mark/H-8709-2014; Apetoh, Lionel/G-3310-2014; Blay,
Jean-Yves/N-3966-2016; Ayyoub, Maha/A-2074-2017; castelli,
chiara/K-6899-2012; Cavallo, Federica/C-5666-2011;
OI Smyth, Mark/0000-0001-7098-7240; Apetoh, Lionel/0000-0002-2774-438X;
Blay, Jean-Yves/0000-0001-7190-120X; castelli,
chiara/0000-0001-6891-8350; Colombo, Mario Paolo/0000-0003-0042-7955;
Cavallo, Federica/0000-0003-4571-1060; MELERO BERMEJO,
IGNACIO/0000-0002-1360-348X
FU American Cancer Society [RSG-11-057-02-LIB]; National Health and Medical
Research Council of Australia [628623]; French National Research Agency
[ANR-13-JSV3-0001]
FX Work in the author's laboratories is supported by grants from the
American Cancer Society (RSG-11-057-02-LIB to A.C.A.), the National
Health and Medical Research Council of Australia (628623 to MJS), and
the French National Research Agency (ANR-13-JSV3-0001 to L.A.). Due to
space and other limitations, it is not possible to include all other
sources of financial support.
NR 97
TC 14
Z9 14
U1 2
U2 20
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2015
VL 4
IS 4
AR e998538
DI 10.1080/2162402X.2014.998538
PG 10
WC Oncology; Immunology
SC Oncology; Immunology
GA CH7NS
UT WOS:000354224400020
PM 26137416
ER
PT J
AU Zhu, LX
Davoodi, M
Srivastava, MK
Kachroo, P
Lee, JM
John, MS
Harris-White, M
Huang, M
Strieter, RM
Dubinett, S
Sharma, S
AF Zhu, Li X.
Davoodi, Michael
Srivastava, Minu K.
Kachroo, Puja
Lee, Jay M.
John, Maie St.
Harris-White, Marni
Huang, Min
Strieter, Robert M.
Dubinett, Steven
Sharma, Sherven
TI GITR agonist enhances vaccination responses in lung cancer
SO ONCOIMMUNOLOGY
LA English
DT Article
DE APC; lung cancer; NK; T cell activation; vaccination responses
ID INDUCED TNF RECEPTOR; T-CELLS; COSTIMULATORY RECEPTOR; TUMOR;
SUPERFAMILY; ACTIVATION; IPILIMUMAB; CARCINOMA; MELANOMA; SURVIVAL
AB An immune tolerant tumor microenvironment promotes immune evasion of lung cancer. Agents that antagonize immune tolerance will thus aid the fight against this devastating disease. Members of the tumor necrosis factor receptor (TNFR) family modulate the magnitude, duration and phenotype of immune responsiveness to antigens. Among these, GITR expressed on immune cells functions as a key regulator in inflammatory and immune responses. Here, we evaluate the GITR agonistic antibody (DTA-1) as a mono-therapy and in combination with therapeutic vaccination in murine lung cancer models. We found that DTA-1 treatment of tumor-bearing mice increased: (i) the frequency and activation of intratumoral natural killer (NK) cells and T lymphocytes, (ii) the antigen presenting cell (APC) activity in the tumor, and (iii) systemic T-cell specific tumor cell cytolysis. DTA-1 treatment enhanced tumor cell apoptosis as quantified by cleaved caspase-3 staining in the tumors. DTA-1 treatment increased expression of IFN gamma, TNF alpha and IL-12 but reduced IL-10 levels in tumors. Furthermore, increased anti-angiogenic chemokines corresponding with decreased pro-angiogenic chemokine levels correlated with reduced expression of the endothelial cell marker Meca 32 in the tumors of DTA-1 treated mice. In accordance, there was reduced tumor growth (8-fold by weight) in the DTA-1 treatment group. NK cell depletion markedly inhibited the antitumor response elicited by DTA-1. DTA-1 combined with therapeutic vaccination caused tumor rejection in 38% of mice and a 20-fold reduction in tumor burden in the remaining mice relative to control. Mice that rejected tumors following therapy developed immunological memory against subsequent re-challenge. Our data demonstrates GITR agonist antibody activated NK cell and T lymphocyte activity, and enhanced therapeutic vaccination responses against lung cancer.
C1 [Zhu, Li X.; Srivastava, Minu K.; Kachroo, Puja; Lee, Jay M.; John, Maie St.; Huang, Min; Dubinett, Steven; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Lung Canc Res Program, Dept Med, Los Angeles, CA 90095 USA.
[Zhu, Li X.; Davoodi, Michael; Srivastava, Minu K.; Lee, Jay M.; Harris-White, Marni; Huang, Min; Dubinett, Steven; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA USA.
[Kachroo, Puja; Lee, Jay M.; John, Maie St.; Dubinett, Steven; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Strieter, Robert M.] Univ Virginia, Dept Med, Charlottesville, VA USA.
RP Sharma, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA Lung Canc Res Program, Dept Med, Los Angeles, CA 90095 USA.
EM ssharma@mednet.ucla.edu
FU University of California Los Angeles Lung Cancer Program, Department of
Veterans Affairs Medical Research Funds, NIH [RO1 CA95686, RO1 CA126944,
P50 CA90388]; National Center for Research Resources [UL1RR033176];
National Center for Advancing Translational Sciences [UL1TR000124];
Tobacco Related Disease Program Award Program of University of
California [15RT-0207, 20FT0082]
FX This work was supported by the: University of California Los Angeles
Lung Cancer Program, Department of Veterans Affairs Medical Research
Funds, NIH Grants (RO1 CA95686, RO1 CA126944 and P50 CA90388), National
Center for Research Resources, Grant UL1RR033176, and is now at the
National Center for Advancing Translational Sciences, Grant UL1TR000124
and Tobacco Related Disease Program Award Program of University of
California (15RT-0207 and 20FT0082). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the NIH.
NR 23
TC 1
Z9 1
U1 2
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2015
VL 4
IS 4
AR e992237
DI 10.4161/2162402X.2014.992237
PG 12
WC Oncology; Immunology
SC Oncology; Immunology
GA CH7NS
UT WOS:000354224400011
ER
PT J
AU Wright, DL
Afeiche, MC
Ehrlich, S
Smith, K
Williams, PL
Chavarro, JE
Batsis, M
Toth, TL
Hauser, R
AF Wright, Diane L.
Afeiche, Myriam C.
Ehrlich, Shelley
Smith, Kristen
Williams, Paige L.
Chavarro, Jorge E.
Batsis, Maria
Toth, Thomas L.
Hauser, Russ
TI Hair mercury concentrations and in vitro fertilization (IVF) outcomes
among women from a fertility clinic
SO REPRODUCTIVE TOXICOLOGY
LA English
DT Article
DE Mercury (Hg); Oocyte; Fertilization; In vitro fertilization (IVF);
Implantation; Human
ID BISPHENOL-A CONCENTRATIONS; LIVE-BIRTH-RATES; OCCUPATIONAL EXPOSURE;
REPRODUCTIVE HEALTH; SEAFOOD CONSUMPTION; HEAVY-METALS; TOXIC METALS;
CADMIUM; BLOOD; FISH
AB Total hair mercury (Hg) was measured among 205 women undergoing in vitro fertilization (IVF) treatment and the association with prospectively collected IVF outcomes (229 IVF cycles) was evaluated. Hair Hg levels (median = 0.62 ppm, range: 0.03-5.66 ppm) correlated with fish intake (r = 0.59), and exceeded the recommended EPA reference of 1 ppm in 33% of women. Generalized linear mixed models with random intercepts accounting for within-woman correlations across treatment cycles were used to evaluate the association of hair Hg with IVF outcomes adjusted for age, body mass index, race, smoking status, infertility diagnosis, and protocol type. Hair Hg levels were not related to ovarian stimulation outcomes (peak estradiol levels, total and mature oocyte yields) or to fertilization rate, embryo quality, clinical pregnancy rate or live birth rate. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Wright, Diane L.; Batsis, Maria; Toth, Thomas L.; Hauser, Russ] Harvard Univ, Sch Med, Vincent Dept Obstet & Gynecol Serv, Div Reprod Med & IVF,Massachusetts Gen Hosp,Ferti, Boston, MA USA.
[Afeiche, Myriam C.; Smith, Kristen; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Ehrlich, Shelley] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA.
[Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Williams, Paige L.; Chavarro, Jorge E.; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Chavarro, Jorge E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA.
[Chavarro, Jorge E.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Batsis, Maria] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA.
[Batsis, Maria] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, Pediat Endocrinol Interinst Training Program, NIH, Bethesda, MD 20892 USA.
RP Wright, DL (reprint author), Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Boston, MA 02114 USA.
EM dwright4@mgh.harvard.edu
RI Ehrlich , Shelley/L-6991-2015
FU National Institutes of Health (NIH) [ES009718, ES000002, T32ES007069]
FX Work supported by grants ES009718, ES000002, and T32ES007069 from the
National Institutes of Health (NIH).
NR 38
TC 2
Z9 2
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0890-6238
J9 REPROD TOXICOL
JI Reprod. Toxicol.
PD JAN
PY 2015
VL 51
BP 125
EP 132
DI 10.1016/j.reprotox.2015.01.003
PG 8
WC Reproductive Biology; Toxicology
SC Reproductive Biology; Toxicology
GA CH6NH
UT WOS:000354152800015
PM 25601638
ER
PT S
AU Guimaraes, C
An, J
Humar, M
Goth, W
Yun, A
AF Guimaraes, Caio
An, Jeesoo
Humar, Matjaz
Goth, Will
Yun, Andy
BE Lee, LP
Rogers, JA
Yun, SHA
TI Biocompatible optical needle array for antibacterial blue light therapy
SO BIOINSPIRED BIOINTEGRATED BIOENGINEERED PHOTONIC DEVICES III
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Bioinspired, Biointegrated, Bioengineered Photonic Devices
III
CY FEB 07-08, 2015
CL San Francisco, CA
SP SPIE
DE biocompatible optical needle array; BONA; antibacterial blue light
therapy; waveguide
AB Biocompatible Optical Needle Array (BONA) is showing to be a powerful tool complementing the novel antibacterial blue light therapy. BONA is able to deliver light to deeper skin tissue layers successfully as shown in experiments. In this study, we will discuss BONA's design, mechanical and optical properties, production method, plus propose improvements to optimize it all. A special skin phantom with photosensitizer was developed in order to investigate how light is delivered inside the tissue. The phantom shows the light scattering pattern through photobleach, allowing us to determine length, thickness and spacing between needles. Other quantitative optical properties as penetration depth were determined using a different phantom (using PDMS). Mechanical properties as needle resistance were determined using one axis of a custom biaxial tensile strain device. The results led us to conclude that besides the great results, there is still room for improvements regarding tip sharpness and manufacturing time and cost, which would be solved with the enhanced fabrication method proposed.
C1 [Guimaraes, Caio] POLI UPE Polytech Sch Pernambuco, Recife, PE, Brazil.
[Guimaraes, Caio] Univ Pernambuco, Recife, PE, Brazil.
[An, Jeesoo; Humar, Matjaz; Yun, Andy] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[An, Jeesoo; Humar, Matjaz; Yun, Andy] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Humar, Matjaz] J Stefan Inst, Condensed Matter Dept, Ljubljana, Slovenia.
[Goth, Will] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.
RP Guimaraes, C (reprint author), POLI UPE Polytech Sch Pernambuco, Recife, PE, Brazil.
RI Humar, Matjaz/I-8862-2012
OI Humar, Matjaz/0000-0003-3338-6723
NR 2
TC 0
Z9 0
U1 2
U2 4
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-431-8
J9 PROC SPIE
PY 2015
VL 9341
AR 93410R
DI 10.1117/12.2083384
PG 7
WC Engineering, Biomedical; Optics
SC Engineering; Optics
GA BC6FE
UT WOS:000353890300007
ER
PT J
AU Perez, DL
Dworetzky, BA
Dickerson, BC
Leung, L
Cohn, R
Baslet, G
Silbersweig, DA
AF Perez, David L.
Dworetzky, Barbara A.
Dickerson, Bradford C.
Leung, Lorene
Cohn, Rachel
Baslet, Gaston
Silbersweig, David A.
TI An Integrative Neurocircuit Perspective on Psychogenic Nonepileptic
Seizures and Functional Movement Disorders: Neural Functional
Unawareness
SO CLINICAL EEG AND NEUROSCIENCE
LA English
DT Review
DE psychogenic nonepileptic seizures; functional movement disorder;
conversion disorder; dissociation; fMRI
ID POSTTRAUMATIC-STRESS-DISORDER; MOTOR CONVERSION DISORDER; DISSOCIATIVE
IDENTITY DISORDER; MEDICALLY UNEXPLAINED SYMPTOMS; PREDICTS TREATMENT
RESPONSE; HUMAN CEREBRAL-CORTEX; EPILEPTIC SEIZURES; PARIETAL CORTEX;
ANTERIOR INSULA; PANIC-ATTACKS
AB Functional neurological disorder (conversion disorder) is a neurobehavioral condition frequently encountered by neurologists. Psychogenic nonepileptic seizure (PNES) and functional movement disorder (FMD) patients present to epileptologists and movement disorder specialists respectively, yet neurologists lack a neurobiological perspective through which to understand these enigmatic groups. Observational research studies suggest that PNES and FMD may represent variants of similar (or the same) conditions given that both groups exhibit a female predominance, have increased prevalence of mood-anxiety disorders, frequently endorse prior abuse, and share phenotypic characteristics. In this perspective article, neuroimaging studies in PNES and FMD are reviewed, and discussed using studies of emotional dysregulation, dissociation and psychological trauma in the context of motor control. Convergent neuroimaging findings implicate alterations in brain circuits mediating emotional expression, regulation and awareness (anterior cingulate and ventromedial prefrontal cortices, insula, amygdala, vermis), cognitive control and motor inhibition (dorsal anterior cingulate, dorsolateral prefrontal, inferior frontal cortices), self-referential processing and perceptual awareness (posterior parietal cortex, temporoparietal junction), and motor planning and coordination (supplementary motor area, cerebellum). Striatal-thalamic components of prefrontal-parietal networks may also play a role in pathophysiology. Aberrant medial prefrontal and amygdalar neuroplastic changes mediated by chronic stress may facilitate the development of functional neurological symptoms in a subset of patients. Improved biological understanding of PNES and FMD will likely reduce stigma and aid the identification of neuroimaging biomarkers guiding treatment development, selection, and prognosis. Additional research should investigate neurocircuit abnormalities within and across functional neurological disorder subtypes, as well as compare PNES and FMD with mood-anxiety-dissociative disorders.
C1 [Perez, David L.; Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Perez, David L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Perez, David L.; Leung, Lorene; Cohn, Rachel; Baslet, Gaston; Silbersweig, David A.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Dworetzky, Barbara A.; Silbersweig, David A.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
RP Perez, DL (reprint author), Massachusetts Gen Hosp, Dept Neurol, 149 13th St, Charlestown, MA 02129 USA.
EM david.lperez@gmail.com
OI Dworetzky, Barbara/0000-0002-3364-2347
FU NINDS [R25NS065743-05S1]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: Dr David
L. Perez was funded by a NINDS R25NS065743-05S1 grant.
NR 135
TC 10
Z9 10
U1 11
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1550-0594
EI 2169-5202
J9 CLIN EEG NEUROSCI
JI Clin. EEG Neurosci.
PD JAN
PY 2015
VL 46
IS 1
SI SI
BP 4
EP 15
DI 10.1177/1550059414555905
PG 12
WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA CH3IM
UT WOS:000353924200002
PM 25432161
ER
PT J
AU Reinsberger, C
Sarkis, R
Papadelis, C
Doshi, C
Perez, DL
Baslet, G
Loddenkemper, T
Dworetzky, BA
AF Reinsberger, Claus
Sarkis, Rani
Papadelis, Christos
Doshi, Chiran
Perez, David L.
Baslet, Gaston
Loddenkemper, Tobias
Dworetzky, Barbara A.
TI Autonomic Changes in Psychogenic Nonepileptic Seizures: Toward a
Potential Diagnostic Biomarker?
SO CLINICAL EEG AND NEUROSCIENCE
LA English
DT Article
DE psychogenic nonepileptic seizures (PNES); autonomic nervous system
(ANS); electrodermal activity (EDA); heart rate variability (HRV)
ID POSTTRAUMATIC-STRESS-DISORDER; HEART-RATE-VARIABILITY; BORDERLINE
PERSONALITY-DISORDER; CARDIAC VAGAL CONTROL; ELECTRODERMAL ACTIVITY;
DEPRESSIVE PATIENTS; SPECTRAL-ANALYSIS; PANIC DISORDER; MODULATION;
SCHIZOPHRENIA
AB Disturbances of the autonomic nervous system (ANS) are common in neuropsychiatric disorders. Disease specific alterations of both sympathetic and parasympathetic activity can be assessed by heart rate variability (HRV), whereas electrodermal activity (EDA) can assess sympathetic activity. In posttraumatic stress disorder (PTSD), parasympathetic HRV parameters are typically decreased and EDA is increased, whereas in major depressive disorder (MDD) and dissociation, both parasympathetic and sympathetic markers are decreased. ANS abnormalities have also been identified in psychogenic nonepileptic seizures (PNES) by using HRV, indicating lower parasympathetic activity at baseline. In addition to reviewing the current literature on ANS abnormalities in PTSD, MDD, and disorders with prominent dissociation, including borderline personality disorder (BPD), this article also presents data from a pilot study on EDA in patients with PNES. Eleven patients with PNES, during an admission to our epilepsy monitoring unit (EMU), were compared with 9 with generalized tonic-clonic seizures (GTCS). The area under the EDA curve, the number of EDA responses lasting longer than 2 seconds, and the number of EDA surges during sleep (sympathetic sleep storms) were calculated on ictal and interictal days by an automated algorithm. EDA changes in PNES patients did not follow a systematic pattern of sympathetic hyperarousal (like EDA after GTCS) but were more variable. How specific PNES semiologies, and/or underlying neuropsychiatric disorders, may influence ictal and interictal EDA patterns, and lead to a novel diagnostic biomarker remains to be evaluated in future larger studies.
C1 [Reinsberger, Claus; Sarkis, Rani; Baslet, Gaston; Dworetzky, Barbara A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Edward B Bromfield Epilepsy Ctr, Boston, MA 02115 USA.
[Reinsberger, Claus] Univ Paderborn, Inst Sports Med, D-33098 Paderborn, Germany.
[Papadelis, Christos; Doshi, Chiran; Loddenkemper, Tobias] Harvard Univ, Sch Med, Dept Neurol, Div Epilepsy & Clin Neurophysiol,Boston Childrens, Boston, MA 02115 USA.
[Perez, David L.; Baslet, Gaston] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Perez, David L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Perez, David L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA.
RP Reinsberger, C (reprint author), Univ Paderborn, Inst Sports Med, Warburger Str 100, D-33098 Paderborn, Germany.
EM reinsberger@sportmed.upb.de
OI Sarkis, Rani/0000-0001-8291-7864; Dworetzky, Barbara/0000-0002-3364-2347
NR 71
TC 6
Z9 6
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1550-0594
EI 2169-5202
J9 CLIN EEG NEUROSCI
JI Clin. EEG Neurosci.
PD JAN
PY 2015
VL 46
IS 1
SI SI
BP 16
EP 25
DI 10.1177/1550059414567739
PG 10
WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA CH3IM
UT WOS:000353924200003
PM 25780264
ER
PT J
AU Dworetzky, BA
Weisholtz, DS
Perez, DL
Baslet, G
AF Dworetzky, Barbara A.
Weisholtz, Daniel S.
Perez, David L.
Baslet, Gaston
TI A Clinically Oriented Perspective on Psychogenic Nonepileptic
Seizure-Related Emergencies
SO CLINICAL EEG AND NEUROSCIENCE
LA English
DT Article
DE nonepileptic psychogenic status; pseudostatus; pregnancy; suicide;
accidents
ID EPILEPSY MONITORING UNIT; STATUS EPILEPTICUS; PSEUDOSTATUS EPILEPTICUS;
CONVERSION DISORDER; PSYCHIATRIC-DISORDERS; SAFETY CONSIDERATIONS;
ANTIEPILEPTIC DRUGS; PREGNANCY; INJURY; MISDIAGNOSIS
AB Psychogenic nonepileptic seizures (PNES) can present emergently and are often mistaken for epileptic seizures. PNES emergencies have not been well studied, and yet there are associated serious morbidities, particularly when patients are seen in an emergency setting and are misdiagnosed. PNES may be prolonged, mimicking status epilepticus, a condition we refer to as nonepileptic psychogenic status (NEPS), and patients may receive aggressive and unnecessary medical treatments that can lead to serious iatrogenic complications, including death. NEPS is also associated with an increased risk of self-harm, including suicide attempts, and may indicate a serious comorbid psychiatric illness. In addition to iatrogenic complications of PNES, accidents and injuries are an underrecognized source of morbidity. PNES may also present during medical procedures, which may not only interfere with their completion, but may alarm practitioners who, fearing liability, may initiate further medical evaluations and treatments. When PNES occur during pregnancy, patients may be misdiagnosed with eclampsia and their offspring delivered prematurely. They also risk being placed on medications that are harmful to the fetus. Increased awareness of PNES is necessary to prevent iatrogenic harm and to identify underlying psychiatric illnesses that carry their own risks. As yet, data available to guide treatment are scant, and further study is needed.
C1 [Dworetzky, Barbara A.; Weisholtz, Daniel S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Perez, David L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Perez, David L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA.
[Perez, David L.; Baslet, Gaston] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
RP Dworetzky, BA (reprint author), Brigham & Womens Hosp, Div Epilepsy, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.
EM bdworetzky@partners.org
OI Dworetzky, Barbara/0000-0002-3364-2347
NR 74
TC 2
Z9 2
U1 2
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1550-0594
EI 2169-5202
J9 CLIN EEG NEUROSCI
JI Clin. EEG Neurosci.
PD JAN
PY 2015
VL 46
IS 1
SI SI
BP 26
EP 33
DI 10.1177/1550059414566880
PG 8
WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA CH3IM
UT WOS:000353924200004
PM 25780265
ER
PT J
AU Baslet, G
Dworetzky, B
Perez, DL
Oser, M
AF Baslet, Gaston
Dworetzky, Barbara
Perez, David L.
Oser, Megan
TI Treatment of Psychogenic Nonepileptic Seizures: Updated Review and
Findings From a Mindfulness-Based Intervention Case Series
SO CLINICAL EEG AND NEUROSCIENCE
LA English
DT Article
DE psychogenic nonepileptic seizures; treatment; therapeutics;
mindfulness-based psychotherapy
ID CONTROLLED CLINICAL-TRIAL; CONVERSION DISORDER; PSEUDOSEIZURE PATIENTS;
NEUROLOGICAL SYMPTOMS; GROUP PSYCHOEDUCATION; MOVEMENT-DISORDERS; CARE
UTILIZATION; GROUP-THERAPY; MOTOR TYPE; DIAGNOSIS
AB Psychogenic nonepileptic seizures (PNES) were first described in the medical literature in the 19th century, as seizure-like attacks not related to an identified central nervous system lesion, and are currently classified as a conversion disorder, according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). While a universally accepted and unifying etiological model does not yet exist, several risk factors have been identified. Management of PNES should be based on interdisciplinary collaboration, targeting modifiable risk factors. The first treatment phase in PNES is patient engagement, which is challenging given the demonstrated low rates of treatment retention. Acute interventions constitute the next phase in treatment, and most research studies focus on short-term evidence-based interventions. Randomized controlled pilot trials support cognitive-behavioral therapy. Other psychotherapeutic and psychopharmacological interventions have been less well-studied using controlled and uncontrolled trials. Within the discussion of acute interventions, we present a preliminary evaluation for feasibility of a mindfulness-based psychotherapy protocol in a very small sample of PNES patients. We demonstrated in 6 subjects that this intervention is feasible in real-life clinical scenarios and warrants further investigation in larger scale studies. The final treatment phase is long-term follow-up. Long-term outcome studies in PNES show that a significant proportion of patients remains symptomatic and experiences continued impairments in quality of life and functionality. We believe that PNES should be understood as a disease that requires different types of intervention during the various phases of treatment.
C1 [Baslet, Gaston; Perez, David L.; Oser, Megan] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Baslet, Gaston; Dworetzky, Barbara; Perez, David L.; Oser, Megan] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Dworetzky, Barbara] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Perez, David L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Perez, David L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Baslet, G (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA.
EM gbaslet@partners.org
OI Dworetzky, Barbara/0000-0002-3364-2347
FU NINDS [R25 NS065743-05S1]
FX Dr. David L. Perez was funded by a NINDS R25 NS065743-05S1 grant.
NR 59
TC 9
Z9 9
U1 2
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1550-0594
EI 2169-5202
J9 CLIN EEG NEUROSCI
JI Clin. EEG Neurosci.
PD JAN
PY 2015
VL 46
IS 1
SI SI
BP 54
EP 64
DI 10.1177/1550059414557025
PG 11
WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA CH3IM
UT WOS:000353924200007
PM 25465435
ER
PT J
AU Shad, MU
Prasad, K
Forman, SD
Haas, GL
Walker, JD
Pisarov, LA
Goldstein, G
AF Shad, Mujeeb U.
Prasad, Konasale
Forman, Steven D.
Haas, Gretchen L.
Walker, Jon D.
Pisarov, Liubomir A.
Goldstein, Gerald
TI Insight and neurocognitive functioning in bipolar subjects
SO COMPREHENSIVE PSYCHIATRY
LA English
DT Article
ID MOOD DISORDERS; CHRONIC-ALCOHOLICS; CORPUS-CALLOSUM; EXECUTIVE FUNCTION;
GRAY-MATTER; SCHIZOPHRENIA; ABNORMALITIES; PSYCHOSIS; ILLNESS; WHITE
AB Background: Insight concerning having a mental illness has been found to influence outcome and effectiveness of treatment. It has been studied mainly in the area of schizophrenia with few studies addressing other disorders. This study evaluates insight in individuals with bipolar disorder using the Scale to Assess Unawareness of Mental Disorder (SUMD), a comprehensive interview for evaluation of awareness of illness and attribution of symptoms. The hypothesis was that in bipolar disorder level of awareness may be associated with numerous factors including neurocognitive function, structural changes in the frontal lobes and hippocampus evaluated by MRI, neurocognitive status, severity of mania and other psychiatric symptoms and comorbid alcoholism.
Method: In order to evaluate this hypothesis 33 individuals with DSM-IV diagnosed bipolar disorder, some with and some without comorbid alcoholism, were administered the SUMD and a number of other procedures including a quantitative MR' measuring volume of the frontal lobes and hippocampus, a brief battery of neurocognitive tests, the Brief Psychiatric Rating Scale, and the Young Mania Rating Scale. The data were analyzed by comparing participants with and without alcoholism on these procedures using t tests and by linear multiple regression, with SUMD ratings of awareness and attribution as the dependent variables and variable sets from the other procedures administered as multivariate independent variables.
Results: The median score obtained from the SUMD for current awareness was in a range between full awareness and uncertainty concerning presence of a mental disorder. For attribution, the median score indicated that attribution was usually made to the illness itself. None of the differences between participants with and without comorbid alcoholism were significant for the SUMD awareness and attribution scores, neurocognitive or MRI variables. The multiple regression analyses only showed a significant degree of association between the SUMD awareness score and the Young Mania Rating Scale (r(2) = .632, p < .05). A stepwise analysis indicated that items assessing degree of insight, irritability, and sleep disturbance met criteria for entry into the regression equation. None of the regression analyses for the SUMD attribution item were significant.
Conclusions: Apparently unlike the case for schizophrenia, most of the participants, all of whom had bipolar disorder, were aware of their symptoms and correctly related them to a mental disorder. Hypotheses concerning the relationships between degree of unawareness and possible contributors to its development including comorbid alcoholism, cognitive dysfunction and structural reduction of gray matter in the frontal region and hippocampus, were not associated with degree of unawareness but symptoms of mania were significantly associated. The apparent reason for this result is that the sample obtained a SUMD modal awareness score of 1 or 2, reflecting the area between full awareness and uncertainty about having a mental disorder. None of the participants were rated as having a 5 response reflecting the belief that s/he does not have a mental disorder. Published by Elsevier Inc.
C1 [Shad, Mujeeb U.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA.
[Prasad, Konasale; Forman, Steven D.; Haas, Gretchen L.; Goldstein, Gerald] Univ Pittsburgh, Sch Med, Dept Psychiat, Educ & Clin Ctr,VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Forman, Steven D.; Haas, Gretchen L.; Walker, Jon D.; Pisarov, Liubomir A.; Goldstein, Gerald] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA 15206 USA.
RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr 151R, Pittsburgh, PA 15206 USA.
EM ggold@nb.net
OI Prasad, Konasale/0000-0003-0245-1393
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development; VISN 4 Mental Illness Research, Education,
and Clinical Center (MIRECC), VA Pittsburgh Healthcare System
FX This material is based upon work supported by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development. The project was funded by infrastructure support funding
from the VISN 4 Mental Illness Research, Education, and Clinical Center
(MIRECC, Director: D. Oslin; Pittsburgh Site Director: G. Haas), VA
Pittsburgh Healthcare System.
NR 39
TC 0
Z9 0
U1 1
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0010-440X
EI 1532-8384
J9 COMPR PSYCHIAT
JI Compr. Psychiat.
PY 2015
VL 56
BP 112
EP 120
DI 10.1016/j.comppsych.2014.04.016
PG 9
WC Psychiatry
SC Psychiatry
GA CH2PM
UT WOS:000353867100014
PM 25439524
ER
PT J
AU Tung, ES
Flessner, CA
Grant, JE
Keuthen, NJ
AF Tung, Esther S.
Flessner, Christopher A.
Grant, Jon E.
Keuthen, Nancy J.
TI Predictors of life disability in trichotillomania
SO COMPREHENSIVE PSYCHIATRY
LA English
DT Article
ID HAIRPULLING SCALE; PRIMARY-CARE; IMPACT; PHENOMENOLOGY; IMPAIRMENT;
DISORDER
AB Background: Limited research has investigated disability and functional impairment in trichotillomania (TTM) subjects. This study examined the relationships between hair pulling (HP) style and severity and disability while controlling for mood severity. Disability was measured in individual life areas (work, social, and family/home life) instead of as a total disability score as in previous studies.
Methods: One hundred fifty three adult hair pullers completed several structured interviews and self-report instruments. HP style and severity, as well as depression, anxiety, and stress were correlated with work, social, and family/home life impairment on the Sheehan Disability Scale (SDS). Multiple regression analyses were performed to determine significant predictors of life impairment.
Results: Depressive severity was a significant predictor for all SDS life areas. In addition, interference/avoidance associated with HP was a predictor for work and social life disability. Distress from HP was a significant predictor of social and family/home life disability. Focused HP score and anxiety were significant predictors of family/home life disability.
Conclusions: As expected, depression in hair pullers predicted disability across life domains. Avoiding work and social situations can seriously impair functioning in those life domains. Severity of distress and worry about HP may be most elevated in social situations with friends and family and thus predict impairment in those areas. Finally, since HP often occurs at home, time spent in focused hair pulling would have a greater negative impact on family and home responsibilities than social and work life. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Tung, Esther S.; Keuthen, Nancy J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Flessner, Christopher A.] Kent State Univ, Dept Psychol, Kent, OH 44242 USA.
[Grant, Jon E.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA.
RP Keuthen, NJ (reprint author), Massachusetts Gen Hosp, OCD & Related Disorders Program, 185 Cambridge St,Suite 2200, Boston, MA 02114 USA.
EM etung2@partners.org; cflessne@kent.edu; jgrant4@bsd.uchicago.edu;
nkeuthen@partners.org
RI Flessner, Christopher/K-1483-2015
FU Trichotillomania Learning Center; Greater Kansas City Foundation
FX This research was financially supported by grants from the
Trichotillomania Learning Center and the Greater Kansas City Foundation.
The funding sponsors had no role in study design, data collection, data
analysis or interpretation, manuscript preparation or the decision to
submit the manuscript for publication.
NR 23
TC 3
Z9 3
U1 0
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0010-440X
EI 1532-8384
J9 COMPR PSYCHIAT
JI Compr. Psychiat.
PY 2015
VL 56
BP 239
EP 244
DI 10.1016/j.comppsych.2014.09.018
PG 6
WC Psychiatry
SC Psychiatry
GA CH2PM
UT WOS:000353867100029
PM 25281991
ER
PT J
AU Tegos, GP
AF Tegos, George P.
TI Versatile Approaches to Target Staphylococcal Infections
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Editorial Material
DE multidrug resistance staphylococci; biocides; target based discovery;
antimicrobial peptides; quorum-sensing inhibitors; drug repurposing;
photoantimicrobials; pathogen-innate immunity dynamics; vaccines
C1 [Tegos, George P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Tegos, George P.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Tegos, George P.] Torrey Pines Inst Mol Studies, Port St Lucie, FL 34987 USA.
RP Tegos, GP (reprint author), Torrey Pines Inst Mol Studies, Port St Lucie, FL 34987 USA.
EM gtegos@tpims.org
NR 12
TC 0
Z9 0
U1 0
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 16
BP 2046
EP 2047
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CG9RK
UT WOS:000353655700001
PM 25760333
ER
PT J
AU Magana, M
Ioannidis, A
Magiorkinis, E
Ursu, O
Bologa, CG
Chatzipanagiotou, S
Hamblin, MR
Tegos, GP
AF Magana, Maria
Ioannidis, Anastasios
Magiorkinis, Emmanouil
Ursu, Oleg
Bologa, Cristian G.
Chatzipanagiotou, Stylianos
Hamblin, Michael R.
Tegos, George P.
TI Therapeutic Options and Emerging Alternatives for Multidrug Resistant
Staphylococcal Infections
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE MRSA; multidrug resistance; staphylococcal infections; drug discovery
ID PANTON-VALENTINE LEUKOCIDIN; SOFT-TISSUE INFECTIONS; INDUCIBLE
CLINDAMYCIN RESISTANCE; VENTILATOR-ASSOCIATED PNEUMONIA; EVALUATING
CEFTAROLINE FOSAMIL; SKIN-STRUCTURE INFECTIONS; AUREUS STRAIN USA300;
PHAGE LYTIC ENZYME; METHICILLIN-RESISTANT; EFFLUX PUMPS
AB Methicillin-resistant Staphylococcus aureus (MRSA) remains the single biggest challenge in infectious disease in the civilized world. Moreover, vancomycin resistance is also spreading, leading to fears of untreatable infections as were common in ancient times. Molecular microbiology and bioinformatics have revealed many of the mechanisms involved in resistance development. Mobile genetic elements, up-regulated virulence factors and multi-drug efflux pumps have been implicated. A range of approved antibiotics from the glycopeptide, lipopeptide, pleuromutilin, macrolide, oxazolidinone, lincosamide, aminoglycoside, tetracycline, steptogramin, and cephalosporin classes has been employed to treat MRSA infections. The upcoming pipeline of drugs for MRSA includes some new compounds from the above classes, together with fluoroquinolones, antibacterial peptide mimetics, aminomethylciclines, porphyrins, peptide deformylase inhibitors, oxadiazoles, and diaminopyrimidines. A range of non-drug alternative approaches has emerged for MRSA treatment. Bacteriophage-therapy including purified lysins has made a comeback after being discovered in the 1930s. Quorum-sensing inhibitors are under investigation. Small molecule inhibitors of multi-drug efflux pumps may potentiate existing antibiotics. The relative failure of staphylococcal vaccines is being revisited by efforts with multi-valent vaccines and improved adjuvants. Photodynamic therapy uses non-toxic photosensitizers and harmless visible light to produce reactive oxygen species that can nonspecifically destroy bacteria while preserving host cells. Preparation of nanoparticles can kill bacteria themselves, as well as improve the delivery of anti-bacterial drugs. Anti-MRSA drug discovery remains an exciting field with great promise for the future.
C1 [Magana, Maria; Ioannidis, Anastasios] Univ Peloponnese, Fac Human Movement & Qual Life Sci, Dept Nursing, Sparta, Greece.
[Ioannidis, Anastasios; Chatzipanagiotou, Stylianos] Aeginit Hosp, Athens Med Sch, Dept Clin Microbiol, Athens, Greece.
[Magiorkinis, Emmanouil] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, GR-11527 Athens, Greece.
[Ursu, Oleg; Bologa, Cristian G.] Univ New Mexico, Hlth Sci Ctr, Dept Internal Med, Translat Informat Div, Albuquerque, NM 87131 USA.
[Ursu, Oleg; Bologa, Cristian G.] Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA.
[Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA.
[Hamblin, Michael R.; Tegos, George P.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.; Tegos, George P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Tegos, George P.] Torrey Pines Inst Mol Studies, Port St Lucie, FL 34987 USA.
RP Tegos, GP (reprint author), Torrey Pines Inst Mol Studies, Port St Lucie, FL 34987 USA.
EM gtegos@mgh.harvard.edu
FU US NIH [5U54MH084690-02, R01AI050875]; US DTRA [HDTRA1-13-C-0005]
FX George P Tegos was supported by the US NIH grant 5U54MH084690-02 (CDP1)
and by the US DTRA contract HDTRA1-13-C-0005 and Michael R Hamblin was
supported by US NIH grant R01AI050875.
NR 180
TC 4
Z9 5
U1 10
U2 39
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 16
BP 2058
EP 2072
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CG9RK
UT WOS:000353655700004
PM 25760340
ER
PT J
AU Agrawal, T
Avci, P
Gupta, GK
Rineh, A
Lakshmanan, S
Batwala, V
Tegos, GP
Hamblin, MR
AF Agrawal, Tanupriya
Avci, Pinar
Gupta, Gaurav K.
Rineh, Ardeshir
Lakshmanan, Shanmugamurthy
Batwala, Vincent
Tegos, George P.
Hamblin, Michael R.
TI Harnessing the Power of Light to Treat Staphylococcal Infections
Focusing on MRSA
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Photodynamic therapy; MRSA; PDI; blue light; UV light; photosensitizer;
multi-drug efflux pump
ID ACTIVATED ANTIMICROBIAL AGENT; MULTIDRUG-RESISTANCE PUMPS; ULTRAVIOLET C
IRRADIATION; STRAIN-DEPENDENT RESPONSE; GENE REGULATOR AGR; INDUCED
DNA-DAMAGE; PHOTODYNAMIC THERAPY; BLUE-LIGHT; IN-VITRO;
HELICOBACTER-PYLORI
AB Methicillin-resistant Staphylococcus aureus (MRSA) has become the most important drug-resistant microbial pathogen in countries throughout the world. Morbidity and mortality due to MRSA infections continue to increase despite efforts to improve infection control measures and to develop new antibiotics. Therefore alternative antimicrobial strategies that do not give rise to development of resistance are urgently required. A group of therapeutic interventions has been developed in the field of photomedicine with the common theme that they rely on electromagnetic radiation with wavelengths between 200 and 1000 nm broadly called "light". These techniques all use simple absorption of photons by specific chromophores to deliver the killing blow to microbial cells while leaving the surrounding host mammalian cells relatively unharmed. Photodynamic inactivation uses dyes called photosensitizers (PS) that bind specifically to MRSA cells and not host cells, and generate reactive oxygen species including singlet oxygen and singlet oxygen upon illumination. Sophisticated molecular strategies to target the PS to MRSA cells have been designed. Ultraviolet C radiation can damage microbial DNA without unduly harming host DNA. Blue light can excite endogenous porphyrins and flavins in MRSA cells that are not present in host cells. Near-infrared lasers can interfere with microbial membrane potentials without raising the temperature of the tissue. Taken together these innovative approaches towards harnessing the power of light suggest that the ongoing threat of MRSA may eventually be defeated.
C1 [Agrawal, Tanupriya; Avci, Pinar; Gupta, Gaurav K.; Rineh, Ardeshir; Lakshmanan, Shanmugamurthy; Tegos, George P.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Agrawal, Tanupriya; Avci, Pinar; Gupta, Gaurav K.; Lakshmanan, Shanmugamurthy; Tegos, George P.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Avci, Pinar] Semmelweis Univ, Sch Med, Dept Dermatol, H-1085 Budapest, Hungary.
[Rineh, Ardeshir] Univ Wollongong, Sch Chem, Wollongong, NSW 2522, Australia.
[Tegos, George P.] Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA.
[Tegos, George P.] Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA.
[Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Batwala, Vincent] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
FU US NIH [R01AI050875]
FX Research in The Hamblin laboratory is supported by US NIH grant
R01AI050875.
NR 139
TC 0
Z9 0
U1 2
U2 13
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 16
BP 2109
EP 2121
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CG9RK
UT WOS:000353655700008
PM 25760339
ER
PT J
AU Bledsoe, JR
Christiani, DC
Kradin, RL
AF Bledsoe, Jacob R.
Christiani, David C.
Kradin, Richard L.
TI Pleural plaques in smoking-associated fibrosis and pulmonary asbestosis
Reply
SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LA English
DT Letter
ID PATHOLOGY; DISEASES
C1 [Bledsoe, Jacob R.; Kradin, Richard L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Christiani, David C.; Kradin, Richard L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Kradin, RL (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren Bldg 253,55 Fruit St, Boston, MA 02114 USA.
EM rkradin@partners.org
NR 6
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2005
J9 INT J CHRONIC OBSTR
JI Int. J. Chronic Obstr. Pulm. Dis.
PY 2015
VL 10
BP 871
EP 871
PG 1
WC Respiratory System
SC Respiratory System
GA CH2XD
UT WOS:000353887500002
PM 26080463
ER
PT J
AU Sasase, T
Yokoi, N
Pezzolesi, MG
Shinohara, M
AF Sasase, Tomohiko
Yokoi, Norihide
Pezzolesi, Marcus G.
Shinohara, Masami
TI Animal Models of Diabetes and Metabolic Disease 2014
SO JOURNAL OF DIABETES RESEARCH
LA English
DT Editorial Material
C1 [Sasase, Tomohiko] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Biol Pharmacol Res Labs, Osaka 5691125, Japan.
[Yokoi, Norihide] Kobe Univ, Grad Sch Med, Dept Physiol & Cell Biol, Div Mol & Metab Med, Kobe, Hyogo 6500017, Japan.
[Pezzolesi, Marcus G.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA.
[Shinohara, Masami] CLEA Japan Inc, Tokyo Anim & Diet Dept, Tokyo 1538533, Japan.
RP Sasase, T (reprint author), Japan Tobacco Inc, Cent Pharmaceut Res Inst, Biol Pharmacol Res Labs, Osaka 5691125, Japan.
EM tomohiko.sasase@jt.com
NR 0
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6745
EI 2314-6753
J9 J DIABETES RES
JI J. Diabetes Res.
PY 2015
AR 571809
DI 10.1155/2015/571809
PG 2
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA CH1MQ
UT WOS:000353786200001
ER
PT J
AU Chandler, PD
Scott, JB
Drake, BF
Ng, K
Chan, AT
Hollis, BW
Emmons, KM
Giovannucci, EL
Fuchs, CS
Bennett, GG
AF Chandler, P. D.
Scott, J. B.
Drake, B. F.
Ng, K.
Chan, A. T.
Hollis, B. W.
Emmons, K. M.
Giovannucci, E. L.
Fuchs, C. S.
Bennett, G. G.
TI Impact of vitamin D supplementation on adiposity in African-Americans
SO NUTRITION & DIABETES
LA English
DT Article
ID FOOD FREQUENCY QUESTIONNAIRE; RANDOMIZED CONTROLLED-TRIALS; NUTRITION
EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; 25-HYDROXYVITAMIN D; OBESE
SUBJECTS; BODY-WEIGHT; CALCIUM; WOMEN; REPRODUCIBILITY
AB BACKGROUND: African-Americans have higher rates of obesity-associated chronic diseases. Serum 25-hydroxyvitamin D (25(OH) D) shows an inverse association with obesity status. We investigated whether vitamin D supplementation changes body mass index (BMI).
SUBJECTS: In total, 328 overweight African-Americans were enrolled over three consecutive winter periods (2007-2010) into a randomized, double-blind, placebo-controlled trial to receive cholecalciferol supplementation (0, 1000 international units (IU), 2000 IU or 4000 IU per day) for 3 months. Plasma concentrations of 25(OH) D and anthropometric measurements were done at baseline, 3 and 6 months.
RESULTS: At 3 months, vitamin D supplementation in three dose groups (1000 IU, 2000 IU or 4000 IU per day) did not cause any significant changes in BMI as compared with placebo group 3-month change in BMI per 1000 IU per day estimate (SE): 0.01 (0.039); P = 0.78.
CONCLUSIONS: In overweight African-Americans, short-term high-dose vitamin D supplementation did not alter BMI.
C1 [Chandler, P. D.] Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02215 USA.
[Chandler, P. D.; Ng, K.; Chan, A. T.; Emmons, K. M.; Giovannucci, E. L.; Fuchs, C. S.] Harvard Univ, Sch Med, Boston, MA USA.
[Scott, J. B.] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
[Drake, B. F.] Washington Univ, Sch Med, Dept Surg, Div Publ Hlth Sci, St Louis, MO 63110 USA.
[Ng, K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Chan, A. T.] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA.
[Hollis, B. W.] Med Univ S Carolina, Div Pediat, Charleston, SC 29425 USA.
[Emmons, K. M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
[Giovannucci, E. L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Giovannucci, E. L.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Bennett, G. G.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA.
RP Chandler, PD (reprint author), Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave,Third Floor, Boston, MA 02215 USA.
EM pchandler@partners.org
OI Drake, Bettina/0000-0001-9340-5848
FU National Cancer Institute [P50CA127003, K07CA148894, K22CA126992,
5K05CA124415, U01CA138962]; Department of Defense Prostate Cancer
Research Program [PC081669]; American Society of Clinical Oncology
Career Development Award; Pharmavite LLC
FX We would like to thank Cara Marcus, MSLIS, AHIP, Director of Library
Services, Brigham and Women's Faulkner Hospital for facilitating access
to reference articles and Harvard Catalyst for statistical support. The
authors' responsibilities were as follows-CSF, ELG, KME, BFD, GGB:
conceived and designed the study; PDC CSF ELG: analyzed the study; and
all authors contributed to the manuscript. This trial was funded by the
National Cancer Institute (P50CA127003; K07CA148894 [Ng]; K22CA126992;
5K05CA124415 [Emmons]; U01CA138962 [Chandler]), the Department of
Defense Prostate Cancer Research Program (PC081669 [Drake]), the
American Society of Clinical Oncology Career Development Award (Ng) and
Pharmavite LLC. The sponsor had no role in designing, developing the
protocol, or conducting the trial; in data collection, analysis,
management, or interpretation of the data; or in preparing the
manuscript.
NR 32
TC 2
Z9 2
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-4052
J9 NUTR DIABETES
JI Nutr. Diabetes
PD JAN
PY 2015
VL 5
AR e147
DI 10.1038/nutd.2014.44
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA CH0EC
UT WOS:000353690900001
PM 25599559
ER
PT S
AU Sinha, L
Elliott, JT
Hasan, T
Pogue, BW
Samkoe, KS
Tichauer, KM
AF Sinha, Lagnojita
Elliott, Jonathan T.
Hasan, Tayyaba
Pogue, Brian W.
Samkoe, Kimberley S.
Tichauer, Kenneth M.
BE Kessel, DH
Hasan, T
TI Early photosensitizer uptake kinetics predict optimum drug-light
interval for photodynamic therapy
SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND
TECHNIQUES IN PHOTODYNAMIC THERAPY XXIV
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Optical Methods for Tumor Treatment and Detection -
Mechanisms and Techniques in Photodynamic Therapy XXIV
CY FEB 07-09, 2015
CL San Francisco, CA
SP SPIE
DE cancer; Photo dynamic therapy; tracer kinetics for PDT; optimum
drug-light interval; photosensitizer uptake kinetics; molecular imaging;
early uptake Prediction; compartment model
ID VASCULAR-PERMEABILITY; AGENTS; TUMORS; DELIVERY; BARRIERS; DAMAGE
AB Photodynamic therapy (PDT) has shown promising results in targeted treatment of cancerous cells by developing localized toxicity with the help of light induced generation of reactive molecular species. The efficiency of this therapy depends on the product of the intensity of light dose and the concentration of photosensitizer (PS) in the region of interest (ROI). On account of this, the dynamic and variable nature of PS delivery and retention depends on many physiological factors that are known to be heterogeneous within and amongst tumors (e.g., blood flow, blood volume, vascular permeability, and lymph drainage rate). This presents a major challenge with respect to how the optimal time and interval of light delivery is chosen, which ideally would be when the concentration of PS molecule is at its maximum in the ROI. In this paper, a predictive algorithm is developed that takes into consideration the variability and dynamic nature of PS distribution in the body on a region-by-region basis and provides an estimate of the optimum time when the PS concentration will be maximum in the ROI. The advantage of the algorithm lies in the fact that it predicts the time in advance as it takes only a sample of initial data points (similar to 12 min) as input. The optimum time calculated using the algorithm estimated a maximum dose that was only 0.58 +/- 1.92% under the true maximum dose compared to a mean dose error of 39.85 +/- 6.45% if a 1 h optimal light deliver time was assumed for patients with different efflux rate constants of the PS, assuming they have the same plasma function. Therefore, if the uptake values of PS for the blood and the ROI is known for only first 12 minutes, the entire curve along with the optimum time of light radiation can be predicted with the help of this algorithm.
C1 [Sinha, Lagnojita; Tichauer, Kenneth M.] IIT, Biomed Engn, Chicago, IL 60616 USA.
[Elliott, Jonathan T.; Pogue, Brian W.; Samkoe, Kimberley S.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
[Hasan, Tayyaba] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Sinha, L (reprint author), IIT, Biomed Engn, Chicago, IL 60616 USA.
NR 19
TC 0
Z9 0
U1 0
U2 4
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-398-4
J9 PROC SPIE
PY 2015
VL 9308
AR 930811
DI 10.1117/12.2077842
PG 8
WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical
Imaging
SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BC6CO
UT WOS:000353802500003
ER
PT S
AU Abdallah, CG
Averill, LA
Krystal, JH
AF Abdallah, Chadi G.
Averill, Lynnette A.
Krystal, John H.
GP New York Acad Sci
TI Ketamine as a promising prototype for a new generation of rapid-acting
antidepressants
SO TRANSLATIONAL NEUROSCIENCE IN PSYCHIATRY
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Translational Psychiatry - Light at the End of the Tunnel
CY APR 08, 2014
CL New York Acad Sci, New York, NY
HO New York Acad Sci
DE ketamine; depression; antidepressant; treatment mechanisms; neurobiology
ID TREATMENT-RESISTANT DEPRESSION; D-ASPARTATE ANTAGONIST;
POSTTRAUMATIC-STRESS-DISORDER; NMDA RECEPTOR BLOCKADE; LOW-DOSE
KETAMINE; ADD-ON TRIAL; MAJOR DEPRESSION; ELECTROCONVULSIVE-THERAPY;
INTRAVENOUS KETAMINE; BIPOLAR DEPRESSION
AB The discovery of ketamine's rapid and robust antidepressant effects opened a window into a new generation of antidepressants. Multiple controlled trials and open-label studies have demonstrated these effects across a variety of patient populations known to often achieve little to no response from traditional antidepressants. Ketamine has been generally well tolerated across patient groups, with transient mild-to-moderate adverse effects during infusion. However, the optimal dosing and route of administration and the safety of chronic treatment are not fully known. This review summarizes the clinical effects of ketamine and its neurobiological underpinnings and mechanisms of action, which may provide insight into the neurobiology of depression, relevant biomarkers, and treatment targets. Moreover, we offer suggestions for future research that may continue to advance the field forward and ultimately improve the psychopharmacologic interventions available for those individuals struggling with depressive and trauma-related disorders.
C1 [Abdallah, Chadi G.; Averill, Lynnette A.; Krystal, John H.] US Dept Vet Affairs, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, VA Connecticut Healthcare Syst, West Haven, CT USA.
[Abdallah, Chadi G.; Averill, Lynnette A.; Krystal, John H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
RP Abdallah, CG (reprint author), US Dept Vet Affairs, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, VA Natl Ctr PTSD, 950 Campbell Ave 151E, West Haven, CT 06516 USA.
EM chadi.abdallah@yale.edu
OI Abdallah, Chadi/0000-0001-5783-6181
FU Brain and Behavior Research Foundation (NARSAD); American Psychiatric
Foundation; Genentech
FX Dr. Averill declares no conflicts of interest. Dr. Abdallah has received
research funding or consultation fees from the Brain and Behavior
Research Foundation (NARSAD), the American Psychiatric Foundation, and
Genentech. Dr. Krystal has served as a scientific consultant to the
following companies (the individual consultant agreements listed are
less than $10000/year): Aisling Capital, Astellas Pharma Global
Development, AstraZeneca Pharmaceuticals, Biocortech, Brintnall &
Nicolini, Easton Associates, Gilead Sciences, GlaxoSmithKline, Janssen
Pharmaceuticals, Lundbeck Research USA, Medivation, Merz
Pharmaceuticals, MK Medical Communications, Hoffmann-La Roche, SK
Holdings, Sunovion Pharmaceuticals, Takeda Industries, and Teva
Pharmaceutical Industries. He is on the Scientific Advisory Board for
the following companies: Abbott Laboratories, Bristol-Myers Squibb,
Eisai, Eli Lilly, Forest Laboratories, Lohocla Research Corporation,
Mnemosyne Pharmaceuticals, Naurex, Pfizer Pharmaceuticals, and Shire
Pharmaceuticals. He holds less than $150 in exercisable warrant options
with Tetragenex Pharmaceuticals. He is also on the Board of Directors of
the Coalition for Translational Research in Alcohol and Substance Use
Disorders and was the principal investigator of a multicenter study in
which Janssen Research Foundation provided drug and some support to the
Department of Veterans Affairs. He is Editor of Biological Psychiatry.
In addition, he has a patent on dopamine and noradrenergic reuptake
inhibitors in the treatment of schizophrenia (patent number 5447948) and
is a coinventor with Dr. Gerard Sanacora on a filed patent application
by Yale University related to targeting the glutamatergic system for the
treatment of neuropsychiatric disorders (PCTWO06108055A1). He has a
patent pending on intranasal administration of ketamine to treat
depression.
NR 88
TC 28
Z9 28
U1 6
U2 13
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077-8923
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2015
VL 1344
BP 66
EP 77
DI 10.1111/nyas.12718
PG 12
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA BC5PU
UT WOS:000353469600006
PM 25727103
ER
PT J
AU Arthur, R
Rodriguez-Vida, A
Zadra, G
Moller, H
Van Hemelrijck, M
AF Arthur, Rhonda
Rodriguez-Vida, Alejo
Zadra, Giorgia
Moller, Henrik
Van Hemelrijck, Mieke
TI Serum lipids as markers of prostate cancer occurrence and prognosis?
SO CLINICAL LIPIDOLOGY
LA English
DT Review
DE apoA-1; apoB; cholesterol; HDL; LDL; prostate cancer; triglycerides
ID HIGH-DENSITY-LIPOPROTEIN; INHIBIT TUMOR-DEVELOPMENT; METABOLIC SYNDROME;
HDL CHOLESTEROL; UNITED-STATES; MOUSE MODEL; RISK; CELLS; PROLIFERATION;
PROGRESSION
AB With the current epidemic of lipid-related disorders and prostate cancer (PCa) in western countries, there is growing interest in the potential causal relationship between lipids and PCa. PCa is a heterogeneous disease, which undermines researchers' ability to determine the mechanistic pathways responsible for its development and progression. Currently, detection and progression of PCa is mainly determined by prostate specific antigen, but this biomarker lacks specificity and is unable to discriminate between indolent and aggressive cancer. Nonetheless, there is evidence to suggest that lipid markers might potentially be useful in conjunction with other markers such as prostate specific antigen in improving detection and management of this disease. This review aims to highlight findings from epidemiological studies which examined the role of serum lipids in PCa occurrence and prognosis.
C1 [Arthur, Rhonda; Moller, Henrik; Van Hemelrijck, Mieke] Kings Coll London, Guys Hosp, Canc Epidemiol Grp, Div Canc Studies,Res Oncol, London SE1 9RT, England.
[Rodriguez-Vida, Alejo] Guys & St Thomas NHS Fdn Trust, Dept Med Oncol, London, England.
[Zadra, Giorgia] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02215 USA.
RP Arthur, R (reprint author), Kings Coll London, Guys Hosp, Canc Epidemiol Grp, Div Canc Studies,Res Oncol, 3rd Floor,Bermondsey Wing, London SE1 9RT, England.
EM rhonda.arthur@kcl.ac.uk
OI Moller, Henrik/0000-0001-8200-5929
FU Experimental Cancer Medicine Centre at King's College London; National
Institute for Health Research (NIHR) Biomedical Research Centre based at
Guy's and St Thomas' NHS Foundation Trust; King's College London
FX This research was supported by the Experimental Cancer Medicine Centre
at King's College London and also by the National Institute for Health
Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas'
NHS Foundation Trust and King's College London. The authors have no
other relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 81
TC 1
Z9 1
U1 3
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-4299
EI 1758-4302
J9 CLIN LIPIDOL
JI Clin. Lipidol.
PY 2015
VL 10
IS 2
BP 145
EP 165
DI 10.2217/CLP.14.69
PG 21
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CG6LJ
UT WOS:000353412100005
ER
PT J
AU Costine, BA
Missios, S
Taylor, SR
McGuone, D
Smith, CM
Dodge, CP
Harris, BT
Duhaime, AC
AF Costine, Beth A.
Missios, Symeon
Taylor, Sabrina R.
McGuone, Declan
Smith, Colin M.
Dodge, Carter P.
Harris, Brent T.
Duhaime, Ann-Christine
TI The Subventricular Zone in the Immature Piglet Brain: Anatomy and Exodus
of Neuroblasts into White Matter after Traumatic Brain Injury
SO DEVELOPMENTAL NEUROSCIENCE
LA English
DT Article
DE Traumatic brain injury; Subventricular zone; Neurogenesis; Neuroblasts
ID MATURATION-DEPENDENT RESPONSE; CENTRAL-NERVOUS-SYSTEM;
CELL-PROLIFERATION; POSTNATAL NEUROGENESIS; OLFACTORY-BULB; DENTATE
GYRUS; IN-VITRO; FOREBRAIN; MIGRATION; MICE
AB Stimulation of postnatal neurogenesis in the subventricular zone (SVZ) and robust migration of neuroblasts to the lesion site in response to traumatic brain injury (TBI) is well established in rodent species; however, it is not yet known whether postnatal neurogenesis plays a role in repair after TBI in gyrencephalic species. Here we describe the anatomy of the SVZ in the piglet for the first time and initiate an investigation into the effect of TBI on the SVZ architecture and the number of neuroblasts in the white matter. Among all ages of immaturity examined the SVZ contained a dense mesh network of neurogenic precursor cells (doublecortin+) positioned directly adjacent to the ependymal cells (ventricular SVZ, Vsvz) and neuroblasts organized into chains that were distinct from the Vsvz (abventricular SVZ, Asvz). Though the architecture of the SVZ was similar among ages, the areas of Vsvz and Asvz neuroblast chains declined with age. At postnatal day (PND) 14 the white matter tracts have a tremendous number of individual neuroblasts. In our scaled corticalimpact model, lesion size increased with age. Similarly, the response of the SVZ to injury was also age dependent. The younger age groups that sustained the proportionately smallest lesions had the largest SVZ areas, which further increased in response to injury. In piglets that were injured at 4 months of age and had the largest lesions, the SVZ did not increase in response to injury. Similar to humans, swine have abundant gyri and gyral white matter, providing a unique platform to study neuroblasts potentially migrating from the SVZ to the lesioned cortex along these white matter tracts. In piglets injured at PND 7, TBI did not increase the total number of neuroblasts in the white matter compared to uninjured piglets, but redistribution occurred with a greater number of neuroblasts in the white matter of the hemisphere ipsilateral to the injury compared to the contralateral hemisphere. At 7 days after injury, less than 1% of neuroblasts in the white matter were born in the 2 days following injury. These data show that the SVZ in the piglet shares many anatomical similarities with the SVZ in the human infant, and that TBI had only modest effects on the SVZ and the number of neuroblasts in the white matter. Piglets at an equivalent developmental stage to human infants were equipped with the largest SVZ and a tremendous number of neuroblasts in the white matter, which may be sufficient in lesion repair without the dramatic stimulation of neurogenic machinery. It has yet to be determined whether neurogenesis and migrating neuroblasts play a role in repair after TBI and/or whether an alteration of normal migration during active postnatal population of brain regions is beneficial in species with gyrencephalic brains. (C) 2015 S. Karger AG, Basel
C1 [Costine, Beth A.; Smith, Colin M.; Duhaime, Ann-Christine] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Charlestown, MA 02114 USA.
[McGuone, Declan] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02114 USA.
[Costine, Beth A.; Duhaime, Ann-Christine] Harvard Univ, Sch Med, Dept Neurosurg, Charlestown, MA 02114 USA.
[Missios, Symeon] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA.
[Taylor, Sabrina R.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA.
[Dodge, Carter P.] Childrens Hosp Dartmouth, Dartmouth Med Sch, Dept Anesthesiol, Lebanon, NH USA.
[Harris, Brent T.] Georgetown Med Sch, Dept Neurol, Washington, DC USA.
[Harris, Brent T.] Georgetown Med Sch, Dept Pathol, Washington, DC USA.
RP Costine, BA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Bldg 149,13th St,Room 3-405, Charlestown, MA 02114 USA.
EM bcostine@mgh.harvard.edu
FU NIH National Institute of Child Health and Human Development [R01
HD45364-5]; Pediatric Neuroscience Fund of the Children's Hospital at
Dartmouth; Nicholas T. Zervas Chair of Harvard Medical School; Joel Alan
Viktor Research Fund at Massachusetts General Hospital; NINDS
[5P30NS045776]
FX This work was supported by R01 HD45364-5 from the NIH National Institute
of Child Health and Human Development, the Pediatric Neuroscience Fund
of the Children's Hospital at Dartmouth, the Nicholas T. Zervas Chair of
Harvard Medical School, and the Joel Alan Viktor Research Fund at
Massachusetts General Hospital. The authors express their gratitude to
Leslie Adams, Kate Hillier, Ijeoma Chinwuba, Michael Simoni, and Kristen
Saliga for their assistance with animal handling, immunohistochemistry
and quantification. The authors also wish to thank Kenneth Orndorff
(Dartmouth Optical Cellular Imaging Shared Resource Center) and Igor
Bagayev (MGH Neuroscience Center Imaging Core supported by NINDS grant
5P30NS045776) for their assistance with confocal microscopy and Emily
Belli for proofreading the manuscript.
NR 43
TC 5
Z9 5
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-5866
EI 1421-9859
J9 DEV NEUROSCI-BASEL
JI Dev. Neurosci.
PY 2015
VL 37
IS 2
BP 115
EP 130
DI 10.1159/000369091
PG 16
WC Developmental Biology; Neurosciences
SC Developmental Biology; Neurosciences & Neurology
GA CG8LB
UT WOS:000353558000003
PM 25678047
ER
PT J
AU Connelly, KJ
Larson, EA
Marks, DL
Klein, RF
AF Connelly, Kara J.
Larson, Emily A.
Marks, Daniel L.
Klein, Robert F.
TI Neonatal Estrogen Exposure Results in Biphasic Age-Dependent Effects on
the Skeletal Development of Male Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID HORMONE-RELEASING-HORMONE; SOMATOSTATIN GENE-EXPRESSION; PEAK BONE MASS;
GROWTH-HORMONE; SEX STEROIDS; ANDROGEN INSENSITIVITY; SECRETORY
PATTERNS; GONADAL-STEROIDS; CORTICAL BONE; MALE-RATS
AB Peak bone mass, one of the most important predictors for fracture risk later in life, is attained during puberty and adolescence and influenced by neonatal and pubertal sex-specific gonadal hormones and GH-IGF-I secretion patterns. This study examined the effects of brief neonatal estrogen (NE) exposure on growth and skeletal development in C57BL/6J mice. A single injection of 100-mu g estradiol or vehicle was administered on the first day of life. Growth parameters were monitored and skeletal phenotyping performed at 16 weeks in female mice and at 4 and 16 weeks in male mice. NE exposure negatively impacted adult femoral length in both sexes, but adult body weight, areal bone density, and bone strength in female mice were unaffected. In contrast, somatic growth was attenuated in estrogen-exposed male mice throughout the study period. At the prepubertal time point, the estrogen-exposed males exhibited higher bone mineral density, cortical volume, and cortical thickness compared with controls. However, by the time of peak bone mass acquisition, the early skeletal findings had reversed; estrogen-exposed mice had lower bone density with reduced cross-sectional area, cortical volume, and cortical thickness, resulting in cortical bones that were less resistant to fracture. NE exposure also resulted in reduced testicular volume and lower circulating IGF-I. Male mice exposed to estrogen on the first day of life experience age-dependent changes in skeletal development. Prepubertal animals experience greater endocortical bone acquisition as a result of estrogen exposure. However, by adulthood, continued developmental changes result in overall reduced skeletal integrity.
C1 [Connelly, Kara J.; Marks, Daniel L.] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Div Pediat Endocrinol, Dept Pediat, Portland, OR 97239 USA.
[Larson, Emily A.; Klein, Robert F.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Dept Med, Portland, OR 97239 USA.
[Marks, Daniel L.] Oregon Hlth & Sci Univ, Pape Pediat Res Inst, Portland, OR 97239 USA.
[Klein, Robert F.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Connelly, KJ (reprint author), Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Child Dev & Rehabil Ctr Pediat CDRC P, 707 Southwest Gaines St, Portland, OR 97239 USA.
EM connellk@ohsu.edu
FU National Institutes of Health Grant [R01 AR44659, R01 DK070333, T32
DK7674-19]; Veterans Affairs Medical Research Service
FX This work was supported by National Institutes of Health Grants R01
AR44659 (to R.F.K.) and R01 DK070333 (to D.L.M.), T32 DK7674-19 (to
K.J.C.), and by the Veterans Affairs Medical Research Service (R.F.K.).
NR 42
TC 2
Z9 2
U1 0
U2 1
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD JAN
PY 2015
VL 156
IS 1
BP 193
EP 202
DI 10.1210/en.2014-1324
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG2TA
UT WOS:000353126800021
PM 25330099
ER
PT J
AU Rosenquist, KJ
Massaro, JM
Pedley, A
Long, MT
Kreger, BE
Vasan, RS
Murabito, JM
Hoffmann, U
Fox, CS
AF Rosenquist, Klara J.
Massaro, Joseph M.
Pedley, Alison
Long, Michelle T.
Kreger, Bernard E.
Vasan, Ramachandran S.
Murabito, Joanne M.
Hoffmann, Udo
Fox, Caroline S.
TI Fat Quality and Incident Cardiovascular Disease, All-Cause Mortality,
and Cancer Mortality
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID BODY-MASS INDEX; ADIPOSE-TISSUE; INSULIN-RESISTANCE;
EXTRACELLULAR-MATRIX; RISK-FACTORS; US ADULTS; OBESITY; ASSOCIATION;
OVERWEIGHT; SENSITIVITY
AB Context: Cellular characteristics of fat quality have been associated with cardiometabolic risk and can be estimated by computed tomography (CT) attenuation.
Objective: The aim was to determine the association between CT attenuation (measured in Hounsfield units [ HU]) and clinical outcomes. Methods: This was a prospective community-based cohort study using data from the Framingham Heart Study (n = 3324, 48% women, mean age 51 years) and Cox proportional hazard models.
Main Outcomes: The primary outcomes of interest were incident cardiovascular disease (CVD) and all-cause mortality. The secondary outcomes of interest were incident cancer, non-CVD death, and cancer death.
Results: There were 111 incident CVD events, 137 incident cancers, 85 deaths including 69 non-CVD deaths, and 45 cancer deaths in up to 23 047 person-years of follow-up. A1-SD increment in visceral adipose tissue (VAT) HU was inversely associated with incident CVD in the age-and sex-adjusted model (hazard ratio [HR] 0.78, P = .02) but not after multivariable adjustment (HR 0.83, P = .11). VAT HU was directly associated with all-cause mortality (multivariable HR 1.40, P = .003), which maintained significance after additional adjustment for body mass index (HR 1.53, P < .001) and VAT volume (HR 1.99, P < .001). Non-CVDdeath remained significant in all 3 models, including after adjustment for VAT volume (HR 1.97, P < .001). VAT HU was also associated with cancer mortality (HR 1.93, P = .002). Similar results were obtained for sc adipose tissue HU.
Conclusions: Fat quality, as estimated by CT attenuation, is associated with all-cause mortality, non-CVD death, and cancer death. These associations highlight how indirect indices of fat quality can potentially add to a better understanding of obesity-related complications.
C1 [Rosenquist, Klara J.; Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol & Metab, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Rosenquist, Klara J.; Long, Michelle T.; Kreger, Bernard E.; Vasan, Ramachandran S.; Murabito, Joanne M.; Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA.
[Rosenquist, Klara J.; Pedley, Alison; Long, Michelle T.; Fox, Caroline S.] Div Intramural Res, Framingham, MA 01702 USA.
[Rosenquist, Klara J.; Pedley, Alison; Long, Michelle T.; Fox, Caroline S.] Ctr Populat Studies, Framingham, MA 01702 USA.
[Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
[Long, Michelle T.] Boston Med Ctr, Sect Gastroenterol, Dept Med, Boston, MA 02118 USA.
[Kreger, Bernard E.; Murabito, Joanne M.] Boston Med Ctr, Sect Gen Internal Med, Dept Med, Boston, MA 02118 USA.
[Vasan, Ramachandran S.; Hoffmann, Udo] Boston Med Ctr, Sect Prevent Med & Epidemiol & Cardiol, Dept Med, Boston, MA 02118 USA.
Boston Univ, Sch Med, Boston, MA 02118 USA.
Massachusetts Gen Hosp, Dept Med, Boston, MA USA.
Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Fox, CS (reprint author), 73 Mt Wayte Ave Suite 2, Framingham, MA 01702 USA.
EM foxca@nhlbi.nih.gov
OI Long, Michelle/0000-0001-6131-3981; Ramachandran,
Vasan/0000-0001-7357-5970
FU NHLBI's FHS [N01-HC-25195, ROI-HL-077477]; Whitaker Cardiovascular
Institute [T32 HL007224]
FX This research was conducted in part using data and resources from the
Framingham Heart Study (FHS) of the National Heart, Lung, and Blood
Institute (NHLBI) of the National Institutes of Health and Boston
University School of Medicine. This work was supported by the NHLBI's
FHS (Contract N01-HC-25195) and ROI-HL-077477 (to R.S.V.). K.J. R. is
supported through funding from the Whitaker Cardiovascular Institute
(T32 HL007224).
NR 40
TC 17
Z9 17
U1 0
U2 4
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JAN
PY 2015
VL 100
IS 1
BP 227
EP 234
DI 10.1210/jc.2013-4296
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG4UA
UT WOS:000353281300072
PM 25226289
ER
PT J
AU Karaca, E
Buyukkaya, R
Pehlivan, D
Charng, WL
Yaykasli, KO
Bayram, Y
Gambin, T
Withers, M
Atik, MM
Arslanoglu, I
Bolu, S
Erdin, S
Buyukkaya, A
Yaykasli, E
Jhangiani, SN
Muzny, DM
Gibbs, RA
Lupski, JR
AF Karaca, Ender
Buyukkaya, Ramazan
Pehlivan, Davut
Charng, Wu-Lin
Yaykasli, Kursat O.
Bayram, Yavuz
Gambin, Tomasz
Withers, Marjorie
Atik, Mehmed M.
Arslanoglu, Ilknur
Bolu, Semih
Erdin, Serkan
Buyukkaya, Ayla
Yaykasli, Emine
Jhangiani, Shalini N.
Muzny, Donna M.
Gibbs, Richard A.
Lupski, James R.
TI Whole-Exome Sequencing Identifies Homozygous GPR161 Mutation in a Family
with Pituitary Stalk Interruption Syndrome
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID PROTEIN-COUPLED RECEPTOR; HEDGEHOG; PHENOTYPE; GLI3; HYPOPITUITARISM;
MECHANISMS; VARIANTS; GENES; ALPHA; GLAND
AB Context: Pituitary stalk interruption syndrome (PSIS) is a rare, congenital anomaly of the pituitary gland characterized by pituitary gland insufficiency, thin or discontinuous pituitary stalk, anterior pituitary hypoplasia, and ectopic positioning of the posterior pituitary gland (neurohypophysis). The clinical presentation of patients with PSIS varies from isolated growth hormone (GH) deficiency to combined pituitary insufficiency and accompanying extrapituitary findings. Mutations in HESX1, LHX4, OTX2, SOX3, and PROKR2 have been associated with PSIS in less than 5% of cases; thus, the underlying genetic etiology for the vast majority of cases remains to be determined.
Objective: We applied whole-exome sequencing (WES) to a consanguineous family with two affected siblings who have pituitary gland insufficiency and radiographic findings of hypoplastic (thin) pituitary gland, empty sella, ectopic neurohypophysis, and interrupted pitiutary stalk-characteristic clinical diagnostic findings of PSIS.
Design and Participants: WES was applied to two affected and one unaffected siblings.
Results: WES of two affected and one unaffected sibling revealed a unique homozygous missense mutation in GPR161, which encodes the orphan G protein-coupled receptor 161, a protein responsible for transducing extracellular signals across the plasma membrane into the cell.
Conclusion: Mutations of GPR161 may be implicated as a potential novel cause of PSIS.
C1 [Karaca, Ender; Pehlivan, Davut; Charng, Wu-Lin; Bayram, Yavuz; Gambin, Tomasz; Withers, Marjorie; Atik, Mehmed M.; Gibbs, Richard A.; Lupski, James R.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Buyukkaya, Ramazan] Duzce Univ, Sch Med, Dept Radiol, TR-81620 Duzce, Turkey.
[Yaykasli, Kursat O.] Kahramanmaras Sutcu Imam Univ, Sch Med, Dept Med Biol, TR-46100 Kahramanmaras, Turkey.
[Arslanoglu, Ilknur; Bolu, Semih] Duzce Univ, Sch Med, Dept Pediat Endocrinol, TR-81620 Duzce, Turkey.
[Erdin, Serkan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Buyukkaya, Ayla] Duzce Ataturk Community Hosp, Dept Radiol, TR-81620 Duzce, Turkey.
[Yaykasli, Emine] Duzce Univ, Inst Hlth Sci, Dept Med Biol & Genet, TR-81620 Duzce, Turkey.
[Jhangiani, Shalini N.; Muzny, Donna M.; Gibbs, Richard A.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Lupski, James R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
[Lupski, James R.] Texas Childrens Hosp, Houston, TX 77030 USA.
RP Lupski, JR (reprint author), Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,Room 604B, Houston, TX 77030 USA.
EM jlupski@bcm.edu
RI Erdin, Serkan/B-4988-2008;
OI Erdin, Serkan/0000-0001-6587-2625; Gambin, Tomasz/0000-0002-0941-4571
FU US National Human Genome Research Institute (NHGRI)/National Heart Lung
and Blood Institute (NHLBI) [U54HG006542]
FX This work was supported by the US National Human Genome Research
Institute (NHGRI)/National Heart Lung and Blood Institute (NHLBI) Grant
No. U54HG006542 to the Baylor-Hopkins Center for Mendelian Genomics.
NR 29
TC 14
Z9 16
U1 0
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JAN
PY 2015
VL 100
IS 1
BP E140
EP E147
DI 10.1210/jc.2014-1984
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG4UA
UT WOS:000353281300033
PM 25322266
ER
PT J
AU Lombardi, A
Inabnet, WB
Owen, R
Farenholtz, KE
Tomer, Y
AF Lombardi, Angela
Inabnet, William Barlow, III
Owen, Randall
Farenholtz, Kaitlyn Ellen
Tomer, Yaron
TI Endoplasmic Reticulum Stress as a Novel Mechanism in Amiodarone-Induced
Destructive Thyroiditis
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; ATRIAL-FIBRILLATION; ER STRESS; INDUCED
THYROTOXICOSIS; RHEUMATOID-ARTHRITIS; HEART-FAILURE; MESSENGER-RNA;
DISEASE; DEGRADATION; CHAPERONES
AB Context: Amiodarone (AMIO) is one of the most effective antiarrhythmic drugs available; however, its use is limited by a serious side effect profile, including thyroiditis. The mechanisms underlying AMIO thyroid toxicity have been elusive; thus, identification of novel approaches in order to prevent thyroiditis is essential in patients treated with AMIO.
Objective: Our aim was to evaluate whether AMIO treatment could induce endoplasmic reticulum (ER) stress in human thyroid cells and the possible implications of this effect in AMIO-induced destructive thyroiditis.
Results: Here we report that AMIO, but not iodine, significantly induced the expression of ER stress markers including Ig heavy chain-binding protein (BiP), phosphoeukaryotic translation initiation factor 2 alpha (eIF2 alpha), CCAAT/enhancer-binding protein homologous protein (CHOP) and spliced X-box binding protein-1 (XBP-1) in human thyroid ML-1 cells and human primary thyrocytes. In both experimental systems AMIO down-regulated thyroglobulin (Tg) protein but had little effect on Tg mRNA levels, suggesting a mechanism involving Tg protein degradation. Indeed, pretreatment with the specific proteasome inhibitor MG132 reversed AMIO-induced down-regulation of Tg protein levels, confirming a proteasome-dependent degradation of Tg protein. Corroborating our findings, pretreatment of ML-1 cells and human primary thyrocytes with the chemical chaperone 4-phenylbutyric acid completely prevented the effect of AMIO on both ER stress induction and Tg down-regulation.
Conclusions: We identified ER stress as a novel mechanism contributing to AMIO-induced destructive thyroiditis. Our data establish that AMIO-induced ER stress impairs Tg expression via proteasome activation, providing a valuable therapeutic avenue for the treatment of AMIO-induced destructive thyroiditis.
C1 [Lombardi, Angela; Farenholtz, Kaitlyn Ellen; Tomer, Yaron] Icahn Sch Med Mt Sinai, Div Endocrinol, New York, NY 10029 USA.
[Inabnet, William Barlow, III; Owen, Randall] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA.
[Tomer, Yaron] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
RP Lombardi, A (reprint author), Icahn Sch Med Mt Sinai, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA.
EM angela.lombardi@mssm.edu; yaron.tomer@mssm.edu
FU NIH from the National Institute of Diabetes and Digestive and Kidney
Diseases [DK061659, DK067555, DK073681]; Department of Veterans Affairs
FX This work was supported by NIH Grants DK061659, DK067555, and DK073681
from the National Institute of Diabetes and Digestive and Kidney
Diseases In addition, this material is based upon work supported in part
by the Department of Veterans Affairs.
NR 51
TC 2
Z9 2
U1 1
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JAN
PY 2015
VL 100
IS 1
BP E1
EP E10
DI 10.1210/jc.2014-2745
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG4UA
UT WOS:000353281300014
PM 25295624
ER
PT J
AU Giavina-Bianchi, M
Giavina-Bianchi, P
Sotto, MN
Muzikansky, A
Kalil, J
Festa-Neto, C
Duncan, LM
AF Giavina-Bianchi, Mara
Giavina-Bianchi, Pedro
Sotto, Mirian Nacagami
Muzikansky, Alona
Kalil, Jorge
Festa-Neto, Cyro
Duncan, Lyn M.
TI Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+T Cells in
Cutaneous Melanoma
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID CANCER-TESTIS ANTIGENS; VERTICAL GROWTH-PHASE; METASTATIC MELANOMA;
LYMPHOCYTE GRADE; OVARIAN-CANCER; STAGE; SURVIVAL; RESPONSES;
IMMUNOGENICITY; IMMUNOTHERAPY
AB NY-ESO-1 is a cancer-testis antigen aberrantly expressed in melanomas, which may serve as a robust and specific target in immunotherapy. NY-ESO-1 antigen expression, tumor features, and the immune profile of tumor infiltrating lymphocytes were assessed in primary cutaneous melanoma. NY-ESO-1 protein was detected in 20% of invasive melanomas (16/79), rarely in in situ melanoma (1/10) and not in benign nevi (0/20). Marked intratumoral heterogeneity of NY-ESO-1 protein expression was observed. NY-ESO-1 expression was associated with increased primary tumor thickness (P = 0.007) and inversely correlated with superficial spreading melanoma (P < 0.02). NY-ESO-1 expression was also associated with reduced numbers and density of CD3+ tumor infiltrating lymphocytes (P = 0.017). When NY-ESO-1 protein was expressed, CD3+ T cells were less diffusely infiltrating the tumor and were more often arranged in small clusters (P = 0.010) or as isolated cells (P = 0.002) than in large clusters of more than five lymphocytes. No correlation of NY-ESO-1 expression with gender, age, tumor site, ulceration, lymph node sentinel status, or survival was observed. NY-ESO-1 expression in melanoma was associated with tumor progression, including increased tumor thickness, and with reduced tumor infiltrating lymphocytes.
C1 [Giavina-Bianchi, Mara; Sotto, Mirian Nacagami; Festa-Neto, Cyro] Univ Sao Paulo, Dept Dermatol, BR-05403900 Sao Paulo, SP, Brazil.
[Giavina-Bianchi, Pedro; Kalil, Jorge] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05403900 Sao Paulo, SP, Brazil.
[Muzikansky, Alona] MGH Biostat Ctr, Boston, MA 02114 USA.
[Duncan, Lyn M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dermatopathol Unit,Pathol Serv, Boston, MA 02114 USA.
RP Giavina-Bianchi, M (reprint author), Univ Sao Paulo, Dept Dermatol, Ave Dr Eneas de Carvalho Aguiar 255,3 Andar, BR-05403900 Sao Paulo, SP, Brazil.
EM clinicadermato@ig.com.br
RI Sotto, Mirian/C-3475-2013
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo); CNPQ
(Conselho Nacional de Pesquisa), Brazil
FX The authors acknowledge Ludwig Institute for Cancer Research, Brazil,
for the donation of antibody E978 and also recognized the expert
technical support of the Laboratorio Diagnostika, Brazil, for performing
immunohistochemical stains and controls. They want to thank Patricia
Della Pelle for T cell immunohistochemical staining. This study was
supported by grants from FAPESP (Fundacao de Amparo a Pesquisa do Estado
de Sao Paulo), and CNPQ (Conselho Nacional de Pesquisa), Brazil, and the
consultative funds of one of the authors (Lyn M. Duncan).
NR 49
TC 0
Z9 0
U1 0
U2 1
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2015
AR 761378
DI 10.1155/2015/761378
PG 8
WC Immunology
SC Immunology
GA CG7JR
UT WOS:000353479700001
ER
PT J
AU Russell, SJ
AF Russell, Steven J.
TI When you come to a fork in the road, take it!
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Editorial Material
ID ARTIFICIAL PANCREAS; GLUCAGON; HYPOGLYCEMIA
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Russell, SJ (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM sjrussell@mgh.harvard.edu
NR 10
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2213-8587
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD JAN
PY 2015
VL 3
IS 1
BP 2
EP 3
DI 10.1016/S2213-8587(14)70195-0
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG1KB
UT WOS:000353030400005
PM 25434966
ER
PT J
AU Shi, CC
Li, HP
Yang, YF
Hou, LF
AF Shi, Chenchen
Li, Haipeng
Yang, Yifu
Hou, Lifei
TI Anti-Inflammatory and Immunoregulatory Functions of Artemisinin and Its
Derivatives
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID NF-KAPPA-B; T-CELL-ACTIVATION; IMMUNOSUPPRESSIVE ACTIVITY;
RHEUMATOID-ARTHRITIS; PLASMODIUM-FALCIPARUM; QINGHAOSU ARTEMISININ; TH17
RESPONSES; TNF-ALPHA; IN-VITRO; ARTESUNATE
AB Artemisinin and its derivatives are widely used in the world as the first-line antimalarial drug. Recently, growing evidences reveal that artemisinin and its derivatives also possess potent anti-inflammatory and immunoregulatory properties. Meanwhile, researchers around the world are still exploring the unknown bioactivities of artemisinin derivatives. In this review, we provide a comprehensive discussion on recent advances of artemisinin derivatives affecting inflammation and autoimmunity, the underlying molecular mechanisms, and also drug development of artemisinins beyond antimalarial functions.
C1 [Shi, Chenchen; Yang, Yifu] Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai, Peoples R China.
[Li, Haipeng] Beijing Army Gen Hosp, Dept Orthoped, Beijing, Peoples R China.
[Hou, Lifei] Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Hou, Lifei] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Yang, YF (reprint author), Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai, Peoples R China.
EM yangyifu@mail.shcnc.ac.cn; lifei.hou@childrens.harvard.edu
NR 41
TC 1
Z9 2
U1 2
U2 14
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2015
AR 435713
DI 10.1155/2015/435713
PG 7
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA CG7OE
UT WOS:000353492400001
ER
PT S
AU Eisen, HN
Schlesinger, S
AF Eisen, Herman N.
Schlesinger, Sondra
BE Littman, DR
Yokoyama, WM
TI Remembrance of Immunology Past: Conversations with Herman Eisen
SO ANNUAL REVIEW OF IMMUNOLOGY VOL 33
SE Annual Review of Immunology
LA English
DT Review; Book Chapter
DE antibodies; affinity maturation; myeloma proteins; CD8(+) T cells
ID PIG T-LYMPHOCYTES; ANTIGEN RECOGNITION; RELATIVE AFFINITY;
IMMUNE-RESPONSE; INFLUENZA-VIRUS; ANTIBODIES; HETEROGENEITY;
SPECIFICITY; MACROPHAGES; MATURATION
AB Herman Eisen and Sondra Schlesinger spent several days together in September 2007 in Woods Hole, Massachusetts, talking about immunology, focusing on his remembrances of the field over the more than 60 years of his involvement. This article is an abridged version of those discussions (the full version is available on the Annual Reviews website). It is both an oral history and a written memory of some important but selected areas of immunology.
C1 [Eisen, Herman N.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Eisen, Herman N.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Eisen, Herman N.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02129 USA.
[Eisen, Herman N.] Harvard Univ, Boston, MA 02129 USA.
[Schlesinger, Sondra] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
RP Eisen, HN (reprint author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM sondra@wusm.wustl.edu
NR 32
TC 1
Z9 1
U1 0
U2 5
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0732-0582
BN 978-0-8243-3033-0
J9 ANNU REV IMMUNOL
JI Annu. Rev. Immunol.
PY 2015
VL 33
BP 1
EP +
DI 10.1146/annurev-immunol-111214-122349
PG 116
WC Immunology
SC Immunology
GA BC4TF
UT WOS:000352911900001
PM 25581308
ER
PT S
AU Yin, Q
Fu, TM
Li, JX
Wu, H
AF Yin, Qian
Fu, Tian-Min
Li, Jixi
Wu, Hao
BE Littman, DR
Yokoyama, WM
TI Structural Biology of Innate Immunity
SO ANNUAL REVIEW OF IMMUNOLOGY VOL 33
SE Annual Review of Immunology
LA English
DT Review; Book Chapter
DE Toll-like receptor; RIG-I-like receptor; intlammasome; cGAS; STING;
death domain superfamily; higher-order assembly
ID CYCLIC DI-GMP; DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTORS; SENSOR RIG-I;
NF-KAPPA-B; ANTIVIRAL SIGNAL ACTIVATION; CRYSTAL-STRUCTURE; ADAPTER
PROTEIN; CYTOSOLIC DNA; PYRIN DOMAIN
AB Innate immune responses depend on timely recognition of pathogenic or danger signals by multiple cell surface or cytoplasmic receptors and transmission of signals for proper counteractions through adaptor and effector molecules. At the forefront of innate immunity are four major signaling pathways, including those elicited by Toll-like receptors, RIG-I-like receptors, inflammasomes, or cGAS, each with its own cellular localization, ligand specificity, and signal relay mechanism. They collectively engage a number of overlapping signaling outcomes, such as NF-kappa B activation, interferon response, cvtokine maturation, and cell death. Several proteins often assemble into a supramolecular complex to enable signal transduction and amplification. In this article, we review the recent progress in mechanistic delineation of proteins in these pathways, their structural features, modes of ligand recognition, conformational changes, and homo- and hetero-oligomeric interactions within the supramolecular complexes. Regardless of seemingly distinct interactions and mechanisms, the recurring themes appear to consist of autoinhibited resting-state receptors, ligand-induced conformational changes, and higher-order assemblies of activated receptors, adaptors, and signaling enzymes through conserved protein-protein interactions.
C1 [Yin, Qian; Fu, Tian-Min; Li, Jixi; Wu, Hao] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Yin, Qian; Fu, Tian-Min; Li, Jixi; Wu, Hao] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Li, Jixi] Fudan Univ, State Key Lab Genet Engn, Shanghai 200438, Peoples R China.
[Li, Jixi] Fudan Univ, Sch Life Sci, Shanghai 200438, Peoples R China.
RP Yin, Q (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM lijixi@fudan.edu.cn; hao.wu@childrens.harvard.edu
FU NIAID NIH HHS [R01 AI045937, AI045937, AI089882, K99 AI108793, R01
AI050872, R01 AI089882, R37 AI050872]
NR 142
TC 11
Z9 11
U1 3
U2 36
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0732-0582
BN 978-0-8243-3033-0
J9 ANNU REV IMMUNOL
JI Annu. Rev. Immunol.
PY 2015
VL 33
BP 393
EP 416
DI 10.1146/annurev-immunol-032414-112258
PG 24
WC Immunology
SC Immunology
GA BC4TF
UT WOS:000352911900013
PM 25622194
ER
PT J
AU Koontz, AM
Ding, D
Jan, YK
de Groot, S
Hansen, A
AF Koontz, Alicia M.
Ding, Dan
Jan, Yih-Kuen
de Groot, Sonja
Hansen, Andrew
TI Wheeled Mobility
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Editorial Material
C1 [Koontz, Alicia M.; Ding, Dan] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA.
[Koontz, Alicia M.; Ding, Dan] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA.
[Jan, Yih-Kuen] Univ Illinois, Dept Kinesiol & Community Hlth, Champaign, IL 61820 USA.
[de Groot, Sonja] Reade, Amsterdam Rehabil Res Ctr, NL-1040 HG Amsterdam, Netherlands.
[de Groot, Sonja] Univ Groningen, Univ Med Ctr Groningen, Ctr Human Movement Sci, NL-9700 AB Groningen, Netherlands.
[Hansen, Andrew] Minneapolis VA Healthcare Syst, Rehabil Engn Res Program, Minneapolis, MN 55417 USA.
[Hansen, Andrew] Univ Minnesota, Program Rehabil Sci, Dept Phys Med & Rehabil, Minneapolis, MN 55455 USA.
RP Koontz, AM (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA.
EM akoontz@pitt.edu
OI Jan, Yih-Kuen/0000-0001-7149-4034
NR 3
TC 0
Z9 0
U1 1
U2 3
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 138176
DI 10.1155/2015/138176
PG 2
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CF9LK
UT WOS:000352886000001
ER
PT B
AU Felsenfeld, AJ
Levine, BS
AF Felsenfeld, Arnold J.
Levine, Barton S.
BE Kimmel, PL
Rosenberg, ME
TI Pathophysiology of Calcium, Phosphorus, and Magnesium in Chronic Kidney
Disease
SO CHRONIC RENAL DISEASE
LA English
DT Article; Book Chapter
ID CHRONIC-RENAL-FAILURE; PARATHYROID-HORMONE LEVELS; GROWTH-FACTOR 23;
LEFT-VENTRICULAR HYPERTROPHY; SERUM PHOSPHATE LEVELS; TRADE-OFF
HYPOTHESIS; INTACT PTH LEVELS; HEMODIALYSIS-PATIENTS; VITAMIN-D; MINERAL
METABOLISM
C1 [Felsenfeld, Arnold J.; Levine, Barton S.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
[Felsenfeld, Arnold J.; Levine, Barton S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Felsenfeld, AJ (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
NR 139
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-411616-0; 978-0-12-411602-3
PY 2015
BP 391
EP 405
DI 10.1016/B978-0-12-411602-3.00033-0
PG 15
WC Primary Health Care; Urology & Nephrology
SC General & Internal Medicine; Urology & Nephrology
GA BC2OW
UT WOS:000351158600033
ER
PT B
AU Maynard, SI
Thadhani, RE
AF Maynard, Sharon I.
Thadhani, Ravi E.
BE Kimmel, PL
Rosenberg, ME
TI Pregnancy and Chronic Kidney Disease
SO CHRONIC RENAL DISEASE
LA English
DT Article; Book Chapter
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GLOMERULAR-FILTRATION-RATE; CONVERTING
ENZYME-INHIBITORS; TYPE-1 DIABETIC WOMEN; SIGNIFICANT PROTEINURIA;
RENAL-DISEASE; ANTIHYPERTENSIVE MEDICATION; PRETERM DELIVERY; GLYCEMIC
CONTROL; IGA NEPHROPATHY
C1 [Maynard, Sharon I.] Univ S Florida, Morsani Coll Med, Lehigh Valley Hlth Network, Allentown, PA 18069 USA.
[Thadhani, Ravi E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Maynard, SI (reprint author), Univ S Florida, Morsani Coll Med, Lehigh Valley Hlth Network, Allentown, PA 18069 USA.
NR 110
TC 0
Z9 0
U1 1
U2 5
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-411616-0; 978-0-12-411602-3
PY 2015
BP 800
EP 812
DI 10.1016/B978-0-12-411602-3.00066-4
PG 13
WC Primary Health Care; Urology & Nephrology
SC General & Internal Medicine; Urology & Nephrology
GA BC2OW
UT WOS:000351158600066
ER
PT J
AU Khan, M
Dhammu, TS
Matsuda, F
Baarine, M
Dhindsa, TS
Singh, I
Singh, AK
AF Khan, Mushfiquddin
Dhammu, Tajinder S.
Matsuda, Fumiyo
Baarine, Mauhammad
Dhindsa, Tejbir Singh
Singh, Inderjit
Singh, Avtar K.
TI Promoting endothelial function by S-nitrosoglutathione through the HIF-1
alpha/VEGF pathway stimulates neurorepair and functional recovery
following experimental stroke in rats
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE GSNO; IR; HIF-1 alpha; VEGF; motor function; subtle behavior;
neuroprotection; neurorepair; angiogenesis; S-nitrosylation; stroke
ID TRAUMATIC BRAIN-INJURY; INDUCIBLE FACTOR-I; AMERICAN-HEART-ASSOCIATION;
FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE DONORS; NEUROVASCULAR UNIT;
LIQUID-CHROMATOGRAPHY; COGNITIVE IMPAIRMENT; PROTECTS BRAIN; CELL
MIGRATION
AB Background: For stroke patients, stimulating neurorepair mechanisms is necessary to reduce morbidity and disability. Our previous studies on brain and spinal cord trauma show that exogenous treatment with the S-nitrosylating agent S-nitrosoglutathione (GSNO) - a nitric oxide and glutathione metabolite of the human body - stimulates neurorepair and aids functional recovery. Using a rat model of cerebral ischemia and reperfusion (IR) in this study, we tested the hypothesis that GSNO invokes the neurorepair process and improves neurobehavioral functions through the angiogenic HIF-1 alpha/VEGF pathway.
Methods: Stroke was induced by middle cerebral artery occlusion for 60 minutes followed by reperfusion in adult male rats. The injured animals were treated with saline (IR group, n=7), GSNO (0.25 mg/kg, GSNO group, n=7), and GSNO plus the HIF-1 alpha inhibitor 2-methoxyestradiol (2-ME) (0.25 mg/kg GSNO + 5.0 mg/kg 2-ME, GSNO + 2-ME group, n=7). The groups were studied for either 7 or 14 days to determine neurorepair mediators and functional recovery. Brain capillary endothelial cells were used to show that GSNO promotes angiogenesis and that GSNO-mediated induction of VEGF and the stimulation of angiogenesis are dependent on HIF-1 alpha activity.
Results: IR injury increased the expression of neurorepair mediators HIF-1 alpha, VEGF, and PECAM-1 and vessel markers to a limited degree that correlate well with significantly compromised neurobehavioral functions compared with sham animals. GSNO treatment of IR not only remarkably enhanced further the expression of HIF-1 alpha, VEGF, and PECAM-1 but also improved functioning compared with IR. The GSNO group also had a higher degree of vessel density than the IR group. Increased expression of VEGF and the degree of tube formation (angiogenesis) by GSNO were reduced after the inhibition of HIF-1 alpha by 2-ME in an endothelial cell culture model. 2-ME treatment of the GSNO group also blocked not only GSNO's effect of reduced infarct volume, decreased neuronal loss, and enhanced expression of PECAM-1 (P<0.001), but also its improvement of motor and neurological functions (P<0.001).
Conclusion: GSNO stimulates the process of neurorepair, promotes angiogenesis, and aids functional recovery through the HIF-1 alpha-dependent pathway, showing therapeutic and translational promise for stroke.
C1 [Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Dhindsa, Tejbir Singh; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan.
[Baarine, Mauhammad; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, 513 Childrens Res Inst,173 Ashley Ave, Charleston, SC 29425 USA.
EM khanm@musc.edu; singha@musc.edu
FU NIH [NS-72511]; VA merit award [BX001062]; NIH from the Extramural
Research Facilities Program of the National Center for Research
Resources [C06 RR018823, C06 RR015455]
FX This work was supported by grants from NIH (NS-72511) and VA merit award
(BX001062). This work was also supported by the NIH, Grants C06 RR018823
and No C06 RR015455 from the Extramural Research Facilities Program of
the National Center for Research Resources. We thank Ms Joyce Bryan and
Ms Terry Hope for their technical help and secretarial assistance. We
are grateful to Dr Harutoshi Sakakima and Dr Yoshihiro Yoshida for their
valuable input. We also acknowledge Dr Tom Smith and Dr Lisa Kerr from
the MUSC Writing Center for their valuable editing of the manuscript.
NR 76
TC 5
Z9 5
U1 2
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2015
VL 9
BP 2233
EP 2247
DI 10.2147/DDDT.S77115
PG 15
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CG1SN
UT WOS:000353054400001
PM 25945035
ER
PT J
AU Richardson, PG
Moreau, P
Laubach, JP
Gupta, N
Hui, AM
Anderson, KC
Miguel, JFS
Kumar, S
AF Richardson, Paul G.
Moreau, Philippe
Laubach, Jacob P.
Gupta, Neeraj
Hui, Ai-Min
Anderson, Kenneth C.
Miguel, Jesus F. San
Kumar, Shaji
TI The investigational proteasome inhibitor ixazomib for the treatment of
multiple myeloma
SO FUTURE ONCOLOGY
LA English
DT Article
DE continuous therapy; induction; multiple myeloma; newly diagnosed; oral
administration; proteasome inhibition; refractory; relapsed
ID SINGLE-AGENT CARFILZOMIB; STEM-CELL TRANSPLANTATION; LOW-DOSE
DEXAMETHASONE; MLN9708 PLUS LENALIDOMIDE; ADVANCED SOLID TUMORS; CITRATE
MLN9708; COMBINATION THERAPY; PRECLINICAL MODELS; REFRACTORY MYELOMA;
ANTITUMOR-ACTIVITY
AB Ixazomib is an investigational, reversible 20S proteasome inhibitor. It is the first oral proteasome inhibitor under clinical investigation in multiple myeloma (MM). Under physiological conditions, the stable citrate ester drug substance, ixazomib citrate (MLN9708), rapidly hydrolyzes to the biologically active boronic acid, ixazomib (MLN2238). Preclinical studies have demonstrated antitumor activity in MM cell lines and xenograft models. In Phase I/II clinical studies ixazomib has had generally manageable toxicities, with limited peripheral neuropathy observed to date. Preliminary data from these studies indicate ixazomib is active as a single agent in relapsed/refractory MM and as part of combination regimens in newly diagnosed patients. Phase III studies in combination with lenalidomide-dexamethasone are ongoing.
C1 [Richardson, Paul G.; Laubach, Jacob P.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Div Hematol Ma, Boston, MA 02215 USA.
[Moreau, Philippe] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France.
[Gupta, Neeraj; Hui, Ai-Min] Millennium Pharmaceut Inc, Cambridge, MA USA.
[Miguel, Jesus F. San] Univ Navarra Clin, CIMA, Pamplona, Spain.
[Kumar, Shaji] Mayo Clin, Div Hematol, Rochester, MN USA.
RP Richardson, PG (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Div Hematol Ma, 450 Brookline Ave, Boston, MA 02215 USA.
EM paul_richardson@dfci.harvard.edu
RI richard, chrystelle/K-8595-2015
FU Celgene; Millennium Pharmaceuticals, Inc.; Novartis; Onyx; Genzyme;
Cephalon
FX PG Richardson is an advisory committee member for Celgene, Janssen
Pharmaceuticals and Millennium Pharmaceuticals, Inc., and has received
research funding from Celgene and Millennium Pharmaceuticals, Inc. P
Moreau is a consultant for and has received honoraria from Millennium
Pharmaceuticals, Inc. JP Laubach has received research funding from
Novartis and Onyx. N Gupta and A-M Hui are employees of Millennium
Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda
Pharmaceutical Company Ltd. KC Anderson is a consultant for Celgene
Corporation, Onyx Pharmaceuticals, Sanofi-Aventis and Gilead, and has
equity ownership in Acetylon Pharmaceuticals and Oncopep. JF San Miguel
serves on advisory boards for Janssen, Celgene, Millennium
Pharmaceuticals, Inc., Novartis and Onyx Pharmaceuticals. S Kumar is a
consultant for Merck, Celgene, Millennium Pharmaceuticals, Inc., and
Onyx, and receives research funding from Millennium Pharmaceuticals,
Inc., Celgene, Novartis, Genzyme, Onyx and Cephalon. The authors have no
other relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 82
TC 6
Z9 6
U1 2
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PY 2015
VL 11
IS 8
BP 1153
EP 1168
DI 10.2217/fon.15.9
PG 16
WC Oncology
SC Oncology
GA CF4IS
UT WOS:000352512900005
PM 25832873
ER
PT J
AU Sun, Q
Cai, HR
Mark, EJ
Miao, LY
Wu, HY
Zhou, Q
Chen, J
Zhang, W
Meng, FQ
AF Sun, Qi
Cai, Hou-Rong
Mark, Eugene J.
Miao, Li-Yun
Wu, Hong-Yan
Zhou, Qiang
Chen, Jun
Zhang, Wei
Meng, Fan-Qing
TI Multfocal micronodular pneumocyte hyperplasia in a Chinese man
masquerading as miliary tuberculosis
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Tuberous sclerosis complex; multifocal micronodular pneumocyte
hyperplasia
ID TUBEROUS SCLEROSIS
AB Multifocal Micronodular Pneumocyte Hyperplasia (MMPH) is a rare and histologically, distinctive pulmonary manifestation of tuberous sclerosis complex (TSC) characterized by numerous and extensive proliferative lesions of type II pneumocytes similar to atypical adenomatous hyperplasia (AAH) or non-mucinous adenocarcinoma in situ (AIS). We reported MMPH in a 38-year-old Chinese man with TSC masquerading for 16 months as miliary tuberculosis and discussed the differential diagnosis.
C1 [Sun, Qi; Wu, Hong-Yan; Zhou, Qiang; Chen, Jun; Meng, Fan-Qing] Nanjing Univ, Sch Med, Affiliated Hosp 1, Nanjing Drum Tower Hosp,Dept Pathol, Nanjing 210008, Jiangsu, Peoples R China.
[Cai, Hou-Rong; Miao, Li-Yun] Nanjing Univ, Sch Med, Affiliated Hosp 1, Nanjing Drum Tower Hosp,Dept Resp Med, Nanjing 210008, Jiangsu, Peoples R China.
[Mark, Eugene J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Mark, Eugene J.] Harvard Univ, Sch Med, Boston, MA USA.
[Zhang, Wei] Chinese Acad Med Sci, Inst Dermatol, Nanjing, Jiangsu, Peoples R China.
[Zhang, Wei] Peking Union Med Coll, Nanjing, Jiangsu, Peoples R China.
RP Meng, FQ (reprint author), Nanjing Univ, Sch Med, Affiliated Hosp 1, Nanjing Drum Tower Hosp,Dept Pathol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
EM fqmeng2004@126.com
NR 14
TC 0
Z9 1
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 2
BP 2165
EP 2170
PG 6
WC Oncology; Pathology
SC Oncology; Pathology
GA CF2IU
UT WOS:000352371800126
PM 25973120
ER
PT J
AU Zhang, LL
Iyer, AK
Yang, XQ
Kobayashi, E
Guo, YQ
Mankin, H
Hornicek, FJ
Amiji, MM
Duan, ZF
AF Zhang, Linlin
Iyer, Arun K.
Yang, Xiaoqian
Kobayashi, Eisuke
Guo, Yuqi
Mankin, Henry
Hornicek, Francis J.
Amiji, Mansoor M.
Duan, Zhenfeng
TI Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits
proliferation and growth of osteosarcoma cells
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE bone tumor; dextran nanoparticles; miR-199a-3p; let-7a; RNAi
ID DOWN-REGULATION; CANCER-THERAPY; MIRNA; SIRNA; EXPRESSION; RNA;
RESISTANCE; MIGRATION; TARGETS; MTOR
AB Our prior screening of microRNAs (miRs) identified that miR-199a-3p expression is reduced in osteosarcoma cells, one of the most common types of bone tumor. miR-199a-3p exhibited functions of tumor cell growth inhibition, suggesting the potential application of miR-199a-3p as an anticancer agent. In the study reported here, we designed and developed a lipid-modified dextran-based polymeric nanoparticle platform for encapsulation of miRs, and determined the efficiency and efficacy of delivering miR-199a-3p into osteosarcoma cells. In addition, another potent miR, let-7a, which also displayed tumor suppressive ability, was selected as a candidate miR for evaluation. Fluorescence microscopy studies and real-time polymerase chain reaction results showed that dextran nanoparticles could deliver both miR199a-3p and let-7a into osteosarcoma cell lines (KHOS and U-2OS) successfully. Western blotting analysis and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays demonstrated that dextran nanoparticles loaded with miRs could efficiently downregulate the expression of target proteins and effectively inhibit the growth and proliferation of osteosarcoma cells. These results demonstrate that a lipid-modified dextran-based polymeric nanoparticle platform may be an effective nonviral carrier for potential miR-based anticancer therapeutics.
C1 [Zhang, Linlin; Yang, Xiaoqian; Kobayashi, Eisuke; Guo, Yuqi; Mankin, Henry; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.
[Zhang, Linlin; Guo, Yuqi] Zhengzhou Univ, Affiliated Hosp 3, Dept Pathol, Zhengzhou 450052, Peoples R China.
[Iyer, Arun K.; Amiji, Mansoor M.] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA.
[Iyer, Arun K.] Wayne State Univ, Dept Pharmaceut Sci, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI USA.
RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, 100 Blossom St,Jackson 1115, Boston, MA 02114 USA.
EM zduan@mgh.harvard.edu
FU National Cancer Institute's Alliance for Nanotechnology in Cancer
through the Cancer Nanotechnology Platform Partnership [U01-CA15145];
Gattegno and Wechsler funds; Sarcoma Foundation of America
FX This study was supported in part by the National Cancer Institute's
Alliance for Nanotechnology in Cancer through the Cancer Nanotechnology
Platform Partnership (grant number U01-CA15145). Support was also
received from the Gattegno and Wechsler funds, and in the form of a
grant from the Sarcoma Foundation of America.
NR 41
TC 6
Z9 6
U1 0
U2 15
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 2913
EP 2924
DI 10.2147/IJN.S79143
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA CG0HQ
UT WOS:000352947800001
PM 25931818
ER
PT J
AU Dougherty, DD
Corse, AK
Chou, T
Duffy, A
Arulpragasam, AR
Deckersbach, T
Jenike, MA
Keuthen, NJ
AF Dougherty, Darin D.
Corse, Andrew K.
Chou, Tina
Duffy, Amanda
Arulpragasam, Amanda R.
Deckersbach, Thilo
Jenike, Michael A.
Keuthen, Nancy J.
TI Open-Label Study of Duloxetine for the Treatment of Obsessive-Compulsive
Disorder
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE duloxetine; obsessive-compulsive disorder; serotonin-norepinephrine
reuptake inhibitors; compulsions; obsessions
ID DOUBLE-BLIND; VENLAFAXINE; PLACEBO; FLUVOXAMINE; MULTICENTER;
DEPRESSION; SERTRALINE; INVENTORY
AB Background: This study sought to investigate the efficacy of duloxetine for the treatment of obsessive-compulsive disorder (DSM-IV).
Methods: Twenty individuals were enrolled in a 17-week, open-label trial of duloxetine at Massachusetts General Hospital. Data were collected between March 2007 and September 2012. Study measures assessing obsessive-compulsive disorder symptoms, quality of life, depression, and anxiety were administered at baseline and weeks 1, 5, 9, 13, and 17. The primary outcome measures were the Yale-Brown Obsessive Compulsive Scale and Clinical Global Improvement scale.
Results: For the 12 study completers, pre- and posttreatment analyses revealed significant improvements (P < .05) on clinician- and self-rated measures of obsessive-compulsive disorder symptoms and quality of life. Among the 12 completers, more than one-half (n = 7) satisfied full medication response criteria. Intention-to-treat analyses (n = 20) showed similar improvements (P < .05) on primary and secondary study outcome measures.
Conclusion: The results of this study suggest that duloxetine may provide a significant reduction in symptoms for patients with obsessive-compulsive disorder.
C1 [Dougherty, Darin D.; Corse, Andrew K.; Chou, Tina; Duffy, Amanda; Arulpragasam, Amanda R.; Deckersbach, Thilo] Massachusetts Gen Hosp, Div Neurotherapeut, Dept Psychiat, Charlestown, MA USA.
[Dougherty, Darin D.; Jenike, Michael A.; Keuthen, Nancy J.] Massachusetts Gen Hosp, OCD, Boston, MA 02114 USA.
[Dougherty, Darin D.; Jenike, Michael A.; Keuthen, Nancy J.] Massachusetts Gen Hosp, Related Disorders Program, Boston, MA 02114 USA.
[Chou, Tina] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Duffy, Amanda] Brown Univ, Dept Neurosci, Providence, RI 02912 USA.
RP Dougherty, DD (reprint author), Massachusetts Gen Hosp, Div Neurotherapeut, 149 13th St,Room 2612, Charlestown, MA 02129 USA.
EM ddougherty@partners.org
FU Eli Lilly and Company
FX This study was supported by a research grant from Eli Lilly and Company.
NR 21
TC 1
Z9 1
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JAN
PY 2015
VL 18
IS 2
DI 10.1093/ijnp/pyu062
PG 4
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA CF4OS
UT WOS:000352530300017
ER
PT J
AU Wisse, LEM
Reijmer, YD
ter Telgte, A
Kuijf, HJ
Leemans, A
Luijten, PR
Koek, HL
Geerlings, MI
Biessels, GJ
AF Wisse, Laura E. M.
Reijmer, Yael D.
ter Telgte, Annemieke
Kuijf, Hugo J.
Leemans, Alexander
Luijten, Peter R.
Koek, Huiberdina L.
Geerlings, Mirjam I.
Biessels, Geert Jan
CA Utrecht Vasc Cognitive Impairment
TI Hippocampal Disconnection in Early Alzheimer's Disease: A 7 Tesla MRI
Study
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; diffusion magnetic resonance imaging; fornix;
hippocampus; mild cognitive impairment; subiculum
ID MILD COGNITIVE IMPAIRMENT; TENSOR IMAGING TRACTOGRAPHY; ASSOCIATION
WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; CINGULUM BUNDLE;
RHESUS-MONKEY; DIFFUSION MRI; MATTER; VOLUME
AB Background: In patients with Alzheimer's disease (AD), atrophy of the entorhinal cortex (ERC) and hippocampal formation may induce degeneration of connecting white matter tracts.
Objective: We examined the association of hippocampal subfield and ERC atrophy at 7 tesla MRI with fornix and parahippocampal cingulum (PHC) microstructure in patients with early AD.
Methods: Twenty-five patients with amnestic mild cognitive impairment (aMCI) (n = 15) or early AD (n = 10) and 17 controls underwent 3 tesla diffusion MRI to obtain fractional anisotropy (FA) of the fornix and PHC and 7 tesla MRI to obtain ERC and hippocampal subfield volumes. Linear regression analyses were performed, adjusted for age, gender, and intracranial volume.
Results: Fornix FA was significantly lower and subiculum, cornu ammonis (CA) 1, and dentate gyrus & CA4 volume were significantly smaller in patients with MCI or AD as compared to controls. In patients with MCI or AD, fornix FA was positively associated with subiculum volume (beta = 0.53, 95% CI 0.10; 0.96), but not with ERC/other subfield volumes. PHC FA was not associated with ERC/subfield volumes.
Conclusion: These findings indicate that in early AD subiculum atrophy is associated with lower FA of the fornix, which primarily consists of axons originating in the subiculum. This suggests that degeneration of subicular cell bodies and their axons are related processes in early AD.
C1 [Wisse, Laura E. M.; Reijmer, Yael D.; ter Telgte, Annemieke; Biessels, Geert Jan] Univ Med Ctr Utrecht, Dept Neurol, Brain Ctr Rudolf Magnus, NL-3508 GA Utrecht, Netherlands.
[Wisse, Laura E. M.; Geerlings, Mirjam I.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands.
[Reijmer, Yael D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, J Philip Kistler Stroke Ctr, Boston, MA USA.
[Kuijf, Hugo J.; Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, NL-3508 GA Utrecht, Netherlands.
[Luijten, Peter R.] Univ Med Ctr Utrecht, Dept Radiol, NL-3508 GA Utrecht, Netherlands.
[Koek, Huiberdina L.] Univ Med Ctr Utrecht, Dept Geriatr, NL-3508 GA Utrecht, Netherlands.
RP Biessels, GJ (reprint author), Univ Med Ctr Utrecht, Dept Neurol, G03-232,POB 85500, NL-3508 GA Utrecht, Netherlands.
EM g.j.biessels@umcutrecht.nl
RI Leemans, Alexander/A-1784-2011;
OI de Bresser, Jeroen/0000-0003-0759-8407
FU VIDI grant from ZonMw [91711384]; Netherlands Organisation for Health
Research and Development; Netherlands Heart Foundation [2010T073]; VIDI
grant from the Netherlands Organization for Scientific Research (NWO)
[917-66-311, 639.072.411]
FX The research of GJB was supported by a VIDI grant 91711384 from ZonMw,
The Netherlands Organisation for Health Research and Development and
grant 2010T073 from the Netherlands Heart Foundation. The research of
MIG was supported by a VIDI grant from the Netherlands Organization for
Scientific Research (NWO: project no. 917-66-311). The research of AL is
supported by a VIDI grant 639.072.411 from the Netherlands Organization
for Scientific Research (NWO).
NR 55
TC 10
Z9 10
U1 1
U2 9
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 45
IS 4
BP 1247
EP 1256
DI 10.3233/JAD-142994
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA CF8NQ
UT WOS:000352819200023
PM 25697703
ER
PT B
AU Bilezikian, JP
Marcus, R
Levine, MA
Marcocci, C
Potts, JT
Silverberg, SJ
AF Bilezikian, John P.
Marcus, Robert
Levine, Michael A.
Marcocci, Claudio
Potts, John T.
Silverberg, Shonni J.
BE Bilezikian, JP
TI THE PARATHYROIDS BASIC AND CLINICAL CONCEPTS Preface to the Third
Edition
SO PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION
LA English
DT Editorial Material; Book Chapter
C1 [Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, Dept Med, Metab Bone Dis Unit,Div Endocrinol, New York, NY 10027 USA.
[Marcus, Robert] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
[Levine, Michael A.] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA.
[Levine, Michael A.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Marcocci, Claudio] Univ Pisa, Dept Clin & Expt Med, Univ Hosp Pisa, Pisa, Italy.
[Potts, John T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Silverberg, Shonni J.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA.
RP Bilezikian, JP (reprint author), Columbia Univ, Coll Phys & Surg, Dept Med, Metab Bone Dis Unit,Div Endocrinol, New York, NY 10027 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-397790-8; 978-0-12-397166-1
PY 2015
BP XIX
EP XX
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BC2OR
UT WOS:000351154500001
ER
PT B
AU Mannstadt, M
Kronenberg, HM
AF Mannstadt, Michael
Kronenberg, Henry M.
BE Bilezikian, JP
TI Parathyroid Hormone Gene Structure, Evolution, and Regulation
SO PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION
LA English
DT Article; Book Chapter
ID FAMILIAL ISOLATED HYPOPARATHYROIDISM; MESSENGER-RIBONUCLEIC-ACID;
PROTEIN-COUPLED-RECEPTORS; PREPROPARATHYROID HORMONE;
NUCLEOTIDE-SEQUENCE; RNA STABILITY; VITAMIN-D; IN-VITRO; TRANSCRIPTIONAL
REGULATION; 3'-UNTRANSLATED REGION
C1 [Mannstadt, Michael; Kronenberg, Henry M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02163 USA.
RP Mannstadt, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02163 USA.
NR 72
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-397790-8; 978-0-12-397166-1
PY 2015
BP 37
EP 44
DI 10.1016/B978-0-12-397166-1.00002-3
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BC2OR
UT WOS:000351154500006
ER
PT B
AU Gardella, TJ
AF Gardella, Thomas J.
BE Bilezikian, JP
TI Interactions of PTH with Receptors and Signaling
SO PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION
LA English
DT Article; Book Chapter
ID PARATHYROID-HORMONE-RECEPTOR; PROTEIN-COUPLED-RECEPTOR;
(PTH)/PTH-RELATED PEPTIDE RECEPTOR; CORTICOTROPIN-RELEASING-FACTOR;
PHOTOAFFINITY CROSS-LINKING; N-TERMINAL REGION; JANSENS METAPHYSEAL
CHONDRODYSPLASIA; EXTRACELLULAR LOOP REGIONS; AMINO ACID SEQUENCE;
CLASS-B GPCRS
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02163 USA.
RP Gardella, TJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02163 USA.
NR 141
TC 3
Z9 3
U1 0
U2 0
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-397790-8; 978-0-12-397166-1
PY 2015
BP 65
EP 80
DI 10.1016/B978-0-12-397166-1.00004-7
PG 16
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BC2OR
UT WOS:000351154500008
ER
PT B
AU Bilezikian, JP
Brandi, ML
Eastell, R
Silverberg, SJ
Udelsman, R
Marcocci, C
Potts, JT
AF Bilezikian, John P.
Brandi, Maria Luisa
Eastell, Richard
Silverberg, Shonni J.
Udelsman, Robert
Marcocci, Claudio
Potts, John T., Jr.
BE Bilezikian, JP
TI Guidelines for the Management of Asymptomatic Primary
Hyperparathyroidism
SO PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION
LA English
DT Article; Book Chapter
ID MILD PRIMARY HYPERPARATHYROIDISM; NORMOCALCEMIC PRIMARY
HYPERPARATHYROIDISM; VITAMIN-D DEFICIENCY; POSTMENOPAUSAL WOMEN;
PARATHYROID-HORMONE; NEUROPSYCHOLOGICAL SYMPTOMS; IMMUNORADIOMETRIC
ASSAY; CLINICAL UTILITY; ORAL ALENDRONATE; BONE
C1 [Bilezikian, John P.; Silverberg, Shonni J.] Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA.
[Brandi, Maria Luisa] Univ Florence, Dept Surg & Translat Med, Bone Metab Dis Unit, Florence, Italy.
[Eastell, Richard] Univ Sheffield, Sheffield, S Yorkshire, England.
[Udelsman, Robert] Yale Univ, Sch Med, Dept Surg, Sect Endocrine Surg, New Haven, CT 06510 USA.
[Marcocci, Claudio] Univ Pisa, Univ Hosp Pisa, Dept Clin & Expt Med, Pisa, Italy.
[Potts, John T., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Bilezikian, JP (reprint author), Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA.
NR 60
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-397790-8; 978-0-12-397166-1
PY 2015
BP 489
EP 497
DI 10.1016/B978-0-12-397166-1.00034-5
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BC2OR
UT WOS:000351154500037
ER
PT B
AU Silve, C
Juppner, H
AF Silve, Caroline
Jueppner, Harald
BE Bilezikian, JP
TI Genetic Disorders Caused by Mutations in the PTH/PTHrP Receptor and
Downstream Effector Molecules
SO PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION
LA English
DT Article; Book Chapter
ID (PTH)/PTH-RELATED PEPTIDE RECEPTOR; HORMONE-RELATED PEPTIDE; JANSENS
METAPHYSEAL CHONDRODYSPLASIA; FAMILIAL ISOLATED HYPOPARATHYROIDISM;
BLOMSTRAND LETHAL OSTEOCHONDRODYSPLASIA; DEPENDENT PROTEIN-KINASE;
AUTOSOMAL-DOMINANT HYPOPARATHYROIDISM; ALBRIGHTS HEREDITARY
OSTEODYSTROPHY; EXTRACELLULAR CA2+-SENSING RECEPTOR; ADVANCED SKELETAL
MATURATION
C1 [Silve, Caroline] Hop Bicetre, INSERM, U986, Paris, France.
[Silve, Caroline] Hop Bicetre, Ctr Reference Malad Rares Calcium & Phosphore, Paris, France.
[Silve, Caroline] Hop Bichat Claude Bernard, Lab Biochim Hormonale & Genet, F-75877 Paris 18, France.
[Jueppner, Harald] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA.
[Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA USA.
[Jueppner, Harald] Massachusetts Gen Hosp, MassGen Hosp Children, Pediat Nephrol, Boston, MA 02114 USA.
RP Silve, C (reprint author), Hop Bicetre, INSERM, U986, Paris, France.
NR 156
TC 1
Z9 1
U1 0
U2 0
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-397790-8; 978-0-12-397166-1
PY 2015
BP 587
EP 605
DI 10.1016/B978-0-12-397166-1.00040-0
PG 19
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BC2OR
UT WOS:000351154500043
ER
PT B
AU Mannstadt, M
Mitchell, DM
AF Mannstadt, Michael
Mitchell, Deborah M.
BE Bilezikian, JP
TI Clinical Manifestations of Hypoparathyroidism
SO PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION
LA English
DT Article; Book Chapter
ID BASAL GANGLIA CALCIFICATION; CALCIUM-SENSING RECEPTOR; HORMONE 2
RECEPTOR; BONE GLA-PROTEIN; IDIOPATHIC HYPOPARATHYROIDISM;
PARATHYROID-HORMONE; HYPOCALCEMIC MYOPATHY; VITAMIN-D; NEUROLOGICAL
MANIFESTATIONS; SURGICAL HYPOPARATHYROIDISM
C1 [Mannstadt, Michael; Mitchell, Deborah M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02138 USA.
[Mitchell, Deborah M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Endocrine Unit, Boston, MA USA.
RP Mannstadt, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02138 USA.
OI Mitchell, Deborah/0000-0003-0364-9107
NR 128
TC 2
Z9 2
U1 0
U2 0
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-397790-8; 978-0-12-397166-1
PY 2015
BP 761
EP 770
DI 10.1016/B978-0-12-397166-1.00053-9
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BC2OR
UT WOS:000351154500056
ER
PT B
AU Leder, BZ
AF Leder, Benjamin Z.
BE Bilezikian, JP
TI Combination Osteoporosis Therapy with Parathyroid Hormone
SO PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION
LA English
DT Article; Book Chapter
ID BONE-MINERAL DENSITY; RANDOMIZED CONTROLLED-TRIAL; FRACTURE RISK
REDUCTION; POSTMENOPAUSAL WOMEN; OVARIECTOMIZED RATS; TERIPARATIDE
TREATMENT; REPLACEMENT THERAPY; VERTEBRAL FRACTURE; ZOLEDRONIC ACID;
OSTEOCLAST DIFFERENTIATION
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Endocrine Unit, Boston, MA 02138 USA.
RP Leder, BZ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Endocrine Unit, Boston, MA 02138 USA.
NR 75
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-397790-8; 978-0-12-397166-1
PY 2015
BP 853
EP 863
DI 10.1016/B978-0-12-397166-1.00061-8
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BC2OR
UT WOS:000351154500064
ER
PT J
AU Choi, JW
Kim, P
Kim, JK
Kim, YR
Fukumura, D
Yun, SH
AF Choi, Jin Woo
Kim, Pilhan
Kim, Jun Ki
Kim, Yi Rang
Fukumura, Dai
Yun, Seok Hyun
TI Longitudinal Tracing of Spontaneous Regression and Anti-angiogenic
Response of Individual Microadenomas during Colon Tumorigenesis
SO THERANOSTICS
LA English
DT Article
DE Angiogenesis; tumorigenesis; colon tumor
ID HEREDITARY COLORECTAL-CANCER; GROWTH-FACTOR RECEPTOR-2; ABERRANT CRYPT
FOCI; IN-VIVO; MOUSE MODEL; SURVIVAL; THERAPY; ENDOMICROSCOPY;
CARCINOGENESIS; CARCINOMATOSIS
AB Angiogenesis is essential for the progression of cancer, but its involvement in the initial phase of colon tumorigenesis is not well understood. Using intravital endomicroscopy, we visualized the natural history of early pre-tumorous lesions and adenomas in the colon of conditional Apc-knockout and Apc/Kras double mutant mouse models. Early lesions emerged about 4 weeks after the onset of somatic mutations, accompanying vascular dilation when the size of lesions reached about 200 mu m, but most lesions regressed spontaneously and cleared within 10 weeks after their emergence. Anti-angiogenic treatments with vascular endothelial growth factor receptor (VEGFR) antagonists reduced the size of the early lesions and the number of polyps. We found surprisingly that anti-angiogenic treatments delayed the natural clearance of transient lesions by up to several weeks in both genetic models. The results represent the previously unexpected role of early angiogenesis on the spontaneous regression of early-stage colon tumors.
C1 [Choi, Jin Woo; Yun, Seok Hyun] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Choi, Jin Woo; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Choi, Jin Woo] Wonkwang Univ, Dept Pharmacol, Iksan 570749, Chonbuk, South Korea.
[Choi, Jin Woo] Wonkwang Univ, Dent Res Inst, Sch Dent, Grad Sch,Dept Smart Life Care Convergence, Iksan 570749, Chonbuk, South Korea.
[Choi, Jin Woo] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon 443270, Gyeonggi Do, South Korea.
[Kim, Pilhan; Kim, Yi Rang; Yun, Seok Hyun] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol, Taejon 305701, South Korea.
[Kim, Jun Ki] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Taejon 305701, South Korea.
[Kim, Yi Rang] Asan Med Ctr, Asan Inst Life Sci, Biomed Engn Res Ctr, Seoul 138736, South Korea.
[Kim, Yi Rang] Univ Ulsan, Coll Med, Seoul 138736, South Korea.
[Kim, Yi Rang] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul 138736, South Korea.
[Fukumura, Dai] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA.
RP Choi, JW (reprint author), Harvard Univ, Sch Med, 40 Blossom St, Boston, MA 02114 USA.
EM jinwoochoi@wku.ac.kr; syun@hms.harvard.edu
RI Kim, Pilhan/C-1836-2011
OI Kim, Pilhan/0000-0001-8388-1840
FU National Institutes of Health [U54CA143837, P01CA080124, P01HL120839,
P41-EB015903]; National Research Foundation of Korea [2008-0062484,
2011K000864, 2012M3A6A4054261, 2013M3A6A4072626, 2014R1A1A1002431]
FX This work was supported by grants from the National Institutes of Health
(U54CA143837, P01CA080124, P01HL120839, P41-EB015903) and the National
Research Foundation of Korea (2008-0062484, 2011K000864,
2012M3A6A4054261, 2013M3A6A4072626 and 2014R1A1A1002431)
NR 31
TC 0
Z9 0
U1 0
U2 0
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2015
VL 5
IS 7
BP 724
EP 732
DI 10.7150/thno.10734
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CG1VX
UT WOS:000353064500006
PM 25897337
ER
PT J
AU Mathew, AR
Cook, JW
Japuntich, SJ
Leventhal, AM
AF Mathew, Amanda R.
Cook, Jessica W.
Japuntich, Sandra J.
Leventhal, Adam M.
TI Post-Traumatic Stress Disorder Symptoms, Underlying Affective
Vulnerabilities, and Smoking for Affect Regulation
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
AB Background and ObjectivesOpioid dependent patients are hospitalized frequently. We aimed to determine if initiation of buprenorphine treatment during hospitalization facilitates entry into treatment following discharge.
MethodsRetrospective case series (n=47).
ResultsTwenty-two (46.8%) patients successfully initiated buprenorphine treatment within 2 months of discharge. Those patients obtaining a referral to a specific program were more successful in continuing treatment, but this difference did not reach statistical significance (59.1% vs 39.1%, p=0.18).
Discussion and ConclusionsHospitalization may be an important opportunity to engage opioid dependent patients to initiate buprenorphine treatment.
Scientific SignificanceThis study provides provisional support for utilizing buprenorphine for hospitalized patients. (Am J Addict 2015;24:10-14)
C1 [Mathew, Amanda R.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Mathew, Amanda R.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Cook, Jessica W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Japuntich, Sandra J.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Psychol, Los Angeles, CA 90033 USA.
RP Mathew, AR (reprint author), Med Univ S Carolina, Dept Neurosci, 67 President St,Room 565 North,MSC 861, Charleston, SC 29425 USA.
EM mathea@musc.edu
FU National Institute on Drug Abuse, Bethesda, MD [R01-DA026831,
K08-DA025041]; National Institute on Drug Abuse [T32 DA007288]; United
States Department of Veterans Affairs Clinical Sciences Research and
Development Service [1IK2CX000918-01A1]
FX This work was supported by grants R01-DA026831 and K08-DA025041 to Dr.
Leventhal from the National Institute on Drug Abuse, Bethesda, MD. Dr
Mathew is supported by National Institute on Drug Abuse grant T32
DA007288. This work was supported in part by Career Development Award
(Japuntich) # 1IK2CX000918-01A1 from the United States Department of
Veterans Affairs Clinical Sciences Research and Development Service. The
contents do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 0
TC 2
Z9 2
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD JAN
PY 2015
VL 24
IS 1
BP 39
EP 46
DI 10.1111/ajad.12170
PG 8
WC Substance Abuse
SC Substance Abuse
GA CE7NZ
UT WOS:000352029900007
PM 25823634
ER
PT J
AU Batki, SL
Schmeling, B
Lasher, B
Pennington, D
Herbst, E
Plaut, Z
Striebel, J
Vrana, S
Straznickas, J
AF Batki, Steven L.
Schmeling, Brandi
Lasher, Brooke
Pennington, David
Herbst, Ellen
Plaut, Zachary
Striebel, Joan
Vrana, Sally
Straznickas, John
TI Combined Naltrexone and Topiramate Treatment of Veterans with Alcohol
Use Disorder: A Case Series
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD JAN
PY 2015
VL 24
IS 1
BP 63
EP 64
PG 2
WC Substance Abuse
SC Substance Abuse
GA CE7NZ
UT WOS:000352029900027
ER
PT J
AU Wilens, T
Zulauf, C
Martelon, M
AF Wilens, Timothy
Zulauf, Courtney
Martelon, Marykate
TI Characteristics of Young Adults Who Misuse Stimulant Medications
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Wilens, Timothy; Zulauf, Courtney; Martelon, Marykate] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wilens, Timothy] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
FU NIH [K24 DA016264, R01 DA12945]
FX NIH grants K24 DA016264 and R01 DA12945.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD JAN
PY 2015
VL 24
IS 1
BP 68
EP 69
PG 2
WC Substance Abuse
SC Substance Abuse
GA CE7NZ
UT WOS:000352029900038
ER
PT J
AU Wilens, TE
Zulauf, C
Ryland, D
Carrellas, N
Catalina-Wellington, I
AF Wilens, Timothy E.
Zulauf, Courtney
Ryland, Denece
Carrellas, Nicholas
Catalina-Wellington, Isela
TI Prescription Medication Misuse among Opioid Abusers
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Wilens, Timothy E.; Zulauf, Courtney; Carrellas, Nicholas] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wilens, Timothy E.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Ryland, Denece; Catalina-Wellington, Isela] Andrew House Detox Ctr, North Quincy, MA USA.
FU NIDA
FX Dr. Zulauf, Ms. Ryland, Mr. Carrellas, and Ms. Catalina-Wellington have
nothing to disclose. Dr. Wilens has received grant support from NIDA and
has served as a consultant for Ethymics/Neurovance, NIDA, Theravance,
the U.S. National Football League, and TRIS. Dr. Wilens provided
clinical services to U.S. Minor/Major League Baseball, and Bay Cove
Human Services. Dr. Wilens has published a book with Guilford Press. Dr.
Wilens currently serves as the Director of the Center for Addiction
Medicine at Massachusetts General Hospital.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD JAN
PY 2015
VL 24
IS 1
BP 68
EP 68
PG 1
WC Substance Abuse
SC Substance Abuse
GA CE7NZ
UT WOS:000352029900037
ER
PT J
AU Wilens, T
Zulauf, C
Martelon, M
AF Wilens, Timothy
Zulauf, Courtney
Martelon, Marykate
TI Substance and Nicotine Use in Young Adults with Bipolar Disorder:
Initial Findings of a Controlled Longitudinal Study
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Wilens, Timothy; Zulauf, Courtney; Martelon, Marykate] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wilens, Timothy] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
FU [R01DA12945]
FX R01DA12945
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD JAN
PY 2015
VL 24
IS 1
BP 69
EP 69
PG 1
WC Substance Abuse
SC Substance Abuse
GA CE7NZ
UT WOS:000352029900039
ER
PT J
AU Jha, MK
Abele, M
Brown, J
AF Jha, Manish K.
Abele, Misoo
Brown, Julie
TI Motivational Interviewing Education of General Psychiatry Residents
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Jha, Manish K.] North Texas State Hosp, BMT Program, Vernon, TX USA.
[Abele, Misoo] Portland VA Med Ctr, Portland, OR USA.
[Brown, Julie] VA North Texas Med Ctr, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD JAN
PY 2015
VL 24
IS 1
BP 73
EP 73
PG 1
WC Substance Abuse
SC Substance Abuse
GA CE7NZ
UT WOS:000352029900046
ER
PT J
AU Lache, D
Ascher, M
Wassef, T
Dhopesh, V
AF Lache, Daniel
Ascher, Michael
Wassef, Tamer
Dhopesh, Vasant
TI Prognosis of Cerebellar Ataxia in Alcohol Dependent Patients: A Case
Report
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 Univ Penn, Philadelphia, PA 19104 USA.
Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD JAN
PY 2015
VL 24
IS 1
BP 75
EP 76
PG 2
WC Substance Abuse
SC Substance Abuse
GA CE7NZ
UT WOS:000352029900051
ER
PT J
AU Santa Ana, E
LaRowe, S
Lamb, K
Tompkins, M
Hartwell, K
AF Santa Ana, Elizabeth
LaRowe, Steve
Lamb, Kayla
Tompkins, Michelle
Hartwell, Karen
TI Impact of Group Motivational Interviewing on Enhancing Treatment
Engagement for Homeless Veterans with Nicotine Dependence and other
Substance Use Disorders: A Pilot Investigation
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 Ralph H Johnson VA Med Ctr, Charleston, SC USA.
Med Univ S Carolina, Charleston, SC USA.
FU American Cancer Society, Institutional Research Grant [IRG-97-219-14]
FX American Cancer Society, Institutional Research Grant #IRG-97-219-14.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD JAN
PY 2015
VL 24
IS 1
BP 81
EP 82
PG 2
WC Substance Abuse
SC Substance Abuse
GA CE7NZ
UT WOS:000352029900063
ER
PT S
AU Fang, A
Wilhelm, S
AF Fang, Angela
Wilhelm, Sabine
BE Cannon, TD
Widiger, T
TI Clinical Features, Cognitive Biases, and Treatment of Body Dysmorphic
Disorder
SO ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 11
SE Annual Review of Clinical Psychology
LA English
DT Article; Book Chapter
DE body image; cognitive bias; cognitive-behavioral model;
cognitive-behavioral therapy
ID OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED-TRIAL; SOCIAL
ANXIETY DISORDER; EMOTION RECOGNITION DEFICITS; POPULATION-BASED SURVEY;
DOMAIN CRITERIA RDOC; BEHAVIORAL THERAPY; D-CYCLOSERINE; RESPONSE
PREVENTION; IMAGINED UGLINESS
AB In the past two decades, research advances have enhanced our understanding of the clinical features, cognitive biases, and treatment of body dysmorphic disorder (BDD). In this review, we critically examine the current state of the evidence on the proposed cognitive and emotional processing mechanisms of BDD. We describe how major findings in these areas made unique contributions to the development of an empirically informed cognitive-behavioral model of BDD, which in turn facilitated the translation of research to treatment strategies. Finally, we outline important areas of future research.
C1 [Fang, Angela; Wilhelm, Sabine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
RP Fang, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
EM swilhelm@mgh.harvard.edu
NR 120
TC 7
Z9 7
U1 5
U2 23
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 1548-5943
BN 978-0-8243-3911-1
J9 ANNU REV CLIN PSYCHO
JI Annu. Rev. Clin. Psychol.
PY 2015
VL 11
BP 187
EP 212
DI 10.1146/annurev-clinpsy-032814-112849
PG 26
WC Psychology, Clinical; Psychology
SC Psychology
GA BC3WH
UT WOS:000352014000009
PM 25581240
ER
PT J
AU Castellanos-Rizaldos, E
Richardson, K
Lin, R
Wu, G
Makrigiorgos, MG
AF Castellanos-Rizaldos, Elena
Richardson, Katherine
Lin, Rui
Wu, Grant
Makrigiorgos, Mike G.
TI Single-Tube, Highly Parallel Mutation Enrichment in Cancer Gene Panels
by Use of Temperature-Tolerant COLD-PCR
SO CLINICAL CHEMISTRY
LA English
DT Article
ID CIRCULATING TUMOR DNA; KRAS MUTATIONS; RARE MUTATIONS; MOLECULAR
DIAGNOSTICS; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; SENSITIVITY;
IDENTIFICATION; AMPLIFICATION; PRODUCTS
AB BACKGROUND: Multiplexed detection of low-level mutations presents a technical challenge for many technologies, including cancer gene panels used for targeted-resequencing. Analysis of mutations below approximately 2%-5% abundance in tumors with heterogeneity, samples with stromal contamination, or biofluids is problematic owing to increased noise from sequencing errors. Technologies that reduce noise via deep sequencing unavoidably reduce throughput and increase cost. Here we provide proof of principle that coamplification at lower denaturation temperature (COLD)-PCR technology enables multiplex low-level mutation detection in cancer gene panels while retaining throughput.
METHODS: We have developed a multiplex temperature-tolerant COLD-PCR (fast-TT-COLD-PCR) approach that uses cancer gene panels developed for massively parallel sequencing. After multiplex preamplification from genomic DNA, we attach tails to all amplicons and perform fast-TT-COLD-PCR. This approach gradually increases denaturation temperatures in a step-wise fashion, such that all possible denaturation temperatures are encompassed. By introducing modified nucleotides, fast-COLD-PCR is adapted to enrich for melting temperature (T-m)-increasing mutations over all amplicons, in a single tube. Therefore, in separate reactions, both T-m-decreasing and T-m-increasing mutations are enriched.
RESULTS: Using custom-made and commercial gene panels containing 8, 50, 190, or 16 000 amplicons, we demonstrate that fast-TT-COLD-PCR enriches mutations on all examined targets simultaneously. Incorporation of deoxyinosine triphosphate (dITP)/2,6-diaminopurine triphosphate (dDTP) in place of deoxyguanosine triphosphate (dGTP)/deoxyadenosine triphosphate (dATP) enables enrichment of T-m-increasing mutations. Serial dilution experiments demonstrate a limit of detection of approximately 0.01%-0.1% mutation abundance by use of Ion-Torrent and 0.1%-0.3% by use of Sanger sequencing.
CONCLUSIONS: Fast-TT-COLD-PCR improves the limit of detection of cancer gene panels by enabling mutation enrichment in multiplex, single-tube reactions. This novel adaptation of COLD-PCR converts subclonal mutations to clonal, thereby facilitating detection and subsequent mutation sequencing. (C) 2014 American Association for Clinical Chemistry
C1 [Castellanos-Rizaldos, Elena; Makrigiorgos, Mike G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div DNA Repair & Genome Stabil, Boston, MA 02115 USA.
[Makrigiorgos, Mike G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div Med Phys & Biophys, Boston, MA 02115 USA.
[Richardson, Katherine; Lin, Rui; Wu, Grant] Transgenomic Inc, Omaha, NE USA.
RP Makrigiorgos, MG (reprint author), Brigham & Womens Hosp, Dana Farber Brigham & Womens Canc Ctr, Radiat Therapy, Level L2,75 Francis St, Boston, MA 02115 USA.
EM mmakrigiorgos@lroc.harvard.edu
FU National Cancer Institute [1 R41 CA180389-01, 1 R21 CA175542-01A1]
FX K. Richardson, National Cancer Institute grant 1 R41 CA180389-01; G.M.
Makrigiorgos, National Cancer Institute grants 1 R41 CA180389-01 and 1
R21 CA175542-01A1.
NR 38
TC 1
Z9 2
U1 8
U2 19
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD JAN
PY 2015
VL 61
IS 1
BP 267
EP 277
DI 10.1373/clinchem.2014.228361
PG 11
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA CE8ZS
UT WOS:000352133500037
PM 25297854
ER
PT J
AU Yeo, S
An, KS
Hong, YM
Choi, YG
Rosen, B
Kim, SH
Lim, S
AF Yeo, Sujung
An, Keon Sang
Hong, Yeon-Mi
Choi, Yeong-Gon
Rosen, Bruce
Kim, Sung-Hoon
Lim, Sabina
TI Neuroprotective changes in degeneration-related gene expression in the
substantia nigra following acupuncture in an MPTP mouse model of
Parkinsonism: Microarray analysis
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE Parkinson's disease; gene array; differentially expressed genes;
neurodegeneration; acupoints
ID V-LIKE ANTIGEN; TRYPTOPHAN-HYDROXYLASE; GABA TRANSPORTER; DISEASE;
SEROTONIN; PROLINE; NEURONS; CELLS; MICE; INHIBITOR
AB Parkinson's disease (PD) is a neurodegenerative disorder characterized by the death of dopamine-generating cells in the substantia nigra (SN). Acupuncture stimulation results in an enhanced survival of dopaminergic neurons in the SN in Parkinsonism animal models. The present study investigated changes in gene expression profiles measured using whole transcript array in the SN region related to the inhibitory effects of acupuncture in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Parkinsonism model. In this model, acupuncture stimulation at GB34 and LR3 attenuated the decrease in tyrosine hydroxylase in the SN region; stimulation at non-acupoints did not suppress this decrease. Gene array analysis revealed that 22 (10 annotated genes: Cdh1, Itih2, Mpzl2, Rdh9, Serping1, Slc6a13, Slc6a20a, Slc6a4, Tph2, and Ucma) probes that were up-regulated in MPTP animals relative to controls were exclusively down-regulated by acupuncture stimulation. In addition, 17 (two annotated genes: 4921530L21Rik and Gm13931) probes that were down-regulated in MPTP animals compared to controls were exclusively up-regulated by acupuncture stimulation. These findings indicate that the 39 probes (12 annotated genes) affected by MPTP and acupuncture may be responsible for the inhibitory effects of acupuncture on degeneration-related gene expression in the SN following damage induced by MPTP intoxication.
C1 [Yeo, Sujung; Hong, Yeon-Mi; Choi, Yeong-Gon; Lim, Sabina] Kyung Hee Univ, East West Med Res Inst, Res Grp Pain & Neurosci, WHO Collaborating Ctr Tradit Med, Seoul 130701, South Korea.
[Yeo, Sujung; An, Keon Sang; Hong, Yeon-Mi; Choi, Yeong-Gon; Rosen, Bruce; Kim, Sung-Hoon; Lim, Sabina] Kyung Hee Univ, Coll Korean Med, Dept Basic Korean Med Sci, Seoul 130701, South Korea.
[Rosen, Bruce] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Athinoula A Martinos Ctr Biomed Imagi, Boston, MA 02115 USA.
RP Lim, S (reprint author), Kyung Hee Univ, East West Med Res Inst, Res Grp Pain & Neurosci, WHO Collaborating Ctr Tradit Med, Seoul 130701, South Korea.
EM lims@khu.ac.kr
FU National Research Foundation of Korea - Korean Government [MEST]
[2007-0054931, NRF-2014R1A1A1004100]
FX This work was supported by a National Research Foundation of Korea grant
funded by the Korean Government [MEST] (No. 2007-0054931,
NRF-2014R1A1A1004100). The funders had no role in the study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 68
TC 2
Z9 2
U1 1
U2 6
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
RIBEIRAO PRET, BRAZIL
SN 1415-4757
EI 1678-4685
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PY 2015
VL 38
IS 1
BP 115
EP 127
DI 10.1590/S1415-475738120140137
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CF3KY
UT WOS:000352448600017
PM 25983633
ER
PT J
AU Alameddine, Y
Ellenbogen, JM
Bianchi, MT
AF Alameddine, Yvonne
Ellenbogen, Jeffrey M.
Bianchi, Matt T.
TI Sleep-Wake Time Perception Varies by Direct or Indirect Query
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Article
DE time perception; inconsistency; subjective; self-report
ID STATE MISPERCEPTION; DISORDER PATIENTS; CHRONIC INSOMNIA;
MEDICAL-CENTER; DURATION; APNEA
AB Study Objectives: The diagnosis of insomnia rests on self-report of difficulty initiating or maintaining sleep. However, subjective reports may be unreliable, and possibly may vary by the method of inquiry. We investigated this possibility by comparing within-individual response to direct versus indirect time queries after overnight polysomnography.
Methods: We obtained self-reported sleep-wake times via morning questionnaires in 879 consecutive adult diagnostic polysomnograms. Responses were compared within subjects (direct versus indirect query) and across groups defined by apnea-hypopnea index and by self-reported insomnia symptoms in presleep questionnaires. Direct queries required a time duration response, while indirect queries required clock times from which we calculated time durations.
Results: Direct and indirect queries of sleep latency were the same in only 41% of cases, and total sleep time queries matched in only 5.4%. For both latency and total sleep, the most common discrepancy involved the indirect value being larger than the direct response. The discrepancy between direct and indirect queries was not related to objective sleep metrics. The degree of discrepancy was not related to the presence of insomnia symptoms, although patients reporting insomnia symptoms showed underestimation of total sleep duration by direct response.
Conclusions: Self-reported sleep latency and total sleep time are often internally inconsistent when comparing direct and indirect survey queries of each measure. These discrepancies represent substantive challenges to effective clinical practice, particularly when diagnosis and management depends on self-reported sleep patterns, as with insomnia. Although self-reported sleep-wake times remains fundamental to clinical practice, objective measures provide clinically relevant adjunctive information.
C1 [Alameddine, Yvonne; Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Sleep Div, Boston, MA 02114 USA.
[Ellenbogen, Jeffrey M.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.
[Bianchi, Matt T.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA.
RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St,Wing 739, Boston, MA 02114 USA.
EM mtbianchi@partners.org
FU Department of Neurology, Massachusetts General Hospital; Young Clinician
Award, Center for Integration of Medicine and Innovative Technology;
Harvard Catalyst KL2 Medical Research Investigator Fellowship; Center
for Integration of Medicine and Innovative Technology
FX Support for this study was provided by the Department of Neurology,
Massachusetts General Hospital; Young Clinician Award, Center for
Integration of Medicine and Innovative Technology; Harvard Catalyst KL2
Medical Research Investigator Fellowship. Dr. Bianchi has consulting
agreement with Sunovion, is on the advisory board of Foramis and is a
co-inventor on a pending patent for a sleep monitoring device. Dr.
Bianchi receives funding from the Department of Neurology, Massachusetts
General Hospital, and a Young Clinician Award from the Center for
Integration of Medicine and Innovative Technology. The other authors
have indicated no financial conflicts of interest.
NR 25
TC 2
Z9 2
U1 1
U2 4
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 1550-9389
EI 1550-9397
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PY 2015
VL 11
IS 2
BP 123
EP U151
DI 10.5664/jcsm.4456
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA CE9CI
UT WOS:000352140800007
PM 25406269
ER
PT J
AU Bianchi, MT
AF Bianchi, Matt T.
TI Evidence that Home Apnea Testing does not Follow AASM Practice
Guidelines or Bayes' Theorem
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Letter
C1 [Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Sleep Div, Boston, MA 02114 USA.
RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Wang Neurol 7, 55 Fruit St, Boston, MA 02114 USA.
EM mtbianchi@partners.org
NR 3
TC 3
Z9 3
U1 0
U2 0
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 1550-9389
EI 1550-9397
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PY 2015
VL 11
IS 2
BP 189
EP 189
DI 10.5664/jcsm.4476
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA CE9CI
UT WOS:000352140800017
PM 25580609
ER
PT J
AU Wu, XJ
Wu, W
Pan, W
Wu, LM
Liu, KD
Zhang, HL
AF Wu, Xiujuan
Wu, Wei
Pan, Wei
Wu, Limin
Liu, Kangding
Zhang, Hong-Liang
TI Acute Necrotizing Encephalopathy: An Underrecognized Clinicoradiologic
Disorder
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID CEREBROSPINAL-FLUID; THALAMIC LESIONS; IMAGING FINDINGS; COMBINED
THERAPY; VIRUS-INFECTION; INFLUENZA; CHILDHOOD; CHILDREN; HYPOTHERMIA;
DIPHTHERIA
AB Acute necrotizing encephalopathy (ANE) is a rare but distinctive type of acute encephalopathy with global distribution. Occurrence of ANE is usually preceded by a virus-associated febrile illness and ensued by rapid deterioration. However, the causal relationship between viral infections and ANE and the exact pathogenesis of ANE remain unclear; both environmental and host factors might be involved. Most cases of ANE are sporadic and nonrecurrent, namely, isolated or sporadic ANE; however, few cases are recurrent and with familial episodes. The recurrent and familial forms of ANE were found to be incompletely autosomal-dominant. Further the missense mutations in the gene encoding the nuclear pore protein Ran Binding Protein 2 (RANBP2) were identified. Although the clinical course and the prognosis of ANE are diverse, the hallmark of neuroradiologic manifestation of ANE is multifocal symmetric brain lesions which are demonstrated by computed tomography (CT) or magnetic resonance imaging (MRI). The treatment of ANE is still under investigation. We summarize the up-to-date knowledge on ANE, with emphasis on prompt diagnosis and better treatment of this rare but fatal disease.
C1 [Wu, Xiujuan; Wu, Limin; Liu, Kangding; Zhang, Hong-Liang] Jilin Univ, Neurosci Ctr, Dept Neurol, Hosp 1, Changchun 130021, Peoples R China.
[Wu, Wei] Jilin Univ, Dept Neurovasc Surg, Hosp 1, Changchun 130021, Peoples R China.
[Pan, Wei] Jilin Univ, Sch Publ Hlth, Changchun 130021, Peoples R China.
[Wu, Limin] Harvard Univ, Sch Med, Neuroprotect Res Lab, Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
RP Zhang, HL (reprint author), Jilin Univ, Neurosci Ctr, Dept Neurol, Hosp 1, Xinmin St 71, Changchun 130021, Peoples R China.
EM hongliang.zhang@ki.se
FU Young Scholars Program of Norman Bethune Health Science Center of Jilin
University [2013205035]; Young Scholars Program of the First Hospital of
Jilin University [JDYY42013003]; Scientific Research Foundation for the
Returned Overseas Chinese Scholars [3C113BK73428]; State Education
Ministry; National Natural Science Foundation of China [81241147]
FX The work was supported by grants from Young Scholars Program of Norman
Bethune Health Science Center of Jilin University (no. 2013205035),
Young Scholars Program of the First Hospital of Jilin University (no.
JDYY42013003), the Scientific Research Foundation for the Returned
Overseas Chinese Scholars (3C113BK73428), State Education Ministry, and
the National Natural Science Foundation of China (no. 81241147).
NR 73
TC 2
Z9 2
U1 1
U2 2
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2015
AR 792578
DI 10.1155/2015/792578
PG 10
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA CF3KG
UT WOS:000352446800001
ER
PT J
AU Liu, G
Sprenger, C
Wu, PJ
Sun, SH
Uo, T
Haugk, K
Epilepsia, KS
Plymate, S
AF Liu, Gang
Sprenger, Cynthia
Wu, Pin-Jou
Sun, Shihua
Uo, Takuma
Haugk, Kathleen
Epilepsia, Kathryn Soriano
Plymate, Stephen
TI MED1 mediates androgen receptor splice variant induced gene expression
in the absence of ligand
SO ONCOTARGET
LA English
DT Article
ID RESISTANT PROSTATE-CANCER; ACTIVATED PROTEIN-KINASE; CELL-PROLIFERATION;
COREGULATORY ROLE; BREAST-CANCER; T-ANTIGEN; CASTRATION; OVEREXPRESSION;
PROGRESSION; GROWTH
AB The appearance of constitutively active androgen receptor splice variants (AR-Vs) has been proposed as one of the causes of castration-resistant prostate cancer (CRPC). However, the underlying mechanism of AR-Vs in CRPC transcriptional regulation has not been defined. A distinct transcriptome enriched with cell cycle genes, e.g. UBE2C, has been associated with AR-Vs, which indicates the possibility of an altered transcriptional mechanism when compared to full-length wild-type AR (AR(fl)). Importantly, a recent study reported the critical role of p-MED1 in enhancing UBE2C expression through a locus looping pattern, which only occurs in CRPC but not in androgen-dependent prostate cancer (ADPC). To investigate the potential correlation between AR-V and MED1, in the present study we performed protein co-immunoprecipitation, chromatin immunoprecipitation, and cell proliferation assays and found that MED1 is necessary for AR(v567es) induced UBE2C up-regulation and subsequent prostate cancer cell growth. Furthermore, p-MED1 is bound to AR(v567es) independent of full-length AR; p-MED1 has higher recruitment to UBE2C promoter and enhancer regions in the presence of AR(v567es). Our data indicate that p-MED1 serves as a key mediator in AR(v567es) induced gene expression and suggests a mechanism by which AR-Vs promote the development and progression of CRPC.
C1 [Liu, Gang; Sprenger, Cynthia; Wu, Pin-Jou; Sun, Shihua; Uo, Takuma; Epilepsia, Kathryn Soriano; Plymate, Stephen] Univ Washington, Dept Med, Seattle, WA 98104 USA.
[Sprenger, Cynthia; Haugk, Kathleen; Plymate, Stephen] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98104 USA.
RP Plymate, S (reprint author), Univ Washington, Dept Med, Seattle, WA 98104 USA.
EM splymate@u.washington.edu
FU National Cancer Institute Pacific Northwest Prostate Cancer Specialized
Program of Research Excellence (SPORE) [2 P50 CA 097186-07]; US Army
Medical Research and Materiel Command Prostate Cancer Research Programs
[W81XWH-11-1-0551, W81XWH-13-2-0093]; Department of Veterans Affairs;
[PO1 CA85859]; [P01 CA163227]
FX We would like to thank Dr. Qianben Wang for providing the UBE2C
luciferase reporter constructs and p-MED1 antibody. This work was
supported by the National Cancer Institute Pacific Northwest Prostate
Cancer Specialized Program of Research Excellence (SPORE; 2 P50 CA
097186-07 Project 5), PO1 CA85859, P01 CA163227, US Army Medical
Research and Materiel Command Prostate Cancer Research Programs
(W81XWH-11-1-0551 and W81XWH-13-2-0093), and Department of Veterans
Affairs, to S.R.P.
NR 55
TC 8
Z9 9
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 1
PY 2015
VL 6
IS 1
BP 288
EP 304
PG 17
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA CE8BE
UT WOS:000352065200024
PM 25481872
ER
PT J
AU Budczies, J
von Winterfeld, M
Klauschen, F
Bockmayr, M
Lennerz, JK
Denkert, C
Wolf, T
Warth, A
Dietel, M
Anagnostopoulos, I
Weichert, W
Wittschieber, D
Stenzinger, A
AF Budczies, Jan
von Winterfeld, Moritz
Klauschen, Frederick
Bockmayr, Michael
Lennerz, Jochen K.
Denkert, Carsten
Wolf, Thomas
Warth, Arne
Dietel, Manfred
Anagnostopoulos, Ioannis
Weichert, Wilko
Wittschieber, Daniel
Stenzinger, Albrecht
TI The landscape of metastatic progression patterns across major human
cancers
SO ONCOTARGET
LA English
DT Article
DE autopsy; metastasis; systemic disease; carcinoma; solid tumor; cancer;
survival
ID BREAST-CANCER; CONSECUTIVE PATIENTS; TUMOR-CELLS; AUTOPSY;
ADENOCARCINOMA; CARCINOMA; LUNG; EVOLUTION; NETWORKS; MELANOMA
AB The majority of patients with solid malignancies die from metastatic burden. However, our current understanding of the mechanisms and resulting patterns of dissemination is limited. Here, we analyzed patterns of metastatic progression across 16 major cancer types in a cohort of 1008 patients with metastatic cancer autopsied between 2000 and 2013 to assess cancer specific progression patterns of disease and related risk predictions. The frequency and location of metastases were evaluated in and across 1) 16 major cancers, 2) smoking- and non-smoking-related cancers and 3) adeno- and squamous cell carcinoma. Associations between primary and secondary sites were analyzed by the fractional and the relative risk methods. We detected significantly different cancer specific patterns of metastatic progression with specific relative risk profiles for secondary site involvement. Histology and smoking etiology influenced these patterns. Backward analysis showed that metastatic patterns help to predict unknown primary sites. Solid malignancies maintain a unique and recurrent organ tropism to specific secondary sites which does not appear to be strongly influenced by advances in cancer medicine as shown by comparison with previous data sets. The delineated landscape of metastatic progression patterns is a comprehensive data resource to both clinical and basic scientists which aids fostering new hypotheses for cancer research and cancer therapies.
C1 [Budczies, Jan; von Winterfeld, Moritz; Klauschen, Frederick; Bockmayr, Michael; Denkert, Carsten; Dietel, Manfred; Anagnostopoulos, Ioannis] Charite, Inst Pathol, Berlin, Germany.
[Budczies, Jan] German Canc Res Ctr, Heidelberg, Germany.
[Lennerz, Jochen K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA.
[Wolf, Thomas; Warth, Arne; Weichert, Wilko; Stenzinger, Albrecht] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany.
[Wittschieber, Daniel] Univ Hosp Munster, Inst Legal Med, Munster, Germany.
[Budczies, Jan; Denkert, Carsten; Wolf, Thomas; Weichert, Wilko] German Consortium Translat Canc Res DKTK, Heidelberg, Germany.
[Weichert, Wilko] Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
RP Stenzinger, A (reprint author), Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany.
EM jan.budczies@charite.de; albrecht.stenzinger@med.uni-heidelberg.de
RI Klauschen, Frederick/C-5637-2015
NR 50
TC 14
Z9 14
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 1
PY 2015
VL 6
IS 1
BP 570
EP 583
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA CE8BE
UT WOS:000352065200045
PM 25402435
ER
PT J
AU Almario, CV
Chey, W
Kaung, A
Whitman, C
Fuller, G
Reid, M
Nguyen, K
Bolus, R
Dennis, B
Encarnacion, R
Martinez, B
Talley, J
Modi, R
Agarwal, N
Lee, A
Kubomoto, S
Sharma, G
Bolus, S
Chang, L
Spiegel, BMR
AF Almario, Christopher V.
Chey, William
Kaung, Aung
Whitman, Cynthia
Fuller, Garth
Reid, Mark
Nguyen, Ken
Bolus, Roger
Dennis, Buddy
Encarnacion, Rey
Martinez, Bibiana
Talley, Jennifer
Modi, Rushaba
Agarwal, Nikhil
Lee, Aaron
Kubomoto, Scott
Sharma, Gobind
Bolus, Sally
Chang, Lin
Spiegel, Brennan M. R.
TI Computer-Generated Vs. Physician-Documented History of Present Illness
(HPI): Results of a Blinded Comparison
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID PATIENT-REPORTED OUTCOMES; GASTROINTESTINAL SYMPTOM SCALES; RECORDS
AB OBJECTIVES: Healthcare delivery now mandates shorter visits with higher documentation requirements, undermining the patient-provider interaction. To improve clinic visit efficiency, we developed a patient-provider portal that systematically collects patient symptoms using a computer algorithm called Automated Evaluation of Gastrointestinal Symptoms (AEGIS). AEGIS also automatically "translates" the patient report into a full narrative history of present illness (HPI). We aimed to compare the quality of computer-generated vs. physician-documented HPIs.
METHODS: We performed a cross-sectional study with a paired sample design among individuals visiting outpatient adult gastrointestinal (GI) clinics for evaluation of active GI symptoms. Participants first underwent usual care and then subsequently completed AEGIS. Each individual thereby had both a physician-documented and a computer-generated HPI. Forty-eight blinded physicians assessed HPI quality across six domains using 5-point scales: (i) overall impression, (ii) thoroughness, (iii) usefulness, (iv) organization, (v) succinctness, and (vi) comprehensibility. We compared HPI scores within patient using a repeated measures model.
RESULTS: Seventy-five patients had both computer-generated and physician-documented HPIs. The mean overall impression score for computer-generated HPIs was higher than physician HPIs (3.68 vs. 2.80; P < 0.001), even after adjusting for physician and visit type, location, mode of transcription, and demographics. Computer-generated HPIs were also judged more complete (3.70 vs. 2.73; P < 0.001), more useful (3.82 vs. 3.04; P < 0.001), better organized (3.66 vs. 2.80; P < 0.001), more succinct (3.55 vs. 3.17; P < 0.001), and more comprehensible (3.66 vs. 2.97; P < 0.001).
CONCLUSIONS: Computer-generated HPIs were of higher overall quality, better organized, and more succinct, comprehensible, complete, and useful compared with HPIs written by physicians during usual care in GI clinics.
C1 [Almario, Christopher V.; Kaung, Aung; Whitman, Cynthia; Fuller, Garth; Nguyen, Ken; Martinez, Bibiana; Talley, Jennifer; Modi, Rushaba; Agarwal, Nikhil; Lee, Aaron; Kubomoto, Scott; Sharma, Gobind; Spiegel, Brennan M. R.] Cedars Sinai Med Ctr, Div Gastroenterol, Los Angeles, CA 90048 USA.
[Almario, Christopher V.; Kaung, Aung; Reid, Mark; Martinez, Bibiana; Talley, Jennifer; Modi, Rushaba; Agarwal, Nikhil; Spiegel, Brennan M. R.] VA Greater Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA.
[Almario, Christopher V.; Modi, Rushaba; Agarwal, Nikhil; Chang, Lin] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA.
[Almario, Christopher V.; Whitman, Cynthia; Fuller, Garth; Reid, Mark; Nguyen, Ken; Bolus, Roger; Martinez, Bibiana; Talley, Jennifer; Bolus, Sally; Spiegel, Brennan M. R.] Cedars Sinai Ctr Outcomes Res & Educ, Los Angeles, CA 90048 USA.
[Chey, William] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA.
[Dennis, Buddy; Encarnacion, Rey] Univ Calif Los Angeles, Comp Technol Res Lab, Los Angeles, CA USA.
RP Spiegel, BMR (reprint author), Cedars Sinai Ctr Outcomes Res & Educ, Cedars Sinai Hlth Syst, Hlth Serv Res, Pacific Theaters Bldg,116 North Robertson Blvd, Los Angeles, CA 90048 USA.
EM brennan.spiegel@cshs.org
FU NIH/NIAMS [U01 AR057936A]; National Institutes of Health through the NIH
Roadmap for Medical Research Grant [AR052177]; National Institutes of
Health [NIH T32DK07180-39]; Ironwood Pharmaceuticals
FX This study was supported by NIH/NIAMS U01 AR057936A, the National
Institutes of Health through the NIH Roadmap for Medical Research Grant
(AR052177). Dr Almario was supported by a National Institutes of Health
T32 training grant (NIH T32DK07180-39) during his gastroenterology and
health services research training at UCLA. Support for the My GI Health
portal used in this study was obtained from Ironwood Pharmaceuticals.
NR 23
TC 5
Z9 5
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JAN
PY 2015
VL 110
IS 1
BP 170
EP 179
DI 10.1038/ajg.2014.356
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CE5ZJ
UT WOS:000351914700017
PM 25461620
ER
PT J
AU Anaya, HD
Butler, JN
Knapp, H
Chan, K
Conners, EE
Rumanes, SF
AF Anaya, Henry D.
Butler, Jaimi N.
Knapp, Herschel
Chan, Kee
Conners, Erin E.
Rumanes, Sophia F.
TI Implementing an HIV Rapid Testing-Linkage-to-Care Project Among Homeless
Individuals in Los Angeles County: A Collaborative Effort Between
Federal, County, and City Government
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID NEW-YORK-CITY; INJECTION-DRUG USERS; TUBERCULOSIS INFECTION;
EMERGENCY-DEPARTMENT; SAN-FRANCISCO; UNITED-STATES; SEROPREVALENCE;
ADULTS; RISK; PREVALENCE
AB Objectives. We developed and implemented an HIV rapid testing-linkage-to-care initiative between federal and local government.
Methods. We used mixed methodology; HIV testing data were collected on-site, and qualitative data were collected via telephone. We used postintervention stakeholder and staff interviews to evaluate barriers and facilitators to this initiative.
Results. We tested 817 individuals. We identified and confirmed 7 preliminary HIV positive individuals (0.86% seropositivity), 5 of whom were linked to care. Mean testing cost was $ 48.95 per client; cost per positive result was $ 5714.
Conclusions. This initiative can be used as a template for other health departments and research teams focusing on homelessness and mitigation of the HIV/ AIDS epidemic.
C1 [Anaya, Henry D.; Butler, Jaimi N.; Knapp, Herschel; Conners, Erin E.] VA Greater Los Angeles Healthcare Syst, VA Greater Los Angeles Hlth Serv Res & Dev IISR&D, Vet Affairs VA Qual Enhancement Res Initiat HIV &, Los Angeles, CA USA.
[Anaya, Henry D.; Butler, Jaimi N.; Knapp, Herschel; Conners, Erin E.] VA Greater Los Angeles Healthcare Syst, VA Greater Los Angeles Hlth Serv Res & Dev IISR&D, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA.
[Chan, Kee] Boston Univ, Dept Hlth Sci, Coll Hlth & Rehabil Sci, Sargent Coll, Boston, MA 02215 USA.
[Rumanes, Sophia F.] Cty Los Angeles Dept Publ Hlth, Div HIV & STD Programs, Los Angeles, CA USA.
RP Anaya, HD (reprint author), 11301 Wilshire Blvd 111G, Los Angeles, CA 90073 USA.
EM hanaya@ucla.edu
FU Gilead Sciences; David Geffen School of Medicine at the University of
California, Los Angeles; University of California
FX This research was funded by a Gilead Sciences grant awarded to H. D.
Anaya and supported by the David Geffen School of Medicine at the
University of California, Los Angeles.; The views and opinions expressed
in this article are those of the authors and do not necessarily
represent the views of Gilead Sciences or the University of California.
Gilead Sciences and the University of California supported this study
but had no input in the design or reporting or in the decision to submit
this article for publication.
NR 36
TC 2
Z9 2
U1 1
U2 2
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JAN
PY 2015
VL 105
IS 1
BP 85
EP 90
DI 10.2105/AJPH.2014.302213
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CE6BG
UT WOS:000351920100031
PM 25393202
ER
PT J
AU Wang, XL
Zhou, XH
AF Wang, Xueli
Zhou, Xiao-Hua
TI Some Results About Standardization for a Non Confounder in Estimators of
(log) Relative Risk
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE Confounding; Non confounder; Precision; Relative risk; Standardization
ID COLLAPSIBILITY; HOMOGENEITY
AB Confounding is very fundamental to the design and analysis of studies of causal effects. A variable is not a confounder if it is not a risk factor to disease or if it has the same distribution in the exposed and unexposed population. Whether or not to adjust for a non confounder to improve the precision of estimation has been argued by many authors. This article shows that if C is a non confounder, the pooled and standardized (log) relative risk estimators are asymptotic normal distributions with the mean being the true (log) relative risk, and that the asymptotic variance of the pooled (log) relative risk estimator is less than that of the stratified estimator.
C1 [Wang, Xueli] Beijing Univ Posts & Telecommun, Sch Sci, Beijing 100876, Peoples R China.
[Wang, Xueli; Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA.
[Wang, Xueli; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Washington, DC USA.
[Zhou, Xiao-Hua] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China.
RP Wang, XL (reprint author), Beijing Univ Posts & Telecommun, Sch Sci, Beijing 100876, Peoples R China.
EM wangxl@bupt.edu.cn
FU National Natural Science Foundation of China [NSFC 10801019, 11471053,
11401037]; Fundamental Research Funds for the Central Universities [BUPT
2012RC0708, 2014RC0905]
FX This research was supported by the National Natural Science Foundation
of China (NSFC 10801019, 11471053, and 11401037) and the Fundamental
Research Funds for the Central Universities (BUPT 2012RC0708 and
2014RC0905).
NR 21
TC 0
Z9 0
U1 1
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0361-0926
EI 1532-415X
J9 COMMUN STAT-THEOR M
JI Commun. Stat.-Theory Methods
PY 2015
VL 44
IS 7
BP 1497
EP 1507
DI 10.1080/03610926.2013.769599
PG 11
WC Statistics & Probability
SC Mathematics
GA CE7GF
UT WOS:000352005700013
ER
PT J
AU Gao, Y
Shen, JK
Milane, L
Hornicek, FJ
Amiji, MM
Duan, ZF
AF Gao, Yan
Shen, Jacson K.
Milane, Lara
Hornicek, Francis J.
Amiji, Mansoor M.
Duan, Zhenfeng
TI Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug
Resistance
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Drug resistance; nanotechnology; targeted cancer therapy
ID TYROSINE KINASE INHIBITORS; TRANS-RETINOIC ACID; HUMAN BREAST-CANCER;
CELL LUNG-CANCER; GASTROINTESTINAL STROMAL TUMORS; MANGANESE
SUPEROXIDE-DISMUTASE; HISTONE DEACETYLASE INHIBITORS; CHRONIC
MYELOGENOUS LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE PROMYELOCYTIC
LEUKEMIA
AB Recent advances in cancer molecular biology have resulted in parallel and unprecedented progress in the development of targeted cancer therapy. Targeted therapy can provide higher efficacy and lower toxicity than conventional chemotherapy for cancer. However, like traditional chemotherapy, molecularly targeted cancer therapy also faces the challenge of drug resistance. Multiple mechanisms are responsible for chemotherapy resistance in tumors, including over-expression of efflux transporters, somatic alterations of drug targets, deregulation of apoptosis, and numerous pharmacokinetic issues. Nanotechnology based approaches are proving to be efficacious in overcoming drug resistance in cancer. Combination of targeted therapies with nanotechnology approaches is a promising strategy to overcome targeted therapy drug resistance in cancer treatment. This review discusses the mechanisms of targeted drug resistance in cancer and discusses nanotechnology approaches to circumvent this resistance.
C1 [Gao, Yan; Shen, Jacson K.; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA.
[Gao, Yan] Zhengzhou Univ, Affiliated Hosp 3, Dept Clin Lab, Zhengzhou 450052, Henan, Peoples R China.
[Milane, Lara; Amiji, Mansoor M.] Northeastern Univ, Bouve Coll Hlth Sci, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Duan, ZF (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Jackson Bldg Room 1115, Boston, MA 02114 USA.
EM zduan@mgh.harvard.edu
FU National Cancer Institute's Alliance for Nanotechnology in Cancer
through the Platform Partnership grant [U01- CA151452]; China
Scholarship Council; Excellent Doctorial Dissertations Grant of
Zhengzhou University
FX Our work on the development of nanotechnology-based therapeutics is
partially supported by the National Cancer Institute's Alliance for
Nanotechnology in Cancer through the Platform Partnership grant U01-
CA151452. Dr. Gao is supported by scholarship from the China Scholarship
Council and Excellent Doctorial Dissertations Grant of Zhengzhou
University.
NR 137
TC 5
Z9 5
U1 3
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2015
VL 22
IS 11
BP 1335
EP 1347
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA CE5HY
UT WOS:000351863400004
PM 25666804
ER
PT J
AU Rinaldi, CA
Burri, H
Thibault, B
Curnis, A
Raos, A
Gras, D
Sperzel, J
Singh, JP
Biffi, M
Bordachar, P
Leclercq, C
AF Rinaldi, Christopher Aldo
Burri, Haran
Thibault, Bernard
Curnis, Antonio
Raos, Archana
Gras, Daniel
Sperzel, Johannes
Singh, Jagmeet P.
Biffi, Mauro
Bordachar, Pierre
Leclercq, Christophe
TI A review of multisite pacing to achieve cardiac resynchronization
therapy
SO EUROPACE
LA English
DT Review
DE Cardiac resynchronization therapy; Dyssynchrony; Heart failure;
Pacemaker; Multisite pacing
ID LEFT-VENTRICULAR LEAD; PHRENIC-NERVE STIMULATION; ACUTE
HEMODYNAMIC-RESPONSE; CHRONIC HEART-FAILURE; SINGLE-CENTER EXPERIENCE;
BUNDLE-BRANCH BLOCK; QUADRIPOLAR LEAD; BIVENTRICULAR STIMULATION;
ACTIVATION PATTERN; RANDOMIZED-TRIAL
AB Non-response to cardiac resynchronization therapy remains a significant problem in up to 30% of patients. Multisite stimulation has emerged as a way of potentially overcoming non-response. This may be achieved by the use of multiple leads placed within the coronary sinus and its tributaries (dual-vein pacing) or more recently by the use of multipolar (quadripolar) left ventricular pacing leads which can deliver pacing stimuli at multiple sites within the same vein. This review covers the role of multisite pacing including the interaction with the underlying pathophysiology, the current and planned studies, and the potential pitfalls of this technology.
C1 [Rinaldi, Christopher Aldo] Guys & St Thomas Hosp, Dept Cardiac, London SE1 7EH, England.
[Burri, Haran] Univ Hosp Geneva, Serv Cardiol, CH-1205 Geneva, Switzerland.
[Thibault, Bernard] Montreal Heart Inst, Dept Med, Montreal, PQ H1T 1C8, Canada.
[Thibault, Bernard] Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada.
[Thibault, Bernard] Univ Montreal, Montreal, PQ, Canada.
[Curnis, Antonio] Univ Brescia, Sect Cardiovasc Dis, Dept Expt & Appl Med, Brescia, Italy.
[Raos, Archana] Liverpool Heart & Chest Hosp, Liverpool L14 3PE, Merseyside, England.
[Gras, Daniel] Nouvelles Clin Nantaises, Nantes, France.
[Sperzel, Johannes] Kerckhoff Klin GmbH, Dept Cardiol & Electrophysiol, D-61231 Bad Nauheim, Germany.
[Singh, Jagmeet P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Heart, Boston, MA 02114 USA.
[Biffi, Mauro] Univ Bologna, Inst Cardiol, I-40138 Bologna, Italy.
[Bordachar, Pierre] Univ Bordeaux 2, Hop Cardiol Haut Leveque, Serv Rythmol, F-33604 Bordeaux, France.
[Leclercq, Christophe] CHU Pontchaillou 2, Dept Cardiol & Malad Vasc, F-35033 Rennes 09, France.
RP Rinaldi, CA (reprint author), Guys & St Thomas Hosp, Dept Cardiac, London SE1 7EH, England.
EM c.rinaldi@virgin.net
FU St Jude Medical
FX This review was prepared by a writing group which was invited on behalf
of the European Heart Rhythm Association Education Committee. This
document was supported by a grant from St Jude Medical; however, the
content has not been influenced in any way by its sponsor.
NR 85
TC 15
Z9 16
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1099-5129
EI 1532-2092
J9 EUROPACE
JI Europace
PD JAN 1
PY 2015
VL 17
IS 1
BP 7
EP 17
DI 10.1093/europace/euu197
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE1WP
UT WOS:000351603900004
PM 25214507
ER
PT J
AU Scirica, BM
Belardinelli, L
Chaitman, BR
Waks, JW
Volo, S
Karwatowska-Prokopczuk, E
Murphy, SA
Cheng, ML
Braunwald, E
Morrow, DA
AF Scirica, Benjamin M.
Belardinelli, Luiz
Chaitman, Bernard R.
Waks, Jonathan W.
Volo, Samuel
Karwatowska-Prokopczuk, Ewa
Murphy, Sabina A.
Cheng, Mei L.
Braunwald, Eugene
Morrow, David A.
TI Effect of ranolazine on at a fibrilla on in patients with non-ST eleva
on acute coronary syndromes: observations from the MERLIN-TIMI 36 trial
SO EUROPACE
LA English
DT Article
DE Atrial fibrillation; Ranolazine; Anti-arrhythmic therapy; Acute coronary
syndromes
ID ONSET ATRIAL-FIBRILLATION; LATE SODIUM CURRENT; MYOCARDIAL-INFARCTION;
SEGMENT-ELEVATION; ANTIANGINAL AGENT; AMIODARONE; THROMBOLYSIS;
MANAGEMENT; CONVERSION; OUTCOMES
AB Aims To determine the effect of ranolazine, an anti-ischaemic agent with anti-arrhythmic properties, on the overall burden of atrial fibrillation (AF) in acute coronary syndromes (ACS) and determine whether ranolazine reduces the long-term incidence of clinical AF after ACS.
Methods and results MERLIN-TIMI 36 randomized patients with non-ST elevation ACS to ranotazine or placebo. Atrial fibrillation episodes detected on continuous electrocardiogram (cECG) monitoring were reviewed in 6351 patients (97% of trial). Atrial fibrillation burden was categorized according to the time in AF: clinically insignificant AF (<0.01% of time), paroxysmal AF (>0.01-98%), or predominantly persistent AF (>98%). Clinical AF events were identified through adverse event reporting for a median 1-year follow-up. Overall, patients assigned to ranolazine had a trend towards fewer episodes of AF [75 (2.4%) vs. 55 (1.7%) patients, P = 0.08] detected on cECG during the first 7 days after randomization. The pattern of new-onset AF differed between ranotazine vs. placebo: clinically insignificant AF (five patients in ranolazine vs. seven in placebo), paroxysmal AF (18 vs. 48 patients), and predominantly chronic AF (28 vs. 20 patients, three-way P < 0.01). Among patients with a paroxysmal AF pattern, the overall burden was lower with ranolazine than with placebo (median 4.4 vs .16.1%, P = 0.015). Over the median 1-year follow-up, fewer patients treated with ranolazine experienced an AF event compared with placebo (2.9 vs. 4.1%, RR 0.71, P = 0.01).
Conclusion Ranolazine, an anti-anginal agent with electrophysiological effects, may reduce the frequency of paroxysmal AF in patients with non-ST elevation ACS with a pattern of tower overall AF burden in this group. Ranolazine reduced the overall 1-year incidence of clinical AF events. These atrial-specific anti-arrhythmic properties of ranolazine may be of clinical interest and warrant additional investigation.
C1 [Scirica, Benjamin M.; Waks, Jonathan W.; Volo, Samuel; Murphy, Sabina A.; Braunwald, Eugene; Morrow, David A.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Scirica, Benjamin M.; Waks, Jonathan W.; Volo, Samuel; Murphy, Sabina A.; Braunwald, Eugene; Morrow, David A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Belardinelli, Luiz; Karwatowska-Prokopczuk, Ewa; Cheng, Mei L.] Gilead Sci Inc, Foster City, CA USA.
[Chaitman, Bernard R.] St Louis Univ, Sch Med, St Louis, MO USA.
RP Scirica, BM (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.
EM bscirica@partners.org
FU Gilead
FX MERLIN-TIMI 36 was funded by CV Therapeutics (now Gilead).
NR 23
TC 19
Z9 20
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1099-5129
EI 1532-2092
J9 EUROPACE
JI Europace
PD JAN 1
PY 2015
VL 17
IS 1
BP 32
EP 37
DI 10.1093/europace/euu217
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CE1WP
UT WOS:000351603900008
PM 25210025
ER
PT J
AU Leff, B
Carlson, CM
Saliba, D
Ritchie, C
AF Leff, Bruce
Carlson, Charlotte M.
Saliba, Debra
Ritchie, Christine
TI The Invisible Homebound: Setting Quality-Of-Care Standards For
Home-Based Primary And Palliative Care
SO HEALTH AFFAIRS
LA English
DT Article
ID OLDER-ADULTS; HOUSE CALLS; HEALTH; BENEFICIARIES; POPULATION;
MANAGEMENT; VETERANS; DEATH; COST
AB Approximately four million adults in the United States are homebound, and many of them cannot access office-based primary care. Home-based medical care can improve outcomes and reduce health care costs, but this care operates in a quality measurement desert, having been largely left out of the national conversation on care quality. To address this shortcoming, two of the authors created the National Home-Based Primary and Palliative Care Network, an organization whose members include exemplary home-based medical practices, professional societies, and patient advocacy groups. This article describes the current status of home-based medical care in the United States and offers a brief narrative of a fictional homebound patient and the health events and fragmented care she faces. The article then describes the network's quality-of-care framework, which includes ten quality-of-care domains, thirty-two standards, and twenty quality indicators that are being tested in the field. The same two authors also developed a practice-based registry that will be used for quality-of-care benchmarking, practice-based quality improvement, performance reporting, and comparative effectiveness research. Together, these steps should help bring home-based medical care further into the mainstream of US health care.
C1 [Leff, Bruce] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD 21205 USA.
[Carlson, Charlotte M.] On Lok Senior Hlth Serv, San Francisco, CA USA.
[Saliba, Debra] Univ Calif Los Angeles, Borun Ctr, Los Angeles, CA 90024 USA.
[Saliba, Debra] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Ritchie, Christine] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Leff, B (reprint author), Johns Hopkins Univ, Sch Med, Med, Baltimore, MD 21205 USA.
EM bleff@jhmi.edu
FU Retirement Research Foundation; Commonwealth Fund; California HealthCare
Foundation; National Institutes of Health; Agency for Healthcare
Research and Quality; John A. Hartford Foundation
FX Portions of this work were presented at the annual meeting of the
American Academy of Home Care Medicine, in Orlando, Florida, May 14,
2014. This work was supported by the Retirement Research Foundation, the
Commonwealth Fund, and the California HealthCare Foundation. The views
presented here are those of the authors and not necessarily those of the
Commonwealth Fund, its directors, officers, or staff. Bruce Leff is a
current member of the board of directors and past president of the
American Academy of Home Care Medicine. He and Debra Saliba are members
of the PostAcute Care/Long-Term Care Workgroup of the Measure
Application Partnership at the National Quality Forum. Christine Ritchie
is president-elect of the American Academy of Hospice and Palliative
Medicine. She is a section editor for UpToDate, Inc. Leff and Ritchie
have received grant funding from the Commonwealth Fund, the Retirement
Research Foundation, the California HealthCare Foundation, the National
Institutes of Health, and the Agency for Healthcare Research and
Quality. Leff has also received funding from the John A. Hartford
Foundation. The authors thank Diane Meier for her thoughtful review of
the manuscript and Debbie Statom for her assistance in preparing the
manuscript.
NR 35
TC 13
Z9 13
U1 0
U2 7
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JAN
PY 2015
VL 34
IS 1
BP 21
EP 29
DI 10.1377/hlthaff.2014.1008
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CE3GZ
UT WOS:000351716000005
PM 25561640
ER
PT J
AU Scott, JW
Sommers, BD
Tsai, TC
Scott, KW
Schwartz, AL
Song, ZR
AF Scott, John W.
Sommers, Benjamin D.
Tsai, Thomas C.
Scott, Kirstin W.
Schwartz, Aaron L.
Song, Zirui
TI Dependent Coverage Provision Led To Uneven Insurance Gains And Unchanged
Mortality Rates In Young Adult Trauma Patients
SO HEALTH AFFAIRS
LA English
DT Article
ID AFFORDABLE CARE ACT; SAFETY-NET HOSPITALS; DATA-BANK; HEALTH-INSURANCE;
PENETRATING TRAUMA; VEHICULAR INJURY; STATUS MATTER; OUTCOMES;
DISPARITIES; RACE
AB Insurance coverage has increased among young adults as a result of the Affordable Care Act (ACA) provision that allows young adults to remain covered under their parents' plans until age twenty-six. However, little is known about the provision's effects on the clinical outcomes and insurance coverage of patients with trauma-the most frequent cause of death and physical disability among young adults. Using 2007-12 data from the National Trauma Data Bank, we conducted a difference-in-differences analysis of coverage rates among trauma patients ages 19-25 (compared to patients ages 26-34, who served as the control group), and we examined trauma-relevant outcomes by patient, injury, and hospital characteristics. We found a 3.4-percentage-point decrease in uninsurance status among younger trauma patients following the policy change. The decrease was concentrated among men, non-Hispanic whites, those with relatively less severe injuries, and those who presented to nonteaching hospitals. We did not detect significant changes in the use of intensive care or in overall mortality. The heterogeneous coverage impact of the ACA dependent coverage provision on high- versus low-risk trauma patients has implications for future efforts to expand coverage.
C1 [Scott, John W.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Sommers, Benjamin D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Sommers, Benjamin D.] Brigham & Womens Hosp, Med, Boston, MA 02115 USA.
[Tsai, Thomas C.] Brigham & Womens Hosp, Gen Surg, Boston, MA 02115 USA.
[Tsai, Thomas C.] Harvard Univ, Sch Publ Health, Dept Hlth Policy & Management, Cambridge, MA 02138 USA.
[Scott, Kirstin W.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA.
[Schwartz, Aaron L.] Harvard Univ, Dept Hlth Care, Cambridge, MA 02138 USA.
[Song, Zirui] Massachusetts Gen Hosp, Internal Med, Boston, MA 02114 USA.
[Song, Zirui] Harvard Univ, Sch Med, Boston, MA USA.
RP Scott, JW (reprint author), Brigham & Womens Hosp, Ctr Surg & Publ Hlth, 75 Francis St, Boston, MA 02115 USA.
EM jwscott@partners.org
OI Scott, John/0000-0002-9916-6523
FU Henry Ellis Warren Fellowship; Center for Surgery and Public Health at
Brigham and Women's Hospital; Agency for Healthcare Research and Quality
(AHRQ) [T32HS000055]; National Science Foundation Graduate Research
Fellowship [NSF 13-584]; National Institute on Aging of the National
Institutes of Health [F30 AG044106]; National Institute on Aging [NIA
F30 AG039175-2]; National Cancer Institute's Program in Cancer Outcomes
Research Training [R25CA92203]
FX Preliminary data from this analysis were presented at the AcademyHealth
Annual Research Meeting in San Diego, California, June 9, 2014. The
authors acknowledge John Orav and Jennifer Polinski for their assistance
in early analyses of these data. John Scott is funded by the Henry Ellis
Warren Fellowship and the Center for Surgery and Public Health at
Brigham and Women's Hospital. Kirstin Scott is funded by the Agency for
Healthcare Research and Quality (AHRQ; Grant No. T32HS000055) and the
National Science Foundation Graduate Research Fellowship (Grant No. NSF
13-584) Aaron Schwartz was supported by the National Institute on Aging
of the National Institutes of Health (Grant No. F30 AG044106). Zirui
Song was supported by the National Institute on Aging (Grant No. NIA F30
AG039175-2). Thomas Tsai was supported by the National Cancer
Institute's Program in Cancer Outcomes Research Training (Grant No.
R25CA92203). Tsai serves as an adviser and Benjamin Sommers serves part
time as an adviser in the Office of the Assistant Secretary for Planning
and Evaluation at the Department of Health and Human Services (HHS). The
content of this article is solely the responsibility of the authors and
does not necessarily represent the official views of AHRQ or HHS.
NR 42
TC 7
Z9 7
U1 1
U2 3
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JAN
PY 2015
VL 34
IS 1
BP 125
EP 133
DI 10.1377/hlthaff.2014.0880
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CE3GZ
UT WOS:000351716000019
PM 25561653
ER
PT J
AU Lee, SW
Fried, SI
AF Lee, Seung Woo
Fried, Shelley I.
TI Suppression of Subthalamic Nucleus Activity by Micromagnetic Stimulation
SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING
LA English
DT Article
DE Deep brain stimulation (DBS); magnetic stimulation; neural prosthesis;
Parkinson's disease (PD); repetitive transcranial magnetic stimulation
(rTMS); subthalamic nucleus (STN)
ID DEEP BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION;
HIGH-FREQUENCY STIMULATION; OBSESSIVE-COMPULSIVE DISORDER;
LIQUID-CRYSTAL POLYMERS; RETINAL GANGLION-CELLS; ELECTRICAL-STIMULATION;
PARKINSONS-DISEASE; MICROELECTRODE ARRAYS; COCHLEAR IMPLANTS
AB Magnetic stimulation delivered via 0.5-mm diameter coils was recently shown to activate retinal neurons; the small coil size raises the possibility that micromagnetic stimulation (mu MS) could underlie a new generation of implanted neural prosthetics. Such an approach has several inherent advantages over conventional electric stimulation, including the potential for selective activation of neuronal targets as well as less susceptibility to inflammatory responses. The viability of mu MS for some applications, e.g., deep brain stimulation (DBS), may require suppression (rather than creation) of neuronal activity, however, and therefore we explore here whether (mu MS) could, in fact, suppress activity. While single pulses elicited weak and inconsistent spiking in neurons of the mouse subthalamic nucleus (in vitro), repetitive stimulation effectively suppressed activity in similar to 70% of targeted neurons. This is the same percentage suppressed by conventional electric stimulation; with both modalities, suppression occurred only after an initial increase in spiking. The latency to the onset of suppression was inversely correlated to the energy of the stimulus waveform: larger amplitudes and lower frequencies had the fastest onset of suppression. These findings continue to support the viability of mu MS as a next-generation implantable neural prosthetic.
C1 [Lee, Seung Woo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA.
[Fried, Shelley I.] Boston Vet Adm Healthcare Syst, Rehabil Res & Dev, Boston, MA 01230 USA.
[Fried, Shelley I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA.
RP Lee, SW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA.
EM Lee.Se-ungwoo@mgh.harvard.edu; Fried.Shelley@mgh.harvard.edu
FU Veterans Administration [MR 1I01RX000350-01A1]; National Eye Institute
[R01EY019967, R01EY023651]
FX This work was supported by the Veterans Administration under Grant MR
1I01RX000350-01A1 and by the National Eye Institute under Grant
R01EY019967 and Grant R01EY023651.
NR 68
TC 5
Z9 5
U1 3
U2 6
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1534-4320
EI 1558-0210
J9 IEEE T NEUR SYS REH
JI IEEE Trans. Neural Syst. Rehabil. Eng.
PD JAN
PY 2015
VL 23
IS 1
BP 116
EP 127
DI 10.1109/TNSRE.2014.2348415
PG 12
WC Engineering, Biomedical; Rehabilitation
SC Engineering; Rehabilitation
GA AZ0CG
UT WOS:000347913400012
PM 25163063
ER
PT J
AU Gaffney, A
AF Gaffney, Adam
TI THE NEOLIBERAL TURN IN AMERICAN HEALTH CARE
SO INTERNATIONAL JOURNAL OF HEALTH SERVICES
LA English
DT Article
AB Leaving millions both uninsured and underinsured, the Affordable Care Act does not create a system of universal health care in the United States. To understand its shortcomings, we have to understand it as part of a historic shift in the political economy of American health care. This "neoliberal turn" began as a reaction against the welfare state as it expanded during the New Deal and post-World War II period. What began as a movement associated with philosophers like Friedrich Hayek ultimately had a powerful impact via the attraction of powerful corporate sponsors and political supporters, and it was to historically transform American health care thought and organization. In health policy circles, for example, it can be seen in a rising emphasis on "moral hazard," overuse, and cost sharing above a concern with universalism and equity. It was likewise manifested by the corporatization of the health maintenance organization and the rise of the "consumer-driven" health care movement. By the time of the health care reform debate, the influence of corporate "stakeholders" was to prove predominant. These developments, however, must be construed as connected parts of a much larger political transformation, reflected in rising inequality and privatization, occurring both domestically and internationally.
C1 [Gaffney, Adam] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gaffney, Adam] Columbia Univ, Med Ctr, New York, NY 10027 USA.
RP Gaffney, A (reprint author), 84 Willow St 2, Cambridge, 02141, England.
EM agaffney@mgh.harvard.edu
NR 0
TC 4
Z9 4
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0020-7314
EI 1541-4469
J9 INT J HEALTH SERV
JI Int. J. Health Serv.
PD JAN
PY 2015
VL 45
IS 1
BP 33
EP 52
DI 10.2190/HS.45.1.d
PG 20
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CE6JT
UT WOS:000351943400004
PM 26460446
ER
PT J
AU Hoggatt, J
Tate, TA
Pelus, LM
AF Hoggatt, Jonathan
Tate, Tiffany A.
Pelus, Louis M.
TI Role of lipegfilgrastim in the management of chemotherapy-induced
neutropenia
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE granulocyte-colony stimulating factor; biosimilar; filgrastim;
neutrophil; XM22; cancer
ID COLONY-STIMULATING FACTOR; TRANSITIONAL-CELL-CARCINOMA; CANCER-PATIENTS;
G-CSF; DAILY FILGRASTIM; ACTIVE-CONTROL; DOUBLE-BLIND; STEM-CELLS;
PROLIFERATION; MULTICENTER
AB Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell populations, which can be life threatening. Neutropenia is the most serious hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality due to opportunistic infection and often is the limiting factor in dose escalation or duration of chemotherapeutic administration. Neutropenic patients often require hospitalization and incur substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupogen (R)) and pegfilgrastim (Neulasta (R)). With the expiration of patent lives of both of these drugs, biosimilars have begun to emerge. In this review, we will summarize the chemical characteristics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex (R)), the first long-acting biosimilar filgrastim to receive regulatory approval and enter the marketplace.
C1 [Hoggatt, Jonathan; Tate, Tiffany A.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02115 USA.
[Pelus, Louis M.] Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
RP Hoggatt, J (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Regenerat Med, Dept Stem Cell & Regenerat Biol, 185 Cambridge St,CPZN 4400, Boston, MA 02114 USA.
EM hoggatt.jonathan@mgh.harvard.edu; ipelus@iupui.edu
FU NCATS NIH HHS [UL1 TR001108]
NR 36
TC 7
Z9 7
U1 1
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 2647
EP 2652
DI 10.2147/IJN.S55796
PG 6
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA CE7IS
UT WOS:000352013200003
PM 25878498
ER
PT J
AU Brommelhoff, JA
Sultzer, DL
AF Brommelhoff, Jessica A.
Sultzer, David L.
TI Brain Structure and Function Related to Depression in Alzheimer's
Disease: Contributions from Neuroimaging Research
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Review
DE Alzheimer's disease; depression; late-life depression; neuroimaging
ID LATE-LIFE DEPRESSION; MILD COGNITIVE IMPAIRMENT; DORSOLATERAL PREFRONTAL
CORTEX; EMISSION COMPUTED-TOMOGRAPHY; VOXEL-BASED MORPHOMETRY;
DEFAULT-MODE NETWORK; WHITE-MATTER CHANGES; GERIATRIC DEPRESSION;
RATING-SCALE; HIPPOCAMPAL VOLUME
AB The development of minimally invasive in vivo methods for imaging the brain has allowed for unprecedented advancement in our understanding of brain-behavior relationships. Structural, functional, and multimodal neuroimaging techniques have become more sophisticated in detecting structural and physiological abnormalities that may underlie various affective disorders and neurological illnesses such as depression in Alzheimer's disease (AD). In general, neuroimaging studies of depression in AD investigate whether depression is associated with damage to structures in specific neural networks involving frontal and subcortical structures or with functional disruption of cortical neural systems. This review provides an overview of how various imaging modalities have contributed to our understanding of the neurobiology of depression in AD. At present, the literature does not conclusively support any specific pathogenesis for depression, and it is not clear whether patients with AD and depression have histopathological and neurochemical characteristics that contribute to mood symptoms that are different from cognitively intact individuals with depression. Neuroimaging studies suggest that atrophy of temporal or frontal structures, white matter lesions in frontal lobe or subcortical systems, reduced activity in dorsolateral frontal cortex, or small vessel cerebrovascular disease may be associated with depression in AD. Conceptual, clinical, and methodological challenges in studying this relationship are discussed. Further work is needed to understand the specific brain structures, relevant white matter tracts, and interactions among them that are most important. This review concludes with potential directions for future research.
C1 [Brommelhoff, Jessica A.; Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Mental Hlth Serv, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA.
[Brommelhoff, Jessica A.; Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
RP Sultzer, DL (reprint author), VA Greater Los Angeles Hlth Care Syst, 11301 Wilshire Blvd,Bldg 401,116AE, Los Angeles, CA 90073 USA.
EM dsultzer@ucla.edu
FU Department of Veteran Affairs (MIRECC Advanced Fellowship); Department
of Veteran Affairs (Merit Review Research Grant)
FX Supported in part by the Department of Veteran Affairs (MIRECC Advanced
Fellowship, Dr. Brommelhoff; Merit Review Research Grant, Dr. Sultzer).
NR 96
TC 5
Z9 6
U1 4
U2 11
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 45
IS 3
BP 689
EP 703
DI 10.3233/JAD-148007
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA CE1YK
UT WOS:000351608700002
PM 25633682
ER
PT J
AU Pan, C
Korff, A
Galasko, D
Ginghina, C
Peskind, E
Li, G
Quinn, J
Montine, TJ
Cain, K
Shi, M
Zhang, J
AF Pan, Catherine
Korff, Ane
Galasko, Douglas
Ginghina, Carmen
Peskind, Elaine
Li, Ge
Quinn, Joseph
Montine, Thomas J.
Cain, Kevin
Shi, Min
Zhang, Jing
TI Diagnostic Values of Cerebrospinal Fluid T-Tau and A beta(42) using Meso
Scale Discovery Assays for Alzheimer's Disease
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE A beta(42); Alzheimer's disease; cerebrospinal fluid; Meso Scale
Discovery; tau
ID QUALITY-CONTROL PROGRAM; CSF ALPHA-SYNUCLEIN; BETA-AMYLOID 1-42;
APOLIPOPROTEIN-E; ASSOCIATION WORKGROUPS; ANALYTICAL PLATFORMS;
PARKINSONS-DISEASE; NATIONAL INSTITUTE; CONFIRMED DEMENTIA; VASCULAR
DEMENTIA
AB Background: Meso Scale Discovery (MSD) recently established electrochemiluminescence-based assays to measure cerebrospinal fluid (CSF) levels of total tau (t-tau) and amyloid-beta 1-42 peptide (A beta(42)) that can aid in the diagnosis of Alzheimer's disease (AD). The goal of this investigation is to independently evaluate this platform and establish cut-off values of these biomarkers for AD diagnosis.
Objective: To validate the analytical and clinical performance of the MSD t-tau and A beta(42) kits and propose diagnostic cut-off values for the field.
Methods: The analytical performance of the CSF t-tau and A beta(42) assays was determined, followed by assessment of diagnostic performance of CSF t-tau, A beta(42), and t-tau/A beta(42) in three clinically characterized cohorts.
Results: Both MSD assays demonstrated consistent and stable analytical performance, as well as resistance to several important pre-analytic variables. Diagnostically, t-tau/A beta(42) performed the best.
Conclusions: Our results independently confirm the analytical and clinical performance of the MSD CSF t-tau and A beta(42) assays. Based on a large, multi-center, clinically-diagnosed cohort, we propose for the first time candidate diagnostic cut-offs for MSD measured CSF t-tau, A beta(42), and t-tau/A beta(42). However, these values needs to be refined as more subjects are included and the assays are tested by other laboratories.
C1 [Pan, Catherine; Korff, Ane; Ginghina, Carmen; Montine, Thomas J.; Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA.
[Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Peskind, Elaine] VA Puget Sound Hlth Care Syst, Northwest Network VISN 20, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Peskind, Elaine; Li, Ge] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Li, Ge] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Quinn, Joseph] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Quinn, Joseph] Portland VA Med Ctr, Portland, OR USA.
[Cain, Kevin] Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA.
RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA.
EM zhangj@uw.edu
RI Shi, Min/G-6165-2012
OI Shi, Min/0000-0002-6901-2558
FU [NINDS: U01 NS082137 03]; [NIA: P50 AG005131 31]; [NIA: P30 AG008017
25]; [NIA: P50 AG005136 31]
FX The authors' efforts were supported by the NINDS: U01 NS082137 03 and
NIA: P50 AG005131 31, P30 AG008017 25, and P50 AG005136 31. The authors
would also like to thank the Friends of Alzheimer's research and the
Department of Veterans Affairs. MSD had no role in the design, conduct,
or analysis of results of the current study.
NR 52
TC 2
Z9 3
U1 0
U2 3
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 45
IS 3
BP 709
EP 719
DI 10.3233/JAD-143099
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA CE1YK
UT WOS:000351608700004
PM 25613100
ER
PT J
AU Gray, NE
Sampath, H
Zweig, JA
Quinn, JF
Soumyanath, A
AF Gray, Nora E.
Sampath, Harini
Zweig, Jonathan A.
Quinn, Joseph F.
Soumyanath, Amala
TI Centella asiatica Attenuates Amyloid-beta-Induced Oxidative Stress and
Mitochondrial Dysfunction
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Amyloid-beta toxicity; calcium homeostasis; Centella asiatica;
mitochondrial dysfunction; neuroprotection; reactive oxygen species
ID ALZHEIMERS-DISEASE; SH-SY5Y CELLS; MOUSE MODEL; INDUCED NEUROTOXICITY;
CAFFEOYLQUINIC ACIDS; CEREBRAL-CORTEX; IN-VIVO; NEURONS; PROTEIN; RATS
AB Background: We previously showed that a water extract of the medicinal plant Centella asiatica (CAW) attenuates amyloid-beta (A beta)-induced cognitive deficits in vivo, and prevents A beta-induced cytotoxicity in vitro. Yet the neuroprotective mechanism of CAW is unknown.
Objective: The goal of this study was to identify biochemical pathways altered by CAW using in vitro models of A beta toxicity.
Methods: The effects of CAW on aberrations in antioxidant response, calcium homeostasis, and mitochondrial function induced by A beta were evaluated in MC65 and SH-SY5Y neuroblastoma cells.
Results: CAW decreased intracellular reactive oxygen species and calcium levels elevated in response to A beta, and induced the expression of antioxidant response genes in both cell lines. In SH-SY5Y cells, CAW increased basal and maximal oxygen consumption without altering spare capacity, and attenuated A beta-induced decreases in mitochondrial respiration. CAW also prevented A beta-induced decreases in ATP and induced the expression of mitochondrial genes and proteins in both cell types. Caffeoylquinic acids from CAW were shown to have a similar effect on antioxidant and mitochondrial gene expression in neuroblastoma cells. Primary rat hippocampal neurons treated with CAW also showed an increase in mitochondrial and antioxidant gene expression.
Conclusions: These data suggest an effect of CAW on mitochondrial biogenesis, which in conjunction with activation of antioxidant response genes and normalizing calcium homeostasis, likely contributes to its neuroprotective action against A beta toxicity.
C1 [Gray, Nora E.; Quinn, Joseph F.; Soumyanath, Amala] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Sampath, Harini] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA.
[Zweig, Jonathan A.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA.
[Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA.
[Quinn, Joseph F.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr PADRECC, Portland, OR USA.
RP Gray, NE (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.
EM grayn@ohsu.edu
FU NIH-NCCAM grant [R01AT008099]; Oregon Alzheimer's Disease Center (OADC)
[3P30-AG008017 24 S1]; OADC [5 P30 AG008017 24]; T32 grant from
NIH-NCCAM [AT002688]; K99 grant [K99DK100640]; Department of Veterans
Affairs Merit Review grant
FX This work was funded by NIH-NCCAM grant R01AT008099, a grant awarded to
A. Soumyanath from the Oregon Alzheimer's Disease Center (OADC)
3P30-AG008017 24 S1 and one to N. Gray from the OADC 5 P30 AG008017 24,
a T32 grant on which N. Gray was a trainee from NIH-NCCAM AT002688, a
K99 grant to H. Sampath K99DK100640 and by a Department of Veterans
Affairs Merit Review grant awarded to J. Quinn. The authors acknowledge
Dr. Stephen Lloyd for his assistance with the Seahorse XF Analyzer
experiments and Barbara Smoody for her help with the primary neuron
experiments. MC65 cells were generously provided by Randy Woltjer, MD,
PhD.
NR 53
TC 8
Z9 9
U1 1
U2 8
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 45
IS 3
BP 933
EP 946
DI 10.3233/JAD-142217
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA CE1YK
UT WOS:000351608700022
PM 25633675
ER
PT J
AU Sikov, WM
Berry, DA
Perou, CM
Singh, B
Cirrincione, CT
Tolaney, SM
Kuzma, CS
Pluard, TJ
Somlo, G
Port, ER
Golshan, M
Bellon, JR
Collyar, D
Hahn, OM
Carey, LA
Hudis, CA
Winer, EP
AF Sikov, William M.
Berry, Donald A.
Perou, Charles M.
Singh, Baljit
Cirrincione, Constance T.
Tolaney, Sara M.
Kuzma, Charles S.
Pluard, Timothy J.
Somlo, George
Port, Elisa R.
Golshan, Mehra
Bellon, Jennifer R.
Collyar, Deborah
Hahn, Olwen M.
Carey, Lisa A.
Hudis, Clifford A.
Winer, Eric P.
TI Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant
Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and
Cyclophosphamide on Pathologic Complete Response Rates in Stage II to
III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CHEMOTHERAPY; TRIAL; CISPLATIN; SURVIVAL; SUBTYPES; THERAPY
AB Purpose
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2 x 2 factorial, open-label, randomized phase II trial, evaluated the impact of adding carboplatin and/or bevacizumab.
Patients and Methods
Patients (N = 443) with stage II to III TNBC received paclitaxel 80 mg/m(2) once per week (wP) for 12 weeks, followed by doxorubicin plus cyclophosphamide once every 2 weeks (ddAC) for four cycles, and were randomly assigned to concurrent carboplatin (area under curve 6) once every 3 weeks for four cycles and/or bevacizumab 10 mg/kg once every 2 weeks for nine cycles. Effects of adding these agents on pCR breast (ypT0/is), pCR breast/axilla (ypT0/isN0), treatment delivery, and toxicities were analyzed.
Results
Patients assigned to either carboplatin or bevacizumab were less likely to complete wP and ddAC without skipped doses, dose modification, or early discontinuation resulting from toxicity. Grade >= 3 neutropenia and thrombocytopenia were more common with carboplatin, as were hypertension, infection, thromboembolic events, bleeding, and postoperative complications with bevacizumab. Employing one-sided P values, addition of either carboplatin (60% v 44%; P = .0018) or bevacizumab (59% v 48%; P = .0089) significantly increased pCR breast, whereas only carboplatin (54% v 41%; P = .0029) significantly raised pCR breast/axilla. More-than-additive interactions between the two agents could not be demonstrated.
Conclusion
In stage II to III TNBC, addition of either carboplatin or bevacizumab to NACT increased pCR rates, but whether this will improve relapse-free or overall survival is unknown. Given results from recently reported adjuvant trials, further investigation of bevacizumab in this setting is unlikely, but the role of carboplatin could be evaluated in definitive studies, ideally limited to biologically defined patient subsets most likely to benefit from this agent. (C) 2014 by American Society of Clinical Oncology
C1 [Sikov, William M.] Brown Univ, Miriam Hosp, Providence, RI USA.
[Sikov, William M.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
[Berry, Donald A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Perou, Charles M.; Carey, Lisa A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Cirrincione, Constance T.] Alliance Stat Ctr, Durham, NC USA.
[Kuzma, Charles S.] Southeast Canc Control Consortium, Winston Salem, NC USA.
[Singh, Baljit] NYU, Med Ctr, New York, NY 10016 USA.
[Port, Elisa R.] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Hudis, Clifford A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Tolaney, Sara M.; Golshan, Mehra; Bellon, Jennifer R.; Winer, Eric P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Pluard, Timothy J.] Washington Univ, Med Ctr, St Louis, MO USA.
[Somlo, George] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Collyar, Deborah] Patient Advocates Res, Danville, CA USA.
[Hahn, Olwen M.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
RP Sikov, WM (reprint author), Women & Infants Hosp Rhode Isl, Breast Hlth Ctr, 101 Dudley St, Providence, RI 02905 USA.
EM wsikov@wihri.org
FU National Cancer Institute [CA31946, CA33601, CA076001, CA025224,
CA32102, CA46368]; Genentech, a division of F. Hoffman-La Roche; Breast
Cancer Research Foundation; American Recovery and Reinvestment Act
FX Supported in part by National Cancer Institute Grants No. CA31946 to the
Alliance for Clinical Trials in Oncology, CA33601 to the Alliance
Statistics and Data Center, CA076001 to the American College of Surgeons
Oncology Group, CA025224 to the North Central Cancer Treatment Group,
and CA32102 and CA46368 to the Southwest Oncology Group; by Genentech, a
division of F. Hoffman-La Roche; by the Breast Cancer Research
Foundation; and by funding provided by the American Recovery and
Reinvestment Act to the Coalition for Cancer Cooperative Groups.
NR 26
TC 122
Z9 131
U1 6
U2 25
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JAN 1
PY 2015
VL 33
IS 1
BP 13
EP U34
DI 10.1200/JCO.2014.57.0572
PG 11
WC Oncology
SC Oncology
GA CE2DP
UT WOS:000351624300006
PM 25092775
ER
PT J
AU Shi, Q
de Gramont, A
Grothey, A
Zalcberg, J
Chibaudel, B
Schmoll, HJ
Seymour, MT
Adams, R
Saltz, L
Goldberg, RM
Punt, CJA
Douillard, JY
Hoff, PM
Hecht, JR
Hurwitz, H
Diaz-Rubio, E
Porschen, R
Tebbutt, NC
Fuchs, C
Souglakos, J
Falcone, A
Tournigand, C
Kabbinavar, FF
Heinemann, V
Van Cutsem, E
Bokemeyer, C
Buyse, M
Sargent, DJ
AF Shi, Qian
de Gramont, Aimery
Grothey, Axel
Zalcberg, John
Chibaudel, Benoist
Schmoll, Hans-Joachim
Seymour, Matthew T.
Adams, Richard
Saltz, Leonard
Goldberg, Richard M.
Punt, Cornelis J. A.
Douillard, Jean-Yves
Hoff, Paulo M.
Hecht, Joel Randolph
Hurwitz, Herbert
Diaz-Rubio, Eduardo
Porschen, Rainer
Tebbutt, Niall C.
Fuchs, Charles
Souglakos, John
Falcone, Alfredo
Tournigand, Christophe
Kabbinavar, Fairooz F.
Heinemann, Volker
Van Cutsem, Eric
Bokemeyer, Carsten
Buyse, Marc
Sargent, Daniel J.
TI Individual Patient Data Analysis of Progression-Free Survival Versus
Overall Survival As a First-Line End Point for Metastatic Colorectal
Cancer in Modern Randomized Trials: Findings From the Analysis and
Research in Cancers of the Digestive System Database
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID PHASE-III TRIAL; COMBINATION CHEMOTHERAPY; INFUSIONAL FLUOROURACIL; PLUS
OXALIPLATIN; CLINICAL-TRIALS; MUTATION STATUS; DOUBLE-BLIND; FINAL
REPORT; LEUCOVORIN; CETUXIMAB
AB Purpose
Progression-free survival (PFS) has previously been established as a surrogate for overall survival (OS) for first-line metastatic colorectal cancer (mCRC). Because mCRC treatment has advanced in the last decade with extended OS, this surrogacy requires re-examination.
Methods
Individual patient data from 16,762 patients were available from 22 first-line mCRC studies conducted from 1997 to 2006; 12 of those studies tested antiangiogenic and/or anti-epidermal growth factor receptor agents. The relationship between PFS (first event of progression or death) and OS was evaluated by using R-2 statistics (the closer the value is to 1, the stronger the correlation) from weighted least squares regression of trial-specific hazard ratios estimated by using Cox and Copula models.
Results
Forty-four percent of patients received a regimen that included biologic agents. Median first-line PFS was 8.3 months, and median OS was 18.2 months. The correlation between PFS and OS was modest (R-2, 0.45 to 0.69). Analyses limited to trials that tested treatments with biologic agents, nonstrategy trials, or superiority trials did not improve surrogacy.
Conclusion
In modern mCRC trials, in which survival after the first progression exceeds time to first progression, a positive but modest correlation was observed between OS and PFS at both the patient and trial levels. This finding demonstrates the substantial variability in OS introduced by the number of lines of therapy and types of effective subsequent treatments and the associated challenge to the use of OS as an end point to assess the benefit attributable to a single line of therapy. PFS remains an appropriate primary end point for first-line mCRC trials to detect the direct treatment effect of new agents. (C) 2014 by American Society of Clinical Oncology
C1 [Shi, Qian; Grothey, Axel] Mayo Clin, Rochester, MN 55905 USA.
[de Gramont, Aimery; Chibaudel, Benoist] Hosp St Antoine, Paris, France.
[Tournigand, Christophe] Univ Paris Est Creteil, Paris, France.
[Douillard, Jean-Yves] Inst Canc Res Western, St Herblain, France.
[Zalcberg, John] Monash Univ, Melbourne, Vic 3004, Australia.
[Tebbutt, Niall C.] Austin Hlth, Melbourne, Vic, Australia.
[Schmoll, Hans-Joachim] Univ Halle Wittenberg, D-06108 Halle, Germany.
[Porschen, Rainer] Klinikum Bremen Ost, Bremen, Germany.
[Heinemann, Volker] Univ Munich, Munich, Germany.
[Bokemeyer, Carsten] Univ Hamburg Hosp, Hamburg, Germany.
[Seymour, Matthew T.] Canc Res UK Clincal Ctr, Leeds, W Yorkshire, England.
[Adams, Richard] Cardiff Univ, Cardiff CF10 3AX, S Glam, Wales.
[Saltz, Leonard] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Goldberg, Richard M.] Ohio State Univ, Columbus, OH 43210 USA.
[Punt, Cornelis J. A.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
[Hoff, Paulo M.] Hosp Sirio Libanes, Sao Paulo, Brazil.
[Hecht, Joel Randolph; Kabbinavar, Fairooz F.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Hurwitz, Herbert] Duke Univ, Durham, NC USA.
[Diaz-Rubio, Eduardo] Hosp Clin San Carlos, Madrid, Spain.
[Fuchs, Charles] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Souglakos, John] Univ Crete, Iraklion, Greece.
[Falcone, Alfredo] Univ Pisa, Pisa, Italy.
[Van Cutsem, Eric] Univ Hosp Gasthuisberg, Leuven, Belgium.
[Buyse, Marc] Int Inst Drug Dev, Louvain La Neuve, Belgium.
RP Sargent, DJ (reprint author), Mayo Clin, 200 First St SW,Harwick 8-27, Rochester, MN 55905 USA.
EM sargent.daniel@mayo.edu
FU Analysis and Research in Cancers of the Digestive System Foundation
FX Supported by the Analysis and Research in Cancers of the Digestive
System Foundation.
NR 43
TC 25
Z9 25
U1 2
U2 16
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JAN 1
PY 2015
VL 33
IS 1
BP 22
EP U47
DI 10.1200/JCO.2014.56.5887
PG 13
WC Oncology
SC Oncology
GA CE2DP
UT WOS:000351624300007
PM 25385741
ER
PT J
AU Yuan, C
Rubinson, DA
Qian, ZR
Wu, C
Kraft, P
Bao, Y
Ogino, S
Ng, K
Clancy, TE
Swanson, RS
Gorman, MJ
Brais, LK
Li, TT
Stampfer, MJ
Hu, FB
Giovannucci, EL
Kulke, MH
Fuchs, CS
Wolpin, BM
AF Yuan, Chen
Rubinson, Douglas A.
Qian, Zhi Rong
Wu, Chen
Kraft, Peter
Bao, Ying
Ogino, Shuji
Ng, Kimmie
Clancy, Thomas E.
Swanson, Richard S.
Gorman, Megan J.
Brais, Lauren K.
Li, Tingting
Stampfer, Meir J.
Hu, Frank B.
Giovannucci, Edward L.
Kulke, Matthew H.
Fuchs, Charles S.
Wolpin, Brian M.
TI Survival Among Patients With Pancreatic Cancer and Long-Standing or
Recent-Onset Diabetes Mellitus
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID PHYSICAL-ACTIVITY; TEMPORAL ASSOCIATION; RISK; GLUCOSE; ADENOCARCINOMA;
INSULIN; OBESITY; METAANALYSIS; DIAGNOSIS; WOMEN
AB Purpose
Long-standing diabetes is a risk factor for pancreatic cancer, and recent-onset diabetes in the several years before diagnosis is a consequence of subclinical pancreatic malignancy. However, the impact of diabetes on survival is largely unknown.
Patients and Methods
We analyzed survival by diabetes status among 1,006 patients diagnosed from 1986 to 2010 from two prospective cohort studies: the Nurses' Health Study (NHS) and Health Professionals Follow-Up Study (HPFS). We validated our results among 386 patients diagnosed from 2004 to 2013 from a clinic-based case series at Dana-Farber Cancer Institute (DFCI). We estimated hazard ratios (HRs) for death using Cox proportional hazards models, with adjustment for age, sex, race/ethnicity, smoking, diagnosis year, and cancer stage.
Results
In NHS and HPFS, HR for death was 1.40 (95% CI, 1.15 to 1.69) for patients with long-term diabetes (> 4 years) compared with those without diabetes (P < .001), with median survival times of 3 months for long-term diabetics and 5 months for nondiabetics. Adjustment for a propensity score to reduce confounding by comorbidities did not change the results. Among DFCI patient cases, HR for death was 1.53 (95% CI, 1.07 to 2.20) for those with long-term diabetes compared with those without diabetes (P = .02), with median survival times of 9 months for long-term diabetics and 13 months for nondiabetics. Compared with nondiabetics, survival times were shorter for long-term diabetics who used oral hypoglycemics or insulin. We observed no statistically significant association of recent-onset diabetes (< 4 years) with survival.
Conclusion
Long-standing diabetes was associated with statistically significantly decreased survival among patients with pancreatic cancer enrolled onto three longitudinal studies. (C) 2014 by American Society of Clinical Oncology
C1 [Yuan, Chen; Rubinson, Douglas A.; Qian, Zhi Rong; Ogino, Shuji; Ng, Kimmie; Gorman, Megan J.; Brais, Lauren K.; Li, Tingting; Kulke, Matthew H.; Fuchs, Charles S.; Wolpin, Brian M.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Wu, Chen; Kraft, Peter; Ogino, Shuji; Stampfer, Meir J.; Hu, Frank B.; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Bao, Ying; Ogino, Shuji; Ng, Kimmie; Clancy, Thomas E.; Swanson, Richard S.; Stampfer, Meir J.; Hu, Frank B.; Giovannucci, Edward L.; Kulke, Matthew H.; Fuchs, Charles S.; Wolpin, Brian M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bao, Ying; Ogino, Shuji; Ng, Kimmie; Clancy, Thomas E.; Swanson, Richard S.; Stampfer, Meir J.; Hu, Frank B.; Giovannucci, Edward L.; Kulke, Matthew H.; Fuchs, Charles S.; Wolpin, Brian M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Wolpin, BM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM bwolpin@partners.org
FU National Cancer Institute (NCI; National Institutes of Health [NIH])
[P01 CA87969, P01 CA55075, U54 CA155626, P50 CA127003, R01 CA124908, R01
CA49449, 1UM1 CA167552]; NCI NIH [P50 CA127003, K07 CA140790]; Robert T.
and Judith B. Hale Fund for Pancreatic Cancer Research; Lustgarten
Foundation for the Dana-Farber Cancer Institute; American Society of
Clinical Oncology Conquer Cancer Foundation; Howard Hughes Medical
Institute; Lustgarten Foundation; Promises for Purple; NIH/NCI [K07
CA148894]
FX Supported by National Cancer Institute (NCI; National Institutes of
Health [NIH]) Grants No. P01 CA87969, P01 CA55075, U54 CA155626, P50
CA127003, R01 CA124908, R01 CA49449, and 1UM1 CA167552 for the Nurses'
Health Study and Health Professionals Follow-up Study; in part by NCI
NIH Grant No. P50 CA127003, the Robert T. and Judith B. Hale Fund for
Pancreatic Cancer Research, and the Lustgarten Foundation for the
Dana-Farber Cancer Institute; in part by NCI NIH Grant No. K07 CA140790,
the American Society of Clinical Oncology Conquer Cancer Foundation, the
Howard Hughes Medical Institute, the Lustgarten Foundation, and Promises
for Purple (B.M.W.); and in part by NIH/NCI Grant No. K07 CA148894 and
the American Society of Clinical Oncology Conquer Cancer Foundation
(K.N.).
NR 43
TC 14
Z9 17
U1 0
U2 11
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JAN 1
PY 2015
VL 33
IS 1
BP 29
EP U58
DI 10.1200/JCO.2014.57.5688
PG 11
WC Oncology
SC Oncology
GA CE2DP
UT WOS:000351624300008
PM 25403204
ER
PT J
AU Vaz-Luis, I
Lin, NU
AF Vaz-Luis, Ines
Lin, Nancy U.
TI Combination Trastuzumab and Chemotherapy May Have a Role in Women With
Small, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive
Breast Cancer Reply
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
C1 [Vaz-Luis, Ines; Lin, Nancy U.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Vaz-Luis, I (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 4
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JAN 1
PY 2015
VL 33
IS 1
BP 125
EP U183
DI 10.1200/JCO.2014.58.9655
PG 2
WC Oncology
SC Oncology
GA CE2DP
UT WOS:000351624300021
PM 25403214
ER
PT J
AU Adams, JM
Alexander, GA
Chisari, RG
Banister, G
McAuley, ME
Whitney, KB
Erickson, JI
AF Adams, Jeffrey M.
Alexander, Gail A.
Chisari, R. Gino
Banister, Gaurdia
McAuley, Mary Elizabeth
Whitney, Kevin B.
Erickson, Jeanette Ives
TI Strengthening New Graduate Nurse Residency Programs in Critical Care:
Recommendations From Nurse Residents and Organizational Stakeholders
SO JOURNAL OF CONTINUING EDUCATION IN NURSING
LA English
DT Article
ID SATISFACTION
AB Background: Thirty-four new graduate nurses participated in a critical care nurse residency program in preparation for opening a new intensive care unit. At the end of the program, multi-constituent focus groups were held to assess program effectiveness.
Method: Participants included 34 new graduate nurses, 18 preceptors and staff nurse partners, five clinical nurse specialists, and five nurse directors. Twelve focus groups were held; groups included four to eight nurses from the same role group. Two independent reviewers analyzed recordings and transcripts of focus group content to identify themes.
Results: Five themes were identified: program design, developing nursing expertise, program impact on the unit, future expectations, and communication. Comments were used to guide program improvements and offer new insights for residency programs in acute and critical care.
Conclusion: Obtaining structured input from multiple program stakeholders is beneficial in evaluating a program's impact and identifying areas for improvement.
C1 [Adams, Jeffrey M.] Massachusetts Gen Hosp, Ctr Innovat Care Delivery, Inst Patient Care, Robert Wood Johnson Fdn, Boston, MA 02114 USA.
[Adams, Jeffrey M.] Massachusetts Gen Hosp, Ctr Innovat Care Delivery, Inst Patient Care, Boston, MA 02114 USA.
[Alexander, Gail A.; Banister, Gaurdia] Massachusetts Gen Hosp, Inst Patient Care, Boston, MA 02114 USA.
[Chisari, R. Gino] Massachusetts Gen Hosp, Inst Patient Care, Norman Knight Nursing Ctr Clin & Profess Dev, Boston, MA 02114 USA.
[McAuley, Mary Elizabeth] Massachusetts Gen Hosp, Intens Care Unit, Boston, MA 02114 USA.
[Whitney, Kevin B.] Massachusetts Gen Hosp, Nurse Surg Orthoped & Neurosci, Boston, MA 02114 USA.
[Erickson, Jeanette Ives] Massachusetts Gen Hosp, Patient Care, Boston, MA 02114 USA.
RP Adams, JM (reprint author), Massachusetts Gen Hosp, Ctr Innovat Care Delivery, Inst Patient Care, Robert Wood Johnson Fdn, Profess Off Bldg Room 432,275 Cambridge St, Boston, MA 02114 USA.
EM jeff.adams@mgh.harvard.edu
NR 20
TC 2
Z9 2
U1 2
U2 9
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0022-0124
EI 1938-2472
J9 J CONTIN EDUC NURS
JI J. Contin. Educ. Nursing
PD JAN
PY 2015
VL 46
IS 1
BP 41
EP 48
DI 10.3928/00220124-20151217-01
PG 8
WC Nursing
SC Nursing
GA CE7DT
UT WOS:000351998200010
PM 25522374
ER
PT J
AU Trygstad, LN
Buccheri, RK
Buffum, MD
Ju, DS
Dowling, GA
AF Trygstad, Louise Nigh
Buccheri, Robin K.
Buffum, Martha D.
Ju, Dau-shen
Dowling, Glenna A.
TI Auditory Hallucinations Interview Guide Promoting Recovery with an
Interactive Assessment Tool
SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES
LA English
DT Article
ID COMMAND HALLUCINATIONS; BEHAVIORAL-MANAGEMENT; SELF-MANAGEMENT; HARM
AB The Auditory Hallucinations Interview Guide (AHIG) is a 32-item tool that helps psychiatric-mental health (PMH) nurses assess past and current experiences of voice hearers so they can provide more individualized care. The AHIG was developed as a research tool but has also been found to be clinically useful in both inpatient and outpatient settings to help voice hearers and nurses develop a shared terminology of auditory hallucinations (AH). Using the AHIG, voice hearers are able to tell their stories in a structured and safe environment, thus encouraging recovery. Through respect and active listening, PMH nurses can communicate unconditional acceptance, caring, and hope for recovery, which helps develop rapport and promote trust in the nurse-patient relationship. Once trust is developed, voice hearers and PMH nurses can work together to find effective strategies for managing AH, including commands to harm self and others.
C1 [Trygstad, Louise Nigh; Buccheri, Robin K.] Univ San Francisco, DNP Dept, Sch Nursing & Hlth Profess, San Francisco, CA 94117 USA.
[Buffum, Martha D.] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA.
[Dowling, Glenna A.] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA.
[Ju, Dau-shen] Iowa City Vet Affairs Hlth Care Syst, Mental Hlth Serv Line, Iowa City, IA USA.
[Buffum, Martha D.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Buccheri, RK (reprint author), Univ San Francisco, DNP Dept, Sch Nursing & Hlth Profess, Cowell Hall 222,2130 Fulton St, San Francisco, CA 94117 USA.
EM buccherir@usfca.edu
FU University of San Francisco Faculty Development Funds
FX The authors have disclosed no potential conflicts of interest, financial
or otherwise. This project was funded by a grant from the University of
San Francisco Faculty Development Funds. This material is the result of
work supported with resources and the use of facilities at the San
Francisco Veterans Affairs Medical Center, San Francisco, California,
and Iowa City Veterans Affairs Health Care System, Iowa City, Iowa. This
article is dedicated to all of the psychiatric-mental health nurses and
other mental health clinicians who work diligently to help their
patients learn how to manage their auditory hallucinations and stay
safe.
NR 16
TC 0
Z9 0
U1 2
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0279-3695
EI 1938-2413
J9 J PSYCHOSOC NURS MEN
JI J. Psychosoc. Nurs. Ment. Health Serv.
PD JAN
PY 2015
VL 53
IS 1
BP 20
EP 28
DI 10.3928/02793695-20141203-01
PG 9
WC Nursing
SC Nursing
GA CE7IL
UT WOS:000352012500009
PM 25490776
ER
PT J
AU Gettinger, SN
Bazhenova, L
Salgia, R
Langer, CJ
Gold, KA
Rosell, R
Shaw, AT
Weiss, GJ
Narasimhan, NI
Dorer, DJ
Rivera, VM
Clackson, T
Haluska, FG
Camidge, DR
AF Gettinger, S. N.
Bazhenova, L.
Salgia, R.
Langer, C. J.
Gold, K. A.
Rosell, R.
Shaw, A. T.
Weiss, G. J.
Narasimhan, N. I.
Dorer, D. J.
Rivera, V. M.
Clackson, T.
Haluska, F. G.
Camidge, D. R.
TI Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer
(NSCLC), including patients with brain metastases
SO LUNG CANCER
LA English
DT Meeting Abstract
C1 [Gettinger, S. N.] Yale Canc Ctr, Thorac Oncol Program, New Haven, CT USA.
[Bazhenova, L.] Univ Calif San Diego, Div Hematol Oncol, Moores Canc Ctr, San Diego, CA 92103 USA.
[Salgia, R.] Univ Chicago Med, Pathol & Dermatol Dept, Chicago, IL USA.
[Langer, C. J.] Univ Penn, Abramson Canc, Dept Med, Philadelphia, PA 19104 USA.
[Gold, K. A.] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
[Rosell, R.] Hosp Badalona Germans Trias & Pujol, Canc Biol & Precis Med Program, Catalan Inst Oncol, Barcelona, Spain.
[Shaw, A. T.] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA.
[Weiss, G. J.] Canc Treatment Ctr Amer, Western Reg Med Ctr, Scottsdale, AZ USA.
[Narasimhan, N. I.; Rivera, V. M.] ARIAD Pharmaceut Inc, Preclin & Translat Res, Cambridge, MA USA.
[Dorer, D. J.; Clackson, T.] ARIAD Pharmaceut Inc, Res & Dev, Cambridge, MA USA.
[Haluska, F. G.] ARIAD Pharmaceut Inc, Cambridge, MA USA.
[Camidge, D. R.] Univ Colorado, Sch Med, Div Oncol, Denver, CO 80202 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD JAN
PY 2015
VL 87
SU 1
MA 81
BP S32
EP S32
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA CE4IQ
UT WOS:000351794700081
ER
PT J
AU Mackie, S
Winkelman, JW
AF Mackie, Susan
Winkelman, John W.
TI Insomnia
SO PSYCHIATRIC ANNALS
LA English
DT Article
ID MAJOR DEPRESSIVE DISORDER; SLEEP; PTSD
AB Insomnia is frequently present in patients with a variety of psychiatric conditions. Both the Diagnostic and Statistical Manual of Mental Disorders, fifth edition and the International Classification of Sleep Disorders, third edition include definitions that emphasize symptoms of difficulty initiating or maintaining sleep in the face of adequate opportunity for sleep. Although insomnia has historically been thought of as merely a symptom of various psychiatric conditions, more recent research indicates that psychiatric patients with comorbid insomnia benefit from identification and specific treatment of the sleep disorder. This review provides an introduction to the changing definitions of insomnia disorder, discusses the complex relationship with psychiatric conditions, and outlines the most effective available treatment options for insomnia, including cognitive behavioral therapy and hypnotic agents.
C1 [Mackie, Susan] Harvard Univ, Sch Med, Brigham & Womens Hosp, Med, Boston, MA 02138 USA.
[Winkelman, John W.] Massachusetts Gen Hosp, Dept Psychiat, Sleep Disorders Clin Res Program, Boston, MA 02114 USA.
[Winkelman, John W.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Winkelman, JW (reprint author), Sleep Disorders Clin Res Program, 1 Bowdoin Sq,9th Floor, Boston, MA 02114 USA.
EM jwwinkelman@partners.org
FU UCB Pharma; Insys; FlexPharma; Merck Co.
FX John W. Winkelman discloses consulting fees from UCB Pharma, Insys,
FlexPharma, and Merck & Co.; contracted research for UCB Pharma and
Purdue; and expert testimony for Cantor Colburn. The remaining author
has no relevant financial relationships to disclose.
NR 17
TC 0
Z9 0
U1 1
U2 10
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD JAN
PY 2015
VL 45
IS 1
DI 10.3928/00485713-20150106-04
PG 9
WC Psychiatry
SC Psychiatry
GA CE6JG
UT WOS:000351942100004
ER
PT J
AU Pusztaszeri, MP
Faquin, WC
AF Pusztaszeri, Marc P.
Faquin, William C.
TI Cytologic evaluation of cervical lymph node metastases from cancers of
unknown primary origin
SO SEMINARS IN DIAGNOSTIC PATHOLOGY
LA English
DT Article
DE HPV; EBV; Oropharynx; Squamous cell carcinoma; Fine-needle aspiration;
Cervical lymph node metastases
ID FINE-NEEDLE-ASPIRATION; SQUAMOUS-CELL CARCINOMA; EPSTEIN-BARR-VIRUS;
IN-SITU HYBRIDIZATION; PAPILLARY THYROID-CARCINOMA; HYBRID CAPTURE 2;
HIGH-RISK HPV; HUMAN-PAPILLOMAVIRUS; NASOPHARYNGEAL CARCINOMA;
NECK-CANCER
AB Fine-needle aspiration biopsy (FNAB) is often the first diagnostic procedure performed in patients with head and neck (RN) masses. Metastatic squamous cell carcinoma (SCC) to cervical lymph nodes is by far the most common malignancy aspirated in the RN, but in approximately 3-10% of patients, a primary tumor will not be found even after complete clinico-radiological workup. Several HN cancers are associated with oncogenic viruses, including HPV-associated SCC and EBV-associated nasopharyngeal carcinoma (NPC). While the primary tumor is sometimes small or undetectable, patients often present initially with cervical lymph node metastases. HPV-associated SCC and EBV-associated NPC are typically non-keratinizing carcinomas that can mimic several other poorly differentiated HN cancers by FNAB but have a significantly better prognosis. Therefore, the precise classification of the metastatic disease in the FNAB material is very useful since it can facilitate the subsequent location of the primary tumor, and it can provide prognostic and therapeutic information as well. In this review, we discuss the major entities that can present as a metastatic cancer of unknown primary in cervical lymph node other than supraclavicular, including their cytologic features and the role of ancillary studies. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Pusztaszeri, Marc P.] Univ Hosp Geneva, Dept Pathol, CH-1211 Geneva 14, Switzerland.
[Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Faquin, William C.] Harvard Univ, Sch Med, Boston, MA USA.
RP Pusztaszeri, MP (reprint author), Univ Hosp Geneva, Dept Pathol, 1 Rue Michel Servet, CH-1211 Geneva 14, Switzerland.
EM Marc.Pusztaszeri@hcuge.ch
NR 52
TC 6
Z9 6
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0740-2570
EI 1930-1111
J9 SEMIN DIAGN PATHOL
JI Semin. Diagn. Pathol.
PD JAN
PY 2015
VL 32
IS 1
BP 32
EP 41
DI 10.1053/j.semdp.2014.12.002
PG 10
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA CE5PD
UT WOS:000351886700005
PM 25618223
ER
PT J
AU Amgarten, B
Rajan, R
Martinez-Saez, N
Oliveira, BL
Albuquerque, IS
Brooks, RA
Reid, DG
Duer, MJ
Bernardes, GJL
AF Amgarten, Beatrice
Rajan, Rakesh
Martinez-Saez, Nuria
Oliveira, Bruno L.
Albuquerque, Ines S.
Brooks, Roger A.
Reid, David G.
Duer, Melinda J.
Bernardes, Goncalo J. L.
TI Collagen labelling with an azide-proline chemical reporter in live cells
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID NEWLY SYNTHESIZED PROTEINS; CONFORMATIONAL STABILITY; MAMMALIAN-CELLS;
CLICK CHEMISTRY; TRIPLE HELICES; LIVING CELLS; COPPER-FREE;
VISUALIZATION
AB We have developed a strategy for selective imaging of collagen in live foetal ovine osteoblasts. Our approach involves the incorporation of an azide-tagged proline in the biosynthesis of collagen followed by labelling using a strain-promoted [3+2] azide-alkyne cycloaddition reaction.
C1 [Amgarten, Beatrice; Martinez-Saez, Nuria; Reid, David G.; Duer, Melinda J.; Bernardes, Goncalo J. L.] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England.
[Rajan, Rakesh; Brooks, Roger A.] Univ Cambridge, Addenbrookes Hosp, Div Trauma & Orthopaed Surg, Cambridge CB2 0QQ, England.
[Oliveira, Bruno L.] Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Sch Med,Dept Radiol, Charlestown, MA USA.
[Albuquerque, Ines S.; Bernardes, Goncalo J. L.] Univ Lisbon, Fac Med, Inst Mol Med, P-1649028 Lisbon, Portugal.
RP Bernardes, GJL (reprint author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.
EM gb453@cam.ac.uk
RI Martinez-Saez, Nuria/L-1955-2016; Albuquerque, Ines/P-5325-2016;
OI Albuquerque, Ines/0000-0002-1108-0961; Oliveira,
Bruno/0000-0002-7687-4746; Bernardes, Goncalo/0000-0001-6594-8917
FU EU; FCT Portugal; EPSRC; National Institute of Health Research
FX We thank the EU (Erasmus studentship to B.A.; Marie Curie CIG to
G.J.L.B.), FCT Portugal (FCT Investigator to G.J.L.B.), the EPSRC and
the National Institute of Health Research for funding. We also thank
Karin Muller for help with confocal microscopy and SEM and Dr Filipa
Cruz for critical reading of the manuscript. G.J.L.B. is a Royal Society
University Research Fellow.
NR 24
TC 1
Z9 1
U1 5
U2 16
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2015
VL 51
IS 25
BP 5250
EP 5252
DI 10.1039/c4cc07974d
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA CD9CG
UT WOS:000351393600009
PM 25415185
ER
PT J
AU Yonekawa, Y
Kim, IK
AF Yonekawa, Yoshihiro
Kim, Ivana K.
TI Clinical Characteristics and Current Treatment of Age-Related Macular
Degeneration
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; TISSUE-PLASMINOGEN ACTIVATOR;
OPTICAL-COHERENCE-TOMOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION;
VERTEPORFIN PHOTODYNAMIC THERAPY; THICK SUBMACULAR HEMORRHAGE;
ENDOTHELIAL GROWTH-FACTOR; BEAVER DAM EYE; VEGF TRAP-EYE; GEOGRAPHIC
ATROPHY
AB Age-related macular degeneration (AMD) is a multifactorial degeneration of photoreceptors and retinal pigment epithelium. The societal impact is significant, with more than 2 million individuals in the United States alone affected by advanced stages of AMD. Recent progress in our understanding of this complex disease and parallel developments in therapeutics and imaging have translated into new management paradigms in recent years. However, there are many unanswered questions, and diagnostic and prognostic precision and treatment outcomes can still be improved. In this article, we discuss the clinical features of AMD, provide correlations with modern imaging and histopathology, and present an overview of treatment strategies.
C1 [Yonekawa, Yoshihiro; Kim, Ivana K.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Retina Serv, Boston, MA 02114 USA.
RP Kim, IK (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Retina Serv, Boston, MA 02114 USA.
EM Ivana_Kim@meei.harvard.edu
NR 124
TC 2
Z9 2
U1 1
U2 3
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD JAN
PY 2015
VL 5
IS 1
AR a017178
DI 10.1101/cshperspect.a017178
PG 18
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CD6YM
UT WOS:000351236900004
ER
PT J
AU Puchner, SB
Ferencik, M
Maurovich-Horvat, P
Nakano, M
Otsuka, F
Kauczor, HU
Virmani, R
Hoffmann, U
Schlett, CL
AF Puchner, Stefan B.
Ferencik, Maros
Maurovich-Horvat, Pal
Nakano, Masataka
Otsuka, Fumiyuki
Kauczor, Hans-Ulrich
Virmani, Renu
Hoffmann, Udo
Schlett, Christopher L.
TI Iterative image reconstruction algorithms in coronary CT angiography
improve the detection of lipid-core plaque - a comparison with histology
SO EUROPEAN RADIOLOGY
LA English
DT Article
DE Coronary CT angiography; Iterative reconstruction algorithm; Vulnerable
plaque; Low attenuation plaque; Diagnostic accuracy
ID 64-SLICE COMPUTED-TOMOGRAPHY; FILTERED BACK-PROJECTION; INTRAVASCULAR
ULTRASOUND; ATHEROSCLEROTIC LESIONS; VULNERABLE PLAQUE; ARTERY CALCIUM;
CARDIAC CT; QUANTIFICATION; STENOSIS; MODEL
AB Objectives To evaluate whether iterative reconstruction algorithms improve the diagnostic accuracy of coronary CT angiography (CCTA) for detection of lipid-core plaque (LCP) compared to histology.
Methods and materials CCTA and histological data were acquired from three ex vivo hearts. CCTA images were reconstructed using filtered back projection (FBP), adaptivestatistical (ASIR) and model-based (MBIR) iterative algorithms. Vessel cross-sections were co-registered between FBP/ASIR/MBIR and histology. Plaque area <60 HU was semiautomatically quantified in CCTA. LCP was defined by histology as fibroatheroma with a large lipid/necrotic core. Area under the curve (AUC) was derived from logistic regression analysis as a measure of diagnostic accuracy.
Results Overall, 173 CCTA triplets (FBP/ASIR/MBIR) were co-registered with histology. LCP was present in 26 crosssections. Average measured plaque area <60 HU was significantly larger in LCP compared to non-LCP cross-sections (mm(2): 5.78 +/- 2.29 vs. 3.39 +/- 1.68 FBP; 5.92 +/- 1.87 vs. 3.43 +/- 1.62 ASIR; 6.40 +/- 1.55 vs. 3.49 +/- 1.50 MBIR; all p<0.0001). AUC for detecting LCP was 0.803/0.850/0.903 for FBP/ASIR/MBIR and was significantly higher for MBIR compared to FBP (p=0.01). MBIR increased sensitivity for detection of LCP by CCTA.
Conclusion Plaque area <60 HU in CCTA was associated with LCP in histology regardless of the reconstruction algorithm. However, MBIR demonstrated higher accuracy for detecting LCP, which may improve vulnerable plaque detection by CCTA.
C1 [Puchner, Stefan B.; Ferencik, Maros; Maurovich-Horvat, Pal; Hoffmann, Udo; Schlett, Christopher L.] Harvard Univ, Sch Med, Dept Radiol, Cardiac MR PET CT Program,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Puchner, Stefan B.] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria.
[Ferencik, Maros] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA.
[Maurovich-Horvat, Pal] Semmelweis Univ, MTA SE Lendulet Cardiovasc Imaging Res Grp, Heart & Vasc Ctr, H-1085 Budapest, Hungary.
[Nakano, Masataka; Otsuka, Fumiyuki; Virmani, Renu] CV Path Inst Inc, Gaithersburg, MD USA.
[Kauczor, Hans-Ulrich; Schlett, Christopher L.] Heidelberg Univ, Dept Diagnost & Intervent Radiol, Univ Heidelberg Hosp, Heidelberg, Germany.
RP Schlett, CL (reprint author), Harvard Univ, Sch Med, Dept Radiol, Cardiac MR PET CT Program,Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM christopher.schlett@post.harvard.edu
FU GE Healthcare, Milwaukee WI
FX The scientific guarantor of this publication is Prof. Dr. Udo Hoffmann,
Division Head of Cardiac and Vascular Imaging, Massachusetts General
Hospital/Harvard Medical School, Boston, MA. The authors of this
manuscript declare relationships with the following companies: This work
was supported by an unrestricted grant from GE Healthcare, Milwaukee WI.
The authors had access to pre-commercial image reconstruction algorithms
as developed by GE Healthcare. Commercially available software for the
(semi-) automated plaque assessment was provided free of charge by Vital
Images, Minnetonka, MN. One of the authors has significant statistical
expertise. Institutional Review Board approval was obtained. Written
informed consent was waived by the Institutional Review Board. Some
study subjects or cohorts have been previously reported as part of the
MGH Multi-Modality Coronary Plaque Imaging Database [Maurovich-Horvat P,
Schlett CL, Alkadhi H, et al. Differentiation of early from advanced
coronary atherosclerotic lesions: systematic comparison of CT,
intravascular US, and optical frequency domain imaging with
histopathologic examination in ex vivo human hearts. Radiology. 2012
Nov; 265(2): 393-401]. Methodology: prospective, experimental (ex vivo),
performed at one institution.
NR 52
TC 9
Z9 9
U1 2
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-7994
EI 1432-1084
J9 EUR RADIOL
JI Eur. Radiol.
PD JAN
PY 2015
VL 25
IS 1
BP 15
EP 23
DI 10.1007/s00330-014-3404-6
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CD6UQ
UT WOS:000351225500003
PM 25182630
ER
PT J
AU Kwon, JY
Zurakowski, D
Ellington, JK
AF Kwon, John Y.
Zurakowski, David
Ellington, J. Kent
TI Influence of Contralateral Radiographs on Accuracy of Anatomic Reduction
in Surgically Treated Calcaneus Fractures
SO FOOT & ANKLE INTERNATIONAL
LA English
DT Article
DE calcaneus; fracture; template; contralateral X-ray
ID ANGLES; BOHLERS; RELIABILITY; POPULATION
AB Background: The purpose of this study was to determine whether obtaining a radiograph of the uninjured contralateral calcaneus (template) before surgery allowed for more precise restoration of Bohler's angle and calcaneal length when performing open reduction internal fixation (ORIF) of intra-articular calcaneus fractures.
Methods: Patients who sustained an intra-articular calcaneus fracture requiring surgery who met inclusion criteria were prospectively randomized into those who had a preoperative template obtained for review at the time of ORIF (group 1) versus those who had the contralateral radiograph obtained after surgery (group 2).
Results: There was no benefit of the preoperative template in allowing for more anatomic restoration of Bohler's angle or calcaneal length. Operative time was decreased with the use of a preoperative template when using the extensile lateral or percutaneous approaches.
Conclusion: Preoperative templating of the uninjured contralateral calcaneus did not allow for more anatomic reduction or restoration of pre-injury morphology of the calcaneus undergoing operative fixation as based on Bohler's angle and calcaneal length. Templating may be of benefit by reducing operative time.
C1 [Kwon, John Y.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA.
[Zurakowski, David] Boston Childrens Hosp, Boston, MA USA.
[Ellington, J. Kent] Foot & Ankle Inst, OrthoCarolina, Charlotte, NC USA.
RP Kwon, JY (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA.
EM johnkwonmd@gmail.com
NR 23
TC 5
Z9 5
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1071-1007
EI 1944-7876
J9 FOOT ANKLE INT
JI Foot Ankle Int.
PD JAN
PY 2015
VL 36
IS 1
BP 75
EP 82
DI 10.1177/1071100714552483
PG 8
WC Orthopedics
SC Orthopedics
GA CD7BD
UT WOS:000351244300013
PM 25301892
ER
PT J
AU Chamberlain, D
Sweeney, CJ
AF Chamberlain, Dominic
Sweeney, Christopher J.
TI Insights into E3805: the CHAARTED trial
SO FUTURE ONCOLOGY
LA English
DT Editorial Material
DE androgen-deprivation therapy; docetaxel; hormone-sensitive metastatic
prostate cancer
C1 [Chamberlain, Dominic] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Sweeney, Christopher J.] Indiana Univ, Med Ctr, Bloomington, IN 47405 USA.
[Sweeney, Christopher J.] Simon Canc Ctr, Indianapolis, IN USA.
[Sweeney, Christopher J.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA.
[Sweeney, Christopher J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Chamberlain, D (reprint author), Dana Farber Canc Inst, Boston, MA 02215 USA.
NR 0
TC 2
Z9 2
U1 1
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PY 2015
VL 11
IS 6
BP 897
EP 899
DI 10.2217/FON.14.310
PG 3
WC Oncology
SC Oncology
GA CD7ON
UT WOS:000351280200005
ER
PT J
AU Zhang, MY
Keel, SB
Walsh, T
Lee, MK
Gulsuner, S
Watts, AC
Pritchard, CC
Salipante, SJ
Jeng, MR
Hofmann, I
Williams, DA
Fleming, MD
Abkowitz, JL
King, MC
Shimamura, A
AF Zhang, Michael Y.
Keel, Sioban B.
Walsh, Tom
Lee, Ming K.
Gulsuner, Suleyman
Watts, Amanda C.
Pritchard, Colin C.
Salipante, Stephen J.
Jeng, Michael R.
Hofmann, Inga
Williams, David A.
Fleming, Mark D.
Abkowitz, Janis L.
King, Mary-Claire
Shimamura, Akiko
TI Genomic analysis of bone marrow failure and myelodysplastic syndromes
reveals phenotypic and diagnostic complexity
SO HAEMATOLOGICA
LA English
DT Article
ID DNA-LIGASE-IV; SHWACHMAN-DIAMOND-SYNDROME; PROTEIN GENE DELETIONS; ACUTE
MYELOID-LEUKEMIA; B-CELL LYMPHOMA; DYSKERATOSIS-CONGENITA; MONOMAC
SYNDROME; FANCONI-ANEMIA; GATA2 MUTATIONS; HIGH-FREQUENCY
AB Accurate and timely diagnosis of inherited bone marrow failure and inherited myelodysplastic syndromes is essential to guide clinical management. Distinguishing inherited from acquired bone marrow failure/myelodysplastic syndrome poses a significant clinical challenge. At present, diagnostic genetic testing for inherited bone marrow failure/myelodysplastic syndrome is performed gene-by-gene, guided by clinical and laboratory evaluation. We hypothesized that standard clinically-directed genetic testing misses patients with cryptic or atypical presentations of inherited bone marrow failure/myelodysplastic syndrome. In order to screen simultaneously for mutations of all classes in bone marrow failure/myelodysplastic syndrome genes, we developed and validated a panel of 85 genes for targeted capture and multiplexed massively parallel sequencing. In patients with clinical diagnoses of Fanconi anemia, genomic analysis resolved subtype assignment, including those of patients with inconclusive complementation test results. Eight out of 71 patients with idiopathic bone marrow failure or myelodysplastic syndrome were found to harbor damaging germline mutations in GATA2, RUNX1, DKC1, or LIG4. All 8 of these patients lacked classical clinical stigmata or laboratory findings of these syndromes and only 4 had a family history suggestive of inherited disease. These results reflect the extensive genetic heterogeneity and phenotypic complexity of bone marrow failure/myelodysplastic syndrome phenotypes. This study supports the integration of broad unbiased genetic screening into the diagnostic workup of children and young adults with bone marrow failure and myelodysplastic syndromes.
C1 [Zhang, Michael Y.; Shimamura, Akiko] Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98104 USA.
[Keel, Sioban B.; Abkowitz, Janis L.] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA.
[Walsh, Tom; Lee, Ming K.; Gulsuner, Suleyman; Watts, Amanda C.; King, Mary-Claire] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Walsh, Tom; Lee, Ming K.; Gulsuner, Suleyman; Watts, Amanda C.; King, Mary-Claire] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Pritchard, Colin C.; Salipante, Stephen J.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[Jeng, Michael R.] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.
[Hofmann, Inga; Williams, David A.] Childrens Hosp, Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA.
[Hofmann, Inga; Williams, David A.] Harvard Univ, Sch Med, Boston, MA USA.
[Williams, David A.] Harvard Stem Cell Inst, Boston, MA USA.
[Fleming, Mark D.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA.
[Shimamura, Akiko] Seattle Childrens Hosp, Dept Pediat Hematol Oncol, Seattle, WA USA.
[Shimamura, Akiko] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
RP Shimamura, A (reprint author), Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA.
EM ashimamu@fhcrc.org
OI Walsh, Tom/0000-0002-8875-0310
FU NIH/NIDDK [R24DK093425, R24DK099808, R24DK094746, T32AG000057];
Ghiglione Aplastic Anemia Fund; Julian's Dinosaur Guild at Seattle
Children's Hospital
FX This work was supported by NIH/NIDDK grants R24DK093425 and R24DK099808
(A.S., M.C.K., J.A.), R24DK094746 (M.D.F., D.A.W.), T32AG000057
(M.Y.Z.), and the Ghiglione Aplastic Anemia Fund and the Julian's
Dinosaur Guild at Seattle Children's Hospital (A.S.). M.C.K. is an
American Cancer Society professor.
NR 48
TC 24
Z9 24
U1 1
U2 5
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JAN
PY 2015
VL 100
IS 1
BP 42
EP 48
DI 10.3324/haematol.2014.113456
PG 7
WC Hematology
SC Hematology
GA CD7NX
UT WOS:000351278500021
PM 25239263
ER
PT J
AU Dimopoulos, MA
Orlowski, RZ
Facon, T
Sonneveld, P
Anderson, KC
Beksac, M
Benboubker, L
Roddie, H
Potamianou, A
Couturier, C
Feng, H
Ataman, O
de Velde, HV
Richardson, PG
AF Dimopoulos, Meletios A.
Orlowski, Robert Z.
Facon, Thierry
Sonneveld, Pieter
Anderson, Kenneth C.
Beksac, Meral
Benboubker, Lotfi
Roddie, Huw
Potamianou, Anna
Couturier, Catherine
Feng, Huaibao
Ataman, Ozlem
de Velde, Helgi van
Richardson, Paul G.
TI Retrospective matched-pairs analysis of bortezomib plus dexamethasone
versus bortezomib monotherapy in relapsed multiple myeloma
SO HAEMATOLOGICA
LA English
DT Article
ID RANDOMIZED PHASE-III; EXTENDED FOLLOW-UP; REFRACTORY MYELOMA;
COMBINATION; SURVIVAL; MULTICENTER; TRIAL; TIME; PROGRAM; DISEASE
AB Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking. This retrospective analysis compared second-line treatment with bortezomib-dexamethasone and bortezomib using 109 propensity score-matched pairs of patients treated in three clinical trials: MMY-2045, APEX, and DOXIL-MMY-3001. Propensity scores were estimated using logistic regression analyses incorporating 13 clinical variables related to drug exposure or clinical outcome. Patients received intravenous bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11, in 21-day cycles, alone or with oral dexamethasone 20 mg on the days of/after bortezomib dosing. Median bortezomib cumulative dose (27.02 and 28.60 mg/m2) and treatment duration (19.6 and 17.6 weeks) were similar with bortezomib-dexamethasone and bortezomib, respectively. The overall response rate was higher (75% vs. 41%; odds ratio=3.467; P<0.001), and median time-to-progression (13.6 vs. 7.0 months; hazard ratio [HR]=0.394; P=0.003) and progression-free survival (11.9 vs. 6.4 months; HR=0.595; P=0.051) were longer with bortezomib-dexamethasone versus bortezomib, respectively. Rates of any-grade adverse events, most common grade 3 or higher adverse events, and discontinuations due to adverse events appeared similar between the groups. Two patients per group died of treatment-related adverse events. These data indicate the potential benefit of bortezomib-dexamethasone compared with single-agent bortezomib at first relapse in myeloma. The MMY-2045, APEX, and DOXIL-MMY-3001 clinical trials were registered at, respectively, clinicaltrials.govidentifier: 00908232, 00048230, and 00103506.
C1 [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Dept Clin Therapeut, GR-10679 Athens, Greece.
[Orlowski, Robert Z.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Facon, Thierry] Hop Claude Huriez, Lille, France.
[Sonneveld, Pieter] Univ Rotterdam Hosp, Erasmus Med Ctr, Dept Hematol, Rotterdam, Netherlands.
[Anderson, Kenneth C.; Richardson, Paul G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Beksac, Meral] Ankara Univ, Sch Med, Dept Hematol, TR-06100 Ankara, Turkey.
[Benboubker, Lotfi] CHRU, Ctr Reg Cancerol Henry Kaplan, Tours, France.
[Benboubker, Lotfi] Hop Bretonneau, Tours, France.
[Roddie, Huw] Western Gen Hosp, Dept Haematol, Edinburgh EH4 2XU, Midlothian, Scotland.
[Potamianou, Anna] Janssen Cilag Pharmaceut SACI, Athens, Greece.
[Couturier, Catherine] Janssen Cilag, Issy Les Moulineaux, France.
[Feng, Huaibao] Janssen Res & Dev LLC, Raritan, NJ USA.
[Ataman, Ozlem] Janssen Cilag UK, High Wycombe, Bucks, England.
[de Velde, Helgi van] Div Janssen Pharmaceut NV, Janssen Res & Dev, Beerse, Belgium.
RP Dimopoulos, MA (reprint author), Univ Athens, Sch Med, Dept Clin Therapeut, GR-10679 Athens, Greece.
EM mdimop@med.uoa.gr
RI FACON, THIERRY/M-9736-2014
OI FACON, THIERRY/0000-0001-7705-8460
FU Janssen Research Development
FX This work was supported by Janssen Research & Development.
NR 43
TC 19
Z9 20
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JAN
PY 2015
VL 100
IS 1
BP 100
EP 106
DI 10.3324/haematol.2014.112037
PG 7
WC Hematology
SC Hematology
GA CD7NX
UT WOS:000351278500029
PM 25261096
ER
PT J
AU Ehret, PJ
LaBrie, JW
Santerre, C
Sherman, DK
AF Ehret, Phillip J.
LaBrie, Joseph W.
Santerre, Craig
Sherman, David K.
TI Self-affirmation and motivational interviewing: integrating perspectives
to reduce resistance and increase efficacy of alcohol interventions
SO HEALTH PSYCHOLOGY REVIEW
LA English
DT Article
DE message processing; intervention efficacy; self-affirmation theory;
resistance; alcohol interventions; motivational interviewing
ID HEALTH-RISK INFORMATION; RANDOMIZED CONTROLLED-TRIAL; POSITIVE-AFFECT;
PHYSICAL-ACTIVITY; BEHAVIOR-CHANGE; DISSONANCE; STRESS; DEFENSIVENESS;
VULNERABILITY; CONSEQUENCES
AB To promote efforts at reducing problematic alcohol use and improving health outcomes, the present review proposes an integration of a social psychological approach - self-affirmation theory - with a clinical psychology intervention - motivational interviewing. Motivational interviewing (MI) is a popular empirically-designed treatment approach that has shown moderate success at reducing drinking and improving health, especially with resistant drinkers. Experiments informed by self-affirmation theory have found that people exhibit reduced defensiveness to threatening health messages and increased intentions to reduce alcohol consumption when affirmed. This review focuses on the mechanisms by which self-affirmation reduces resistance and how these mechanisms are complementary to the MI approach. Further, the review outlines suggestions for conducting and integrating self-affirmation into a MI intervention and provides recommendations for future empirical research.
C1 [Ehret, Phillip J.; Sherman, David K.] Univ Calif Santa Barbara, Dept Psychol & Brain Sci, Santa Barbara, CA 93106 USA.
[LaBrie, Joseph W.] Loyola Marymount Univ, Dept Psychol, Los Angeles, CA 90045 USA.
[Santerre, Craig] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA.
RP Ehret, PJ (reprint author), Univ Calif Santa Barbara, Dept Psychol & Brain Sci, Santa Barbara, CA 93106 USA.
EM ehret@psych.ucsb.edu
NR 80
TC 2
Z9 2
U1 3
U2 16
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1743-7199
EI 1743-7202
J9 HEALTH PSYCHOL REV
JI Health Psychol. Rev.
PD JAN 1
PY 2015
VL 9
IS 1
BP 83
EP 102
DI 10.1080/17437199.2013.840953
PG 20
WC Psychology, Clinical
SC Psychology
GA CE3SJ
UT WOS:000351748500010
PM 25793492
ER
PT J
AU Cummings, J
Mintzer, J
Brodaty, H
Sano, M
Banerjee, S
Devanand, DP
Gauthier, S
Howard, R
Lanctot, K
Lyketsos, CG
Peskind, E
Porsteinsson, AP
Reich, E
Sampaio, C
Steffens, D
Wortmann, M
Zhong, K
AF Cummings, Jeffrey
Mintzer, Jacobo
Brodaty, Henry
Sano, Mary
Banerjee, Sube
Devanand, D. P.
Gauthier, Serge
Howard, Robert
Lanctot, Krista
Lyketsos, Constantine G.
Peskind, Elaine
Porsteinsson, Anton P.
Reich, Edgardo
Sampaio, Cristina
Steffens, David
Wortmann, Marc
Zhong, Kate
TI Agitation in cognitive disorders: International Psychogeriatric
Association provisional consensus clinical and research definition
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Article
DE Alzheimer's disease; agitation; cognitive impairment; aggression;
International Psychogeriatric Association; Food and Drug Administration;
clinical trials; intervention; epidemiology
ID NEUROPSYCHIATRIC SYMPTOMS; ALZHEIMERS-DISEASE; BEHAVIORAL SYMPTOMS;
NURSING-HOME; DEMENTIA; MANAGEMENT; EFFICACY; MEMORY
AB Background: Agitation is common across neuropsychiatric disorders and contributes to disability, institutionalization, and diminished quality of life for patients and their caregivers. There is no consensus definition of agitation and no widespread agreement on what elements should be included in the syndrome. The International Psychogeriatric Association formed an Agitation Definition Work Group (ADWG) to develop a provisional consensus definition of agitation in patients with cognitive disorders that can be applied in epidemiologic, non-interventional clinical, pharmacologic, non-pharmacologic interventional, and neurobiological studies. A consensus definition will facilitate communication and cross-study comparison and may have regulatory applications in drug development programs.
Methods: The ADWG developed a transparent process using a combination of electronic, face-to-face, and survey-based strategies to develop a consensus based on agreement of a majority of participants. Nine-hundred twenty-eight respondents participated in the different phases of the process.
Results: Agitation was defined broadly as: (1) occurring in patients with a cognitive impairment or dementia syndrome; (2) exhibiting behavior consistent with emotional distress; (3) manifesting excessive motor activity, verbal aggression, or physical aggression; and (4) evidencing behaviors that cause excess disability and are not solely attributable to another disorder (psychiatric, medical, or substance-related). A majority of the respondents rated all surveyed elements of the definition as "strongly agree" or "somewhat agree" (68-88% across elements). A majority of the respondents agreed that the definition is appropriate for clinical and research applications.
Conclusions: A provisional consensus definition of agitation has been developed. This definition can be used to advance interventional and non-interventional research of agitation in patients with cognitive impairment.
C1 [Cummings, Jeffrey; Zhong, Kate] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA.
[Mintzer, Jacobo] Roper St Francis Hosp, Clin Biotechnol Res Inst, Charleston, SC USA.
[Brodaty, Henry] Univ New S Wales, Ctr Hlth Brain Ageing, Sydney, NSW, Australia.
[Sano, Mary] Mt Sinai Sch Med, New York, NY USA.
[Banerjee, Sube] Univ Sussex, Trafford Ctr Med Res, Brighton & Sussex Med Sch, Brighton, E Sussex, England.
[Devanand, D. P.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Gauthier, Serge] Douglas Mental Hlth Univ Inst Montreal, McGill Ctr Studies Aging, Montreal, PQ, Canada.
[Howard, Robert] Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
[Lanctot, Krista] Univ Toronto, Sunnybrook Res Inst, Toronto, ON, Canada.
[Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Johns Hopkins Memory & Alzheimers Treatment Ctr, Baltimore, MD USA.
[Peskind, Elaine] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Porsteinsson, Anton P.] Monroe Community Hosp, Rochester, NY USA.
[Reich, Edgardo] Univ Buenos Aires, Hosp Julio Mendez, Dept Neurosci, Buenos Aires, DF, Argentina.
[Sampaio, Cristina] CHDI Fdn, Princeton, NJ USA.
[Steffens, David] Univ Connecticut, Ctr Hlth, Dept Psychiat, Farmington, CT 06032 USA.
[Wortmann, Marc] Alzheimers Dis Int, London, England.
RP Cummings, J (reprint author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 888 W Bonneville Ave, Las Vegas, NV 89106 USA.
EM cumminj@ccf.org
FU Otsuka and Avanir Pharmaceutricals; Eli Lilly; Associated Jewish
Federation of Baltimore; Weinberg Foundation; Forest; GlaxoSmithKline;
Eisai; Pfizer; Astra-Zeneca; Lilly; Ortho-McNeil; Bristol-Myers;
Novartis; National Football League; Elan; Functional Neuromodulation;
Takeda Global Research and Development Center; Genentech; Merck; Accera;
Avanir; F. Hoffmann-La Roche; Baxter; Wyeth; Janssen Alzheimer
Initiative; Genentech/Roche; Toyama; Bayer; MerckSerono; Mertz; Teva;
National Institute of Mental Health; American Psychiatric Press
FX The sponsors, Otsuka and Avanir Pharmaceutricals, gave unrestricted
education grants to help support the international meeting that was part
of the definition-building process.; Dr. Jeffrey Cummings has provided
consultation to Acadia, ADAMAS, Anavex, Avanir, Boehinger-Ingelheim,
Eisai, EnVivo, GE Healthcare, Genentech, Lilly, Lundbeck, Medavante,
Merck, Novartis, Otsuka, Pfizer, Prana, QR Pharma, Resverlogix, Roche,
Sonexa, Suven, Takeda, and Toyoma companies. Dr. Cummings owns the
copyright of the Neuropsychiatric Inventory.; Professor Sube Banerjee
has received consultancy fees, honoraria for speaking, and support in
attending conferences from the makers of anti-dementia medication and
other psychotropics, including Abbvie, Eisai, Pfizer, Novartis, Lilly,
and Shire.; Professor Henry Brodaty has served as investigator for
Janssen, Lilly, Medivation, Merck, Sanofi, Servier, and Tau
Therapeutics, and has been on the advisory boards of Pfizer, Novartis,
Janssen, Lundbeck, and Nutricia. Dr. Brodaty has provided consultation
to Baxter, Lilly, Merck, and Nutricia.; D.P. Devanand has received
research support from Eli Lilly, and has provided consultation to
AbbVie.; Dr. Serge Gauthier has been on the scientific advisory board or
investigator with Abbvie, Affiris, Eisai, Lilly, Navidea, Novartis,
Pfizer, Sanofi-Synthelabo, Servier, and TauRx.; Professor Robert Howard
reports that he has no relevant disclosures to make.; Dr. Krista Lanctot
has had research support and/or speaker's honoraria from Abbvie Canada,
Lundbeck Canada Inc., Pfizer Canada Inc., Janssen Ortho, and Rocheand
Wyeth.; Dr. Constantine Lyketsos has received grant support (research or
CME) from Associated Jewish Federation of Baltimore, Weinberg
Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, Astra-Zeneca, Lilly,
Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan,
and Functional Neuromodulation. Dr. Lyketsos has been a consultant or
advisor to Astra-Zeneca, GlaxoSmithKline, Eisai, Novartis, Forest,
Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer,
Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir,
Zinfandel, BMS, Abvie, Janssen, and Orion. Honorarium or travel support
has been received from Pfizer, Forest, GlaxoSmithKline, and Health
Monitor.; Dr. Jacobo Mintzer reports receipt of grants to his
institution from Takeda Global Research and Development Center, Pfizer,
Genentech, Merck, Accera, Elan, Avanir, F. Hoffmann-La Roche, Novartis,
Baxter, Eli Lilly, Wyeth, and Janssen Alzheimer Initiative; and
employment with NeuroQuest, and BioPharma Connex.; Dr. Elaine Peskind
has been on the speakers' bureau for Forest Pharmaceuticals and on the
Advisory Committee for Avanir. Dr. Peskind served on the Adjudication
Committee for Takeda Pharmaceuticals.; Dr. Anton Porsteinsson has
received a grant for his institution from Avanir, Eisai, Elan,
Genentech/Roche, Janssen Alzheimer Initiative, Merck, Pfizer, and
Toyama. He has provided consultation for Elan, Janssen Alzheimer
Initiative, and TransTech Pharma. Dr. Porsteinsson has membership on
data safety and monitoring boards for Quintiles.; Dr. Edgardo Reich has
participated as investigator in different pharmaceutical-sponsored
trials for Ely Lilly, Glaxo, Forest, Mertz. Astra Zeneca, Novartis,
Roche, and Janssen. He has received travel grants from Bayer,
MerckSerono, Novartis, Mertz, and Teva.; Dr. Cristina Sampaio has been a
consultant for Abbvie, Alkermes, AstraZeneca, Avanir, Biogen, BMS,
Chelsea, Genzyme, Lilly, Lundbeck, Otsuka, Pfizer, Roche, Sanofi,
Servier, Takeda, and Teva.; Dr. Mary Sano has been on the Scientific
Advisory Board for Medication and as a consultant for Bayer Schering
Pharma, Bristol-Meyers Squibb, Elan, Genentech, Medivation, Medpace,
Pfizer, Janssen, Takeda, and United Biosource.; Dr. David Steffens is
supported through grants from the National Institute of Mental Health,
and he receives textbook royalties from the American Psychiatric Press.;
Dr. Marc Wortmann reports no other salaries than from Alzheimer's
Disease International.; Dr. Kate Zhong has provided consultation to
Avanir, Pfizer, Janssen, and Wyeth Pharmaceuticals.
NR 31
TC 24
Z9 24
U1 5
U2 12
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
EI 1741-203X
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD JAN
PY 2015
VL 27
IS 1
BP 7
EP 17
DI 10.1017/S1041610214001963
PG 11
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA CD4LX
UT WOS:000351055400003
PM 25311499
ER
PT J
AU Crnej, A
Omoto, M
Dohlman, TH
Dohlman, CH
Dana, R
AF Crnej, Alja
Omoto, Masahiro
Dohlman, Thomas H.
Dohlman, Claes H.
Dana, Reza
TI Corneal Inflammation After Miniature Keratoprosthesis Implantation
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Boston Keratoprosthesis; penetrating keratoplasty; cornea inflammation;
syngeneic; allogeneic
ID REPEAT PENETRATING KERATOPLASTY; LONG-TERM OUTCOMES; BOSTON
KERATOPROSTHESIS; I KERATOPROSTHESIS; CROSS-LINKING; GRAFT FAILURE;
DONOR CORNEAS; RISK-FACTORS; TRANSPLANTATION; MULTICENTER
AB PURPOSE. To compare corneal inflammation after syngeneic and allogeneic penetrating keratoplasty (PK) with miniature Keratoprosthesis (m-KPro) implantation in mice.
METHODS. BALB/C (syngeneic) or C57BL/6 (allogeneic) corneas were transplanted onto BALB/C host beds as part of PK or m-KPro implantation. Corneal inflammation was assessed by determining the frequencies of CD45(+) leukocytes, CD4(+) T cells, CD11b(+) cells, and Gr-1(+) granulocytes/monocytes by flow cytometry at 2, 4, and 8 weeks post transplantation. In addition, expression levels of the proinflammatory cytokines TNF-alpha and IL-1 beta were analyzed using real-time qPCR at 8 weeks post transplantation.
RESULTS. Cell frequencies in the syngeneic (syn) and allogeneic (allo) m-KPro groups were higher compared with the syngeneic and allogeneic PK groups, respectively, at all time points. However, after week 4, frequencies of all analyzed immune cells were higher in the alloPK group as compared with synKPro group. At 8 weeks, the expression of TNF-alpha was higher in synKPro, alloPK, and alloKPro groups compared with the naive and synPK groups. The expression of IL-1 beta was significantly higher in both KPro groups as compared with PK groups.
CONCLUSIONS. Although the m-KPro device augments the inflammatory response in the cornea after its implantation, allogenicity (of the carrier tissue) is also a significant contributor to corneal inflammation. These data suggest that using syngeneic or decellularized corneal tissue as a Boston-KPro carrier could reduce the postoperative inflammation response.
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
RP Dana, R (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM reza_dana@meei.harvard.edu
FU Boston-KPro research fund (Boston, MA, USA); National Institutes of
Health (Bethesda, MD, USA) [R01-EY 12963]
FX Supported by grants from the Boston-KPro research fund (Boston, MA, USA)
and the National Institutes of Health (Grant R01-EY 12963; Bethesda, MD,
USA).
NR 36
TC 1
Z9 1
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2015
VL 56
IS 1
BP 185
EP 189
DI 10.1167/iovs.14-15884
PG 5
WC Ophthalmology
SC Ophthalmology
GA CE0TQ
UT WOS:000351519800021
ER
PT J
AU Mukherjee, S
Zhou, XH
Rajaiya, J
Chodosh, J
AF Mukherjee, Santanu
Zhou, Xiaohong
Rajaiya, Jaya
Chodosh, James
TI Ultrastructure of Adenovirus Keratitis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE adenovirus; keratitis; mouse; electron microscopy
ID NUCLEAR-PORE COMPLEX; EPIDEMIC KERATOCONJUNCTIVITIS; BIOINFORMATICS
ANALYSIS; CELL ENTRY; IN-VITRO; MACROPINOCYTOSIS; RECEPTOR; DNA;
ENDOCYTOSIS; ACTIVATION
AB PURPOSE. We determined the ultrastructure of mouse adenovirus keratitis, a model for human adenovirus keratitis.
METHODS. Adenovirus keratitis was induced in C57Bl/6j mice by intrastromal injection of human adenovirus species D type 37 (HAdV-D37) with a heat-pulled, glass, micropipette needle under compressed air. At select time points after infection, mice were euthanized and their corneas removed, fixed, and sectioned at 70-nm thickness for electron microscopy.
RESULTS. Injection of HAdV-D37 into the mouse corneal stroma placed virus predominantly in the pericellular corneal stromal matrix. Virus was seen bound to and entering stromal cells at 1 and 2 hours after infection, respectively. Cell membrane transit by virus was seen to involve two distinct structures resembling caveolae and macropinosomes. However, later during infection intracellular virus was not seen within membrane-bound organelles. By 8 hours after infection, intracellular virus had accumulated into densely packed, perinuclear arrays. Virus disassembly was not obvious at any time point after infection. Infiltrating neutrophils seen by one day after infection had engulfed degraded stromal cells by 4 days after infection.
CONCLUSIONS. By transmission electron microscopy, injected HAdV-D37 readily enters stromal cells in the C57Bl/6j mouse cornea and induces stromal inflammation, as was shown previously by light microscopy. However, electron microscopy also revealed dense, static arrays of intracytoplasmic virus, suggesting a block in viral capsid disassembly and viral DNA nuclear entry. These findings may explain why human adenoviruses do not replicate in the mouse corneal stroma.
C1 [Mukherjee, Santanu; Zhou, Xiaohong; Rajaiya, Jaya; Chodosh, James] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Lab, Boston, MA USA.
RP Chodosh, J (reprint author), Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
EM jaya_rajaiya@meei.harvard.edu; James_Chodosh@meei.harvard.edu
FU National Institutes of Health (Bethesda, MD, USA) [EY013124, EY021558,
P30EY014104]; Research to Prevent Blindness, Inc., New York, NY;
Massachusetts Lions Eye Research Fund; Falk Foundation
FX Supported by National Institutes of Health (Bethesda, MD, USA) Grants
EY013124, EY021558, and P30EY014104, a Senior Scientific Investigator
Award (JC) from Research to Prevent Blindness, Inc., New York, NY, the
Massachusetts Lions Eye Research Fund, and the Falk Foundation.
NR 39
TC 3
Z9 3
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2015
VL 56
IS 1
BP 472
EP 477
DI 10.1167/iovs.14-15635
PG 6
WC Ophthalmology
SC Ophthalmology
GA CE0TQ
UT WOS:000351519800053
PM 25564451
ER
PT J
AU Meeker, KD
Meabon, JS
Cook, DG
AF Meeker, Kole D.
Meabon, James S.
Cook, David G.
TI Partial Loss of the Glutamate Transporter GLT-1 Alters Brain Akt and
Insulin Signaling in a Mouse Model of Alzheimer's Disease
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Amyloid-beta; EAAT2; excitotoxicity; GLT1; metabolism; SLC1A2
ID SYNAPTICALLY RELEASED GLUTAMATE; AMYOTROPHIC-LATERAL-SCLEROSIS;
DEGRADING ENZYME; NEURODEGENERATIVE DISORDERS; HUNTINGTONS-DISEASE;
COGNITIVE DECLINE; BETA-PEPTIDE; MICE LACKING; S6 KINASE; IN-VIVO
AB The glutamate transporter GLT-1 (also called EAAT2 in humans) plays a critical role in regulating extracellular glutamate levels in the central nervous system (CNS). In Alzheimer's disease (AD), EAAT2 loss is associated with neuropathology and cognitive impairment. In keeping with this, we have reported that partial GLT-1 loss (GLT-1+/-) causes early-occurring cognitive deficits in mice harboring familial AD A beta PPswe/PS1 Delta E9 mutations. GLT-1 plays important roles in several molecular pathways that regulate brain metabolism, including Akt and insulin signaling in astrocytes. Significantly, AD pathogenesis also involves chronic Akt activation and reduced insulin signaling in the CNS. In this report we tested the hypothesis that GLT-1 heterozygosity (which reduces GLT-1 to levels that are comparable to losses in AD patients) in A beta PPswe/PS1 Delta E9 mice would induce sustained activation of Akt and disturb components of the CNS insulin signaling cascade. We found that partial GLT-1 loss chronically increased Akt activation (reflected by increased phosphorylation at serine 473), impaired insulin signaling (reflected by decreased IR beta phosphorylation of tyrosines 1150/1151 and increased IRS-1 phosphorylation at serines 632/635 - denoted as 636/639 in humans), and reduced insulin degrading enzyme (IDE) activity in brains of mice expressing familial A beta PPswe/PS1 Delta E9 AD mutations. GLT-1 loss also caused an apparent compensatory increase in IDE activity in the liver, an organ that has been shown to regulate peripheral amyloid-beta levels and expresses GLT-1. Taken together, these findings demonstrate that partial GLT-1 loss can cause insulin/Akt signaling abnormalities that are in keeping with those observed in AD.
C1 [Meeker, Kole D.; Cook, David G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA.
[Meeker, Kole D.; Cook, David G.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Meabon, James S.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Meabon, James S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Cook, David G.] Univ Washington, Sch Med, Dept Med, Div Gerontol, Seattle, WA 98195 USA.
RP Cook, DG (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM dgcook@u.washington.edu
FU Veteran's Affairs Office of Research and Development Medical Research
Service; NIH Pharmacological Sciences training grant [5T32GM00775033];
NIH [T32 AG000258]; Cellular Functional Analysis Core of the University
of Washington Diabetes Research Center [PO1 DK17047]
FX This work was supported by funding from the Veteran's Affairs Office of
Research and Development Medical Research Service (DGC), an NIH
Pharmacological Sciences training grant [5T32GM00775033] (KDM), an NIH
institutional fellowship [T32 AG000258] (JSM), and services by the
Cellular Functional Analysis Core of the University of Washington
Diabetes Research Center (PO1 DK17047). Original GLT-1 (+/-) mice were
graciously made availabe by Kohichi Tanaka (Tokyo Medical and Dental
University).
NR 75
TC 7
Z9 7
U1 0
U2 5
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 45
IS 2
BP 509
EP 520
DI 10.3233/JAD-142304
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA CE1PL
UT WOS:000351583900017
PM 25589729
ER
PT J
AU Wang, XB
Lopez, O
Sweet, RA
Becker, JT
DeKosky, ST
Barmada, MM
Feingold, E
Demirci, FY
Kamboh, MI
AF Wang, Xingbin
Lopez, Oscar
Sweet, Robert A.
Becker, James T.
DeKosky, Steven T.
Barmada, Mahmud M.
Feingold, Eleanor
Demirci, F. Yesim
Kamboh, M. Ilyas
TI Genetic Determinants of Survival in Patients with Alzheimer's Disease
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Gene-based analysis; genome-wide association studies; late-onset
Alzheimer's disease; survival
ID GENOME-WIDE ASSOCIATION; APOLIPOPROTEIN-E; INCREASED RISK; PROMOTER
POLYMORPHISM; INTERLEUKIN-10 GENE; IDENTIFIES VARIANTS; COMMON VARIANTS;
POPULATION; DEMENTIA; MORTALITY
AB There is a strong genetic basis for late-onset of Alzheimer's disease (LOAD), and thus far >20 genes/loci have been identified that affect the risk of LOAD. In addition to disease risk, genetic variation at these loci may also affect components of the natural history of AD, such as survival in AD. In this study, we first examined the role of known LOAD genes with survival time in 983 AD patients. We then performed genome-wide single-nucleotide polymorphism (SNP) and gene-based association analyses to identify novel loci that may influence survival of AD. Survival analysis was conducted using Cox proportional hazards regression under an additive genetics model. We found multiple nominally significant associations (p < 0.01) either within or adjacent to known LOAD genes. Genome-wide SNP analysis identified multiple suggestive novel loci and two of them were also significant in gene-based analysis (CCDC85C and NARS2) that survived after controlling for false-discovery rate at 0.05. In summary, we have identified two novel genes for survival in AD that need to be replicated in independent samples. Our findings highlight the importance of focusing on AD-related phenotypes that may help to identify additional genes relevant to AD.
C1 [Wang, Xingbin; Barmada, Mahmud M.; Feingold, Eleanor; Demirci, F. Yesim; Kamboh, M. Ilyas] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA.
[Wang, Xingbin; Feingold, Eleanor] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
[Lopez, Oscar; Sweet, Robert A.; Becker, James T.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15261 USA.
[Lopez, Oscar; Sweet, Robert A.; Becker, James T.; Kamboh, M. Ilyas] Univ Pittsburgh, Alzheimers Dis Res Ctr, Pittsburgh, PA 15261 USA.
[Sweet, Robert A.; Kamboh, M. Ilyas] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15261 USA.
[DeKosky, Steven T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15261 USA.
RP Kamboh, MI (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
EM kamboh@pitt.edu
OI Feingold, Eleanor/0000-0003-2898-6484; Demirci, F.
Yesim/0000-0001-6907-9843; Kamboh, M. Ilyas/0000-0002-3453-1438;
Barmada, M Michael/0000-0002-3604-6460
FU National Institutes of Health [AG030653, AG041718, AG005133, AG027224]
FX This study was supported by the National Institutes of Health grants
AG030653, AG041718, AG005133, and AG027224. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the Department of Veterans Affairs, the National
Institutes of Health, or the United States Government.
NR 51
TC 0
Z9 0
U1 1
U2 3
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 45
IS 2
BP 651
EP 658
DI 10.3233/JAD-142442
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA CE1PL
UT WOS:000351583900029
PM 25649651
ER
PT J
AU Seda, G
Sanchez-Ortuno, MM
Welsh, CH
Halbower, AC
Edinger, JD
AF Seda, Gilbert
Sanchez-Ortuno, Maria M.
Welsh, Carolyn H.
Halbower, Ann C.
Edinger, Jack D.
TI Comparative Meta-Analysis of Prazosin and Imagery Rehearsal Therapy for
Nightmare Frequency, Sleep Quality, and Posttraumatic Stress
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Article
DE posttraumatic stress disorder; nightmares; prazosin; imagery rehearsal
therapy; cognitive behavior therapy; insomnia
ID RANDOMIZED CONTROLLED-TRIAL; SEXUAL ASSAULT SURVIVORS; BEHAVIORAL
TREATMENT; COMBAT VETERANS; CLINICAL-TRIAL; PTSD; DISORDER; TRAUMA;
DISTURBANCES; SYMPTOMS
AB Study Objective: In this meta-analysis, we compare the short-term efficacy of prazosin vs. IRT on nightmares, sleep quality, and posttraumatic stress symptoms (PTSS).
Methods: Reference databases were searched for randomized controlled trials using IRT or prazosin for nightmares, sleep disturbance, and/or PTSS. Effect sizes were calculated by subtracting the mean posttest score in the control group from the mean posttest score in the treatment group, and dividing the result by the pooled standard deviation of both groups. Mixed effects models were performed to evaluate effects of treatment characteristics, as well as sample characteristics (veteran vs. civilian) on treatment efficacy.
Results: Four studies used prazosin, 10 used IRT alone or in combination with another psychological treatment, and 1 included a group receiving prazosin and another group receiving IRT. Overall effect sizes of both treatments were of moderate magnitude for nightmare frequency, sleep quality, and PTSS (p < 0.01). Effect size was not significantly different with type of treatment (psychological vs. pharmacological) on nightmare frequency (p = 0.79), sleep quality (p = 0.65), or PTSS, (p = 0.52). IRT combined with CBT for insomnia showed more improvement in sleep quality compared to prazosin (p = 0.03), IRT alone (p = 0.03), or IRT combined with another psychological intervention, (p < 0.01).
Conclusion: Although IRT interventions and prazosin yield comparable acute effects for the treatment of nightmares, adding CBT for insomnia to IRT seems to enhance treatment outcomes pertaining to sleep quality and PTSS. More randomized clinical trials with long-term follow-up are warranted.
Commentary: A commentary on this article appears in this issue on page 9.
C1 [Seda, Gilbert] Naval Med Ctr, Dept Pulm & Sleep Med, San Diego, CA USA.
[Sanchez-Ortuno, Maria M.] Univ Murcia, Sch Nursing, Murcia, Spain.
[Welsh, Carolyn H.] Univ Colorado, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO USA.
[Halbower, Ann C.] Childrens Hosp Colorado, Dept Pulm Med, Denver, CO USA.
[Halbower, Ann C.] Univ Colorado, Denver, CO 80202 USA.
[Sanchez-Ortuno, Maria M.; Edinger, Jack D.] Natl Jewish Hlth, Dept Med, Denver, CO USA.
[Welsh, Carolyn H.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Edinger, Jack D.] Duke Univ, Med Ctr, Durham, NC USA.
RP Seda, G (reprint author), 8546 Chevy Chase Dr, La Mesa, CA 91941 USA.
EM gilbert.seda@gmail.com
FU Fundacion Seneca, Murcia, Spain
FX This was not an industry supported study. The authors have indicated no
financial conflicts of interest. Dr. Sanchez-Ortuno was supported by a
research fellowship award from Fundacion Seneca, Murcia, Spain. The
opinions expressed herein are those of the authors and do not
necessarily reflect those of the Department of the Navy, Department of
Defense, the U.S. Government, or any of its agencies.
NR 51
TC 5
Z9 5
U1 5
U2 16
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 1550-9389
EI 1550-9397
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PY 2015
VL 11
IS 1
BP 11
EP 22
DI 10.5664/jcsm.4354
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA CD5ZN
UT WOS:000351167800004
PM 25325592
ER
PT J
AU Dzierzewski, JM
Mitchell, M
Rodriguez, JC
Fung, CH
Jouldjian, S
Alessi, CA
Martin, JL
AF Dzierzewski, Joseph M.
Mitchell, Michael
Rodriguez, Juan Carlos
Fung, Constance H.
Jouldjian, Stella
Alessi, Cathy A.
Martin, Jennifer L.
TI Patterns and Predictors of Sleep Quality Before, During, and After
Hospitalization in Older Adults
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Article
DE sleep; hospitalization; aging; latent class analysis; clinical cutoffs
ID POST-ACUTE REHABILITATION; LATENT CLASS ANALYSIS; ILLNESS RATING-SCALE;
CLINICAL-OUTCOMES; POOR SLEEP; INDEX; PAIN; DEPRESSION; INSOMNIA; PEOPLE
AB Study Objectives: The impact of hospitalization on sleep in late-life is underexplored. The current study examined patterns of sleep quality before, during, and following hospitalization, investigated predictors of sleep quality patterns, and examined predictors of classification discordance between two suggested clinical cutoffs used to demarcate poor/good sleep.
Methods: This study included older adults (n = 163; mean age 79.7 +/- 6.9 years, 31% female) undergoing inpatient post-acute rehabilitation. Upon admission to inpatient postacute rehabilitation, patients completed the Pittsburgh Sleep Quality Index (PSQI) retrospectively regarding their sleep prior to hospitalization. They subsequently completed the PSQI at discharge, and 3 months, 6 months, 9 months, and 1 year post discharge. Patient demographic and clinical characteristics (pain, depression, cognition, comorbidity) were collected upon admission.
Results: Using latent class analysis methods, older adults could be classified into (1) Consistently Good Sleepers and (2) Chronically Poor Sleepers based on patterns of self-reported sleep quality pre-illness, during, and up to 1 year following inpatient rehabilitation. This pattern was maintained regardless of the clinical cutoff employed (> 5 or > 8). Logistic regression analyses indicated that higher pain and depressive symptoms were consistently associated with an increased likelihood of being classified as a chronic poor sleeper. While there was substantial classifi cation discordance based on clinical cutoff employed, no significant predictors of this discordance emerged.
Conclusions: Clinicians should exercise caution in assessing sleep quality in inpatient settings. Alterations in the cutoffs employed may result in discordant clinical classifi cations of older adults. Pain and depression warrant detailed considerations when working with older adults on inpatient units when poor sleep is a concern.
C1 [Dzierzewski, Joseph M.; Rodriguez, Juan Carlos; Fung, Constance H.; Alessi, Cathy A.; Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Dzierzewski, Joseph M.; Mitchell, Michael; Rodriguez, Juan Carlos; Fung, Constance H.; Jouldjian, Stella; Alessi, Cathy A.; Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Rodriguez, Juan Carlos] Pontificia Univ Catolica Chile, Sch Med, Santiago, Chile.
RP Martin, JL (reprint author), VA GRECC 11E,16111 Plummer St, North Hills, CA 91343 USA.
EM jennifer.martin@va.gov
FU UCLA Claude Pepper Older Americans Independence Center by NIA
[5P30AG028748, AG-10415]; NIH/NCATS UCLA CTSI [UL1TR000124]; NIA [K23
AG028452]; VA Health Services Research Development [IIR-01-053-1, IIR
04-321-2, AIA-03-047]; VA Advanced Geriatrics Fellowship Program; VA
Greater Los Angeles Healthcare System Geriatric Research, Education and
Clinical Center; National Institute on Aging [K23AG045937]
FX This work was performed at the University of California, Los Angeles and
the VA Greater Los Angeles Healthcare System. This work was supported by
UCLA Claude Pepper Older Americans Independence Center by NIA
(5P30AG028748 & AG-10415), NIH/NCATS UCLA CTSI (UL1TR000124), NIA K23
AG028452, VA Health Services Research & Development IIR-01-053-1, IIR
04-321-2, and AIA-03-047, VA Advanced Geriatrics Fellowship Program, and
VA Greater Los Angeles Healthcare System Geriatric Research, Education
and Clinical Center. CHF was supported by National Institute on Aging
(K23AG045937). The content is solely the responsibility of the authors
and not necessarily the responsibility of the funding agencies (VA or
NIH). The authors have indicated no financial conflicts of interest.
NR 40
TC 0
Z9 0
U1 2
U2 10
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 1550-9389
EI 1550-9397
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PY 2015
VL 11
IS 1
BP 45
EP 51
DI 10.5664/jcsm.4362
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA CD5ZN
UT WOS:000351167800008
PM 25325580
ER
PT J
AU Domoto, AL
Cormock, RA
Viswanothon, AN
AF Domoto, Antonio L.
Cormock, Robert A.
Viswanothon, Akilo N.
TI A novel intracavitary applicator design for the treatment of deep
vaginal fornices: preliminary dose metrics and geometric analysis
SO JOURNAL OF CONTEMPORARY BRACHYTHERAPY
LA English
DT Article
ID SOCIETY CONSENSUS GUIDELINES; ENDOMETRIAL CANCER; RATE BRACHYTHERAPY;
CUFF BRACHYTHERAPY; OPTIMIZATION; HYSTERECTOMY; RECURRENCES; CYLINDER
C1 [Domoto, Antonio L.; Cormock, Robert A.; Viswanothon, Akilo N.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Domoto, AL (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, ASB1,L2,75 Francis St, Boston, MA 02115 USA.
EM adamato@lroc.harvard.edu
NR 20
TC 0
Z9 0
U1 0
U2 0
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA WENEDOW ST 9-1, POZNAN, 61-614, POLAND
SN 1689-832X
EI 2081-2841
J9 J CONTEMP BRACHYTHER
JI J. Contemp. Brachytherapy
PD JAN-FEB
PY 2015
VL 7
IS 1
BP 48
EP 54
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CD6IH
UT WOS:000351192300009
ER
PT J
AU Akhigbe, T
Chin, AS
Svircev, JN
Hoenig, H
Burns, SP
Weaver, FM
Bailey, L
Carbone, L
AF Akhigbe, Titilola
Chin, Amy S.
Svircev, Jelena N.
Hoenig, Helen
Burns, Stephen P.
Weaver, Frances M.
Bailey, Lauren
Carbone, Laura
TI A retrospective review of lower extremity fracture care in patients with
spinal cord injury
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Lower extremity fractures; Spinal cord injury; Wheelchairs; Osteoporosis
therapies
ID ANKLE FRACTURES; OSTEOPOROTIC FRACTURES; HIP FRACTURE; RISK-FACTORS;
WHEELCHAIR; WOMEN; PARAPLEGIA; COHORT
AB Context/Objective: To identify circumstances surrounding incident lower extremity fractures (ILEFs) in patients with spinal cord injury (SCI) and to describe the impact of these fractures on service needs and provision of pharmacological therapies for osteoporosis.
Design: Retrospective medical record review.
Setting: Four Veterans Affairs Medical Centers in the USA.
Participants: One hundred and forty patients with traumatic SCI who sustained an ILEF from 2002 to 2007.
Outcome measures: Fracture circumstances and use of assistive devices were described using percentages, means, and standard deviations. Fisher's exact test was used to determine the relationship between fracture site, and patient age and duration of SCI. Differences in pharmacological provision of therapies for osteoporosis pre- and post-fracture were examined using exact McNemar's test.
Results: One hundred and fifty-five ILEFs were identified in 140 patients. Tibia/fibula and femur fractures were the most common fractures. Fracture site was not related to patient's age or duration of SCI. Almost one-third of all fractures occurred during transfers to and from wheelchairs. Post-fracture, the provision of new or modified assistive devices, primarily wheelchairs, was frequent, occurring in 83% of patients in the year post-fracture. Few patients transferred residence to a nursing home following the fracture. There was a significant difference in the use of pharmacological therapies for osteoporosis in the first year post-fracture compared with the year prior to the fracture (P < 0.01), with significant differences in the volume of prescriptions for calcium supplements (P < 0.01) and bisphosphonates (P = 0.02). Overall, the amount of prescriptions for osteoporosis increased the year post-fracture (56%) from the year pre-fracture (39%); this increase was secondary to increases in prescriptions for calcium supplements (pre = 13%; post = 30%) and bisphosphonates (pre = 2%; post = 7%).
Conclusions: We have identified that wheelchair and other transfer activities are a key area that could be a focus of fracture prevention in SCI. The need for new or modified assistive devices and/or wheelchair skills retraining post-fracture should be anticipated. Examination of whether treatments for osteoporosis following a fracture can prevent future osteoporotic fractures is warranted.
C1 [Akhigbe, Titilola; Carbone, Laura] Dept Vet Affairs Med Ctr, Memphis, TN USA.
[Akhigbe, Titilola; Carbone, Laura] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA.
[Chin, Amy S.; Weaver, Frances M.; Bailey, Lauren] Edward J Hines Jr Vet Affairs Hosp, Hines, IL USA.
[Svircev, Jelena N.; Burns, Stephen P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Hoenig, Helen] Durham Vet Affairs Med Ctr, Durham, NC USA.
[Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA.
RP Carbone, L (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Med, Div Rheumatol, 956 Court Ave,Room G326, Memphis, TN 38163 USA.
EM lcarbone@uthsc.edu
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development [IIR 08-033]
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Health Services Research and Development #IIR
08-033.
NR 36
TC 5
Z9 5
U1 0
U2 1
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
EI 2045-7723
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD JAN
PY 2015
VL 38
IS 1
BP 2
EP 9
DI 10.1179/2045772313Y.0000000156
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA CD4RJ
UT WOS:000351070900001
PM 24621029
ER
PT J
AU Bauman, WA
La Fountaine, MF
Cirnigliaro, CM
Kirshblum, SC
Spungen, AM
AF Bauman, William A.
La Fountaine, Michael F.
Cirnigliaro, Christopher M.
Kirshblum, Steven C.
Spungen, Ann M.
TI Lean tissue mass and energy expenditure are retained in hypogonadal men
with spinal cord injury after discontinuation of testosterone
replacement therapy
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Spinal cord injury; Lean tissue mass; Hypogonadism; Testosterone
ID DENSITY LIPOPROTEIN CHOLESTEROL; ANDROGEN DEFICIENCY SYNDROMES;
CLINICAL-PRACTICE GUIDELINE; BODY-COMPOSITION; CARDIOVASCULAR-DISEASE;
MUSCLE STRENGTH; ADULT MEN; INDIVIDUALS; PLASMA; RISK
AB Objective: To determine whether favorable changes to lean tissue mass (LTM), resting energy expenditure (REE), and testosterone (T) that occurred with 12 months of physiological testosterone replacement therapy (TRT) were retained 6 months after discontinuing treatment.
Design: Prospective, open-label, controlled drug intervention trial.
Setting: Metropolitan area hospitals.
Subjects: Eugonadal (n = 11) and hypogonadal (n = 13) men with chronic spinal cord injury (SCI).
Interventions: Hypogonadal subjects received a 5 or 10 mg transdermal T patch daily for 12 months, with adjustment of the dose to normalize the serum T concentration; TRT was discontinued after 12 months (TRT-12M) and subjects were followed for an additional 6 months and re-evaluated (Post-TRT). Total body dual energy X-ray absorptiometry and blood draws were performed at baseline (BL) prior to TRT, TRT-12M, and Post-TRT. Eugonadal subjects did not receive treatment and were evaluated at comparable time points.
Results: There were no significant differences between groups prior to TRT at BL for any of the study endpoints. In the hypogonadal group, a significant increase in LTM was observed from BL to TRT-12M (50.2 +/- 7.4 vs. 52.9 +/- 6.8 kg, P < 0.01), which persisted Post-TRT compared to BL (52.2 +/- 7.8 kg, P < 0.05). The increase in REE from BL to TRT-12M (1283 +/- 246 vs. 1410 +/- 250 kcal/day) was also retained at Post-TRT (1393 +/- 220 kcal/day). These sustained improvements in LTM and REE after termination of anabolic hormonal therapy may be associated with persistent beneficial effects on health and physical function of hypogonadal men with chronic SCI.
C1 [Bauman, William A.; La Fountaine, Michael F.; Cirnigliaro, Christopher M.; Spungen, Ann M.] James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, Bronx, NY 10468 USA.
[Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA.
[Bauman, William A.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
[Bauman, William A.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA.
[La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, Dept Phys Therapy, S Orange, NJ 07079 USA.
[Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
[Kirshblum, Steven C.] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA.
RP Bauman, WA (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM william.bauman@va.gov
FU Veteran Affairs Rehabilitation Research and Development Service
[B9212-C, B4162-C, B2468-C]; James J. Peters VA Medical Center
FX Veteran Affairs Rehabilitation Research and Development Service
(#B9212-C, #B4162-C, and #B2468-C) and the James J. Peters VA Medical
Center.
NR 41
TC 3
Z9 3
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1079-0268
EI 2045-7723
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD JAN
PY 2015
VL 38
IS 1
BP 38
EP 47
DI 10.1179/2045772314Y.0000000206
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA CD4RJ
UT WOS:000351070900005
PM 24968251
ER
PT J
AU Hausmann, LRM
Myaskovsky, L
Niyonkuru, C
Oyster, ML
Switzer, GE
Burkitt, KH
Fine, MJ
Gao, SS
Boninger, ML
AF Hausmann, Leslie R. M.
Myaskovsky, Larissa
Niyonkuru, Christian
Oyster, Michelle L.
Switzer, Galen E.
Burkitt, Kelly H.
Fine, Michael J.
Gao, Shasha
Boninger, Michael L.
TI Examining implicit bias of physicians who care for individuals with
spinal cord injury: A pilot study and future directions
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Racism; Social discrimination; Spinal cord injuries; Wheelchair
ID ASSOCIATION TEST; HEALTH-STATUS; MEDICAL-CARE; RACIAL/ETHNIC
DISCRIMINATION; RACIAL-DISCRIMINATION; ETHNIC IDENTIFICATION; UNFAIR
TREATMENT; NATIONAL LATINO; ASIAN-AMERICANS; ATTITUDES
AB Context: Despite evidence that healthcare providers have implicit biases that can impact clinical interactions and decisions, implicit bias among physicians caring for individuals with spinal cord injury (SCI) has not been examined.
Objective: Conduct a pilot study to examine implicit racial bias of SCI physicians and its association with functioning and wellbeing for individuals with SCI.
Design: Combined data from cross-sectional surveys of individuals with SCI and their SCI physicians.
Setting: Four national SCI Model Systems sites.
Participants: Individuals with SCI (N = 162) and their SCI physicians (N = 14).
Outcome measures: SCI physicians completed online surveys measuring implicit racial (pro-white/anti-black) bias. Individuals with SCI completed questionnaires assessing mobility, physical independence, occupational functioning, social integration, self-reported health, depression, and life satisfaction. We used multilevel regression analyses to examine the associations of physician bias and outcomes of individuals with SCI.
Results: Physicians had a mean bias score of 0.62 (SD = 0.35), indicating a strong pro-white/anti-black bias. Greater physician bias was associated with disability among individuals with SCI in the domain of social integration (odds ratio = 4.80, 95% confidence interval (CI) = 1.44, 16.04), as well as higher depression (B = 3.24, 95% CI = 1.06, 5.41) and lower life satisfaction (B = -4.54, 95% CI= -8.79, -0.28).
Conclusion: This pilot study indicates that SCI providers are susceptible to implicit racial bias and provides preliminary evidence that greater implicit racial bias of physicians is associated with poorer psychosocial health outcomes for individuals with SCI. It demonstrates the feasibility of studying implicit bias among SCI providers and provides guidance for future research on physician bias and patient outcomes.
C1 [Hausmann, Leslie R. M.; Myaskovsky, Larissa; Switzer, Galen E.; Burkitt, Kelly H.; Fine, Michael J.; Gao, Shasha] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA.
[Hausmann, Leslie R. M.; Myaskovsky, Larissa; Switzer, Galen E.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Niyonkuru, Christian; Oyster, Michelle L.; Boninger, Michael L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Oyster, Michelle L.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Associated Rehabil E, Pittsburgh, PA 15240 USA.
RP Hausmann, LRM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Bldg 30,Univ Dr 151C, Pittsburgh, PA 15240 USA.
EM leslie.hausmann@gmail.com
OI Boninger, Michael/0000-0001-6966-919X
FU Veterans Affairs Health Services Research and Development Career
Development Program [RCD 06-287]; National Institute on Disability and
Rehabilitation Research, Office of Special Education and Rehabilitation
Services, U.S. Department of Education [H133N060019]
FX This research was funded by the National Institute on Disability and
Rehabilitation Research, Office of Special Education and Rehabilitation
Services, U.S. Department of Education (grant no. H133N060019; PI:
M.L.B.). Dr L.R.M.H.'s effort was supported by the Veterans Affairs
Health Services Research and Development Career Development Program (RCD
06-287).
NR 46
TC 10
Z9 10
U1 5
U2 8
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
EI 2045-7723
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD JAN
PY 2015
VL 38
IS 1
BP 102
EP 110
DI 10.1179/2045772313Y.0000000184
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA CD4RJ
UT WOS:000351070900013
PM 24621034
ER
PT S
AU Hove, MJ
Keller, PE
AF Hove, Michael J.
Keller, Peter E.
BE Bigand, E
Tillmann, B
Peretz, I
Zatorre, RJ
Lopez, L
Majno, M
TI Impaired movement timing in neurological disorders: rehabilitation and
treatment strategies
SO NEUROSCIENCES AND MUSIC V: COGNITIVE STIMULATION AND REHABILITATION
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Neurosciences and Music V
CY MAY 29-JUN 01, 2014
CL Dijon, FRANCE
DE gait rehabilitation; Parkinson's disease; rhythmic auditory stimulation;
adaptive timing; groove
ID RHYTHMIC AUDITORY-STIMULATION; PARKINSONS-DISEASE PATIENTS; SENSORIMOTOR
SYNCHRONIZATION; PHASE CORRECTION; VISUOMOTOR SYNCHRONIZATION; FRACTAL
DYNAMICS; TIME PERCEPTION; MOTOR TEMPO; HUMAN GAIT; MUSIC
AB Timing abnormalities have been reported in many neurological disorders, including Parkinson's disease (PD). In PD, motor-timing impairments are especially debilitating in gait. Despite impaired audiomotor synchronization, PD patients' gait improves when they walk with an auditory metronome or with music. Building on that research, we make recommendations for optimizing sensory cues to improve the efficacy of rhythmic cuing in gait rehabilitation. Adaptive rhythmic metronomes (that synchronize with the patient's walking) might be especially effective. In a recent study we showed that adaptive metronomes synchronized consistently with PD patients' footsteps without requiring attention; this improved stability and reinstated healthy gait dynamics. Other strategies could help optimize sensory cues for gait rehabilitation. Groove music strongly engages the motor system and induces movement; bass-frequency tones are associated with movement and provide strong timing cues. Thus, groove and bass-frequency pulses could deliver potent rhythmic cues. These strategies capitalize on the close neural connections between auditory and motor networks; and auditory cues are typically preferred. However, moving visual cues greatly improve visuomotor synchronization and could warrant examination in gait rehabilitation. Together, a treatment approach that employs groove, auditory, bass-frequency, and adaptive (GABA) cues could help optimize rhythmic sensory cues for treating motor and timing deficits.
C1 [Hove, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Keller, Peter E.] Univ Western Sydney, MARCS Inst, Sydney, NSW, Australia.
RP Hove, MJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 149 13th St, Charlestown, MA 02129 USA.
EM michaeljhove@gmail.com
OI Keller, Peter/0000-0001-7579-6515
FU National Institute of Mental Health Grant [T32-MH16259]
FX M.J.H. received support from a National Institute of Mental Health Grant
(T32-MH16259).
NR 71
TC 11
Z9 11
U1 3
U2 21
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077-8923
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2015
VL 1337
BP 111
EP 117
DI 10.1111/nyas.12615
PG 7
WC Clinical Neurology; Psychology; Psychology, Experimental; Rehabilitation
SC Neurosciences & Neurology; Psychology; Rehabilitation
GA BC3ER
UT WOS:000351580900016
PM 25773624
ER
PT J
AU Manchikanti, L
Nampiaparampil, DE
Candido, KD
Bakshi, S
Do, JSG
Falco, FJE
Sehgal, N
Hirsch, JA
AF Manchikanti, Laxmaiah
Nampiaparampil, Devi E.
Candido, Kenneth D.
Bakshi, Sanjay
Do, Jay S. Grider
Falco, Frank J. E.
Sehgal, Nalini
Hirsch, Joshua A.
TI Do Cervical Epidural Injections Provide Long-Term Relief in Neck and
Upper Extremity Pain? A Systematic Review
SO PAIN PHYSICIAN
LA English
DT Review
DE Chronic neck pain; cervical disc herniation; cervical spinal stenosis;
cervical post surgery syndrome; cervical discogenic pain; cervical
epidural injections; interlaminar epidural injections; transforaminal
epidural injections; steroids; local anesthetic
ID ACTIVE-CONTROL TRIAL; 2-YEAR FOLLOW-UP; CHRONIC LOW-BACK; PHYSICIANS
ASIPP GUIDELINES; LUMBAR DISC HERNIATION; STEROID INJECTION;
DOUBLE-BLIND; INTERVENTIONAL TECHNIQUES; SPINAL STENOSIS; RADICULAR PAIN
AB Background: The high prevalence of chronic persistent neck pain not only leads to disability but also has a significant economic, societal, and health impact. Among multiple modalities of treatments prescribed in the management of neck and upper extremity pain, surgical, interventional and conservative modalities have been described. Cervical epidural injections are also common modalities of treatments provided in managing neck and upper extremity pain. They are administered by either an interlaminar approach or transforaminal approach.
Objectives: To determine the long-term efficacy of cervical interlaminar and transforaminal epidural injections in the treatment of cervical disc herniation, spinal stenosis, discogenic pain without facet joint pain, and post surgery syndrome.
Methods: The literature search was performed from 1966 to October 2014 utilizing data from PubMed, Cochrane Library, US National Guideline Clearinghouse, previous systematic reviews, and cross-references.
The evidence was assessed based on best evidence synthesis with Level I to Level V.
Results: There were 7 manuscripts meeting inclusion criteria. Of these, 4 assessed the role of interlaminar epidural injections for managing disc herniation or radiculitis, and 3 assessed these injections for managing central spinal stenosis, discogenic pain without facet joint pain, and post surgery syndrome. There were 4 high quality manuscripts. A qualitative synthesis of evidence showed there is Level II evidence for each etiology category. The evidence is based on one relevant, high quality trial supporting the efficacy of cervical interlaminar epidural injections for each particular etiology.
There were no randomized trials available assessing the efficacy of cervical transforaminal epidural injections.
Limitations: Paucity of available literature, specifically conditions other than disc herniation.
Conclusion: This systematic review with qualitative best evidence synthesis shows Level II evidence for the efficacy of cervical interlaminar epidural injections with local anesthetic with or without steroids, based on at least one high-quality relevant randomized control trial in each category for disc herniation, discogenic pain without facet joint pain, central spinal stenosis, and post surgery syndrome.
C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY 42003 USA.
[Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA.
[Nampiaparampil, Devi E.] NYU, Sch Med, New York, NY USA.
[Candido, Kenneth D.] Advocate Illinois Mason Med Ctr, Dept Anesthesiol, Chicago, IL USA.
[Candido, Kenneth D.] Univ Illinois, Coll Med, Chicago, IL USA.
[Bakshi, Sanjay] Manhattan Spine & Pain Med, New York, NY USA.
[Do, Jay S. Grider] Univ Kentucky, UK Healthcare Pain Serv, Lexington, KY USA.
[Falco, Frank J. E.] Mid Atlant Spine & Pain Phys, Newark, DE USA.
[Falco, Frank J. E.] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA.
[Sehgal, Nalini] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Manchikanti, L (reprint author), MD 2831 Lone Oak Rd, Paducah, KY 42003 USA.
EM drlm@thepainmd.com
NR 123
TC 26
Z9 26
U1 0
U2 7
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD JAN-FEB
PY 2015
VL 18
IS 1
BP 39
EP 60
PG 22
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CE0JF
UT WOS:000351489600005
PM 25675059
ER
PT J
AU Koury, KM
Tsui, B
Gulur, P
AF Koury, Katharine M.
Tsui, Becky
Gulur, Padma
TI Incidence of Serotonin Syndrome in Patients Treated with Fentanyl on
Serotonergic Agents
SO PAIN PHYSICIAN
LA English
DT Article
DE Fentanyl; serotonin syndrome; serotonergic drugs; opioids; SSRI;
antidepressant
ID PAROXETINE; TOXICITY
AB Background: There has been a recent surge in the literature highlighting the association of fentanyl as precipitating serotonin syndrome in patients on a serotonergic agent.
Objective: The purpose of our study was to understand the incidence of serotonin syndrome in patients who receive fentanyl while on serotonergic agents.
Study Design: This retrospective analysis was conducted from 2012 to 2013 after approval from the Institutional Review Board. We searched for all patients that had received a serotonergic agent and were admitted to the hospital during the study period. Next, we split these patients into 2 groups by placing all patients who had received fentanyl and a serotonergic agent into one group. We then searched for any of the Hunter Serotonin Toxicity Criteria in the records of patients that had received both fentanyl and a serotonergic agent. Further, we searched for all patients with serotonin syndrome mentioned in their records.
Setting: This study was conducted at a 900 bed tertiary care academic center.
Results: Over the 2 year study period, 112,045 patients were on a serotonergic agent, and 4,538 of these patients were treated with both fentanyl and a serotonergic agent. A search for Hunter's Criteria through the records of the patients receiving both fentanyl and a serotonergic agent revealed 23 patients had been documented with some of these symptoms. On detailed chart review, only 4 [95% CI 1 - 10] of these patients truly met Hunter's Criteria for serotonin syndrome. We then searched all admissions for a diagnosis code of serotonin syndrome during the study period. Five additional cases of serotonin syndrome were found, but none of these patients were treated with fentanyl.
Limitations: Some of the limitations of our study include that it represents a single institution, although it is a large academic center. An inherent limitation may be the under diagnosis of serotonin syndrome.
Conclusion: The incidence of serotonin syndrome in patients who receive both fentanyl and a serotonergic agent is low.
C1 [Koury, Katharine M.; Tsui, Becky; Gulur, Padma] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Gulur, P (reprint author), Massachusetts Gen Hosp, 15 Parkman St, Boston, MA 02114 USA.
EM pgulur@yahoo.com
NR 8
TC 4
Z9 4
U1 3
U2 3
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD JAN-FEB
PY 2015
VL 18
IS 1
BP E27
EP E30
PG 4
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CE0JF
UT WOS:000351489600014
PM 25675067
ER
PT J
AU Reish, A
Bastas, G
Popescu, A
Friedberger, M
AF Reish, Andrew
Bastas, Gerasimos
Popescu, Adrian
Friedberger, Marylouis
TI Newly Diagnosed Lumbar Nerve Root Intradural Mass in the Setting of
Chronic Lumbar Radicular Pain Refractory to Conservative Management
SO PAIN PHYSICIAN
LA English
DT Article
ID DISK DISEASE; SHEATH; TUMORS
C1 [Reish, Andrew] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA.
[Bastas, Gerasimos] Vanderbilt Univ, Med Ctr, Dept Phys Med & Rehabil, Nashville, TN USA.
[Popescu, Adrian] Univ Penn, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
[Friedberger, Marylouis] Vet Affairs Med Ctr, Pain Clin Philadelphia, Philadelphia, PA USA.
RP Reish, A (reprint author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower Pkwy,Suite 100, Ann Arbor, MI 48108 USA.
EM reisha@med.umich.edu
NR 10
TC 0
Z9 0
U1 3
U2 4
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD JAN-FEB
PY 2015
VL 18
IS 1
BP E79
EP E82
PG 4
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CE0JF
UT WOS:000351489600022
PM 25675075
ER
PT S
AU Song, JW
Bazou, D
Munn, LL
AF Song, Jonathan W.
Bazou, Despina
Munn, Lance L.
BE Ribatti, D
TI Microfluidic Model of Angiogenic Sprouting
SO VASCULAR MORPHOGENESIS: METHODS AND PROTOCOLS
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE Angiogenesis on a chip; Sprouting; Microfluidics; Microfabrication;
Shear stress; Gradients; bioMEMS
ID CELL-CULTURE; SOFT LITHOGRAPHY; TISSUE ANALOG; DEVICES; ADHESION;
DESIGN; FUTURE; FLOW
AB Microfluidic systems have emerged as an important technology for modeling cellular microenvironments in vitro. These systems enable unprecedented levels of control of chemical gradients, fluid flow, and localized 3-D extracellular matrices (ECM), all of which can be integrated to provide a physiologically relevant context for studying complex cellular processes such as angiogenesis. Here, we describe the design and use of microfluidic systems for reproducing the dynamic events of vascular morphogenesis.
C1 [Song, Jonathan W.; Bazou, Despina; Munn, Lance L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Charlestown, MA 02129 USA.
[Song, Jonathan W.; Bazou, Despina; Munn, Lance L.] Harvard Univ, Sch Med, Charlestown, MA USA.
RP Song, JW (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Charlestown, MA 02129 USA.
RI Munn, Lance/L-3950-2016;
OI Munn, Lance/0000-0003-0698-7232; Song, Jonathan/0000-0002-6991-5298
FU NCI NIH HHS [R01CA149285, T32CA073479]; NHLBI NIH HHS [R01 HL106584]
NR 27
TC 0
Z9 0
U1 0
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-4939-1462-3; 978-1-4939-1461-6
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2015
VL 1214
BP 243
EP 254
DI 10.1007/978-1-4939-1462-3_15
D2 10.1007/978-1-4939-1462-3
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BC1TI
UT WOS:000350416800016
PM 25468609
ER
PT J
AU Cerulli, C
Kothari, C
Dichter, M
Marcus, S
Kim, TK
Wiley, J
Rhodes, KV
AF Cerulli, Catherine
Kothari, Catherine
Dichter, Melissa
Marcus, Steve
Kim, Tae Kuen
Wiley, Jim
Rhodes, Karin V.
TI Help-Seeking Patterns Among Women Experiencing Intimate Partner
Violence: Do They Forgo the Criminal Justice System if Their
Adjudication Wishes Are Not Met?
SO VIOLENCE AND VICTIMS
LA English
DT Article
DE domestic violence; prosecution; displacement; resources
ID DOMESTIC VIOLENCE; PROCEDURAL JUSTICE; AFRICAN-AMERICAN; LEGAL; RISK;
VICTIMS; CHRONICITY; PREVALENCE; DECISION; BARRIERS
AB Following a criminal case disposition, an intimate partner violence (IPV) victim's willingness to seek future police and prosecutorial assistance may depend on her prior experiences within the system. This longitudinal study examines the relationship between IPV victims' future help-seeking based on past experiences. We hypothesized women would return to the criminal justice system if their adjudication wishes corresponded with prosecutors' actions. Contrary to the hypothesis, results suggest women return to the criminal system and other venues even if prosecutors' actions do not correspond to their earlier stated wishes. This has important policy implications given pro-prosecution protocols that encourage adjudication regardless of a woman's participation.
C1 [Cerulli, Catherine] Univ Rochester, Sch Med & Dent, Rochester, NY USA.
[Kothari, Catherine] Western Michigan Univ, Kalamazoo, MI 49008 USA.
[Dichter, Melissa] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Marcus, Steve; Rhodes, Karin V.] Univ Penn, Philadelphia, PA 19104 USA.
[Kim, Tae Kuen] Adelphi Univ, New York, NY USA.
[Wiley, Jim] Univ Calif San Francisco, Inst Hlth Policy Studies & Family & Community Med, San Francisco, CA 94143 USA.
RP Cerulli, C (reprint author), Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
EM Catherine_Cerulli@urmc.rochester.edu
NR 42
TC 0
Z9 0
U1 6
U2 20
PU SPRINGER PUBLISHING CO
PI NEW YORK
PA 11 WEST 42ND STREET, NEW YORK, NY 10036 USA
SN 0886-6708
EI 1945-7073
J9 VIOLENCE VICTIMS
JI Violence Vict.
PY 2015
VL 30
IS 1
BP 16
EP 31
DI 10.1891/0886-6708.VV-D-13-00064
PG 16
WC Criminology & Penology
SC Criminology & Penology
GA CE1VR
UT WOS:000351601300002
PM 25774412
ER
PT S
AU Hu, W
MacDonald, ML
Elswick, DE
Sweet, RA
AF Hu, Wei
MacDonald, Matthew L.
Elswick, Daniel E.
Sweet, Robert A.
BE Geschwind, DH
TI The glutamate hypothesis of schizophrenia: evidence from human brain
tissue studies
SO YEAR IN NEUROLOGY AND PSYCHIATRY
SE Annals of the New York Academy of Sciences
LA English
DT Article; Book Chapter
DE brain tissue; EAAT; glutamate receptors; glutamatergic neurons;
schizophrenia
ID MESSENGER-RNA EXPRESSION; MEDIAL TEMPORAL-LOBE; AMINO-ACID OXIDASE;
ANTERIOR CINGULATE CORTEX; DENDRITIC SPINE DENSITY; DORSOLATERAL
PREFRONTAL CORTEX; CORTICAL PYRAMIDAL NEURONS; PRIMARY AUDITORY-CORTEX;
D-ASPARTATE RECEPTOR; NEUROLEPTIC-FREE SCHIZOPHRENICS
AB A number of studies have indicated that antagonists of the N-methyl-d-aspartate subtypes of glutamate receptors can cause schizophrenia-like symptoms in healthy individuals and exacerbate symptoms in individuals with schizophrenia. These findings have led to the glutamate hypothesis of schizophrenia. Here we review the evidence for this hypothesis in postmortem studies of brain tissue from individuals affected by schizophrenia, summarizing studies of glutamate neuron morphology, of expression of glutamate receptors and transporters, and of the synthesizing and metabolizing enzymes for glutamate and its co-agonists. We found consistent evidence of morphological alterations of dendrites of glutamatergic neurons in the cerebral cortex of subjects with schizophrenia and of reduced levels of the axon bouton marker synaptophysin. There were no consistent alterations of mRNA expression of glutamate receptors, although there has been limited study of the corresponding proteins. Studies of the glutamate metabolic pathway have been limited, although there is some evidence that excitatory amino acid transporter-2, glutamine synthetase, and glutaminase have altered expression in schizophrenia. Future studies would benefit from additional direct examination of glutamatergic proteins. Further advances, such as selective testing of synaptic microdomains, cortical layers, and neuronal subtypes, may also be required to elucidate the nature of glutamate signaling impairments in schizophrenia.
C1 [Hu, Wei; Elswick, Daniel E.] W Virginia Univ, Hlth Sci Ctr, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA.
[MacDonald, Matthew L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Biomed Sci Tower,Room W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
FU NIMH NIH HHS [R01 MH071533, MH 071533, MH 103204, MH 16804, P50
MH103204, R21 MH066231, T32 MH016804]
NR 181
TC 18
Z9 18
U1 7
U2 27
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077-8923
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2015
VL 1338
BP 38
EP 57
DI 10.1111/nyas.12547
PG 20
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA BC3ES
UT WOS:000351581400004
PM 25315318
ER
PT J
AU Axon, RN
Gebregziabher, M
Craig, J
Zhang, JW
Mauldin, P
Moran, WP
AF Axon, R. Neal
Gebregziabher, Mulugeta
Craig, Janet
Zhang, Jingwen
Mauldin, Patrick
Moran, William P.
TI Frequency and Costs of Hospital Transfers for Ambulatory Care-Sensitive
Conditions
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID NURSING-HOME RESIDENTS; LONG-TERM-CARE; RANDOMIZED CONTROLLED-TRIAL;
PREVENTABLE HOSPITALIZATIONS; EARLY READMISSION; INPATIENT CARE;
HEALTH-CARE; QUALITY; MEDICAID; ASSOCIATION
AB Objectives
Nursing home (NH) patients are frequently transferred to emergency departments (EDs) and/or hospitalized in situations in which transfer might have been avoided. This study describes the frequency of NH transfers for ambulatory care-sensitive conditions (ACSCs) and estimates associated expenditures.
Study Design
Retrospective cohort study of 62,379 NH patients with Medicare coverage receiving care in South Carolina between 2007 and 2009.
Methods
Subjects were analyzed to determine the frequency of acute ED or hospital care for conditions. Comparison is made to similar patients transferred for acute treatment of non-ACSCs. Generalized linear models were used to estimate the costs attributable to treating ACSCs.
Results
Over 3 years, 20,867 NH subjects were transferred from NHs to acute care facilities, and 85.3% of subjects had at least 1 episode of care for an ACSC. An average of 13,317 subjects per year were transferred for an average of 17,060 episodes of ED or hospital care per year between 2007 and 2009. More ACSC patients transferred to EDs were subsequently admitted to the hospital (50.4% vs 25%; P < .0001). In adjusted analyses, mean ED costs per episode of care ($401 vs $294; P < .0001) were higher, but mean hospitalization costs per episode of care were lower ($8356 vs $10,226; P < .0001) for ACSC patients compared with non-ACSC patients.
Conclusions
A significant proportion of Medicare NH patients are treated acutely for ACSCs, which are associated with higher healthcare utilization and costs. Better access to onsite evaluation might enable significant cost savings and reduce morbidity in this population.
C1 [Axon, R. Neal] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, NC USA.
[Axon, R. Neal; Zhang, Jingwen; Mauldin, Patrick; Moran, William P.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Publ Hlth Serv, Charleston, SC 29425 USA.
[Craig, Janet] Clemson Univ, Sch Nursing, Clemson, SC USA.
[Craig, Janet] Hlth Sci South Carolina, Columbia, SC USA.
RP Axon, RN (reprint author), Ralph H Johnson VAMC, 109 Bee St, Charleston, SC 29401 USA.
EM axon@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU South Carolina Clinical & Translational Research Institute; NIH [UL1
RR029882, UL1 TR000062]
FX This project was supported by the South Carolina Clinical &
Translational Research Institute, with an academic home at the Medical
University of South Carolina, through NIH grant numbers UL1 RR029882 and
UL1 TR000062.
NR 38
TC 1
Z9 1
U1 0
U2 2
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD JAN
PY 2015
VL 21
IS 1
BP 51
EP 59
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA CD3GC
UT WOS:000350965300013
PM 25880150
ER
PT J
AU Rinne, ST
Wong, ES
Lemon, JM
Perkins, M
Bryson, CL
Liu, CF
AF Rinne, Seppo T.
Wong, Edwin S.
Lemon, Jaclyn M.
Perkins, Mark
Bryson, Christopher L.
Liu, Chuan-Fen
TI Survey Nonresponders Incurred Higher Medical Utilization and Lower
Medication Adherence
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID HEALTH-CARE UTILIZATION; PATIENT SATISFACTION; DIABETES-MELLITUS;
RISK-ADJUSTMENT; BIAS; POPULATION; VALIDATION; IMPACT; COHORT; ADULTS
AB Objectives
To compare healthcare costs, utilization, and medication adherence between diabetic responders and nonresponders to a patient satisfaction survey.
Study Design
We performed a retrospective cohort study of 40,766 patients with diabetes who had been randomly selected to receive the 2006 Veterans Affairs' Survey of Healthcare Experiences of Patients. Outcomes were measured during the following year.
Methods
We used multivariable models to compare healthcare costs (generalized linear models), utilization (negative binomial regression), and adherence to oral hypoglycemic medications (logistic regression) between survey responders and nonresponders.
Results
There were 26,051 patients (64%) who responded to the survey. Survey nonresponders incurred significantly higher healthcare costs (incremental effect, $792; 95% CI, $599-$986; P < .01). Nonresponders had a modest increase in primary care (incidence rate ratio [IRR], 1.06; 95% CI, 1.05-1.08; P < .01) and specialty care visits (IRR, 1.17; 95% CI, 1.12-1.22; P < .01), but more substantial increases in mental health visits (IRR, 1.74; 95% CI, 1.62-1.87; P < .01) and hospitalizations (IRR, 1.60; 95% CI, 1.46-1.75; P < .01). Medication adherence was significantly lower among survey nonresponders (odds ratio, 0.68; 95% CI, 0.65-0.74; P < .01).
Conclusions
Nonresponders to a patient satisfaction survey incurred higher healthcare costs and utilization, but had lower medication adherence. Understanding these characteristics helps to assess the impact of nonresponse bias on patient satisfaction surveys and identifies clinical practices to improve care delivery.
C1 [Rinne, Seppo T.; Wong, Edwin S.; Lemon, Jaclyn M.; Perkins, Mark; Bryson, Christopher L.; Liu, Chuan-Fen] Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Rinne, Seppo T.] Univ Washington, Div Pulm, Seattle, WA 98195 USA.
[Rinne, Seppo T.] Univ Washington, Div Crit Care, Seattle, WA 98195 USA.
[Rinne, Seppo T.; Bryson, Christopher L.] Univ Washington, Dept Med, Seattle, WA USA.
[Bryson, Christopher L.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA.
[Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
RP Rinne, ST (reprint author), 1100 Ol Way,Ste 1400, Seattle, WA 98104 USA.
EM srinne@uw.edu
FU US Department of Veterans Affairs, Office of Research and Development,
Health Services Research Development
FX This research is based upon work supported by the US Department of
Veterans Affairs, Office of Research and Development, Health Services
Research & Development. The views expressed in this article are those of
the authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States government.
NR 41
TC 0
Z9 0
U1 3
U2 4
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD JAN
PY 2015
VL 21
IS 1
BP E1
EP E8
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA CD3GC
UT WOS:000350965300001
PM 25880264
ER
PT S
AU Mandal, AK
Mount, DB
AF Mandal, Asim K.
Mount, David B.
BE Julius, D
TI The Molecular Physiology of Uric Acid Homeostasis
SO ANNUAL REVIEW OF PHYSIOLOGY, VOL 77
SE Annual Review of Physiology
LA English
DT Review; Book Chapter
DE uric acid; hyperuricemia; URAT1; SLC2A9; ABCG2
ID BRUSH-BORDER MEMBRANE; GENOME-WIDE ASSOCIATION; P-AMINOHIPPURATE
TRANSPORT; ORGANIC ANION TRANSPORTER; XANTHINE OXIDOREDUCTASE GENE;
HUMAN ARTICULAR CHONDROCYTES; NUTRITION EXAMINATION SURVEY; RENAL
MICROVILLUS MEMBRANES; SERUM URATE CONCENTRATIONS; KIDNEY PROXIMAL
TUBULES
AB Uric acid, generated from the metabolism of purines, has proven and emerging roles in human disease. Serum uric acid is determined by production and the net balance of reabsorption or secretion by the kidney and intestine. A detailed understanding of epithelial absorption and secretion of uric acid has recently emerged, aided in particular by the results of genome-wide association studies of hyperuricemia. Novel genetic and regulatory networks with effects on uric acid homeostasis have also emerged. These developments promise to lead to a new understanding of the various diseases associated with hyperuricemia and to novel, targeted therapies for hyperuricemia.
C1 [Mandal, Asim K.] Harvard Univ, Brigham & Womens Hosp, Div Renal, Sch Med, Boston, MA 02115 USA.
Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
RP Mandal, AK (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Renal, Sch Med, Boston, MA 02115 USA.
EM dmount@partners.org
NR 179
TC 19
Z9 23
U1 5
U2 18
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0066-4278
BN 978-0-8243-0377-8
J9 ANNU REV PHYSIOL
JI Annu. Rev. Physiol.
PY 2015
VL 77
BP 323
EP 345
DI 10.1146/annurev-physiol-021113-170343
PG 23
WC Physiology
SC Physiology
GA BC2JD
UT WOS:000350992800016
PM 25422986
ER
PT J
AU Grindle, GG
Wang, HW
Jeannis, H
Teodorski, E
Cooper, RA
AF Grindle, Garrett G.
Wang, Hongwu
Jeannis, Hervens
Teodorski, Emily
Cooper, Rory A.
TI Design and User Evaluation of a Wheelchair Mounted Robotic Assisted
Transfer Device
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID SITTING PIVOT TRANSFERS; SPINAL-CORD-INJURY; MANIPULATION APPLIANCE;
PERSONAL MOBILITY; CARE FACILITIES; LIFTING DEVICES; KINEMATICS;
SHOULDER; OVERHEAD; SYSTEM
AB Purpose. The aim of this study is to describe the robotic assisted transfer device (RATD) and an initial focus group evaluation by end users. The purpose of the device is to aid in the transfers of people with disabilities to and from their electric powered wheelchair (EPW) onto other surfaces. The device can be used for both stand-pivot transfers and fully dependent transfers, where the person being transferred is in a sling and weight is fully on the robot. The RATD is fixed to an EPW to allow for its use in community settings. Method. A functional prototype of the RATD was designed and fabricated. The prototype was presented to a group of 16 end users and feedback on the device was obtained via a survey and group discussion. Results. Thirteen out of sixteen (83%) participants agreed that it was important to develop this type of technology. They also indicated that user, caregiver, and robotic controls were important features to be included in the device. Conclusions. Participants in this study suggested that they would be accepting the use of robotic technology for transfers and a majority did not feel that they would be embarrassed to use this technology.
C1 [Grindle, Garrett G.; Wang, Hongwu; Jeannis, Hervens; Teodorski, Emily; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15232 USA.
[Grindle, Garrett G.; Wang, Hongwu; Jeannis, Hervens; Teodorski, Emily; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15232 USA.
RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15232 USA.
EM rcooper@pitt.edu
RI Wang, Hongwu/J-6133-2013
OI Wang, Hongwu/0000-0002-6567-9144
FU National Science Foundation [EEC-540865, ERC-0540865]; Office of
Research and Development; Rehabilitation Research & Development Service;
Department of Veterans Affairs [B3142C]; Quality of Life Technology
Engineering Research Center; VA Rehabilitation Research and Development
Service [B6789C]
FX This material is based upon work supported in part by the National
Science Foundation Grant no. EEC-540865, Office of Research and
Development, Rehabilitation Research & Development Service, Department
of Veterans Affairs, Grant no. B3142C, Quality of Life Technology
Engineering Research Center, National Science Foundation (ERC-0540865),
and the VA Rehabilitation Research and Development Service (B6789C). The
contents of this paper do not represent the views of the Department of
Veterans Affairs or the United States Government.
NR 26
TC 0
Z9 0
U1 1
U2 10
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 198476
DI 10.1155/2015/198476
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CD4ZX
UT WOS:000351097200001
ER
PT J
AU Rehani, MM
AF Rehani, M. M.
TI Limitations of diagnostic reference level (DRL) and introduction of
acceptable quality dose (AQD)
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Editorial Material
C1 [Rehani, M. M.] Harvard Univ, Sch Med, Boston, MA 02138 USA.
[Rehani, M. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Rehani, MM (reprint author), Harvard Univ, Sch Med, Boston, MA 02138 USA.
EM madan.rehani@gmail.com
NR 6
TC 5
Z9 5
U1 0
U2 0
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
EI 1748-880X
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD JAN
PY 2015
VL 88
IS 1045
AR 20140344
DI 10.1259/bjr.20140344
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CD2BX
UT WOS:000350879900002
PM 25430807
ER
PT J
AU Gehlhausen, JR
Park, SJ
Hickox, AE
Shew, M
Staser, K
Rhodes, SD
Menon, K
Lajiness, JD
Mwanthi, M
Yang, XL
Yuan, J
Territo, P
Hutchins, G
Nalepa, G
Yang, FC
Conway, SJ
Heinz, MG
Stemmer-Rachamimov, A
Yates, CW
Clapp, DW
AF Gehlhausen, Jeffrey R.
Park, Su-Jung
Hickox, Ann E.
Shew, Matthew
Staser, Karl
Rhodes, Steven D.
Menon, Keshav
Lajiness, Jacquelyn D.
Mwanthi, Muithi
Yang, Xianlin
Yuan, Jin
Territo, Paul
Hutchins, Gary
Nalepa, Grzegorz
Yang, Feng-Chun
Conway, Simon J.
Heinz, Michael G.
Stemmer-Rachamimov, Anat
Yates, Charles W.
Clapp, D. Wade
TI A murine model of neurofibromatosis type 2 that accurately phenocopies
human schwannoma formation
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID NERVE SHEATH TUMORS; VESTIBULAR SCHWANNOMA; MOUSE MODELS; HEARING-LOSS;
CELLS; MICE; ORIGIN; NF1
AB Neurofibromatosis type 2 (NF2) is an autosomal dominant genetic disorder resulting from germline mutations in the NF2 gene. Bilateral vestibular schwannomas, tumors on cranial nerve VIII, are pathognomonic for NF2 disease. Furthermore, schwannomas also commonly develop in other cranial nerves, dorsal root ganglia and peripheral nerves. These tumors are a major cause of morbidity and mortality, and medical therapies to treat them are limited. Animal models that accurately recapitulate the full anatomical spectrum of human NF2-related schwannomas, including the characteristic functional deficits in hearing and balance associated with cranial nerve VIII tumors, would allow systematic evaluation of experimental therapeutics prior to clinical use. Here, we present a genetically engineered NF2 mouse model generated through excision of the Nf2 gene driven by Cre expression under control of a tissue-restricted 3.9kbPeriostin promoter element. By 10 months of age, 100% of Postn-Cre; Nf2(flox/flox) mice develop spinal, peripheral and cranial nerve tumors histologically identical to human schwannomas. In addition, the development of cranial nerve VIII tumors correlates with functional impairments in hearing and balance, as measured by auditory brainstem response and vestibular testing. Overall, the Postn-Cre; Nf2(flox/flox) tumor model provides a novel tool for future mechanistic and therapeutic studies of NF2-associated schwannomas.
C1 [Gehlhausen, Jeffrey R.; Park, Su-Jung; Shew, Matthew; Staser, Karl; Rhodes, Steven D.; Menon, Keshav; Lajiness, Jacquelyn D.; Mwanthi, Muithi; Yang, Xianlin; Yuan, Jin; Nalepa, Grzegorz; Yang, Feng-Chun; Conway, Simon J.; Clapp, D. Wade] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA.
[Gehlhausen, Jeffrey R.; Park, Su-Jung; Staser, Karl; Lajiness, Jacquelyn D.; Nalepa, Grzegorz; Conway, Simon J.; Clapp, D. Wade] Indiana Univ Sch Med, Dept Biochem, Indianapolis, IN 46202 USA.
[Rhodes, Steven D.; Yang, Feng-Chun; Conway, Simon J.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
[Mwanthi, Muithi; Clapp, D. Wade] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
[Territo, Paul; Hutchins, Gary] Indiana Univ Sch Med, Dept Radiol, Indianapolis, IN 46202 USA.
[Yates, Charles W.] Indiana Univ Sch Med, Dept Otolaryngol, Indianapolis, IN 46202 USA.
[Hickox, Ann E.; Heinz, Michael G.] Purdue Univ, Dept Biomed Engn, W Lafayette, IN 47907 USA.
[Hickox, Ann E.; Heinz, Michael G.] Purdue Univ, Dept Speech Language & Hearing Sci, W Lafayette, IN 47907 USA.
[Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Stemmer-Rachamimov, Anat] Harvard Univ, Sch Med, Boston, MA USA.
RP Yates, CW (reprint author), Dept Otolaryngol, 705 Riley Hosp Dr,RI0860, Indianapolis, IN 46202 USA.
EM cwyates@iupui.edu; dclapp@iupui.edu
OI Nalepa, Grzegorz/0000-0002-5779-9103; Lab, Nalepa/0000-0002-7560-1906;
Hickox, Ann E./0000-0003-1033-9887
FU Department of Defense [NF110107]; National Institute of Health [P30
CA082709-14, P30 DC004665]; Children's Tumor Foundation [2012-01-013]
FX This work was supported by the Department of Defense (NF110107 to
D.W.C.); National Institute of Health (P30 CA082709-14 and P30 DC004665
to R.A.C.); and the Children's Tumor Foundation (2012-01-013 to J.R.G.).
NR 30
TC 5
Z9 6
U1 2
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 1
PY 2015
VL 24
IS 1
BP 1
EP 8
DI 10.1093/hmg/ddu414
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CC1WH
UT WOS:000350135400001
PM 25113746
ER
PT J
AU Bujakowska, KM
Zhang, Q
Siemiatkowska, AM
Liu, Q
Place, E
Falk, MJ
Consugar, M
Lancelot, ME
Antonio, A
Lonjou, C
Carpentier, W
Mohand-Said, S
den Hollander, AI
Cremers, FPM
Leroy, BP
Gai, XW
Sahel, JA
van den Born, LI
Collin, RWJ
Zeitz, C
Audo, I
Pierce, EA
AF Bujakowska, Kinga M.
Zhang, Qi
Siemiatkowska, Anna M.
Liu, Qin
Place, Emily
Falk, Marni J.
Consugar, Mark
Lancelot, Marie-Elise
Antonio, Aline
Lonjou, Christine
Carpentier, Wassila
Mohand-Said, Saddek
den Hollander, Anneke I.
Cremers, Frans P. M.
Leroy, Bart P.
Gai, Xiaowu
Sahel, Jose-Alain
van den Born, L. Ingeborgh
Collin, Rob W. J.
Zeitz, Christina
Audo, Isabelle
Pierce, Eric A.
TI Mutations in IFT172 cause isolated retinal degeneration and Bardet-Biedl
syndrome
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID LEBER CONGENITAL AMAUROSIS; NONSYNDROMIC RETINITIS-PIGMENTOSA;
INTRAFLAGELLAR TRANSPORT PROTEIN; STATIONARY NIGHT BLINDNESS;
CENTROSOMAL PROTEIN; JOUBERT-SYNDROME; GENE ABCR; IN-VIVO; DYSTROPHY;
CILIARY
AB Primary cilia are sensory organelles present on most mammalian cells. The assembly and maintenance of primary cilia are facilitated by intraflagellar transport (IFT), a bidirectional protein trafficking along the cilium. Mutations in genes coding for IFT components have been associated with a group of diseases called ciliopathies. These genetic disorders can affect a variety of organs including the retina. Using whole exome sequencing in three families, we identified mutations in Intraflagellar Transport 172 Homolog[IFT172(Chlamydomonas)] that underlie an isolated retinal degeneration and Bardet Biedl syndrome. Extensive functional analyses of the identified mutations in cell culture, rat retina and in zebrafish demonstrated their hypomorphic or null nature. It has recently been reported that mutations in IFT1 72 cause a severe ciliopathy syndrome involving skeletal, renal, hepatic and retinal abnormalities (Jeune and Mainzer-Saldino syndromes). Here, we report for the first time that mutations in this gene can also lead to an isolated form of retinal degeneration. The functional data for the mutations can partially explain milder phenotypes; however, the involvement of modifying alleles in the 1FT172-associated phenotypes cannot be excluded. These findings expand the spectrum of disease associated with mutations in IFT172and suggest that mutations in genes originally reported to be associated with syndromic ciliopathies should also be considered in subjects with non-syndromic retinal dystrophy.
C1 [Bujakowska, Kinga M.; Zhang, Qi; Liu, Qin; Place, Emily; Consugar, Mark; Gai, Xiaowu; Pierce, Eric A.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ocular Genom Inst, Boston, MA 02114 USA.
[Bujakowska, Kinga M.; Lancelot, Marie-Elise; Antonio, Aline; Mohand-Said, Saddek; Sahel, Jose-Alain; Zeitz, Christina; Audo, Isabelle] Inst Natl Sante & Rech Med, U968, F-75012 Paris, France.
[Bujakowska, Kinga M.; Lancelot, Marie-Elise; Antonio, Aline; Mohand-Said, Saddek; Sahel, Jose-Alain; Zeitz, Christina; Audo, Isabelle] Univ Paris 06, Sorbonne Univ, Inst Vis, UMR S 968, F-75012 Paris, France.
[Bujakowska, Kinga M.; Lancelot, Marie-Elise; Antonio, Aline; Mohand-Said, Saddek; Sahel, Jose-Alain; Zeitz, Christina; Audo, Isabelle] CNRS, UMR 7210, F-75012 Paris, France.
[Siemiatkowska, Anna M.; den Hollander, Anneke I.; Cremers, Frans P. M.; Collin, Rob W. J.] Radboud Univ Nijmegen Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands.
[den Hollander, Anneke I.; Cremers, Frans P. M.; Collin, Rob W. J.] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, NL-6500 HB Nijmegen, Netherlands.
[den Hollander, Anneke I.] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands.
[Falk, Marni J.] Childrens Hosp Philadelphia, Div Human Genet, Dept Pediat, Philadelphia, PA 19104 USA.
[Falk, Marni J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Lonjou, Christine; Carpentier, Wassila] Hop La Pitie Salpetriere, Plateforme Postgenom P3S, F-75013 Paris, France.
[Mohand-Said, Saddek; Sahel, Jose-Alain; Audo, Isabelle] Ctr Hosp Natl Ophtalmol Quinze Vingts, Inst Natl Sante & Rech Med, F-75012 Paris, France.
[Mohand-Said, Saddek; Sahel, Jose-Alain; Audo, Isabelle] Ctr Hosp Natl Ophtalmol Quinze Vingts, Direct Hosp & Org Soins Ctr Invest Clin 1423, F-75012 Paris, France.
[Leroy, Bart P.] Ghent Univ Hosp, Dept Ophthalmol, B-9000 Ghent, Belgium.
[Leroy, Bart P.] Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium.
[Leroy, Bart P.] Univ Ghent, B-9000 Ghent, Belgium.
[Leroy, Bart P.] Childrens Hosp Philadelphia, Div Ophthalmol, Ophthalm Genet & Visual Electrophysiol, Philadelphia, PA 19104 USA.
[Sahel, Jose-Alain] Fdn Ophtalmol Adolphe Rothschild, F-75019 Paris, France.
[Sahel, Jose-Alain] Inst France, Acad Sci, F-75006 Paris, France.
[Sahel, Jose-Alain; Audo, Isabelle] UCL, Inst Ophthalmol, London EC1V 9EL, England.
[van den Born, L. Ingeborgh] Rotterdam Eye Hosp, NL-3000 LM Rotterdam, Netherlands.
RP Pierce, EA (reprint author), Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
EM eric_pierce@meei.harvard.edu
RI Hollander, Anneke/N-4911-2014; Collin, Rob/N-3575-2014; Cremers,
Frans/A-5625-2014; Tracewska, Anna/N-7087-2015; Zeitz,
Christina/F-2757-2017; Sahel, Jose-Alain/F-3172-2017;
OI Pierce, Eric/0000-0002-2354-4102
FU National Eye Institute [EY012910]; Foundation Fighting Blindness (FFB);
Research to Prevent Blindness; Fleming Family Foundation; FFB
[CD-CL-0808-0466-CHNO]; FFB center [C-CMM-0907-0428-INSERM04];
Foundation Voir et Entendre; Fondation Dalloz prix 'pour la recherche en
ophtalmologie'; Ville de Paris and Region Ile de France; Labex
LIFESENSES [ANR-10-LABX-65]; French state funds managed by the Agence
Nationale de la Recherche within the Investissements d'Avenir program
[ANR-11-IDEX-0004-0]; Netherlands Organisation for Scientific Research
[91209047]; Stichting Wetenschappelijk Onderzoek Oogziekenhuis Prof Dr
H.J. Flieringa Foundation
FX This work was supported by grants from the National Eye Institute
(EY012910, E.A.P), the Foundation Fighting Blindness (FFB) (E.A.P. and
Q.L.), Research to Prevent Blindness (E.A.P.) and the Fleming Family
Foundation (K.M.B); FFB grant CD-CL-0808-0466-CHNO (I.A.), FFB center
grant C-CMM-0907-0428-INSERM04, Foundation Voir et Entendre (C.Z.),
Fondation Dalloz prix 'pour la recherche en ophtalmologie' (C.Z.), Ville
de Paris and Region Ile de France, and Labex LIFESENSES
(ANR-10-LABX-65), supported by French state funds managed by the Agence
Nationale de la Recherche within the Investissements d'Avenir program
(ANR-11-IDEX-0004-0). The research studies of A.M.S. and R.W.J.C. were
supported by the Netherlands Organisation for Scientific Research
(TOP-grant 91209047, to F.P.M.C. and A.I.d.H.) and the Stichting
Wetenschappelijk Onderzoek Oogziekenhuis Prof Dr H.J. Flieringa
Foundation.
NR 96
TC 26
Z9 27
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 1
PY 2015
VL 24
IS 1
BP 230
EP 242
DI 10.1093/hmg/ddu441
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CC1WH
UT WOS:000350135400018
PM 25168386
ER
PT J
AU Forbes, D
Lockwood, E
Elhai, JD
Creamer, M
Bryant, R
McFarlane, A
Silove, D
Miller, MW
Nickerson, A
O'Donnell, M
AF Forbes, David
Lockwood, Emma
Elhai, Jon D.
Creamer, Mark
Bryant, Richard
McFarlane, Alexander
Silove, Derrick
Miller, Mark W.
Nickerson, Angela
O'Donnell, Meaghan
TI An evaluation of the DSM-5 factor structure for posttraumatic stress
disorder in survivors of traumatic injury
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Posttraumatic stress disorder; PTSD; DSM-5; Factor analysis
ID ADMINISTERED PTSD SCALE; NEUROPSYCHIATRIC INTERVIEW MINI; CONFIRMATORY
FACTOR-ANALYSIS; SYMPTOM STRUCTURE; FIT INDEXES; MODEL; RELIABILITY;
ANXIETY; COMORBIDITY; INSTRUMENT
AB Confirmatory factor analytic studies of the latent structure of DSM-5 PTSD symptoms using self-report data (Elhai et al., 2012; Miller et al., 2013) have found that the four-factor model implied by the DSM-5 diagnostic criteria provided adequate fit to their data. However, the fit of this model is yet to be assessed using data derived from gold standard structured interview measures. This study evaluated the fit of the DSM-5 four-factor model and an alternative four-factor model in 570 injury survivors six years post-injury using the Clinician Administered PTSD Scale (Blake et al., 1990), updated to include items measuring new DSM-5 symptoms. While both four-factor models fitted the data well, very high correlations between the 'Intrusions' and 'Avoidance' factors in both models and between the 'Negative Alterations in Cognitions and Mood' and 'Arousal and Reactivity' factors in the DSM-5 model and the 'Dysphoria' and 'Hyperarousal' factors in the alternative model were evident, suggesting that a more parsimonious two-factor model combining these pairs of factors may adequately represent the latent structure. Such a two-factor model fitted the data less well according to chi(2) difference testing, but demonstrated broadly equivalent fit using other fit indices. Relationships between the factors of each of the four-factor models and the latent factors of Fear and Anxious-Misery/Distress underlying Internalizing disorders (Krueger, 1999) were also explored, with findings providing further support for the close relationship between the Intrusion and Avoidance factors. However, these findings also suggested that there may be some utility to distinguishing Negative Alterations in Cognition and Mood symptoms from Arousal and Reactivity symptoms, and/or Dysphoria symptoms from Hyperarousal symptoms. Further studies are required to assess the potential discriminant validity of the two four-factor models. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Forbes, David; Lockwood, Emma; Creamer, Mark; O'Donnell, Meaghan] Australian Ctr Posttraumat Mental Hlth, Carlton, Vic 3053, Australia.
[Forbes, David; Lockwood, Emma; Creamer, Mark; O'Donnell, Meaghan] Dept Psychiat, Melbourne, Vic 3053, Australia.
[Elhai, Jon D.] Univ Toledo, Dept Psychol, Toledo, OH 43606 USA.
[Elhai, Jon D.] Univ Toledo, Dept Psychiat, Toledo, OH 43606 USA.
[Bryant, Richard; Nickerson, Angela] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.
[McFarlane, Alexander] Ctr Traumat Stress Studies, Adelaide, SA 5000, Australia.
[Silove, Derrick] Liverpool Hosp, Psychiat Res & Teaching Unit, Mental Hlth Ctr, Liverpool, NSW 2170, Australia.
[Miller, Mark W.] VA Boston Healthcare Syst, Natl Ctr PTSD 116B 2, Boston, MA 02130 USA.
RP Forbes, D (reprint author), Australian Ctr Posttraumat Mental Hlth, Level 3,161 Barry St, Carlton, Vic 3053, Australia.
EM dforbes@unimelb.edu.au
RI Miller, Mark/G-7322-2011;
OI Miller, Mark/0000-0001-6393-8563; Bryant, Richard/0000-0002-9607-819X
FU National Health and Medical Research Council (NHMRC) [300304]
FX This study was supported by a National Health and Medical Research
Council (NHMRC) Program Grant (300304).
NR 51
TC 9
Z9 9
U1 5
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD JAN
PY 2015
VL 29
BP 43
EP 51
DI 10.1016/j.janxdis.2014.11.004
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA CC3RC
UT WOS:000350265700007
PM 25465886
ER
PT J
AU Eddy, KT
Lawson, EA
Meade, C
Meenaghan, E
Horton, SE
Misra, M
Klibanski, A
Miller, KK
AF Eddy, Kamryn T.
Lawson, Elizabeth A.
Meade, Christina
Meenaghan, Erinne
Horton, Sarah E.
Misra, Madhusmita
Klibanski, Anne
Miller, Karen K.
TI Appetite Regulatory Hormones in Women With Anorexia Nervosa:
Binge-Eating/Purging Versus Restricting Type
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID BODY-MASS INDEX; BONE-MINERAL DENSITY; BULIMIA-NERVOSA; PEPTIDE YY;
EATING-DISORDERS; LEPTIN LEVELS; WEIGHT REGULATION; FOOD-INTAKE; BDNF;
GHRELIN
AB Objective: Anorexia nervosa is a psychiatric illness characterized by low weight, disordered eating, and hallmark neuroendocrine dysfunction. Behavioral phenotypes are defined by predominant restriction or bingeing/purging; binge-eating/purging type anorexia nervosa is associated with poorer outcome. The pathophysiology underlying anorexia nervosa types is unknown, but altered hormones, known to be involved in eating behaviors, may play a role.
Method: To examine the role of anorexigenic hormones in anorexia nervosa subtypes, we examined serum levels of peptide YY (PYY; total and active [3-36] forms), brain-derived neurotrophic factor (BDNF), and leptin as primary outcomes in women with DSM-5 restricting type anorexia nervosa (n = 50), binge-eating/purging type anorexia nervosa (n = 25), and healthy controls (n = 22). In addition, women completed validated secondary outcome measures of eating disorder psychopathology (Eating Disorder Examination-Questionnaire) and depression and anxiety symptoms (Hamilton Rating Scales for Depression [HDRS] and Anxiety [HARS]). The study samples were collected from May 22, 2004, to February 7, 2012.
Results: Mean PYY 3-36 and leptin levels were lower and BDNF levels higher in binge-eating/purging type anorexia nervosa than in restricting type anorexia nervosa (all P values < .05). After controlling for body mass index, differences in PYY and PYY 3-36 between anorexia nervosa types were significant (P < .05) and differences in BDNF were at the trend level (P <.10). PYY 3-36 was positively (r = 0.27, P = .02) and leptin was negatively (r = -0.51, P < .0001) associated with dietary restraint; BDNF was positively associated with frequency of purging (r = 0.21, P = .04); and leptin was negatively associated with frequency of bingeing (r = -0.29, P = .007) and purging (r = -0.31, P = .004).
Conclusions: Among women with anorexia nervosa, the anorexigenic hormones PYY, BDNF, and leptin are differentially regulated between the restricting and binge/purge types. Whether these hormone pathways play etiologic roles with regard to anorexia nervosa behavioral types or are compensatory merits further study. (C) Copyright 2014 Physicians Postgraduate Press, Inc.
C1 [Eddy, Kamryn T.] Massachusetts Gen Hosp, Dept Psychiat, Eating Disorders Clin & Res Program, Boston, MA 02114 USA.
[Lawson, Elizabeth A.; Meade, Christina; Meenaghan, Erinne; Misra, Madhusmita; Klibanski, Anne; Miller, Karen K.] Massachusetts Gen Hosp, Dept Med, Neuroendocrine Unit, Boston, MA 02114 USA.
RP Eddy, KT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Eating Disorders Clin & Res Program,Dept Psychiat, 2 Longfellow Pl,Ste 200, Boston, MA 02114 USA.
EM keddy@mgh.harvard.edu
FU National Institutes of Health [R01 MH083657, UL1 RR025758]
FX Supported in part by National Institutes of Health grants R01 MH083657
and UL1 RR025758.
NR 35
TC 7
Z9 7
U1 1
U2 20
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JAN
PY 2015
VL 76
IS 1
BP 19
EP 24
DI 10.4088/JCP.13m08753
PG 6
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA CD3JC
UT WOS:000350973400015
PM 25098834
ER
PT J
AU Mischoulon, D
Nierenberg, AA
Schettler, PJ
Kinkead, BL
Fehling, K
Martinson, MA
Rapaport, MH
AF Mischoulon, David
Nierenberg, Andrew A.
Schettler, Pamela J.
Kinkead, Becky L.
Fehling, Kiki
Martinson, Max A.
Rapaport, Mark Hyman
TI A Double-Blind, Randomized Controlled Clinical Trial Comparing
Eicosapentaenoic Acid Versus Docosahexaenoic Acid for Depression
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; PLACEBO-CONTROLLED TRIAL;
POSTTRAUMATIC-STRESS-DISORDER; FISH-OIL SUPPLEMENTATION;
STAR-ASTERISK-D; MAJOR DEPRESSION; OMEGA-3 SUPPLEMENTATION; PATIENT
CHARACTERISTICS; ACCIDENTAL INJURY; RATING-SCALE
AB Objective: To compare 2 omega-3 (n-3) preparations enriched with eicosapentaenoic acid (EPA) versus docosahexaenoic acid (DHA) as monotherapy for major depressive disorder (MDD) in a 2-site, placebo-controlled, randomized, double-blind clinical trial.
Method: 196 adults (53% female; mean [SD] age = 44.7 [13.4] years) with DSM-IV MDD and a baseline 17-item Hamilton Depression Rating Scale (HDRS-17) score >= 15 were randomized equally from May 18, 2006, to June 30, 2011, to 8 weeks of double-blind treatment with oral EPA-enriched n-3 1000 mg/d, DHA-enriched n-3 1,000 mg/d, or placebo.
Results: 154 subjects completed the study. Modified intent-to-treat (mITT) analysis (n = 177 subjects with >= 1 postbaseline visit; 59.3% female, mean [SD] age 45.8 [12.5] years) employed mixed-model repeated measures (MMRM). All 3 groups demonstrated statistically significant improvement in the HDRS-17 (primary outcome measure), 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR-16), and Clinical Global Improvement-Severity Scale (CGI-S) (P < .05), but neither n-3 preparation separated from placebo (P > .05). Response and remission rates were in the range of 40%-50% and 30%, respectively, for all treatments, with no significant differences between groups. One subject receiving EPA-enriched n-3 discontinued due to worsening depression, and 1 subject receiving placebo discontinued due to an unspecified "negative reaction" to pills.
Conclusions: Neither EPA-enriched nor DHA-enriched n-3 was superior to placebo for the treatment of MDD. (C) Copyright 2014 Physicians Postgraduate Press, Inc.
C1 [Mischoulon, David; Nierenberg, Andrew A.; Fehling, Kiki; Martinson, Max A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA.
[Schettler, Pamela J.; Kinkead, Becky L.; Rapaport, Mark Hyman] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
RP Mischoulon, D (reprint author), 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM dmisc.houlon@partners.org
FU National Institutes of Health (NIH) [5R01MH74085]
FX The study was funded by grant 5R01MH74085 from the National Institutes
of Health (NIH) to Drs Mischoulon and Rapaport. EPA-enriched and
DHA-enriched preparations and matching placebos were kindly provided by
NordicNaturals.
NR 51
TC 15
Z9 15
U1 8
U2 25
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JAN
PY 2015
VL 76
IS 1
BP 54
EP +
DI 10.4088/JCP.14m08986
PG 11
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA CD3JC
UT WOS:000350973400021
PM 25272149
ER
PT J
AU Walker, J
AF Walker, Jennifer
TI Practice improves performance on a coronary anastomosis simulator,
attending surgeon supervision does not
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Walker, J (reprint author), Massachusetts Gen Hosp, 55 Fruit St,EDR 105, Boston, MA 02114 USA.
EM jdwalker@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD JAN
PY 2015
VL 149
IS 1
BP 18
EP 18
DI 10.1016/j.jtcvs.2014.09.058
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CC7LW
UT WOS:000350550100009
PM 25524669
ER
PT J
AU Lin, AY
Kotova, S
Yanagawa, J
Elbuluk, O
Wang, G
Kar, N
Elashoff, D
Grogan, T
Cameron, RB
Singh, A
Chmielowski, B
Federman, N
Nelson, SD
Lee, P
Eilber, FC
Lee, JM
AF Lin, Anthony Y.
Kotova, Svetlana
Yanagawa, Jane
Elbuluk, Osama
Wang, Gerald
Kar, Nivedita
Elashoff, David
Grogan, Tristan
Cameron, Robert B.
Singh, Arun
Chmielowski, Bartosz
Federman, Noah
Nelson, Scott D.
Lee, Percy
Eilber, Fritz C.
Lee, Jay M.
TI Risk stratification of patients undergoing pulmonary metastasectomy for
soft tissue and bone sarcomas
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID LONG-TERM SURVIVAL; HIGH-GRADE OSTEOSARCOMA; PROGNOSTIC-FACTORS;
RESECTION; CHEMOTHERAPY; OUTCOMES; BENEFIT
AB Objectives: Our objective was to identify risk factors associated with survival in patients who underwent pulmonary metastasectomy for soft tissue or bone sarcoma and to create a risk stratification model.
Methods: A retrospective review of the prospectively maintained University of California Los Angeles Sarcoma Database was performed. Clinical, pathologic, and treatment variables were analyzed for overall survival and disease-free survival. Univariate and multivariate analyses were performed, and variables that were identified as significant were included to create a risk model. A total of 155 patients who underwent pulmonary metastasectomy for soft tissue sarcoma (n = 108 patients) or bone sarcoma (n = 47 patients) from 1994 to 2010 were identified.
Results: Multivariate analysis identified 7 factors associated with poor overall survival: age more than 45 years, disease-free interval less than 1 year, thoracotomy, synchronous disease, location and type of sarcoma (soft tissue vs bone sarcoma), and performance of a lobectomy. The number of factors present was associated with poor overall survival, which varied widely from 64% in patients with 2 factors to 3% in those with 5 factors.
Conclusions: We have identified prognostic variables associated with overall survival after lung metastasectomy. Our model may be used as a risk stratification model to guide treatment decisions on the basis of the number of risk factors present. Although prospective studies are warranted to determine the benefit of surgical intervention in all cohorts compared with other local therapies or medical therapy, given the attendant dismal prognosis in patients with 5 or more risk factors, the benefit of surgical resection in this group is questioned.
C1 [Lin, Anthony Y.; Kotova, Svetlana; Yanagawa, Jane; Elbuluk, Osama; Cameron, Robert B.; Lee, Jay M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Thorac Surg, Los Angeles, CA 90095 USA.
[Wang, Gerald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.
[Kar, Nivedita] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA.
[Kar, Nivedita] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Elashoff, David; Grogan, Tristan] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Singh, Arun; Chmielowski, Bartosz] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Med Oncol, Los Angeles, CA 90095 USA.
[Federman, Noah] Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Hematol & Med Oncol, Dept Pediat, Los Angeles, CA 90095 USA.
[Nelson, Scott D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Lee, Percy] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA.
[Eilber, Fritz C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Surg Oncol, Dept Surg, Los Angeles, CA 90095 USA.
[Kotova, Svetlana; Cameron, Robert B.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Thorac Surg, Dept Surg, Los Angeles, CA USA.
RP Lee, JM (reprint author), Univ Calif Los Angeles, Med Ctr, Div Thorac Surg, Box 957313,Room 64-128 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM jaymoonlee@mednet.ucla.edu
OI Chmielowski, Bartosz/0000-0002-2374-3320
FU Jonsson Comprehensive Cancer Center Sarcoma Program
FX Funded by the Jonsson Comprehensive Cancer Center Sarcoma Program.
NR 20
TC 7
Z9 7
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD JAN
PY 2015
VL 149
IS 1
BP 85
EP 92
DI 10.1016/j.jtcvs.2014.09.039
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CC7LW
UT WOS:000350550100030
PM 25312228
ER
PT J
AU You, ML
Zhong, JJ
Hong, Y
Duan, ZF
Lin, M
Xu, F
AF You, Minli
Zhong, Junjie
Hong, Yuan
Duan, Zhenfeng
Lin, Min
Xu, Feng
TI Inkjet printing of upconversion nanoparticles for anti-counterfeit
applications
SO NANOSCALE
LA English
DT Article
ID CONTROLLED CONTACT-ANGLE; NAYF4 NANOCRYSTALS; REYNOLDS-NUMBERS;
SOLID-SURFACE; LOW WEBER; LUMINESCENCE; PAPER; ELECTRONICS; GRAPHENE;
INKS
AB Patterning of upconversion luminescent materials has been widely used for anti-counterfeit and security applications, where the preferred method should be easy, fast, multicolor, high-throughput and designable. However, conventional patterning methods are complex and inflexible. Here, we report a digital and flexible inkjet printing based approach for producing high-resolution and high-luminescence anti-counterfeit patterns. We successfully printed different multicolor luminescent patterns by inkjet printing of upconversion nanoparticles with controlled and uniform luminescence intensity through optimizing the inks and substrates. Combined with another downconversion luminescent material, we achieved two different patterns in the same area, which show up separately under excitation by different wavelength laser sources. The developed technology is promising to use one single substrate for carrying abundant information by printing multilayer patterns composed of luminescent materials with different excitation light sources.
C1 [You, Minli; Lin, Min; Xu, Feng] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.
[You, Minli; Zhong, Junjie; Hong, Yuan; Lin, Min; Xu, Feng] Xi An Jiao Tong Univ, BEBC, Xian 710049, Peoples R China.
[Zhong, Junjie] Xi An Jiao Tong Univ, Sch Energy & Power Engn, Xian 710049, Peoples R China.
[Hong, Yuan] Nanjing Agr Univ, Coll Life Sci, Nanjing 210095, Jiangsu, Peoples R China.
[Duan, Zhenfeng; Lin, Min] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.
RP Xu, F (reprint author), Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.
EM minlin@mail.xjtu.edu.cn; fengxu@mail.xjtu.edu.cn
RI Xu, Feng/C-7430-2011; Xu, Feng/H-4468-2011
OI Xu, Feng/0000-0003-4351-0222
FU Major International Joint Research Program of China [11120101002];
International Science & Technology Cooperation Program of China
[2013DFG02930]; National Key Scientific Apparatus Development of Special
Item [2013YQ190467]; Fundamental Research Funds for the Central
Universities [2012jdhz46]; China Scholarship of Council; China Young
1000-Talent Program; Program for New Century Excellent Talents in
University
FX This work was financially supported by the Major International Joint
Research Program of China (11120101002), the International Science &
Technology Cooperation Program of China (2013DFG02930), National Key
Scientific Apparatus Development of Special Item (2013YQ190467), and the
Fundamental Research Funds for the Central Universities (2012jdhz46).
Min Lin is supported by a scholarship from the China Scholarship of
Council. Feng Xu was also partially supported by the China Young
1000-Talent Program and the Program for New Century Excellent Talents in
University. The TEM work was done at International Center for Dielectric
Research (ICDR), Xi'an Jiaotong University, Xi'an, China. The authors
also thank Ms Lu Lu and Mr Ma Chuan Sheng for their help in using TEM.
NR 55
TC 32
Z9 33
U1 622
U2 709
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2015
VL 7
IS 10
BP 4423
EP 4431
DI 10.1039/c4nr06944g
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA CC9ED
UT WOS:000350669900017
PM 25613526
ER
PT S
AU Yang, XH
Friedl, A
AF Yang, Xinhai
Friedl, Andreas
BE Diakonova, M
TI A Positive Feedback Loop Between Prolactin and STAT5 Promotes
Angiogenesis
SO RECENT ADVANCES IN PROLACTIN RESEARCH
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
ID BREAST-CANCER-CELLS; CAPILLARY ENDOTHELIAL-CELLS; GROWTH-HORMONE FAMILY;
N-TERMINAL FRAGMENTS; CYCLIN D1 PROMOTER; SIGNAL-TRANSDUCTION;
MESSENGER-RNA; 16-KDA PROLACTIN; JAK/STAT PATHWAY; SERINE
PHOSPHORYLATION
AB The signal transduction events that orchestrate cellular activities required for angiogenesis remain incompletely understood. We and others recently described that proangiogenic mediators such as fibroblast growth factors can activate members of the signal transducers and activators of transcription (STAT) family. STAT5 activation is necessary and sufficient to induce migration, invasion and tube formation of endothelial cells. STAT5 effects on endothelial cells require the secretion of the prolactin (PRL) family member proliferin-1 (PLF1) in mice and PRL in humans. In human endothelial cells, PRL activates the PRL receptor (PRLR) resulting in MAPK and STAT5 activation, thus closing a positive feedback loop. In vivo, endothelial cell-derived PRL is expected to combine with PRL of tumor cell and pituitary origin to raise the concentration of this polypeptide hormone in the tumor microenvironment. Thus, PRL may stimulate tumor angiogenesis via autocrine, paracrine, and endocrine pathways. The disruption of tumor angiogenesis by interfering with PRL signaling may offer an attractive target for therapeutic intervention.
C1 [Yang, Xinhai; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA.
[Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs, Med Ctr, Madison, WI 53705 USA.
[Friedl, Andreas] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
RP Friedl, A (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, 6051 WIMR,MC-2275,1111 Highland Ave, Madison, WI 53705 USA.
EM afriedl@wisc.edu
FU NCI NIH HHS [P30 CA014520]
NR 134
TC 4
Z9 4
U1 3
U2 10
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
BN 978-3-319-12114-7; 978-3-319-12113-0
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2015
VL 846
BP 265
EP 280
DI 10.1007/978-3-319-12114-7_12
D2 10.1007/978-3-319-12114-7
PG 16
WC Biology; Medicine, Research & Experimental; Physiology
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
Medicine; Physiology
GA BC1TY
UT WOS:000350422800013
PM 25472543
ER
PT J
AU Kalman, RS
Pedrosa, MC
AF Kalman, Richard S.
Pedrosa, Marcos C.
TI Evidence-based Review of Gastrointestinal Bleeding in the Chronic Kidney
Disease Patient
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID CHRONIC-RENAL-FAILURE; VASCULAR MALFORMATIONS; HEMODIALYSIS-PATIENTS;
HORMONAL-THERAPY; ISCHEMIC COLITIS; STERCORAL ULCER; ANGIODYSPLASIA;
PREVENTION; PREVALENCE; HEMORRHAGE
AB Patients with end-stage renal disease are more likely to suffer from gastrointestinal (GI) problems, including bleeding from upper and lower sources. Peptic ulcer disease is the most common cause of upper GI bleeding, and although there is some debate in the literature regarding whether the frequency of ulcer disease is higher in patients with kidney disease, it is well established that outcomes are worse in patients with compromised renal function. Angioectasias can be found throughout the GI tract and are another common cause of bleeding; management can be divided into localized endoscopic therapy and systemic hormonal treatment, or surgery for refractory cases. The most frequent causes of lower GI bleeding in this population, in addition to angioectasias, are diverticulosis, hemorrhoids, and ischemic colitis.
C1 [Kalman, Richard S.] Boston Univ, Med Ctr, Dept Med, Gastroenterol Sect, Boston, MA USA.
[Pedrosa, Marcos C.] VA Boston Healthcare Syst, Dept Med, Gastroenterol Sect, Boston, MA USA.
RP Kalman, RS (reprint author), Boston Med Ctr, 85 East Concord St,Suite 7720, Boston, MA 02118 USA.
EM richard.kalman@bmc.org
NR 42
TC 4
Z9 4
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
EI 1525-139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD JAN-FEB
PY 2015
VL 28
IS 1
BP 68
EP 74
DI 10.1111/sdi.12301
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA CD4KA
UT WOS:000351050000015
PM 25215610
ER
PT J
AU Dilwali, S
Roberts, D
Stankovic, KM
AF Dilwali, Sonam
Roberts, Daniel
Stankovic, Konstantina M.
TI Interplay between VEGF-A and cMET signaling in human vestibular
schwannomas and schwann cells
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE hepatocyte growth factor; Schwann cells; siRNA; cross-talk; vascular
endothelial growth factor; vestibular schwannoma
ID HEPATOCYTE GROWTH-FACTOR; NEUROFIBROMATOSIS TYPE-2; C-MET; BEVACIZUMAB;
EXPRESSION; PATHWAYS; RECEPTOR
AB Vestibular schwannoma (VS), the fourth most common intracranial tumor, arises from the Schwann cells of the vestibular nerve. Although several pathways have been independently implicated in VS pathobiology, interactions among these pathways have not been explored in depth. We have investigated the potential cross-talk between hepatocyte growth factor (HGF) and vascular endothelial growth factor-A (VEGF-A) in human VS, an interaction that has been described in other physiological and pathological cell types. We affirmed previous findings that VEGF-A signaling is aberrantly upregulated in VS, and established that expression of HGF and its receptor cMET is also significantly higher in sporadic VS than in healthy nerves. In primary human VS and Schwann cell cultures, we found that VEGF-A and HGF signaling pathways modulate each other. siRNAs targeting cMET decreased both cMET and VEGF-A protein levels, and siRNAs targeting VEGF-A reduced cMET expression. Additionally, siRNA-mediated knockdown of VEGF-A or cMET and pharmacologic inhibition of cMET decreased cellular proliferation in primary human VS cultures. Our data suggest cross-talk between these 2 prominent pathways in VS and highlight the HGF/cMET pathway as an additional important therapeutic target in VS.
C1 [Dilwali, Sonam; Roberts, Daniel; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Dilwali, Sonam; Roberts, Daniel; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Dilwali, Sonam; Stankovic, Konstantina M.] Harvard Massachusetts Inst Technol, Program Speech & Hearing Biosci & Technol, Boston, MA USA.
[Roberts, Daniel; Stankovic, Konstantina M.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA USA.
RP Stankovic, KM (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
EM konstantina_stankovic@meei.harvard.edu
FU National Institute on Deafness and Other Communication Disorders [T32
DC00038, K08DC010419]; Bertarelli Foundation; US. Department of Defense
[W81XWH-14-1-0091]
FX This study was supported by the National Institute on Deafness and Other
Communication Disorders Grants T32 DC00038 (SD, KMS) and K08DC010419
(KMS), the Bertarelli Foundation (KMS) and the US. Department of Defense
Grant W81XWH-14-1-0091 (KMS).
NR 15
TC 1
Z9 1
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JAN
PY 2015
VL 16
IS 1
BP 170
EP 175
DI 10.4161/15384047.2014.972765
PG 6
WC Oncology
SC Oncology
GA CC0AJ
UT WOS:000349996700021
PM 25692621
ER
PT J
AU Aguilar, C
Beltran, B
Quinones, P
Carbajal, T
Vilcapaza, J
Yabar, A
Segura, P
Quintanilla-Martinez, L
Miranda, RN
Castillo, JJ
AF Aguilar, Cristian
Beltran, Brady
Quinones, Pilar
Carbajal, Tomas
Vilcapaza, Jorge
Yabar, Alejandro
Segura, Pedro
Quintanilla-Martinez, Leticia
Miranda, Roberto N.
Castillo, Jorge J.
TI Large B-cell lymphoma arising in cardiac myxoma or intracardiac
fibrinous mass: a localized lymphoma usually associated with
Epstein-Barr virus?
SO CARDIOVASCULAR PATHOLOGY
LA English
DT Article
DE Cardiac myxoma; B-cell lymphoma; Epstein-Barr virus; EBER; Chronic
inflammation
ID LEFT ATRIAL-MYXOMA; INTERLEUKIN-6
AB Primary cardiac neoplasms are rare. However, among them, cardiac myxoma is the most common tumor. In contrast, primary cardiac lymphoma within a cardiac myxoma is extremely rare and might be difficult to diagnose because of non-specific clinical manifestations. We report the case of a previously healthy 52-year-old man who presented with acute onset of transient dysarthria and left hemiplegia. A transthoracic echocardiography showed a 6x2.5-cm solid mass in the left atrium, which was subsequently resected. Histological, immunohistochemical, and molecular analyses revealed an EBV-associated CD30-positive large B-cell lymphoma with anaplastic morphology within a cardiac myxoma and fibrinous material. Staging studies showed no evidence of lymphoma elsewhere. The patient achieved complete remission and is alive 42 months after diagnosis, and did not receive chemotherapy. We discuss the clinical and pathologic features of lymphoma arising in cardiac myxoma or in intra-atrial fibrinoid mass and the potential role of IL-6 in its pathogenesis. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Aguilar, Cristian; Quinones, Pilar; Carbajal, Tomas; Vilcapaza, Jorge; Yabar, Alejandro] Hosp Edgardo Rebagliati, Dept Patol, Lima, Peru.
[Beltran, Brady] Edgardo Rebagliati Hosp, Dept Oncol & Radiotherapy, Lima, Peru.
[Segura, Pedro] Edgardo Rebagliati Hosp, Dept Cardiol, Lima, Peru.
[Quintanilla-Martinez, Leticia] Univ Tubingen, Inst Pathol, Tubingen, Germany.
[Quintanilla-Martinez, Leticia] Univ Tubingen, Ctr Comprehens Canc, Tubingen, Germany.
[Miranda, Roberto N.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.
[Castillo, Jorge J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
RP Aguilar, C (reprint author), Hosp Edgardo Rebagliati, Dept Patol, Ave Salaverry, Lima, Peru.
EM dr.cris85@yahoo.com
OI Miranda, Roberto/0000-0002-8467-5464; Segura-Saldana,
Pedro/0000-0002-7859-8466; Beltran, Brady/0000-0003-4469-3817; Castillo,
Jorge/0000-0001-9490-7532
NR 27
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-8807
EI 1879-1336
J9 CARDIOVASC PATHOL
JI Cardiovasc. Pathol.
PD JAN-FEB
PY 2015
VL 24
IS 1
BP 60
EP 64
DI 10.1016/j.carpath.2014.08.007
PG 5
WC Cardiac & Cardiovascular Systems; Pathology
SC Cardiovascular System & Cardiology; Pathology
GA CC3EU
UT WOS:000350229400009
PM 25307939
ER
PT J
AU Boros, E
Gale, EM
Caravan, P
AF Boros, Eszter
Gale, Eric M.
Caravan, Peter
TI MR imaging probes: design and applications
SO DALTON TRANSACTIONS
LA English
DT Article
ID HUMAN SERUM-ALBUMIN; AORTOILIAC OCCLUSIVE DISEASE; ANGIOGRAPHY CONTRAST
AGENT; SATURATION-TRANSFER CEST; WATER EXCHANGE-RATE; HIGH-RELAXIVITY;
PROTEIN-BINDING; GADOLINIUM COMPLEX; GD3+ COMPLEXES; ENHANCED MRI
AB This perspective outlines strategies towards the development of MR imaging probes that our lab has explored over the last 15 years. Namely, we discuss methods to enhance the signal generating capacity of MR probes and how to achieve tissue specificity through protein targeting or probe activation within the tissue microenvironment.
C1 [Caravan, Peter] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Caravan, P (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM caravan@nmr.mgh.harvard.edu
FU National Cancer Institute [CA161221, CA009502]; National Institute for
Biomedical Imaging and Bioengineering [EB009062]; Swiss National Science
Foundation
FX This work was supported by grants from the National Cancer Institute
(CA161221 to PC and a T32 post-doctoral fellowship to EMG, CA009502) and
the National Institute for Biomedical Imaging and Bioengineering
(EB009062). E.B. thanks the Swiss National Science Foundation (advanced.
postdoc mobility fellowship) for support. The contributions of our
co-authors to the papers cited is warmly acknowledged.
NR 154
TC 22
Z9 22
U1 7
U2 54
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1477-9226
EI 1477-9234
J9 DALTON T
JI Dalton Trans.
PY 2015
VL 44
IS 11
BP 4804
EP 4818
DI 10.1039/c4dt02958e
PG 15
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA CC6PO
UT WOS:000350488300003
PM 25376893
ER
PT J
AU Locatelli, SM
Turcios, S
LaVela, SL
AF Locatelli, Sara M.
Turcios, Stephanie
LaVela, Sherri L.
TI Optimizing the Patient-Centered Environment: Results of Guided Tours
With Health Care Providers and Employees
SO HERD-HEALTH ENVIRONMENTS RESEARCH & DESIGN JOURNAL
LA English
DT Article
DE patient-centered care; design; architecture; patient and/or family;
health care
ID PARTICIPATORY ACTION RESEARCH; DESIGN; COMPLEMENTARY; INTERVENTION;
EXPERIENCE; VETERANS; MEDICINE; STORIES; QUALITY; EXPLORE
AB Objective: To examine providers' perspectives on the care environment and patient-centered care (PCC) through the eyes of the veteran patient, using guided tours qualitative methodology. Background: Environmental factors, such as attractiveness and function, have the potential to improve patients' experiences. Participatory qualitative methods allow researchers to explore the environment and facilitate discussion. Methods: Guided tours were conducted with 25 health care providers/employees at two Veterans Affairs (VA) health care facilities. In guided tours, participants lead the researcher through an environment, commenting on their surroundings, thoughts, and feelings. The researcher walks along with the participant, asking open-ended questions as needed to foster discussion and gain an understanding of the participant's view. Participants were asked to walk through the facility as though they were a veteran. Tours were audio recorded, with participant permission, and transcribed verbatim by research assistants. Three qualitative researchers were responsible for code-book development and coding transcripts and used data-driven coding approaches. Results: Participants discussed physical appearance of the environment and how that influences perceptions about care. Overall, participants highlighted the need to shed the "institutional'' appearance. Differences between VA and non-VA health care facilities were discussed, including availability of private rooms and staff to assist with navigating the facility. They reviewed resources in the facility, such as the information desk to assist patients and families. Finally, they offered suggestions for future improvements, including improvements to waiting areas and quiet areas for patients to relax and "get away'' from their rooms. Conclusions: Participants highlighted many small changes to the care environment that could enhance the patient experience. Additionally, they examined the environment from the patient's perspective, to identify elements that enhance, or detract from, the patient's care experience.
C1 [Locatelli, Sara M.; LaVela, Sherri L.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA.
[Locatelli, Sara M.; Turcios, Stephanie; LaVela, Sherri L.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Evaluat Practices & Experiences Patient Ctr C, Hines, IL 60141 USA.
[LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA.
RP Locatelli, SM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Innovat Complex Chron Healthcare, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
EM sara.locatelli@va.gov
FU Veterans Affairs (VA) Office of Patient-Centered Care & Cultural
Transformation; VA Health Services Research & Development Quality
Enhancement Research Initiative [PCE 13-002]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This
article is based on an evaluation funded by the Veterans Affairs (VA)
Office of Patient-Centered Care & Cultural Transformation and the VA
Health Services Research & Development Quality Enhancement Research
Initiative (PCE 13-002, PI: LaVela).
NR 42
TC 3
Z9 3
U1 1
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1937-5867
EI 2167-5112
J9 HERD-HEALTH ENV RES
JI Herd-Health Env. Res. Des. J.
PD JAN
PY 2015
VL 8
IS 2
BP 18
EP 30
DI 10.1177/1937586714565610
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CC5QF
UT WOS:000350414800004
PM 25816378
ER
PT J
AU Bloom, M
Markovitz, S
Silverman, S
Yost, C
AF Bloom, Mara
Markovitz, Sarah
Silverman, Susan
Yost, Carl
TI Ten Trends Transforming Cancer Care and Their Effects on Space Planning
for Academic Medical Centers
SO HERD-HEALTH ENVIRONMENTS RESEARCH & DESIGN JOURNAL
LA English
DT Article
DE academic medical centers; cancer care; space planning; master planning;
architecture; interior design
AB Objective: This article aims to define the major trends currently affecting space needs for academic medical center (AMC) cancer centers. It will distinguish between the trends that promote the concentration of services with those that promote decentralization as well as identify opportunities for achieving greater effectiveness in cancer care space planning. Background: Changes in cancer care-higher survival rates, increased clinical trials, new technology, and changing practice models-increasingly fill hospitals' and clinicians' schedules and strain clinical space resources. Conflicts among these trends are concentrating some services and dispersing others. As a result, AMCs must expand and renovate intelligently to continue providing state-of-the-art, compassionate care. Conclusions: Although the typical AMC cancer center can expect to utilize more space than it would have 10 years ago, a deeper understanding of the cancer center enterprise can lead to opportunities for more effectively using available facility resources. Each AMC must determine for itself the appropriate balance of patient volume, clinical activity, and services between its main hospital campus and satellite branches. As well, space allocation should be flexible, as care trends, medical technology, and the provider's own priorities shift over time. The goal isn't necessarily more space-it's better space.
C1 [Bloom, Mara] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Markovitz, Sarah] NBBJ, Boston, MA USA.
[Silverman, Susan; Yost, Carl] NBBJ, New York, NY 10006 USA.
RP Silverman, S (reprint author), NBBJ, New York, NY 10006 USA.
EM ssilverman@nbbj.com
NR 25
TC 0
Z9 0
U1 2
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1937-5867
EI 2167-5112
J9 HERD-HEALTH ENV RES
JI Herd-Health Env. Res. Des. J.
PD JAN
PY 2015
VL 8
IS 2
BP 85
EP 94
DI 10.1177/1937586714565598
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CC5QF
UT WOS:000350414800010
PM 25816384
ER
PT J
AU Kawano, Y
Moschetta, M
Manier, S
Glavey, S
Gorgun, GT
Roccaro, AM
Anderson, KC
Ghobrial, IM
AF Kawano, Yawara
Moschetta, Michele
Manier, Salomon
Glavey, Siobhan
Goerguen, Guellue T.
Roccaro, Aldo M.
Anderson, Kenneth C.
Ghobrial, Irene M.
TI Targeting the bone marrow microenvironment in multiple myeloma
SO IMMUNOLOGICAL REVIEWS
LA English
DT Review
DE myeloma; bone marrow; immune cells; BMSCs; vessel formation
ID REGULATORY T-CELLS; PLASMACYTOID DENDRITIC CELLS; NATURAL-KILLER-CELL;
HYPOXIA-ACTIVATED PRODRUG; MESENCHYMAL STEM-CELLS; BREAST-CANCER
PATIENTS; NF-KAPPA-B; SUPPRESSOR-CELLS; STROMAL CELLS; IN-VIVO
AB Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in the bone marrow (BM). Despite the significant advances in treatment, MM is still a fatal malignancy. This is mainly due to the supportive role of the BM microenvironment in differentiation, migration, proliferation, survival, and drug resistance of the malignant plasma cells. The BM microenvironment is composed of a cellular compartment (stromal cells, osteoblasts, osteoclasts, endothelial cells, and immune cells) and a non-cellular compartment. In this review, we discuss the interaction between the malignant plasma cell and the BM microenvironment and the strategy to target them.
C1 [Kawano, Yawara; Moschetta, Michele; Manier, Salomon; Glavey, Siobhan; Goerguen, Guellue T.; Roccaro, Aldo M.; Anderson, Kenneth C.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA.
EM irene_ghobrial@dfci.harvard.edu
OI Roccaro, Aldo/0000-0002-1872-5128
FU Leukemia & Lymphoma Society; [R01CA181683]
FX This work was supported in part by the R01CA181683 and The Leukemia &
Lymphoma Society. There are no conflicts of interest associated with
this review.
NR 166
TC 40
Z9 40
U1 5
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-2896
EI 1600-065X
J9 IMMUNOL REV
JI Immunol. Rev.
PD JAN
PY 2015
VL 263
IS 1
SI SI
BP 160
EP 172
DI 10.1111/imr.12233
PG 13
WC Immunology
SC Immunology
GA CC2HN
UT WOS:000350166200011
PM 25510276
ER
PT J
AU Lamont, EB
Schilsky, RL
He, YL
Muss, H
Cohen, HJ
Hurria, A
Meilleur, A
Kindler, HL
Venook, A
Lilenbaum, R
Niell, H
Goldberg, RM
Joffe, S
AF Lamont, Elizabeth B.
Schilsky, Richard L.
He, Yulei
Muss, Hyman
Cohen, Harvey Jay
Hurria, Arti
Meilleur, Ashley
Kindler, Hedy L.
Venook, Alan
Lilenbaum, Rogerio
Niell, Harvey
Goldberg, Richard M.
Joffe, Steven
CA Alliance Clinical Trials Oncology
TI Generalizability of Trial Results to Elderly Medicare Patients With
Advanced Solid Tumors (Alliance 70802)
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID CELL LUNG-CANCER; LEUKEMIA GROUP-B; CLINICAL-TRIALS; OLDER WOMEN;
CHEMOTHERAPY REGIMENS; SOCIOECONOMIC-STATUS; COLORECTAL-CANCER;
BREAST-CANCER; DISPARITIES; PARTICIPATION
AB In the United States, patients who enroll in chemotherapy trials seldom reflect the attributes of the general population with cancer, as they are often younger, more functional, and have less comorbidity. We compared survival following three chemotherapy regimens according to the setting in which care was delivered (ie, clinical trial vs usual care) to determine the generalizability of clinical trial results to unselected elderly Medicare patients.
Using SEER-Medicare data, we estimated survival for elderly patients (ie, age 65 years or older, n = 14097) with advanced pancreatic or lung cancer following receipt of one of three guideline-recommended first-line chemotherapy regimens. We compared their survival to that of similarly treated clinical trial enrollees, without age restrictions, with the same diagnosis and stage (n = 937). All statistical tests were two-sided.
Trial patients were 9.5 years younger than elderly Medicare patients. Medicare patients were more often white and tended to live in areas of greater educational attainment than trial enrollees. For each tumor type, Medicare patients who were 75 years or older had median survivals that were six to eight weeks shorter than those of trial patients (4.3 vs 5.8 months following treatment with single agent gemcitabine for advanced pancreatic cancer, P = .03; 7.3 vs 8.9 months following treatment with carboplatin and paclitaxel for stage IV non-small cell lung cancer, P = .91; 8.2 vs 10.2 months following treatment with CDDP/ VP16 for extensive stage small cell lung cancer, P a parts per thousand currency sign .01), whereas younger Medicare patients had survival times that were similar to those of trial patients.
Results of clinical trials for advanced pancreatic cancer and lung cancers tended to correctly estimate survival for Medicare patients aged 65 to 74 years, but to overestimate survival for older Medicare patients by six to eight weeks. These estimates of Medicare patients' survival may aid subsequent patients and their oncologists in treatment decision-making.
C1 [Lamont, Elizabeth B.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Lamont, Elizabeth B.; He, Yulei; Meilleur, Ashley] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Lamont, Elizabeth B.; He, Yulei; Meilleur, Ashley] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Schilsky, Richard L.] Amer Soc Clin Oncol, Alexandria, VA USA.
[Muss, Hyman] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
[Cohen, Harvey Jay] Duke Univ, Dept Med, Durham, NC USA.
[Hurria, Arti] City Hope Natl Med Ctr, Duarte, CA USA.
[Kindler, Hedy L.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Venook, Alan] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Lilenbaum, Rogerio] Yale Canc Ctr, New Haven, CT USA.
[Niell, Harvey] Univ Tennessee, Dept Med, Memphis, TN 38104 USA.
[Goldberg, Richard M.] Ohio State Univ, Dept Med, Columbus, OH 43210 USA.
[Joffe, Steven] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
RP Lamont, EB (reprint author), 180A Longwood Ave, Boston, MA 02115 USA.
EM lamont@hcp.med.harvard.edu
FU National Cancer Institute (NCI) [R01 CA132900, CA31946, CA33601]
FX The research for 70802 (Alliance) was supported, in part, by grants from
the National Cancer Institute (NCI) (R01 CA132900) to Harvard Medical
School (Elizabeth B. Lamont, MD, Principal Investigator), (CA31946) to
the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, MD,
Chair), and (CA33601) to the Alliance Statistics and Data Center (Daniel
J. Sargent, PhD). The authors also acknowledge K07 CA9389204 (Lamont),
without which this paper would not have been possible.
NR 39
TC 1
Z9 1
U1 2
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JAN
PY 2015
VL 107
IS 1
AR dju336
DI 10.1093/jnci/dju336
PG 7
WC Oncology
SC Oncology
GA CC3FW
UT WOS:000350232800003
ER
PT J
AU Martinez-Quintanilla, J
Shah, K
AF Martinez-Quintanilla, Jordi
Shah, Khalid
TI RE: Reassurance Against Future Risk of Precancer and Cancer Conferred by
a Negative Human Papillomavirus Test Response
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Letter
ID GLIOBLASTOMA STEM-CELLS; HERPES-SIMPLEX-VIRUS; GLIOMA; EFFICACY;
THERAPY; MODEL
C1 [Martinez-Quintanilla, Jordi; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA USA.
[Martinez-Quintanilla, Jordi; Shah, Khalid] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Shah, Khalid] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Shah, Khalid] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Shah, K (reprint author), 149,13th St, Charlestown, MA USA.
EM kshah@mgh.harvard.edu
NR 9
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JAN
PY 2015
VL 107
IS 1
AR dju370
DI 10.1093/jnci/dju370
PG 2
WC Oncology
SC Oncology
GA CC3FW
UT WOS:000350232800021
ER
PT J
AU Ng, K
Meyerhardt, JA
Chan, AT
Sato, K
Chan, JA
Niedzwiecki, D
Saltz, LB
Mayer, RJ
Benson, A
Schaefer, PL
Whittom, R
Hantel, A
Goldberg, RM
Venook, AP
Ogino, S
Giovannucci, EL
Fuchs, CS
AF Ng, Kimmie
Meyerhardt, Jeffrey A.
Chan, Andrew T.
Sato, Kaori
Chan, Jennifer A.
Niedzwiecki, Donna
Saltz, Leonard B.
Mayer, Robert J.
Benson, Al B., III
Schaefer, Paul L.
Whittom, Renaud
Hantel, Alexander
Goldberg, Richard M.
Venook, Alan P.
Ogino, Shuji
Giovannucci, Edward L.
Fuchs, Charles S.
TI Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; PREVENT COLORECTAL ADENOMAS;
ANTIINFLAMMATORY DRUG-USE; IMPROVES SURVIVAL; PIK3CA MUTATION;
CELL-GROWTH; DIAGNOSIS; MORTALITY; RISK; CELECOXIB
AB We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.
C1 [Ng, Kimmie; Meyerhardt, Jeffrey A.; Sato, Kaori; Chan, Jennifer A.; Mayer, Robert J.; Ogino, Shuji; Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Chan, Andrew T.; Giovannucci, Edward L.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Niedzwiecki, Donna] Duke Univ, Med Ctr, Alliance Stat & Data Ctr, Durham, NC USA.
[Saltz, Leonard B.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Benson, Al B., III] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA.
[Schaefer, Paul L.] Toledo Community Hosp Oncol Program, Toledo, OH USA.
[Whittom, Renaud] Univ Montreal, Hop Sacre Coeur Montreal, Quebec City, PQ, Canada.
[Hantel, Alexander] Edward Canc Ctr, Naperville, IL USA.
[Goldberg, Richard M.] Ohio State Univ, Ctr Comprehens Canc, Div Med Oncol, Columbus, OH 43210 USA.
[Venook, Alan P.] Univ Calif San Francisco, Div Med Oncol, San Francisco, CA 94143 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA USA.
[Ogino, Shuji; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
RP Ng, K (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM kng4@partners.org
OI Saltz, Leonard/0000-0001-8353-4670
FU National Cancer Institute, National Institutes of Health [P50 CA127003,
K07 CA148894, CA31946, CA33601]; Conquer Cancer Foundation of the
American Society of Clinical Oncology; Damon Runyan Cancer Research
Foundation; Pfizer Oncology
FX This work was supported by the National Cancer Institute, National
Institutes of Health (P50 CA127003 and K07 CA148894 to KN), the Conquer
Cancer Foundation of the American Society of Clinical Oncology (to KN),
the Damon Runyan Cancer Research Foundation (to ATC), and the Pharmacia
and Upjohn Company, now Pfizer Oncology. The research for CALGB 89803
was also supported, in part, by grants from the National Cancer
Institute, National Institutes of Health (CA31946) to the Alliance for
Clinical Trials in Oncology (Monica Bertagnolli, MD, Chairman) and to
the Alliance Statistics and Data Center (Daniel J. Sargent, PhD,
CA33601).
NR 40
TC 1
Z9 1
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JAN
PY 2015
VL 107
IS 1
AR dju345
DI 10.1093/jnci/dju345
PG 5
WC Oncology
SC Oncology
GA CC3FW
UT WOS:000350232800004
ER
PT J
AU Yeo, H
Niland, J
Milne, D
ter Veer, A
Bekaii-Saab, T
Farma, JM
Lai, L
Skibber, JM
Small, W
Wilkinson, N
Schrag, D
Weiser, MR
AF Yeo, Heather
Niland, Joyce
Milne, Dana
ter Veer, Anna
Bekaii-Saab, Tanios
Farma, Jeffrey M.
Lai, Lily
Skibber, John M.
Small, William, Jr.
Wilkinson, Neal
Schrag, Deborah
Weiser, Martin R.
TI Incidence of Minimally Invasive Colorectal Cancer Surgery at National
Comprehensive Cancer Network Centers
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID SHORT-TERM OUTCOMES; LAPAROSCOPIC-ASSISTED COLECTOMY; TOTAL MESORECTAL
EXCISION; MRC CLASICC TRIAL; RECTAL-CANCER; RANDOMIZED-TRIAL;
COLON-CANCER; LEARNING-CURVE; UNITED-STATES; RESECTION
AB Laparoscopic colectomy has been shown to have equivalent oncologic outcomes to open colectomy for the management of colon cancer, but its adoption nationally has been slow. This study investigates the prevalence and factors associated with laparoscopic colorectal resection at National Comprehensive Cancer Network (NCCN) centers.
Data on patients undergoing surgery for colon and rectal cancer at NCCN centers from 2005 to 2010 were obtained from chart review of medical records for the NCCN Outcomes Project and included information on socioeconomic status, insurance coverage, comorbidity, and physician-reported Eastern Cooperative Oncology Group (ECOG) performance status. Associations between receipt of minimally invasive surgery and patient and clinical variables were analyzed with univariate and multivariable logistic regression. All statistical tests were two-sided.
A total of 4032 patients, diagnosed between September 2005 and December 2010, underwent elective colon or rectal resection for cancer at NCCN centers. Median age of colon cancer patients was 62.6 years, and 49% were men. The percent of colon cancer patients treated with minimally invasive surgery (MIS) increased from 35% in 2006 to 51% in 2010 across all centers but varied statistically significantly between centers. On multivariable analysis, factors associated with minimally invasive surgery for colon cancer patients who had surgery at an NCCN institution were older age (P = .02), male sex (P = .006), fewer comorbidities (P a parts per thousand currency sign .001), lower final T-stage (P < .001), median household income greater than or equal to $80000 (P < .001), ECOG performance status = 0 (P = .02), and NCCN institution (P a parts per thousand currency sign .001).
The use of MIS increased at NCCN centers. However, there was statistically significant variation in adoption of MIS technique among centers.
C1 [Yeo, Heather; Weiser, Martin R.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Niland, Joyce; ter Veer, Anna; Lai, Lily; Schrag, Deborah] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Milne, Dana; Lai, Lily] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Bekaii-Saab, Tanios] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Bekaii-Saab, Tanios] Solove Res Inst, Columbus, OH USA.
[Farma, Jeffrey M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Skibber, John M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Small, William, Jr.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Wilkinson, Neal] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
RP Weiser, MR (reprint author), Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, 1275 York Ave,Room C-1075, New York, NY 10065 USA.
EM weiser1@mskcc.org
RI Bekaii-Saab, Tanios/E-2733-2011
FU cancer center core grant [P30 CA008748]; core grant
FX This study was funded in part by the cancer center core grant P30
CA008748. The core grant provides funding to institutional cores, such
as Biostatistics and Pathology, which were used in this study.
NR 42
TC 1
Z9 1
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JAN
PY 2015
VL 107
IS 1
AR dju362
DI 10.1093/jnci/dju362
PG 8
WC Oncology
SC Oncology
GA CC3FW
UT WOS:000350232800014
ER
PT J
AU Calderwood, SB
Hooper, DC
AF Calderwood, Stephen B.
Hooper, David C.
TI In Memoriam: Morton N. Swartz
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Biographical-Item
C1 [Calderwood, Stephen B.; Hooper, David C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Calderwood, SB (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA.
EM scalderwood@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 1
PY 2015
VL 211
IS 1
BP 1
EP 3
DI 10.1093/infdis/jiu392
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CC3BY
UT WOS:000350220600001
PM 25030059
ER
PT J
AU Powis, KM
Shapiro, RL
AF Powis, Kathleen M.
Shapiro, Roger L.
TI Protease Inhibitors and Adverse Birth Outcomes: Is Progesterone the
Missing Piece to the Puzzle?
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
DE HIV; protease inhibitors; progesterone; pregnancy outcomes
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED WOMEN; TO-CHILD
TRANSMISSION; INDUCED BLOCKING FACTOR; PRETERM DELIVERY; INCREASED RISK;
PREMATURE DELIVERY; DOSE NEVIRAPINE; PREGNANT-WOMEN; PREECLAMPSIA
C1 [Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Powis, Kathleen M.; Shapiro, Roger L.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Shapiro, Roger L.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
RP Powis, KM (reprint author), Massachusetts Gen Hosp, 100 Cambridge St,15th Fl, Boston, MA 02114 USA.
EM kpowis@mgh.harvard.edu
FU NICHD NIH HHS [K23 HD070774, 1K23HD070774-01A1]
NR 38
TC 5
Z9 5
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 1
PY 2015
VL 211
IS 1
BP 4
EP 7
DI 10.1093/infdis/jiu397
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CC3BY
UT WOS:000350220600002
PM 25030057
ER
PT J
AU Genther, DJ
Betz, J
Pratt, S
Kritchevsky, SB
Martin, KR
Harris, TB
Helzner, E
Satterfield, S
Xue, QL
Yaffe, K
Simonsick, EM
Lin, FR
AF Genther, Dane J.
Betz, Joshua
Pratt, Sheila
Kritchevsky, Steven B.
Martin, Kathryn R.
Harris, Tamara B.
Helzner, Elizabeth
Satterfield, Suzanne
Xue, Qian-Li
Yaffe, Kristine
Simonsick, Eleanor M.
Lin, Frank R.
CA Hlth ABC Study
TI Association of Hearing Impairment and Mortality in Older Adults
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Epidemiology; Longevity; Outcomes; Public health; Successful aging
ID BLUE-MOUNTAINS HEARING; HEALTH INTERVIEW SURVEY; UNITED-STATES;
LONGITUDINAL ANALYSIS; GAIT SPEED; SURVIVAL; RISK; PREDICTORS; DISEASE;
DEPRESSION
AB Background. Hearing impairment (HI) is highly prevalent in older adults and is associated with social isolation, depression, and risk of dementia. Whether HI is associated with broader downstream outcomes is unclear. We undertook this study to determine whether audiometric HI is associated with mortality in older adults.
Methods. Prospective observational data from 1,958 adults >= 70 years of age from the Health, Aging, and Body Composition Study were analyzed using Cox proportional hazards regression. Participants were followed for 8 years after audiometric examination. Mortality was adjudicated by obtaining death certificates. Hearing was defined as the pure-tone average of hearing thresholds in decibels re: hearing level (dB HL) at frequencies from 0.5 to 4 kHz. HI was defined as pure-tone average >25 dB HL in the better ear.
Results. Of the 1,146 participants with HI, 492 (42.9%) died compared with 255 (31.4%) of the 812 with normal hearing (odds ratio = 1.64, 95% CI: 1.36-1.98). After adjustment for demographics and cardiovascular risk factors, HI was associated with a 20% increased mortality risk compared with normal hearing (hazard ratio = 1.20, 95% CI: 1.03-1.41). Confirmatory analyses treating HI as a continuous predictor yielded similar results, demonstrating a nonlinear increase in mortality risk with increasing HI (hazard ratio = 1.14, 95% CI: 1.00-1.29 per 10 dB of threshold elevation up to 35 dB HL).
Conclusions. HI in older adults is associated with increased mortality, independent of demographics and cardiovascular risk factors. Further research is necessary to understand the basis of this association and whether these pathways might be amenable to hearing rehabilitation.
C1 [Genther, Dane J.; Lin, Frank R.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA.
[Genther, Dane J.; Betz, Joshua; Xue, Qian-Li; Lin, Frank R.] Johns Hopkins Ctr Aging & Hlth, Baltimore, MD USA.
[Betz, Joshua] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA.
[Pratt, Sheila] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
[Pratt, Sheila] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA.
[Kritchevsky, Steven B.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA.
[Kritchevsky, Steven B.] J Paul Sticht Ctr Aging, Winston Salem, NC USA.
[Martin, Kathryn R.] Univ Aberdeen, Dept Epidemiol, Aberdeen AB9 1FX, Scotland.
[Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA.
[Helzner, Elizabeth] Suny Downstate Med Ctr, Dept Epidemiol & Biostat, Brooklyn, NY 11203 USA.
[Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
[Xue, Qian-Li; Simonsick, Eleanor M.; Lin, Frank R.] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Dept Med, Baltimore, MD 21287 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Simonsick, Eleanor M.] NIA, Intramural Res Program, Bethesda, MD 20892 USA.
[Lin, Frank R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Lin, Frank R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
RP Genther, DJ (reprint author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, 601 N Caroline St,JHOC 6210, Baltimore, MD 21287 USA.
EM dgenthe2@jhmi.edu
OI Genther, Dane/0000-0002-7925-012X; Betz, Joshua/0000-0003-4488-9799
FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103,
N01-AG-6-2106, R01-AG028050, K24AG031155]; National Institute of Nursing
Research (NINR) [R01-NR012459]; National Institutes of Health (NIH)
[T32DC000027]; National Institute on Deafness and Other Communication
Disorders (NIDCD) [K23DC011279]; Intramural Research Program of the
National Institute on Aging; Triological Society; American College of
Surgeons through the Clinician Scientist Award; Eleanor Schwartz
Charitable Foundation
FX This research was supported by National Institute on Aging (NIA)
(N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106); NIA grant (R01-AG028050);
and National Institute of Nursing Research (NINR) grant (R01-NR012459).
This study was further supported in part by National Institutes of
Health (NIH) grant (T32DC000027), NIA grant (K24AG031155), National
Institute on Deafness and Other Communication Disorders (NIDCD) grant
(K23DC011279), Intramural Research Program of the National Institute on
Aging, Triological Society and American College of Surgeons through the
Clinician Scientist Award, and Eleanor Schwartz Charitable Foundation.
S.P. was supported with resources and the use of facilities at the VA
Pittsburgh Healthcare System, Pittsburgh, PA; however, the contents do
not represent the views of the Department of Veterans Affairs or the
United States Government. The sponsors had no role in the design and
conduct of the study; in the collection, analysis, and interpretation of
the data; or in the preparation of the manuscript.
NR 41
TC 14
Z9 15
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
EI 1758-535X
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD JAN
PY 2015
VL 70
IS 1
BP 85
EP 90
DI 10.1093/gerona/glu094
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA CC1RJ
UT WOS:000350119900011
PM 25024235
ER
PT J
AU Zhang, YS
Dai, TH
Wang, M
Vecchio, D
Chiang, LY
Hamblin, MR
AF Zhang, Yunsong
Dai, Tianhong
Wang, Min
Vecchio, Daniela
Chiang, Long Y.
Hamblin, Michael R.
TI Potentiation of antimicrobial photodynamic inactivation mediated by a
cationic fullerene by added iodide: in vitro and in vivo studies
SO NANOMEDICINE
LA English
DT Article
DE antimicrobial photodynamic therapy; bioluminescent bacteria;
decacationic fullerene; decatertiary-amine chain; in vivo infection
model; iodide potentiation
ID ACINETOBACTER-BAUMANNII; YEAST PHASE; THERAPY; INFECTIONS; WATER; C-60;
SYSTEM; MECHANISMS; TOXICITY; BACTERIA
AB Background: Antimicrobial photodynamic inactivation with fullerenes bearing cationic charges may overcome resistant microbes. Methods & results: We synthesized C-60-fullerene (LC16) bearing decaquaternary chain and deca-tertiary-amino groups that facilitates electron-transfer reactions via the photoexcited fullerene. Addition of the harmless salt, potassium iodide (10 mM) potentiated the ultraviolet A (UVA) or white light-mediated killing of Gram-negative bacteria Acinetobacter baumannii, Gram-positive methicillin-resistant Staphylococcus aureus and fungal yeast Candida albicans by 1-2+ logs. Mouse model infected with bioluminescent Acinetobacter baumannii gave increased loss of bioluminescence when iodide (10 mM) was combined with LC16 and UVA/white light. Conclusion: The mechanism may involve photoinduced electron reduction of (1)(C-60>)* or (3)(C-60>)* by iodide producing I center dot or I-2 followed by subsequent intermolecular electron-transfer events of (C-60>)(-center dot) to produce reactive radicals.
C1 [Zhang, Yunsong] Jinan Univ, Guangzhou Red Cross Hosp, Dept Burn & Plast Surg, Guangzhou, Guangdong, Peoples R China.
[Zhang, Yunsong; Dai, Tianhong; Vecchio, Daniela; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Zhang, Yunsong; Dai, Tianhong; Vecchio, Daniela; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Wang, Min; Chiang, Long Y.] Univ Massachusetts, Dept Chem, Lowell, MA USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM Hamblin@helix.mgh.harvard.edu
FU US NIH [R01AI050875, R01CA137108]; Medical Science Foundation of
Guangzhou City [20112121220025]
FX This research was supported by US NIH grants R01AI050875 and
R01CA137108. Yunsong Zhang was supported by the Medical Science
Foundation of Guangzhou City (grant 20112121220025). The authors have no
other relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 46
TC 11
Z9 11
U1 2
U2 20
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2015
VL 10
IS 4
BP 603
EP 614
DI 10.2217/nnm.14.131
PG 12
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
Topics
GA CC7YD
UT WOS:000350583800007
PM 25723093
ER
PT J
AU Wen, PY
AF Wen, Patrick Y.
TI Message from the Editor-in-Chief
SO NEURO-ONCOLOGY
LA English
DT Editorial Material
C1 [Wen, Patrick Y.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA.
RP Wen, PY (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
EM pwen@partners.org
NR 2
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JAN
PY 2015
VL 17
IS 1
BP 1
EP 1
DI 10.1093/neuonc/nou334
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CC1XF
UT WOS:000350138000001
PM 25538095
ER
PT J
AU Kaley, TJ
Wen, P
Schiff, D
Ligon, K
Haider, S
Karimi, S
Lassman, AB
Nolan, CP
DeAngelis, LM
Gavrilovic, I
Norden, A
Drappatz, J
Lee, EQ
Purow, B
Plotkin, SR
Batchelor, T
Abrey, LE
Omura, A
AF Kaley, Thomas J.
Wen, Patrick
Schiff, David
Ligon, Keith
Haider, Sam
Karimi, Sasan
Lassman, Andrew B.
Nolan, Craig P.
DeAngelis, Lisa M.
Gavrilovic, Igor
Norden, Andrew
Drappatz, Jan
Lee, Eudocia Quant
Purow, Benjamin
Plotkin, Scott R.
Batchelor, Tracy
Abrey, Lauren E.
Omura, Antonio
TI Phase II trial of sunitinib for recurrent and progressive atypical and
anaplastic meningioma
SO NEURO-ONCOLOGY
LA English
DT Article
DE chemotherapy; malignant meningioma; sunitinib; tyrosine kinase
ID GROWTH-FACTOR; THERAPY; PDGF; BEVACIZUMAB; EXPRESSION; RECEPTORS;
ADULTS; TUMORS; BRAIN; CELLS
AB Background. No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor, abundant in meningiomas.
Methods. This was a prospective, multicenter, investigator-initiated single-arm phase II trial. The primary cohort enrolled patients with surgery and radiation-refractory recurrent World Health Organization (WHO) grades II-III meningioma. An exploratory cohort enrolled patients with WHO grade I meningioma, hemangiopericytoma, or hemangioblastoma. Sunitinib was administered at 50 mg/d for days 1-28 of every 42-day cycle. The primary endpoint was the rate of 6-month progression-free survival (PFS6), with secondary endpoints of radiographic response rate, safety, PFS, and overall survival. Exploratory objectives include analysis of tumoral molecular markers and MR perfusion imaging.
Results. Thirty-six patients with high-grade meningioma (30 atypical and 6 anaplastic) were enrolled. Patients were heavily pre-treated (median number of 5 recurrences, range 2-10). PFS6 rate was 42%, meeting the primary endpoint. Median PFS was 5.2 months (95% CI: 2.8-8.3 mo), and median overall survival was 24.6 months (95% CI: 16.5-38.4 mo). Thirteen patients enrolled in the exploratory cohort. Overall toxicity included 1 grade 5 intratumoral hemorrhage, 2 grade 3 and 1 grade 4 CNS/intratumoral hemorrhages, 1 grade 3 and 1 grade 4 thrombotic microangiopathy, and 1 grade 3 gastrointestinal perforation. Expression of VEGFR2 predicted PFS of a median of 1.4 months in VEGFR2-negative patients versus 6.4 months in VEGFR2-positive patients (P = .005).
Conclusion. Sunitinib is active in recurrent atypical/malignant meningioma patients. A randomized trial should be performed.
C1 [Kaley, Thomas J.; Karimi, Sasan; Lassman, Andrew B.; Nolan, Craig P.; DeAngelis, Lisa M.; Gavrilovic, Igor; Abrey, Lauren E.; Omura, Antonio] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10065 USA.
[Wen, Patrick; Ligon, Keith; Haider, Sam; Norden, Andrew; Drappatz, Jan; Lee, Eudocia Quant] Brigham & Womens Ctr, Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA USA.
[Schiff, David; Purow, Benjamin] Univ Virginia, Dept Neurol, Charlottesville, VA USA.
[Plotkin, Scott R.; Batchelor, Tracy] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Kaley, TJ (reprint author), Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10065 USA.
EM kaleyt@mskcc.org
OI Nolan, Craig/0000-0003-3534-4615; Gavrilovic, Igor/0000-0001-9104-6132;
Kaley, Thomas/0000-0002-2540-8518; Omuro, Antonio/0000-0003-4299-3664
FU Pfizer; Brain Science Foundation
FX This work was supported by Pfizer and the Brain Science Foundation.
NR 37
TC 33
Z9 33
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JAN
PY 2015
VL 17
IS 1
BP 116
EP 121
DI 10.1093/neuonc/nou148
PG 6
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CC1XF
UT WOS:000350138000013
PM 25100872
ER
PT J
AU Zhao, W
Wang, J
Varghese, M
Ho, L
Mazzola, P
Haroutunian, V
Katsel, PL
Gibson, GE
Levine, S
Dubner, L
Pasinetti, GM
AF Zhao, Wei
Wang, Jun
Varghese, Merina
Ho, Lap
Mazzola, Paolo
Haroutunian, Vahram
Katsel, Pavel L.
Gibson, Gary E.
Levine, Samara
Dubner, Lauren
Pasinetti, Giulio Maria
TI Impaired mitochondrial energy metabolism as a novel risk factor for
selective onset and progression of dementia in oldest-old subjects
SO NEUROPSYCHIATRIC DISEASE AND TREATMENT
LA English
DT Article
DE Alzheimer disease; energy metabolism; neuropathology; mitochondria;
dementia
ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; 6-PHOSPHOFRUCTO-1-KINASE
ISOZYMES; OXIDATIVE STRESS; BRAIN; PATHOPHYSIOLOGY; NEUROPATHOLOGY;
PREVALENCE; NITRATION; PROTEINS
AB Recent evidence shows that Alzheimer disease (AD) dementia in the oldest-old subjects was associated with significantly less amyloid plaque and fibrillary tangle neuropathology than in the young-old population. In this study, using quantitative (q) PCR studies, we validated genome-wide microarray RNA studies previously conducted by our research group. We found selective downregulation of mitochondrial energy metabolism genes in the brains of oldest-old, but not young-old, AD dementia cases, despite a significant lack of classic AD neuropathology features. We report a significant decrease of genes associated with mitochondrial pyruvate metabolism, the tricarboxylic acid cycle (TCA), and glycolytic pathways. Moreover, significantly higher levels of nitrotyrosylated (3-NT)-proteins and 4-hydroxy-2-nonenal (HNE) adducts, which are indexes of cellular protein oxidation and lipid peroxidation, respectively, were detected in the brains of oldest-old subjects at high risk of developing AD, possibly suggesting compensatory mechanisms. These findings support the hypothesis that although oldest-old AD subjects, characterized by significantly lower AD neuropathology than young-old AD subjects, have brain mitochondrial metabolism impairment, which we hypothesize may selectively contribute to the development of dementia. Outcomes from this study provide novel insights into the molecular mechanisms underlying clinical dementia in young-old and oldest-old AD subjects and provide novel strategies for AD prevention and treatment in oldest-old dementia cases.
C1 [Zhao, Wei; Wang, Jun; Varghese, Merina; Ho, Lap; Mazzola, Paolo; Levine, Samara; Dubner, Lauren; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
[Zhao, Wei; Wang, Jun; Ho, Lap; Haroutunian, Vahram; Katsel, Pavel L.; Pasinetti, Giulio Maria] James J Peter VA Med Ctr, Geriatr Res Educ Clin Ctr, Bronx, NY USA.
[Mazzola, Paolo] Univ Milano Bicocca, Dept Hlth Sci, Monza, Italy.
[Haroutunian, Vahram; Katsel, Pavel L.; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA.
[Gibson, Gary E.] Weill Cornell Med Coll, Burke Med Res Inst, Dept Neurol & Neurosci, New York, NY USA.
[Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Geriatr, New York, NY 10029 USA.
RP Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
OI Mazzola, Paolo/0000-0002-0484-1136; Varghese, Merina/0000-0002-1517-3903
FU Career Scientist Award in the Research and Development unit
FX This material is the result of work supported in part with resources and
the use of facilities at the James J. Peters Veterans Affairs Medical
Center, Bronx, NY. In addition, Dr. Pasinetti holds a Career Scientist
Award in the Research and Development unit and is the Director of the
Basic and Biomedical Research and Training Program, GRECC, James J.
Peters Veterans Affairs Medical Center. We also acknowledge that the
contents of this manuscript do not represent the views of the U.S.
Department of Veterans Affairs or the United States Government.
NR 40
TC 7
Z9 7
U1 1
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2021
J9 NEUROPSYCH DIS TREAT
JI Neuropsychiatr. Dis. Treat.
PY 2015
VL 11
BP 565
EP 574
DI 10.2147/NDT.S74898
PG 10
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CC4SK
UT WOS:000350343500001
PM 25784811
ER
PT J
AU Vassy, JL
McLaughlin, HL
MacRae, CA
Seidman, CE
Lautenbach, D
Krier, JB
Lane, WJ
Kohane, IS
Murray, MF
McGuire, AL
Rehm, HL
Green, RC
AF Vassy, Jason L.
McLaughlin, Heather L.
MacRae, Calum A.
Seidman, Christine E.
Lautenbach, Denise
Krier, Joel B.
Lane, William J.
Kohane, Isaac S.
Murray, Michael F.
McGuire, Amy L.
Rehm, Heidi L.
Green, Robert C.
CA MedSeq Project
TI A One-Page Summary Report of Genome Sequencing for the Healthy Adult
SO PUBLIC HEALTH GENOMICS
LA English
DT Article
DE Whole-genome sequencing; Genomic screening; Laboratory reporting;
Molecular testing
ID MEDICINE; STANDARDS; DIAGNOSIS; KNOWLEDGE; CANCER
AB As genome sequencing technologies increasingly enter medical practice, genetics laboratories must communicate sequencing results effectively to nongeneticist physicians. We describe the design and delivery of a clinical genome sequencing report, including a one-page summary suitable for interpretation by primary care physicians. To illustrate our preliminary experience with this report, we summarize the genomic findings from 10 healthy participants in a study of genome sequencing in primary care. (C) 2015 S. Karger AG, Basel
C1 [Vassy, Jason L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA.
[MacRae, Calum A.; Seidman, Christine E.; Lautenbach, Denise; Krier, Joel B.; Green, Robert C.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA.
[MacRae, Calum A.; Seidman, Christine E.] Brigham & Womens Hosp, Dept Med, Div Cardiol, Boston, MA 02115 USA.
[Vassy, Jason L.; MacRae, Calum A.; Seidman, Christine E.; Krier, Joel B.; Kohane, Isaac S.; Green, Robert C.] Harvard Univ, Sch Med, Boston, MA USA.
[Vassy, Jason L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[McLaughlin, Heather L.; Lane, William J.; Rehm, Heidi L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[McLaughlin, Heather L.; Rehm, Heidi L.; Green, Robert C.] Partners Personalized Med, Boston, MA USA.
[Murray, Michael F.] Geisinger Hlth Syst, Genom Med Inst, Danville, PA USA.
[McGuire, Amy L.] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA.
RP Vassy, JL (reprint author), VA Boston Healthcare Syst, Gen Internal Med Sect, 150 South Huntington Ave,152-G, Boston, MA 02130 USA.
EM jvassy@partners.org
FU National Human Genome Research Institute of NIH [U01-HG006500,
U41-HG006834, R01-HG005092]; National Institute of Child Health and
Human Development of NIH [U19-HD077671]
FX We thank the physician participants and patient participants of the
MedSeq Project. We received funding through grants U01-HG006500,
U41-HG006834 and R01-HG005092 from the National Human Genome Research
Institute and grant U19-HD077671 from the National Institute of Child
Health and Human Development, both of the NIH. The NIH had no role in
the study design; collection, analysis, and interpretation of data; the
writing of this report; or the decision to submit the paper for
publication.
NR 22
TC 4
Z9 4
U1 1
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1662-4246
EI 1662-8063
J9 PUBLIC HEALTH GENOM
JI Pub. Health Genomics
PY 2015
VL 18
IS 2
BP 123
EP 129
DI 10.1159/000370102
PG 7
WC Genetics & Heredity; Public, Environmental & Occupational Health
SC Genetics & Heredity; Public, Environmental & Occupational Health
GA CC8BV
UT WOS:000350594000007
PM 25612602
ER
PT J
AU Ford, JM
Palzes, VA
Roach, BJ
Potkin, SG
van Erp, TGM
Turner, JA
Mueller, BA
Calhoun, VD
Voyvodic, J
Belger, A
Bustillo, J
Vaidya, JG
Preda, A
McEwen, SC
Mathalon, DH
AF Ford, Judith M.
Palzes, Vanessa A.
Roach, Brian J.
Potkin, Steven G.
van Erp, Theo G. M.
Turner, Jessica A.
Mueller, Bryon A.
Calhoun, Vincent D.
Voyvodic, Jim
Belger, Aysenil
Bustillo, Juan
Vaidya, Jatin G.
Preda, Adrian
McEwen, Sarah C.
Mathalon, Daniel H.
CA Functional Imaging Biomed
TI Visual Hallucinations Are Associated With Hyperconnectivity Between the
Amygdala and Visual Cortex in People With a Diagnosis of Schizophrenia
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
ID PARKINSONS-DISEASE PATIENTS; MULTI-FEATURE PARADIGM; AUDITORY
HALLUCINATIONS; MISMATCH NEGATIVITY; CONSCIOUS PERCEPTION; BRAIN; FMRI;
MEMORY; FRAMEWORK; SYSTEM
AB While auditory verbal hallucinations (AH) are a cardinal symptom of schizophrenia, people with a diagnosis of schizophrenia (SZ) may also experience visual hallucinations (VH). In a retrospective analysis of a large sample of SZ and healthy controls (HC) studied as part of the functional magnetic resonance imaging (fMRI) Biomedical Informatics Research Network (FBIRN), we asked if SZ who endorsed experiencing VH during clinical interviews had greater connectivity between visual cortex and limbic structures than SZ who did not endorse experiencing VH.
We analyzed resting state fMRI data from 162 SZ and 178 age- and gender-matched HC. SZ were sorted into groups according to clinical ratings on AH and VH: SZ with VH (VH-SZ; n = 45), SZ with AH but no VH (AH-SZ; n = 50), and SZ with neither AH nor VH (NoH-SZ; n = 67). Our primary analysis was seed based, extracting connectivity between visual cortex and the amygdala (because of its role in fear and negative emotion) and visual cortex and the hippocampus (because of its role in memory).
Compared with the other groups, VH-SZ showed hyperconnectivity between the amygdala and visual cortex, specifically BA18, with no differences in connectivity among the other groups. In a voxel-wise, whole brain analysis comparing VH-SZ with AH-SZ, the amygdala was hyperconnected to left temporal pole and inferior frontal gyrus in VH-SZ, likely due to their more severe thought broadcasting.
VH-SZ have hyperconnectivity between subcortical areas subserving emotion and cortical areas subserving higher order visual processing, providing biological support for distressing VH in schizophrenia.
C1 [Ford, Judith M.; Palzes, Vanessa A.; Roach, Brian J.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA.
[Ford, Judith M.; Palzes, Vanessa A.; Roach, Brian J.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Potkin, Steven G.; van Erp, Theo G. M.; Preda, Adrian] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA.
[Turner, Jessica A.; Calhoun, Vincent D.] Mind Res Network, Albuquerque, NM USA.
[Turner, Jessica A.] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA.
[Turner, Jessica A.] Georgia State Univ, Dept Neurosci, Atlanta, GA 30303 USA.
[Mueller, Bryon A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
[Calhoun, Vincent D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA.
[Voyvodic, Jim; Belger, Aysenil] Duke Univ, Univ N Carolina, Brain Imaging & Anal Ctr, Durham, NC USA.
[Belger, Aysenil] Univ N Carolina, Dept Psychiat, Durham, NC USA.
[Bustillo, Juan] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA.
[Vaidya, Jatin G.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA.
[McEwen, Sarah C.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Functional Imaging Biomed] Funct Imaging Biomed Informat Res Network FBIRN, Sao Paulo, Brazil.
RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA.
EM Judith.Ford@ucsf.edu
RI Preda, Adrian /K-8889-2013;
OI Preda, Adrian /0000-0003-3373-2438; Roach, Brian/0000-0002-3264-1465;
Potkin, Steven/0000-0003-1028-1013
FU Biomedical Informatics Research Network [U24RR021992]
FX Biomedical Informatics Research Network (U24RR021992).
NR 42
TC 20
Z9 20
U1 1
U2 23
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD JAN
PY 2015
VL 41
IS 1
BP 223
EP 232
DI 10.1093/schbul/sbu031
PG 10
WC Psychiatry
SC Psychiatry
GA CC0WA
UT WOS:000350057900031
PM 24619536
ER
PT J
AU Lener, MS
Wong, E
Tang, CY
Byne, W
Goldstein, KE
Blair, NJ
Haznedar, MM
New, AS
Chemerinski, E
Chu, KW
Rimsky, LS
Siever, LJ
Koenigsberg, HW
Hazlett, EA
AF Lener, Marc S.
Wong, Edmund
Tang, Cheuk Y.
Byne, William
Goldstein, Kim E.
Blair, Nicholas J.
Haznedar, M. Mehmet
New, Antonia S.
Chemerinski, Eran
Chu, King-Wai
Rimsky, Liza S.
Siever, Larry J.
Koenigsberg, Harold W.
Hazlett, Erin A.
TI White Matter Abnormalities in Schizophrenia and Schizotypal Personality
Disorder
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE DTI; MRI; schizotypal personality disorder; schizophrenia; psychosis;
white matter; genu; cingulum; inferior longitudinal fasciculus
ID DIFFUSION TENSOR TRACTOGRAPHY; INTERNAL CAPSULE; CORPUS-CALLOSUM;
1ST-EPISODE SCHIZOPHRENIA; UNCINATE FASCICULUS; RHESUS-MONKEY; ANTERIOR
LIMB; IMAGING DTI; BRAIN; INTEGRITY
AB Prior diffusion tensor imaging (DTI) studies examining schizotypal personality disorder (SPD) and schizophrenia, separately have shown that compared with healthy controls (HCs), patients show frontotemporal white matter (WM) abnormalities. This is the first DTI study to directly compare WM tract coherence with tractography and fractional anisotropy (FA) across the schizophrenia spectrum in a large sample of demographically matched HCs (n = 55), medication-naive SPD patients (n = 49), and unmedicated/never-medicated schizophrenia patients (n = 22) to determine whether (a) frontal-striatal-temporal WM tract abnormalities in schizophrenia are similar to, or distinct from those observed in SPD; and (b) WM tract abnormalities are associated with clinical symptom severity indicating a common underlying pathology across the spectrum. Compared with both the HC and SPD groups, schizophrenia patients showed WM abnormalities, as indexed by lower FA in the temporal lobe (inferior longitudinal fasciculus) and cingulum regions. SPD patients showed lower FA in the corpus callosum genu compared with the HC group, but this regional abnormality was more widespread in schizophrenia patients. Across the schizophrenia spectrum, greater WM disruptions were associated with greater symptom severity. Overall, frontal-striatal-temporal WM dysconnectivity is attenuated in SPD compared with schizophrenia patients and may mitigate the emergence of psychosis.
C1 [Lener, Marc S.; Byne, William; Goldstein, Kim E.; Haznedar, M. Mehmet; New, Antonia S.; Chemerinski, Eran; Rimsky, Liza S.; Siever, Larry J.; Koenigsberg, Harold W.; Hazlett, Erin A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Wong, Edmund; Tang, Cheuk Y.] Icahn Sch Med Mt Sinai, Translat & Mol Imaging Inst, Dept Radiol, New York, NY 10029 USA.
[Byne, William; Blair, Nicholas J.; New, Antonia S.; Chu, King-Wai; Siever, Larry J.; Hazlett, Erin A.] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN 3, Bronx, NY USA.
[Byne, William; Haznedar, M. Mehmet; Chemerinski, Eran; Siever, Larry J.; Koenigsberg, Harold W.] James J Peters Vet Affairs Med Ctr, Dept Outpatient Psychiat, Bronx, NY USA.
[Blair, Nicholas J.; Chu, King-Wai; Hazlett, Erin A.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Hazlett, EA (reprint author), James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, 130 West Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA.
EM erin.hazlett@mssm.edu
FU National Institutes of Health; Veterans Administration
[NIMH-R01-MH073911, VA MERIT-I01CX00026]
FX National Institutes of Health and the Veterans Administration
(NIMH-R01-MH073911 and VA MERIT-I01CX00026 to E.A.H.). Partial support
for the schizophrenia sample was also provided (NIMH-R01-MH069947 to
H.W.K.).
NR 71
TC 12
Z9 12
U1 8
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD JAN
PY 2015
VL 41
IS 1
BP 300
EP 310
DI 10.1093/schbul/sbu093
PG 11
WC Psychiatry
SC Psychiatry
GA CC0WA
UT WOS:000350057900038
PM 24962608
ER
PT J
AU Patel, BR
AF Patel, Bina R.
TI Caregivers of Veterans with "Invisible" Injuries: What We Know and
Implications for Social Work Practice
SO SOCIAL WORK
LA English
DT Article
DE caregivers; Iraq; Afghanistan caregivers; military caregivers; Operation
Iraqi Freedom and Operation Enduring Freedom caregivers; veteran
caregivers
ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH;
WAR VETERANS; MILITARY; FAMILIES; PARTNERS; SPOUSES; SUPPORT; BURDEN
AB Today, as a result of the longest volunteer-fought conflict in U.S. history, there are many wounded coming home not only with posttraumatic stress disorder (PTSD), but also with traumatic brain injury (TBI), which together have been called the "signature" or "invisible" injuries of the Iraq and Afghanistan wars. Caregivers are an important part of their recovery, yet little is known about them, as previous research on caregivers mostly focused on geriatric populations. According to one estimate 275,000 to 1 million people are currently caring or have cared for loved ones who have returned from Iraq and Afghanistan. These caregivers are unique in that they are younger, some with children, and they are caring for a unique understudied population for longer periods of time. This article summarizes literature on caregivers of veterans who suffer from PTSD, TBI, or both; provides a theoretical framework; and discusses implications for social workers in assisting caregivers and their families.
C1 US Dept Vet Affairs, Social Work, Gainesville, FL 32608 USA.
RP Patel, BR (reprint author), US Dept Vet Affairs, Social Work, 1601 SW Archer Rd,Mail Code 116A-4, Gainesville, FL 32608 USA.
EM beepat617@hotmail.com
NR 52
TC 0
Z9 0
U1 3
U2 17
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0037-8046
EI 1545-6846
J9 SOC WORK
JI Soc. Work
PD JAN
PY 2015
VL 60
IS 1
BP 9
EP 17
DI 10.1093/sw/swu043
PG 9
WC Social Work
SC Social Work
GA CC1PJ
UT WOS:000350113200002
PM 25643571
ER
PT J
AU Lee, J
Willis, L
Newman, D
Hazan, A
Kurobe, A
Giordano, L
Kaafarani, H
Laidlaw, C
Shah, K
AF Lee, Jarone
Willis, Lucy
Newman, David
Hazan, Alberto
Kurobe, Aileen
Giordano, Lorraine
Kaafarani, Haytham
Laidlaw, Caitlin
Shah, Kaushal
TI Are Sexual Assault Victims Presenting to the Emergency Department in a
Timely Manner?
SO SOCIAL WORK
LA English
DT Article
DE chi-square test; emergency department; multivariate regression; sexual
assault; victims
ID INJURY; WOMEN; RAPE; ACQUAINTANCE; PREDICTORS; STRANGER
AB Social workers regularly assist sexual assault victims and would benefit from a greater understanding of causes for delayed presentation to seek medical care. Delays in presentation of sexual assault victims affect the legal value of collected evidence. The authors of this study sought to characterize the nature and frequency of delayed presentation among victims. To do so, they performed a chart review from 2001 to 2007 of the Sexual Assault Forensic Examiner program at their institution. Delayed presentation was defined as presentation more than 12 hours after the assault. Chi-square test was used to contrast frequencies, and multivariate regression was used to control for confounders. Among 482 victims, more than half presented delayed. Of the victims who documented whether they knew the perpetrator, 63 percent knew the perpetrator, with 58 percent of these presenting delayed. Knowing the perpetrator was significantly associated with delayed presentation. Age, ethnicity, and gender were not associated with delayed presentation.
C1 [Lee, Jarone] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Lee, Jarone] Massachusetts Gen Hosp, Div Trauma, Emergency Surg, Surg Crit Care, Boston, MA 02114 USA.
[Willis, Lucy] New York Downtown Hosp, New York, NY USA.
[Newman, David; Shah, Kaushal] Mt Sinai Sch Med, Emergency Med, New York, NY USA.
[Hazan, Alberto] Valley Hlth Syst, Las Vegas, NV USA.
[Kurobe, Aileen] Univ Calif Irvine, Irvine Sch Med, Irvine, CA USA.
[Giordano, Lorraine] St Lukes Roosevelt Hosp, New York, NY USA.
[Kaafarani, Haytham; Laidlaw, Caitlin] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Lee, J (reprint author), Harvard Univ, Sch Med, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM lee.jarone@mgh.harvard.edu
NR 11
TC 0
Z9 0
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0037-8046
EI 1545-6846
J9 SOC WORK
JI Soc. Work
PD JAN
PY 2015
VL 60
IS 1
BP 29
EP 33
DI 10.1093/sw/swu051
PG 5
WC Social Work
SC Social Work
GA CC1PJ
UT WOS:000350113200004
PM 25643573
ER
PT J
AU Patil, V
Gupta, R
Estepar, RS
Lacson, R
Cheung, A
Wong, JM
Popp, AJ
Golby, A
Ogilvy, C
Vosburgh, KG
AF Patil, Vaibhav
Gupta, Rajiv
Estepar, Raul San Jose
Lacson, Ronilda
Cheung, Arnold
Wong, Judith M.
Popp, A. John
Golby, Alexandra
Ogilvy, Christopher
Vosburgh, Kirby G.
TI Smart Stylet: The Development and Use of a Bedside External Ventricular
Drain Image-Guidance System
SO STEREOTACTIC AND FUNCTIONAL NEUROSURGERY
LA English
DT Article
DE Ventriculostomy; Image-guided surgery; Electromagnetic concepts;
Neuronavigation
ID FRAMELESS STEREOTACTIC SYSTEMS; CATHETER PLACEMENT; PEDIATRIC-PATIENTS;
RISK-FACTORS; ACCURACY; NAVIGATION; HYDROCEPHALUS; TRACKING; MONITOR
AB Background: Placement accuracy of ventriculostomy catheters is reported in a wide and variable range. Development of an efficient image-guidance system may improve physician performance and patient safety. Objective: We evaluate the prototype of Smart Stylet, a new electromagnetic image-guidance system for use during bedside ventriculostomy. Methods: Accuracy of the Smart Stylet system was assessed. System operators were evaluated for their ability to successfully target the ipsilateral frontal horn in a phantom model. Results: Target registration error across 15 intracranial targets ranged from 1.3 to 4.6 mm (mean 3.1 mm). Using Smart Stylet guidance, a test operator successfully passed a ventriculostomy catheter to a shifted ipsilateral frontal horn 20/20 (100%) times from the frontal approach in a skull phantom. Without Smart Stylet guidance, the operator was successful 4/10 (40%) times from the right frontal approach and 6/10 (60%) times from the left frontal approach. In a separate experiment, resident operators were successful 2/4 (50%) times when targeting the shifted ipsilateral frontal horn with Smart Stylet guidance and 0/4 (0%) times without image guidance using a skull phantom. Conclusions: Smart Stylet may improve the ability to successfully target the ventricles during frontal ventriculostomy. (C) 2015 S. Karger AG, Basel
C1 [Patil, Vaibhav; Estepar, Raul San Jose; Lacson, Ronilda; Golby, Alexandra; Vosburgh, Kirby G.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Wong, Judith M.; Popp, A. John; Golby, Alexandra] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
[Gupta, Rajiv; Cheung, Arnold] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Ogilvy, Christopher] Beth Israel Deaconess Med Ctr, Dept Neurosurg, Boston, MA 02215 USA.
RP Patil, V (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, 75 Francis St,ASBI L1-050, Boston, MA 02115 USA.
EM patil@bwh.harvard.edu
FU NIH [R42 CA115112-03, T15 M007092-19]; Center for Integration of
Medicine and Innovative Technology (CIMIT), Boston, Mass., USA
FX Funding: NIH, R42 CA115112-03, Kirby G. Vosburgh, PhD; NIH, T15
M007092-19, Alexa T. McCray, PhD; Center for Integration of Medicine and
Innovative Technology (CIMIT), Boston, Mass., USA.
NR 26
TC 0
Z9 0
U1 1
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1011-6125
EI 1423-0372
J9 STEREOT FUNCT NEUROS
JI Stereotact. Funct. Neurosurg.
PY 2015
VL 93
IS 1
BP 50
EP 58
DI 10.1159/000368906
PG 9
WC Neurosciences; Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA CC3SC
UT WOS:000350268700008
PM 25662506
ER
PT J
AU Saff, RR
Banerji, A
AF Saff, Rebecca R.
Banerji, Aleena
TI Management of patients with nonaspirin-exacerbated respiratory disease
aspirin hypersensitivity reactions
SO ALLERGY AND ASTHMA PROCEEDINGS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STEVENS-JOHNSON-SYNDROME; TOXIC
EPIDERMAL NECROLYSIS; CUTANEOUS REACTIONS; CONTACT-DERMATITIS;
ASTHMATIC-PATIENTS; CHRONIC URTICARIA; NATURAL-HISTORY; DESENSITIZATION;
SENSITIVITY
AB Because of widespread use, nonsteroidal anti-inflammatory drugs (NSAIDs) are the second most common cause of all adverse drug reactions, with hypersensitivity reported in similar to 1% of the population. NSAID hypersensitivity can be categorized into five types by the underlying disease, symptoms of reaction, and timing of reaction. These include rhinitis and asthma induced by NSAIDs (also known as aspirin-exacerbated respiratory disease), NSAID-exacerbated cutaneous disease (NECD), urticaria or angioedema induced by multiple NSAIDs, single NSAID-induced reactions, and delayed NSAID reactions. NECD occurs in one-third of patients with chronic urticaria who develop an exacerbation of their urticaria, sometimes with angioedema, typically beginning 30-90 minutes after ingestion of NSAIDs that inhibit cyclooxygenase (COX)-1. In urticaria. or angioedema induced by multiple NSAIDs, patients without underlying disease develop urticaria or angioedema 30-90 minutes after ingestion of COX-1-inhibiting NSAIDs including aspirin. Single NSAID-induced reactions are immediate and specific to a single NSAID and are thought to occur because of an IgE-mediated reaction against a specific epitope of the NSAID. Delayed NSAID reactions occur days to weeks after initiating an NSAID. These are T-cell mediated and not amenable to desensitization or rechallenge. Classifying the type of NSAID hypersensitivity is important because many patients with a prior history of urticaria or angioedema induced by multiple NSAIDs will often tolerate aspirin test dose. This would allow the use of an aspirin for primary or secondary prevention in patients with coronary artery disease despite a presumed history of NSAID hypersensitivity.
C1 [Saff, Rebecca R.; Banerji, Aleena] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Rheumatol Allergy & Immunol, Boston, MA USA.
RP Saff, RR (reprint author), Dept Med, Div Rheumatol Allergy & Immunol, 55 Fruit St,COX 201, Boston, MA 02114 USA.
EM rsaff@partners.org
NR 55
TC 4
Z9 4
U1 0
U2 2
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1088-5412
EI 1539-6304
J9 ALLERGY ASTHMA PROC
JI Allergy Asthma Proc.
PD JAN-FEB
PY 2015
VL 36
IS 1
BP 34
EP 39
DI 10.2500/aap.2015.36.3800
PG 6
WC Allergy
SC Allergy
GA CC0EB
UT WOS:000350007500008
PM 25562554
ER
PT J
AU Lorius, N
Locascio, JJ
Rentz, DM
Johnson, KA
Sperling, RA
Viswanathan, A
Marshall, GA
AF Lorius, Natacha
Locascio, Joseph J.
Rentz, Dorene M.
Johnson, Keith A.
Sperling, Reisa A.
Viswanathan, Anand
Marshall, Gad A.
CA Alzheimer's Dis Neuroimaging
TI Vascular Disease and Risk Factors are Associated With Cognitive Decline
in the Alzheimer Disease Spectrum
SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS
LA English
DT Article
DE Alzheimer disease; processing speed; memory; mild cognitive impairment;
vascular risk factors
ID BODY-MASS INDEX; APOLIPOPROTEIN-E; DEMENTIA; PROGRESSION; HOMOCYSTEINE;
IMPAIRMENT; PATHOLOGY; BURDEN; COHORT; BRAIN
AB We investigated the relationship between vascular disease and risk factors versus cognitive decline cross-sectionally and longitudinally in normal older control, mild cognitive impairment, and mild Alzheimer disease (AD) dementia subjects. A total of 812 participants (229 normal older control, 395 mild cognitive impairment, 188 AD) underwent cognitive testing, brain magnetic resonance imaging, and clinical evaluations at baseline and over a period of 3 years. General linear, longitudinal mixed-effects, and Cox proportional hazards models were used. Greater homocysteine level and white matter hyperintensity volume were associated with processing speed impairment (homocysteine: P = 0.02; white matter hyperintensity: P < 0.0001); greater Vascular Index score was associated with memory impairment (P = 0.007); and greater number of apolipoprotein E epsilon 4 (APOE4) alleles was associated with global cognitive impairment (P = 0.007) at baseline. Apolipoprotein E epsilon 4 was associated with greater rate of increase in global cognitive impairment (P = 0.002) and processing speed impairment (P = 0.001) over time, whereas higher total cholesterol was associated with greater rate of increase in global cognitive impairment (P = 0.02) and memory impairment (P = 0.06) over time. These results suggest a significant association of increased vascular disease and risk factors with cognitive impairment at baseline and over time in the AD spectrum in a sample that was selected to have low vascular burden at baseline.
C1 [Lorius, Natacha; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Harvard Univ, Sch Med, Dept Neurol, Ctr Alzheimer Res & Treatment,Brigham & Womens Ho, Boston, MA 02115 USA.
[Lorius, Natacha; Locascio, Joseph J.; Rentz, Dorene M.; Sperling, Reisa A.; Viswanathan, Anand; Marshall, Gad A.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Johnson, Keith A.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Marshall, GA (reprint author), Harvard Univ, Sch Med, Dept Neurol, Ctr Alzheimer Res & Treatment,Brigham & Womens Ho, 221 Longwood Ave,BL-104H, Boston, MA 02115 USA.
EM gamarshall@partners.org
FU Gilbert Foundation/AFAR New Investigator Awards in Alzheimer's disease;
Massachusetts Alzheimer's Disease Research Center [P50 AG005134];
Harvard Aging Brain Study [P01 AGO36694]; ADNI (NIH) [U01 AG024904];
Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes
of Health) [U01 AG024904]; NIH [P30 AG010129, K01 AG030514];
Massachusetts General Hospital; Brigham and Women's Hospital; Harvard
Medical School; NIA/NIH; [R01 AG027435]; [K23 AG033634]; [K24
AG035007]; [NIH/NIA2P50AG05134-26]; [1K23AG028726-01A2]
FX Supported by R01 AG027435, K23 AG033634, K24 AG035007, Gilbert
Foundation/AFAR New Investigator Awards in Alzheimer's disease,
Massachusetts Alzheimer's Disease Research Center (P50 AG005134),
Harvard Aging Brain Study (P01 AGO36694), and ADNI (NIH Grant U01
AG024904). Data collection and sharing for this project was funded by
the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National
Institutes of Health Grant U01 AG024904). The grantee organization is
the Northern California Institute for Research and Education, and the
study is coordinated by the Alzheimer's Disease Cooperative Study at the
University of California, San Diego. ADNI data are disseminated by the
Laboratory for Neuroimaging at the University of California, Los
Angeles. This research was also supported by NIH Grants P30 AG010129 and
K01 AG030514.; A.V. has 2 conflicts of interest to report, the following
grants/funds: NIH/NIA2P50AG05134-26 and 1K23AG028726-01A2. KAJ has the
following conflicts of interest to report: Massachusetts General
Hospital, Brigham and Women's Hospital, Harvard Medical School, NIA/NIH
funds/grants, a consultant for GEHC, Piramal, Avid/Lilly, and Siemems.
The remaining authors declare no conflicts of interest.
NR 42
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0893-0341
J9 ALZ DIS ASSOC DIS
JI Alzheimer Dis. Assoc. Dis.
PD JAN-MAR
PY 2015
VL 29
IS 1
BP 18
EP 25
PG 8
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA CC1RG
UT WOS:000350119500004
PM 24787033
ER
PT J
AU Mendez, MF
Sabodash, V
AF Mendez, Mario F.
Sabodash, Valeriy
TI Clinical Amyloid Imaging in Logopenic Progressive Aphasia
SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS
LA English
DT Article
DE primary progressive aphasia (PPA); logopenic; Alzheimer disease; amyloid
imaging; florbetapir
ID ALZHEIMERS-DISEASE
AB The introduction of florbetapir (Amyvid) positron emission tomography biomarkers could dramatically change how we clinically evaluate young patients who present with nonamnestic cognitive complaints for possible Alzheimer disease (AD). Logopenic progressive aphasia (LPA) may be the most common example of this type of clinical problem. In most, but not all, cases, LPA is an early-onset AD variant presenting with language changes that can be difficult to distinguish from other progressive aphasias. We clinically evaluated 3 patients with LPA, in comparison with age-matched and severity-matched patients with typical amnestic AD, using florbetapir amyloid neuroimaging. The fluorodeoxyglucose-positron emission tomography scans of LPA patients revealed focal hypometabolism in the left temporoparietal areas, and the florbetapir scans were diffusely positive for the presence of amyloid deposition. The florbetapir scans did not differ in distribution between patients with LPA and those with typical amnestic AD. Clinical amyloid imaging, although lacking localizing value, is a major advance in the assessment of early-onset and nonamnestic patients for the presence of beta-amyloid Alzheimer pathology.
C1 [Mendez, Mario F.; Sabodash, Valeriy] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Mendez, Mario F.; Sabodash, Valeriy] VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, Los Angeles, CA 90073 USA.
RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@UCLA.edu
FU National Institute on Aging [R01 AG034499]
FX M.F.M. supported by National Institute on Aging R01 AG034499.
NR 10
TC 2
Z9 2
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0893-0341
J9 ALZ DIS ASSOC DIS
JI Alzheimer Dis. Assoc. Dis.
PD JAN-MAR
PY 2015
VL 29
IS 1
BP 94
EP 96
PG 3
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA CC1RG
UT WOS:000350119500016
PM 23995816
ER
PT J
AU Sadeghian, H
Motiei-Langroudi, R
AF Sadeghian, Homa
Motiei-Langroudi, Rouzbeh
TI Comparison of Levetiracetam and sodium Valproate in migraine
prophylaxis: A randomized placebo-controlled study
SO ANNALS OF INDIAN ACADEMY OF NEUROLOGY
LA English
DT Article
DE Efficacy; levetiracetam; migraine; prophylaxis; valproate
ID CORTICAL SPREADING DEPRESSION; HEALTH STROKE SCALE; PEDIATRIC MIGRAINE;
OPEN-LABEL; MULTIPLE-SCLEROSIS; IRANIAN PATIENTS; UNITED-STATES; AGENTS;
BRAIN; AURA
AB Background: Migraine is a chronic and disabling disorder. Treatment of migraine often comprises of symptomatic (abortive) and preventive (prophylactic) treatment. The current drugs used in migraine prophylaxis include antidepressant drugs (Serotonin Reuptake Inhibitors, Tricyclic antidepressants), and anti-epileptic drugs (valproate, gabapentin, etc). Objective: The objective of our study was to assess the efficacy and tolerability of levetiracetam in adult migraine prophylaxis, compared to valproate and placebo. Materials and Methods: We conducted a prospective, randomized, placebo-controlled study. A total of 85 patients were randomized to receive levetiracetam 500 mg/d (n = 27), valproate 500 mg/d (n = 32) or placebo (n = 26). The patients were evaluated for treatment efficacy after 6 months. Efficacy was assessed as a more than 50% decrease in headache frequency. Results: In levetiracetam group, 17 (63.0%) patients experienced a more than 50% decrease in headache frequency, while this efficacy number was 21 (65.6%) for valproate group and 4 (15.4%) for placebo group. The difference was not statistically significant between levetiracetam and valproate, while it was significant when comparing either levetiracetam or valproate to placebo. Conclusion: Compared to placebo, levetiracetam offers improvement in headache frequency in patients with migraine. The efficacy of levetiracetam in migraine prophylaxis is comparable to currently used drugs such as valproate.
C1 [Sadeghian, Homa] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neurovasc Res Lab, Charlestown, MA 02129 USA.
[Motiei-Langroudi, Rouzbeh] Shefa Neurosci Res Ctr, Tehran, Iran.
RP Sadeghian, H (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neurovasc Res Lab, Charlestown, MA 02129 USA.
EM hsadeghian@mgh.harvard.edu
NR 36
TC 3
Z9 3
U1 0
U2 4
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 0972-2327
EI 1998-3549
J9 ANN INDIAN ACAD NEUR
JI Ann. Indian Acad. Neurol.
PD JAN-MAR
PY 2015
VL 18
IS 1
BP 45
EP 48
DI 10.4103/0972-2327.144290
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA CB7XG
UT WOS:000349841400010
PM 25745310
ER
PT J
AU Singh, JA
Noorbaloochi, S
MacDonald, R
Maxwell, LJ
AF Singh, Jasvinder A.
Noorbaloochi, Shahrzad
MacDonald, Roderick
Maxwell, Lara J.
TI Chondroitin for osteoarthritis
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID SYMPTOMATIC KNEE OSTEOARTHRITIS; PLACEBO-CONTROLLED TRIAL; CLINICALLY
SIGNIFICANT DIFFERENCE; ANALOG SCALE PAIN; DOUBLE-BLIND; GLUCOSAMINE
HYDROCHLORIDE; MANGANESE ASCORBATE; HIP OSTEOARTHRITIS; OSTEO-ARTHRITIS;
6 SULFATE
AB Background
Osteoarthritis, a common joint disorder, is one of the leading causes of disability. Chondroitin has emerged as a new treatment. Previous meta-analyses have shown contradictory results on the efficacy of chondroitin. This, in addition to the publication of more trials, necessitates a systematic review.
Objectives To evaluate the benefit and harm of oral chondroitin for treating osteoarthritis compared with placebo or a comparator oral medication including, but not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, opioids, and glucosamine or other "herbal" medications.
Search methods
We searched seven databases up to November 2013, including the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, CINAHL, EMBASE, Science Citation Index (Web of Science) and Current Controlled Trials. We searched the US Food andDrug Administration (FDA) and EuropeanMedicines Agency (EMEA) websites for adverse effects. Trial registers were not searched.
Selection criteria
All randomized or quasi-randomized clinical trials lasting longer than two weeks, studying adults with osteoarthritis in any joint, and comparing chondroitin with placebo, an active control such as NSAIDs, or other "herbal" supplements such as glucosamine.
Data collection and analysis
Two review authors independently performed all title assessments, data extractions, and risk of bias assessments.
Main results
Forty-three randomized controlled trials including 4,962 participants treated with chondroitin and 4,148 participants given placebo or another control were included. The majority of trials were in knee OA, with few in hip and hand OA. Trial duration varied from 1 month to 3 years. Participants treated with chondroitin achieved statistically significantly and clinically meaningful better pain scores (0-100) in studies less than 6 months than those given placebo with an absolute risk difference of 10% lower (95% confidence interval (CI), 15% to 6% lower; number needed to treat (NNT) = 5 (95% CI, 3 to 8; n = 8 trials) (level of evidence, low; risk of bias, high); but there was high heterogeneity between the trials (T-2 = 0.07; I-2 = 70%, which was not easily explained by differences in risk of bias or study sample size). In studies longer than 6 months, the absolute risk difference for pain was 9% lower (95% CI 18% lower to 0%); n = 6 trials; T-2 = 0.18; I-2 = 83%), again with low level of evidence.
For the Western Ontario and McMaster Universities Osteoarthritis Index Minimal Clinically Important Improvement (WOMAC MCII Pain subscale) outcome, a reduction in knee pain by 20% was achieved by 53/100 in the chondroitin group versus 47/100 in the placebo group, an absolute risk difference of 6% (95% CI 1% to 11%), (RR 1.12, 95% CI 1.01 to 1.24; T-2 = 0.00; I-2 = 0%) (n = 2 trials, 1253 participants; level of evidence, high; risk of bias, low).
Differences in Lequesne's index (composite of pain, function and disability) statistically significantly favoured chondroitin as compared with placebo in studies under six months, with an absolute risk difference of 8% lower (95% CI 12% to 5% lower; T-2 = 0.78; n = 7 trials) (level of evidence, moderate; risk of bias, unclear), also clinically meaningful. Loss of minimum joint space width in the chondroitin group was statistically significantly less than in the placebo group, with a relative risk difference of 4.7% less (95% CI 1.6% to 7.8% less; n = 2 trials) (level of evidence, high; risk of bias, low). Chondroitin was associated with statistically significantly lower odds of serious adverse events compared with placebo with Peto odds ratio of 0.40 (95% CI 0.19 to 0.82; n = 6 trials) (level of evidence, moderate). Chondroitin did not result in statistically significant numbers of adverse events or withdrawals due to adverse events compared with placebo or another drug. Adverse events were reported in a limited fashion, with some studies providing data and others not.
Comparisons of chondroitin taken alone or in combination with glucosamine or another supplement showed a statistically significant reduction in pain (0-100) when compared with placebo or an active control, with an absolute risk difference of 10% lower (95% CI 14% to 5% lower); NNT = 4 (95% CI 3 to 6); T-2 = 0.33; I-2 = 91%; n = 17 trials) (level of evidence, low). For physical function, chondroitin in combination with glucosamine or another supplement showed no statistically significant difference from placebo or an active control, with an absolute risk difference of 1% lower (95% CI 6% lower to 3% higher with T-2 = 0.04; n = 5 trials) (level of evidence, moderate). Differences in Lequesne's index statistically significantly favoured chondroitin as compared with placebo, with an absolute risk difference of 8% lower (95% CI, 12% to 4% lower; T-2 = 0.12; n = 10 trials) (level of evidence, moderate). Chondroitin in combination with glucosamine did not result in statistically significant differences in the numbers of adverse events, withdrawals due to adverse events, or in the numbers of serious adverse events compared with placebo or with an active control.
The beneficial effects of chondroitin in pain and Lequesne's index persisted when evidence was limited to studies with adequate blinding or studies that used appropriate intention to treat (ITT) analyses. These beneficial effects were uncertain when we limited data to studies with appropriate allocation concealment or a large study sample (>200) or to studies without pharmaceutical funding.
Authors' conclusions
A review of randomized trials of mostly low quality reveals that chondroitin (alone or in combination with glucosamine) was better than placebo in improving pain in participants with osteoarthritis in short-term studies. The benefit was small to moderate with an 8 point greater improvement in pain (range 0 to 100) and a 2 point greater improvement in Lequesne's index (range 0 to 24), both seeming clinically meaningful. These differences persisted in some sensitivity analyses and not others. Chondroitin had a lower risk of serious adverse events compared with control. More high-quality studies are needed to explore the role of chondroitin in the treatment of osteoarthritis. The combination of some efficacy and low risk associated with chondroitin may explain its popularity among patients as an over-the-counter supplement.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35294 USA.
[Noorbaloochi, Shahrzad] Minneapolis VA Med Ctr, Dept Med, Minneapolis, MN USA.
[Noorbaloochi, Shahrzad] Univ Minnesota, Minneapolis, MN USA.
[MacDonald, Roderick] VA Med Ctr, Minneapolis, MN USA.
[Maxwell, Lara J.] Univ Ottawa, Inst Populat Hlth, Ctr Global Hlth, Ottawa, ON, Canada.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA.
EM jasvinder.md@gmail.com
FU University of Alabama at Birmingham, Birmingham, Alabama, USA;
Birmingham VA Medical Center, Birmingham, Alabama, USA; Center for
Chronic Disease Outcomes Research and Center for Epidemiological and
Clinical Research, Minneapolis VA Medical Center, Minneapolis,
Minnesota, USA; Cochrane Complementary Medicine Field Bursary, USA;
Cochrane Complementary Medicine Field Bursary
FX Internal sources; University of Alabama at Birmingham and the Birmingham
VA Medical Center, Birmingham, Alabama, USA.; Center for Chronic Disease
Outcomes Research and Center for Epidemiological and Clinical Research,
Minneapolis VA Medical Center, Minneapolis, Minnesota, USA.; External
sources; Cochrane Complementary Medicine Field Bursary, USA.; We
received a $5,000 Cochrane Complementary Medicine Field Bursary to
complete this review. This money was used to pay research associates to
perform data abstraction and data quality assurance/quality improvement.
NR 153
TC 4
Z9 4
U1 3
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2015
IS 1
AR CD005614
DI 10.1002/14651858.CD005614.pub2
PG 304
WC Medicine, General & Internal
SC General & Internal Medicine
GA CB5ST
UT WOS:000349688600008
ER
PT J
AU Ruggiero, KJ
Davidson, TM
McCauley, J
Gros, KS
Welsh, K
Price, M
Resnick, HS
Danielson, CK
Soltis, K
Galea, S
Kilpatrick, DG
Saunders, BE
Nissenboim, J
Muzzy, W
Fleeman, A
Amstadter, AB
AF Ruggiero, Kenneth J.
Davidson, Tatiana M.
McCauley, Jenna
Gros, Kirstin Stauffacher
Welsh, Kyleen
Price, Matthew
Resnick, Heidi S.
Danielson, Carla Kmett
Soltis, Kathryn
Galea, Sandro
Kilpatrick, Dean G.
Saunders, Benjamin E.
Nissenboim, Josh
Muzzy, Wendy
Fleeman, Anna
Amstadter, Ananda B.
TI Bounce Back Now! Protocol of a population-based randomized controlled
trial to examine the efficacy of a Web-based intervention with
disaster-affected families
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Disaster mental health; Population-based research; Web intervention;
Adolescents
ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL TREATMENT;
NEW-YORK-CITY; MENTAL-HEALTH; SUBSTANCE USE; HURRICANE KATRINA; RARE
VARIANTS; YOUNG-PEOPLE; CHILDREN; ADOLESCENTS
AB Disasters have far-reaching and potentially long-lasting effects on youth and families. Research has consistently shown a clear increase in the prevalence of several mental health disorders after disasters, including depression and posttraumatic stress disorder. Widely accessible evidence-based interventions are needed to address this unmet need for youth and families, who are underrepresented in disaster research. Rapid growth in Internet and Smartphone access, as well as several Web based evaluation studies with various adult populations has shown that Web-based interventions are likely to be feasible in this context and can improve clinical outcomes. Such interventions also are generally cost-effective, can be targeted or personalized, and can easily be integrated in a stepped care approach to screening and intervention delivery. This is a protocol paper that describes an innovative study design in which we evaluate a self-help Web-based resource, Bounce Back Now, with a population-based sample of disaster affected adolescents and families. The paper includes description and justification for sampling selection and procedures, selection of assessment measures and methods, design of the intervention, and statistical evaluation of critical outcomes. Unique features of this study design include the use of address-based sampling to recruit a population-based sample of disaster-affected adolescents and parents, telephone and Web-based assessments, and development and evaluation of a highly individualized Web intervention for adolescents. Challenges related to large-scale evaluation of technology-delivered interventions with high-risk samples in time-sensitive research are discussed, as well as implications for future research and practice. Published by Elsevier Inc.
C1 [Ruggiero, Kenneth J.; Davidson, Tatiana M.; Soltis, Kathryn; Muzzy, Wendy] Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, Charleston, SC 29425 USA.
[Ruggiero, Kenneth J.; Gros, Kirstin Stauffacher; Welsh, Kyleen; Muzzy, Wendy] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Davidson, Tatiana M.; Welsh, Kyleen; Resnick, Heidi S.; Danielson, Carla Kmett; Soltis, Kathryn; Kilpatrick, Dean G.; Saunders, Benjamin E.] MUSC, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, Charleston, SC USA.
[McCauley, Jenna] MUSC, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC USA.
[Price, Matthew] Univ Vermont, Ctr Res Emot Stress & Technol, Burlington, VT USA.
[Galea, Sandro] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
[Nissenboim, Josh] Fuzzco Inc, Charleston, SC USA.
[Fleeman, Anna] Abt SRBI, New York, NY USA.
[Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Dept Psychiat Psychol & Human & Mol Genet, Richmond, VA USA.
RP Ruggiero, KJ (reprint author), Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, Charleston, SC 29425 USA.
EM ruggierk@musc.edu
RI Emchi, Karma/Q-1952-2016
FU National Institute of Mental Health (NIMH) [R01 MH081056]; NIMH
[MH081056, T32 MH018869]; National Institute on Drug Abuse (NIDA) [R01
DA031285]; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
[P50 AA010761]; NIDA [K12 DA031794]; NIAAA [K02 AA023239]; [R21
MH086313]
FX This research was supported by National Institute of Mental Health
(NIMH) Grant R01 MH081056 (PI: KJ Ruggiero). This includes two
supplements to NIMH Grant MH081056: an OppNet supplement awarded to Dr.
Amstadter, and a Diversity supplement awarded to Dr. Davidson. Grant R21
MH086313 (PI: CK Danielson) also supported some elements of this work.
The preparation of this manuscript was supported by National Institute
on Drug Abuse (NIDA) Grant R01 DA031285 (PI: CK Danielson) and National
Institute on Alcohol Abuse and Alcoholism (NIAAA) Grant P50 AA010761
(PI: Becker); NIDA Grant K12 DA031794 (PI: Brady; support to JM), NIMH
Grant T32 MH018869 (PI: Kilpatrick; support to MP), and NIAAA K02
AA023239 (PI: Amstadter). All views and opinions expressed herein are
those of the authors and do not necessarily reflect those of the funding
agency or respective institutions.
NR 85
TC 6
Z9 6
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD JAN
PY 2015
VL 40
BP 138
EP 149
DI 10.1016/j.cct.2014.11.018
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CB6IZ
UT WOS:000349732000016
PM 25478956
ER
PT J
AU Oreskovic, NM
Goodman, E
Park, ER
Robinson, AI
Winickoff, JP
AF Oreskovic, Nicolas M.
Goodman, Elizabeth
Park, Elyse R.
Robinson, Alyssa I.
Winickoff, Jonathan P.
TI Design and implementation of a physical activity intervention to enhance
children's use of the built environment (the CUBE study)
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Physical activity; Built environment; Adolescents; Obesity; Intervention
ID RANDOMIZED CONTROLLED-TRIAL; ADOLESCENT FEMALES; UNITED-STATES;
ACCELEROMETER; OVERWEIGHT; CHILDHOOD; OBESITY; COMMUNITIES; PATTERNS
AB Background: Adequate physical activity promotes physical and mental health and decreases obesity risk. However, most adolescents do not attain recommended physical activity levels and effective interventions are lacking. Physical activity trials rarely incorporate built environment use patterns.
Purpose: This paper describes the design and rationale of the Children's Use of the Built Environment (CUBE) Study, an office-based intervention designed to teach youth how to use their surrounding built environment to increase physical activity.
Methods: CUBE is a 6-month intervention trial among 60 overweight and obese 10-16 year old adolescents from a community health center in Massachusetts. The study began in the winter of 2013. Patients are sequentially assigned to either the intervention or control group. Baseline physical activity by accelerometry and location by GPS, along with measured height, weight, and blood pressure are collected. Control subjects receive standard of care lifestyle counseling. Intervention subjects receive tailored recommendations on how to increase their physical activity based on their accelerometer and GPS data. Data collections are repeated at end-of-treatment, and again 3 months later.
Conclusion: The findings from this study should help guide future efforts to design interventions aimed at increasing adolescent physical activity as well as to inform design professionals and government officials charged with creating outdoor spaces where adolescents spend time. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Oreskovic, Nicolas M.; Goodman, Elizabeth; Robinson, Alyssa I.; Winickoff, Jonathan P.] MassGen Hosp Children, Div Gen Acad Pediat, Boston, MA USA.
[Oreskovic, Nicolas M.; Goodman, Elizabeth; Winickoff, Jonathan P.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Oreskovic, Nicolas M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Oreskovic, Nicolas M.; Goodman, Elizabeth; Park, Elyse R.; Winickoff, Jonathan P.] Harvard Univ, Sch Med, Boston, MA USA.
[Park, Elyse R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Oreskovic, NM (reprint author), Massachusetts Gen Hosp, Div Gen Acad Pediat, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM noreskovic@mgh.harvard.edu; egoodman3@mgh.hanrard.edu;
epark@mgh.harvard.edu; arobinson13@mgh.harvard.edu;
jwinickoff@mgh.harvard.edu
OI Oreskovic, Nicolas/0000-0001-8702-8636; Goodman,
Elizabeth/0000-0002-9640-9884
FU National Institutes of Health/National Heart, Lung, and Blood Institute
[5K23HL103841]
FX The authors wish to thank the CUBE study participants and the
Massachusetts General Hospital Revere HealthCare Center staff for their
participation and cooperation. This trial is sponsored by the National
Institutes of Health/National Heart, Lung, and Blood Institute grant
#5K23HL103841.
NR 32
TC 3
Z9 3
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD JAN
PY 2015
VL 40
BP 172
EP 179
DI 10.1016/j.cct.2014.12.009
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CB6IZ
UT WOS:000349732000020
PM 25533728
ER
PT J
AU Awad, MM
Sullivan, RJ
AF Awad, Mark M.
Sullivan, Ryan J.
TI Dabrafenib in combination with trametinib for the treatment of
metastatic melanoma
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE BRAF; MEK; melanoma; resistance; targeted therapy
ID DOSE-ESCALATION TRIAL; MEK INHIBITOR TRAMETINIB; ACQUIRED-RESISTANCE;
IMPROVED SURVIVAL; BRAF INHIBITION; PHASE-III; CANCER; SAFETY;
VEMURAFENIB; MUTATIONS
AB Oncogenic BRAF mutations are present in approximately 40-50% of patients with metastatic melanoma. Targeting BRAF mutations with either small molecule inhibitors of BRAF or one of the downstream mediators of oncogenic BRAF - MEK - is associated with improved outcomes compared with chemotherapy and has led to the US FDA approval of two BRAF inhibitors - vemurafenib and dabrafenib - and the MEK inhibitor trametinib. Further, the combination of dabrafenib and trametinib is well tolerated and associated with higher responses and improved survival compared with single-agent BRAF inhibitors.
C1 [Awad, Mark M.; Sullivan, Ryan J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Sullivan, RJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
EM rsullivan7@partners.org
NR 40
TC 4
Z9 6
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1751-2433
EI 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD JAN
PY 2015
VL 8
IS 1
BP 25
EP 33
DI 10.1586/17512433.2015.974556
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CC0JV
UT WOS:000350022500005
PM 25473943
ER
PT J
AU Linkov, F
Edwards, RP
Althouse, A
Rauh-Hain, JA
Del Carmen, MG
Freese, KE
Kelley, JL
Olawaiye, AB
AF Linkov, Faina
Edwards, Robert P.
Althouse, Andrew
Rauh-Hain, Jose A.
Del Carmen, Marcela G.
Freese, Kyle E.
Kelley, Joseph L.
Olawaiye, Alexander B.
TI Obesity, lymphadenectomy and survival outcomes in intermediate to
high-risk, early-stage endometrial cancer patients
SO FUTURE ONCOLOGY
LA English
DT Article
DE endometrial cancer; gynecology; lymphadenectomy; obesity; oncology;
survival
ID BODY-MASS INDEX; GYNECOLOGIC-ONCOLOGY-GROUP; PARAAORTIC LYMPHADENECTOMY;
THERAPEUTIC ROLE; TRIAL; CARCINOMA; PROGNOSIS; IMPACT; ASTEC
AB Aim: Lymphadenectomy or lymph node dissection is a topic of controversy in endometrial cancer (EC) treatment. Materials & methods: Associations between lymph node dissections and clinical factors were retrospectively examined in obese, endometrioid endometrial cancer patients with early-stage disease between 1995 and 2005. Overall, EC-specific and recurrence-free survival were also evaluated. Results: Out of 192 patients, 61 (32%) did not have a lymph node examination, 55 (29%) had less than ten lymph nodes removed and 76 (39%) had 10 removed. Lymph node dissection count was not significantly associated with overall, EC-specific or recurrence-free survival. Conclusion: Analysis revealed no significant associations between 10 dissected lymph nodes and survival outcomes among obese, EC patients, which supports the need for additional investigation of the merit of lymphadenectomy among these patients.
C1 [Linkov, Faina; Freese, Kyle E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
[Linkov, Faina; Edwards, Robert P.; Althouse, Andrew; Kelley, Joseph L.; Olawaiye, Alexander B.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, Pittsburgh, PA 15261 USA.
[Rauh-Hain, Jose A.; Del Carmen, Marcela G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA 02115 USA.
RP Olawaiye, AB (reprint author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM olawaiyea@mail.magee.edu
FU American Cancer Society [MRSG-10-079-01-CPPB]
FX Funding for this study was partially provided by an American Cancer
Society Mentored Research Award # MRSG-10-079-01-CPPB. The authors have
no other relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 35
TC 0
Z9 0
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PY 2015
VL 11
IS 4
BP 607
EP 615
DI 10.2217/fon.14.247
PG 9
WC Oncology
SC Oncology
GA CC0UY
UT WOS:000350054200009
PM 25686116
ER
PT J
AU Pascoe, VL
Kimball, AB
AF Pascoe, Vanessa L.
Kimball, Alexandra B.
TI Expanding Scope of Dermatologic Mid-Level Practitioners Includes
Prescription of Complex Medication
SO JAMA DERMATOLOGY
LA English
DT Letter
C1 [Pascoe, Vanessa L.; Kimball, Alexandra B.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Kimball, Alexandra B.] Harvard Univ, Sch Med, Boston, MA USA.
RP Kimball, AB (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Clin Unit Res Trials & Outcomes Skin, 50 Staniford St,Ste 240, Boston, MA 02114 USA.
EM harvardskinstudies@partners.org
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD JAN
PY 2015
VL 151
IS 1
BP 106
EP 107
DI 10.1001/jamadermatol.2014.3295
PG 3
WC Dermatology
SC Dermatology
GA CB6RI
UT WOS:000349753900028
PM 25321608
ER
PT J
AU Karlin, BE
Trockel, M
Brown, GK
Gordienko, M
Yesavage, J
Taylor, CB
AF Karlin, Bradley E.
Trockel, Mickey
Brown, Gregory K.
Gordienko, Maria
Yesavage, Jerome
Taylor, C. Barr
TI Comparison of the Effectiveness of Cognitive Behavioral Therapy for
Depression among Older Versus Younger Veterans: Results of a National
Evaluation
SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL
SCIENCES
LA English
DT Article
DE Cognitive behavioral therapy; Department of Veterans Affairs;
Depression; Geriatrics; Older adultsVeterans
ID LATE-LIFE DEPRESSION; WORKING ALLIANCE INVENTORY; COLLABORATIVE
RESEARCH-PROGRAM; GERIATRIC MENTAL-HEALTH; QUALITY-OF-LIFE; PSYCHOMETRIC
PROPERTIES; ELDERLY-PATIENTS; ADULTS; PSYCHOTHERAPY; CARE
AB Objectives. The effectiveness of cognitive behavioral therapy for depression (CBT-D) among older adults in routine clinical settings has received limited attention. The current article examines and compares outcomes of older versus younger veterans receiving CBT-D nationally.
Method. Patient outcomes were assessed using the Beck Depression Inventory-II and World Health Organization Quality of Life-BREF. Therapeutic alliance was assessed using the Working Alliance Inventory-Short Revised.
Results. A total of 764 veterans aged 18-64 and 100 veterans aged 65+ received CBT-D; 68.0% of older and 68.3% of younger patients completed all sessions or finished early due to symptom relief, and mean depression scores declined from 27.0 (standard deviation [SD] = 10.7) to 16.2 (SD = 12.4) in the older group and from 29.1 (SD = 11.2) to 17.8 (SD = 13.5) in the younger group. Within-group effect sizes were d = 1.01 for both groups. Significant increases in quality of life and therapeutic alliance were observed for both groups.
Discussion. CBT-D resulted in significant improvements in depression and quality of life among older patients. Outcomes and rate of attrition were equivalent to younger patients. Findings indicate that CBT-D is an effective and acceptable treatment for older veterans in real-world settings with often high levels of depression.
C1 [Karlin, Bradley E.] US Dept Vet Affairs, Mental Hlth Serv, Cent Off, Washington, DC USA.
[Karlin, Bradley E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Trockel, Mickey; Gordienko, Maria; Yesavage, Jerome; Taylor, C. Barr] Stanford Univ, Med Ctr, Dept Psychiat, Palo Alto, CA 94304 USA.
[Trockel, Mickey; Gordienko, Maria; Yesavage, Jerome; Taylor, C. Barr] Vet Affairs Palo Alto Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 21, Palo Alto, CA 94304 USA.
[Brown, Gregory K.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA.
[Brown, Gregory K.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Karlin, BE (reprint author), VA Cent Off, Mental Hlth Serv 10P4M, 810 Vermont Ave NW, Washington, DC 20420 USA.
EM Bradley.Karlin2@va.gov
FU Mental Health Services, U. S. Department of Veterans Affairs (VA)
Central Office
FX This project was supported by Mental Health Services, U. S. Department
of Veterans Affairs (VA) Central Office.
NR 71
TC 2
Z9 2
U1 2
U2 18
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5014
EI 1758-5368
J9 J GERONTOL B-PSYCHOL
JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci.
PD JAN
PY 2015
VL 70
IS 1
BP 3
EP 12
DI 10.1093/geronb/gbt096
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology,
Multidisciplinary
SC Geriatrics & Gerontology; Psychology
GA CC0QA
UT WOS:000350039400002
PM 24218096
ER
PT J
AU Phipps, C
Gopal, AK
Storer, BE
Cassaday, RD
Press, OW
Till, BG
Pagel, JM
Palanca-Wessels, MC
Philip, M
Bensinger, WI
Holmberg, LA
Shustov, AR
Green, DJ
Chauncey, T
Maloney, DG
Libby, EN
AF Phipps, Colin
Gopal, Ajay K.
Storer, Barry E.
Cassaday, Ryan D.
Press, Oliver W.
Till, Brian G.
Pagel, John M.
Palanca-Wessels, Maria C.
Philip, Mary
Bensinger, William I.
Holmberg, Leona A.
Shustov, Andrei R.
Green, Damian J.
Chauncey, Thomas
Maloney, David G.
Libby, Edward N., III
TI Autologous transplant for relapsed follicular lymphoma: impact of
pre-transplant rituximab sensitivity
SO LEUKEMIA & LYMPHOMA
LA English
DT Article
DE Follicular lymphoma; autologous transplant; rituximab-refractory
ID STEM-CELL TRANSPLANTATION; INTERNATIONAL PROGNOSTIC INDEX;
NON-HODGKIN-LYMPHOMA; EVENT-FREE SURVIVAL; MARROW-TRANSPLANTATION;
THERAPY; EXPRESSION; RESISTANCE; BENDAMUSTINE; CHEMOTHERAPY
AB Patients with rituximab-refractory follicular lymphoma (FL) have limited options. Before the rituximab era, autologous stem cell transplant (ASCT) was shown to improve outcomes in chemotherapy-sensitive, relapsed FL, but the impact of rituximab-sensitivity on these results is unknown. We analyzed 194 consecutive relapsed patients with FL who underwent ASCT at out center and categorized them as rituximab-sensitive (RS, n = 35), rituximab-refractory (RR, n = 65) or no rituximab (NoR, n = 94) if transplanted before rituximab was used. Progression-free survival at 3 years was 85% in RS and 35% in RR patients (p = 0.0004). Only rituximab-sensitivity was significant on multivariate analysis with improved overall survival (OS) (hazard ratio [HR] 0.24, p = 0.01) and progression-free survival (PFS) (HR 0.35, p = 0.006) in RS patients and increased relapse in RR patients (HR 2.11, p = 0.01). Pre-transplant rituximab-sensitivity is a strong independent predictor of post-transplant outcomes in relapsed FL, although one-third of RR patients achieved a PFS of over 3 years with ASCT.
C1 [Phipps, Colin; Gopal, Ajay K.; Storer, Barry E.; Cassaday, Ryan D.; Press, Oliver W.; Till, Brian G.; Pagel, John M.; Palanca-Wessels, Maria C.; Philip, Mary; Bensinger, William I.; Holmberg, Leona A.; Shustov, Andrei R.; Green, Damian J.; Chauncey, Thomas; Maloney, David G.; Libby, Edward N., III] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA.
[Phipps, Colin] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore.
[Gopal, Ajay K.; Press, Oliver W.; Till, Brian G.; Pagel, John M.; Palanca-Wessels, Maria C.; Philip, Mary; Bensinger, William I.; Holmberg, Leona A.; Shustov, Andrei R.; Green, Damian J.; Chauncey, Thomas; Maloney, David G.; Libby, Edward N., III] Univ Washington, Sch Med, Seattle, WA USA.
[Storer, Barry E.] Univ Washington, Sch Publ Hlth & Biostat, Seattle, WA USA.
[Chauncey, Thomas] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Phipps, C (reprint author), Seattle Canc Care Alliance, 825 Eastlake Ave East, Seattle, WA 98109 USA.
EM phipps_8@msn.com
FU NIH [PO1CA44991]; Mary A. Wright Memorial Research Fund
FX This study received funding from NIH PO1CA44991, the Mary A. Wright
Memorial Research Fund and a donation from Frank and Betty Vandermeer.
A.K.G. is a Scholar in Clinical Research of the Leukemia and Lymphoma
Society. The authors also thank members of the research and clinical
staff at the Seattle Cancer Care Alliance, and referring physicians for
their contribution to the care of our patients.
NR 23
TC 0
Z9 0
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD JAN
PY 2015
VL 56
IS 1
BP 92
EP 96
DI 10.3109/10428194.2014.911866
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA CB5IR
UT WOS:000349661200016
PM 24707941
ER
PT J
AU Hui, T
Sorensen, ES
Rittling, SR
AF Hui, Tommy
Sorensen, Esben S.
Rittling, Susan R.
TI Osteopontin binding to the alpha 4 integrin requires highest affinity
integrin conformation, but is independent of post-translational
modifications of osteopontin
SO MATRIX BIOLOGY
LA English
DT Article
DE Osteopontin; Adhesion; Integrin Alpha4; VLA-4; Phosphorylation; VCAM
ID REAL-TIME ANALYSIS; CELL-ADHESION; ALPHA(4)BETA(1) INTEGRIN;
ALPHA-4-BETA-1; LIGAND; INFLAMMATION; ACTIVATION; RECEPTOR; SITES
AB Osteopontin (OPN) is a ligand for the alpha 4 beta 1 integrin, but the physiological importance of this binding is not well understood. Here, we have assessed the effect of post-translational modifications on OPN binding to the alpha 4 integrin on cultured human leukocyte cell lines and compared OPN interaction with alpha 4 integrin to that of VCAM and fibronectin. Jurkat cells, whose alpha 4 integrins are inherently activated, adhered to different preparations of OPN in the presence of Mn2+: the EC50 of adhesion was not affected by phosphorylation or glycosylation status. Thrombin cleavage of OPN at the C-terminus of the alpha 4 integrin-binding site also did not affect binding affinity. THP-1 cells express a low-affinity conformation of the integrin and adhered to OPN only in the presence of Mn2+ plus PMA or an activating antibody. This was in contrast to VCAM and fibronectin: THP-1 cells adhered to these ligands without integrin activation. Studies with ligand-induced binding site antibodies demonstrated that the SVVYGLR peptide of OPN bound to the alpha 4 integrin with a similar affinity as the LDV peptide of fibronectin, suggesting that a high off-rate is responsible for the reduced binding of OPN to the low-affinity forms of this integrin. Together, the results suggest OPN has very low affinity for the alpha 4 integrin on human leukocytes under physiological conditions. (C) 2014 The Authors. Published by Elsevier B.V.
C1 [Hui, Tommy; Rittling, Susan R.] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA 02115 USA.
[Sorensen, Esben S.] Aarhus Univ, Dept Mol Biol & Genet, Aarhus, Denmark.
[Rittling, Susan R.] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
RP Rittling, SR (reprint author), Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA 02115 USA.
EM srittling@forsyth.org
FU NIDCR of the NIH [RO1DE022380]
FX The authors thank Dr. Toshimitsu Uede for the kind gift of the RAA OPN
construct, Dr. Aritsune Matsui for help with the FACS analysis, Dr.
Toshi Kawai for the gift of Jurkat cells, and Dr. Markus Hardt for mass
spectrometry. Research reported in this publication was supported by the
NIDCR of the NIH under award no. RO1DE022380. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.
NR 30
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0945-053X
EI 1569-1802
J9 MATRIX BIOL
JI Matrix Biol.
PD JAN
PY 2015
VL 41
BP 19
EP 25
DI 10.1016/j.matbio.2014.11.005
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CB8LZ
UT WOS:000349882400004
PM 25446551
ER
PT B
AU Walker, RH
AF Walker, Ruth H.
BE LeDoux, MS
TI Genetics of Huntington Disease (HD), HD-Like Disorders, and Other
Choreiform Disorders
SO MOVEMENT DISORDERS: GENETICS AND MODELS, 2ND EDITION
LA English
DT Article; Book Chapter
ID BENIGN HEREDITARY CHOREA; AGE-OF-ONSET; CAG REPEAT LENGTH; PAROXYSMAL
KINESIGENIC DYSKINESIA; MCLEOD-SYNDROME; TRINUCLEOTIDE REPEAT; INFANTILE
CONVULSIONS; CLINICAL PROGRESSION; HEMIPLEGIC MIGRAINE; JAPANESE FAMILY
C1 [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA.
RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
NR 132
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-405516-2; 978-0-12-405195-9
PY 2015
BP 519
EP 532
DI 10.1016/B978-0-12-405195-9.00030-5
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA BB9KO
UT WOS:000348389700032
ER
PT B
AU Handforth, A
AF Handforth, Adrian
BE LeDoux, MS
TI Use of the Harmaline and alpha 1 Knockout Models to Identify Molecular
Targets for Essential Tremor
SO MOVEMENT DISORDERS: GENETICS AND MODELS, 2ND EDITION
LA English
DT Article; Book Chapter
ID INFERIOR OLIVARY NEURONS; DRUG-INDUCED TREMOR; OPEN-LABEL TRIAL;
CEREBELLAR CLIMBING FIBERS; GABA(A) RECEPTOR SUBTYPES; CALCIUM-CHANNEL
BLOCKERS; PLACEBO-CONTROLLED TRIAL; COMPLEX SPIKE ACTIVITY; RAT SENSORY
NEURONS; OLIVOCEREBELLAR SYSTEM
C1 Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA.
RP Handforth, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA.
NR 150
TC 1
Z9 1
U1 0
U2 1
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-405516-2; 978-0-12-405195-9
PY 2015
BP 615
EP 629
DI 10.1016/B978-0-12-405195-9.00037-8
PG 15
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA BB9KO
UT WOS:000348389700039
ER
PT B
AU Daneshvar, DH
McKee, AC
AF Daneshvar, Daniel H.
McKee, Ann C.
BE Zigmond, MJ
Rowland, LP
Coyle, JT
TI Traumatic Brain Injury
SO NEUROBIOLOGY OF BRAIN DISORDERS: BIOLOGICAL BASIS OF NEUROLOGICAL AND
PSYCHIATRIC DISORDERS
LA English
DT Article; Book Chapter
ID HEAD-INJURY; ALZHEIMERS-DISEASE; TAU; ENCEPHALOPATHY; DEMENTIA; BETA;
CONCUSSION; PATHOLOGY; FOOTBALL; PET
C1 [Daneshvar, Daniel H.; McKee, Ann C.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA.
[Daneshvar, Daniel H.; McKee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA.
[Daneshvar, Daniel H.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA.
[McKee, Ann C.] VA Boston HealthCare Syst, Boston, MA USA.
RP Daneshvar, DH (reprint author), Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA.
NR 54
TC 0
Z9 0
U1 1
U2 6
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND
BN 978-0-12-398280-3; 978-0-12-398270-4
PY 2015
BP 219
EP 235
DI 10.1016/B978-0-12-398270-4.00016-1
PG 17
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA BB9KQ
UT WOS:000348393900017
ER
PT J
AU Jain, D
Sheth, H
Green, JA
Bender, FH
Weisbord, SD
AF Jain, Deepika
Sheth, Heena
Green, Jamie A.
Bender, Filitsa H.
Weisbord, Steven D.
TI Health Literacy in Patients on Maintenance Peritoneal Dialysis:
Prevalence and Outcomes
SO PERITONEAL DIALYSIS INTERNATIONAL
LA English
DT Article
ID ASSOCIATIONS; HEMODIALYSIS; ADHERENCE; DISEASE
C1 [Jain, Deepika; Sheth, Heena; Bender, Filitsa H.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15260 USA.
[Green, Jamie A.] Geisinger Med Ctr, Dept Nephrol, Danville, PA 17822 USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Jain, D (reprint author), Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15260 USA.
EM 26.deepika@gmail.com
NR 14
TC 3
Z9 3
U1 0
U2 6
PU MULTIMED INC
PI TORONTO
PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA
SN 0896-8608
J9 PERITON DIALYSIS INT
JI Perit. Dial. Int.
PD JAN-FEB
PY 2015
VL 35
IS 1
DI 10.3747/pdi.2013.00211
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA CB9XM
UT WOS:000349987600017
PM 25700462
ER
PT J
AU Shadel, WG
Elliott, MN
Haas, AC
Haviland, AM
Orr, N
Farmer, MM
Ma, S
Weech-Maldonado, R
Farley, DO
Cleary, PD
AF Shadel, William G.
Elliott, Marc N.
Haas, Ann C.
Haviland, Amelia M.
Orr, Nate
Farmer, Melissa M.
Ma, Sai
Weech-Maldonado, Robert
Farley, Donna O.
Cleary, Paul D.
TI Clinician advice to quit smoking among seniors
SO PREVENTIVE MEDICINE
LA English
DT Article
DE Physician/patient communication; Medicare; Patient education; Smoking
cessation
ID ALZHEIMER-DISEASE; TOBACCO MEASURES; HEALTH-CARE; CESSATION; SMOKERS;
OLDER; RISK; INTERVENTIONS; US; DISPARITIES
AB Objective. Little smoking research in the past 20 years includes persons 50 and older; herein we describe patterns of clinician cessation advice to US seniors, including variation by Medicare beneficiary characteristics.
Method. In 2012-4, we analyzed 2010 Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey data from Medicare beneficiaries over age 64 (n=346,674). We estimated smoking rates and the proportion of smokers whose clinicians encouraged cessation.
Results. 12% of male and 8% of female respondents aged 65 and older smoke. The rate decreases with age (14% of 65-69,3% of 85+) and education (12-15% with no high school degree, 5-6% with BA +). Rates are highest among American Indian/Alaskan Native (16%), multiracial (14%), and African-American (13%) seniors, and in the Southeast (14%). Only 51% of smokers say they receive cessation advice "always" or "usually" at doctor visits, with advice more often given to the young, those in low-smoking regions, Asians, and women. For all results cited p < 0.05.
Conclusions. Smoking cessation advice to seniors is variable. Providers may focus on groups or areas in which smoking is less common or when they are most comfortable giving advice. More consistent interventions are needed, including cessation advice from clinicians. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Shadel, William G.; Haas, Ann C.; Haviland, Amelia M.; Farley, Donna O.] RAND Corp, Pittsburgh, PA 15213 USA.
[Elliott, Marc N.; Orr, Nate] RAND Corp, Santa Monica, CA 90407 USA.
[Haviland, Amelia M.] Carnegie Mellon Univ, H John Heinz Coll 3, Pittsburgh, PA 15213 USA.
[Orr, Nate] Ctr Medicare & Medicaid Serv, Baltimore, MD 21244 USA.
[Weech-Maldonado, Robert] Univ Alabama Birmingham, Dept Hlth Serv Adm, Birmingham, AL 35294 USA.
[Farmer, Melissa M.] VA Greater Los Angeles Healthcare Syst, Vet Adm HSR&D Ctr Study Healthcare Innovat Implem, Sepulveda, CA 91343 USA.
[Cleary, Paul D.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA.
RP Elliott, MN (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.
EM shadel@rand.org; elliott@rand.org; ahaas@rand.org; haviland@cmu.edu;
orr@rand.org; Melissa.Farmer@va.gov; sai.ma@cms.hhs.gov; rweech@uab.edu;
farley@rand.org; paul.cleary@yale.edu
FU CMS [HHSM-500-2005-00028I]
FX This study was funded by CMS contract HHSM-500-2005-00028I to RAND.
NR 48
TC 5
Z9 5
U1 1
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
EI 1096-0260
J9 PREV MED
JI Prev. Med.
PD JAN
PY 2015
VL 70
BP 83
EP 89
DI 10.1016/j.ypmed.2014.11.020
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA CB9GB
UT WOS:000349938900016
PM 25482423
ER
PT J
AU Lauriol, J
Jaffre, F
Kontaridis, MI
AF Lauriol, Jessica
Jaffre, Fabrice
Kontaridis, Maria I.
TI The role of the protein tyrosine phosphatase SHP2 in cardiac development
and disease
SO SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE PTPN11; SHP2; Phosphatase; Cardiac development; Congenital heart
disease; Myocardium
ID CONGENITAL HEART-DISEASES; LEFT-RIGHT ASYMMETRY; NOONAN-SYNDROME;
LEOPARD-SYNDROME; VALVE DEVELOPMENT; SIGNALING PATHWAY; EMBRYONIC HEART;
CELL-MIGRATION; NUCLEAR-FACTOR; NEURAL CREST
AB Congenital heart disease is the most common human developmental disorder, affecting similar to 1:100 newborns, and is the primary cause of birth-defect related deaths worldwide. As a major regulator of receptor tyrosine kinase (RTK), cytokine and G-protein coupled receptor signaling, the non-receptor protein tyrosine phosphatase SHP2 plays a critical role in normal cardiac development and function. Indeed, SHP2 participates in a wide variety of cellular functions, including proliferation, survival, differentiation, migration, and cell-cell communication. Moreover, human activating and inactivating mutations of SHP2 are responsible for two related developmental disorders called Noonan and LEOPARD Syndromes, respectively, which are both characterized, in part, by congenital heart defects. Structural, enzymologic, biochemical, and SHP2 mouse model studies have together greatly enriched our knowledge of SHP2 and, as such, have also uncovered the diverse roles for SHP2 in cardiac development, including its contribution to progenitor cell specification, cardiac morphogenesis, and maturation of cardiac valves and myocardial chambers. By delineating the precise mechanisms by which SHP2 is involved in regulating these processes, we can begin to better understand the pathogenesis of cardiac disease and find more strategic and effective therapies for treatment of patients with congenital heart disorders. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Lauriol, Jessica; Jaffre, Fabrice; Kontaridis, Maria I.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Kontaridis, Maria I.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
RP Kontaridis, MI (reprint author), BIDMC, Div Cardiol, Dept Med, Ctr Life Sci, Room 908,3 Blackfan Circle, Boston, MA 02115 USA.
EM mkontari@bidmc.harvard.edu
OI Kontaridis, Maria/0000-0002-6121-0533
FU National Institutes of Health [R01-HL102368, R01-HL114775]; Children's
Cardiomyopathy Foundation Grant; Harvard Stem Cell Institute Seed Grant;
American Heart Association Postdoctoral Fellowship; Beth Israel
Deaconess Medical Center Division of Cardiology
FX This work was supported by National Institutes of Health Grants
R01-HL102368 and R01-HL114775 to M.I.K., Children's Cardiomyopathy
Foundation Grant to M.I.K., the Harvard Stem Cell Institute Seed Grant
to M.I.K., and by an American Heart Association Postdoctoral Fellowship
to J.L. This work was also supported in part by the Beth Israel
Deaconess Medical Center Division of Cardiology.
NR 85
TC 3
Z9 3
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1084-9521
J9 SEMIN CELL DEV BIOL
JI Semin. Cell Dev. Biol.
PD JAN
PY 2015
VL 37
BP 73
EP 81
DI 10.1016/j.semcdb.2014.09.013
PG 9
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA CC2ES
UT WOS:000350158600011
PM 25256404
ER
PT J
AU Kveraga, K
Boshyan, J
Adams, RB
Mote, J
Betz, N
Ward, N
Hadjikhani, N
Bar, M
Barrett, LF
AF Kveraga, Kestutis
Boshyan, Jasmine
Adams, Reginald B., Jr.
Mote, Jasmine
Betz, Nicole
Ward, Noreen
Hadjikhani, Nouchine
Bar, Moshe
Barrett, Lisa F.
TI If it bleeds, it leads: separating threat from mere negativity
SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE
LA English
DT Article
DE affect; emotion; scenes; fMRI; valence; arousal
ID MIDBRAIN PERIAQUEDUCTAL GRAY; AMINO-ACID MICROINJECTION; PARAHIPPOCAMPAL
CORTEX; CONTEXTUAL ASSOCIATIONS; PREFRONTAL CORTEX; MACAQUE MONKEYS;
HUMAN AMYGDALA; RHESUS-MONKEY; EMOTION; BRAIN
AB Most theories of emotion hold that negative stimuli are threatening and aversive. Yet in everyday experiences some negative sights (e.g. car wrecks) attract curiosity, whereas others repel (e.g. a weapon pointed in our face). To examine the diversity in negative stimuli, we employed four classes of visual images (Direct Threat, Indirect Threat, Merely Negative and Neutral) in a set of behavioral and functional magnetic resonance imaging studies. Participants reliably discriminated between the images, evaluating Direct Threat stimuli most quickly, and Merely Negative images most slowly. Threat images evoked greater and earlier blood oxygen level-dependent (BOLD) activations in the amygdala and periaqueductal gray, structures implicated in representing and responding to the motivational salience of stimuli. Conversely, the Merely Negative images evoked larger BOLD signal in the para-hippocampal, retrosplenial, and medial prefrontal cortices, regions which have been implicated in contextual association processing. Ventrolateral as well as medial and lateral orbitofrontal cortices were activated by both threatening and Merely Negative images. In conclusion, negative visual stimuli can repel or attract scrutiny depending on their current threat potential, which is assessed by dynamic shifts in large-scale brain network activity.
C1 [Kveraga, Kestutis; Boshyan, Jasmine; Ward, Noreen; Hadjikhani, Nouchine; Bar, Moshe; Barrett, Lisa F.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Kveraga, Kestutis; Hadjikhani, Nouchine; Bar, Moshe] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02215 USA.
[Boshyan, Jasmine] Brandeis Univ, Dept Psychol, Waltham, MA 02453 USA.
[Adams, Reginald B., Jr.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.
[Mote, Jasmine] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA.
[Betz, Nicole; Barrett, Lisa F.] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.
[Bar, Moshe; Barrett, Lisa F.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
[Bar, Moshe] Bar Ilan Univ, Gonda Multidisciplinary Brain Res Ctr, IL-5290002 Ramat Gan, Israel.
RP Kveraga, K (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Radiol, Room 2301, Charlestown, MA 02129 USA.
EM kestas@nmr.mgh.harvard.edu
OI Hadjikhani, Nouchine/0000-0003-4075-3106
FU NIMH NIH HHS [K01 MH084011]
NR 66
TC 3
Z9 3
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1749-5016
EI 1749-5024
J9 SOC COGN AFFECT NEUR
JI Soc. Cogn. Affect. Neurosci.
PD JAN
PY 2015
VL 10
IS 1
BP 28
EP 35
DI 10.1093/scan/nsu007
PG 8
WC Neurosciences; Psychology; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA CC1NT
UT WOS:000350108600005
PM 24493851
ER
PT J
AU Jash, S
Adhya, S
AF Jash, Sukanta
Adhya, Samit
TI Effects of Transient Hypoxia versus Prolonged Hypoxia on Satellite Cell
Proliferation and Differentiation In Vivo
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID MUSCLE REGENERATION; ADULT MYOGENESIS; OXYGEN; NOTCH; MICE;
ANGIOGENESIS; TISSUE
AB The microenvironment of the injury site can have profound effects on wound healing. Muscle injury results in ischemia leading to short-term local hypoxia, but there are conflicting reports on the role of hypoxia on the myogenic program in vivo and in vitro. In our rat model of mitochondrial restoration (MR), temporary upregulation of mitochondrial activity by a cocktail of organelle-encoded RNAs results in satellite cell proliferation and initiation of myogenesis. We now report that MR leads to a transient hypoxic response in situ. Inhibition of hypoxia by lowering mitochondrial O-2 consumption, either by respiratory electron transport inhibitors, or by NO-mediated inhibition of O-2 binding to cytochrome c oxidase, resulted in exacerbation of inflammation. Lentivirus-mediated knockdown of hypoxia-inducible factor 1 alpha(HIF1 alpha) or of Notch signaling components had a similar effect, and pharmacologic inhibition of HIF orNotch reduced the number of proliferating Pax(7+) cells. In contrast, a prolonged hypoxic response induced either by uncoupling of respiration from oxidative phosphorylation or through HIF stabilization by dimethyloxalylglycine (DMOG) had an immediate anti-inflammatory effect. Although significant satellite cell proliferation occurred in presence of DMOG, expression of differentiation markers was affected. These results emphasize the importance of transient hypoxia as opposed to prolonged hypoxia for myogenesis.
C1 [Jash, Sukanta; Adhya, Samit] CSIR, Indian Inst Chem Biol, Mol & Human Genet Div, Kolkata 700032, India.
[Jash, Sukanta] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
RP Adhya, S (reprint author), CSIR, Indian Inst Chem Biol, Mol & Human Genet Div, 4 Raja SC Mullick Rd, Kolkata 700032, India.
EM nilugrandson@gmail.com
FU CSIR; Council of Scientific and Industrial Research
FX This work is supported by the CSIR Suprainstitutional Project BeND.
Sukanta Jash received a Senior Research Fellowship from the Council of
Scientific and Industrial Research.
NR 24
TC 1
Z9 1
U1 0
U2 6
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1687-966X
EI 1687-9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2015
AR 961307
DI 10.1155/2015/961307
PG 9
WC Cell & Tissue Engineering
SC Cell Biology
GA CC9CV
UT WOS:000350666200001
ER
PT J
AU Shamran, HA
Kadhim, HS
Hussain, AR
Kareem, A
Taub, DD
Price, RL
Nagarkatti, M
Nagarkatti, PS
Singh, UP
AF Shamran, Haidar A.
Kadhim, Haider S.
Hussain, Aws R.
Kareem, Abdulameer
Taub, Dennis D.
Price, Robert L.
Nagarkatti, Mitzi
Nagarkatti, Prakash S.
Singh, Udai P.
TI Detection of Human Cytomegalovirus in Different Histopathological Types
of Glioma in Iraqi Patients
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; HUMAN BRAIN-TUMORS; CELL-TO-CELL;
GLYCOPROTEIN-B; GLIOBLASTOMA; EXPRESSION; INFECTION; FUSION;
ASSOCIATION; THERAPY
AB Human Cytomegalovirus (HCMV) is an endemic herpes virus that reemerges in cancer patients enhancing oncogenic potential. HCMV infection is associated with certain types of cancer morbidity such as glioblastomas. HCMV, like all other herpes viruses, has the ability to remain latent within the body of the host and can contribute in chronic inflammation. To determine the role of HCMV in glioma pathogenesis, paraffin-embedded blocks from glioma patients (n = 50) and from benign meningioma patients (n = 30) were obtained and evaluated by immunohistochemistry and polymerase chain reaction for the evidence of HCMV antigen expression and the presence of viral DNA. We detected HCMV antigen and DNA for IEI-72, pp65, and late antigen in 33/36, 28/36, and 26/36 in glioblastoma multiforme patients whereas 12/14, 10/14, and 9/14 in anaplastic astrocytoma patients, respectively. Furthermore, 84% of glioma patients were positive for immunoglobulin G (IgG) compared to 72.5% among control samples (P = 0.04). These data indicate the presence of the HCMV virus in a high percentage of glioma samples demonstrating distinct histopathological grades and support previous reports showing the presence of HCMV infection in glioma tissue. These studies demonstrate that detection of low-levels of latent viral infections may play an active role in glioma development and pathogenesis.
C1 [Shamran, Haidar A.] Univ Al Nahrain, Sch Med, Med Res Unit, Baghdad 10066, Iraq.
[Kadhim, Haider S.] Univ Al Nahrain, Sch Med, Dept Microbiol, Baghdad 10066, Iraq.
[Hussain, Aws R.] Univ Al Qadisiya, Sch Med, Dept Pathol, Dewaniya 58011, Iraq.
[Kareem, Abdulameer] Univ Al Qadisiya, Sch Nursing, Dept Med Sci, Dewaniya 58011, Iraq.
[Taub, Dennis D.] US Dept Vet Affairs, Ctr Translat Studies, VA Med Ctr, Med Serv, Washington, DC 20422 USA.
[Price, Robert L.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC 29208 USA.
[Nagarkatti, Mitzi; Nagarkatti, Prakash S.; Singh, Udai P.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
RP Singh, UP (reprint author), Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
EM udai.singh@uscmed.sc.edu
OI Kadhim, Haider/0000-0003-4561-5669; Nagarkatti,
Mitzi/0000-0002-5977-5615
NR 37
TC 0
Z9 0
U1 0
U2 2
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 642652
DI 10.1155/2015/642652
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CB5WN
UT WOS:000349698700001
ER
PT J
AU Fishman, JA
AF Fishman, Jay A.
TI Immune Reconstitution Syndrome: How Do We "Tolerate" Our Microbiome?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
DE immune reconstitution; regulatory T lymphocytes; immunopathogenesis;
Cryptococcus neoformans; meningitis
ID REGULATORY T-CELLS; NERVOUS-SYSTEM CRYPTOCOCCOSIS; ACTIVE ANTIRETROVIRAL
THERAPY; ORGAN TRANSPLANT RECIPIENTS; INFLAMMATORY SYNDROME; DISEASE;
NEOFORMANS; HIV; CALCINEURIN; INFECTION
C1 [Fishman, Jay A.] Massachusetts Gen Hosp, Div Infect Dis, Transplant Infect Dis & Immunocompromised Host Pr, Boston, MA 02114 USA.
[Fishman, Jay A.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
[Fishman, Jay A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Fishman, JA (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,WH510A, Boston, MA 02114 USA.
EM jfishman@mgh.harvard.edu
NR 40
TC 1
Z9 1
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 1
PY 2015
VL 60
IS 1
BP 45
EP 47
DI 10.1093/cid/ciu717
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CB5LJ
UT WOS:000349668300009
PM 25210022
ER
PT J
AU Kadri, SS
Hohmann, SF
Orav, EJ
Bonne, SL
Moffa, MA
Timpone, JG
Strich, JR
Palmore, T
Christopher, KB
Varughese, C
Hooper, DC
Danner, RL
AF Kadri, Sameer S.
Hohmann, Samuel F.
Orav, E. John
Bonne, Stephanie L.
Moffa, Matthew A.
Timpone, Joseph G.
Strich, Jeffrey R.
Palmore, Tara
Christopher, Kenneth B.
Varughese, Christy
Hooper, David C.
Danner, Robert L.
TI Tracking Colistin-Treated Patients to Monitor the Incidence and Outcome
of Carbapenem-Resistant Gram-Negative Infections
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE colistin; carbapenem resistance; gram-negative infection; extensively
drug resistant; surveillance
ID BLOOD-STREAM INFECTIONS; CRITICALLY-ILL PATIENTS; PSEUDOMONAS-AERUGINOSA
COLONIZATION; CYSTIC-FIBROSIS; ANTIMICROBIAL THERAPY;
BACTERIAL-INFECTIONS; SEVERE SEPSIS; EPIDEMIOLOGY; MORTALITY;
ENTEROBACTERIACEAE
AB Background. Existing surveillance mechanisms may underestimate the incidence of carbapenem-resistant gram-negative infections (CRGNIs). Although carbapenem resistance increases the risk of death, the trend in mortality over time is unknown.
Methods. A retrospective cohort study was conducted at 40 academic medical centers using a discharge database to identify adult hospital admissions without cystic fibrosis in 2006-2012 and received intravenous colistin for >3 consecutive days or died during therapy (termed colistin cases). The primary outcomes were the number of colistin cases per 100 000 admissions per year and change in the hospital mortality rate over time compared with the rate of discharges to home. Secondary outcomes included median overall and intensive care unit lengths of stay.
Results. From 2006 to 2012, a total of 5011 unique patients were identified as colistin cases. The number per 100 000 admissions per year increased from 35.56 to 92.98 during the 7-year study (P < .001). The odds of in-hospital death among colistin cases (compared with discharge to home) decreased by a mean of 5.2%/y (P = .04), whereas discharge to an institution (P = .24) or hospice (P = .89) remained steady over time. The median overall and intensive care unit lengths of stay decreased by 7.5 and 6 days, respectively (P < .001). In a 4-hospital chart review, 81.6% of colistin cases were found to have culture-positive CRGNIs. Conversely, 53% of extensively drug-resistant bloodstream CRGNIs at 2 of these hospitals met colistin case criteria.
Conclusions. Colistin cases represent a severely ill population with a high probability of having culture-confirmed CRGNIs. Colistin tracking is a novel strategy for monitoring the incidence and mortality of CRGNIs, particularly those caused by extensively drug-resistant bacteria. Although the incidence of colistin cases nearly tripled within 7 years, more of these patients are surviving hospitalization and going home.
C1 [Kadri, Sameer S.; Danner, Robert L.] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA.
[Palmore, Tara] NIH, Hosp Epidemiol Serv, Ctr Clin, Bethesda, MD 20892 USA.
[Kadri, Sameer S.; Hooper, David C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Varughese, Christy] Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA.
[Orav, E. John] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Christopher, Kenneth B.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA.
[Hohmann, Samuel F.] Rush Univ, Univ HealthSyst Consortium, Chicago, IL 60612 USA.
[Hohmann, Samuel F.] Rush Univ, Dept Hlth Syst Management, Chicago, IL 60612 USA.
[Bonne, Stephanie L.] Barnes Jewish Hosp, Dept Gen Surg, St Louis, MO 63110 USA.
[Moffa, Matthew A.; Timpone, Joseph G.] Georgetown Univ Hosp, Div Infect Dis & Travel Med, Washington, DC 20007 USA.
[Strich, Jeffrey R.] Georgetown Univ Hosp, Dept Med, Washington, DC 20007 USA.
RP Kadri, SS (reprint author), NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr,Room 2C145, Bethesda, MD 20892 USA.
EM sameer.kadri@nih.gov
FU intramural National Institutes of Health funds
FX This work was supported by intramural National Institutes of Health
funds.
NR 38
TC 6
Z9 7
U1 2
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 1
PY 2015
VL 60
IS 1
BP 79
EP 87
DI 10.1093/cid/ciu741
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CB5LJ
UT WOS:000349668300014
PM 25246597
ER
PT J
AU Lyons, JL
Erkkinen, MG
Vodopivec, I
AF Lyons, Jennifer L.
Erkkinen, Michael G.
Vodopivec, Ivana
TI Cerebrospinal Fluid (1,3)-beta-D-Glucan in Isolated Candida Meningitis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
ID FUNGAL MENINGITIS; (1-3)-BETA-D-GLUCAN; INFECTIONS; DIAGNOSIS
C1 [Lyons, Jennifer L.; Erkkinen, Michael G.; Vodopivec, Ivana] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Lyons, Jennifer L.; Erkkinen, Michael G.; Vodopivec, Ivana] Harvard Univ, Sch Med, Boston, MA USA.
[Erkkinen, Michael G.; Vodopivec, Ivana] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Lyons, JL (reprint author), Brigham & Womens Hosp, Div Neurol Infect, Dept Neurol, 45 Francis St, Boston, MA 02115 USA.
EM jlyons5@partners.org
NR 4
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 1
PY 2015
VL 60
IS 1
BP 161
EP U3333
DI 10.1093/cid/ciu737
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CB5LJ
UT WOS:000349668300028
PM 25228700
ER
PT J
AU Limbago, BM
Pierce, VM
Lonsway, DR
Ferraro, MJ
AF Limbago, Brandi M.
Pierce, Virginia M.
Lonsway, David R.
Ferraro, Mary Jane
TI Elevated Staphylococcus Ceftriaxone MICs are an Etest Artifact
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Limbago, Brandi M.; Lonsway, David R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA.
[Pierce, Virginia M.; Ferraro, Mary Jane] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Pierce, Virginia M.; Ferraro, Mary Jane] Harvard Univ, Sch Med, Boston, MA USA.
RP Limbago, BM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS C-16, Atlanta, GA 30329 USA.
EM BBL7@cdc.gov
NR 5
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 1
PY 2015
VL 60
IS 1
BP 162
EP U4444
DI 10.1093/cid/ciu743
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CB5LJ
UT WOS:000349668300029
PM 25266286
ER
PT J
AU Deutsch, MB
Mendez, MF
Teng, E
AF Deutsch, Mariel B.
Mendez, Mario F.
Teng, Edmond
TI Interactions between Traumatic Brain Injury and Frontotemporal
Degeneration
SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
LA English
DT Article
DE Brain injuries; Frontotemporal degeneration; Frontotemporal dementia;
Frontotemporal lobar degeneration; Primary progressive aphasia;
Neuropsychological features in subjects with dementia
ID ENVIRONMENTAL RISK-FACTORS; MILD COGNITIVE IMPAIRMENT; DATA SET UDS;
HEAD-INJURY; FUNCTIONAL-ACTIVITIES; CLINICAL PHENOTYPE; LOBAR
DEGENERATION; ALZHEIMERS-DISEASE; SEMANTIC DEMENTIA; ENCEPHALOPATHY
AB Background/Aims: Prior work in smaller cohorts suggests that traumatic brain injury (TBI) may be a risk factor for frontotemporal degeneration (FTD). We sought to confirm and extend these results using the National Alzheimer's Coordinating Center Uniform Data Set. Methods: We compared the TBI prevalence between FTD subjects and matched normal controls. Indices of cognitive, behavioral, functional, and global dementia severity were compared between FTD subjects with and without prior TBI. Results: Remote TBI with extended loss of consciousness (TBI-ext) was more common in individuals with FTD than in controls (OR: 1.67; 95% CI: 1.004-2.778). With TBI-ext, less functional and global impairment was seen in the behavioral variant of FTD, but more behavioral pathology was seen in the semantic variant. Conclusion: TBI may increase the FTD risk and influence clinical symptomatology and severity in FTD sub-types. (C) 2014 S. Karger AG, Basel
C1 [Deutsch, Mariel B.; Mendez, Mario F.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol Sci, Los Angeles, CA 90095 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Deutsch, Mariel B.; Mendez, Mario F.; Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Deutsch, MB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mdeutsch@mednet.ucla.edu
OI Deutsch, Mariel/0000-0003-1228-8868
FU NIA [P50 AG16570, K08 AG34628, R01AG034499-05, U01 AG016976]; NIA
(American Federation for Aging Research); NIA (John A. Hartford
Foundation); NIA (Atlantic Philanthropies); NIA (Starr Foundation);
Alzheimer's Disease Research Centers of California; Sidell-Kagan
Foundation
FX This study was supported by the NIA (P50 AG16570 and K08 AG34628 to
E.T.; jointly sponsored by the NIA, the American Federation for Aging
Research, the John A. Hartford Foundation, the Atlantic Philanthropies,
the Starr Foundation, and an anonymous donor) and R01AG034499-05 (M. F.
M., principle investigator), the Alzheimer's Disease Research Centers of
California, and the Sidell-Kagan Foundation. The NACC database is funded
by the NIA (U01 AG016976).
NR 47
TC 3
Z9 3
U1 1
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1420-8008
EI 1421-9824
J9 DEMENT GERIATR COGN
JI Dement. Geriatr. Cogn. Disord.
PY 2015
VL 39
IS 3-4
BP 143
EP 153
DI 10.1159/000369787
PG 11
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA CB5UJ
UT WOS:000349692800003
PM 25531628
ER
PT J
AU Teng, E
Chow, N
Hwang, KS
Thompson, PM
Gylys, KH
Cole, GM
Jack, CR
Shaw, LM
Trojanowski, JQ
Soares, HD
Weiner, MW
Apostolova, LG
AF Teng, Edmond
Chow, Nicole
Hwang, Kristy S.
Thompson, Paul M.
Gylys, Karen H.
Cole, Gregory M.
Jack, Clifford R., Jr.
Shaw, Leslie M.
Trojanowski, John Q.
Soares, Holly D.
Weiner, Michael W.
Apostolova, Liana G.
CA Alzheimer's Dis Neuroimaging Initi
TI Low Plasma ApoE Levels Are Associated with Smaller Hippocampal Size in
the Alzheimer's Disease Neuroimaging Initiative Cohort
SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
LA English
DT Article
DE Alzheimer's disease; Mild cognitive impairment; Magnetic resonance
imaging; Hippocampus; Biomarkers; ADNI; Apolipoprotein E
ID MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E; BRAIN; GENOTYPE; MRI;
POLYMORPHISM; SEGMENTATION; BIOMARKERS; DEPOSITION; CLEARANCE
AB Apolipoprotein E (APOE) genotype is the strongest known genetic risk factor for sporadic Alzheimer's disease (AD), but the utility of plasma ApoE levels for assessing the severity of underlying neurodegenerative changes remains uncertain. Here, we examined cross-sectional associations between plasma ApoE levels and volumetric magnetic resonance imaging indices of the hippocampus from 541 participants [57 with normal cognition (NC), 375 with mild cognitive impairment (MCI), and 109 with mild AD] who were enrolled in the Alzheimer's Disease Neuroimaging Initiative. Across the NC and MCI groups, lower plasma ApoE levels were significantly correlated with smaller hippocampal size, as measured by either hippocampal volume or hippocampal radial distance. These associations were driven primarily by findings from carriers of an APOE epsilon 4 allele and are consistent with prior reports that lower plasma ApoE levels correlate with greater global cortical Pittsburgh Compound B retention. In this high-risk group, plasma ApoE levels may represent a peripheral marker of underlying AD neuropathology in nondemented elderly individuals. (C) 2014 S. Karger AG, Basel
C1 [Teng, Edmond; Chow, Nicole; Hwang, Kristy S.; Thompson, Paul M.; Cole, Gregory M.; Apostolova, Liana G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Chow, Nicole; Hwang, Kristy S.; Thompson, Paul M.; Apostolova, Liana G.] Univ Calif Los Angeles, Lab Neuro Imaging, Imaging Genet Ctr, Los Angeles, CA USA.
[Thompson, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst, Los Angeles, CA 90095 USA.
[Gylys, Karen H.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[Teng, Edmond; Cole, Gregory M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Jack, Clifford R., Jr.] Mayo Clin, Dept Diagnost Radiol, Rochester, MN USA.
[Shaw, Leslie M.; Trojanowski, John Q.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Soares, Holly D.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Weiner, Michael W.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
RP Teng, E (reprint author), West Los Angeles Vet Affairs Healthcare Ctr, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM eteng@ucla.edu
RI Jack, Clifford/F-2508-2010
OI Jack, Clifford/0000-0001-7916-622X
FU ADNI; National Institute on Aging [U01 AG024904]; National Institute of
Biomedical Imaging and Bioengineering; NIH [K01 AG030514, K08 AG34628,
R01 MH097268, R01 AG040060, R01 AG040770, P50 AG16570]; Easton
Consortium for Alzheimer's Drug Discovery and Biomarker Development
FX Data collection and sharing for this project was funded by ADNI, which
is supported by the National Institute on Aging (U01 AG024904), the
National Institute of Biomedical Imaging and Bioengineering, and
contributions from: Abbott; Alzheimer's Association; Alzheimer's Drug
Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer
HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb
Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company;
F. Hoffmann-La Roche Ltd./Genentech, Inc.; GE Healthcare; Innogenetics,
N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research and
Development, LLC.; Johnson & Johnson Pharmaceutical Research and
Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale
Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.;
Servier; Synarc Inc., and Takeda Pharmaceutical Company. Private sector
contributions are facilitated by the Foundation for the National
Institutes of Health (www.fnih.org). The grantee organization is the
Northern California Institute for Research and Education, and the study
is coordinated by the Alzheimer's Disease Cooperative Study at the
University of California San Diego. ADNI data are disseminated by the
Laboratory for Neuro Imaging at the University of Southern California.
This research was also supported by NIH grants (K01 AG030514, K08
AG34628, R01 MH097268, R01 AG040060, R01 AG040770, P50 AG16570, and P30
AG010129) and the Easton Consortium for Alzheimer's Drug Discovery and
Biomarker Development.
NR 51
TC 7
Z9 8
U1 2
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1420-8008
EI 1421-9824
J9 DEMENT GERIATR COGN
JI Dement. Geriatr. Cogn. Disord.
PY 2015
VL 39
IS 3-4
BP 154
EP 166
DI 10.1159/000368982
PG 13
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA CB5UJ
UT WOS:000349692800004
PM 25547651
ER
PT J
AU Prokosch-Willing, V
Hoerste, MMZ
Mertsch, S
Stupp, T
Thanos, S
AF Prokosch-Willing, Verena
Hoerste, Melissa Meyer zu
Mertsch, Sonja
Stupp, Tobias
Thanos, Solon
TI Postnatal Visual Deprivation in Rats Regulates Several Retinal Genes and
Proteins, Including Differentiation-Associated Fibroblast Growth
Factor-2
SO DEVELOPMENTAL NEUROSCIENCE
LA English
DT Article
DE Visual deprivation; Amblyopia; Rat; Retina; Transcripts
ID OPTICAL COHERENCE TOMOGRAPHY; EARLY MONOCULAR DEPRIVATION; GANGLION-CELL
LAYER; MESSENGER-RNA; MULLER CELLS; ADULT-RATS; ENVIRONMENTAL
ENRICHMENT; SUPRACHIASMATIC NUCLEUS; UNILATERAL AMBLYOPIA; EXPRESSION
AB Little is known about the retinal cellular basis of amblyopia, which is a developmental disease characterized by impaired visual acuity. This study examined the retinal transcripts associated with experimentally induced unilateral amblyopia in rats. Surgical tarsorrhaphy of the eyelids on one side was performed in pups prior to eye opening at postnatal day 14, thereby preventing any visual experience. This condition was maintained for over 2 months, after which electroretino-grams (ERGs) were recorded, the retinal ganglion cell (RGC) arrangement and number were determined using neuroanatomical tracing, the retinal transcripts were studied using microarray analysis, regulated mRNAs were confirmed with quantitative reverse-transcriptase PCR, and proteins were stained using Western blotting and immunohistochemistry. An attenuated ERG was found in eyes that were deprived of visual experience. Retrograde neuroanatomical staining disclosed a larger number of RGCs within the retina on the visually deprived side compared to the non-deprived, control side, and a multilayered distribution of RGCs. At the retinomic level, several transcripts associated with retinal differentiation, such as fibroblast growth factor 2 (FGF-2), were either up-or downregulated. Most of the transcripts could be verified at the mRNA level. To unravel the role of a differentiation-associated protein, we tested FGF-2 in dissociated postnatal retinal cell cultures and found that FGF-2 is a potent factor triggering ganglion cell differentiation. The data suggest that visual experience shapes the postnatal retinal differentiation, whereas visual deprivation induces changes at the functional, cellular and molecular levels within the retina. (C) 2014 S. Karger AG, Basel
C1 [Prokosch-Willing, Verena; Mertsch, Sonja; Stupp, Tobias; Thanos, Solon] Univ Munster, Sch Med, Inst Expt Ophthalmol, DE-48149 Munster, Germany.
[Hoerste, Melissa Meyer zu] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
RP Thanos, S (reprint author), Univ Munster, Sch Med, Inst Expt Ophthalmol, Albert Schweitzer Campus 1,D15, DE-48149 Munster, Germany.
EM solon@uni-muenster.de
OI Mertsch, Sonja/0000-0001-8803-9150
NR 92
TC 2
Z9 2
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-5866
EI 1421-9859
J9 DEV NEUROSCI-BASEL
JI Dev. Neurosci.
PY 2015
VL 37
IS 1
BP 14
EP 28
DI 10.1159/000367651
PG 15
WC Developmental Biology; Neurosciences
SC Developmental Biology; Neurosciences & Neurology
GA CB5IK
UT WOS:000349660500002
PM 25402196
ER
PT J
AU Haley, KP
Gaddy, JA
AF Haley, Kathryn P.
Gaddy, Jennifer A.
TI Helicobacter pylori: Genomic Insight into the Host-Pathogen Interaction
SO INTERNATIONAL JOURNAL OF GENOMICS
LA English
DT Review
ID GASTRIC EPITHELIAL-CELLS; IV SECRETION SYSTEM; VACUOLATING TOXIN;
IRON-DEFICIENCY; INFECTION; VACA; CANCER; EAST; CARCINOGENESIS;
EXPRESSION
AB The advent of genomic analyses has revolutionized the study of human health. Infectious disease research in particular has experienced an explosion of bacterial genomic, transcriptomic, and proteomic data complementing the phenotypic methods employed in traditional bacteriology. Together, these techniques have revealed novel virulence determinants in numerous pathogens and have provided information for potential chemotherapeutics. The bacterial pathogen, Helicobacter pylori, has been recognized as a class 1 carcinogen and contributes to chronic inflammation within the gastric niche. Genomic analyses have uncovered remarkable coevolution between the human host and H. pylori. Perturbation of this coevolution results in dysregulation of the host-pathogen interaction, leading to oncogenic effects. This review discusses the relationship of H. pylori with the human host and environment and the contribution of each of these factors to disease progression, with an emphasis on features that have been illuminated by genomic tools.
C1 [Haley, Kathryn P.; Gaddy, Jennifer A.] Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA.
[Gaddy, Jennifer A.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.
RP Gaddy, JA (reprint author), Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA.
EM jennifer.a.gaddy@vanderbilt.edu
FU Office of Medical Research, Department of Veterans Affairs
[IK2BX001701]; NIH [P30DK058404]; National Center for Research Resources
[UL1 RR024975-01]; National Center for Advancing Translational Sciences
[2 UL1 TR000445-06]
FX This work has been funded primarily by a Career Development Award
IK2BX001701 (to Jennifer A. Gaddy) from the Office of Medical Research,
Department of Veterans Affairs. Core Services including use of the Cell
Imaging Shared Resource were performed through both Vanderbilt
University Medical Center's Digestive Disease Research Center supported
by NIH Grant P30DK058404 Core Scholarship and Vanderbilt Institute for
Clinical and Translational Research Program supported by the National
Center for Research Resources, Grant UL1 RR024975-01, and the National
Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06.
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIH.
NR 73
TC 7
Z9 7
U1 1
U2 13
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-436X
EI 2314-4378
J9 INT J GENOMICS
JI Int. J. Genomics
PY 2015
AR 386905
DI 10.1155/2015/386905
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
GA CB6ZS
UT WOS:000349776200001
ER
PT J
AU Claxton, A
Baker, LD
Hanson, A
Trittschuh, EH
Cholerton, B
Morgan, A
Callaghan, M
Arbuckle, M
Behl, C
Craft, S
AF Claxton, Amy
Baker, Laura D.
Hanson, Angela
Trittschuh, Emily H.
Cholerton, Brenna
Morgan, Amy
Callaghan, Maureen
Arbuckle, Matthew
Behl, Colin
Craft, Suzanne
TI Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults
with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease
Dementia
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; clinical trials; randomized; insulin; intranasal
drug administration; mild cognitive impairment
ID APOLIPOPROTEIN-E GENOTYPE; AMYLOID PRECURSOR PROTEIN; NPH INSULIN; BETA;
BRAIN; MEMORY; RESISTANCE; GLUCOSE; THERAPY; ALBUMIN
AB Previous trials have shown promising effects of intranasally administered insulin for adults with Alzheimer's disease dementia (AD) or amnestic mild cognitive impairment (MCI). These trials used regular insulin, which has a shorter half-life compared to long-lasting insulin analogues such as insulin detemir. The current trial examined whether intranasal insulin detemir improves cognition or daily functioning for adults with MCI or AD. Sixty adults diagnosed with MCI or mild to moderate AD received placebo (n = 20), 20 IU of insulin detemir (n = 21), or 40 IU of insulin detemir (n = 19) for 21 days, administered with a nasal drug delivery device. Results revealed a treatment effect for the memory composite for the 40 IU group compared with placebo (p < 0.05). This effect was moderated by APOE status (p < 0.05), reflecting improvement for APOE-epsilon 4 carriers (p < 0.02), and worsening for non-carriers (p < 0.02). Higher insulin resistance at baseline predicted greater improvement with the 40 IU dose (r = 0.54, p < 0.02). Significant treatment effects were also apparent for verbal working memory (p < 0.03) and visuospatial working memory (p < 0.04), reflecting improvement for subjects who received the high dose of intranasal insulin detemir. No significant differences were found for daily functioning or executive functioning. In conclusion, daily treatment with 40 IU insulin detemir modulated cognition for adults with AD or MCI, with APOE-related differences in treatment response for the primary memory composite. Future research is needed to examine the mechanistic basis of APOE-related treatment differences, and to further assess the efficacy and safety of intranasal insulin detemir.
C1 [Claxton, Amy; Hanson, Angela; Trittschuh, Emily H.; Morgan, Amy; Callaghan, Maureen; Behl, Colin] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Claxton, Amy; Hanson, Angela; Trittschuh, Emily H.; Cholerton, Brenna; Morgan, Amy; Callaghan, Maureen; Behl, Colin] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Baker, Laura D.; Craft, Suzanne] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA.
[Arbuckle, Matthew] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
RP Craft, S (reprint author), Wake Forest Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM suzcraft@wakehealth.edu
FU National Institute of Aging [P50 AG05136, T32 AG000258]; Department of
Veterans Affairs
FX Suzanne Craft and Amy Claxton had full access to all of the data in the
study and take responsibility for the integrity of the data and the
accuracy of the data analysis. This research was supported by National
Institute of Aging grants P50 AG05136 (to Dr. Craft) and T32 AG000258
(to Dr. Claxton), and the Department of Veterans Affairs.
NR 48
TC 47
Z9 48
U1 4
U2 24
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 44
IS 3
BP 897
EP 906
DI 10.3233/JAD-141791
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA CB4RQ
UT WOS:000349616000018
PM 25374101
ER
PT J
AU West, RK
Ravona-Springer, R
Heymann, A
Schmeidler, J
Leroith, D
Koifman, K
Guerrero-Berroa, E
Preiss, R
Hoffman, H
Silverman, JM
Beeri, MS
AF West, Rebecca K.
Ravona-Springer, Ramit
Heymann, Anthony
Schmeidler, James
Leroith, Derek
Koifman, Keren
Guerrero-Berroa, Elizabeth
Preiss, Rachel
Hoffman, Hadas
Silverman, Jeremy M.
Beeri, Michal Schnaider
TI Shorter Adult Height is Associated with Poorer Cognitive Performance in
Elderly Men with Type II Diabetes
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Cognitive performance; height; risk factors; type 2 diabetes mellitus;
vascular dementia
ID CORONARY-HEART-DISEASE; ALZHEIMERS-DISEASE; BODY HEIGHT; RISK-FACTORS;
LATE-LIFE; LEG LENGTH; DEMENTIA; CIRCUMFERENCE; EDUCATION; GROWTH
AB We studied the relationship of adult body height with five cognitive outcomes (executive functioning, semantic categorization, attention/working memory, episodic memory, and an overall cognition measure) in 897 cognitively normal elderly with type 2 diabetes. Regression analyses controlling for sociodemographic, cardiovascular, and diabetes-related risk factors and depression demonstrated that in males, shorter stature was associated with poorer executive functioning (p = 0.001), attention/working memory (p = 0.007), and overall cognition (p = 0.016), but not with episodic memory (p = 0.715) or semantic categorization (p = 0.948). No relationship between height and cognition was found for females. In cognitively normal type 2 diabetes male subjects, shorter stature, a surrogate for early-life stress and poor nutrition, was associated with cognitive functions.
C1 [West, Rebecca K.; Schmeidler, James; Guerrero-Berroa, Elizabeth; Silverman, Jeremy M.; Beeri, Michal Schnaider] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Ravona-Springer, Ramit; Koifman, Keren; Preiss, Rachel; Hoffman, Hadas; Beeri, Michal Schnaider] Sheba Med Ctr, Joseph Sagol Neurosci Ctr, Ramat Gan, Israel.
[Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Heymann, Anthony] Maccabi Healthcare Serv, Tel Aviv, Israel.
[Leroith, Derek] Icahn Sch Med Mt Sinai, Dept Med, Div Med Endocrinol Diabet & Bone Dis, New York, NY 10029 USA.
RP West, RK (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1230,One Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.
EM rebecca.west@mssm.edu
FU NIA [R01 AG034087, P50 AG05138]; Helen Bader Foundation; Leroy Schecter
Foundation; Irma T. Hirschl Scholar award; American Federation for Aging
Research (AFAR) Young Investigator award; Alzheimer's Association
[NIRG-11-205083]
FX This study was supported by NIA grants R01 AG034087 to Dr. Beeri and P50
AG05138 to Dr. Sano, the Helen Bader Foundation, the Leroy Schecter
Foundation, and the Irma T. Hirschl Scholar award to Dr. Beeri, the
American Federation for Aging Research (AFAR) Young Investigator award,
and the Alzheimer's Association grant NIRG-11-205083 to Dr.
Ravona-Springer.
NR 40
TC 2
Z9 2
U1 1
U2 4
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 44
IS 3
BP 927
EP 935
DI 10.3233/JAD-142049
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA CB4RQ
UT WOS:000349616000021
PM 25374105
ER
PT J
AU Saidi, LJ
Polydoro, M
Kay, KR
Sanchez, L
Mandelkow, EM
Hyman, BT
Spires-Jones, TL
AF Saidi, Laiq-Jan
Polydoro, Manuela
Kay, Kevin R.
Sanchez, Laura
Mandelkow, Eva-Maria
Hyman, Bradley T.
Spires-Jones, Tara L.
TI Carboxy Terminus Heat Shock Protein 70 Interacting Protein Reduces
Tau-Associated Degenerative Changes
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; caspase; CHIP; mitochondrial transport; tau protein
ID UBIQUITIN-PROTEASOME SYSTEM; ALZHEIMERS-DISEASE; PHOSPHORYLATED TAU;
AXONAL-TRANSPORT; 4-REPEAT TAU; MOUSE MODEL; IN-VIVO; ACCUMULATION;
AGGREGATION; DEGRADATION
AB One of the hallmarks of Alzheimer's disease is the formation of neurofibrillary tangles, intracellular aggregates of hyperphosphorylated, mislocalized tau protein, which are associated with neuronal loss. Changes in tau are known to impair cellular transport (including that of mitochondria) and are associated with cell death in cell culture and mouse models of tauopathy. Thus clearing pathological forms of tau from cells is a key therapeutic strategy. One critical modulator in the degradation and clearance of misfolded proteins is the co-chaperone CHIP (Carboxy terminus Hsp70 interacting Protein), which is known to play a role in refolding and clearance of hyperphosphorylated tau. Here, we tested the hypothesis that CHIP could ameliorate pathological changes associated with tau. We find that co-expressing CHIP with full-length tau, tau truncated at D421 mimicking caspase cleavage, or the short tau(RD)Delta K280 tau construct containing only the tau repeat domain with a tauopathy mutation, decreases tau protein levels in human H4 neuroglioma cells in a manner dependent on the Hsp70-binding TPR domain of CHIP. The observed reduction in tau levels by CHIP is associated with a decrease of tau phosphorylation and reduced levels of cleaved Caspase 3 indicating that CHIP plays an important role in preventing tau-induced pathological changes. Furthermore, tau-associated mitochondrial transport deficits are rescued by CHIP co-expression in H4 cells. Together, these data suggest that the co-chaperone CHIP can rescue the pathological effects of tau, and indicate that other diseases of protein misfolding and accumulation may also benefit from CHIP upregulation.
C1 [Saidi, Laiq-Jan; Polydoro, Manuela; Kay, Kevin R.; Sanchez, Laura; Hyman, Bradley T.; Spires-Jones, Tara L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA.
[Saidi, Laiq-Jan; Mandelkow, Eva-Maria] German Ctr Neurodegenerat Dis, DZNE, Bonn, Germany.
[Mandelkow, Eva-Maria] Caesar Res Ctr, Bonn, Germany.
[Mandelkow, Eva-Maria] Max Planck Inst Metab Res, Cologne, Germany.
[Spires-Jones, Tara L.] Univ Edinburgh, Ctr Cognit & Neural Syst, Edinburgh EH9 3EL, Midlothian, Scotland.
[Spires-Jones, Tara L.] Univ Edinburgh, Euan MacDonald Ctr, Edinburgh EH9 3EL, Midlothian, Scotland.
RP Spires-Jones, TL (reprint author), Univ Edinburgh, Coll Med & Vet Med, Sch Biomed Sci, Ctr Cognit & Neural Syst, 1 George Sq, Edinburgh EH9 3EL, Midlothian, Scotland.
EM Tara.spires-jones@ed.ac.uk
FU Alzheimer's Association Zenith Award; Alzheimer's Research UK/Chief
Scientist Office Scotland; German National Academic Foundation;
Foundation Family Klee Young Scientist Award; DZNE; Tau Consortium (USA)
FX This work was funded by The Alzheimer's Association Zenith Award,
Alzheimer's Research UK/Chief Scientist Office Scotland, German National
Academic Foundation, Foundation Family Klee Young Scientist Award, DZNE,
Tau Consortium (USA).
NR 34
TC 5
Z9 5
U1 0
U2 2
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 44
IS 3
BP 937
EP 947
DI 10.3233/JAD-142094
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA CB4RQ
UT WOS:000349616000022
PM 25374103
ER
PT J
AU Vaduganathan, M
Gheorghiade, M
AF Vaduganathan, Muthiah
Gheorghiade, Mihai
TI A roadmap to inpatient heart failure management
SO JOURNAL OF CARDIOLOGY
LA English
DT Review
DE Diuretics; Heart failure; Outcomes
ID OBSTRUCTIVE PULMONARY-DISEASE; REDUCED EJECTION FRACTION; CLINICAL
CHARACTERISTICS; EVEREST TRIAL; POSTDISCHARGE OUTCOMES; NONINVASIVE
VENTILATION; MEDICARE BENEFICIARIES; RENAL-FUNCTION; OPTIMIZE-HF;
OF-LIFE
AB Heart failure (HF) accounts for over 1 million primary hospitalizations in the USA each year and carries a tremendous burden on costs and patient outcomes. The clinical syndrome of HF is not a single disease, but represents the complex interplay between various cardiac and non-cardiac processes, each of which need to be individually addressed. This review provides an updated, contemporary roadmap for inpatient worsening chronic HF management with a focus on identifying and addressing initiating mechanisms, amplifying factors, and cardiac structural abnormalities. Inpatient risk stratification should guide patient education, team structuring, disposition, and post-discharge monitoring. (C) 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
C1 [Vaduganathan, Muthiah] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Gheorghiade, Mihai] Northwestern Univ, Ctr Cardiovasc Innovat, Feinberg Sch Med, Chicago, IL 60601 USA.
RP Gheorghiade, M (reprint author), Northwestern Univ, Ctr Cardiovasc Innovat, Feinberg Sch Med, 201 East Huron,Galter 3-150, Chicago, IL 60601 USA.
EM m-gheorghiade@northwestern.edu
NR 45
TC 0
Z9 0
U1 4
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0914-5087
EI 1876-4738
J9 J CARDIOL
JI J. Cardiol.
PD JAN-FEB
PY 2015
VL 65
IS 1-2
BP 26
EP 31
DI 10.1016/j.jjcc.2014.08.011
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CB4FI
UT WOS:000349583200005
PM 25238886
ER
PT S
AU Mendez-Ferrer, S
Scadden, DT
Sanchez-Aguilera, A
AF Mendez-Ferrer, Simon
Scadden, David T.
Sanchez-Aguilera, Abel
BE Zaidi, M
TI Bone marrow stem cells: current and emerging concepts
SO MARROW
SE Annals of the New York Academy of Sciences
LA English
DT Review; Book Chapter
DE mesenchymal stem/stromal cells; hematopoietic stem cells; bone marrow
stem cell niche; hierarchical crosstalk
ID HEMATOPOIETIC STEM; IN-VIVO; PROGENITOR CELLS; STROMAL CELLS; CD34
EXPRESSION; SELF-RENEWAL; NICHE; QUIESCENCE; MICE; DIFFERENTIATION
AB The interactions of stromal cells with hematopoietic cells in the bone marrow have long been a subject of research, but only recently have technologies allowed us to dissect them at the stem cell level. On the other hand, limitations of these technical tools might explain numerous discrepancies in this field. It is becoming increasingly clear that mesenchymal stem cells (MSCs) represent an important component of the hematopoietic stem cell (HSC) niche in the bone marrow. However, there is heterogeneity among HSCs, and many putatively different mesenchymal progenitors identified in the bone marrow using Cre recombinase-driven mouse lines seem to exhibit HSC niche properties. Development of better reporter lines has demonstrated that some of these Cre lines do not always specifically mark the expected cells. Also, characterization of different cell populations has often been partial, and issues of redundancy and compensation might explain apparently contradictory results. Recognizing and overcoming these limitations, while also clearly defining the distinctions between subgroups of mesenchymal cells, will be essential to advance the field.
C1 [Mendez-Ferrer, Simon; Sanchez-Aguilera, Abel] CNIC, Stem Cell Niche Pathophysiol Grp, Madrid, Spain.
[Scadden, David T.] Harvard Univ, Stem Cell & Regenerat Biol Dept, Cambridge, MA 02138 USA.
[Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA USA.
RP Mendez-Ferrer, S (reprint author), Natl Cardiovasc Res Ctr CNIC, Calle Melchor Fernandez Almagro 3,Planta 3 Sur, Madrid 28029, Spain.
EM smendez@cnic.es; abel.sanchez-aguilera@cnic.es
OI Mendez-Ferrer, Simon/0000-0002-9805-9988
FU Howard Hughes Medical Institute
NR 83
TC 17
Z9 17
U1 9
U2 23
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077-8923
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2015
VL 1335
BP 32
EP 44
DI 10.1111/nyas.12641
PG 13
WC Cell Biology
SC Cell Biology
GA BC0DA
UT WOS:000348920600004
PM 25573321
ER
PT J
AU Chu, Q
Moellering, RE
Hilinski, GJ
Kim, YW
Grossmann, TN
Yeh, JTH
Verdine, GL
AF Chu, Qian
Moellering, Raymond E.
Hilinski, Gerard J.
Kim, Young-Woo
Grossmann, Tom N.
Yeh, Johannes T. -H.
Verdine, Gregory L.
TI Towards understanding cell penetration by stapled peptides
SO MEDCHEMCOMM
LA English
DT Article
ID SUPERCHARGED PROTEINS; MECHANISMS; TAT; INTERNALIZATION; STABILIZATION;
THERAPEUTICS; TRANSDUCTION; ENDOCYTOSIS; INHIBITION; DELIVERY
AB Hydrocarbon-stapled a-helical peptides are a new class of targeting molecules capable of penetrating cells and engaging intracellular targets formerly considered intractable. This technology has been applied to the development of cell-permeable ligands targeting key intracellular protein-protein interactions. However, the properties governing cell penetration of hydrocarbon-stapled peptides have not yet been rigorously investigated. Herein we report our studies to systematically probe cellular uptake of stapled peptides. We developed a high-throughput epifluorescence microscopy assay to quantitatively measure stapled peptide intracellular accumulation and demonstrated that this assay yielded highly reproducible results. Using this assay, we analyzed more than 200 peptides with various sequences, staple positions and types, and found that cell penetration ability is strongly related to staple type and formal charge, whereas other physicochemical parameters do not appear to have a significant effect. We next investigated the mechanism(s) involved in stapled peptide internalization and have demonstrated that stapled peptides penetrate cells through a clathrin-and caveolin-independent endocytosis pathway that involves, in part, sulfated cell surface proteoglycans, but that also seems to exploit a novel, uncharacterized pathway. Taken together, staple type and charge are the key physical properties in determining the cell penetration ability of stapled peptides, and anionic cell surface proteoglycans might serve as receptors to mediate stapled peptide internalization. These findings improve our understanding of stapled peptides as chemical probes and potential targeted therapeutics, and provide useful guidelines for the design of next-generation stapled peptides with enhanced cell permeability.
C1 [Chu, Qian; Moellering, Raymond E.; Hilinski, Gerard J.; Kim, Young-Woo; Grossmann, Tom N.; Yeh, Johannes T. -H.; Verdine, Gregory L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Chu, Qian; Moellering, Raymond E.; Hilinski, Gerard J.; Kim, Young-Woo; Grossmann, Tom N.; Yeh, Johannes T. -H.; Verdine, Gregory L.] Harvard Univ, Cambridge, MA 02138 USA.
[Verdine, Gregory L.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA.
RP Verdine, GL (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, 12 Oxford St, Cambridge, MA 02138 USA.
EM gregory_verdine@harvard.edu
RI Grossmann, Tom/A-4175-2015
OI Grossmann, Tom/0000-0003-0179-4116
FU Deutsche Akademie der Naturforscher Leopoldina [LPDS 2009-2]; Susan G.
Komen for the Cure fellowship; AACR Centennial Pre-doctoral Research
Fellowship in Cancer Research; Damon Runyon Cancer Research Foundation
FX This research was supported by GlaxoSmithKline. We thank J. McGee, R.-J.
Sung and S. Berkovitch for useful discussions and comments on the
manuscript. We also thank N. Tolliday and T. Hasaka at the Broad
Institute for the access to instrumentation. We are grateful for
Professor David R. Liu at Harvard University for kindly providing the
wild- type CHO cells (CHO-K1) and proteoglycan-deficient CHO cells
(pgsA-745). T.N.G. is grateful for a fellowship from Deutsche Akademie
der Naturforscher Leopoldina (LPDS 2009-2). J.T.-H.Y. is the recipient
of a Susan G. Komen for the Cure fellowship. R.E.M was supported by an
AACR Centennial Pre-doctoral Research Fellowship in Cancer Research and
an HHMI Fellowship from the Damon Runyon Cancer Research Foundation.
NR 41
TC 33
Z9 34
U1 6
U2 61
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 2040-2503
EI 2040-2511
J9 MEDCHEMCOMM
JI MedChemComm
PY 2015
VL 6
IS 1
BP 111
EP 119
DI 10.1039/c4md00131a
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA CB5XD
UT WOS:000349700400011
ER
PT J
AU Bove, R
Healy, BC
Secor, E
Vaughan, T
Katic, B
Chitnis, T
Wicks, P
De Jager, PL
AF Bove, R.
Healy, B. C.
Secor, E.
Vaughan, T.
Katic, B.
Chitnis, T.
Wicks, P.
De Jager, P. L.
TI Patients report worse MS symptoms after menopause: Findings from an
online cohort
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Article
DE Estrogen; Multiple sclerosis; Hot flashes; Menopause; Patient-powered
research networks; Online communities
ID MULTIPLE-SCLEROSIS; WOMEN; AMENORRHEA; ESTROGEN; THERAPY; DISEASE
AB Background: Many women with multiple sclerosis (MS) are postmenopausal, yet the impact of menopause on MS symptoms is unknown.
Objective: To investigate patient-reported impact of menopause in a large online research platform, PatientsLikeMe (PLM).
Methods: A detailed reproductive history survey was deployed to PLM members, and responses were linked to PLM's prospectively collected patient-reported severity score (MS Rating Scale, MSRS). The MSRS has previously shown good correlation with physician-derived EDSS scores.
Results: Of the 513 respondents, 55% were postmenopausal; 54% of these reported induced menopause. Median age at natural menopause was 51. Surgical menopause occurred at an earlier age (p<0.001) and was associated with more hormone replacement therapy use (p=0.02) than natural menopause. Postmenopausal status, surgical menopause, and earlier age at menopause were all associated with worse MSRS scores (p <= 0.01) in regressions adjusting for age, disease type and duration.
Conclusion: Postmenopausal patients in this study reported worse MS disease severity. Further, this study highlights a utility for online research platforms, which allow for rapid generation of hypotheses that then require validation in clinical settings. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Bove, R.; Healy, B. C.; Chitnis, T.; De Jager, P. L.] Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Dept Neurol, Brookline, MA 02445 USA.
[Bove, R.; Healy, B. C.; Chitnis, T.; De Jager, P. L.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Bove, R.; Healy, B. C.; Secor, E.; Chitnis, T.; De Jager, P. L.] Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.
[Healy, B. C.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Vaughan, T.; Katic, B.; Wicks, P.] PatientsLikeMe Inc, Cambridge, MA USA.
RP Bove, R (reprint author), Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, 1 Brookline Pl,2nd Floor, Brookline, MA 02445 USA.
EM rbove@partners.org; bchealy@partners.org; secor.elizabeth@gmail.com;
tvaughan@patientslikeme.com; bkatic@patientslikeme.com;
tchitnis@rics.bwh.harvard.edu; pwicks@patientslikeme.com;
pdejager@rics.bwh.harvard.edu
FU National Multiple Sclerosis Society/American Brain Foundation Clinician
Scientist Award [FAN 1761-A-1]; National MS Society Harry Weaver
Neuroscience Scholar Award
FX This research was supported by the National Multiple Sclerosis
Society/American Brain Foundation Clinician Scientist Award FAN 1761-A-1
(RB). PLD is a National MS Society Harry Weaver Neuroscience Scholar
Award Recipient.
NR 22
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD JAN
PY 2015
VL 4
IS 1
BP 18
EP 24
DI 10.1016/j.msard.2014.11.009
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA CB5KR
UT WOS:000349666400004
PM 25787049
ER
PT J
AU Chen, HH
Yuan, HS
Cho, H
Sosnovik, DE
Josephson, L
AF Chen, Howard H.
Yuan, Hushan
Cho, Hoonsung
Sosnovik, David E.
Josephson, Lee
TI Cytoprotective nanoparticles by conjugation of a polyhis tagged annexin
V to a nanoparticle drug
SO NANOSCALE
LA English
DT Article
ID MAGNETIC-RESONANCE; ISCHEMIA-REPERFUSION; APOPTOTIC CELLS; PURIFICATION;
PHOSPHATIDYLSERINE; EXPRESSION; DIANNEXIN; INJURY
AB We synthesized a cytoprotective magnetic nanoparticle by reacting a maleimide functionalized Feraheme (FH) with a disulfide linked dimer of a polyhis tagged annexin V. Following reductive cleavage of disulfide, the resulting annexin-nanoparticle (diameter = 28.0 +/- 2.0 nm by laser light scattering, 7.6 annexin's/nanoparticle) was cytoprotective to cells subjected to plasma membrane disrupting chemotherapeutic or mechanical stresses, and significantly more protective than the starting annexin V. Annexin-nanoparticles provide an approach to the design of nanomaterials which antagonize the plasma membrane permeability characteristic of necrosis and which may have applications as cytoprotective agents.
C1 [Yuan, Hushan; Josephson, Lee] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02129 USA.
[Chen, Howard H.; Sosnovik, David E.; Josephson, Lee] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
[Cho, Hoonsung] Chonnam Natl Univ, Sch Mat Sci & Engn, Kwangju 500757, South Korea.
RP Josephson, L (reprint author), Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02129 USA.
EM ljosephson@mgh.harvard.edu
FU NIH [EB011996, EB009691, HL093038, HL112831, K99 HL121152]
FX This work was supported by NIH R01's EB011996 (LJ), EB009691 (LJ),
HL093038 (DES), HL112831 (DES), and K99 HL121152 (HHC).
NR 31
TC 1
Z9 1
U1 3
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2015
VL 7
IS 6
BP 2255
EP 2259
DI 10.1039/c4nr06861k
PG 5
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA CB2QH
UT WOS:000349472300011
PM 25572921
ER
PT J
AU Rosas, HD
AF Rosas, H. Diana
TI Paradigm for Neuroprotection in Presymptomatic Huntington Disease
SO NEUROTHERAPEUTICS
LA English
DT Meeting Abstract
C1 [Rosas, H. Diana] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1933-7213
EI 1878-7479
J9 NEUROTHERAPEUTICS
JI Neurotherapeutics
PD JAN
PY 2015
VL 12
IS 1
BP 264
EP 265
PG 2
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA CB3PX
UT WOS:000349541800028
ER
PT J
AU Zhang, QX
Ren, H
Baker, GL
AF Zhang, Quanxuan
Ren, Hong
Baker, Gregory L.
TI Synthesis and click chemistry of a new class of biodegradable
polylactide towards tunable thermo-responsive biomaterials
SO POLYMER CHEMISTRY
LA English
DT Article
ID DRUG-DELIVERY SYSTEMS; RING-OPENING POLYMERIZATION; TRANSITION
TEMPERATURES; BIOMEDICAL APPLICATIONS; TRIBLOCK COPOLYMERS;
AQUEOUS-SOLUTIONS; BLOCK-COPOLYMERS; GRAFT-COPOLYMERS; C-13 NMR;
POLYMERS
AB A new class of clickable and biodegradable polylactide was designed and prepared via bulk polymerization of 3,6-dipropargyloxymethyl-1,4-dioxane-2,5-dione (1) which was synthesized from easily accessible propargyloxylactic acid (5). A homopolymer of 1 and random copolymer of 1 with L-lactide were obtained as amorphous materials and exhibit low T-g of 8.5 and 34 degrees C, respectively, indicating their promising potentials for biomedical applications. The statistical nature of random copolymers was investigated by DSC analysis and C-13 NMR spectroscopy, which implies the random distribution of terminal alkyne groups along the back bone of copolymers. The efficient click post-modification of this new class of polylactide with alkyl and mPEG azides affords novel hydrophilic biomaterials, which exhibit reversible thermo-responsive properties as evidenced by their tunable LCST ranging from 22 to 69 degrees C depending on the balance of the incorporated hydrophilic/hydrophobic side chains. These results indicate the generality of this new class of clickable polylactide in preparing novel smart biomaterials in a simple and efficient manner via click chemistry.
C1 [Zhang, Quanxuan; Baker, Gregory L.] Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.
[Ren, Hong] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Ren, Hong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02129 USA.
RP Zhang, QX (reprint author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.
EM zhangqua@msu.edu
RI Ren, Hong/J-5191-2015
OI Ren, Hong/0000-0003-0375-0360
FU NIH [5RC2ES018756-02]
FX This manuscript is in memory of my advisor, Prof. Gregory L. Baker, who
passed away unexpectedly while this paper was under preparation. The
authors are grateful to Prof. William D. Wulff at Michigan State
University for his invaluable guidance, discussions and assistance
during preparation of this manuscript. This work was funded by NIH
5RC2ES018756-02.
NR 62
TC 3
Z9 3
U1 6
U2 41
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1759-9954
EI 1759-9962
J9 POLYM CHEM-UK
JI Polym. Chem.
PY 2015
VL 6
IS 8
BP 1275
EP 1285
DI 10.1039/c4py01425a
PG 11
WC Polymer Science
SC Polymer Science
GA CB5KT
UT WOS:000349666600008
PM 25685199
ER
PT B
AU Gray, PJ
Aizer, AA
Efstathiou, JA
AF Gray, Phillip J.
Aizer, Ayal A.
Efstathiou, Jason A.
BE Dicker, AP
Kelly, WK
Zaorsky, NG
Trabulsi, EJ
TI Treatment of Low-Risk, Localized Prostate Cancer: Use of Proton Therapy
SO PROSTATE CANCER: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND
MANAGEMENT
SE Current Multidisciplinary Oncology
LA English
DT Article; Book Chapter
ID INTENSITY-MODULATED RADIOTHERAPY; CONFORMAL RADIATION-THERAPY; RADICAL
PROSTATECTOMY; ADENOCARCINOMA; CONTROVERSIES; SURGERY; CARE
C1 [Gray, Phillip J.] Massachusetts Gen Hosp, Dept Radiat Oncol, Harvard Radiat Oncol Program, Boston, MA 02114 USA.
[Aizer, Ayal A.; Efstathiou, Jason A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Gray, PJ (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Harvard Radiat Oncol Program, Boston, MA 02114 USA.
NR 27
TC 0
Z9 0
U1 0
U2 0
PU DEMOS MEDICAL PUBLICATIONS
PI NEW YORK
PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA
BN 978-1-936287-59-8
J9 CURR MULTIDISC ONCOL
PY 2015
BP 196
EP 200
PG 5
WC Oncology
SC Oncology
GA BB8YU
UT WOS:000347857300028
ER
PT B
AU Orio, P
Bittner, N
AF Orio, Peter
Bittner, Nathan
BE Dicker, AP
Kelly, WK
Zaorsky, NG
Trabulsi, EJ
TI Prognosis After Biochemical Failure and Surrogate Endpoints for Prostate
Cancer-Specific Mortality
SO PROSTATE CANCER: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND
MANAGEMENT
SE Current Multidisciplinary Oncology
LA English
DT Article; Book Chapter
ID ANDROGEN SUPPRESSION THERAPY; CAPRA-S SCORE; RADICAL PROSTATECTOMY;
RADIATION-THERAPY; CLINICAL-TRIALS; DEPRIVATION THERAPY;
NATURAL-HISTORY; PSA RECURRENCE; FREE SURVIVAL; RADIOTHERAPY
C1 [Orio, Peter] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Orio, Peter] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA.
[Bittner, Nathan] Tacoma Valley Radiat Oncol Ctr, Tacoma, WA USA.
RP Orio, P (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
NR 35
TC 0
Z9 0
U1 1
U2 1
PU DEMOS MEDICAL PUBLICATIONS
PI NEW YORK
PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA
BN 978-1-936287-59-8
J9 CURR MULTIDISC ONCOL
PY 2015
BP 269
EP 273
PG 5
WC Oncology
SC Oncology
GA BB8YU
UT WOS:000347857300041
ER
PT J
AU Admon, R
Nickerson, LD
Dillon, DG
Holmes, AJ
Bogdan, R
Kumar, P
Dougherty, DD
Iosifescu, DV
Mischoulon, D
Fava, M
Pizzagalli, DA
AF Admon, R.
Nickerson, L. D.
Dillon, D. G.
Holmes, A. J.
Bogdan, R.
Kumar, P.
Dougherty, D. D.
Iosifescu, D. V.
Mischoulon, D.
Fava, M.
Pizzagalli, D. A.
TI Dissociable cortico-striatal connectivity abnormalities in major
depression in response to monetary gains and penalties
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Caudate; cingulate; depression; PPI; reward; treatment prediction
ID PSYCHOPHYSIOLOGICAL INTERACTIONS; FUNCTIONAL CONNECTIVITY; UNIPOLAR
DEPRESSION; NEURAL RESPONSES; DECISION-MAKING; POSITIVE AFFECT;
DISORDER; REWARD; PERFORMANCE; ACTIVATION
AB Background. Individuals with major depressive disorder (MDD) are characterized by maladaptive responses to both positive and negative outcomes, which have been linked to localized abnormal activations in cortical and striatal brain regions. However, the exact neural circuitry implicated in such abnormalities remains largely unexplored.
Method. In this study 26 unmedicated adults with MDD and 29 matched healthy controls (HCs) completed a monetary incentive delay task during functional magnetic resonance imaging (fMRI). Psychophysiological interaction (PPI) analyses probed group differences in connectivity separately in response to positive and negative outcomes (i.e. monetary gains and penalties).
Results. Relative to HCs, MDD subjects displayed decreased connectivity between the caudate and dorsal anterior cingulate cortex (dACC) in response to monetary gains, yet increased connectivity between the caudate and a different, more rostral, dACC subregion in response to monetary penalties. Moreover, exploratory analyses of 14 MDD patients who completed a 12-week, double-blind, placebo-controlled clinical trial after the baseline fMRI scans indicated that a more normative pattern of cortico-striatal connectivity pre-treatment was associated with greater improvement in symptoms 12 weeks later.
Conclusions. These results identify the caudate as a region with dissociable incentive-dependent dACC connectivity abnormalities in MDD, and provide initial evidence that cortico-striatal circuitry may play a role in MDD treatment response. Given the role of cortico-striatal circuitry in encoding action-outcome contingencies, such dysregulated connectivity may relate to the prominent disruptions in goal-directed behavior that characterize MDD.
C1 [Admon, R.; Dillon, D. G.; Kumar, P.; Pizzagalli, D. A.] Harvard Univ, McLean Hosp, Sch Med, Ctr Depress Anxiety & Stress Res, Belmont, MA USA.
[Nickerson, L. D.; Pizzagalli, D. A.] Harvard Univ, McLean Hosp, Sch Med, McLean Imaging Ctr, Belmont, MA USA.
[Holmes, A. J.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Holmes, A. J.; Dougherty, D. D.; Mischoulon, D.; Fava, M.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Bogdan, R.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA.
[Iosifescu, D. V.] Mt Sinai Sch Med, Mood & Anxiety Disorders Program, New York, NY USA.
RP Pizzagalli, DA (reprint author), McLean Hosp, Ctr Depress Anxiety & Stress Res, Room 233C,115 Mill St, Belmont, MA 02478 USA.
EM dap@mclean.harvard.edu
OI Dillon, Daniel/0000-0002-1977-700X; Bogdan, Ryan/0000-0002-1430-1045
FU National Institute of Mental Health (NIMH) [R01 MH068376]; National
Center for Complementary and Alternative Medicine (NCCAM) [R21
AT002974]; NCCAM [R01 AT001638]; [K01 MH099232]; [K99 MH094438]
FX We are grateful to E. L. Goetz, J. Birk, S. J. Dutra and N. B. Hall for
their skilled assistance with this study. This study was supported by
National Institute of Mental Health (NIMH) grant R01 MH068376 and
National Center for Complementary and Alternative Medicine (NCCAM) grant
R21 AT002974 (both awarded to D.A.P.) and NCCAM grant R01 AT001638
(awarded to M.F). A.J.H. and D.G.D. were supported by grants K01
MH099232 and K99 MH094438 respectively.
NR 60
TC 12
Z9 13
U1 4
U2 15
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD JAN
PY 2015
VL 45
IS 1
BP 121
EP 131
DI 10.1017/S0033291714001123
PG 11
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA CB4RY
UT WOS:000349616800010
PM 25055809
ER
PT J
AU Tsai, J
El-Gabalawy, R
Sledge, WH
Southwick, SM
Pietrzak, RH
AF Tsai, J.
El-Gabalawy, R.
Sledge, W. H.
Southwick, S. M.
Pietrzak, R. H.
TI Post-traumatic growth among veterans in the USA: results from the
National Health and Resilience in Veterans Study
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Coping behavior; post-traumatic stress disorder; spirituality; veterans
ID SOCIAL SUPPORT; STRESS SYMPTOMS; 5-FACTOR MODEL; PHYSICAL HEALTH;
MENTAL-HEALTH; TRAUMA; DISORDER; PTSD; WAR; VALIDATION
AB Background. There is increasing recognition that, in addition to negative psychological consequences of trauma such as post-traumatic stress disorder (PTSD), some individuals may develop post-traumatic growth (PTG) following such experiences. To date, however, data regarding the prevalence, correlates and functional significance of PTG in population-based samples are lacking.
Method. Data were analysed from the National Health and Resilience in Veterans Study, a contemporary, nationally representative survey of 3157 US veterans. Veterans completed a survey containing measures of sociodemographic, military, health and psychosocial characteristics, and the Posttraumatic Growth Inventory-Short Form.
Results. We found that 50.1% of all veterans and 72.0% of veterans who screened positive for PTSD reported at least 'moderate' PTG in relation to their worst traumatic event. An inverted U-shaped relationship was found to best explain the relationship between PTSD symptoms and PTG. Among veterans with PTSD, those with PTSD reported better mental functioning and general health than those without PTG. Experiencing a life-threatening illness or injury and re-experiencing symptoms were most strongly associated with PTG. In multivariable analysis, greater social connectedness, intrinsic religiosity and purpose in life were independently associated with greater PTG.
Conclusions. PTG is prevalent among US veterans, particularly among those who screen positive for PTSD. These results suggest that there may be a 'positive legacy' of trauma that has functional significance for veterans. They further suggest that interventions geared toward helping trauma-exposed US veterans process their re-experiencing symptoms, and to develop greater social connections, sense of purpose and intrinsic religiosity may help promote PTG in this population.
C1 [Tsai, J.] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA.
[Tsai, J.; Sledge, W. H.; Southwick, S. M.; Pietrzak, R. H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[El-Gabalawy, R.] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada.
[Southwick, S. M.; Pietrzak, R. H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA.
RP Tsai, J (reprint author), 950 Campbell Ave,151D, West Haven, CT 06516 USA.
EM Jack.Tsai@yale.edu
FU United States Department of Veterans Affairs National Center for
Posttraumatic Stress Disorder; United States Department of Veterans
Affairs, Office of Research and Development
FX This work was supported in part by the United States Department of
Veterans Affairs National Center for Posttraumatic Stress Disorder, the
United States Department of Veterans Affairs, Office of Research and
Development, and a private donation. The views presented here are those
of the authors alone and do not represent the position of any federal
agency or of the United States Government. None of the authors reports
any conflicts of interest with this work.
NR 58
TC 15
Z9 15
U1 8
U2 31
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD JAN
PY 2015
VL 45
IS 1
BP 165
EP 179
DI 10.1017/S0033291714001202
PG 15
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA CB4RY
UT WOS:000349616800014
PM 25065450
ER
PT J
AU Shin, SS
Grandhi, R
Henchir, J
Yan, HQ
Badylak, SF
Dixon, CE
AF Shin, Samuel S.
Grandhi, Ramesh
Henchir, Jeremy
Yan, Hong Q.
Badylak, Stephen F.
Dixon, C. Edward
TI Neuroprotective effects of collagen matrix in rats after traumatic brain
injury
SO RESTORATIVE NEUROLOGY AND NEUROSCIENCE
LA English
DT Article
DE Collagen; matrix; traumatic brain injury; bioscaffold;
neuroregeneration; neurorepair
ID CONTROLLED CORTICAL IMPACT; NEURAL STEM-CELLS; SYSTEM
EXTRACELLULAR-MATRIX; SPINAL-CORD; CEREBRAL-ISCHEMIA; PROGENITOR CELLS;
DURAL GRAFT; SCAFFOLDS; GROWTH; TRANSPLANTATION
AB Purpose: In previous studies, collagen based matrices have been implanted into the site of lesion in different models of brain injury. We hypothesized that semisynthetic collagen matrix can have neuroprotective function in the setting of traumatic brain injury.
Methods: Rats were subjected to sham injury or controlled cortical impact. They either received extracellular matrix graft (DuraGen) over the injury site or did not receive any graft and underwent beam balance/beam walking test at post injury days 1-5 and Morris water maze at post injury days 14-18. Animals were sacrificed at day 18 for tissue analysis.
Results: Collagen matrix implantation in injured rats did not affect motor function (beam balance test: p = 0.627, beam walking test: p = 0.921). However, injured group with collagen matrix had significantly better spatial memory acquisition (p < 0.05). There was a significant reduction in lesion volume, as well as neuronal loss in CA1 (p < 0.001) and CA3 (p < 0.05) regions of the hippocampus in injured group with collagen matrix (p < 0.05).
Conclusions: Collagen matrix reduces contusional lesion volume, neuronal loss, and cognitive deficit after traumatic brain injury. Further studies are needed to demonstrate the mechanisms of neuroprotection by collagen matrix.
C1 [Shin, Samuel S.; Henchir, Jeremy; Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA.
[Shin, Samuel S.; Grandhi, Ramesh; Henchir, Jeremy; Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA.
[Shin, Samuel S.; Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.
[Badylak, Stephen F.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA.
[Dixon, C. Edward] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Dixon, CE (reprint author), Univ Pittsburgh, Dept Neurol Surg, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA.
EM dixonec@upmc.edu
OI Badylak, Stephen/0000-0003-3555-0689
FU NIH/NINDS; Pittsburgh Foundation Walter L. Copeland Fund
FX This work was supported by NIH/NINDS and by the Pittsburgh Foundation
Walter L. Copeland Fund.
NR 34
TC 1
Z9 1
U1 0
U2 5
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6028
EI 1878-3627
J9 RESTOR NEUROL NEUROS
JI Restor. Neurol. Neurosci.
PY 2015
VL 33
IS 2
BP 95
EP 104
DI 10.3233/RNN-140430
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA CB7UX
UT WOS:000349835000001
PM 25624423
ER
PT J
AU Giampietro, PF
Armstrong, L
Stoddard, A
Blank, RD
Livingston, J
Raggio, CL
Rasmussen, K
Pickart, M
Lorier, R
Turner, A
Sund, S
Sobrera, N
Neptune, E
Sweetser, D
Santiago-Cornier, A
Broeckel, U
AF Giampietro, Philip F.
Armstrong, Linlea
Stoddard, Alex
Blank, Robert D.
Livingston, Janet
Raggio, Cathy L.
Rasmussen, Kristen
Pickart, Michael
Lorier, Rachel
Turner, Amy
Sund, Sarah
Sobrera, Nara
Neptune, Enid
Sweetser, David
Santiago-Cornier, Alberto
Broeckel, Ulrich
TI Whole Exome Sequencing Identifies a POLRID Mutation Segregating in a
Father and Two Daughters with Findings of Klippel-Feil and Treacher
Collins Syndromes
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE Klippel-Feil; autosomal dominant; Treacher Collins syndrome
ID CAUSES SPONDYLOCOSTAL DYSOSTOSIS; OSTEOGENESIS IMPERFECTA; VERTEBRAL
MALFORMATIONS; CLEFT-PALATE; ANOMALIES; PROTEIN; GENE; SEGMENTATION;
DEFICIENCY; SCOLIOSIS
AB We report on a father and his two daughters diagnosed with Klippel-Feil syndrome (KFS) but with craniofacial differences (zygomatic and mandibular hypoplasia and cleft palate) and external ear abnormalities suggestive of Treacher Collins syndrome (TCS). The diagnosis of KFS was favored, given that the neck anomalies were the predominant manifestations, and that the diagnosis predated later recognition of the association between spinal segmentation abnormalities and TCS. Genetic heterogeneity and the rarity of large families with KFS have limited the ability to identify mutations by traditional methods. Whole exome sequencing identified a nonsynonymous mutation in POLR1D (subunit of RNA polymerase I and II): exon2:c. T332C:p.L111P. Mutations in POLR1D are present in about 5% of individuals diagnosed with TCS. We propose that this mutation is causal in this family, suggesting a pathogenetic link between KFS and TCS. (C) 2014 Wiley Periodicals, Inc.
C1 [Giampietro, Philip F.; Sund, Sarah] Univ Wisconsin, Madison, WI 53705 USA.
[Armstrong, Linlea; Livingston, Janet] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Stoddard, Alex; Blank, Robert D.; Lorier, Rachel; Turner, Amy; Broeckel, Ulrich] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Raggio, Cathy L.] Hosp Special Surg, New York, NY 10021 USA.
[Rasmussen, Kristen] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA.
[Pickart, Michael] Concordia Univ, Mequon, WI USA.
[Sobrera, Nara; Neptune, Enid] Johns Hopkins Univ, Baltimore, MD USA.
[Sweetser, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Santiago-Cornier, Alberto] Ponce Sch Med, San Juan, PR USA.
RP Giampietro, PF (reprint author), Univ Wisconsin, Dept Pediat, Waisman Ctr Room 351,1500 Highland Ave, Madison, WI 53705 USA.
EM pfgiampietro@pediatrics.wisc.edu
OI Blank, Robert Daniel/0000-0003-2950-1944
FU University of Wisconsin-Madison Pediatrics Research and Development fund
FX Grant sponsor: University of Wisconsin-Madison Pediatrics Research and
Development fund.
NR 40
TC 0
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD JAN
PY 2015
VL 167
IS 1
BP 95
EP 102
DI 10.1002/ajmg.a.36799
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA CA3ZD
UT WOS:000348843000013
PM 25348728
ER
PT J
AU Wiederhold, NP
Najvar, LK
Fothergill, AW
McCarthy, DI
Bocanegra, R
Olivo, M
Kirkpatrick, WR
Everson, MP
Duncanson, FP
Patterson, TF
AF Wiederhold, Nathan P.
Najvar, Laura K.
Fothergill, Annette W.
McCarthy, Dora I.
Bocanegra, Rosie
Olivo, Marcos
Kirkpatrick, William R.
Everson, Michael P.
Duncanson, Frederick P.
Patterson, Thomas F.
TI The Investigational Agent E1210 Is Effective in Treatment of
Experimental Invasive Candidiasis Caused by Resistant Candida albicans
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID BROAD-SPECTRUM ANTIFUNGAL; IN-VITRO ACTIVITY; BROTH MICRODILUTION
METHODS; SUSCEPTIBILITY; CLSI; MODELS; FAMILY; SPP.
AB The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandin-resistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections.
C1 [Wiederhold, Nathan P.; Najvar, Laura K.; Fothergill, Annette W.; McCarthy, Dora I.; Bocanegra, Rosie; Olivo, Marcos; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Najvar, Laura K.; Bocanegra, Rosie; Olivo, Marcos; Kirkpatrick, William R.; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Everson, Michael P.; Duncanson, Frederick P.] Eisai Inc, Woodcliff Lake, NJ USA.
RP Wiederhold, NP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
EM wiederholdn@uthscsa.edu
OI Wiederhold, Nathan/0000-0002-2225-5122
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services
[HHS272201000018I, HHSN272201000038I, A03, A13]; Astellas; Dow; F2G;
Merck; Merz; Viamet
FX This project utilized preclinical services funded by the National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Department of Health and Human Services, under contract no.
HHS272201000018I and HHSN272201000038I, task orders A03 and A13,
respectively.; N.P.W. has received research support from Astellas, Dow,
F2G, Merck, Merz, and Viamet and has served on advisory boards for
Merck, Astellas, Toyama, and Viamet. T.F.P. has received research grants
to UT Health Science Center San Antonio from Astellas and Merck and has
served as a consultant for Astellas, Merck, Toyama, Viamet, and
Scynexis. M.P.E. and F.P.D. are salaried employees of Eisai Inc. All
other authors have no conflicts.
NR 18
TC 4
Z9 6
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 2015
VL 59
IS 1
BP 690
EP 692
DI 10.1128/AAC.03944-14
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA CA0LO
UT WOS:000348609500089
PM 25331706
ER
PT B
AU Katz, DH
Rasmussen-Torvik, LJ
AF Katz, Daniel H.
Rasmussen-Torvik, Laura J.
BE Shah, SJ
Arnett, DK
TI Genome-Wide Association Studies
SO CARDIOVASCULAR GENETICS AND GENOMICS IN CLINICAL PRACTICE
LA English
DT Article; Book Chapter
ID CORONARY-ARTERY-DISEASE; COMPLEX HUMAN-DISEASES; LINKAGE DISEQUILIBRIUM;
CARDIOVASCULAR-DISEASE; SUSCEPTIBILITY LOCI; COMMON DISEASES;
QUALITY-CONTROL; VARIANTS; RISK; GENE
C1 [Katz, Daniel H.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA 02138 USA.
[Rasmussen-Torvik, Laura J.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Katz, DH (reprint author), Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA 02138 USA.
NR 68
TC 0
Z9 0
U1 1
U2 1
PU DEMOS MEDICAL PUBLICATIONS
PI NEW YORK
PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA
BN 978-1-62070-014-3
PY 2015
BP 23
EP 33
PG 11
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA BB8EI
UT WOS:000346457500004
ER
PT B
AU Shaikh, AY
Lubitz, SA
Lin, HH
Benjamin, EJ
McManus, DD
AF Shaikh, Amir Y.
Lubitz, Steven A.
Lin, Honghuang
Benjamin, Emelia J.
McManus, David D.
BE Shah, SJ
Arnett, DK
TI Atrial Fibrillation Genetics and Genomics
SO CARDIOVASCULAR GENETICS AND GENOMICS IN CLINICAL PRACTICE
LA English
DT Article; Book Chapter
ID FAMILIAL AGGREGATION; WIDE ASSOCIATION; CHROMOSOME 4Q25;
CARDIOVASCULAR-DISEASE; CIRCULATING MICRORNAS; CARDIAC CONDUCTION;
AFRICAN-AMERICANS; RANDOMIZED-TRIAL; DOWN-REGULATION; HEART-FAILURE
C1 [Shaikh, Amir Y.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA.
[Lubitz, Steven A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Lubitz, Steven A.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
[Lubitz, Steven A.] Harvard Univ, Sch Med, Boston, MA USA.
[Lin, Honghuang] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[McManus, David D.] Univ Massachusetts, Sch Med, Div Cardiol, Worcester, MA USA.
RP Shaikh, AY (reprint author), Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA.
NR 102
TC 0
Z9 0
U1 0
U2 0
PU DEMOS MEDICAL PUBLICATIONS
PI NEW YORK
PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA
BN 978-1-62070-014-3
PY 2015
BP 140
EP 152
PG 13
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA BB8EI
UT WOS:000346457500014
ER
PT B
AU Mauer, AC
Owens, DS
O'Donnell, CJ
Post, WS
Thanassoulis, G
AF Mauer, Andreas C.
Owens, David S.
O'Donnell, Christopher J.
Post, Wendy S.
Thanassoulis, George
BE Shah, SJ
Arnett, DK
TI Genetics of Valvular Heart Disease
SO CARDIOVASCULAR GENETICS AND GENOMICS IN CLINICAL PRACTICE
LA English
DT Article; Book Chapter
ID MITRAL-VALVE-PROLAPSE; BICUSPID AORTIC-VALVE; LATE SYSTOLIC-MURMUR;
CORONARY-ARTERY-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; OUTFLOW TRACT
OBSTRUCTION; WILLIAMS-BEUREN-SYNDROME; GENOME-WIDE ASSOCIATION;
ALL-CAUSE MORTALITY; ANNULAR CALCIFICATION
C1 [Mauer, Andreas C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02138 USA.
[Owens, David S.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[O'Donnell, Christopher J.] NHLBI, Cardiovasc Epidemiol & Human Genom Branch, Div Intramural Res, Bethesda, MD 20892 USA.
[O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, NHLBIs Framingham Heart Study,Cardiol Div, Boston, MA USA.
[Post, Wendy S.] Johns Hopkins Sch Med, Baltimore, MD USA.
[Thanassoulis, George] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
[Thanassoulis, George] McGill Univ, Dept Med, Montreal, PQ, Canada.
RP Mauer, AC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02138 USA.
NR 183
TC 0
Z9 0
U1 0
U2 1
PU DEMOS MEDICAL PUBLICATIONS
PI NEW YORK
PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA
BN 978-1-62070-014-3
PY 2015
BP 265
EP 286
PG 22
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA BB8EI
UT WOS:000346457500022
ER
PT J
AU Bhatt, AB
Rajabali, A
He, W
Benavidez, OJ
AF Bhatt, Ami B.
Rajabali, Alefiyah
He, Wei
Benavidez, Oscar J.
TI High Resource Use among Adult Congenital Heart Surgery Admissions in
Adult Hospitals: Risk Factors and Association with Death and
Comorbidities
SO CONGENITAL HEART DISEASE
LA English
DT Article
DE Adult Congenital Heart Disease; Outcomes; Resource Use
ID PEDIATRIC HOSPITALS; DISEASE PATIENTS; CARE; DYSFUNCTION; ADJUSTMENT;
TETRALOGY; MORBIDITY; MORTALITY; FALLOT; REPAIR
AB ObjectiveAdult hospitals are a common location of adult congenital heart disease (ACHD) admissions, including cardiac surgical admissions. Understanding the patterns and predictors of resource use could aid these institutions by identifying and targeting potentially modifiable determinants of high resource use (HRU). Our objectives were to examine resource use during adult congenital heart surgical admissions in adult hospitals, determine the association of HRU with mortality, and identify risk factors for HRU.
DesignPopulation-based retrospective study We obtained data from the Nationwide Inpatient Sample 2005-2009 and examined ACHD surgical admissions ages 18-49 years (n = 16 231).
Outcome MeasuresWe defined HRU as admissions with >90th percentile for total hospital charges.
ResultsDespite representing 10% of admissions, HRU admissions accounted for 32% of total charges. HRU admissions had a higher mortality rate (9.7% vs. 1.8%, P < .001). Multivariable analysis demonstrated that HRU is associated with government insurance adjusted odds ratio (AOR) 2.0 (95% confidence interval [CI] 1.6,2.4), emergency admissions AOR 3.9 (95% CI 3.1,4.8), complications AOR 4.2 (95% CI 3.3,5.2), renal failure AOR 1.8 (95% CI 1.4,2.2), congestive heart failure AOR 1.2 (95% CI 1,1.4), surgical complexity risk category-2 AOR 2.0 (95% CI 1.0,3.6), and category-3+ AOR 2.3 (95% CI 1.4,3.8).
ConclusionsHRU admissions for adult congenital heart surgery consumed a disproportionate amount of resources and were associated with higher mortality. HRU risk factors included nonelective admissions, government insurance, heart failure, surgical complexity, renal failure, and complications. Complications, if preventable, may be a target for improvement strategies to decrease resource use. Other risk factors may require a broader patient care approach.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pediat Congenital Cardiol,Heart Ctr, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Adult Congenital Heart Dis Program,Heart Ctr, Boston, MA USA.
RP Benavidez, OJ (reprint author), Massachusetts Gen Hosp, Div Pediat Congenital Cardiol, 175 Cambridge St, Boston, MA 02114 USA.
EM ojbenavidez@partners.org
FU Robert Wood Johnson foundation Amos Medical Faculty Development Program
FX Dr. Benavidez is supported by the Robert Wood Johnson foundation Amos
Medical Faculty Development Program.
NR 21
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-079X
EI 1747-0803
J9 CONGENIT HEART DIS
JI Congenit. Heart Dis.
PD JAN-FEB
PY 2015
VL 10
IS 1
BP 13
EP 20
DI 10.1111/chd.12169
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CB2MU
UT WOS:000349462600009
PM 24521268
ER
PT J
AU Juillerat, P
Sokol, H
Froehlich, F
Yajnik, V
Beaugerie, L
Lucci, M
Burnand, B
Macpherson, AJ
Cosnes, J
Korzenik, JR
AF Juillerat, Pascal
Sokol, Harry
Froehlich, Florian
Yajnik, Vijay
Beaugerie, Laurent
Lucci, Matthew
Burnand, Bernard
Macpherson, Andrew J.
Cosnes, Jacques
Korzenik, Joshua R.
TI Factors Associated with Durable Response to Infliximab in Crohn's
Disease 5 Years and Beyond: A Multicenter International Cohort
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE Crohn's disease; inflammatory bowel disease; infliximab; long-term;
clinical; response
ID INFLAMMATORY-BOWEL-DISEASE; PATIENTS LOSING RESPONSE; LONG-TERM
DURABILITY; MAINTENANCE INFLIXIMAB; BIOLOGICAL THERAPIES; EFFICACY;
ANTIBODIES; METAANALYSIS; SWITZERLAND; PREVALENCE
AB Background: Infliximab (IFX) has been used for over a decade worldwide. Less is known about the natural history of IFX use beyond a few years and which patients are more likely to sustain benefits.
Methods: Patients with Crohn's disease (CD) exposed to IFX from Massachusetts General Hospital, Boston, Saint-Antoine Hospital, Paris, and the Swiss IBD Cohort Study were identified through retrospective and prospective data collection, complemented by chart abstraction of electronic medical records. We compared long-term users of IFX (>5 yr of treatment, long-term users of infliximab [LTUI]), with non-LTUI patients to identify prognostic factors.
Results: We pooled data on 1014 patients with CD from 3 different databases, of whom 250 were defined as LTUI. The comparison group comprised 290 patients with CD who discontinued IFX: 48 primary nonresponses, 95 loss of responses, and 147 adverse events. Factors associated with LTUI were colonic involvements and an earlier age at the start of IFX. The prevalence of active smokers and obese patients differed markedly, but inversely, between American and European centers but did not impact outcome. The discontinuation rate was stable around 3% to 6%, each year from years 3 to 10.
Conclusions: Young age at start of IFX and colonic CD are factors associated with a beneficial long-term use of IFX. After 5 years of IFX, there is still a 3% to 5% discontinuation rate annually. Several factors associated with a good initial response such as nonsmoker and shorter disease duration at IFX initiation do not seem associated with a longer term response.
C1 [Juillerat, Pascal; Yajnik, Vijay; Lucci, Matthew; Korzenik, Joshua R.] Massachusetts Gen Hosp, Dept Gastroenterol & Hepatol, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA.
[Juillerat, Pascal; Macpherson, Andrew J.] Univ Hosp Bern, Inselspital, Clin Visceral Surg & Med, Dept Gastroenterol, CH-3010 Bern, Switzerland.
[Sokol, Harry; Beaugerie, Laurent; Cosnes, Jacques] Univ Paris 06, St Antoine Hosp, Dept Gastroenterol & Nutr, Paris, France.
[Froehlich, Florian; Burnand, Bernard] Univ Lausanne Hosp, Inst Social & Prevent Med, Healthcare Evaluat Unit, Lausanne, Switzerland.
[Froehlich, Florian] Univ Hosp Bern, Div Gastroenterol & Hepatol, CH-3010 Bern, Switzerland.
[Lucci, Matthew; Korzenik, Joshua R.] Brigham & Womens Hosp, Dept Gastroenterol, Boston, MA 02115 USA.
RP Juillerat, P (reprint author), Univ Hosp Bern, Inselspital, Clin Visceral Surg & Med, CH-3010 Bern, Switzerland.
EM pascal.juillerat@insel.ch
OI sokol, harry/0000-0002-2914-1822
FU AbbVie; UCB; Merck Sharp Dohme; Vifor; Enterome; Danone; Astellas;
Ferring; Tilliots; Takeda; Procter and Gamble; Warner Chilcott
FX Supported by the Swiss National Science Foundation (SNF): grant
PBLAP3-124341.; P. Juillerat has received consulting and lecture fees
from AbbVie, UCB, Merck Sharp & Dohme and Vifor. H. Sokol has received
consulting fees from Enterome, Danone, and Astellas. L. Beaugerie has
received consulting fees from Ferring and has been involved in advisory
committees or review panels for AbbVie and Merck Sharp & Dohme. J.
Cosnes has received consulting fees from Tilliots and has been involved
in advisory committees or review panels for AbbVie and Merck Sharp &
Dohme. V. Yajnik has received consulting fees from Takeda. J. R.
Korzenik has been a consultant and a member of advisory boards for Shire
Pharmaceuticals, Prometheus, Roche, AbbVie, Merck Sharp & Dohme, Pfizer,
and Warner-Chilcott and receives research support from Procter and
Gamble and Warner Chilcott. The remaining authors have no conflicts of
interest to disclose.
NR 41
TC 4
Z9 5
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JAN
PY 2015
VL 21
IS 1
BP 60
EP 70
DI 10.1097/MIB.0000000000000225
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CA4WD
UT WOS:000348906500012
PM 25517594
ER
PT J
AU Liu, S
Ren, JN
Li, JS
AF Liu, Song
Ren, Jianan
Li, Jieshou
TI IL-17RA in Intestinal Inflammation: Structure, Signaling, Function, and
Clinical Application
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE IL-17RA; IL-17; IL-25; IBD; signaling; trial
ID PLACEBO-CONTROLLED TRIAL; NF-KAPPA-B; CHRONIC PLAQUE PSORIASIS;
PROOF-OF-CONCEPT; INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; ACTIVE
RHEUMATOID-ARTHRITIS; TO-SEVERE PSORIASIS; EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS; MODIFYING ANTIRHEUMATIC DRUGS; ALLERGIC AIRWAY
INFLAMMATION
AB Interleukin-17 receptor A (IL-17RA) is responsible for both IL-17A and IL-25 (IL-17E) signaling pathways. Current evidences suggest distinct but interactive responses between IL-17A and IL-25 signaling, both of which are critical for intestinal immune homeostasis. IL-17RA is assumed to regulate this counterbalance and therefore becomes a crucial molecule in mucosal immunology. In this review, we will describe the structure of IL-17RA, compare IL-17A and IL-25 signaling pathways, and emphasize on the function of IL-17RA in intestinal inflammation and discuss current evidences of accomplished and ongoing clinical trials with monoclonal antibodies targeting Th17 pathway, especially IL-17RA.
C1 [Liu, Song; Ren, Jianan; Li, Jieshou] Nanjing Univ, Jinling Hosp, Dept Surg, Sch Med, Nanjing 210008, Jiangsu, Peoples R China.
[Liu, Song] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Gastrointestinal Unit, Boston, MA USA.
[Liu, Song] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Study Inflammatory Bowel Dis, Boston, MA USA.
RP Ren, JN (reprint author), 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM jiananr@gmail.com
FU China Scholarship Council; Program B for Outstanding PhD candidate of
Nanjing University; National Natural Science Foundation of China
[81270478]
FX Supported by China Scholarship Council (SL), Program B for Outstanding
PhD candidate of Nanjing University (SL), and National Natural Science
Foundation of China (No. 81270478) (JR).
NR 155
TC 3
Z9 3
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JAN
PY 2015
VL 21
IS 1
BP 154
EP 166
DI 10.1097/MIB.0000000000000217
PG 13
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CA4WD
UT WOS:000348906500021
PM 25272188
ER
PT J
AU Goracci, A
Casamassima, F
Iovieno, N
di Volo, S
Benbow, J
Bolognesi, S
Fagiolini, A
AF Goracci, Arianna
Casamassima, Francesco
Iovieno, Nadia
di Volo, Silvia
Benbow, Jim
Bolognesi, Simone
Fagiolini, Andrea
TI Binge Eating Disorder: From Clinical Research to Clinical Practice
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Editorial Material
DE anticonvulsants; antidepressants; binge eating disorder; substance abuse
treatment agents
ID PLACEBO-CONTROLLED TRIAL; BULIMIA-NERVOSA; FOOD ADDICTION; OBESITY;
NALTREXONE; ANTIDEPRESSANT; ZONISAMIDE
AB This case report describes the clinical course of a young woman suffering from binge eating disorder (BED) associated with obesity. It illustrates the efficacy of different medications in the treatment of BED and related conditions and is followed by the comments and clinical observations of 2 practicing psychiatrists. The issues described in this paper have important clinical implications and are topical, given that BED is now recognized as a specific disorder in the new Diagnostic and Statistical Manual of Mental Disorders, fifth edition classification system, but neither the US Food and Drug Administration nor any other regulatory agency has yet approved a drug for treatment of this disease, despite its very prevalent and disabling nature. Growing evidence from the fields of psychopathology and neurobiology, including preclinical and clinical studies, converges to support the idea that "overeating" has much in common with other behavioral addictions, and substance abuse treatment agents may show promise for the treatment of BED.
C1 [Goracci, Arianna; di Volo, Silvia; Bolognesi, Simone; Fagiolini, Andrea] Univ Siena, Sch Med, Dept Mol Med, Div Psychiat, I-53100 Siena, Italy.
[Casamassima, Francesco] Univ Pisa, Dept Psychiat Neurobiol Pharmacol & Biotechnol, Pisa, Italy.
[Iovieno, Nadia] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Benbow, Jim] Univ Washington, Sch Social Work, Seattle, WA 98195 USA.
RP Goracci, A (reprint author), Univ Siena, Sch Med, Dept Neurosci, Div Psychiat, Viale Bracci 1, I-53100 Siena, Italy.
EM agoracci@gmail.com
OI FAGIOLINI, ANDREA/0000-0001-5827-0853
NR 23
TC 0
Z9 0
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD JAN-FEB
PY 2015
VL 9
IS 1
BP 20
EP 24
DI 10.1097/ADM.0000000000000085
PG 5
WC Substance Abuse
SC Substance Abuse
GA CB0TP
UT WOS:000349340500002
PM 25629882
ER
PT J
AU Restrepo, P
Jameson, DL
Carroll, DL
AF Restrepo, Paula
Jameson, Deborah L.
Carroll, Diane L.
TI Improving Deep Vein Thrombosis Prophylaxis With Mechanical Modalities in
Surgical Intensive Care Unit
SO JOURNAL OF NURSING CARE QUALITY
LA English
DT Article
DE deep vein thrombosis prophylaxis; graduated compression stockings;
guidelines; intermittent pneumatic compression device; quality
improvement; surgery
ID GRADUATED COMPRESSION STOCKINGS; CLINICAL-PRACTICE GUIDELINES;
RANDOMIZED CONTROLLED-TRIAL; ED AMERICAN-COLLEGE; ANTITHROMBOTIC
THERAPY; PNEUMATIC COMPRESSION; PREVENTION; PHYSICIANS; MULTICENTER;
RISK
AB Deep vein thrombosis remains a source of adverse outcomes in surgical patients. Deep vein thrombosis is preventable with prophylactic intervention. The success of noninvasive mechanical modalities for prophylaxis relies on compliance with correct application. The goals of this project were to create a guideline that reflected current evidence and expert thinking about mechanical modalities use, assess compliance with mechanical modalities, and develop strategies to disseminate an evidence-based guideline for deep vein thrombosis prophylaxis.
C1 [Restrepo, Paula] Massachusetts Gen Hosp, Patient Care Serv, Boston, MA 02114 USA.
[Jameson, Deborah L.] Massachusetts Gen Hosp, Treadwell Lib, Boston, MA 02114 USA.
[Carroll, Diane L.] Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, Inst Patient Care, Boston, MA 02114 USA.
RP Carroll, DL (reprint author), Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, POB 430, Boston, MA 02114 USA.
EM dcarroll3@mgh.harvard.edu
FU NCRR NIH HHS [UL1 RR025758, UL1RR025758]
NR 17
TC 0
Z9 0
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-3631
EI 1550-5065
J9 J NURS CARE QUAL
JI J. Nurs. Care Qual.
PD JAN-MAR
PY 2015
VL 30
IS 1
BP 31
EP 37
DI 10.1097/NCQ.0000000000000075
PG 7
WC Nursing
SC Nursing
GA CB3SR
UT WOS:000349549300007
PM 24991980
ER
PT J
AU Bober, SL
Recklitis, CJ
Bakan, J
Garber, JE
Patenaude, AF
AF Bober, Sharon L.
Recklitis, Christopher J.
Bakan, Jennifer
Garber, Judy E.
Patenaude, Andrea F.
TI Addressing Sexual Dysfunction After Risk-Reducing Salpingo-Oophorectomy:
Effects of a Brief, Psychosexual Intervention
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Article
DE Risk-Reducing Salpingo-Oophorectomy and Sexual Dysfunction; Sexual
Health and Cancer; Quality of Life and Cancer
ID QUALITY-OF-LIFE; FUNCTION INDEX FSFI; CANCER SURVIVORS; OVARIAN-CANCER;
GYNECOLOGICAL CANCER; BRCA MUTATION; BODY-IMAGE; WOMEN; CARRIERS;
THERAPY
AB IntroductionWomen at high risk for ovarian cancer due to BRCA1 orBRCA2 mutation or family history are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) after age 35 or completion of childbearing. This potentially life-saving surgery leads to premature menopause, frequently resulting in distressing and unaddressed sexual dysfunction.
AimTo pilot a novel sexual health intervention for women with BRCA1/2 mutations who previously underwent RRSO a using a single-arm trial. Feasibility and primary outcomes including sexual dysfunction and psychological distress were assessed.
MethodsThis single-arm trial included a one-time, half-day educational session comprised of targeted sexual health education, body awareness and relaxation training, and mindfulness-based cognitive therapy strategies, followed by two sessions of tailored telephone counseling. Assessments were completed at baseline and 2 months postintervention.
Main Outcome MeasureStudy end points include feasibility and effectiveness as reported by the participant.
ResultsThirty-seven women completed baseline and postintervention assessments. At baseline, participants had a mean age of 44.4 (standard deviation [SD]=3.9) years and mean duration of 3.8 (SD=2.7) years since RRSO. Overall sexual functioning (P=0.018), as well as desire (P=0.003), arousal (P=0.003), satisfaction (P=0.028), and pain (P=0.018), improved significantly. There were significant reductions in somatization (P=0.029) and anxiety scores (P<0.001), and, overall, for the Global Severity Index (P<0.001) of the Brief Symptom Inventory. Sexual self-efficacy and sexual knowledge also improved significantly from baseline to postintervention (both P<0.001). Women were highly satisfied with the intervention content and reported utilizing new skills to manage sexual dysfunction.
ConclusionsThis intervention integrates elements of cognitive behavioral therapy with sexual health education to address a much-neglected problem after RRSO. Results from this promising single-arm study provide preliminary data to move toward conducting a randomized, controlled trial. Bober SL, Recklitis CJ, Bakan J, Garber JE, and Patenaude AF. Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: Effects of a brief, psychosexual intervention. J Sex Med 2015;12:189-197.
C1 [Bober, Sharon L.; Recklitis, Christopher J.; Bakan, Jennifer; Garber, Judy E.; Patenaude, Andrea F.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bober, Sharon L.; Recklitis, Christopher J.; Garber, Judy E.; Patenaude, Andrea F.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
FU NCI NIH HHS [R03 CA153815, 1 R03 CA153815-01A1]
NR 39
TC 8
Z9 8
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-6095
EI 1743-6109
J9 J SEX MED
JI J. Sex. Med.
PD JAN
PY 2015
VL 12
IS 1
BP 189
EP 197
DI 10.1111/jsm.12713
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA CA4CO
UT WOS:000348852100021
PM 25311333
ER
PT J
AU Arora, P
Reingold, J
Baggish, A
Guanaga, DP
Wu, C
Ghorbani, A
Song, YN
Chen-Tournaux, A
Khan, AM
Tainsh, LT
Buys, ES
Williams, JS
Heublein, DM
Burnett, JC
Semigran, MJ
Bloch, KD
Scherrer-Crosbie, M
Newton-Cheh, C
Kaplan, LM
Wang, TJ
AF Arora, Pankaj
Reingold, Jason
Baggish, Aaron
Guanaga, Derek P.
Wu, Connie
Ghorbani, Anahita
Song, Yanna
Chen-Tournaux, Annabel
Khan, Abigail May
Tainsh, Laurel T.
Buys, Emmanuel S.
Williams, Jonathan S.
Heublein, Denise M.
Burnett, John C.
Semigran, Marc J.
Bloch, Kenneth D.
Scherrer-Crosbie, Marielle
Newton-Cheh, Christopher
Kaplan, Lee M.
Wang, Thomas J.
TI Weight Loss, Saline Loading, and the Natriuretic Peptide System
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE natriuretic peptide; obesity; salt intake
ID BODY-MASS INDEX; PLASMA-LEVELS; BLOOD-PRESSURE; OBESE SUBJECTS;
EXPRESSION; ATRIAL; DISEASE; RISK; ECHOCARDIOGRAPHY; HYPERTENSION
AB Background-In epidemiologic studies, obesity has been associated with reduced natriuretic peptide (NP) concentrations. Reduced NP production could impair the ability of obese individuals to respond to salt loads, increasing the risk of hypertension and other disorders. We hypothesized that weight loss enhances NP production before and after salt loading.
Methods and Results-We enrolled 15 obese individuals (mean BMI 45 +/- 5.4 kg/m(2)) undergoing gastric bypass surgery. Before and 6 months after surgery, subjects were admitted to the clinical research center and administered a large-volume intravenous saline challenge. Echocardiography and serial blood sampling were performed. From the pre-operative visit to 6 months after surgery, subjects had a mean BMI decrease of 27%. At the 6-month visit, N-terminal pro-atrial NP (Nt-proANP) levels were 40% higher before, during, and after the saline infusion, compared with levels measured at the same time points during the pre-operative visit (P<0.001). The rise in Nt-pro-ANP induced by the saline infusion (approximate to 50%) was similar both before and after surgery (saline, P<0.001; interaction, P=0.2). Similar results were obtained for BNP and Nt-proBNP; resting concentrations increased by 50% and 31%, respectively, after gastric bypass surgery. The increase in NP concentrations after surgery was accompanied by significant decreases in mean arterial pressure (P=0.004) and heart rate (P<0.001), and an increase in mitral annular diastolic velocity (P=0.02).
Conclusion-In obese individuals, weight loss is associated with a substantial increase in the "setpoint" of circulating NP concentrations. Higher NP concentrations could contribute to an enhanced ability to handle salt loads after weight loss.
C1 [Arora, Pankaj] Univ Alabama Birmingham, Dept Med, Div Cardiol, Birmingham, AL USA.
[Reingold, Jason] St Josephs Res Inst, Atlanta Cardiol & Primary Care, Atlanta, GA USA.
[Baggish, Aaron; Guanaga, Derek P.; Ghorbani, Anahita; Semigran, Marc J.; Bloch, Kenneth D.; Scherrer-Crosbie, Marielle; Newton-Cheh, Christopher] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Wu, Connie; Tainsh, Laurel T.; Buys, Emmanuel S.; Bloch, Kenneth D.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Div Cardiol, Boston, MA 02114 USA.
[Kaplan, Lee M.] Massachusetts Gen Hosp, Gastrointestinal Unit, Div Cardiol, Boston, MA 02114 USA.
[Song, Yanna] Vanderbilt Univ, Dept Biostat, Nashville, TN 37235 USA.
[Chen-Tournaux, Annabel] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada.
[Khan, Abigail May] Univ Penn, Perelman Sch Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA.
[Williams, Jonathan S.] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA.
[Heublein, Denise M.; Burnett, John C.] Mayo Clin, Div Cardiol, Rochester, MN USA.
[Wang, Thomas J.] Vanderbilt Univ, Div Cardiovasc Med, Nashville, TN 37235 USA.
RP Wang, TJ (reprint author), Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, 2220 Pierce Ave,383 PRB, Nashville, TN 37232 USA.
EM thomas.j.wang@vanderbilt.edu
OI Arora, Pankaj/0000-0003-2420-3550
FU National Institutes of Health [R01 HL102780, R21 DK092909, 1 UL1
RR025758-01]; National Center for Research Resources; Foundation LeDucq
FX This study has been supported by the following grants: R01 HL102780, R21
DK092909, and 1 UL1 RR025758-01 from the National Institutes of Health
and the National Center for Research Resources. The research was also
supported by a grant from the Foundation LeDucq.
NR 26
TC 7
Z9 7
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JAN
PY 2015
VL 4
IS 1
AR e001265
DI 10.1161/JAHA.114.001265
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CA0HI
UT WOS:000348597500011
PM 25595796
ER
PT J
AU Landenhed, M
Engstrom, G
Gottsater, A
Caulfield, MP
Hedblad, B
Newton-Cheh, C
Melander, O
Smith, JG
AF Landenhed, Maya
Engstrom, Gunnar
Gottsater, Anders
Caulfield, Michael P.
Hedblad, Bo
Newton-Cheh, Christopher
Melander, Olle
Smith, J. Gustav
TI Risk Profiles for Aortic Dissection and Ruptured or Surgically Treated
Aneurysms: A Prospective Cohort Study
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE aneurysm; aorta; dissection; epidemiology; risk factor
ID INTERNATIONAL REGISTRY; PRACTICE GUIDELINES; EUROPEAN-SOCIETY;
TASK-FORCE; DISEASE; MANAGEMENT; HEALTH; IRAD; VALIDATION; SURGERY
AB Background-Community screening to guide preventive interventions for acute aortic disease has been recommended in high-risk individuals. We sought to prospectively assess risk factors in the general population for aortic dissection (AD) and severe aneurysmal disease in the thoracic and abdominal aorta.
Methods and Results-We studied the incidence of AD and ruptured or surgically treated aneurysms in the abdominal (AAA) or thoracic aorta (TAA) in 30 412 individuals without diagnosis of aortic disease at baseline from a contemporary, prospective cohort of middle-aged individuals, the Malmo Diet and Cancer study. During up to 20 years of follow-up (median 16 years), the incidence rate per 100 000 patient-years at risk was 15 (95% CI 11.7 to 18.9) for AD, 27 (95% CI 22.5 to 32.1) for AAA, and 9 (95% CI 6.8 to 12.6) for TAA. The acute and in-hospital mortality was 39% for AD, 34% for ruptured AAA, and 41% for ruptured TAA. Hypertension was present in 86% of individuals who subsequently developed AD, was strongly associated with incident AD (hazard ratio [HR] 2.64, 95% CI 1.33 to 5.25), and conferred a population-attributable risk of 54%. Hypertension was also a risk factor for AAA with a smaller effect. Smoking (HR 5.07, 95% CI 3.52 to 7.29) and high apolipoprotein B/A1 ratio (HR 2.48, 95% CI 1.73 to 3.54) were strongly associated with AAA and conferred a population-attributable risk of 47% and 25%, respectively. Smoking was also a risk factor for AD and TAA with smaller effects.
Conclusions-This large prospective study identified distinct risk factor profiles for different aortic diseases in the general population. Hypertension accounted for more than half of the population risk for AD, and smoking for half of the population risk of AAA.
C1 [Landenhed, Maya] Lund Univ, Dept Cardiothorac Surg, S-22185 Lund, Sweden.
[Smith, J. Gustav] Lund Univ, Dept Cardiol, S-22185 Lund, Sweden.
Skane Univ Hosp, Lund, Sweden.
[Engstrom, Gunnar; Hedblad, Bo; Smith, J. Gustav] Lund Univ, Dept Clin Sci, Malmo, Sweden.
[Gottsater, Anders] Skane Univ Hosp, Vasc Ctr, Malmo, Sweden.
[Caulfield, Michael P.] Quest Diagnost Nichols Inst, Dept Endocrinol, San Juan Capistrano, CA USA.
[Caulfield, Michael P.] Quest Diagnost Nichols Inst, CVD, San Juan Capistrano, CA USA.
[Newton-Cheh, Christopher; Smith, J. Gustav] Harvard Univ, Sch Med, Cardiovasc Res Ctr, Boston, MA USA.
[Newton-Cheh, Christopher; Smith, J. Gustav] Harvard Univ, Sch Med, Ctr Human Genet Res, Boston, MA USA.
[Newton-Cheh, Christopher; Smith, J. Gustav] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Newton-Cheh, Christopher; Smith, J. Gustav] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Melander, Olle] Lund Univ, Dept Internal Med, Malmo, Sweden.
[Melander, Olle] Skane Univ Hosp, Malmo, Sweden.
RP Landenhed, M (reprint author), Lund Univ, Dept Cardiothorac Surg, S-22185 Lund, Sweden.
EM maya.landenhed@med.lu.se
OI Engstrom, Gunnar/0000-0002-8618-9152
FU Swedish Cancer Society; Swedish Medical Research Council; Swedish Dairy
Association; Albert Pahlsson and Gunnar Nilsson Foundations; Malmo City
Council; Hulda Almroths Research Foundation; Skane University Hospital
in Malmo; Ernhold Lundstroms Research Foundation; US National Institutes
of Health [HL080025, HL098283]; Burroughs Wellcome Fund; Medical Faculty
of Lund University; Albert Pahlsson Research Foundation; Crafoord
Foundation; Swedish National Health Service; Hulda and Conrad Mossfelt
Foundation; King Gustaf V and Queen Victoria Fund; Lennart Hanssons
Memorial Fund; Marianne and Marcus Wallenberg Foundation; Knut and Alice
Wallenberg Foundation; Swedish Heart-Lung Foundation; Swedish Research
Council; Skane University Hospital in Lund; Quest Diagnostics
FX The MDCS was made possible by grants from the Swedish Cancer Society,
the Swedish Medical Research Council, the Swedish Dairy Association, the
Albert Pahlsson and Gunnar Nilsson Foundations, and the Malmo City
Council. Dr Gottsater was supported by the Hulda Almroths Research
Foundation. Drs Gottsater and Melander were supported by Skane
University Hospital in Malmo and the Ernhold Lundstroms Research
Foundation. Drs Hedblad and Melander were supported by the Swedish
Medical Research Council. Dr Newton-Cheh was supported by grants from
the US National Institutes of Health (HL080025, HL098283) and the
Burroughs Wellcome Fund. Dr Melander was supported by grants from the
Medical Faculty of Lund University, the Albert Pahlsson Research
Foundation, the Crafoord Foundation, the Swedish National Health
Service, the Hulda and Conrad Mossfelt Foundation, the King Gustaf V and
Queen Victoria Fund, the Lennart Hanssons Memorial Fund, the Marianne
and Marcus Wallenberg Foundation, and the Knut and Alice Wallenberg
Foundation. Dr Smith was supported by the Swedish Heart-Lung Foundation,
the Swedish Research Council, the Crafoord Foundation, the Swedish
National Health Service, and Skane University Hospital in Lund.
Measurement of apolipoproteins was performed and supported by Quest
Diagnostics. The funding sources had no role in the study design; in the
collection, analysis, and interpretation of data; in the writing of the
report; or in the decision to submit the manuscript for publication.
NR 41
TC 20
Z9 21
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JAN
PY 2015
VL 4
IS 1
AR e001513
DI 10.1161/JAHA.114.001513
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CA0HI
UT WOS:000348597500017
PM 25609416
ER
PT J
AU Shaefi, S
O'Gara, B
Kociol, RD
Joynt, K
Mueller, A
Nizamuddin, J
Mahmood, E
Talmor, D
Shahul, S
AF Shaefi, Shahzad
O'Gara, Brian
Kociol, Robb D.
Joynt, Karen
Mueller, Ariel
Nizamuddin, Junaid
Mahmood, Eitezaz
Talmor, Daniel
Shahul, Sajid
TI Effect of Cardiogenic Shock Hospital Volume on Mortality in Patients
With Cardiogenic Shock
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE acute coronary syndromes; cardiogenic shock; hospital volume
ID ACUTE MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION;
TO-BALLOON TIME; MECHANICAL VENTILATION; ADMINISTRATIVE DATA;
HEART-FAILURE; CARE UNITS; OUTCOMES; SUPPORT; ANGIOPLASTY
AB Background-Cardiogenic shock (CS) is associated with significant morbidity, and mortality rates approach 40% to 60%. Treatment for CS requires an aggressive, sophisticated, complex, goal-oriented, therapeutic regimen focused on early revascularization and adjunctive supportive therapies, suggesting that hospitals with greater CS volume may provide better care. The association between CS hospital volume and inpatient mortality for CS is unclear.
Methods and Results-We used the Nationwide Inpatient Sample to examine 533 179 weighted patient discharges from 2675 hospitals with CS from 2004 to 2011 and divided them into quartiles of mean annual hospital CS case volume. The primary outcome was in-hospital mortality. Multivariate adjustments were performed to account for severity of illness, relevant comorbidities, hospital characteristics, and differences in treatment. Compared with the highest volume quartile, the adjusted odds ratio for inpatient mortality for persons admitted to hospitals in the lowest-volume quartile (<= 27 weighted cases per year) was 1.27 (95% CI 1.15 to 1.40), whereas for admission to hospitals in the low-volume and medium-volume quartiles, the odds ratios were 1.20 (95% CI 1.08 to 1.32) and 1.12 (95% CI 1.01 to 1.24), respectively. Similarly, improved survival was observed across quartiles, with an adjusted inpatient mortality incidence of 41.97% (95% CI 40.87 to 43.08) for hospitals with the lowest volume of CS cases and a drop to 37.01% (95% CI 35.11 to 38.96) for hospitals with the highest volume of CS cases. Analysis of treatments offered between hospital quartiles revealed that the centers with volumes in the highest quartile demonstrated significantly higher numbers of patients undergoing coronary artery bypass grafting, percutaneous coronary intervention, or intra-aortic balloon pump counterpulsation. A similar relationship was demonstrated with the use of mechanical circulatory support (ventricular assist devices and extracorporeal membrane oxygenation), for which there was significantly higher use in the higher volume quartiles.
Conclusions-We demonstrated an association between lower CS case volume and higher mortality. There is more frequent use of both standard supportive and revascularization techniques at the higher volume centers. Future directions may include examining whether early stabilization and transfer improve outcomes of patients with CS who are admitted to lower volume centers.
C1 [Shaefi, Shahzad; O'Gara, Brian; Mueller, Ariel; Nizamuddin, Junaid; Mahmood, Eitezaz; Talmor, Daniel; Shahul, Sajid] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA.
[Kociol, Robb D.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Cardiovasc Inst,Dept Med, Boston, MA 02215 USA.
[Joynt, Karen] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med,Dept Med, Boston, MA 02115 USA.
RP Shahul, S (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA.
EM sshahul@bidmc.harvard.edu
FU Foundation for Anesthesia Research (FAER); Beth Israel Deaconess
Department of Anesthesia; Critical Care and Pain Medicine; Center for
Anesthesia Research Excellence (CARE)
FX This study was supported by Foundation for Anesthesia Research (FAER),
Beth Israel Deaconess Department of Anesthesia, Critical Care and Pain
Medicine, Center for Anesthesia Research Excellence (CARE).
NR 34
TC 4
Z9 4
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JAN
PY 2015
VL 4
IS 1
AR e001462
DI 10.1161/JAHA.114.001462
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CA0HI
UT WOS:000348597500023
PM 25559014
ER
PT J
AU Waks, JW
Soliman, EZ
Henrikson, CA
Sotoodehnia, N
Han, L
Agarwal, SK
Arking, DE
Siscovick, DS
Solomon, SD
Post, WS
Josephson, ME
Coresh, J
Tereshchenko, LG
AF Waks, Jonathan W.
Soliman, Elsayed Z.
Henrikson, Charles A.
Sotoodehnia, Nona
Han, Lichy
Agarwal, Sunil K.
Arking, Dan E.
Siscovick, David S.
Solomon, Scott D.
Post, Wendy S.
Josephson, Mark E.
Coresh, Josef
Tereshchenko, Larisa G.
TI Beat-to-Beat Spatiotemporal Variability in the T Vector Is Associated
With Sudden Cardiac Death in Participants Without Left Ventricular
Hypertrophy: The Atherosclerosis Risk in Communities (ARIC) Study
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE atherosclerosis; electrocardiography; electrophysiology; epidemiology;
sudden cardiac death; TT' angle
ID CORONARY-HEART-DISEASE; VECTORCARDIOGRAPHIC LOOP ALIGNMENT;
REPOLARIZATION VARIABILITY; QT VARIABILITY; ECG; ELECTROCARDIOGRAM;
ANGLE; STRATIFICATION; MECHANISMS; PREDICTION
AB Background-Despite advances in prevention and treatment of cardiovascular disease, sudden cardiac death (SCD) remains a clinical challenge. Risk stratification in the general population is needed.
Methods and Results-Beat-to-beat spatiotemporal variability in the T vector was measured as the mean angle between consecutive T-wave vectors (mean TT' angle) on standard 12-lead ECGs in 14 024 participants in the Atherosclerosis Risk in Communities (ARIC) study. Subjects with left ventricular hypertrophy, atrial arrhythmias, frequent ectopy, ventricular pacing, or QRS duration >= 120 ms were excluded. The mean spatial TT' angle was 5.21 +/- 3.55 degrees. During a median of 14 years of follow-up, 235 SCDs occurred (1.24 per 1000 person-years). After adjustment for demographics, coronary heart disease risk factors, and known ECG markers for SCD, mean TT' angle was independently associated with SCD (hazard ratio 1.089; 95% CI 1.044 to 1.137; P<0.0001). A mean TT' angle >90th percentile (>9.57 degrees) was associated with a 2-fold increase in the hazard for SCD (hazard ratio 2.01; 95% CI 1.28 to 3.16; P=0.002). In a subgroup of patients with T-vector amplitude >= 0.2 mV, the association with SCD was almost twice as strong (hazard ratio 3.92; 95% CI 1.91 to 8.05; P<0.0001). A significant interaction between mean TT' angle and age was found: TT' angle was associated with SCD in participants aged <55 years (hazard ratio 1.096; 95% CI 0.043 to 1.152; P<0.0001) but not in participants aged >= 55 years (P-interaction=0.009).
Conclusions-In a large, prospective, community-based cohort of left ventricular hypertrophy-free participants, increased beat-to-beat spatiotemporal variability in the T vector, as assessed by increasing TT' angle, was associated with SCD.
C1 [Waks, Jonathan W.; Josephson, Mark E.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA USA.
[Soliman, Elsayed Z.] Epidemiol Cardiol Res Ctr EPICARE, Div Publ Hlth Sci, Winston Salem, NC USA.
[Soliman, Elsayed Z.] Wake Forest Sch Med, Dept Med, Cardiol Sect, Winston Salem, NC USA.
[Henrikson, Charles A.; Tereshchenko, Larisa G.] Oregon Hlth & Sci Univ, Knight Cardiovascular Inst, Portland, OR 97201 USA.
[Sotoodehnia, Nona; Siscovick, David S.] Univ Washington, Seattle, WA 98195 USA.
[Han, Lichy] Johns Hopkins Univ, Whitening Sch Engn, Baltimore, MD USA.
[Agarwal, Sunil K.; Coresh, Josef] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Agarwal, Sunil K.; Coresh, Josef] Johns Hopkins Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
[Arking, Dan E.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
[Post, Wendy S.; Tereshchenko, Larisa G.] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA.
[Solomon, Scott D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA.
[Siscovick, David S.] New York Acad Med, New York, NY USA.
RP Tereshchenko, LG (reprint author), 3181 SW Sam Jackson Pk Rd,UHN62, Portland, OR 97239 USA.
EM tereshch@ohsu.edu
OI Tereshchenko, Larisa/0000-0002-6976-1313
FU National Institutes of Health (NIH) [HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN2682 01100008C,
HHSN268201100009C, HHSN268201100010C, HHSN268201100011C,
HHSN268201100012C, 1R01HL118277]; Johns Hopkins Institute for Clinical
and Translational Research grant
FX The Atherosclerosis Risk in Communities study is carried out as a
collaborative study supported by the National Institutes of Health (NIH)
contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
HHSN268201100011C, and HHSN268201100012C). This work was supported by
the NIH (1R01HL118277) and the Johns Hopkins Institute for Clinical and
Translational Research grant (Tereshchenko).
NR 45
TC 6
Z9 6
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JAN
PY 2015
VL 4
IS 1
AR e001357
DI 10.1161/JAHA.114.001357
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CA0HI
UT WOS:000348597500005
PM 25600143
ER
PT J
AU Perl, L
Zemer-Wassercug, N
Rechavia, E
Vaduganathan, M
Orvin, K
Weissler-Snir, A
Lerman-Shivek, H
Kornowski, R
Lev, EI
AF Perl, Leor
Zemer-Wassercug, Noa
Rechavia, Eldad
Vaduganathan, Muthiah
Orvin, Katia
Weissler-Snir, Adaya
Lerman-Shivek, Hila
Kornowski, Ran
Lev, Eli I.
TI Comparison of platelet inhibition by prasugrel versus ticagrelor over
time in patients with acute myocardial infarction
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article
DE Prasugrel; Ticagrelor; Platelet reactivity; Acute myocardial infarction
ID PERCUTANEOUS CORONARY INTERVENTION; ASPIRIN-TREATED PATIENTS;
ARTERY-DISEASE; ADENOSINE-DIPHOSPHATE; RETICULATED PLATELETS;
CARDIOVASCULAR EVENTS; CLOPIDOGREL; REACTIVITY; CYP2C19; IMPACT
AB High on-treatment platelet reactivity (HTPR) despite use of P2Y12 antagonists is associated with adverse cardiac events. The long-term variability in response to prasugrel and ticagrelor is unclear. Our aim was to assess residual platelet reactivity (PR) and rates of HTPR during treatment with prasugrel versus ticagrelor in patients with myocardial infarction (MI). 114 patients with MI treated with percutaneous coronary intervention (PCI) were included. Sixty-two patients were treated with prasugrel (mean age 58 +/- 8 years, 21 % women, 29 % diabetes), and 52 patients with ticagrelor (mean age 63 +/- 9, 19 % women, 37 % diabetes). Patients were tested for PR at 2-4 days and 30 days post-PCI, using the VerifyNow P2Y12 assay and the multiple-electrode aggregometry. Our results show a higher residual PR in patients treated with prasugrel than those treated with ticagrelor (VerifyNow: 65.4 +/- 60.6 vs. 26.0 +/- 24.2 P2Y12 reaction units, p < 0.001 at 2-4 days, and 67.3 +/- 62.5 vs. 21.1 +/- 26.1, p < 0.001 at follow-up). HTPR rates were higher in the prasugrel group (8.1-11.3 % vs. none with ticagrelor in the early test, and 8.7-10.9 % vs. none with ticagrelor at follow-up). In conclusion, in patients with MI undergoing PCI, treatment with ticagrelor resulted in greater platelet inhibition and lower HTPR rates compared with prasugrel, up to 30 days after the event.
C1 [Perl, Leor; Zemer-Wassercug, Noa; Rechavia, Eldad; Orvin, Katia; Weissler-Snir, Adaya; Kornowski, Ran; Lev, Eli I.] Rabin Med Ctr, Dept Cardiol, IL-49100 Petah Tiqwa, Israel.
[Perl, Leor; Zemer-Wassercug, Noa; Rechavia, Eldad; Orvin, Katia; Weissler-Snir, Adaya; Kornowski, Ran; Lev, Eli I.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
[Vaduganathan, Muthiah] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Lerman-Shivek, Hila] Hebrew Univ Jerusalem, Sch Pharm, Dept Clin Pharm, IL-91120 Jerusalem, Israel.
RP Lev, EI (reprint author), Rabin Med Ctr, Dept Cardiol, Jabotinski St 39, IL-49100 Petah Tiqwa, Israel.
EM elil@clalit.org.il
NR 31
TC 9
Z9 9
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD JAN
PY 2015
VL 39
IS 1
BP 1
EP 7
DI 10.1007/s11239-014-1119-9
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA CA1GH
UT WOS:000348660300001
PM 25085573
ER
PT J
AU Halaby, R
Popma, CJ
Cohen, A
Chi, G
Zacarkim, MR
Romero, G
Goldhaber, SZ
Hull, R
Hernandez, A
Mentz, R
Harrington, R
Lip, G
Peacock, F
Welker, J
Martin-Loeches, I
Daaboul, Y
Korjian, S
Gibson, CM
AF Halaby, Rim
Popma, Christopher J.
Cohen, Ander
Chi, Gerald
Zacarkim, Marcelo Rodrigues
Romero, Gonzalo
Goldhaber, Samuel Z.
Hull, Russell
Hernandez, Adrian
Mentz, Robert
Harrington, Robert
Lip, Gregory
Peacock, Frank
Welker, James
Martin-Loeches, Ignacio
Daaboul, Yazan
Korjian, Serge
Gibson, C. Michael
TI D-Dimer elevation and adverse outcomes
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Review
DE D-Dimer; Deep vein thrombosis; Mortality; Prognosis; Pulmonary embolism
ID POSTOPERATIVE VENOUS THROMBOEMBOLISM; COMMUNITY-ACQUIRED PNEUMONIA;
ACUTE AORTIC DISSECTION; CRITICALLY-ILL PATIENTS; DEEP-VEIN THROMBOSIS;
LUNG-CANCER PATIENTS; PLASMA D-DIMER; PULMONARY-EMBOLISM; RISK-FACTORS;
ANTICOAGULANT-THERAPY
AB D-Dimer is a biomarker of fibrin formation and degradation. While a D-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated D-dimer with adverse outcomes has received far less emphasis. An elevated D-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated D-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the D-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.
C1 [Halaby, Rim; Popma, Christopher J.; Chi, Gerald; Zacarkim, Marcelo Rodrigues; Romero, Gonzalo; Daaboul, Yazan; Korjian, Serge; Gibson, C. Michael] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc,Dept Med, Boston, MA 02215 USA.
[Cohen, Ander] Kings Coll Hosp London, London, England.
[Goldhaber, Samuel Z.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Cardiovasc, Boston, MA 02215 USA.
[Hull, Russell] Foothills Prov Gen Hosp, Dept Med Calgary, Calgary, AB T2N 2T9, Canada.
[Hernandez, Adrian; Mentz, Robert] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA.
[Harrington, Robert] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
[Lip, Gregory] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England.
[Peacock, Frank] Baylor Coll Med, Emergency Dept, Houston, TX 77030 USA.
[Welker, James] Univ Maryland, Sch Med, Anne Arundel Hlth Syst Res Inst, Anne Arundel Med Ctr, Baltimore, MD 21201 USA.
[Martin-Loeches, Ignacio] Corp Sanitaria I Univ Parc, Tauli Hosp Sabadell Parc Tauli, Crit Care Ctr, Barcelona, Spain.
RP Gibson, CM (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc,Dept Med, East Campus,RW 459, Boston, MA 02215 USA.
EM charlesmichaelgibson@gmail.com
RI Hernandez, Adrian F./A-7818-2016;
OI Hernandez, Adrian F./0000-0003-3387-9616; Chi,
Gerald/0000-0002-8371-1689
NR 51
TC 3
Z9 6
U1 2
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD JAN
PY 2015
VL 39
IS 1
BP 55
EP 59
DI 10.1007/s11239-014-1101-6
PG 5
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA CA1GH
UT WOS:000348660300008
PM 25006010
ER
PT J
AU Quesada, CJG
Giugliano, RP
AF Quesada, Carlos J. Gonzalez
Giugliano, Robert P.
TI Selecting an oral anticoagulant for patients with nonvalvular atrial
fibrillation
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article
DE Atrial fibrillation; Dabigatran; Apixaban; Rivaroxaban; Edoxaban;
Warfarin
ID WARFARIN; METAANALYSIS
AB While the use of warfarin has been the cornerstone of thromboembolism prevention in patients with atrial fibrillation (AF), its limitations have led to the introduction of a new generation of direct-acting oral anticoagulants. Evidence from large phase III clinical trials, observational studies and pharmacokinetic analyses can guide clinicians to select the most effective and safest form of anticoagulation for patients with nonvalvular AF. This manuscript describes the main pharmacologic, clinical and epidemiological characteristics of each new oral anticoagulant and their use in selected clinical scenarios, including patients with: advanced age; at low or high risk of stroke; potential drug-drug interactions; on concomitant antiplatelet therapy; at high risk for acute coronary syndrome; with recent gastrointestinal bleeding; with renal impairment; and with hepatic dysfunction.
C1 [Quesada, Carlos J. Gonzalez] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Giugliano, Robert P.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc Med, Boston, MA 02115 USA.
RP Giugliano, RP (reprint author), Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc Med, 350 Longwood Ave 1st Floor Off, Boston, MA 02115 USA.
EM carlosjgquesada@mail.harvard.edu; rgiugliano@partners.org
FU Daiichi Sankyo; Janssen Pharmaceuticals; Merck; Portola; Bristol-Myers
Squibb; Sanofi; Johnson Johnson; AstraZeneca
FX Dr. Gonzalez Quesada reports no conflict of interests. Dr. Giugliano
reports receiving consulting fees from Daiichi Sankyo, Janssen
Pharmaceuticals, Merck, and Portola; lecture fees from Bristol-Myers
Squibb, Daiichi Sankyo, Merck, and Sanofi; and Grant support through his
institution from Daiichi Sankyo, Merck, Johnson & Johnson, Sanofi, and
AstraZeneca.
NR 10
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD JAN
PY 2015
VL 39
IS 1
BP 129
EP 138
DI 10.1007/s11239-014-1148-4
PG 10
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA CA1GH
UT WOS:000348660300018
ER
PT J
AU Goral, VN
Au, SH
Faris, RA
Yuen, PK
AF Goral, Vasiliy N.
Au, Sam H.
Faris, Ronald A.
Yuen, Po Ki
TI Methods for advanced hepatocyte cell culture in microwells utilizing air
bubbles
SO LAB ON A CHIP
LA English
DT Article
ID MULTICELLULAR SPHEROIDS; PERFUSION-CULTURE; GROWTH; SYSTEM; ARRAY
AB Flat, two-dimensional (2D) cell culture substrates are simple to use but offer little control over cell morphologies and behavior. In this article, we present a number of novel and unique methods for advanced cell culture in microwells utilizing air bubbles as a way to seed cells in order to provide substantial control over cellular microenvironments and organization to achieve specific cell-based applications. These cell culture methods enable controlled formation of stable air bubbles in the microwells that spontaneously formed when polar solvents such as cell culture media are loaded. The presence of air bubbles (air bubble masking) enables highly controllable cell patterning and organization of seeded cells as well as cell co-culture in microwells. In addition, these cell culture methods are simple to use and implement, yet versatile, and have the potential to provide a wide range of microenvironments to improve in vivo-like behavior for a number of cell types and applications. The air bubble masking technique can also be used to produce a micron thick layer of collagen film suspended on top of the microwells. These collagen film enclosed microwells could provide an easy way for high throughput drug screening and cytotoxicity assays as different drug compounds could be pre-loaded and dried in selected microwells and then released during cell culture.
C1 [Goral, Vasiliy N.; Faris, Ronald A.; Yuen, Po Ki] Corning Inc, Sci & Technol, Corning, NY 14831 USA.
[Au, Sam H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
RP Goral, VN (reprint author), Corning Inc, Sci & Technol, Corning, NY 14831 USA.
EM goralvn@corning.com; yuenp@corning.com
NR 18
TC 2
Z9 2
U1 3
U2 16
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PY 2015
VL 15
IS 4
BP 1032
EP 1037
DI 10.1039/c4lc01178c
PG 6
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience
& Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
Other Topics
GA CB1QY
UT WOS:000349404200011
PM 25474691
ER
PT J
AU Ng, EX
Miller, MA
Jing, TY
Lauffenburger, DA
Chen, CH
AF Ng, Ee Xien
Miller, Miles A.
Jing, Tengyang
Lauffenburger, Doug A.
Chen, Chia-Hung
TI Low-volume multiplexed proteolytic activity assay and inhibitor analysis
through a pico-injector array
SO LAB ON A CHIP
LA English
DT Article
ID BREAST-CANCER CELLS; EPIDERMAL-GROWTH-FACTOR; MICROFLUIDIC PLATFORM;
DROPLETS; GENERATION; ADAM10; METALLOPROTEINASE-9; EXPRESSION; ADAM-10;
MODEL
AB Secreted active proteases, from families of enzymes such as matrix metalloproteinases (MMPs) and ADAMs (a disintegrin and metalloproteinases), participate in diverse pathological processes. To simultaneously measure multiple specific protease activities, a series of parallel enzyme reactions combined with a series of inhibitor analyses for proteolytic activity matrix analysis (PrAMA) are essential but limited due to the sample quantity requirements and the complexity of performing multiple reactions. To address these issues, we developed a pico-injector array to generate 72 different reactions in picoliter-volume droplets by controlling the sequence of combinational injections, which allowed simultaneous recording of a wide range of multiple enzyme reactions and measurement of inhibitor effects using small sample volumes (similar to 10 mu L). Multiple MMP activities were simultaneously determined by 9 different substrates and 2 inhibitors using injections from a pico-injector array. Due to the advantages of inhibitor analysis, the MMP/ADAM activities of MDA-MB-231, a breast cancer cell line, were characterized with high MMP-2, MMP-3 and ADAM-10 activity. This platform could be customized for a wide range of applications that also require multiple reactions with inhibitor analysis to enhance the sensitivity by encapsulating different chemical sensors.
C1 [Ng, Ee Xien; Jing, Tengyang; Chen, Chia-Hung] Natl Univ Singapore, Dept Biomed Engn, Singapore 117575, Singapore.
[Miller, Miles A.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Miller, Miles A.; Lauffenburger, Doug A.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Jing, Tengyang] Singapore MIT Alliance Res & Technol SMART Ctr, Singapore 1385602, Singapore.
[Chen, Chia-Hung] Singapore Inst Neurotechnol SINAPSE, Singapore 117456, Singapore.
RP Chen, CH (reprint author), Natl Univ Singapore, Dept Biomed Engn, 9 Engn Dr 1, Singapore 117575, Singapore.
EM biecch@nus.edu.sg
FU NUS start-up grant [R-397-000-137-133]; NUS Engineering-Medicine Seed
grant [R-397-000-152-112]; MOE Tier-1 [R-397-000-153-112]; Singapore MIT
Alliance for Research and Technology (SMART) research
[R-397-000-146-592]
FX We gratefully acknowledge the funding provided by the NUS start-up grant
R-397-000-137-133, NUS Engineering-Medicine Seed grant
R-397-000-152-112, MOE Tier-1 R-397-000-153-112 the Singapore MIT
Alliance for Research and Technology (SMART) research grant
R-397-000-146-592, and the facilities provided by Singapore Institute
for Neurotechnology (SINAPSE).
NR 34
TC 7
Z9 7
U1 3
U2 15
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PY 2015
VL 15
IS 4
BP 1153
EP 1159
DI 10.1039/c4lc01162g
PG 7
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience
& Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
Other Topics
GA CB1QY
UT WOS:000349404200026
PM 25553996
ER
PT S
AU Haake, DA
Levett, PN
AF Haake, David A.
Levett, Paul N.
BE Adler, B
TI Leptospirosis in Humans
SO LEPTOSPIRA AND LEPTOSPIROSIS
SE Current Topics in Microbiology and Immunology
LA English
DT Review; Book Chapter
ID ACUTE-RENAL-FAILURE; LINKED-IMMUNOSORBENT-ASSAY; INTERROGANS SEROVAR
ICTEROHAEMORRHAGIAE; LATEX AGGLUTINATION ASSAY;
POLYMERASE-CHAIN-REACTION; QUANTITATIVE PCR ASSAY; TANDEM-REPEAT
ANALYSIS; ACUTE FEBRILE ILLNESS; ACUTE KIDNEY INJURY; REAL-TIME PCR
AB Leptospirosis is a widespread and potentially fatal zoonosis that is endemic in many tropical regions and causes large epidemics after heavy rainfall and flooding. Infection results from direct or indirect exposure to infected reservoir host animals that carry the pathogen in their renal tubules and shed pathogenic leptospires in their urine. Although many wild and domestic animals can serve as reservoir hosts, the brown rat (Rattus norvegicus) is the most important source of human infections. Individuals living in urban slum environments characterized by inadequate sanitation and poor housing are at high risk of rat exposure and leptospirosis. The global burden of leptospirosis is expected to rise with demographic shifts that favor increases in the number of urban poor in tropical regions subject to worsening storms and urban flooding due to climate change. Data emerging from prospective surveillance studies suggest that most human leptospiral infections in endemic areas are mild or asymptomatic. Development of more severe outcomes likely depends on three factors: epidemiological conditions, host susceptibility, and pathogen virulence (Fig. 1). Mortality increases with age, particularly in patients older than 60 years of age. High levels of bacteremia are associated with poor clinical outcomes and, based on animal model and in vitro studies, are related in part to poor recognition of leptospiral LPS by human TLR4. Patients with severe leptospirosis experience a cytokine storm characterized by high levels of IL-6, TNF-alpha, and IL-10. Patients with the HLA DQ6 allele are at higher risk of disease, suggesting a role for lymphocyte stimulation by a leptospiral superantigen. Leptospirosis typically presents as a nonspecific, acute febrile illness characterized by fever, myalgia, and headache and may be confused with other entities such as influenza and dengue fever. Newer diagnostic methods facilitate early diagnosis and antibiotic treatment. Patients progressing to multisystem organ failure have widespread hematogenous dissemination of pathogens. Nonoliguric (high output) renal dysfunction should be supported with fluids and electrolytes. When oliguric renal failure occurs, prompt initiation of dialysis can be life saving. Elevated bilirubin levels are due to hepatocellular damage and disruption of intercellular junctions between hepatocytes, resulting in leaking of bilirubin out of bile caniliculi. Hemorrhagic complications are common and are associated with coagulation abnormalities. Severe pulmonary hemorrhage syndrome due to extensive alveolar hemorrhage has a fatality rate of >50 %. Readers are referred to earlier, excellent summaries related to this subject (Adler and de la Pena-Moctezuma 2010; Bharti et al. 2003; Hartskeerl et al. 2011; Ko et al. 2009; Levett 2001; McBride et al. 2005).
C1 [Haake, David A.] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
[Levett, Paul N.] Saskatchewan Dis Control Lab, Regina, SK, Canada.
RP Haake, DA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA.
EM dhaake@ucla.edu; plevett@health.gov.sk.ca
FU BLRD VA [I01 BX002003]; NIAID NIH HHS [R01 AI034431]
NR 186
TC 25
Z9 27
U1 3
U2 32
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0070-217X
BN 978-3-662-45059-8; 978-3-662-45058-1
J9 CURR TOP MICROBIOL
JI Curr.Top.Microbiol.Immunol.
PY 2015
VL 387
BP 65
EP 97
DI 10.1007/978-3-662-45059-8_5
D2 10.1007/978-3-662-45059-8
PG 33
WC Immunology; Microbiology
SC Immunology; Microbiology
GA BC0EH
UT WOS:000348986500006
PM 25388133
ER
PT S
AU Haake, DA
Zuckert, WR
AF Haake, David A.
Zueckert, Wolfram R.
BE Adler, B
TI The Leptospiral Outer Membrane
SO LEPTOSPIRA AND LEPTOSPIROSIS
SE Current Topics in Microbiology and Immunology
LA English
DT Review; Book Chapter
ID INTERROGANS SEROVAR COPENHAGENI; SURFACE-EXPOSED LIPOPROTEIN;
IMMUNOGLOBULIN-LIKE PROTEINS; PROXIMAL TUBULE CELLS; PATHOGENIC
LEPTOSPIRA; ESCHERICHIA-COLI; BORRELIA-BURGDORFERI;
EXTRACELLULAR-MATRIX; PROTECTIVE IMMUNITY; MOLECULAR-CLONING
AB The outer membrane (OM) is the front line of leptospiral interactions with their environment and the mammalian host. Unlike most invasive spirochetes, pathogenic leptospires must be able to survive in both free-living and host-adapted states. As organisms move from one set of environmental conditions to another, the OM must cope with a series of conflicting challenges. For example, the OM must be porous enough to allow nutrient uptake, yet robust enough to defend the cell against noxious substances. In the host, the OM presents a surface decorated with adhesins and receptors for attaching to, and acquiring, desirable host molecules such as the complement regulator, Factor H. On the other hand, the OM must enable leptospires to evade detection by the host's immune system on their way from sites of invasion through the bloodstream to the protected niche of the proximal tubule. The picture that is emerging of the leptospiral OM is that, while it shares many of the characteristics of the OMs of spirochetes and Gram-negative bacteria, it is also unique and different in ways that make it of general interest to microbiologists. For example, unlike most other pathogenic spirochetes, the leptospiral OM is rich in lipopolysaccharide (LPS). Leptospiral LPS is similar to that of Gram-negative bacteria but has a number of unique structural features that may explain why it is not recognized by the LPS-specific Toll-like receptor 4 of humans. As in other spirochetes, lipoproteins are major components of the leptospiral OM, though their roles are poorly understood. The functions of transmembrane outer membrane proteins (OMPs) in many cases are better understood, thanks to homologies with their Gram-negative counterparts and the emergence of improved genetic techniques. This chapter will review recent discoveries involving the leptospiral OM and its role in leptospiral physiology and pathogenesis.
C1 [Haake, David A.] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
[Zueckert, Wolfram R.] Univ Kansas, Sch Med, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66160 USA.
RP Haake, DA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA.
EM dhaake@ucla.edu; wzueckert@kumc.edu
FU BLRD VA [I01 BX002003]; NIAID NIH HHS [R01 AI034431]; NIGMS NIH HHS [P30
GM103326]
NR 117
TC 3
Z9 3
U1 2
U2 9
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0070-217X
BN 978-3-662-45059-8; 978-3-662-45058-1
J9 CURR TOP MICROBIOL
JI Curr.Top.Microbiol.Immunol.
PY 2015
VL 387
BP 187
EP 221
DI 10.1007/978-3-662-45059-8_8
D2 10.1007/978-3-662-45059-8
PG 35
WC Immunology; Microbiology
SC Immunology; Microbiology
GA BC0EH
UT WOS:000348986500009
PM 25388136
ER
PT B
AU Klein, E
AF Klein, Eran
BE VanRysewyk, SP
Pontier, M
TI Models of the Patient-Machine-Clinician Relationship in Closed-Loop
Machine Neuromodulation
SO MACHINE MEDICAL ETHICS
SE Intelligent Systems Control and Automation Science and Engineering
LA English
DT Article; Book Chapter
ID DEEP BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE;
PROFESSION
AB Closed-loop neuromodulation represents an emerging area in clinical medicine. Neural devices capable of measuring brain function and using measurements to iteratively guide output, such as deep brain stimulation, will be a significant advance in neuromodulatory technology. The introduction of closed-loop devices, particularly "smart" machines, will require changes in clinical ethical practice. A model of the clinical relationship could be a useful tool for addressing ethical challenges arising in this new area. Traditional models of the clinical relationship, like Emanuel and Emanuel's "four models," are suited to current unidirectional forms of neuromodulation. An adequate model of the patient-machine-clinician relationship may need to move beyond traditional models. Thus, I explore three new models: the design model, the customer service model, and the quality monitoring model. The exploration of these models of the patient-machine-clinician relationship will benefit from keeping an Aristotelian ideal of friendship in mind.
C1 [Klein, Eran] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Klein, Eran] Portland VA Med Ctr, Portland, OR USA.
[Klein, Eran] Univ Washington, Dept Philosophy, Seattle, WA 98195 USA.
[Klein, Eran] Univ Washington, Ctr Sensorimotor Neural Engn, Seattle, WA 98195 USA.
RP Klein, E (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
EM kleine@ohsu.edu
NR 36
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 978-3-319-08108-3; 978-3-319-08107-6
J9 INTEL SYST CONTR AUT
PY 2015
VL 74
BP 273
EP 290
DI 10.1007/978-3-319-08108-3_17
D2 10.1007/978-3-319-08108-3
PG 18
WC Ethics; Robotics
SC Social Sciences - Other Topics; Robotics
GA BB8KL
UT WOS:000346771800018
ER
PT J
AU Hiremath, SV
Intille, SS
Kelleher, A
Cooper, RA
Ding, D
AF Hiremath, Shivayogi V.
Intille, Stephen S.
Kelleher, Annmarie
Cooper, Rory A.
Ding, Dan
TI Detection of physical activities using a physical activity monitor
system for wheelchair users
SO MEDICAL ENGINEERING & PHYSICS
LA English
DT Article
DE Spinal cord injury; Physical activity; Wheelchair users; Activity
monitor system; Smartphones; Machine learning; Classification
ID SPINAL-CORD-INJURY; ENERGY-EXPENDITURE; VALIDATION
AB Availability of physical activity monitors for wheelchair users can potentially assist these individuals to track regular physical activity (PA), which in turn could lead to a healthier and more active lifestyle. Therefore, the aim of this study was to develop and validate algorithms for a physical activity monitoring system (PAMS) to detect wheelchair based activities. The PAMS consists of a gyroscope based wheel rotation monitor (G-WRM) and an accelerometer device (wocket) worn on the upper arm or on the wrist. A total of 45 persons with spinal cord injury took part in the study, which was performed in a structured university-based laboratory environment, a semi-structured environment at the National Veterans Wheelchair Games, and in the participants' home environments. Participants performed at least ten PAs, other than resting, taken from a list of PAs. The classification performance for the best classifiers on the testing dataset for PAMS-Arm (G-WRM and wocket on upper arm) and PAMS-Wrist (G-WRM and wocket on wrist) was 89.26% and 88.47%, respectively. The outcomes of this study indicate that multi-modal information from the PAMS can help detect various types of wheelchair-based activities in structured laboratory, semi-structured organizational, and unstructured home environments. (C) 2014 IPEM. Published by Elsevier Ltd. All rights reserved.
C1 [Hiremath, Shivayogi V.; Kelleher, Annmarie; Cooper, Rory A.; Ding, Dan] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA USA.
[Kelleher, Annmarie; Cooper, Rory A.; Ding, Dan] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA.
[Hiremath, Shivayogi V.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15206 USA.
[Intille, Stephen S.] Northeastern Univ, Coll Comp & Informat Sci, Boston, MA 02115 USA.
[Intille, Stephen S.] Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USA.
[Cooper, Rory A.; Ding, Dan] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15206 USA.
RP Ding, D (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Human Engn Res Labs, VA Pittsburgh Healthcare Syst, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA.
EM dad5@pitt.edu
FU Department of Defense [W81XWH-10-1-0816]; National Institute on
Disability and Rehabilitation Research, Department of Education
[H133F110032]; Human Engineering Research Laboratories, VA Pittsburgh
Healthcare System
FX The work is supported by the Department of Defense (W81XWH-10-1-0816).
SVH's work on this article was funded through the Switzer Research
Fellowship (H133F110032) awarded by the National Institute on Disability
and Rehabilitation Research, Department of Education. The work is also
supported by the Human Engineering Research Laboratories, VA Pittsburgh
Healthcare System. The contents do not represent the views of the
Department of Veterans Affairs or the United States Government. The
authors thank their colleagues at the Human Engineering Research
Laboratories, especially Alejandra Manoela Ojeda, Monsak Socharoentum,
Natthasit Wongsirikul, and Matthew Hannan for their input and effort
during development and data collection.
NR 17
TC 5
Z9 5
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1350-4533
EI 1873-4030
J9 MED ENG PHYS
JI Med. Eng. Phys.
PD JAN
PY 2015
VL 37
IS 1
BP 68
EP 76
DI 10.1016/j.medengphy.2014.10.009
PG 9
WC Engineering, Biomedical
SC Engineering
GA CB4GB
UT WOS:000349585100009
PM 25465284
ER
PT J
AU Nilsagard, Y
Gunn, H
Freeman, J
Hoang, P
Lord, S
Mazumder, R
Cameron, M
AF Nilsagard, Y.
Gunn, H.
Freeman, J.
Hoang, P.
Lord, S.
Mazumder, Rajarshi
Cameron, Michelle
TI Falls in people with MS-an individual data meta-analysis from studies
from Australia, Sweden, United Kingdom and the United States
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE Accidental falls; multiple sclerosis; risk factors; cohort studies;
meta-analysis
ID DISABILITY STATUS SCALE; PREDICTING ACCIDENTAL FALLS;
MULTIPLE-SCLEROSIS; RISK-FACTORS; OLDER-ADULTS; BALANCE; PREVENTION;
IMBALANCE; STRENGTH; COHORT
AB Background: Falls are common in people with multiple sclerosis (PwMS). Previous studies have generally included small samples and had varied methods.
Objectives: The objectives of this paper are to compile fall rates across a broad range of ages and disease severity and to definitively assess the extent to which MS-associated and demographic factors influence fall rates.
Methods: Individual data from studies in four countries that prospectively measured falls for three months were analyzed. We determined fall rates, prevalence of fallers (1 falls) and frequent fallers (2 falls), location and timing of falls, and fall-related demographic factors.
Results: A total of 537 participants reported 1721 falls: 56% were fallers and 37% frequent fallers. Most falls occurred indoors (65%) between 6 a.m. and 6 p.m. (75%). Primary progressive MS was associated with significantly increased odds of being a faller (odds ratio (OR) 2.02; CI 1.08-3.78). Fall risk peaked at EDSS levels of 4.0 and 6.0 with significant ORs between 5.30 (2.23-12.64) and 5.10 (2.08-12.47). The fall rate was lower in women than men (relative risk (RR) 0.80; CI 0.67-0.94) and decreased with increasing age (RR 0.97 for each year, CI 0.95-0.98).
Conclusion: PwMS are at high risk of falls and there are important associations between falls and MS-associated disability, gender and age.
C1 [Nilsagard, Y.] Orebro Cty Council, Ctr Hlth Care Sci, Orebro, Sweden.
[Nilsagard, Y.] Orebro Univ, Sch Hlth & Med Sci, SE-70113 Orebro, Sweden.
[Gunn, H.; Freeman, J.] Univ Plymouth, Sch Hlth Profess, Plymouth PL4 8AA, Devon, England.
[Hoang, P.; Lord, S.] Univ NSW, Neurosci Res Australia NeuRA, Sydney, NSW, Australia.
[Mazumder, Rajarshi; Cameron, Michelle] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Cameron, Michelle] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
RP Nilsagard, Y (reprint author), Orebro Univ, Sch Hlth & Med Sci, Orebro Cty Council, Ctr Hlth Care Sci, POB 1324, SE-70113 Orebro, Sweden.
EM ylva.nilsagard@orebroll.se
RI Lord, Stephen/C-9612-2011
FU Research Committee in Orebro County Council; Biogen Idec; Norrbacka-
Eugenia Foundation; VA, Rehabilitation Research & Development Service;
Agency for Healthcare Research and Quality (AHRQ) [T32 HS017582];
Foundation of the Consortium of Multiple Sclerosis Centers; NHMRC;
Multiple Sclerosis Research Australia; Physiotherapy Research
Foundation, Chartered Society of Physiotherapy, UK
FX SE: Ylva Nilsagard was supported by the Research Committee in Orebro
County Council, Biogen Idec and the Norrbacka- Eugenia Foundation.; US:
Michelle Cameron was supported by a Career Development Award from the
VA, Rehabilitation Research & Development Service.; Rajarshi Mazumder
was supported by the Oregon Multidisciplinary Training Program in Health
Services Research, grant number T32 HS017582 from the Agency for
Healthcare Research and Quality (AHRQ) and the 2012 Foundation of the
Consortium of Multiple Sclerosis Centers.; AUS: Phu Hoang and Stephen
Lord were supported by NHMRC Fellowships and a grant from Multiple
Sclerosis Research Australia.; UK: Hillary Gunn and Jennifer Freeman
were supported by a grant from the Physiotherapy Research Foundation,
Chartered Society of Physiotherapy, UK.
NR 35
TC 11
Z9 11
U1 2
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD JAN
PY 2015
VL 21
IS 1
BP 92
EP 100
DI 10.1177/1352458514538884
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CB0AW
UT WOS:000349288100014
PM 24948687
ER
PT J
AU Bag, S
Tseng, JC
Rochford, J
AF Bag, S.
Tseng, J. -C.
Rochford, J.
TI A BODIPY-luminol chemiluminescent resonance energy-transfer (CRET)
cassette for imaging of cellular superoxide
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID IN-VIVO; INFLAMMATION; MYELOPEROXIDASE; DISEASE; OXIDANTS
AB Spectroscopic and in cellulo studies are here reported on the very first BODIPY-luminol chemiluminescent resonance energy-transfer (CRET) cassette where the luminol CL agent is covalently linked to the BODIPY energy-transfer acceptor in a molecular dyad. The efficiency of intramolecular CRET investigated for the BODIPY-luminol dyad was found to be 64% resulting in a dual emissive response. Successful in cellulo biochemiluminescence via CRET was achieved in PMA activated splenocytes.
C1 [Bag, S.; Rochford, J.] Univ Massachusetts, Dept Chem, Boston, MA 02125 USA.
[Tseng, J. -C.] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02215 USA.
RP Tseng, JC (reprint author), Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02215 USA.
EM Jen-Chieh.Tseng@perkinelmer.com; jonathan.rochford@umb.edu
NR 25
TC 4
Z9 4
U1 2
U2 26
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 1477-0520
EI 1477-0539
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2015
VL 13
IS 6
BP 1763
EP 1767
DI 10.1039/c4ob02413c
PG 5
WC Chemistry, Organic
SC Chemistry
GA CA6NV
UT WOS:000349032400021
PM 25500943
ER
PT J
AU Yildiz, A
Nikodem, M
Vieta, E
Correll, CU
Baldessarini, RJ
AF Yildiz, A.
Nikodem, M.
Vieta, E.
Correll, C. U.
Baldessarini, R. J.
TI A network meta-analysis on comparative efficacy and all-cause
discontinuation of antimanic treatments in acute bipolar mania
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE All-cause discontinuations; antimanic; bipolar; mania; multiple
treatments meta-analysis
ID MULTIPLE-TREATMENTS METAANALYSIS; DOUBLE-BLIND; I DISORDER;
CONTROLLED-TRIALS; MOOD DISORDERS; LITHIUM; VALPROATE; CARBAMAZEPINE;
SCHIZOPHRENIA; HALOPERIDOL
AB Background. Evidence synthesis methods enabling direct and indirect comparisons over the entire set of relevant clinical data produce quantitative point estimates for the treatments contrasts between competing interventions, and provide a hierarchical rank ordering between them. We aimed to provide evidence-based guidance on the efficacy and all-cause discontinuation of antimanic treatments.
Method. We conducted a network meta-analysis within a Bayesian framework. We searched all standard literature databases without language restrictions up to 15 January 2014 to identify reports of short-term, randomized, blinded trials of putative antimanic drugs as monotherapy for adults with bipolar-I mania.
Results. Altogether, 14256 manic patients randomized to one of 18 active treatments or placebo provided 95 direct comparisons on 128 data points. For the primary outcome, standardized mean difference as Hedges' g (standardized mean difference; SMD), the hierarchies indicated by surface under the cumulative ranking (SUCRA) probabilities were in agreement with the point estimates for all antimanic drugs identified as effective. For the 12 effective antimanic drugs on clinical use, SMDs against placebo ranged from 0.32 to 0.66 without superiority of one over another, except for risperidone v. aripiprazole and valproate. Aripiprazole, olanzapine, quetiapine, risperidone, and valproate had less all-cause discontinuation rates than placebo. Sensitivity analysis by drug class indicated similar efficacy profiles for haloperidol, second-generation antipsychotics, and mood stabilizers.
Conclusions. Hierarchical rank ordering by comparative efficacy and risk of all-cause discontinuations should help to guide antimanic treatment choices by clinicians, healthcare policy makers, and guideline developers.
C1 [Yildiz, A.] Dokuz Eylul Univ, Dept Psychiat, Izmir, Turkey.
[Yildiz, A.; Vieta, E.; Baldessarini, R. J.] Massachusetts Gen Hosp, Int Consortium Bipolar Disorder Res, Boston, MA 02114 USA.
[Yildiz, A.; Vieta, E.; Baldessarini, R. J.] Massachusetts Gen Hosp, Psychopharmacol Program, McLean Div, Boston, MA 02114 USA.
[Nikodem, M.] AGH Univ Sci & Technol, Fac Appl Math, PL-30059 Krakow, Poland.
[Vieta, E.] Univ Barcelona, CIBERSAM, Barcelona,IDIBAPS, Bipolar Disorders Program,Inst Clin Neurosci,Hosp, Barcelona, Catalonia, Spain.
[Correll, C. U.] Zucker Hillside Hosp, Dept Psychiat, Div Psychiat Res, New York, NY USA.
[Baldessarini, R. J.] Harvard Univ, Med Sch Boston, Dept Psychiat, Cambridge, MA 02138 USA.
RP Yildiz, A (reprint author), Depress & Bipolar Disorders Fdn Duygudurum Vakfi, Yenikale Mah Sutculer Sok 7-3 Narlidere, Izmir, Turkey.
EM agul_yildiz@hotmail.com
OI Vieta, Eduard/0000-0002-0548-0053
FU Abdi Ibrahim Corporation; Actavis Corporation; Ali Raif Corporation;
AstraZeneca Corporation; Bristol-Myers-Squibb Corporation; Janssen-Cilag
Corporation; Pfizer Corporation; Sanofi-Aventis Corporation; Servier
Corporation; Janssen/Johnson Johnson; Otsuka; Adamed; Alexza; Almirall;
Cephalon; Eli Lilly; Ferrer; Forest Research Institute; Gedeon Richter;
Glaxo-Smith-Kline; Janssen; Jazz; Johnson Johnson; Lundbeck; Merck
Sharpe Dohme; Novartis; Roche; Sanofi; Senovel; Servier; Shering-Plough;
Shire; Sunovion; Takeda; Teva; United Biosource Corporation
FX A. Yildiz has received research grants from and/or served as a
consultant or speaker for Abdi Ibrahim, Actavis, Ali Raif, AstraZeneca,
Bristol-Myers-Squibb, Janssen-Cilag, Pfizer, Sanofi-Aventis, and Servier
Corporations. C. U. Correll has been a consultant or advisor to or has
received honoraria from: Actelion, Alexza, AstraZeneca,
Bristol-Myers-Squibb, Cephalon, Eli Lilly, Gerson Lehrman Group,
Genentech, IntraCellular Therapies, Lundbeck, Medavante, Medscape,
Merck, Novartis, Ortho-McNeill/Janssen/Johnson & Johnson, Otsuka,
Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva and Vanda. He has
received grant support from Bristol-Myers-Squibb, Janssen/Johnson &
Johnson, and Otsuka. E. Vieta has received grants and honoraria related
to consultancy or advisory boards from several pharmaceutical companies,
including Adamed, Alexza, Almirall, AstraZeneca, Bristol-Myers-Squibb,
Cephalon, Eli Lilly, Ferrer, Forest Research Institute, Gedeon Richter,
Glaxo-Smith-Kline, Janssen, Jazz, Johnson & Johnson, Lundbeck, Merck
Sharpe & Dohme, Novartis, Otsuka, Pfizer, Roche, Sanofi, Senovel,
Servier, Shering-Plough, Shire, Sunovion, Takeda, Teva, and United
Biosource Corporation. M. Nikodem, R. J. Baldessarini, and the immediate
family members of all authors have no current financial relationships
with commercial entities that might represent potential conflicts of
interest in this work.
NR 73
TC 11
Z9 12
U1 2
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD JAN
PY 2015
VL 45
IS 2
BP 299
EP 317
DI 10.1017/S0033291714001305
PG 19
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA CB4SB
UT WOS:000349617100007
PM 25036226
ER
PT J
AU Harris, AHS
Bowe, T
Del Re, AC
Finlay, AK
Oliva, E
Myrick, HL
Rubinsky, AD
AF Harris, Alex H. S.
Bowe, Thomas
Del Re, Aaron C.
Finlay, Andrea K.
Oliva, Elizabeth
Myrick, Hugh L.
Rubinsky, Anna D.
TI Extended Release Naltrexone for Alcohol Use Disorders:
Quasi-Experimental Effects on Mortality and Subsequent Detoxification
Episodes
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Alcohol Use Disorders; Alcohol Dependence; Naltrexone;
Medication-Assisted Treatment; Veterans Health Administration; Veterans
ID DEPENDENCE; PHARMACOTHERAPY; BARRIERS; METAANALYSIS; REGRESSION; TRIAL;
DEPOT
AB BackgroundUtilization of extended release naltrexone (XRN) for alcohol use disorders (AUDs) in the U.S. Veterans Health Administration (VHA) has been limited, perhaps due to high cost, lack of established superiority over less expensive alternatives including oral naltrexone, and related formulary restrictions. Despite these barriers, pockets of higher utilization exist in VHA, allowing for the quasi-experimental examination of the effects of XRN on 1-year mortality and number of subsequent detoxification episodes among patients with high rates of psychiatric comorbidities and previous psychosocial and pharmacological addiction treatment.
MethodsUsing propensity score-weighted mixed-effects logistic regression, 1-year mortality was compared between patients with AUDs who received XRN in fiscal year 2010 (n=387) and a random sample of patients with AUDs who did not receive XRN (n=3,759). Among the subgroup of patients who had at least 1 detoxification episode in the previous year, 1-year mortality and number of subsequent detoxification episodes were compared between those who did and did not receive XRN.
ResultsOverall, 1-year mortality for the patients receiving XRN was significantly lower than for the comparison group who did not receive XRN (odds ratio [OR]=0.30; p<0.001). Among patients with a detoxification episode in the previous year, those receiving XRN had, on average, 0.80 fewer subsequent detoxification episodes (p<0.001) and significantly lower mortality (OR=0.78, p<0.001) in the postindex year.
ConclusionsAmong patients with AUDs, those receiving XRN had lower 1-year mortality and fewer detoxifications compared to similar patients not receiving XRN. These results, although observational, support the use of XRN, especially among patients with high rates of psychiatric comorbidities and previous addiction treatment who are still struggling with AUDs and/or facing a period of vulnerability to relapse.
C1 [Harris, Alex H. S.; Bowe, Thomas; Del Re, Aaron C.; Finlay, Andrea K.; Oliva, Elizabeth; Rubinsky, Anna D.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, VA Subst Use Disorder Qual Enhancement Res Initia, Menlo Pk, CA 94025 USA.
[Myrick, Hugh L.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
RP Harris, AHS (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat MPD 152, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM alexander.harris2@va.gov
OI Del Re, Aaron/0000-0002-9571-7623
FU VA Substance Use Disorder Quality Enhancement Research Initiative
Locally Initiated Project [LIP QLP 59-028]
FX This work was supported by a VA Substance Use Disorder Quality
Enhancement Research Initiative Locally Initiated Project (LIP QLP
59-028). The views expressed do not represent those of the U.S.
Department of Veterans Affairs.
NR 17
TC 1
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JAN
PY 2015
VL 39
IS 1
BP 79
EP 83
DI 10.1111/acer.12597
PG 5
WC Substance Abuse
SC Substance Abuse
GA CA2DM
UT WOS:000348719100010
PM 25623408
ER
PT J
AU Worley, MJ
Witkiewitz, K
Brown, SA
Kivlahan, DR
Longabaugh, R
AF Worley, Matthew J.
Witkiewitz, Katie
Brown, Sandra A.
Kivlahan, Daniel R.
Longabaugh, Richard
TI Social Network Moderators of Naltrexone and Behavioral Treatment Effects
on Heavy Drinking in the COMBINE Study
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Alcohol Dependence; Naltrexone; Pharmacotherapy; Social Network;
Moderators
ID ALCOHOL-USE DISORDERS; COMBINED PHARMACOTHERAPIES; CONTROLLED-TRIAL;
MISSING DATA; DEPENDENCE; OUTCOMES; SUPPORT; PHARMACOGENETICS;
INTERVENTIONS; MEDICATIONS
AB BackgroundOral naltrexone is an efficacious medication for treatment of alcohol dependence, but small effect sizes and variability in outcomes suggest the presence of person-level moderators of naltrexone response. Identification of contextual or psychosocial moderators may assist in guiding clinical recommendations. Given the established importance of social networks in drinking outcomes, as well as the potential effects of naltrexone in reducing cue reactivity which may be especially important among those with more heavy drinkers and more alcohol cues in their networks, we examined pretreatment social network variables as potential moderators of naltrexone treatment effects in the COMBINE study.
MethodsThe sample included all COMBINE study participants in medication conditions with full data on the Important People Inventory (IPI) and covariates at intake (N=1,197). The intake IPI assessed whether participants had any frequent drinkers in their network and the average frequency of contact with these drinkers. The effects of treatment condition, pretreatment network variables, and their interactions on percent heavy drinking days were tested in hierarchical linear models, controlling for demographics and baseline clinical covariates.
ResultsIn treatment conditions involving medical management and combined behavioral intervention (CBI), the effects of active naltrexone on heavy drinking were significantly greater for individuals with frequent drinkers in their network (z=-2.66, p<0.01) and greater frequency of contact with those drinkers (z=-3.19, p<0.01). These network variables did not moderate the effects of active naltrexone without CBI.
ConclusionsWhen delivered in conjunction with behavioral interventions, naltrexone can be more potent for alcohol-dependent adults who have greater contact with frequent drinkers prior to treatment, which may indicate patterns of environmental exposure to alcohol. Contextual, social risk factors are a potential avenue to guide personalized treatment of alcohol dependence.
C1 [Worley, Matthew J.] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90024 USA.
[Witkiewitz, Katie] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA.
[Brown, Sandra A.] Univ Calif San Diego, Off Res Affairs, La Jolla, CA 92093 USA.
[Kivlahan, Daniel R.] VA Puget Sound Healthcare Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
Univ Washington, Seattle, WA 98195 USA.
[Longabaugh, Richard] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA.
RP Worley, MJ (reprint author), Univ Calif Los Angeles, 10880 Wilshire Blvd,Suite 1800, Los Angeles, CA 90024 USA.
EM mworley@mednet.ucla.edu
FU NIAAA NIH HHS [R01 AA022328]; NIDA NIH HHS [F31 DA030861]
NR 50
TC 2
Z9 2
U1 3
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JAN
PY 2015
VL 39
IS 1
BP 93
EP 100
DI 10.1111/acer.12605
PG 8
WC Substance Abuse
SC Substance Abuse
GA CA2DM
UT WOS:000348719100012
PM 25623409
ER
PT J
AU Khawaja, RDA
Singh, S
Vettiyil, B
Lim, R
Gee, M
Westra, S
Kalra, MK
AF Khawaja, Ranish Deedar Ali
Singh, Sarabjeet
Vettiyil, Beth
Lim, Ruth
Gee, Michael
Westra, Sjirk
Kalra, Mannudeep K.
TI Simplifying Size-Specific Radiation Dose Estimates in Pediatric CT
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE body diameter; body weight; pediatric CT; size-specific dose estimate
ID COMPUTED-TOMOGRAPHY; PROTOCOLS; INDEX
AB OBJECTIVE. Size-specific dose estimates (SSDEs) require manual measurement of torso diameters for individual patients-anteroposterior (hereafter, D-AP), lateral (hereafter, D-LAT), and effective (hereafter, D-E)-which can be tedious in clinical settings. We aimed to determine whether body weight can be used as a surrogate for measuring diameter in children.
MATERIALS AND METHODS. D-AP and D-LAT were measured in 522 consecutive CT examinations (chest, 187 and abdomen-pelvis, 335) performed in 483 (+/- SD) children (13 +/- 7 years). Effective diameter (D-E1) was calculated as the square root of the product of D-AP and D-LAT. A second measurement of effective diameter (D-E2) was obtained using automated software. Correlation coefficients between patient body weight, age, and diameter were measured in addition to 95% prediction interval analysis for diameters corresponding to body weight.
RESULTS. Median body weight was 51 kg, and mean D-AP, D-LAT, D-E1, and D-E2 were 207.1 +/- 50.8 mm, 289.8 +/- 72.6 mm, 243.3 +/- 62.0 mm, and 233.6 +/- 55.4 mm, respectively. Overall body weight had a strong correlation with diameter (0.88, 0.85, 0.86, and 0.93 respectively; all p < 0.0001). SSDE measured using body weight was statistically not different than SSDE measured using effective diameters (p = 0.9). Children weighing less than 27 kg and between 46 and 100 kg had statistically significant correlations with torso diameters, whereas only anteroposterior and effective diameters were correlated with children weighing between 27 and 45 kg. Children less than 4 years old had strong correlation with all diameters. Adolescents (15-18 years) did not have statistically significant correlation with any of the diameters.
CONCLUSION. Body weight, instead of body diameter, can be used as a surrogate to estimate size-specific dose in children, making dose estimation clinically simpler and more rapid.
C1 [Khawaja, Ranish Deedar Ali; Singh, Sarabjeet; Vettiyil, Beth; Gee, Michael; Kalra, Mannudeep K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Lim, Ruth; Westra, Sjirk] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Pediat Imaging, Boston, MA 02114 USA.
RP Khawaja, RDA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 25 New Chardon St,4th Fl, Boston, MA 02114 USA.
EM rkhawaja@mgh.harvard.edu
NR 10
TC 3
Z9 3
U1 1
U2 2
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JAN
PY 2015
VL 204
IS 1
BP 167
EP 176
DI 10.2214/AJR.13.12191
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AZ9UO
UT WOS:000348562300048
PM 25539253
ER
PT J
AU Kambadakone, A
Yoon, SS
Kim, TM
Karl, DL
Duda, DG
DeLaney, TF
Sahani, DV
AF Kambadakone, Avinash
Yoon, Sam S.
Kim, Tae-Min
Karl, Daniel L.
Duda, Dan G.
DeLaney, Thomas F.
Sahani, Dushyant V.
TI CT Perfusion as an Imaging Biomarker in Monitoring Response to
Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas:
Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and
Gene Expression
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE bevacizumab; CT perfusion; radiation therapy; soft-tissue sarcoma
ID ADVANCED HEPATOCELLULAR-CARCINOMA; COMPUTED-TOMOGRAPHY PERFUSION;
ELECTRON-BEAM RADIOTHERAPY; GUIDELINE VERSION 1.1; RECTAL-CANCER; SOLID
TUMORS; EVALUATION CRITERIA; PANCREATIC-CANCER; TARGETED THERAPY;
RANDOMIZED-TRIAL
AB OBJECTIVE. The purpose of this study was to evaluate the role of CT perfusion in monitoring response to neoadjuvant antiangiogenic and radiation therapy in resectable soft-tissue-sarcomas and correlate the findings with tumor size, circulating and tumor biomarkers, and gene expression.
SUBJECTS AND METHODS. This phase II clinical trial included 20 patients (13 men and 7 women; mean age, 55 years) with soft-tissue sarcomas who were undergoing treatment with the antiangiogenic drug bevacizumab followed by bevacizumab, radiation, and surgical resection. The patients underwent CT perfusion and diagnostic contrast-enhanced CT at baseline, at 2 weeks after bevacizumab therapy, and after completion of bevacizumab and radiation therapy. Multiple CT perfusion parameters (blood flow, blood volume, mean transit time, and permeability) were correlated with tumor size, circulating and tumor biomarkers, and gene expression.
RESULTS. Two weeks after bevacizumab therapy, there was substantial fall in blood volume (31.9% reduction, p = 0.01) with more pronounced reduction in blood flow, blood volume, and permeability after treatment completion (53-64% reduction in blood flow, blood volume, and permeability; p = 0.001), whereas tumor size showed no significant change (p = 0.34). Tumors with higher baseline blood volume and lower baseline tumor size showed superior response to bevacizumab and radiation (p = 0.05). There was also an increase in median plasma vascular endothelial growth factor and placental-derived growth factor concentration after bevacizumab therapy paralleled by a decrease in tumor perfusion depicted by CT perfusion, although this was not statistically significant (p = 0.4). The baseline tumor microvessel density (MVD) correlated with blood flow (p = 0.04). At least 20 different genes were differentially expressed in tumors with higher and lower baseline perfusion.
CONCLUSION. CT perfusion is more sensitive than tumor size for monitoring early and late response to bevacizumab and radiation therapy. CT perfusion parameters correlate with MVD, and the gene expression levels of baseline tumors could potentially predict treatment response.
C1 [Kambadakone, Avinash; Sahani, Dushyant V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Abdominal Imaging & Intervent, Boston, MA 02114 USA.
[Yoon, Sam S.; Karl, Daniel L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
[Yoon, Sam S.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA.
[Kim, Tae-Min] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02114 USA.
[Kim, Tae-Min] Ctr Personalized Genet Med, New York, NY USA.
[Duda, Dan G.; DeLaney, Thomas F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Kambadakone, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Abdominal Imaging & Intervent, White 270,55 Fruit St, Boston, MA 02114 USA.
EM akambadakone@mgh.harvard.edu
FU National Institutes of Health/National Cancer Institute [1R21
CA117128-01, 1R01 CA158301-01]; Society for Surgical Oncology Clinical
Investigator Award
FX The phase II clinical trial was supported by National Institutes of
Health/National Cancer Institute grants 1R21 CA117128-01 and 1R01
CA158301-01 (S. S. Yoon), Society for Surgical Oncology Clinical
Investigator Award (S. S. Yoon), and Ira J. Spiro Translational Research
Award (D. G. Duda).
NR 47
TC 8
Z9 8
U1 0
U2 8
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JAN
PY 2015
VL 204
IS 1
BP W11
EP W18
DI 10.2214/AJR.13.12412
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AZ9UO
UT WOS:000348562300003
PM 25539263
ER
PT J
AU Lira, D
Padole, A
Kalra, MK
Singh, S
AF Lira, Diego
Padole, Atul
Kalra, Mannudeep K.
Singh, Sarabjeet
TI Tube Potential and CT Radiation Dose Optimization
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Review
DE image quality; radiation dose; tube potential
ID IMAGE-QUALITY; PEDIATRIC CT; ABDOMINAL CT; REDUCTION; ANGIOGRAPHY;
VOLTAGE; PROTOCOLS; CHEST; SIZE
AB OBJECTIVE. This article describes tube potential and its effect on image quality and radiation dose for CT in different body regions and clinical indications.
CONCLUSION. Tube potential is an important scanning parameter for radiation dose optimization. Reduction of tube potential results in increased image contrast of iodine-enhanced CT as well as increased image noise.
C1 [Lira, Diego; Padole, Atul; Kalra, Mannudeep K.; Singh, Sarabjeet] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
RP Singh, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 55 Fruit St,Founders 202, Boston, MA 02114 USA.
EM ssingh6@mgh.harvard.edu
NR 15
TC 7
Z9 7
U1 0
U2 4
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JAN
PY 2015
VL 204
IS 1
BP W4
EP W10
DI 10.2214/AJR.14.13281
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AZ9UO
UT WOS:000348562300002
PM 25539272
ER
PT J
AU Nishino, M
Araki, T
Sholl, LM
AF Nishino, Mizuki
Araki, Tetsuro
Sholl, Lynette M.
TI Reply to "Usefulness of CT in Differentiating Lymphoid Thymic
Hyperplasia From True Thymic Hyperplasia: Added Value of Thymic
Measurements and CT Attenuation"
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Letter
ID AGE
C1 [Nishino, Mizuki] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Araki, Tetsuro; Sholl, Lynette M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
RP Nishino, M (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 8
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JAN
PY 2015
VL 204
IS 1
BP W115
EP W115
DI 10.2214/AJR.14.13368
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AZ9UO
UT WOS:000348562300021
PM 25539268
ER
PT J
AU Vassileva, J
Rehani, M
AF Vassileva, Jenia
Rehani, Madan
TI Diagnostic Reference Levels
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Editorial Material
DE diagnostic reference levels; dose optimization; patient doses
C1 [Vassileva, Jenia] Natl Ctr Radiobiol & Radiat Protect, Sofia, Bulgaria.
[Rehani, Madan] IAEA, Vienna Int Ctr, A-1400 Vienna, Austria.
[Rehani, Madan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Rehani, M (reprint author), IAEA, Vienna Int Ctr, A-1400 Vienna, Austria.
EM madan.rehani@gmail.com
NR 10
TC 3
Z9 3
U1 1
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JAN
PY 2015
VL 204
IS 1
BP W1
EP W3
DI 10.2214/AJR.14.12794
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AZ9UO
UT WOS:000348562300001
PM 25539261
ER
PT S
AU Halperin, DM
Kulke, MH
Yao, JC
AF Halperin, Daniel M.
Kulke, Matthew H.
Yao, James C.
BE Caskey, CT
TI A Tale of Two Tumors: Treating Pancreatic and Extrapancreatic
Neuroendocrine Tumors
SO ANNUAL REVIEW OF MEDICINE, VOL 66
SE Annual Review of Medicine
LA English
DT Review; Book Chapter
DE gastroenteropancreatic neuroendocrine tumors; carcinoid; therapy
ID ISLET-CELL-CARCINOMA; ZOLLINGER-ELLISON-SYNDROME; SOMATOSTATIN ANALOG
SMS-201-995; LIVER-TRANSPLANTATION; ENDOCRINE TUMORS; LOW-GRADE; HEPATIC
METASTASES; PROGNOSTIC-FACTORS; WATERY-DIARRHEA; CHROMOGRANIN-A
AB Despite their perceived rarity, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rising in incidence and prevalence. The biology, natural history, and therapeutic options for GEP-NETs are heterogeneous: NETs arising in the pancreas can be distinguished from those arising elsewhere in the gastrointestinal tract, and therapy is dichotomized between these two groups. Somatostatin analogues are the mainstay of oncologic management of bowel NETs; everolimus, streptozocin, and sunitinib are approved to treat pancreatic NETs. There are significant differences in molecular genetics between pancreatic and extrapancreatic NETs, and studies are evaluating whether additional NET patients may benefit from targeted agents. We discuss the distinguishing features of these two groups of tumors, as well as the therapeutic implications of the distinction. We also examine the evolving therapeutic landscape and discuss the likelihood that treatment will be developed independently for pancreatic and extrapancreatic gastrointestinal NETs, with novel therapeutics effective for newly identified pathologically or molecularly defined subgroups.
C1 [Halperin, Daniel M.; Yao, James C.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
[Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP Halperin, DM (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
EM dmhalperin@mdanderson.org; Matthew_Kulke@dfci.harvard.edu;
jyao@mdanderson.org
OI Halperin, Daniel M/0000-0002-3113-930X
FU NCI NIH HHS [P30 CA016672]
NR 96
TC 5
Z9 5
U1 0
U2 7
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0066-4219
BN 978-0-8243-0566-6
J9 ANNU REV MED
JI Annu. Rev. Med.
PY 2015
VL 66
BP 1
EP 16
DI 10.1146/annurev-med-061813-012908
PG 16
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BB9PT
UT WOS:000348560300001
PM 25341008
ER
PT S
AU Lipshultz, SE
Franco, VI
Miller, TL
Colan, SD
Sallan, SE
AF Lipshultz, Steven E.
Franco, Vivian I.
Miller, Tracie L.
Colan, Steven D.
Sallan, Stephen E.
BE Caskey, CT
TI Cardiovascular Disease in Adult Survivors of Childhood Cancer
SO ANNUAL REVIEW OF MEDICINE, VOL 66
SE Annual Review of Medicine
LA English
DT Review; Book Chapter
DE etiology; screening; prevention; treatment
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDRENS ONCOLOGY GROUP;
ANTHRACYCLINE-INDUCED CARDIOTOXICITY; LONG-TERM SURVIVORS;
DEXRAZOXANE-ASSOCIATED RISK; PEDIATRIC HODGKINS-DISEASE;
CONGESTIVE-HEART-FAILURE; DOXORUBICIN-TREATED SURVIVORS; CHRONIC
MYELOID-LEUKEMIA; REFRACTORY SOLID TUMORS
AB Treatment advances have increased survival in children with cancer, but subclinical, progressive, irreversible, and sometimes fatal treatment-related cardiovascular effects may appear years later. Cardio-oncologists have identified promising preventive and treatment strategies. Dexrazoxane provides long-term cardioprotection from doxorubicin-associated cardiotoxicity without compromising the efficacy of anticancer treatment. Continuous infusion of doxorubicin is as effective as bolus administration in leukemia treatment, but no evidence has indicated that it provides long-term cardioprotection; continuous infusions should be eliminated from pediatric cancer treatment. Angiotensin-converting enzyme inhibitors can delay the progression of subclinical and clinical cardiotoxicity. All survivors, regardless of whether they were treated with anthracyclines or radiation, should be monitored for systemic inflammation and the risk of premature cardiovascular disease. Echocardiographic screening must be supplemented with screening for biomarkers of cardiotoxicity and perhaps by identification of genetic susceptibilities to cardiovascular diseases; optimal strategies need to be identified. The health burden related to cancer treatment will increase as this population expands and ages.
C1 [Lipshultz, Steven E.; Franco, Vivian I.] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA.
[Lipshultz, Steven E.] Childrens Hosp Michigan, Detroit, MI 48201 USA.
[Miller, Tracie L.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33101 USA.
[Colan, Steven D.] Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
[Colan, Steven D.; Sallan, Stephen E.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Sallan, Stephen E.] Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA.
[Sallan, Stephen E.] Boston Childrens Hosp, Boston, MA 02115 USA.
RP Lipshultz, SE (reprint author), Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA.
EM slipshultz@med.wayne.edu; vfranco@med.wayne.edu; tmiller2@med.miami.edu;
steven.colan@cardio.chboston.org; stephen_sallan@dfci.harvard.edu
FU NCI NIH HHS [CA068484, CA127642, P01 CA068484, R01 CA127642]; NHLBI NIH
HHS [F31 HL094100, HL004537, HL007188, HL053392, HL072705, HL078522,
HL079233, HL087000, HL087708, HL094100, HL095127, K30 HL004537, R01
HL053392, R01 HL072705, R01 HL078522, R01 HL087000, R01 HL095127, R13
HL087708, T32 HL007188]; NIAID NIH HHS [AI50274, U01 AI050274]; NICHD
NIH HHS [U01 HD052104, HD052102, HD052104, HD80002, U01 HD052102]
NR 103
TC 15
Z9 15
U1 0
U2 9
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0066-4219
BN 978-0-8243-0566-6
J9 ANNU REV MED
JI Annu. Rev. Med.
PY 2015
VL 66
BP 161
EP 176
DI 10.1146/annurev-med-070213-054849
PG 16
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BB9PT
UT WOS:000348560300011
PM 25587648
ER
PT S
AU Lin, MV
King, LY
Chung, RT
AF Lin, Ming V.
King, Lindsay Y.
Chung, Raymond T.
BE Abbas, AK
Galli, SJ
Howley, PM
TI Hepatitis C Virus-Associated Cancer
SO ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 10
SE Annual Review of Pathology-Mechanisms of Disease
LA English
DT Review; Book Chapter
DE liver; cirrhosis; hepatocellular carcinoma; cancer
ID EPIDERMAL-GROWTH-FACTOR; HUMAN HEPATOCELLULAR-CARCINOMA; GENOTYPE 1
INFECTION; SUSTAINED VIROLOGICAL RESPONSE; NONSTRUCTURAL 5A PROTEIN;
TREATMENT-NAIVE PATIENTS; RNA-POLYMERASE ACTIVITY; INTERFERON-ALPHA 2A;
THAN-G POLYMORPHISM; BETA-CATENIN GENE
AB Hepatitis C virus (HCV) is one of the major etiologic agents of liver cancer. HCV is an RNA virus that, unlike hepatitis B virus, is unable to integrate into the host genome. Through complex interactions between viral and host proteins that induce host responses and promote inflammation, fibrosis, and ultimately cirrhosis, HCV infection can result in the development of hepatocellular carcinoma (HCC). The HCV oncogenic process involves genetic and epigenetic alterations and oncogenic effects mediated by viral proteins in the activation of cellular oncogenes, inactivation of tumor-suppressor genes, and dysregulation of multiple signal-transduction pathways. Advances in genetics and gene expression profiling have enhanced our current understanding of the pathways involved in HCV-associated liver cancer development. In this review, we summarize the current understanding of mechanisms of hepatocarcinogenesis induced by HCV infection.
C1 [Lin, Ming V.] Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Lin, MV (reprint author), Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Boston, MA 02114 USA.
EM mvlin@mgh.harvard.edu; lyking@partners.org; rtchung@partners.org
NR 193
TC 15
Z9 15
U1 2
U2 14
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 1553-4006
BN 978-0-8243-4310-1
J9 ANNU REV PATHOL-MECH
JI Annu. Rev. Pathol.-Mech Dis.
PY 2015
VL 10
BP 345
EP 370
DI 10.1146/annurev-pathol-012414-040323
PG 26
WC Pathology
SC Pathology
GA BB9PX
UT WOS:000348560600012
PM 25387053
ER
PT S
AU Parker-Lue, S
Santoro, M
Koski, G
AF Parker-Lue, Sara
Santoro, Michael
Koski, Greg
BE Insel, PA
TI The Ethics and Economics of Pharmaceutical Pricing
SO ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55
SE Annual Review of Pharmacology and Toxicology
LA English
DT Review; Book Chapter
DE drug access; patents; innovation; differential pricing; price controls;
rationing; prescribing
ID PATIENT-ASSISTANCE PROGRAMS; MEDICARE PART D; INTELLECTUAL
PROPERTY-RIGHTS; RESEARCH-AND-DEVELOPMENT; UNITED-STATES; ORPHAN DRUGS;
HEALTH-CARE; GENERIC SUBSTITUTION; PATENT CHALLENGES; PARALLEL IMPORTS
AB The cost of drugs is a major and rapidly rising component of health-care expenditures. We survey recent literature on the ethics and economics of skyrocketing pharmaceutical prices and find that advances in economic research have increased the sharpness and focus of the ethically based calls to increase access by modifying patent protection and reducing prices. In some cases, research supports ethical arguments for broader access. Other research suggests that efforts to broaden access result in unintended consequences for innovation and the medical needs of patients. Both ethicists and economists need to be more cognizant of the real clinical settings in which physicians practice medicine with real patients. Greater cross-disciplinary interaction among economists, ethicists, and physicians can help reduce the disjunction between innovation and access and improve access and patient care. This dialogue will impact private industry and may spur new multistakeholder paradigms for drug discovery, development, and pricing.
C1 [Parker-Lue, Sara; Santoro, Michael] Rutgers Business Sch Newark & New Brunswick, Dept Management & Global Business, Newark, NJ 07102 USA.
[Koski, Greg] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care,James Mongan Inst Hlt, Boston, MA 02114 USA.
RP Parker-Lue, S (reprint author), Rutgers Business Sch Newark & New Brunswick, Dept Management & Global Business, Newark, NJ 07102 USA.
EM sparker@business.rutgers.edu; msantoro@business.rutgers.edu;
gkoski@mgh.harvard.edu
NR 127
TC 6
Z9 6
U1 13
U2 40
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0362-1642
BN 978-0-8243-0455-3
J9 ANNU REV PHARMACOL
JI Annu. Rev. Pharmacol. Toxicol.
PY 2015
VL 55
BP 191
EP +
DI 10.1146/annurev-pharmtox-010814-124649
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA BB9PW
UT WOS:000348560500012
PM 25149920
ER
PT S
AU Gyorgy, B
Hung, ME
Breakefield, XO
Leonard, JN
AF Gyoergy, Bence
Hung, Michelle E.
Breakefield, Xandra O.
Leonard, Joshua N.
BE Insel, PA
TI Therapeutic Applications of Extracellular Vesicles: Clinical Promise and
Open Questions
SO ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55
SE Annual Review of Pharmacology and Toxicology
LA English
DT Review; Book Chapter
DE exosomes; extracellular RNA; microvesicles; drug delivery; liposomes;
gene medicine; gene therapy; mesenchymal stem cells; nanoparticles
ID CELL-DERIVED EXOSOMES; OUTER-MEMBRANE VESICLES; MESENCHYMAL STROMAL
CELLS; MARROW DENDRITIC CELLS; ENDOTHELIAL-CELLS; IMMUNE-RESPONSES;
CANCER-CELLS; STEM-CELLS; T-CELLS; INTERCELLULAR TRANSFER
AB This review provides an updated perspective on rapidly proliferating efforts to harness extracellular vesicles (EVs) for therapeutic applications. We summarize current knowledge, emerging strategies, and open questions pertaining to clinical potential and translation. Potentially useful EVs comprise diverse products of various cell types and species. EV components may also be combined with liposomes and nanoparticles to facilitate manufacturing as well as product safety and evaluation. Potential therapeutic cargoes include RNA, proteins, and drugs. Strategic issues considered herein include choice of therapeutic agent, means of loading cargoes into EVs, promotion of EV stability, tissue targeting, and functional delivery of cargo to recipient cells. Some applications may harness natural EV properties, such as immune modulation, regeneration promotion, and pathogen suppression. These properties can be enhanced or customized to enable a wide range of therapeutic applications, including vaccination, improvement of pregnancy outcome, and treatment of autoimmune disease, cancer, and tissue injury.
C1 [Gyoergy, Bence; Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA.
[Gyoergy, Bence; Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Radiol, Ctr Mol Imaging Res, Boston, MA 02114 USA.
[Gyoergy, Bence; Breakefield, Xandra O.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA.
[Gyoergy, Bence] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Hung, Michelle E.] Northwestern Univ, Interdept Biol Sci Grad Program, Evanston, IL 60208 USA.
[Leonard, Joshua N.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chem Life Proc Inst, Dept Chem & Biol Engn, Evanston, IL 60208 USA.
RP Gyorgy, B (reprint author), Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA.
EM breakefield@hms.harvard.edu; j-leonard@northwestern.edu
RI Leonard, Joshua/B-7649-2009; Hung, Michelle/J-3336-2014
OI Hung, Michelle/0000-0002-1909-8162
FU Howard Hughes Medical Institute; NCI NIH HHS [P50 CA090386, CA069246,
P01 CA069246, U19 CA179563]
NR 147
TC 67
Z9 67
U1 11
U2 65
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0362-1642
BN 978-0-8243-0455-3
J9 ANNU REV PHARMACOL
JI Annu. Rev. Pharmacol. Toxicol.
PY 2015
VL 55
BP 439
EP 464
DI 10.1146/annurev-pharmtox-010814-124630
PG 26
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA BB9PW
UT WOS:000348560500024
PM 25292428
ER
PT J
AU Freire, M
Choi, JH
Nguyen, A
Chee, YD
Kook, JK
You, HK
Zadeh, HH
AF Freire, Marcelo
Choi, Jeong-Ho
Nguyen, Anthony
Chee, Young Deok
Kook, Joong-Ki
You, Hyung-Keun
Zadeh, Homayoun H.
TI Application of AMOR in Craniofacial Rabbit Bone Bioengineering
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID MEDIATED OSSEOUS REGENERATION; LUMBAR INTERBODY FUSION; GROWTH-FACTOR
DELIVERY; MORPHOGENETIC PROTEIN-2; MONOCLONAL-ANTIBODIES;
CLINICAL-EVALUATION; DEVELOPMENT TRENDS; IN-VITRO; TISSUE; RECOMBINANT
AB Endogenous molecular and cellular mediators modulate tissue repair and regeneration. We have recently described antibody mediated osseous regeneration (AMOR) as a novel strategy for bioengineering bone in rat calvarial defect. This entails application of anti-BMP-2 antibodies capable of in vivo capturing of endogenous osteogenic BMPs (BMP-2, BMP-4, and BMP-7). The present study sought to investigate the feasibility of AMOR in other animal models. To that end, we examined the efficacy of a panel of anti-BMP-2 monoclonal antibodies (mAbs) and a polyclonal Ab immobilized on absorbable collagen sponge (ACS) to mediate bone regeneration within rabbit calvarial critical size defects. After 6 weeks, de novo bone formation was demonstrated by micro-CT imaging, histology, and histomorphometric analysis. Only certain anti-BMP-2 mAb clones mediated significant in vivo bone regeneration, suggesting that the epitopes with which anti-BMP-2 mAbs react are critical to AMOR. Increased localization of BMP-2 protein and expression of osteocalcin were observed within defects, suggesting accumulation of endogenous BMP-2 and/or increased de novo expression of BMP-2 protein within sites undergoing bone repair by AMOR. Considering the ultimate objective of translation of this therapeutic strategy in humans, preclinical studies will be necessary to demonstrate the feasibility of AMOR in progressively larger animal models.
C1 [Freire, Marcelo] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA USA.
[Freire, Marcelo] Harvard Univ, Sch Dent Med, Dept Infect & Immun, Boston, MA 02115 USA.
[Choi, Jeong-Ho] Seoul Natl Univ, Sch Dent, Dept Orthodont, Seoul 110749, South Korea.
[Nguyen, Anthony; Zadeh, Homayoun H.] Univ So Calif, Ostrow Sch Dent, Los Angeles, CA 90033 USA.
[Chee, Young Deok; You, Hyung-Keun] Wonkwang Univ, Coll Dent, Dept Periodontol, Iksan, South Korea.
[Kook, Joong-Ki] Chosun Univ, Sch Dent, Dept Oral Biochem, Kwangju, South Korea.
[Zadeh, Homayoun H.] Univ So Calif, Herman Ostrow Sch Dent, Lab Immunoregulat & Tissue Engn, Los Angeles, CA 90089 USA.
RP Zadeh, HH (reprint author), Univ So Calif, Ostrow Sch Dent, Los Angeles, CA 90033 USA.
EM zadeh@usc.edu
OI Choi, Jeong-Ho/0000-0003-4529-7218; You, Hyung-Keun/0000-0002-4585-0477;
Freire, Marcelo/0000-0003-4906-7698
NR 48
TC 0
Z9 0
U1 1
U2 5
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 628769
DI 10.1155/2015/628769
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CA9PQ
UT WOS:000349257600001
ER
PT J
AU Nakao, S
Kimura, A
Hagiwara, Y
Hasegawa, K
AF Nakao, Shunichiro
Kimura, Akio
Hagiwara, Yusuke
Hasegawa, Kohei
CA Japanese Emergency Med Network
TI Trauma airway management in emergency departments: a multicentre,
prospective, observational study in Japan
SO BMJ OPEN
LA English
DT Article
ID INTUBATION; MEDICINE; INJURY
AB Objectives: Although successful airway management is essential for emergency trauma care, comprehensive studies are limited. We sought to characterise current trauma care practice of airway management in the emergency departments (EDs) in Japan.
Design: Analysis of data from a prospective, observational, multicentre registry-the Japanese Emergency Airway Network (JEAN) registry.
Setting: 13 academic and community EDs from different geographic regions across Japan.
Participants: 723 trauma patients who underwent emergency intubation from March 2010 through August 2012.
Outcome measures: ED characteristics, patient and operator demographics, methods of airway management, intubation success or failure at each attempt and adverse events.
Results: A total of 723 trauma patients who underwent emergency intubation were eligible for the analysis. Traumatic cardiac arrest comprised 32.6% (95% CI 29.3% to 36.1%) of patients. Rapid sequence intubation (RSI) was the initial method chosen in 23.9% (95% CI 21.0% to 27.2%) of all trauma patients and in 35.5% (95% CI 31.4% to 39.9%) of patients without cardiac arrest. Overall, intubation was successful in <= 3 attempts in 96% of patients (95% CI 94.3% to 97.2%). There was a wide variation in the initial methods of intubation; RSI as the initial method was performed in 0-50.9% of all trauma patients among 12 EDs. Similarly, there was a wide variation in success rates and adverse event rates across the EDs. Success rates varied between 35.5% and 90.5% at the first attempt, and 85.1% and 100% within three attempts across the 12 EDs.
Conclusions: In this multicentre prospective study in Japan, we observed a high overall success rate in airway management during trauma care. However, the methods of intubation and success rates were highly variable among hospitals.
C1 [Nakao, Shunichiro; Kimura, Akio] Natl Ctr Global Hlth & Med, Dept Emergency Med & Crit Care, Shinjuku Ku, Tokyo, Japan.
[Hagiwara, Yusuke] Tokyo Metropolitan Childrens Med Ctr, Dept Emergency Med, Fuchu, Tokyo, Japan.
[Hasegawa, Kohei] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Nakao, S (reprint author), Natl Ctr Global Hlth & Med, Dept Emergency Med & Crit Care, Shinjuku Ku, Tokyo, Japan.
EM shunichiro-nakao@umin.ac.jp
FU St Luke's Life Science Institute; Massachusetts General Hospital;
Brigham and Women's Hospital
FX This study was supported by a grant from St Luke's Life Science
Institute and a grant from Massachusetts General Hospital and Brigham
and Women's Hospital.
NR 20
TC 1
Z9 1
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2015
VL 5
IS 2
AR e006623
DI 10.1136/bmjopen-2014-006623
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA CA2ZK
UT WOS:000348774900008
PM 25652800
ER
PT J
AU Blashill, AJ
Safren, SA
AF Blashill, Aaron J.
Safren, Steven A.
TI Body dissatisfaction and condom use self-efficacy: A meta-analysis
SO BODY IMAGE
LA English
DT Review
DE Body image; Body dissatisfaction; Condom use self-efficacy;
Meta-analysis; Sexual risk behaviors
ID PSYCHOSOCIAL HEALTH-PROBLEMS; SEXUAL-BEHAVIOR; RISK BEHAVIORS; HIV RISK;
IMAGE; MEN; WOMEN; INTERVENTIONS; ADOLESCENTS; ADULTS
AB The consistent use of condoms is the most effective behavior for reducing the acquisition of sexually transmitted infections (STIs), and condom use self-efficacy has been shown to be a key construct related to condom use. However, the examination of modifiable psychosocial and behavioral correlates of condom use self-efficacy is lacking. Recent investigations have highlighted the association of body dissatisfaction with condom use self-efficacy, and the current study conducted a meta-analysis on all available data addressing this relationship. Eleven individual effect-size parameters from nine studies yielded a total sample of 2495 men and women participants. A random-effects model revealed an average effect-size of r=-.25, Cohen's d= -0.52, which is moderate in strength. As body dissatisfaction increases, ones' self-efficacy regarding the use of condoms diminishes. Integrating interventions to decrease body dissatisfaction and sexual risk behaviors may prove to be an effective strategy to decrease STIs. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Blashill, Aaron J.; Safren, Steven A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Blashill, Aaron J.; Safren, Steven A.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA.
RP Blashill, AJ (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA.
EM ablashill@mgh.harvard.edu
FU National Institute of Mental Health of the National Institutes of Health
[K23MH096647, K24MH094214]
FX Research reported in this publication was supported by the National
Institute of Mental Health of the National Institutes of Health under
award numbers K23MH096647, to Aaron Blashill, and K24MH094214, to Steven
Safren.
NR 38
TC 5
Z9 5
U1 3
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1740-1445
EI 1873-6807
J9 BODY IMAGE
JI Body Image
PD JAN
PY 2015
VL 12
BP 73
EP 77
DI 10.1016/j.bodyim.2014.10.002
PG 5
WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary
SC Psychology; Psychiatry
GA CA5NG
UT WOS:000348954500010
PM 25462884
ER
PT J
AU Hall, KT
Tolkin, BR
Chinn, GM
Kirsch, I
Kelley, JM
Lembo, AJ
Kaptchuk, TJ
Kokkotou, E
Davis, RB
Conboy, LA
AF Hall, Kathryn T.
Tolkin, Benjamin R.
Chinn, Garrett M.
Kirsch, Irving
Kelley, John M.
Lembo, Anthony J.
Kaptchuk, Ted J.
Kokkotou, Efi
Davis, Roger B.
Conboy, Lisa A.
TI Conscientiousness is modified by genetic variation in
catechol-O-methyltransferase to reduce symptom complaints in IBS
patients
SO BRAIN AND BEHAVIOR
LA English
DT Article
DE Catechol-O-methyltransferase; complaints; COMT; conscientiousness;
personality
ID IRRITABLE-BOWEL-SYNDROME; PERSONALITY-TRAITS; PLACEBO GROUPS;
POLYMORPHISMS; ANXIETY; NOCEBO; SEVERITY; GENOTYPE
AB Background Attention to and perception of physical sensations and somatic states can significantly influence reporting of complaints and symptoms in the context of clinical care and randomized trials. Although anxiety and high neuroticism are known to increase the frequency and severity of complaints, it is not known if other personality dimensions or genes associated with cognitive function or sympathetic tone can influence complaints. Genetic variation in catechol-O-methyltransferase (COMT) is associated with anxiety, personality, pain, and response to placebo treatment. We hypothesized that the association of complaint reporting with personality might be modified by variation in the COMT val158met genotype. Methods We administered a standard 25-item complaint survey weekly over 3-weeks to a convenience sample of 187 irritable bowel syndrome patients enrolled in a placebo intervention trial and conducted a repeated measures analysis. Results We found that complaint severity rating, our primary outcome, was negatively associated with the personality measures of conscientiousness (=-0.31 SE 0.11, P=0.003) and agreeableness (=-0.38 SE 0.12, P=0.002) and was positively associated with neuroticism (=0.24 SE 0.09, P=0.005) and anxiety (=0.48 SE 0.09, P<0.0001). We also found a significant interaction effect of COMT met alleles (=-32.5 SE 14.1, P=0.021). in patients genotyped for COMT val158met (N =87) specifically COMTxconscientiousness (=0.73 SE 0.26, P=0.0042) and COMTxanxiety (=-0.42 SE 0.16, P=0.0078) interaction effects. Conclusion These findings potentially broaden our understanding of the factors underlying clinical complaints to include the personality dimension of conscientiousness and its modification by COMT.
C1 [Hall, Kathryn T.; Tolkin, Benjamin R.; Kirsch, Irving; Kelley, John M.; Lembo, Anthony J.; Kaptchuk, Ted J.; Kokkotou, Efi; Davis, Roger B.; Conboy, Lisa A.] Beth Israel Deaconess Med Ctr, Program Placebo Studies, Boston, MA 02215 USA.
[Hall, Kathryn T.; Tolkin, Benjamin R.; Chinn, Garrett M.; Kirsch, Irving; Kelley, John M.; Lembo, Anthony J.; Kaptchuk, Ted J.; Kokkotou, Efi; Davis, Roger B.; Conboy, Lisa A.] Harvard Univ, Sch Med, Boston, MA USA.
[Hall, Kathryn T.; Tolkin, Benjamin R.; Kaptchuk, Ted J.; Davis, Roger B.; Conboy, Lisa A.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Chinn, Garrett M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Kirsch, Irving] Univ Plymouth, Sch Psychol, Plymouth PL4 8AA, Devon, England.
[Kelley, John M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA.
[Kelley, John M.] Endicott Coll, Beverly, MA USA.
[Lembo, Anthony J.; Kokkotou, Efi] Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Boston, MA 02215 USA.
RP Hall, KT (reprint author), Beth Israel Deaconess Med Ctr, Program Placebo Studies, Boston, MA 02215 USA.
EM kthall@bidmc.harvard.edu
FU National Center for Complementary and Alternative Medicine (NCCAM),
National Institute Health (NIH) [R01 AT004662, K24 AT004095,
3R01AT004662-02S1, T32 AT000051, R21 AT002860]
FX This work was supported by National Center for Complementary and
Alternative Medicine (NCCAM), National Institute Health (NIH), grants #
R01 AT004662, K24 AT004095, 3R01AT004662-02S1, T32 AT000051, and R21
AT002860.
NR 32
TC 6
Z9 6
U1 1
U2 8
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2162-3279
J9 BRAIN BEHAV
JI Brain Behav.
PD JAN
PY 2015
VL 5
IS 1
AR e00294
DI 10.1002/brb3.294
PG 6
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA CA6OO
UT WOS:000349034700005
PM 25722948
ER
PT J
AU Jahshan, C
Wynn, JK
Mathis, KI
Green, MF
AF Jahshan, Carol
Wynn, Jonathan K.
Mathis, Kristopher I.
Green, Michael F.
TI The neurophysiology of biological motion perception in schizophrenia
SO BRAIN AND BEHAVIOR
LA English
DT Article
DE Biological motion; electroencephalography; event-related potential;
schizophrenia; visual perception
ID EVENT-RELATED POTENTIALS; RECOGNITION; ATTENTION; COGNITION; SPECTRUM;
FORM
AB Introduction: The ability to recognize human biological motion is a fundamental aspect of social cognition that is impaired in people with schizophrenia. However, little is known about the neural substrates of impaired biological motion perception in schizophrenia. In the current study, we assessed event-related potentials (ERPs) to human and nonhuman movement in schizophrenia. Methods: Twenty-four subjects with schizophrenia and 18 healthy controls completed a biological motion task while their electroencephalography (EEG) was simultaneously recorded. Subjects watched clips of point-light animations containing 100%, 85%, or 70% biological motion, and were asked to decide whether the clip resembled human or nonhuman movement. Three ERPs were examined: P1, N1, and the late positive potential (LPP). Results: Behaviorally, schizophrenia subjects identified significantly fewer stimuli as human movement compared to healthy controls in the 100% and 85% conditions. At the neural level, P1 was reduced in the schizophrenia group but did not differ among conditions in either group. There were no group differences in N1 but both groups had the largest N1 in the 70% condition. There was a conditionxgroup interaction for the LPP: Healthy controls had a larger LPP to 100% versus 85% and 70% biological motion; there was no difference among conditions in schizophrenia subjects. Conclusions: Consistent with previous findings, schizophrenia subjects were impaired in their ability to recognize biological motion. The EEG results showed that biological motion did not influence the earliest stage of visual processing (P1). Although schizophrenia subjects showed the same pattern of N1 results relative to healthy controls, they were impaired at a later stage (LPP), reflecting a dysfunction in the identification of human form in biological versus nonbiological motion stimuli.
C1 [Jahshan, Carol; Wynn, Jonathan K.; Mathis, Kristopher I.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA 90073 USA.
[Jahshan, Carol; Wynn, Jonathan K.; Mathis, Kristopher I.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
RP Jahshan, C (reprint author), VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Bldg 210,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM carol.jahshan@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU Department of Veterans Affairs Desert Pacific Mental Illness Research,
Education and Clinical Center (MIRECC); National Institute of Mental
Health [MH065707]
FX Funding for this study was provided by grants from the Department of
Veterans Affairs Desert Pacific Mental Illness Research, Education and
Clinical Center (MIRECC), and the National Institute of Mental Health
(MH065707 to MFG). The MIRECC and National Institutes of Health had no
role in study design; in the collection, analysis, and interpretation of
data; in the writing of the report; and in the decision to submit the
paper for publication. The authors thank C. Gibson, C. Tripp, K. Weiner,
M. McGee, and A. Bender for their assistance with recruitment and
testing. The authors also thank Jejoong Kim, Ph.D. for providing the
biological motion task.
NR 31
TC 0
Z9 0
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2162-3279
J9 BRAIN BEHAV
JI Brain Behav.
PD JAN
PY 2015
VL 5
IS 1
AR e00303
DI 10.1002/brb3.303
PG 10
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA CA6OO
UT WOS:000349034700008
ER
PT J
AU Pinheiro, AP
Vasconcelos, M
Dias, M
Arrais, N
Goncalves, OF
AF Pinheiro, Ana P.
Vasconcelos, Margarida
Dias, Marcelo
Arrais, Nuno
Goncalves, Oscar F.
TI The music of language: An ERP investigation of the effects of musical
training on emotional prosody processing
SO BRAIN AND LANGUAGE
LA English
DT Article
DE Event-related potentials; Emotional prosody; Language; Musical training
ID EVENT-RELATED POTENTIALS; SPEECH PROSODY; AUDITORY-CORTEX; VOCAL
EMOTION; FOREIGN-LANGUAGE; NEURAL RESPONSES; HESCHLS GYRUS; EVOKED
FIELDS; BRAIN; PERCEPTION
AB Recent studies have demonstrated the positive effects of musical training on the perception of vocally expressed emotion. This study investigated the effects of musical training on event-related potential (ERP) correlates of emotional prosody processing.
Fourteen musicians and fourteen control subjects listened to 228 sentences with neutral semantic content, differing in prosody (one third with neutral, one third with happy and one third with angry intonation), with intelligible semantic content (semantic content condition - SCC) and unintelligible semantic content (pure prosody condition - PPC).
Reduced P50 amplitude was found in musicians. A difference between SCC and PPC conditions was found in P50 and N100 amplitude in non-musicians only, and in P200 amplitude in musicians only. Furthermore, musicians were more accurate in recognizing angry prosody in PPC sentences.
These findings suggest that auditory expertise characterizing extensive musical training may impact different stages of vocal emotional processing. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Pinheiro, Ana P.; Vasconcelos, Margarida; Dias, Marcelo; Goncalves, Oscar F.] Univ Minho, Sch Psychol, CIPsi, Neuropsychophysiol Lab, P-4710057 Braga, Portugal.
[Pinheiro, Ana P.] Harvard Univ, Sch Med, Dept Psychiat, Cognit Neurosci Lab, Boston, MA 02115 USA.
[Arrais, Nuno] Univ Minho, Inst Arts & Human Sci, Music Dept, P-4710057 Braga, Portugal.
[Goncalves, Oscar F.] Harvard Univ, Spaulding Rehabil Hosp, Spaulding Ctr Neuromodulat, Dept Phys Med & Rehabil, Boston, MA 02115 USA.
[Goncalves, Oscar F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
RP Pinheiro, AP (reprint author), Univ Minho, Sch Psychol, CIPsi, Neuropsychophysiol Lab, Campus Gualtar, P-4710057 Braga, Portugal.
EM ana.pinheiro@psi.uminho.pt
RI Goncalves, Oscar/G-5278-2010;
OI Goncalves, Oscar/0000-0003-2735-9155; Pinheiro, Ana/0000-0002-7981-3682
FU Fundacao para a Ciencia e a Tecnologia (FCT, Portugal) [IF/00334/2012,
PTDC/PSI-PCL/116626/2010, PTDC/MHN-PCN/3606/2012]; FEDER (Fundo Europeu
de Desenvolvimento Regional) through the European programs QREN (Quadro
de Referenda Estrategico Nacional); COMPETE (Programa Operacional
Factores de Competitividade)
FX This work was supported by Grants IF/00334/2012,
PTDC/PSI-PCL/116626/2010 and PTDC/MHN-PCN/3606/2012 funded by Fundacao
para a Ciencia e a Tecnologia (FCT, Portugal) and FEDER (Fundo Europeu
de Desenvolvimento Regional) through the European programs QREN (Quadro
de Referenda Estrategico Nacional), and COMPETE (Programa Operacional
Factores de Competitividade), awarded to A.P.P.
NR 107
TC 1
Z9 3
U1 9
U2 26
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0093-934X
EI 1090-2155
J9 BRAIN LANG
JI Brain Lang.
PD JAN
PY 2015
VL 140
BP 24
EP 34
DI 10.1016/j.bandl.2014.10.009
PG 11
WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences;
Psychology, Experimental
SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences &
Neurology; Psychology
GA CA0UF
UT WOS:000348631100004
PM 25461917
ER
PT J
AU Chan, ST
Evans, KC
Rosen, BR
Song, TY
Kwong, KK
AF Chan, Suk-tak
Evans, Karleyton C.
Rosen, Bruce R.
Song, Tian-yue
Kwong, Kenneth K.
TI A case study of magnetic resonance imaging of cerebrovascular
reactivity: A powerful imaging marker for mild traumatic brain injury
SO BRAIN INJURY
LA English
DT Article
DE Cerebrovascular reactivity; functional magnetic resonance imaging; mild
brain injury
ID LEVEL-DEPENDENT MRI; RECURRENT CONCUSSION; FOOTBALL PLAYERS;
WHITE-MATTER; IMPAIRMENT; PERFUSION; CO2; SOFTWARE; FMRI
AB Primary objective: To use breath-hold functional magnetic resonance imaging (fMRI) to localize the brain regions with impaired cerebrovascular reactivity (CVR) in a female patient diagnosed with mild traumatic brain injury (mTBI). The extent of impaired CVR was evaluated 2 months after concussion. Follow-up scan was performed 1 year post-mTBI using the same breath-hold fMRI technique.
Research design: Case report.
Methods and procedures: fMRI blood oxygenation dependent level (BOLD) signals were measured under breath-hold challenge in a female mTBI patient 2 months after concussion followed by a second fMRI with breath-hold challenge 1 year later. CVR was expressed as the percentage change of BOLD signals per unit time of breath-hold.
Main outcomes: In comparison with CVR measurement of normal control subjects, statistical maps of CVR revealed substantial neurovascular deficits and hemispheric asymmetry within grey and white matter in the initial breath-hold fMRI scan. Follow-up breath-hold fMRI performed 1 year post-mTBI demonstrated normalization of CVR accompanied with symptomatic recovery.
Conclusions: CVR may serve as an imaging biomarker to detect subtle deficits in both grey and white matter for individual diagnosis of mTBI. The findings encourage further investigation of hypercapnic fMRI as a diagnostic tool for mTBI.
C1 [Chan, Suk-tak; Rosen, Bruce R.; Song, Tian-yue; Kwong, Kenneth K.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Boston, MA 02114 USA.
[Evans, Karleyton C.; Song, Tian-yue] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Chan, ST (reprint author), Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,Thirteenth St,Mail Code 149-2301, Charlestown, MA 02129 USA.
EM phoebe@nmr.mgh.harvard.edu
RI Chan, Suk-tak/G-5846-2015
FU National Institute of Biomedical Imaging and Bioengineering (NIBIB),
National Institutes of Health [P41EB015896]; [NIH-K23MH086619]
FX This research was carried out in whole at the Athinoula A. Martinos
Center for Biomedical Imaging at the Massachusetts General Hospital,
using resources provided by the Center for Functional Neuroimaging
Technologies, P41EB015896, a P41 Biotechnology Resource Grant supported
by the National Institute of Biomedical Imaging and Bioengineering
(NIBIB), National Institutes of Health. This work was also supported, in
part, by NIH-K23MH086619. The authors report no conflicts of interest.
The authors alone are responsible for the content and writing of the
paper.
NR 26
TC 5
Z9 6
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PY 2015
VL 29
IS 3
BP 403
EP 407
DI 10.3109/02699052.2014.974209
PG 5
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA CB0HQ
UT WOS:000349307000015
PM 25384127
ER
PT J
AU Braunstein, LZ
Brock, JE
Chen, YH
Truong, L
Russo, AL
Arvold, ND
Harris, JR
AF Braunstein, Lior Z.
Brock, Jane E.
Chen, Yu-Hui
Linh Truong
Russo, Andrea L.
Arvold, Nils D.
Harris, Jay R.
TI Invasive lobular carcinoma of the breast: local recurrence after
breast-conserving therapy by subtype approximation and surgical margin
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Invasive lobular carcinoma; Local recurrence;
Breast-conserving surgery; Lumpectomy; Biologic subtype
ID CLINICAL-PATHOLOGICAL FEATURES; ONCOLOGY CONSENSUS GUIDELINE; DUCTAL
CARCINOMA; TUMOR CHARACTERISTICS; CONSERVATION SURGERY; AMERICAN
SOCIETY; HORMONAL-THERAPY; STAGES I; CANCER; OUTCOMES
AB Invasive lobular carcinoma (ILC) typically presents at a later stage than invasive ductal carcinoma (IDC) and poses unique radiographic and surgical challenges. However, current principles of breast-conserving therapy (BCT) do not distinguish between histologic subtypes, raising uncertainty about the optimal approach for patients with ILC. We studied 998 BCT patients from 1998-2007, comprised 74 % IDC, 8 % ILC, and 18 % with mixed ILC/IDC. In light of recent guidelines addressing surgical margins, specimens were assessed for margin width and biologic subtype. The Kaplan-Meier method and Cox proportional hazards models were used to analyze effects of patient and disease characteristics on local recurrence (LR). At a median of 119 months, 45 patients had an isolated LR. 10-year LR was 5.5 % for patients with IDC, 4.4 % for ILC, and 1.2 % for mixed histology (p = 0.08). The majority of ILC cases had luminal A biologic subtype (91.1 %), and analysis among all luminal A cases revealed 10-year LR of 2.6 % for IDC, 3.4 % for ILC, and 0 % for mixed tumors (p = 0.12). Patients with ILC were more likely to have initially positive surgical margins (45.0 vs 17.5 %; p < 0.001) resulting in more frequent re-excision (57.1 % vs 40.4 %; p = 0.02), though final margins were similar between ILC and IDC (p = 0.88). No LR was observed among ILC or mixed histology patients with margins < 2 mm (n = 28). On multivariate analysis, histologic subtype was not associated with LR (p = 0.52). Modern approaches confer similarly favorable LR rates for ILC, IDC, and mixed histology breast cancers despite inherent histologic differences. Patients with ILC did not require more extensive surgical margins than those with IDC.
C1 [Braunstein, Lior Z.] Harvard Radiat Oncol Program, Boston, MA USA.
[Brock, Jane E.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA.
[Brock, Jane E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chen, Yu-Hui] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
[Linh Truong; Arvold, Nils D.; Harris, Jay R.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02215 USA.
[Linh Truong; Arvold, Nils D.; Harris, Jay R.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA.
[Russo, Andrea L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Harris, JR (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Dana 1622,450 Brookline Ave, Boston, MA 02215 USA.
EM jharris@lroc.harvard.edu
NR 38
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2015
VL 149
IS 2
BP 555
EP 564
DI 10.1007/s10549-015-3273-y
PG 10
WC Oncology
SC Oncology
GA CA5VT
UT WOS:000348976600024
PM 25604797
ER
PT J
AU Pusztaszeri, M
Wang, H
Cibas, ES
Powers, CN
Bongiovanni, M
Ali, S
Khurana, KK
Michaels, PJ
Faquin, WC
AF Pusztaszeri, Marc
Wang, He
Cibas, Edmund S.
Powers, Celeste N.
Bongiovanni, Massimo
Ali, Syed
Khurana, Kamal K.
Michaels, Paul J.
Faquin, William C.
TI Fine-Needle Aspiration Biopsy of Secondary Neoplasms of the Thyroid
Gland: A Multi-Institutional Study of 62 Cases
SO CANCER CYTOPATHOLOGY
LA English
DT Article
DE thyroid; secondary neoplasm; metastasis; renal cell carcinoma; squamous
cell carcinoma; adenocarcinoma; lymphoma; adenoid cystic carcinoma;
fine-needle aspiration; cytology
ID ADENOID CYSTIC CARCINOMA; RENAL-CELL CARCINOMA; TO-TUMOR METASTASIS;
FOLLICULAR ADENOMA; PAPILLARY CARCINOMA; DIAGNOSIS; CYTOLOGY;
MALIGNANCY; EXPERIENCE; MANAGEMENT
AB BACKGROUNDSecondary neoplasms of the thyroid gland (SNTGs) are uncommon, and it is important to recognize them in thyroid fine-needle aspiration biopsy (FNAB).
METHODSThe authors report a cohort of 62 SNTGs from 7 institutions in the United States and Europe. Patients were identified retrospectively by searching through medical records of the respective institutions. All initial diagnoses were rendered by FNAB.
RESULTSSNTGs represented 0.16% of all thyroid FNABs and were more frequent among women (ratio of women to men, 1.2:1.0). The mean patient age was of 59 years (range, 7-84 years), the mean tumor size was 3 cm (range, 0.9-7 cm), and the mean interval from diagnosis of the primary tumor was 45 months (range, 0-156 months). Eighty-seven percent of SNTGs were diagnosed as malignant by FNAB, and there was a specific SNTG diagnosis in 93% of patients. Immunocytochemistry and flow cytometry, which were used in 30% of patients, were useful ancillary studies. Adenocarcinomas (n=23; 37%) and squamous cell carcinomas (SCCs) (n=22; 35.5%) represented the majority of SNTGs, followed by lymphoma (n=5; 8%), melanoma (n=5; 8%), adenoid cystic carcinoma (n=3; 5%), and various sarcomas (n=3; 5%). Adenocarcinomas originated from the kidney (n=9; 39%), lung (n=6; 26%), breast (n=5; 22%), and colon (n=3; 13%). SCCs originated mostly from the head and neck (n=13; 59%), followed by lung (n=3; 13%), esophagus (n=3; 14%), and unknown primary sites (n=3; 14%).
CONCLUSIONSAdenocarcinomas from the kidney, lung, breast, and colon along with SCCs represent the majority of SNTGs. The current results indicate that FNAB is a sensitive and accurate method for diagnosing SNTG; however, diagnostic difficulties can occur. Knowledge of clinical history and the judicious application of ancillary studies can increase the sensitivity and accuracy of FNAB for detecting SNTGs. Cancer (Cancer Cytopathol) 2015;123:19-29. (c) 2014 American Cancer Society.
Adenocarcinomas from the kidney, lung, breast, and colon along with squamous cell carcinomas represent the majority of secondary neoplasms of the thyroid gland (SNTGs). Fine-needle aspiration biopsy is a sensitive and accurate method for diagnosing SNTGs; however, diagnostic difficulties can occur, and knowledge of clinical history and judicious application of ancillary studies can increase the sensitivity and accuracy of fine-needle aspiration biopsy for detecting SNTGs.
C1 [Pusztaszeri, Marc] Hop Univ Geneve, Dept Pathol, CH-1211 Geneva 14, Switzerland.
[Wang, He] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Cibas, Edmund S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Cibas, Edmund S.; Faquin, William C.] Harvard Univ, Sch Med, Boston, MA USA.
[Powers, Celeste N.] Virginia Commonwealth Univ Hlth Syst, Dept Pathol, Richmond, VA USA.
[Bongiovanni, Massimo] Inst Pathol, Locarno, Switzerland.
[Ali, Syed] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA.
[Khurana, Kamal K.] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA.
[Michaels, Paul J.; Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Pusztaszeri, M (reprint author), Hop Univ Geneve, Serv Pathol Clin, 1 Rue Michel Servet, CH-1211 Geneva 14, Switzerland.
EM marc.pusztaszeri@hcuge.ch
RI Bongiovanni, Massimo/C-3144-2017
OI Bongiovanni, Massimo/0000-0001-9846-6682
NR 70
TC 10
Z9 10
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-662X
EI 1934-6638
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD JAN
PY 2015
VL 123
IS 1
BP 19
EP 29
DI 10.1002/cncy.21494
PG 11
WC Oncology; Pathology
SC Oncology; Pathology
GA CA7AP
UT WOS:000349069700006
PM 25369542
ER
PT J
AU Nakshatri, H
Appaiah, HN
Anjanappa, M
Gilley, D
Tanaka, H
Badve, S
Crooks, PA
Mathews, W
Sweeney, C
Bhat-Nakshatri, P
AF Nakshatri, H.
Appaiah, H. N.
Anjanappa, M.
Gilley, D.
Tanaka, H.
Badve, S.
Crooks, P. A.
Mathews, W.
Sweeney, C.
Bhat-Nakshatri, P.
TI NF-kappa B-dependent and -independent epigenetic modulation using the
novel anti-cancer agent DMAPT
SO CELL DEATH & DISEASE
LA English
DT Article
ID BREAST-CANCER CELLS; GENE-EXPRESSION SIGNATURE; HISTONE H3; LYSINE 36;
PROTEIN; PARTHENOLIDE; METHYLATION; APOPTOSIS; METHYLTRANSFERASE;
TRIMETHYLATION
AB The transcription factor nuclear factor-kappaB (NF-kappa B) is constitutively active in several cancers and is a target of therapeutic development. We recently developed dimethylaminoparthenolide (DMAPT), a clinical grade water-soluble analog of parthenolide, as a potent inhibitor of NF-kappa B and demonstrated in vitro and in vivo anti-tumor activities in multiple cancers. In this study, we show DMAPT is an epigenetic modulator functioning in an NF-kappa B-dependent and -independent manner. DMAPT-mediated NF-kappa B inhibition resulted in elevated histone H3K36 trimethylation (H3K36me3), which could be recapitulated through genetic ablation of the p65 subunit of NF-kappa B or inhibitor-of-kappaB alpha super-repressor overexpression. DMAPT treatment and p65 ablation increased the levels of H3K36 trimethylases NSD1 (KMT3B) and SETD2 (KMT3A), suggesting that NF-kappa B directly represses their expression and that lower H3K36me3 is an epigenetic marker of constitutive NF-kappa B activity. Overexpression of a constitutively active p65 subunit of NF-kappa B reduced NSD1 and H3K36me3 levels. NSD1 is essential for DMAPT-induced expression of pro-apoptotic BIM, indicating a functional link between epigenetic modification and gene expression. Interestingly, we observed enhanced H4K20 trimethylation and induction of H4K20 trimethylase KMT5C in DMAPT-treated cells independent of NF-kappa B inhibition. These results add KMT5C to the list NF-kappa B-independent epigenetic targets of parthenolide, which include previously described histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1. As NSD1 and SETD2 are known tumor suppressors and loss of H4K20 trimethylation is an early event in cancer progression, which contributes to genomic instability, we propose DMAPT as a potent pharmacologic agent that can reverse NF-kappa B-dependent and -independent cancer-specific epigenetic abnormalities.
C1 [Nakshatri, H.; Appaiah, H. N.; Anjanappa, M.; Bhat-Nakshatri, P.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
[Nakshatri, H.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
[Gilley, D.; Tanaka, H.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
[Badve, S.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA.
[Crooks, P. A.] Univ Arkansas, Dept Pharmaceut Sci, Little Rock, AR 72204 USA.
[Mathews, W.] Leuchemix Inc, Woodside, CA USA.
[Sweeney, C.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
RP Nakshatri, H (reprint author), Indiana Univ Sch Med, Dept Surg, 980 Walther Hall,West Walnut St C218C, Indianapolis, IN 46202 USA.
EM hnakshat@iupui.edu
FU NIH [CA143994-01A1]; IUPUI Breast Cancer Signature Center initiative
FX We thank Dr. Alex Hoffman for MEFs and Nikail R Collins for technical
assistance. This work is supported by a grant from NIH CA143994-01A1 to
HN. IUPUI Breast Cancer Signature Center initiative provided funding for
establishing prognostic database.
NR 55
TC 5
Z9 5
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JAN
PY 2015
VL 6
AR e1608
DI 10.1038/cddis.2014.569
PG 11
WC Cell Biology
SC Cell Biology
GA CA6JZ
UT WOS:000349020500027
PM 25611383
ER
PT J
AU Marechal, A
Zou, L
AF Marechal, Alexandre
Zou, Lee
TI RPA-coated single-stranded DNA as a platform for post-translational
modifications in the DNA damage response
SO CELL RESEARCH
LA English
DT Review
DE RPA; post-translational modification; phosphorylation; ubiquitination;
SUMOylation
ID REPLICATION-PROTEIN-A; NUCLEOTIDE EXCISION-REPAIR; UBIQUITIN E3 LIGASE;
S-PHASE CHECKPOINT; N-TERMINAL DOMAIN; HOMOLOGOUS RECOMBINATION;
IN-VITRO; BINDING-PROTEIN; CELL-CYCLE; PHYSICAL INTERACTION
AB The Replication Protein A (RPA) complex is an essential regulator of eukaryotic DNA metabolism. RPA avidly binds to single-stranded DNA (ssDNA) through multiple oligonucleotide/oligosaccharide-binding folds and coordinates the recruitment and exchange of genome maintenance factors to regulate DNA replication, recombination and repair. The RPA-ssDNA platform also constitutes a key physiological signal which activates the master ATR kinase to protect and repair stalled or collapsed replication forks during replication stress. In recent years, the RPA complex has emerged as a key target and an important regulator of post-translational modifications in response to DNA damage, which is critical for its genome guardian functions. Phosphorylation and SUMOylation of the RPA complex, and more recently RPA-regulated ubiquitination, have all been shown to control specific aspects of DNA damage signaling and repair by modulating the interactions between RPA and its partners. Here, we review our current understanding of the critical functions of the RPA-ssDNA platform in the maintenance of genome stability and its regulation through an elaborate network of covalent modifications.
C1 [Marechal, Alexandre; Zou, Lee] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Charlestown, MA 02129 USA.
[Zou, Lee] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med,Dept Pathol, Boston, MA 02114 USA.
RP Marechal, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Charlestown, MA 02129 USA.
EM amarechal@mgh.harvard.edu; zou.lee@mgh.harvard.edu
FU NIH [GM076388]; federal share of proton program
FX We apologize to all of our colleagues whose work we could not cite due
to space restrictions. We want to thank Remi Buisson, Jian Ouyang, Hai
Dang Nguyen and Stephanie A Yazinski for critical reading of the
manuscript and all members of the Zou Lab for fruitful discussions. This
work is supported by the NIH grant GM076388 and the federal share of
proton program to LZ.
NR 183
TC 29
Z9 30
U1 1
U2 19
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD JAN
PY 2015
VL 25
IS 1
BP 9
EP 23
DI 10.1038/cr.2014.147
PG 15
WC Cell Biology
SC Cell Biology
GA CB0QE
UT WOS:000349330800005
PM 25403473
ER
PT J
AU Sahara, M
Hansson, EM
Wernet, O
Lui, KO
Spater, D
Chien, KR
AF Sahara, Makoto
Hansson, Emil M.
Wernet, Oliver
Lui, Kathy O.
Spaeter, Daniela
Chien, Kenneth R.
TI Manipulation of a VEGF-Notch signaling circuit drives formation of
functional vascular endothelial progenitors from human pluripotent stem
cells (vol 24, pg 820, 2014)
SO CELL RESEARCH
LA English
DT Correction
C1 [Sahara, Makoto; Hansson, Emil M.; Lui, Kathy O.; Spaeter, Daniela; Chien, Kenneth R.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Sahara, Makoto; Hansson, Emil M.; Lui, Kathy O.; Spaeter, Daniela; Chien, Kenneth R.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Sahara, Makoto; Lui, Kathy O.; Spaeter, Daniela] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Sahara, Makoto; Chien, Kenneth R.] Karolinska Inst, Dept Med Cardiol Cell & Mol Biol, SE-17177 Stockholm, Sweden.
[Wernet, Oliver] Charite, Dept Anesthesiol & Intens Care Med, D-10117 Berlin, Germany.
RP Sahara, M (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, 7 Divin Ave, Cambridge, MA 02138 USA.
RI Lui, Kathy O./E-4883-2015
OI Lui, Kathy O./0000-0002-1616-3643
NR 1
TC 2
Z9 2
U1 1
U2 6
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD JAN
PY 2015
VL 25
IS 1
BP 148
EP 148
DI 10.1038/cr.2015.2
PG 1
WC Cell Biology
SC Cell Biology
GA CB0QE
UT WOS:000349330800017
PM 25553820
ER
PT J
AU Qian, F
Goel, G
Meng, HL
Wang, XM
You, FP
Devine, L
Raddassi, K
Garcia, MN
Murray, KO
Bolen, CR
Gaujoux, R
Shen-Orr, SS
Hafler, D
Fikrig, E
Xavier, R
Kleinstein, SH
Montgomery, RR
AF Qian, Feng
Goel, Gautam
Meng, Hailong
Wang, Xiaomei
You, Fuping
Devine, Lesley
Raddassi, Khadir
Garcia, Melissa N.
Murray, Kristy O.
Bolen, Christopher R.
Gaujoux, Renaud
Shen-Orr, Shai S.
Hafler, David
Fikrig, Erol
Xavier, Ramnik
Kleinstein, Steven H.
Montgomery, Ruth R.
TI Systems Immunology Reveals Markers of Susceptibility to West Nile Virus
Infection
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID GENE-EXPRESSION; INFLUENZA; ENCEPHALITIS; RESPONSES; CELLS;
PATHOGENESIS; INTERFERON; MICROARRAY; RESISTANCE; PROTEINS
AB West Nile virus (WNV) infection is usually asymptomatic but can cause severe neurological disease and death, particularly in older patients, and how individual variations in immunity contribute to disease severity is not yet defined. Animal studies identified a role for several immunity-related genes that determine the severity of infection. We have integrated systems-level transcriptional and functional data sets from stratified cohorts of subjects with a history of WNV infection to define whether these markers can distinguish susceptibility in a human population. Transcriptional profiles combined with immunophenotyping of primary cells identified a predictive signature of susceptibility that was detectable years after acute infection (67% accuracy), with the most prominent alteration being decreased IL1B induction following ex vivo infection of macrophages with WNV. Deconvolution analysis also determined a significant role for CXCL10 expression in myeloid dendritic cells. This systems analysis identified markers of pathogenic mechanisms and offers insights into potential therapeutic strategies.
C1 [Qian, Feng; Wang, Xiaomei; Montgomery, Ruth R.] Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520 USA.
[Meng, Hailong; Bolen, Christopher R.; Kleinstein, Steven H.] Yale Univ, Sch Med, Interdept Program Computat Biol & Bioinformat, New Haven, CT USA.
[You, Fuping] Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT USA.
[Devine, Lesley] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA.
[Raddassi, Khadir; Hafler, David] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
[Kleinstein, Steven H.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
[Fikrig, Erol] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.
[Garcia, Melissa N.; Murray, Kristy O.] Baylor Coll Med, Houston, TX 77030 USA.
[Goel, Gautam; Xavier, Ramnik] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Gaujoux, Renaud; Shen-Orr, Shai S.] Technion Israel Inst Technol, Fac Med, Rappaport Inst Med Res, Dept Immunol, Haifa, Israel.
[Gaujoux, Renaud; Shen-Orr, Shai S.] Technion Israel Inst Technol, Fac Biol, Haifa, Israel.
RP Montgomery, RR (reprint author), Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520 USA.
EM ruth.montgomery@yale.edu
RI Qian, Feng/F-8186-2010;
OI Montgomery, Ruth/0000-0002-8661-4454
FU National Institutes of Health (HHS grants) [N272201100019C, U19AI089992,
AI091816, AI057229]; Gillson Longenbaugh Foundation
FX This work was supported in part by the National Institutes of Health
(HHS grants N272201100019C, U19AI089992, AI091816, and AI057229) and the
Gillson Longenbaugh Foundation.
NR 49
TC 11
Z9 11
U1 3
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD JAN
PY 2015
VL 22
IS 1
BP 6
EP 16
DI 10.1128/CVI.00508-14
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CA2YK
UT WOS:000348771800002
PM 25355795
ER
PT J
AU Yachimski, P
Wani, S
Givens, T
Howard, E
Higginbotham, T
Price, A
Berman, K
Hosford, L
Katcher, PM
Ozanne, E
Perzan, K
Hur, C
AF Yachimski, Patrick
Wani, Sachin
Givens, Tonya
Howard, Eric
Higginbotham, Tina
Price, Angie
Berman, Kenneth
Hosford, Lindsay
Katcher, Paul Menard
Ozanne, Elissa
Perzan, Katherine
Hur, Chin
TI Preference of Endoscopic Ablation Over Medical Prevention of Esophageal
Adenocarcinoma by Patients With Barrett's Esophagus
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE COX Inhibitor; Surgery; Patient Choice; Esophageal Cancer
ID HIGH-GRADE DYSPLASIA; RADIOFREQUENCY ABLATION; DECISION AIDS;
CANCER-RISK; SURVEILLANCE; METAANALYSIS; CRITERIA; THERAPY
AB BACKGROUND & AIMS: Endoscopic intervention or pharmacologic inhibition of cyclooxygenase might be used to prevent progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC). We investigated whether patients with BE prefer endoscopic therapy or chemoprevention of EAC.
METHODS: Eighty-one subjects with nondysplastic BE were given a survey that described 2 scenarios. The survey explained that treatment A (ablation), endoscopy, reduced lifetime risk of EAC by 50%, with 5% risk for esophageal stricture, whereas treatment B (aspirin) reduced lifetime risk of EAC by 50% and the risk of heart attack by 30%, yet increased the risk for ulcer by 75%. Subjects indicated their willingness to undergo either treatment A and/or treatment B if endoscopic surveillance were required every 3-5 years, every 10 years, or were not required. Visual aids were included to represent risk and benefit percentages.
RESULTS: When surveillance was required every 3-5 years, more subjects were willing to undergo treatment A than treatment B (78%, 63 of 81 vs 53%, 43 of 81; P < .01). There were no differences in age, sex, education level, or history of cancer, heart disease, or ulcer between patients willing to undergo treatment A and those willing to undergo treatment B. Altering the frequency of surveillance did not affect patients' willingness to undergo either treatment.
CONCLUSIONS: In a simulated scenario, patients with BE preferred endoscopic intervention over chemoprevention for EAC. Further investigation of the shared decision-making process regarding preventive strategies for patients with BE may be warranted.
C1 [Yachimski, Patrick; Givens, Tonya; Howard, Eric; Higginbotham, Tina] Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Med Ctr, Nashville, TN 37232 USA.
[Wani, Sachin; Hosford, Lindsay; Katcher, Paul Menard] Univ Colorado, Div Gastroenterol & Hepatol, Aurora, CO USA.
[Price, Angie; Berman, Kenneth] Vet Adm Eastern Colorado Hlth Care Syst, Denver, CO USA.
[Ozanne, Elissa] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA.
[Perzan, Katherine; Hur, Chin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA.
RP Yachimski, P (reprint author), Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Med Ctr, 1660 Vanderbilt Clin, Nashville, TN 37232 USA.
EM patrick.yachimski@vanderbilt.edu
OI Hur, Chin/0000-0002-2819-7576
FU National Institutes of Health [R01CA140574]; AGA Takeda Research Scholar
Award in GERD and Barrett's esophagus; Barrett's esophagus; NCATS/NIH
[UL1 TR000445]
FX Supported by the National Institutes of Health grant R01CA140574 to Dr
Hur. Dr Wani is supported by the AGA Takeda Research Scholar Award in
GERD and Barrett's esophagus. Research Electronic Data Capture (REDCap)
is supported by grant UL1 TR000445 from NCATS/NIH.
NR 26
TC 4
Z9 4
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JAN
PY 2015
VL 13
IS 1
BP 84
EP 90
DI 10.1016/j.cgh.2014.03.017
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AZ2BW
UT WOS:000348040500016
PM 24681073
ER
PT J
AU Beste, LA
Ioannou, GN
Yang, Y
Chang, MF
Ross, D
Dominitz, JA
AF Beste, Lauren A.
Ioannou, George N.
Yang, Yin
Chang, Michael F.
Ross, David
Dominitz, Jason A.
TI Improved Surveillance for Hepatocellular Carcinoma With a Primary
Care-Oriented Clinical Reminder
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Liver Cancer; Screening; Veterans; Cirrhosis
ID UNITED-STATES; HEPATITIS-C; LIVER-TRANSPLANTATION; PATIENT SURVIVAL;
CIRRHOSIS; CANCER; RATES; STAGE; VETERANS; FUTURE
AB BACKGROUND & AIMS: Surveillance of patients with cirrhosis for hepatocellular carcinoma (HCC) with liver ultrasound every 6 months has been linked to longer survival and greater use of definitive treatment. However, less than 20% of patients typically undergo routine surveillance.
METHODS: We conducted a quasi-experimental study to assess whether a primary care-oriented, point-of-care clinical reminder improves HCC surveillance. Our study included patients with cirrhosis who made 1 or more primary care visits to 8 Veterans Affairs (VA) facilities over 18 months. Clinicians at 1 facility were sent a reminder to perform liver ultrasound assessments for patients with cirrhosis who had not received surveillance in the preceding 6 months. Outcomes included the proportion of patients receiving adequate HCC surveillance (defined as >2 instances of liver imaging >6 months apart) and HCC diagnosis and stage. Because it was a quality improvement project, this study did not require approval by an institutional review board under Federal law and VA policy.
RESULTS: Baseline rates of adequate HCC surveillance were similar at all facilities (18.2% at the intervention site vs 16.1% elsewhere; P = .23). After the reminder was implemented, adequate surveillance at the intervention site (for 790 patients) increased by 51%, but was unchanged at the other facilities (for 2094 patients) (27.6% vs 17.5%; P < .001). Adequate surveillance occurred more often at the intervention site (adjusted odds ratio, 1.29; 95% confidence interval, 1.03-1.61; P = .02). A higher crude percentage of patients was diagnosed with HCC at the intervention site than elsewhere (3.2% vs 1.9%; P = .03). We detected no difference in tumor stage at diagnosis.
CONCLUSIONS: In a VA population, a clinical reminder system increased HCC surveillance in patients with cirrhosis.
C1 [Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Gen Internal Med, Seattle, WA USA.
[Beste, Lauren A.; Yang, Yin; Dominitz, Jason A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Ioannou, George N.; Dominitz, Jason A.] Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA USA.
[Beste, Lauren A.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA.
[Ioannou, George N.; Dominitz, Jason A.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA.
[Chang, Michael F.] Portland VA Med Ctr, Dept Gastroenterol & Hepatol, Portland, OR USA.
[Chang, Michael F.] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA.
[Ross, David] Dept Vet Affairs, Off Clin Publ Hlth, HIV Hepatitis & Publ Hlth Pathogens Program C, Washington, DC USA.
[Ross, David] George Washington Univ, Div Infect Dis, Washington, DC USA.
RP Beste, LA (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way, Seattle, WA 98018 USA.
EM lauren.beste@va.gov
OI Dominitz, Jason/0000-0002-8070-7086
FU Veterans Affairs Puget Sound Health Care System; Veterans Affairs
National Hepatitis C Resource Centers program, through the Office of
HIV, Hepatitis C, and Public Health Pathogens
FX This material is the result of work supported by resources from the
Veterans Affairs Puget Sound Health Care System and the Portland
Veterans Affairs Medical Center. Funding also was provided by the
Veterans Affairs National Hepatitis C Resource Centers program, through
the Office of HIV, Hepatitis C, and Public Health Pathogens. The views
expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs.
NR 32
TC 15
Z9 15
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JAN
PY 2015
VL 13
IS 1
BP 172
EP 179
DI 10.1016/j.cgh.2014.04.033
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AZ2BW
UT WOS:000348040500030
PM 24813175
ER
PT J
AU Ghany, MG
Perrillo, R
Li, RS
Belle, SH
Janssen, HLA
Terrault, NA
Shuhart, MC
Lau, DTY
Kim, WR
Fried, MW
Sterling, RK
Di Bisceglie, AM
Han, SHB
Ganova-Raeva, LM
Chang, KM
Lok, ASF
AF Ghany, Marc G.
Perrillo, Robert
Li, Ruosha
Belle, Steven H.
Janssen, Harry L. A.
Terrault, Norah A.
Shuhart, Margaret C.
Lau, Daryl T-Y.
Kim, W. Ray
Fried, Michael W.
Sterling, Richard K.
Di Bisceglie, Adrian M.
Han, Steven-Huy B.
Ganova-Raeva, Lilia Milkova
Chang, Kyong-Mi
Lok, Anna Suk-Fong
CA Hepatitis B Res Network
TI Characteristics of Adults in the Hepatitis B Research Network in North
America Reflect Their Country of Origin and Hepatitis B Virus Genotype
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE HBeAg; Chronic Hepatitis B Virus Infection; USA; ALT
ID UNITED-STATES; HBV INFECTION; EPIDEMIOLOGY; PREVALENCE; WORLDWIDE;
DISEASE; BURDEN; HEALTH
AB BACKGROUND & AIMS: Chronic hepatitis B virus (HBV) infection is an important cause of cirrhosis and hepatocellular carcinoma worldwide; populations that migrate to the United States and Canada might be affected disproportionately. The Hepatitis B Research Network (HBRN) is a cooperative network of investigators from the United States and Canada, created to facilitate clinical, therapeutic, and translational research in adults and children with hepatitis B. We describe the structure of the network and baseline characteristics of adults with hepatitis B enrolled in the network.
METHODS: The HBRN collected data on the clinical characteristics of 1625 adults with chronic HBV infection who are not receiving antiviral therapy from 21 clinical centers in North America.
RESULTS: Half of the subjects in the HBRN are men, and the median age is 42 years; 72% are Asian, 15% are black, and 11% are white; with 82% born outside of North America. The most common HBV genotype was B (39%); 74% of subjects were negative for the hepatitis B e antigen. The median serum level of HBV DNA when the study began was 3.6 log(10) IU/mL; 68% of male subjects and 67% of female subjects had alanine aminotransferase levels higher than the normal range.
CONCLUSIONS: The HBRN cohort is used to address important clinical and therapeutic questions for North Americans infected with chronic HBV and to guide health policies on HBV prevention and management in North America.
C1 [Ghany, Marc G.] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA.
[Perrillo, Robert] Baylor Univ, Med Ctr, Hepatol Div, Dallas, TX USA.
[Li, Ruosha; Belle, Steven H.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Janssen, Harry L. A.] Toronto Western Hosp, Div Gastroenterol, Univ Hlth Network, Toronto, ON M5T 2S8, Canada.
[Janssen, Harry L. A.] Toronto Gen Hosp, Div Gastroenterol, Univ Hlth Network, Toronto, ON, Canada.
[Terrault, Norah A.] Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA.
[Shuhart, Margaret C.] Univ Washington, Harborview Med Ctr, Viral Hepatitis & Liver Clin, Seattle, WA 98104 USA.
[Lau, Daryl T-Y.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA.
[Kim, W. Ray] Stanford Univ, Sch Med, Div Gastroenterol, Palo Alto, CA 94304 USA.
[Fried, Michael W.] Univ N Carolina, Ctr Liver, Sect Hepatol, Chapel Hill, NC USA.
[Sterling, Richard K.] Virginia Commonwealth Univ Hlth Syst, Sect Hepatol, Richmond, VA USA.
[Di Bisceglie, Adrian M.] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO USA.
[Han, Steven-Huy B.] Univ Calif Los Angeles, David Geffen Sch Med, Pfleger Liver Inst Clin, Los Angeles, CA 90095 USA.
[Ganova-Raeva, Lilia Milkova] Ctr Dis Control & Prevent, Div Viral Hepatitis, Mol Epidemiol & Bioinformat Sequencing Lab, Atlanta, GA USA.
[Chang, Kyong-Mi] Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Penn Ctr Viral Hepatitis, Philadelphia, PA 19104 USA.
[Lok, Anna Suk-Fong] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA.
RP Ghany, MG (reprint author), NIDDK, Liver Dis Branch, NIH, Bdg 10,Room 9B-16,10 Ctr Dr,MSC 1800, Bethesda, MD 20892 USA.
EM marcg@intra.niddk.nih.gov
OI Barritt, Alfred/0000-0002-4200-3256; Cloonan, Yona/0000-0003-3893-3693;
Wahed, Abdus/0000-0001-6911-7221
FU National Institute of Diabetes and Digestive and Kidney Diseases [U01
DK082872, DK082864, DK082874, U01 DK082944, DK082943, DK082919, DK
082843, DK082867, DK082923, DK082871, DK082927, DK082866, DK082863,
A-DK-3002-001]; National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health; Immunology Center (National
Institutes of Health/National Institute of Diabetes and Digestive and
Kidney Diseases, Center of Molecular Studies in Digestive and Liver
Diseases) [P30DK50306]; Immunology Center (National Institutes of Health
Public Health Service Research) [M01RR00040]; National Center for
Advancing Translational Sciences, National Institutes of Health
[UL1TR000058]; Clinical and Translational Science Awards [UL1TR000004,
UL1TR001111, UL1RR024986]; Gilead Sciences, Inc; Roche Molecular Systems
through National Institute of Diabetes and Digestive and Kidney Diseases
FX The Hepatitis B Research Network was funded by grants from the National
Institute of Diabetes and Digestive and Kidney Diseases to the following
investigators: U01 DK082872 (W.L.), DK082864 (S.B.), DK082874 (H.J.),
U01 DK082944 (N.T.), DK082943 (R.C.), DK082919 (D.T.-Y.L.), DK 082843
(L.R.R.), DK082867 (M.W.F.), DK082923 (R.K.S.), DK082871 (A.D.B.),
DK082927 (S.-H.B.H.), DK082866 (K.-M.C.), and DK082863 (A.S.-F.L.); an
interagency agreement with the National Institute of Diabetes and
Digestive and Kidney Diseases: A-DK-3002-001 (L.M.G.-R.); and support
from the intramural program, National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health (M.G.G.).
Additional funding for this study was provided by the Immunology Center
(National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases, Center of Molecular Studies in Digestive
and Liver Diseases: P30DK50306; and a National Institutes of Health
Public Health Service Research grant: M01RR00040 to K.-M.C.), by the
National Center for Advancing Translational Sciences, National
Institutes of Health (UL1TR000058 to R.K.S.); and Clinical and
Translational Science Awards grants: UL1TR000004 (N.A.T.), UL1TR001111
(M.W.F.), and UL1RR024986 (A.S.-F.L.). Additional support was provided
by Gilead Sciences, Inc, and Roche Molecular Systems via a Cooperative
Research And Development Agreement through the National Institute of
Diabetes and Digestive and Kidney Diseases.
NR 15
TC 11
Z9 11
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JAN
PY 2015
VL 13
IS 1
BP 183
EP 192
DI 10.1016/j.cgh.2014.06.028
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AZ2BW
UT WOS:000348040500032
PM 25010003
ER
PT J
AU Toiviainen, A
Jalasvuori, H
Lahti, E
Gursoy, U
Salminen, S
Fontana, M
Flannagan, S
Eckert, G
Kokaras, A
Paster, B
Soderling, E
AF Toiviainen, Aino
Jalasvuori, Heli
Lahti, Emilia
Gursoy, Ulvi
Salminen, Seppo
Fontana, Margherita
Flannagan, Susan
Eckert, George
Kokaras, Alexis
Paster, Bruce
Soderling, Eva
TI Impact of orally administered lozenges with Lactobacillus rhamnosus GG
and Bifidobacterium animalis subsp lactis BB-12 on the number of
salivary mutans streptococci, amount of plaque, gingival inflammation
and the oral microbiome in healthy adults
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Lactobacillus rhamnosus GG; Bifidobacterium lactis BB-12; Probiotic;
HOMIM; Mutans streptococci; Lactobacilli; Plaque index; Gingival index
ID LONG-TERM CONSUMPTION; PROBIOTIC LACTOBACILLI; EARLY-CHILDHOOD;
DENTAL-CARIES; DOUBLE-BLIND; ATCC 55730; INFECTIONS; CHILDREN; REUTERI;
MILK
AB The aim was to evaluate the effects of orally administered Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the number of salivary mutans streptococci (MS), amount of plaque, gingival inflammation and the oral microbiota in healthy young adults.
The study was a randomised, controlled, double-blind trial. Healthy volunteers used lozenges containing a combination of LGG and BB-12 (test group, n = 29) or lozenges without added probiotics (control group, n = 31) for 4 weeks. At baseline and at the end of the test period, the plaque index (PI) and gingival index (GI) were determined, and stimulated saliva was collected. The microbial composition of saliva was assessed using human oral microbe identification microarray (n = 30). MS and lactobacilli (LB) were plate cultured.
The probiotic lozenge decreased both PI and GI (p < 0.05) while no changes were observed in the control group. However, no probiotic-induced changes were found in the microbial compositions of saliva in either group.
The probiotic lozenge improved the periodontal status without affecting the oral microbiota.
Short-term consumption of LGG and BB-12 decreased the amount of plaque which was associated with a clinical impact: a decrease in gingival inflammation.
C1 [Toiviainen, Aino; Jalasvuori, Heli; Lahti, Emilia; Gursoy, Ulvi; Soderling, Eva] Univ Turku, Inst Dent, FIN-20520 Turku, Finland.
[Salminen, Seppo] Univ Turku, Funct Foods Forum, FIN-20520 Turku, Finland.
[Fontana, Margherita; Flannagan, Susan; Eckert, George] Univ Michigan, Sch Dent, Dept Cariol Restorat Sci & Endodont, Ann Arbor, MI 48109 USA.
[Kokaras, Alexis; Paster, Bruce] Forsyth Inst, Dept Microbiol, Cambridge, MA 02142 USA.
[Paster, Bruce] Harvard Univ, Dept Oral Med Infect & Immun, Sch Dent Med, Boston, MA 02115 USA.
RP Soderling, E (reprint author), Univ Turku, Inst Dent, Lemminkaisenkatu 2, FIN-20520 Turku, Finland.
EM eva.soderling@utu.fi
OI Fontana, Margherita/0000-0003-2357-7534; Gursoy, Ulvi
Kahraman/0000-0002-1225-5751
FU TEKES, Finland; Finnish Dental Society Apollonia; Turku University
Foundation
FX The excellent technical assistance of biomedical research technician
Oona Hallfors is gratefully acknowledged. The STABPRO project (funded by
TEKES, Finland), Finnish Dental Society Apollonia and Turku University
Foundation are acknowledged for providing funding for the study.
NR 44
TC 12
Z9 12
U1 6
U2 15
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1432-6981
EI 1436-3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD JAN
PY 2015
VL 19
IS 1
BP 77
EP 83
DI 10.1007/s00784-014-1221-6
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA CA5XG
UT WOS:000348981100010
PM 24638207
ER
PT J
AU Thames, AD
Panos, SE
Arentoft, A
Byrd, DA
Hinkin, CH
Arbid, N
AF Thames, April D.
Panos, Stella E.
Arentoft, Alyssa
Byrd, Desiree A.
Hinkin, Charles H.
Arbid, Natalie
TI Mild Test Anxiety Influences Neurocognitive Performance Among African
Americans and European Americans: Identifying Interfering and
Facilitating Sources
SO CULTURAL DIVERSITY & ETHNIC MINORITY PSYCHOLOGY
LA English
DT Article
DE anxiety; assessment; cognition; ethnicity; performance
ID OBSESSIVE-COMPULSIVE DISORDER; STEREOTYPE THREAT; NEUROPSYCHOLOGICAL
PERFORMANCE; WORKING-MEMORY; ACADEMIC-PERFORMANCE; SELF-REPORT; RACE;
CORTISOL; ABILITY; CORTICOSTEROIDS
AB The current study examined ethnic/racial differences in test-related anxiety and its relationship to neurocognitive performance in a community sample of African American (n = 40) and European American (n = 36) adults. The authors hypothesized the following: (a) Test-anxiety related to negative performance evaluation would be associated with lower neurocognitive performance, whereas anxiety unrelated to negative evaluation would be associated with higher neurocognitive performance. (b) African American participants would report higher levels of anxiety about negative performance evaluation than European Americans. (c) European Americans would report higher levels of anxiety unrelated to negative performance evaluation. The first two hypotheses were supported: Ethnic/racial differences in test-taking anxiety emerged such that African Americans reported significantly higher levels of negative performance evaluation, which was associated with lower cognitive performance. The third hypothesis was not supported: African Americans and European Americans reported similar levels of test-anxiety unrelated to negative evaluation.
C1 [Thames, April D.; Panos, Stella E.; Arentoft, Alyssa; Hinkin, Charles H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Panos, Stella E.; Arentoft, Alyssa; Hinkin, Charles H.; Arbid, Natalie] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Byrd, Desiree A.] Mt Sinai Sch Med, Dept Neurol & Psychiat, New York, NY USA.
RP Thames, AD (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza C8-226, Los Angeles, CA 90095 USA.
EM athames@mednet.ucla.edu
OI Arentoft, Alyssa/0000-0002-4235-4638
FU National Academy of Neuropsychology, Clinical Research Grants; National
Institutes of Health/National Institute of Mental Health Career
Development Award [K23 MH095661]
FX This work was supported by the National Academy of Neuropsychology,
Clinical Research Grants (Principal Investigator: April D. Thames) and
National Institutes of Health/National Institute of Mental Health Career
Development Award K23 MH095661 (Principal Investigator: April D.
Thames).
NR 61
TC 3
Z9 3
U1 8
U2 15
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1099-9809
EI 1939-0106
J9 CULT DIVERS ETHN MIN
JI Cult. Divers. Ethn. Minor. Psychol.
PD JAN
PY 2015
VL 21
IS 1
BP 105
EP 113
DI 10.1037/a0037530
PG 9
WC Ethnic Studies; Psychology, Social
SC Ethnic Studies; Psychology
GA AZ6YH
UT WOS:000348364300011
PM 25111554
ER
PT J
AU Leonard, MM
Cureton, PA
Fasano, A
AF Leonard, M. M.
Cureton, P. A.
Fasano, A.
TI Managing coeliac disease in patients with diabetes
SO DIABETES OBESITY & METABOLISM
LA English
DT Review
DE coeliac disease; gluten-free diet; type 1 diabetes
ID GLUTEN-FREE DIET; METABOLIC-CONTROL; BONE MINERALIZATION;
AUTOIMMUNE-DISEASES; GLYCEMIC INDEX; MELLITUS; CHILDREN; PREVALENCE;
DIAGNOSIS; GROWTH
AB The association between coeliac disease and type 1 diabetes has long been established. The combination of genetic susceptibility along with a potential role for gluten in the pathogenesis of autoimmunity makes defining gluten's role in type 1 diabetes extremely important. Evidence supporting the role of a gluten-free diet to improve complications associated with type 1 diabetes is not robust. However there is evidence to support improved growth, bone density and potentially the prevention of additional autoimmune diseases in patients with coeliac disease and type 1 diabetes. The gluten free diet is expensive and challenging to adhere to in people already on a modified diet. Early identification of those who have coeliac disease and would benefit from a gluten-free diet is of utmost importance to prevent complications associated with type 1 diabetes and coeliac disease.
C1 [Leonard, M. M.; Cureton, P. A.; Fasano, A.] Massachusetts Gen Hosp, Ctr Celiac Res, Boston, MA 02114 USA.
[Leonard, M. M.; Cureton, P. A.; Fasano, A.] Massachusetts Gen Hosp Children, Div Pediat Gastroenterol & Nutr, Boston, MA 02111 USA.
[Cureton, P. A.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
RP Leonard, MM (reprint author), Massachusetts Gen Hosp Children, Dept Pediat Gastroenterol & Nutr, 165 Cambridge St, Boston, MA 02111 USA.
EM Mleonard7@mgh.harvard.edu
NR 54
TC 2
Z9 2
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
EI 1463-1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD JAN
PY 2015
VL 17
IS 1
BP 3
EP 8
DI 10.1111/dom.12310
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CA4BD
UT WOS:000348848300002
PM 24814173
ER
PT J
AU Zhu, YJ
Fotinos, A
Mao, LLJ
Atassi, N
Zhou, EW
Ahmad, S
Guan, YJ
Berry, JD
Cudkowicz, ME
Wang, X
AF Zhu, Yongjin
Fotinos, Anastasios
Mao, Lilly L. J.
Atassi, Nazem
Zhou, Edward W.
Ahmad, Sarfraz
Guan, Yingjun
Berry, James D.
Cudkowicz, Merit E.
Wang, Xin
TI Neuroprotective agents target molecular mechanisms of disease in ALS
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; HEAT-SHOCK
PROTEINS; BODY-MASS INDEX; CANNABINOID CB2 RECEPTOR; PROLONGS SURVIVAL;
EXTENDS SURVIVAL; SYMPTOM ONSET; CELL-DEATH; REACTIVE ASTROGLIOSIS
AB Amyotrophic lateral sclerosis (ALS) is a debilitating disease characterized by progressive loss of voluntary motor neurons leading to muscle atrophy, weight loss and respiratory failure. Evidence suggests that inflammation, oxidative stress, mitochondrial dysfunction, apoptosis, glutamate excitotoxicity and proteasomal dysfunction are all responsible for ALS pathogenesis. We review neuroprotective agents with the ability to reduce ALS-related bodyweight loss, summarize the various therapies tested on animal models targeting the proposed molecular mechanisms, compare their effects on bodyweight loss, muscle damage, disease onset, duration and survival, and analyze their structure-activity relationships, with the overall goal of creating a screening strategy for further clinical application.
C1 [Zhu, Yongjin; Fotinos, Anastasios; Zhou, Edward W.; Wang, Xin] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
[Mao, Lilly L. J.; Ahmad, Sarfraz] Aimcan Pharma Res & Technol, Guelph, ON N1G 3X7, Canada.
[Atassi, Nazem; Berry, James D.; Cudkowicz, Merit E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurol Clin Res Inst, Boston, MA USA.
[Guan, Yingjun] Weifang Med Univ, Dept Histol & Embryol, Weifang, Shandong, Peoples R China.
RP Wang, X (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
EM xwang@rics.bwh.harvard.edu
RI Zhu, Yongjin/N-9617-2014
FU Muscular Dystrophy Association [254530]; ALS Therapy Alliance; Bill &
Melinda Gates Foundation; National Natural Science Foundation of China
[81271413]
FX The authors thank Drs Rachna S. Pandya and Wei Li for review discussion.
This work is supported by grants from the Muscular Dystrophy Association
(254530 to X.W.), the ALS Therapy Alliance (to X.W.), the Bill & Melinda
Gates Foundation (to X.W.) and the National Natural Science Foundation
of China (81271413 to Y.G.).
NR 99
TC 14
Z9 14
U1 2
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD JAN
PY 2015
VL 20
IS 1
BP 65
EP 75
DI 10.1016/j.drudis.2014.08.016
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CA8TL
UT WOS:000349193700008
PM 25205348
ER
PT J
AU Abramovitch, A
Pizzagalli, DA
Geller, DA
Reuman, L
Wilhelm, S
AF Abramovitch, Amitai
Pizzagalli, Diego A.
Geller, Daniel A.
Reuman, Lillian
Wilhelm, Sabine
TI Cigarette smoking in obsessive-compulsive disorder and unaffected
parents of OCD patients
SO EUROPEAN PSYCHIATRY
LA English
DT Article
DE Obsessive-compulsive disorder OCD; Cigarette smoking; Nicotine;
Familial; Unaffected relatives
ID NATIONAL EPIDEMIOLOGIC SURVEY; NICOTINE DEPENDENCE; SELF-MEDICATION;
TOBACCO SMOKING; UNITED-STATES; PSYCHIATRIC-DISORDERS;
PERSONALITY-TRAITS; ANXIETY DISORDERS; CHECKING BEHAVIOR; MENTAL-ILLNESS
AB Background: Cigarette smoking is more prevalent among individuals with psychiatric disorders than the general population. Obsessive-compulsive disorder (OCD) may be an intriguing exception, although no recent study has investigated this hypothesis in OCD patients. Moreover, it is unknown whether reduced smoking rates are present in unaffected first-degree relatives of OCD patients.
Methods: We assessed smoking prevalence in adults with OCD and unaffected parents of youth with OCD (PYOCD). To this end, 113 adults with OCD completed online questionnaires assessing symptom severity and smoking status. Smoking status was obtained from an independent sample of 210 PYOCD assessed for psychiatric diagnoses.
Results: Smoking prevalence rates in adults with OCD (13.3%; n = 15) and PYOCD (9.5%; n = 20) samples were significantly lower than those found in representative samples of the general population (19-24%, all P < .001) and Axis I disorders (36-64%; all P < .001). There were no smokers in the adult OCD subset without clinically significant depressive symptoms (n = 54).
Conclusion: Low prevalence of smoking in OCD may be familial and unique among psychiatric disorders, and might represent a possible state-independent OCD marker. Hypotheses concerning the uncharacteristically low prevalence rates are discussed with relation to OCD phenomenology and pathophysiology. (C) 2014 Elsevier Masson SAS. All rights reserved.
C1 [Abramovitch, Amitai; Pizzagalli, Diego A.; Geller, Daniel A.; Wilhelm, Sabine] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Abramovitch, Amitai; Geller, Daniel A.; Reuman, Lillian; Wilhelm, Sabine] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Pizzagalli, Diego A.] McLean Hosp, Ctr Depress Anxiety & Stress Res, Belmont, MA 02178 USA.
RP Abramovitch, A (reprint author), Massachusetts Gen Hosp, Dept Psychiat, OCD & Related Disorders Program, 185 Cambridge St,Suite 2000, Boston, MA 02114 USA.
EM aabramovitch@mgh.harvard.edu
OI Abramovitch, Amitai/0000-0001-9640-0970
FU National Institute of Mental Health [K08 MH01481]; Boehringer Ingelheim
FX The present work was funded in part by a grant from the National
Institute of Mental Health K08 MH01481 (Dr Geller). Dr Pizzagalli served
as a consultant for AstraZeneca, Shire, Ono Pharma USA and Servier, and
received royalties from Advanced Neuro Technology. Dr Geller received
research support from Boehringer Ingelheim and received honoraria for
speaking engagements from Eli Lily and has sat on the Eli Lily Bureau
and Medical Advisory Board. The other authors have not transmitted any
conflicts of interest pertaining to the present work.
NR 81
TC 5
Z9 5
U1 2
U2 10
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0924-9338
EI 1778-3585
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PD JAN
PY 2015
VL 30
IS 1
DI 10.1016/j.eurpsy.2013.12.003
PG 8
WC Psychiatry
SC Psychiatry
GA AZ1YX
UT WOS:000348032300022
PM 24637253
ER
PT J
AU Jung, M
AF Jung, Minsoo
TI National Cancer Screening Programs and Evidence-Based Healthcare Policy
in South Korea
SO HEALTH POLICY
LA English
DT Review
DE Cancer screening; National Program; Bias; Effectiveness; South Korea
ID SERVICES TASK-FORCE; BREAST
AB Background: South Korea has managed its National Cancer Screening Program (NCSP) since 1999 with free cancer screenings for the five major types of cancer (stomach, liver, colorectal, breast, and cervical cancer). Despite the tremendous amount of government funding, the necessity of this policy and scientific evidence pertaining to it have been questioned.
Objective: This study reviewed the NCSP's effectiveness and its evidence.
Findings: First, the lead-time bias of diagnosis and the length-time bias regarding the average survival time may increase the misunderstanding that the early detection of cancer will contribute to lower mortality rates and higher survival rates. Second, the positive predictive values (PPVs) of the five major types of cancer checked by the NCSP have remained at 0.6-5.7%. The sensitivity of the screening programs also stood at less than 50% on average.
Conclusion: This study showed that the NCSP program has been less effective, as shown by its low PPVs and sensitivity values, and that its anticipated contribution to lowering the number of cancer-related deaths may have been a product of biased reasoning. To develop the NCSP, adequate explanations of the benefits and potential risks of cancer examinations as well as the accuracy of examinations need to be provided to patients. (c) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Jung, Minsoo] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
[Jung, Minsoo] Dongduk Womens Univ, Dept Hlth Sci, Seoul, South Korea.
RP Jung, M (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave,LW 601, Boston, MA 02215 USA.
EM mins.jung@gmail.com
OI Jung, Minsoo/0000-0003-3317-6507
NR 30
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0168-8510
EI 1872-6054
J9 HEALTH POLICY
JI Health Policy
PD JAN
PY 2015
VL 119
IS 1
BP 26
EP 32
DI 10.1016/j.healthpol.2014.08.012
PG 7
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CA4RI
UT WOS:000348891800004
PM 25220569
ER
PT J
AU Damodarasamy, M
Vernon, RB
Chan, CK
Plymate, SR
Wight, TN
Reed, MJ
AF Damodarasamy, Mamatha
Vernon, Robert B.
Chan, Christina K.
Plymate, Stephen R.
Wight, Thomas N.
Reed, May J.
TI Hyaluronan in aged collagen matrix increases prostate epithelial cell
proliferation
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
LA English
DT Article
DE Aging; Benign prostatic hypertrophy; Collagen gel; 3-Dimensional;
Extracellular matrix; In vitro
ID TUMOR PROGRESSION; I COLLAGEN; CANCER; EXPRESSION; GROWTH;
MICROENVIRONMENT; ANGIOGENESIS; MIGRATION; DENSITY; GLYCOSAMINOGLYCANS
AB The extracellular matrix (ECM) of the prostate, which is comprised primarily of collagen, becomes increasingly disorganized with age, a property that may influence the development of hyperplasia and cancer. Collageous ECM extracted from the tails of aged mice exhibits many characteristics of collagen in aged tissues, including the prostate. When polymerized into a 3-dimensional (3D) gel, these collagen extracts can serve as models for the study of specific cell-ECM interactions. In the present study, we examined the behaviors of human prostatic epithelial cell lines representing normal prostate epithelial cells (PEC), benign prostatic hyperplasia (BPH-1), and adenocarcinoma (LNCaP) cultured in contact with 3D gels made from collagen extracts of young and aged mice. We found that proliferation of PEC, BPH-1, and LNCaP cells were all increased by culture on aged collagen gels relative to young collagen gels. In examining age-associated differences in the composition of the collagen extracts, we found that aged and young collagen had a similar amount of several collagen-associated ECM components, but aged collagen had a much greater content of the glycosaminoglycan hyaluronan (HA) than young collagen. The addition of HA (of similar size and concentration to that found in aged collagen extracts) to cells placed in young collagen elicited significantly increased proliferation in BPH-1 cells, but not in PEC or LNCaP cells, relative to controls not exposed to HA. Of note, histochemical analyses of human prostatic tissues showed significantly higher expression of HA in BPH and prostate cancer stroma relative to stroma of normal prostate. Collectively, these results suggest that changes in ECM involving increased levels of HA contribute to the growth of prostatic epithelium with aging.
C1 [Damodarasamy, Mamatha; Plymate, Stephen R.; Reed, May J.] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA.
[Vernon, Robert B.; Chan, Christina K.; Wight, Thomas N.] Benaroya Res Inst Virginia Mason, Matrix Biol Program, Seattle, WA 98101 USA.
[Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Reed, MJ (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, 325 9th Ave,Box 359625, Seattle, WA 98104 USA.
EM mjr@uw.edu
FU NIA/NIH [R21 AG033391]; NIBIB/NIH [R01 EB012558]
FX R21 AG033391 NIA/NIH (M.J.R.); R01 EB012558, NIBIB/NIH (R.B.V./T.N.W)
NR 51
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-2690
EI 1543-706X
J9 IN VITRO CELL DEV-AN
JI In Vitro Cell. Dev. Biol.-Anim.
PD JAN
PY 2015
VL 51
IS 1
BP 50
EP 58
DI 10.1007/s11626-014-9800-z
PG 9
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA CA6AF
UT WOS:000348989700008
PM 25124870
ER
PT J
AU Michel, SG
Madariaga, MLL
Villani, V
Shanmugarajah, K
AF Michel, Sebastian G.
Madariaga, Maria Lucia L.
Villani, Vincenzo
Shanmugarajah, Kumaran
TI Current progress in xenotransplantation and organ bioengineering
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Review
DE Organ shortage; Xenotransplantation; Bioengineering
ID PORCINE ENDOGENOUS RETROVIRUS; DECAY-ACCELERATING FACTOR; ACUTE
LIVER-FAILURE; CARDIAC XENOTRANSPLANTATION; BIOARTIFICIAL LIVER;
PHASE-I; HEPATOCYTE TRANSPLANTATION; ORTHOTOPIC TRANSPLANTATION;
REGENERATIVE MEDICINE; PULMONARY XENOGRAFTS
AB Organ transplantation represents a unique method of treatment to cure people with end-stage organ failure. Since the first successful organ transplant in 1954, the field of transplantation has made great strides forward. However, despite the ability to transform and save lives, transplant surgery is still faced with a fundamental problem the number of people requiring organ transplants is simply higher than the number of organs available. To put this in stark perspective, because of this critical organ shortage 18 people every day in the United States alone die on a transplant waiting list (U. S. Department of Health & Human Services, http://organdonor. gov/about/data. html). To address this problem, attempts have been made to increase the organ supply through xenotransplantation and more recently, bioengineering. Here we trace the development of both fields, discuss their current status and highlight limitations going forward. Ultimately, lessons learned in each field may prove widely applicable and lead to the successful development of xenografts, bioengineered constructs, and bioengineered xeno-organs, thereby increasing the supply of organs for transplantation. (C) 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
C1 [Michel, Sebastian G.; Madariaga, Maria Lucia L.; Villani, Vincenzo; Shanmugarajah, Kumaran] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
[Michel, Sebastian G.] Univ Munich, Dept Cardiac Surg, D-81377 Munich, Germany.
[Madariaga, Maria Lucia L.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02129 USA.
[Shanmugarajah, Kumaran] Univ London Imperial Coll Sci Technol & Med, Div Surg, London SW7 2AZ, England.
RP Michel, SG (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Bldg 149,13th St, Boston, MA 02114 USA.
EM sebastian.michel@med.uni-muenchen.de;
kumaran.shanmugarajah@tbrc.mgh.harvard.edu
NR 83
TC 7
Z9 7
U1 3
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1743-9191
EI 1743-9159
J9 INT J SURG
JI Int. J. Surg.
PD JAN
PY 2015
VL 13
BP 239
EP 244
DI 10.1016/j.ijsu.2014.12.011
PG 6
WC Surgery
SC Surgery
GA CA1IL
UT WOS:000348666000044
PM 25496853
ER
PT J
AU Goyal, A
Moore, JB
Gimbel, D
Carter, JB
Kroshinsky, D
Ferry, JA
Harris, NL
Duncan, LM
AF Goyal, Amrita
Moore, Johanna B.
Gimbel, Devon
Carter, Joi B.
Kroshinsky, Daniela
Ferry, Judith A.
Harris, Nancy L.
Duncan, Lyn M.
TI PD-1, S-100 and CD1a expression in pseudolymphomatous folliculitis,
primary cutaneous marginal zone B-cell lymphoma (MALT lymphoma) and
cutaneous lymphoid hyperplasia
SO JOURNAL OF CUTANEOUS PATHOLOGY
LA English
DT Article
DE CD1a; lymphoid hyperplasia; MALT lymphoma; PD-1; pseudolymphomatous
folliculitis
ID PROGRAMMED DEATH-1; CLASSIFICATION; ENTITIES; FEATURES; MARKERS; TISSUE;
SKIN
AB BackgroundPseudolymphomatous folliculitis is a lymphoid proliferation that clinically and histopathologically mimics primary cutaneous extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In this study, we assessed the diagnostic value of three immunohistochemical markers, programmed death-1 (PD-1), CD1a and S100.
MethodsWe evaluated 25 cases of cutaneous lymphoid proliferations with established diagnoses, including 9 patients with pseudolymphomatous folliculitis, 11 with MALT lymphoma, and 5 with cutaneous lymphoid hyperplasia (CLH). The clinical, histopathologic and immunohistochemical characteristics were reviewed and three major characteristics assessed: (a) proportion of T cells expressing PD-1, (b) pattern of expression of CD1a by dendritic cells and (c) pattern of expression of S100 by dendritic cells.
ResultsWe found pseudolymphomatous folliculitis to have a significant increase in PD-1+ T cells compared with MALT lymphoma (p < 0.0001). The pattern of CD1a staining is also informative: MALT lymphoma is significantly more likely to demonstrate a peripheral concentration of CD1a+ dendritic cells around lymphoid nodules than pseudolymphomatous folliculitis (p < 0.0003) or CLH (p < 0.05). Pseudolymphomatous folliculitis demonstrates an interstitial distribution of CD1a+ cells more often than MALT lymphoma (p < 0.04). S100 staining was not a helpful discriminator.
ConclusionsHistopathologic factors including PD-1 and CD1a staining patterns may allow for more certainty in distinguishing lymphoid hyperplasia, including pseudolymphomatous folliculitis, from MALT lymphoma.
C1 [Goyal, Amrita; Moore, Johanna B.; Gimbel, Devon; Carter, Joi B.; Kroshinsky, Daniela; Ferry, Judith A.; Harris, Nancy L.; Duncan, Lyn M.] Massachusetts Gen Hosp, Dermatopathol Unit, Boston, MA 02114 USA.
RP Duncan, LM (reprint author), Massachusetts Gen Hosp, Dermatopathol Unit, WRN 825, 55 Fruit St, Boston, MA 02114 USA.
EM duncan@helix.mgh.harvard.edu
NR 39
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-6987
EI 1600-0560
J9 J CUTAN PATHOL
JI J. Cutan. Pathol.
PD JAN
PY 2015
VL 42
IS 1
BP 6
EP 15
DI 10.1111/cup.12440
PG 10
WC Dermatology; Pathology
SC Dermatology; Pathology
GA CA5BD
UT WOS:000348921300002
PM 25384543
ER
PT J
AU Kahraman, S
Aydin, C
Elpek, GO
Dirice, E
Sanlioglu, AD
AF Kahraman, S.
Aydin, C.
Elpek, G. O.
Dirice, E.
Sanlioglu, A. D.
TI Diabetes-Resistant NOR Mice Are More Severely Affected by Streptozotocin
Compared to the Diabetes-Prone NOD Mice: Correlations with Liver and
Kidney GLUT2 Expressions
SO JOURNAL OF DIABETES RESEARCH
LA English
DT Review
ID PANCREATIC BETA-CELLS; GLUCOSE-TRANSPORTER; UP-REGULATION; GENE;
ALLOXAN; ISLETS; CYCLOPHOSPHAMIDE; CYTOTOXICITY; HEPATOCYTES; PREVENTION
AB Nonobese Diabetic (NOD) mice are susceptible strains for Type 1 diabetes development, and Nonobese Diabetes-Resistant (NOR) mice are defined as suitable controls for NOD mice in non-MHC-related research. Diabetes is often accelerated in NOD mice via Streptozotocin (STZ). STZ is taken inside cells via GLUT2 transmembrane carrier proteins, the major glucose transporter isoforms in pancreatic beta cells, liver, kidneys, and the small intestine. We observed severe adverse effects in NOR mice treated with STZ compared to NOD mice that were made diabetic with a similar dose. We suggested that the underlying mechanism could be differential GLUT2 expressions in pancreatic beta cells, yet immunofluorescent and immunohistochemical studies revealed similar GLUT2 expression levels. We also detected GLUT2 expression profiles in NOD and NOR hepatic and renal tissues by western blot analysis and observed considerably higher GLUT2 expression levels in liver and kidney tissues of NOR mice. Although beta cell GLUT2 expression levels are frequently evaluated as a marker predicting STZ sensitivity in animal models, we report here very different diabetic responses to STZ in two different animal strains, in spite of similar initial GLUT2 expressions in beta cells. Furthermore, use of NOR mice in STZ-mediated experimental diabetes settings should be considered accordingly.
C1 [Kahraman, S.; Sanlioglu, A. D.] Akdeniz Univ, Ctr Gene & Cell Therapy, TR-07058 Antalya, Turkey.
[Aydin, C.] Akdeniz Univ, Ctr Genet Diag, TR-07058 Antalya, Turkey.
[Elpek, G. O.] Akdeniz Univ, Fac Med, Dept Pathol, TR-07058 Antalya, Turkey.
[Dirice, E.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Cell & Regenerat Med, Boston, MA 02215 USA.
RP Sanlioglu, AD (reprint author), Akdeniz Univ, Ctr Gene & Cell Therapy, TR-07058 Antalya, Turkey.
EM ahter@akdeniz.edu.tr
RI Sanlioglu, Ahter/C-6504-2016; Dirice, Ercument/B-2825-2017;
OI Sanlioglu, Ahter/0000-0003-4504-0375; Kahraman,
Sevim/0000-0002-2880-6589
FU Akdeniz University Research Fund [2011.01.0103.001]; Scientific and
Technological Research Council of Turkey (TUBITAK) [SBAG 112S450]
FX This work was supported by Akdeniz University Research Fund no.
2011.01.0103.001 and the Scientific and Technological Research Council
of Turkey (TUBITAK), by the Project no. SBAG 112S450.
NR 30
TC 0
Z9 0
U1 1
U2 5
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6745
EI 2314-6753
J9 J DIABETES RES
JI J. Diabetes Res.
PY 2015
AR 450128
DI 10.1155/2015/450128
PG 8
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA CB0AI
UT WOS:000349286700001
ER
PT J
AU Norden, AD
Schiff, D
Ahluwalia, MS
Lesser, GJ
Nayak, L
Lee, EQ
Rinne, ML
Muzikansky, A
Dietrich, J
Purow, B
Doherty, LM
LaFrankie, DC
Pulverenti, JR
Rifenburg, JA
Ruland, SF
Smith, KH
Gaffey, SC
McCluskey, C
Ligon, KL
Reardon, DA
Wen, PY
AF Norden, Andrew D.
Schiff, David
Ahluwalia, Manmeet S.
Lesser, Glenn J.
Nayak, Lakshmi
Lee, Eudocia Q.
Rinne, Mikael L.
Muzikansky, Alona
Dietrich, Jorg
Purow, Benjamin
Doherty, Lisa M.
LaFrankie, Debra C.
Pulverenti, Julee R.
Rifenburg, Jennifer A.
Ruland, Sandra F.
Smith, Katrina H.
Gaffey, Sarah C.
McCluskey, Christine
Ligon, Keith L.
Reardon, David A.
Wen, Patrick Y.
TI Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib
in recurrent high-grade gliomas
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE High-grade glioma; Nintedanib; Anti-angiogenic therapy
ID ADVANCED SOLID TUMORS; MALIGNANT GLIOMA; BIBF 1120; GLIOBLASTOMA;
ANGIOGENESIS; BEVACIZUMAB; COMBINATION; MECHANISMS; SORAFENIB; EFFICACY
AB Bevacizumab is FDA-approved for patients with recurrent GBM. However, the median duration of response is only 4 months. Potential mechanisms of resistance include upregulated FGF signaling and increased PDGF-mediated pericyte coverage. Nintedanib is an oral, small-molecule tyrosine kinase inhibitor of PDGFR a/b, FGFR 1-3, and VEGFR 1-3 that may overcome resistance to anti-VEGF therapy. This was a two-stage phase II trial in adults with first or second recurrence of GBM, stratified by prior bevacizumab therapy (ClinicalTrials.gov number NCT01380782;1199.94). The primary endpoint was PFS6 in the bevacizumab-naive arm (Arm A) and PFS3 in the post-bevacizumab arm (Arm B). Up to 10 anaplastic glioma (AG) patients were accrued to each arm in exploratory cohorts. Twenty-two patients enrolled in Arm A and 14 in Arm B. Arm A included 12 GBMs (55%), 13 patients with one prior regimen (59%), and median age 54 years (range 28-75). Arm B included 10 GBMs (71%), one patient with one prior regimen (7%), and median age 52 years (range 32-70). Median KPS overall was 90 (range 60-100). There were no responses. In Arm A (GBM only), PFS6 was 0%, median PFS 28 days (95% CI 27-83), and median OS 6.9 months (3.7-8.1). In Arm B (GBM only), PFS3 was 0%, median PFS 28 days (22-28), and median OS 2.6 months (1.0-6.9). Among AG patients in each arm, PFS6 was 0%. Treatment was well tolerated. In conclusion, nintedanib is not active against recurrent high-grade glioma, regardless of prior bevacizumab therapy.
C1 [Norden, Andrew D.; Nayak, Lakshmi; Lee, Eudocia Q.; Rinne, Mikael L.; Wen, Patrick Y.] Brigham & Womens Hosp, Dept Neurol, Div Neurooncol, Boston, MA 02115 USA.
[Norden, Andrew D.; Nayak, Lakshmi; Lee, Eudocia Q.; Rinne, Mikael L.; Doherty, Lisa M.; LaFrankie, Debra C.; Pulverenti, Julee R.; Rifenburg, Jennifer A.; Ruland, Sandra F.; Smith, Katrina H.; Gaffey, Sarah C.; McCluskey, Christine; Reardon, David A.; Wen, Patrick Y.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02215 USA.
[Norden, Andrew D.; Nayak, Lakshmi; Lee, Eudocia Q.; Rinne, Mikael L.; Ligon, Keith L.; Reardon, David A.; Wen, Patrick Y.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Schiff, David; Purow, Benjamin] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
[Ahluwalia, Manmeet S.] Cleveland Clin, Cleveland, OH 44195 USA.
[Lesser, Glenn J.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA.
[Muzikansky, Alona] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
[Dietrich, Jorg] Massachusetts Gen Hosp, Ctr Canc, Pappas Ctr Neurooncol, Boston, MA 02114 USA.
[Ligon, Keith L.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, Boston, MA 02215 USA.
[Ligon, Keith L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Norden, AD (reprint author), Dana Farber Canc Inst, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM anorden@partners.org
NR 25
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD JAN
PY 2015
VL 121
IS 2
BP 297
EP 302
DI 10.1007/s11060-014-1631-y
PG 6
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CA6GZ
UT WOS:000349010200008
PM 25338318
ER
PT J
AU Harper, DC
Selleck, CS
Eagerton, G
Froelich, K
AF Harper, Doreen C.
Selleck, Cynthia S.
Eagerton, Gregory
Froelich, Kimberly
TI PARTNERSHIP TO IMPROVE QUALITY CARE FOR VETERANS: THE VA NURSING ACADEMY
SO JOURNAL OF PROFESSIONAL NURSING
LA English
DT Article
DE Veterans; Partnerships; Nursing education; VA Nursing Academy
AB More than 22 million living veterans reside in the United States. In fact, understanding military culture and the experiences of these veterans is important to their ongoing health care and the unique challenges faced by many. The Veterans Affairs (VA) Nursing Academy began in 2007 to fund pilot partnerships between schools of nursing and local VA health care facilities to better serve our veteran population. Fifteen academic/service partnerships were selected for funding between 2007 and 2009 with the goals of expanding faculty and professional development, increasing nursing student enrollment, providing opportunities for educational and practice innovations, and increasing the recruitment and retention of VA nurses. This article details critical components of the partnership developed between the Birmingham VA Medical Center and the University of Alabama at Birmingham School of Nursing, a VA Nursing Academy partnership funded in the 2009 cohort. Site-specific goals of the partnership are described along with a discussion of the framework used to develop the Birmingham VA Nursing Academy, which includes relationship building, engagement, governance, evaluation of outcomes, and sustainability. The logic model developed for the partnership is included, and the interim outputs and outcomes of this practice academic partnership are detailed, a number of which can be replicated by VAs and schools of nursing across the country. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Harper, Doreen C.; Selleck, Cynthia S.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL 35294 USA.
[Eagerton, Gregory] Durham VA Med Ctr, Durham, NC 27705 USA.
[Eagerton, Gregory] Birmingharn VA Med Ctr, Birmingham, AL 35233 USA.
[Froelich, Kimberly] Birmingham VA Med Ctr, Patient Care Serv Outpatient & Staff Dev, Birmingham, AL 35294 USA.
RP Selleck, CS (reprint author), Univ Alabama Birmingham, Sch Nursing, 1720 2nd Ave South, Birmingham, AL 35294 USA.
EM cselleck@uab.edu
NR 4
TC 3
Z9 3
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 8755-7223
EI 1532-8481
J9 J PROF NURS
JI J. Prof. Nurs.
PD JAN-FEB
PY 2015
VL 31
IS 1
BP 57
EP 63
DI 10.1016/j.profnurs.2014.06.004
PG 7
WC Nursing
SC Nursing
GA CA1RR
UT WOS:000348689800009
PM 25601246
ER
PT J
AU Schumacher, S
Herwig, U
Baur, V
Mueller-Pfeiffer, C
Martin-Soelch, C
Rufer, M
Bruhl, AB
AF Schumacher, Sonja
Herwig, Uwe
Baur, Volker
Mueller-Pfeiffer, Christoph
Martin-Soelch, Chantal
Rufer, Michael
Bruehl, Annette B.
TI Psychophysiological Responses During the Anticipation of Emotional
Pictures
SO JOURNAL OF PSYCHOPHYSIOLOGY
LA English
DT Article
DE emotion; anticipation; facial electromyogram; skin conductance; heart
rate
ID STARTLE MODULATION; NEURAL RESPONSES; FACIAL REACTIONS; UNCERTAINTY;
EXPERIENCE; STIMULI; VALENCE; EXPECTANCY; ATTENTION; AVERSION
AB The present study sought to investigate peripheral physiological responses to the anticipation of explicitly and ambiguously cued emotional pictures. Emotionally positive and negative as well as neutral pictures were presented to 32 healthy subjects. At the beginning of an anticipation period they were cued about the valence of the upcoming picture (neutral, positive, negative, or ambiguous). Skin conductance, heart rate, and zygomaticus and corrugator electromyogram responses were measured during anticipation and perception. Responses specific to the emotional conditions were observed during anticipation as well as during perception. During the anticipation of ambiguously cued pictures, responses were similar to responses elicited by anticipating negative pictures. In line with results from brain imaging studies, peripheral physiological responses could be interpreted to reflect a negative bias for ambiguous events.
C1 [Schumacher, Sonja; Baur, Volker; Mueller-Pfeiffer, Christoph; Martin-Soelch, Chantal; Rufer, Michael] Univ Zurich Hosp, Dept Psychiat & Psychotherapy, CH-8091 Zurich, Switzerland.
[Herwig, Uwe; Bruehl, Annette B.] Univ Zurich, Dept Psychiat Psychotherapy & Psychosomat, CH-8006 Zurich, Switzerland.
[Herwig, Uwe] Univ Ulm, Dept Psychiat & Psychotherapy 3, D-89069 Ulm, Germany.
[Mueller-Pfeiffer, Christoph] Ctr Educ & Res COEUR, Psychiat Serv Cty St Gallen North, Wil, Switzerland.
[Mueller-Pfeiffer, Christoph] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Mueller-Pfeiffer, Christoph] Harvard Univ, Sch Med, Boston, MA USA.
[Martin-Soelch, Chantal] Univ Fribourg, Dept Psychol, Div Clin & Hlth Psychol, CH-1700 Fribourg, Switzerland.
[Bruehl, Annette B.] Univ Cambridge, Dept Psychiat, Cambridge CB2 1TN, England.
[Bruehl, Annette B.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 1TN, England.
RP Schumacher, S (reprint author), Univ Zurich Hosp, Dept Psychiat & Psychotherapy, Haldenbachstr 18, CH-8091 Zurich, Switzerland.
EM sonja.schumacher@usz.ch
NR 34
TC 0
Z9 0
U1 5
U2 12
PU HOGREFE & HUBER PUBLISHERS
PI GOTTINGEN
PA ROHNSWEG 25, D-37085 GOTTINGEN, GERMANY
SN 0269-8803
EI 2151-2124
J9 J PSYCHOPHYSIOL
JI J. Psychophysiol.
PY 2015
VL 29
IS 1
BP 13
EP 19
DI 10.1027/0269-8803/a000129
PG 7
WC Psychology, Biological; Neurosciences
SC Psychology; Neurosciences & Neurology
GA CA9BX
UT WOS:000349216500002
ER
PT J
AU Nargiso, JE
Ballard, EL
Skeer, MR
AF Nargiso, Jessica E.
Ballard, Erica L.
Skeer, Margie R.
TI A Systematic Review of Risk and Protective Factors Associated With
Nonmedical Use of Prescription Drugs Among Youth in the United States: A
Social Ecological Perspective
SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
LA English
DT Review
ID NATIONALLY REPRESENTATIVE SAMPLE; OF-THE-LITERATURE; COLLEGE-STUDENTS;
OPIOID MISUSE; SUBSTANCE USE; YOUNG-ADULTS; ADOLESCENTS; STIMULANTS;
PREVALENCE; ABUSE
AB Objective: The purpose of this study was to identify the strongest and most consistent risk and protective factors associated with nonmedical use of prescription drugs (NMUPD) in multiple contexts, specifically in community-, school-, interpersonal-, and individual-level domains. Method: A literature search was conducted to review studies published from 2006 to 2012 that examined NMUPD among adolescents. Included were original research studies that focused specifically on risk and protective factors or review articles that included a section on factors associated with NMUPD. Risk and protective factors were included only if a minimum of two methodologically sound research studies reviewed the variable. Results: A variety of risk and protective factors were associated with adolescent NMUPD. At the community level, evidence suggested that ease of access increased the risk of NMUPD. Parental and peer prescription drug use and approval of NMUPD were associated with misuse of prescription drugs within the interpersonal domain. At the school level, academic failure/low educational attainment was associated with high school student NMUPD. However, results for college students' academic failure and NMUPD were inconclusive. At the individual level, previous use of substances was found to be a significant risk factor for NMUPD, as was adolescent aggressive/delinquent behavior and greater perceived risk or harm of use. Conclusions: NMUPD is a serious concern among adolescents and emerging adults. Several areas exist for prevention efforts within the context of the community, school, interpersonal, and individual domains. Thus, to curb NMUPD, multifaceted approaches are needed that target factors across multiple domains.
C1 [Nargiso, Jessica E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Ballard, Erica L.; Skeer, Margie R.] Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 02111 USA.
[Skeer, Margie R.] Harvard Univ, Sch Med, Dept Social & Behav Sci, Boston, MA 02114 USA.
RP Nargiso, JE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 151 Merrimac St,6th Floor, Boston, MA 02114 USA.
EM jnargiso@partners.org
NR 60
TC 10
Z9 10
U1 6
U2 22
PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV
PI PISCATAWAY
PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA
SN 1937-1888
EI 1938-4114
J9 J STUD ALCOHOL DRUGS
JI J. Stud. Alcohol Drugs
PD JAN
PY 2015
VL 76
IS 1
BP 5
EP 20
PG 16
WC Substance Abuse; Psychology
SC Substance Abuse; Psychology
GA CA0RX
UT WOS:000348625300001
PM 25486389
ER
PT J
AU Gabayan, GZ
Sarkisian, CA
Liang, LJ
Sun, BC
AF Gabayan, Gelareh Z.
Sarkisian, Catherine A.
Liang, Li-Jung
Sun, Benjamin C.
TI Predictors of Admission After Emergency Department Discharge in Older
Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE emergency department; Medicare; outcomes
ID PUBLIC HOSPITAL EMERGENCY; ADVERSE HEALTH OUTCOMES; DEATH
AFTER-DISCHARGE; ELDERLY-PATIENTS; UNSCHEDULED RETURNS; MEDICAL ADVICE;
RISK-FACTORS; CARE; ACCIDENT; VISITS
AB ObjectivesTo identify predictors of hospital inpatient admission of older Medicare beneficiaries after discharge from the emergency department (ED).
DesignRetrospective cohort study.
SettingNonfederal California hospitals (n=284).
ParticipantsVisits of Medicare beneficiaries aged 65 and older discharged from California EDs in 2007 (n=505,315).
MeasurementsUsing the California Office of Statewide Health Planning and Development files, predictors ofhospital inpatient admission within 7days of ED discharge in older adults (65) with Medicare were evaluated.
ResultsHospital inpatient admissions within 7days of ED discharge occurred in 23,340 (4.6%) visits and were associated with older age (70-74: adjusted odds ratio (AOR)=1.12, 95% confidence interval (CI)=1.07-1.17; 75-79: AOR=1.18, 95% CI=1.13-1.23; 80: AOR= 1.4, 95% CI=1.35-1.46), skilled nursing facility use (AOR=1.82, 95% CI=1.72-1.94), leaving the ED against medical advice (AOR=1.82, 95% CI=1.67-1.98), and the following diagnoses with the highest odds of admission: end-stage renal disease (AOR=3.83, 95% CI=2.42-6.08), chronic renal disease (AOR=3.19, 95% CI=2.26-4.49), and congestive heart failure (AOR= 3.01, 95% CI=2.59-3.50).
ConclusionFive percent of older Medicare beneficiaries have a hospital inpatient admission after discharge from the ED. Chronic conditions such as renal disease and heart failure were associated with the greatest odds of admission.
C1 [Gabayan, Gelareh Z.; Sarkisian, Catherine A.; Liang, Li-Jung] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Gabayan, Gelareh Z.; Sarkisian, Catherine A.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Med, Portland, OR USA.
[Sun, Benjamin C.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA.
RP Gabayan, GZ (reprint author), Dept Med, 11301 Wilshire Blvd,Bldg 500,111-G, Los Angeles, CA 90073 USA.
EM Gelareh@gabayan.com
FU Emergency Medicine Foundation; Agency for Healthcare Research and
Quality [R03 HS18098]; University of California at Los Angeles Older
American Independence Center National Institutes of Health (NIH);
National Institute on Aging (NIA) pilot grant; NIH, National Center for
Research Resources; National Center for Advancing Translational
Sciences; University of California at Los Angeles Clinical and
Translational Science Institute [KL2TR000122]
FX This research was supported by the Emergency Medicine Foundation (Sun),
the Agency for Healthcare Research and Quality (Sun R03 HS18098), and
the University of California at Los Angeles Older American Independence
Center National Institutes of Health (NIH), National Institute on Aging
(NIA) pilot grant. Dr. Gabayan receives support from the NIH, National
Center for Research Resources, National Center for Advancing
Translational Sciences, University of California at Los Angeles Clinical
and Translational Science Institute (Grant KL2TR000122). The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the NIH or the NIA.
NR 32
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JAN
PY 2015
VL 63
IS 1
BP 39
EP 45
DI 10.1111/jgs.13185
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AZ7BW
UT WOS:000348374200005
PM 25537073
ER
PT J
AU Ganz, DA
Kim, SB
Zingmond, DS
Ramirez, KD
Roth, CP
Jennings, LA
Mori, T
Keeler, EB
Wenger, NS
Reuben, DB
AF Ganz, David A.
Kim, Sung-Bou
Zingmond, David S.
Ramirez, Karina D.
Roth, Carol P.
Jennings, Lee A.
Mori, Takahiro
Keeler, Emmett B.
Wenger, Neil S.
Reuben, David B.
TI Effect of a Falls Quality Improvement Program on Serious Fall-Related
Injuries
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE quality improvement; practice redesign; ACOVE; falls; fall-related
injuries
ID OLDER-ADULTS; CONTROLLED-TRIAL; PREVENTION; RISK; FRACTURES; CARE;
DISSEMINATION; INTERVENTION; PEOPLE
AB ObjectivesTo determine whether a program that improves the quality of care for falls reduces the number of episodes of care for serious fall-related injuries.
DesignNonrandomized controlled trial.
SettingFour community-based primary care practices.
ParticipantsIndividuals aged 75 and older who screened positive for fall risk.
InterventionA multicomponent quality improvement program (Assessing Care of Vulnerable Elders Practice Redesign for Improved Medical Care for Elders) involving face-to-face clinician education about falls and decision support to prompt primary care providers to implement appropriate care, including referral to appropriate community resources, in response to individuals screening positive for fall risk.
MeasurementsEpisodes of care for selected fall-related injuries, based on healthcare claims.
ResultsOf 1,791 individuals with data available for analysis, 1,187 were in the intervention group, and 604 were in the control group. Mean age was 83, and more than two-thirds of the sample were women. After adjusting for potential confounders, there were no statistically significant differences between intervention and control groups in episodes of care for fall-related injuries during the 12-month (incidence rate ratio (IRR) 1.27, 95% confidence interval (CI)=0.93-1.73) or 24-month (IRR 1.18, 95% CI=0.93-1.49) period after initiation of the intervention.
ConclusionDespite improving the care of falls, this quality improvement initiative did not result in a change in the number of episodes of care for serious fall-related injuries. Future work in community-based settings should test higher-intensity interventions to reduce fall-related injuries.
C1 [Ganz, David A.; Ramirez, Karina D.; Jennings, Lee A.; Mori, Takahiro; Reuben, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA.
[Ganz, David A.; Mori, Takahiro] Vet Affairs Los Greater Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Ganz, David A.; Roth, Carol P.; Keeler, Emmett B.; Wenger, Neil S.] RAND Hlth, Santa Monica, CA USA.
[Kim, Sung-Bou] Pardee RAND Grad Sch, Santa Monica, CA USA.
[Zingmond, David S.; Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
RP Ganz, DA (reprint author), VA Greater Los Angeles Healthcare Syst 11G, 11301 Wilshire Blvd,Bldg 220,Room 313, Los Angeles, CA 90073 USA.
EM dganz@mednet.ucla.edu
FU National Institute on Aging (NIA) [R01AG036776]; UCLA Claude Pepper
Older Americans Independence Center - NIA [5P30AG028748]; National
Institutes of Health; National Center for Advancing Translational
Science UCLA Clinical and Translational Science Institute Grant
[UL1TR000124]
FX This project was supported by Grant R01AG036776 from the National
Institute on Aging (NIA). Dr. Jennings was supported by the UCLA Claude
Pepper Older Americans Independence Center funded by the NIA
(5P30AG028748) and National Institutes of Health. National Center for
Advancing Translational Science UCLA Clinical and Translational Science
Institute Grant UL1TR000124.
NR 24
TC 3
Z9 3
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JAN
PY 2015
VL 63
IS 1
BP 63
EP 70
DI 10.1111/jgs.13154
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AZ7BW
UT WOS:000348374200008
PM 25597558
ER
PT J
AU Aspinall, SL
Zhao, XH
Semla, TP
Cunningham, FE
Paquin, AM
Pugh, MJ
Schmader, KE
Stone, RA
Hanlon, JT
AF Aspinall, Sherrie L.
Zhao, Xinhua
Semla, Todd P.
Cunningham, Francesca E.
Paquin, Allison M.
Pugh, Mary Jo
Schmader, Kenneth E.
Stone, Roslyn A.
Hanlon, Joseph T.
CA Vet Affairs Community Living Ctr
TI Epidemiology of Drug-Disease Interactions in Older Veteran Nursing Home
Residents
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE drug-disease interactions; Beers criteria; nursing homes
ID INAPPROPRIATE MEDICATION USE; PHARMACOLOGICAL MANAGEMENT; BEERS
CRITERIA; RISK; CARE; PEOPLE; ADULTS; FALLS; DEMENTIA; HOSPITALIZATIONS
AB ObjectivesTo describe the prevalence of and factors associated with drug-disease interactions (DDIs) in older nursing home residents according to the American Geriatrics Society 2012 Beers Criteria.
DesignCross-sectional.
SettingFifteen Veterans Affairs Community Living Centers.
ParticipantsIndividuals aged 65 and older with a diagnosis of dementia or cognitive impairment, a history of falls or hip fracture, heart failure (HF), a history of peptic ulcer disease (PUD), or Stage IV or V chronic kidney disease (CKD).
MeasurementsMedications that could exacerbate the above conditions (DDIs).
ResultsThree hundred sixty-one of 696 (51.9%) eligible residents had one or more DDIs. None involved residents with a history of PUD, one involved a resident with CKD, and four occurred in residents with HF. Of 540 residents with dementia or cognitive impairment, 50.7% took a drug that could exacerbate these conditions; the most commonly involved medications were antipsychotics (35.4%) and benzodiazepines (14.4%). Of 267 with a history of falls or hip fracture, 67.8% received an interacting medication, with selective serotonin reuptake inhibitors (33.1%), antipsychotics (30.7%), and anticonvulsants (25.1%) being most commonly involved. Using separate multivariable logistic regression models, factors associated with DDIs in dementia or cognitive impairment and falls or fractures included age 85 and older (adjusted odds ratio (aOR)=0.38, 95% confidence interval (CI)=0.24-0.60 and aOR=0.48, 95% CI=0.24-0.96, respectively), taking five to eight medications (aOR=2.06, 95% CI=1.02-4.16 and aOR=4.76, 95% CI=1.68-13.5, respectively), taking nine or more medications (aOR=1.99, 95% CI=1.03-3.85 and aOR=3.68, 95% CI=1.41-9.61, respectively), and being a long-stay resident (aOR=1.80, 95% CI=1.04-3.12 and aOR=2.35, 95% CI=1.12-4.91, respectively).
ConclusionDDIs were common in older nursing home residents with dementia or cognitive impairment or a history of falls or fractures.
C1 [Aspinall, Sherrie L.; Semla, Todd P.; Cunningham, Francesca E.] Vet Affairs Pharm Benefits Management Serv, Hines, IL USA.
[Aspinall, Sherrie L.; Zhao, Xinhua; Stone, Roslyn A.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Aspinall, Sherrie L.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA.
[Semla, Todd P.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA.
[Semla, Todd P.] Northwestern Univ, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
[Paquin, Allison M.] Vet Affairs Boston Healthcare Syst, Dept Pharm, Boston, MA USA.
[Pugh, Mary Jo] South Texas Vet Hlth Care Syst, Res, San Antonio, TX USA.
[Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA.
[Schmader, Kenneth E.] Duke Univ, Med Ctr, Div Geriatr, Durham, NC USA.
[Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA.
RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equity Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA.
EM sherrie.aspinall@va.gov
FU National Institute on Aging [R01-AG 027017, P30-AG024827, K07-AG033174,
R01 AG037451]; Agency for Healthcare Research and Quality Grant [R01
HS018721]; ASHP Grant
FX Dr. Hanlon was supported by National Institute on Aging Grants R01-AG
027017, P30-AG024827, K07-AG033174, and R01 AG037451 and Agency for
Healthcare Research and Quality Grant R01 HS018721.; Dr. Semla has
author or editor royalties from LexiComp, Inc. and honoraria from
Omnicare, Inc. for serving on its Pharmacy and Therapeutics Committee.
His spouse is an employee of AbbVie and owns stock in Hospira, Abbott,
and Abbvie through her employment benefits. Dr. Paquin has an ASHP Grant
for Award in Excellence in Medication-Use Safety to support
dissemination of a postdischarge telephone program focused on helping
older adults with cognitive difficulties transition from hospital to
home.
NR 38
TC 2
Z9 2
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JAN
PY 2015
VL 63
IS 1
BP 77
EP 84
DI 10.1111/jgs.13197
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AZ7BW
UT WOS:000348374200010
PM 25537124
ER
PT J
AU Lo-Ciganic, WH
Perera, S
Gray, SL
Boudreau, RM
Zgibor, JC
Strotmeyer, ES
Donohue, JM
Bunker, CH
Newman, AB
Simonsick, EM
Bauer, DC
Satterfield, S
Caserotti, P
Harris, T
Shorr, RI
Hanlon, JT
AF Lo-Ciganic, Wei-Hsuan
Perera, Subashan
Gray, Shelly L.
Boudreau, Robert M.
Zgibor, Janice C.
Strotmeyer, Elsa S.
Donohue, Julie M.
Bunker, Clareann H.
Newman, Anne B.
Simonsick, Eleanor M.
Bauer, Douglas C.
Satterfield, Suzanne
Caserotti, Paolo
Harris, Tamara
Shorr, Ronald I.
Hanlon, Joseph T.
CA Hlth Aging Body Composition Study
TI Statin Use and Decline in Gait Speed in Community-Dwelling Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE hydroxymethylglutaryl-CoA reductase inhibitors; statins; gait speed;
physical function; aged
ID PERIPHERAL ARTERIAL-DISEASE; COA REDUCTASE INHIBITORS; PHYSICAL
PERFORMANCE; HEALTH; ATORVASTATIN; CHOLESTEROL; PREDICTOR; SYMPTOMS;
THERAPY; PEOPLE
AB ObjectivesTo examine the association between statin use and objectively assessed decline in gait speed in community-dwelling older adults.
DesignLongitudinal cohort study.
SettingHealth, Aging and Body Composition (Health ABC) Study.
ParticipantsTwo thousand five participants aged 70-79 at baseline with medication and gait speed data at 1998-99, 1999-2000, 2001-02, and 2002-03.
MeasurementsThe independent variables were any statin use and their standardized daily doses (low, moderate, high) and lipophilicity. The primary outcome measure was decline in gait speed of 0.1m/s or more in the following year of statin use. Multivariable generalized estimating equations were used, adjusting for demographic characteristics, health-related behaviors, health status, and access to health care.
ResultsStatin use increased from 16.2% in 1998-99 to 25.6% in 2002-03. The overall proportions of those with decline in gait speed of 0.1m/s or more increased from 22.2% in 1998 to 23.9% in 2003. Statin use was not associated with decline in gait speed of 0.1m/s or more (adjusted odds ratio (AOR)=0.90, 95% confidence interval (CI)=0.77-1.06). Similar nonsignificant trends were also seen with the use of hydrophilic or lipophilic statins. Users of low-dose statins were found to have a 22% lower risk of decline in gait speed than nonusers (AOR=0.78, 95% CI=0.61-0.99), which was mainly driven by the results from 1999-2000 follow-up.
ConclusionThese results suggest that statin use did not increase decline in gait speed in community-dwelling older adults.
C1 [Lo-Ciganic, Wei-Hsuan; Hanlon, Joseph T.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Hlth Policy Inst, Pittsburgh, PA 15261 USA.
[Perera, Subashan; Newman, Anne B.; Hanlon, Joseph T.] Univ Pittsburgh, Div Geriatr, Dept Med, Sch Med, Pittsburgh, PA 15261 USA.
[Gray, Shelly L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA.
[Boudreau, Robert M.; Zgibor, Janice C.; Strotmeyer, Elsa S.; Bunker, Clareann H.; Newman, Anne B.; Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Donohue, Julie M.] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Simonsick, Eleanor M.; Harris, Tamara] NIA, Intramural Res Program, Baltimore, MD 21224 USA.
[Bauer, Douglas C.] Univ Calif San Francisco, Sch Med, Div Gen Med, San Francisco, CA USA.
[Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
[Caserotti, Paolo] Univ Southern Denmark, Inst Sports Sci & Clin Biomech, Odense, Denmark.
[Shorr, Ronald I.] North Florida South Georgia Vet Hlth Syst, Geriatr Res Educ & Clin Ctr, Gainesville, FL USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Lo-Ciganic, WH (reprint author), Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, 130 DeSoto St,A636, Pittsburgh, PA 15261 USA.
EM wel32@pitt.edu
RI Newman, Anne/C-6408-2013;
OI Newman, Anne/0000-0002-0106-1150; Strotmeyer, Elsa/0000-0002-4093-6036;
Boudreau, Robert/0000-0003-0162-5187; Donohue, Julie/0000-0003-2418-6017
FU National Institute on Aging [R01-AG 027017, P30-AG024827, T32-AG021885,
K07-AG033174, R01-AG034056, R01-AG028050, N01-AG-6-2101, N01-AG-6-2103,
N01-AG-6-2106]; National Institute of Nursing Research grants
[R01-NR010135, R01-NR012459]; Agency for Healthcare Research and Quality
grants [R01-HS017695, R01-HS018721]; Intramural Research Program of the
National Institutes of Health, National Institute on Aging
FX This work was supported by National Institute on Aging grants and
contracts (R01-AG 027017, P30-AG024827, T32-AG021885, K07-AG033174,
R01-AG034056, R01-AG028050, N01-AG-6-2101, N01-AG-6-2103,
N01-AG-6-2106), National Institute of Nursing Research grants
(R01-NR010135, R01-NR012459), Agency for Healthcare Research and Quality
grants (R01-HS017695, R01-HS018721), and the Intramural Research Program
of the National Institutes of Health, National Institute on Aging.
NR 30
TC 3
Z9 3
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JAN
PY 2015
VL 63
IS 1
BP 124
EP 129
DI 10.1111/jgs.13134
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AZ7BW
UT WOS:000348374200017
PM 25537649
ER
PT J
AU Inouye, SK
Robinson, T
Blaum, C
Busby-Whitehead, J
Boustani, M
Chalian, A
Deiner, S
Fick, D
Hutchison, L
Johanning, J
Katlic, M
Kempton, J
Kennedy, M
Kimchi, E
Ko, C
Leung, J
Mattison, M
Mohanty, S
Nana, A
Needham, D
Neufeld, K
Richter, H
Radcliff, S
Weston, C
Patil, S
Rocco, G
Yue, JR
Aiello, SE
Drootin, M
Ickowicz, E
Samuel, MJ
AF Inouye, Sharon K.
Robinson, Tom
Blaum, Caroline
Busby-Whitehead, Jan
Boustani, Malaz
Chalian, Ara
Deiner, Stacie
Fick, Donna
Hutchison, Lisa
Johanning, Jason
Katlic, Mark
Kempton, James
Kennedy, Maura
Kimchi, Eyal
Ko, Cliff
Leung, Jacqueline
Mattison, Melissa
Mohanty, Sanjay
Nana, Arvind
Needham, Dale
Neufeld, Karin
Richter, Holly
Radcliff, Sue
Weston, Christine
Patil, Sneeha
Rocco, Gina
Yue, Jirong
Aiello, Susan E.
Drootin, Marianna
Ickowicz, Elvy
Samuel, Mary Jordan
CA Amer Geriatrics Soc Expert Panel
TI American Geriatrics Society Abstracted Clinical Practice Guideline for
Postoperative Delirium in Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE delirium; clinical practice guidelines; post-operative delirium;
delirium prevention
ID ELDER LIFE PROGRAM; PREVENT DELIRIUM; HIP-FRACTURE; MULTICOMPONENT
INTERVENTION; TARGETED INTERVENTION; QUALITY IMPROVEMENT; REDUCING
DELIRIUM; CARE; TRIAL; WARDS
AB The abstracted set of recommendations presented here provides essential guidance both on the prevention of postoperative delirium in older patients at risk of delirium and on the treatment of older surgical patients with delirium, and is based on the 2014 American Geriatrics Society (AGS) Guideline. The full version of the guideline, American Geriatrics Society Clinical Practice Guideline for Postoperative Delirium in Older Adults is available at the website of the AGS. The overall aims of the study were twofold: first, to present nonpharmacologic and pharmacologic interventions that should be implemented perioperatively for the prevention of postoperative delirium in older adults; and second, to present nonpharmacologic and pharmacologic interventions that should be implemented perioperatively for the treatment of postoperative delirium in older adults. Prevention recommendations focused on primary prevention (i.e., preventing delirium before it occurs) in patients who are at risk for postoperative delirium (e.g., those identified as moderate-to-high risk based on previous risk stratification models such as the National Institute for Health and Care Excellence (NICE) guidelines, Delirium: Diagnosis, Prevention and Management. Clinical Guideline 103; London (UK): 2010 July 29). For management of delirium, the goals of this guideline are to decrease delirium severity and duration, ensure patient safety and improve outcomes.
C1 [Amer Geriatrics Soc Expert Panel] Amer Geriatr Soc, New York, NY 10024 USA.
[Inouye, Sharon K.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Inouye, Sharon K.] Aging Brain Ctr, Inst Aging Res, Boston, MA USA.
[Robinson, Tom] Univ Colorado, Sch Med, Aurora, CO USA.
[Blaum, Caroline] NYU, Sch Med, New York, NY USA.
[Busby-Whitehead, Jan] Univ N Carolina, Sch Med, Ctr Aging & Hlth, Chapel Hill, NC USA.
[Boustani, Malaz] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Chalian, Ara] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Deiner, Stacie] Mt Sinai Hosp, New York, NY 10029 USA.
[Fick, Donna] Penn State Univ, Coll Nursing & Med, University Pk, PA 16802 USA.
[Hutchison, Lisa] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
[Johanning, Jason] Univ Nebraska Med Ctr, Omaha, NE USA.
[Katlic, Mark] Sinai Hosp, Baltimore, MD 21215 USA.
[Kempton, James] Yale Univ, New Haven, CT 06520 USA.
[Kennedy, Maura] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Kimchi, Eyal] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ko, Cliff] Univ Calif Los Angeles, Los Angeles, CA USA.
[Leung, Jacqueline] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Mattison, Melissa] Harvard Univ, Boston, MA 02115 USA.
[Mattison, Melissa] Beth Israel Deaconess Med Sch, Boston, MA USA.
[Mohanty, Sanjay] Amer Coll Surg, Chicago, IL USA.
[Nana, Arvind] JPS Hlth, Ft Worth, TX USA.
[Needham, Dale] Johns Hopkins Univ, Baltimore, MD USA.
[Neufeld, Karin] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Richter, Holly] Univ Alabama Birmingham, Birmingham, AL USA.
RP Samuel, MJ (reprint author), Amer Geriatr Soc, 40 Fulton St,18th Floor, New York, NY 10024 USA.
EM mjsamuel@americangeriatrics.org
FU American Geriatrics Society Geriatrics-for-Specialists Initiative
(AGS-GSI) through John A. Hartford Foundation; NIH; ADRC; AGS Foundation
for Anesthesia Education and Research; Brookdale; SLACK Inc.; National
Institute of Nursing Research; MedEd Portal/Josiah Macy Foundation IPE
Award; Practical Reviews in Hospital Medicine; ORNIM medical
manufacturing; Pelvalon; Medtronics, Inc.; Karl Storz Endoscopy America;
Covidien
FX Sue Radcliff, Independent Researcher, Denver, CO, and Christine Weston,
Independent Researcher, Baltimore, MD, led the literature review efforts
of the panel. Additional research assistance was provided by Sneeha
Patil, Gina Rocco, and Jirong Yue. Susan E. Aiello, DVM, ELS, provided
editorial services. Marianna Drootin, MPA, Elvy Ickowicz, MPH, and Mary
Jordan Samuel provided additional research and administrative support.
The development of this paper was supported in part by the American
Geriatrics Society Geriatrics-for-Specialists Initiative (AGS-GSI)
through an unrestricted grant from the John A. Hartford Foundation.;
Conflict of Interest: Drs. Blaum, Boustani, Chalian, Inouye, Katlic,
Kempton, Kennedy, Kimchi, Ko, Mattison, Mohanty, and Nana indicated no
conflicts of interest. Dr. Busby-Whitehead indicated her spouse is a
paid consultant for Ironwood Pharma, Ono Pharma: Fecal Incontinence and
Irritable Bowel Syndrome, and her spouse has received a grant from Salix
Pharma, Ono Pharma: Fecal Incontinence and Irritable Bowel Syndrome. Dr.
Deiner has received grants from the NIH, ADRC, and AGS Foundation for
Anesthesia Education and Research, and Dr. Deiner's spouse has received
grants from NIH, ADRC, AGS Foundation for Anesthesia Education and
Research, and Brookdale. Dr. Deiner's spouse is also on the speaker's
panel for Baxter. Both Dr. Deiner and spouse receive product support
from Covidien and Aspect. Dr. Fick is a paid consultant for SLACK Inc.
as Editor of the Journal of Gerontological Nursing. Dr. Fick has current
R01 funding from the NIH and from the National Institute of Nursing
Research. Ms. Giovannetti is employed by the National Committee for
Quality Assurance (NCQA) which conducts healthcare quality research,
develops healthcare quality measures, publishes healthcare quality data,
and distributes healthcare quality products (e.g., Accreditation,
Certification). Dr. Hutchison received grants from MedEd Portal/Josiah
Macy Foundation IPE Award, and Dr. Hutchison and spouse hold shares in
Cardinal Health and Care Fusion. Dr. Johanning received a royalty on
Isolation Station from Harloff Corporation. Dr. Mattison is a paid
consultant for Practical Reviews in Hospital Medicine and is an UpToDate
contributor. Dr. Leung and her husband receive funding from the NIH. Dr.
Leung's husband is the cofounder of Mynosys Inc. Dr. Needham is Chair of
the Early Mobility Committee for the upcoming Society of Critical Care
Medicine Clinical Practice Guideline for pain, agitation, delirium,
early mobility, and sleep. Dr. Neufeld is participating on a grant from
ORNIM medical manufacturing that is funding a portion of her salary. Dr.
Richter is a paid consultant for and has received a research grant from
Pelvalon. She has also received royalties from UpToDate. Dr. Robinson
has received research grants from Medtronics, Inc., Karl Storz Endoscopy
America, and Covidien. Gina Rocco and Jirong Yue have no conflicts of
interest to disclose. Sneha Patil has commercial interest in Oracle.
NR 35
TC 21
Z9 23
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JAN
PY 2015
VL 63
IS 1
BP 142
EP 150
DI 10.1111/jgs.13281
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AZ7BW
UT WOS:000348374200020
ER
PT J
AU Ventura, MM
Brittain, K
Pruskowski, J
Hogan, D
Walker, T
AF Ventura, MaryAnne M.
Brittain, Kevin
Pruskowski, Jennifer
Hogan, Diana
Walker, Tiffany
TI DEVELOPMENT OF AN AGE-DEPENDENT ANTIBIOGRAM IN A VETERANS AFFAIRS
COMMUNITY
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Letter
C1 [Ventura, MaryAnne M.; Brittain, Kevin; Pruskowski, Jennifer; Hogan, Diana; Walker, Tiffany] William Jennings Bryan Dorn Vet Affairs Med Ctr, Columbia, SC 29209 USA.
[Pruskowski, Jennifer] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Ventura, MM (reprint author), William Jennings Bryan Dorn Vet Affairs Med Ctr, Columbia, SC 29209 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JAN
PY 2015
VL 63
IS 1
BP 186
EP 188
DI 10.1111/jgs.13224
PG 3
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AZ7BW
UT WOS:000348374200034
PM 25597575
ER
PT J
AU Xu, N
Yao, M
Farinelli, W
Hajjarian, Z
Wang, Y
Redmond, RW
Kochevar, IE
AF Xu, Nan
Yao, Min
Farinelli, William
Hajjarian, Zeinab
Wang, Ying
Redmond, Robert W.
Kochevar, Irene E.
TI Light-Activated Sealing of Skin Wounds
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE wound closure; incision closure; Rose Bengal; photochemical tissue
bonding; photo tissue bonding; protein crosslinking; Yucatan swine skin;
Yorkshire swine skin; sealing incisions; pigmented skin; melanin;
epidermal melanin
ID PHOTOCHEMICAL KERATODESMOS; CORNEAL INCISIONS; PORCINE SKIN; IN-VIVO;
REPAIR; LASER; CLOSURE
AB Background and ObjectivesWe have developed a light-activated technology for rapidly sealing skin surgical wounds called photochemical tissue bonding (PTB). The goals of this study were to evaluate parameters influencing PTB in order to optimize its clinical efficacy and to determine whether PTB can be used to seal wounds in moderately to highly pigmented skin.
Study Design/Materials and MethodsApplication of Rose Bengal (RB) followed by exposure to 532nm was used to seal linear incisions (1.5mm deep, 2cm long) in lightly pigmented (Yorkshire) and darkly pigmented (Yucatan) swine skin. The force required to open the seal (the bonding strength) was measured by in situ tensiometry. Reflectance spectra, epidermal transmission spectra, and histology were used to characterize the skin. The relationships of RB concentration and fluence to bonding strength were established in Yorkshire skin. Surface temperature was measured during irradiations and cooling was used while sealing incisions in Yucatan skin. Monte Carlo simulations were carried out to estimate the effect of epidermal melanin on the power absorbed in the dermis at the incision interface.
ResultsThe lowest fluence, 25J/cm(2), delivered at an irradiance of 0.5W/cm(2) substantially increased the bonding strength (approximate to 10-fold) compared to controls in Yorkshire swine skin. Increasing the fluence to 100J/cm(2) enhanced bonding strength by a further 1.5-fold. Application of 0.1% RB for 2minutes produced the greatest bonding strength using 100J/cm(2) and limited the penetration of RB to an approximate to 50m band on the dermal incision wall. Reflectance spectra indicated that Yorkshire skin had minimal melanin and that Yucatan skin was a good model for highly pigmented human skin. In Yucatan skin, the bonding strength increased 1.7-fold using 0.1% RB and 200J/cm(2) at 1.5W/cm(2) with cooling and epinephrine. Monte Carlo simulation indicated that absorption of 532nm light by epidermal melanin in dark skin decreased the power absorbed along the incision in the dermis by a factor of 2.7.
ConclusionsThese results suggest that in lightly pigmented skin the PTB treatment time can be shortened without compromising the bonding strength. Sealing incisions using PTB in moderately and highly pigmented skin will require a careful balance of irradiance and cooling. Lasers Surg. Med. 47:17-29, 2015. (c) 2014 Wiley Periodicals, Inc.
C1 [Xu, Nan; Yao, Min; Farinelli, William; Hajjarian, Zeinab; Wang, Ying; Redmond, Robert W.; Kochevar, Irene E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
[Xu, Nan] Tongji Univ, Shanghai East Hosp, Dept Dermatol, Shanghai 200092, Peoples R China.
[Yao, Min] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 200030, Peoples R China.
[Yao, Min] 3 Peoples Hosp, Dept Burns & Plast Surg, Shanghai, Peoples R China.
RP Kochevar, IE (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Thier 224,50 Fruit St, Boston, MA 02114 USA.
EM kochevar@helix.mgh.harvard.edu
FU US Department of Defense [FA9550-11-1-033]; Aura Medsystems; Chinese
National Natural Science Foundation [81201234]; Shanghai Health Bureau
[2012143]
FX Contract grant sponsor: US Department of Defense Contract; Contract
grant number: FA9550-11-1-033; Contract grant sponsor: Aura Medsystems;
Contract grant sponsor: Chinese National Natural Science Foundation,
2013; Contract grant number: 81201234; Contract grant sponsor: Shanghai
Health Bureau; Contract grant number: 2012143.
NR 27
TC 6
Z9 7
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD JAN
PY 2015
VL 47
IS 1
BP 17
EP 29
DI 10.1002/lsm.22308
PG 13
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CA4BP
UT WOS:000348849600003
PM 25418831
ER
PT J
AU Phillips, E
Pojednic, R
Polak, R
Bush, J
Trilk, J
AF Phillips, Edward
Pojednic, Rachele
Polak, Rani
Bush, Jennifer
Trilk, Jennifer
TI Including lifestyle medicine in undergraduate medical curricula
SO MEDICAL EDUCATION ONLINE
LA English
DT Article
DE behavior change; lifestyle medicine; physician education; undergraduate
medical education; curriculum
ID PHYSICIANS; EDUCATION; STUDENTS; EXERCISE; CARE
AB Purpose: Currently, there is no model to integrate the discipline of lifestyle medicine (LM) into undergraduate medical education. Furthermore, there are no guidelines, validated assessment tools, or evaluation or implementation plans in place.
Background: The World Health Organization predicts that by 2020, two-thirds of disease worldwide will be the result of poor lifestyle choices. Fewer than 50% of US primary care physicians routinely provide specific guidance on nutrition, physical activity, or weight control.
Methods: We are establishing a plan to integrate LM into medical school education in collaboration with the investing stakeholders, including medical school deans and students, medical curriculum developers and researchers, medical societies, governing bodies, and policy institutes. Three planning and strategy meetings are being held to address key areas of focus - with a particular interest in nutrition, physical activity, student self-care, and behavior change - to develop specific implementation guidelines and landmarks.
Results: After the first two meetings, the proposed areas of focus were determined to be: 1) supporting of deans and key personnel, 2) creation of federal and state policy commitments, 3) use of assessment as a driver of LM, 4) provision of high-quality evidence-based curricular material on an easily navigated site, and 5) engaging student interest. Implementation strategies for each focus area will be addressed in an upcoming planning meeting in early 2015.
Conclusion: This initiative is expected to have important public health implications by efficiently promoting the prevention and treatment of non-communicable chronic disease with a scalable and sustainable model to educate physicians in training and practice.
C1 [Phillips, Edward; Pojednic, Rachele; Polak, Rani] Harvard Univ, Sch Med, Joslin Diabet Ctr, Inst Lifestyle Med, Boston, MA 02115 USA.
[Bush, Jennifer] LevelSmart Consulting, Atlanta, GA USA.
[Trilk, Jennifer] Univ S Carolina, Sch Med Greenville, Dept Biomed Sci, Greenville, SC 29605 USA.
RP Trilk, J (reprint author), Univ S Carolina, Sch Med Greenville, Dept Biomed Sci, Hlth Sci Adm Bldg,701 Grove Rd, Greenville, SC 29605 USA.
EM TRILK@greenvillemed.sc.edu
NR 15
TC 3
Z9 3
U1 1
U2 5
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1087-2981
J9 MED EDUC ONLINE
JI Med. Educ. Online
PY 2015
VL 20
AR 26150
DI 10.3402/meo.v20.26150
PG 4
WC Education & Educational Research
SC Education & Educational Research
GA CB0VG
UT WOS:000349345100001
PM 28229659
ER
PT J
AU Verzi, MP
Shin, H
Roman, AKS
Liu, XS
Shivdasani, RA
AF Verzi, Michael P.
Shin, Hyunjin
Roman, Adrianna K. San
Liu, X. Shirley
Shivdasani, Ramesh A.
TI Intestinal Master Transcription Factor CDX2 Controls Chromatin Access
for Partner Transcription Factor Binding (vol 33, pg 281, 2013)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Correction
C1 [Verzi, Michael P.; Liu, X. Shirley; Shivdasani, Ramesh A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Shin, Hyunjin; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Verzi, Michael P.; Shivdasani, Ramesh A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Verzi, Michael P.; Roman, Adrianna K. San; Shivdasani, Ramesh A.] Harvard Univ, Sch Med, Boston, MA USA.
[Verzi, Michael P.] Rutgers State Univ, Dept Genet, New Brunswick, NJ 08903 USA.
[Shivdasani, Ramesh A.] Harvard Univ, Sch Med, Grad Program Biol & Biomed Sci, Boston, MA USA.
RP Verzi, MP (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
NR 1
TC 0
Z9 0
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JAN
PY 2015
VL 35
IS 2
BP 496
EP 496
DI 10.1128/MCB.01396-14
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CB0CW
UT WOS:000349293700012
ER
PT J
AU Betz, RC
Petukhova, L
Ripke, S
Huang, HL
Menelaou, A
Redler, S
Becker, T
Heilmann, S
Yamany, T
Duvic, M
Hordinsky, M
Norris, D
Price, VH
Mackay-Wiggan, J
de Jong, A
DeStefano, GM
Moebus, S
Bohm, M
Blume-Peytavi, U
Wolff, H
Lutz, G
Kruse, R
Bian, L
Amos, CI
Lee, A
Gregersen, PK
Blaumeiser, B
Altshuler, D
Clynes, R
de Bakker, PIW
Nothen, MM
Daly, MJ
Christiano, AM
AF Betz, Regina C.
Petukhova, Lynn
Ripke, Stephan
Huang, Hailiang
Menelaou, Androniki
Redler, Silke
Becker, Tim
Heilmann, Stefanie
Yamany, Tarek
Duvic, Madeliene
Hordinsky, Maria
Norris, David
Price, Vera H.
Mackay-Wiggan, Julian
de Jong, Annemieke
DeStefano, Gina M.
Moebus, Susanne
Boehm, Markus
Blume-Peytavi, Ulrike
Wolff, Hans
Lutz, Gerhard
Kruse, Roland
Bian, Li
Amos, Christopher I.
Lee, Annette
Gregersen, Peter K.
Blaumeiser, Bettina
Altshuler, David
Clynes, Raphael
de Bakker, Paul I. W.
Noethen, Markus M.
Daly, Mark J.
Christiano, Angela M.
TI Genome-wide meta-analysis in alopecia areata resolves HLA associations
and reveals two new susceptibility loci
SO NATURE COMMUNICATIONS
LA English
DT Article
ID BH3-ONLY PROTEIN BIM; LATENT TGF-BETA; RHEUMATOID-ARTHRITIS; RISK LOCUS;
T-CELLS; GARP; APOPTOSIS; CANCER; AUTOPHAGOSOMES; EXPRESSION
AB Alopecia areata (AA) is a prevalent autoimmune disease with 10 known susceptibility loci. Here we perform the first meta-analysis of research on AA by combining data from two genome-wide association studies (GWAS), and replication with supplemented ImmunoChip data for a total of 3,253 cases and 7,543 controls. The strongest region of association is the major histocompatibility complex, where we fine-map four independent effects, all implicating human leukocyte antigen-DR as a key aetiologic driver. Outside the major histocompatibility complex, we identify two novel loci that exceed the threshold of statistical significance, containing ACOXL/BCL2L11(BIM) (2q13); GARP (LRRC32) (11q13.5), as well as a third nominally significant region SH2B3(LNK)/ATXN2 (12q24.12). Candidate susceptibility gene expression analysis in these regions demonstrates expression in relevant immune cells and the hair follicle. We integrate our results with data from seven other autoimmune diseases and provide insight into the alignment of AA within these disorders. Our findings uncover new molecular pathways disrupted in AA, including autophagy/apoptosis, transforming growth factor beta/Tregs and JAK kinase signalling, and support the causal role of aberrant immune processes in AA.
C1 [Betz, Regina C.; Redler, Silke; Heilmann, Stefanie; Noethen, Markus M.] Univ Bonn, Inst Human Genet, D-53127 Bonn, Germany.
[Petukhova, Lynn; Yamany, Tarek; Mackay-Wiggan, Julian; de Jong, Annemieke; Bian, Li; Clynes, Raphael; Christiano, Angela M.] Columbia Univ, Dept Dermatol, New York, NY 10032 USA.
[Petukhova, Lynn] Columbia Univ, Dept Epidemiol, New York, NY 10032 USA.
[Ripke, Stephan; Huang, Hailiang; Altshuler, David; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Ripke, Stephan; Huang, Hailiang; Altshuler, David; Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Ripke, Stephan; Huang, Hailiang; Altshuler, David; Daly, Mark J.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02114 USA.
[Menelaou, Androniki; de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Med Genet, NL-3584 CG Utrecht, Netherlands.
[Becker, Tim] German Ctr Neurodegenerat Dis, D-53175 Bonn, Germany.
[Becker, Tim] Univ Bonn, Inst Med Biometry Informat & Epidemiol, D-53127 Bonn, Germany.
[Heilmann, Stefanie; Noethen, Markus M.] Univ Bonn, Life & Brain Ctr, Dept Genom, D-53127 Bonn, Germany.
[Duvic, Madeliene] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA.
[Hordinsky, Maria] Univ Minnesota, Dept Dermatol, Minneapolis, MN 55455 USA.
[Norris, David] Univ Colorado, Dept Dermatol, Denver, CO 80204 USA.
[Price, Vera H.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94110 USA.
[DeStefano, Gina M.; Christiano, Angela M.] Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA.
[Moebus, Susanne] Univ Duisburg Essen, Inst Med Informat Biometry & Epidemiol, D-45122 Essen, Germany.
[Boehm, Markus] Univ Munster, Dept Dermatol, D-48149 Munster, Germany.
[Blume-Peytavi, Ulrike] Charite, Clin Res Ctr Hair & Skin Sci, Dept Dermatol & Allergy, D-10117 Berlin, Germany.
[Wolff, Hans] Univ Munich, Dept Dermatol, D-80337 Munich, Germany.
[Amos, Christopher I.] Dartmouth Coll, Hanover, NH 03755 USA.
[Lee, Annette; Gregersen, Peter K.] Feinstein Inst Med Res, Manhasset, NY 11030 USA.
[Blaumeiser, Bettina] Univ Antwerp, Dept Med Genet, BE-2650 Antwerp, Belgium.
[Clynes, Raphael] Columbia Univ, Dept Med, New York, NY 10032 USA.
[de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Epidemiol, NL-3584 CG Utrecht, Netherlands.
RP Christiano, AM (reprint author), Columbia Univ, Dept Dermatol, New York, NY 10032 USA.
EM amc65@columbia.edu
RI de Bakker, Paul/B-8730-2009;
OI de Bakker, Paul/0000-0001-7735-7858; de Jong,
Annemieke/0000-0001-6707-6585; Heilmann-Heimbach,
Stefanie/0000-0003-1057-465X; Nothen, Markus/0000-0002-8770-2464
FU National Alopecia Areata Foundation; Heinz Nixdorf Foundation;
DFG-funded Excellence Cluster ImmunoSensation; German Research
Foundation (DFG); DFG [BE 2346/5-1]; BONFOR; Netherlands Organization
for Scientific Research [016.126.354]; USPHS NIH/NIAMS [R01AR52579,
R01AR56016]
FX We are deeply indebted to the many patients and their family members who
participated in this study. We are thankful to Drs Lawrence Shapiro and
Tatyana Gindin for guidance on the structural effects of HLA
associations. We thank Spandon V. Shah, Holly Jiang, Matthew Ding and
Steven Chiu for their assistance and contributions in isolating the
immune cells by FACS and Jane E. Cerise for her bioinformatic expertise.
We are most grateful for the support of the National Alopecia Areata
Foundation for funding the initial studies, and Ms Vicki Kalabokes and
her staff at NAAF for their efforts on our behalf. The US patient cohort
was collected and maintained by the National Alopecia Areata Registry
(N01-AR62279) (to M.D.). Some controls were drawn from the Heinz Nixdorf
Recall Study cohort, which was established with the support of the Heinz
Nixdorf Foundation. R.C.B. and M.M.N. are members, T.B. is an associate
member, of the DFG-funded Excellence Cluster ImmunoSensation. R.C.B. is
a recipient of a Heisenberg Professorship of the German Research
Foundation (DFG). This work was supported in part by the DFG grant BE
2346/5-1, as well as by local funding (BONFOR) to R.C.B.,
Vernieuwingsimpuls VIDI Award from the Netherlands Organization for
Scientific Research for project 016.126.354 to P.I.W.d.B., and USPHS
NIH/NIAMS grants R01AR52579 and R01AR56016 (to A.M.C.).
NR 41
TC 21
Z9 20
U1 6
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2015
VL 6
AR 5966
DI 10.1038/ncomms6966
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA3MO
UT WOS:000348811100010
PM 25608926
ER
PT J
AU Wessel, J
Chu, AY
Willems, SM
Wang, S
Yaghootkar, H
Brody, JA
Dauriz, M
Hivert, MF
Raghavan, S
Lipovich, L
Hidalgo, B
Fox, K
Huffman, JE
An, P
Lu, YC
Rasmussen-Torvik, LJ
Grarup, N
Ehm, MG
Li, L
Baldridge, AS
Stancakova, A
Abrol, R
Besse, CL
Boland, A
Bork-Jensen, J
Fornage, M
Freitag, DF
Garcia, ME
Guo, XQ
Hara, K
Isaacs, A
Jakobsdottir, J
Lange, LA
Layton, JC
Li, M
Zhao, JH
Meidtner, K
Morrison, AC
Nalls, MA
Peters, MJ
Sabater-Lleal, M
Schurmann, C
Silveira, A
Smith, AV
Southam, L
Stoiber, MH
Strawbridge, RJ
Taylor, KD
Varga, TV
Allin, KH
Amin, N
Aponte, JL
Aung, T
Barbieri, C
Bihlmeyer, NA
Boehnke, M
Bombieri, C
Bowden, DW
Burns, SM
Chen, YN
Chen, YD
Cheng, CY
Correa, A
Czajkowski, J
Dehghan, A
Ehret, GB
Eiriksdottir, G
Escher, SA
Farmaki, AE
Franberg, M
Gambaro, G
Giulianini, F
Goddard, WA
Goel, A
Gottesman, O
Grove, ML
Gustafsson, S
Hai, Y
Hallmans, G
Heo, J
Hoffmann, P
Ikram, MK
Jensen, RA
Jorgensen, ME
Jorgensen, T
Karaleftheri, M
Khor, CC
Kirkpatrick, A
Kraja, AT
Kuusisto, J
Lange, EM
Lee, IT
Lee, WJ
Leong, A
Liao, JM
Liu, CY
Liu, YM
Lindgren, CM
Linneberg, A
Malerba, G
Mamakou, V
Marouli, E
Maruthur, NM
Matchan, A
McKean-Cowdin, R
McLeod, O
Metcalf, GA
Mohlke, KL
Muzny, DM
Ntalla, I
Palmer, ND
Pasko, D
Peter, A
Rayner, NW
Renstrom, F
Rice, K
Sala, CF
Sennblad, B
Serafetinidis, I
Smith, JA
Soranzo, N
Speliotes, EK
Stahl, EA
Stirrups, K
Tentolouris, N
Thanopoulou, A
Torres, M
Traglia, M
Tsafantakis, E
Javad, S
Yanek, LR
Zengini, E
Becker, DM
Bis, JC
Brown, JB
Cupples, LA
Hansen, T
Ingelsson, E
Karter, AJ
Lorenzo, C
Mathias, RA
Norris, JM
Peloso, GM
Sheu, WHH
Toniolo, D
Vaidya, D
Varma, R
Wagenknecht, LE
Boeing, H
Bottinger, EP
Dedoussis, G
Deloukas, P
Ferrannini, E
Franco, OH
Franks, PW
Gibbs, RA
Gudnason, V
Hamsten, A
Harris, TB
Hattersley, AT
Hayward, C
Hofman, A
Jansson, JH
Langenberg, C
Launer, LJ
Levy, D
Oostra, BA
O'Donnell, CJ
O'Rahilly, S
Padmanabhan, S
Pankow, JS
Polasek, O
Province, MA
Rich, SS
Ridker, PM
Rudan, I
Schulze, MB
Smith, BH
Uitterlinden, AG
Walker, M
Watkins, H
Wong, TY
Zeggini, E
Laakso, M
Borecki, IB
Chasman, DI
Pedersen, O
Psaty, BM
Tai, ES
van Duijn, CM
Wareham, NJ
Waterworth, DM
Boerwinkle, E
Kao, WHL
Florez, JC
Loos, RJF
Wilson, JG
Frayling, TM
Siscovick, DS
Dupuis, J
Rotter, JI
Meigs, JB
Scott, RA
Goodarzi, MO
Sharp, SJ
Forouhi, NG
Kerrison, ND
Lucarelli, DM
Sims, M
Barroso, I
McCarthy, MI
Arriola, L
Balkau, B
Barricarte, A
Gonzalez, C
Grioni, S
Kaaks, R
Key, TJ
Navarro, C
Nilsson, PM
Overvad, K
Palli, D
Panico, S
Quiros, JR
Rolandsson, O
Sacerdote, C
Sanchez, MJ
Slimani, N
Tjonneland, A
Tumino, R
van der A, DL
van der Schouw, YT
Riboli, E
AF Wessel, Jennifer
Chu, Audrey Y.
Willems, Sara M.
Wang, Shuai
Yaghootkar, Hanieh
Brody, Jennifer A.
Dauriz, Marco
Hivert, Marie-France
Raghavan, Sridharan
Lipovich, Leonard
Hidalgo, Bertha
Fox, Keolu
Huffman, Jennifer E.
An, Ping
Lu, Yingchang
Rasmussen-Torvik, Laura J.
Grarup, Niels
Ehm, Margaret G.
Li, Li
Baldridge, Abigail S.
Stancakova, Alena
Abrol, Ravinder
Besse, Celine
Boland, Anne
Bork-Jensen, Jette
Fornage, Myriam
Freitag, Daniel F.
Garcia, Melissa E.
Guo, Xiuqing
Hara, Kazuo
Isaacs, Aaron
Jakobsdottir, Johanna
Lange, Leslie A.
Layton, Jill C.
Li, Man
Zhao, Jing Hua
Meidtner, Karina
Morrison, Alanna C.
Nalls, Mike A.
Peters, Marjolein J.
Sabater-Lleal, Maria
Schurmann, Claudia
Silveira, Angela
Smith, Albert V.
Southam, Lorraine
Stoiber, Marcus H.
Strawbridge, Rona J.
Taylor, Kent D.
Varga, Tibor V.
Allin, Kristine H.
Amin, Najaf
Aponte, Jennifer L.
Aung, Tin
Barbieri, Caterina
Bihlmeyer, Nathan A.
Boehnke, Michael
Bombieri, Cristina
Bowden, Donald W.
Burns, Sean M.
Chen, Yuning
Chen, Yii-Deri
Cheng, Ching-Yu
Correa, Adolfo
Czajkowski, Jacek
Dehghan, Abbas
Ehret, Georg B.
Eiriksdottir, Gudny
Escher, Stefan A.
Farmaki, Aliki-Eleni
Franberg, Mattias
Gambaro, Giovanni
Giulianini, Franco
Goddard, William A., III
Goel, Anuj
Gottesman, Omri
Grove, Megan L.
Gustafsson, Stefan
Hai, Yang
Hallmans, Goeran
Heo, Jiyoung
Hoffmann, Per
Ikram, Mohammad K.
Jensen, Richard A.
Jorgensen, Marit E.
Jorgensen, Torben
Karaleftheri, Maria
Khor, Chiea C.
Kirkpatrick, Andrea
Kraja, Aldi T.
Kuusisto, Johanna
Lange, Ethan M.
Lee, I. T.
Lee, Wen-Jane
Leong, Aaron
Liao, Jiemin
Liu, Chunyu
Liu, Yongmei
Lindgren, Cecilia M.
Linneberg, Allan
Malerba, Giovanni
Mamakou, Vasiliki
Marouli, Eirini
Maruthur, Nisa M.
Matchan, Angela
McKean-Cowdin, Roberta
McLeod, Olga
Metcalf, Ginger A.
Mohlke, Karen L.
Muzny, Donna M.
Ntalla, Ioanna
Palmer, Nicholette D.
Pasko, Dorota
Peter, Andreas
Rayner, Nigel W.
Renstroem, Frida
Rice, Ken
Sala, Cinzia F.
Sennblad, Bengt
Serafetinidis, Ioannis
Smith, Jennifer A.
Soranzo, Nicole
Speliotes, Elizabeth K.
Stahl, Eli A.
Stirrups, Kathleen
Tentolouris, Nikos
Thanopoulou, Anastasia
Torres, Mina
Traglia, Michela
Tsafantakis, Emmanouil
Javad, Sundas
Yanek, Lisa R.
Zengini, Eleni
Becker, Diane M.
Bis, Joshua C.
Brown, James B.
Cupples, L. Adrienne
Hansen, Torben
Ingelsson, Erik
Karter, Andrew J.
Lorenzo, Carlos
Mathias, Rasika A.
Norris, Jill M.
Peloso, Gina M.
Sheu, Wayne H. -H.
Toniolo, Daniela
Vaidya, Dhananjay
Varma, Rohit
Wagenknecht, Lynne E.
Boeing, Heiner
Bottinger, Erwin P.
Dedoussis, George
Deloukas, Panos
Ferrannini, Ele
Franco, Oscar H.
Franks, Paul W.
Gibbs, Richard A.
Gudnason, Vilmundur
Hamsten, Anders
Harris, Tamara B.
Hattersley, Andrew T.
Hayward, Caroline
Hofman, Albert
Jansson, Jan-Hakan
Langenberg, Claudia
Launer, Lenore J.
Levy, Daniel
Oostra, Ben A.
O'Donnell, Christopher J.
O'Rahilly, Stephen
Padmanabhan, Sandosh
Pankow, James S.
Polasek, Ozren
Province, Michael A.
Rich, Stephen S.
Ridker, Paul M.
Rudan, Igor
Schulze, Matthias B.
Smith, Blair H.
Uitterlinden, Andre G.
Walker, Mark
Watkins, Hugh
Wong, Tien Y.
Zeggini, Eleftheria
Laakso, Markku
Borecki, Ingrid B.
Chasman, Daniel I.
Pedersen, Oluf
Psaty, Bruce M.
Tai, E. Shyong
van Duijn, Cornelia M.
Wareham, Nicholas J.
Waterworth, Dawn M.
Boerwinkle, Eric
Kao, W. H. Linda
Florez, Jose C.
Loos, Ruth J. F.
Wilson, James G.
Frayling, Timothy M.
Siscovick, David S.
Dupuis, Josee
Rotter, Jerome I.
Meigs, James B.
Scott, Robert A.
Goodarzi, Mark O.
Sharp, Stephen J.
Forouhi, Nita G.
Kerrison, Nicola D.
Lucarelli, Debora M. E.
Sims, Matt
Barroso, Ines
McCarthy, Mark I.
Arriola, Larraitz
Balkau, Beverley
Barricarte, Aurelio
Gonzalez, Carlos
Grioni, Sara
Kaaks, Rudolf
Key, Timothy J.
Navarro, Carmen
Nilsson, Peter M.
Overvad, Kim
Palli, Domenico
Panico, Salvatore
Quiros, J. Ramon
Rolandsson, Olov
Sacerdote, Carlotta
Sanchez, Maria-Jose
Slimani, Nadia
Tjonneland, Anne
Tumino, Rosario
van der A, Daphne L.
van der Schouw, Yvonne T.
Riboli, Elio
CA The EPIC-InterAct Consortium
TI Low-frequency and rare exome chip variants associate with fasting
glucose and type 2 diabetes susceptibility
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GLUCAGON-LIKE PEPTIDE-1; GENOME-WIDE ASSOCIATION; RECEPTOR GENE;
TRIGLYCERIDE LEVELS; GERMLINE MUTATIONS; INSULIN-RESISTANCE; CODING
VARIATION; GLYCEMIC TRAITS; SEQUENCING DATA; PLASMA-GLUCOSE
AB Fasting glucose and insulin are intermediate traits for type 2 diabetes. Here we explore the role of coding variation on these traits by analysis of variants on the HumanExome BeadChip in 60,564 non-diabetic individuals and in 16,491 T2D cases and 81,877 controls. We identify a novel association of a low-frequency nonsynonymous SNV in GLP1R (A316T; rs10305492; MAF = 1.4%) with lower FG (beta = -0.09 +/- 0.01 mmol l(-1), P = 3.4 x 10(-12)), T2D risk (OR[95% CI] = 0.86[0.76-0.96], P = 0.010), early insulin secretion (beta = -0.07 +/- 0.035 pmol(insulin) mmol(glucose)(-1), P = 0.048), but higher 2-h glucose (beta = 0.16 +/- 0.05 mmol l(-1), P = 4.3 x 10(-4)). We identify a gene-based association with FG at G6PC2 (p(SKAT) = 6.8 x 10(-6)) driven by four rare protein-coding SNVs (H177Y, Y207S, R283X and S324P). We identify rs651007 (MAF = 20%) in the first intron of ABO at the putative promoter of an antisense lncRNA, associating with higher FG (beta = 0.02 +/- 0.004 mmol l(-1), P = 1.3 x 10(-8)). Our approach identifies novel coding variant associations and extends the allelic spectrum of variation underlying diabetes-related quantitative traits and T2D susceptibility.
C1 [Wessel, Jennifer] Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46202 USA.
[Wessel, Jennifer] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
[Chu, Audrey Y.; Giulianini, Franco; Ridker, Paul M.; Chasman, Daniel I.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA.
[Chu, Audrey Y.; Huffman, Jennifer E.; Liu, Chunyu; Cupples, L. Adrienne; O'Donnell, Christopher J.; Dupuis, Josee] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA.
[Willems, Sara M.; Isaacs, Aaron; Amin, Najaf; Oostra, Ben A.; van Duijn, Cornelia M.] Erasmus Univ, Ctr Med, Dept Epidemiol, Genet Epidemiol Unit, NL-3000 CE Rotterdam, Netherlands.
[Willems, Sara M.; Zhao, Jing Hua; Javad, Sundas; Langenberg, Claudia; Wareham, Nicholas J.; Scott, Robert A.; Sharp, Stephen J.; Forouhi, Nita G.; Kerrison, Nicola D.; Lucarelli, Debora M. E.; Sims, Matt] Univ Cambridge, Sch Clin Med, Inst Metab Sci, MRC Epidemiol Unit, Cambridge CB2 0SL, England.
[Wang, Shuai; Chen, Yuning; Cupples, L. Adrienne; Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
[Yaghootkar, Hanieh; Pasko, Dorota; Hattersley, Andrew T.; Frayling, Timothy M.] Univ Exeter, Sch Med, Exeter EX1 2LU, Devon, England.
[Brody, Jennifer A.; Jensen, Richard A.; Rice, Ken; Bis, Joshua C.; Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA.
[Brody, Jennifer A.; Fox, Keolu; Jensen, Richard A.; Bis, Joshua C.; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Dauriz, Marco; Raghavan, Sridharan; Leong, Aaron; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Dauriz, Marco; Raghavan, Sridharan; Leong, Aaron; O'Donnell, Christopher J.; Florez, Jose C.; Meigs, James B.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Dauriz, Marco] Univ Verona, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, I-37126 Verona, Italy.
[Dauriz, Marco] Hosp Trust Verona, I-37126 Verona, Italy.
[Hivert, Marie-France] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA 02215 USA.
[Hivert, Marie-France] Univ Sherbrooke, Dept Med, Div Endocrinol & Metab, Sherbrooke, PQ J1K 2R1, Canada.
[Hivert, Marie-France; Burns, Sean M.; Florez, Jose C.] Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA.
[Lipovich, Leonard] Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48201 USA.
[Lipovich, Leonard] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48202 USA.
[Hidalgo, Bertha] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35233 USA.
[Fox, Keolu] Univ Washington, Dept Gen Sci, Seattle, WA 98195 USA.
[Huffman, Jennifer E.; Hayward, Caroline] Univ Edinburgh, MRC IGMM, MRC Human Genet, Edinburgh EH4 2XU, Midlothian, Scotland.
[An, Ping; Czajkowski, Jacek; Kraja, Aldi T.; Province, Michael A.; Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet, Div Stat Genom, St Louis, MO 63108 USA.
[Lu, Yingchang; Hara, Kazuo; Isaacs, Aaron; Schurmann, Claudia; Gottesman, Omri; Bottinger, Erwin P.; Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA.
[Lu, Yingchang; Hara, Kazuo; Schurmann, Claudia; Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Genet Obes & Related Metab Traits Program, New York, NY 10029 USA.
[Rasmussen-Torvik, Laura J.; Baldridge, Abigail S.] Northwestern Univ Feinberg, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
[Grarup, Niels; Bork-Jensen, Jette; Allin, Kristine H.; Hansen, Torben; Pedersen, Oluf] Univ Copenhagen, Fac Med & Hlth Sci, Novo Nordisk Fdn Ctr Basic Metab Res, DK-2200 Copenhagen, Denmark.
[Stancakova, Alena] Univ Eastern Finland, Inst Clin Med, FI-70211 Kuopio, Finland.
[Abrol, Ravinder; Goodarzi, Mark O.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.
[Abrol, Ravinder; Goodarzi, Mark O.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA.
[Abrol, Ravinder; Goddard, William A., III; Kirkpatrick, Andrea] CALTECH, Mat & Proc Simulat Ctr, Pasadena, CA 91125 USA.
[Besse, Celine; Boland, Anne] CEA, Ctr Natl Genotypage, Inst Genom, F-91057 Evry, France.
[Fornage, Myriam] Univ Texas Houston, Hlth Sci Ctr, Brown Fdn Inst Mol Med, Houston, TX 77030 USA.
[Freitag, Daniel F.; Southam, Lorraine; Matchan, Angela; Rayner, Nigel W.; Soranzo, Nicole; Stirrups, Kathleen; Zeggini, Eleftheria; Barroso, Ines] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, England.
[Freitag, Daniel F.] Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge CB1 8RN, England.
[Garcia, Melissa E.; Harris, Tamara B.; Launer, Lenore J.] Natl Inst Aging, Intramural Res Program, Bethesda, MD 21224 USA.
[Guo, Xiuqing; Taylor, Kent D.; Chen, Yii-Deri; Hai, Yang; Rotter, Jerome I.] Univ Calif Los Angeles, Med Ctr, Los Angeles Biomed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90502 USA.
[Jakobsdottir, Johanna; Smith, Albert V.; Eiriksdottir, Gudny; Gudnason, Vilmundur] Iceland Heart Assoc, IS-201 Kopavogur, Iceland.
[Lange, Leslie A.; Lange, Ethan M.; Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Layton, Jill C.] Indiana Univ, Fairbanks Sch Publ Hlth, Indianapolis, IN 46202 USA.
[Li, Man; Kao, W. H. Linda] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD 21205 USA.
[Meidtner, Karina; Schulze, Matthias B.] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Epidemiol, DE-14558 Nuthetal, Germany.
[Morrison, Alanna C.; Grove, Megan L.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77225 USA.
[Nalls, Mike A.] NIA, Neurogenet Lab, Bethesda, MD 20892 USA.
[Peters, Marjolein J.; Uitterlinden, Andre G.] Erasmus Univ, Med Ctr, Dept Internal Med, NL-3000 Rotterdam, Netherlands.
[Peters, Marjolein J.] NGI NCHA, NL-2300 RC Leiden, Netherlands.
[Sabater-Lleal, Maria; Silveira, Angela; Strawbridge, Rona J.; Franberg, Mattias; McLeod, Olga; Sennblad, Bengt; Hamsten, Anders] Karolinska Inst, Dept Med Solna, Atherosclerosis Res Unit, S-17177 Stockholm, Sweden.
[Smith, Albert V.; Gudnason, Vilmundur] Univ Iceland, IS-101 Reykjavik, Iceland.
[Southam, Lorraine; Rayner, Nigel W.; McCarthy, Mark I.] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
[Stoiber, Marcus H.; Brown, James B.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Dept Genome Dynam, Berkeley, CA 94720 USA.
[Varga, Tibor V.; Escher, Stefan A.; Renstroem, Frida; Franks, Paul W.; Nilsson, Peter M.] Lund Univ, Skane Univ Hosp, Dept Clin Sci Genet & Mol Epidemiol Unit, SE-20502 Malmo, Sweden.
[Aung, Tin; Cheng, Ching-Yu; Ikram, Mohammad K.; Liao, Jiemin; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
[Aung, Tin; Cheng, Ching-Yu; Khor, Chiea C.; Liao, Jiemin; Wong, Tien Y.] Natl Univ Singapore, Dept Ophthalmol, Singapore 119228, Singapore.
[Aung, Tin; Cheng, Ching-Yu; Khor, Chiea C.; Liao, Jiemin; Wong, Tien Y.] Natl Univ Hlth Syst, Singapore 119228, Singapore.
[Barbieri, Caterina; Sala, Cinzia F.; Traglia, Michela; Toniolo, Daniela] San Raffaele Res Inst, Div Genet & Cell Biol, I-20132 Milan, Italy.
[Bihlmeyer, Nathan A.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Predoctoral Training Program Human Genet, Baltimore, MD 21205 USA.
[Bihlmeyer, Nathan A.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.
[Boehnke, Michael] Univ Michigan, Ctr Stat Genet, Dept Biostat, Ann Arbor, MI 48109 USA.
[Bombieri, Cristina; Malerba, Giovanni] Univ Verona, Dept Life & Reprod Sci, Sect Biol & Genet, I-37100 Verona, Italy.
[Bowden, Donald W.; Palmer, Nicholette D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.
[Cheng, Ching-Yu; Khor, Chiea C.; Tai, E. Shyong] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 119228, Singapore.
[Cheng, Ching-Yu; Khor, Chiea C.; Tai, E. Shyong] Natl Univ Hlth Syst, Singapore 119228, Singapore.
[Cheng, Ching-Yu; Ikram, Mohammad K.; Wong, Tien Y.] Natl Univ Singapore, Duke NUS Grad Med Sch, Off Clin Sci, Singapore 169857, Singapore.
[Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA.
[Dehghan, Abbas; Franco, Oscar H.; Hofman, Albert; Uitterlinden, Andre G.] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3000 Rotterdam, Netherlands.
[Ehret, Georg B.] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.
[Ehret, Georg B.] Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva, Switzerland.
[Farmaki, Aliki-Eleni; Marouli, Eirini; Ntalla, Ioanna; Dedoussis, George] Harokopio Univ, Sch Hlth Sci & Educ, Dept Nutr & Dietet, Athens 17671, Greece.
[Franberg, Mattias] Stockholm Univ, Dept Numer Anal & Comp Sci, Sci Life Lab, SE-10691 Stockholm, Sweden.
[Gambaro, Giovanni] Catholic Univ, Columbus Gemelli Univ Hosp, Dept Internal Med & Med Specialties, Div Nephrol, I-00168 Rome, Italy.
[Goel, Anuj; Watkins, Hugh] Univ Oxford, Wellcome Trust Ctr Human Genet, Dept Cardiovasc Med, Oxford OX3 7BN, England.
[Gustafsson, Stefan; Ingelsson, Erik] Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, SE-75185 Uppsala, Sweden.
[Hallmans, Goeran; Rolandsson, Olov] Umea Univ, Dept Biobank Res, SE-90187 Umea, Sweden.
[Heo, Jiyoung] Sangmyung Univ, Dept Biomed Technol, Chungnam 330720, South Korea.
[Hoffmann, Per] Univ Bonn, Life & Brain Ctr, Inst Human Genet, Dept Genom, DF-53127 Bonn, Germany.
[Hoffmann, Per] Univ Basel Hosp, Dept Biomed, Div Med Genet, Human Genom Res Grp, CH-4031 Basel, Switzerland.
[Hoffmann, Per] Genom Imaging Res Ctr Juelich, Inst Neurosci & Med INM 1, DE-52425 Julich, Germany.
[Ikram, Mohammad K.] Natl Univ Hlth Syst, MACC, Singapore 117599, Singapore.
[Jorgensen, Marit E.] Steno Diabet Ctr, DK-2820 Gentofte, Denmark.
[Jorgensen, Torben; Linneberg, Allan] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, DK-2600 Glostrup, Denmark.
[Jorgensen, Torben] Aalborg Univ, Fac Med, DK-9220 Aalborg, Denmark.
[Karaleftheri, Maria] Echinos Med Ctr, Fchinos 67300, Greece.
[Khor, Chiea C.] Genome Inst Singapore, Div Human Genet, Singapore 138672, Singapore.
[Kuusisto, Johanna; Laakso, Markku] Univ Eastern Finland, Inst Clin Med, FI-70211 Kuopio, Finland.
[Kuusisto, Johanna; Laakso, Markku] Kuopio Univ Hosp, FI-70211 Kuopio, Finland.
[Lange, Ethan M.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA.
[Lee, I. T.; Sheu, Wayne H. -H.] Taichung Vet Gen Hosp, Dept Internal Med, Div Endocrine & Metab, Taichung 407, Taiwan.
[Lee, I. T.; Sheu, Wayne H. -H.] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
[Lee, Wen-Jane] Taichung Vet Gen Hosp, Dept Med Res, Taichung 407, Taiwan.
[Liu, Yongmei] Wake Forest Univ, Dept Epidemiol & Prevent, Div Publ Hlth Sci, Winston Salem, NC 27106 USA.
[Lindgren, Cecilia M.; Ingelsson, Erik] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
[Linneberg, Allan] Univ Copenhagen, Glostrup Hosp, Dept Clin Expt Res, DK-2600 Glostrup, Denmark.
[Linneberg, Allan] Univ Copenhagen, Fac Med & Hlth Sci, Dept Clin Med, DK-2200 Copenhagen, Denmark.
[Mamakou, Vasiliki] Univ Athens, Fac Med, Athens 11527, Greece.
[Mamakou, Vasiliki; Zengini, Eleni] Dromokaiteio Psychiat Hosp, Athens 12461, Greece.
[Maruthur, Nisa M.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
[Maruthur, Nisa M.; Kao, W. H. Linda] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA.
[McKean-Cowdin, Roberta; Torres, Mina; Varma, Rohit] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Metcalf, Ginger A.; Muzny, Donna M.; Gibbs, Richard A.; Boerwinkle, Eric] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Ntalla, Ioanna] Univ Leicester, Leicester LE1 7RH, Leics, England.
[Palmer, Nicholette D.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27106 USA.
[Peter, Andreas] Univ Tubingen, Dept Internal Med, Div Endocrinol Metab Pathobiochem & Clin Chem, DE-72076 Tubingen, Germany.
[Peter, Andreas] Univ Tubingen, Inst Diabet Res & Metab Dis, DE-72076 Tubingen, Germany.
[Peter, Andreas; Schulze, Matthias B.] German Ctr Diabet Res DZD, DE-85764 Neuherberg, Germany.
[Rayner, Nigel W.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LE, England.
[Rice, Ken] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Sennblad, Bengt] Karolinska Inst, Sci Life Lab, SE-17177 Stockholm, Sweden.
[Serafetinidis, Ioannis] Gennimatas Gen Hosp, Dept Gastroenterol, Athens 11527, Greece.
[Smith, Jennifer A.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Soranzo, Nicole] Dept Hematol, Cambridge CB2 0XY, England.
[Speliotes, Elizabeth K.] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA.
[Speliotes, Elizabeth K.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
[Stahl, Eli A.] Icahn Sch Med Mt Sinai, Div Psychiat Gen, New York, NY 10029 USA.
[Stirrups, Kathleen; Deloukas, Panos] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London E1 4NS, England.
[Tentolouris, Nikos] Univ Athens, Laiko Gen Hosp, Sch Med, Dept Propaedeut & Internal Med 1, GR-11527 Athens, Greece.
[Thanopoulou, Anastasia] Natl Tech Univ Athens, Hippokration Gen Hosp, Ctr Diabet, Dept Internal Med 2nd, Athens 11527, Greece.
[Tsafantakis, Emmanouil] Anogia Med Ctr, Anogia 74051, Greece.
[Isaacs, Aaron; Yanek, Lisa R.; Becker, Diane M.; Mathias, Rasika A.; Vaidya, Dhananjay] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med,GeneSTAR Res Program, Baltimore, MD 21205 USA.
[Zengini, Eleni] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England.
[Brown, James B.] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA.
[Hansen, Torben] Univ Copenhagen, Fac Hlth Sci, Copenhagen 1165, Denmark.
[Karter, Andrew J.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA.
[Lorenzo, Carlos] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 77030 USA.
[Norris, Jill M.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80204 USA.
[Peloso, Gina M.; Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Peloso, Gina M.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Sheu, Wayne H. -H.] Coll Med, Natl Def Med Ctr, Taipei 114, Taiwan.
[Wagenknecht, Lynne E.] Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27106 USA.
[Boeing, Heiner] German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, DE-14558 Nuthetal, Germany.
[Deloukas, Panos] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
[Deloukas, Panos] King Abdulaziz Univ, Princess Al Jawhara Al Brahim Ctr Excellence Res, Jeddah 22254, Saudi Arabia.
[Ferrannini, Ele] CNR, Inst Clin Physiol, I-73100 Pisa, Italy.
[Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Franks, Paul W.; Jansson, Jan-Hakan] Umea Univ, Dept Publ Hlth & Clin Med, SE-90187 Umea, Sweden.
[Jansson, Jan-Hakan] Res Unit, SE-93187 Skelleftea, Sweden.
[Levy, Daniel] NHLBI, Populat Sci Branch, NIH, Bethesda, MD 20892 USA.
[Levy, Daniel] Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA.
[O'Donnell, Christopher J.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02115 USA.
[O'Donnell, Christopher J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[O'Rahilly, Stephen; Barroso, Ines] Univ Cambridge, Metab Res Labs, MRC Metab Dis Unit, Cambridge CB2 1TN, England.
[O'Rahilly, Stephen; Barroso, Ines] Addenbrookes Hosp, Wellcome Trust MRC Inst Metab Sci, NIHR Cambridge Biomed Res Ctr, Cambridge CB2 1TN, England.
[Padmanabhan, Sandosh] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8TA, Lanark, Scotland.
[Pankow, James S.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA.
[Polasek, Ozren] Univ Split, Fac Med, Dept Publ Hlth, Split 21000, Croatia.
[Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Gen, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA.
[Ridker, Paul M.] Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA.
[Ridker, Paul M.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Rudan, Igor] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland.
[Smith, Blair H.] Univ Dundee, Med Res Inst, Dundee DD1 9SY, Scotland.
[Walker, Mark] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Chasman, Daniel I.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[Chasman, Daniel I.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98195 USA.
[Tai, E. Shyong] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117597, Singapore.
[van Duijn, Cornelia M.] Ctr Med Syst Biol, NL-2300 Leiden, Netherlands.
[Waterworth, Dawn M.] GlaxoSmithKline, PCPS, Genet, Philadelphia, PA 19104 USA.
[Kao, W. H. Linda] Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA.
[Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA.
[Wilson, James G.] Univ Mississippi, Ctr Med, Dept Physiol & Biophys, University, MS 38677 USA.
[Siscovick, David S.] New York Acad Med, New York, NY 10029 USA.
[Siscovick, David S.] Univ Washington, Dept Med & Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Goodarzi, Mark O.] Cedars Sinai Med Ctr, Div Endocrinol Diabet & Metab, Los Angeles, CA 90048 USA.
Oxford NIHR Biomed Res Ctr, Oxford, England.
[Arriola, Larraitz] Publ Hlth Div Gipuzkoa, San Sebastian, Spain.
[Arriola, Larraitz] Basque Govt, Inst BIO Donostia, San Sebastian, Spain.
[Arriola, Larraitz; Barricarte, Aurelio; Navarro, Carmen; Sanchez, Maria-Jose] CIBERESP, Barcelona, Spain.
[Balkau, Beverley] INSERM, CESP, U1018, Villejuif, France.
[Balkau, Beverley] Univ Paris Sud, UMRS 1018, Villejuif, France.
[Barricarte, Aurelio] Navarre Publ Hlth Inst ISPN, Pamplona, Spain.
[Gonzalez, Carlos] Catalan Inst Oncol ICO, Barcelona, Spain.
[Grioni, Sara] Epidemiol & Prevent Unit, Milan, Italy.
[Kaaks, Rudolf] German Canc Res Ctr, Heidelberg, Germany.
[Key, Timothy J.] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England.
[Navarro, Carmen] Murcia Reg Hlth Council, Dept Epidemiol, Murcia, Spain.
[Navarro, Carmen] Univ Murcia, Sch Med, Unit Prevent Med & Publ Hlth, Murcia, Spain.
[Overvad, Kim] Univ Aarhus, Dept Publ Hlth, Epidemiol Sect, Aarhus, Denmark.
[Overvad, Kim] Aalborg Univ Hosp, Aalborg, Denmark.
[Palli, Domenico] Canc Res & Prevent Inst ISPO, Florence, Italy.
[Panico, Salvatore] Univ Naples Federico II, Dipt Med Clin & Chirurg, Naples, Italy.
[Quiros, J. Ramon] Publ Hlth Directorate, Asturias, Spain.
[Sacerdote, Carlotta] Univ Turin, Citta Salute & Sci Hosp, Canc Epidemiol Unit, Turin, Italy.
[Sacerdote, Carlotta] Ctr Canc Prevent CPO, Turin, Italy.
[Sacerdote, Carlotta] Human Genet Fdn HuGeF, Turin, Italy.
[Sanchez, Maria-Jose] Andalusian Sch Publ Hlth, Granada, Spain.
[Sanchez, Maria-Jose] Inst Invest Biosanitaria Granada Granada ibs, Granada, Spain.
[Slimani, Nadia] Int Agcy Res Canc, F-69372 Lyon, France.
[Tjonneland, Anne] Danish Canc Soc Res Ctr, Copenhagen, Denmark.
[Tumino, Rosario] ASP Ragusa, Ragusa, Italy.
[Tumino, Rosario] Aire Onlus, Ragusa, Italy.
[van der A, Daphne L.] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
[van der Schouw, Yvonne T.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[Riboli, Elio] Imperial Coll London, Sch Publ Hlth, London, England.
RP Wessel, J (reprint author), Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46202 USA.
EM robert.scott@mrc-epid.cam.ac.uk; mark.goodarzi@cshs.org
RI Grioni, Sara/K-5320-2016; SANCHEZ-PEREZ, MARIA JOSE/D-1087-2011; Grarup,
Niels/K-2807-2015; Gudnason, Vilmundur/K-6885-2015; Polasek,
Ozren/B-6002-2011; Smith, Albert/K-5150-2015; Schurmann,
Claudia/L-1204-2016; Deloukas, Panos/B-2922-2013; Padmanabhan,
Sandosh/S-3963-2016; Dauriz, Marco/S-5843-2016;
OI Hattersley, Andrew/0000-0001-5620-473X; Dehghan,
Abbas/0000-0001-6403-016X; Linneberg, Allan/0000-0002-0994-0184; Sabater
Lleal, Maria/0000-0002-0128-379X; Schulze, Matthias
B./0000-0002-0830-5277; Sacerdote, Carlotta/0000-0002-8008-5096;
Forouhi, Nita/0000-0002-5041-248X; Jorgensen,
Torben/0000-0001-9453-2830; Watkins, Hugh/0000-0002-5287-9016; Khor,
Chiea Chuen/0000-0002-1128-4729; Varga, Tibor/0000-0002-2383-699X;
Smith, Blair/0000-0002-5362-9430; Vaidya, Dhananjay/0000-0002-7164-1601;
Smith, Jennifer/0000-0002-3575-5468; Tai, E Shyong/0000-0003-2929-8966;
Pankow, James/0000-0001-7076-483X; Strawbridge,
Rona/0000-0001-8506-3585; Malerba, Giovanni/0000-0001-8705-8560;
THANOPOULOU, ANASTASIA/0000-0002-2902-8053; Peters,
Marjolein/0000-0003-3167-9063; Padmanabhan, Sandosh/0000-0003-3869-5808;
Zeggini, Eleftheria/0000-0003-4238-659X; Wessel,
Jennifer/0000-0002-7031-0085; Grioni, Sara/0000-0002-5891-8426;
SANCHEZ-PEREZ, MARIA JOSE/0000-0003-4817-0757; Grarup,
Niels/0000-0001-5526-1070; Franks, Paul/0000-0002-0520-7604; Soranzo,
Nicole/0000-0003-1095-3852; Gudnason, Vilmundur/0000-0001-5696-0084;
Polasek, Ozren/0000-0002-5765-1862; Smith, Albert/0000-0003-1942-5845;
Schurmann, Claudia/0000-0003-4158-9192; Deloukas,
Panos/0000-0001-9251-070X; Dauriz, Marco/0000-0002-5542-5941; Meidtner,
Karina/0000-0001-5810-4062
FU NIH through the American Recovery and Reinvestment Act [5RC2HL102419];
Eric Boerwinkle on behalf of the Atherosclerosis Risk in Communities
(ARIC) Study; NHLBI [HHSN268201200036C, HHSN268200800007C, N01HC55222,
N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086,
HL080295, HL087652, HL103612, HL068986, N02-HL-6-4278]; CHARGE
infrastructure grant [HL105756]; LDRD [14-200, 4R00HG006698-03]; NIA
[N01-AG-12100, N01AG62101, N01AG62103, N01AG62106, 1R01AG032098-01A1];
NEI; NIDCD; NIA Intramural Research Program; Hjartavernd (the Icelandic
Heart Association); Althingi (the Icelandic Parliament); National Heart,
Lung, and Blood Institute (NHLBI) [HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641,
R01HL59367, R01HL086694, N01-HC-95159, N01-HC-95169, RR-024156];
National Human Genome Research Institute [U01HG004402]; National
Institutes of Health [HHSN268200625226C, U01-HG004729, R01-HL093029,
R01-HL084099]; NIH Roadmap for Medical Research; National Heart, Lung,
and Blood Institute; University of Alabama at Birmingham
[HHSN268201300025C, HHSN268201300026C]; Northwestern University
[HHSN268201300027C]; University of Minnesota [HHSN268201300028C]; Kaiser
Foundation Research Institute [HHSN268201300029C]; Johns Hopkins
University School of Medicine [HHSN268200900041C]; Intramural Research
Program of the National Institute on Aging; Chinese-American Eye Study
(CHES) [EY017337]; Research to Prevent Blindness; Genetics of Latinos
Diabetic Retinopathy (GOLDR) [EY14684]; National Institute of
Neurological Disorders and Stroke (NINDS); National Institute on Aging
(NIA) [AG023629]; National Center for Advancing Translational Sciences;
CTSI [UL1TR000124]; National Institute of Diabetes and Digestive and
Kidney Disease Diabetes Research Center (DRC) [DK063491];
GlaxoSmithKline; Faculty of Biology and Medicine of Lausanne,
Switzerland; Swiss National Science Foundation [3200B0-105993,
33CSCO-122661]; GlaxoSmithKline (Drug Discovery-Verona, RD); Medical
Research Council UK; Ministry of Science, Education and Sport in the
Republic of Croatia [108-1080315-0302]; South West NHS Research and
Development; Exeter NHS Research and Development; Darlington Trust;
Peninsula NIHR Clinical Research Facility at the University of Exeter;
European Research Council [SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC,
ERC-2011-StG 280559-SEPI]; German Federal Ministry of Education and
Research (BMBF); Federal Ministry of Science, Germany [01 EA 9401];
European Union [SOC 95201408 05 F02]; German Cancer Aid [70-2488-Ha I];
European Community [SOC 98200769 05 F02]; Netherlands Organization for
Scientific Research (NWO); NWO; Russian Foundation for Basic research
[047.016.009, 047.017.043]; Erasmus MC; Centre for Medical Systems
Biology (CMSB; National Genomics Initiative); ZonMw [91111025]; NIH from
NHLBI [R01-HL-087700, R01-HL-088215]; NIH from NIDDK [R01-DK-8925601,
R01-DK-075681]; Medical Research Council [MC_U106179471, G0700931];
Wellcome Trust [098051, WT098051, WT091310, 084723/Z/08/Z]; National
Heart, Lung and Blood Institute Division of Intramural Research;
National Institute for Diabetes and Digestive and Kidney Diseases
(NIDDK) [R01 DK078616, R01DK079888, P30DK063491]; NIDDK [K24 DK080140];
American Diabetes Association Mentor-Based Postdoctoral Fellowship
[7-09-MN-32]; Canadian Diabetes Association Research Fellowship Award;
University of Verona, Italy; NIDDK Research Career Award [K23 DK65978];
Massachusetts General Hospital Physician Scientist Development Award;
Doris Duke Charitable Foundation Clinical Scientist Development Award;
Swedish Heart-Lung Foundation; Umea Medical Research Foundation;
Vasterbotten County Council; NIH grants through the National Heart,
Lung, and Blood Institute [HL58625-01A1, HL59684, HL071025-01A1,
U01HL72518, HL112064, HL087698]; National Institute of Nursing Research
[NR0224103]; U.S. Federal Government from the National Heart, Lung, and
Blood Institute [HHSN268201100037C]; Novo Nordisk; Swedish Research
Council; Pahlssons Foundation; Heart Foundation of Northern Sweden;
Swedish Heart Lung Foundation; Skane Regional Health Authority; Swedish
Diabetes Association; Chief Scientist Office of the Scottish Government
Health Directorates [CZD/16/6]; Scottish Funding Council; Faculty of
Biology and Medicine of Lausanne; Intramural Research Program of the
NIH, National Institute on Aging [Z01 AG000949-02, Z01 AG007390-07];
Timber Merchant Vilhelm Bang's Foundation; Danish Heart Foundation
[07-10-R61-A1754-B838-22392F]; Health Insurance Foundation (Helsefonden)
[2012B233]; EU FP7 [257082, HEALTH-F5-2011-282510]; Danish Research
Council; Danish Centre for Health Technology Assessment; Novo Nordisk
Inc.; Research Foundation of Copenhagen County; Ministry of Internal
Affairs and Health; Danish Heart Foundation; Danish Pharmaceutical
Association; Augustinus Foundation; Ib Henriksen Foundation; Becket
Foundation; Danish Diabetes Association; Lundbeck Foundation; Novo
Nordisk Foundation; EU FP6 programme [LSHM_CT_2006_037197]; Andrea and
Charles Bronfman Philanthropies; Department of Scientific Computing at
the Icahn School of Medicine at Mount Sinai; National Institute of
Diabetes and Digestive and Kidney Diseases [HL060944, HL061019,
HL060919, HL047887, HL047889, HL047890, HL47902]; National Heart, Lung
and Blood Institute [HHSN268201300046C, HHSN268201300047C,
HHSN268201300048C, HHSN268201300049C, HHSN268201300050C]; National
Institute on Minority Health and Health Disparities; NHLBI of the
National Institutes of Health [R01HL107816]; National Institute for
Health Research Comprehensive Biomedical Research Centre Imperial
College Healthcare NHS Trust; British Heart Foundation [SP/04/002];
National Institute for Health Research [RP-PG-0407-10371]; United States
Environmental Protection Agency (EPA) [RD83169701]; National Center for
Advancing Translational Sciences [UL1-TR000124]; Cedars-Sinai Winnick
Clinical Scholars Award; Academy of Finland [77299, 124243]; NIH
[DK062370, DK093757, DK072193]; Diabetes UK; Magnus Bergvall Foundation;
Foundation for Old Servants; Tore Nilsson foundation; Fredrik and Ingrid
Thuring foundation; Ake-wiberg Foundation; Karolinska Institutet
Foundation; Swedish e-science Research Center (SeRC); EU
[QLG1-CT-2001-01252]; AstraZeneca (Sweden); European Union grant
[QLG1-CT-2001-01252]; AstraZeneca; Boehringer-Ingelheim; LillyCo;
Research Institute for Diseases in the Elderly [014-93-015; RIDE2];
Netherlands Genomics Initiative (NGI)/Netherlands Organization for
Scientific Research (NWO) [050-060-810]; CHANCES [242244]; Erasmus
Medical Center; Erasmus University Rotterdam; Netherlands Organization
for the Health Research and Development (ZonMw); Research Institute for
Diseases in the Elderly (RIDE); Ministry of Education, Culture and
Science; Ministry for Health, Welfare and Sports; European Commission
(DG XII); Municipality of Rotterdam; NWO grant veni (veni) [916.12.154];
EUR Fellowship; Foundation for Strategic Research; Swedish Research
Council [8691, 12660, 20653]; European Commission [LSHM-CT-2007-037273];
Knut and Alice Wallenberg Foundation; Torsten and Ragnar Soderberg
Foundation; Strategic Cardiovascular and Diabetes Programmes of
Karolinska Institutet; Stockholm County Council [560183]; National
Medical Research Council (NMRC), Singapore [0796/2003, IRG07nov013,
IRG09nov014, NMRC 1176/2008, STaR/0003/2008, CG/SERI/2010]; Biomedical
Research Council (BMRC), Singapore [08/1/35/19/550, 09/1/35/19/616];
European Union (European Social Fund-ESF); National Strategic Reference
Framework (NSRF); Uppsala University; Knut och Alice Wallenberg
Foundation; European Research Council; Swedish Diabetes Foundation
[2013-024]; Swedish Heart-Lung Foundation [20120197]; Wellcome Trust
Research Career Development Fellowship [086596/Z/08/Z]; Fondazione
Compagnia di San Paolo-Torino; Fondazione Cariplo-Milano; Italian
Ministry of Health Progetto Finalizzato; Italian Ministry of Health
Progetto [CCM 2010, PRIN 2009]; National Heart, Lung, and Blood
Institute [HL043851, HL080467]; National Cancer Institute [CA047988];
Donald W. Reynolds Foundation; Fondation Leducq; [HL120393];
[UL1RR025005]; [M01-RR000052]; [DK081350]; [HG007112];
[R01HL071051]; [R01HL071205]; [R01HL071250]; [R01HL071251];
[R01HL071252]; [R01HL071258]; [R01HL071259]
FX CHARGE: Funding support for 'Building on GWAS for NHLBI-diseases: the
U.S. CHARGE consortium' was provided by the NIH through the American
Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419). Sequence
data for 'Building on GWAS for NHLBI-diseases: the U.S. CHARGE
consortium' was provided by Eric Boerwinkle on behalf of the
Atherosclerosis Risk in Communities (ARIC) Study, L. Adrienne Cupples,
principal investigator for the Framingham Heart Study, and Bruce Psaty,
principal investigator for the Cardiovascular Health Study. Sequencing
was carried out at the Baylor Genome Center (U54 HG003273). Further
support came from HL120393, 'Rare variants and NHLBI traits in deeply
phenotyped cohorts' (Bruce Psaty, principal investigator). Supporting
funding was also provided by NHLBI with the CHARGE infrastructure grant
HL105756. In addition, M.J.P. was supported through the 2014 CHARGE
Visiting Fellow grant-HL105756, Dr Bruce Psaty, PI.; ENCODE: ENCODE
collaborators Ben Brown and Marcus Stoiber were supported by the LDRD#
14-200 (B.B. and M.S.) and 4R00HG006698-03 (B.B.) grants.; AGES: This
study has been funded by NIA contract N01-AG-12100 with contributions
from NEI, NIDCD and NHLBI, the NIA Intramural Research Program,
Hjartavernd (the Icelandic Heart Association) and the Althingi (the
Icelandic Parliament).; ARIC: The Atherosclerosis Risk in Communities
(ARIC) Study is carried out as a collaborative study supported by
National Heart, Lung, and Blood Institute (NHLBI) contracts
(HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
HHSN268201100011C and HHSN268201100012C), R01HL087641, R01HL59367 and
R01HL086694; National Human Genome Research Institute contract
U01HG004402; and National Institutes of Health contract
HHSN268200625226C. We thank the staff and participants of the ARIC study
for their important contributions. Infrastructure was partly supported
by Grant Number UL1RR025005, a component of the National Institutes of
Health and NIH Roadmap for Medical Research.; CARDIA: The CARDIA Study
is conducted and supported by the National Heart, Lung, and Blood
Institute in collaboration with the University of Alabama at Birmingham
(HHSN268201300025C & HHSN268201300026C), Northwestern University
(HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser
Foundation Research Institute (HHSN268201300029C), and Johns Hopkins
University School of Medicine (HHSN268200900041C). CARDIA is also
partially supported by the Intramural Research Program of the National
Institute on Aging. Exome chip genotyping and data analyses were funded
in part by grants U01-HG004729, R01-HL093029 and R01-HL084099 from the
National Institutes of Health to Dr Myriam Fornage. This manuscript has
been reviewed by CARDIA for scientific content.; CHES: This work was
supported in part by The Chinese-American Eye Study (CHES) grant
EY017337, an unrestricted departmental grant from Research to Prevent
Blindness, and the Genetics of Latinos Diabetic Retinopathy (GOLDR)
Study grant EY14684.; CHS: This CHS research was supported by NHLBI
contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079,
N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI
grants HL080295, HL087652, HL103612, HL068986 with additional
contribution from the National Institute of Neurological Disorders and
Stroke (NINDS). Additional support was provided through AG023629 from
the National Institute on Aging (NIA). A full list of CHS investigators
and institutions can be found at http://www.chs-nhlbi.org/pi.htm. The
provision of genotyping data was supported in part by the National
Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and
the National Institute of Diabetes and Digestive and Kidney Disease
Diabetes Research Center (DRC) grant DK063491 to the Southern California
Diabetes Endocrinology Research Center. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.; The CoLaus Study:
We thank the co-primary investigators of the CoLaus study, Gerard Waeber
and Peter Vollenweider, and the PI of the PsyColaus Study Martin
Preisig. We gratefully acknowledge Yolande Barreau, Anne-Lise Bastian,
Binasa Ramic, Martine Moranville, Martine Baumer, Marcy Sagette, Jeanne
Ecoffey and Sylvie Mermoud for their role in the CoLaus data collection.
The CoLaus study was supported by research grants from GlaxoSmithKline
and from the Faculty of Biology and Medicine of Lausanne, Switzerland.
The PsyCoLaus study was supported by grants from the Swiss National
Science Foundation (#3200B0-105993) and from GlaxoSmithKline (Drug
Discovery-Verona, R&D).; CROATIA-Korcula: The CROATIA-Korcula study
would like to acknowledge the invaluable contributions of the
recruitment team in Korcula, the administrative teams in Croatia and
Edinburgh and the people of Korcula. Exome array genotyping was
performed at the Wellcome Trust Clinical Research Facility Genetics Core
at Western General Hospital, Edinburgh, UK. The CROATIA-Korcula study on
the Croatian island of Korucla was supported through grants from the
Medical Research Council UK and the Ministry of Science, Education and
Sport in the Republic of Croatia (number 108-1080315-0302).; EFSOCH: We
are extremely grateful to the EFSOCH study participants and the EFSOCH
study team. The opinions given in this paper do not necessarily
represent those of NIHR, the NHS or the Department of Health. The EFSOCH
study was supported by South West NHS Research and Development, Exeter
NHS Research and Development, the Darlington Trust, and the Peninsula
NIHR Clinical Research Facility at the University of Exeter. Timothy
Frayling, PI, is supported by the European Research Council grant:
SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC.; EPIC-Potsdam: We thank all
EPIC-Potsdam participants for their invaluable contribution to the
study. The study was supported in part by a grant from the German
Federal Ministry of Education and Research (BMBF) to the German Center
for Diabetes Research (DZD e.V.). The recruitment phase of the
EPIC-Potsdam study was supported by the Federal Ministry of Science,
Germany (01 EA 9401) and the European Union (SOC 95201408 05 F02). The
follow-up of the EPIC-Potsdam study was supported by German Cancer Aid
(70-2488-Ha I) and the European Community (SOC 98200769 05 F02).
Furthermore, we thank Ellen Kohlsdorf for data management as well as the
follow-up team headed by Dr Manuala Bergmann for case ascertainment.;
ERF: The ERF study was supported by grants from the Netherlands
Organization for Scientific Research (NWO) and a joint grant from NWO
and the Russian Foundation for Basic research (Pionier, 047.016.009,
047.017.043), Erasmus MC, and the Centre for Medical Systems Biology
(CMSB; National Genomics Initiative). Exome sequencing analysis in ERF
was supported by the ZonMw grant (91111025).; For the ERF Study, we are
grateful to all participants and their relatives, to general
practitioners and neurologists for their contributions, to P. Veraart
for her help in genealogy and to P. Snijders for his help in data
collection.; FamHS: The Family Heart Study (FamHS) was supported by NIH
grants R01-HL-087700 and R01-HL-088215 (Michael A. Province, PI) from
NHLBI; and R01-DK-8925601 and R01-DK-075681 (Ingrid B. Borecki, PI) from
NIDDK.; FENLAND: The Fenland Study is funded by the Medical Research
Council (MC_U106179471) and Wellcome Trust. We are grateful to all the
volunteers for their time and help, and to the General Practitioners and
practice staff for assistance with recruitment. We thank the Fenland
Study Investigators, Fenland Study Co-ordination team and the
Epidemiology Field, Data and Laboratory teams. The Fenland Study is
funded by the Medical Research Council (MC_U106179471) and Wellcome
Trust.; FHS: Genotyping, quality control and calling of the Illumina
HumanExome BeadChip in the Framingham Heart Study was supported by
funding from the National Heart, Lung and Blood Institute Division of
Intramural Research (Daniel Levy and Christopher J. O'Donnell, Principle
Investigators). A portion of this research was conducted using the Linux
Clusters for Genetic Analysis (LinGA) computing resources at Boston
University Medical Campus. Also supported by National Institute for
Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616, NIDDK
K24 DK080140 and American Diabetes Association Mentor-Based Postdoctoral
Fellowship Award #7-09-MN-32, all to Dr Meigs, a Canadian Diabetes
Association Research Fellowship Award to Dr Leong, a research grant from
the University of Verona, Italy to Dr Dauriz, and NIDDK Research Career
Award K23 DK65978, a Massachusetts General Hospital Physician Scientist
Development Award and a Doris Duke Charitable Foundation Clinical
Scientist Development Award to Dr Florez.; FIA3: We are indebted to the
study participants who dedicated their time and samples to these
studies. We thank Asa Agren (Umea Medical Biobank) for data organization
and Kerstin Enquist and Thore Johansson (Vasterbottens County Council)
for technical assistance with DNA extraction. This particular project
was supported by project grants from the Swedish Heart-Lung Foundation,
Umea Medical Research Foundation and Vasterbotten County Council.; The
Genetics Epidemiology of Metabolic Syndrome (GEMS) Study: We thank
Metabolic Syndrome GEMs investigators: Scott Grundy, Jonathan Cohen,
Ruth McPherson, Antero Kesaniemi, Robert Mahley, Tom Bersot, Philip
Barter and Gerard Waeber. We gratefully acknowledge the contributions of
the study personnel at each of the collaborating sites: John Farrell,
Nicholas Nikolopoulos and Maureen Sutton (Boston); Judy Walshe, Monica
Prentice, Anne Whitehouse, Julie Butters and Tori Nicholls (Australia);
Heather Doelle, Lynn Lewis and Anna Toma (Canada); Kari Kervinen, Seppo
Poykko, Liisa Mannermaa and Sari Paavola (Finland); Claire Hurrel, Diane
Morin, Alice Mermod, Myriam Genoud and Roger Darioli (Switzerland); Guy
Pepin, Sibel Tanir, Erhan Palaoglu, Kerem Ozer, Linda Mahley and Aysen
Agacdiken (Turkey); and Deborah A. Widmer, Rhonda Harris and Selena
Dixon (United States). Funding for the GEMS study was provided by
GlaxoSmithKline.; GeneSTAR: The Johns Hopkins Genetic Study of
Atherosclerosis Risk (GeneSTAR) Study was supported by NIH grants
through the National Heart, Lung, and Blood Institute (HL58625-01A1,
HL59684, HL071025-01A1, U01HL72518, HL112064, and HL087698) and the
National Institute of Nursing Research (NR0224103) and by M01-RR000052
to the Johns Hopkins General Clinical Research Center. Genotyping
services were provided through the RS&G Service by the Northwest
Genomics Center at the University of Washington, Department of Genome
Sciences, under U.S. Federal Government contract number
HHSN268201100037C from the National Heart, Lung, and Blood Institute.;
GLACIER: We are indebted to the study participants who dedicated their
time, data and samples to the GLACIER Study as part of the Vasterbottens
halsoundersokningar (Vasterbottens Health Survey). We thank John
Hutiainen and Asa Agren (Northern Sweden Biobank) for data organization
and Kerstin Enquist and Thore Johansson (Vasterbottens County Council)
for extracting DNA. We also thank M. Sterner, M. Juhas and P. Storm
(Lund University Diabetes Center) for their expert technical assistance
with genotyping and genotype data preparation. The GLACIER Study was
supported by grants from Novo Nordisk, the Swedish Research Council,
Pahlssons Foundation, The Heart Foundation of Northern Sweden, the
Swedish Heart Lung Foundation, the Skane Regional Health Authority, Umea
Medical Research Foundation and the Wellcome Trust. This particular
project was supported by project grants from the Swedish Heart-Lung
Foundation, the Swedish Research Council, the Swedish Diabetes
Association, Pahlssons Foundation and Novo nordisk (all grants to P. W.
Franks).; GOMAP (Genetic Overlap between Metabolic and Psychiatric
Disease): This work was funded by the Wellcome Trust (098051). We thank
all participants for their important contribution. We are grateful to
Georgia Markou, Laiko General Hospital Diabetes Centre, Maria Emetsidou
and Panagiota Fotinopoulou, Hippokratio General Hospital Diabetes
Centre, Athina Karabela, Dafni Psychiatric Hospital, Eirini Glezou and
Marios Matzioros, Dromokaiteio Psychiatric Hospital, Angela Rentari,
Harokopio University of Athens, and Danielle Walker, Wellcome Trust
Sanger Institute.; Generation Scotland: Scottish Family Health Study
(GS:SFHS): GS:SFHS is funded by the Chief Scientist Office of the
Scottish Government Health Directorates, grant number CZD/16/6 and the
Scottish Funding Council. Exome array genotyping for GS:SFHS was funded
by the Medical Research Council UK and performed at the Wellcome Trust
Clinical Research Facility Genetics Core at Western General Hospital,
Edinburgh, UK. We also acknowledge the invaluable contributions of the
families who took part in the Generation Scotland: Scottish Family
Health Study, the general practitioners and Scottish School of Primary
Care for their help in recruiting them, and the whole Generation
Scotland team, which includes academic researchers, IT staff, laboratory
technicians, statisticians and research managers. The chief
investigators of Generation Scotland are David J. Porteous (University
of Edinburgh), Lynne Hocking (University of Aberdeen), Blair Smith
(University of Dundee), and Sandosh Padmanabhan (University of
Glasgow).; GSK (CoLaus, GEMS, Lolipop): We thank the GEMS Study
Investigators: Philip Barter, PhD; Y. Antero Kesaniemi, PhD; Robert W.
Mahley, PhD; Ruth McPherson, FRCP; and Scott M. Grundy, PhD. Dr Waeber
MD, the CoLaus PI's Peter Vollenweider MD and Gerard Waeber MD, the
LOLIPOP PI's, Jaspal Kooner MD and John Chambers MD, as well as the
participants in all the studies. The GEMS study was sponsored in part by
GlaxoSmithKline. The CoLaus study was supported by grants from
GlaxoSmithKline, the Swiss National Science Foundation (Grant
33CSCO-122661) and the Faculty of Biology and Medicine of Lausanne.;
Health ABC: The Health, Aging and Body Composition (HABC) Study is
supported by NIA contracts N01AG62101, N01AG62103 and N01AG62106. The
exome-wide association study was funded by NIA grant 1R01AG032098-01A1
to Wake Forest University Health Sciences and was supported in part by
the Intramural Research Program of the NIH, National Institute on Aging
(Z01 AG000949-02 and Z01 AG007390-07, Human subjects protocol UCSF IRB
is H5254-12688-11). Portions of this study utilized the high-performance
computational capabilities of the Biowulf Linux cluster at the National
Institutes of Health, Bethesda, MD. (http:/biowulf.nih.gov).;
Health2008: The Health2008 cohort was supported by the Timber Merchant
Vilhelm Bang's Foundation, the Danish Heart Foundation (Grant number
07-10-R61-A1754-B838-22392F), and the Health Insurance Foundation
(Helsefonden) (Grant number 2012B233).; HELIC: This work was funded by
the Wellcome Trust (098051) and the European Research Council
(ERC-2011-StG 280559-SEPI). The MANOLIS cohort is named in honour of
Manolis Giannakakis, 1978-2010. We thank the residents of Anogia and
surrounding Mylopotamos villages, and of the Pomak villages, for taking
part. The HELIC study has been supported by many individuals who have
contributed to sample collection (including Antonis Athanasiadis, Olina
Balafouti, Christina Batzaki, Georgios Daskalakis, Eleni Emmanouil,
Chrisoula Giannakaki, Margarita Giannakopoulou,; Anastasia Kaparou,
Vasiliki Kariakli, Stella Koinaki, Dimitra Kokori, Maria Konidari, Hara
Koundouraki, Dimitris Koutoukidis, Vasiliki Mamakou, Eirini Mamalaki,
Eirini Mpamiaki, Maria Tsoukana, Dimitra Tzakou, Katerina Vosdogianni,
Niovi Xenaki, Eleni Zengini), data entry (Thanos Antonos, Dimitra
Papagrigoriou, Betty Spiliopoulou), sample logistics (Sarah Edkins, Emma
Gray), genotyping (Robert Andrews, Hannah Blackburn, Doug Simpkin,
Siobhan Whitehead), research administration (Anja Kolb-Kokocinski, Carol
Smee, Danielle Walker) and informatics (Martin Pollard, Josh Randall).;
INCIPE: NIcole Soranzo's research is supported by the Wellcome Trust
(Grant Codes WT098051 and WT091310), the EU FP7 (EPIGENESYS Grant Code
257082 and BLUEPRINT Grant Code HEALTH-F5-2011-282510).; Inter99: The
Inter99 was initiated by Torben Jorgensen (PI), Knut Borch-Johnsen
(co-PI), Hans Ibsen and Troels F. Thomsen. The steering committee
comprises the former two and Charlotta Pisinger. The study was
financially supported by research grants from the Danish Research
Council, the Danish Centre for Health Technology Assessment, Novo
Nordisk Inc., Research Foundation of Copenhagen County, Ministry of
Internal Affairs and Health, the Danish Heart Foundation, the Danish
Pharmaceutical Association, the Augustinus Foundation, the Ib Henriksen
Foundation, the Becket Foundation and the Danish Diabetes Association.
Genetic studies of both Inter99 and Health 2008 cohorts were funded by
the Lundbeck Foundation and produced by The Lundbeck Foundation Centre
for Applied Medical Genomics in Personalised Disease Prediction,
Prevention and Care (LuCamp, www.lucamp.org). The Novo Nordisk
Foundation Center for Basic Metabolic Research is an independent
Research Center at the University of Copenhagen partially funded by an
unrestricted donation from the Novo Nordisk Foundation
(www.metabol.ku.dk).; InterAct Consortium: Funding for the InterAct
project was provided by the EU FP6 programme (grant number
LSHM_CT_2006_037197). We thank all EPIC participants and staff for their
contribution to the study. We thank the lab team at the MRC Epidemiology
Unit for sample management and Nicola Kerrison for data management.; IPM
BioMe Biobank: The Mount Sinai IPM BioMe Program is supported by The
Andrea and Charles Bronfman Philanthropies. Analyses of BioMe data was
supported in part through the computational resources and staff
expertise provided by the Department of Scientific Computing at the
Icahn School of Medicine at Mount Sinai.; The Insulin Resistance
Atherosclerosis Family Study (IRASFS): The IRASFS was conducted and
supported by the National Institute of Diabetes and Digestive and Kidney
Diseases (HL060944, HL061019, and HL060919). Exome chip genotyping and
data analyses were funded in part by grants DK081350 and HG007112. A
subset of the IRASFS exome chips were contributed with funds from the
Department of Internal Medicine at the University of Michigan. Computing
resources were provided, in part, by the Wake Forest School of Medicine
Center for Public Health Genomics.; The Insulin Resistance
Atherosclerosis Study (IRAS): The IRAS was conducted and supported by
the National Institute of Diabetes and Digestive and Kidney Diseases
(HL047887, HL047889, HL047890 and HL47902). Exome chip genotyping and
data analyses were funded in part by grants DK081350 and HG007112).
Computing resources were provided, in part, by the Wake Forest School of
Medicine Center for Public Health Genomics.; JHS: The JHS is supported
by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C,
HHSN268201300049C, HHSN268201300050C from the National Heart, Lung and
Blood Institute and the National Institute on Minority Health and Health
Disparities. ExomeChip genotyping was supported by the NHLBI of the
National Institutes of Health under award number R01HL107816 to S.
Kathiresan. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health.; The London Life Sciences Prospective Population
(LOLIPOP) Study: We thank the co-primary investigators of the LOLIPOP
study: Jaspal Kooner, John Chambers and Paul Elliott. The LOLIPOP study
is supported by the National Institute for Health Research Comprehensive
Biomedical Research Centre Imperial College Healthcare NHS Trust, the
British Heart Foundation (SP/04/002), the Medical Research Council
(G0700931), the Wellcome Trust (084723/Z/08/Z) and the National
Institute for Health Research (RP-PG-0407-10371).; MESA: The
Multi-Ethnic Study of Atherosclerosis (MESA) and MESA SHARe project are
conducted and supported by contracts N01-HC-95159 through N01-HC-95169
and RR-024156 from the National Heart, Lung, and Blood Institute
(NHLBI). Funding for MESA SHARe genotyping was provided by NHLBI
Contract N02-HL-6-4278. MESA Family is conducted and supported in
collaboration with MESA investigators; support is provided by grants and
contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251,
R01HL071252, R01HL071258, R01HL071259. MESA Air is conducted and
supported by the United States Environmental Protection Agency (EPA) in
collaboration with MESA Air investigators; support is provided by grant
RD83169701. We thank the participants of the MESA study, the
Coordinating Center, MESA investigators, and study staff for their
valuable contributions. A full list of participating MESA investigators
and institutions can be found at http://www.mesa-nhlbi.org. Additional
support was provided by the National Institute for Diabetes and
Digestive and Kidney Diseases (NIDDK) grants R01DK079888 and P30DK063491
and the National Center for Advancing Translational Sciences grant
UL1-TR000124. Further support came from the Cedars-Sinai Winnick
Clinical Scholars Award (to M.O. Goodarzi).; METSIM: The METSIM study
was funded by the Academy of Finland (grants no. 77299 and 124243). M.L.
acknowledges funding from the Academy of Finland. M.B. and K.M.
acknowledge grant funding from NIH grants DK062370, DK093757, DK072193.;
MRC Ely: The Ely Study was funded by the Medical Research Council
(MC_U106179471) and Diabetes UK. We are grateful to all the volunteers,
and to the staff of St Mary's Street Surgery, Ely and the study team.;
PROCARDIS: We thank all participants in this study. The European
Community Sixth Framework Program (LSHM-CT-2007-037273), AstraZeneca,
the British Heart Foundation, the Oxford British Heart Foundation Centre
of Research Excellence, the Wellcome Trust (075491/Z/04), the Swedish
Research Council, the Knut and Alice Wallenberg Foundation, the Swedish
Heart-Lung Foundation, the Torsten and Ragnar Soderberg Foundation, the
Strategic Cardiovascular and Diabetes Programs of Karolinska Institutet
and Stockholm County Council, the Foundation for Strategic Research and
the Stockholm County Council (560283). Bengt Sennblad acknowledges
funding from the Magnus Bergvall Foundation and the Foundation for Old
Servants. Rona J. Strawbridge is supported by the Swedish Heart-Lung
Foundation, the Tore Nilsson foundation, the Fredrik and Ingrid Thuring
foundation and the Foundation for Old Servants. Maria Sabater-Lleal
acknowledges funding from Ake-wiberg, Tore Nilsson and Karolinska
Institutet Foundations. Mattias Frnberg acknowledges funding from the
Swedish e-science Research Center (SeRC).; RISC: We are extremely
grateful to the RISC study participants and the RISC study team. The
RISC Study is partly supported by EU grant QLG1-CT-2001-01252.
Additional support for the RISC Study has been provided by AstraZeneca
(Sweden). The RISC Study was supported by European Union grant
QLG1-CT-2001-01252 and AstraZeneca. Ele Ferrannini acknowledges grant
funding from Boehringer-Ingelheim and Lilly&Co and works as a consultant
for Boehringer-Ingelheim, Lilly&Co., MSD, Sanofi, GSK, Janssen,
Menarini, Novo Nordisk, AstraZeneca.; Rotterdam Study: The Rotterdam
Study is funded by the Research Institute for Diseases in the Elderly
(014-93-015; RIDE2), the Netherlands Genomics Initiative
(NGI)/Netherlands Organization for Scientific Research (NWO) project nr.
050-060-810, CHANCES (nr 242244), Erasmus Medical Center and Erasmus
University Rotterdam, Netherlands Organization for the Health Research
and Development (ZonMw), the Research Institute for Diseases in the
Elderly (RIDE), the Ministry of Education, Culture and Science, the
Ministry for Health, Welfare and Sports, the European Commission (DG
XII) and the Municipality of Rotterdam. Abbas Dehghan is supported by
NWO grant veni (veni, 916.12.154) and the EUR Fellowship. We are
grateful to the study participants, the staff from the Rotterdam Study
and the participating general practitioners and pharmacists.; SCARF: We
thank all participants in this study. The study was funded by the
Foundation for Strategic Research, the Swedish Heart-Lung Foundation,
the Swedish Research Council (8691, 12660, 20653), the European
Commission (LSHM-CT-2007-037273), the Knut and Alice Wallenberg
Foundation, the Torsten and Ragnar Soderberg Foundation, the Strategic
Cardiovascular and Diabetes Programmes of Karolinska Institutet and the
Stockholm County Council, and the Stockholm County Council (560183).
Bengt Sennblad acknowledges funding from the Magnus Bergvall Foundation
and the Foundation for Old Servants. Mattias Franberg acknowledges
funding from the Swedish e-Science Research Center (SeRC).; SCES: The
Singapore Chinese Eye Study (SCES) was supported by the National Medical
Research Council (NMRC), Singapore (grants 0796/2003, IRG07nov013,
IRG09nov014, NMRC 1176/2008, STaR/0003/2008, CG/SERI/2010) and
Biomedical Research Council (BMRC), Singapore (08/1/35/19/550 and
09/1/35/19/616).; TEENAGE (TEENs of Attica: Genes and Environment): This
research has been co-financed by the European Union (European Social
Fund-ESF) and Greek national funds through the Operational Program
'Education and Lifelong Learning' of the National Strategic Reference
Framework (NSRF)-Research Funding Program: Heracleitus II. Investing in
knowledge society through the European Social Fund. This work was funded
by the Wellcome Trust (098051).; Uppsala Longitudinal Study of Adult Men
(ULSAM): The exome chip genotyping and data analyses were supported by
Uppsala University, Knut och Alice Wallenberg Foundation, European
Research Council, Swedish Diabetes Foundation (grant no. 2013-024),
Swedish Research Council (grant no. 2012-1397), and Swedish Heart-Lung
Foundation (20120197). C.M.L. is supported by a Wellcome Trust Research
Career Development Fellowship (086596/Z/08/Z).; INGI-VB: The Val Borbera
study (INGI-VB) thanks the inhabitants of the Val Borbera for
participating in the study, the local administrations and the ASL-Novi
Ligure for support and Fiammetta Vigano for technical help. We also
thank Professor Clara Camaschella, Professor Federico Caligaris-Cappio
and the MDs of the Medicine Dept. of the San Raffaele Hospital for help
with clinical data collection. The study was supported by funds from
Fondazione Compagnia di San Paolo-Torino, Fondazione Cariplo-Milano,
Italian Ministry of Health Progetto Finalizzato 2007 and 2012, Italian
Ministry of Health Progetto CCM 2010, and PRIN 2009.; WGHS: The WGHS is
supported by HL043851 and HL080467 from the National Heart, Lung, and
Blood Institute and CA047988 from the National Cancer Institute, the
Donald W. Reynolds Foundation and the Fondation Leducq, with
collaborative scientific support and funding for genotyping provided by
Amgen.
NR 70
TC 43
Z9 43
U1 5
U2 37
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2015
VL 6
AR 5897
DI 10.1038/ncomms6897
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA2ME
UT WOS:000348741700001
PM 25631608
ER
PT J
AU Dickey, MW
Warren, T
AF Dickey, Michael Walsh
Warren, Tessa
TI The influence of event-related knowledge on verb-argument processing in
aphasia
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Language comprehension; Conceptual semantics; Aphasia; Sentence
processing
ID MINI-MENTAL STATE; LANGUAGE COMPREHENSION; EYE-MOVEMENTS; SENTENCE
COMPREHENSION; SELECTIONAL RESTRICTION; SEMANTIC IMPAIRMENT; WORLD
KNOWLEDGE; CORTEX; PLAUSIBILITY; INTEGRATION
AB Event-related conceptual knowledge outside the language system rapidly affects verb-argument processing in unimpaired adults (McRae and Matsuki, 2009). Some have argued that verb-argument processing is in fact reducible to the activation of such event-related knowledge. However, data favoring this conclusion have come primarily from college-aged healthy adults, for whom both linguistic and conceptual semantic processing is fast and automatic. This study examined the influence of event-related knowledge on verb-argument processing among adults with aphasia (n=8) and older unimpaired controls (n=60), in two self-paced reading studies. Participants read sentences containing a plausible verb-argument combination (Mary used a knife to chop the large carrots before dinner), a combination that violated event-related world knowledge (Mary used some bleach to clean the large carrots before dinner), or a combination that violated the verb's selectional restrictions (Mary used a pump to inflate the large carrots before dinner). The participants with aphasia naturally split into two groups: Group 1 (n=4) had conceptual-semantic impairments (evidenced by poor performance on tasks like Pyramids & Palm Trees) but reasonably intact language processing (higher Western Aphasia Battery Aphasia Quotients), while Group 2 (n=4) had intact conceptual semantics but poorer language processing. Older unimpaired controls and aphasic Group 1 showed rapid on-line disruption for sentences with selectional-restriction violations (SRVs) and event-related knowledge violations, and also showed SRV-specific penalties in sentence-final acceptability judgments (Experiment 1) and comprehension questions (Experiment 2). In contrast, Group 2 showed very few reliable differences across conditions in either on-line or off-line measures. This difference between aphasic groups suggests that verb-related information and event-related knowledge may be dissociated in aphasia. Furthermore, it suggests that intact language processing is more critical for successful verb-argument integration than intact access to event-related world knowledge. This pattern is unexpected if verb-argument processing is reducible to activation of event-related conceptual knowledge. Published by Elsevier Ltd.
C1 [Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[Dickey, Michael Walsh; Warren, Tessa] Univ Pittsburgh, Learning Res & Dev Ctr, Pittsburgh, PA 15213 USA.
RP Dickey, MW (reprint author), Dept Commun Sci & Disorders, 4032 Forbes Tower, Pittsburgh, PA 15260 USA.
EM mdickey@pitt.edu
OI Dickey, Michael Walsh/0000-0002-9068-3313
FU National Institutes of Health [R01DC011520]; University of Pittsburgh
[UL1TR000005]
FX This research was supported by the National Institutes of Health through
Grant number R01DC011520 to the authors and by Grant number UL1TR000005
to the Clinical and Translational Science Institute of the University of
Pittsburgh. It is the result of work supported with resources and the
use of facilities at the VA Pittsburgh Healthcare System. Thanks are due
to Minas Abovyan, Amanda Fryd, Emily Kosenske, Molly Lane, Evelyn
Milburn, Hannah Rosenberg, Hyunsoo Yoo, and Lidia Zacharczuk for help
running participants, to Alice Proverbio and Federica Riva for sharing
their picture stimuli from Proverbio and Riva (2009), and to audiences
at the 2012 and 2013 CUNY Sentence Processing Conference and the 2013
Academy of Aphasia meeting for comments and suggestions. Special thanks
are due to the adults with aphasia who participated in these studies. A
preliminary version of this work was published as Warren and Dickey
(2013).
NR 62
TC 3
Z9 3
U1 1
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
EI 1873-3514
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD JAN
PY 2015
VL 67
BP 63
EP 81
DI 10.1016/j.neuropsychologia.2014.12.003
PG 19
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA CA4NH
UT WOS:000348880800007
PM 25484306
ER
PT J
AU Williams, BA
Ibinson, JW
Mangione, MP
Scanlan, RL
Cohen, PZ
AF Williams, Brian A.
Ibinson, James W.
Mangione, Michael P.
Scanlan, Rick L.
Cohen, Peter Z.
TI Clinical Benchmarks Regarding Multimodal Peripheral Nerve Blocks for
Postoperative Analgesia: Observations Regarding Combined Perineural
Midazolam-Clonidine-Buprenorphine-Dexamethasone
SO PAIN MEDICINE
LA English
DT Editorial Material
ID OUTPATIENT KNEE SURGERY; CARE-UNIT BYPASS; SAME-DAY DISCHARGE;
LOCAL-ANESTHETICS; ARTHROPLASTY; FALLS; ADJUVANTS; PAIN; TIME
C1 [Williams, Brian A.; Ibinson, James W.; Mangione, Michael P.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.
[Cohen, Peter Z.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA.
[Williams, Brian A.; Ibinson, James W.] Vet Affairs Pittsburgh Healthcare Syst, Dept Anesthesiol, Pittsburgh, PA USA.
[Williams, Brian A.; Ibinson, James W.; Mangione, Michael P.; Scanlan, Rick L.; Cohen, Peter Z.] Vet Affairs Pittsburgh Healthcare Syst, Surg Serv Line, Pittsburgh, PA USA.
[Williams, Brian A.; Ibinson, James W.; Mangione, Michael P.; Scanlan, Rick L.; Cohen, Peter Z.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Williams, BA (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.
OI Ibinson, James/0000-0002-5525-5225
NR 20
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JAN
PY 2015
VL 16
IS 1
BP 1
EP 6
DI 10.1111/pme.12599
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA CA2IN
UT WOS:000348732200001
PM 25351887
ER
PT J
AU Williams, BA
Ibinson, JW
Mangione, MP
Modrak, RT
Tonarelli, EJ
Rakesh, H
Kmatz, AM
Cohen, PZ
AF Williams, Brian A.
Ibinson, James W.
Mangione, Michael P.
Modrak, Robert T.
Tonarelli, Elizabeth J.
Rakesh, Hulimangala
Kmatz, Alissa M.
Cohen, Peter Z.
TI Research Priorities Regarding Multimodal Peripheral Nerve Blocks for
Postoperative Analgesia and Anesthesia Based on Hospital Quality Data
Extracted from Over 1,300 Cases (2011-2014)
SO PAIN MEDICINE
LA English
DT Editorial Material
ID LOCAL-ANESTHETICS; PAIN; PREDICTORS
C1 [Williams, Brian A.; Ibinson, James W.; Mangione, Michael P.; Cohen, Peter Z.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Williams, Brian A.; Ibinson, James W.; Mangione, Michael P.; Rakesh, Hulimangala] Vet Affairs Pittsburgh Healthcare Syst, Anesthesia Serv, Pittsburgh, PA USA.
[Modrak, Robert T.; Cohen, Peter Z.] Vet Affairs Pittsburgh Healthcare Syst, Orthopaed Surg Serv, Pittsburgh, PA USA.
[Tonarelli, Elizabeth J.; Kmatz, Alissa M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Williams, BA (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.
OI Ibinson, James/0000-0002-5525-5225
NR 13
TC 7
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JAN
PY 2015
VL 16
IS 1
BP 7
EP 12
DI 10.1111/pme.12609
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA CA2IN
UT WOS:000348732200002
PM 25377071
ER
PT J
AU Oliva, EM
Midboe, AM
Lewis, ET
Henderson, PT
Dalton, AL
Im, JJ
Seal, K
Paik, MC
Trafton, JA
AF Oliva, Elizabeth M.
Midboe, Amanda M.
Lewis, Eleanor T.
Henderson, Patricia T.
Dalton, Aaron L.
Im, Jinwoo J.
Seal, Karen
Paik, Meenah C.
Trafton, Jodie A.
TI Sex Differences in Chronic Pain Management Practices for Patients
Receiving Opioids from the Veterans Health Administration
SO PAIN MEDICINE
LA English
DT Article
DE Pain Management; Opioids; Sex; Veterans
ID PRIMARY-CARE; MUSCULOSKELETAL PAIN; IRAQI FREEDOM; GENDER; WOMEN;
PREVALENCE; ORGANIZATION; COMORBIDITY; POPULATION; PATTERNS
AB BackgroundWomen experience chronic pain and use pain-related health care at higher rates than men. It is not known whether the pain-related health care female veterans receive is consistent with clinical practice guideline recommendations or whether receipt of this care differs between men and women.
ObjectiveThe aim of this study was to identify whether sex differences in chronic pain management care exist for patients served by the Veterans Health Administration (VHA).
DesignData on patient demographics, diagnostic criteria, and health care utilization were extracted from VHA administrative databases for fiscal year 2010 (FY10).
PatientsPatients in this study included all VHA patients (excluding metastatic cancer patients) who received more than 90 days of a short-acting opioid medication or a long-acting opioid medication prescription in FY10 study.
MeasuresMultilevel logistic regressions were conducted to identify sex differences in receipt of guideline-recommended chronic pain management.
ResultsA total of 480,809 patients met inclusion criteria. Female patients were more likely to receive most measures of guideline-recommended care for chronic pain including mental health assessments, psychotherapy, rehabilitation therapy, and pharmacy reconciliation. However, women were more likely to receive concurrent sedative prescriptions, which is inconsistent with guideline recommendations. Most of the observed sex differences persisted after controlling for key demographic and diagnostic differences.
ConclusionsFindings suggest that female VHA patients are more likely to receive an array of pain management practices than male patients, including both contraindicated and recommended polypharmacy. Quality improvement efforts to address underutilization of mental health and rehabilitative services for pain by male patients and polypharmacy in female patients should be considered.
C1 [Oliva, Elizabeth M.; Midboe, Amanda M.; Lewis, Eleanor T.; Henderson, Patricia T.; Dalton, Aaron L.; Paik, Meenah C.; Trafton, Jodie A.] Ctr Innovat Implementat, Dept Vet Affairs, Menlo Pk, CA USA.
[Seal, Karen] San Francisco VA Med Ctr, Integrated Care Clin, San Francisco, CA USA.
[Seal, Karen] San Francisco VA Med Ctr, Med Practice Pain Clin, San Francisco, CA USA.
[Trafton, Jodie A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Trafton, Jodie A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Im, Jinwoo J.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA.
[Seal, Karen] Samsung Econ Res Inst, Ind & Strategy Dept, Seoul, South Korea.
RP Oliva, EM (reprint author), VA Ctr Innovat Implementat, 795Willow Rd 152, Menlo Pk, CA 94025 USA.
EM Elizabeth.Oliva@va.gov
FU Department of Veterans' Affairs (VA) Health Services Research and
Development program (HSRD); Quality Enhancement Research Initiative
(QUERI) [RRP 10-106, RRP 12-445]; VA Office of Mental Health
FX This project was funded by grants awarded by the Department of Veterans'
Affairs (VA) Health Services Research and Development program (HSR&D)
and Quality Enhancement Research Initiative (QUERI) to Dr. Trafton-RRP
10-106 entitled "Assessment of Gaps in Chronic Opioid Therapy Guideline
Adherence"-and Dr. Lewis-RRP 12-445 entitled "Adherence to Practice
Recommendations for Veterans with SUDs Receiving Opioids." Additional
funding was provided by the VA Office of Mental Health Operations to the
Program Evaluation and Resource Center (PERC). The authors gratefully
acknowledge Dr. Robert Kerns, Dr. William Becker, Dr. Francine Goodman,
Dr. Jack Rosenberg, and Dr. Rollin (Mac) Gallagher for their role in
creating the CPG adherence metrics. We gratefully acknowledge the
sacrifices of the men and women who have served in the United States
military.
NR 20
TC 3
Z9 3
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JAN
PY 2015
VL 16
IS 1
BP 112
EP 118
DI 10.1111/pme.12501
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA CA2IN
UT WOS:000348732200018
PM 25039721
ER
PT J
AU Williams, BA
Butt, MT
Zeller, JR
Coffee, S
Pippi, MA
AF Williams, Brian A.
Butt, Mark T.
Zeller, Jillynne R.
Coffee, Samantha
Pippi, Michael A.
TI Multimodal Perineural Analgesia with Combined
Bupivacaine-Clonidine-Buprenorphine-Dexamethasone: Safe In Vivo and
Chemically Compatible in Solution
SO PAIN MEDICINE
LA English
DT Article
DE Bupivacaine; Clonidine; Buprenorphine; Dexamethasone; Midazolam; Nerve
Block
ID BRACHIAL-PLEXUS BLOCKADE; PERIPHERAL-NERVE BLOCKS; LOCAL-ANESTHETICS;
NEUROTOXICITY; ROPIVACAINE; ADJUVANTS; PROLONGS; MEPIVACAINE; LIDOCAINE;
TRIALS
AB ObjectivesThe use of adjuvants in regional anesthesia has increased. However, there are knowledge gaps pertaining to 1) in vivo local tissue effects of these adjuvants; and 2) chemical compatibility and solubility of these drugs in solution with each other and with local anesthetics. This study addresses these gaps in knowledge.
DesignIn vivo rat safety/toxicopathology study and analytical chemistry study.
SettingCollaborating Good Laboratory Practice laboratories under the direction of the university-based principal investigator.
MethodsSingle-injection formulations of clonidine, buprenorphine, and dexamethasone were combined with either bupivacaine or midazolam, and were administered to groups of rats. Post-injection behavior was monitored to assess changes related to the block. A continuous infusion of bupivacaine, clonidine, and dexamethasone was administered to another group of rats, and behavioral effects were recorded. After 15 days, rats were sacrificed and their nerves/dorsal root ganglia were examined by the pathologist. Samples of combined drug solutions were processed at an analytical chemistry laboratory for compatibility, solubility, and stability.
ResultsEach of the single-injection formulations produced reversible sensory and/or motor block. None of the study drugs caused damage to any of the nerve segments or related tissue. The text describes the concentrations at which compatibility and solubility of the combined drug solutions were achieved.
ConclusionsFour-drug single-injection formulations are described that 1) had compatible and stable concentrations in solution; and 2) produced reversible nerve block without causing long-term motor or sensory deficits or damage to sciatic nerves/dorsal root ganglia.
C1 [Williams, Brian A.] Vet Affairs Pittsburgh Healthcare Syst, Dept Anesthesiol, Pittsburgh, PA USA.
[Williams, Brian A.; Pippi, Michael A.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15261 USA.
[Butt, Mark T.] TPS, Frederick, MD USA.
[Zeller, Jillynne R.] NBR, Spring Lake, MI USA.
[Coffee, Samantha] WIL Res Labs, Ashland, OH USA.
RP Williams, BA (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, 200 Lothrop St,A-1305 Scaife Hall, Pittsburgh, PA 15261 USA.
EM williamsba@anes.upmc.edu
FU VA Pittsburgh Health System
FX The methodology was designed in detailed consultation with the
participating GLP facilities (animal surgery and behavioral experiments,
along with animal sacrifice and tissue harvest/preservation at Northern
Biomedical Research [NBR], Inc., Spring Lake, Michigan, United States;
Randall Reed, BA, SRS, laboratory director; and Tox Path Specialists
[TPS], LLC, Frederick, Maryland, United States; co-author Mark T. Butt,
DVM, DAVCP, study pathologist and company president). The contents of
this manuscript do not reflect the views of the Department of Veterans
Affairs or the United States Government. VA Pittsburgh Health System is
acknowledged for support of lead author BAW. This manuscript/study was
underwritten by the Department of Defense (OR090012 to author BAW) Peer
Reviewed Orthopaedic Research Program (PRORP), Translational Research
Partnership Award (TRPA), of the Office of the Congressionally Directed
Medical Research Programs (CDMRP).
NR 20
TC 8
Z9 8
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JAN
PY 2015
VL 16
IS 1
BP 186
EP 198
DI 10.1111/pme.12592
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA CA2IN
UT WOS:000348732200026
PM 25339320
ER
PT J
AU Mahajan, A
Sim, X
Ng, HJ
Manning, A
Rivas, MA
Highland, HM
Locke, AE
Grarup, N
Im, HK
Cingolani, P
Flannick, J
Fontanillas, P
Fuchsberger, C
Gaulton, KJ
Teslovich, TM
Rayner, NW
Robertson, NR
Beer, NL
Rundle, JK
Bork-Jensen, J
Ladenvall, C
Blancher, C
Buck, D
Buck, G
Burtt, NP
Gabriel, S
Gjesing, AP
Groves, CJ
Hollensted, M
Huyghe, JR
Jackson, AU
Jun, G
Justesen, JM
Mangino, M
Murphy, J
Neville, M
Onofrio, R
Small, KS
Stringham, HM
Syvanen, AC
Trakalo, J
Abecasis, G
Bell, GI
Blangero, J
Cox, NJ
Duggirala, R
Hanis, CL
Seielstad, M
Wilson, JG
Christensen, C
Brandslund, I
Rauramaa, R
Surdulescu, GL
Doney, ASF
Lannfelt, L
Linneberg, A
Isomaa, B
Tuomi, T
Jorgensen, ME
Jorgensen, T
Kuusisto, J
Uusitupa, M
Salomaa, V
Spector, TD
Morris, AD
Palmer, CNA
Collins, FS
Mohlke, KL
Bergman, RN
Ingelsson, E
Lind, L
Tuomilehto, J
Hansen, T
Watanabe, RM
Prokopenko, I
Dupuis, J
Karpe, F
Groop, L
Laakso, M
Pedersen, O
Florez, JC
Morris, AP
Altshuler, D
Meigs, JB
Boehnke, M
McCarthy, MI
Lindgren, CM
Gloyn, AL
AF Mahajan, Anubha
Sim, Xueling
Ng, Hui Jin
Manning, Alisa
Rivas, Manuel A.
Highland, Heather M.
Locke, Adam E.
Grarup, Niels
Im, Hae Kyung
Cingolani, Pablo
Flannick, Jason
Fontanillas, Pierre
Fuchsberger, Christian
Gaulton, Kyle J.
Teslovich, Tanya M.
Rayner, N. William
Robertson, Neil R.
Beer, Nicola L.
Rundle, Jana K.
Bork-Jensen, Jette
Ladenvall, Claes
Blancher, Christine
Buck, David
Buck, Gemma
Burtt, Noel P.
Gabriel, Stacey
Gjesing, Anette P.
Groves, Christopher J.
Hollensted, Mette
Huyghe, Jeroen R.
Jackson, Anne U.
Jun, Goo
Justesen, Johanne Marie
Mangino, Massimo
Murphy, Jacquelyn
Neville, Matt
Onofrio, Robert
Small, Kerrin S.
Stringham, Heather M.
Syvanen, Ann-Christine
Trakalo, Joseph
Abecasis, Goncalo
Bell, Graeme I.
Blangero, John
Cox, Nancy J.
Duggirala, Ravindranath
Hanis, Craig L.
Seielstad, Mark
Wilson, James G.
Christensen, Cramer
Brandslund, Ivan
Rauramaa, Rainer
Surdulescu, Gabriela L.
Doney, Alex S. F.
Lannfelt, Lars
Linneberg, Allan
Isomaa, Bo
Tuomi, Tiinamaija
Jorgensen, Marit E.
Jorgensen, Torben
Kuusisto, Johanna
Uusitupa, Matti
Salomaa, Veikko
Spector, Timothy D.
Morris, Andrew D.
Palmer, Colin N. A.
Collins, Francis S.
Mohlke, Karen L.
Bergman, Richard N.
Ingelsson, Erik
Lind, Lars
Tuomilehto, Jaakko
Hansen, Torben
Watanabe, Richard M.
Prokopenko, Inga
Dupuis, Josee
Karpe, Fredrik
Groop, Leif
Laakso, Markku
Pedersen, Oluf
Florez, Jose C.
Morris, Andrew P.
Altshuler, David
Meigs, James B.
Boehnke, Michael
McCarthy, Mark I.
Lindgren, Cecilia M.
Gloyn, Anna L.
CA T2D-GENES Consortium
Go T2D Consortium
TI Identification and Functional Characterization of G6PC2 Coding Variants
Influencing Glycemic Traits Define an Effector Transcript at the
G6PC2-ABCB11 Locus
SO PLOS GENETICS
LA English
DT Article
ID TYPE-2 DIABETES RISK; FASTING PLASMA-GLUCOSE; GENETIC ARCHITECTURE;
TRIGLYCERIDE LEVELS; QUANTITATIVE TRAIT; P446L VARIANT; ASSOCIATION;
GENOME; PROTEIN; POLYMORPHISMS
AB Genome wide association studies (GWAS) for fasting glucose (FG) and insulin (FI) have identified common variant signals which explain 4.8% and 1.2% of trait variance, respectively. It is hypothesized that low-frequency and rare variants could contribute substantially to unexplained genetic variance. To test this, we analyzed exome-array data from up to 33,231 non-diabetic individuals of European ancestry. We found exome-wide significant (P<5x10-7) evidence for two loci not previously highlighted by common variant GWAS: GLP1R (p.Ala316Thr, minor allele frequency (MAF)=1.5%) influencing FG levels, and URB2 (p.Glu594Val, MAF = 0.1%) influencing FI levels. Coding variant associations can highlight potential effector genes at (non-coding) GWAS signals. At the G6PC2/ABCB11 locus, we identified multiple coding variants in G6PC2 (p.Val219Leu, p.His177Tyr, and p Tyr207Ser) influencing FG levels, conditionally independent of each other and the non-coding GWAS signal. In vitro assays demonstrate that these associated coding alleles result in reduced protein abundance via proteasomal degradation, establishing G6PC2 as an effector gene at this locus. Reconciliation of single-variant associations and functional effects was only possible when haplotype phase was considered. In contrast to earlier reports suggesting that, paradoxically, glucose-raising alleles at this locus are protective against type 2 diabetes (T2D), the p.Val219Leu G6PC2 variant displayed a modest but directionally consistent association with T2D risk. Coding variant associations for glycemic traits in GWAS signals highlight PCSK1, RREB1, and ZHX3 as likely effector transcripts. These coding variant association signals do not have a major impact on the trait variance explained, but they do provide valuable biological insights.
C1 [Mahajan, Anubha; Rivas, Manuel A.; Gaulton, Kyle J.; Rayner, N. William; Robertson, Neil R.; Morris, Andrew D.; Ingelsson, Erik; Prokopenko, Inga; Morris, Andrew P.; McCarthy, Mark I.; Lindgren, Cecilia M.] Univ Oxford, Wellcome Trust Ctr Human Genet, Nuffield Dept Med, Oxford, England.
[Sim, Xueling; Locke, Adam E.; Fuchsberger, Christian; Teslovich, Tanya M.; Huyghe, Jeroen R.; Jackson, Anne U.; Jun, Goo; Stringham, Heather M.; Abecasis, Goncalo; Boehnke, Michael] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
[Sim, Xueling; Locke, Adam E.; Fuchsberger, Christian; Teslovich, Tanya M.; Huyghe, Jeroen R.; Jackson, Anne U.; Jun, Goo; Stringham, Heather M.; Abecasis, Goncalo; Boehnke, Michael] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Ng, Hui Jin; Rayner, N. William; Robertson, Neil R.; Beer, Nicola L.; Rundle, Jana K.; Groves, Christopher J.; Neville, Matt; Prokopenko, Inga; Karpe, Fredrik; McCarthy, Mark I.; Gloyn, Anna L.] Univ Oxford, Radcliffe Dept Med, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[Manning, Alisa; Flannick, Jason; Fontanillas, Pierre; Burtt, Noel P.; Gabriel, Stacey; Murphy, Jacquelyn; Onofrio, Robert; Florez, Jose C.; Altshuler, David; Lindgren, Cecilia M.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Highland, Heather M.] Univ Texas Hlth Sci Ctr Houston, Univ Texas Grad Sch Biomed Sci Houston, Ctr Human Genet, Houston, TX 77030 USA.
[Grarup, Niels; Bork-Jensen, Jette; Gjesing, Anette P.; Hollensted, Mette; Justesen, Johanne Marie; Hansen, Torben; Pedersen, Oluf] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark.
[Im, Hae Kyung] Univ Chicago, Dept Hlth Studies, Biostat Lab, Chicago, IL 60637 USA.
[Cingolani, Pablo] McGill Univ, Sch Comp Sci, Montreal, PQ, Canada.
[Cingolani, Pablo] McGill Univ, Montreal, PQ, Canada.
[Cingolani, Pablo] Genome Quebec Innovat Ctr, Montreal, PQ, Canada.
[Flannick, Jason; Altshuler, David] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Rayner, N. William] Wellcome Trust Sanger Inst, Dept Human Genet, Hinxton, Cambs, England.
[Ladenvall, Claes; Groop, Leif] Lund Univ, Ctr Diabet, Dept Clin Sci Diabet & Endocrinol, Malmo, Sweden.
[Blancher, Christine; Buck, David; Buck, Gemma; Trakalo, Joseph] Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, High Throughput Genom Oxford Genom Ctr, Oxford, England.
[Mangino, Massimo; Small, Kerrin S.; Surdulescu, Gabriela L.; Spector, Timothy D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
[Syvanen, Ann-Christine] Uppsala Univ, Dept Med Sci, Mol Med & Sci Life Lab, Uppsala, Sweden.
[Bell, Graeme I.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Bell, Graeme I.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
[Blangero, John; Duggirala, Ravindranath] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA.
[Cox, Nancy J.] Univ Chicago, Dept Med, Med Genet Sect, Chicago, IL 60637 USA.
[Hanis, Craig L.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA.
[Seielstad, Mark] Blood Syst Res Inst, San Francisco, CA USA.
[Seielstad, Mark] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
[Seielstad, Mark] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
[Wilson, James G.] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA.
[Christensen, Cramer] Vejle Hosp, Dept Internal Med & Endocrinol, Vejle, Denmark.
[Brandslund, Ivan] Vejle Hosp, Dept Clin Biochem, Vejle, Denmark.
[Brandslund, Ivan] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark.
[Rauramaa, Rainer] Kuopio Res Inst Exercise Med, Fdn Res Hlth Exercise & Nutr, Kuopio, Finland.
[Doney, Alex S. F.] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Div Cardiovasc & Diabet Med, Dundee DD1 9SY, Scotland.
[Lannfelt, Lars] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden.
[Linneberg, Allan] Glostrup Univ Hosp, Dept Clin Expt Res, Glostrup, Denmark.
[Linneberg, Allan] Univ Copenhagen, Dept Clin Med, Fac Hlth & Med Sci, Copenhagen, Denmark.
[Linneberg, Allan; Jorgensen, Torben] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark.
[Isomaa, Bo] Dept Social Serv & Hlth Care, Pietarsaari, Finland.
[Isomaa, Bo; Tuomi, Tiinamaija] Folkhalsan Res Ctr, Helsinki, Finland.
[Tuomi, Tiinamaija] Univ Helsinki, Cent Hosp, Dept Endocrinol, Helsinki, Finland.
[Jorgensen, Marit E.] Steno Diabet Ctr, DK-2820 Gentofte, Denmark.
[Jorgensen, Torben] Aalborg Univ, Fac Med, Aalborg, Denmark.
[Kuusisto, Johanna; Laakso, Markku] Univ Eastern Finland, Inst Clin Med Internal Med, Fac Hlth Sci, Kuopio, Finland.
[Kuusisto, Johanna; Laakso, Markku] Kuopio Univ Hosp, SF-70210 Kuopio, Finland.
[Uusitupa, Matti] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland.
[Salomaa, Veikko] Natl Inst Hlth & Welf, Helsinki, Finland.
[Morris, Andrew D.] Univ Dundee, Ninewells Hosp & Med Sch, Clin Res Ctr, Ctr Mol Med, Dundee DD1 9SY, Scotland.
[Palmer, Colin N. A.] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Pat Macpherson Ctr Pharmacogenet & Pharmacogenom, Dundee DD1 9SY, Scotland.
[Collins, Francis S.] NHGRI, Med Genom & Metab Genet Branch, NIH, Bethesda, MD 20892 USA.
[Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Bergman, Richard N.] Cedars Sinai Diabet & Obes Res Inst, Los Angeles, CA USA.
[Ingelsson, Erik] Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, Uppsala, Sweden.
[Lind, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
[Tuomilehto, Jaakko] King Abdulaziz Univ, Diabet Res Grp, Jeddah 21413, Saudi Arabia.
[Tuomilehto, Jaakko] Autonomous Univ Madrid, Univ Hosp LaPaz, Inst Invest Sanitaria Hosp Univ LaPaz IdiPAZ, E-28049 Madrid, Spain.
[Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria.
[Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Diabet Prevent Unit, Helsinki, Finland.
[Hansen, Torben] Univ Southern Denmark, Fac Hlth Sci, Odense, Denmark.
[Watanabe, Richard M.] Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA.
[Watanabe, Richard M.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Watanabe, Richard M.] Univ So Calif, Keck Sch Med, Diabet & Obes Res Inst, Los Angeles, CA 90033 USA.
[Prokopenko, Inga] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Genom Common Dis, London, England.
[Dupuis, Josee] Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA.
[Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Karpe, Fredrik; McCarthy, Mark I.; Gloyn, Anna L.] Oxford Univ Hosp Trust, Oxford NIHR Biomed Res Ctr, Oxford, England.
[Florez, Jose C.; Altshuler, David] Massachusetts Gen Hosp, Dept Med, Diabet Res Ctr, Diabet Unit, Boston, MA 02114 USA.
[Florez, Jose C.; Altshuler, David] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Florez, Jose C.] Massachusetts Gen Hosp, Dept Med, Ctr Human Genet Res, Boston, MA 02114 USA.
[Morris, Andrew P.] Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England.
[Morris, Andrew P.] Univ Tartu, Estonian Genome Ctr, EE-50090 Tartu, Estonia.
[Altshuler, David] MIT, Dept Biol, Cambridge, MA USA.
[Altshuler, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Meigs, James B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med, Boston, MA USA.
[Meigs, James B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Mahajan, A (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Nuffield Dept Med, Oxford, England.
EM celi@well.ox.ac.uk; anna.gloyn@drl.ox.ac.uk
RI Palmer, Colin/C-7053-2008; Grarup, Niels/K-2807-2015; Prokopenko,
Inga/H-3241-2014; Justesen, Johanne Marie/L-6023-2015; kinnunen,
leena/B-7059-2012; Study, GoDARTS/K-9448-2016; mangino,
massimo/F-5134-2011; Hrabe de Angelis, Martin/F-5531-2012; Jun,
Goo/F-1941-2017;
OI Gieger, Christian/0000-0001-6986-9554; Meisinger,
Christa/0000-0002-9026-6544; Tuomi, Tiinamaija/0000-0002-8306-6202;
Jorgensen, Torben/0000-0001-9453-2830; Small,
Kerrin/0000-0003-4566-0005; Khor, Chiea Chuen/0000-0002-1128-4729; Tai,
E Shyong/0000-0003-2929-8966; Linneberg, Allan/0000-0002-0994-0184;
Palmer, Colin/0000-0002-6415-6560; Grarup, Niels/0000-0001-5526-1070;
Prokopenko, Inga/0000-0003-1624-7457; Justesen, Johanne
Marie/0000-0002-0484-8522; kinnunen, leena/0000-0001-8739-4812; mangino,
massimo/0000-0002-2167-7470; Hrabe de Angelis,
Martin/0000-0002-7898-2353; Jun, Goo/0000-0003-0891-0204; Fuchsberger,
Christian/0000-0002-5918-8947; Kim, Yongkang/0000-0002-8837-2620; Locke,
Adam/0000-0001-6227-198X
FU Agency for Science, Technology and Research in Singapore; Austrian
Science Fund (FWF) [J-3401]; MGH Research Scholars Award; NIDDK [R01
DK078616, K24 DK080140, DK098032]; NIH [U01 DK085526, U01 DK085501, U01
DK085524, U01 DK085545, U01 DK085584, U01 DK088389]; Wellcome Trust
[090367, 098381, 090532, 083948, 085475, WT098017, WT064890, WT090532];
MRC [G0601261]; EU (Framework 7) [HEALTH-F4-2007-201413]; Oxford
Biomedical Research Centre; National NIHR Bioresource; Uppsala
University; Uppsala University Hospital; Swedish Research Council;
Swedish Heart-Lung Foundation; Wellcome Trust Study Cohort Wellcome
Trust Functional Genomics Grant [072960/2/03/2]; Wellcome Trust Scottish
Health Informatics Programme (SHIP) [086113/Z/08/Z]; Wellcome Trust;
European Community's Seventh Framework Programme (FP7); National
Institute for Health Research (NIHR) BioResource Clinical Research
Facility and Biomedical Research Centre based at Guy's and St Thomas'
NHS Foundation Trust; King's College London; ERC Advanced Principal
Investigator award; Lundbeck Foundation (Lundbeck Foundation Centre for
Applied Medical Genomics in Personalised Disease Prediction, Prevention
and Care (LuCamp)); Danish Council for Independent Research; Novo
Nordisk Foundation; Academy of Finland [124243, 139635, 129293, 117844,
40758, 211497, 118590, 102318, 123885]; Finnish Heart Foundation;
Finnish Diabetes Foundation; Tekes [1510/31/06, 70103/06, 40058/07];
Commission of the European Community [HEALTH-F2-2007-201681]; US
National Institutes of Health [DK093757, DK072193, DK062370, 1Z01
HG000024]; Finnish Foundation for Cardiovascular Research; hospital
district of Pirkanmaa; hospital district of South Ostrobothnia; hospital
district of Central Finland; National Institute for Health and Welfare;
Finnish Diabetes Association; Ministry of Social Affairs and Health in
Finland; Commission of the European Communities; Directorate C-Public
Health [2004310]; Finland's Slottery Machine Association; Ministry of
Health and Social Affairs [5254]; Finnish Funding Agency for Technology
and Innovation [40058/07]; Nordic Centre of Excellence on 'Systems
biology in controlled dietary interventions and cohort studies, SYSDIET
[070014]; Finnish Diabetes Research Foundation; Yrjo Jahnsson Foundation
[56358]; Sigrid Juselius Foundation; Ministry of Education and Culture
of Finland [627]; Kuopio University Hospital; Finnish Heart Association;
Paivikki and Sakari Sohlberg Foundation; European Commission FP6
Integrated Project (EXGENESIS); City of Kuopio and Social Insurance
Institution of Finland [LSHM-CT-2004-005272]
FX HJN was supported by the Agency for Science, Technology and Research in
Singapore. CF was supported by the Austrian Science Fund (FWF) grant
J-3401. JCF was supported by MGH Research Scholars Award. APM is a
Wellcome Trust Senior Research Fellow in Basic and Biomedical Science.
JBM was supported by NIDDK R01 DK078616 and K24 DK080140. MIM is a
Wellcome Trust Senior Investigator (WT098381); and a National Institute
of Health Research Senior Investigator. CML is a Wellcome Trust Research
Career Development Fellow (086596/Z/08/Z). ALG is a Wellcome Trust
Senior Research Fellow in Basic and Biomedical Science (095010/Z/10/Z).
Funding for the GoT2D and T2D-GENES studies was provided by grants NIH
U01s DK085526, DK085501, DK085524, DK085545, and DK085584 (Multiethnic
Study of Type 2 Diabetes Genes) and DK088389 (Low-Pass Sequencing and
High-Density SNP Genotyping for Type 2 Diabetes). Analysis and
genotyping of the British UK cohorts was supported by Wellcome Trust
funding 090367, 098381, 090532, 083948, 085475, MRC (G0601261), EU
(Framework 7) HEALTH-F4-2007-201413, and NIDDK DK098032. The Oxford
Biobank is supported by the Oxford Biomedical Research Centre and part
of the National NIHR Bioresource. The PIVUS/ULSAM cohort was supported
by Wellcome Trust Grants WT098017, WT064890, WT090532, Uppsala
University, Uppsala University Hospital, the Swedish Research Council
and the Swedish Heart-Lung Foundation. GoDARTS study was funded by The
Wellcome Trust Study Cohort Wellcome Trust Functional Genomics Grant
(2004-2008) (Grant No: 072960/2/03/2) and The Wellcome Trust Scottish
Health Informatics Programme (SHIP) (2009-2012) (Grant No:
086113/Z/08/Z). TwinsUK study was funded by the Wellcome Trust; European
Community's Seventh Framework Programme (FP7/2007-2013). The study also
receives support from the National Institute for Health Research (NIHR)
BioResource Clinical Research Facility and Biomedical Research Centre
based at Guy's and St Thomas' NHS Foundation Trust and King's College
London. TDS is holder of an ERC Advanced Principal Investigator award.
The Danish studies were supported by the Lundbeck Foundation (Lundbeck
Foundation Centre for Applied Medical Genomics in Personalised Disease
Prediction, Prevention and Care (LuCamp); http://www.lucamp.org/) and
the Danish Council for Independent Research. The Novo Nordisk Foundation
Center for Basic Metabolic Research is an independent Research Center at
the University of Copenhagen, partially funded by an unrestricted
donation from the Novo Nordisk Foundation (http://www.metabol.ku.dk/).
The METSIM study was supported by the Academy of Finland (contract
124243), the Finnish Heart Foundation, the Finnish Diabetes Foundation,
Tekes (contract 1510/31/06), and the Commission of the European
Community (HEALTH-F2-2007-201681), and the US National Institutes of
Health grants DK093757, DK072193, DK062370, and 1Z01 HG000024. The
FUSION study was supported by DK093757, DK072193, DK062370, and 1Z01
HG000024. Genotyping of the METSIM and DPS studies was conducted at the
Genetic Resources Core Facility (GRCF) at the Johns Hopkins Institute of
Genetic Medicine. VS is funded by the Finnish Foundation for
Cardiovascular Research and the Academy of Finland (grant # 139635).;
The FIN-D2D 2007 study has been financially supported by the hospital
districts of Pirkanmaa, South Ostrobothnia, and Central Finland, the
Finnish National Public Health Institute (current National Institute for
Health and Welfare), the Finnish Diabetes Association, the Ministry of
Social Affairs and Health in Finland, the Academy of Finland (grant
number 129293), Commission of the European Communities, Directorate
C-Public Health (grant agreement no. 2004310) and Finland's Slottery
Machine Association. The DPS has been financially supported by grants
from the Academy of Finland (117844 and 40758, 211497, and 118590 (MU);
The EVO funding of the Kuopio University Hospital from Ministry of
Health and Social Affairs (5254), Finnish Funding Agency for Technology
and Innovation (40058/07), Nordic Centre of Excellence on 'Systems
biology in controlled dietary interventions and cohort studies, SYSDIET
(070014), The Finnish Diabetes Research Foundation, Yrjo Jahnsson
Foundation (56358), Sigrid Juselius Foundation and TEKES grants 70103/06
and 40058/07. The DR's EXTRA Study was supported by grants to RR by the
Ministry of Education and Culture of Finland (627; 2004-2011), Academy
of Finland (102318; 123885), Kuopio University Hospital, Finnish
Diabetes Association, Finnish Heart Association, Paivikki and Sakari
Sohlberg Foundation and by grants from European Commission FP6
Integrated Project (EXGENESIS); LSHM-CT-2004-005272, City of Kuopio and
Social Insurance Institution of Finland (4/26/2010). The Broad Genomics
Platform for genotyping of the FIN-D2D 2007, FINRISK 2007, DR'sEXTRA,
FUSION, and PPP studies. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 41
TC 21
Z9 21
U1 2
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD JAN
PY 2015
VL 11
IS 1
AR e1004876
DI 10.1371/journal.pgen.1004876
PG 25
WC Genetics & Heredity
SC Genetics & Heredity
GA CB0KL
UT WOS:000349314600012
PM 25625282
ER
PT J
AU Murdoch, JD
Gupta, AR
Sanders, SJ
Walker, MF
Keaney, J
Fernandez, TV
Murtha, MT
Anyanwu, S
Ober, GT
Raubeson, MJ
DiLullo, NM
Villa, N
Waqar, Z
Sullivan, C
Gonzalez, L
Willsey, AJ
Choe, SY
Neale, BM
Daly, MJ
State, MW
AF Murdoch, John D.
Gupta, Abha R.
Sanders, Stephan J.
Walker, Michael F.
Keaney, John
Fernandez, Thomas V.
Murtha, Michael T.
Anyanwu, Samuel
Ober, Gordon T.
Raubeson, Melanie J.
DiLullo, Nicholas M.
Villa, Natalie
Waqar, Zainabdul
Sullivan, Catherine
Gonzalez, Luis
Willsey, A. Jeremy
Choe, So-Yeon
Neale, Benjamin M.
Daly, Mark J.
State, Matthew W.
TI No Evidence for Association of Autism with Rare Heterozygous Point
Mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other
Contactin-Associated Proteins or Contactins
SO PLOS GENETICS
LA English
DT Article
ID SPECTRUM DISORDERS; RISK; GENE; LINKAGE; SPEECH; IDENTIFICATION;
VARIANTS; CONTACTIN-ASSOCIATED-PROTEIN-LIKE-2; DISRUPTION; EPILEPSY
AB Contactins and Contactin-Associated Proteins, and Contactin-Associated Protein-Like 2 (CNTNAP2) in particular, have been widely cited as autism risk genes based on findings from homozygosity mapping, molecular cytogenetics, copy number variation analyses, and both common and rare single nucleotide association studies. However, data specifically with regard to the contribution of heterozygous single nucleotide variants (SNVs) have been inconsistent. In an effort to clarify the role of rare point mutations in CNTNAP2 and related gene families, we have conducted targeted next-generation sequencing and evaluated existing sequence data in cohorts totaling 2704 cases and 2747 controls. We find no evidence for statistically significant association of rare heterozygous mutations in any of the CNTN or CNTNAP genes, including CNTNAP2, placing marked limits on the scale of their plausible contribution to risk.
C1 [Murdoch, John D.; Sanders, Stephan J.; Willsey, A. Jeremy; State, Matthew W.] Yale Univ, Dept Genet, New Haven, CT USA.
[Gupta, Abha R.; Fernandez, Thomas V.; Murtha, Michael T.; Anyanwu, Samuel; Ober, Gordon T.; Raubeson, Melanie J.; DiLullo, Nicholas M.; Waqar, Zainabdul; Sullivan, Catherine; Gonzalez, Luis; State, Matthew W.] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.
[Gupta, Abha R.] Yale Univ, Dept Pediat, New Haven, CT 06520 USA.
[Sanders, Stephan J.; Walker, Michael F.; Willsey, A. Jeremy; State, Matthew W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Keaney, John] Yale Coll, New Haven, CT USA.
[Villa, Natalie] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Choe, So-Yeon] Univ Calif Los Angeles, Sch Law, Los Angeles, CA 90024 USA.
[Neale, Benjamin M.; Daly, Mark J.] Broad Inst Harvard, Cambridge, MA USA.
[Neale, Benjamin M.; Daly, Mark J.] MIT, Cambridge, MA 02139 USA.
[Neale, Benjamin M.; Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Neale, Benjamin M.; Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Murdoch, JD (reprint author), European Neurosci Inst, Gottingen, Germany.
EM matthew.state@ucsf.edu
RI Fernandez, Thomas/D-4295-2009;
OI Fernandez, Thomas/0000-0003-0830-022X; Sanders,
Stephan/0000-0001-9112-5148
FU [R01 MH081754]; [RC2 MH089956]; [K08MH087639]
FX This work was supported by grants R01 MH081754 and RC2 MH089956 to MWS,
and by K08MH087639 to ARG. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 42
TC 15
Z9 15
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7390
EI 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD JAN
PY 2015
VL 11
IS 1
AR e1004852
DI 10.1371/journal.pgen.1004852
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA CB0KL
UT WOS:000349314600008
PM 25621974
ER
PT J
AU Wood, NE
Rosasco, ML
Suris, AM
Spring, JD
Marin, MF
Lasko, NB
Goetz, JM
Fischer, AM
Orr, SP
Pitman, RK
AF Wood, Nellie E.
Rosasco, Maria L.
Suris, Alina M.
Spring, Justin D.
Marin, Marie-France
Lasko, Natasha B.
Goetz, Jared M.
Fischer, Avital M.
Orr, Scott P.
Pitman, Roger K.
TI Pharmacological blockade of memory reconsolidation in posttraumatic
stress disorder: Three negative psychophysiological studies
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Stress disorders; Post-traumatic; Propranolol; Mifepristone;
Cycloserine; Imagery; Psychophysiology (all MeSH terms)
ID ADMINISTERED PTSD SCALE; FEAR MEMORY; GLUCOCORTICOID-RECEPTORS;
RETRIEVAL; AMYGDALA; CONSOLIDATION; REACTIVATION; PROPRANOLOL; IMAGERY
AB Posttraumatic stress disorder (PTSD) may involve over-consolidated emotional memories of the traumatic event. Reactivation (RP) can return a memory to an unstable state, from which it must be restabilized (reconsolidated) if it is to persist. Pharmacological agents administered while the memory is unstable have been shown to impair reconsolidation. The N-methyl-D-aspartate (NMDA) partial agonist D-cycloserine (DCS) may promote memory destabilization. In the three studies reported here, we investigated whether the beta-adrenergic blocker propranolol or the glucocorticoid (GR) antagonist mifepristone, given at the time of traumatic memory reactivation, could reduce PTSD symptoms and physiological responding during subsequent traumatic imagery. Individuals with PTSD were randomized as follows: Study One: propranolol with memory reactivation (n=10) or without reactivation (n=8); Study Two: reactivation mifepristone (n=13), non-reactivation (NRP) mifepristone (n=15), or double placebo (PL) (0=15); Study Three: reactivation mifepristone plus D-cycloserine (n=16), or two placebos (n=15). Subjects underwent memory retrieval by describing their traumatic event. A week later they engaged in script-driven traumatic mental imagery, while heart rate (HR), skin conductance (SC), and facial electromyogram (EMG) responses were measured. There were no significant group differences in physiological responsivity or change in PTSD symptoms in any of the studies. These results do not support successful blockade of reconsolidation of traumatic memories in PTSD. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Wood, Nellie E.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Rosasco, Maria L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Suris, Alina M.] Univ Texas SW Med Ctr Dallas, VA North Texas Hlth Care Syst, Dallas, TX 75390 USA.
[Suris, Alina M.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Spring, Justin D.] Columbia Univ Coll Phys & Surg, New York, NY USA.
[Marin, Marie-France; Lasko, Natasha B.; Goetz, Jared M.; Orr, Scott P.; Pitman, Roger K.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02129 USA.
[Marin, Marie-France; Lasko, Natasha B.; Goetz, Jared M.; Orr, Scott P.; Pitman, Roger K.] Harvard Univ, Sch Med, Boston, MA 02129 USA.
[Fischer, Avital M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Pitman, RK (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 120 Second Ave, Boston, MA 02129 USA.
EM roger_pitman@hms.harvard.edu
FU U.S. Army [W81XWH-08-2-0126]
FX This study was funded by U.S. Army grant # W81XWH-08-2-0126.
NR 34
TC 30
Z9 30
U1 14
U2 40
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD JAN
PY 2015
VL 225
IS 1-2
BP 31
EP 39
DI 10.1016/j.psychres.2014.09.005
PG 9
WC Psychiatry
SC Psychiatry
GA CA5LJ
UT WOS:000348949600003
PM 25441015
ER
PT J
AU Bhuvaneswar, C
Colon, J
Matthews, J
Burke, B
Stern, TA
AF Bhuvaneswar, Chaya
Colon, Jesus
Matthews, John
Burke, Bethany
Stern, Theodore A.
TI Psychiatric Care of Deaf Patients in the General Hospital: An Overview
SO PSYCHOSOMATICS
LA English
DT Review
ID HEARING INPATIENTS; HEALTH; LANGUAGE; ADULTS; PREVALENCE; ISSUES; BRAIN;
ABUSE
AB Background: While the number of Deaf and hard-alhearing patients worldwide is estimated at six hundred million, few specialized psychiatric services or training resources exist to support the provision of mental health care to this population. This presents a particularly acute problem in the general hospital, where the consultant psychiatrist is likely to be confronted with the challenges of providing comprehensive psychiatric evaluation, diagnosis and treatment to patients with whom he or she may have limited experience or confidence. Method: We review critical considerations in the work-up differential diagnosis, and management of commonly-presenting psychiatric disorders among Deaf patients in the general hospital setting.
C1 [Bhuvaneswar, Chaya] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA.
Univ Massachusetts, Worcester Recovery Ctr, Worcester, MA 01655 USA.
[Matthews, John; Stern, Theodore A.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Bhuvaneswar, C (reprint author), Univ Massachusetts, Sch Med, Dept Psychiat, 55 Lake Ave, Worcester, MA 01655 USA.
EM chayab77@gmail.com
NR 47
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD JAN-FEB
PY 2015
VL 56
IS 1
BP 1
EP 11
PG 11
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA AZ9CY
UT WOS:000348510300001
PM 25619669
ER
PT J
AU Brown, TM
AF Brown, Thomas M.
TI Neuropsychiatric Scurvy
SO PSYCHOSOMATICS
LA English
DT Review
ID ACETYL-L-CARNITINE; VITAMIN-C-DEFICIENCY; ASCORBIC ACID DEFICIENCY;
PARKINSONS-DISEASE; CATALYTIC METALS; BRAIN; STRIATUM; OXYGEN;
PREVALENCE; DOPAMINE
AB Background: Scurvy is a disease with well-known peripheral symptoms, such as bleeding and pain. Method: The clinical and historical evidence for a distinct form of scurvy affecting the central nervous system, called neuropsychiatric scurvy, is reviewed. Pathophysiologic factors are described, as well as its diagnosis and management.
C1 Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA.
RP Brown, TM (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, 7400 Merton Minton Blvd, San Antonio, TX 78229 USA.
EM thomas.brown5@va.gov
NR 61
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD JAN-FEB
PY 2015
VL 56
IS 1
BP 12
EP 20
PG 9
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA AZ9CY
UT WOS:000348510300002
PM 25619670
ER
PT J
AU Rustad, JK
Stern, TA
Prabhakar, M
Musselman, D
AF Rustad, James K.
Stern, Theodore A.
Prabhakar, Maithri
Musselman, Dominique
TI Risk Factors for Alcohol Relapse Following Orthotopic Liver
Transplantation: A Systematic Review
SO PSYCHOSOMATICS
LA English
DT Review
ID SCORING SYSTEM; UNITED-STATES; DISEASE; PREDICTORS; ABSTINENCE;
HEPATITIS; DRINKING; RECIDIVISM; DEPENDENCE; CIRRHOSIS
AB Background: Each year, 5000-6000 individuals undergo orthotopic liver transplantation (OLT) in the United States, and of these, nearly 18N have alcoholic liver disease. Relapse to alcohol occurs in more than 40% of patients with OLT for alcoholic liver disease. Objectives: We sought to identify factors that predict relapse to alcohol or medication nonadherence following OLT in patients with alcoholic liver disease and to review what randomized clinical interventions have addressed these factors following OLT Our hypothesis was that there would be factors before and after OLT that predict relapse to alcohol following OLT, and that these, if targeted, might improve sobriety and associated outcomes of adherence with medications and appointments. Methods: We performed a review (focusing on articles published since 2004) with Pub Med and MEDLINE searches using the following search terms: liver transplantation, recidivism, alcohol relapse, and predictors of alcohol relapse. We supplemented the online searches with manual reviews' of article reference lists and selected relevant articles far farther review by author consensus. Results: In largely white populations, prospective studies document that shorter length of pretransplantation sobriety is a significant predictor of time to first drink and time to binge use. Presence of psychiatric comorbidity, high score on standardized High-risk Alcoholism Relapse Scale, and diagnosis of Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) alcohol dependence are predictive of posttran,splantation alcohol relapse, Pretransplantation alcohol use history variables (e.g., family history of alcoholism) reliably discriminate between complete abstainers' and those who drink, while medical and psychosocial characteristics at early post liver transplantation period (e.g., More bodily pain) maximally discriminate patterns of alcohol use Alcoholic individuals with early-onset, rapidly accelerating moderate use and early-onset, continuously increasing heavy use have more than double the prevalence of steatohepatitis or rejection on biopsy and graft failure and more,frequent mortality resulting from recurrent alcoholic liver disease than late-onset (i.e., peak of heaviest drinking at 6 y posttransplantation) alcohol users do. Fortunately, pretransplantation screening combined with a structured pretransplantation management program and a 12-step program attendance reduced recidivism. No randomized clinical trials have been performed that target pretransplantation risk factors in individuals with alcoholic liver disease before or after OLT to improve post-OLT outcomes. Conclusions: Recent research findings suggest that screening can reveal individuals who are vulnerable to alcohol relapse and targeted intervention can prevent their relapse to alcohol. Based on existing addiction treatments (e.g., relapse prevention plan construction), randomized clinical trials tailored to post-OLT patients should be conducted to improve their survival and quality of life.
C1 [Rustad, James K.] Univ S Florida, Morsani Coll Med, Dept Psychiat & Behav Neurosci, Tampa, FL USA.
[Stern, Theodore A.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Prabhakar, Maithri] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Epidemiol, Miami, FL 33199 USA.
[Musselman, Dominique] Univ Miami, Leonard H Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL USA.
RP Rustad, JK (reprint author), 3515 E Fletcher Ave, Tampa, FL 33613 USA.
EM jkrustad@health.usf.edu
NR 70
TC 5
Z9 5
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD JAN-FEB
PY 2015
VL 56
IS 1
BP 21
EP 35
PG 15
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA AZ9CY
UT WOS:000348510300003
PM 25619671
ER
PT J
AU Penzkofer, T
Tuncali, K
Fedorov, A
Song, SE
Tokuda, J
Fennessy, FM
Vangel, MG
Kibel, AS
Mulkern, RV
Wells, WM
Hata, N
Tempany, CMC
AF Penzkofer, Tobias
Tuncali, Kemal
Fedorov, Andriy
Song, Sang-Eun
Tokuda, Junichi
Fennessy, Fiona M.
Vangel, Mark G.
Kibel, Adam S.
Mulkern, Robert V.
Wells, William M.
Hata, Nobuhiko
Tempany, Clare M. C.
TI Transperineal In-Bore 3-T MR Imaging-guided Prostate Biopsy: A
Prospective Clinical Observational Study
SO RADIOLOGY
LA English
DT Article
ID TRANSRECTAL ULTRASOUND BIOPSY; CANCER-DETECTION; RADICAL PROSTATECTOMY;
FUSION; REGISTRATION; FEASIBILITY; VALIDATION; SOFTWARE; SYSTEM; FUTURE
AB Purpose: To determine the detection rate, clinical relevance, Gleason grade, and location of prostate cancer (PCa) diagnosed with and the safety of an in-bore transperineal 3-T magnetic resonance (MR) imaging-guided prostate biopsy in a clinically heterogeneous patient population.
Materials and Methods: This prospective retrospectively analyzed study was HIPAA compliant and institutional review board approved, and informed consent was obtained. Eighty-seven men (mean age, 66.2 years +/- 6.9) underwent multiparametric endorectal prostate MR imaging at 3 T and transperineal MR imaging-guided biopsy. Three subgroups of patients with at least one lesion suspicious for cancer were included: men with no prior PCa diagnosis, men with PCa who were undergoing active surveillance, and men with treated PCa and suspected recurrence. Exclusion criteria were prior prostatectomy and/or contraindication to 3-T MR imaging. The transperineal MR imaging-guided biopsy was performed in a 70-cm wide-bore 3-T device. Overall patient biopsy outcomes, cancer detection rates, Gleason grade, and location for each subgroup were evaluated and statistically compared by using x(2) and one-way analysis of variance followed by Tukey honestly significant difference post hoc comparisons.
Results: Ninety biopsy procedures were performed with no serious adverse events, with a mean of 3.7 targets sampled per gland. Cancer was detected in 51 (56.7%) men: 48.1% (25 of 52) with no prior PCa, 61.5% (eight of 13) under active surveillance, and 72.0% (18 of 25) in whom recurrence was suspected. Gleason pattern 4 or higher was diagnosed in 78.1% (25 of 32) in the no prior PCa and active surveillance groups. Gleason scores were not assigned in the suspected recurrence group. MR targets located in the anterior prostate had the highest cancer yield (40 of 64, 62.5%) compared with those for the other parts of the prostate (P < .001).
Conclusion: In-bore 3-T transperineal MR imaging-guided biopsy, with a mean of 3.7 targets per gland, allowed detection of many clinically relevant cancers, many of which were located anteriorly. (C) RSNA, 2014
C1 [Penzkofer, Tobias; Tuncali, Kemal; Fedorov, Andriy; Song, Sang-Eun; Tokuda, Junichi; Fennessy, Fiona M.; Mulkern, Robert V.; Wells, William M.; Hata, Nobuhiko; Tempany, Clare M. C.] Brigham & Womens Hosp, Dept Radiol, Div MRI, Boston, MA 02115 USA.
[Kibel, Adam S.] Brigham & Womens Hosp, Div Urol, Boston, MA 02115 USA.
[Penzkofer, Tobias] RWTH Aachen Univ Hosp, Dept Diagnost & Intervent Radiol, Aachen, Germany.
[Vangel, Mark G.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Fennessy, Fiona M.] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA.
[Mulkern, Robert V.] Childrens Hosp, Dept Radiol, Boston, MA 02115 USA.
RP Tempany, CMC (reprint author), Brigham & Womens Hosp, Dept Radiol, Div MRI, 75 Francis St, Boston, MA 02115 USA.
EM ctempanyafdhal@partners.org
OI Fedorov, Andrey/0000-0003-4806-9413
FU National Institutes of Health [R01CA111288, P41RR019703, P41EB015898,
P01CA067165, U01CA151261, U54EB005149]
FX This research was supported by the National Institutes of Health (grants
R01CA111288, P41RR019703, P41EB015898, P01CA067165, U01CA151261, and
U54EB005149).
NR 49
TC 18
Z9 18
U1 0
U2 5
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JAN
PY 2015
VL 274
IS 1
BP 170
EP 180
DI 10.1148/radiol.14140221
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CA1WK
UT WOS:000348699400021
PM 25222067
ER
PT J
AU Ginat, DT
Moonis, G
AF Ginat, Daniel Thomas
Moonis, Gul
TI CASE 217
SO RADIOLOGY
LA English
DT Article
AB History A 15-year-old boy presented to the emergency department with intractable epistaxis. He had a prior history of epistaxis typically lasting 5-10 minutes and consisting of up to four episodes per year for several years. Otherwise, the patient had no relevant medical history, and he denied having prior trauma, surgery, bleeding diathesis, fever, chills, or vision changes. Likewise, the patient had no relevant family history. The patient's coagulation panel was unremarkable and included a prothrombin time of 15.4 seconds, an international normalized ratio of 1.2, and a partial thromboplastin time of 29.3 seconds.
A thin-section unenhanced sinus computed tomography (CT) examination was performed (Fig 1). In addition, magnetic resonance (MR) imaging of the sinuses without and with intravenous contrast material was performed (Fig 2).
The epistaxis was treated with nasal packing, which prevented further bleeding. Biopsy of the lesion was subsequently performed.
C1 [Ginat, Daniel Thomas] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA.
[Moonis, Gul] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
[Moonis, Gul] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Ginat, DT (reprint author), Univ Chicago, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM ginatd01@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JAN
PY 2015
VL 274
IS 1
BP 296
EP 297
DI 10.1148/radiol.14131965
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CA1WK
UT WOS:000348699400034
PM 25531482
ER
PT J
AU Ng, MC
Gaspard, N
Cole, AJ
Hoch, DB
Cash, SS
Bianchi, M
O'Rourke, DA
Rosenthal, ES
Chu, CJ
Westover, MB
AF Ng, Marcus C.
Gaspard, Nicolas
Cole, Andrew J.
Hoch, Daniel B.
Cash, Sydney S.
Bianchi, Matt
O'Rourke, Deirdre A.
Rosenthal, Eric S.
Chu, Catherine J.
Westover, M. Brandon
TI The standardization debate: A conflation trap in critical care
electroencephalography
SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
LA English
DT Review
DE Electroencephalography Critical care; Intensive care; Long-term
monitoring; Standardization; Nomenclature
ID NONCONVULSIVE STATUS EPILEPTICUS; TRIPHASIC WAVES; EEG PATTERNS;
THERAPEUTIC HYPOTHERMIA; SEIZURES DAMAGE; CARDIAC-ARREST; ILL;
TERMINOLOGY; BRAIN; ENCEPHALOPATHY
AB Purpose: Persistent uncertainty over the clinical significance of various pathological continuous electroencephalography (cEEG) findings in the intensive care unit (ICU) has prompted efforts to standardize ICU cEEG terminology and an ensuing debate. We set out to understand the reasons for, and a satisfactory resolution to, this debate.
Method: We review the positions for and against standardization, and examine their deeper philosophical basis.
Results: We find that the positions for and against standardization are not fundamentally irreconcilable. Rather, both positions stem from conflating the three cardinal steps in the classic approach to EEG, which we term "description", "interpretation", and "prescription". Using real-world examples we show how this conflation yields muddled clinical reasoning and unproductive debate among electroencephalographers that is translated into confusion among treating clinicians. We propose a middle way that judiciously uses both standardized terminology and clinical reasoning to disentangle these critical steps and apply them in proper sequence.
Conclusion: The systematic approach to ICU cEEG findings presented herein not only resolves the standardization debate but also clarifies clinical reasoning by helping electroencephalographers assign appropriate weights to cEEG findings in the face of uncertainty. (C) 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
C1 [Ng, Marcus C.] Univ Manitoba, Dept Internal Med, Hlth Sci Ctr, Neurol Sect, Winnipeg, MB, Canada.
[Gaspard, Nicolas] Yale Univ, Sch Med, Dept Neurol, Comprehens Epilepsy Ctr, New Haven, CT 06510 USA.
[Cole, Andrew J.; Hoch, Daniel B.; Cash, Sydney S.; Bianchi, Matt; O'Rourke, Deirdre A.; Rosenthal, Eric S.; Chu, Catherine J.; Westover, M. Brandon] Harvard Univ, Sch Med, Dept Neurol, Epilepsy Serv,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Westover, MB (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM mng2@hsc.mb.ca; nicolas.gaspard@yale.edu; ajcole1@mgh.harvard.edu;
dhoch@mgh.harvard.edu; scash@mgh.harvard.edu; mtbianchi@mgh.harvard.edu;
daorourke@mgh.harvard.edu; erosenthal@mgh.harvard.edu;
cjchu@mgh.harvard.edu; mwestover@mgh.harvard.edu
OI Rosenthal, Eric/0000-0003-3900-356X
FU NINDS NIH HHS [K12 NS066225]
NR 33
TC 1
Z9 1
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1059-1311
EI 1532-2688
J9 SEIZURE-EUR J EPILEP
JI Seizure
PD JAN
PY 2015
VL 24
BP 52
EP 58
DI 10.1016/j.seizure.2014.09.017
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CA5OK
UT WOS:000348957500010
PM 25457454
ER
PT J
AU Tsai, AC
Pierce, CM
Papachristos, AV
AF Tsai, Alexander C.
Pierce, Chester M.
Papachristos, Andrew V.
TI From social networks to health: Durkheim after the turn of the
millennium Introduction
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Editorial Material
ID INTEGRATION; MORTALITY; SPREAD; TIES; INTERVENTIONS; EPIDEMIOLOGY;
ADOLESCENTS; CONTAGION; BEHAVIOR; SUPPORT
C1 [Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Pierce, Chester M.] Massachusetts Gen Hosp, Div Global Psychiat, Boston, MA 02114 USA.
[Pierce, Chester M.] Harvard Univ, Sch Med, Boston, MA USA.
[Pierce, Chester M.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Papachristos, Andrew V.] Yale Univ, Dept Sociol, New Haven, CT USA.
RP Tsai, AC (reprint author), Massachusetts Gen Hosp, Ctr Global Hlth, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM actsai@partners.org
OI Tsai, Alexander/0000-0001-6397-7917
FU NIMH NIH HHS [K23 MH096620]
NR 70
TC 4
Z9 4
U1 9
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD JAN
PY 2015
VL 125
SI SI
BP 1
EP 7
DI 10.1016/j.socscimed.2014.10.045
PG 7
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA CA5LI
UT WOS:000348949500001
PM 25695107
ER
PT J
AU Pachucki, MC
Ozer, EJ
Barrat, A
Cattuto, C
AF Pachucki, Mark C.
Ozer, Emily J.
Barrat, Alain
Cattuto, Ciro
TI Mental health and social networks in early adolescence: A dynamic study
of objectively-measured social interaction behaviors
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE Social networks; Self-esteem; Depression; Early adolescence; Stochastic
actor-based modeling
ID DEPRESSIVE SYMPTOMS; FRIENDSHIP NETWORKS; SELF-ESTEEM; PEER CONTAGION;
AMERICAN ADOLESCENTS; PHYSICAL-ACTIVITY; SCHOOL; MECHANISMS;
SOCIALIZATION; EXPERIENCE
AB How are social interaction dynamics associated with mental health during early stages of adolescence? The goal of this study is to objectively measure social interactions and evaluate the roles that multiple aspects of the social environment such as physical activity and food choice may jointly play in shaping the structure of children's relationships and their mental health. The data in this study are drawn from a longitudinal network-behavior study conducted in 2012 at a private K-8 school in an urban setting in California. We recruited a highly complete network sample of sixth-graders (n = 40, 91% of grade, mean age = 12.3), and examined how two measures of distressed mental health (self-esteem and depressive symptoms) are positionally distributed in an early adolescent interaction network. We ascertained how distressed mental health shapes the structure of relationships over a three-month period, adjusting for relevant dimensions of the social environment. Cross-sectional analyses of interaction networks revealed that self-esteem and depressive symptoms are differentially stratified by gender. Specifically, girls with more depressive symptoms have interactions consistent with social inhibition, while boys' interactions suggest robustness to depressive symptoms. Girls higher in self-esteem tended towards greater sociability. Longitudinal network behavior models indicate that gender similarity and perceived popularity are influential in the formation of social ties. Greater school connectedness predicts the development of self-esteem, though social ties contribute to more self-esteem improvement among students who identify as European-American. Cross-sectional evidence shows associations between distressed mental health and students' network peers. However, there is no evidence that connected students' mental health status becomes more similar in their over time because of their network interactions. These findings suggest that mental health during early adolescence may be less subject to mechanisms of social influence than network research in even slightly older adolescents currently indicates. (C) 2014 Published by Elsevier Ltd.
C1 [Pachucki, Mark C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gen Acad Pediat Massachusetts Gen Hosp Children,M, Boston, MA 02114 USA.
[Ozer, Emily J.] Univ Calif Berkeley, Sch Publ Hlth, Dept Community Hlth & Human Dev, Berkeley, CA 94720 USA.
[Barrat, Alain] Aix Marseille Univ, Univ Toulon, CNRS, CPT,UMR 7332, F-13288 Marseille, France.
[Barrat, Alain; Cattuto, Ciro] ISI Fdn, Data Sci Lab, Turin, Italy.
RP Pachucki, MC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gen Acad Pediat Massachusetts Gen Hosp Children,M, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM mpachucki@mgh.harvard.org
RI Cattuto, Ciro/K-6133-2016
OI Cattuto, Ciro/0000-0001-9526-4364
FU Robert Wood Johnson Foundation (RWJF) Health & Society Scholars program;
RWJF pilot grant
FX This work was conducted while MCP was in the Robert Wood Johnson
Foundation (RWJF) Health & Society Scholars program, and the project
benefited from an RWJF pilot grant. There are no reported conflicts of
interest. The Committee on Human Subjects at UC Berkeley approved the
original study protocol.
NR 73
TC 7
Z9 7
U1 4
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD JAN
PY 2015
VL 125
SI SI
BP 40
EP 50
DI 10.1016/j.socscimed.2014.04.015
PG 11
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA CA5LI
UT WOS:000348949500005
PM 24797692
ER
PT J
AU Dzik, S
Murphy, MF
AF Dzik, Sunny
Murphy, Michael F.
TI Clinical Guidelines in Transfusion Medicine
SO TRANSFUSION MEDICINE REVIEWS
LA English
DT Editorial Material
C1 [Dzik, Sunny] J 224 Massachusetts Gen Hosp 55, Blood Transfus Serv, Boston, MA 02114 USA.
RP Dzik, S (reprint author), J 224 Massachusetts Gen Hosp 55, Blood Transfus Serv, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0887-7963
EI 1532-9496
J9 TRANSFUS MED REV
JI Transf. Med. Rev.
PD JAN
PY 2015
VL 29
IS 1
BP 1
EP 2
DI 10.1016/j.tmrv.2014.11.005
PG 2
WC Hematology
SC Hematology
GA CA5TV
UT WOS:000348971600001
PM 25542643
ER
PT J
AU Israeli, M
Pollack, MS
Shaut, CAE
Halpin, A
DiPaola, NR
Youngs, D
Saidman, SL
AF Israeli, Moshe
Pollack, Marilyn S.
Shaut, Carley A. E.
Halpin, Anne
DiPaola, Nicholas R.
Youngs, Danny
Saidman, Susan L.
CA ASHI Proficiency Testing Program
TI Concordance and discordance in anti-HLA antibody testing
SO TRANSPLANT IMMUNOLOGY
LA English
DT Article
DE Antibodies; ASHI; Consensus; HLA; Proficiency testing; Luminex
ID HUMAN-LEUKOCYTE ANTIGEN; DONOR-SPECIFIC ANTIBODIES;
KIDNEY-TRANSPLANTATION; CLINICAL-RELEVANCE; HEART-TRANSPLANTATION;
MEDIATED REJECTION; GRAFT LOSS; ASSAY; LUMINEX(R)
AB Background: Correct identification of the specificity of antibodies directed against HLA using single antigen Luminex beads (SALB) is essential in current HLA laboratory practice for transplantation. The aim of this study was to investigate the magnitude of concordance and discordance among laboratories in testing for anti-HLA antibodies using SALB.
Method: 35 sera were distributed by the ASHI Proficiency Testing Program to HLA laboratories worldwide. We analyzed 4335 test results submitted between April 2010 and April 2013 by participating laboratories.
Results: SALB was used by approximately 94% of the participating laboratories, yet concordant assignment of antibody specificity was imperfect. For each serum, the assignment of an average of 10 antibody specificities was discordant. Disagreement was observed for antibodies directed against common as well as uncommon antigens. The assignment of an average of 15 antibody specificities in each "positive" serum appeared to be influenced by vendor-dependent causes. Inter-vendor concordance was lower than intra-vendor concordance, indicating that vendor dependent factors may be a central cause for disagreement.
Conclusions: Our study illustrates the prevalence of concordance and discordance, also affected by unpremeditated causes, in reporting SALB antibody results. Insufficient concordance and standardization in antibody testing may have practical implications for organ allocation and organ sharing programs. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Israeli, Moshe] Rabin Med Ctr, Tissue Typing Lab, IL-49100 Petah Tiqwa, Israel.
[Israeli, Moshe] Leiden Univ, Med Ctr, Dept lmmunohematol & Blood Transfus, Leiden, Netherlands.
[Pollack, Marilyn S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Shaut, Carley A. E.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA.
[Halpin, Anne] Univ Alberta Hosp, Histocompatibil Lab, Edmonton, AB T6G 2B7, Canada.
[DiPaola, Nicholas R.] Ohio State Univ, Wexner Med Ctr, Clin Histocompatibil Lab, Columbus, OH 43210 USA.
[Youngs, Danny] Puget Sound Blood Ctr, Seattle, WA 98104 USA.
[Saidman, Susan L.] Massachusetts Gen Hosp, Histocompatibil Lab, Boston, MA 02114 USA.
RP Israeli, M (reprint author), Leiden Univ, Med Ctr, Dept lmmunohematol & Blood Transfus, Leiden, Netherlands.
EM israelimoshe@yahoo.com
OI Israeli, Moshe/0000-0002-3776-8692
NR 34
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0966-3274
EI 2210-3384
J9 TRANSPL IMMUNOL
JI Transpl. Immunol.
PD JAN
PY 2015
VL 32
IS 1
BP 1
EP 8
DI 10.1016/j.trim.2014.10.003
PG 8
WC Immunology; Transplantation
SC Immunology; Transplantation
GA CA4RT
UT WOS:000348892900001
PM 25460810
ER
PT J
AU Chait, SR
Thompson, JK
Jacobsen, PB
AF Chait, Sari R.
Thompson, J. Kevin
Jacobsen, Paul B.
TI Preliminary development and evaluation of an appearance-based dissonance
induction intervention for reducing UV exposure
SO BODY IMAGE
LA English
DT Article
DE Appearance-based tanning interventions; Cognitive dissonance; Tanning;
UV exposure; Skin cancer
ID EATING-DISORDER PREVENTION; RANDOMIZED EFFICACY TRIAL; SUN PROTECTION;
YOUNG-WOMEN; MOTIVATION; PROGRAMS; VALIDITY
AB The current study examined the feasibility of an appearance-based dissonance induction approach for the modification of tanning and sunscreen use behaviors. Undergraduate female students were randomized to: a healthy lifestyle condition, an appearance-based dissonance condition, or an appearance-based psychoeducation condition. Reports of tanning and sunscreen use were collected immediately before and 1 month following intervention (N=225). Relative to the healthy lifestyle condition, participants in the dissonance condition reported a significant reduction in daily hours spent tanning. Additionally, sunscreen use on the body decreased significantly for the healthy lifestyle group, but did not change for the dissonance group. The psychoeducation condition did not differ from the healthy lifestyle condition on any measure. These findings should encourage additional research into the use of dissonance induction as an appearance-based strategy for promoting reductions in UV exposure. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Chait, Sari R.] VA Boston Healthcare Syst, Boston, MA USA.
[Chait, Sari R.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Thompson, J. Kevin] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA.
[Jacobsen, Paul B.] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA.
[Jacobsen, Paul B.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA.
RP Thompson, JK (reprint author), Univ S Florida, Dept Psychol, Tampa, FL 33620 USA.
EM JKThompson@usf.edu
NR 26
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1740-1445
EI 1873-6807
J9 BODY IMAGE
JI Body Image
PD JAN
PY 2015
VL 12
BP 68
EP 72
DI 10.1016/j.bodyim.2014.09.004
PG 5
WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary
SC Psychology; Psychiatry
GA CA5NG
UT WOS:000348954500009
PM 25462883
ER
PT J
AU Zheng, BH
Zhu, SY
Wu, X
AF Zheng, Baohui
Zhu, Shunying
Wu, Xu
TI Clickable Analogue of Cerulenin as Chemical Probe to Explore Protein
Palmitoylation
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID MAMMALIAN-CELLS; ACYLTRANSFERASES; 2-BROMOPALMITATE; IDENTIFICATION;
TRAFFICKING; STABILITY; CANCER; YEAST
AB Dynamic palmitoylation is an important post-translational modification regulating protein localization, trafficking, and signaling activities. The Asp-His-His-Cys (DHHC) domain containing enzymes are evolutionarily conserved palmitoyl acyltransferases (PATs) mediating diverse protein S-palmitoylation. Cerulenin is a natural product inhibitor of fatty acid biosynthesis and protein palmitoylation, through irreversible alkylation of the cysteine residues in the enzymes. Here, we report the synthesis and characterization of a clickable and long alkyl chain analogue of cerulenin as a chemical probe to investigate its cellular targets and to label and profile PATs in vitro and in live cells. Our results showed that the probe could stably label the DHHC-family PATs and enable mass spectrometry studies of PATs and other target proteins in the cellular proteome. Such probe provides a new chemical tool to dissect the functions of palmitoylating enzymes in cell signaling and diseases and reveals new cellular targets of the natural product cerulenin.
C1 [Zheng, Baohui; Zhu, Shunying; Wu, Xu] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
RP Wu, X (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM xwu@cbrc2.mgh.harvard.edu
RI zheng, baohui/O-6828-2014
OI zheng, baohui/0000-0002-3272-843X
FU Stewart Rahr-MRA (Melanoma Research Alliance) Young Investigator Award;
Department of Defense (DoD) Career Development Award [W81XWH-13-1-0203];
MGH Institutional fund
FX This work is supported by Stewart Rahr-MRA (Melanoma Research Alliance)
Young Investigator Award, Department of Defense (DoD) Career Development
Award (W81XWH-13-1-0203) and MGH Institutional fund (to X. W.). We thank
Drs. M. DeRan, Q. Wu, and M. Fukata for reagents and discussions, and
the Taplin Mass Spec Facility at Harvard Medical School for proteomic
studies.
NR 36
TC 6
Z9 7
U1 1
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD JAN
PY 2015
VL 10
IS 1
BP 115
EP 121
DI 10.1021/cb500758s
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AZ6LU
UT WOS:000348332100011
PM 25322207
ER
PT J
AU Huang, ZF
Tan, L
Wang, HY
Liu, Y
Blais, S
Deng, JJ
Neubert, TA
Gray, NS
Li, XK
Mohammadi, M
AF Huang, Zhifeng
Tan, Li
Wang, Huiyan
Liu, Yang
Blais, Steven
Deng, Jingjing
Neubert, Thomas A.
Gray, Nathanael S.
Li, Xiaokun
Mohammadi, Moosa
TI DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable
of Overcoming Gate-Keeper Mutations in FGF Receptors
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE DOMAIN; ACTIVATING MUTATIONS;
PONATINIB AP24534; MULTIPLE-MYELOMA; BREAST-CANCER; PD173074; DESIGN;
IDENTIFICATION; CONFORMATIONS
AB Drug-resistance acquisition through kinase gate-keeper mutations is a major hurdle in the clinic. Here, we determined the first crystal structures of the human FGFR4 kinase domain (FGFR4K) alone and complexed with ponatinib, a promiscuous type-2 (DFG-out) kinase inhibitor, and an oncogenic FGFR4K harboring the V550L gate-keeper mutation bound to FIIN-2, a new type-1 irreversible inhibitor. Remarkably, like ponatinib, FIIN-2 also binds in the DFG-out mode despite lacking a functional group necessary to occupy the pocket vacated upon the DFG-out flip. Structural analysis reveals that the covalent bond between FIIN-2 and a cysteine, uniquely present in the glycine-rich loop of FGFR kinases, facilitates the DFG-out conformation, which together with the internal flexibility of FIIN-2 enables FIIN-2 to avoid the steric clash with the gate-keeper mutation that causes the ponatinib resistance. The structural data provide a blueprint for the development of next generation anticancer inhibitors through combining the salient inhibitory mechanisms of ponatinib and FIIN-2.
C1 [Huang, Zhifeng; Wang, Huiyan; Li, Xiaokun] Wenzhou Med Univ, Sch Pharm, Wenzhou 325035, Zhejiang, Peoples R China.
[Huang, Zhifeng; Wang, Huiyan; Liu, Yang; Neubert, Thomas A.; Mohammadi, Moosa] NYU, Sch Med, Skirball Inst, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.
[Blais, Steven; Deng, Jingjing; Neubert, Thomas A.] NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med, New York, NY 10016 USA.
[Tan, Li; Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
RP Li, XK (reprint author), Wenzhou Med Univ, Sch Pharm, Wenzhou 325035, Zhejiang, Peoples R China.
EM xiaokunli@163.net; moosa.mohammadi@nyumc.org
OI Mohammadi, Moosa/0000-0003-2434-9437
FU U.S. National Institutes of Health NIDCR [DE13686, CA130876-05]; DF/HCC
Lung Spore Developmental Project [CA016087]; National Institutes of
Health [S10RR027990]; Natural Science Foundation of China [31270789,
81102486, 81273421]
FX The authors are thankful to R. Goetz and A. Belov for critically reading
the manuscript and making thoughtful suggestions. This work was
supported by the U.S. National Institutes of Health NIDCR Grant DE13686
(to M.M.), CA130876-05 and DF/HCC Lung Spore Developmental Project (to
N.S.G), CA016087 and National Institutes of Health Shared
Instrumentation Grant S10RR027990 (to T.A.N.) and grants from Natural
Science Foundation of China 31270789, 81102486, and 81273421 (to H.C,
Z.H. and H.W.).
NR 55
TC 9
Z9 10
U1 0
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD JAN
PY 2015
VL 10
IS 1
BP 299
EP 309
DI 10.1021/cb500674s
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AZ6LU
UT WOS:000348332100030
PM 25317566
ER
PT S
AU Khaleghi, M
Furlong, C
Guignard, J
Dobrev, I
Cheng, JT
Rosowski, JJ
AF Khaleghi, Morteza
Furlong, Cosme
Guignard, Jeremie
Dobrev, Ivo
Cheng, Jeffrey Tao
Rosowski, John J.
BE Jin, H
Sciammarella, C
Yoshida, S
Lamberti, L
TI Multiplexed Holography for Single-Shot Three-Dimensional Shape and
Displacement Measurements
SO ADVANCEMENT OF OPTICAL METHODS IN EXPERIMENTAL MECHANICS, VOL 3
SE Conference Proceedings of the Society for Experimental Mechanics Series
LA English
DT Proceedings Paper
CT SEM Annual Conference and Exposition on Experimental and Applied
Mechanics
CY JUN 02-05, 2014
CL Greenville, SC
SP Soc Expt Mech
DE 3D Displacement measurements; Digital holography; Image registration;
Multiplexed hologram; Tympanic membrane
AB Holographic interferometric methods for measuring 3D displacement fields require at least three individual sensitivity vectors. Methods based on multiple directions of illumination have limited application when studying transient phenomena, including, but not limited to, measurements of biological tissues that have temporally-varying responses, such as the eardrum or Tympanic Membrane (TM). Therefore, to measure 3D displacements in such applications, all the measurements have to be done concomitantly. In this paper, we propose a new multiple illumination direction approach to measure 3D displacements from a single-shot hologram that contains displacement information from three sensitivity vectors. In our approach, the hologram of an object of interest is recorded with three simultaneous incoherently-superimposed pairs of reference and object beams, such that the modulation image corresponding to each illumination direction is reconstructed at a particular position on the image. Incoherent superposition of the beams is implemented by using three different laser diodes. Because of the differences in the position of each reference beam and wavelength of each pair of beams, the reconstruction distance and magnification of each sensitivity vector are different. We, therefore, developed and implemented a registration algorithm to accurately translate individual views into a single global coordinate system. Representative results will include measurements of shape and sound-induced 3D displacements of the TM.
C1 [Khaleghi, Morteza; Furlong, Cosme; Dobrev, Ivo] Worcester Polytech Inst, Ctr Holograph Studies & Laser MicromechaTron CHS, Dept Mech Engn, Worcester, MA 01609 USA.
[Furlong, Cosme; Guignard, Jeremie; Cheng, Jeffrey Tao; Rosowski, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Furlong, Cosme; Guignard, Jeremie; Cheng, Jeffrey Tao; Rosowski, John J.] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA 02114 USA.
RP Khaleghi, M (reprint author), Worcester Polytech Inst, Ctr Holograph Studies & Laser MicromechaTron CHS, Dept Mech Engn, Worcester, MA 01609 USA.
EM mkm@wpi.edu
NR 8
TC 0
Z9 0
U1 0
U2 6
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 2191-5644
BN 978-3-319-06985-2
J9 C PROC SOC EXP MECH
PY 2015
BP 103
EP 108
DI 10.1007/978-3-319-06986-9_10
PG 6
WC Optics; Physics, Applied
SC Optics; Physics
GA BB8XF
UT WOS:000347773500010
ER
PT S
AU Dobrev, I
Furlong, C
Rosowski, JJ
Cheng, JT
AF Dobrev, I.
Furlong, C.
Rosowski, J. J.
Cheng, J. T.
BE Jin, H
Sciammarella, C
Yoshida, S
Lamberti, L
TI High-Speed Digital Holography for Transient Response of the Human
Tympanic Membrane
SO ADVANCEMENT OF OPTICAL METHODS IN EXPERIMENTAL MECHANICS, VOL 3
SE Conference Proceedings of the Society for Experimental Mechanics Series
LA English
DT Proceedings Paper
CT SEM Annual Conference and Exposition on Experimental and Applied
Mechanics
CY JUN 02-05, 2014
CL Greenville, SC
SP Soc Expt Mech
DE Acoustic-solid interaction; Digital holography; High-speed cameras;
Local phase correlation; Otology
ID MIDDLE-EAR; EMISSIONS; SURFACE; MOTION
AB The tympanic membrane (TM; eardrum) transforms sound energy from the ear canal into mechanical vibrations of the ossicles (middle-ear bones), whence energy enters the inner ear and stimulates auditory hair cells for hearing. Our past efforts toward understanding of the energy transformation within the middle-ear has been focused on the TM's response to single tones. In this paper, we report results of the development of high-speed holographic capabilities to measure the transient characteristics of the TM.
We have developed a high-speed holographic system (HHS) that incorporates a transient (i.e., >40 kHz) acquisition method to quantify the displacements on the TM surface excited by sharp (i.e., <50 mu s) acoustic clicks. The performance of the HHS is compared with Laser-Doppler Vibrometery (LDV) measurements on both artificial membrane and human cadaveric TM. The instantaneous response of > 100 k data points on the TM surface measured by the HHS can be used to quantify spatially-dependent motion parameters such as modal frequencies, mode shapes, time constants, and acoustic delays. In addition, the local material properties across the surface of the TM can be inferred.
C1 [Dobrev, I.; Furlong, C.] Ctr Holog Studies & Laser MicromechaTron CHSLT, 100 Inst Rd, Worcester, MA 01609 USA.
[Dobrev, I.; Furlong, C.] Wrocester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA.
[Furlong, C.; Rosowski, J. J.; Cheng, J. T.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Furlong, C.; Rosowski, J. J.; Cheng, J. T.] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA 02114 USA.
RP Dobrev, I (reprint author), Ctr Holog Studies & Laser MicromechaTron CHSLT, 100 Inst Rd, Worcester, MA 01609 USA.
EM ivo_d@wpi.edu
FU National Institute on Deafness and Other Communication Disorders (
NIDCD); National Institute of Health ( NIH); Massachusetts Eye and Ear
Infirmary ( MEEI); Mittal Fund
FX This work has been funded by the National Institute on Deafness and
Other Communication Disorders ( NIDCD), the National Institute of Health
( NIH), the Massachusetts Eye and Ear Infirmary ( MEEI), and the Mittal
Fund. The authors should like to acknowledge the help of Michael Ravicz
at the Eaton- Peabody Laboratory ( EPL) of the Massachusetts Eye and Ear
Infirmary ( MEEI), Ellery Harrington and Morteza Khaleghi at the Center
for Holographic Studies and Laser micro- mechaTronics ( CHSLT) at
Worcester Polytechnic Institute.
NR 13
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 2191-5644
BN 978-3-319-06985-2
J9 C PROC SOC EXP MECH
PY 2015
BP 337
EP 342
DI 10.1007/978-3-319-06986-9_39
PG 6
WC Optics; Physics, Applied
SC Optics; Physics
GA BB8XF
UT WOS:000347773500039
ER
PT J
AU Klunk, WE
Koeppe, RA
Price, JC
Benzinger, TL
Devous, MD
Jagust, WJ
Johnson, KA
Mathis, CA
Minhas, D
Pontecorvo, MJ
Rowe, CC
Skovronsky, DM
Mintun, MA
AF Klunk, William E.
Koeppe, Robert A.
Price, Julie C.
Benzinger, Tammie L.
Devous, Michael D., Sr.
Jagust, William J.
Johnson, Keith A.
Mathis, Chester A.
Minhas, Davneet
Pontecorvo, Michael J.
Rowe, Christopher C.
Skovronsky, Daniel M.
Mintun, Mark A.
TI The Centiloid Project: Standardizing quantitative amyloid plaque
estimation by PET
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Amyloid imaging; Positron emission tomography; Pittsburgh compound B;
Centiloid scale; Standardize
ID PITTSBURGH COMPOUND-B; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; TAU
PATHOLOGY; BETA; DEPOSITION; DEMENTIA; BRAIN; SEGMENTATION; MULTICENTER
AB Although amyloid imaging with PiB-PET ([C-11]Pittsburgh Compound-B positron emission tomography), and now with F-18-labeled tracers, has produced remarkably consistent qualitative findings across a large number of centers, there has been considerable variability in the exact numbers reported as quantitative outcome measures of tracer retention. In some cases this is as trivial as the choice of units, in some cases it is scanner dependent, and of course, different tracers yield different numbers. Our working group was formed to standardize quantitative amyloid imaging measures by scaling the outcome of each particular analysis method or tracer to a 0 to 100 scale, anchored by young controls (<= 45 years) and typical Alzheimer's disease patients. The units of this scale have been named "Centiloids." Basically, we describe a "standard" method of analyzing PiB PET data and then a method for scaling any "nonstandard" method of PIE PET analysis (or any other tracer) to the Centiloid scale. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
C1 [Klunk, William E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Klunk, William E.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Koeppe, Robert A.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA.
[Price, Julie C.; Minhas, Davneet] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA.
[Benzinger, Tammie L.; Johnson, Keith A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Benzinger, Tammie L.] Washington Univ, Dept Neurosurg, St Louis, MO USA.
[Devous, Michael D., Sr.] UT Southwestern Med Ctr Dallas, Dept Neurol, Dallas, TX USA.
[Devous, Michael D., Sr.] UT Southwestern Med Ctr Dallas, Dept Radiol, Dallas, TX USA.
[Jagust, William J.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
[Johnson, Keith A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, Dept Pharmacol & Biol Chem, Pittsburgh, PA 15260 USA.
[Mathis, Chester A.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA.
[Pontecorvo, Michael J.; Skovronsky, Daniel M.; Mintun, Mark A.] Avid Radiopharmaceut, Philadelphia, PA USA.
[Rowe, Christopher C.] Austin Hlth, Dept Nucl Med, Melbourne, Vic, Australia.
[Rowe, Christopher C.] Austin Hlth, Ctr PET, Melbourne, Vic, Australia.
RP Klunk, WE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
EM klunkwe@upmc.edu
FU National Institute on Aging [R37 AG025516, P01 AG025204, P50 AG005133,
R01 AG034570, P01 A0026276, U19 AG032438]
FX This work was supported in-part by grants from the National Institute on
Aging: R37 AG025516 (WEK), P01 AG025204 (WEK), P50 AG005133 (WEK), R01
AG034570 (WJ), P01 A0026276 (TB), and U19 AG032438 (TB). We would like
to thank Marybeth Howlett for her organizational and administrative
support.
NR 38
TC 37
Z9 38
U1 4
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JAN
PY 2015
VL 11
IS 1
BP 1
EP 15
DI 10.1016/j.jalz.2014.07.003
PG 15
WC Clinical Neurology
SC Neurosciences & Neurology
GA CA0UX
UT WOS:000348632800001
PM 25443857
ER
PT J
AU Albers, MW
Gilmore, GC
Kaye, J
Murphy, C
Wingfield, A
Bennett, DA
Boxer, AL
Buchman, AS
Cruickshanks, KJ
Devanand, DP
Duffy, CJ
Gall, CM
Gates, GA
Granholm, AC
Hensch, T
Holtzer, R
Hyman, BT
Lin, FR
Mc Kee, AC
Morris, JC
Petersen, RC
Silbert, LC
Stuble, RG
Trojanowski, JQ
Verghese, J
Wilson, DA
Xu, S
Zhang, LI
AF Albers, Mark W.
Gilmore, Grover C.
Kaye, Jeffrey
Murphy, Claire
Wingfield, Arthur
Bennett, David A.
Boxer, Adam L.
Buchman, Aron S.
Cruickshanks, Karen J.
Devanand, Davangere P.
Duffy, Charles J.
Gall, Christine M.
Gates, George A.
Granholm, Ann-Charlotte
Hensch, Takao
Holtzer, Roee
Hyman, Bradley T.
Lin, Frank R.
Mc Kee, Ann C.
Morris, John C.
Petersen, Ronald C.
Silbert, Lisa C.
Stuble, Robert G.
Trojanowski, John Q.
Verghese, Joe
Wilson, Donald A.
Xu, Shunbin
Zhang, Li I.
TI At the interface of sensory and motor dysfunctions and Alzheimer's
disease
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Sensory; Motor; Olfaction; Vision; Auditory function; Alzheimer's
disease; Aging
ID MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; CENTRAL AUDITORY
DYSFUNCTION; AGE-RELATED-CHANGES; OPTICAL COHERENCE TOMOGRAPHY;
EVENT-RELATED POTENTIALS; NERVE-FIBER LAYER; FRONTOTEMPORAL LOBAR
DEGENERATION; TRANSCRANIAL MAGNETIC STIMULATION; POSTERIOR CORTICAL
ATROPHY
AB Recent evidence indicates that sensory and motor changes may precede the cognitive symptoms of Alzheimer's disease (AD) by several years and may signify increased risk of developing AD. Traditionally, sensory and motor dysfunctions in aging and AD have been studied separately. To ascertain the evidence supporting the relationship between age-related changes in sensory and motor systems and the development of AD and to facilitate communication between several disciplines, the National Institute on Aging held an exploratory workshop titled "Sensory and Motor Dysfunctions in Aging and AD." The scientific sessions of the workshop focused on age-related and neuropathologic changes in the olfactory, visual, auditory, and motor systems, followed by extensive discussion and hypothesis generation related to the possible links. among sensory, cognitive, and motor domains in aging and AD. Based on the data presented and discussed at this workshop, it is clear that sensory and motor regions of the central nervous system are affected by AD pathology and that interventions targeting. amelioration of sensory-motor deficits in AD may enhance patient function as AD progresses. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
C1 [Albers, Mark W.; Hyman, Bradley T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Charlestown, MA 02129 USA.
[Gilmore, Grover C.] Case Western Reserve Univ, Jack Joseph & Morton Mandel Sch Appl Social Sci, Cleveland, OH 44106 USA.
[Kaye, Jeffrey; Silbert, Lisa C.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Murphy, Claire] San Diego State Univ, SDSU UCSD Joint Doctoral Program Clin Psychol, San Diego, CA 92182 USA.
[Wingfield, Arthur] Brandeis Univ, Volen Natl Ctr Complex Syst, Waltham, MA USA.
[Wingfield, Arthur] Brandeis Univ, Dept Psychol, Waltham, MA USA.
[Bennett, David A.; Buchman, Aron S.; Xu, Shunbin] Rush Univ, Ctr Med, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA.
[Boxer, Adam L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Cruickshanks, Karen J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
[Cruickshanks, Karen J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA.
[Devanand, Davangere P.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.
[Duffy, Charles J.] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA.
[Gall, Christine M.] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA.
[Gates, George A.] Univ Washington, Bloedel Hearing Res Ctr, Seattle, WA 98195 USA.
[Granholm, Ann-Charlotte] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Granholm, Ann-Charlotte] Med Univ S Carolina, Ctr Aging, Charleston, SC 29425 USA.
[Hensch, Takao] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Holtzer, Roee; Verghese, Joe] Yeshiva Univ, Albert Einstein Coll Med, Dept Neurol, Bronx, NY USA.
[Lin, Frank R.] Johns Hopkins Sch Med, Div Otol Neurotol & Skull Base Surg, Baltimore, MD USA.
[Mc Kee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Bedford, MA USA.
[Mc Kee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Bedford, MA USA.
[Morris, John C.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
[Petersen, Ronald C.] Mayo Clin, Coll Med, Mayo Alzheimers Dis Res Ctr, Rochester, MN USA.
[Stuble, Robert G.] So Illinois Univ, Sch Med, Ctr Alzheimer Dis & Related Disorders, Springfield, IL USA.
[Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.
[Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Inst Aging, Philadelphia, PA 19104 USA.
[Wilson, Donald A.] Nathan S Kline Inst Psychiat Res, Emot Brain Inst, Orangeburg, NY USA.
[Zhang, Li I.] Univ So Calif, Keck Sch Med, Zilkha Neurogenat Inst, Los Angeles, CA 90033 USA.
RP Albers, MW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Charlestown, MA 02129 USA.
EM albers.mark@mgh.harvard.edu
OI Kaye, Jeffrey/0000-0002-9971-3478
FU NIA NIH HHS [P30 AG010124, P50 AG005134, R01 AG017917, R01 AG019714, R01
AG031278, R01 AG037693, R01 AG038791, R01 AG041795, R01 AG044920, RF1
AG015819]; NIDCD NIH HHS [K23 DC011279, R01 DC008983]; NIH HHS [DP2
OD006662]; NINDS NIH HHS [R21 NS085711]
NR 354
TC 33
Z9 35
U1 6
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JAN
PY 2015
VL 11
IS 1
BP 70
EP 98
DI 10.1016/j.jalz.2014.04.514
PG 29
WC Clinical Neurology
SC Neurosciences & Neurology
GA CA0UX
UT WOS:000348632800008
PM 25022540
ER
PT J
AU Scripko, P
Oaklander, AL
Koeppen, AH
Frosch, MP
Schmahmann, JD
AF Scripko, Patricia
Oaklander, Anne Louise
Koeppen, Arnulf H.
Frosch, Matthew P.
Schmahmann, Jeremy D.
TI A 40-Year-Old Woman with Difficulty Going Down Stairs in High-Heeled
Shoes
SO ANNALS OF NEUROLOGY
LA English
DT Editorial Material
ID DOMINANT CEREBELLAR-ATAXIA; ALPHA-SYNUCLEIN TOXICITY; RETINAL
DEGENERATION; REPEAT EXPANSION; MUTANT ATAXIN-7; CAG REPEATS; 7 SCA7;
SPINOCEREBELLAR; ATROPHY; PHENOTYPE
C1 [Scripko, Patricia; Schmahmann, Jeremy D.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Oaklander, Anne Louise] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Oaklander, Anne Louise] Massachusetts Gen Hosp, Dept Pathol Neuropathol, Boston, MA 02114 USA.
[Koeppen, Arnulf H.] Albany Med Coll, Albany, NY 12208 USA.
[Koeppen, Arnulf H.] VA Med Ctr, Res Serv, Albany, NY USA.
[Koeppen, Arnulf H.] VA Med Ctr, Neurol Serv, Albany, NY USA.
[Frosch, Matthew P.] Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA 02114 USA.
[Frosch, Matthew P.] MassGen Inst Neurodegenerat Dis, Charlestown, MA USA.
[Schmahmann, Jeremy D.] Harvard Univ, Sch Med, Boston, MA USA.
RP Scripko, P (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
FU NIA NIH HHS [P50AG005134]; NINDS NIH HHS [K24NS059892, R01NS069454]
NR 34
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD JAN
PY 2015
VL 77
IS 1
BP 1
EP 7
DI 10.1002/ana.24301
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AZ7UN
UT WOS:000348423200001
PM 25380064
ER
PT J
AU Butovsky, O
Jedrychowski, MP
Cialic, R
Krasemann, S
Murugaiyan, G
Fanek, Z
Greco, DJ
Wu, PM
Doykan, CE
Kiner, O
Lawson, RJ
Frosch, MP
Pochet, N
El Fatimy, R
Krichevsky, AM
Gygi, SP
Lassmann, H
Berry, J
Cudkowicz, ME
Weiner, HL
AF Butovsky, Oleg
Jedrychowski, Mark P.
Cialic, Ron
Krasemann, Susanne
Murugaiyan, Gopal
Fanek, Zain
Greco, David J.
Wu, Pauline M.
Doykan, Camille E.
Kiner, Olga
Lawson, Robert J.
Frosch, Matthew P.
Pochet, Nathalie
El Fatimy, Rachid
Krichevsky, Anna M.
Gygi, Steven P.
Lassmann, Hans
Berry, James
Cudkowicz, Merit E.
Weiner, Howard L.
TI Targeting miR-155 Restores Abnormal Microglia and Attenuates Disease in
SOD1 Mice
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; MOUSE MODEL; EXTRACELLULAR NUCLEOTIDES;
DENDRITIC CELLS; INHERITED ALS; MICRORNA-155; MACROPHAGES; EXPRESSION;
BRAIN; PROGRESSION
AB ObjectiveTo investigate miR-155 in the SOD1 mouse model and human sporadic and familial amyotrophic lateral sclerosis (ALS).
MethodsNanoString microRNA, microglia and immune gene profiles, protein mass spectrometry, and RNA-seq analyses were measured in spinal cord microglia, splenic monocytes, and spinal cord tissue from SOD1 mice and in spinal cord tissue of familial and sporadic ALS. miR-155 was targeted by genetic ablation or by peripheral or centrally administered anti-miR-155 inhibitor in SOD1 mice.
ResultsIn SOD1 mice, we found loss of the molecular signature that characterizes homeostatic microglia and increased expression of miR-155. There was loss of the microglial molecules P2ry12, Tmem119, Olfml3, transcription factors Egr1, Atf3, Jun, Fos, and Mafb, and the upstream regulators Csf1r, Tgfb1, and Tgfbr1, which are essential for microglial survival. Microglia biological functions were suppressed including phagocytosis. Genetic ablation of miR-155 increased survival in SOD1 mice by 51 days in females and 27 days in males and restored the abnormal microglia and monocyte molecular signatures. Disease severity in SOD1 males was associated with early upregulation of inflammatory genes, including Apoe in microglia. Treatment of adult microglia with apolipoprotein E suppressed the M0-homeostatic unique microglia signature and induced an M1-like phenotype. miR-155 expression was increased in the spinal cord of both familial and sporadic ALS. Dysregulated proteins that we identified in human ALS spinal cord were restored in SOD1(G93A)/miR-155(-/-) mice. Intraventricular anti-miR-155 treatment derepressed microglial miR-155 targeted genes, and peripheral anti-miR-155 treatment prolonged survival.
InterpretationWe found overexpression of miR-155 in the SOD1 mouse and in both sporadic and familial human ALS. Targeting miR-155 in SOD1 mice restores dysfunctional microglia and ameliorates disease. These findings identify miR-155 as a therapeutic target for the treatment of ALS. ANN NEUROL 2015;77:75-99
C1 [Butovsky, Oleg; Cialic, Ron; Murugaiyan, Gopal; Fanek, Zain; Greco, David J.; Wu, Pauline M.; Doykan, Camille E.; Kiner, Olga; El Fatimy, Rachid; Krichevsky, Anna M.; Weiner, Howard L.] Harvard Univ, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Dept Neurol,Med Sch, Boston, MA 02115 USA.
[Jedrychowski, Mark P.; Gygi, Steven P.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA.
[Krasemann, Susanne] Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, Hamburg, Germany.
[Lawson, Robert J.; Berry, James; Cudkowicz, Merit E.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,Neurol Clin Res Inst, Boston, MA 02115 USA.
[Frosch, Matthew P.] Harvard Univ, Massachusetts Gen Hosp, Alzheimers Dis Res Ctr, Boston, MA 02115 USA.
[Pochet, Nathalie] Harvard Med Sch Broad Inst Massachusetts Inst Tec, Brigham & Womens Hosp, Program Translat NeuroPsychiat Genom, Cambridge, MA USA.
[Lassmann, Hans] Med Univ Vienna, Ctr Brain Res, Vienna, Austria.
[Butovsky, Oleg; Weiner, Howard L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Evergrande Ctr Immunol Dis, Boston, MA 02112 USA.
RP Butovsky, O (reprint author), Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, 77 Ave Louis Pasteur HIM 614, Boston, MA 02115 USA.
EM obutovsky@rics.bwh.harvard.edu
OI Cialic, Ron/0000-0002-1589-2262
FU Amyotrophic Lateral Sclerosis Association [1V78RI, ALSA2087]; Department
of Defense ALS Research Program [AL120029]; Nancy Davis Foundation;
Edward N. and Della L. Thome Memorial Foundation; National Multiple
Sclerosis Society [5092A1]; NIH-NINDS [1R01NS088137]
FX This work was supported by the Amyotrophic Lateral Sclerosis Association
(1V78RI (H.L.W.), ALSA2087 (O.B.)), Department of Defense ALS Research
Program (AL120029 (H.L.W.)), Nancy Davis Foundation Junior Faculty Award
(O.B.), Edward N. and Della L. Thome Memorial Foundation (H.L.W.),
National Multiple Sclerosis Society (5092A1) (O.B.), NIH-NINDS
(1R01NS088137) (O.B.). We thank Prize4Life, a non-profit organization
dedicated to the discovery of treatments and a cure for ALS, for
providing SOD1 mice.
NR 61
TC 39
Z9 39
U1 4
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD JAN
PY 2015
VL 77
IS 1
BP 75
EP 99
DI 10.1002/ana.24304
PG 25
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AZ7UN
UT WOS:000348423200009
PM 25381879
ER
PT J
AU Evans, KC
Song, TY
Zimmerman, JP
Gustin, MJ
McLaren, DG
AF Evans, Karleyton C.
Song, Tian-Yue
Zimmerman, Jared P.
Gustin, Michael J.
McLaren, Donald G.
TI Air hunger evokes greater anxiety and insular cortical activity in panic
disorder than in healthy individuals: An arterial spin labeled fMRI
study
SO BIOLOGICAL PSYCHOLOGY
LA English
DT Meeting Abstract
CT 20th Annual Meeting of the
International-Society-for-the-Advancement-of-Respiratory-Psychophysiolog
y (ISARP)
CY SEP 27-29, 2013
CL Leuven, BELGIUM
SP Int Soc Advancement Respiratory Psychophysiol
C1 [Evans, Karleyton C.; Song, Tian-Yue; Zimmerman, Jared P.; Gustin, Michael J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Evans, Karleyton C.; McLaren, Donald G.] Harvard Univ, Sch Med, Boston, MA USA.
[McLaren, Donald G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-0511
EI 1873-6246
J9 BIOL PSYCHOL
JI Biol. Psychol.
PD JAN
PY 2015
VL 104
BP 150
EP 151
PG 2
WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology,
Experimental
SC Psychology; Behavioral Sciences
GA AZ1ZS
UT WOS:000348034700029
ER
PT J
AU Badejo, OA
Chang, CC
So-Armah, KA
Tracy, RP
Baker, JV
Rimland, D
Butt, AA
Gordon, AJ
Rinaldo, CR
Kraemer, K
Samet, JH
Tindle, HA
Goetz, MB
Rodriguez-Barradas, MC
Bedimo, R
Gibert, CL
Leaf, DA
Kuller, LH
Deeks, SG
Justice, AC
Freiberg, MS
AF Badejo, Oluwatosin A.
Chang, Chung-Chou
So-Armah, Kaku A.
Tracy, Russell P.
Baker, Jason V.
Rimland, David
Butt, Adeel A.
Gordon, Adam J.
Rinaldo, Charles R., Jr.
Kraemer, Kevin
Samet, Jeffrey H.
Tindle, Hilary A.
Goetz, Matthew B.
Rodriguez-Barradas, Maria C.
Bedimo, Roger
Gibert, Cynthia L.
Leaf, David A.
Kuller, Lewis H.
Deeks, Steven G.
Justice, Amy C.
Freiberg, Matthew S.
TI CD8(+) T-Cells Count in Acute Myocardial Infarction in HIV Disease in a
Predominantly Male Cohort
SO Biomed Research International
LA English
DT Article
ID INFECTED WOMEN; RISK; ACTIVATION; SYSTEM; RATES
AB Human Immunodeficiency Virus-(HIV-) infected persons have a higher risk for acute myocardial infarction (AMI) than HIVuninfected persons. Earlier studies suggest that HIV viral load, CD4 + T-cell count, and antiretroviral therapy are associated with cardiovascular disease (CVD) risk. Whether CD8 + T-cell count is associated with CVD risk is not clear. We investigated the association between CD8 + T-cell count and incident AMI in a cohort of 73,398 people (of which 97.3% were men) enrolled in the U. S. Veterans Aging Cohort Study-Virtual Cohort (VACS-VC). Compared to uninfected people, HIV-infected people with high baselineCD8 + T-cell counts (> 1065 cells/ mm 3) had increasedAMI risk (adjustedHR = 1.82,.. < 0.001, 95% CI: 1.46 to 2.28). There was evidence that the effect of CD8 + T-cell tertiles on AMI risk differed by CD4 + T-cell level: compared to uninfected people, HIVinfected people with CD4 + T-cell counts = 200 cells/ mm 3 had increased AMI risk with high CD8 + T-cell count, while those with CD4 + T-cell counts < 200 cells/ mm 3 had increased AMI risk with low CD8 + T-cell count. CD8 + T-cell counts may add additional AMI risk stratification information beyond that provided by CD4 + T-cell counts alone.
C1 [Badejo, Oluwatosin A.; Chang, Chung-Chou; Gordon, Adam J.; Kraemer, Kevin] Univ Pittsburgh, UPMC, Div Gen Internal Med, Montefiore Hosp, Pittsburgh, PA 15213 USA.
[Chang, Chung-Chou] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[So-Armah, Kaku A.] Yale Univ, Sch Med, New Haven, CT 06510 USA.
[Tracy, Russell P.] Univ Vermont, Burlington, VT 05446 USA.
[Baker, Jason V.] Univ Minnesota, Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA.
[Rimland, David] Emory Univ, Sch Med, VA Med Ctr, Atlanta, GA 30033 USA.
[Butt, Adeel A.] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA 15213 USA.
[Butt, Adeel A.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[Butt, Adeel A.] Hamad Med Corp, Doha, Qatar.
[Rinaldo, Charles R., Jr.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA.
[Rinaldo, Charles R., Jr.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
[Samet, Jeffrey H.] Boston Univ, Sch Med, Clin Addict Res & Educ Unit, Boston, MA 02118 USA.
[Samet, Jeffrey H.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.
[Tindle, Hilary A.] Vanderbilt Univ, Med Ctr, Dept Gen Internal Med & Publ Hlth, Nashville, TN 37203 USA.
[Goetz, Matthew B.; Leaf, David A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
[Goetz, Matthew B.; Leaf, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Infect Dis Sect, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Bedimo, Roger] VA North Texas Healthcare Syst, Dallas, TX 75216 USA.
[Bedimo, Roger] Univ Texas SW Med Ctr Dallas, Div Infect Dis, Dallas, TX 75390 USA.
[Gibert, Cynthia L.] Washington DC VA Med Ctr, Washington, DC 20422 USA.
[Gibert, Cynthia L.] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
[Kuller, Lewis H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Justice, Amy C.] Yale Univ, Sch Med, West Haven Vet Adm Med Ctr, Vet Affairs Connecticut Hlth Care Syst, New Haven, CT 06516 USA.
[Freiberg, Matthew S.] Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN 37203 USA.
RP Freiberg, MS (reprint author), Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, 2525 West End,Suite 300-A, Nashville, TN 37203 USA.
EM matthew.s.freiberg@vanderbilt.edu
OI Butt, Adeel/0000-0002-1118-1826; Goetz, Matthew/0000-0003-4542-992X;
Justice, Amy/0000-0003-0139-5502
NR 12
TC 0
Z9 0
U1 1
U2 4
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 246870
DI 10.1155/2015/246870
PG 5
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CA7DU
UT WOS:000349078600001
ER
PT J
AU Nislow, C
Lee, AY
Allen, PL
Giaever, G
Smith, A
Gebbia, M
Stodieck, LS
Hammond, JS
Birdsall, HH
Hammond, TG
AF Nislow, Corey
Lee, Anna Y.
Allen, Patricia L.
Giaever, Guri
Smith, Andrew
Gebbia, Marinella
Stodieck, Louis S.
Hammond, Jeffrey S.
Birdsall, Holly H.
Hammond, Timothy G.
TI Genes Required for Survival in Microgravity Revealed by Genome-Wide
Yeast Deletion Collections Cultured during Spaceflight
SO Biomed Research International
LA English
DT Article
ID SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; SMALL MOLECULES; APOPTOSIS;
ORGANISM; CELLS; MITOXANTRONE; PATHWAY
AB Spaceflight is a unique environment with profound effects on biological systems including tissue redistribution and musculoskeletal stresses. However, the more subtle biological effects of spaceflight on cells and organisms are difficult to measure in a systematic, unbiased manner. Here we test the utility of the molecularly barcoded yeast deletion collection to provide a quantitative assessment of the effects of microgravity on a model organism. We developed robust hardware to screen, in parallel, the complete collection of similar to 4800 homozygous and similar to 5900 heterozygous (including similar to 1100 single-copy deletions of essential genes) yeast deletion strains, each carrying unique DNA that acts as strain identifiers. We compared strain fitness for the homozygous and heterozygous yeast deletion collections grown in spaceflight and ground, as well as plus and minus hyperosmolar sodium chloride, providing a second additive stressor. The genome-wide sensitivity profiles obtained from these treatments were then queried for their similarity to a compendium of drugs whose effects on the yeast collection have been previously reported. We found that the effects of spaceflight have high concordance with the effects of DNA-damaging agents and changes in redox state, suggesting mechanisms by which spaceflight may negatively affect cell fitness.
C1 [Nislow, Corey; Giaever, Guri] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada.
[Lee, Anna Y.; Smith, Andrew; Gebbia, Marinella] Univ Toronto, Donnelly CCBR, Toronto, ON M5S 3E1, Canada.
[Allen, Patricia L.; Hammond, Timothy G.] Durham VA Med Ctr, Res & Dev Serv, Durham, NC 27705 USA.
[Stodieck, Louis S.] Univ Colorado, Bioserve Space Technol, Boulder, CO 80309 USA.
[Hammond, Jeffrey S.] Inst Med Res, Durham, NC 27705 USA.
[Birdsall, Holly H.; Hammond, Timothy G.] US Dept Vet Affairs, Off Res & Dev, Washington, DC 20420 USA.
[Birdsall, Holly H.] Baylor Coll Med, Dept Otorhinolaryngol, Houston, TX 77030 USA.
[Birdsall, Holly H.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA.
[Birdsall, Holly H.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA.
[Hammond, Timothy G.] Duke Univ, Sch Med, Dept Internal Med, Div Nephrol, Durham, NC 27705 USA.
[Hammond, Timothy G.] George Washington Univ, Sch Med, Dept Internal Med, Nephrol Sect, Washington, DC 20052 USA.
RP Hammond, TG (reprint author), Durham VA Med Ctr, Res & Dev Serv, Durham, NC 27705 USA.
EM grumpy70115@yahoo.com
OI Nislow, Corey/0000-0002-4016-8874
FU NASA [NNX10AP01G]
FX These studies were supported by NASA Grant no. NNX10AP01G. The authors
thank NASA for spaceflight access under the auspices of the
International Space Station National Lab Pathfinder program. This
material is the result of work supported with resources and the use of
facilities at the Durhan Veterans Affairs Medical Center and the Office
of Research and Development, Department of Veterans Affairs, Veterans
Health Administration. Sequencing was performed, in part at UBCSeq,
Vancouver. Contents do not represent the views of the Department of
Veterans Affairs or the United States of America.
NR 33
TC 0
Z9 0
U1 0
U2 5
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 976458
DI 10.1155/2015/976458
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CA3DL
UT WOS:000348786200001
ER
PT J
AU Tan, EK
Srivastava, AK
Arnold, WD
Singh, MP
Zhang, YY
AF Tan, E. K.
Srivastava, Amit K.
Arnold, W. David
Singh, Mahendra P.
Zhang, Yiying
TI Neurodegeneration: Etiologies and New Therapies
SO Biomed Research International
LA English
DT Editorial Material
C1 [Tan, E. K.] Singapore Gen Hosp, Natl Inst Neurosci, Dept Neurol, Singapore 169857, Singapore.
[Tan, E. K.] Duke NUS Grad Med Sch, Singapore 169857, Singapore.
[Srivastava, Amit K.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA.
[Srivastava, Amit K.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA.
[Arnold, W. David] Ohio State Univ, Dept Neurol, Div Neuromuscular Med, Columbus, OH 43210 USA.
[Arnold, W. David] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.
[Singh, Mahendra P.] Indian Inst Toxicol Res, CSIR, Toxicogen & Predict Toxicol Div, Lucknow 226001, Uttar Pradesh, India.
[Zhang, Yiying] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA.
RP Tan, EK (reprint author), Singapore Gen Hosp, Natl Inst Neurosci, Dept Neurol, Singapore 169857, Singapore.
EM tan.eng.king@sgh.com.sg
NR 2
TC 0
Z9 0
U1 0
U2 3
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 272630
DI 10.1155/2015/272630
PG 2
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CA7EA
UT WOS:000349079200001
ER
PT J
AU Mansour, MR
Reed, C
Eisenberg, AR
Tseng, JC
Twizere, JC
Daakour, S
Yoda, A
Rodig, SJ
Tal, N
Shochat, C
Berezovskaya, A
DeAngelo, DJ
Sallan, SE
Weinstock, DM
Izraeli, S
Kung, AL
Kentsis, A
Look, AT
AF Mansour, Marc R.
Reed, Casie
Eisenberg, Amy R.
Tseng, Jen-Chieh
Twizere, Jean-Claude
Daakour, Sarah
Yoda, Akinori
Rodig, Scott J.
Tal, Noa
Shochat, Chen
Berezovskaya, Alla
DeAngelo, Daniel J.
Sallan, Stephen E.
Weinstock, David M.
Izraeli, Shai
Kung, Andrew L.
Kentsis, Alex
Look, A. Thomas
TI Targeting oncogenic interleukin-7 receptor signalling with
N-acetylcysteine in T cell acute lymphoblastic leukaemia
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE acute leukaemia; T-cell lymphoma; therapy
ID OF-FUNCTION MUTATIONS; PHOSPHATIDYLINOSITOL-3 KINASE; ACETAMINOPHEN
OVERDOSE; PHARMACOKINETICS; ACTIVATION; IL7R; PROLIFERATION; VIABILITY;
EFFICACY; PATHWAY
AB Activating mutations of the interleukin-7 receptor (IL7R) occur in approximately 10% of patients with T cell acute lymphoblastic leukaemia (T-ALL). Most mutations generate a cysteine at the transmembrane domain leading to receptor homodimerization through disulfide bond formation and ligand-independent activation of STAT5. We hypothesized that the reducing agent N-acetylcysteine (NAC), a well-tolerated drug used widely in clinical practice to treat acetaminophen overdose, would reduce disulfide bond formation, and inhibit mutant IL7R-mediated oncogenic signalling. We found that treatment with NAC disrupted IL7R homodimerization in IL7R-mutant DND-41 cells as assessed by non-reducing Western blot, as well as in a luciferase complementation assay. NAC led to STAT5 dephosphorylation and cell apoptosis at clinically achievable concentrations in DND-41 cells, and Ba/F3 cells transformed by an IL7R-mutant construct containing a cysteine insertion. The apoptotic effects of NAC could be rescued in part by a constitutively active allele of STAT5. Despite using doses lower than those tolerated in humans, NAC treatment significantly inhibited the progression of human DND-41 cells engrafted in immunodeficient mice. Thus, targeting leukaemogenic IL7R homodimerization with NAC offers a potentially effective and feasible therapeutic strategy that warrants testing in patients with T-ALL.
C1 [Mansour, Marc R.; Reed, Casie; Eisenberg, Amy R.; Berezovskaya, Alla; DeAngelo, Daniel J.; Sallan, Stephen E.; Kentsis, Alex; Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Mansour, Marc R.] UCL, UCL Canc Inst, Dept Haematol, London, England.
[Eisenberg, Amy R.; Kentsis, Alex] Mem Sloan Kettering Canc Ctr, Dept Pediat, Sloan Kettering Inst, Mol Pharmacol & Chem Program, New York, NY 10065 USA.
[Tseng, Jen-Chieh] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02115 USA.
[Twizere, Jean-Claude; Daakour, Sarah] Univ Liege, Interdisciplinary Cluster Appl Genoprote GIGA R, Lab Prot Signalling & Interact, B-4000 Sart Tilman Par Liege, Belgium.
[Yoda, Akinori; Weinstock, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Rodig, Scott J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Tal, Noa; Shochat, Chen; Izraeli, Shai] Chaim Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel.
[Tal, Noa; Shochat, Chen; Izraeli, Shai] Tel Aviv Univ, Sch Med, IL-69978 Tel Aviv, Israel.
[Shochat, Chen] Migal Galilee Bio Technol Ctr, Tel Hai, Israel.
[Shochat, Chen] Tel Hai Acad Coll, Tel Hai, Israel.
[Kung, Andrew L.] Columbia Univ, Dept Pediat, New York, NY 10027 USA.
[Look, A. Thomas] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
RP Look, AT (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 630, Boston, MA 02115 USA.
EM kentsisresearchgroup@gmail.com; thomas_look@dfci.harvard.edu
OI Kung, Andrew/0000-0002-9091-488X
FU Kay Kendall Leukaemia Fund of the UK; Claudia Adams Barr Innovative
Basic Science Research Program; National Cancer Institute [5P01CA109901,
5P01CA68484, 5K08CA160660]; Intramural Research Program of the NIH,
National Cancer Institute, Center for Cancer Research; ISF, ICRF and
WLBH foundation
FX This research was supported by the Kay Kendall Leukaemia Fund of the UK
(M.R.M), the Claudia Adams Barr Innovative Basic Science Research
Program (M.R.M), grants from the National Cancer Institute
(5P01CA109901, 5P01CA68484 and 5K08CA160660) by the Intramural Research
Program of the NIH, National Cancer Institute, Center for Cancer
Research and by the ISF, ICRF and WLBH foundation (to SI). We would like
to thank John Gilbert for editorial advice.
NR 46
TC 4
Z9 4
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JAN
PY 2015
VL 168
IS 2
BP 230
EP 238
DI 10.1111/bjh.13115
PG 9
WC Hematology
SC Hematology
GA AZ9WF
UT WOS:000348564000008
PM 25256574
ER
PT J
AU Demner-Fushman, D
Antani, S
Kalpathy-Cramer, J
Muller, H
AF Demner-Fushman, Dina
Antani, Sameer
Kalpathy-Cramer, Jayashree
Mueller, Henning
TI A decade of community-wide efforts in advancing medical image
understanding and retrieval
SO COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
LA English
DT Editorial Material
C1 [Demner-Fushman, Dina; Antani, Sameer] Natl Lib Med, NIH, Bethesda, MD USA.
[Kalpathy-Cramer, Jayashree] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Kalpathy-Cramer, Jayashree] Harvard Univ, Sch Med, Boston, MA USA.
[Mueller, Henning] Univ Appl Sci Western Switzerland HES SO, Sierre, Switzerland.
RP Muller, H (reprint author), Univ Appl Sci Western Switzerland HES SO, Sierre, Switzerland.
EM henning.mueller@hevs.ch
OI Muller, Henning/0000-0001-6800-9878; Kalpathy-Cramer,
Jayashree/0000-0001-8906-9618
NR 11
TC 0
Z9 0
U1 3
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-6111
EI 1879-0771
J9 COMPUT MED IMAG GRAP
JI Comput. Med. Imaging Graph.
PD JAN
PY 2015
VL 39
SI SI
BP 1
EP 2
DI 10.1016/j.compmedimag.2014.12.002
PG 2
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA AZ6NZ
UT WOS:000348337500001
PM 25572585
ER
PT J
AU Kalpathy-Cramer, J
de Herrera, AGS
Demner-Fushman, D
Antani, S
Bedrick, S
Muller, H
AF Kalpathy-Cramer, Jayashree
de Herrera, Alba Garcia Seco
Demner-Fushman, Dina
Antani, Sameer
Bedrick, Steven
Mueller, Henning
TI Evaluating performance of biomedical image retrieval systems An overview
of the medical image retrieval task at ImageCLEF 2004-2013
SO COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
LA English
DT Article
DE Multimodal medical retrieval; Image retrieval; Biomedical literature;
Content-based retrieval; Text-based image retrieval
ID INFORMATION; FUSION; TRACK; TEXT
AB Medical image retrieval and classification have been extremely active research topics over the past 15 years. Within the ImageCLEF benchmark in medical image retrieval and classification, a standard test bed was created that allows researchers to compare their approaches and ideas on increasingly large and varied data sets including generated ground truth. This article describes the lessons learned in ten evaluation campaigns. A detailed analysis of the data also highlights the value of the resources created. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Kalpathy-Cramer, Jayashree] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Kalpathy-Cramer, Jayashree] Harvard Univ, Sch Med, Boston, MA USA.
[de Herrera, Alba Garcia Seco; Mueller, Henning] Univ Appl Sci Western Switzerland HES SO, Sierre, Switzerland.
[Demner-Fushman, Dina; Antani, Sameer] Natl Lib Med, NIH, Bethesda, MD USA.
[Bedrick, Steven] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Kalpathy-Cramer, J (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
EM kalpathy@nmr.mgh.harvard.edu
OI Bedrick, Steven/0000-0002-0163-9397; Muller,
Henning/0000-0001-6800-9878; Kalpathy-Cramer,
Jayashree/0000-0001-8906-9618; Antani, Sameer/0000-0002-0040-1387
FU NIH [U01CA154602, R00LM009889]
FX JKC is funded in part by the NIH grants U01CA154602 and R00LM009889.
NR 46
TC 11
Z9 11
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-6111
EI 1879-0771
J9 COMPUT MED IMAG GRAP
JI Comput. Med. Imaging Graph.
PD JAN
PY 2015
VL 39
SI SI
BP 55
EP 61
DI 10.1016/j.compmedimag.2014.03.004
PG 7
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA AZ6NZ
UT WOS:000348337500007
PM 24746250
ER
PT J
AU Oldenburg, CE
Jain, S
Mayer, KH
Mimiaga, MJ
AF Oldenburg, Catherine E.
Jain, Sachin
Mayer, Kenneth H.
Mimiaga, Matthew J.
TI Post-exposure prophylaxis use and recurrent exposure to HIV among men
who have sex with men who use crystal methamphetamine
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Post-exposure prophylaxis; HIV prevention; Crystal methamphetamine; Men
who have sex with men
ID SUBSTANCE-ABUSE TREATMENT; CONTINGENCY MANAGEMENT; BISEXUAL MEN;
PREVENTION; GAY; INFECTION
AB Background: Men who have sex with men (MSM) who use aystal methamphetamine (CM) are at increased risk for HIV infection. Post-exposure prophylaxis (PEP) is a useful HIV prevention strategy if individuals are able to identify high-risk exposures and seek timely care, however to date there has been limited data on the use of PEP by CM users.
Methods: A: Retrospective cohort study of all PEP prescriptions (N = 1130 prescriptions among 788 MSM) at Fenway Community Health in Boston, MA was undertaken. Multivariable models were used to assess the association between CM use during exposure (7.4% used CM during exposure) and chronically (7.4% of MSM were chronic CM users) and individual-level and event-level outcomes among MSM who used PEP at least once.
Results: Compared to those who had not used CM, MSM PEP users who used CM more frequently returned for repeat PEP (aOR 5.13, 95% CI 2.82 to 9.34) and were significantly more likely to seroconvert over the follow-up period (aHR 3.61, 95% CI 1.51 to 8.60). MSM who used CM had increased odds of unprotected anal intercourse as the source of exposure (aOR 2.12,95% CI 1.16 to 3.87) and knowing that their partner was HIV infected (aOR 2.27,95% CI 1.42 to 3.64).
Conclusions: While MSM who use CM may have challenges accessing ART in general, these data highlight the fact that those who were able to access PEP subsequently remained at increased risk of HIV seroconversion. Counseling and/or substance use interventions during the PEP course should be considered for CM-using MSM. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Oldenburg, Catherine E.; Mimiaga, Matthew J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Oldenburg, Catherine E.; Jain, Sachin; Mayer, Kenneth H.] Fenway Community Hlth, Fenway Inst, Boston, MA USA.
[Jain, Sachin; Mayer, Kenneth H.; Mimiaga, Matthew J.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
[Mayer, Kenneth H.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
[Mimiaga, Matthew J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Oldenburg, CE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave,9th Floor, Boston, MA 02115 USA.
EM ceo242@mail.harvard.edu
FU NIAID NIH HHS [T32 AI007535]; NIDA NIH HHS [T32 DA013911]
NR 25
TC 3
Z9 3
U1 2
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD JAN 1
PY 2015
VL 146
BP 75
EP 80
DI 10.1016/j.drugalcdep.2014.11.010
PG 6
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA AZ5LD
UT WOS:000348261600011
PM 25482500
ER
PT J
AU Dunn, EC
Richmond, TK
Milliren, CE
Subramanian, SV
AF Dunn, Erin C.
Richmond, Tracy K.
Milliren, Carly E.
Subramanian, S. V.
TI Using cross-classified multilevel models to disentangle school and
neighborhood effects: An example focusing on smoking behaviors among
adolescents in the United States
SO HEALTH & PLACE
LA English
DT Article
DE Cross-classified; Multilevel modeling; Adolescents; School environments;
Neighborhoods
ID HEALTH; OUTCOMES; DISADVANTAGE; GLOSSARY
AB Background: Despite much interest in understanding the influence of contexts on health, most research has focused on one context at a time, ignoring the reality that individuals have simultaneous memberships in multiple settings.
Method: Using the example of smoking behavior among adolescents in the National Longitudinal Study of Adolescent Health, we applied cross classified multilevel modeling (CCMM) to examine fixed and random effects for schools and neighborhoods. We compared the CCMM results with those obtained from a traditional multilevel model (MEM) focused on either the school and neighborhood separately.
Results: In the MEMs, 52% of the variation in smoking was due to differences between neighborhoods (when schools were ignored) and 6.3% of the variation in smoking was due to differences between schools (when neighborhoods were ignored). However in the CCMM examining neighborhood and school variation simultaneously, the neighborhood level variation was reduced to 0.4%.
Conclusion: Results suggest that using MEM, instead of CCMM, could lead to overestimating the importance of certain contexts and could ultimately lead to targeting interventions or policies to the wrong settings. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Dunn, Erin C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Dunn, Erin C.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Dunn, Erin C.] Broad Inst, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.
[Richmond, Tracy K.] Boston Childrens Hosp, Div Adolescent Med, Boston, MA 02115 USA.
[Milliren, Carly E.] Boston Childrens Hosp, Dept Med, Clin Res Ctr, Boston, MA 02115 USA.
[Subramanian, S. V.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
RP Subramanian, SV (reprint author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave, Boston, MA 02115 USA.
EM edunn2@mgh.harvard.edu; tracy.k.richmond@childrens.harvard.edu;
carly.milliren@childrens.harvard.edu; svsubram@hsph.harvard.edu
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development [P01-HD31921]; Eunice Kennedy Shriver National Institute of
Child Health and Human Development (NICHD) [K01HD058042]; RWJ
Investigator Award in Health Policy Research
FX This research uses data from Add Health, a program project directed by
Kathleen Mullan Harris and designed by J. Richard Udry, Peter S.
Bearman, and Kathleen Mullan Harris at the University of North Carolina
at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy
Shriver National Institute of Child Health and Human Development, with
cooperative funding from 23 other federal agencies and foundations.
Special acknowledgment is due Ronald R. Rindfuss and Barbara Entwisle
for assistance in the original design. Information on how to obtain the
Add Health data files is available on the Add Health website
(http://www.cpc.unc.edu/addhealth). No direct support was received from
grant P01-HD31921 for this analysis.; Research reported in this
publication was supported by the Eunice Kennedy Shriver National
Institute of Child Health and Human Development (NICHD) under Award
Number K01HD058042. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health. SVS was supported in part by the RWJ
Investigator Award in Health Policy Research.
NR 30
TC 9
Z9 9
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8292
EI 1873-2054
J9 HEALTH PLACE
JI Health Place
PD JAN
PY 2015
VL 31
BP 224
EP 232
DI 10.1016/j.healthplace.2014.12.001
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AZ4ON
UT WOS:000348202100028
PM 25579227
ER
PT J
AU McCarthy, AJ
Lauwers, GY
Sheahan, K
AF McCarthy, Aoife J.
Lauwers, Gregory Y.
Sheahan, Kieran
TI Iatrogenic pathology of the intestines
SO HISTOPATHOLOGY
LA English
DT Review
DE colon; damage; drug-induced; gastrointestinal tract; iatrogenic; injury;
large intestine; medication-induced; side effects; small intestine
ID SODIUM POLYSTYRENE SULFONATE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
OF-THE-LITERATURE; MOFETIL-RELATED COLITIS; VERSUS-HOST-DISEASE;
SOLID-ORGAN TRANSPLANTATION; T-LYMPHOCYTE ANTIGEN-4; CHRONIC
HEPATITIS-C; MYCOPHENOLATE-MOFETIL; ISCHEMIC COLITIS
AB Many drugs and chemical agents can cause enteritis and colitis, producing clinical gastrointestinal side effects, the most common of which are diarrhoea, constipation, nausea and vomiting. Significant histological overlap exists between some patterns of medication or chemical injury and various disease entities. A particular medication may cause multiple patterns of injury and may mimic common entities such as coeliac disease, Crohn's disease, infectious enteritis and colitis. Thus, given the common absence of specific histopathological features, the diagnosis often relies upon thorough clinicopathological correlation. This review concentrates on selected examples of medication-induced injury of the intestinal tract in which the pathology can be recognized, particularly on biopsies, with a focus on newly described medication-induced gastrointestinal effects.
C1 [McCarthy, Aoife J.; Sheahan, Kieran] St Vincents Univ Hosp, Dept Histopathol, Dublin 4, Ireland.
[Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Sheahan, K (reprint author), St Vincents Univ Hosp, Dept Histopathol, Elm Pk, Dublin 4, Ireland.
EM k.sheahan@st-vincents.ie
NR 116
TC 5
Z9 5
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD JAN
PY 2015
VL 66
IS 1
BP 15
EP 28
DI 10.1111/his.12598
PG 14
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA AZ8CX
UT WOS:000348443500003
PM 25639479
ER
PT J
AU Jaff, MR
AF Jaff, Michael R.
TI The THUNDER Trial Results Clearing the Way or Ushering the Storm?*
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
DE drug coated balloons; peripheral artery disease; restenosis
ID PERIPHERAL ARTERY-DISEASE; ANGIOPLASTY; PACLITAXEL; LESIONS
C1 [Jaff, Michael R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
RP Jaff, MR (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Warren 905, Boston, MA 02114 USA.
EM mjaff@partners.org
NR 15
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
EI 1876-7605
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD JAN
PY 2015
VL 8
IS 1
BP 109
EP 110
DI 10.1016/j.jcin.2014.09.008
PN A
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AZ4MP
UT WOS:000348195900022
PM 25616823
ER
PT J
AU Ravona-Springer, R
Haratz, S
Tanne, D
Schmeidler, J
Efrati, S
Rosendorff, C
Beeri, MS
Silverman, JM
AF Ravona-Springer, Ramit
Haratz, Salo
Tanne, David
Schmeidler, James
Efrati, Shai
Rosendorff, Clive
Beeri, Michal Schnaider
Silverman, Jeremy M.
TI Arterial Wall Function is Associated with Cognitive Performance
Primarily in Elderly with Type 2 Diabetes
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Arterial wall function; cognitive function; large artery elasticity
index; total vascular impedance; type 2 diabetes
ID PULSE-WAVE VELOCITY; MINI-MENTAL-STATE; ALZHEIMER-DISEASE;
CEREBROVASCULAR REACTIVITY; CAROTID ATHEROSCLEROSIS; ENDOTHELIAL
FUNCTION; FASTING GLUCOSE; OLDEST-OLD; STIFFNESS; DEMENTIA
AB Regression analyses compared 41 type 2 diabetes (T2D) and 131 non-T2D cognitively normal elderly males on the associations of arterial wall function measures [large artery elasticity index (LAEI), small artery elasticity index (SAEI), systemic vascular resistance (SVR), and total vascular impedance (TVI)] with cognitive performance (memory, language, and executive functions), controlling for socio-demographic and cardiovascular factors. Higher LAEI and lower TVI were significantly associated with better executive functions performance in T2D but not in non-T2D subjects. Lower TVI was more associated with better language performance in T2D. Results suggest that arterial wall function is associated with cognition in T2D.
C1 [Ravona-Springer, Ramit] Sheba Med Ctr, Memory Clin, IL-52621 Ramat Gan, Israel.
[Ravona-Springer, Ramit; Haratz, Salo; Tanne, David; Efrati, Shai] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
[Haratz, Salo; Tanne, David] Sheba Med Ctr, Dept Neurol, Stroke Unit, IL-52621 Ramat Gan, Israel.
[Schmeidler, James; Beeri, Michal Schnaider; Silverman, Jeremy M.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Efrati, Shai] Assaf Harofeh Med Ctr, Inst Hyperbar Med, IL-70300 Zerifin, Israel.
[Efrati, Shai] Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel.
[Efrati, Shai] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel.
[Rosendorff, Clive; Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Rosendorff, Clive] Mt Sinai Sch Med, Dept Med Cardiol, New York, NY USA.
[Beeri, Michal Schnaider] Sheba Med Ctr, Josef Sagol Neurosci Ctr, IL-52621 Ramat Gan, Israel.
RP Ravona-Springer, R (reprint author), Sheba Med Ctr, IL-52621 Ramat Gan, Israel.
EM ramit.ravona@sheba.health.gov.il
RI Tanne, David/F-2560-2010
OI Tanne, David/0000-0002-6699-2220
FU American Federation for Aging Research (AFAR) [NIRG-11-205083]; NIA [R01
AG034087, NIA-AG02219]; Helen Bader Foundation; Leroy Schecter
Foundation; National Institute of Aging [P01-AG02219]; United States
Department of Veterans Affairs
FX This study was supported by the American Federation for Aging Research
(AFAR), Young investigator award 2011 and NIRG-11-205083 Alzheimer's
Association, 2012 to Dr. Ravona-Springer, NIA grant R01 AG034087 to Dr.
Beeri, NIA-AG02219 (VH), the Helen Bader Foundation and the Irma T.
Hirschl Scholar Award as well as the Leroy Schecter Foundation Award to
Dr. Beeri, National Institute of Aging grant P01-AG02219 (to Mary Sano),
a Merit Award to Dr. Silverman from the United States Department of
Veterans Affairs.
NR 46
TC 0
Z9 0
U1 1
U2 2
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2015
VL 44
IS 2
BP 687
EP 693
DI 10.3233/JAD-141197
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA AZ6WC
UT WOS:000348357600029
PM 25352451
ER
PT J
AU Lo, WK
Burakoff, R
Goldberg, HJ
Feldman, N
Chan, WW
AF Lo, Wai-Kit
Burakoff, Robert
Goldberg, Hilary J.
Feldman, Natan
Chan, Walter W.
TI Pre-transplant impedance measures of reflux are associated with early
allograft injury after lung transplantation
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
DE gastroesophageal reflux disease; lung transplantation; esophageal
multichannel intraluminal impedance; pre-transplant evaluation; early
allograft injury; acute rejection; lymphocytic bronchiolitis
ID BRONCHIOLITIS OBLITERANS SYNDROME; GASTROESOPHAGEAL-REFLUX; LYMPHOCYTIC
BRONCHIOLITIS; ACUTE REJECTION; INTERNATIONAL-SOCIETY; ESOPHAGEAL
MOTILITY; NORMAL VALUES; PH-IMPEDANCE; RISK-FACTORS; DISEASE
AB BACKGROUND: Acid reflux has been associated with poorer outcomes after lung transplantation. Standard pre-transplant reflux assessment has not been universally adopted. Non-acid reflux may also induce a pulmonary inflammatory cascade, leading to acute and chronic rejection. Esophageal multichannel intraluminal impedance and pH testing (MII-pH) may be valuable in standard pre-transplant evaluation. We assessed the association between pre-transplant MIT-pH measures and early allograft injury in lung transplant patients.
METHODS: This was a retrospective cohort study of lung transplant recipients who underwent pre-transplant MII-pH at a tertiary center from 2007 to 2012. Results from pre-transplant MII-pH, cardiopulmonary function testing, and results of biopsy specimen analysis of the transplanted lung were recorded. Time-to-event analyses were performed using Cox proportional hazards and Kaplan-Maier methods to assess the associations between MII-pH measures and development of acute rejection or lymphocytic bronchiolitis.
RESULTS: Thirty patients (46.7% men; age, 54.2 years) met the inclusion criteria. Pre-transplant cardiopulmonary function and pulmonary diagnoses were similar between outcome groups. Prolonged bolus clearance (hazard ratio [HR], 4.11; 95% confidence interval [CI], 1.34-12.57; p = 0.01), increased total distal reflux episodes (HR, 4.80; 95% CI, 1.33-17.25; p = 0.02), and increased total proximal reflux episodes (HR, 4.43; 95% CI, 1.14-17.31; p = 0.03) were significantly associated with decreased time to early allograft injury. Kaplan-Meier curves also demonstrated differences in time to rejection by prolonged bolus clearance.(p = 0.01) and increased total distal reflux episodes (p = 0.01). Sub-group analysis including only patients with MII-pH performed off proton pump inhibitors (n = 24) showed similar results.
CONCLUSIONS: Prolonged bolus clearance, increased total distal reflux episodes, and increased total proximal reflux episodes on pre-transplant MII-pH were associated with decreased time to early allograft injury after lung transplantation. Routine pre-transplant MII-pH may provide clinically relevant data regarding transplant outcomes and pen-transplant care. (C) 2015 International Society for Heart and Lung Transplantation. All rights reserved.
C1 [Lo, Wai-Kit; Burakoff, Robert; Feldman, Natan; Chan, Walter W.] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA.
[Lo, Wai-Kit] Boston VA Healthcare Syst, Dept Gastroenterol, Boston, MA USA.
[Lo, Wai-Kit; Burakoff, Robert; Goldberg, Hilary J.; Chan, Walter W.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Goldberg, Hilary J.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
RP Chan, WW (reprint author), Brigham & Womens Hosp, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA.
EM wwchan@partners.org
OI Lo, Wai-Kit/0000-0002-1526-352X
NR 40
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD JAN
PY 2015
VL 34
IS 1
BP 26
EP 35
DI 10.1016/j.healun.2014.09.005
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA AZ5PW
UT WOS:000348273400003
PM 25444368
ER
PT J
AU Speicher, PJ
Ganapathi, AM
Englum, BR
Gulack, BC
Osho, AA
Hirji, SA
Castleberry, AW
Snyder, LD
Davis, RD
Hartwig, MG
AF Speicher, Paul. J.
Ganapathi, Asvin M.
Englum, Brian R.
Gulack, Brian C.
Osho, Asishana A.
Hirji, Sameer A.
Castleberry, Anthony W.
Snyder, Laurie D.
Davis, R. Duane
Hartwig, Matthew G.
TI Single-lung transplantation in the United States: What happens to the
other lung?
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
DE single-lung transplantation; resource utilization; donor allocation
ID OBSTRUCTIVE PULMONARY-DISEASE; DONOR SELECTION; MANAGEMENT; SURVIVAL;
REGISTRY
AB BACKGROUND: This study assessed treatment patterns and examined organ utilization in the setting of single-lung transplantation (SLT).
METHODS: The United Network for Organ Sharing database was queried for all SLTs performed from 1987 to 2011. Trends in utilization of the second donor lung were assessed, both from recipient and donor perspectives. Donors were stratified into 2 groups: those donating both lungs and those donating only 1 lung. Independent predictors of using only 1 donor lung were identified using multivariable logistic regression.
RESULTS: We identified 10,361 SLTs originating from 7,232 unique donors. Of these donors, both lungs were used in only 3,129 (43.3%), resulting in more than 200 second donor lungs going unused annually since 2005, with no significant increase in use over time (p = 0.95). After adjustment, donor characteristics predicting the second donor lung going unused included B/AB blood groups (adjusted odds ratio [AOR]: 1.69 and 2.62, respectively; p < 0.001), smaller body surface area (AOR, 1.30; p = 0.02), lower donor partial pressure of arterial oxygen (AOR, 0.90 per 50 mm Hg increase; p < 0.001), pulmonary infection (AOR, 1.15; p = 0.04), extended criteria donor Status (AOR, 1.66; p < 0.001), and death caused by head trauma (AOR, 1.57; p < 0.001) or anoxia (AOR, 1.53; p = 0.001).
CONCLUSIONS: Among donors for SLT, less than half of all cases led to use of the second donor lung. Although anatomic, infectious, or other pathophysiologic issues prohibit 100% utilization, more aggressive donor matching efforts may be a simple method of increasing the utilization of this scarce resource, particularly for less common blood types. (C) 2015 International Society for Heart and Lung Transplantation. All rights reserved.
C1 [Speicher, Paul. J.; Ganapathi, Asvin M.; Englum, Brian R.; Gulack, Brian C.; Castleberry, Anthony W.; Davis, R. Duane; Hartwig, Matthew G.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
[Osho, Asishana A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Hirji, Sameer A.] Duke Univ, Sch Med, Durham, NC 27710 USA.
[Snyder, Laurie D.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
RP Speicher, PJ (reprint author), Duke Univ, Med Ctr, Campus Box 3443, Durham, NC 27710 USA.
EM paul.speicher@duke.edu
FU National Institutes of Health-funded Cardiothoracic Surgery Trials
Network [5U01-HL-088953-05]
FX This work was supported by the National Institutes of Health-funded
Cardiothoracic Surgery Trials Network (5U01-HL-088953-05; M.G.H.).
NR 15
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD JAN
PY 2015
VL 34
IS 1
BP 36
EP 42
DI 10.1016/j.healun.2014.08.018
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
Transplantation
GA AZ5PW
UT WOS:000348273400004
PM 25305097
ER
PT J
AU Choi, HR
Kwon, YM
AF Choi, Ho-Rim
Kwon, Young-Min
TI Calf swelling associated with a long-standing total knee arthroplasty
SO JOURNAL OF ORTHOPAEDIC SCIENCE
LA English
DT Article
ID DISSECTING POPLITEAL CYST; PATELLAR COMPONENT; WEAR DEBRIS; MIMICKING;
FAILURE; MASS
C1 [Choi, Ho-Rim; Kwon, Young-Min] Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthopaed Lab, Boston, MA 02114 USA.
RP Choi, HR (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthopaed Lab, 55 Fruit St,GRJ-1126, Boston, MA 02114 USA.
EM choinagoya@yahoo.co.kr
FU MAKO
FX No benefits in any form have been received from a commercial party
related directly or indirectly to the subject of this article. The
institution of one or more of the authors (HRC, YMK) has received
funding from the MAKO for participation in review activities such as
data monitoring boards, statistical analysis, end point committees, and
the like.
NR 11
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
JAPAN
SN 0949-2658
EI 1436-2023
J9 J ORTHOP SCI
JI J. Orthop. Sci.
PD JAN
PY 2015
VL 20
IS 1
BP 209
EP 212
DI 10.1007/s00776-013-0425-y
PG 4
WC Orthopedics
SC Orthopedics
GA AZ6CY
UT WOS:000348307300028
PM 23779270
ER
PT J
AU Wang, C
Du, XL
Yang, R
Liu, J
Xu, D
Shi, JD
Chen, LF
Shao, R
Fan, GW
Gao, XM
Tian, G
Zhu, Y
Zhang, J
AF Wang, Chao
Du, Xiaoling
Yang, Rui
Liu, Jie
Xu, Da
Shi, Jiandang
Chen, Linfeng
Shao, Rui
Fan, Guanwei
Gao, Xiumei
Tian, Guo
Zhu, Yan
Zhang, Ju
TI The prevention and treatment effects of tanshinone IIA on
oestrogen/androgen-induced benign prostatic hyperplasia in rats
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Benign prostatic hyperplasia; Tanshinone IIA; Androgen receptor;
Oestrogen receptor alpha; Cyclins
ID SALVIA-MILTIORRHIZA BUNGE; ESTROGEN-RECEPTOR-ALPHA; SMOOTH-MUSCLE-CELLS;
CANCER-CELLS; ANDROGEN RECEPTOR; STROMAL CELLS; ANTICANCER ACTIVITY;
GROWTH-INHIBITION; BREAST-CANCER; CYCLIN D1
AB Benign prostatic hyperplasia (BPH) is one of the major diseases of the urinary system in elderly men. Tanshinone IIA (Tan IIA) is the active ingredient extracted from the traditional Chinese medicine Salvia, and it has effects of anti-oxidation, anti-inflammation, vascular smooth muscle relaxation and tumour growth inhibition. The present study aimed to investigate the therapeutic potential of Tan IIA in the prevention and treatment of BPH. In a rat model of oestradiol/testosterone-induced BPH, Tan IIA inhibited the increase in the thickness of the pen-glandular smooth muscle layer, suppressed the expression of proliferating cell nuclear antigen (PCNA) in both prostate epithelial cells and stromal cells, downregulated the expression of androgen receptor (AR), oestrogen receptor alpha (ER alpha), cyclin B1 (CCNB1) and cyclin D1 (CCND1), and effectively prevented the development of the disorder. In vitro, Tan IIA inhibited the proliferation of human prostate stromal cell line WPMY-1 and epithelial cell line RWPE-1 in a dose- and time-dependent manner. In WPMY-1 cells, Tan IIA treatment arrested the cell cycle at the G2/ M phase and downregulated the expression of CCNB1. However, in RWPE-1 cells, Tan IIA treatment arrested cell cycle at the G0/G1 phase and reduced the expression of CCND1. Tan IIA also reduced the expression of ER alpha and AR in WPMY-1 and RWPE-1 cells. These results suggest that Tan IIA can inhibit the growth of prostate stromal and epithelial cells both in vivo and in vitro by a mechanism that may involve arresting the cell cycle and downregulating ER alpha and AR expression. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Wang, Chao; Du, Xiaoling; Yang, Rui; Xu, Da; Shi, Jiandang; Shao, Rui; Tian, Guo; Zhang, Ju] Nankai Univ, Coll Life Sci, Dept Biochem & Mol Biol, Bioact Mat Key Lab,Minist Educ, Tianjin 300071, Peoples R China.
[Liu, Jie; Fan, Guanwei; Gao, Xiumei; Zhu, Yan] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin 300193, Peoples R China.
[Chen, Linfeng] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02445 USA.
RP Shi, JD (reprint author), Nankai Univ, Coll Life Sci, Dept Biochem & Mol Biol, Bioact Mat Key Lab,Minist Educ, Tianjin 300071, Peoples R China.
EM shijd@nankai.edu.cn; zhangju@nankai.edu.cn
FU National Natural Science Foundation of China [81370859]; National Basic
Research Programs (973 Programs) [2010CB945003, 2012CB723500]; Tianjin
Municipal Science and Technology Commission [12ZCDZSY17000]; 111 Project
[B08011]
FX This research was funded by the National Natural Science Foundation of
China, grant no. 81370859; the National Basic Research Programs (973
Programs), grants no. 2010CB945003 and 2012CB723500; the Tianjin
Municipal Science and Technology Commission, grant no. 12ZCDZSY17000;
and The 111 Project, grant no. B08011.
NR 55
TC 7
Z9 8
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD JAN
PY 2015
VL 145
BP 28
EP 37
DI 10.1016/j.jsbmb.2014.09.026
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AY7YJ
UT WOS:000347771400004
PM 25290459
ER
PT J
AU Cheng, TM
Freund, KM
Winter, M
Orlander, JD
AF Cheng, Teresa M.
Freund, Karen M.
Winter, Michael
Orlander, Jay D.
TI Limited Adoption of Current Guidelines for Clinical Breast Examination
by Primary Care Physician Educators
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID CANCER; MAMMOGRAPHY; PERFORMANCE; EXAM
AB Background: In 2004, the CDC and the American Cancer Society (ACS) published performance guidelines recommending a validated method of clinical breast exams (CBE) using the vertical strips method (VSM) along with other key exam components. We examined the use of the VSM by academic medicine physicians and identified predictor variables for its adoption.
Methods: Clinician educators in the Society of General Internal Medicine (SGIM) and physicians in the Society of Teachers of Family Medicine (STFM) were administered web-based surveys on CBE practices in 2009.
Results: A total of 1,772 (42%) physicians responded. Only 40% of respondents reported using the VSM, compared with 53% using the circular search method. Variables and their odds ratios (ORs) associated with an increase adoption of the VSM were having a primary teaching hospital affiliation (OR 1.4 [1.1, 1.9]), having taken a course on breast health or breast cancer in the past 5 years (OR 1.5 [1.1, 2.0]), and having completed residency in the past 5 years (OR 2.3 [1.6, 3.4]) and/or 10-15 years (OR 1.6 [1.2, 2.2]) compared to more than 15 years. The extent of teaching responsibilities was not associated with adoption of the VSM.
Conclusions: A majority of physician responders highly involved in education of students and residents continue to practice methods of CBE that do not reflect the current guidelines. Faculty development and training on updated CBE practices may accelerate adoption of guideline-recommended care.
C1 [Cheng, Teresa M.; Freund, Karen M.] Boston Univ, Sch Med, Div Gen Internal Med, Boston, MA 01118 USA.
[Freund, Karen M.] Tufts Univ, Sch Med, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA.
[Winter, Michael] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 01118 USA.
[Orlander, Jay D.] Boston Univ, Sch Med, Dept Med, Boston, MA 01118 USA.
[Orlander, Jay D.] VA Boston HealthCare Syst, West Roxbury, MA USA.
RP Freund, KM (reprint author), Boston Univ, Sch Med, Div Gen Internal Med, 801 Massachusetts Ave,2nd Floor, Boston, MA 01118 USA.
EM tmcheng@bu.edu
NR 24
TC 1
Z9 1
U1 1
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JAN 1
PY 2015
VL 24
IS 1
BP 11
EP 17
DI 10.1089/jwh.2014.4772
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AZ6JC
UT WOS:000348325100003
PM 25405388
ER
PT J
AU Bakhoum, SF
Kabeche, L
Wood, MD
Laucius, CD
Qu, D
Laughney, AM
Reynolds, GE
Louie, RJ
Phillips, J
Chan, DA
Zaki, BI
Murnane, JP
Petritsch, C
Compton, DA
AF Bakhoum, Samuel F.
Kabeche, Lilian
Wood, Matthew D.
Laucius, Christopher D.
Qu, Dian
Laughney, Ashley M.
Reynolds, Gloria E.
Louie, Raymond J.
Phillips, Joanna
Chan, Denise A.
Zaki, Bassem I.
Murnane, John P.
Petritsch, Claudia
Compton, Duane A.
TI Numerical chromosomal instability mediates susceptibility to radiation
treatment
SO NATURE COMMUNICATIONS
LA English
DT Article
ID INDUCED CELL-DEATH; EXTRA CENTROSOMES; MIS-SEGREGATION; DNA; MITOSIS;
CANCER; FRACTIONATION; ANEUPLOIDY; MECHANISM; SENSITIZERS
AB The exquisite sensitivity of mitotic cancer cells to ionizing radiation (IR) underlies an important rationale for the widely used fractionated radiation therapy. However, the mechanism for this cell cycle-dependent vulnerability is unknown. Here we show that treatment with IR leads to mitotic chromosome segregation errors in vivo and long-lasting aneuploidy in tumour-derived cell lines. These mitotic errors generate an abundance of micronuclei that predispose chromosomes to subsequent catastrophic pulverization thereby independently amplifying radiation-induced genome damage. Experimentally suppressing whole-chromosome missegregation reduces downstream chromosomal defects and significantly increases the viability of irradiated mitotic cells. Further, orthotopically transplanted human glioblastoma tumours in which chromosome missegregation rates have been reduced are rendered markedly more resistant to IR, exhibiting diminished markers of cell death in response to treatment. This work identifies a novel mitotic pathway for radiation-induced genome damage, which occurs outside of the primary nucleus and augments chromosomal breaks. This relationship between radiation treatment and whole-chromosome missegregation can be exploited to modulate therapeutic response in a clinically relevant manner.
C1 [Bakhoum, Samuel F.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA.
[Kabeche, Lilian; Laucius, Christopher D.; Compton, Duane A.] Geisel Sch Med Dartmouth, Dept Biochem, Hanover, NH 03755 USA.
[Kabeche, Lilian; Laucius, Christopher D.; Compton, Duane A.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA.
[Wood, Matthew D.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.
[Qu, Dian; Phillips, Joanna; Petritsch, Claudia] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
[Qu, Dian; Phillips, Joanna; Petritsch, Claudia] Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA.
[Qu, Dian; Phillips, Joanna; Petritsch, Claudia] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Laughney, Ashley M.] Harvard Univ, Sch Med, Dept Radiol, Ctr Syst Biol,Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Reynolds, Gloria E.; Louie, Raymond J.; Chan, Denise A.; Murnane, John P.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
[Zaki, Bassem I.] Geisel Sch Med, Sect Radiat Oncol, Dept Med, Lebanon, NH 03756 USA.
RP Bakhoum, SF (reprint author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10065 USA.
EM samuel.bakhoum@gmail.com
OI Bakhoum, Samuel/0000-0002-4779-8422
FU National Institutes of Health [R37GM051542, R01GM008704, R01CA120205,
R01CA164746, R01NS080619]; John H. Copenhaver Jr and William H. Thomas,
MD Junior Fellowship; Hitchcock-Foundation [250-4041]; RSNA [1304]
FX We thank Bernardo Orr, Alan C. Hartford, Ethan Dmitrosvky and Hal Swartz
(Dartmouth College), Mathieu Bakhoum (University of Texas Medical
Branch), Giulio Genovese (Broad Institute of Harvard and MIT), Jeffrey
Guenette (Harvard Medical School), Daphne Haas-Kogan (University of
California San Francisco), Barry Rosenstein (Mount Sinai School of
Medicine) and members of the Murnane (UCSF) and Compton (Dartmouth)
Laboratories for critical feedback. This study was supported by the
following grants: R37GM051542 (D. A. Compton), R01GM008704 (L.K.),
R01CA120205 (J.P.M., G.E.R.) R01CA164746 and R01NS080619 (C.P., D.Q.)
from the National Institutes of Health, and the John H. Copenhaver Jr
and William H. Thomas, MD 1952 Junior Fellowship (L.K.),
Hitchcock-Foundation 250-4041 and RSNA 1304 (S.B.).
NR 44
TC 7
Z9 7
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2015
VL 6
AR 5990
DI 10.1038/ncomms6990
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA3MY
UT WOS:000348812100008
PM 25606712
ER
PT J
AU The, I
Ruijtenberg, S
Bouchet, BP
Cristobal, A
Prinsen, MBW
van Mourik, T
Koreth, J
Xu, HH
Heck, AJR
Akhmanova, A
Cuppen, E
Boxem, M
Munoz, J
van den Heuvel, S
AF The, Inge
Ruijtenberg, Suzan
Bouchet, Benjamin P.
Cristobal, Alba
Prinsen, Martine B. W.
van Mourik, Tim
Koreth, John
Xu, Huihong
Heck, Albert J. R.
Akhmanova, Anna
Cuppen, Edwin
Boxem, Mike
Munoz, Javier
van den Heuvel, Sander
TI Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and
human cancer cells
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ANAPHASE-PROMOTING COMPLEX; CYCLIN-DEPENDENT KINASES; HUMAN
BREAST-CANCER; CAENORHABDITIS-ELEGANS; S-PHASE; UBIQUITIN LIGASE;
MITOTIC CYCLINS; DISTINCT ROLES; PERSISTS UNTIL; PROTEOLYSIS
AB Cyclin-dependent kinases 4 and 6 (CDK4/6) in complex with D-type cyclins promote cell cycle entry. Most human cancers contain overactive CDK4/6-cyclin D, and CDK4/6-specific inhibitors are promising anti-cancer therapeutics. Here, we investigate the critical functions of CDK4/6-cyclin D kinases, starting from an unbiased screen in the nematode Caenorhabditis elegans. We found that simultaneous mutation of lin-35, a retinoblastoma (Rb)-related gene, and fzr-1, an orthologue to the APC/C co-activator Cdh1, completely eliminates the essential requirement of CDK4/6-cyclin D (CDK-4/CYD-1) in C. elegans. CDK-4/CYD-1 phosphorylates specific residues in the LIN-35 Rb spacer domain and FZR-1 amino terminus, resembling inactivating phosphorylations of the human proteins. In human breast cancer cells, simultaneous knockdown of Rb and FZR1 synergistically bypasses cell division arrest induced by the CDK4/6-specific inhibitor PD-0332991. Our data identify FZR1 as a candidate CDK4/6-cyclin D substrate and point to an APC/C-FZR1 activity as an important determinant in response to CDK4/6-inhibitors.
C1 [The, Inge; Ruijtenberg, Suzan; Bouchet, Benjamin P.; Prinsen, Martine B. W.; van Mourik, Tim; Akhmanova, Anna; Boxem, Mike; van den Heuvel, Sander] Univ Utrecht, Fac Sci, Dept Biol, NL-3584 CH Utrecht, Netherlands.
[Cristobal, Alba; Heck, Albert J. R.; Munoz, Javier] Univ Utrecht, Bijvoet Ctr Biomol Res, Biomol Mass Spectrometry & Prote Grp, NL-3584 CH Utrecht, Netherlands.
[Cristobal, Alba; Heck, Albert J. R.; Munoz, Javier] Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CH Utrecht, Netherlands.
[Koreth, John] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Xu, Huihong] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.
[Xu, Huihong] Boston Med Ctr, Boston, MA 02118 USA.
[Cuppen, Edwin] Hubrecht Inst, NL-3584 CT Utrecht, Netherlands.
RP van den Heuvel, S (reprint author), Univ Utrecht, Fac Sci, Dept Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.
EM s.j.l.vandenHeuvel@uu.nl
RI Munoz, Javier/I-4891-2012; Cuppen, Edwin/H-2389-2016; van den Heuvel,
Sander/B-8892-2011; Boxem, Mike/B-8857-2011
OI Munoz, Javier/0000-0003-3288-3496; Cuppen, Edwin/0000-0002-0400-9542;
Boxem, Mike/0000-0003-3966-4173
FU NIH Office of Research Infrastructure Programs [P40 OD010440];
Netherlands Organisation for Scientific Research (NWO) [819.02.016];
Marie Curie Intra-European Fellowships for Career Development [273872];
NWO ALW; NWO [H01.205]
FX We thank E. Kipreos, A. Hyman and A. Pozniakovsky for reagents; A.
Thomas for critically reading the manuscript; and members of the van den
Heuvel and Boxem groups for help and critical comments. Several strains
were provided by the CGC, which is funded by NIH Office of Research
Infrastructure Programs (P40 OD010440). This work is part of research
programme 819.02.016, financed by the Netherlands Organisation for
Scientific Research (NWO). B.P.B. was supported by a Marie Curie
Intra-European Fellowships for Career Development 273872, NWO ALW
provided support for TvM (CGDB graduate programme grant from NWO
H01.205), M.B. (Innovational Research Incentives Scheme VIDI grant
864.09.008) and A. A. (ALW VICI 865.08.002). We acknowledge the PRIDE
team for proteomics data dissemination.
NR 58
TC 7
Z9 7
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2015
VL 6
AR 5906
DI 10.1038/ncomms6906
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA2MG
UT WOS:000348741900004
PM 25562820
ER
PT J
AU Wang, LZ
Liu, RH
Ye, PY
Wong, CS
Chen, GY
Zhou, PH
Sakabe, K
Zheng, X
Wu, W
Zhang, P
Jiang, TJ
Bassetti, MF
Jube, S
Sun, Y
Zhang, YP
Zheng, P
Liu, Y
AF Wang, Lizhong
Liu, Runhua
Ye, Peiying
Wong, Chunshu
Chen, Guo-Yun
Zhou, Penghui
Sakabe, Kaoru
Zheng, Xincheng
Wu, Wei
Zhang, Peng
Jiang, Taijiao
Bassetti, Michael F.
Jube, Sandro
Sun, Yi
Zhang, Yanping
Zheng, Pan
Liu, Yang
TI Intracellular CD24 disrupts the ARF-NPM interaction and enables
mutational and viral oncogene-mediated p53 inactivation
SO NATURE COMMUNICATIONS
LA English
DT Article
ID INDEPENDENT PROGNOSTIC MARKER; TUMOR-SUPPRESSOR; PROSTATE-CANCER;
CARCINOMA-CELLS; RETINOBLASTOMA-PROTEIN; MULTIPLE-SCLEROSIS;
CERVICAL-CARCINOMA; P-SELECTIN; IN-VIVO; MOUSE
AB CD24 is overexpressed in nearly 70% human cancers, whereas TP53 is the most frequently mutated tumour-suppressor gene that functions in a context-dependent manner. Here we show that both targeted mutation and short hairpin RNA (shRNA) silencing of CD24 retard the growth, progression and metastasis of prostate cancer. CD24 competitively inhibits ARF binding to NPM, resulting in decreased ARF, increase MDM2 and decrease levels of p53 and the p53 target p21/CDKN1A. CD24 silencing prevents functional inactivation of p53 by both somatic mutation and viral oncogenes, including the SV40 large T antigen and human papilloma virus 16 E6-antigen. In support of the functional interaction between CD24 and p53, in silico analyses reveal that TP53 mutates at a higher rate among glioma and prostate cancer samples with higher CD24 mRNA levels. These data provide a general mechanism for functional inactivation of ARF and reveal an important cellular context for genetic and viral inactivation of TP53.
C1 [Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
[Ye, Peiying; Wong, Chunshu; Chen, Guo-Yun; Sakabe, Kaoru; Jube, Sandro; Zheng, Pan; Liu, Yang] Childrens Natl Med Ctr, Childrens Res Inst, Ctr Canc & Immunol Res, Washington, DC 20010 USA.
[Ye, Peiying; Wong, Chunshu; Chen, Guo-Yun; Sakabe, Kaoru; Jube, Sandro; Zheng, Pan; Liu, Yang] Childrens Natl Med Ctr, Childrens Res Inst, Div Pathol, Washington, DC 20010 USA.
[Ye, Peiying] Univ Michigan, Sch Med, Program Immunol, Integrated Biomed Grad Program, Ann Arbor, MI 48103 USA.
[Zhou, Penghui] Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zheng, Xincheng; Wu, Wei] OncoImmune Inc, Rockville, MD 20852 USA.
[Zhang, Peng; Jiang, Taijiao] Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China.
[Bassetti, Michael F.; Sun, Yi] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48105 USA.
[Zhang, Yanping] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
[Zhang, Yanping] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
RP Zheng, P (reprint author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
EM lwang12@uab.edu; pzheng@cnmc.org; yaliu@cnmc.org
OI Zhang, Peng/0000-0002-6218-1885; Zheng, Pan/0000-0003-2598-3544
FU National Institutes of Health [AI64350, CA171972, CA58033, AG036690,
R21CA164688, U54 CA118948]; Department of Defense
[DOD-W81XWH-10-PCRP-SIDA]; NIH [P50 CA093990]
FX This study was supported by grants from the National Institutes of
Health (AI64350, CA171972 and CA58033 and to Y.L., AG036690 to P.Z.,
R21CA164688 and a pilot grant from U54 CA118948 to L.W.) and the
Department of Defense (DOD-W81XWH-10-PCRP-SIDA to Y.L.). We thank the
Department of Radiology at the University of Michigan for the use of the
Center for Molecular Imaging, which is supported in part by NIH grant
P50 CA093990.
NR 70
TC 11
Z9 12
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2015
VL 6
DI 10.1038/ncomms6909
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA2MG
UT WOS:000348741900007
PM 25600590
ER
PT J
AU Yoda, A
Adelmant, G
Tamburini, J
Chapuy, B
Shindoh, N
Yoda, Y
Weigert, O
Kopp, N
Wu, SC
Kim, SS
Liu, H
Tivey, T
Christie, AL
Elpek, KG
Card, J
Gritsman, K
Gotlib, J
Deininger, MW
Makishima, H
Turley, SJ
Javidi-Sharifi, N
Maciejewski, JP
Jaiswal, S
Ebert, BL
Rodig, SJ
Tyner, JW
Marto, JA
Weinstock, DM
Lane, AA
AF Yoda, Akinori
Adelmant, Guillaume
Tamburini, Jerome
Chapuy, Bjoern
Shindoh, Nobuaki
Yoda, Yuka
Weigert, Oliver
Kopp, Nadja
Wu, Shuo-Chieh
Kim, Sunhee S.
Liu, Huiyun
Tivey, Trevor
Christie, Amanda L.
Elpek, Kutlu G.
Card, Joseph
Gritsman, Kira
Gotlib, Jason
Deininger, Michael W.
Makishima, Hideki
Turley, Shannon J.
Javidi-Sharifi, Nathalie
Maciejewski, Jaroslaw P.
Jaiswal, Siddhartha
Ebert, Benjamin L.
Rodig, Scott J.
Tyner, Jeffrey W.
Marto, Jarrod A.
Weinstock, David M.
Lane, Andrew A.
TI Mutations in G protein beta subunits promote transformation and kinase
inhibitor resistance
SO NATURE MEDICINE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; DENDRITIC CELL NEOPLASM; GAMMA-SUBUNITS;
MYELODYSPLASTIC SYNDROMES; COUPLED RECEPTORS; GENOME; CANCER;
ACTIVATION; LANDSCAPE; MELANOMA
AB Activating mutations in genes encoding G protein alpha (G alpha) subunits occur in 4-5% of all human cancers(1), but oncogenic alterations in G beta subunits have not been defined. Here we demonstrate that recurrent mutations in the G beta proteins GNB1 and GNB2 confer cytokine-independent growth and activate canonical G protein signaling. Multiple mutations in GNB1 affect the protein interface that binds G alpha subunits as well as downstream effectors and disrupt G alpha interactions with the dimer G beta gamma Different mutations in G beta proteins clustered partly on the basis of lineage; for example, all 11 GNB1 K57 mutations were in myeloid neoplasms, and seven of eight GNB1 180 mutations were in B cell neoplasms. Expression of patient-derived GNB1 variants in Cdkn2a-deficient mouse bone marrow followed by transplantation resulted in either myeloid or B cell malignancies. In vivo treatment with the dual PI3K-mTOR inhibitor BEZ235 suppressed GNB1-induced signaling and markedly increased survival. In several human tumors, mutations in the gene encoding GNB1 co-occurred with oncogenic kinase alterations, including the BCR-ABL fusion protein, the V617F substitution in JAK2 and the V600K substitution in BRAF. Coexpression of patient-derived GNB1 variants with these mutant kinases resulted in inhibitor resistance in each context. Thus, GNB1 and GNB2 alterations confer transformed and resistance phenotypes across a range of human tumors and may be targetable with inhibitors of G protein signaling.
C1 [Yoda, Akinori; Tamburini, Jerome; Chapuy, Bjoern; Shindoh, Nobuaki; Yoda, Yuka; Kopp, Nadja; Wu, Shuo-Chieh; Kim, Sunhee S.; Liu, Huiyun; Tivey, Trevor; Christie, Amanda L.; Gritsman, Kira; Weinstock, David M.; Lane, Andrew A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Adelmant, Guillaume; Card, Joseph; Marto, Jarrod A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Adelmant, Guillaume; Marto, Jarrod A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02115 USA.
[Shindoh, Nobuaki] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Weigert, Oliver] Astellas Pharma Inc, Drug Discovery Res, Tsukuba, Ibaraki, Japan.
[Weigert, Oliver] Univ Munich, Dept Med 3, Munich, Germany.
[Elpek, Kutlu G.; Turley, Shannon J.] Helmholtz Ctr, Munich, Germany.
[Elpek, Kutlu G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Gotlib, Jason] Jounce Therapeut Inc, Cambridge, MA USA.
[Deininger, Michael W.] Stanford Univ, Sch Med, Stanford Canc Inst, Dept Hematol, Stanford, CA USA.
[Makishima, Hideki] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA.
[Javidi-Sharifi, Nathalie; Tyner, Jeffrey W.] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA.
[Jaiswal, Siddhartha; Rodig, Scott J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA.
[Jaiswal, Siddhartha; Ebert, Benjamin L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Ebert, Benjamin L.; Weinstock, David M.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA.
Broad Inst, Cambridge, MA USA.
RP Weinstock, DM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM dweinstock@partners.org; andrew_lane@dfci.harvard.edu
FU Aplastic Anemia and MDS International Foundation; Edwards P. Evans
Foundation; Max-Eder Program of the Deutsche Krebshilfe [110659];
Leukemia and Lymphoma Society; US National Institutes of Health NCI
[1R01CA183947, 5R00CA151457]; V Foundation for Cancer Research;
Gabrielle's Angel Foundation; Claudia Adams Barr Fund; American Cancer
Society Research Scholar Grant; Stand Up To Cancer Innovative Research
Grant; American Society of Hematology Scholar Award
FX We thank T. Radimersld, T. Haferlach, L. Garraway, M. Walter and N.
Wagle for contributing to the manuscript. We thank A. Hawkins and the
Brigham and Women's Hospital Cytogenomics Core Facility for karyotyping.
This research was supported by the Aplastic Anemia and MDS International
Foundation (AT.), the Edwards P. Evans Foundation (A.Y.), the Max-Eder
Program of the Deutsche Krebshilfe (#110659 to O.W), the Leukemia and
Lymphoma Society (J.W.T.), US National Institutes of Health NCI
(1R01CA183947 and 5R00CA151457 to J.W.T.), the V Foundation for Cancer
Research (J.W.T.), Gabrielle's Angel Foundation for Cancer Research
(J.W.T.), the Claudia Adams Barr Fund (A.Y. and D.M.W.), an American
Cancer Society Research Scholar Grant (D.M.W.), a Stand Up To Cancer
Innovative Research Grant (D.M.W.), and an American Society of
Hematology Scholar Award (A.A.L.).
NR 30
TC 10
Z9 10
U1 3
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JAN
PY 2015
VL 21
IS 1
BP 71
EP 75
DI 10.1038/nm.3751
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA AZ7OM
UT WOS:000348408000015
PM 25485910
ER
PT J
AU Sabuncu, MR
Konukoglu, E
AF Sabuncu, Mert R.
Konukoglu, Ender
CA Alzheimer's Dis Neuroimaging
TI Clinical Prediction from Structural Brain MRI Scans: A Large-Scale
Empirical Study
SO NEUROINFORMATICS
LA English
DT Article
DE Image-based prediction; Computer aided diagnosis; Machine learning; MRI
ID SUPPORT VECTOR MACHINE; MILD COGNITIVE IMPAIRMENT; VOXEL-BASED
MORPHOMETRY; SURFACE-BASED ANALYSIS; ALZHEIMERS-DISEASE;
FEATURE-SELECTION; PATTERN-CLASSIFICATION; CORTICAL SURFACE; HEALTHY
CONTROLS; SCHIZOPHRENIA-PATIENTS
AB Multivariate pattern analysis (MVPA) methods have become an important tool in neuroimaging, revealing complex associations and yielding powerful prediction models. Despite methodological developments and novel application domains, there has been little effort to compile benchmark results that researchers can reference and compare against. This study takes a significant step in this direction. We employed three classes of state-of-the-art MVPA algorithms and common types of structural measurements from brain Magnetic Resonance Imaging (MRI) scans to predict an array of clinically relevant variables (diagnosis of Alzheimer's, schizophrenia, autism, and attention deficit and hyperactivity disorder; age, cerebrospinal fluid derived amyloid-beta levels and mini-mental state exam score). We analyzed data from over 2,800 subjects, compiled from six publicly available datasets. The employed data and computational tools are freely distributed , making this the largest, most comprehensive, reproducible benchmark image-based prediction experiment to date in structural neuroimaging. Finally, we make several observations regarding the factors that influence prediction performance and point to future research directions. Unsurprisingly, our results suggest that the biological footprint (effect size) has a dramatic influence on prediction performance. Though the choice of image measurement and MVPA algorithm can impact the result, there was no universally optimal selection. Intriguingly, the choice of algorithm seemed to be less critical than the choice of measurement type. Finally, our results showed that cross-validation estimates of performance, while generally optimistic, correlate well with generalization accuracy on a new dataset.
C1 [Sabuncu, Mert R.; Konukoglu, Ender] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Sabuncu, Mert R.] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
RP Sabuncu, MR (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St,Room 2301, Charlestown, MA 02129 USA.
EM msabuncu@nmr.mgh.harvard.edu
FU National Institute of Biomedical Imaging and Bioengineering (NIBIB),
National Institutes of Health [P41EB015896]; AHAF (BrightFocus)
Alzheimer's Disease pilot grant [AHAF A2012333]; NIH K25 grant [NIBIB
1K25EB013649-01]; National Center for Research Resources [U24 RR021382];
National Institute for Biomedical Imaging and Bioengineering
[R01EB006758]; National Institute for Neurological Disorders and Stroke
[R01 NS052585-01, 1R21NS072652-01, 1R01NS070963, R01NS083534]; Shared
Instrumentation Grants [1S10RR023401, 1S10RR019307, 1S10RR023043]; NIH
Blueprint for Neuroscience Research part of the multi-institutional
Human Connectome Project [5U01-MH093765]
FX This research was carried out in whole or in part at the Athinoula A.
Martinos Center for Biomedical Imaging at the Massachusetts General
Hospital, using resources provided by the Center for Functional
Neuroimaging Technologies, P41EB015896, a P41 Biotechnology Resource
Grant supported by the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), National Institutes of Health. Dr. Sabuncu
received support from an AHAF (BrightFocus) Alzheimer's Disease pilot
grant (AHAF A2012333), and an NIH K25 grant (NIBIB 1K25EB013649-01).
Further support for this research was provided in part by the National
Center for Research Resources (U24 RR021382), the National Institute for
Biomedical Imaging and Bioengineering (R01EB006758), National Institute
for Neurological Disorders and Stroke (R01 NS052585-01, 1R21NS072652-01,
1R01NS070963, R01NS083534), and was made possible by the resources
provided by Shared Instrumentation Grants 1S10RR023401, 1S10RR019307,
and 1S10RR023043. Additional support was provided by the NIH Blueprint
for Neuroscience Research (5U01-MH093765), part of the
multi-institutional Human Connectome Project.
NR 85
TC 11
Z9 11
U1 2
U2 14
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1539-2791
EI 1559-0089
J9 NEUROINFORMATICS
JI Neuroinformatics
PD JAN
PY 2015
VL 13
IS 1
BP 31
EP 46
DI 10.1007/s12021-014-9238-1
PG 16
WC Computer Science, Interdisciplinary Applications; Neurosciences
SC Computer Science; Neurosciences & Neurology
GA AZ7UD
UT WOS:000348422200004
PM 25048627
ER
PT J
AU Wells, TS
Seelig, AD
Ryan, MAK
Jones, JM
Hooper, TI
Jacobson, IG
Boyko, EJ
AF Wells, Timothy S.
Seelig, Amber D.
Ryan, Margaret A. K.
Jones, Jason M.
Hooper, Tomoko I.
Jacobson, Isabel G.
Boyko, Edward J.
TI Hearing loss associated with US military combat deployment
SO NOISE & HEALTH
LA English
DT Article
DE Combat disorders; hearing loss; military personnel
ID TRAUMATIC BRAIN-INJURY; MILLENNIUM COHORT; SERVICE MEMBERS;
NATIONAL-HEALTH; IMPULSE NOISE; ADULTS; PERSONNEL; RISK; POPULATION;
IMPAIRMENT
AB The objective of this study was to define the risk of hearing loss among US military members in relation to their deployment experiences. Data were drawn from the Millennium Cohort Study. Self-reported data and objective military service data were used to assess exposures and outcomes. Among all 48,540 participants, 7.5% self-reported new-onset hearing loss. Self-reported hearing loss showed moderate to substantial agreement (k = 0.57-0.69) with objective audiometric measures. New-onset hearing loss was associated with combat deployment (adjusted odds ratio [AOR] = 1.63, 95% confidence interval [CI] = 1.49-1.77), as well as male sex and older age. Among deployers, new-onset hearing loss was also associated with proximity to improvised explosive devices (AOR = 2.10, 95% CI = 1.62-2.73) and with experiencing a combat-related head injury (AOR = 6.88, 95% CI = 3.77-12.54). These findings have implications for health care and disability planning, as well as for prevention programs.
C1 [Wells, Timothy S.] Adv Analyt Optum, Ann Arbor, MI USA.
[Wells, Timothy S.] Adv Analyt Optum, San Diego, CA USA.
[Seelig, Amber D.; Jacobson, Isabel G.] Naval Hlth Res Ctr, San Diego, CA USA.
[Ryan, Margaret A. K.; Jones, Jason M.] Naval Hosp Camp Pendleton, San Diego, CA USA.
[Hooper, Tomoko I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA.
[Seelig, Amber D.; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA.
RP Wells, TS (reprint author), 1839 Waverly Rd, Holt, MI USA.
EM tmlbwells@wowway.com
NR 48
TC 2
Z9 2
U1 3
U2 7
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 1463-1741
EI 1998-4030
J9 NOISE HEALTH
JI Noise Health
PD JAN-FEB
PY 2015
VL 17
IS 74
BP 34
EP 42
PG 9
WC Audiology & Speech-Language Pathology; Public, Environmental &
Occupational Health
SC Audiology & Speech-Language Pathology; Public, Environmental &
Occupational Health
GA AZ7EH
UT WOS:000348381200005
PM 25599756
ER
PT J
AU Chabner, BA
AF Chabner, Bruce A.
TI Two Decades of The Oncologist
SO ONCOLOGIST
LA English
DT Editorial Material
C1 [Chabner, Bruce A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Chabner, BA (reprint author), 10 North Grove St,LRH 214, Boston, MA 02114 USA.
EM bchabner@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JAN
PY 2015
VL 20
IS 1
BP 1
EP 2
DI 10.1634/theoncologist.2014-0490
PG 2
WC Oncology
SC Oncology
GA AZ8IO
UT WOS:000348459100001
PM 25589499
ER
PT J
AU Dizon, DS
AF Dizon, Don S.
TI Toward Eubiosia: Bridging Oncology and Palliative Care
SO ONCOLOGIST
LA English
DT Editorial Material
C1 [Dizon, Don S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Dizon, DS (reprint author), 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM ddizon@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JAN
PY 2015
VL 20
IS 1
BP 5
EP 6
DI 10.1634/theoncologist.2014-0462
PG 2
WC Oncology
SC Oncology
GA AZ8IO
UT WOS:000348459100003
PM 25492921
ER
PT J
AU Sikalidis, AK
AF Sikalidis, Angelos K.
TI Amino Acids and Immune Response: A Role for Cysteine, Glutamine,
Phenylalanine, Tryptophan and Arginine in T-cell Function and Cancer?
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Review
DE T-cell; Amino acids; Cysteine; Glutamine; Phenylalanine; Tryptophan;
Arginine; Immune response; Signaling; Immunomodulation; Avidity
ID INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; GENE-EXPRESSION;
SUPPRESSOR-CELLS; OXIDATIVE-STRESS; DENDRITIC CELLS; PROTEIN-KINASE;
IN-VIVO; METABOLISM; ACTIVATION; RECEPTOR
AB While proteins are critical for immunity, T-cells constitute a critical component of adaptive immunity by clearing cancerous cells among other abnormal cells. However, cancer cells exhibit a potential to escape T-cell control by employing mechanisms not completely delineated. Interesting work has investigated how certain amino acids affect the proliferation rate of T-cells as well as their effectiveness in clearing tumors. The role of amino acids cysteine, glutamine, phenylalanine, tryptophan and arginine in immunomodulation and particularly regarding T-cell proliferation and activation is discussed. The redox balance is reported to affect T-cell proliferation via modulation of cysteine availability. In addition antigen presenting cells (APCs), similar to myeloid cells determine the availability of amino acids in the extracellular microenvironment affecting T-cell proliferation and activation. A better mechanistic understanding of T-cell function modulation via amino acid signaling or metabolic properties may be helpful towards optimization of adaptive immunity with implications for cancer prognosis and treatment.
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Harvard Inst Med,Immunobiol Lab, Boston, MA 02115 USA.
RP Sikalidis, AK (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Harvard Inst Med,Immunobiol Lab, 77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM angelos_sikalidis@dfci.harvard.edu
NR 76
TC 13
Z9 14
U1 7
U2 27
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JAN
PY 2015
VL 21
IS 1
BP 9
EP 17
DI 10.1007/s12253-014-9860-0
PG 9
WC Oncology; Pathology
SC Oncology; Pathology
GA AY8AL
UT WOS:000347776700002
PM 25351939
ER
PT J
AU Baumer, FM
Kamihara, J
Gorman, MP
AF Baumer, Fiona M.
Kamihara, Junne
Gorman, Mark P.
TI Neuromyelitis Optica in an Adolescent After Bone Marrow Transplantation
SO PEDIATRIC NEUROLOGY
LA English
DT Article
DE myelitis; optic neuritis; neuromyelitis optica; bone marrow
transplantation; stem cell transplant; acute myeloid leukemia
ID STEM-CELL TRANSPLANTATION; IMMUNE-MEDIATED MYELOPATHY;
VERSUS-HOST-DISEASE; AQUAPORIN-4; MYELITIS; ANTIBODY
AB BACKGROUND: Central nervous system complications of bone marrow transplant are a common occurrence and the differential diagnosis is quite broad, including opportunistic infections, medications toxicities, graft versus host disease, and other autoimmune processes. PATIENT DESCRIPTION: We summarize previously reported cases of autoimmune myelitis in post-transplant patients and discuss a 17-year-old boy who presented with seronegative neuromyelitis optica after a bone marrow transplant for acute myeloid leukemia. Our patient had a marked improvement in symptoms after plasmapheresis. CONCLUSION: Including our patient, there have been at least eight cases of post-transplant autoimmune myelitis presented in the literature, and at least three of these are suspicious for neuromyelitis optica. Several of these patients had poor outcomes with persistent symptoms after the myelitis. Autoimmune processes such as neuromyelitis optica should be carefully considered in patients after transplant as aggressive treatment like early plasmapheresis may improve outcomes.
C1 [Baumer, Fiona M.; Gorman, Mark P.] Harvard Univ, Sch Med, Dept Neurol, Boston Childrens Hosp, Boston, MA 02115 USA.
[Kamihara, Junne] Harvard Univ, Sch Med, Dept Pediat Oncol, Div Hematol Oncol,Dana Farber Canc Inst, Boston, MA USA.
RP Baumer, FM (reprint author), Boston Childrens Hosp, 300 Longwood Ave,Fegan 11, Boston, MA 02115 USA.
EM Fiona.baumer@childrens.harvard.edu
NR 11
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD JAN
PY 2015
VL 52
IS 1
BP 119
EP 124
DI 10.1016/j.pediatrneurol.2014.07.007
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA AZ7QA
UT WOS:000348411800019
PM 25444090
ER
PT J
AU Rybin, D
Doros, G
Rosenheck, R
Lew, R
AF Rybin, Denis
Doros, Gheorghe
Rosenheck, Robert
Lew, Robert
TI The impact of missing data on the results of a schizophrenia study
SO PHARMACEUTICAL STATISTICS
LA English
DT Article
DE missing data; sensitivity analysis; Bayesian analysis; pattern mixture
ID PATTERN-MIXTURE MODELS; RISPERIDONE; HALOPERIDOL; OLANZAPINE; TRIAL
AB Missing data pose a serious challenge to the integrity of randomized clinical trials, especially of treatments for prolonged illnesses such as schizophrenia, in which long-term impact assessment is of great importance, but the follow-up rates are often no more than 50%. Sensitivity analysis using Bayesian modeling for missing data offers a systematic approach to assessing the sensitivity of the inferences made on the basis of observed data. This paper uses data from an 18-month study of veterans with schizophrenia to demonstrate this approach. Data were obtained from a randomized clinical trial involving 369 patients diagnosed with schizophrenia that compared long-acting injectable risperidone with a psychiatrist's choice of oral treatment. Bayesian analysis utilizing a pattern-mixture modeling approach was used to validate the reported results by detecting bias due to non-random patterns of missing data. The analysis was applied to several outcomes including standard measures of schizophrenia symptoms, quality of life, alcohol use, and global mental status. The original study results for several measures were confirmed against a wide range of patterns of non-random missingness. Robustness of the conclusions was assessed using sensitivity parameters. The missing data in the trial did not likely threaten the validity of previously reported results. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Rybin, Denis; Doros, Gheorghe; Lew, Robert] Boston Univ, Boston, MA 02215 USA.
[Rybin, Denis] VA Boston Healthcare Syst, Boston VA Res Inst, Boston, MA USA.
[Doros, Gheorghe; Lew, Robert] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
[Rosenheck, Robert] VA New England, Mental Illness Res Educ & Clin Ctr, West Haven, CT USA.
[Rosenheck, Robert] Yale Univ, Sch Med, New Haven, CT USA.
RP Rybin, D (reprint author), Boston Univ, Boston, MA 02215 USA.
EM drybine@bu.edu
OI Rybin, Denis/0000-0002-3657-4829
NR 16
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1539-1604
EI 1539-1612
J9 PHARM STAT
JI Pharm. Stat.
PD JAN-FEB
PY 2015
VL 14
IS 1
BP 4
EP 10
DI 10.1002/pst.1651
PG 7
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA AZ9FZ
UT WOS:000348520200002
PM 25327503
ER
PT J
AU Katiyar, SK
AF Katiyar, Santosh K.
TI Proanthocyanidins from Grape Seeds Inhibit UV-Radiation-Induced Immune
Suppression in Mice: Detection and Analysis of Molecular and Cellular
Targets
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Review
ID ULTRAVIOLET-INDUCED CARCINOGENESIS; CD8(+) T-CELLS; SKIN-CANCER; CONTACT
HYPERSENSITIVITY; DENDRITIC CELLS; INDUCED IMMUNOSUPPRESSION; TRANSPLANT
RECIPIENTS; PYRIMIDINE DIMERS; IRRADIATED MICE; RISK-FACTOR
AB Ultraviolet (UV)-radiation-induced immunosuppression has been linked with the risk of skin carcinogenesis. Approximately, 2million new cases of skin cancers, including melanoma and nonmelanoma, diagnosed each year in the USA and therefore have a tremendous bad impact on public health. Dietary phytochemicals are promising options for the development of effective strategy for the prevention of photodamaging effects of UV radiation including the risk of skin cancer. Grape seed proanthocyanidins (GSPs) are such phytochemicals. Dietary administration of GSPs with AIN76A control diet significantly inhibits UV-induced skin tumor development as well as suppression of immune system. UV-induced suppression of immune system is commonly determined using contact hypersensitivity (CHS) model which is a prototype of T-cell-mediated immune response. We present evidence that inhibition of UV-induced suppression of immune system by GSPs is mediated through: (i) the alterations in immunoregulatory cytokines, interleukin (IL)-10 and IL-12, (ii) DNA repair, (iii) stimulation of effector T cells and (iv) DNA repair-dependent functional activation of dendritic cells in mouse model. These information have important implications for the use of GSPs as a dietary supplement in chemoprevention of UV-induced immunosuppression as well as photocarcinogenesis.
C1 [Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU National Cancer Institute/NCCAM/NIH [CA140197, CA140832]; Veterans
Administration Merit Review Award
FX The work reported from Dr. Katiyar's laboratory was supported by the
funds from National Cancer Institute/NCCAM/NIH (CA140197, CA140832) and
Veterans Administration Merit Review Award (S.K.K.). The content of this
article does not necessarily reflect the views or policies of the
funding agencies.
NR 55
TC 1
Z9 1
U1 4
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD JAN-FEB
PY 2015
VL 91
IS 1
BP 156
EP 162
DI 10.1111/php.12330
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AZ8CN
UT WOS:000348442600019
PM 25112437
ER
PT J
AU Nasti, TH
Timares, L
AF Nasti, Tahseen H.
Timares, Laura
TI MC1R, Eumelanin and Pheomelanin: Their Role in Determining the
Susceptibility to Skin Cancer
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Review
ID MELANOCYTE-STIMULATING HORMONE; MOUSE EPIDERMAL MELANOCYTES;
T-CELL-ACTIVATION; NF-KAPPA-B; HUMAN MELANOCORTIN-1 RECEPTOR;
FIBROBLAST-GROWTH-FACTOR; ALPHA-MSH; RED HAIR; TRANSCRIPTION FACTOR;
1,25-DIHYDROXYVITAMIN D-3
AB Skin pigmentation is due to the accumulation of two types of melanin granules in the keratinocytes. Besides being the most potent blocker of ultraviolet radiation, the role of melanin in photoprotection is complex. This is because one type of melanin called eumelanin is UV absorbent, whereas the other, pheomelanin, is photounstable and may even promote carcinogenesis. Skin hyperpigmentation may be caused by stress or exposure to sunlight, which stimulates the release of -melanocyte stimulating hormone (-MSH) from damaged keratinocytes. Melanocortin 1 receptor (MC1R) is a key signaling molecule on melanocytes that responds to -MSH by inducing expression of enzymes responsible for eumelanin synthesis. Persons with red hair have mutations in the MC1R causing its inactivation; this leads to a paucity of eumelanin production and makes red-heads more susceptible to skin cancer. Apart from its effects on melanin production, the -MSH/MC1R signaling is also a potent anti-inflammatory pathway and has been shown to promote antimelanoma immunity. This review will focus on the role of MC1R in terms of its regulation of melanogenesis and influence on the immune system with respect to skin cancer susceptibility.
C1 [Nasti, Tahseen H.; Timares, Laura] Univ Alabama Birmingham, Dept Dermatol, Sch Med, Birmingham, AL 35294 USA.
[Timares, Laura] Univ Alabama Birmingham, Skin Dis Res Ctr, Sch Med, Birmingham, AL USA.
[Timares, Laura] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Timares, L (reprint author), Univ Alabama Birmingham, Dept Dermatol, Sch Med, Birmingham, AL 35294 USA.
EM timares@uab.edu
FU VA Merit Award from NIAMS; UAB Skin Diseases Research Center award from
NIAMS
FX The authors extend their thanks to Dr. Craig Elmets for his constant
support and intellectual guidance for our research-most recently on the
regulation of melanoma initiation and progression by immune factors. It
was he who pointed out that the increased susceptibility to melanoma
development in C3H mouse strains mimics one of the most important risk
factors for humans, specifically blond and red hair color-which was the
inspiration for this review article. This work was supported by funding
from a VA Merit Award and The UAB Skin Diseases Research Center award
from NIAMS.
NR 133
TC 7
Z9 8
U1 3
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD JAN-FEB
PY 2015
VL 91
IS 1
BP 188
EP 200
DI 10.1111/php.12335
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AZ8CN
UT WOS:000348442600022
PM 25155575
ER
PT J
AU Li, H
Prasad, R
Katiyar, SK
Yusuf, N
Elmets, CA
Xu, H
AF Li, Hui
Prasad, Ram
Katiyar, Santosh K.
Yusuf, Nabiha
Elmets, Craig A.
Xu, Hui
TI Interleukin-17 Mediated Inflammatory Responses Are Required for
Ultraviolet Radiation-Induced Immune Suppression
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID CONTACT HYPERSENSITIVITY RESPONSES; POLYMORPHIC LIGHT ERUPTION; CD8(+)
T-CELLS; INDUCED IMMUNOSUPPRESSION; LANGERHANS CELLS; UV-RADIATION;
SKIN-CANCER; IN-VIVO; SYSTEMIC IMMUNOSUPPRESSION; TUMOR-DEVELOPMENT
AB Ultraviolet radiation (UVR) induces immunosuppression and is a major factor for development of skin cancer. Numerous efforts have been made to determine mechanisms for UVR-induced immunosuppression and to develop strategies for prevention and treatment of UVR-induced cancers. In the current study, we use IL-17 receptor (IL-17R) deficient mice to examine whether IL-17 mediated responses have a role in UVB (290-320)-induced immunosuppression of contact hypersensitivity responses. Results demonstrate that IL-17 mediated responses are required for UVB-induced immunosuppression of contact hypersensitivity responses. The systemic immune suppression and development of regulatory T cells are inhibited in UVB-treated IL-17R deficient mice compared to wild-type animals. The deficiency in IL-17R inhibits the infiltration and development of a tolerogenic myeloid cell population in UVB-treated skin, which expresses CD11b and Gr-1 and produces reactive oxygen species. We speculate that the development of the tolerogenic myeloid cells is dependent on IL-17-induced chemokines and inflammatory mediators in UVB-treated skin. The inhibition of the tolerogenic myeloid cells may be attributed to the suppression of regulatory T cells in UVR-treated IL-17R(-/-) mice. The findings may be exploited to new strategies for prevention and treatment of UVR-induced skin diseases and cancers.
C1 [Li, Hui; Prasad, Ram; Katiyar, Santosh K.; Yusuf, Nabiha; Elmets, Craig A.; Xu, Hui] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.; Yusuf, Nabiha; Elmets, Craig A.; Xu, Hui] Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.; Yusuf, Nabiha; Elmets, Craig A.; Xu, Hui] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Xu, H (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
EM xuhui@uabmc.edu
FU VA Merit Review [18-103-02]; [R01CA140197]; [P30 AR050948]; [P30
CA013148]
FX This study was supported by R01CA140197, P30 AR050948, P30 CA013148, and
by VA Merit Review18-103-02.
NR 68
TC 3
Z9 3
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD JAN-FEB
PY 2015
VL 91
IS 1
BP 235
EP 241
DI 10.1111/php.12351
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AZ8CN
UT WOS:000348442600027
PM 25250896
ER
PT J
AU Lovejoy, T
Heckman, T
Sikkema, K
Hansen, N
Kochman, A
AF Lovejoy, Travis I.
Heckman, Timothy G.
Sikkema, Kathleen J.
Hansen, Nathan B.
Kochman, Arlene
TI Changes in Sexual Behavior of HIV-Infected Older Adults Enrolled in a
Clinical Trial of Standalone Group Psychotherapies Targeting Depression
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV/AIDS; Aging; Depression; Clinical trial; Unprotected sex
ID RANDOMIZED CONTROLLED-TRIAL; IMPROVEMENT GROUP INTERVENTION; SECONDARY
PREVENTION; RISK BEHAVIORS; MEN; HIV/AIDS; AGE
AB By 2015, one-half of all HIV-positive persons in the U.S. will be 50-plus years of age, and as many as 30 % of older adults living with HIV/AIDS continue to engage in unprotected sexual intercourse. Contemporary positive prevention models often include mental health treatment as a key component of HIV prevention interventions. This secondary data analysis characterized longitudinal patterns of sexual behavior in HIV-positive older adults enrolled in a randomized controlled trial of group mental health interventions and assessed the efficacy of psychosocial treatments that targeted depression to reduce sexual risk behavior. Participants were 295 HIV-positive adults a parts per thousand yen50 years of age experiencing mild to severe depressive symptoms, randomized to one of three study conditions: a 12-session coping improvement group intervention, a 12-session interpersonal support group intervention, or individual therapy upon request. Approximately one-fifth of participants reported one or more occasions of unprotected anal or vaginal intercourse with HIV-negative sexual partners or persons of unknown HIV serostatus over the study period. Changes in sexual behavior did not vary by intervention condition, indicating that standalone treatments that target and reduce depression may be insufficient to reduce sexual risk behavior in depressed HIV-positive older adults.
C1 [Lovejoy, Travis I.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Lovejoy, Travis I.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA.
[Heckman, Timothy G.; Hansen, Nathan B.] Univ Georgia, Coll Publ Hlth, Athens, GA 30602 USA.
[Sikkema, Kathleen J.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA.
RP Lovejoy, T (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM travis.lovejoy@va.gov
RI Hansen, Nathan/F-2074-2016
FU NIMH NIH HHS [R01 MH067566, R01-MH067568, R01 MH067568]
NR 29
TC 3
Z9 3
U1 1
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JAN
PY 2015
VL 19
IS 1
BP 1
EP 8
DI 10.1007/s10461-014-0746-7
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA AZ6OT
UT WOS:000348339500001
PM 24668254
ER
PT J
AU Chan, B
Weiser, S
Boum, Y
Haberer, J
Kembabazi, A
Hunt, P
Martin, J
Mocello, A
Bangsberg, D
Tsai, A
AF Chan, Brian T.
Weiser, Sheri D.
Boum, Yap
Haberer, Jessica E.
Kembabazi, Annet
Hunt, Peter W.
Martin, Jeffrey N.
Mocello, A. Rain
Bangsberg, David R.
Tsai, Alexander C.
TI Declining Prevalence of Probable Depression Among Patients Presenting
for Antiretroviral Therapy in Rural Uganda: The Role of Early Treatment
Initiation
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Depression; Trends; Physical health; Antiretroviral therapy; HIV; Uganda
ID QUALITY-OF-LIFE; ANTIDEPRESSANT MEDICATION TREATMENT; RANDOMIZED
CONTROLLED-TRIAL; HIV-POSITIVE WOMEN; CD4 CELL COUNT; SOUTH-AFRICA;
SYMPTOMS; DISEASE; MORTALITY; ADULTS
AB Little is known about trends in depression at antiretroviral therapy (ART) initiation among people living with HIV (PLHIV) in low- and middle-income countries. We used data from an ongoing cohort of treatment-na < ve PLHIV in rural Uganda to estimate secular trends in depression among PLHIV at ART initiation. We fitted linear regression models with depression symptom severity as the outcome variable and year of cohort entry (2005-2012) as the explanatory variable, adjusting for socio-demographic variables and assessing physical health score, body mass index (BMI), and CD4 count as potential mediators of a secular trend in depression symptom severity. There was a statistically significant negative association between year of entry and depression symptom severity, suggesting a 3.1 % relative decline in the mean depression symptom severity score at ART initiation in each year of study recruitment after the first year. This trend remained statistically significant after inclusion of baseline socio-demographic characteristics to the model and appeared to be driven by improved physical health scores, but not CD4 count or BMI.
C1 [Chan, Brian T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Chan, Brian T.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Chan, Brian T.; Haberer, Jessica E.; Bangsberg, David R.; Tsai, Alexander C.] Harvard Univ, Sch Med, Boston, MA USA.
[Weiser, Sheri D.; Hunt, Peter W.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA USA.
[Weiser, Sheri D.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
[Boum, Yap] Epictr, Mbarara, Uganda.
[Haberer, Jessica E.; Bangsberg, David R.; Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Kembabazi, Annet; Bangsberg, David R.; Tsai, Alexander C.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Martin, Jeffrey N.; Mocello, A. Rain] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Dept Psychiat, MD Div Global Psychiat, Boston, MA 02114 USA.
RP Chan, B (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St GRJ 504, Boston, MA 02114 USA.
EM bchan@partners.org
OI Tsai, Alexander/0000-0001-6397-7917
FU NCI NIH HHS [U01CA066529, U01 CA066529]; NIAID NIH HHS [P30 AI027763,
P30AI27763, T32 AI007433, T32AI007433]; NIMH NIH HHS [K23 MH079713, K23
MH087228, K23 MH096620, K23MH079713, K23MH087228, K23MH096620, K24
MH087227, K24MH087227, R01 MH054907, R01MH054907]
NR 43
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JAN
PY 2015
VL 19
IS 1
BP 19
EP 26
DI 10.1007/s10461-014-0785-0
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA AZ6OT
UT WOS:000348339500003
PM 24788780
ER
PT J
AU Psaros, C
Haberer, JE
Boum, Y
Tsai, AC
Martin, JN
Hunt, PW
Bangsberg, DR
Safren, SA
AF Psaros, Christina
Haberer, Jessica E.
Boum, Yap, II
Tsai, Alexander C.
Martin, Jeffrey N.
Hunt, Peter W.
Bangsberg, David R.
Safren, Steven A.
TI The Factor Structure and Presentation of Depression Among HIV-Positive
Adults in Uganda
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV/AIDS; Depression; Assessment; Validity
ID QUALITY-OF-LIFE; ANTIDEPRESSANT MEDICATION TREATMENT; HOPKINS SYMPTOM
CHECKLIST-25; SURVEY MOS-HIV; RURAL UGANDA; ANTIRETROVIRAL THERAPY;
SOUTH-AFRICA; INITIATING HAART; SOMATIC SYMPTOMS; FOOD INSECURITY
AB Depression is one of the most prevalent psychiatric comorbidities of HIV and one of the greatest barriers to HIV self-care and adherence. Despite this, little consensus exists on how to best measure depression among people living with HIV/AIDS (PLWHA) in African settings. Measurement of depression among PLWHA may be confounded by somatic symptoms. Some research recommends excluding these items to enhance measurement validity; sensitivity may be lost with this approach. We sought to characterize depression among a cohort (N = 453) of PLWHA initiating antiretroviral therapy in Uganda via factor analysis of a widely used measure of depression, the Hopkins Symptom Checklist (HSCLD). Common factor analysis was performed, associations between HSCLD and the Mental Health subscale of the Medical Outcomes Study HIV (MOS-HIV) estimated, and a Cronbach's alpha calculated to examine validity. Factor analysis yielded two factors: (1) somatic-cognitive symptoms and (2) behavioral disengagement. Persons with more versus less advanced disease (CD4 cell count of a parts per thousand currency sign200 cells/mm(3)) showed no statistically significant differences in depression scores (1.7 vs. 1.7, P a parts per thousand yen 0.5). Both factors were significantly associated with the MOS-HIV (P < .01). Factor one was highly reliable (alpha = .81); factor two had only modest reliability (alpha = .65). Somatic-cognitive symptoms of depression and disengagement from life's activities appear to be distinct components of depression in this sample. Consideration of somatic items may be valuable in identifying depression in this setting.
C1 [Psaros, Christina; Safren, Steven A.] Massachusetts Gen Hosp, Behav Med Serv, Dept Psychiat, Boston, MA 02114 USA.
[Psaros, Christina; Haberer, Jessica E.; Tsai, Alexander C.; Bangsberg, David R.; Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA USA.
[Haberer, Jessica E.; Tsai, Alexander C.; Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Boum, Yap, II; Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Boum, Yap, II] Uganda Res Ctr, Epictr, Mbarara, Uganda.
[Martin, Jeffrey N.] Univ San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94117 USA.
[Hunt, Peter W.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA USA.
RP Psaros, C (reprint author), Massachusetts Gen Hosp, Behav Med Serv, Dept Psychiat, One Bowdoin Sq,7th Floor, Boston, MA 02114 USA.
EM cpsaros@partners.org
OI Tsai, Alexander/0000-0001-6397-7917
FU NIAID NIH HHS [P30 AI027763, P30AI27763]; NIMH NIH HHS [K23MH096620, K23
MH087228, K23 MH096620, K23 MH096651, K23MH087228, K23MH096651, K24
MH087227, K24 MH094214, K24MH087227, K24MH094214, R01 MH054907,
R01MH054907]
NR 47
TC 1
Z9 1
U1 12
U2 15
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JAN
PY 2015
VL 19
IS 1
BP 27
EP 33
DI 10.1007/s10461-014-0796-x
PG 7
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA AZ6OT
UT WOS:000348339500004
PM 24854877
ER
PT J
AU Magidson, JF
Blashill, AJ
Safren, SA
Wagner, GJ
AF Magidson, Jessica F.
Blashill, Aaron J.
Safren, Steven A.
Wagner, Glenn J.
TI Depressive Symptoms, Lifestyle Structure, and ART Adherence Among
HIV-Infected Individuals: A Longitudinal Mediation Analysis
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Depression; Antiretroviral therapy; Adherence; Lifestyle structure;
Mediation
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; SELF-REPORTED
ADHERENCE; ANTIRETROVIRAL THERAPY; MEDICATION ADHERENCE; INHIBITOR
THERAPY; DRUG-USERS; VIRAL LOAD; CBT-AD; ACTIVATION
AB Despite the well-documented relationship between depression and antiretroviral therapy (ART) nonadherence, few studies have identified explanatory pathways through which depression affects adherence. The current study tested lifestyle structure-the degree of organization and routinization of daily activities-as a mediator of this relationship, given previous evidence of lifestyle structure being associated with both depression and ART nonadherence. HIV-infected individuals starting or re-starting ART in the California Collaborative Treatment Group 578 study (n = 199) were assessed over 48 weeks. Adherence was measured using electronic monitoring caps to determine dose timing and doses taken, and viral load was assessed. The mediating role of lifestyle structure was tested using generalized linear mixed-effects modeling and bootstrapping. Lifestyle significantly mediated the relationship between depression and both measures of ART adherence behavior. Interventions that minimize disruptions to lifestyle structure and link adherence to daily activities may be useful for individuals with depression and ART nonadherence.
C1 [Magidson, Jessica F.; Blashill, Aaron J.; Safren, Steven A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Wagner, Glenn J.] RAND Corp, Santa Monica, CA USA.
RP Magidson, JF (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, One Bowdoin Sq,7th Floor, Boston, MA 02114 USA.
EM jmagidson@partners.org
FU NIDA NIH HHS [R36 DA034513, R36DA034513]; NIMH NIH HHS [K23 MH096647,
K23MH096647, K24 MH094214, K24MH094214, R01 MH061695, R01MH61695, T32
MH093310, T32MH093310]
NR 44
TC 3
Z9 3
U1 4
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JAN
PY 2015
VL 19
IS 1
BP 34
EP 40
DI 10.1007/s10461-014-0802-3
PG 7
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA AZ6OT
UT WOS:000348339500005
PM 24874725
ER
PT J
AU O'Cleirigh, C
Valentine, SE
Pinkston, M
Herman, D
Bedoya, CA
Gordon, JR
Safren, SA
AF O'Cleirigh, Conall
Valentine, Sarah E.
Pinkston, Megan
Herman, Debra
Bedoya, C. Andres
Gordon, Janna R.
Safren, Steven A.
TI The Unique Challenges Facing HIV-Positive Patients Who Smoke Cigarettes:
HIV Viremia, Art Adherence, Engagement in HIV care, and Concurrent
Substance Use
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV/AIDS; Smoking; Adherence; Substance use; Engagement in care
ID QUALITY-OF-LIFE; ACTIVE ANTIRETROVIRAL THERAPY; ADDICTION SEVERITY
INDEX; CLINICAL-TRIAL; CESSATION STRATEGIES; MEDICATION ADHERENCE;
INCREASED RISK; HEALTH-RISKS; TOBACCO USE; HAART ERA
AB Evidence suggests that smoking may have negative associations with HIV health outcomes. The smoking rate in our sample of people living with HIV (N = 333) was triple that of the general population (57 v. 19 %). Regression analyses revealed that (smokers v. non-smokers) reported lower medication adherence (unstandardized beta = 9.01) and were more likely to have a detectable viral load (OR = 2.85, 95 % CI [1.53-5.30]). Smokers attended fewer routine medical visits (beta = -0.16) and were more likely to report recent hospitalization (OR = 1.89, 95 % CI [0.99, 3.57]). Smokers ranked "health" as less important to their quality of life (beta = -0.13) and were more likely to report problematic alcohol (OR = 2.40, 95 % CI [1.35, 4.30]), cocaine (OR = 2.87, 95 % CI [1.48-5.58]), heroin (OR = 4.75, 95 % CI [1.01, 22.30]), or marijuana use (OR = 3.08, 95 % CI [1.76-5.38]). Findings underscore the need for integrated behavioral smoking cessation interventions and routine tobacco screenings in HIV primary care.
C1 [O'Cleirigh, Conall; Valentine, Sarah E.; Bedoya, C. Andres; Gordon, Janna R.; Safren, Steven A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[O'Cleirigh, Conall; Valentine, Sarah E.; Bedoya, C. Andres; Gordon, Janna R.; Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA USA.
[O'Cleirigh, Conall; Safren, Steven A.] Fenway Inst, Boston, MA USA.
[Pinkston, Megan] Miriam Hosp, Providence, RI 02906 USA.
[Herman, Debra] Butler Hosp, Providence, RI 02906 USA.
RP O'Cleirigh, C (reprint author), Massachusetts Gen Hosp, Dept Psychiat, One Bowdoin Sq,7th Floor, Boston, MA 02114 USA.
EM cocleirigh@mgh.harvard.edu
FU NIMH NIH HHS [R01 MH084757, K24 MH094214, 5R01MH084757]
NR 46
TC 7
Z9 7
U1 2
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JAN
PY 2015
VL 19
IS 1
BP 178
EP 185
DI 10.1007/s10461-014-0762-7
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA AZ6OT
UT WOS:000348339500020
PM 24770984
ER
PT J
AU Timpone, VM
Lev, MH
Kamalian, S
Morais, LT
Franceschi, AM
Souza, L
Schaefer, PW
AF Timpone, V. M.
Lev, M. H.
Kamalian, S.
Morais, L. T.
Franceschi, A. M.
Souza, L.
Schaefer, P. W.
TI Percentage Insula Ribbon Infarction of > 50% Identifies Patients Likely
to Have Poor Clinical Outcome Despite Small DWI Infarct Volume
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID CEREBRAL-ARTERY INFARCTION; ACUTE STROKE; ISCHEMIC-STROKE; LESION
VOLUMES; CT; PREDICTOR; SCALE
AB BACKGROUND AND PURPOSE: Large admission DWI infarct volume (>70 mL) is an established marker for poor clinical outcome in acute stroke. Outcome is more variable in patients with small infarcts (<70 mL). Percentage insula ribbon infarct correlates with infarct growth. We hypothesized that percentage insula ribbon infarct can help identify patients with stroke likely to have poor clinical outcome, despite small admission DWI lesion volumes.
MATERIALS AND METHODS: We analyzed the admission NCCT, CTP, and DWI scans of 55 patients with proximal anterior circulation occlusions on CTA. Percentage insula ribbon infarct (>50%, <= 50%) on DWI, NCCT, CT-CBF, and CT-MIT were recorded. DWI infarct volume, percentage DWI motor strip infarct, NCCT-ASPECTS, and CTA collateral score were also recorded. Statistical analyses were performed to determine accuracy in predicting poor outcome (mRS >2 at 90 days).
RESULTS: Admission DWI of >70 mL and DWI percentage insula ribbon infarct of >50% were among significant univariate imaging markers of poor outcome (P < .001). In the multivariate analysis, DWI percentage insula ribbon infarct of >50% (P = .045) and NIHSS score (P < .001) were the only independent predictors of poor outcome. In the subgroup with admission DWI infarct of <70 mL (n = 40), 90-day mRS was significantly worse in those with DWI percentage insula ribbon infarct of <= 50% (n = 9, median mRS = 5, interquartile range = 2-5) compared with those with DWI percentage insula ribbon infarct of <= 50% (n = 31, median mRS = 2, interquartile range = 0.25-4, P = .036). In patients with admission DWI infarct of >70 mL, DWI percentage insula ribbon infarct did not have added predictive value for poor outcome (P = .931).
CONCLUSIONS: DWI percentage insula ribbon infarct of >50% independently predicts poor clinical outcome and can help identify patients with stroke likely to have poor outcome despite small admission DWI lesion volumes.
C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Schaefer, PW (reprint author), Massachusetts Gen Hosp, Div Neuroradiol, Dept Radiol, Gray B241H,55 Fruit St, Boston, MA 02114 USA.
EM pschaefer@partners.org
RI Kamalian, Shervin/D-7667-2013;
OI Kamalian, Shervin/0000-0001-8962-4773; Franceschi,
Ana/0000-0003-2577-9738
FU National Institute of Neurological Disorders and Stroke
FX Michael H. Lev-RELATED: Grant: for Specialized Programs of Translational
Research in Acute Stroke, National Institute of Neurological Disorders
and Stroke,star for Screening Technology and Outcomes Project
in Stroke, National Institute of Neurological Disorders and
Strokestar: UNRELATED: Consultancy: GE Healthcare,
Grants/Grants Pending: GE Healthcare. Sheryin Kamalian-UNRELATED:
Grants/Grants Pending: GE Healthcare. starMoney paid to the
institution.
NR 18
TC 3
Z9 3
U1 0
U2 4
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD JAN
PY 2015
VL 36
IS 1
BP 40
EP 45
DI 10.3174/ajnr.A4091
PG 6
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA AZ1ON
UT WOS:000348008200009
PM 25190204
ER
PT J
AU Wellen, J
Chatterjee, P
Venkataramani, A
Vijayan, A
Martin, E
AF Wellen, Jason
Chatterjee, Paula
Venkataramani, Atheendar
Vijayan, Anitha
Martin, Erika
TI The Impact of State Policies on Organ Donation and Transplantation in
the United States
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 15th Annual State of the Art Winter Symposium of the
American-Society-of-Transplant-Surgeons (ASTS)
CY JAN 15-18, 2015
CL Miami, FL
SP Amer Soc Transplant Surg
C1 [Wellen, Jason; Vijayan, Anitha] Washington Univ, Sch Med, St Louis, MO USA.
[Chatterjee, Paula] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Venkataramani, Atheendar] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Martin, Erika] SUNY Albany, Albany, NY 12222 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2015
VL 15
SU 1
SI SI
MA O-7
BP 50
EP 50
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AZ1YF
UT WOS:000348030600025
ER
PT J
AU Adler, J
Yeh, HD
Markmann, J
Nguyen, L
Axelrod, D
AF Adler, Joel
Yeh, Heidi
Markmann, James
Nguyen, Louis
Axelrod, David
TI Does DSA Market Competition Influence OPO Performance?
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 15th Annual State of the Art Winter Symposium of the
American-Society-of-Transplant-Surgeons (ASTS)
CY JAN 15-18, 2015
CL Miami, FL
SP Amer Soc Transplant Surg
C1 [Adler, Joel; Yeh, Heidi; Markmann, James] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nguyen, Louis] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Axelrod, David] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2015
VL 15
SU 1
SI SI
MA P-1
BP 53
EP 53
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AZ1YF
UT WOS:000348030600031
ER
PT J
AU Patel, M
Kohn, R
Kratz, J
Shah, J
Markmann, J
Vagefi, P
AF Patel, Madhukar
Kohn, Rachel
Kratz, Johannes
Shah, Jigesh
Markmann, James
Vagefi, Parsia
TI The Race To Liver Transplant: A Comparison Between HCC and Non-HCC
Candidates
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 15th Annual State of the Art Winter Symposium of the
American-Society-of-Transplant-Surgeons (ASTS)
CY JAN 15-18, 2015
CL Miami, FL
SP Amer Soc Transplant Surg
C1 [Patel, Madhukar; Shah, Jigesh; Markmann, James; Vagefi, Parsia] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kohn, Rachel] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Kratz, Johannes] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2015
VL 15
SU 1
SI SI
MA P-100
BP 92
EP 92
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AZ1YF
UT WOS:000348030600127
ER
PT J
AU LaQuaglia, M
Grijalva, J
Mueller, K
Sadri-Vakili, G
Vakili, K
AF LaQuaglia, Michael
Grijalva, James
Mueller, Kaly
Sadri-Vakili, Ghazaleh
Vakili, Khashayar
TI siRNA Knockdown of YAP Inhibits Liver Regeneration in Rat Model
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 15th Annual State of the Art Winter Symposium of the
American-Society-of-Transplant-Surgeons (ASTS)
CY JAN 15-18, 2015
CL Miami, FL
SP Amer Soc Transplant Surg
C1 [LaQuaglia, Michael; Grijalva, James; Vakili, Khashayar] Boston Childrens Hosp, Boston, MA USA.
[Mueller, Kaly; Sadri-Vakili, Ghazaleh] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2015
VL 15
SU 1
SI SI
MA P-107
BP 94
EP 94
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AZ1YF
UT WOS:000348030600133
ER
PT J
AU Adler, J
Hyder, J
Markmann, J
Yeh, HD
AF Adler, Joel
Hyder, Joseph
Markmann, James
Yeh, Heidi
TI "Traveling" Livers: Measuring the Flow Between Donors and Recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 15th Annual State of the Art Winter Symposium of the
American-Society-of-Transplant-Surgeons (ASTS)
CY JAN 15-18, 2015
CL Miami, FL
SP Amer Soc Transplant Surg
C1 [Adler, Joel; Markmann, James; Yeh, Heidi] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hyder, Joseph] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2015
VL 15
SU 1
SI SI
MA P-110
BP 95
EP 95
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AZ1YF
UT WOS:000348030600136
ER
PT J
AU Avruch, J
Bruinsma, B
Weeder, P
Yeh, HD
Uygun, K
Markmann, J
AF Avruch, James
Bruinsma, Bote
Weeder, Pepijn
Yeh, Heidi
Uygun, Korkut
Markmann, James
TI Simulated Transplantation By Ex Vivo Diluted Whole Blood Reperfusion
Following Liver Preservation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 15th Annual State of the Art Winter Symposium of the
American-Society-of-Transplant-Surgeons (ASTS)
CY JAN 15-18, 2015
CL Miami, FL
SP Amer Soc Transplant Surg
C1 [Avruch, James; Bruinsma, Bote; Weeder, Pepijn; Yeh, Heidi; Uygun, Korkut; Markmann, James] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2015
VL 15
SU 1
SI SI
MA P-130
BP 101
EP 101
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AZ1YF
UT WOS:000348030600154
ER
PT J
AU Weeder, P
op den Dries, S
Yeh, HD
Markmann, J
Uygun, K
Porte, R
Martins, P
AF Weeder, Pepijn
op den Dries, Sanna
Yeh, Heidi
Markmann, Jim
Uygun, Korkut
Porte, Robert
Martins, Paulo
TI Bile Duct Histopathology and Donor Demographics as Predictors of
Ischemic Cholangiopathy After Liver Transplant: A Prospective Study
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 15th Annual State of the Art Winter Symposium of the
American-Society-of-Transplant-Surgeons (ASTS)
CY JAN 15-18, 2015
CL Miami, FL
SP Amer Soc Transplant Surg
C1 [Weeder, Pepijn; Yeh, Heidi; Markmann, Jim] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[op den Dries, Sanna; Porte, Robert] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[Uygun, Korkut] Harvard Univ, Sch Med, Boston, MA USA.
[Martins, Paulo] UMass Mem Med Ctr, Worcester, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2015
VL 15
SU 1
SI SI
MA P-139
BP 104
EP 104
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AZ1YF
UT WOS:000348030600161
ER
PT J
AU Sarantopoulos, S
Blazar, BR
Cutler, C
Ritz, J
AF Sarantopoulos, Stefanie
Blazar, Bruce R.
Cutler, Corey
Ritz, Jerome
TI B Cells in Chronic Graft-versus-Host Disease
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Stem cell transplantation; Chronic graft-versus-host; disease; B cell
ID MINOR HISTOCOMPATIBILITY ANTIGEN; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CD4(+)
T-CELLS; CHRONIC GVHD; BRONCHIOLITIS OBLITERANS; TYROSINE KINASE; MARROW
TRANSPLANT; ANTIBODY-RESPONSE; ACTIVATING FACTOR; DENDRITIC CELLS
AB Chronic graft-versus-host disease (cGVHD) continues to be a common complication of allogeneic hematopoietic stem cell transplantation. Unlike acute graft-versus-host disease, which is mediated almost entirely by donor T cells, the immune pathology of cGVHD is more complex and donor B cells have also been found to play an important role. Recent studies from several laboratories have enhanced our understanding of how donor B cells contribute to this clinical syndrome and this has led to new therapeutic opportunities. Here, Dr Sarantopoulos reviews some of the important mechanisms responsible for persistent B cell activation and loss of B cell tolerance in patients with cGVHD. Dr Blazar describes recent studies in preclinical models that have identified novel B cell directed agents that may be effective for prevention or treatment of cGVHD. Some B cell directed therapies have already been tested in patients with cGVHD and Dr Cutler reviews the results of these studies documenting the potential efficacy of this approach. Supported by mechanistic studies in patients and preclinical models, new B cell directed therapies for cGVHD will now be evaluated in clinical trials. (C) 2015 American Society for Blood and Marrow Transplantation.
C1 [Sarantopoulos, Stefanie] Duke Univ, Duke Canc Inst, Dept Med, Div Cell Therapy & Hematol Malignancies, Durham, NC USA.
[Blazar, Bruce R.] Univ Minnesota, Mason Canc Ctr, Dept Pediat, Div Blood & Marrow Transplantat, Minneapolis, MN USA.
[Cutler, Corey; Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02215 USA.
RP Ritz, J (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, 450 Brookline Ave, Boston, MA 02215 USA.
EM jerome_ritz@dfci.harvard.edu
OI Ritz, Jerome/0000-0001-5526-4669
FU NIH [CA142106, K08HL107756, AI056299]; DOD [CA100254]; Kadmon
Pharmaceuticals Inc; Leukemia and Lymphoma Society of America [6458-15]
FX The authors thank jing Du, Katelyn Goodman, and Drs Ryan Flynn, Jay
Bradner, Jun Qi, An Melnick, Raphael Clynes, Alexandra Zanin-Zhorov,
Jason Dubovsky, John Byrd, and Lawrence Elias for performing
experiments, providing reagents and/or helpful discussions. We thank
Rigel Pharmaceuticals for providing fostamatinib, Kadmon Pharmaceuticals
for KD025, and Pharmacyclics for providing ibrutinib for laboratory
studies. Studies described in this review were supported by NIH grants
CA142106, K08HL107756, and AI056299, DOD grant CA100254, Kadmon
Pharmaceuticals Inc and a translational grant from the Leukemia and
Lymphoma Society of America (LLS Grant 6458-15).
NR 87
TC 16
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JAN
PY 2015
VL 21
IS 1
BP 16
EP 23
DI 10.1016/j.bbmt.2014.10.029
PG 8
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA AY6JB
UT WOS:000347671600005
PM 25452031
ER
PT J
AU Eapen, M
Logan, BR
Appelbaum, FR
Antin, JH
Anasetti, C
Couriel, DR
Chen, JF
Maziarz, RT
McCarthy, PL
Nakamura, R
Ratanatharathorn, V
Vij, R
Champlin, RE
AF Eapen, Mary
Logan, Brent R.
Appelbaum, Fredrick R.
Antin, Joseph H.
Anasetti, Claudio
Couriel, Daniel R.
Chen, Junfang
Maziarz, Richard T.
McCarthy, Philip L.
Nakamura, Ryotaro
Ratanatharathorn, Voravit
Vij, Ravi
Champlin, Richard E.
TI Long-Term Survival after Transplantation of Unrelated Donor Peripheral
Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Chronic graft-versus-host; disease; Mortality; Leukemia
ID VERSUS-HOST-DISEASE; RANDOMIZED-TRIAL; CHRONIC GRAFT; MOBILIZED BLOOD;
STEM-CELLS; FOLLOW-UP; PROPHYLAXIS; GLOBULIN
AB We sought to determine whether differences in chronic graft-versus-host disease (GVHD) rates would lead to survival differences by comparing 2463 peripheral blood (PB) and 1713 bone marrow (BM) hematopoietic cell transplant recipients. Patients had acute leukemia, chronic myeloid leukemia (CML), or myelodysplastic syndrome, and they received myeloablative conditioning regimens and calcineurin-inhibitor GVHD prophylaxis. There were no significant differences in long-term survival after transplantation of PB and BM, except for patients in first chronic phase CML. For these patients, the 5-year rate of survival was lower after transplantation of PB compared with transplantation of BM (35% versus 56%, P = .001). Although mortality risks were higher in patients with chronic GVHD after both PB (hazard ratio [HR], 1.58; P < .001) and BM (HR 1.73; P < .001) transplantations, its effect on mortality did not differ by graft type (P = 42). BM is the preferred graft for first chronic phase CML, whereas as either graft is suitable for other leukemias. (C) 2015 American Society for Blood and Marrow Transplantation.
C1 [Eapen, Mary; Logan, Brent R.; Chen, Junfang] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Logan, Brent R.] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
[Appelbaum, Fredrick R.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Antin, Joseph H.] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA.
[Anasetti, Claudio] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Couriel, Daniel R.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[McCarthy, Philip L.] Roswell Pk Canc Inst, Dept Med, Blood & Marrow Transplant Program, Buffalo, NY 14263 USA.
[Nakamura, Ryotaro] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA.
[Ratanatharathorn, Voravit] Wayne State Univ, Karmanos Canc Inst, Dept Clin Arrangements, Detroit, MI USA.
[Ratanatharathorn, Voravit] JP McCarthy Cord Stem Cell Bank, Detroit, MI USA.
[Vij, Ravi] Washington Univ, Sch Med, Div Hematol & Oncol, St Louis, MO USA.
[Champlin, Richard E.] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.
RP Eapen, M (reprint author), Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.
EM meapen@mcw.edu
FU Public Health Service from the National Cancer Institute [U24-CA76518];
National Heart Lung and Blood Institute; National Institute of Allergy
and Infectious Diseases; Health Resources and Services Administration
[HHSH234200637015C]; Public Health Service
FX Supported by a Public Health Service grant (U24-CA76518) from the
National Cancer Institute, the National Heart Lung and Blood Institute
and the National Institute of Allergy and Infectious Diseases, and
Health Resources and Services Administration (HHSH234200637015C) for the
CW Bill Young Stem Cell Transplantation program's contract for the Stem
Cell Therapeutic Outcomes Database. M.E. is a Clinical Scholar of the
Leukemia and Lymphoma Society.
NR 12
TC 8
Z9 8
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JAN
PY 2015
VL 21
IS 1
BP 55
EP 59
DI 10.1016/j.bbmt.2014.09.006
PG 5
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA AY6JB
UT WOS:000347671600010
PM 25255165
ER
PT J
AU Duncan, CN
Majhail, NS
Brazauskas, R
Wang, Z
Cahn, JY
Frangoul, HA
Hayashi, RJ
Hsu, JW
Kamble, RT
Kasow, KA
Khera, N
Lazarus, HM
Loren, AW
Marks, DI
Maziarz, RT
Mehta, P
Myers, KC
Norkin, M
Pidala, JA
Porter, DL
Reddy, V
Saber, W
Savani, BN
Schouten, HC
Steinberg, A
Wall, DA
Warwick, AB
Wood, WA
Yu, LC
Jacobsohn, DA
Sorror, ML
AF Duncan, Christine N.
Majhail, Navneet S.
Brazauskas, Ruta
Wang, Zhiwei
Cahn, Jean-Yves
Frangoul, Haydar A.
Hayashi, Robert J.
Hsu, Jack W.
Kamble, Rammurti T.
Kasow, Kimberly A.
Khera, Nandita
Lazarus, Hillard M.
Loren, Alison W.
Marks, David I.
Maziarz, Richard T.
Mehta, Paulette
Myers, Kasiani C.
Norkin, Maxim
Pidala, Joseph A.
Porter, David L.
Reddy, Vijay
Saber, Wael
Savani, Bipin N.
Schouten, Harry C.
Steinberg, Amir
Wall, Donna A.
Warwick, Anne B.
Wood, William A.
Yu, Lolie C.
Jacobsohn, David A.
Sorror, Mohamed L.
TI Long-Term Survival and Late Effects among One-Year Survivors of Second
Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute
Leukemia and Myelodysplastic Syndromes
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Hematopoietic cell transplantation; Allogeneic transplantation; Second
transplantation; Long-term survival; Late effects
ID BONE-MARROW-TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE
MYELOID-LEUKEMIA; PREVENTIVE PRACTICES; OUTCOMES; MALIGNANCIES;
CHILDREN; BURDEN; ADULTS
AB We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second allogeneic hematopoietic cell transplantation (HCT) for relapsed acute leukemia or myelodysplastic syndromes between 1980 and 2009. A total of 1285 patients received a second allogeneic transplant after disease relapse; among these, 325 were relapse free at 1 year after the second HCT. The median time from first to second HO' was 17 and 24 months for children and adults, respectively. A myeloablative preparative regimen was used in the second transplantation in 62% of children and 45% of adult patients. The overall 10-year conditional survival rates after second transplantation in this cohort of patients who had survived disease-free for at least 1 year was 55% in children and 39% in adults. Relapse was the leading cause of mortality (77% and 54% of deaths in children and adults, respectively). In multivariate analyses, only disease status before second HCT was significantly associated with higher risk for overall mortality (hazard ratio, 1.71 for patients with disease not in complete remission before second HCT; P < .01). Chronic graft-versus-host disease (GVHD) developed in 43% and 75% of children and adults after second transplantation. Chronic GVHD was the leading cause of nonrelapse mortality, followed by organ failure and infection. The cumulative incidence of developing at least 1 of the studied late effects within 10 years after second HCT was 63% in children and 55% in adults. The most frequent late effects in children were growth disturbance (10-year cumulative incidence, 22%) and cataracts (20%); in adults they were cataracts (20%) and avascular necrosis (13%). Among patients with acute leukemia and myelodysplastic syndromes who receive a second allogeneic HCT for relapse and survive disease free for at least 1 year, many can be expected to survive long term. However, they continue to be at risk for relapse and nonrelapse morbidity and mortality. Novel approaches are needed to minimize relapse risk and long-term transplantation morbidity in this population. (C) 2015 American Society for Blood and Marrow Transplantation.
C1 [Duncan, Christine N.] Dana Farber Canc Inst, Dept Pediat Stem Cell Transplant, Boston, MA 02115 USA.
[Majhail, Navneet S.] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Oncol, Cleveland, OH 44106 USA.
[Brazauskas, Ruta; Wang, Zhiwei; Saber, Wael] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Brazauskas, Ruta] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
[Cahn, Jean-Yves] Univ Hosp, Dept Hematol, Grenoble, France.
[Frangoul, Haydar A.] Vanderbilt Univ, Sch Med, Dept Pediat, Div Hematol Oncol, Nashville, TN 37235 USA.
[Hayashi, Robert J.] Washington Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, St Louis, MO 63110 USA.
[Hsu, Jack W.; Norkin, Maxim] Shands HealthCare, Dept Med, Div Hematol & Oncol, Gainesville, FL USA.
[Hsu, Jack W.; Norkin, Maxim] Univ Florida, Gainesville, FL USA.
[Kamble, Rammurti T.] Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA.
[Kasow, Kimberly A.] Univ N Carolina, Dept Pediat, Div Hematol Oncol, Chapel Hill, NC USA.
[Khera, Nandita] Mayo Clin, Dept Hematol Oncol, Phoenix, AZ USA.
[Lazarus, Hillard M.] Univ Hosp, Case Med Ctr, Seidman Canc Ctr, Div Hematol & Oncol, Cleveland, OH USA.
[Loren, Alison W.; Porter, David L.] Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.
[Marks, David I.] Univ Hosp Bristol NHS Trust, Dept Pediat Bone Marrow Transplant, Bristol, Avon, England.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Portland, OR 97201 USA.
[Mehta, Paulette] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA.
[Mehta, Paulette] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
[Myers, Kasiani C.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Bone Marrow Transplant & Immune Deficiency, Cincinnati, OH 45229 USA.
[Pidala, Joseph A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant, Tampa, FL USA.
[Reddy, Vijay] Univ Cent Florida, Coll Med, Dept Internal Med, Orlando, FL 32816 USA.
[Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37235 USA.
[Schouten, Harry C.] Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands.
[Steinberg, Amir] Mt Sinai Hosp, Dept Hematol Oncol, New York, NY 10029 USA.
[Wall, Donna A.] CancerCare Manitoba, Cellular Therapy Lab, Winnipeg, MB, Canada.
[Wall, Donna A.] Univ Manitoba, Dept Pediat & Child Hlth & Immunol, Winnipeg, MB, Canada.
[Warwick, Anne B.] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA.
[Wood, William A.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA.
[Yu, Lolie C.] Louisiana State Univ, Med Ctr, Ctr Canc & Blood Disorders, Div Hematol Oncol,Childrens Hosp, New Orleans, LA USA.
[Jacobsohn, David A.] Childrens Natl Hlth Syst, Ctr Canc & Blood Disorders, Div Blood & Marrow Transplantat, Washington, DC USA.
[Sorror, Mohamed L.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Sorror, Mohamed L.] Univ Washington, Sch Med, Dept Med, Div Med Oncol, Seattle, WA 98195 USA.
RP Majhail, NS (reprint author), Cleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, 9500 Euclid Ave,Desk R35, Cleveland, OH 44195 USA.
EM majhain@cccf.org
FU National Cancer Institute (NCI) [U24-CA76518]; National Heart, Lung, and
Blood Institute (NHLBI); National Institute of Allergy and Infectious
Diseases (NIAID); NHLBI [5U01HL069294]; Health Resources and Services
Administration (HRSA/DHHS); Office of Naval Research [N00014-06-1-0704,
N00014-08-1-0058]; Allos, Inc.; Amgen, Inc.; Angioblast;
[HHSH234200637015C]
FX CIBMTR funding support: CIBMTR is supported by Public Health Service
grant/cooperative agreement U24-CA76518 from the National Cancer
Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI)
and the National Institute of Allergy and Infectious Diseases (NIAID); a
grant/cooperative agreement 5U01HL069294 from NHLBI and NCI; a contract
HHSH234200637015C with Health Resources and Services Administration
(HRSA/DHHS); 2 grants N00014-06-1-0704 and N00014-08-1-0058 from the
Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.;
Angioblast; anonymous donation to the Medical College of Wisconsin;
Ariad; Be The Match Foundation; Blue Cross and Blue Shield Association;
Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix,
GmbH; Children's Leukemia Research Association; Fresenius-Biotech North
America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;
Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis
Pharma; The Leukemia & Lymphoma Society; The Medical College of
Wisconsin; Merck & Co., Inc.; Millennium: The Takeda Oncology Co.;
Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor
Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.;
Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics;
Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord
Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan
Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS,
Inc.; and WellPoint, Inc.. The views expressed in this article do not
reflect the official policy or position of the National Institute of
Health, the Department of the Navy, the Department of Defense, or any
other agency of the US Government.
NR 34
TC 10
Z9 11
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JAN
PY 2015
VL 21
IS 1
BP 151
EP 158
DI 10.1016/j.bbmt.2014.10.006
PG 8
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA AY6JB
UT WOS:000347671600023
PM 25316109
ER
PT J
AU Allegretti, AS
Flythe, JE
Benda, V
Robinson, ES
Charytan, D
AF Allegretti, Andrew S.
Flythe, Jennifer E.
Benda, Vinod
Robinson, Emily S.
Charytan, DavidM.
TI The Effect of Bicarbonate Administration via Continuous Venovenous
Hemofiltration on Acid-Base Parameters in Ventilated Patients
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; RENAL-REPLACEMENT THERAPY; INTENSIVE-CARE-UNIT;
SODIUM-BICARBONATE; METABOLIC-ACIDOSIS; LACTIC-ACIDOSIS; INTRACELLULAR
PH; MIXED ACIDEMIA; CARDIAC-ARREST; FAILURE
AB Background. Acute kidney injury (AKI) and metabolic acidosis are common in the intensive care unit. The effect of bicarbonate administration on acid-base parameters is unclear in those receiving continuous venovenous hemofiltration (CVVH) and mechanical ventilatory support. Methods. Metabolic and ventilatory parameters were prospectively examined in 19 ventilated subjects for up to 96 hours following CVV Hinitiation for AKI at an academic tertiary care center. Mixed linear regression modeling was performed to measure changes in pH, partial pressure of carbon dioxide (pCO(2)), serum bicarbonate, and base excess over time. Results. During the 96-hour study period, pCO(2) levels remained stable overall (initial pCO(2) 42.0 +/- 14.6 versus end-study pCO(2) 43.8 +/- 16.1 mmHg; P = 0.13 for interaction with time), for those with initial pCO(2) <= 40 mmHg (31.3 +/- 5.7 versus 35.0 +/- 4.8; P = 0.06) and for those with initial pCO(2) >40 mmHg (52.7 +/- 12.8 versus 53.4 +/- 19.2; P = 0.57). pCO(2) decreased during the immediate hours following CVVH initiation (42.0 +/- 14.6 versus 37.3 +/- 12.6 mmHg), though this change was nonsignificant (P = 0.052). Conclusions. We did not detect a significant increase in pCO(2) in response to the administration of bicarbonate via CVVH in a ventilated population. Additional studies of larger populations are needed to confirm this finding.
C1 [Allegretti, Andrew S.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Flythe, Jennifer E.] Univ N Carolina, Sch Med, Kidney Ctr, Dept Med & Genet,Div Nephrol & Hypertens, Chapel Hill, NC 27599 USA.
[Benda, Vinod; Robinson, Emily S.; Charytan, DavidM.] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.
RP Allegretti, AS (reprint author), Massachusetts Gen Hosp, Dept Med, Div Nephrol, 7 Whittier Pl,Suite 106, Boston, MA 02114 USA.
EM aallegretti@partners.org
FU NIH [DK096189, HL11831402, DK100772, 5T32DK007540-29]
FX David M. Charytan is supported by NIH Grants DK096189, HL11831402, and
DK100772. Andrew S. Allegretti is supported by NIH Grant
5T32DK007540-29. David M. Charytan has consulted to Tengion, Keryx, and
Medtronic Inc. and has provided expert witness services to Fresenius
Inc. in matters related to maintenance hemodialysis and the dialysis
prescription. Jennifer E. Flythe has received speaking honorarium from
Dialysis Clinic, incorporated on matters related to maintenance
hemodialysis.
NR 32
TC 0
Z9 0
U1 0
U2 3
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 901590
DI 10.1155/2015/901590
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AZ5ZR
UT WOS:000348297800001
ER
PT J
AU Rinker, JR
Salter, AR
Walker, H
Amara, A
Meador, W
Cutter, GR
AF Rinker, John R., II
Salter, Amber R.
Walker, Harrison
Amara, Amy
Meador, William
Cutter, Gary R.
TI Prevalence and characteristics of tremor in the NARCOMS multiple
sclerosis registry: a cross-sectional survey
SO BMJ OPEN
LA English
DT Article
ID ADULT MOVEMENT-DISORDER; POPULATION; DISABILITY; VALIDATION; COMMON
AB Objectives: (1) To describe the prevalence and severity of tremor in patients with multiple sclerosis (MS) registered within a large North American MS registry; (2) to provide detailed descriptions on the characteristics and severity of tremor in a subset of registrants and (3) to compare several measures of tremor severity for strength of agreement.
Setting: The North American Research Committee on MS (NARCOMS) registry.
Participants: Registrants of NARCOMS reporting mild or greater tremor severity.
Outcome measures: We determined the cross-sectional prevalence of tremor in the NARCOMS registry over three semiannual updates between fall 2010 and fall 2011. A subset of registrants (n=552) completed a supplemental survey providing detailed descriptions of their tremor. Outcomes included descriptive characteristics of their tremors and correlations between outcome measures to determine the strength of agreement in assessing tremor severity.
Results: The estimated prevalence of tremor in NARCOMS ranged from 45% to 46.8%, with severe tremor affecting 5.5-5.9% of respondents. In the subset completing the supplemental survey, mild tremor severity was associated with younger age of MS diagnosis and tremor onset than those with moderate or severe tremor. However, tremor severity did not differ by duration of disease or tremor. Respondents provided descriptions of tremor symptoms on the Clinical Ataxia Rating Scale, which had a moderate to good (rho=0.595) correlation with the Tremor Related Activities of Daily Living (TRADL) scale. Objectively scored Archimedes' spirals had a weaker (rho=0.358) correlation with the TRADL. Rates of unemployment, disability and symptomatic medication use increased with tremor severity, but were high even among those with mild tremor.
Conclusions: Tremor is common among NARCOMS registrants and severely disabling for some. Both ADL-based and symptom-descriptive measures of tremor severity can be used to stratify patients.
C1 [Rinker, John R., II; Walker, Harrison; Amara, Amy; Meador, William] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
[Rinker, John R., II] Birmingham VA Med Ctr, Birmingham, AL USA.
[Salter, Amber R.; Cutter, Gary R.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
RP Rinker, JR (reprint author), Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA.
EM rinkerj@uab.edu
OI Amara, Amy/0000-0003-0762-9656
FU Biogen Idec [US-TYS-11-10238]; National Institutes of Health/National
Institutes of Neurological Disorders and Stroke; [K23NS067053];
[K23NS080912]
FX This study was funded by an Investigator Initiated Grant/Trial Award
from Biogen Idec (US-TYS-11-10238). HW and AA receive grant support from
the National Institutes of Health/National Institutes of Neurological
Disorders and Stroke. HW is supported by K23NS067053 and AA is supported
by K23NS080912.
NR 18
TC 3
Z9 3
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2015
VL 5
IS 1
AR e006714
DI 10.1136/bmjopen-2014-006714
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA AZ4DH
UT WOS:000348171800041
PM 25573524
ER
PT J
AU Reijmer, YD
Fotiadis, P
Martinez-Ramirez, S
Salat, DH
Schultz, A
Shoamanesh, A
Ayres, AM
Vashkevich, A
Rosas, D
Schwab, K
Leemans, A
Biessels, GJ
Rosand, J
Johnson, KA
Viswanathan, A
Gurol, ME
Greenberg, SM
AF Reijmer, Yael D.
Fotiadis, Panagiotis
Martinez-Ramirez, Sergi
Salat, David H.
Schultz, Aaron
Shoamanesh, Ashkan
Ayres, Alison M.
Vashkevich, Anastasia
Rosas, Diana
Schwab, Kristin
Leemans, Alexander
Biessels, Geert-Jan
Rosand, Jonathan
Johnson, Keith A.
Viswanathan, Anand
Gurol, M. Edip
Greenberg, Steven M.
TI Structural network alterations and neurological dysfunction in cerebral
amyloid angiopathy
SO BRAIN
LA English
DT Article
DE small vessel disease; mild cognitive impairment; stroke: imaging;
amyloid imaging; executive function; tractography
ID SMALL-VESSEL DISEASE; INFORMATION-PROCESSING SPEED; DIFFUSION TENSOR;
COGNITIVE IMPAIRMENT; ALZHEIMER-DISEASE; TOPOLOGICAL ORGANIZATION; HUMAN
CONNECTOME; BRAIN; DISRUPTION; LESIONS
AB Cerebral amyloid angiopathy is an important risk factor for cognitive impairment. Reijmer et al. use multimodal MRI and amyloid PET imaging to report changes in the brain network structure, which may represent a key step between small vessel brain disease and cognitive and gait impairment.Cerebral amyloid angiopathy is a common form of small-vessel disease and an important risk factor for cognitive impairment. The mechanisms linking small-vessel disease to cognitive impairment are not well understood. We hypothesized that in patients with cerebral amyloid angiopathy, multiple small spatially distributed lesions affect cognition through disruption of brain connectivity. We therefore compared the structural brain network in patients with cerebral amyloid angiopathy to healthy control subjects and examined the relationship between markers of cerebral amyloid angiopathy-related brain injury, network efficiency, and potential clinical consequences. Structural brain networks were reconstructed from diffusion-weighted magnetic resonance imaging in 38 non-demented patients with probable cerebral amyloid angiopathy (69 +/- 10 years) and 29 similar aged control participants. The efficiency of the brain network was characterized using graph theory and brain amyloid deposition was quantified by Pittsburgh compound B retention on positron emission tomography imaging. Global efficiency of the brain network was reduced in patients compared to controls (0.187 +/- 0.018 and 0.201 +/- 0.015, respectively, P < 0.001). Network disturbances were most pronounced in the occipital, parietal, and posterior temporal lobes. Among patients, lower global network efficiency was related to higher cortical amyloid load (r = -0.52; P = 0.004), and to magnetic resonance imaging markers of small-vessel disease including increased white matter hyperintensity volume (P < 0.001), lower total brain volume (P = 0.02), and number of microbleeds (trend P = 0.06). Lower global network efficiency was also related to worse performance on tests of processing speed (r = 0.58, P < 0.001), executive functioning (r = 0.54, P = 0.001), gait velocity (r = 0.41, P = 0.02), but not memory. Correlations with cognition were independent of age, sex, education level, and other magnetic resonance imaging markers of small-vessel disease. These findings suggest that reduced structural brain network efficiency might mediate the relationship between advanced cerebral amyloid angiopathy and neurologic dysfunction and that such large-scale brain network measures may represent useful outcome markers for tracking disease progression.
C1 [Reijmer, Yael D.; Fotiadis, Panagiotis; Martinez-Ramirez, Sergi; Shoamanesh, Ashkan; Ayres, Alison M.; Vashkevich, Anastasia; Schwab, Kristin; Rosand, Jonathan; Viswanathan, Anand; Gurol, M. Edip; Greenberg, Steven M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Stroke Res, Boston, MA USA.
[Salat, David H.; Schultz, Aaron] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Rosas, Diana; Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, Utrecht, Netherlands.
[Biessels, Geert-Jan] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, Utrecht, Netherlands.
[Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
RP Greenberg, SM (reprint author), JP Kistler Stroke Res Ctr, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.
EM sgreenberg@mgh.harvard.edu
RI Leemans, Alexander/A-1784-2011; Gurol, Edip/J-2279-2014
OI Gurol, Edip/0000-0002-2169-4457
FU National Institutes of Health [R01 AG26484, R01 NS070834, K23 NS083711,
R01NR010827]; American Heart Association [14POST20010031]; Netherlands
Organization for Scientific Research (NWO) [VIDI] [639.072.411]
FX This work is supported by grants from the National Institutes of Health
[R01 AG26484 and R01 NS070834, K23 NS083711 and R01NR010827], from the
American Heart Association [14POST20010031], and from the Netherlands
Organization for Scientific Research (NWO) [VIDI grant 639.072.411].
NR 59
TC 29
Z9 29
U1 5
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD JAN 1
PY 2015
VL 138
BP 179
EP 188
DI 10.1093/brain/awu316
PN 1
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AZ4KM
UT WOS:000348189800025
PM 25367025
ER
PT J
AU Iverson, GL
Schatz, P
AF Iverson, Grant L.
Schatz, Philip
TI Advanced topics in neuropsychological assessment following sport-related
concussion
SO BRAIN INJURY
LA English
DT Article
DE Cognitive functioning; concussion; mild traumatic brain injury;
neuropsychological assessment; psychometrics; reliable change
ID TEST-RETEST RELIABILITY; HEALTHY OLDER-ADULTS; SCHOOL FOOTBALL PLAYERS;
TRAUMATIC BRAIN-INJURY; IMPACT TEST BATTERY; TEST-PERFORMANCE;
PROFESSIONAL FOOTBALL; CLINICAL-SIGNIFICANCE; BASE RATES;
INTERNATIONAL-CONFERENCE
AB Objective: This study examined seven topics relating to neuropsychological assessment following sport-related concussion: (i) traditional vs. computerized tests; (ii) the value of baseline, pre-season testing; (iii) invalid baseline scores and poor effort; (iv) when to assess following injury; (v) the reliability of neuropsychological tests; (vi) reliable change methodology; and (vii) new methods for identifying cognitive impairment.
Main results: Baseline testing can be helpful for quantifying cognitive deficits following injury and for assessing recovery. At present, however, there is insufficient evidence to conclude that having baseline test results is clearly superior to not having baseline test results. Although invalid baseline test performance can be detected in some athletes, validity indicators cannot determine the extent to which the results were due to deliberately poor performance, confusion or misunderstanding regarding some aspect of the test, distractions in group testing environments or some combination of factors. When interpreting baseline and post-injury data, sophisticated psychometric methods (e.g. reliable change, multivariate base rates) are available to assist with more accurate identification of cognitive impairment and the serial monitoring of recovery.
Conclusions: The value of neuropsychological assessment in the management of sport-related concussion has a strong empirical foundation. Additional research is needed, however, to refine its use.
C1 [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Charlestown, MA 02129 USA.
[Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA.
[Iverson, Grant L.] MassGeneral Hosp Children Sport Concuss Program, Boston, MA USA.
[Iverson, Grant L.] Red Sox Fdn, Boston, MA USA.
[Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA.
[Iverson, Grant L.; Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA.
RP Iverson, GL (reprint author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Neuropsychol Outcome Assessment Lab, 79-96 Thirteenth St, Charlestown, MA 02129 USA.
EM giverson@mgh.harvard.edu
FU ImPACT Applications, Inc.; CNS Vital Signs; Psychological Assessment
Resources (PAR, Inc.)
FX Grant Iverson, PhD, has been reimbursed by the government, professional
scientific bodies and commercial organizations for discussing or
presenting research relating to mild TBI and sport-related concussion at
meetings, scientific conferences and symposiums. He has a clinical and
consulting practice in forensic neuropsychology involving individuals
who have sustained mild TBIs (including professional athletes). He has
received research funding from several test publishing companies,
including ImPACT Applications, Inc., CNS Vital Signs and Psychological
Assessment Resources (PAR, Inc.). He has not received research support
from ImPACT Applications, Inc. in the past 3 years. He receives
royalties from two books relating to neuropsychology and one test
(WCST-64). Philip Schatz, PhD, has served as a consultant to the
International Brain Research Foundation, the Sports Concussion Center of
New Jersey and ImPACT Applications, Inc., to study the effects of
concussion in high school and collegiate athletes. However, these
entities had no role in the conceptualization or content of the current
manuscript or the decision to submit for publication.
NR 101
TC 7
Z9 7
U1 2
U2 15
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PY 2015
VL 29
IS 2
BP 263
EP 275
DI 10.3109/02699052.2014.965214
PG 13
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AZ4OI
UT WOS:000348201500015
PM 25313596
ER
PT J
AU Tolaney, S
Burris, H
Gartner, E
Mayer, IA
Saura, C
Maurer, M
Ciruelos, E
Garcia, AA
Campana, F
Wu, B
Xu, Y
Jiang, J
Winer, E
Krop, I
AF Tolaney, Sara
Burris, Howard
Gartner, Elaina
Mayer, Ingrid A.
Saura, Cristina
Maurer, Matthew
Ciruelos, Eva
Garcia, Agustin A.
Campana, Frank
Wu, Bin
Xu, Yi
Jiang, Jason
Winer, Eric
Krop, Ian
TI Phase I/II study of pilaralisib (SAR245408) in combination with
trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory
HER2-positive metastatic breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE HER2-positive; PI3K; Pilaralisib; Trastuzumab; Metastatic breast cancer
ID ADVANCED SOLID TUMORS; I PI3K INHIBITOR; PIK3CA MUTATIONS; DOUBLE-BLIND;
CHEMOTHERAPY; DOCETAXEL; PATHWAY; SAFETY; PERTUZUMAB; RESISTANCE
AB This phase I/II dose-escalation study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, and efficacy of the pan-class I phosphoinositide 3-kinase inhibitor pilaralisib in combination with trastuzumab (Arm 1) or trastuzumab plus paclitaxel (Arm 2) in patients with HER2-positive metastatic breast cancer. Patients had progressed on prior trastuzumab (Arms 1 and 2) and received prior taxane (Arm 2). The MTD of pilaralisib was determined using a 3 + 3 dose-escalation design (starting dose 200 mg once daily). Forty-two patients were enrolled (21 in each arm). Five patients had a dose-limiting toxicity (DLT; three in Arm 1 and two in Arm 2). Dose-limiting toxicities were rash (three patients) and neutropenia (two patients). The MTD of pilaralisib was determined at 400 mg once daily in both arms. The most frequently reported treatment-related adverse events (AEs) were diarrhea (23.8 % in Arm 1 vs. 66.7 % in Arm 2), fatigue (14.3 vs. 42.9 %), and rash (33.3 vs. 38.1 %). The most frequently reported treatment-related grade a parts per thousand yen3 AEs were erythematous rash (9.5 %) in Arm 1 and diarrhea, peripheral neuropathy, and neutropenia (14.3 % each) in Arm 2. Steady-state pilaralisib exposure was similar to previous studies with pilaralisib monotherapy. No responses occurred in Arm 1; four of 20 evaluable patients (20 %) in Arm 2 had a partial response. Observed PIK3CA mutations in cell-free circulating DNA did not correlate with response. Pilaralisib in combination with trastuzumab with or without paclitaxel had an acceptable safety profile in metastatic HER2-positive breast cancer, with clinical activity in the paclitaxel arm.
C1 [Tolaney, Sara; Winer, Eric; Krop, Ian] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Burris, Howard] Sarah Cannon Res Inst, Nashville, TN USA.
[Gartner, Elaina] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
[Mayer, Ingrid A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Saura, Cristina] Vall dHebron Univ Hosp, VHIO, Barcelona, Spain.
[Maurer, Matthew] Columbia Univ, Med Ctr, New York, NY USA.
[Ciruelos, Eva] Hosp 12 Octubre, E-28041 Madrid, Spain.
[Garcia, Agustin A.] Univ So Calif, Los Angeles, CA USA.
[Campana, Frank; Wu, Bin; Xu, Yi] Sanofi, Cambridge, MA USA.
[Jiang, Jason] Sanofi, Bridgewater, NJ USA.
RP Tolaney, S (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM stolaney@partners.org
OI Ciruelos, Eva /0000-0002-2796-1042; Saura, Cristina/0000-0001-8296-5065
FU Sanofi
FX This study was funded by Sanofi. The authors received editorial support
from Simone Blagg of MediTech Media, funded by Sanofi. The authors would
like to thank the patients included in the trial and Patricia M.
LoRusso, DO at the Yale Cancer Center for her contributions to the
study.
NR 30
TC 12
Z9 12
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2015
VL 149
IS 1
BP 151
EP 161
DI 10.1007/s10549-014-3248-4
PG 11
WC Oncology
SC Oncology
GA AZ4IB
UT WOS:000348183700016
PM 25537644
ER
PT J
AU Strasser-Weippl, K
Ramchandani, R
Fan, L
Li, JJ
Hurlbert, M
Finkelstein, D
Shao, ZM
Goss, PE
AF Strasser-Weippl, Kathrin
Ramchandani, Ritesh
Fan, Lei
Li, Junjie
Hurlbert, Marc
Finkelstein, Dianne
Shao, Zhi-Ming
Goss, Paul E.
TI Pregnancy-associated breast cancer in women from Shanghai: risk and
prognosis
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Pregnancy; Risk; Prognosis; Asian
ID PROGESTERONE-RECEPTOR STATUS; JOINT ESTROGEN-RECEPTOR; FULL-TERM
PREGNANCY; REPRODUCTIVE FACTORS; TRANSIENT INCREASE; YOUNG-WOMEN; 1ST
BIRTH; AGE; DIAGNOSIS; LACTATION
AB Breast cancer (BC) has been associated with pregnancy if diagnosed within 5-10 years after delivery (pregnancy-associated BC, PABC). PABC carries a poor prognosis compared to sporadic BC in Western populations. Data are limited regarding PABC in Asian populations, where longer periods of breastfeeding, higher birth rates and a lower median age of BC at diagnosis have been noted, all of which are known to influence prognosis. We used two datasets of women treated for early BC in Shanghai 1990-2012 (n = 10,161 and n = 7,411). For the analysis of BC risk after pregnancy we compared the distribution of pregnancy in our dataset to that in Shanghai using age-specific fertility rates. For disease-free survival (DFS) evaluation, we restricted our data to women a parts per thousand currency sign45 years. Women < 30 years had a significantly elevated BC risk within 5 years of completing a pregnancy compared to women who had not been pregnant in the previous 5 years. In women aged 20-24 the relative risk (RR) was 3.33 (P = 0.012), and for women aged 25-29 the RR was 1.76 (P = 0.0074). For women > 30, the RR was decreased. Patients with PABC had a higher risk of recurrence or death (hazard ratio (HR) for DFS 1.72, P = 0.019) compared to women with non-PABC by univariable analysis. Age was eliminated from the multivariable model by backward selection, resulting in tumor stage (3 versus 1, HR 3.08, P < .001) and recent pregnancy (HR 1.62, P < 0.05) as significant independent prognosticators. Having had a full-term pregnancy in the previous 5 years was associated with a 62 % increased risk of recurrence. We show that recent full-term pregnancy significantly elevates BC risk in women < 30 in Shanghai, and that women diagnosed with PABC have a particularly adverse prognosis. Health care providers and women in Asian populations should be made aware of these results.
C1 [Strasser-Weippl, Kathrin] Wilhelminen Hosp, Vienna, Austria.
[Ramchandani, Ritesh; Finkelstein, Dianne] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Fan, Lei; Li, Junjie; Shao, Zhi-Ming] Fudan Univ, Breast Canc Inst, Shanghai 200032, Peoples R China.
[Hurlbert, Marc; Goss, Paul E.] Avon Fdn Women, New York, NY USA.
[Hurlbert, Marc; Goss, Paul E.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Shao, ZM (reprint author), Fudan Univ, Breast Canc Inst, 399 Ling Ling Rd, Shanghai 200032, Peoples R China.
EM pabc.research@yahoo.com
OI Hurlbert, Marc/0000-0003-3301-3572
FU Avon Foundation, NY
FX This work was supported be the Avon Foundation, NY.
NR 42
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2015
VL 149
IS 1
BP 255
EP 261
DI 10.1007/s10549-014-3219-9
PG 7
WC Oncology
SC Oncology
GA AZ4IB
UT WOS:000348183700027
PM 25504083
ER
PT J
AU Robinson, ES
Feng, R
Okawa, J
Werth, VP
AF Robinson, E. S.
Feng, R.
Okawa, J.
Werth, V. P.
TI Improvement in the cutaneous disease activity of patients with
dermatomyositis is associated with a better quality of life
SO BRITISH JOURNAL OF DERMATOLOGY
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS; SEVERITY INDEX; SKIN-DISEASE;
VALIDITY; SMOKING; RESPONSIVENESS; RELIABILITY; INSTRUMENT; IMPACT
AB BackgroundCutaneous dermatomyositis (DM) disease activity is associated with decreased quality of life.
ObjectivesTo assess if an improvement in quality of life, as measured by the Skindex-29 and patient-reported itch and pain on a 10-point visual analogue scale (VAS), correlated with an improvement in cutaneous DM disease activity.
MethodsPatients with a completed cutaneous DM disease area and severity index [Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)] at two visits separated by at least 2months were classified into responder (n=15) and nonresponder (n=30) groups according to the point change in the CDASI activity scores between visits. Responders had at least a four-point improvement in CDASI activity, indicating clinically relevant improvement.
ResultsThe change from baseline to the follow-up visit of the Skindex-29 subscale scores for the responders vs. the nonresponders were significantly different for emotions (P<001), functioning (P<001) and symptoms (P<001). The change in VAS score between responders and nonresponders was also significant for itch (P=001) and pain (P=004). There was no significant difference between the groups in terms of disease subtype, sex, race, age, treatment for DM, smoking history or a history of malignancy within 5years of a diagnosis of DM.
ConclusionsThis is the first study to demonstrate that the quality of life of patients with DM improved as their cutaneous disease activity decreased.
C1 [Robinson, E. S.; Okawa, J.; Werth, V. P.] Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Robinson, E. S.; Okawa, J.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Feng, R.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
RP Werth, VP (reprint author), Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
FU NIAMS NIH HHS [K24 AR002207, K24-AR 02207, R21 AR066286]
NR 16
TC 4
Z9 5
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-0963
EI 1365-2133
J9 BRIT J DERMATOL
JI Br. J. Dermatol.
PD JAN
PY 2015
VL 172
IS 1
BP 169
EP 174
DI 10.1111/bjd.13167
PG 6
WC Dermatology
SC Dermatology
GA AY7FK
UT WOS:000347726500026
PM 24909747
ER
PT J
AU Haak, CS
Togsverd-Bo, K
Thaysen-Petersen, D
Wulf, HC
Paasch, U
Anderson, RR
Haedersdal, M
AF Haak, C. S.
Togsverd-Bo, K.
Thaysen-Petersen, D.
Wulf, H. C.
Paasch, U.
Anderson, R. R.
Haedersdal, M.
TI Fractional laser-mediated photodynamic therapy of high-risk basal cell
carcinomas - a randomized clinical trial
SO BRITISH JOURNAL OF DERMATOLOGY
LA English
DT Article
ID TOPICAL METHYL AMINOLEVULINATE; NONMELANOMA SKIN-CANCER; 5-YEAR
FOLLOW-UP; 5-AMINOLEVULINIC ACID; PROTOPORPHYRIN-IX; ACTINIC KERATOSES;
GUIDELINES; SURGERY; DELIVERY; PHOTOTHERMOLYSIS
AB BackgroundPhotodynamic therapy (PDT) is approved for selected nodular basal cell carcinomas (nBCC) but efficacy is reduced for large and thick tumours. Ablative fractional lasers (AFXL) facilitate uptake of methyl aminolaevulinate (MAL) and may thus improve PDT outcome.
ObjectivesTo evaluate efficacy and safety of AFXL-mediated PDT (AFXL-PDT) compared with conventional PDT of high-risk nBCC.
MethodsPatients with histologically verified facial nBCC (n=32) defined as high-risk tumours were included; diameter >15mm, tumours located in high-risk zones, or on severely sun-damaged skin. Tumours were debulked and patients randomized to either AFXL-PDT (n=16) or PDT (n=16). Fractional CO2 laser treatment was applied at 5% density and 1000m (80mJ) ablation depth. MAL was applied under occlusion for 3h and illuminated with a 633-nm light-emitting diode source, 37Jcm(-2). Clinical assessments were performed at 3, 6, 9 and 12months and biopsies were taken at 12months.
ResultsClinical cure rates at 3months were 100% (16 of 16 AFXL-PDT) and 88% (14 of 16 PDT, P=0484). Recurrences tended to occur later and in lower numbers after AFXL-PDT at 6, 9 and 12months (6%, 19%, 19%) than PDT (25%, 38%, 44%) (P=0114). Histology at 12months documented equal tumour clearance after AFXL-PDT (63%, 10 of 16) and PDT (56%, 9 of 16). Cosmetic outcomes were highly satisfactory after both treatments (P>0090).
ConclusionsLong-term efficacy was similar after PDT and AFXL-PDT with a trend for a favourable short-term cure rate after AFXL-PDT. AFXL-PDT needs further refinement for nBCC and at present is not recommended over PDT.
C1 [Haak, C. S.; Togsverd-Bo, K.; Thaysen-Petersen, D.; Wulf, H. C.; Haedersdal, M.] Univ Copenhagen, Bispebjerg Hosp, Dept Dermatol, DK-2400 Copenhagen NV, Denmark.
[Haak, C. S.; Anderson, R. R.; Haedersdal, M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
[Paasch, U.] Univ Leipzig, Dept Dermatol, D-04109 Leipzig, Germany.
[Paasch, U.] Univ Leipzig, Dept Venereol, D-04109 Leipzig, Germany.
[Paasch, U.] Univ Leipzig, Dept Allergol, D-04109 Leipzig, Germany.
RP Haak, CS (reprint author), Univ Copenhagen, Bispebjerg Hosp, Dept Dermatol, D-92,Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.
EM christinahaak@dadlnet.dk
NR 43
TC 11
Z9 11
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-0963
EI 1365-2133
J9 BRIT J DERMATOL
JI Br. J. Dermatol.
PD JAN
PY 2015
VL 172
IS 1
BP 215
EP 222
DI 10.1111/bjd.13166
PG 8
WC Dermatology
SC Dermatology
GA AY7FK
UT WOS:000347726500032
PM 24903544
ER
PT J
AU Ananthakrishnan, AN
Du, MM
Berndt, SI
Brenner, H
Caan, BJ
Casey, G
Chang-Claude, J
Duggan, D
Fuchs, CS
Gallinger, S
Giovannucci, EL
Harrison, TA
Hayes, RB
Hoffmeister, M
Hopper, JL
Hou, LF
Hsu, L
Jenkins, MA
Kraft, P
Ma, J
Nan, HM
Newcomb, PA
Ogino, S
Potter, JD
Seminara, D
Slattery, ML
Thornquist, M
White, E
Wu, KN
Peters, U
Chan, AT
AF Ananthakrishnan, Ashwin N.
Du, Mengmeng
Berndt, Sonja I.
Brenner, Hermann
Caan, Bette J.
Casey, Graham
Chang-Claude, Jenny
Duggan, David
Fuchs, Charles S.
Gallinger, Steven
Giovannucci, Edward L.
Harrison, Tabitha A.
Hayes, Richard B.
Hoffmeister, Michael
Hopper, John L.
Hou, Lifang
Hsu, Li
Jenkins, Mark A.
Kraft, Peter
Ma, Jing
Nan, Hongmei
Newcomb, Polly A.
Ogino, Shuji
Potter, John D.
Seminara, Daniela
Slattery, Martha L.
Thornquist, Mark
White, Emily
Wu, Kana
Peters, Ulrike
Chan, Andrew T.
TI Red Meat Intake, NAT2, and Risk of Colorectal Cancer: A Pooled Analysis
of 11 Studies
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GENETIC SUSCEPTIBILITY; COLON-CANCER;
HETEROCYCLIC AMINES; EXCISION-REPAIR; POULTRY INTAKE; POLYMORPHISMS;
CONSUMPTION; SMOKING; COHORT
AB Background: Red meat intake has been associated with risk of colorectal cancer, potentially mediated through heterocyclic amines. The metabolic efficiency of N-acetyltransferase 2 (NAT2) required for the metabolic activation of such amines is influenced by genetic variation. The interaction between red meat intake, NAT2 genotype, and colorectal cancer has been inconsistently reported.
Methods: We used pooled individual-level data from the Colon Cancer Family Registry and the Genetics and Epidemiology of Colorectal Cancer Consortium. Red meat intake was collected by each study. We inferred NAT2 phenotype based on polymorphism at rs1495741, highly predictive of enzyme activity. Interaction was assessed using multiplicative interaction terms in multivariate-adjusted models.
Results: From 11 studies, 8,290 colorectal cancer cases and 9,115 controls were included. The highest quartile of red meat intake was associated with increased risk of colorectal cancer compared with the lowest quartile [ OR, 1.41; 95% confidence interval (CI), 1.29-1.55]. However, a significant association was observed only for studies with retrospective diet data, not for studies with diet prospectively assessed before cancer diagnosis. Combining all studies, high red meat intake was similarly associated with colorectal cancer in those with a rapid/intermediate NAT2 genotype (OR, 1.38; 95% CI, 1.20-1.59) as with a slow genotype (OR, 1.43; 95% CI, 1.28-1.61; P interaction = 0.9).
Conclusion: We found that high red meat intake was associated with increased risk of colorectal cancer only from retrospective case-control studies and not modified by NAT2 enzyme activity.
Impact: Our results suggest no interaction between NAT2 genotype and red meat intake in mediating risk of colorectal cancer. (C)2014 AACR.
C1 [Ananthakrishnan, Ashwin N.; Chan, Andrew T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ananthakrishnan, Ashwin N.; Ogino, Shuji; Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA USA.
[Du, Mengmeng; Harrison, Tabitha A.; Hsu, Li; Newcomb, Polly A.; Potter, John D.; Seminara, Daniela; Slattery, Martha L.; White, Emily; Peters, Ulrike] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Berndt, Sonja I.] NCI, NIH, Bethesda, MD 20892 USA.
[Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Caan, Bette J.] German Canc Consortium, Heidelberg, Germany.
[Caan, Bette J.] Kaiser Permanente Med Care, Oakland, CA USA.
[Casey, Graham] Univ So Calif, Los Angeles, CA USA.
[Chang-Claude, Jenny] German Canc Res Ctr DFKZ, Div Canc Epidemiol, Heidelberg, Germany.
[Duggan, David] Translat Genom Res Inst, Phoenix, AZ USA.
[Fuchs, Charles S.; Ma, Jing] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Fuchs, Charles S.; Giovannucci, Edward L.; Ma, Jing; Ogino, Shuji; Wu, Kana] Channing Div Network Med, Boston, MA USA.
[Gallinger, Steven] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Hayes, Richard B.] NYU, Sch Med, New York, NY USA.
[Hopper, John L.; Jenkins, Mark A.] Univ Melbourne, Melbourne Sch Populat Hlth, Melbourne, Vic, Australia.
[Hou, Lifang] Northwestern Univ, Dept Prevent Med, Evanston, IL USA.
[Hou, Lifang] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Evanston, IL USA.
[Nan, Hongmei] Indiana Univ, Simon Canc Ctr, Richard M Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46204 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Potter, John D.; Peters, Ulrike] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Potter, John D.] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand.
[Slattery, Martha L.] Univ Utah Hlth Sci, Salt Lake City, UT USA.
RP Chan, AT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St, Boston, MA 02114 USA.
EM upeters@fhcrc.org; achan@mgh.harvard.edu
RI Hoffmeister, Michael/B-5745-2012; Jenkins, Mark/P-7803-2015; Gallinger,
Steven/E-4575-2013; Brenner, Hermann/B-4627-2017;
OI Hoffmeister, Michael/0000-0002-8307-3197; Jenkins,
Mark/0000-0002-8964-6160; Brenner, Hermann/0000-0002-6129-1572; Potter,
John/0000-0001-5439-1500; Hayes, Richard/0000-0002-0918-661X
FU NIH [K23 DK097142, UM1 CA167551, U01 CA122839, R01 CA143237, R01
CA48998, P01 CA 055075, UM1 CA167552, R01 CA137178, R01 CA151993, P01 CA
087969, P50 CA 127003, R01 CA042182, U01 HG004446, K05 CA154337]; GECCO;
NCI; U.S. Department of Health and Human Services [U01 CA137088, R01
CA059045, R25 CA094880]; Australasian Colorectal Cancer Family Registry
[U01/U24 CA097735]; Ontario Registry for Studies of Familial Colorectal
Cancer [U01/U24 CA074783]; Seattle Colorectal Cancer Family Registry
[U01/U24 CA074794]; German Research Council (Deutsche
Forschungsgemeinschaft) [BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH
117/1-1]; German Federal Ministry of Education and Research [01KH0404,
01ER0814]; NIH through Ontario Registry for Studies of Familial
Colorectal Cancer [U01 CA074783]; Ontario Research Fund [GL2]; Canadian
Institutes of Health Research; Cancer Risk Evaluation (CaRE) Program
grant from the Canadian Cancer Society Research Institute; Intramural
Research Program of the Division of Cancer Epidemiology and Genetics
and; Division of Cancer Prevention, NCI, NIH, DHHS; NIH, Genes,
Environment and Health Initiative (GEI) [Z01 CP 010200]; NIH GEI [U01 HG
004438]; National Heart, Lung, and Blood Institute, National Institutes
of Health, U.S. Department of Health and Human Services
[HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]
FX A. Ananthakrishnan is supported by a grant from the NIH (K23 DK097142).
M. Du, T. A Harrison, L. Hsu, M. Thornquist, and U. Peters are
affiliated with GECCO, which is supported by the following grants from
the NCI, NIH and U.S. Department of Health and Human Services (U01
CA137088, R01 CA059045, R25 CA094880; to M. Du).; G. Casey, J.L. Hopper,
M.A. Jenkins, and P.A. Newcomb are affiliated with CCFR, which is
supported by the NIH (UM1 CA167551) and through cooperative agreements
with members of the Colon Cancer Family Registry and Principal
Investigators. This genome-wide scan was supported by the NCI, NIH by
U01 CA122839 and R01 CA143237 (to G. Casey). The following Colon CFR
centers contributed data to this article and were supported by the NIH:;
Australasian Colorectal Cancer Family Registry (U01/U24 CA097735),
Ontario Registry for Studies of Familial Colorectal Cancer (U01/U24
CA074783). Seattle Colorectal Cancer Family Registry (U01/U24
CA074794).; H. Brenner, J. Chang-Claude, and M. Hoffmeister are
affiliated with DACHS, which was supported by grants from the German
Research Council (Deutsche Forschungsgemeinschaft, BR 1704/6-1, BR
1704/6-3, BR 1704/6-4, and CH 117/1-1), and the German Federal Ministry
of Education and Research (01KH0404 and 01ER0814).; J.D. Potter and M.L.
Slattery are affiliated with DALS, which was supported by the NIH (R01
CA48998; to M.L. Slattery).; A.T. Chan, C.S. Fuchs, K. Wu, E.L.
Giovannucci, J. Ma, and S. Ogino are affiliated with HPFS, NHS, and PHS,
which are supported by the NIH. HPFS is supported by the NIH (P01 CA
055075, UM1 CA167552, R01 CA137178, R01 CA151993, and P50 CA 127003),
NHS by the NIH (R01 CA137178, R01 CA151993, P01 CA 087969, and P50 CA
127003) and PHS by the NIH (R01 CA042182).; S. Gallinger is affiliated
with theOFCCR, which is supported by funding from the NIH through
funding allocated to the Ontario Registry for Studies of Familial
Colorectal Cancer (U01 CA074783); see CCFR section above. As subset of
ARCTIC, OFCCR is supported by a GL2 grant from the Ontario Research
Fund, the Canadian Institutes of Health Research, and the Cancer Risk
Evaluation (CaRE) Program grant from the Canadian Cancer Society
Research Institute.; S.I. Berndt and R.B. Hayes are affiliated with the
PLCO, which is supported by the Intramural Research Program of the
Division of Cancer Epidemiology and Genetics and supported by contracts
from the Division of Cancer Prevention, NCI, NIH, DHHS. In addition, a
subset of control samples were genotyped as part of the Cancer Genetic
Markers of Susceptibility (CGEMS) Prostate Cancer GWAS (Yeager and
colleagues Nat Genet 2007; 39: 645-9), Colon CGEMS pancreatic cancer
scan (PanScan; Amundadottir and colleagues Nat Genet 2009; 41: 986-90
and Petersen and colleagues Nat Genet 2010; 42: 224-8), and the Lung
Cancer and Smoking study. The prostate and PanScan study datasets were
accessed with appropriate approval through the dbGaP online resource
(http://cgems.cancer.gov/data/) accession numbers phs000207.v1.p1 and
phs000206. v3. p2, respectively, and the lung datasets were accessed
from the dbGaP website (http://www. ncbi. nlm. nih. gov/gap) through
accession number phs000093.v2.p2. Funding for the Lung Cancer and
Smoking study was provided by NIH, Genes, Environment and Health
Initiative (GEI) Z01 CP 010200, NIH U01 HG004446, and NIH GEI U01 HG
004438. For the lung study, the GENEVA Coordinating Center provided
assistance with genotype cleaning and general study coordination, and
the Johns Hopkins University Center for Inherited Disease Research
conducted genotyping.; P. A. Newcomb is affiliated with PMH, which is
supported by the NIH (R01 CA076366; to P. A. Newcomb).; E. White is
affiliated with VITAL, which is supported by the NIH (K05 CA154337).; D.
Duggan is affiliated with TGEN and funded through a subaward with GECCO
(R01 CA059045).; The WHI program is funded by the National Heart, Lung,
and Blood Institute, National Institutes of Health, U.S. Department of
Health and Human Services through contracts HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, and HHSN271201100004C.
NR 51
TC 6
Z9 6
U1 1
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JAN
PY 2015
VL 24
IS 1
BP 198
EP 205
DI 10.1158/1055-9965.EPI-14-0897
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA AZ1YG
UT WOS:000348030700023
PM 25342387
ER
PT J
AU Penney, KL
Sinnott, JA
Tyekucheva, S
Gerke, T
Shui, IM
Kraft, P
Sesso, HD
Freedman, ML
Loda, M
Mucci, LA
Stampfer, MJ
AF Penney, Kathryn L.
Sinnott, Jennifer A.
Tyekucheva, Svitlana
Gerke, Travis
Shui, Irene M.
Kraft, Peter
Sesso, Howard D.
Freedman, Matthew L.
Loda, Massimo
Mucci, Lorelei A.
Stampfer, Meir J.
TI Association of Prostate Cancer Risk Variants with Gene Expression in
Normal and Tumor Tissue
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; PROBE LEVEL DATA; SUSCEPTIBILITY LOCI; COMMON
VARIANT; MULTIPLE LOCI; HNF1B GENE; 8Q24; IDENTIFICATION; SUMMARIES;
ARRAY
AB Background: Numerous germline genetic variants are associated with prostate cancer risk, but their biologic role is not well understood. One possibility is that these variants influence gene expression in prostate tissue. We therefore examined the association of prostate cancer risk variants with the expression of genes nearby and genome-wide.
Methods: We generated mRNA expression data for 20,254 genes with the Affymetrix GeneChip Human Gene 1.0 ST microarray from normal prostate (N = 160) and prostate tumor (N = 264) tissue from participants of the Physicians' Health Study and Health Professionals Follow-up Study. With linear models, we tested the association of 39 risk variants with nearby genes and all genes, and the association of each variant with canonical pathways using a global test.
Results: In addition to confirming previously reported associations, we detected several new significant (P < 0.05) associations of variants with the expression of nearby genes including C2orf43, ITGA6, MLPH, CHMP2B, BMPR1B, and MTL5. Genome-wide, five genes (MSMB, NUDT11, RBPMS2, NEFM, and KLHL33) were significantly associated after accounting for multiple comparisons for each SNP (P < 2.5 x 10(-6)). Many more genes had an FDR <10%, including SRD5A1 and PSCA, and we observed significant associations with pathways in tumor tissue.
Conclusions: The risk variants were associated with several genes, including promising prostate cancer candidates and lipid metabolism pathways, suggesting mechanisms for their impact on disease. These genes should be further explored in biologic and epidemiologic studies.
Impact: Determining the biologic role of these variants can lead to improved understanding of prostate cancer etiology and identify new targets for chemoprevention. (C) 2014 AACR.
C1 [Penney, Kathryn L.; Sinnott, Jennifer A.; Gerke, Travis; Shui, Irene M.; Kraft, Peter; Sesso, Howard D.; Mucci, Lorelei A.; Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Penney, Kathryn L.; Sinnott, Jennifer A.; Mucci, Lorelei A.; Stampfer, Meir J.] Brigham & Womens Hosp, Channing Div Network Med, Dept Med, Boston, MA 02115 USA.
[Penney, Kathryn L.; Sinnott, Jennifer A.; Sesso, Howard D.; Loda, Massimo; Mucci, Lorelei A.; Stampfer, Meir J.] Harvard Univ, Sch Med, Boston, MA USA.
[Sinnott, Jennifer A.; Tyekucheva, Svitlana; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Tyekucheva, Svitlana] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
[Freedman, Matthew L.; Loda, Massimo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Freedman, Matthew L.; Loda, Massimo] Broad Inst, Cambridge, MA USA.
[Loda, Massimo] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
RP Penney, KL (reprint author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM kpenney@hsph.harvard.edu
FU Prostate Cancer Foundation Young Investigator Awards; Department of
Defense Prostate Cancer Research Fellowship; A. David Mazzone Research
Awards Program; [CA34944]; [CA40360]; [CA097193]; [HL26490];
[HL34595]; [CA133891]; [CA141298]; [P01CA055075]; [5U01CA098233];
[CA136578]; [CA131945]; [P50CA090381]; [T32CA09001]
FX The PHS was supported by grants CA34944, CA40360, CA097193, HL26490, and
HL34595. The HPFS was supported by grants CA133891, CA141298, and
P01CA055075. This study and the following authors were supported by
5U01CA098233 (P. Kraft), CA136578 (L.A. Mucci), CA141298 (M.J.
Stampfer), CA131945 (M. Loda), and P50CA090381 (L.A. Mucci and S.
Tyekucheva). J.A. Sinnott received support from T32CA09001. K.L. Penney
and L.A. Mucci were supported by Prostate Cancer Foundation Young
Investigator Awards. I.M. Shui was supported by a Department of Defense
Prostate Cancer Research Fellowship. K.L. Penney was supported by the A.
David Mazzone Research Awards Program.
NR 34
TC 13
Z9 13
U1 2
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JAN
PY 2015
VL 24
IS 1
BP 255
EP 260
DI 10.1158/1055-9965.EPI-14-0694-T
PG 6
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA AZ1YG
UT WOS:000348030700030
PM 25371445
ER
PT J
AU Peterlongo, P
Chang-Claude, J
Moysich, KB
Rudolph, A
Schmutzler, RK
Simard, J
Soucy, P
Eeles, RA
Easton, DF
Hamann, U
Wilkening, S
Chen, BW
Rookus, MA
Schmidt, M
van der Baan, FH
Spurdle, AB
Walker, LC
Lose, F
Maia, AT
Montagna, M
Matricardi, L
Lubinski, J
Jakubowska, A
Garcia, EBG
Olopade, OI
Nussbaum, RL
Nathanson, KL
Domchek, SM
Rebbeck, TR
Arun, BK
Karlan, BY
Orsulic, S
Lester, J
Chung, WK
Miron, A
Southey, MC
Goldgar, DE
Buys, SS
Janavicius, R
Dorfling, CM
van Rensburg, EJ
Ding, YC
Neuhausen, SL
Hansen, TVO
Gerdes, AM
Ejlertsen, B
Jonson, L
Osorio, A
Martinez-Bouzas, C
Benitez, J
Conway, EE
Blazer, KR
Weitzel, JN
Manoukian, S
Peissel, B
Zaffaroni, D
Scuvera, G
Barile, M
Ficarazzi, F
Mariette, F
Fortuzzi, S
Viel, A
Giannini, G
Papi, L
Martayan, A
Tibiletti, MG
Radice, P
Vratimos, A
Fostira, F
Garber, JE
Donaldson, A
Brewer, C
Foo, C
Evans, DGR
Frost, D
Eccles, D
Brady, A
Cook, J
Tischkowitz, M
Adlard, J
Barwell, J
Walker, L
Izatt, L
Side, LE
Kennedy, MJ
Rogers, MT
Porteous, ME
Morrison, PJ
Platte, R
Davidson, R
Hodgson, SV
Ellis, S
Cole, T
Godwin, AK
Claes, K
Van Maerken, T
Meindl, A
Gehrig, A
Sutter, C
Engel, C
Niederacher, D
Steinemann, D
Plendl, H
Kast, K
Rhiem, K
Ditsch, N
Arnold, N
Varon-Mateeva, R
Wappenschmidt, B
Wang-Gohrke, S
Bressac-de Paillerets, B
Buecher, B
Delnatte, C
Houdayer, C
Stoppa-Lyonnet, D
Damiola, F
Coupier, I
Barjhoux, L
Venat-Bouvet, L
Golmard, L
Boutry-Kryza, N
Sinilnikova, OM
Caron, O
Pujol, P
Mazoyer, S
Belotti, M
Piedmonte, M
Friedlander, ML
Rodriguez, GC
Copeland, LJ
de la Hoya, M
Segura, PP
Nevanlinna, H
Aittomaki, K
van Os, TAM
Meijers-Heijboer, HEJ
van der Hout, AH
Vreeswijk, MPG
Hoogerbrugge, N
Ausems, MGEM
van Doorn, HC
Collee, JM
Olah, E
Diez, O
Blanco, I
Lazaro, C
Brunet, J
Feliubadalo, L
Cybulski, C
Gronwald, J
Durda, K
Jaworska-Bieniek, K
Sukiennicki, G
Arason, A
Chiquette, J
Teixeira, MR
Olswold, C
Couch, FJ
Lindor, NM
Wang, XS
Szabo, CI
Offit, K
Corines, M
Jacobs, L
Robson, ME
Zhang, LY
Joseph, V
Berger, A
Singer, CF
Rappaport, C
Kaulich, DG
Pfeiler, G
Tea, MKM
Phelan, CM
Greene, MH
Mai, PL
Rennert, G
Mulligan, AM
Glendon, G
Tchatchou, S
Andrulis, IL
Toland, AE
Bojesen, A
Pedersen, IS
Thomassen, M
Jensen, UB
Laitman, Y
Rantala, J
von Wachenfeldt, A
Ehrencrona, H
Askmalm, MS
Borg, A
Kuchenbaecker, KB
McGuffog, L
Barrowdale, D
Healey, S
Lee, A
Pharoah, PDP
Chenevix-Trench, G
Antoniou, AC
Friedman, E
AF Peterlongo, Paolo
Chang-Claude, Jenny
Moysich, Kirsten B.
Rudolph, Anja
Schmutzler, Rita K.
Simard, Jacques
Soucy, Penny
Eeles, Rosalind A.
Easton, Douglas F.
Hamann, Ute
Wilkening, Stefan
Chen, Bowang
Rookus, Matti A.
Schmidt, MarjankaK.
van der Baan, Frederieke H.
Spurdle, Amanda B.
Walker, Logan C.
Lose, Felicity
Maia, Ana-Teresa
Montagna, Marco
Matricardi, Laura
Lubinski, Jan
Jakubowska, Anna
Garcia, Encarna B. Gomez
Olopade, Olufunmilayo I.
Nussbaum, Robert L.
Nathanson, Katherine L.
Domchek, Susan M.
Rebbeck, Timothy R.
Arun, Banu K.
Karlan, Beth Y.
Orsulic, Sandra
Lester, Jenny
Chung, Wendy K.
Miron, Alex
Southey, Melissa C.
Goldgar, David E.
Buys, Saundra S.
Janavicius, Ramunas
Dorfling, Cecilia M.
van Rensburg, Elizabeth J.
Ding, Yuan Chun
Neuhausen, Susan L.
Hansen, Thomas V. O.
Gerdes, Anne-Marie
Ejlertsen, Bent
Jonson, Lars
Osorio, Ana
Martinez-Bouzas, Cristina
Benitez, Javier
Conway, Edye E.
Blazer, Kathleen R.
Weitzel, Jeffrey N.
Manoukian, Siranoush
Peissel, Bernard
Zaffaroni, Daniela
Scuvera, Giulietta
Barile, Monica
Ficarazzi, Filomena
Mariette, Frederique
Fortuzzi, Stefano
Viel, Alessandra
Giannini, Giuseppe
Papi, Laura
Martayan, Aline
Tibiletti, Maria Grazia
Radice, Paolo
Vratimos, Athanassios
Fostira, Florentia
Garber, Judy E.
Donaldson, Alan
Brewer, Carole
Foo, Claire
Evans, D. Gareth R.
Frost, Debra
Eccles, Diana
Brady, Angela
Cook, Jackie
Tischkowitz, Marc
Adlard, Julian
Barwell, Julian
Walker, Lisa
Izatt, Louise
Side, Lucy E.
Kennedy, M. John
Rogers, Mark T.
Porteous, Mary E.
Morrison, Patrick J.
Platte, Radka
Davidson, Rosemarie
Hodgson, Shirley V.
Ellis, Steve
Cole, Trevor
Godwin, Andrew K.
Claes, Kathleen
Van Maerken, Tom
Meindl, Alfons
Gehrig, Andrea
Sutter, Christian
Engel, Christoph
Niederacher, Dieter
Steinemann, Doris
Plendl, Hansjoerg
Kast, Karin
Rhiem, Kerstin
Ditsch, Nina
Arnold, Norbert
Varon-Mateeva, Raymonda
Wappenschmidt, Barbara
Wang-Gohrke, Shan
Bressac-de Paillerets, Brigitte
Buecher, Bruno
Delnatte, Capucine
Houdayer, Claude
Stoppa-Lyonnet, Dominique
Damiola, Francesca
Coupier, Isabelle
Barjhoux, Laure
Venat-Bouvet, Laurence
Golmard, Lisa
Boutry-Kryza, Nadia
Sinilnikova, Olga M.
Caron, Olivier
Pujol, Pascal
Mazoyer, Sylvie
Belotti, Muriel
Piedmonte, Marion
Friedlander, Michael L.
Rodriguez, Gustavo C.
Copeland, Larry J.
de la Hoya, Miguel
Perez Segura, Pedro
Nevanlinna, Heli
Aittomaeki, Kristiina
van Os, Theo A. M.
Meijers-Heijboer, Hanne E. J.
van der Hout, Annemarie H.
Vreeswijk, Maaike P. G.
Hoogerbrugge, Nicoline
Ausems, Margreet G. E. M.
van Doorn, Helena C.
Collee, J. Margriet
Olah, Edith
Diez, Orland
Blanco, Ignacio
Lazaro, Conxi
Brunet, Joan
Feliubadalo, Lidia
Cybulski, Cezary
Gronwald, Jacek
Durda, Katarzyna
Jaworska-Bieniek, Katarzyna
Sukiennicki, Grzegorz
Arason, Adalgeir
Chiquette, Jocelyne
Teixeira, Manuel R.
Olswold, Curtis
Couch, Fergus J.
Lindor, Noralane M.
Wang, Xianshu
Szabo, Csilla I.
Offit, Kenneth
Corines, Marina
Jacobs, Lauren
Robson, Mark E.
Zhang, Liying
Joseph, Vijai
Berger, Andreas
Singer, Christian F.
Rappaport, Christine
Kaulich, Daphne Geschwantler
Pfeiler, Georg
Tea, Muy-Kheng M.
Phelan, Catherine M.
Greene, Mark H.
Mai, Phuong L.
Rennert, Gad
Mulligan, Anna Marie
Glendon, Gord
Tchatchou, Sandrine
Andrulis, Irene L.
Toland, Amanda Ewart
Bojesen, Anders
Pedersen, Inge Sokilde
Thomassen, Mads
Jensen, Uffe Birk
Laitman, Yael
Rantala, Johanna
von Wachenfeldt, Anna
Ehrencrona, Hans
Askmalm, Marie Stenmark
Borg, Ake
Kuchenbaecker, Karoline B.
McGuffog, Lesley
Barrowdale, Daniel
Healey, Sue
Lee, Andrew
Pharoah, Paul D. P.
Chenevix-Trench, Georgia
Antoniou, Antonis C.
Friedman, Eitan
CA EMBRACE
GEMO Study Collaborators
HEBON
KConFab Investigators
TI Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1
and BRCA2 Mutation Carriers
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID ASSOCIATION
AB Background: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes.
Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach.
Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments.
Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.
Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies. (C)2014 AACR.
C1 [Peterlongo, Paolo; Ficarazzi, Filomena; Mariette, Frederique; Fortuzzi, Stefano] Fdn Ist FIRC Oncol Molecolare, IFOM, I-20139 Milan, Italy.
[Peterlongo, Paolo; Radice, Paolo] Fdn IRCCS Ist Nazl Tumori INT, Dept Prevent & Predict Med, Unit Mol Bases Genet Risk & Genet Testing, Milan, Italy.
[Chang-Claude, Jenny; Rudolph, Anja] German Canc Res Ctr, Div Cancer Epidemiol, Heidelberg, Germany.
[Moysich, Kirsten B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
[Schmutzler, Rita K.; Rhiem, Kerstin; Wappenschmidt, Barbara] Univ Hosp Cologne, Fac Med, Ctr Hereditary Breast & Ovarian Canc, Cologne, Germany.
[Schmutzler, Rita K.; Rhiem, Kerstin; Wappenschmidt, Barbara] Univ Hosp Cologne, Fac Med, Ctr Integrated Oncol, Cologne, Germany.
[Schmutzler, Rita K.] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany.
[Simard, Jacques; Soucy, Penny] Ctr Hosp Univ Quebec Res Ctr, Quebec City, PQ, Canada.
[Simard, Jacques; Soucy, Penny] Univ Laval, Quebec City, PQ, Canada.
[Eeles, Rosalind A.] Inst Canc Res, Oncogenet Team, Surrey, England.
[Eeles, Rosalind A.] Royal Marsden NHS Fdn Trust, Surrey, England.
[Easton, Douglas F.; Frost, Debra; Platte, Radka; Ellis, Steve; Kuchenbaecker, Karoline B.; McGuffog, Lesley; Barrowdale, Daniel; Lee, Andrew; Antoniou, Antonis C.; EMBRACE] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Cambridge, England.
[Hamann, Ute; Wilkening, Stefan; Chen, Bowang] German Canc Res Ctr, Heidelberg, Germany.
[Rookus, Matti A.; van der Baan, Frederieke H.; HEBON] Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands.
[Schmidt, MarjankaK.] Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, Amsterdam, Netherlands.
[Spurdle, Amanda B.; Lose, Felicity; Healey, Sue; Chenevix-Trench, Georgia] QIMR Berghofer, Dept Genet & Computat Biol, Brisbane, Qld, Australia.
[Walker, Logan C.] Univ Otago, Dept Pathol, Christchurch, New Zealand.
[Maia, Ana-Teresa] Univ Algarve, Dept Biomed Sci & Med, Algarve, Portugal.
[Montagna, Marco; Matricardi, Laura] IRCCS, Ist Oncol Veneto, Immunol & Mol Oncol Unit, Padua, Italy.
[Lubinski, Jan; Jakubowska, Anna; Cybulski, Cezary; Gronwald, Jacek; Durda, Katarzyna; Jaworska-Bieniek, Katarzyna; Sukiennicki, Grzegorz] Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland.
[Garcia, Encarna B. Gomez] MUMC, Dept Clin Genet, Maastricht, Netherlands.
[Olopade, Olufunmilayo I.] Univ Chicago, Med Ctr, Dept Med & Human Genet, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
[Nussbaum, Robert L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Nussbaum, Robert L.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
[Nathanson, Katherine L.; Domchek, Susan M.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Dept Med, Philadelphia, PA 19104 USA.
[Rebbeck, Timothy R.] Univ Penn, Dept Epidemiol & Biostat, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Arun, Banu K.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Karlan, Beth Y.; Orsulic, Sandra; Lester, Jenny] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA.
[Chung, Wendy K.] Columbia Univ, Dept Pediat, New York, NY 10027 USA.
[Chung, Wendy K.] Columbia Univ, Dept Med, New York, NY USA.
[Miron, Alex] Case Western Reserve Med Sch, Dept Genet & Genom, Cleveland, OH USA.
[Southey, Melissa C.] Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Parkville, Vic 3052, Australia.
[Goldgar, David E.] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA.
[Buys, Saundra S.] Univ Utah, Sch Med, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT USA.
[Janavicius, Ramunas] Vilnius Univ Hosp Santariskiu Clin, Hematol Oncol & Transfus Med Ctr, Dept Mol & Regenerat Med, Vilnius, Lithuania.
[Janavicius, Ramunas] State Res Inst Ctr Innovat Med, Vilnius, Lithuania.
[Dorfling, Cecilia M.; van Rensburg, Elizabeth J.] Univ Pretoria, Dept Genet, ZA-0002 Pretoria, South Africa.
[Ding, Yuan Chun; Neuhausen, Susan L.] Beckman Res Inst City Hope, Dept Populat Sci, Duarte, CA USA.
[Hansen, Thomas V. O.; Jonson, Lars] Univ Copenhagen Hosp, Rigshosp, Ctr Genom Med, DK-2100 Copenhagen, Denmark.
[Gerdes, Anne-Marie] Univ Copenhagen Hosp, Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark.
[Ejlertsen, Bent] Univ Copenhagen Hosp, Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark.
[Osorio, Ana; Benitez, Javier] Biomed Network Rare Dis CIBERER, Madrid, Spain.
[Osorio, Ana; Benitez, Javier] Spanish Natl Canc Ctr CNIO, Human Genet Grp, Madrid, Spain.
[Martinez-Bouzas, Cristina] Cruces Hosp Barakaldo, Dept Biochem, Mol Genet Lab, Barakaldo Bizkaia 48903, Spain.
[Benitez, Javier] Spanish Natl Canc Ctr CNIO, Genotyping Unit, Madrid, Spain.
[Conway, Edye E.] City Hope Clin Canc Genet Community Res Network, St Alphonsus Reg Med Ctr, Duarte, CA USA.
[Blazer, Kathleen R.] City Hope Natl Med Ctr, Duarte, CA USA.
[Weitzel, Jeffrey N.] City Hope Clin Canc Genet Community Res Network, City Hope, Duarte, CA USA.
[Manoukian, Siranoush; Peissel, Bernard; Zaffaroni, Daniela; Scuvera, Giulietta] Fdn IRCCS Ist Nazl Tumori INT, Dept Prevent & Predictive Med, Unit Med Genet, Milan, Italy.
[Barile, Monica] Ist Europeo Oncol, Div Canc Prevent & Genet, Milan, Italy.
[Ficarazzi, Filomena; Mariette, Frederique; Fortuzzi, Stefano] Cogentech Canc Genet Test Lab, Milan, Italy.
[Viel, Alessandra] CRO Aviano Natl Canc Inst, Div Expt Oncol 1, Aviano, PN, Italy.
[Giannini, Giuseppe] Univ Roma La Sapienza, Dept Mol Med, I-00185 Rome, Italy.
[Papi, Laura] Univ Florence, Dept Biomed Expt & Clin Sci, Unit Med Genet, Florence, Italy.
[Martayan, Aline] Ist Nazl Tumori Regina Elena, Dept Med Oncol, Unit Genet Counseling, Rome, Italy.
[Tibiletti, Maria Grazia] Polo Univ Varese, UO Anat Patolog Osped Circolo & Fdn Macchi, Varese, Italy.
[Vratimos, Athanassios; Fostira, Florentia] Natl Ctr Sci Res Demokritos, INRASTES, Mol Diagnost Lab, Athens, Greece.
[Garber, Judy E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Donaldson, Alan] St Michaels Hosp, Dept Clin Genet, Bristol, Avon, England.
[Brewer, Carole] Royal Devon & Exeter Hosp, Dept Clin Genet, Exeter EX2 5DW, Devon, England.
[Foo, Claire] Liverpool Womens NHS Fdn Trust, Cheshire & Merseyside Clin Genet Serv, Liverpool, Merseyside, England.
[Evans, D. Gareth R.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
[Eccles, Diana] Univ Southampton, Fac Med, Southampton Univ Hosp NHS Trust, Southampton SO9 5NH, Hants, England.
[Brady, Angela] Kennedy Galton Ctr, North West Thames Reg Genet Serv, Harrow, Middx, England.
[Cook, Jackie] Sheffield Childrens Hosp, Sheffield Clin Genet Serv, Sheffield, S Yorkshire, England.
[Tischkowitz, Marc] Addenbrookes Hosp, East Anglian Reg Genet Serv, Dept Clin Genet, Cambridge, England.
[Adlard, Julian] Yorkshire Reg Genet Serv, Leeds, W Yorkshire, England.
[Barwell, Julian] Univ Hosp Leicester NHS Trust, Leicestershire Clin Genet Serv, Leicester, Leics, England.
[Walker, Lisa] Churchill Hosp, Oxford Reg Genet Serv, Oxford OX3 7LJ, England.
[Izatt, Louise] Guys & St Thomas NHS Fdn Trust, London, England.
[Side, Lucy E.] Great Ormond St Hosp Sick Children, North East Thames Reg Genet Serv, London WC1N 3JH, England.
[Kennedy, M. John] Univ Dublin Trinity Coll, Acad Unit Clin & Mol Oncol, Dublin 2, Ireland.
[Kennedy, M. John] St James Hosp, Dublin 8, Ireland.
[Rogers, Mark T.] Univ Wales Hosp, All Wales Med Genet Serv, Cardiff CF4 4XW, S Glam, Wales.
[Porteous, Mary E.] Western Gen Hosp, South East Scotland Reg Genet Serv, Edinburgh EH4 2XU, Midlothian, Scotland.
[Morrison, Patrick J.] Queens Univ Belfast, Dept Med Genet, Belfast HSC Trust, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
[Davidson, Rosemarie] So Gen Hosp, West Scotland Reg Genet Serv, Glasgow G51 4TF, Lanark, Scotland.
[Hodgson, Shirley V.] St Georges Univ London, Med Genet Unit, London, England.
[Cole, Trevor] Birmingham Womens Hosp Healthcare NHS Trust, West Midlands Reg Genet Serv, Birmingham, W Midlands, England.
[Godwin, Andrew K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, MO USA.
[Claes, Kathleen; Van Maerken, Tom] Univ Ghent, Ctr Genet Med, B-9000 Ghent, Belgium.
[Meindl, Alfons] Tech Univ Munich, Klinikum Rechts Isar, Div Tumor Genet, Dept Gynecol & Obstet, D-80290 Munich, Germany.
[Gehrig, Andrea] Univ Wurzburg, Inst Human Genet, Wurzburg, Germany.
[Sutter, Christian] Heidelberg Univ, Heidelberg, Germany.
[Engel, Christoph] Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04109 Leipzig, Germany.
[Niederacher, Dieter] Univ Dusseldorf, Dusseldorf, Germany.
[Steinemann, Doris] Hannover Med Sch, Hannover, NH, Germany.
[Plendl, Hansjoerg] Univ Kiel, Inst Human Genet, Univ Hosp Schleswig Holstein, Kiel, Germany.
[Kast, Karin] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Gynecol & Obstet, Dresden, Germany.
[Rhiem, Kerstin; Wappenschmidt, Barbara] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany.
[Ditsch, Nina] Univ Munich, Dept Gynecol & Obstet, Munich, Germany.
[Arnold, Norbert] Univ Kiel, Dept Gynecol & Obstet, Univ Hosp Schleswig Holstein, Kiel, Germany.
[Varon-Mateeva, Raymonda] Charite, Inst Human Genet, Berlin, Germany.
[Wang-Gohrke, Shan] Univ Hosp Ulm, Dept Gynecol & Obstet, Ulm, Germany.
[Bressac-de Paillerets, Brigitte] Fdn Jean Dausset, INSERM U946, Paris, France.
[Bressac-de Paillerets, Brigitte] Inst Cancerol Gustave Roussy, Serv Genet, Villejuif, France.
[Buecher, Bruno; Houdayer, Claude; Stoppa-Lyonnet, Dominique; Golmard, Lisa; Belotti, Muriel] Inst Curie, Dept Tumour Biol, Paris, France.
[Delnatte, Capucine] Ctr Rene Gauducheau, F-44035 Nantes, France.
[Houdayer, Claude; Stoppa-Lyonnet, Dominique] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
[Stoppa-Lyonnet, Dominique] INSERM U830, Inst Curie, Paris, France.
[Damiola, Francesca; Sinilnikova, Olga M.; Mazoyer, Sylvie] Univ Lyon 1, Ctr Rech Cancerol Lyon, INSERM U1052, CNRS UMR5286, F-69365 Lyon, France.
[Coupier, Isabelle; Pujol, Pascal] CHU Arnaud Villeneuve, Unit Oncogenet, Montpellier, France.
[Coupier, Isabelle; Barjhoux, Laure] CRLCC Val Aurelle, Unit Oncogenet, Montpellier, France.
[Venat-Bouvet, Laurence] Ctr Hosp Univ Dupuytren, Dept Med Oncol, Limoges, France.
[Boutry-Kryza, Nadia; Sinilnikova, Olga M.] Hosp Civils Lyon, Ctr Leon Berard, Unite Mixte Genet Constitutionnelle Canc Frequent, Lyon, France.
[Caron, Olivier] Inst Cancerol Gustave Roussy, Dept Med, Villejuif, France.
[Pujol, Pascal] INSERM 896, CRCM Val Aurelle, Montpellier, France.
[GEMO Study Collaborators] GEMO Study Natl Canc Genet Network, UNICANCER Genet Grp, Paris, France.
[Piedmonte, Marion] Roswell Pk Canc Inst, Stat & Data Ctr, Gynecol Oncol Grp, Buffalo, NY 14263 USA.
[Friedlander, Michael L.] Australia New Zealand Gynaecol Oncol Grp, Coordinating Ctr, Camperdown, NSW, Australia.
[Rodriguez, Gustavo C.] NorthShore Univ HealthSyst, Div Gynecol Oncol, Evanston, IL USA.
[Copeland, Larry J.] Ohio State Univ, Dept Obstet & Gynecol, Hilliard, OH USA.
[de la Hoya, Miguel] Hosp Clin San Carlos, IdISSC, Mol Oncol Lab, Madrid, Spain.
[Perez Segura, Pedro] Hosp Clin San Carlos, IdISSC, Dept Oncol, Madrid, Spain.
[Nevanlinna, Heli] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland.
[Nevanlinna, Heli] Univ Helsinki, Helsinki, Finland.
[Aittomaeki, Kristiina] Univ Helsinki, Cent Hosp, Dept Clin Genet, Helsinki, Finland.
[van Os, Theo A. M.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
[Meijers-Heijboer, Hanne E. J.] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.
[van der Hout, Annemarie H.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.
[Vreeswijk, Maaike P. G.] Leiden Univ, Med Ctr LUMC, Dept Human Genet, Leiden, Netherlands.
[Hoogerbrugge, Nicoline] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
[Ausems, Margreet G. E. M.] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands.
[van Doorn, Helena C.] Erasmus Univ, Dept Obstet & Ginecol, Div Gynecol Oncol, MC Canc Inst, Rotterdam, Netherlands.
[Collee, J. Margriet] Erasmus Univ, Med Ctr, Dept Clin Genet, Family Canc Clin, Rotterdam, Netherlands.
[Olah, Edith] Natl Inst Oncol, Dept Mol Genet, Budapest, Hungary.
[Diez, Orland] Univ Hosp Vall Hebron, Oncol Grp, Barcelona, Spain.
[Diez, Orland] Univ Autonoma Barcelona, E-08193 Barcelona, Spain.
[Diez, Orland] Vall Hebron Inst Oncol, Barcelona, Spain.
[Diez, Orland] Vall Hebron Res Inst, Barcelona, Spain.
[Blanco, Ignacio] IDIBELL Catalan Inst Oncol, Hereditary Canc Program, Genet Counseling Unit, Barcelona, Spain.
[Lazaro, Conxi] IDIBELL Catalan Inst Oncol, Hereditary Canc Program, Mol Diagnost Unit, Barcelona, Spain.
[Brunet, Joan] IDIBGI Catalan Inst Oncol, Hereditary Canc Program, Genet Counseling Unit, Girona, Spain.
[Feliubadalo, Lidia; Arason, Adalgeir] Univ Iceland, Fac Med, BMC, Reykjavik, Iceland.
[Arason, Adalgeir] Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland.
[Chiquette, Jocelyne] Univ Quebec, Ctr Rech FRSQ Ctr Hosp Affilie, Ctr Malad Sein Deschenes Fabia, Unite Rech Sante Populat, Quebec City, PQ, Canada.
[Teixeira, Manuel R.] Univ Porto, Biomed Sci Inst ICBAS, P-4100 Oporto, Portugal.
[Teixeira, Manuel R.] Portuguese Oncol Inst, Dept Genet, Oporto, Portugal.
[Olswold, Curtis] Mayo Clin, Dept Hlth Sci Res, Rochester, NY USA.
[Couch, Fergus J.] Mayo Clin, Dept Lab Med & Pathol & Hlth Sci Res, Rochester, NY USA.
[Lindor, Noralane M.] Mayo Clin, Scottsdale, AZ USA.
[Wang, Xianshu] Mayo Clin, Dept Lab Med & Pathol, Rochester, NY USA.
[Szabo, Csilla I.] NIH, NHGRI, Bethesda, MD 20892 USA.
[Offit, Kenneth; Robson, Mark E.; Joseph, Vijai] Mem Sloan Kettering Canc Ctr, Clin Genet Res Lab, New York, NY 10021 USA.
[Corines, Marina; Jacobs, Lauren] Mem Sloan Kettering Canc Ctr, Dept Med, Clin Genet Serv, New York, NY 10021 USA.
[Zhang, Liying] Mem Sloan Kettering Canc Ctr, Dept Pathol, Diagnost Mol Genet Lab, New York, NY 10021 USA.
[Berger, Andreas; Singer, Christian F.; Rappaport, Christine; Kaulich, Daphne Geschwantler; Pfeiler, Georg; Tea, Muy-Kheng M.] Med Univ Vienna, Dept OB GYN, Vienna, Austria.
[Berger, Andreas; Singer, Christian F.; Rappaport, Christine; Kaulich, Daphne Geschwantler; Pfeiler, Georg; Tea, Muy-Kheng M.] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria.
[Phelan, Catherine M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA.
[Greene, Mark H.; Mai, Phuong L.] NIH, Natl Canc Inst, Div Canc Epidemiol & Genet, Clin Genet Branch, Rockville, MD USA.
[Rennert, Gad] Clalit Natl Canc Control Ctr, Haifa, Israel.
[Mulligan, Anna Marie] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada.
[Mulligan, Anna Marie] Univ Hlth Network, Lab Med Program, Toronto, ON, Canada.
[Glendon, Gord] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Ontario Canc Genet Network, Toronto, ON M5G 1X5, Canada.
[Tchatchou, Sandrine; Andrulis, Irene L.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
[Andrulis, Irene L.] Ohio State Univ, Ctr Comprehens Canc, Dept Med Genet, Columbus, OH 43210 USA.
[Toland, Amanda Ewart] Ohio State Univ, Ctr Comprehens Canc, Dept Immunol, Columbus, OH 43210 USA.
[Toland, Amanda Ewart] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med & Mol Virol, Div Human Canc Genet, Columbus, OH 43210 USA.
[Bojesen, Anders] Vejle Hosp, Dept Clin Genet, Vejle, Denmark.
[Pedersen, Inge Sokilde] Aalborg Univ Hosp, Dept Biochem, Sect Mol Diagnost, Aalborg, Denmark.
[Thomassen, Mads] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark.
[Jensen, Uffe Birk] Aarhus Univ Hosp, Dept Clin Genet, DK-8000 Aarhus, Denmark.
[Laitman, Yael] Sheba Med Ctr, Tel Aviv, Israel.
[Rantala, Johanna] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden.
[von Wachenfeldt, Anna] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden.
[Ehrencrona, Hans] Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.
[Ehrencrona, Hans] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden.
[Askmalm, Marie Stenmark] Linkoping Univ, Dept Clin & Expt Med, Div Clin Genet, Linkoping, Sweden.
[Borg, Ake] Lund Univ, Dept Oncol, Lund, Sweden.
[Pharoah, Paul D. P.] Univ Cambridge, Dept Oncol, Cambridge, England.
[KConFab Investigators] kConFab Kathleen Cuningham Consortium Res Familia, Peter Mac Callum Canc Ctr, Melbourne, Vic, Australia.
RP Peterlongo, P (reprint author), Fdn Ist FIRC Oncol Molecolare, IFOM, Via Adamello 16, I-20139 Milan, Italy.
EM paolo.peterlongo@ifom.eu; eitan.friedman@sheba.health.gov.il
RI Spurdle, Amanda/A-4978-2011; Feliubadalo, Lidia/G-4577-2016; Andrulis,
Irene/E-7267-2013; Jansen van Rensburg, Elizabeth (Lizette)/B-9104-2011;
Giannini, Giuseppe/B-5672-2013; montagna, marco/E-2225-2012;
Hoogerbrugge, Nicoline/O-1016-2013; Osorio, Ana/I-4324-2014; Maia,
Ana-Teresa/F-4404-2012; Teixeira, Manuel/E-4885-2011; Gronwald,
Jacek/A-4576-2017; manoukian, siranoush/E-7132-2017; Peissel,
Bernard/E-8187-2017;
OI Brunet, Joan/0000-0003-1945-3512; Joseph, Vijai/0000-0002-7933-151X;
VENAT-BOUVET, Laurence/0000-0002-0716-2550; Evans,
Gareth/0000-0002-8482-5784; Papi, Laura/0000-0003-4552-9517; Robson,
Mark/0000-0002-3109-1692; Barrowdale, Daniel/0000-0003-1661-3939; Lose,
Felicity/0000-0001-8337-3547; Nevanlinna, Heli/0000-0002-0916-2976;
Eeles, Rosalind/0000-0002-3698-6241; Blanco,
Ignacio/0000-0002-7414-7481; Spurdle, Amanda/0000-0003-1337-7897;
Feliubadalo, Lidia/0000-0002-1736-0112; Ehrencrona,
Hans/0000-0002-5589-3622; Rappaport-Fuerhauser,
Christine/0000-0002-6820-0020; Giannini, Giuseppe/0000-0003-0299-4056;
montagna, marco/0000-0002-4929-2150; Osorio, Ana/0000-0001-8124-3984;
Maia, Ana-Teresa/0000-0002-0454-9207; Teixeira,
Manuel/0000-0002-4896-5982; Gronwald, Jacek/0000-0002-3643-2871;
manoukian, siranoush/0000-0002-6034-7562; Peissel,
Bernard/0000-0001-9233-3571; Fortuzzi, Stefano/0000-0002-5662-3800
FU European Community (COGS) [223175, HEALTH-F2-2009-223175]; Cancer
Research UK [C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014,
C5047/A8384, C5047/ A15007, C5047/A10692, C1287/A16563, C1287/A17523,
C5047/A8385]; NIH [CA128978, R01-CA102776, R01CA083855]; Post-Cancer
GWAS initiative [1U19CA148537, 1U19 CA148065, 1U19 CA148112]; Department
of Defence [W81XWH-10-1-0341]; Canadian Institutes of Health Research
(CIHR) for the CIHR Team in Familial Risks of Breast Cancer; Komen
Foundation; Breast Cancer Research Foundation; Ovarian Cancer Research
Fund; National Cancer Institute [UM1 CA164920, RC4CA153828]; Research
Council of Lithuania [LIG-07/2012]; Cancer Association of South Africa
(CANSA); Spanish Association against Cancer [AECC08, RTICC 06/0020/1060,
FISPI12/00070]; Mutua Madrilena Foundation (FMMA); City of Hope Clinical
Cancer Genetics Community Research Network and the Hereditary Cancer
Research Registry (COH-CCGCRN); Fondazione IRCCS Istituto Nazionale dei
Tumori; DKFZ; NIHR grant to the Biomedical Research Centre, Manchester;
NIHR grant to the Biomedical Research Centre at The Institute of Cancer
Research; Royal Marsden NHS Foundation Trust; German Cancer Aid
[109078]; Center for Molecular Medicine Cologne (CMMC); Ligue National
Contre le Cancer; Association "Le cancer du sein, parlons-en!" Award;
Canadian Institutes of Health Research for the "CIHR Team in Familial
Risks of Breast Cancer" program; Helsinki University Central Hospital
Research Fund, Academy of Finland [266528]; Finnish Cancer Society and
the Sigrid Juselius Foundation; Dutch Cancer Society [NKI1998-1854,
NKI2004-3088, NKI2007-3756]; Netherlands Organization of Scientific
Research [NWO 91109024]; Pink Ribbon [110005]; BBMRI [NWO
184.021.007/CP46]; Hungarian Research Grants [KTIA OTKA CK-80745, OTKA
K-112228]; Asociacion Espanola Contra el Cancer; Spanish Health Research
Fund; Carlos III Health Institute; Catalan Health Institute and
Autonomous Government of Catalonia [ISCIIIRETIC RD06/0020/1051,
RD12/0036/008, PI10/01422, PI10/00748, PI13/00285, 2009SGR290];
Icelandic Association "Walking for Breast Cancer Research"; Landspitali
University Hospital Research Fund; Ministero della Salute; Istituto
Oncologico Veneto; National Breast Cancer Foundation; National Health
and Medical Research Council (NHMRC); Queensland Cancer Fund; Cancer
Councils of New South Wales, Victoria, Tasmania and South Australia;
Cancer Foundation of Western Australia; NCI Specialized Program of
Research Excellence (SPORE) in Breast Cancer [CA116201]; U.S. Department
of Defence Ovarian Cancer Idea award [W81XWH-10-1-0341]; David and
Margaret T. Grohne Family Foundation; Ting Tsung and Wei Fong Chao
Foundation; Robert and Kate Niehaus Clinical Cancer Genetics Initiative;
Ohio State University Comprehensive Cancer Center; Swedish Cancer
Society; Women's Cancer Program (WCP) at the Samuel Oschin Comprehensive
Cancer Institute - American Cancer Society Early Detection Professorship
[SIOP-06-258-01-COUN]; NEYE Foundation; European Union (European Social
Fund - ESF); Greek national funds through the Operational Program
"Education and Lifelong Learning" of the National Strategic Reference
Framework (NSRF) - Research Funding Program of the General Secretariat
for Research Technology:; University of Kansas Cancer Center [P30
CA168524]; Kansas Bioscience Authority Eminent Scholar Program; National
Cancer Institute grants to the Gynecologic Oncology Group (GOG)
Administrative Office and Tissue Bank [CA 27469]; GOG Statistical and
Data Center [CA 37517]; NCI's Community Clinical Oncology Program (CCOP)
grant [CA 101165]; Canadian Breast Cancer Research Alliance-grant
[019511]; Ministry of Economic Development, Innovation and Export Trade
- grant [PSR-SIIRI-701]; Israel Cancer Association; Israeli Inherited
Breast Cancer Consortium; Susan G. Komen Foundation; Basser Research
Center; ISCIII [RD12/00369/0006]; European Regional Development funds,
Spain; Morris and Horowitz Families Endowed Professorship; Chancellors
Distinguished Chair in Biomedical Sciences Professorship; Intramural
Research Program of the US National Cancer Institute; NIH; Westat, Inc;
[PBZ_KBN_122/P05/2004]; [1R01 CA149429-01]; [5U01CA113916];
[R01CA140323]; [NO2-CP-11019- 50]; [N02-CP-65504]; Associazione
Italiana per la Ricerca sul Cancro
FX Funding for the iCOGS infrastructure came from: the European Community's
Seventh Framework Programme under grant agreement no 223175
(HEALTH-F2-2009-223175; COGS), Cancer Research UK (C1287/A10118, C1287/A
10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/ A15007,
C5047/A10692), the NIH (CA128978) and Post-Cancer GWAS initiative
(1U19CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAMEON initiative),
the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of
Health Research (CIHR) for the CIHR Team in Familial Risks of Breast
Cancer, Komen Foundation for the Cure, the Breast Cancer Research
Foundation, and the Ovarian Cancer Research Fund. BCFR was supported by
grant UM1 CA164920 from the National Cancer Institute. BFBOCC was partly
supported by: Research Council of Lithuania grant LIG-07/2012; BRCA-gene
mutations and breast cancer in South African women (BMBSA) was supported
by grants from the Cancer Association of South Africa (CANSA) to
Elizabeth J. van Rensburg; the CNIO study was supported by Spanish
Association against Cancer (AECC08), RTICC 06/0020/1060 and
FISPI12/00070 and Mutua Madrilena Foundation (FMMA); City of Hope
Clinical Cancer Genetics Community Research Network and the Hereditary
Cancer Research Registry (COH-CCGCRN) was supported in part by Award
Number RC4CA153828 (PI: J. Weitzel) from the National Cancer Institute
and the Office of the Director, NIH. CONSIT TEAM was partially supported
by funds from Italian citizens who allocated the 5 x 1000 share of their
tax payment in support of the Fondazione IRCCS Istituto Nazionale dei
Tumori, according to Italian laws (INT-Institutional strategic projects
'5 x 1000'); the DKFZ study was supported by the DKFZ; EMBRACE was
supported by Cancer Research UK Grants C1287/A10118, C1287/A16563 and
C1287/A17523. D. Gareth Evans and Fiona Lalloo are supported by an NIHR
grant to the Biomedical Research Centre, Manchester. The Investigators
at The Institute of Cancer Research and The Royal Marsden NHS Foundation
Trust were supported by an NIHR grant to the Biomedical Research Centre
at The Institute of Cancer Research and The Royal Marsden NHS Foundation
Trust. Ros Eeles and Elizabeth Bancroft were supported by Cancer
Research UK Grant C5047/A8385; the German Consortium of Hereditary
Breast and Ovarian Cancer (GC-HBOC) is kindly supported by the German
Cancer Aid to Rita K. Schmutzler (grant no. 109078) and by the Center
for Molecular Medicine Cologne (CMMC); the GEMO study was supported by
the Ligue National Contre le Cancer; the Association "Le cancer du sein,
parlons-en!" Award; and the Canadian Institutes of Health Research for
the "CIHR Team in Familial Risks of Breast Cancer" program; the HEBCS
was financially supported by the Helsinki University Central Hospital
Research Fund, Academy of Finland (266528), the Finnish Cancer Society
and the Sigrid Juselius Foundation; The HEBON study was supported by the
Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756,
the Netherlands Organization of Scientific Research grant NWO 91109024,
the Pink Ribbon grant 110005 and the BBMRI grant NWO 184.021.; 007/CP46;
Hungarian Breast and Ovarian Cancer Study (HUNBOCS) was supported by
Hungarian Research Grants KTIA OTKA CK-80745 and OTKA K-112228; ICO was
sponsored by Asociacion Espanola Contra el Cancer, Spanish Health
Research Fund; Carlos III Health Institute; Catalan Health Institute and
Autonomous Government of Catalonia, contract grant numbers: ISCIIIRETIC
RD06/0020/1051, RD12/0036/008, PI10/01422, PI10/00748, PI13/00285, and
2009SGR290; The IHCC was supported by Grant PBZ_KBN_122/P05/2004; The
ILUH group was supported by the Icelandic Association "Walking for
Breast Cancer Research" and by the Landspitali University Hospital
Research Fund; IOVHBOCS was supported by Ministero della Salute and "5 x
1000" Istituto Oncologico Veneto grant; kConFab was supported by grants
from the National Breast Cancer Foundation, the National Health and
Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the
Cancer Councils of New South Wales, Victoria, Tasmania and South
Australia, and the Cancer Foundation of Western Australia; MAYO was
supported by NIH grant CA128978, an NCI Specialized Program of Research
Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of
Defence Ovarian Cancer Idea award (W81XWH-10-1-0341) and a grant from
the Breast Cancer Research Foundation, the David and Margaret T. Grohne
Family Foundation, and the Ting Tsung and Wei Fong Chao Foundation;
MSKCC was supported by grants from the Breast Cancer Research Foundation
and Robert and Kate Niehaus Clinical Cancer Genetics Initiative; OSUCCG
was supported by the Ohio State University Comprehensive Cancer Center;
SWE-BRCA collaborators are supported by the Swedish Cancer Society; the
Women's Cancer Program (WCP) at the Samuel Oschin Comprehensive Cancer
Institute was funded by the American Cancer Society Early Detection
Professorship (SIOP-06-258-01-COUN).; This work was supported by the
NEYE Foundation; by the European Union (European Social Fund - ESF) and
Greek national funds through the Operational Program "Education and
Lifelong Learning" of the National Strategic Reference Framework (NSRF)
- Research Funding Program of the General Secretariat for Research&
Technology: ARISTEIA, Investing in knowledge society through the
European Social Fund; by the University of Kansas Cancer Center (P30
CA168524) and the Kansas Bioscience Authority Eminent Scholar Program;
by National Cancer Institute grants to the Gynecologic Oncology Group
(GOG) Administrative Office and Tissue Bank (CA 27469), the GOG
Statistical and Data Center (CA 37517), and by NCI's Community Clinical
Oncology Program (CCOP) grant (CA 101165); by the Canadian Institutes of
Health Research for the "CIHR Team in Familial Risks of Breast Cancer"
program, the Canadian Breast Cancer Research Alliance-grant #019511 and
the Ministry of Economic Development, Innovation and Export Trade -
grant #PSR-SIIRI-701; through a grant by the Israel Cancer Association
and the funding for the Israeli Inherited Breast Cancer Consortium; by
NIH (R01-CA102776 and R01CA083855; by Breast Cancer Research Foundation;
by Susan G. Komen Foundation; by Basser Research Center; by
RD12/00369/0006 from ISCIII and the European Regional Development funds,
Spain and by 1R01 CA149429-01 grant.; Susan L. Neuhausen was partially
supported by the Morris and Horowitz Families Endowed Professorship;
Andrew K. Godwin was funded by 5U01CA113916, R01CA140323, and by the
Chancellors Distinguished Chair in Biomedical Sciences Professorship;
the research of Mark H Greene and Phuong L Mai was supported by the
Intramural Research Program of the US National Cancer Institute, NIH,
and by support services contracts NO2-CP-11019- 50 and N02-CP-65504 with
Westat, Inc, Rockville, MD.
NR 8
TC 3
Z9 3
U1 3
U2 29
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JAN
PY 2015
VL 24
IS 1
BP 308
EP 316
DI 10.1158/1055-9965.EPI-14-0532
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA AZ1YG
UT WOS:000348030700038
PM 25336561
ER
PT J
AU Takx, RAP
Blomberg, BA
El Aidi, H
Habets, J
de Jong, PA
Nagel, E
Hoffmann, U
Leiner, T
AF Takx, Richard A. P.
Blomberg, Bjorn A.
El Aidi, Hamza
Habets, Jesse
de Jong, Pim A.
Nagel, Eike
Hoffmann, Udo
Leiner, Tim
TI Diagnostic Accuracy of Stress Myocardial Perfusion Imaging Compared to
Invasive Coronary Angiography With Fractional Flow Reserve Meta-Analysis
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Article
DE fractional flow reserve, myocardial; meta-analysis; myocardial perfusion
imaging
ID CARDIAC MAGNETIC-RESONANCE; ARTERY-DISEASE; CLINICAL-OUTCOMES;
STATEMENT; SEVERITY; REVASCULARIZATION; CATHETERIZATION; QUANTIFICATION;
INTERVENTION; ASSOCIATION
AB Background-Hemodynamically significant coronary artery disease is an important indication for revascularization. Stress myocardial perfusion imaging is a noninvasive alternative to invasive fractional flow reserve for evaluating hemodynamically significant coronary artery disease. The aim was to determine the diagnostic accuracy of myocardial perfusion imaging by single-photon emission computed tomography, echocardiography, MRI, positron emission tomography, and computed tomography compared with invasive coronary angiography with fractional flow reserve for the diagnosis of hemodynamically significant coronary artery disease.
Methods and Results-The meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. PubMed, EMBASE, and Web of Science were searched until May 2014. Thirty-seven studies, reporting on 4721 vessels and 2048 patients, were included. Meta-analysis yielded pooled sensitivity, pooled specificity, pooled likelihood ratios (LR), pooled diagnostic odds ratio, and summary area under the receiver operating characteristic curve. The negative LR (NLR) was chosen as the primary outcome. At the vessel level, MRI (pooled NLR, 0.16; 95% confidence interval [CI], 0.13-0.21) was performed similar to computed tomography (pooled NLR, 0.22; 95% CI, 0.12-0.39) and positron emission tomography (pooled NLR, 0.15; 95% CI, 0.05-0.44), and better than single-photon emission computed tomography (pooled NLR, 0.47; 95% CI, 0.37-0.59). At the patient level, MRI (pooled NLR, 0.14; 95% CI, 0.10-0.18) performed similar to computed tomography (pooled NLR, 0.12; 95% CI, 0.04-0.33) and positron emission tomography (pooled NLR, 0.14; 95% CI, 0.02-0.87), and better than single-photon emission computed tomography (pooled NLR, 0.39; 95% CI, 0.27-0.55) and echocardiography (pooled NLR, 0.42; 95% CI, 0.30-0.59).
Conclusions-Stress myocardial perfusion imaging with MRI, computed tomography, or positron emission tomography can accurately rule out hemodynamically significant coronary artery disease and can act as a gatekeeper for invasive revascularization. Single-photon emission computed tomography and echocardiography are less suited for this purpose.
C1 [Takx, Richard A. P.; Blomberg, Bjorn A.; El Aidi, Hamza; Habets, Jesse; de Jong, Pim A.; Leiner, Tim] UMC Utrecht, Dept Radiol, NL-3584 CX Utrecht, Netherlands.
[El Aidi, Hamza] UMC Utrecht, Dept Cardiol, NL-3584 CX Utrecht, Netherlands.
[Takx, Richard A. P.; Hoffmann, Udo] Harvard Univ, Sch Med, Dept Radiol, Cardiac MR PET CT Program,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Takx, Richard A. P.; Hoffmann, Udo] St Thomas Hosp, Div Imaging Sci & Biomed Engn, London, England.
RP Takx, RAP (reprint author), UMC Utrecht, Dept Radiol, Heidelberglaan 100,POB 85500, NL-3584 CX Utrecht, Netherlands.
EM rtakx@umcutrecht.nl
RI de Jong, Pim/G-7220-2014
OI de Jong, Pim/0000-0003-4840-6854
FU Bayer Healthcare; Philips Healthcare
FX Dr Nagel has received significant grant support from Bayer Healthcare
and Philips Healthcare. The other authors report no conflicts.
NR 26
TC 25
Z9 25
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD JAN
PY 2015
VL 8
IS 1
AR e002666
DI 10.1161/CIRCIMAGING.114.002666
PG 7
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA AZ3SL
UT WOS:000348146900007
ER
PT J
AU Kumar, A
Matheny, ME
Ho, KKL
Yeh, RW
Piemonte, TC
Waldman, H
Shah, PB
Cope, R
Normand, SLT
Donnelly, S
Robbins, S
Resnic, FS
AF Kumar, Amit
Matheny, Michael E.
Ho, Kalon K. L.
Yeh, Robert W.
Piemonte, Thomas C.
Waldman, Howard
Shah, Pinak B.
Cope, Richard
Normand, Sharon-Lise T.
Donnelly, Sharon
Robbins, Susan
Resnic, Frederic S.
TI The Data Extraction and Longitudinal Trend Analysis Network Study of
Distributed Automated Postmarket Cardiovascular Device Safety
Surveillance
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE safety
ID MEDICAL DEVICES; VASCULAR COMPLICATIONS; CLOSURE DEVICES; CARDIOLOGY;
COMMITTEE; RISK
AB Background-Current approaches for postmarket medical device safety surveillance are limited in their ability to produce timely and accurate assessments of adverse event rates.
Methods and Results-The Data Extraction and Longitudinal Trend Analysis (DELTA) network study was a multicenter prospective observational study designed to evaluate the safety of devices used during percutaneous coronary interventions. All adult patients undergoing percutaneous coronary intervention from January 2008 to December 2012 at 5 participating Massachusetts sites were included. A safety alert was triggered if the cumulative observed adverse event rates for the study device exceeded the upper 95% confidence interval of the event rates of propensity-matched control cohort. Prespecified sensitivity analyses were developed to validate any identified safety signal. A total of 23 805 consecutive percutaneous coronary intervention procedures were evaluated. Two of 24 safety analyses triggered safety alerts. Patients receiving Perclose vascular closure device experienced an increased risk of minor vascular complications (relative risk, 4.14; P < 0.01) and any vascular complication (relative risk, 2.06; P = 0.01) when compared with propensitymatched patients receiving alternative vascular closure device, a result primarily driven by relatively high event rates at 1 participating center. Sensitivity analyses based on alternative risk adjustment methods confirmed a pattern of increased rate of complications at 1 of the 5 participating sites in their use of Perclose vascular closure device.
Conclusions-The DELTA network study demonstrates that distributed automated prospective safety surveillance has the potential of providing near real-time assessment of safety risks of newly approved medical devices.
C1 [Kumar, Amit; Piemonte, Thomas C.; Robbins, Susan; Resnic, Frederic S.] Lahey Hosp & Med Ctr, Burlington, MA USA.
[Kumar, Amit; Piemonte, Thomas C.; Resnic, Frederic S.] Tufts Sch Med, Boston, MA USA.
[Matheny, Michael E.] VA Tennessee Valley Healthcare Syst, Nashville, TN USA.
[Matheny, Michael E.] Vanderbilt Univ, Nashville, TN 37235 USA.
[Ho, Kalon K. L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Ho, Kalon K. L.; Yeh, Robert W.; Waldman, Howard; Shah, Pinak B.; Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Boston, MA USA.
[Yeh, Robert W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Waldman, Howard] North Shore Med Ctr, Salem, MA USA.
[Shah, Pinak B.; Donnelly, Sharon] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Cope, Richard] Boston Adv Analyt, Newton, MA USA.
[Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Resnic, FS (reprint author), Lahey Clin Fdn, Dept Cardiovasc Med, 41 Mall Rd, Burlington, MA 01805 USA.
EM frederic.resnic@lahey.org
FU National Library of Medicine [R01 LM008142]; US Food and Drug
Administration (HHSF) [223200830058C]; MDEpiNet Methodology Center from
US Food and Drug Administration [HHSF223201110172C]; MDEpiNet from US
Food and Drug Administration [1U01 FD004493-01]
FX This research was supported through research grants from the National
Library of Medicine (R01 LM008142) and the US Food and Drug
Administration (HHSF contract 223200830058C). In addition, efforts of
Drs Resnic and Dr Normand were funded, in part, by contract
HHSF223201110172C (MDEpiNet Methodology Center) and grant 1U01
FD004493-01 (MDEpiNet Medical Counter Measures Study), both from the US
Food and Drug Administration.
NR 28
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7705
EI 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JAN
PY 2015
VL 8
IS 1
BP 38
EP 46
DI 10.1161/CIRCOUTCOMES.114.001123
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AZ3RT
UT WOS:000348145100008
PM 25491915
ER
PT J
AU Yeh, RW
Czarny, MJ
Normand, SLT
Kereiakes, DJ
Holmes, DR
Brindis, RG
Weaver, WD
Rumsfeld, JS
Roe, MT
Kim, S
Driscoll-Shempp, P
Mauri, L
AF Yeh, Robert W.
Czarny, Matthew J.
Normand, Sharon-Lise T.
Kereiakes, Dean J.
Holmes, David R., Jr.
Brindis, Ralph G.
Weaver, W. Douglas
Rumsfeld, John S.
Roe, Matthew T.
Kim, Sunghee
Driscoll-Shempp, Priscilla
Mauri, Laura
TI Evaluating the Generalizability of a Large Streamlined Cardiovascular
Trial Comparing Hospitals and Patients in the Dual Antiplatelet Therapy
Study Versus the National Cardiovascular Data Registry
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE clinical trial; coronary disease; methods; stents
ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION;
CLINICAL-TRIALS; EXTERNAL VALIDITY; ACCESS SITE; SAFE-PCI; WOMEN;
DESIGN; REPRESENTATION; PARTICIPANTS
AB Background-The Dual Antiplatelet Therapy Study is large streamlined clinical trial designed to evaluate antiplatelet treatment strategies in a broadly inclusive population of subjects treated with coronary stents. Whether large streamlined trials can successfully include a representative group of study sites and patients has not been formally assessed.
Methods and Results-Within the National Cardiovascular Data Registry CathPCI Registry, we compared characteristics and outcomes of hospitals participating versus not participating in the Dual Antiplatelet Therapy Study. We also compared clinical and procedural characteristics of trial subjects undergoing percutaneous coronary intervention (PCI) with drug-eluting stents to contemporaneous patients within the National Cardiovascular Data Registry CathPCI Registry. Standardized differences between groups were estimated. Between September 2009 and July 2011, 1.1 million PCIs were performed among 1276 hospitals, of which 309 (24.2%) participated in the Dual Antiplatelet Therapy Study. Participating hospitals were larger (468 versus 311 beds), more frequently located in urban settings (61.2% versus 42.6%), and had higher annual PCI volumes (858 versus 378) compared with nonparticipating hospitals, although hospital case mix and procedural outcomes were similar. Compared with CathPCI patients, trial patients undergoing PCI with drug-eluting stents were similar with respect to race, sex, and rates of diabetes mellitus, hypertension, and smoking, although they had lower rates of prior cardiovascular disease.
Conclusions-Within the Dual Antiplatelet Therapy Study, clinical trial sites had similar patient case mix and clinical outcomes as nonparticipating sites. Although trial participants were representative of PCI patients with respect to race, sex and most comorbidities, they had a lower prevalence of chronic cardiovascular disease compared with registry patients. Although a streamlined cardiovascular clinical trial may successfully involve a large number of hospitals and rapidly enroll a diverse population of patients, differences between eligible patients and those actually enrolled remained.
Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00977938.
C1 [Yeh, Robert W.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA.
[Normand, Sharon-Lise T.] Brigham & Womens Hosp, Dept Hlth Care Policy Biostat, Boston, MA 02115 USA.
[Mauri, Laura] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA.
[Yeh, Robert W.; Normand, Sharon-Lise T.; Mauri, Laura] Harvard Univ, Sch Med, Boston, MA USA.
[Yeh, Robert W.; Driscoll-Shempp, Priscilla; Mauri, Laura] Harvard Clin Res Inst, Boston, MA USA.
[Czarny, Matthew J.] Johns Hopkins Univ, Sch Med, Dept Med, Cardiol Div,Johns Hopkins Hosp, Baltimore, MD 21205 USA.
[Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Kereiakes, Dean J.] Christ Hosp, Heart & Vasc Ctr, Lindner Res Ctr, Cincinnati, OH 45219 USA.
[Holmes, David R., Jr.] Mayo Clin, Div Cardiol, Rochester, MN USA.
[Brindis, Ralph G.] Univ Calif San Francisco, Dept Med, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA USA.
[Weaver, W. Douglas] Henry Ford Hlth Syst, Inst Heart & Vasc, Detroit, MI USA.
[Rumsfeld, John S.] Vet Hlth Adm, Denver VA Med Ctr, Div Cardiol, Denver, CO USA.
[Roe, Matthew T.; Kim, Sunghee] Duke Clin Res Inst, Durham, NC USA.
RP Yeh, RW (reprint author), Massachusetts Gen Hosp, Div Cardiol, GRB 800, Boston, MA 02114 USA.
EM ryeh@partners.org
FU Abbott Vascular; Boston Scientific; Cordis; Medtronic Cardiovascular;
Health and Human Services [1R01FD003870-01]; American College of
Cardiology Foundation; National Heart, Lung, and Blood Institute
[1K23HL118138]
FX Funding for the Dual Antiplatelet Therapy (DAPT) Study is provided by
four US manufacturers of drug-eluting stents (Abbott Vascular, Boston
Scientific, Cordis, and Medtronic Cardiovascular) and the current
manufacturers of thienopyridine medications (Eli Lilly/Daiichii Sankyo
and Bristol Myers Squibb/Sanofi-Aventis) with supplementary funding from
the Health and Human Services 1R01FD003870-01 (PI Dr Mauri). The
National Cardiovascular Data Registry CathPCI Registry is funded by the
American College of Cardiology Foundation. Dr Yeh is supported by a
Career Development Award (1K23HL118138) from the National Heart, Lung,
and Blood Institute.
NR 26
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7705
EI 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JAN
PY 2015
VL 8
IS 1
BP 96
EP 102
DI 10.1161/CIRCOUTCOMES.114.001239
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AZ3RT
UT WOS:000348145100014
PM 25399847
ER
PT J
AU Drye, BD
Drye, EE
AF Drye, Barbara D.
Drye, Elizabeth E.
TI Older Patients With Cardiac Devices The Need for Better Patient-Doctor
Conversations
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Editorial Material
DE communication; defibrilators, implantable; informed consent; patient
care planning; patient preference
C1 San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.
Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
RP Drye, EE (reprint author), Yale Univ, Sch Med, 1 Church St,Suite 200, New Haven, CT 06510 USA.
EM Elizabeth.Drye@Yale.edu
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7705
EI 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JAN
PY 2015
VL 8
IS 1
BP 112
EP 113
DI 10.1161/CIRCOUTCOMES.114.000916
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AZ3RT
UT WOS:000348145100017
PM 25604558
ER
PT J
AU Jones, LG
Sin, MK
Hage, FG
Kheirbek, RE
Morgan, CJ
Zile, MR
Wu, WC
Deedwania, P
Fonarow, GC
Aronow, WS
Prabhu, SD
Fletcher, RD
Ahmed, A
Allman, RM
AF Jones, Linda G.
Sin, Mo-Kyung
Hage, Fadi G.
Kheirbek, Raya E.
Morgan, Charity J.
Zile, Michael R.
Wu, Wen-Chih
Deedwania, Prakash
Fonarow, Gregg C.
Aronow, Wilbert S.
Prabhu, Sumanth D.
Fletcher, Ross D.
Ahmed, Ali
Allman, Richard M.
TI Characteristics and Outcomes of Patients With Advanced Chronic Systolic
Heart Failure Receiving Care at the Veterans Affairs Versus Other
Hospitals Insights From the Beta-blocker Evaluation of Survival Trial
(BEST)
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE hospitals; outcomes; systolic heart failure; veterans
ID VENTRICULAR EJECTION FRACTION; VASODILATOR THERAPY; ATRIAL-FIBRILLATION;
INCREASED MORTALITY; NATURAL-HISTORY; HEALTH; RACE; ASSOCIATION;
AMIODARONE; BUCINDOLOL
AB Background-Characteristics and outcomes of patients with heart failure and reduced ejection fraction receiving care at Veterans Affairs (VA) versus non-VA hospitals have not been previously reported.
Methods and Results-In the randomized controlled Beta-blocker Evaluation of Survival Trial (BEST; 1995-1999), of the 2707 (bucindolol=1353; placebo=1354) patients with heart failure and left ventricular ejection fraction <= 35%, 918 received care at VA hospitals, of which 98% (n=898) were male. Of the 1789 receiving care at non-VA hospitals, 68% (n=1216) were male. Our analyses were restricted to these 2114 male patients. VA patients were older with higher symptom and comorbidity burdens. There was no significant between-group difference in unadjusted primary end point of 2-year all-cause mortality (35% VA versus 32% non-VA; hazard ratio associated with VA hospitals, 1.09; 95% confidence interval, 0.94-1.26), which remained unchanged after adjustment for age and race (hazard ratio, 1.00; 95% confidence interval, 0.86-1.16) or multivariable adjustment, including cardiovascular morbidities (hazard ratio, 0.94; 95% confidence interval, 0.80-1.10). There was no between-group difference in cause-specific mortalities or hospitalizations. Chronic kidney disease, pulmonary edema, left ventricular ejection fraction <20%, and peripheral arterial disease were significant predictors of mortality for both groups. African America race, New York Heart Association class IV symptoms, atrial fibrillation, and right ventricular ejection fraction <20% were associated with higher mortality among non-VA hospital patients only; however, these differences from VA patients were not significant.
Conclusions-Patients with heart failure and reduced ejection fraction receiving care at VA hospitals were older and sicker; yet their risk of mortality and hospitalization was similar to younger and healthier patients receiving care at non-VA hospitals.
C1 [Jones, Linda G.; Hage, Fadi G.; Prabhu, Sumanth D.] Vet Affairs Med Ctr, Dept Med, Birmingham, AL USA.
[Jones, Linda G.; Hage, Fadi G.; Prabhu, Sumanth D.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA.
[Morgan, Charity J.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL USA.
[Sin, Mo-Kyung] Seattle Univ, Coll Nursing, Dept Adult Hlth, Seattle, WA 98122 USA.
[Kheirbek, Raya E.; Fletcher, Ross D.; Ahmed, Ali] Vet Affairs Med Ctr, Off Chief Staff, Washington, DC USA.
[Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC USA.
[Zile, Michael R.] Med Univ S Carolina, Dept Med, Charleston, SC USA.
[Wu, Wen-Chih] Vet Affairs Med Ctr, Dept Med, Providence, RI USA.
[Wu, Wen-Chih] Brown Univ, Dept Med, Providence, RI 02912 USA.
[Deedwania, Prakash] Univ Calif San Francisco, Dept Med, Fresno, CA USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Aronow, Wilbert S.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA.
[Allman, Richard M.] Dept Vet Affairs, Geriatr Serv, Washington, DC USA.
[Allman, Richard M.] Dept Vet Affairs, Extended Care Serv, Washington, DC USA.
RP Ahmed, A (reprint author), Washington DC VA Med Ctr, 50 Irving St NW, Washington, DC 20422 USA.
EM aliahmedmdmph@gmail.com
OI Hage, Fadi/0000-0002-1397-4942
FU National Heart, Lung, and Blood Institute (NHLBI), Bethesda, Maryland
[R01-HL085561, R01-HL097047]; University of Alabama at Birmingham
Comprehensive Cardiovascular Center, Birmingham, Alabama
FX Dr Ahmed was in part supported by grants (R01-HL085561 and R01-HL097047)
from the National Heart, Lung, and Blood Institute (NHLBI), Bethesda,
Maryland, and an intramural support from the University of Alabama at
Birmingham Comprehensive Cardiovascular Center, Birmingham, Alabama.
NR 35
TC 3
Z9 3
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD JAN
PY 2015
VL 8
IS 1
BP 17
EP 24
DI 10.1161/CIRCHEARTFAILURE.114.001300
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AZ3RX
UT WOS:000348145400004
PM 25480782
ER
PT J
AU Jotwani, V
Scherzer, R
Abraham, A
Estrella, MM
Bennett, M
Cohen, MH
Nowicki, M
Sharma, A
Young, M
Tien, PC
Ix, JH
Sarnak, MJ
Parikh, CR
Shlipak, MG
AF Jotwani, Vasantha
Scherzer, Rebecca
Abraham, Alison
Estrella, Michelle M.
Bennett, Michael
Cohen, Mardge H.
Nowicki, Marek
Sharma, Anjali
Young, Mary
Tien, Phyllis C.
Ix, Joachim H.
Sarnak, Mark J.
Parikh, Chirag R.
Shlipak, Michael G.
TI Association of Urine alpha 1-Microglobulin with Kidney Function Decline
and Mortality in HIV-Infected Women
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
DE HIV nephropathy; CKD; proximal tubule
ID SERUM CYSTATIN-C; IMMUNODEFICIENCY-VIRUS-INFECTION; ACUTE
TUBULAR-NECROSIS; STAGE RENAL-DISEASE; ANTIRETROVIRAL THERAPY;
INTERAGENCY HIV; PROXIMAL TUBULE; ESTIMATING GFR; TENOFOVIR; INJURY
AB Background and objectivesDespite advances in therapy, HIV-infected individuals remain at higher risk for kidney dysfunction than uninfected individuals. It was hypothesized that urine levels of 1-microglobulin, a biomarker of proximal tubular dysfunction, would predict kidney function decline and mortality risk in HIV-infected and uninfected women.Design, setting, participants, & measurementsIn the Women's Interagency HIV Study, urine 1-microglobulin and creatinine concentrations were measured in 903 HIV-infected and 287 uninfected women using stored urine from 1999 to 2000, when prevalence of tenofovir use was <1%. Participants were categorized into three categories by level of 1-microglobulin-to-creatinine ratio, and associations with kidney decline and all-cause mortality over 8 years were evaluated.ResultsUrine 1-microglobulin was detectable in 60% of HIV-infected and 40% of uninfected women (P<0.001). Among HIV-infected women, there were 177 (22%), 61 (7%), and 128 (14%) patients with incident CKD, with 10% annual eGFR decline, and who died, respectively. Compared with HIV-infected women in the lowest 1-microglobulin category, HIV-infected women in the highest 1-microglobulin category had a 2.1-fold risk of incident CKD (95% confidence interval, 1.3 to 3.4), 2.7-fold risk of 10% annual eGFR decline (95% confidence interval, 1.2 to 5.9), and 1.6-fold mortality risk (95% confidence interval, 1.0 to 2.6) in models adjusting for kidney risk factors, baseline eGFR, and albuminuria. Among uninfected women, the highest 1-microglobulin category was associated with 3% (relative risk, 2.2; 95% confidence interval, 1.4 to 3.5) and 5% (relative risk, 2.2; 95% confidence interval, 1.1 to 4.3) annual eGFR decline relative to the lowest 1-microglobulin category.ConclusionsProximal tubular dysfunction, indicated by urine 1-microglobulin, was independently associated with kidney function decline in HIV-infected and uninfected women and mortality risk among HIV-infected women.
C1 San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA.
RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, Dept Med, 4150 Clement Street, San Francisco, CA 94121 USA.
EM Michael.Shlipak@ucsf.edu
FU National Institute of Allergy and Infectious Diseases; Eunice Kennedy
Shriver National Institute of Child Health and Human Development;
National Cancer Institute; National Institute on Drug Abuse; National
Institute on Mental Health; National Institute of Dental and
Craniofacial Research; National Institute on Alcohol Abuse and
Alcoholism; National Institute on Deafness and Other Communication
Disorders; National Institutes of Health (NIH) Office of Research on
Women's Health; [1 R01 AG034853-01A2]; [1K23-DK-081317];
[U01-AI-103401]; [U01-AI-103408]; [U01-AI-035004]; [U01-AI-031834];
[U01-AI-034993]; [U01-AI-034994]; [U01-AI-103397]; [U01-AI-103390];
[U01-AI-034989]; [U01-AI-042590]; [U01-HD-032632]; [UL1-TR000004];
[UL1-TR000454]
FX The WIHS Kidney Aging Study is funded by Grant 1 R01 AG034853-01A2
(Principal Investigator: M.G.S.), which was administered by the Northern
California Institute for Research and Education with resources of the
Veterans Affairs Medical Center (San Francisco, California). M.M.E. is
supported by Grant 1K23-DK-081317. Data in this manuscript were
collected by the Women's Interagency HIV Study (WIHS). WIHS (Principal
Investigators): UAB-MS WIHS (Michael Saag, Mirjam-Colette Kempf, and
Deborah Konkle-Parker), Grant U01-AI-103401; Atlanta WIHS (Ighovwerha
Ofotokun and Gina Wingood), Grant U01-AI-103408; Bronx WIHS (Kathryn
Anastos), Grant U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah
Gustafson), Grant U01-AI-031834; Chicago WIHS (M.H.C.), Grant
U01-AI-034993; Metropolitan Washington WIHS (M.Y.), Grant U01-AI-034994;
Miami WIHS (Margaret Fischl and Lisa Metsch), Grant U01-AI-103397; UNC
WIHS (Adaora Adimora), Grant U01-AI-103390; Connie Wofsy Women's HIV
Study, northern California (Ruth Greenblatt, Bradley Aouizerat, and
Phyllis Tien), Grant U01-AI-034989; WIHS Data Management and Analysis
Center (Stephen Gange and Elizabeth Golub), Grant U01-AI-042590; and
Southern California WIHS (Alexandra Levine and M.N.), Grant
U01-HD-032632 (WIHS I to WIHS IV). The WIHS is funded primarily by the
National Institute of Allergy and Infectious Diseases, with additional
cofunding from the Eunice Kennedy Shriver National Institute of Child
Health and Human Development, the National Cancer Institute, the
National Institute on Drug Abuse, and the National Institute on Mental
Health. Targeted supplemental funding for specific projects is also
provided by the National Institute of Dental and Craniofacial Research,
the National Institute on Alcohol Abuse and Alcoholism, the National
Institute on Deafness and Other Communication Disorders, and the
National Institutes of Health (NIH) Office of Research on Women's
Health. WIHS data collection is also supported by Grants UL1-TR000004
(to UCSF CTSA) and UL1-TR000454 (to Atlanta CTSA).
NR 41
TC 7
Z9 7
U1 0
U2 4
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JAN
PY 2015
VL 10
IS 1
BP 63
EP 73
DI 10.2215/CJN.03220314
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA AY7BS
UT WOS:000347716900011
PM 25370597
ER
PT J
AU Alge, JL
Arthur, JM
AF Alge, Joseph L.
Arthur, John M.
TI Biomarkers of AKI: A Review of Mechanistic Relevance and Potential
Therapeutic Implications
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Review
DE acute renal failure; pathophysiology of renal disease and progression;
renin-angiotensin system
ID ACUTE KIDNEY INJURY; ACID-BINDING PROTEIN; ACUTE-RENAL-FAILURE;
GELATINASE-ASSOCIATED LIPOCALIN; ISCHEMIA-REPERFUSION INJURY; EARLY
URINARY BIOMARKER; ADULT CARDIAC-SURGERY; INTENSIVE-CARE-UNIT; CHAIN
FATTY-ACID; GROWTH-FACTOR-I
AB AKI is a common clinical condition associated with a number of adverse outcomes. More timely diagnosis would allow for earlier intervention and could improve patient outcomes. The goal of early identification of AKI has been the primary impetus for AKI biomarker research, and has led to the discovery of numerous novel biomarkers. However, in addition to facilitating more timely intervention, AKI biomarkers can provide valuable insight into the molecular mechanisms of this complex and heterogeneous disease. Furthermore, AKI biomarkers could also function as molecular phenotyping tools that could be used to direct clinical intervention. This review highlights the major studies that have characterized the diagnostic and prognostic predictive power of these biomarkers. The mechanistic relevance of neutrophil gelatinase-associated lipocalin, kidney injury molecule 1, IL-18, liver-type fatty acid-binding protein, angiotensinogen, tissue inhibitor of metalloproteinase-2, and IGF-binding protein 7 to the pathogenesis and pathobiology of AKI is discussed, putting these biomarkers in the context of the progressive phases of AKI. A biomarker-integrated model of AKI is proposed, which summarizes the current state of knowledge regarding the roles of these biomarkers and the molecular and cellular biology of AKI.
C1 [Alge, Joseph L.; Arthur, John M.] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA.
[Arthur, John M.] Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC USA.
RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas Street,MSC 629, Charleston, SC 29425 USA.
EM arthurj@musc.edu
OI Alge, Joseph/0000-0002-2491-1066
FU Department of Veterans Affairs; National Institutes of Health
[R01-DK080234]
FX This manuscript was supported by the Department of Veterans Affairs and
National Institutes of Health Grant R01-DK080234.
NR 86
TC 37
Z9 39
U1 1
U2 16
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JAN
PY 2015
VL 10
IS 1
BP 147
EP 155
DI 10.2215/CJN.12191213
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA AY7BS
UT WOS:000347716900020
PM 25092601
ER
PT J
AU Goldenberg, D
Goyal, N
AF Goldenberg, David
Goyal, Neerav
TI Impact factor: What is it and is it still relevant?
SO ENT-EAR NOSE & THROAT JOURNAL
LA English
DT Editorial Material
ID JOURNALS; CITATION; INDEX
C1 [Goldenberg, David] Penn State Univ, Coll Med, Hershey, PA 17033 USA.
[Goldenberg, David] Penn State Hershey Canc Inst, Hershey, PA USA.
[Goyal, Neerav] Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
RP Goldenberg, D (reprint author), Penn State Univ, Coll Med, Hershey, PA 17033 USA.
OI Goyal, Neerav/0000-0001-7783-1097
NR 15
TC 0
Z9 0
U1 1
U2 4
PU VENDOME GROUP LLC
PI NEW YORK
PA 6 EAST 32 ST, 8 FLOOR, NEW YORK, NY 10016 USA
SN 0145-5613
EI 1942-7522
J9 ENT-EAR NOSE THROAT
JI ENT-Ear Nose Throat J.
PD JAN
PY 2015
VL 94
IS 1
BP 14
EP +
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA AZ4GX
UT WOS:000348180800001
PM 25606828
ER
PT J
AU Metra, M
Mentz, RJ
Chiswell, K
Bloomfield, DM
Cleland, JGF
Cotter, G
Davison, BA
Dittrich, HC
Fiuzat, M
Givertz, MM
Lazzarini, V
Mansoor, GA
Massie, BM
Ponikowski, P
Teerlink, JR
Voors, AA
O'Connor, CM
AF Metra, Marco
Mentz, Robert J.
Chiswell, Karen
Bloomfield, Daniel M.
Cleland, John G. F.
Cotter, Gad
Davison, Beth A.
Dittrich, Howard C.
Fiuzat, Mona
Givertz, Michael M.
Lazzarini, Valentina
Mansoor, George A.
Massie, Barry M.
Ponikowski, Piotr
Teerlink, John R.
Voors, Adriaan A.
O'Connor, Christopher M.
TI Acute heart failure in elderly patients: worse outcomes and differential
utility of standard prognostic variables. Insights from the PROTECT
trial
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Age; Elderly; Acute heart failure; Blood pressure
ID CLINICAL CHARACTERISTICS; EJECTION FRACTION; PULSE PRESSURE; TASK-FORCE;
RISK; ASSOCIATION; AGE; ROLOFYLLINE; PREVALENCE; ANTAGONIST
AB AimsPrevious heart failure (HF) trials suggested that age influences patient characteristics and outcome; however, under-representation of elderly patients has limited characterization of this cohort. Whether standard prognostic variables have differential utility in various age groups is unclear.
Methods and resultsThe PROTECT trial investigated 2033 patients (median age 72 years) with acute HF randomized to rolofylline or placebo. Patients were divided into five groups based on the quintiles of age: 59, 60-68, 69-74, 75-79, and 80years. Baseline characteristics, medications, and outcomes (30-day death or cardiovascular/renal hospitalization, and death at 30 and 180 days) were explored. The prognostic utility of baseline characteristics for outcomes was investigated in the different groups and in those aged <80years vs. 80years. With increasing age, patients were more likely to be women with hypertension, AF, and higher EF. Increased age was associated with increased risk of 30- and 180-day outcomes, which persisted after multivariable adjustment (hazard ratio for 180-day death=1.17; 95% confidence interval 1.11-1.24 for each 5-year increase). The prognostic utility of baseline characteristics such as previous HF hospitalization and serum sodium, systolic blood pressure, and NYHA class was attenuated in the elderly for the endpoint of 180-day mortality. An increase in albumin was associated with a greater reduction in risk in patients aged 80years vs. <80years.
ConclusionsIn a large trial of acute HF, there were differences in baseline characteristics and outcomes amongst patients of different ages. Standard prognostic variables exhibit different utility in elderly patients.
C1 [Metra, Marco; Lazzarini, Valentina] Univ Brescia, Dept Med & Surg Specialties, Brescia, Italy.
[Mentz, Robert J.; Fiuzat, Mona; O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Div Cardiovasc Med, Durham, NC USA.
[Chiswell, Karen] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Bloomfield, Daniel M.; Mansoor, George A.] Merck Res Labs, Rahway, NJ USA.
[Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Royal Brompton Hosp, Kingston Upon Hull, Yorks, England.
[Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Harefield Hosp, Kingston Upon Hull, Yorks, England.
[Cleland, John G. F.] Univ Hull, Dept Cardiol, Castle Hill Hosp, Kingston Upon Hull, Yorks, England.
[Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA.
[Dittrich, Howard C.] Univ Iowa, Carver Coll Med Cardiovasc Res Ctr, Iowa City, IA USA.
[Givertz, Michael M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA.
[Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.; Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ponikowski, Piotr] Med Univ, Mil Hosp, Wroclaw, Poland.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
RP Metra, M (reprint author), Spedali Civil Brescia, Piazza Spedali Civili 1, I-25123 Brescia, Italy.
EM metramarco@libero.it
RI Ponikowski, Piotr/O-6454-2015;
OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland,
John/0000-0002-1471-7016; Metra, Marco/0000-0001-6691-8568
FU National Institute of General Medical Sciences [5-T32GM086330]
FX R.J.M. is supported by grant no. 5-T32GM086330 from the National
Institute of General Medical Sciences.
NR 23
TC 15
Z9 15
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD JAN
PY 2015
VL 17
IS 1
BP 109
EP 118
DI 10.1002/ejhf.207
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AZ2IU
UT WOS:000348058300014
PM 25431336
ER
PT J
AU Littman, AJ
Damschroder, LJ
Verchinina, L
Lai, ZS
Kim, HM
Hoerster, KD
Klingaman, EA
Goldberg, RW
Owen, RR
Goodrich, DE
AF Littman, Alyson J.
Damschroder, Laura J.
Verchinina, Lilia
Lai, Zongshan
Kim, Hyungjin Myra
Hoerster, Katherine D.
Klingaman, Elizabeth A.
Goldberg, Richard W.
Owen, Richard R.
Goodrich, David E.
TI National evaluation of obesity screening and treatment among veterans
with and without mental health disorders
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Obesity; Weight management; Veterans; Serious mental illness; Depressive
disorder
ID WEIGHT-MANAGEMENT PROGRAM; LIFE-STYLE INTERVENTION; UNITED-STATES;
CARDIOVASCULAR RISK; METABOLIC SYNDROME; ANXIETY DISORDERS;
CONTROLLED-TRIAL; PRIMARY-CARE; ILLNESS; ADULTS
AB Objective: The objective was to determine whether obesity screening and weight management program participation and outcomes are equitable for individuals with serious mental illness (SMI) and depressive disorder (DD) compared to those without SMI/DD in Veterans Health Administration (VHA), the largest integrated US health system, which requires obesity screening and offers weight management to all in need.
Methods: We used chart-reviewed, clinical and administrative VHA data from fiscal years 2010-2012 to estimate obesity screening and participation in the VHA's weight management program (MOVE!) across groups. Six-and 12-month weight changes in MOVE! participants were estimated using linear mixed models adjusted for confounders.
Results: Compared to individuals without SMI/DD, individuals with SMI or DD were less frequently screened for obesity (94%-94.7% vs. 95.7%) but had greater participation in MOVE! (10.1%-10.4% vs. 7.4%). MOVE! participants with SMI or DD lost approximately 1 lb less at 6 months. At 12 months, average weight loss for individuals with SMI or neither SMI/DD was comparable (-3.5 and -3.3 lb, respectively), but individuals with DD lost less weight (mean=-2.7 lb).
Conclusions: Disparities in obesity screening and treatment outcomes across mental health diagnosis groups were modest. However, participation in MOVE! was low for every group, which limits population impact. Published by Elsevier Inc.
C1 [Littman, Alyson J.] VA Puget Sound Healthcare Syst, Seattle Div Epidemiol Res & Informat Ctr ERIC, Seattle, WA 98108 USA.
[Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Damschroder, Laura J.; Verchinina, Lilia; Lai, Zongshan; Kim, Hyungjin Myra; Goodrich, David E.] VA Ann Arbor Healthcare Syst, CCMR, Ann Arbor, MI 48105 USA.
[Lai, Zongshan; Goodrich, David E.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Kim, Hyungjin Myra] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA.
[Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Seattle Div Mental Hlth Serv, Seattle, WA 98108 USA.
[Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Klingaman, Elizabeth A.; Goldberg, Richard W.] VA Capitol Hlth Care Network, Mental Illness Res Educ & Clin Ctr, Baltimore, MD USA.
[Owen, Richard R.] Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, Little Rock, AR USA.
[Owen, Richard R.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Little Rock, AR 72205 USA.
[Klingaman, Elizabeth A.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA.
RP Littman, AJ (reprint author), VA Puget Sound Healthcare Syst, Seattle Epidemiol Res & Informat Ctr ERIC, 1660 South Columbia Way,S-152-E, Seattle, WA 98108 USA.
EM Alyson.littman@va.gov; Laura.damschroder@va.gov;
Lilia.verchinina@va.gov; Zongshan.Lai@va.gov; Myrakim@umich.edu;
Katherine.hoerster@va.gov; Elizabeth.klingaman@va.gov;
Richard.goldberg@va.gov; Richard.Owen2@va.gov; David.goodrich2@va.gov
OI Damschroder, Laura/0000-0002-3657-8459; Goodrich,
David/0000-0003-3232-2189
FU VHA Center for Health Promotion & Disease Prevention (NCP); VA Health
Services Research and Development Quality Enhancement Research
Initiative (QUERI) [QLP 55-017]; Rehabilitation R&D Career Development
Award [6982]
FX This study was funded by was initiated at the request of the VHA Center
for Health Promotion & Disease Prevention (NCP). Funding was provided by
VA Health Services Research and Development Quality Enhancement Research
Initiative (QUERI) programs for Diabetes and Mental Health research as a
locally initiated project (QLP 55-017). Dr. Littman's time was supported
by a Rehabilitation R&D Career Development Award (#6982). The authors
would like to acknowledge the support of Dr. Amy M. Kilbourne, Dr.
Kenneth J. Jones, Dr. Caroline R. Richardson and Ms. Trang Lance in this
work. The views expressed in this article are those of the authors and
do not necessarily represent the views of the Veterans Administration.
NR 59
TC 10
Z9 10
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD JAN-FEB
PY 2015
VL 37
IS 1
BP 7
EP 13
DI 10.1016/j.genhosppsych.2014.11.005
PG 7
WC Psychiatry
SC Psychiatry
GA AZ2CQ
UT WOS:000348042700005
PM 25500194
ER
PT J
AU Iyer, SP
Young, AS
AF Iyer, Sharat P.
Young, Alexander S.
TI Health screening, counseling, and hypertension control for people with
serious mental illness at primary care visits
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Primary care; Serious mental illness; Health screening; Health
counseling; Hypertension
ID MEDICAL-CARE; SCHIZOPHRENIA; MORTALITY; COHORT; OUTPATIENTS; DISORDERS;
BARRIERS; RECEIPT; STATE
AB Objective: This study sought to determine if primary care visits for people with serious mental illness (SMI) demonstrate different rates of basic physical health services compared to others, and to determine factors associated with differing rates of these measures in people with SMI.
Method: The study used 2005-2010 visit-level primary care data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. The provision of health counseling, receipt of any diagnostic or screening test, measurement of blood pressure or weight and evidence of hypertension control were assessed, adjusting for identified patient, provider and visit-level factors.
Results: After adjustment for covariates, we found no significant differences between visits for people with SMI and those without for any outcome. Probability of blood pressure measurement and diagnostic or screening testing significantly increased over time.
Conclusion: The lack of significant differences found here might be due to adjustment for covariates, a focus only on primary care visits, the use of visit-level data or evolution over time. Mortality differences for people with SMI may be attributable to those not receiving primary care, self-management of disease or subsets of the population requiring targeted interventions. Published by Elsevier Inc.
C1 [Iyer, Sharat P.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN3, Bronx, NY 10468 USA.
[Iyer, Sharat P.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Young, Alexander S.] West Los Angeles VA Med Ctr, Desert Pacific Mental Illness Res Educ & Clin Ctr, Los Angeles, CA 90073 USA.
[Young, Alexander S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
RP Iyer, SP (reprint author), VA Med Ctr MIRECC OOMH, 130 W Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA.
EM sharu.p@mssm.edu; ayoung@ucla.edu
RI Young, Alexander/A-1523-2009
OI Young, Alexander/0000-0002-9367-9213
FU Robert Wood Johnson Foundation Clinical Scholars program; US Department
of Veterans Affairs
FX This material is the result of work supported with resources and the use
of facilities at the James J. Peters VA Medical Center, Bronx, NY, and
the West Los Angeles VA Medical Center, Los Angeles, CA. Additional
support was provided by the Mount Sinai Conduits Institutes for
Translational Sciences. Assistance for this article was provided by
Kenneth Wells, M.D., M.P.H., and Lisa Dixon, M.D., M.P.H., who reviewed
the manuscript and contributed to the discussion, and Alan Weinberg,
M.S., who contributed to the analytic plan. Funding for Dr. Parameswaran
was provided by the Robert Wood Johnson Foundation Clinical Scholars
program and the US Department of Veterans Affairs. The views expressed
in this article are those of the authors and do not necessarily reflect
the position or policy of the Department of Veterans Affairs or the
United States government.
NR 24
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD JAN-FEB
PY 2015
VL 37
IS 1
BP 60
EP 66
DI 10.1016/j.genhosppsych.2014.10.003
PG 7
WC Psychiatry
SC Psychiatry
GA AZ2CQ
UT WOS:000348042700014
PM 25480463
ER
PT J
AU Smith, SL
Grelotti, DJ
Fils-Aime, R
Uwimana, E
Ndikubwimana, JS
Therosme, T
Severe, J
Dushimiyimana, D
Uwamariya, C
Bienvenu, R
Alcindor, Y
Eustache, E
Raviola, GJ
Fricchione, GL
AF Smith, Stephanie L.
Grelotti, David J.
Fils-Aime, Reginald
Uwimana, Eugenie
Ndikubwimana, Jean-Sauveur
Therosme, Tatiana
Severe, Jennifer
Dushimiyimana, Dominique
Uwamariya, Clemence
Bienvenu, Robert
Alcindor, Yoldie
Eustache, Eddy
Raviola, Giuseppe J.
Fricchione, Gregory L.
TI Catatonia in resource-limited settings: A case series and treatment
protocol
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Catatonia; Africa; Caribbean region; Psychosomatic medicine;
Neuropsychiatry
ID GLOBAL MENTAL-HEALTH; LORAZEPAM
AB Objective: The catatonic syndrome ("catatonia") is characterized by motor and motivation dysregulation and is associated with a number of neuropsychiatric and medical disorders. It is recognizable in a variety of clinical settings. We present observations from the treatment of four individuals with catatonia in Haiti and Rwanda and introduce a treatment protocol for use in resource-limited settings.
Methods: Four patients from rural Haiti and Rwanda with clinical signs of catatonia and a positive screen using the Bush-Francis Catatonia Rating Scale were treated collaboratively by general physicians and mental health clinicians with either lorazepam or diazepam. Success in treatment was clinically assessed by complete remittance of catatonia symptoms.
Results: The four patients in this report exhibited a range of characteristic and recognizable signs of catatonia, including immobility/stupor, stereotypic movements, echophenomena, posturing, odd mannerisms, mutism and refusal to eat or drink. All four cases presented initially to rural outpatient general health services in resource-limited settings. In some cases, diagnostic uncertainty initially led to treatment with typical antipsychotics. In each case, proper identification and treatment of catatonia with benzodiazepines led to significant clinical improvement.
Conclusion: Catatonia can be effectively and inexpensively treated in resource-limited settings. Identification and management of catatonia are critical for the health and safety of patients with this syndrome. Familiarity with the clinical features of catatonia is essential for health professionals working in any setting. To facilitate early recognition of this treatable disorder, catatonia should feature more prominently in global mental health discourse. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Smith, Stephanie L.; Raviola, Giuseppe J.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA.
[Smith, Stephanie L.; Grelotti, David J.; Raviola, Giuseppe J.] Partners Hlth, Boston, MA 02215 USA.
[Smith, Stephanie L.] Brigham & Womens Hosp, Div Med Psychiat, Boston, MA 02115 USA.
[Grelotti, David J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Fils-Aime, Reginald; Therosme, Tatiana; Severe, Jennifer; Alcindor, Yoldie; Eustache, Eddy] Dept Mental Hlth & Psychosocial Serv, Zanmi Lasante, Haiti.
[Uwimana, Eugenie; Ndikubwimana, Jean-Sauveur; Dushimiyimana, Dominique; Uwamariya, Clemence; Bienvenu, Robert] Minist Hlth, Butaro Hosp, Burera Dist, Rwanda.
[Fricchione, Gregory L.] Massachusetts Gen Hosp, Pierce Div Global Psychiat, Div Psychiat & Med, Boston, MA 02114 USA.
RP Smith, SL (reprint author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, 641 Huntington Ave, Boston, MA 02115 USA.
EM Stephanie_Smith@hms.harvard.edu
OI FILS-AIME, Joseph/0000-0002-1840-8755
FU NIMH NIH HHS [T32 MH017119]
NR 24
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD JAN-FEB
PY 2015
VL 37
IS 1
BP 89
EP 93
DI 10.1016/j.genhosppsych.2014.10.009
PG 5
WC Psychiatry
SC Psychiatry
GA AZ2CQ
UT WOS:000348042700018
PM 25467078
ER
PT J
AU Scheuner, MT
Peredo, J
Benkendorf, J
Bowdish, B
Feldman, G
Fleisher, L
Mulvihill, JJ
Watson, M
Herman, GE
Evans, J
AF Scheuner, Maren T.
Peredo, Jane
Benkendorf, Judith
Bowdish, Bruce
Feldman, Gerald
Fleisher, Lynn
Mulvihill, John J.
Watson, Michael
Herman, Gail E.
Evans, James
TI Reporting genomic secondary findings: ACMG members weigh in
SO GENETICS IN MEDICINE
LA English
DT Article
DE incidental findings; informed consent; next-generation sequencing;
return of results; secondary findings
ID INCIDENTAL FINDINGS; GENETICS PROFESSIONALS; CLINICAL GENOME; RETURN;
EXOME; PERSPECTIVES; VIEWS
AB Purpose: The aim of this study was to survey American College of Medical Genetics and Genomics members about secondary findings from clinical genome-scale sequencing.
Methods: A Web-based survey was mailed to 1,687 members of the American College of Medical Genetics and Genomics. Exploratory factor analysis identified underlying factors assessed by survey items. Linear regression assessed associations between factor scores and respondent characteristics.
Results: The response rate was 29%. Four factors explained 51% of the survey variance: best practices, patient preferences, guidance, and informed consent. Most agreed with "best practice" items describing seeking and reporting of secondary findings as consistent with medical standards, having sufficient evidence, and, for adults, the benefits generally outweighing potential harms. There was lack of agreement regarding benefits versus harms for children and impact on health-care resources. The majority agreed that patient preferences should be considered, including ability to opt out, and that informed consent was feasible and critical. Characteristics significantly associated with factor scores included country of residence, sequencing experience, and years in practice.
Conclusion: The American College of Medical Genetics and Genomics should update a list of genes to be assessed when clinical genome-scale sequencing is performed. Informed consent is necessary, and reporting of secondary findings should be optional. Research on implementation of secondary findings reporting is needed.
C1 [Scheuner, Maren T.; Peredo, Jane] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Med Genet, Los Angeles, CA 90073 USA.
[Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Benkendorf, Judith; Bowdish, Bruce; Watson, Michael] Amer Coll Med Genet & Genom, Bethesda, MD USA.
[Feldman, Gerald] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI USA.
[Feldman, Gerald] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA.
[Feldman, Gerald] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.
[Fleisher, Lynn] Sidley & Austin, Chicago, IL USA.
[Mulvihill, John J.] Univ Oklahoma, Dept Pediat, Oklahoma City, OK USA.
[Herman, Gail E.] Ohio State Univ, Nationwide Childrens Res Inst, Columbus, OH 43210 USA.
[Herman, Gail E.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.
[Evans, James] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Evans, James] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
RP Scheuner, MT (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, Div Med Genet, Los Angeles, CA 90073 USA.
EM maren.scheuner@va.gov
NR 19
TC 9
Z9 9
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD JAN
PY 2015
VL 17
IS 1
BP 27
EP 35
DI 10.1038/gim.2014.165
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA AY7MT
UT WOS:000347744900005
PM 25394173
ER
PT J
AU Dunn, EC
Brown, RC
Dai, Y
Rosand, J
Nugent, NR
Amstadter, AB
Smoller, JW
AF Dunn, Erin C.
Brown, Ruth C.
Dai, Yael
Rosand, Jonathan
Nugent, Nicole R.
Amstadter, Ananda B.
Smoller, Jordan W.
TI Genetic Determinants of Depression: Recent Findings and Future
Directions
SO HARVARD REVIEW OF PSYCHIATRY
LA English
DT Review
DE copy-number variant; depression; genetics; gene-environment interaction;
genome-wide association study; genome-wide environment interaction
study; rare variants
ID GENOME-WIDE ASSOCIATION; NATIONAL COMORBIDITY SURVEY; SEROTONIN
TRANSPORTER GENE; RESEARCH DOMAIN CRITERIA; STRESSFUL LIFE EVENTS;
REPLICATION NCS-R; DSM-IV-DISORDERS; DE-NOVO CNVS; MAJOR DEPRESSION;
ENVIRONMENT INTERACTIONS
AB Depression is one of the most prevalent, disabling, and costly mental health conditions in the Unite States and also worldwide. One promising avenue for preventing depression and informing its clinical treatment lies in uncovering the genetic and environmental determinants of the disorder as well as their interaction (GxE). The overarching goal of this review article is to translate recent findings from studies of genetic association and GxE related to depression, particularly for readers without in-depth knowledge of genetics or genetic methods. The review is organized into three major sections. In the first, we summarize what is currently known about the genetic determinants of depression, focusing on findings from genome-wide association studies (GWAS). In the second section, we review findings from studies of GxE, which seek to simultaneously examine the role of genes and exposure to specific environments or experiences in the etiology of depression. In the third section, we describe the challenges to genetic discovery in depression and promising strategies for future progress.
C1 [Dunn, Erin C.; Smoller, Jordan W.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Dunn, Erin C.; Dai, Yael; Rosand, Jonathan; Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Dunn, Erin C.; Smoller, Jordan W.] Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Rosand, Jonathan] Program Med & Populat Genet, Cambridge, MA USA.
[Brown, Ruth C.; Amstadter, Ananda B.] Broad Inst Harvard, Cambridge, MA USA.
[Brown, Ruth C.; Amstadter, Ananda B.] MIT, Cambridge, MA 02139 USA.
[Brown, Ruth C.; Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Boston, MA USA.
[Rosand, Jonathan] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Nugent, Nicole R.] Alpert Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA.
[Smoller, Jordan W.] Harvard Univ, Ctr Dev Child, Cambridge, MA 02138 USA.
RP Dunn, EC (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Simches Res Bldg,6th Floor,185 Cambridge St, Boston, MA 02114 USA.
EM edunn2@mgh.harvard.edu
FU Harvard University Center on the Developing Child; National Institute of
Mental Health [K01MH087240, K24MH094614]
FX Supported, in part, by the Harvard University Center on the Developing
Child (Dr. Dunn) and by National Institute of Mental Health grant nos.
K01MH087240 (Dr. Nugent) and K24MH094614 (Dr. Smoller).
NR 162
TC 20
Z9 21
U1 8
U2 47
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1067-3229
EI 1465-7309
J9 HARVARD REV PSYCHIAT
JI Harv. Rev. Psychiatr.
PD JAN-FEB
PY 2015
VL 23
IS 1
BP 1
EP 18
DI 10.1097/HRP.0000000000000054
PG 18
WC Psychiatry
SC Psychiatry
GA AZ3XM
UT WOS:000348157100001
PM 25563565
ER
PT J
AU Saini, S
Pratt, DS
AF Saini, Sanjay
Pratt, Daniel S.
TI Time to update radiological criteria for non-invasive diagnosis of
hepatocellular carcinoma
SO HEPATOLOGY INTERNATIONAL
LA English
DT Editorial Material
ID LIVER-TRANSPLANTATION; GUIDELINES; MANAGEMENT; PATHOLOGY
C1 [Saini, Sanjay] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Saini, Sanjay; Pratt, Daniel S.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Pratt, Daniel S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Saini, S (reprint author), Massachusetts Gen Hosp, Dept Radiol, 32 Fruit St, Boston, MA 02114 USA.
EM ssaini@partners.org
NR 16
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1936-0533
EI 1936-0541
J9 HEPATOL INT
JI Hepatol. Int.
PD JAN
PY 2015
VL 9
IS 1
BP 1
EP 2
DI 10.1007/s12072-014-9584-y
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AZ4XH
UT WOS:000348223800001
PM 25788371
ER
PT J
AU Sayegh, AI
Washington, MC
Johnson, RE
Johnson-Rouse, T
Freeman, C
Harrison, A
Lucas, J
Shelby, M
Fisher, B
Willis, W
Reeve, JJ
AF Sayegh, Ayman I.
Washington, Martha C.
Johnson, Ruth E.
Johnson-Rouse, Tanisha
Freeman, Corren
Harrison, Anna
Lucas, Jennifer
Shelby, Mandy
Fisher, Brittley
Willis, William
Reeve, Joseph J., Jr.
TI Celiac and the cranial mesenteric arteries supply gastrointestinal sites
that regulate meal size and intermeal interval length via
cholecystokinin-58 in male rats
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Cholecystokinin-58; Meal size; Intermeal interval; Celiac artery;
Cranial mesenteric artery
ID DORSAL VAGAL COMPLEX; REDUCE FOOD-INTAKE; MYENTERIC PLEXUS;
INTESTINAL-MUCOSA; CCK1 RECEPTOR; CCK-58; SATIETY; SECRETION; TRACT;
IMMUNOREACTIVITY
AB The site(s) of action that control meal size and intermeal interval (IMI) length by cholecystokinin-58 (CCK-58), the only detectable endocrine form of CCK in the rat, are not known. To test the hypothesis that the gastrointestinal tract may contain such sites, we infused low doses of CCK-58 (0.01, 0.05, 0.15 and 0.25 nmol/kg) into the celiac artery (CA, supplying stomach and upper duodenum), the cranial mesenteric artery (CMA, supplying small and most of the large intestines), the femoral artery (FA, control) and the portal vein (PV, draining the gastrointestinal tract) prior to the onset of the dark cycle in freely fed male rats. We measured the first meal size (chow), second meal size, IMI and satiety ratio (SR, IMI/meal size). We found that (1) all doses of CCK-58 given in the CA and the highest dose given in the CMA reduced the first meal size, (2) all doses of CCK-58 given in the CA reduced the second meal size, (3) a CCK-58 dose of 0.15 nmol/kg given in the CA and 0.15 and 0.25 nmol/kg given in the CMA prolonged the IMI, (4) CCK-58.(0.05, 0.15, 0.25 nmol/kg) given in the CA and 0.25 nmol/kg given in the CMA increased the SR, and (5) CCK-58 given in the FA and PV had no effect on the meal size or intermeal interval. These results support our hypothesis that the gastrointestinal tract contains sites of action that regulate meal size and IMI length via CCK-58. The stomach and upper duodenum may contain sites regulating meal size, whereas the small intestine and part of the large intestine may contain sites regulating the IMI. Published by Elsevier Inc.
C1 [Sayegh, Ayman I.; Washington, Martha C.; Johnson, Ruth E.; Johnson-Rouse, Tanisha; Freeman, Corren; Harrison, Anna; Lucas, Jennifer; Shelby, Mandy; Fisher, Brittley; Willis, William; Reeve, Joseph J., Jr.] Tuskegee Univ, Coll Vet Med, Dept Biomed Sci, Gastroenterol Lab, Tuskegee, AL 36088 USA.
[Reeve, Joseph J., Jr.] Vet Adm Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA USA.
[Reeve, Joseph J., Jr.] Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA USA.
RP Sayegh, AI (reprint author), Tuskegee Univ, Coll Vet Med, Dept Biomed Sci, Gastroenterol Lab, Tuskegee, AL 36088 USA.
EM sayeghai@mytu.tuskegee.edu
FU NIH [5R01DK083449]; [1SC1DK094972-01A1]
FX The research was supported by grant 1SC1DK094972-01A1 (AS) and NIH grant
5R01DK083449 (J.R.R, Jr.)
NR 40
TC 8
Z9 8
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD JAN
PY 2015
VL 67
BP 48
EP 53
DI 10.1016/j.yhbeh.2014.11.011
PG 6
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA AZ5GX
UT WOS:000348249300006
PM 25479193
ER
PT J
AU Pauk, M
Grgurevic, L
Brkljacic, J
Kufner, V
Bordukalo-Niksic, T
Grabusic, K
Razdorov, G
Rogic, D
Zuvic, M
Oppermann, H
Babitt, JL
Lin, HY
Volarevic, S
Vukicevic, S
AF Pauk, Martina
Grgurevic, Lovorka
Brkljacic, Jelena
Kufner, Vera
Bordukalo-Niksic, Tatjana
Grabusic, Kristina
Razdorov, Genadij
Rogic, Dunja
Zuvic, Marijan
Oppermann, Hermann
Babitt, Jodie L.
Lin, Herbert Y.
Volarevic, Sinisa
Vukicevic, Slobodan
TI Exogenous BMP7 corrects plasma iron overload and bone loss in Bmp6-/-
mice
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Article
DE Iron; Haemochromatosis; Hepcidin; Bone morphogenetic protein
ID HEPCIDIN EXPRESSION; PROTEIN 6; IN-VIVO; MORPHOGENETIC PROTEINS; PEPTIDE
HEPCIDIN; MOUSE-LIVER; GENE; CELLS; HFE; HEMOCHROMATOSIS
AB Purpose Iron overload accelerates bone loss in mice lacking the bone morphogenetic protein 6 (Bmp6) gene, which is the key endogenous regulator of hepcidin, iron homeostasis gene. We investigated involvement of other BMPs in preventing haemochromatosis and subsequent osteopenia in Bmp6-/- mice.
Methods Iron-treated wild-type (WT) and Bmp6-/- mice were analysed for hepcidin messenger RNA (mRNA) and tissue and blood BMP levels by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), immunohistochemistry, Western blot, enzyme-linked immunosorbent assay (ELISA) and proximity extension assay. BMPs labeled with technetium-99m were used in pharmacokinetic studies.
Results In WT mice, 4 h following iron challenge, liver Bmp6 and hepcidin expression were increased, while expression of other Bmps was not affected. In parallel, we provided the first evidence that BMP6 circulates in WT mice and that iron increased the BMP6 serum level and the specific liver uptake of Tc-99m-BMP6. In Bmp6-/- mice, iron challenge led to blunted activation of liver Smad signaling and hepcidin expression with a delay of 24 h, associated with increased Bmp5 and Bmp7 expression and increased Bmp2, 4, 5 and 9 expression in the duodenum. Liver Bmp7 expression and increased circulating BMP9 eventually contributed to the late hepcidin response. This was further supported by exogenous BMP7 therapy resulting in an effective hepcidin expression followed by a rapid normalisation of plasma iron values and restored osteopenia in Bmp6-/- mice.
Conclusion In Bmp6-/- mice, iron activated endogenous compensatory mechanisms of other BMPs that were not sufficient for preventing hemochromatosis and bone loss. Administration of exogenous BMP7 was effective in correcting the plasma iron level and bone loss, indicating that BMP6 is an essential but not exclusive in vivo regulator of iron homeostasis.
C1 [Pauk, Martina; Grgurevic, Lovorka; Brkljacic, Jelena; Kufner, Vera; Bordukalo-Niksic, Tatjana; Razdorov, Genadij; Vukicevic, Slobodan] Univ Zagreb, Ctr Translat & Clin Res, Sch Med, Zagreb 10000, Croatia.
[Grabusic, Kristina; Volarevic, Sinisa] Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia.
[Rogic, Dunja] Univ Hosp Ctr Zagreb, Dept Lab Diag, Zagreb, Croatia.
[Zuvic, Marijan] Univ Hosp Ctr Zagreb, Dept Nucl Med & Radiat Protect, Div Haematol, Zagreb, Croatia.
[Oppermann, Hermann] Genera Res, Rakov Potok, Croatia.
[Babitt, Jodie L.; Lin, Herbert Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol,Div Nephrol,Program Membrane Biol, Boston, MA USA.
RP Vukicevic, S (reprint author), Univ Zagreb, Ctr Translat & Clin Res, Sch Med, Salata 11, Zagreb 10000, Croatia.
EM martina.pauk@mef.hr; lovorka.grgurevic@mef.hr; jelena.brkljacic@mef.hr;
vera.kufner@gmail.com; tbordukalo@gmail.com; grabusic@medri.hr;
genadijrazdorov@yahoo.com; dunjarogic@hotmail.com; mzuvic@kbc-zagreb.hr;
hermann.oppermann@gmail.com; Babitt.Jodie@mgh.harvard.edu;
Lin.Herbert@mgh.harvard.edu; vsinisa@medri.hr; vukicev@mef.hr
FU Ministry of Science and Technology of the Republic of Croatia; NIH [RO1
DK087727]
FX This study was supported by grants from the Ministry of Science and
Technology of the Republic of Croatia. No conflict of interest for any
authors. JLB was supported in part by NIH grant RO1 DK087727.
NR 37
TC 4
Z9 4
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2695
EI 1432-5195
J9 INT ORTHOP
JI Int. Orthop.
PD JAN
PY 2015
VL 39
IS 1
BP 161
EP 172
DI 10.1007/s00264-014-2550-4
PG 12
WC Orthopedics
SC Orthopedics
GA AY7GX
UT WOS:000347730200022
PM 25300398
ER
PT J
AU Phipps, JE
Vela, D
Hoyt, T
Halaney, DL
Mancuso, JJ
Buja, LM
Asmis, R
Milner, TE
Feldman, MD
AF Phipps, Jennifer E.
Vela, Deborah
Hoyt, Taylor
Halaney, David L.
Mancuso, J. Jacob
Buja, L. Maximilian
Asmis, Reto
Milner, Thomas E.
Feldman, Marc D.
TI Macrophages and Intravascular OCT Bright Spots A Quantitative Study
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE intravascular optical; coherence tomography; macrophages; quantitative
analysis bright spots
ID OPTICAL COHERENCE TOMOGRAPHY; CORONARY PLAQUE CHARACTERISTICS;
VULNERABLE PLAQUE; ATHEROSCLEROSIS; INFLAMMATION
AB OBJECTIVES This study hypothesized that bright spots in intravascular optical coherence tomography (IVOCT) images may originate by colocalization of plaque materials of differing indexes of refraction. To quantitatively identify bright spots, we developed an algorithm that accounts for factors including tissue depth, distance from light source, and signal-to-noise ratio. We used this algorithm to perform a bright spot analysis of IVOCT images and compared these results with histological examination of matching tissue sections.
BACKGROUND Bright spots are thought to represent macrophages in IVOCT images, and studies of alternative etiologies have not been reported.
METHODS Fresh human coronary arteries (n = 14 from 10 hearts) were imaged with IVOCT in a mock catheterization Laboratory and then processed for histological analysis. The quantitative bright spot algorithm was applied to all images.
RESULTS Results are reported for 1,599 IVOCT images co-registered with histology. Macrophages alone were responsible for only 23% of the bright spot-positive regions, although they were present in 57% of bright spot-positive regions (as determined by histology). Additional etiologies for bright spots included cellular fibrous tissue (8%), interfaces between calcium and fibrous tissue (10%), calcium and Lipids (5%), and fibrous cap and Lipid pool (3%). Additionally, we showed that Large pools of macrophages in CD68(+) histology sections corresponded to dark regions in comparative IVOCT images; this is due to the fact that a pool of lipid-rich macrophages will have the same index of refraction as a pool of Lipid and thus will not cause bright spots.
CONCLUSIONS Bright spots in IVOCT images were correlated with a variety of plaque components that cause sharp changes in the index of refraction. Algorithms that incorporate these correlations may be developed to improve the identification of some types of vulnerable plaque and allow standardization of IVOCT image interpretation. (C) 2015 by the American College of Cardiology Foundation.
C1 [Phipps, Jennifer E.; Hoyt, Taylor; Halaney, David L.; Mancuso, J. Jacob; Asmis, Reto; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Vela, Deborah; Buja, L. Maximilian] Texas Heart Inst, Houston, TX 77025 USA.
[Halaney, David L.; Feldman, Marc D.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA.
[Milner, Thomas E.] Univ Texas Austin, Austin, TX 78712 USA.
RP Feldman, MD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr,MSC 7872, San Antonio, TX 78229 USA.
EM feldmanm@uthscsa.edu
OI Buja, Louis Maximilian/0000-0001-8386-7029; Halaney,
David/0000-0003-4437-0516
FU Veterans Health Administration merit grant [I01 BX000397]; Clayton
Foundation; Janey and Dolph Briscoe Division of Cardiology at the
University of Texas Health Science Center [NIH T32 HL007446]; American
Heart Association [13POST17080074]; Biomedical Engineering Advancement
fund at the University of Texas at Austin
FX This study was funded by the Veterans Health Administration merit grant
I01 BX000397, Clayton Foundation, Janey and Dolph Briscoe Division of
Cardiology at the University of Texas Health Science Center (NIH T32
HL007446), American Heart Association (13POST17080074), and the
Biomedical Engineering Advancement fund at the University of Texas at
Austin. The intravascular optical coherence tomography system used in
this study was provided by Volcano Corporation. All authors have
reported that they have no relationships relevant to the contents of
this paper to disdose.
NR 27
TC 22
Z9 22
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
EI 1876-7591
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD JAN
PY 2015
VL 8
IS 1
BP 63
EP 72
DI 10.1016/j.jcmg.2014.07.027
PG 10
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA AZ4GZ
UT WOS:000348181000011
PM 25499133
ER
PT J
AU Tearney, GJ
AF Tearney, Guillermo J.
TI OCT Imaging of Macrophages A Bright Spot in the Study of Inflammation in
Human Atherosclerosis
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Editorial Material
DE intravascular imaging; macrophage; optical coherence tomography;
vulnerable plaque
ID OPTICAL COHERENCE TOMOGRAPHY; STENTS
C1 [Tearney, Guillermo J.] Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
[Tearney, Guillermo J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Tearney, GJ (reprint author), Massachusetts Gen Hosp, Dept Pathol, BHX604A, Boston, MA 02114 USA.
EM gtearney@partners.org
NR 11
TC 4
Z9 4
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
EI 1876-7591
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD JAN
PY 2015
VL 8
IS 1
BP 73
EP 75
DI 10.1016/j.jcmg.2014.09.019
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA AZ4GZ
UT WOS:000348181000012
PM 25592697
ER
PT J
AU Chang, DC
Evans, C
Parker, J
AF Chang, David C.
Evans, Christopher
Parker, Joseph
TI Conceptualizing Administrative Databases as Screening Tools for Health
System Quality Rethinking the Issue of Data Accuracy
SO JAMA SURGERY
LA English
DT Editorial Material
ID COMPLICATIONS
C1 [Chang, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
[Chang, David C.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.
[Evans, Christopher] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.
[Parker, Joseph] Off Statewide Hlth Planning & Dev, Sacramento, CA USA.
RP Chang, DC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, 165 Cambridge St,Ste 403, Boston, MA 02114 USA.
EM dchang8@mgh.harvard.edu
NR 7
TC 6
Z9 6
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD JAN
PY 2015
VL 150
IS 1
BP 5
EP 6
DI 10.1001/jamasurg.2014.1352
PG 2
WC Surgery
SC Surgery
GA AZ5AO
UT WOS:000348232900001
PM 25409092
ER
PT J
AU Ju, MH
Ko, CY
Hall, BL
Bosk, CL
Bilimoria, KY
Wick, EC
AF Ju, Mila H.
Ko, Clifford Y.
Hall, Bruce L.
Bosk, Charles L.
Bilimoria, Karl Y.
Wick, Elizabeth C.
TI A Comparison of 2 Surgical Site Infection Monitoring Systems
SO JAMA SURGERY
LA English
DT Article
ID CARE-ASSOCIATED INFECTIONS; ADMINISTRATIVE DATA; RISK ADJUSTMENT;
NATIONAL-HEALTH; SAFETY NETWORK; SURVEILLANCE; HOSPITALS; COSTS; STATE
AB IMPORTANCE Surgical site infection (SSI) has emerged as the leading publicly reported surgical outcome and is tied to payment determinations. Many hospitals monitor SSIs using the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP), in addition to mandatory participation (for most states) in the Centers for Disease Control and Prevention's National Healthcare Safety Network (NHSN), which has resulted in duplication of effort and incongruent data.
OBJECTIVE To identify discrepancies in the implementation of the NHSN and the ACS NSQIP at hospitals that may be affecting the respective SSI rates.
DESIGN, SETTING, AND PARTICIPANTS A pilot sample of hospitals that participate in both the NHSN and the ACS NSQIP.
INTERVENTIONS For each hospital, observed rates and risk-adjusted observed to expected ratios for year 2012 colon SSIs were collected from both programs. The implementation methods of both programs were identified, including telephone interviews with infection preventionists who collect data for the NHSN at each hospital.
MAIN OUTCOMES AND MEASURES Collection methods and colon SSI rates for the NHSN at each hospital were compared with those of the ACS NSQIP.
RESULTS Of 16 hospitals, 11 were teaching hospitals with at least 500 beds. The mean observed colon SSI rates were dissimilar between the 2 programs, 5.7%(range, 2.0%-14.5%) for the NHSN vs 13.5%(range, 4.6%-26.7%) for the ACS NSQIP. The mean difference between the NHSN and the ACS NSQIP was 8.3%(range, 1.6%-18.8%), with the ACS NSQIP rate always higher. The correlation between the observed to expected ratios for the 2 programs was nonsignificant (Pearson product moment correlation, rho = 0.4465; P =.08). The NHSN collection methods were dissimilar among interviewed hospitals. An SSI managed as an outpatient case would usually be missed under the current NHSN practices.
CONCLUSIONS AND RELEVANCE Colon SSI rates from the NHSN and the ACS NSQIP cannot be used interchangeably to evaluate hospital performance and determine reimbursement. Hospitals should not use the ACS NSQIP colon SSI rates for the NHSN reports because that would likely result in the hospital being an outlier for performance. It is imperative to reconcile SSI monitoring, develop consistent definitions, and establish one reliable method. The current state hinders hospital improvement efforts by adding unnecessary confusion to the already complex arena of perioperative improvement.
C1 [Ju, Mila H.; Ko, Clifford Y.; Hall, Bruce L.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Ju, Mila H.; Bilimoria, Karl Y.] Northwestern Univ, NW Mem Hosp, Feinberg Sch Med, Surg Outcomes & Qual Improvement Ctr,Dept Surg, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA.
[Hall, Bruce L.] St Louis Vet Affairs Med Ctr, St Louis, MO USA.
[Hall, Bruce L.] BJC HealthCare, St Louis, MO USA.
[Bosk, Charles L.] Univ Penn, Leonard Davis Inst Hlth Econ, Dept Sociol, Philadelphia, PA 19104 USA.
[Bosk, Charles L.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.
[Wick, Elizabeth C.] Johns Hopkins Univ, Dept Surg, Baltimore, MD 21287 USA.
RP Wick, EC (reprint author), Johns Hopkins Univ, Dept Surg, 600 N Wolfe St,Blalock Room 658, Baltimore, MD 21287 USA.
EM ewick1@jhmi.edu
FU National Institutes of Health [5T32HL094293]; American College of
Surgeons Clinical Scholars in Residence program
FX Dr Ju reported receiving a stipend that is partially supported by grant
5T32HL094293 from the National Institutes of Health and the American
College of Surgeons Clinical Scholars in Residence program. Dr Hall
reported being a paid consultant for the American College of Surgeons.
No other disclosures were reported.
NR 23
TC 16
Z9 16
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD JAN
PY 2015
VL 150
IS 1
BP 51
EP 57
DI 10.1001/jamasurg.2014.2891
PG 7
WC Surgery
SC Surgery
GA AZ5AO
UT WOS:000348232900011
PM 25426765
ER
PT J
AU Golberg, A
Broelsch, GF
Vecchio, D
Khan, S
Hamblin, MR
Austen, WG
Sheridan, RL
Yarmush, ML
AF Golberg, Alexander
Broelsch, G. Felix
Vecchio, Daniela
Khan, Saiqa
Hamblin, Michael R.
Austen, William G., Jr.
Sheridan, Robert L.
Yarmush, Martin L.
TI Pulsed Electric Fields for Burn Wound Disinfection in a Murine Model
SO JOURNAL OF BURN CARE & RESEARCH
LA English
DT Article
ID IRREVERSIBLE ELECTROPORATION; ACINETOBACTER-BAUMANNII; PHOTODYNAMIC
THERAPY; IN-VIVO; INFECTIONS; MANAGEMENT; RESISTANCE; CELLS; ABLATION;
EFFICACY
AB Emerging bacterial resistance renders many antibiotics ineffective, making alternative strategies of wound disinfection important. Here the authors report on a new, physical burn wound disinfection method: pulsed electric fields (PEFs). High voltage, short PEFs create nonthermal, permanent damage to cell membranes, possibly by irreversible electroporation. In medicine, PEF technology has recently been used for nonthermal ablation of solid tumors. The authors have expanded the spectrum of PEF applications in medicine to burn wound disinfection. A third-degree burn was induced on the dorsal skin of C57BL/6 mice. Immediately after the injury, the burn wound was infected with Acinetobacter baumannii expressing the luxCDABE operon. Thirty minutes after infection, the infected areas were treated with 80 pulses delivered at 500 V/mm, 70 mu s, 1 Hz. The authors used bioluminescence to quantify bacteria on skin. Three animals were used for each experimental condition. PEFs were effective in the disinfection of infected burned murine skin. The bacterial load reduction correlated with the number of delivered pulses. Forty pulses of 500 V/mm led to a 2.04 +/- 0.29 Log10 reduction in bacterial load; 80 pulses led to the immediate 5.53 +/- 0.30 Log10 reduction. Three hours after PEF, the bacterial reduction of the skin treated with 500 V/mm, 80 pulses was 4.91 +/- 0.71 Log10. The authors introduce a new method of wound disinfection using high voltage, short PEFs. They believe that PEF technology may represent an important alternative to antibiotics in addressing bacterial contamination of wounds, particularly those contaminated with multidrug-resistant bacteria.
C1 [Golberg, Alexander; Yarmush, Martin L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Dept Surg, Boston, MA 02114 USA.
[Golberg, Alexander; Yarmush, Martin L.] Shriners Burns Hosp, Boston, MA 02114 USA.
[Broelsch, G. Felix; Khan, Saiqa; Austen, William G., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA 02114 USA.
[Vecchio, Daniela; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Sheridan, Robert L.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Sheridan, Robert L.] Shriners Hosp Children, Boston, MA USA.
[Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA.
RP Yarmush, ML (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Dept Surg, Boston, MA 02114 USA.
EM ireis@sbi.org
FU Shriners Grant [85120-BOS]; MGH ECOR postdoctoral award; U.S. grant [NIH
R01AI050875]
FX The research of A.G. and M.L.Y. was supported by Shriners Grant
#85120-BOS and MGH ECOR postdoctoral award. Research in the Hamblin
laboratory was supported by U.S. grant NIH R01AI050875
NR 48
TC 8
Z9 8
U1 2
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1559-047X
EI 1559-0488
J9 J BURN CARE RES
JI J. Burn Care Res.
PD JAN-FEB
PY 2015
VL 36
IS 1
BP 7
EP 13
DI 10.1097/BCR.0000000000000157
PG 7
WC Emergency Medicine; Dermatology; Surgery
SC Emergency Medicine; Dermatology; Surgery
GA AY3AG
UT WOS:000347456400005
PM 25167374
ER
PT J
AU Ryan, CM
Lee, A
Kazis, LE
Schneider, JC
Shapiro, GD
Sheridan, RL
Meyer, WJ
Palmieri, T
Pidcock, FS
Reilly, D
Tompkins, RG
AF Ryan, Colleen M.
Lee, Austin
Kazis, Lewis E.
Schneider, Jeffrey C.
Shapiro, Gabriel D.
Sheridan, Robert L.
Meyer, Walter J.
Palmieri, Tina
Pidcock, Frank S.
Reilly, Debra
Tompkins, Ronald G.
CA Multictr Burn Outcome Grp
TI Recovery Trajectories After Burn Injury in Young Adults: Does Burn Size
Matter?
SO JOURNAL OF BURN CARE & RESEARCH
LA English
DT Article
ID QUALITY-OF-LIFE; ASSOCIATION/SHRINERS-HOSPITALS; FAMILY ENVIRONMENT;
POSTBURN PRURITUS; CHILDREN; SURVIVORS; OUTCOMES; QUESTIONNAIRE;
VALIDATION; EXERCISE
AB The impact of burn size on mortality is well known, but the association of burn size with the trajectories of long-term functional outcomes remains poorly studied. This prospective multi-center study included burned adults ages 19 to 30 years who completed the Young Adult Burn Outcome Questionnaire at initial baseline contact, 2 weeks, and at 6 and 12 months after initial questionnaire administration. Non-burned adults of comparable ages also completed the questionnaire as a reference group. The association between functional recovery and TBSA burned was analyzed longitudinally using generalized linear models with the generalized estimation equation technique. Functional status was characterized in 15 domains: physical function, fine motor function, pain, itch, social function limited by physical function, perceived appearance, social function limited by appearance, sexual function, emotion, family function, family concern, satisfaction with symptom relief, satisfaction with role, work reintegration, and religion. Scores were standardized to a mean of 50 and a SD of 10 based on non-burned controls. There were 153 burned and 112 non-burned subjects with a total of 620 questionnaires. TBSA burned was 11 +/- 14% (mean +/- SD); 31% had face involvement and 57% had hand involvement. The lag time from burn injury to questionnaire administration was on average 7 +/- 7.7 months, with a maximum of 36 months. Lower recovery levels were associated with increasing burn size for physical function, pain, itch, work reintegration, emotion, satisfaction with symptom relief, satisfaction with role, family function, and family concern (P value ranged from .04-<.0001). No significant differences in recovery levels were found with increasing burn size for fine motor function, social function limited by physical function, sexual function, and religion; these areas tracked toward the age-matched non-burned group regardless of burn size. Perceived appearance and social function limited by appearance remained below the non-burn levels throughout the 3-year period regardless of burn size. Three-year recovery trajectories of survivors with larger burn size showed improvements in most areas, but these improvements lagged behind those with smaller burns. Poor perceived appearance was persistent and prevalent regardless of burn size and was found to limit social function in these young adult burn survivors. Expectations for multidimensional recovery from burns in young adults can be benchmarked based on burn size with important implications for patient monitoring and intervening in clinical care.
C1 [Ryan, Colleen M.; Lee, Austin; Schneider, Jeffrey C.; Sheridan, Robert L.; Tompkins, Ronald G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ryan, Colleen M.; Schneider, Jeffrey C.; Sheridan, Robert L.; Tompkins, Ronald G.] Harvard Univ, Sch Med, Boston, MA USA.
[Ryan, Colleen M.; Schneider, Jeffrey C.; Sheridan, Robert L.] Shriners Hosp Children, Boston, MA USA.
[Kazis, Lewis E.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, CAPP, Boston, MA USA.
[Schneider, Jeffrey C.] Spaulding Rehabil Hosp, Boston, MA USA.
[Shapiro, Gabriel D.] St Justine Univ, Ctr Hlth, Montreal, PQ, Canada.
[Shapiro, Gabriel D.] Univ Montreal, Montreal, PQ H3C 3J7, Canada.
[Meyer, Walter J.] Shriners Hosp Children, Galveston, TX 77550 USA.
[Meyer, Walter J.] Univ Texas Med Branch, Galveston, TX 77555 USA.
[Palmieri, Tina] Shriners Hosp Children, Sacramento, CA USA.
[Palmieri, Tina] Univ Calif Davis, Los Angeles, CA USA.
[Pidcock, Frank S.] Kennedy Krieger Inst, Baltimore, MD USA.
[Reilly, Debra] Univ Nebraska, Omaha, NE 68182 USA.
[Lee, Austin] Xian Univ Finance & Econ, Res Ctr Med Stat & Actuarial Sci, Xian, Peoples R China.
[Lee, Austin] Bentley Univ, Dept Math Sci, Waltham, MA USA.
RP Ryan, CM (reprint author), Massachusetts Gen Hosp, Bigelow 1302,55 Fruit St, Boston, MA 02114 USA.
EM cryan@mgh.harvard.edu
FU Fraser Fund at the Massachusetts General Hospital; American Burn
Association; Shriners Hospitals for Children; National Institute of
Disability and Rehabilitation Research [H133A120034, H133A130023]
FX This work is supported in part by the authors' institutions, the Fraser
Fund at the Massachusetts General Hospital, the American Burn
Association, the Shriners Hospitals for Children and the National
Institute of Disability and Rehabilitation Research #H133A120034 and
#H133A130023.
NR 53
TC 7
Z9 8
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1559-047X
EI 1559-0488
J9 J BURN CARE RES
JI J. Burn Care Res.
PD JAN-FEB
PY 2015
VL 36
IS 1
BP 118
EP 129
DI 10.1097/BCR.0000000000000214
PG 12
WC Emergency Medicine; Dermatology; Surgery
SC Emergency Medicine; Dermatology; Surgery
GA AY3AG
UT WOS:000347456400019
PM 25501787
ER
PT J
AU Schneider, JC
Nadler, DL
Herndon, DN
Kowalske, K
Matthews, K
Wiechman, SA
Carrougher, GJ
Gibran, NS
Meyer, WJ
Sheridan, RL
Ryan, CM
AF Schneider, Jeffrey C.
Nadler, Deborah L.
Herndon, David N.
Kowalske, Karen
Matthews, Katie
Wiechman, Shelley A.
Carrougher, Gretchen J.
Gibran, Nicole S.
Meyer, Walter J.
Sheridan, Robert L.
Ryan, Colleen M.
TI Pruritus in Pediatric Burn Survivors: Defining the Clinical Course
SO JOURNAL OF BURN CARE & RESEARCH
LA English
DT Article
ID VISUAL ANALOG SCALE; QUALITY-OF-LIFE; ASSOCIATION/SHRINERS-HOSPITALS;
OUTCOMES QUESTIONNAIRE; POSTBURN PRURITUS; FOR-CHILDREN; PAIN; ITCH;
RELIABILITY; GABAPENTIN
AB Pruritus is a frequent and severe symptom and a significant cause of distress for adult burn patients. Its effects in children are largely unstudied. The aim of this study is to characterize postburn itch in the pediatric population. This is a retrospective review from 2006 to 2013 for pediatric burn survivors who were enrolled in a longitudinal multicenter outcomes study. Demographic data, injury characteristics, associated symptoms (skin-related problems, pain, and sleep), and incidence and intensity (Numerical Rating Scale) of itch were examined. Measures were completed at hospital discharge and at 6, 12, and 24 months after injury. Spearman's correlations were used to examine the correlation between itch intensity and associated symptoms. Multivariate regression analyses examined the impact of associated symptoms on itch intensity. There were 430 pediatric burn survivors with a mean age of 7.8 years and a mean TBSA of 40.8%. Pruritus is present in most children (93%) and is of moderate intensity (5.7 +/- 3.1) at discharge. The frequency and intensity of pruritus decreases over time; a majority of children continue to report symptoms at 2 years (63%). Itch was significantly correlated with associated symptoms. Regression analyses showed a correlation between itch intensity and pain at each time point. There was no association between itch intensity and burn etiology, age, gender, or burn size. Pruritus is a frequent complication that lasts for at least 2 years after injury in a majority of pediatric burn survivors. This information will enable better tracking of outcomes and will serve as a baseline for assessing interventions.
C1 [Schneider, Jeffrey C.; Nadler, Deborah L.; Matthews, Katie; Ryan, Colleen M.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02129 USA.
[Schneider, Jeffrey C.; Sheridan, Robert L.; Ryan, Colleen M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Sumner Redstone Burn Ctr, Surg Serv,Shriners Hosp Children, Boston, MA USA.
[Herndon, David N.; Meyer, Walter J.] Univ Texas Med Branch, Shriners Hosp Children, Galveston, TX 77555 USA.
[Kowalske, Karen] Univ Texas SW Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA.
[Wiechman, Shelley A.; Carrougher, Gretchen J.; Gibran, Nicole S.] Univ Washington, UW Med Reg Burn Ctr, Seattle, WA 98195 USA.
RP Schneider, JC (reprint author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 300 First Ave, Boston, MA 02129 USA.
FU Department of Education, NIDRR [H133A120034]
FX The contents of this article were developed under a grant from the
Department of Education, NIDRR grant number H133A120034. However, those
contents do not necessarily represent the policy of the Department of
Education, and you should not assume endorsement by the Federal
Government.
NR 38
TC 5
Z9 6
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1559-047X
EI 1559-0488
J9 J BURN CARE RES
JI J. Burn Care Res.
PD JAN-FEB
PY 2015
VL 36
IS 1
BP 151
EP 158
DI 10.1097/BCR.0000000000000145
PG 8
WC Emergency Medicine; Dermatology; Surgery
SC Emergency Medicine; Dermatology; Surgery
GA AY3AG
UT WOS:000347456400023
PM 25162949
ER
PT J
AU Gamelli, L
Mykychack, I
Kushnir, A
Driscoll, DN
Fuzaylov, G
AF Gamelli, Liza
Mykychack, Iryna
Kushnir, Antin
Driscoll, Daniel N.
Fuzaylov, Gennadiy
TI Targeting Burn Prevention in Ukraine: Evaluation of Base Knowledge in
Burn Prevention and First Aid Treatment
SO JOURNAL OF BURN CARE & RESEARCH
LA English
DT Article
ID CHILDREN; ZAMBIA; TRENDS; CARE
AB Burn prevention has been identified by the World Health Organization (WHO) as a topic in need of further investigation and education throughout the world, with an increased need in low-income countries. It has been noted that implementing educational programs for prevention in high income countries has aided in lowering the rate of burn injuries. The purpose of this study is to evaluate the current education level of knowledge of prevention and first aid treatment of scald burns. A prevention campaign will target these educational needs as a part of an outreach program to improve burn care in Ukraine. The research team evaluated the current health structure in Ukraine and how it could benefit from the increased knowledge of burn prevention and first aid. A test was designed to assess the baseline level of knowledge with regard to first aid and scald prevention in parents, pregnant woman, and healthcare and daycare providers. A total of 14,456 tests were sent to pediatric clinics, obstetrician clinics, and daycare facilities to test respondents. A total of 6,120 completed tests were returned. Doctors presented with the highest level of knowledge averaging 77.0% on prevention and 67.5% on first aid while daycare workers presented the largest gap in knowledge at 65.0% in prevention and 54.3% in first aid. Interest in further educational materials was reported by 92% of respondents. The results of this study clearly show a lack of knowledge in first aid and prevention of scald burn injury in all the populations tested.
C1 [Gamelli, Liza] Shriners Hosp Children, Boston, MA 02114 USA.
[Mykychack, Iryna] State Adm, Dept Hlth, Lvov, Ukraine.
[Mykychack, Iryna] Western Ukrainian Specialized Children Med Ctr, Lvov, Ukraine.
[Driscoll, Daniel N.; Fuzaylov, Gennadiy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Gamelli, L (reprint author), Shriners Hosp Children, Boston, MA 02114 USA.
NR 21
TC 2
Z9 2
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1559-047X
EI 1559-0488
J9 J BURN CARE RES
JI J. Burn Care Res.
PD JAN-FEB
PY 2015
VL 36
IS 1
BP 225
EP 231
DI 10.1097/BCR.0000000000000103
PG 7
WC Emergency Medicine; Dermatology; Surgery
SC Emergency Medicine; Dermatology; Surgery
GA AY3AG
UT WOS:000347456400033
PM 25055008
ER
PT J
AU Wibbenmeyer, L
Gittelman, MA
Kluesner, K
Liao, JL
Xing, YF
Faraklas, I
Anyan, W
Gamero, C
Moulton, S
Nederveld, C
Banks, A
Ryan, CM
Conway, JA
Reilly, DA
Fish, J
Kelly, C
Peltier, G
Schwantke, E
Conrad, PF
Caruso, DM
Richey, KJ
McCrory, K
Elfar, MSA
Pittinger, T
Sadie, C
Greenhalgh, D
Palmieri, T
Grossman, PH
Richards, KM
Joyce, T
Pozez, AL
Savetamal, A
Harrington, DT
Duncan, K
Pomerantz, WJ
Dillard, BD
AF Wibbenmeyer, Lucy
Gittelman, Michael A.
Kluesner, Karen
Liao, Junlin
Xing, Yunfan
Faraklas, Iris
Anyan, Walter
Gamero, Chelsea
Moulton, Steven
Nederveld, Cindy
Banks, Ashley
Ryan, Colleen M.
Conway, Jennifer A.
Reilly, Debra A.
Fish, Joel
Kelly, Charis
Peltier, George
Schwantke, Emily
Conrad, Peggie F.
Caruso, Daniel M.
Richey, Karen J.
McCrory, Kristine
Elfar, Mohamed S. A.
Pittinger, Timothy
Sadie, Christine
Greenhalgh, David
Palmieri, Tina
Grossman, Peter H.
Richards, Kurt M.
Joyce, Teresa
Pozez, Andrea L.
Savetamal, Alisa
Harrington, David T.
Duncan, Kimberley
Pomerantz, Wendy J.
Dillard, B. Daniel
TI A Multicenter Study of Preventable Contact Burns From Glass Fronted Gas
Fireplaces
SO JOURNAL OF BURN CARE & RESEARCH
LA English
DT Article
ID PEDIATRIC BURNS; FACIAL BURNS; HAND BURNS; MANAGEMENT; EXPERIENCE;
TODDLERS; CHILDREN; PALM
AB Glass fronted gas fireplaces (GFGFs) have exterior surfaces that can reach extremely high temperatures. Burn injuries from contact with the glass front can be severe with long-term sequelae. The Consumer Product Safety Commission reported that these injuries are uncommon, whereas single-center studies indicate a much higher frequency. The purpose of this multi-institutional study was to determine the magnitude and severity of GFGF injuries in North America. Seventeen burn centers elected to participate in this retrospective chart review. Chart review identified 402 children <= 10 years of age who sustained contact burns from contact with GFGF, who were seen or admitted to the study hospitals from January 2006 to December 2010. Demographic, burn, treatment, and financial data were collected. The mean age of the study group was 16.8 +/- 13.3 months. The majority suffered burns to their hands (396, 98.5%), with burns to the face being the second, much less common site (14, 3.5%). Two hundred and sixty-nine required rehabilitation therapy (66.9%). The number of GFGF injuries reported was 20 times greater than the approximately 30 injuries estimated by the Consumer Product Safety Commission's 10-year review. For the affected children, these injuries are painful, often costly and occasionally can lead to long-term sequelae. Given that less than a quarter of burn centers contributed data, the injury numbers reported herein support a need for broader safety guidelines for gas fireplaces in order to have a significant impact on future injuries.
C1 [Wibbenmeyer, Lucy; Kluesner, Karen; Liao, Junlin; Xing, Yunfan] Univ Iowa, Carver Coll Med, Dept Surg, Iowa City, IA 52246 USA.
[Gittelman, Michael A.; Pomerantz, Wendy J.] Cincinnati Childrens Hosp Med Ctr, Comprehens Childrens Injury Ctr, Div Emergency Med, Cincinnati, OH 45229 USA.
[Faraklas, Iris; Anyan, Walter; Gamero, Chelsea] Univ Utah, Dept Surg, Salt Lake City, UT USA.
[Moulton, Steven; Nederveld, Cindy; Banks, Ashley] Childrens Hosp, Dept Surg, Denver, CO 80218 USA.
[Ryan, Colleen M.; Conway, Jennifer A.] Shriners Hosp Children, Dept Surg, Boston, MA USA.
[Ryan, Colleen M.; Conway, Jennifer A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Ryan, Colleen M.; Conway, Jennifer A.] Harvard Univ, Sch Med, Boston, MA USA.
[Reilly, Debra A.] Univ Nebraska, Dept Surg, Omaha, NE 68182 USA.
[Fish, Joel; Kelly, Charis] Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada.
[Peltier, George; Schwantke, Emily] Hennepin Cty Hosp, Dept Surg, St Paul, MN USA.
[Conrad, Peggie F.] Loyola Univ, Dept Surg, Chicago, IL 60611 USA.
[Caruso, Daniel M.; Richey, Karen J.; McCrory, Kristine] Maricopa Cty Gen Hosp, Arizona Burn Ctr, Dept Surg, Phoenix, AZ USA.
[Elfar, Mohamed S. A.] SUNY Upstate Med Univ, Dept Surg, Clark Burn Ctr, Syracuse, NY 13210 USA.
[Pittinger, Timothy; Sadie, Christine] Akron Childrens Hosp, Dept Surg, Akron, OH USA.
[Greenhalgh, David; Palmieri, Tina] Shriners Hosp Children Northern Calif Sacramento, Dept Surg, Sacramento, CA USA.
[Grossman, Peter H.; Richards, Kurt M.] West Hills Hosp West Hills, Dept Burn Med, West Hills, CA USA.
[Joyce, Teresa] Shriners Hosp Children, Dept Surg, Cincinnati, OH USA.
[Pozez, Andrea L.] Virginia Commonwealth Univ, Richmond, VA USA.
[Savetamal, Alisa] Bridgeport Hosp, Dept Surg, Bridgeport, CT USA.
[Harrington, David T.; Duncan, Kimberley] Rhode Isl Hosp, Dept Surg, Providence, RI USA.
[Dillard, B. Daniel] Burn Prevent Network, Allentown, PA USA.
RP Wibbenmeyer, L (reprint author), Univ Iowa, Carver Coll Med, 200 Hawkins Dr,8321 JCP, Iowa City, IA 52246 USA.
EM lucy-wibbenmeyer@uiowa.edu
FU University of Iowa Injury Prevention Center
FX This study was supported by a grant from the University of Iowa Injury
Prevention Center. The study sponsor did not have any role in study
design; collection, analysis, or interpretation of data. The study
sponsor had no role in writing the report and the decision as to where
to submit the report for publication.
NR 27
TC 0
Z9 0
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1559-047X
EI 1559-0488
J9 J BURN CARE RES
JI J. Burn Care Res.
PD JAN-FEB
PY 2015
VL 36
IS 1
BP 240
EP 245
DI 10.1097/BCR.0000000000000215
PG 6
WC Emergency Medicine; Dermatology; Surgery
SC Emergency Medicine; Dermatology; Surgery
GA AY3AG
UT WOS:000347456400036
PM 25559733
ER
EF